<SEC-DOCUMENT>0001564590-21-013016.txt : 20210315
<SEC-HEADER>0001564590-21-013016.hdr.sgml : 20210315
<ACCEPTANCE-DATETIME>20210315082007
ACCESSION NUMBER:		0001564590-21-013016
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210315
DATE AS OF CHANGE:		20210315

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ovid Therapeutics Inc.
		CENTRAL INDEX KEY:			0001636651
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				465270895
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38085
		FILM NUMBER:		21739912

	BUSINESS ADDRESS:	
		STREET 1:		1460 BROADWAY
		STREET 2:		SUITE 15044
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		212-776-4381

	MAIL ADDRESS:	
		STREET 1:		1460 BROADWAY
		STREET 2:		SUITE 15044
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ovid-10k_20201231.htm
<DESCRIPTION>10-K 2020
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ovid-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:17pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:17pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.11%;margin-right:42.04%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:17pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-K</p>
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.11%;margin-right:42.04%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark One)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Fiscal Year Ended December&#160;31, 2020</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Transition Period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number: 001-38085</p>
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.11%;margin-right:42.04%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ovid Therapeutics Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its charter)</p>
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.11%;margin-right:42.04%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2834</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">46-5270895</p></td>
</tr>
<tr>
<td valign="top"  style="width:32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporation or Organization)</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Primary Standard Industrial</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Classification Code Number)</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification Number)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1460 Broadway, Suite 15021</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">New York, New York 10036</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(646) 661-7661</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices)</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act:</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:15%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top"  style="width:38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock, par value $0.001 per share</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:15%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OVID</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Nasdaq Stock Market LLC</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: None</p>
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.11%;margin-right:42.04%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font>&#160;&#160;&#160;&#160;No&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font>&#160;&#160;&#160;&#160;No&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to the filing requirements for the past 90 days.&#160;&#160;&#160;&#160;Yes&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font>&#160;&#160;&#160;&#160;No&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;Yes&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font>&#160;&#160;&#160;&#160;No&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:20.03%;"></td>
<td style="width:1.13%;"></td>
<td style="width:52.74%;"></td>
<td style="width:1.12%;"></td>
<td style="width:21.94%;"></td>
<td style="width:1.12%;"></td>
<td style="width:1.93%;"></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;Accelerated&#160;Filer</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;Filer</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated Filer</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;<font style="font-family:Times New Roman;">&#160;</font></p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;Reporting&#160;Company</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8.5pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;Yes&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font>&#160;&#160;&#160;&#160;No&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)&#160;&#160;&#160;&#160;Yes&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font>&#160;&#160;&#160;&#160;No&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2020, the last day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the Common Stock held by non-affiliates of the registrant was approximately $293.7 million based on the closing price of the registrant&#8217;s common stock on June 30, 2020.&nbsp;&nbsp;The calculation excludes shares of the registrant&#8217;s common stock held by current executive officers, directors and stockholders that the registrant has concluded are affiliates of the registrant.&nbsp;&nbsp;This determination of affiliate status is not a determination for other purposes.</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 8, 2021, there were 65,753,570 shares of common stock outstanding.</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:4.54%;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the registrant&#8217;s definitive proxy statement for its 2021 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year ended December&#160;31, 2020, are incorporated by reference into Part III of this Annual Report on Form 10-K.</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_"></a>TABLE OF CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SPECIAL_NOTE_REGARDING_FORWARDLOOKING_ST"><font style="text-decoration:underline;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></a></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><font style="text-decoration:underline;">PART&#160;I</font></a></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><font style="text-decoration:underline;">Business</font></a><font style="text-decoration:none;"> </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><font style="text-decoration:underline;">Risk Factors</font></a><font style="text-decoration:none;"> </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1B.</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><font style="text-decoration:underline;">Unresolved Staff Comments</font></a><font style="text-decoration:none;"> </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><font style="text-decoration:underline;">Properties</font></a><font style="text-decoration:none;"> </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><font style="text-decoration:underline;">Legal Proceedings</font></a><font style="text-decoration:none;"> </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><font style="text-decoration:underline;">Mine Safety Disclosures</font></a><font style="text-decoration:none;"> </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><font style="text-decoration:underline;">PART II</font></a></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 5.</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><font style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuers Purchases of Equity Securities</font></a><font style="text-decoration:none;"> </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 6.</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><font style="text-decoration:underline;">Selected Financial Data</font></a><font style="text-decoration:none;"> </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 7.</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><font style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a><font style="text-decoration:none;"> </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 7A.</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><font style="text-decoration:underline;">Quantitative and Qualitative Disclosures about Market Risk</font></a><font style="text-decoration:none;"> </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 8.</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><font style="text-decoration:underline;">Financial Statements and Supplementary Data</font></a><font style="text-decoration:none;"> </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 9.</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><font style="text-decoration:underline;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a><font style="text-decoration:none;"> </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 9A.</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><font style="text-decoration:underline;">Controls and Procedures</font></a><font style="text-decoration:none;"> </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 9B.</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><font style="text-decoration:underline;">Other Information</font></a><font style="text-decoration:none;"> </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_III"><font style="text-decoration:underline;">PART III</font></a></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 10.</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><font style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</font></a><font style="text-decoration:none;"> </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 11.</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><font style="text-decoration:underline;">Executive Compensation</font></a><font style="text-decoration:none;"> </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 12.</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><font style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a><font style="text-decoration:none;"> </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 13.</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><font style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</font></a><font style="text-decoration:none;"> </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
</tr>
<tr>
<td valign="top"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 14.</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTANT_FEES_SERVIC"><font style="text-decoration:underline;">Principal Accountant Fees and Services</font></a><font style="text-decoration:none;"> </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IV"><font style="text-decoration:underline;">PART IV</font></a></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 15.</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENTS_SC"><font style="text-decoration:underline;">Exhibits and Financial Statement Schedules</font></a><font style="text-decoration:none;"> </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.7pt;;text-indent:-6.7pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 16.</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:83%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><font style="text-decoration:underline;">Form 10-K Summary</font></a><font style="text-decoration:none;"> </font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="line-height:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SPECIAL_NOTE_REGARDING_FORWARDLOOKING_ST"></a><a name="SPECIAL_NOTE_REGARDING_FORWARDLOOKING_ST"></a>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of this Annual Report on Form 10-K. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;positioned,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative or plural of those terms, and similar expressions.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forward-looking statements include, but are not limited to, statements about:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">statements regarding the impact of the COVID-19 pandemic and its effects on our operations, access to capital, research and development and clinical trials and potential disruption in the operations and business of third-party manufacturers, contract research organizations, or CROs, other service providers, and collaborators with whom we conduct business;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability to identify additional novel compounds with significant commercial potential to acquire or in-license;&#160;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability to successfully acquire or in-license additional drug candidates on reasonable terms; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability to obtain regulatory approval of our current and future drug candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our expectations regarding the potential market size and the rate and degree of market acceptance of such drug candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability to fund our working capital requirements; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the implementation of our business model and strategic plans for our business and drug candidates; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>developments or disputes concerning our intellectual property or other proprietary rights; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability to maintain and establish collaborations or obtain additional funding; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our expectations regarding government and third-party payor coverage and reimbursement; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability to compete in the markets we serve; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the impact of government laws and regulations; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>developments relating to our competitors and our industry; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the factors that may impact our financial results. </p></td></tr></table></div>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Factors that may cause actual results to differ materially from current expectations include, among other things, those set forth in Part I, Item&#160;1A, &#8220;Risk Factors,&#8221; herein and for the reasons described elsewhere in this Annual Report on Form 10-K. Any forward-looking statement in this Annual Report on Form 10-K reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Given these uncertainties, you should not rely on these forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our business and the markets for certain drugs and consumer products, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources and we have not independently verified the data from third party sources. In some cases, we do not expressly refer to the sources from which these data are derived.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In this Annual Report on Form 10-K, unless otherwise stated or as the context otherwise requires, references to &#8220;Ovid,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar references refer to Ovid Therapeutics Inc. and its wholly owned subsidiaries. This Annual Report on Form 10-K also contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to, including logos, artwork and other visual displays, may appear without the &#174; or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applicable law, their rights thereto. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;"><font style="text-decoration:underline;">Summary of Selected Risks Associated with Our Business</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business is subject to numerous risks and uncertainties, including those discussed at length in the section titled &#8220;Risk Factors.&#8221; These risks include, among others, the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;">We have incurred significant operating losses since inception and expect to continue to incur substantial operating losses for the foreseeable future.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;">We have never generated any revenue from drug sales. Our operating history may make it difficult to evaluate the success of our business to date and to assess our future viability.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;">We will require additional capital to finance our operations, which may not be available on acceptable terms, if at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our drug development efforts or other operations.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;">Our future success is dependent on the successful clinical development, regulatory approval and commercialization of our current and future drug candidates. If we, or our licensees, are not able to obtain required regulatory approvals, we will not be able to commercialize our drug candidates, and our ability to generate revenue will be adversely affected.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;">Because the results of preclinical studies or earlier clinical trials are not necessarily predictive of future results, our drug candidates may not have favorable results in planned or future preclinical studies or clinical trials, or may not receive regulatory approval.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;">Interim topline and preliminary results from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures, which could result in material changes in the final data.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;">We may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;">Angelman syndrome has no treatments approved by the U.S. Food and Drug Administration, and the primary clinical endpoint, CGI-I-AS, has not previously been used as a sole primary endpoint in a pivotal clinical trial.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;">If we are not successful in discovering, developing and commercializing additional drug candidates, our ability to expand our business and achieve our strategic objectives would be impaired.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;">Our drug candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;">Even if our current or future drug candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;">If we are unable to establish sales and marketing capabilities, or enter into agreements with third parties to market and sell our current or any future drug candidates, we may be unable to generate any revenue from drug sales.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;">We are heavily dependent on our relationship with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;) for the development and commercialization of OV935. Any disruption in our relationship with Takeda could lead to delays in, or the termination of, the development of OV935, which would materially harm our business.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;">We are dependent on our relationship with Angelini Pharma Rare Diseases AG (&#8220;Angelini&#8221;) for the development and commercialization of OV101 in the European Economic Area as well as Switzerland, the United Kingdom, Russia and Turkey. Any disruption in our relationship with Angelini could lead to delays in the development and achievement of regulatory approval in these countries, which would materially harm our business.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;">We may be required to make significant payments in connection with our licenses of OV101 from H. Lundbeck A/S and OV935 from Takeda.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;">Our relationships with customers, physicians, and third-party payors may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;">Coverage and adequate reimbursement may not be available for our current or any future drug candidates, which could make it difficult for us to sell profitably, if approved.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;">If we are unable to obtain and maintain patent protection for our current or any future drug candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;">We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;">We do not have our own manufacturing capabilities and will rely on third parties to produce clinical and commercial supplies of our current and any future drug candidates.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;">We intend to rely on third parties to conduct, supervise and monitor our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:9pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:9pt;">COVID-19 could adversely impact our business, including our clinical trials and access to capital.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;">We may need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:9pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:9pt;">We may be subject to numerous and varying privacy and security laws, and our failure to comply could result in penalties and reputational damage.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_I"></a><a name="PART_I"></a>PART I</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_BUSINESS"></a><a name="ITEM_1_BUSINESS"></a>Item&#160;1. BUSINESS</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="text-align:justify;margin-top:4pt;margin-bottom:0pt;text-indent:5.55%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a biopharmaceutical company focused on developing impactful medicines for patients and families living with rare neurological disorders. We believe these disorders represent an attractive area for drug development as the understanding of the underlying biology has grown meaningfully over the last few years and today represent a substantial opportunity medically and commercially. Based on the rapid increase in scientific understanding of the role of genetics and key biological pathways relevant to diseases of the brain, we aim to identify, discover and develop novel compounds for the treatment of rare neurological disorders. We have built a deep knowledge of such diseases, how to treat them and how to develop the clinically meaningful endpoints required for development of a compound in these disorders. As a result of this knowledge, we have developed a pipeline of first-in-class compounds and programs and have demonstrated our model by progressing compounds through to late-stage development. We continue to execute on our strategy to build this pipeline by discovering, in-licensing and collaborating with leading biopharmaceutical companies and academic institutions.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Focus: Rare Neurological Disorders</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rare neurological disorders are among the most devastating in their impact on patients and their families. Patients suffering from these disorders typically require full-time care, and yet are among the most underserved. We believe that there are at least 100 neurodevelopmental disorders, epileptic encephalopathies and other related rare neurological disorders that we may be able to target. These disorders are characterized by impairments in the growth, development and functioning of the brain. Due to a historical overwhelming preference in the drug industry to develop drugs for broader neurological indications, many of these disorders have no approved therapies. As a result, recent scientific advancements have been overlooked, which we believe presents us with an opportunity to pursue these indications. These reasons include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;">High penetrance linking genetic defect to disorder pathology.</font> Some rare neurological disorders have a genetic origin and typically have a strong correlation, or penetrance, between the presence of a gene and the manifestation of the corresponding disease pathology. As a result, we believe in those cases we can develop drug candidates that will be efficacious in patients with a given genetic profile.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;">Predictive genetic and other models.</font> Recent advances in genetics enable us to employ predictive <font style="font-style:italic;">in vitro</font> and<font style="font-style:italic;"> in vivo</font> genetic models of certain of these disorders. These models allow us to evaluate and observe a drug candidate&#8217;s potential activity prior to initiation of clinical trials. Through these models, we believe we will be able to select the most relevant clinical endpoints for our trials and increase the potential for clinical success.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;">Overlapping pathophysiology and symptoms.</font> Neurological disorders are often characterized by a number of overlapping symptoms, such as seizures, sleep disturbances, movement deficiencies and behavioral manifestations. We believe these commonalities will enable us to employ clinical endpoints that may be translatable from one disorder to another, and to develop drugs that may provide a clinical benefit across multiple indications.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;">Early observation of proof-of-concept.</font> By employing clinical endpoints that are highly relevant and are designed to detect meaningful clinical benefits, we anticipate that many of our studies may provide early proof-of-concept in clinical development.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;">Potential ability to affect disease progression.&#160;&#160;&#160;</font>We are focusing on disorders that are typically diagnosed in early childhood when the brain is still developing. We believe that we may be able to meaningfully address symptoms and potentially alter the progression of disease, especially if the drug can be administered early in life.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;">Motivated and accessible patient populations.&#160;&#160;&#160;</font>We are targeting our programs for disorders with motivated and accessible patient populations. We believe that the patients and caregivers affected by these disorders are avid users of social media, in order to learn about and share relevant information and experiences. We use digital platforms to efficiently identify new patients for our clinical trials, raise disease awareness and help connect the patient and caregiver communities.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The Ovid Strategy</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our strategy is to pursue drug discovery and development for rare neurological disorders in a manner that is scientifically driven, patient focused and is coupled with an integrated and discipled approach to research, clinical development and business development. As we build on our understanding of these rare neurological conditions, we gain an appreciation of the way the different molecular mechanisms and pathways underlying these disorders help drive the symptoms patients suffer. This, in turn, benefits us with the knowledge gained about genetics, relevant molecular pathways, physiological impact and clinical endpoints from one disorder to another, which we believe will enable us to build a scalable scientific platform and efficient development capabilities. Ovid has set out to be a leader in this field, and by keeping our focus on neurology, it is our belief that this offers us the potential to produce multiple medicines in the future, and thereby succeed in our mission.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Scientifically Driven</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We take a scientifically driven approach to identify promising drug candidates for our pipeline. We are building our portfolio based on the existence of clear biological rationales, including a focus on disorders that&#160;have, where possible, a direct genetic linkage. We use our deep understanding of the area to identify mechanisms of action, appropriate targets and initial drug candidates. As we advance our drug candidates into and through the clinical evaluation, we are building on the emerging body of scientific and clinical insights developed by us and others in the biopharmaceutical industry to target these important disease pathways of the brain. As we evaluate data from previous and ongoing preclinical studies and clinical trials, we intend to refine and improve our scientific approach and apply these insights to continue to build our pipeline and conduct our clinical trials.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In particular, our approach is driven by the following scientific principles:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>identify the genetic origin of the disorder;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>develop understanding of gene expression and link to pathophysiology;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>target biological pathways or genes for which proof-of-concept has been established via<font style="font-style:italic;"> in vitro</font> or animal models;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>focus on the pathways and mechanisms that cause the pathology of the disorder and that generate the symptoms that we can target;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>target optimal mechanism of action for drug candidates; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>utilize biomarkers if present that can provide evidence of the activity of our drug candidates.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patient Focused</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are focused on the patient communities affected by the rare neurological disorders we address. We believe this aspect of our approach is critical. Each of these disorders affect small populations of patients, but carry serious morbidities and require extensive and specialized involvement from the patients&#8217; families, caregivers, physicians and patient advocacy groups.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our strategy is enhanced by the following patient-focused principles:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>develop close relationships with patients, caregivers, families, disease foundations and key opinion leaders, to better understand the history of these disorders, raise awareness, identify patients and facilitate enrollment of clinical trials;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>identify clinically meaningful endpoints based on input from patients and their physicians and caregivers; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>develop digital capabilities to engage, foster and maintain close relationships with patient communities.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Coupled with Business Development</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:2.27%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have built a broad pipeline of potential drug candidates to treat rare neurological disorders.&nbsp;&nbsp; Initially we in-licensed or partnered drug candidates. More recently our pipeline has been built through our internal research and development efforts in collaboration with external leaders in the field. The intended result is to develop a diversified pipeline to mitigate development risk and provide for scientific and medical opportunity.<font style="color:#FF0000;"> </font><font style="color:#000000;">Central to the success of this process is coupling a highly focused and disciplined effort to link our research effort in key laboratories around the world aimed at discovering and securing relevant assets in selected rare neurological disorders.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:2.27%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, we have built a specialized, scalable and robust infrastructure that we believe will make us a leader in rare neurological disorders and the partner of choice for leading biopharmaceutical companies or academic institutions that wish to maximize the value of their neurology drug candidates or research platforms in these areas. This infrastructure spans across critical domains which include but are not exclusive of target discovery, drug delivery and clinical development. If and when our drug candidates are approved, we also plan to establish over time a focused commercial and distribution network dedicated to rare neurological disorders in the United States and Europe, where we believe the patient populations and medical specialists are sufficiently concentrated to effectively market our drug candidates. We believe that we are particularly well positioned to execute on our business development strategy because of both the extensive network of our Chairman and Chief Executive Officer Dr. Jeremy Levin and other members of our management team, as well as our demonstrated success in collaboration with partners including Takeda.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:2.27%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Pipeline</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our efforts have already brought two drug candidates from proof of concept and either through pivotal trials or to the initiation of pivotal trials. The following table sets forth the status and mechanism of action of our drug candidates:</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g30vudsvo52a000001.jpg" title="" alt="" style="width:660px;height:318px;"></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">OV935 (soticlestat) </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:11pt;text-indent:5.55%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OV935 is being developed in a joint collaboration with Takeda for the treatment of rare epileptic encephalopathies. In January 2017, we entered into a license and collaboration agreement with Takeda, or the Takeda collaboration agreement, to develop and commercialize OV935 (soticlestat or TAK-935). Under the Takeda collaboration agreement, all costs and all profits are shared on a worldwide basis and Ovid leads development and in addition is responsible for commercialization in North America, Europe and Israel. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:11pt;text-indent:5.55%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we entered into a royalty, license and termination agreement, or the Takeda License and Termination Agreement, with Takeda under which Takeda will secure global rights at closing from us to develop and commercialize the investigational medicine OV935 for the treatment of developmental and epileptic encephalopathies, including DS and LGS. Closing of the Takeda License and Termination Agreement is subject to the satisfaction of customary closing conditions. See &#8220;Business&#8212;License and Collaboration Agreements&#8212;Agreements with Takeda&#8212;2021 Royalty, License and Termination Agreement with Takeda&#8221; for a discussion of the terms of the Takeda License and Termination Agreement.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;margin-left:0.2%;text-indent:4.07%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OV935 is a potent, highly selective inhibitor of the enzyme cholesterol 24-hydroxylase, or CH24H. We believe, if approved, OV935 has the potential to become a first-in-class <font style="color:#000000;">and only-in-class compound targeting the metabolism of cholesterol in the brain. We believe that OV935 inhibits a key enzyme in cholesterol metabolism pathway in the brain and may modulate the excitatory signals involved in epilepsy, which may suppress seizures</font>. CH24H is predominantly expressed in the brain, where it plays a central role in cholesterol homeostasis and neuronal physiology. Recent literature suggests that in addition to its impact on membrane cholesterol homeostasis in the central nervous system, modulation of CH24H may have an impact on over-activation of neurotransmitter pathways that have been implicated in a number of neurological disorders, such as epilepsy. <font style="Background-color:#FFFFFF;color:#1C1C1C;">Preclinical data suggest that inhibition of brain CH24H indirectly reduces glutamatergic signaling via NMDA receptors and modulates glial function and inflammation, which may impact disease pathology and epileptogenesis. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:11pt;text-indent:5.55%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that because OV935 is an inhibitor of CH24H it may modulate the excitatory signals involved in epilepsy, which may suppress seizures. In addition to these effects on seizures and excitability of the brain, we believe that OV935 may reduce inflammation in and neurotoxic damage to the brain, which may lead to long-term, disease modifying effect. As a result, OV935 is being developed in rare and difficult to treat epilepsies with the goal to develop OV935 not just as a potential medicine to treat the seizures but also one that may have long-term disease-modifying potential. We believe that OV935 if successful in these areas may have utility in other areas as well. OV935 is initially being studied in those suffering from severe and often intractable forms of DEE, including Dravet syndrome, or DS, Lennox-Gastaut syndrome, or LGS, CDKL5 Deficiency Disorder, or CDD, and Duplication 15q, or Dup15q syndrome. There are limited or no therapeutic options in each of these disorders. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:11pt;text-indent:5.55%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have completed multiple trials on OV935 and expect to initiate pivotal phase 3 trials in second quarter of 2021.&nbsp;&nbsp;Previously w</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e completed a Phase 1b/2a clinical trial of OV935 in a mixed group of adults with DEE and announced the results in December 2018. The trial achieved its primary endpoint of safety and tolerability, dose proportional reduction in a potential plasma biomarker called 24HC, and a robust reduction in seizure frequency (61% at day 92), with two patients becoming seizure-free at the end of the treatment period. Following this trial and as further discussed below, we reported the initial data from the Phase 2 open-label extension study</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (which we refer to as the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ENDYMION</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> trial)</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of OV935 in six patients who previously completed our 12-week Phase 1b/2a clinical trial of OV935 in adults with DEE.</font></p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;margin-left:0.2%;text-indent:4.07%;color:#1C1C1C;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">On August 25, 2020, we, together with Takeda, announced positive topline results from the ELEKTRA trial which was a phase 2 trial in DS and LGS, along with updated findings from the ENDYMION trial. </font><font style="Background-color:#FFFFFF;color:#000000;">Based on the trial results of ELEKTRA and after presentation of the data and review of the phase 3 pivotal trial approach with regulatory authorities in the US (</font><font style="color:#000000;">FDA), EU (CHMP), and Japan (PMDA)</font><font style="Background-color:#FFFFFF;color:#000000;">, we expect to initiate two separate multinational Phase 3 pivotal registrational trials in Dravet syndrome and LGS with OV935 in the second quarter of 2021.</font></p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;margin-left:0.2%;text-indent:4.07%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has granted orphan drug designation for OV935 for the treatment of Dravet syndrome and <font style="Background-color:#FFFFFF;color:#1C1C1C;">LGS</font>.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dravet Syndrome</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dravet syndrome is a severe form of childhood epilepsy largely genetically driven by the mutation of the<font style="font-style:italic;"> SCN1A</font> gene that typically presents during the first year of life. Eighty percent of patients have a mutation of the<font style="font-style:italic;"> SCN1A-</font>gene. Children experience frequent seizures, loss of muscle control, cognitive deficits and, in approximately 10% of cases, death before the age of 12 years. Children continue to suffer from seizures and severe cognitive and developmental impairment throughout their lifetime. While some patients may survive into adulthood, their long-term intellectual development and seizure outcomes are typically extremely poor. The incidence of Dravet syndrome in the United States ranges from 1 in 15,700 to 1 in 20,900 births. </p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lennox-Gastaut Syndrome</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lennox<font style="font-weight:bold;">-</font>Gastaut syndrome is a rare disorder that is often diagnosed between three and five years of age. Patients diagnosed with Lennox<font style="font-weight:bold;">-</font>Gastaut syndrome experience a multitude of seizure types that are difficult to manage and have many of the same symptomologies as other rare pediatric epilepsies. <font style="color:#000000;">Lennox</font><font style="font-weight:bold;color:#000000;">-</font><font style="color:#000000;">Gastaut syndrome affects over 30,000 people in the United States with approximately half being children under the age of 18.&nbsp;&nbsp;</font>Some patients have de novo genetic mutations, including a mutation of the<font style="font-style:italic;"> SCN2A</font> gene. The annual incidence of Lennox<font style="font-weight:bold;">-</font>Gastaut syndrome in childhood is estimated to be two per 100,000 children. It is also estimated that between 1% and 4% of childhood epilepsies are a result of Lennox<font style="font-weight:bold;">-</font>Gastaut syndrome.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CDKL5 Deficiency Disorder</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients with cyclin-dependent kinase-like 5 (CDKL5) mutations present with early epilepsy.<font style="color:#0000FF;"> </font>In particular, early drug-resistant epilepsy, usually starting in the first months of life, tends to be the most common feature. Complex partial seizures, infantile spasms, myoclonic, generalized tonic-clonic, and tonic seizures have all been reported. Stereotypic hand movements, severe hypotonia, and impaired psychomotor development are usually associated with CDKL5 mutations and common to the general clinical manifestations. </p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dup15q syndrome</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Duplications of the proximal arm of chromosome 15q11.2-q13.1 result in the genetic condition Dup15q syndrome. Multiple genes including UBE3A from this region are implicated in the pathogenesis of autism spectrum disorders, epilepsy, and schizophrenia.<font style="color:#0000FF;"> </font>Increased expression of the UBE3A gene contributes to epilepsy in Dup15q syndrome and it is thought to be the underlying cause of the autistic features of the syndrome as well. The most devastating feature of Dup15q syndrome is difficult to control seizures.<font style="color:#0000FF;"> </font>The most common seizure types are infantile spasm and generalized tonic&#8211;clonic seizures followed by atonic, myoclonic, focal-onset, and tonic seizures.<font style="color:#0000FF;"> </font>Poorly controlled seizures severely impact the quality of life of both affected individuals and their caregivers. Current treatment options for Dup15q syndrome-associated epilepsy are often ineffective. GABAergic promoting antiepileptics are typically ineffective while broad-spectrum antiepileptic medications such as valproic acid and rufinamide provide some relief.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">OV935 Clinical Data</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Phase 1 Trials</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OV935 has been tested in 86 healthy volunteers across four Phase 1 trials. Single oral doses of up to 1,350mg of OV935 were well-tolerated. The most frequently reported adverse events were headache, ECG electrode application site dermatitis and nausea. All reported events were mild with no apparent dose-response. In a 14-day repeat dosing trial, doses of 100mg QD, 300mg QD and 400mg QD were well-tolerated. One volunteer at the 300mg BID experienced an event of confusional state and another volunteer at the 600mg QD dose experienced acute psychosis. Both volunteers discontinued the trial at day 11. One volunteer receiving placebo reported events of nightmares, spatial disorientation, insomnia and dizziness. All AEs resolved with continued dosing through day 15. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SAEs</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> were reported. Overall, no safety issues of concern were identified in the Phase&#160;1 trials based on assessments of physical examinations, vital sign measurements, clinical laboratory values or 12-lead electrocardiogram findings.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes each Phase 1 trial:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:1pt;">
<td valign="bottom"  style="width:5.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Trial</p></td>
<td valign="bottom"  style="width:2.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:29.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Purpose</p></td>
<td valign="bottom"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:30.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Design</p></td>
<td valign="bottom"  style="width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:10.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Volunteers</p></td>
<td valign="bottom"  style="width:2.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:17.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dosage</p></td>
</tr>
<tr style="height:30.95pt;">
<td valign="top"  style="width:5.02%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  style="width:2.24%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:29.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Safety and tolerability</p></td>
<td valign="bottom"  style="width:2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:30.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 1, randomized, double-blind, placebo-controlled, single ascending dose trial</p></td>
<td valign="bottom"  style="width:2.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:10.04%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
<td valign="bottom"  style="width:2.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:17.06%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15-1,350mg, oral</p></td>
</tr>
<tr style="height:1pt;">
<td valign="top"  style="width:5.02%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.24%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:29.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.04%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:17.06%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:30.95pt;">
<td valign="top"  style="width:5.02%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  style="width:2.24%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:29.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Safety and tolerability</p></td>
<td valign="bottom"  style="width:2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:30.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose trial</p></td>
<td valign="bottom"  style="width:2.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:10.04%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td valign="bottom"  style="width:2.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:17.06%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100-600mg&#160;QD, and&#160;300mg&#160;BID, 14&#160;days, oral</p></td>
</tr>
<tr style="height:1pt;">
<td valign="top"  style="width:5.02%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.24%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:29.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.04%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:17.06%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:20.65pt;">
<td valign="top"  style="width:5.02%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  style="width:2.24%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:29.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brain CH24H enzyme occupancy using positron emission tomography, or PET</p></td>
<td valign="bottom"  style="width:2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:30.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Open-label, non-randomized</p></td>
<td valign="bottom"  style="width:2.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:10.04%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="bottom"  style="width:2.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:17.06%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50-600mg, oral</p></td>
</tr>
<tr style="height:1pt;">
<td valign="top"  style="width:5.02%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.24%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:29.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:10.04%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:2.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:17.06%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:20.65pt;">
<td valign="top"  style="width:5.02%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  style="width:2.24%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:29.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Relative bioavailability of tablet versus solution formulation; effect of food</p></td>
<td valign="bottom"  style="width:2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:30.1%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 1, randomized, open-label, single dose trial</p></td>
<td valign="bottom"  style="width:2.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:10.04%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom"  style="width:2.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:17.06%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300mg&#160;(tablet),&#160;oral; 300mg&#160;(solution),&#160;oral</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Phase 1b/2a Trial - 2001</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Phase 1b/2a trial of OV935 achieved its primary endpoint of safety and tolerability and showed OV935 was generally well tolerated.&nbsp;&nbsp;</font><font style="Background-color:#FFFFFF;color:#1C1C1C;">The trial was designed to have two parts. Part 1 was a randomized, double-blind, placebo-controlled (OV935 vs. placebo with a ratio of 4:1), 30-day phase that included a titration period (20 days: 100 mg, 200 mg twice daily), and treatment period (10 days). </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OV935 achieved the primary endpoint of safety and tolerability as measured by incidence of AEs. AEs in patients treated with OV935 were similar to those who received placebo in Part 1. The majority of AEs in both treatment arms were mild. Overall, the data are consistent with a favorable safety and tolerability profile and support the continued clinical development of OV935.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AEs that occurred more frequently in the OV935-treatment group versus the placebo group were: dysarthria, insomnia, lethargy, seizure cluster, and upper respiratory infection. <font style="color:#000000;">Four patients discontinued due to an AE or an SAE in the OV935 treatment arm</font>. Of these, in Part 1, one patient discontinued due to difficulty with walking and worsening lethargy and a second discontinued due to weakness. In Part 2, one patient discontinued due to a single episode of seizure cluster and a second experienced multiple seizure clusters.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An increase in seizure frequency was seen in three patients, all of whom were on perampanel. This suggests the potential for a drug-drug interaction between medicines acting on different glutamatergic receptors. Accordingly, changes in seizure frequency data for the Phase 1b/2a trial are now reported with the inclusion and exclusion of the three patients on perampanel, respectively. </p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.5%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">ENDYMION</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#1C1C1C;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">ENDYMION is a Phase 2 prospective, multi-center, open-label extension study of OV935 in patients with DEE who have participated in a previous OV935 clinical study. The primary objective is to assess the long-term safety and tolerability of OV935 over four years of treatment in patients with rare epilepsies. A secondary endpoint evaluates the effect of OV935 on seizure frequency over time.&#160;</font>ENDYMION enrolled eligible patients from the ELEKTRA and ARCADE trials, each discussed below.&nbsp;&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#1C1C1C;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, we announced initial data from the first six patients in ENDYMION who were previously enrolled in the Phase 1b/2a clinical trial of OV935 in adults with DEE and subsequently ceased taking OV935 for a period of between 6 weeks and 12 months. Therefore, in most cases the seizure frequency increased from the end of the adult DEE trial until they were enrolled in ENDYMION. As shown in Table 1, longer-term data from ENDYMION out to 48 weeks suggest increased seizure reduction with prolonged treatment of OV935 and is consistent with the believed mechanism of action of OV935. Median seizure frequency reductions were 84% following 25 to 36 weeks (n=6) and 90% following 37 to 48 weeks (n=4) of treatment.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table 1: % Reduction from Baseline in Seizure Frequency</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:54.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:10.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:10.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:10.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="width:10.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.18%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:10.9%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weeks 1-12</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.46%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:10.96%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weeks 13-24</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.76%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:10.34%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weeks 25-36</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.46%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:10.98%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weeks 37-48</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Overall median % reduction in seizure frequency from baseline</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:10.9%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48%<br />(n=6)</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:0.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:10.96%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65%<br />(n=6)</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:0.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:10.34%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84%<br />(n=6)</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:0.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="width:10.98%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90%<br />(n=4)*</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of Patients with&#160;&#179;50% reduction in seizure frequency from baseline</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:10.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:10.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:10.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:10.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75%</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:2pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the time of data analysis, two patients had not yet completed 48 weeks of dosing.</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.17%;color:#1C1C1C;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient baseline seizure frequency ranged from 2 to 71 (median=11.5). In general, a greater reduction in seizure frequency was observed in those with higher baseline seizure frequency. In terms of overall&#160;seizure-free&#160;interval during treatment, one patient experienced 264 consecutive days and one patient experienced 150 consecutive days without a seizure.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.17%;color:#1C1C1C;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the six patients from the Phase 1b/2a adult DEE trial included in this data analysis, all patients who have completed the ARCADE and ELEKTRA trials to date have enrolled in ENDYMION. Data from patients who have completed ARCADE, our Phase 2, multi-center, open-label, pilot study evaluating the treatment of OV935 in patients with epileptic seizures associated with CDD or Dup15q syndrome, are not included the above analysis due to their limited treatment duration in ENDYMION. Data from patients previously treated in ELEKTRA are not included in the above analysis due to the ELEKTRA trial being double-blinded and placebo-controlled at the time of the analysis.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.17%;color:#1C1C1C;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Overall, at 48 weeks, safety observations were consistent with the completed Phase 1b/2a clinical trial in adults with DEE. OV935 continues to show a favorable safety and tolerability profile. The majority of adverse events were mild and comparable with those from the Phase 1b/2a trial. Specifically, adverse events that occurred included upper abdominal pain, pyrexia, bronchial wall thickening and rales. There was one treatment-related adverse event of nausea. No serious adverse events were observed.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.17%;color:#1C1C1C;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed below, in August 2020 and September 2020, we announced updated findings from ENDYMION from patients who completed the ELEKTRA and ARCADE studies, respectively, and elected to enroll in ENDYMION.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.5%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">ELEKTRA</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:11pt;text-indent:5.55%;color:#1C1C1C;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">ELEKTRA was an international, multi-center, randomized, double-blind, placebo-controlled study designed to evaluate treatment with soticlestat in pediatric patients, aged 2 to 17 years, with highly refractory epileptic seizures associated with convulsive seizures (DS) or drop seizures (LGS). The study consisted of a four- to six-week screening period to establish baseline seizure frequency, followed by a 20-week double-blind treatment period, including an 8-week dose optimization period and a 12-week maintenance period. During the 8-week dose optimization period, patients were titrated from 100mg twice daily (BID), to 200mg BID to 300mg BID (mg/kg dosing for &lt;60 kg) of orally administered soticlestat.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:11pt;text-indent:5.55%;color:#1C1C1C;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">A total of 141 patients were enrolled in ELEKTRA and 126 completed the study. A modified intent-to-treat, or mITT, analysis of 139 patients was performed to evaluate the efficacy endpoints, which includes any patient who enrolled in the study and received at least one dose of study drug. Patients in the study were allowed to be on one to four concomitant anti-epileptic drugs, or AEDs, with the majority of patients concomitantly treated with at least three AEDs. The most common AEDs taken by the patients were valproate, clobazam, levetiracetam and topiramate. Further, all patients who completed ELEKTRA enrolled in the ENDYMION open-label extension study.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:11pt;text-indent:5.55%;color:#1C1C1C;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">On August 25, 2020, we, together with Takeda, announced positive topline results from ELEKTRA and updated findings from ENDYMION. The ELEKTRA study achieved its primary endpoint with high statistical significance, demonstrating a 27.8% median reduction from baseline in convulsive seizure (DS) and drop seizure (LGS) frequency compared to a 3.1% median increase in patients taking placebo during the 12-week maintenance period (median placebo-adjusted reduction=30.5%; p=0.0007, based on the efficacy analysis set of 120 patients with seizure data in the maintenance period). In addition, DS and LGS patients treated with soticlestat demonstrated a 29.8% median reduction in convulsive seizure (DS) and drop seizure (LGS) frequency compared to 0.0% change in median seizure frequency in patients taking placebo during the full 20-week treatment period (titration plus maintenance) of the ELEKTRA study (placebo-adjusted reduction=25.1%; p=0.0024). Soticlestat was generally well-tolerated in the ELEKTRA study and demonstrated a safety profile consistent with those of previous studies, with no new safety signals identified. All patients who completed the ELEKTRA study elected to enroll into the ENDYMION open-label extension study and findings from ENDYMION were also reported on August 25, 2020.&nbsp;&nbsp;The ENDYMION study data of rolled-over </font><font style="Background-color:#FFFFFF;color:#000000;">ELEKTRA patients support results in the ELEKTRA study. The ENDYMION data indicated maintenance of effect over 6 months in those patients originally randomized to soticlestat, and similarly reduced seizure frequency as compared to baseline in those patients previously assigned to the placebo arm. No new safety signals were identified in ENDYMION.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.5%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">ARCADE</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:11pt;text-indent:5.55%;color:#1C1C1C;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">ARCADE is a Phase 2 open-label, signal-finding pilot study designed to inform the potential for future development of soticlestat in CDD and Dup15q syndrome. The study enrolled 20 patients, ages 2 to 55 years, with refractory epileptic seizures associated with CDD (n=12) or Dup15q (n=8) and consisted of a four- to six-week screening period to establish baseline seizure frequency, followed by a 20-week treatment period, including an eight-week titration/dose optimization period and a 12-week maintenance period. Patients in the study were allowed to be on one to six concomitant AEDs, with the majority of patients </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:11pt;color:#1C1C1C;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">concomitantly treated with at least four AEDs, representing a highly refractory patient population. The primary objective of the ARCADE study was to determine percent change from baseline in motor seizure frequency during the 12-week maintenance period.&#160;&#160;Further, all patients who completed ARCADE enrolled in the ENDYMION open-label extension study.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:11pt;text-indent:5.55%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 30, 2020, we announced results from ARCADE and updated findings from ENDYMION. Together, data from the ARCADE and ENDYMION studies showed seizure frequency reduction over time. In CDD patients (n=12), median motor seizure frequency reduction was 24% during the 12-week maintenance period in the ARCADE study, increasing to a 50% reduction in the ENDYMION long-term extension study in the five CDD patients who reached nine months of continuous treatment. In Dup15q patients (n=8), there was an increase in median motor seizure frequency in the ARCADE study during the 12-week maintenance period; however, longer-term data from the four Dup15q patients who reached nine months of continuous treatment showed a 74% reduction in median motor seizure frequency. Soticlestat was generally well tolerated in both studies and continues to demonstrate a favorable safety profile. We believe the results are encouraging and next steps are being evaluated with Takeda.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">OV101 (gaboxadol)</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0.2%;text-indent:4.07%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have been developing OV101 for the treatment of Angelman syndrome and Fragile X syndrome, two neurodevelopmental disorders that are characterized by similar symptoms.&#160;In December 2020, we reported the primary endpoint of the Pivotal Phase 3 trial in pediatric individuals with Angelman syndrome (the NEPTUNE trial) was not achieved.&#160;Based on the results of the NEPTUNE trial, further development of OV101, other than the ongoing long-term extension study with Angelman syndrome patients who had previously been in a trial for OV101 (the ELARA trial), is currently on hold. The data from all trials is under review and further development of OV101, if any, will be the subject of full analysis of this data.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0.2%;text-indent:4.07%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Angelman syndrome and Fragile X syndrome have overlapping symptoms, including sleep disorder, aberrant behavior, anxiety and cognitive or intellectual disabilities thought to be&#160;caused&#160;by&#160;decreased tonic inhibition, an important mechanism whereby it is believed that the brain distinguishes signal from noise. Both of these disorders are typically diagnosable in early childhood and require full-time care for the patients affected. In September 2016, the FDA granted orphan drug designation for OV101 for the treatment of Angelman syndrome; in October 2017 the FDA granted orphan drug designation for OV101 for the treatment of Fragile X syndrome; in December 2017 the FDA granted fast track designation for the treatment of Angelman syndrome; and in March 2018, the FDA granted fast track designation for the treatment of Fragile X syndrome.&#160; In June 2019, the European Commission granted OV101 orphan drug designation for the treatment of Angelman syndrome based on the results of the STARS clinical trial.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">OV101 and Tonic Inhibition</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tonic inhibition is a critical physiological regulatory mechanism that allows a healthy human brain to decipher excitatory and inhibitory neurological signals correctly without being overloaded. Defects of this system are thought to play a role in multiple disease states, including Angelman syndrome, Fragile X syndrome and insomnia. Because of its unique mode of action, OV101 represents a promising compound targeting this mechanism.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decreased tonic inhibition results in an imbalance in the ratio of excitation to inhibition. If tonic inhibition is reduced, the brain becomes inundated with signals and loses the ability to separate background noise from critical information. This imbalance disrupts normal brain functioning, including sensory processing and integration. <font style="color:#000000;">Disruption of tonic inhibition can lead to a multiplicity of symptoms including, but not limited to, sleep abnormalities, motor deficiencies, behavioral manifestations, delayed development, intellectual disability and severe speech impairment</font>. By modulating tonic inhibition, OV101 may have the potential to alleviate important symptoms and provide a meaningful clinical benefit to patients across several disorders.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that OV101 modulates tonic inhibition. Disruption of tonic inhibition can lead to a multiplicity of symptoms including, but not limited to, sleep abnormalities, motor deficiencies, behavioral manifestations, delayed development, intellectual disability and severe speech impairment. We believe modulating tonic inhibition may have a meaningful clinical impact in patients with Angelman syndrome and Fragile X syndrome.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Angelman Syndrome</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Overview.<font style="font-style:normal;">&#160;&#160;&#160;Angelman syndrome is a rare genetic disorder that is typically diagnosed in the United States after one year of age when parents notice severe developmental delays or the child suffers seizures. Characteristic features of this disorder include delayed development, intellectual disability, severe speech impairment, problems with movement and balance, seizures, sleep disorders and anxiety. Individual patients with Angelman syndrome can have varied symptoms, including the inability to walk or control motor movement, which can limit their ability to handle daily functions such as feeding, dressing or bathing. These patients are also often hyperactive, leading to various behavioral problems. Angelman syndrome symptoms, such as poor sleeping patterns, can lead to serious consequences, including increased frequency of seizures and exacerbation of behavioral manifestations. Different patients with identical genetic defects can show different degrees of these symptoms. Most Angelman syndrome patients require full-time care and are unable to live independently, which can represent a substantial emotional and financial burden on their families. In addition, Angelman syndrome has been associated with poor parental sleep and high parental stress.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">According to the National Organization for Rare Disorders, the approximate prevalence of Angelman syndrome is between 1 in 12,000 and 1 in 20,000 people. There are currently no approved therapies in the United States or ex-US specifically for the treatment of Angelman syndrome. No standard of care exists for Angelman syndrome, and current therapeutic options are symptomatic, suggesting a high unmet clinical need. Given the likely high burden of Angelman syndrome, new treatments targeting the aetiology of the syndrome that result in even small improvements in features of the syndrome may be clinically meaningful for patients and their families.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fragile X Syndrome</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Overview.&#160;&#160;&#160;<font style="font-style:normal;">Fragile X syndrome is a genetic condition that results in intellectual disability, anxiety disorders, behavioral and learning challenges and various physical disabilities. Patients with Fragile X syndrome exhibit autism-like symptoms, including cognitive impairment, anxiety, mood swings, hyperactivity, attention deficit and heightened sensitivity to various stimuli, such as sound. The severity of an individual patient&#8217;s impairment can range from mild learning disabilities to more severe cognitive or intellectual disabilities. Fragile X syndrome is one of the most commonly inherited intellectual disability disorders. Children with Fragile X syndrome also often have unusual sleep patterns and may have difficulty with routine activities such as feeding and dressing. The challenges presented by Fragile X syndrome often extend beyond the patient and can lead to significant hardships on the emotional and financial health of their families.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fragile X syndrome is caused by mutations in the fragile X mental retardation gene, or<font style="font-style:italic;"> FMR1</font> gene.<font style="font-style:italic;"> FMR1</font> is a gene that leads to the synthesis of the fragile X mental retardation protein, FMRP, which is needed for normal brain development. The<font style="font-style:italic;"> FMR1</font> gene normally contains in its sequence between 5 and 44 copies of a short, repeated motif, or recurring pattern in DNA. In Fragile X syndrome, there are more than 200 copies of this motif in the<font style="font-style:italic;"> FMR1</font> gene, a genetic change that prevents the synthesis of FMRP. Patients with intermediate numbers of repeats are able to make some FMRP and have milder symptoms.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">According to the National Fragile X Foundation, Fragile X syndrome affects approximately 1 in 3,600 to 4,000 males and 1 in 4,000 to 6,000 females. The average age of diagnosis of Fragile X syndrome is approximately three years. Currently, there are no approved therapies for the treatment of Fragile X syndrome. The current standard of care for the psychiatric challenges of Fragile X syndrome is tailored to each patient and may include antipsychotics, antidepressants and drugs to treat attention deficit and sleep disorders. Special education and symptomatic treatments for anxiety and irritability are often employed to lessen the burden of illness. Fragile X syndrome patients also may experience seizures, which are treated with traditional anticonvulsants.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0.2%;text-indent:4.07%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have conducted a number of clinical trials with OV101. In 2017, we completed a successful Phase 1 clinical trial in adolescent patients with Angelman and Fragile X syndrome. In 2018, we completed a Phase 2 trial of OV101 in adults and adolescents with Angelman syndrome, which we refer to as the STARS clinical trial. The STARS clinical trial achieved its primary endpoint of safety and tolerability and showed statistically significant improvement in the once-daily OV101 dosing group on the pre-specified physician-rated Clinical Global Impressions-Improvement, or CGI-I, exploratory endpoint as well as improvements in relevant symptoms such as sleep, motor function and behavior.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the results of the NEPTUNE trial, further development of OV101, other than the ELARA trial, is currently on hold. The data is under review and further development, if any, will be the subject of full analysis of the data from this trial together with the data from ELARA.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Angelman Syndrome</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:2.5%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">STARS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<font style="color:#000000;"> July of 2018, we completed the Phase 2 STARS trial, </font>a 12-week, double blind, placebo-controlled study in adults and adolescents with Angelman syndrome that randomized 88 patients aged 13 to 49 years. The study achieved its primary endpoint of safety and tolerability with a similar incidence of adverse events, or AEs, across the OV101 and placebo treatment arms. The investigational medicine showed a favorable safety profile and was well tolerated in adults and adolescents with Angelman syndrome through the 12 weeks of treatment. The most common AEs reported in the trial were vomiting, somnolence, irritability, aggression, and pyrexia. Serious adverse events, or SAEs, of seizure were reported in two patients with a previous history of seizures: one patient </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the once-daily, QD, dose group experienced a seizure that was deemed unrelated to study drug; one patient experienced a seizure in the twice-daily, BID, dose group that was assessed as possibly related to study drug by the investigator.&nbsp;&nbsp;At the prespecified efficacy analysis at 12 weeks of treatment, OV101 QD and BID dose groups showed a statistically significant improvement compared to placebo in the CGI-I. CGI-I was ranked first in the prespecified hierarchy of the statistical analysis plan. Data from the full analysis indicate that OV101 positively impacts several relevant clinical features of Angelman syndrome (global functioning, sleep, motor disruption). We met with the FDA in November 2018 to discuss OV101 as part of our End of Phase 2 Meeting. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:2.5%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">NEPTUNE</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the End of Phase 2 Meeting, we initiated the NEPTUNE trial and enrolled our first pediatric patient in September 2019. NEPTUNE was a randomized, double-blind, placebo-controlled, Phase 3 study that enrolled and treated 97 pediatric patients diagnosed with Angelman syndrome, four to 12 years of age, and seven patients diagnosed with Angelman syndrome ages two to three years for safety and pharmacokinetic evaluation only. The study was designed to assess the effects of treatment with OV101 (oral, once-daily dosing) versus placebo over 12 weeks. The sole primary endpoint was change in overall score on the Clinical Global Impression-Improvement-Angelman syndrome, or CGI-I-AS, scale. Secondary endpoints included sleep, communication, motor function, socialization, daily living skills and behaviour domains.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary endpoint of the NEPTUNE study was not achieved. Patients given OV101 showed a 0.7-point improvement in CGI-I-AS over baseline while placebo also showed a 0.8-point improvement in CGI-I-AS (p=NS). Secondary endpoints continue to be evaluated, although initial results show no difference between OV101 and placebo.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OV101 was well-tolerated, with no significant safety issues observed. We plan to complete a full analysis of the results of the NEPTUNE study and discuss these results with the&#160;FDA to determine next steps, if any, for the program. We will continue to offer study drug to patients enrolled in the open-label extension trial, ELARA, pending further analysis of the NEPTUNE study. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:2.5%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ELARA</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.07%;">Based on the STARS clinical trial data, we also initiated ELARA, an open-label extension trial which enrolled its first patient in February 2019, and enrollment is ongoing. We expect to report data from the&#160;ELARA&#160;study in the first half of 2021.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the results of the NEPTUNE trial, further development of OV101, other than the ELARA trial, is currently on hold. The data is under review and further development, if any, will be the subject of full analysis of the data from this trial together with the data from ELARA.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fragile X Syndrome</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ROCKET</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, we completed a Phase 2 trial evaluating OV101 in adolescent and young male adults with Fragile X syndrome, which we refer to as the ROCKET clinical trial. The trial&#160;met&#160;its&#160;primary&#160;objective and&#160;OV101&#160;appeared to be well tolerated&#160;over 12 weeks&#160;of treatment&#160;with no serious adverse events reported&#160;across all three dose cohorts.&#160;OV101&#160;demonstrated&#160;a&#160;statistically significant&#160;effect&#160;on&#160;secondary&#160;behavioral endpoints&#160;in&#160;the three&#160;combined&#160;study groups&#160;as follows:&#160;26.2%&#160;mean&#160;improvement in the Aberrant Behavior Checklist for Fragile X (ABC-CFXS) total score from baseline to week 12 (p=0.002);&#160;and a&#160;21.6%&#160;mean&#160;improvement&#160;in the Anxiety, Depression and Mood&#160;Scale&#160;(ADAMS) total score&#160;from baseline to week 12&#160;(p=0.004).&#160;Statistically significant&#160;improvements were also&#160;observed&#160;across various ABC-FXS and ADAMS subscales.&#160;In addition,&#160;OV101&#160;demonstrated a&#160;statistically significant&#160;mean&#160;reduction&#160;of 0.4&#160;in&#160;the&#160;Clinical Global Impressions&#160;Scale-Severity (CGI-S)&#160;total score (p=0.002)&#160;from baseline to week 12.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">SKYROCKET</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also initiated the SKYROCKET study in the fourth quarter of 2018.&nbsp;&nbsp;SKYROCKET was a 12-week, non-drug study to assess the suitability of several behavioral scales in individuals with Fragile X syndrome. The trial was an observational study designed to provide additional data on the key endpoints that are being explored in the ROCKET trial as well as provide contextual data on the benefit offered by the standard of care. The&#160;participating&#160;clinicians&#160;and caregivers were aware that the trial was non-interventional. The mean changes from baseline to week 12 were evaluated in&#160;the&#160;ABC total and subscale scores, the ADAMS subscale scores,&#160;and&#160;the CGI-S&#160;subscale scores as well as&#160;the mean change in&#160;CGI-I&#160;score at week 12. Other exploratory scales were also assessed. High variability was seen among caregiver-administered assessments (ABC-c, ADAMS) compared to clinician-assessed scales (CGI-I, CGI-S). The caregiver-administered assessments&#160;showed&#160;a placebo response as seen with&#160;previous&#160;Fragile X syndrome&#160;trials. In these other trials,&#160;placebo response rates&#160;were&#160;highly variable. Therefore, the&#160;SKYROCKET trial data will help inform&#160;future&#160;study design,&#160;including&#160;potential&#160;endpoints and&#160;measures&#160;to mitigate placebo response.&#8239;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the results of the NEPTUNE trial, development of OV101 in Fragile X syndrome is under review to enable us to fully understand the ramifications if any, for any potential future trial in Fragile X syndrome.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Previous Clinical Development of OV10</font><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">1 in Insomnia</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We acquired worldwide rights to OV101 from H. Lundbeck A/S, or Lundbeck, in March 2015. Prior to the acquisition, Lundbeck filed an investigational new drug application, or IND, with the FDA for the treatment of insomnia. Pursuant to this IND, Lundbeck and Merck&#160;&amp; Co., Inc., or Merck, partnered to conduct several Phase 3 trials for primary insomnia between 2004 and 2007. Over the course of the development of OV101, over 4,000 adults were administered OV101, resulting in an OV101 exposure of approximately 950 patient years. These trials were primarily randomized, placebo-controlled short-term and long-term safety and efficacy clinical studies, using classic sleep parameters such as total sleep time, time to sleep onset, wakefulness after sleep onset, and number of nocturnal awakenings as clinical endpoints.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Phase 3 program consisted of three trials: two 3-month placebo-controlled trials conducted in the United States and one 2-week trial conducted in Europe and Canada, each evaluating OV101 against placebo and the active comparator, zolpidem (Ambien). The primary endpoints of the trials included total sleep time and time-to-sleep onset and the secondary endpoints included number of nocturnal awakenings, wakefulness after sleep onset and daytime function. In Phase 3 trials, which were conducted for durations of up to 12 months, OV101 was observed to have efficacy that was largely comparable to zolpidem (Ambien) on several sleep metrics. In the first 3-month trial, a dose of 15mg of OV101 met both of the primary endpoints as well as the secondary endpoints at week one and month three compared to placebo. In the second 3-month trial, the same dose met only total sleep time and number of awakenings at week one, but significance was lost after adjusting for multiplicity at month three. The 2-week trial met all primary endpoints and wakefulness after sleep onset, for 15mg of OV101 at weeks one and two. Additionally, subjects who were administered OV101 showed no evidence of withdrawal symptoms or rebound insomnia after discontinuation of short-term treatment, whereas transient rebound insomnia was observed in subjects receiving zolpidem. In addition, clear differences were observed between OV101 and zolpidem from a sleep architecture perspective. OV101 has shown consistent increases in slow wave sleep compared to zolpidem with no significant effect on stage 2 or REM sleep in healthy adult, elderly subjects. It is believed that slow wave sleep is important for encoding long-term, fact-based memories. Slow wave sleep has been associated with physical changes in neuronal connections.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Safety and Tolerability</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;letter-spacing:-0.2pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Overall, OV101 was observed to be well-tolerated in adult patients aged 18-64 years in the Phase 2 and Phase 3 insomnia trials at doses of 5mg to 15mg given as evening doses. Success in these previous trials does not ensure that our clinical trials in OV101 will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of OV101. The most common reported adverse events were headache, nausea, vomiting, somnolence and dizziness. In general, the adverse events appeared to be dose-related. The majority of the serious adverse events observed were considered to not be related to treatment with OV101. One SAE, fatigue, was considered by Lundbeck and Merck as probably related to OV101 treatment. Among the nine SAEs considered by Lundbeck and Merck to be possibly related to OV101 treatment, there were three cases of fainting and one case each of: radius fracture, abnormal QRS axis, transient ischemic attack, non-cardiac chest pain, unresponsive to stimuli and atrial fibrillation. Across trials there were no apparent clinical trends regarding SAEs with respect to frequency, distribution across system organ classes or preferred terms. Also, there were no apparent clinical differences versus placebo. In the Phase 3 trials at the 15mg dose, at least one SAE was observed in 1.3% of subjects at two weeks and 3 months and 3.0% of subjects at 12 months versus 0.0% to 1.0% on placebo over the same time frame.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consistent with the clinical development of other insomnia drugs, the FDA requested that Lundbeck and Merck conduct a series of preclinical and clinical abuse studies as part of their development program. In preclinical studies, OV101 demonstrated low abuse potential. In one clinical trial, the abuse potential of OV101 was investigated in doses up to 45mg in male and female subjects with a history of hypnotic/sedative abuse and other drug abuse. Safety results showed that OV101 administered at doses of 30mg and 45mg in women and 45mg in men was not tolerated in this population of drug abusers, contrary to previous experience with the same doses in healthy volunteers. This indicated that a history of drug abuse decreased tolerability to OV101 in these subjects. Adverse events that were associated with a dose-dependent lack of tolerability in this trial included psychiatric, nervous system, musculoskeletal and gastrointestinal disorders.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2007, following the completion of all clinical trials for OV101 in insomnia, Lundbeck and Merck discontinued the development program for insomnia, and announced that the overall clinical profile did not support further development of OV101 for insomnia.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Early-stage </font><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Research Programs</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk64617538"></a><a name="_Hlk64568859"></a>OV329 (GABA aminotransferase inhibitor) is a preclinical compound being developed by us<a name="_Hlk64617538"></a> for the treatment of seizures associated with Tuberous Sclerosis Complex and Infantile Spasms. OV329 functions by substantially reducing the activity of GABA aminotransferase (GABA-AT), a key enzyme responsible for the degradation of the brain&#8217;s major inhibitory neurotransmitter, GABA. OV329 leads to increased concentrations of GABA by inhibiting its metabolism<a name="_Hlk64568859"></a>. Given that epilepsy is characterized by excessive neuronal excitation, the increased levels of GABA may suppress this excitatory signaling and may reduce seizures. If successful, we anticipate OV329 could be used to treat seizures associated with Tuberous Sclerosis Complex and Infantile Spasms and we are currently assessing this approach in the pre-clinical setting.<font style="color:#000000;"> In December 2016, we entered into a license agreement with Northwestern University, or Northwestern, pursuant to which Northwestern granted us an exclusive, worldwide license to patent rights in certain inventions, or the Northwestern Patent Rights, which relate to a specific compound and related methods of use for such compound, along with certain Know-How related to the practice of the inventions claimed in the Northwestern Patents.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OV882 is a short hairpin RNA (shRNA-551) we are evaluating as a potential disease-modifying gene therapy for Angelman syndrome. The most common cause of Angelman syndrome is the loss of functional UBE3A protein due to a defect in the maternal copy of the UBE3A gene. Our aim is to develop a disease-modifying noncoding RNA vector that reduces expression of UBE3A-antisense and restores UBE3A expression via the paternal gene copy. We are in early stages of our research. This research program is being conducted in collaboration with the University of Connecticut School of Medicine</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#1C1C1C;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;"><font style="color:#000000;">In June 2020, we began a strategic research collaboration with Columbia University Irving Medical Center, or Columbia, to advance genetic based therapies for a range of rare neurological conditions, complementary of our pipeline. This collaboration provides us with the potential to expand our future drug development portfolio and impact individuals living with rare genetic neurological conditions by working closely with the Precision Medicine Resource in the Irving Institute at Columbia. Our first research program with Columbia is OV815 and focuses on the kinesin-family of proteins and KIF1A-associated neurological disorder (KAND), under this research and translational development alliance, Columbia will align its expertise in rare disease genetics and deep clinical understanding of rare neurological diseases with our discovery, translational, and clinical development expertise in neurodevelopmental disorders and rare epilepsies.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">License and Collaboration Agreements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Collaboration Agreement with Angelini Pharma</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:13pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;9, 2020, we entered into the Angelini License Agreement with Angelini, pursuant to which we granted to Angelini exclusive rights to develop and commercialize OV101, a selective agonist of the GABAA&#160;receptor, for the treatment of Angelman syndrome in the European Economic Area as well as Switzerland, the United Kingdom, Russia and Turkey, or the European Territory.&#160;&#160;The licenses granted to Angelini include sublicenses under the Lundbeck Agreement, as well as licenses under our patents and know-how covering OV101.&#160;&#160;Angelini will be responsible for conducting any clinical trials necessary to obtain regulatory approval for OV101 for Angelman syndrome in the European Territory, and we will be responsible for bearing a portion of the costs for such trials.&#160;&#160;We will also be responsible, at our expense, for the completion of certain ongoing clinical trials for OV101, to the extent applicable to obtaining regulatory approval for OV101 in the European Territory.&#160;&#160;Angelini has the exclusive right, at its election, to develop and commercialize OV101 for the treatment of Fragile X Syndrome in the European Territory.&#160;&#160;The parties may also mutually agree to pursue additional indications for OV101 in the European Territory, and in such case, Angelini would have the exclusive rights to commercialize in such additional indications. Angelini is required to use commercially reasonable efforts to conduct development activities for OV101, and following regulatory approval, to commercialize OV101 in each approved indication.</p>
<p style="text-align:justify;margin-bottom:13pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In conjunction with the entry into the Angelini License Agreement, the parties entered into a separate supply agreement, pursuant to which we will be responsible for supply of OV101 to Angelini for development and commercialization in the European Territory, through Angelini&#8217;s existing supply relationship with Lundbeck.&#160;&#160;The Angelini License Agreement also provides for a transfer, at Angelini&#8217;s expense, of the relevant manufacturing technology from us and Lundbeck to Angelini, in order to enable Angelini to assume responsibility for its own manufacture and supply of OV101 in the future.</p>
<p style="text-align:justify;margin-bottom:13pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Angelini License Agreement, Angelini made an upfront payment and a milestone payment related to the transfer of a specified amount of compound and related information to the Company of $25.0 million during the year ended December 31, 2020.&#160; Angelini will be required to make additional milestone payments to us upon the completion of the specified components of the technology transfer and achievement of specified regulatory milestones for OV101 in Angelman syndrome of up to $55.0&#160;million in the aggregate, as well as up to &#8364;162.5 million ($199.9 million) in sales milestone payments for achievement of specified levels of net sales in the European Territory.&#160;&#160;In addition, Angelini will be required to pay tiered royalties on net sales by Angelini, its affiliates or sublicensees at double-digit percentages above the teens, subject to certain reductions and offsets.&#160;&#160;Royalties will be payable on a product-by-product and country-by-country basis until the latest of the expiration of the licensed patents covering such product in such country, the expiration of market exclusivity for such product in such country, and fifteen years from first commercial sale of such product in such country.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Either party may terminate the Angelini License Agreement for an uncured material breach of the other party or in the case of insolvency.&#160;&#160;</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may terminate the Angelini License Agreement if Angelini challenges any of the licensed patents.&#160;&#160;Angelini may terminate the Angelini License Agreement for convenience </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">during</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> specified notice periods, which are determined based upon whether the product has been commercially launched in the European Territory.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">License Agreement with H. Lundbeck A/S</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2015, we entered into a license agreement with Lundbeck, which we subsequently amended in May 2019, or the Lundbeck agreement, pursuant to which we obtained from Lundbeck an exclusive (subject to certain reserved non-commercial rights), worldwide license to develop, manufacture, and commercialize OV101, also known as gaboxadol, for the treatment of human disease. Under the Lundbeck agreement, we are responsible for and will use commercially reasonable efforts to carry out all future development and commercialization of OV101. Initially, we will purchase OV101 compound from Lundbeck&#8217;s existing inventory at a specified price. Following the depletion of the existing inventory, we may purchase the compound from a third party or, if the parties agree, Lundbeck may continue to supply the compound to us. We are also obligated to make certain manufacturing-related payments to Lundbeck, including for its preparation of a drug master file for OV101. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:8.71%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:8.71%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Lundbeck agreement, we issued 489,756&#160;shares of our common stock to Lundbeck. We also agreed to pay to Lundbeck milestone payments up to an aggregate of $189.0&#160;million upon the achievement of certain global development, regulatory and sales milestone events. Pursuant to the Lundbeck agreement, the first milestone payment is $1.0 million, which is due upon the successful completion of the first Phase 3 trial for a product in which OV101 is an active ingredient.&#160; In addition, if we successfully develop and commercialize OV101, we will be obligated to pay to Lundbeck tiered royalties based on single-digit and low-double digit percentage of net sales of OV101, subject to certain reductions for generic product sales and for royalties paid for licenses to third party intellectual property. If Lundbeck manufactures OV101 compound for us after the expiration of the royalty term, we will pay to Lundbeck, in addition to the fully burdened cost of such manufacture, a low, single-digit manufacturing royalty on the net sales of OV101 manufactured by Lundbeck.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Lundbeck agreement will continue until the expiration of all relevant royalty terms and may be earlier terminated by either party for the other party&#8217;s uncured material breach or insolvency. In addition, we can terminate the Lundbeck agreement upon advance notice for convenience at any time prior to first regulatory approval of OV101. If the Lundbeck agreement is terminated by us for convenience or by Lundbeck for our breach or insolvency, the OV101 compound will revert to Lundbeck and we will grant Lundbeck an exclusive license to develop and commercialize OV101; such license will be royalty-bearing if we filed an application for regulatory approval prior to termination. If we terminate the Lundbeck agreement for Lundbeck&#8217;s breach or insolvency, our license will continue and our obligations to make royalty payments to Lundbeck and to share Asian Partner payments with Lundbeck will continue but we will not be obligated to make further milestone payments to Lundbeck or to purchase any additional quantities of OV101 compound from Lundbeck&#8217;s existing inventory.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Agreements with Takeda</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2017 License and Collaboration Agreement with Takeda</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2017, we entered into the <font style="color:#000000;">Takeda collaboration agreement </font>with Takeda. All activities of the collaboration regarding OV935 will be guided by the Takeda/Ovid &#8220;One Team&#8221; concept, an integrated and interdisciplinary team from both companies devoted to the successful advancement of OV935 across rare epilepsy syndromes. Pursuant to the Takeda collaboration agreement, we will take the lead in nonclinical and clinical development activities and commercialization of the compound OV935 and products containing this compound (as well as certain other similar compounds, including any prodrug where TAK-935 is the primary pharmacologically active metabolite) for the treatment of certain rare neurological diseases in the United States, Canada, the European Union and Israel. Takeda will take the lead in commercialization of OV935 in Japan and has the option to lead in Asia and the rest of the world, or the Takeda Territory. While we and Takeda have agreed to initially focus on certain rare neurological disorders, the scope of the collaboration may in the future include other mutually agreed upon rare neurological disorders.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Takeda collaboration agreement, Takeda granted to us an exclusive license in our territory under certain patents and other intellectual property controlled by Takeda to commercialize OV935 and products containing OV935 for the treatment of certain rare neurological disorders. Takeda also granted to us a worldwide, co-exclusive license to develop, manufacture and otherwise exploit (but not commercialize) OV935 and products containing OV935 for the treatment of certain rare neurological disorders.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Takeda collaboration agreement, we granted to Takeda an exclusive license in the Takeda Territory under certain patents and other intellectual property controlled by us to commercialize OV935 and products containing OV935 for the treatment of certain rare neurological disorders. We also granted to Takeda a worldwide, co-exclusive license to develop, manufacture and otherwise exploit (but not commercialize) OV935 and products containing OV935 for the treatment of certain rare neurological disorders and a co-exclusive license in certain countries to commercialize OV935 and products containing OV935 for the treatment of certain rare neurological disorders that are subsequently included in the collaboration.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and Takeda </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are collaborating</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the development of OV935. Pursuant to the terms of the Takeda </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaboration</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> agreement, each party is required to use commercially reasonable efforts to develop OV935 for the treatment of certain rare neurological disorders in accordance with a mutually agreed upon development plan. We are primarily responsible for activities related to the development of OV935, and as such Takeda will transition certain development activities to us. Takeda is initially responsible for regulatory activities in all countries (excluding Israel). We are initially responsible for regulatory activities in Israel, and, upon regulatory approval in the United States, Canada, and the European Union, we will assume responsibility for further regulatory activities in such jurisdictions.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and Takeda are collaborating in the commercialization of OV935. Pursuant to the terms of the Takeda collaboration agreement, each party is required to use commercially reasonable efforts to commercialize OV935 for the treatment of certain rare neurological disorders in its territory. We are responsible for commercialization of OV935 in the United States, Canada, the European Union and Israel, and Takeda is responsible for commercialization of OV935 in Japan and has the first right to elect to commercialize the products in the Takeda Territory. Additionally, Takeda has the right to jointly commercialize the products with us in the United States and/or the European Union for any additional mutually agreed upon rare neurological indication.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Takeda collaboration agreement, we and Takeda initially share equally all development and commercialization costs and expenses prior to launch of a product and all revenues and commercialization costs and expenses after launch. In the event that we and Takeda agree to expand the scope of the collaboration to include additional rare neurological disorders, either party may elect not to fund all or a portion of the development of such indication, in which case such party&#8217;s overall share of revenues and commercialization costs and expenses after launch of a product may be reduced under certain circumstances.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the period commencing on the effective date of the Takeda collaboration agreement, we and Takeda have both agreed that we will not, directly or indirectly, and will cause all of our respective affiliates, not to, alone or with others, commercialize any competing product in the field of rare neurological disorders. For these purposes, a competing product is any product or compound directed against CH24H as its primary, intended mode of action. If, during such period, we or any of our affiliates is acquired by a third party that is commercializing a competing product, then we must divest our interest or terminate the commercialization of the competing product or cause our affiliate to do so.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Takeda collaboration agreement will expire upon the cessation of commercialization of the products by both us and Takeda. Either party may terminate the Takeda collaboration agreement as a result of the other party&#8217;s uncured material breach or insolvency, for safety reasons, or, after completion of the first proof of mechanism clinical trial, for convenience. Takeda may terminate the Takeda collaboration agreement for our (or our sublicensee&#8217;s) challenge to the patents licensed under the Takeda collaboration agreement. If the agreement is terminated by Takeda for our material breach, bankruptcy or patent challenge or by us for convenience or safety reasons, our rights to the products will cease, we will transition all activities related to the products to Takeda, and we will grant Takeda an exclusive, royalty-bearing license under certain patents and other intellectual property controlled by us to commercialize OV935 and products containing OV935 for the treatment of certain rare neurological disorders. If the agreement is terminated by us for Takeda&#8217;s material breach or bankruptcy or by Takeda for convenience or safety reasons, Takeda&#8217;s rights to the products will cease, Takeda will transition all activities related to the products to us, and Takeda will grant us an exclusive, royalty-bearing license under certain patents and other intellectual property controlled by Takeda to commercialize OV935 and products containing OV935 for the treatment of certain rare neurological disorders.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Takeda collaboration agreement, in the event of an acquisition of us by certain types of acquirers prior to the final dosing of a patient in the first Phase 3 trial, Takeda would have the right to elect to take over all development and commercialization activities with respect to the products, so long as Takeda at such time has (or will have) sufficient commercial infrastructure to commercialize the products. Even if Takeda exercises such right to take over all development and commercialization activities with respect to the products, we and Takeda will continue to share equally all development and commercialization costs and expenses prior to launch of a product and all revenues and commercialization costs and expenses after launch, unless otherwise set forth in the agreement.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Takeda collaboration agreement and in consideration of certain license rights granted to us by Takeda, we issued 1,781,996 shares of our Series B-1 convertible preferred stock to Takeda. The shares of Series B-1 preferred stock held by Takeda automatically converted into 1,781,996 shares of our common stock in May 2017. Under the Takeda collaboration agreement, we are obligated to pay Takeda future payments if and when certain milestones are achieved. Upon the first patient enrollment in the first Phase 3 trial for the first of the initial disorders we and Takeda are focusing on, we are obligated to issue to Takeda the number of unregistered shares of our common stock equal to the lesser of (a) 8% of our outstanding capital stock on the issuance date or (b) $50.0&#160;million divided by the applicable share price, unless certain events occur. In the event such payment would cause Takeda to own over 19.99% of our outstanding capital stock or other events occur, such payment must be paid in cash. The remaining potential global commercial and regulatory milestone payments equal approximately $35.0&#160;million and can be satisfied in cash or unregistered shares of our common stock at our election.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:2.5%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2021 Royalty, License and Termination Agreement with Takeda</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 2, 2021, <font style="color:#000000;">we</font> entered into a royalty, license and termination agreement, or the <font style="color:#000000;">Takeda License and Termination Agreement</font>, with Takeda, relating to the Takeda collaboration agreement described above. Under the terms of the <font style="color:#000000;">Takeda License and Termination Agreement</font>, upon closing of the transaction, the Takeda collaboration agreement will be terminated by mutual agreement, and Takeda will secure rights to our 50% global share in OV935 (soticlestat), and an exclusive license under our relevant intellectual property rights, in exchange for an upfront payment, development and commercial milestone payments, and royalties.&#160;&#160;Takeda will </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assume all responsibility for, and costs of, both development and commercialization of </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">soticlestat</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> following closing. At closing, we will receive an upfront payment of $196.0 million and are eligible to receive up to an additional $660.0 million in development, regulatory and sales milestones.&#160;&#160;In addition, if </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">soticlestat</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> achieves regulatory approval, we will receive tiered royalties on net sales of </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">soticlestat</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> at percentages ranging from the low double-digits up to 20%, subject to standard reductions in certain circumstances.&#160;&#160;Royalties are payable on a country-by-country and product-by-product basis during the period beginning on the date of the first commercial sale of such product in such country and ending on the later to occur of the expiration of patent rights covering the product in such country and a specified anniversary of such first commercial sale. The </font><font style="color:#000000;">Takeda </font><font style="color:#000000;">collaboration agreement </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will remain in effect until Takeda&#8217;s cessation of commercialization of </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">soticlestat</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;&#160;</font><font style="color:#000000;">We expect to close the </font><font style="color:#000000;">Takeda License and Termination Agreement </font><font style="color:#000000;">in the </font><font style="color:#000000;">first half of</font><font style="color:#000000;"> 2021, subject to the satisfaction of customary closing conditions, including regulatory review by the appropriate regulatory agencies under the Hart-Scott-</font><font style="color:#000000;">Rodino</font><font style="color:#000000;"> </font><font style="color:#000000;">Antitrust Improvements Act of 1976, as amended.</font><font style="color:#000000;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The </font><font style="color:#000000;">Takeda License and Termination Agreement</font><font style="color:#000000;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may be terminated upon the mutual agreement of the parties, or by either Takeda or the Company, if the closing has not occurred on or before May 14, 2021.</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Northwestern License<font style="font-style:italic;"> </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2016, we entered into a license agreement with Northwestern, pursuant to which Northwestern granted us an exclusive, worldwide license to patent rights in certain inventions, or the Northwestern Patent Rights, which relate to a specific compound and related methods of use for such compound, along with certain Know-How related to the practice of the inventions claimed in the Northwestern Patents.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Northwestern agreement, we were granted exclusive rights to research, develop, manufacture and commercialize products utilizing the Northwestern Patent Rights for all uses. We have agreed that we will not use the Northwestern Patent Rights to develop any products for the treatment of cancer, but Northwestern may not grant rights in the technology to others for use in cancer. We also have an option, exercisable during the term of the agreement to an exclusive license under certain intellectual property rights covering novel compounds with the same or similar mechanism of action as the primary compound that is the subject of the license agreement.&nbsp;&nbsp;Northwestern has retained the right, on behalf of itself and other non-profit institutions, to use the Northwestern Patent Rights and practice the inventions claimed therein for educational and research purposes and to publish information about the inventions covered by the Northwestern Patent Rights.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entry into the Northwestern agreement, we paid an upfront non-creditable one-time license issuance fee of $75,000, and we are required to pay an annual license maintenance fee of $20,000, which will be creditable against any royalties payable to Northwestern following first commercial sale of licensed products under the agreement.&nbsp;&nbsp;We are responsible for all ongoing costs of filing, prosecuting and maintaining the Northwestern Patents, but we also have the right to control such activities using our own patent counsel.&nbsp;&nbsp;In consideration for the rights granted to us under the Northwestern agreement, we are required to pay to Northwestern up to an aggregate of $5.3 million upon the achievement of certain development and regulatory milestones for the first product covered by the Northwestern Patents, and, upon commercialization of any such products, will be required to pay to Northwestern a tiered royalty on net sales of such products by the Company, its affiliates or sublicensees, at percentages in the low to mid-single-digits, subject to standard reductions and offsets.&nbsp;&nbsp;Our royalty obligations continue on a product-by-product and country-by-country basis until the later of the expiration of the last-to-expire valid claim in a licensed patent covering the applicable product in such country and 10 years following the first commercial sale of such product in such country.&nbsp;&nbsp;If Ovid sublicenses a Northwestern Patent Right, it will be obligated to pay to Northwestern a specified percentage of sublicense revenue received by us, ranging from the high single digits to the low-teens.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Northwestern agreement requires that we use commercially reasonable efforts to develop and commercialize at least one product that is covered by the Northwestern Patent Rights.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated, the Northwestern agreement will remain in force until the expiration of our payment obligations thereunder.&nbsp;&nbsp;We have the right to terminate the agreement for any reason upon prior written notice or for an uncured material breach by Northwestern.&nbsp;&nbsp;Northwestern may terminate the agreement for our uncured material breach or insolvency. </p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sales and Marketing</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given our stage of development, we have not yet established a commercial organization or distribution capabilities, however, in November 2019 we hired a Chief Commercial Officer to begin planning to establish a commercial organization. We plan to build focused capabilities in the United States and European Union to commercialize our development programs focused on rare disorders of the brain. In other markets for which commercialization may be less capital efficient for us, we may selectively pursue strategic collaborations with third parties in order to maximize the commercial potential of our drug candidates.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing and Supply</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently outsource all manufacturing, and we intend to use our collaborators and contract manufacturers for the foreseeable future. However, certain members of our management have broad experience in manufacturing, which we believe may provide a competitive advantage.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Competition</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe Sage Therapeutics, Inc., Marinus Pharmaceuticals, Inc. and Zynerba Pharmaceuticals, Inc. are our most direct competitors with respect to OV101 in Angelman syndrome and Fragile X syndrome. <font style="color:#000000;">Biogen Inc. in collaboration with Ionis Pharmaceuticals, Inc., Roche Holding AG, PTC Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc. in collaboration with GeneTx Biotherapeutics LLC are working on genetic approaches to Angelman syndrome. </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe Zogenix, Inc., GW Pharmaceuticals plc, Sage Therapeutics, Inc., Marinus Pharmaceuticals, Inc., Zynerba Pharmaceuticals, Inc., Stoke Therapeutics, Inc. and PTC Therapeutics, Inc. are our most direct competitors with respect to OV935.<font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug development is highly competitive and subject to rapid and significant technological advancements. Our ability to compete will significantly depend upon our ability to complete necessary clinical trials and regulatory approval processes, and effectively market any drug that we may successfully develop. Our current and potential future competitors include pharmaceutical and biotechnology companies, academic institutions and government agencies. The primary competitive factors that will affect the commercial success of any drug candidate for which we may receive marketing approval include efficacy, safety and tolerability profile, dosing convenience, price, coverage and reimbursement. Many of our existing or potential competitors have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of drug candidates, as well as in obtaining regulatory approvals of those drug candidates in the United States and in foreign countries.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current and potential future competitors also have significantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources being concentrated among a small number of our competitors.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, our competitors may be more successful than us in obtaining regulatory approval for therapies and in achieving widespread market acceptance of their drugs. It is also possible that the development of a cure or more effective treatment method for the disorders we are targeting by a competitor could render our current or future drug candidates non-competitive or obsolete or reduce the demand for our drug candidates before we can recover our development and commercialization expenses.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our current and future drug candidates, novel discoveries, product development technologies and know-how, to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, filing or in-licensing U.S. and foreign patents and patent applications related to technology, inventions and improvements that are important to the development and implementation of our business. We also rely on trademarks, trade secrets, copyright protection, know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain our proprietary position. For example, the proprietary map of disease-relevant biological pathways underlying orphan disorders of the brain that we developed would not be appropriate for patent protection and, as a result, we rely on trade secrets to protect this aspect of our business.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we seek broad coverage under our existing patent applications, there is always a risk that an alteration to the product or process may provide sufficient basis for a competitor to avoid infringement claims. In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued and courts can reinterpret patent scope after issuance. Moreover, many jurisdictions including the United States permit third parties to challenge issued patents in administrative proceedings, which may result in further narrowing or even cancellation of patent claims. Moreover, we cannot provide any assurance that any patents will be issued from our pending or any future applications or that any potentially issued patents will adequately protect our intellectual property.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently own issued U.S. patents directed to treatment of Angelman syndrome and Fragile X syndrome with OV101 that expire in 2035, excluding any regulatory extensions. We also have exclusively licensed a portfolio of issued U.S. and international patents from Lundbeck directed to polymorphic forms of OV101 and their preparation, and these patents expire on dates ranging from 2025 to 2028. In addition, we have exclusively licensed from Lundbeck an issued U.S. patent that will expire in 2036 and a pending application directed to an OV101 manufacturing processes that, if issued, would have a statutory expiration in 2036. We have also filed, and own, multiple patent families directed to methods of treatment and formulations with OV101. Additional issued patents and pending applications are directed to methods of treating neurodegenerative diseases and developmental disorders. We are seeking or will seek patent protection for these inventions in numerous countries and regions including, among others, Europe, Australia, Canada, Mexico, Israel, Japan, China, and Korea.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We licensed from Takeda a portfolio of U.S. and international patents and applications directed to the OV935 composition of matter, and these patents and applications expire in 2032, excluding any regulatory extensions.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individual patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, utility patents issued for applications filed in the United States are granted a term of 20 years from the earliest effective filing date of a non-provisional patent application. In addition, in certain instances, a patent term can be extended to recapture a portion of the U.S. Patent and Trademark Office, or the USPTO, delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five years and the total patent term including the restoration period must not exceed 14 years following FDA approval. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date. The actual protection afforded by a patent may vary on a product-by-product basis, from country to country and can depend upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, we rely upon trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our employees and consultants and any potential commercial partners and collaborators and invention assignment agreements with our employees. We also have or intend to implement confidentiality agreements or invention assignment agreements with our selected consultants and any potential commercial partners. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners, collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, or our drugs or processes, obtain licenses or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future drugs may have an adverse impact on us. Since patent applications in the United States and certain other jurisdictions are maintained in secrecy for 18 months or potentially longer, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending patent applications. Moreover, we may have to participate in Interference, Derivation, Reexam, Post-Grant Review, Inter Partes Review, or Opposition proceedings brought by third parties or declared by the USPTO.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture, marketing and distribution of drugs, such as those we are developing. These agencies and other federal, state and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of drugs and drug candidates.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">U.S. Government Regulation</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending New Drug Applications (NDAs) or Biologics License Applications (BLAs), withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process required by the FDA before a drug product may be marketed in the United States generally involves the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice, or GLP, regulations.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>submission to the FDA of an IND which must become effective before human clinical trials may begin.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>performance of adequate and well controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish the safety and efficacy of the proposed drug product for each indication.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>submission to the FDA of an NDA or BLA.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>satisfactory completion of an FDA advisory committee review, if applicable.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practice, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>FDA review and approval of the NDA or BLA.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preclinical Studies</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical Trials</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the investigational new drug to human patients under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research patients provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their www.clinicaltrials.gov website.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Phase 1 clinical trial: The drug is initially introduced into healthy human volunteers or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Phase 2 clinical trial: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Phase 3 clinical trial: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Each of Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Marketing Approval</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA or BLA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA or BLA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under the Pediatric Research Equity Act of 2003, or PREA, as amended and reauthorized, certain must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA also may require submission of a risk evaluation and mitigation strategy, or REMS, plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication plans, assessment plans, or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving an NDA or BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After evaluating the application and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA or BLA and may require additional clinical or preclinical testing in order for FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that particular contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Orphan Drug Act</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act of 1983, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for this type of disease or condition will be recovered from sales in the United States for that drug. Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the name of the sponsor, identity of the drug or biologic and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not shorten the duration of the regulatory review or approval process, but does provide certain advantages, such as a waiver of PDUFA fees, enhanced access to FDA staff and potential waiver of pediatric research requirements.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full NDA or BLA, or an abbreviated NDA (ANDA) or Biosimilar application, to market a drug or biologic with the same active moiety for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the application user fee. A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;text-indent:2.5%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fast Track Designation </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA is required to facilitate the development and expedite the review of pharmaceutical products that are intended for the treatment of a serious or life-threatening condition for which there is no effective treatment, and which demonstrate the potential to address unmet medical needs for the condition. Under the fast-track program, the sponsor of a new drug candidate may request the FDA to designate the product for a specific indication as a fast-track product concurrent with or after the filing of the IND for the product candidate. The FDA must determine if the product candidate qualifies for fast-track designation within 60 days after receipt of the sponsor&#8217;s request. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to other benefits, such as the ability to have more frequent interactions with the FDA, the agency may initiate review of sections of a fast-track product&#8217;s NDA or BLA before the application is complete. This rolling review is available if the applicant provides and the FDA approves a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA&#8217;s PDUFA review period for a fast-track application does not begin until the last section of the application is submitted. In addition, the fast-track designation may be withdrawn by the FDA if the agency believes that the designation is no longer supported by data emerging in the clinical trial process. </p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Post-Approval Requirements</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may impose a number of post-approval requirements as a condition of approval of a marketing authorization. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>fines, warning letters or holds on post-approval clinical trials;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>refusal of the FDA to approve related pending applications or supplements to approved applications, or suspension or revocation of product approvals;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>product seizure or detention, or refusal to permit the import or export of products; or</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>injunctions or the imposition of civil or criminal penalties.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Coverage and Reimbursement</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk64536862"></a><a name="_Hlk63328530"></a><a name="_Hlk64536838"></a>Sales of our drug candidates, if approved, will depend, in part, on the extent to which such products will be covered by third-party payors, such as government health care programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly limiting coverage or reducing reimbursements for medical products and services. In addition, the U.S. government, state legislatures, and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Third-party payors decide which therapies they will pay for and establish reimbursement levels. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. Further, no uniform policy for coverage and reimbursement exists in the United States. Therefore, decisions regarding the extent of coverage and amount of reimbursement to be provided for any drug candidates that we develop will be made on a payor-by-payor basis. Each payor determines whether or not<a name="_Hlk64536862"></a><a name="_Hlk63328530"></a> it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier of its formulary it will be placed. The position on a payor&#8217;s list of covered drugs, or formulary, generally determines the co-payment that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Decreases in third-party reimbursement for our drug candidates or a decision by a third-party payor to not cover our drug candidates could reduce physician usage of our drug candidates, once approved, and have a material adverse effect on our sales, results of operations and financial condition. C<a name="_Hlk64536838"></a>overage policies and third-party payor reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Healthcare Laws</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors, we will also be subject to healthcare regulation and enforcement by the federal government and the states and foreign governments in which we will conduct our business, including our clinical research, proposed sales, marketing and educational programs. Failure to comply with these laws, where applicable, can result in the imposition of significant civil, criminal, and administrative penalties.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63950064"></a><a name="_Hlk63412530"></a>The U.S. laws that may affect our ability to operate, among others, include: the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; certain state laws governing the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts; the federal Anti-Kickback Statute, which prohibits, among other things, individuals or entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs; federal false claims laws  and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; the Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics, and medical supplies to report annually to the U.S. Department of Health and Human Services information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and ownership and investment </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">interests held by physicians and their immediate family members.</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Beginning in 2022,</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> applicable manufacturers also will be required to report such information regarding </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">their</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63950064"></a> payments and other transfers of value to physician assistants, nurse practitioners</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk63412530"></a>, </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, many states have similar laws and regulations, such as anti-kickback and false claims laws that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Additionally, to the extent that our product is sold in a foreign country, we may be subject to similar foreign laws.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Healthcare Reform</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current and future legislative proposals to further reform healthcare or reduce healthcare costs may result in lower reimbursement for our products. The cost containment measures that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could significantly reduce our revenues from the sale of our products.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk64230210"></a><a name="_Hlk63949794"></a><a name="_Hlk64656358"></a><a name="_Hlk63547205"></a><a name="_Hlk63619061"></a><a name="_Hlk63412788"></a><a name="_Hlk63619700"></a>For example, implementation of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively the Affordable Care Act, or the PPACA, has substantially changed healthcare financing and delivery by both governmental and private insurers, and significantly impacted the pharmaceutical industry. The PPACA, among other things, established an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents, revised the methodology by which rebates owed by manufacturers to the state and federal government for covered outpatient drugs under the Medicaid Drug Rebate Program are calculated, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research and created a licensure frame work for follow-on biologic products. Since its enactment there have been executive, judicial and Congressional challenges to certain aspects of the PPACA. For example, President Trump has signed several Executive Orders and other directives designed to delay the implementation of certain provisions of the PPACA or otherwise circumvent some of the requirements for health insurance mandated by the PPACA. Concurrently, Congress considered legislation to repeal or repeal and replace all or part of the PPACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the PPACA have been signed into law. The Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. Additionally, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the PPACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. Further, the Bipartisan Budget Act of 2018, or the BBA, among other things, amends the PPACA, effective January 1, 2019, to increase from 50 percent to 70 percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; <a name="_Hlk64230210"></a>Moreover, on December 14, 2018, a Texas U.S. District Court Judge ruled that the PPACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the PPACA are invalid as well. <a name="_Hlk63949794"></a><a name="_Hlk64656358"></a>The U.S. Supreme Court is currently reviewing this case<a name="_Hlk63547205"></a>, <a name="_Hlk63619061"></a><a name="_Hlk63412788"></a>but it is unknown when a decision will be reached. Although the Supreme Court has not yet ruled on the constitutionality of the PPACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the PPACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create barriers to obtaining access to health insurance coverage through Medicaid or the PPACA. <a name="_Hlk63619700"></a>It is unclear how the Supreme Court ruling, other such litigation, and the healthcare reform measures of the Biden administration will impact the PPACA.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk64229427"></a><a name="_Hlk64233896"></a><a name="_Hlk63953881"></a><a name="_Hlk64535003"></a>In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. In August 2011, then President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals for spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes reductions to Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments, including the BBA, will remain in effect through 2030<a name="_Hlk64229427"></a><a name="_Hlk64233896"></a> unless additional Congressional action is taken. <font style="color:#000000;"><a name="_Hlk63953881"></a>H<a name="_Hlk64535003"></a>owever, COVID-19 relief support legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2021. </font>Additionally, in January 2013, then President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Further, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. For example, there have been presidential executive orders and several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufacturer patient programs, and reform government program reimbursement methodologies for drug products.</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</font><font style="color:#000000;">I</font><font style="color:#000000;">t is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that additional federal and state, as well as foreign, healthcare reform measures will be adopted in the future, particularly in light of the new presidential administration, any of which could result in reduced demand for our products or additional pricing pressure. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. </p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Employees and Human Capital Resources</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had 67 full-time employees, 40 of whom were primarily engaged in research and development activities and 16 of whom had an MD or PhD degree.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of equity-based compensation awards and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Facilities</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We lease the space for our principal executive offices, which are located at 1460 Broadway, New York, New York, on a monthly basis. We believe that our facilities are adequate to meet our current needs.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Corporate and Other Information</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in Delaware in April 2014. Our principal executive offices are located at 1460 Broadway, Suite 15021 New York, New York 10036 and our telephone number is (646)&#160;661-7661. Our corporate website address is www.ovidrx.com. Information contained on or accessible through our website is not a part of this Annual Report, and the inclusion of our website address in this Annual Report is an inactive textual reference only.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We file electronically with the Securities and Exchange Commission, or the SEC, our annual reports on Form 10-K, Annual reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange Act. We make available on our website at <font style="text-decoration:underline;">www.ovidrx.com</font> under &#8220;Investors,&#8221; free of charge, copies of these reports as soon as reasonably practicable after filing or furnishing these reports with the SEC.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1A_RISK_FACTORS"></a><a name="ITEM_1A_RISK_FACTORS"></a>Item&#160;1A. Risk Factors</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">An investment in our securities involves a high degree of risk.&#160;You should carefully consider the following information about these risks, together with the other information appearing elsewhere in this Annual Report on Form 10-K, including our audited condensed financial statements and related notes hereto, before deciding to invest in our common stock. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. In these circumstances, the market price of our common stock could decline and you may lose all or part of your investment. We cannot assure you that any of the events discussed below will not occur. In addition, such risks may be amplified by the COVID-19 pandemic and its potential impact on Ovid&#8217;s business and the global economy.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Financial Position and Need for Additional Capital</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have incurred significant operating losses since inception and expect to continue to incur substantial operating losses for the foreseeable future. These factors raise substantial doubt about our ability to continue as a going concern if we are unsuccessful raising additional capital.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception in April 2014, we have incurred significant operating losses. Our net loss was $81.0 million for the year ended December&#160;31, 2020. As of December 31, 2020, we had an accumulated deficit of $294.2 million. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. Since inception, we have devoted substantially all of our efforts to research and preclinical and clinical development of our drug candidates, as well as hiring employees and building our infrastructure. It could be several years, if ever, before we have a commercialized drug. The net losses we incur may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if, and as, we:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">continue the ongoing and planned preclinical and clinical development of our drug candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">continue to build a portfolio of drug candidates through the acquisition or in-license of drugs, drug candidates or technologies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">initiate preclinical studies and clinical trials for any additional drug candidates that we may pursue in the future;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">experience further delays in our preclinical studies and clinical trials due to the ongoing COVID-19 pandemic;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">seek marketing approvals for our current and future drug candidates that successfully complete clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">establish a sales, marketing and distribution infrastructure to commercialize any drug candidate for which we may obtain marketing approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">develop, maintain, expand and protect our intellectual property portfolio;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">implement operational, financial and management systems; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">attract, hire and retain additional administrative, clinical, regulatory and scientific personnel.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management has identified certain conditions or events, which, considered in the aggregate, raise substantial doubt about our ability to continue as a going concern, including the risk that we will be unable to raise adequate additional capital to fund our operations through at least the 12 months following the filing date of the this annual report on Form 10-K. Substantial doubt about our ability to continue as a going concern may create negative reactions to the price of our common stock. If we are unable to raise capital, we may be required to delay, reduce the scope of or eliminate research and development programs, or obtain funds through arrangements with collaborators or others that may require us to relinquish rights to certain drug candidates that we might otherwise seek to develop or commercialize independently. In addition, if we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our financial statements, and it is likely that investors will lose all or a part of their investment. Further, the perception that we may be unable to continue as a going concern may impede our ability to pursue strategic opportunities or operate our business due to concerns regarding our ability to discharge our contractual obligations.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have never generated any revenue from drug sales. Our operating history may make it difficult to evaluate the success of our business to date and to assess our future viability.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations have consumed substantial amounts of cash since our inception in April 2014, primarily due to organizing and staffing our company, business planning, raising capital, acquiring assets and undertaking the development of OV101 and OV935. We have not yet demonstrated the ability to, obtain marketing approvals, manufacture a commercial-scale drug or conduct sales and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketing activities necessary for successful commercialization. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had more experience developing drug candidates.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to generate revenue from drug sales and achieve profitability depends on our ability, alone or with any current or future collaborative partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, our current and future drug candidates. We do not anticipate generating revenue from drug sales for the next several years, if ever. Our ability to generate revenue from drug sales depends heavily on our, or any current or future collaborators&#8217;, success in the following areas, including but not limited to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">timely and successfully completing preclinical and clinical development of our current and future drug candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">obtaining regulatory approvals for our current and future drug candidates for which we successfully complete clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">launching and commercializing any drug candidates for which we obtain regulatory approval by establishing a sales force, marketing and distribution infrastructure or, alternatively, collaborating with a commercialization partner;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">qualifying for coverage and adequate reimbursement by government and third-party payors for any drug candidates for which we obtain regulatory approval, both in the United States and internationally;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">developing, validating and maintaining a commercially viable, sustainable, scalable, reproducible and transferable manufacturing process for our current and future drug candidates that is compliant with current good manufacturing practices, (&#8220;cGMP&#8221;);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">establishing and maintaining supply and manufacturing relationships with third parties that can provide an adequate amount and quality of drugs and services to support clinical development, as well as the market demand for our current and future drug candidates, if approved;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">obtaining market acceptance, if and when approved, of our current or any future drug candidates as a viable treatment option by physicians, patients, third-party payors and others in the medical community;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">effectively addressing any competing technological and market developments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">implementing additional internal systems and infrastructure, as needed;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our obligations pursuant to such arrangements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to obtain and maintain orphan drug exclusivity for any of our current and future drug candidates for which we obtain regulatory approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">avoiding and defending against third-party interference or infringement claims; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">securing appropriate pricing in the United States, the European Union and other countries.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our financial condition and operating results to continue to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. We will need to eventually transition from a company with a research and development focus to a company capable of undertaking commercial activities. We may encounter unforeseen expenses, difficulties, complications and delays and may not be successful in such a transition.&#160;</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will require additional capital to finance our operations, which may not be available on acceptable terms, if at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our drug development efforts or other operations.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations have consumed substantial amounts of cash since our inception. We expect our expenses to increase in connection with our ongoing and planned activities, particularly as we continue to develop and commercialize our drug candidates, in addition to costs associated with the acquisition or in-licensing of any additional drug candidates we may pursue. Our expenses could increase beyond expectations if the FDA or other regulatory authorities require us to perform clinical and other studies in addition to those that we currently anticipate. In addition, if we obtain marketing approval for our drug candidates, we expect to incur significant expenses related to manufacturing, marketing, sales and distribution. Furthermore, we expect to continue to incur additional costs associated with operating as a public company.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.89%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, our cash and cash equivalents were $72.0 million and we had an accumulated deficit of $294.2 million. Management has identified certain conditions or events, which, considered in the aggregate, raise substantial doubt about our ability to continue as a going concern, including the risk that we will be unable to raise adequate additional capital to fund our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operations through at least the 12 months following the filing date of this annual report on Form 10-K. Substantial doubt about our ability to continue as a going concern may create negative reactions to the price of our common stock. If we are unable to raise capital, we may be required to delay, reduce the scope of or eliminate research and development programs, or obtain funds through arrangements with collaborators or others that may require us to relinquish rights to certain drug candidates that we might otherwise seek to develop or commercialize independently. In addition, if we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our financial statements, and it is likely that investors will lose all or a part of their investment. Further, the perception that we may be unable to continue as a going concern may impede our ability to pursue strategic opportunities or operate our business due to concerns regarding our ability to discharge our contractual obligations. </font></p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_97"></a>We will require more capital in order to<a name="_cp_text_1_97"></a> continue our preclinical and clinical activities, to obtain regulatory approval and for the commercialization of our current or future drug candidates. Any additional capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our current and future drug candidates. The COVID-19 pandemic has already resulted in a significant disruption of global financial markets.&nbsp;&nbsp;If the disruption persists and deepens, we could experience an inability to access additional capital.&nbsp;&nbsp;If we do not raise additional capital in sufficient amounts, or on terms acceptable to us, we may be prevented from pursuing development and commercialization efforts, which will harm our business, operating results and prospects.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Raising additional capital or acquiring or licensing assets by issuing equity or debt securities may cause dilution to our stockholders, and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time as we can generate substantial revenue from drug sales, if ever, we expect to finance our cash needs through a combination of equity and debt financings, strategic alliances, and license and development agreements in connection with any collaborations. We do not have any committed external source of funds. To the extent that we issue additional equity securities, our stockholders may experience substantial dilution, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. In addition, we may issue equity or debt securities as consideration for obtaining rights to additional compounds. For example, in our arrangement with Takeda, upon the achievement of a certain development milestone, we will be obligated to issue to Takeda additional securities equal to up to 8% of our outstanding capital stock in certain situations which will dilute our stockholders. In addition, further dilution may occur if we elect to issue shares of common stock to Takeda as payment for the remaining potential global commercial and regulatory milestone payments, which aggregate to approximately $35.0&#160;million. In March 2021, we<font style="color:#000000;"> entered into a royalty, license and termination agreement (&#8220;Takeda License and Termination Agreement&#8221;) with Takeda under which Takeda will secure global rights at closing from us to develop and commercialize the investigational medicine OV935 for the treatment of developmental and epileptic encephalopathies, including DS and LGS. Closing of the Takeda License and Termination Agreement is subject to satisfaction of customary closing conditions. See &#8220;Business&#8212;License and Collaboration Agreements&#8212;Agreements with Takeda&#8212;2021 Royalty, License and Termination Agreement with Takeda&#8221; for a discussion of the terms of the Takeda License and Termination Agreement.</font></p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt and equity financings, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as redeeming our shares, making investments, issuing additional equity, incurring additional debt, making capital expenditures, declaring dividends or placing limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could negatively impact our ability to conduct our business. If we raise additional capital through future collaborations, strategic alliances or third-party licensing arrangements, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or drug candidates, or grant licenses on terms that may not be favorable to us. For example, on July&#160;9, 2020, we entered into a collaboration and license agreement (the &#8220;Angelini License Agreement&#8221;) with Angelini Pharma Rare Diseases AG, pursuant to which we granted to Angelini exclusive rights to develop and commercialize OV101 in the European Economic Area as well as Switzerland, the United Kingdom, Russia and Turkey.&#160;&#160;The licenses granted to Angelini include sublicenses under our existing license agreement with H. Lundbeck A/S (&#8220;Lundbeck&#8221;), as well as licenses under our patents and know-how covering OV101.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to raise additional capital when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts, or grant rights to develop and market drug candidates that we would otherwise develop and market ourselves.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to use our net operating loss (&#8220;NOL&#8221;) carryforwards and certain other tax attributes to offset future taxable income may be subject to limitation.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our NOL carryforwards could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law.&#160;</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our federal NOLs generated in tax years beginning on or before December 31, 2017 are permitted to be carried forward for only 20 years under applicable U.S. tax law.&nbsp;&nbsp;</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Tax Cuts and Jobs</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Act</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or the Tax Act, as modified by the </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Coronavirus Aid, Relief, and Economic Security Act, </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or the CARES</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Act, federal NOLs incurred in taxable years beginning after December 31, 2017 may be carried forward indefinitely, but the </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">utilization </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of such federal NOLs incurred in the taxable year beginning after December 31, 2020 is limited. It is uncertain how various states will respond to the Tax Act and CARES Act.</font></p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; its ability to use its pre-change NOL carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change income may be limited. A Section 382 &#8220;ownership change&#8221; generally occurs if one or more stockholders or groups of stockholders who own at least 5% of our stock increase their ownership by more than 50 percentage points (by value) over their lowest ownership percentage over a rolling three-year period. We may have experienced ownership changes in the past and may experience ownership changes in the future as a result of shifts in our stock ownership (some of which are outside our control). As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset such taxable income may be subject to limitations. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consequently, even if we achieve profitability, we may not be able to utilize a material portion of our NOL carryforwards and certain other tax attributes, which could have a material adverse effect on cash flow and results of operations.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Development and Commercialization of Our Drug Candidates</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our future success is dependent on the successful clinical development, regulatory approval and commercialization of our current and future drug candidates. If we, or our&#160;licensees, are not able to obtain required regulatory approvals, we will not be able to commercialize our drug candidates, and our ability to generate revenue will be adversely affected.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any drugs that have received regulatory approval. Our business is dependent on our ability to successfully complete preclinical and clinical development of, obtain regulatory approval for, and, if approved, successfully commercialize our current and future drug candidates in a timely manner. Activities associated with the development and commercialization of our current and future drug candidates are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and similar regulatory authorities outside the United States. Failure to obtain regulatory approval in the United States or other jurisdictions would prevent us from commercializing and marketing our current and future drug candidates. An inability to effectively develop and commercialize our current and future drug candidates, whether due to the impacts of the ongoing COVID-19 pandemic or otherwise, could have an adverse effect on our business, financial condition, results of operations and growth prospects.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, activities associated with the development and commercialization of our current and future drug candidates are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and similar regulatory authorities outside the United States. Failure to obtain regulatory approval in the United States or other jurisdictions would prevent us from commercializing and marketing our current and future drug candidates.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain approval from the FDA and comparable foreign regulatory authorities for our current and future drug candidates, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval, or any approval contains significant limitations, we may not be able to obtain sufficient funding or generate sufficient revenue to continue the development of that drug candidate or any other drug candidate that we may in-license, develop or acquire in the future.&nbsp;&nbsp;In certain circumstances, including under our license agreement with Angelini for OV101, our third-party licensees are responsible for obtaining regulatory approvals in the countries covered by the license, and we are dependent on their efforts in order to achieve the necessary approvals in order to commercialize our products.&nbsp;&nbsp;If Angelini, or any future licensees fail to perform their obligations to develop and obtain regulatory approvals for the licensed products, we may not be able to commercialize our products in the affected countries, or our ability to do so may be substantially delayed.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, even if we obtain regulatory approval for our current and future drug candidates, we will still need to develop a commercial organization, establish a commercially viable pricing structure and obtain approval for adequate reimbursement from third-party and government payors. If we are unable to successfully commercialize our current and future drug candidates, we may not be able to generate sufficient revenue to continue our business.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because the results of preclinical studies or earlier clinical trials are not necessarily predictive of future results, our drug candidates may not have favorable results in planned or future preclinical studies or clinical trials, or may not receive regulatory approval.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Success in preclinical testing and early clinical trials does not ensure that subsequent clinical trials will generate similar results or otherwise provide adequate data to demonstrate the efficacy and safety of a drug candidate. Frequently, drug candidates that have shown promising results in early clinical trials have subsequently suffered significant setbacks in later clinical trials. For instance, our STARS trial was the first clinical trial evaluating efficacy of OV101 in patients with Angelman syndrome and OV101 has not been evaluated in a clinical trial to treat Fragile X syndrome. We may be unable to demonstrate efficacy in any future trials, including any future clinical trials of OV101 to treat Angelman syndrome. </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For instance, </font><font style="color:#000000;">i</font><font style="color:#000000;">n </font><font style="color:#000000;">December 2020</font><font style="color:#000000;">, we reported the primary endpoint of the NEPTUNE study was not achieved. </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the results of the NEPTUNE trial, further development of OV101, other than the ELARA trial, is currently on hold. </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similarly, our Phase 1b/2a adult study in OV935 showed exploratory signals of efficacy in seizure frequency reduction, but we may be unable to demonstrate efficacy in future trials in patients with DEE, or the related indications of </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dravet</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> syndrome, Lennox-</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gastaut</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> syndrome, CDKL5 Deficiency Disorder or Duplication 15q (&#8220;Dup15q&#8221;) syndrome, and the FDA has not yet made any determination regarding safety and efficacy of OV935 in any of these indications. The results from preclinical studies of OV101 and OV935 in animal models and the results from our STARS clinical trial of OV101 in patients with Angelman syndrome and clinical trials of OV101 in patients with primary insomnia may not be predictive of the effects of these compounds in later stage clinical trials. Our approach of targeting the </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">extrasynaptic</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> GABA</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">A</sub></font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> receptor with OV101, and cholesterol 24-hydroxylase (CH24H) with OV935, are both novel and unproven, and as such, the cost and time needed to develop OV101 and OV935 is difficult to </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">predict</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and our efforts may not be successful. If we do not observe favorable results in clinical trials of one of our drug candidates, we may decide to delay or abandon clinical development of that drug candidate. Any such delay or abandonment could harm our business, financial condition, results of operations and prospects.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Interim&#160;topline&#160;and&#160;preliminary results from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures, which could result in material changes in the final data.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we have and may in the future publish or report preliminary or interim data from our clinical trials, such as the initial data we announced from the ENDYMION open label extension trial for OV935 in September 2019, which involved data from the first six patients enrolled in that extension trial which showed promising signs of efficacy over the treatment period, or the topline data from the ELEKTRA trial for OV935 in August 2020. Preliminary or interim data from our clinical trials and those of our partners may not be indicative of the final results of the trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. Preliminary or topline results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published or reported. As a result, preliminary or interim data should be considered carefully and with caution until final data are available. <font style="Background-color:#FFFFFF;">Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before obtaining marketing approval from regulatory authorities for the sale of our drug candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the drug candidate for its intended indications. Clinical trials are expensive, time-consuming and uncertain as to outcome. Further, delays and interruptions to ongoing trials related to the COVID-19 pandemic may also increase the duration and costs of such trials. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;">delays in reaching a consensus with regulatory authorities on trial </font><font style="color:#000000;">design;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">delays in reaching agreement on acceptable terms with prospective clinical research organizations (&#8220;CROs&#8221;) and clinical trial sites;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">delays in opening investigational sites;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">delays or difficulty in recruiting and enrollment of suitable patients to participate in our clinical trials, whether as a result of the COVID-19 pandemic or otherwise;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">imposition of a clinical hold by regulatory authorities because of a serious adverse event, concerns with a class of drug candidates or after an inspection of our clinical trial operations or trial sites;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">delays in having patients complete participation in a trial or return for post-treatment follow-up;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">occurrence of serious adverse events associated with the drug candidate that are viewed to outweigh its potential benefits; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters and public health epidemics.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our clinical trials may be affected by the COVID-19 pandemic.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, could be limited, which in turn could adversely impact our clinical trial operations.&#160;Additionally, we may experience interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel, quarantines or social distancing protocols imposed or recommended by federal or state governments, employers and others in connection with the ongoing COVID-19 pandemic. As a result of the COVID-19 pandemic, we have faced and may continue to face delays in meeting our anticipated timelines for our ongoing and planned clinical trials.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, clinical endpoints for certain diseases we are targeting, such as Angelman syndrome and Fragile X syndrome, have not been established, and accordingly we may have to develop new modalities or modify existing endpoints to measure efficacy, which may increase the time it takes for us to commence or complete clinical trials. In addition, we believe investigators in this area may be inexperienced in conducting trials in this area due to the current lack of drugs to treat these disorders, which may result in increased time and expense to train investigators and open clinical sites.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue from future drug sales and regulatory and commercialization milestones. In addition, if we make manufacturing or formulation changes to our drug candidates, we may need to conduct additional testing to bridge our modified drug candidate to earlier versions. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our drug candidates, if approved, or allow our competitors to bring comparable drugs to market before we do, which could impair our ability to successfully commercialize our drug candidates and may harm our business, financial condition, results of operations and prospects.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if the results of our clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our drug candidates, we may:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;">be delayed in obtaining marketing approval, if at </font><font style="color:#000000;">all;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">obtain approval for indications or patient populations that are not as broad as intended or desired;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">be subject to additional post-marketing testing requirements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">have regulatory authorities withdraw, or suspend, their approval of the drug or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy (&#8220;REMS&#8221;);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">be subject to the addition of labeling statements, such as warnings or contraindications;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="color:#000000;">be sued;&#160;or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>experience damage to our reputation.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our drug development costs will also increase if we experience delays in testing or obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, need to be restructured or be completed on schedule, if at all.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, we, the FDA or an institutional review board (&#8220;IRB&#8221;) may suspend our clinical trials at any time if it appears that we or our collaborators are failing to conduct a trial in accordance with regulatory requirements, including the FDA&#8217;s current Good Clinical Practice (&#8220;GCP) regulations, that we are exposing participants to unacceptable health risks, or if the FDA finds deficiencies in our investigational new drug (&#8220;IND&#8221;) applications or the conduct of these trials. Therefore, we cannot predict with any certainty the schedule for commencement and completion of future clinical trials. If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of our drug candidates could be negatively impacted, and our ability to generate revenues from our drug candidates may be delayed.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Angelman syndrome has no treatments approved by the U.S. Food and Drug Administration, and the primary clinical endpoint, CGI-I-AS, has not previously been used as a sole primary endpoint in a pivotal clinical trial.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Angelman syndrome is characterized by a variety of signs and symptoms, such as delayed development, intellectual disability, severe speech impairment, problems with movement and balance, seizures, sleep disorders and anxiety. In order to obtain a broad indication for treatment of Angelman syndrome from the FDA, we may need to demonstrate efficacy on several of the key symptoms of Angelman syndrome. If we fail to do so, our clinical development may be delayed and/or our label may be limited. I<font style="color:#000000;">n December 2020, we reported the primary endpoint of the NEPTUNE study was not achieved. </font>Based on the results of the NEPTUNE trial, further development of OV101, other than the ELARA trial, is currently on hold. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may need to develop a new liquid formulation of OV101 for use in infant patients if our existing formulation in capsules that can be opened and sprinkled on semi-solid foods is not acceptable to the regulatory authorities, and we may be unable to successfully develop an appropriate liquid formulation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our existing formulation of OV101 is an oral capsule. We have recently developed lower strength capsules that can be opened and sprinkled on applesauce or similar semi-solid foods. However, we may need to develop an oral liquid formulation of OV101 for use in very young pediatric patients. While we have begun developing this formulation, we do not know if our efforts will be successful or if the FDA will agree that the new formulation is comparable to our current formulation. We may experience manufacturing problems that may affect solubility or stability, or we may discover that the new formulation is less effective than an oral capsule. In addition, we will need to conduct bridging studies to demonstrate that the new formulation is equivalent to our oral capsule, which could result in delays in development and additional costs.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are not successful in discovering, developing and commercializing additional drug candidates, our ability to expand our business and achieve our strategic objectives would be impaired.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A key element of our strategy is to develop and potentially commercialize a portfolio of drug candidates to treat rare neurological disorders. We intend to do so by in-licensing and entering into collaborations with leading biopharmaceutical companies or academic institutions for new drug candidates. Identifying new drug candidates requires substantial technical, financial and human resources, whether or not any drug candidates are ultimately identified. Our approach to business development, including our efforts to map the biological pathways related to orphan disorders of the brain and our relationships among the pharmaceutical industry, may not result in viable drug candidates for clinical development. The COVID-19 pandemic could also impact our ability to do in person due diligence, negotiations and other interactions to identify new opportunities. Even if we identify drug candidates that initially show promise, we may fail to in-license or acquire these assets and may also fail to successfully develop and commercialize such drug candidates for many reasons, including the following:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the research methodology used may not be successful in identifying potential drug </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>competitors may develop alternatives that render any drug candidate we develop obsolete;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>any drug candidate we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>a drug candidate may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>a drug candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>a drug candidate may not be accepted as safe and effective by physicians, patients, the medical community or third-party payors.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited financial and management resources and, as a result, we may forego or delay pursuit of opportunities with other drug candidates or for other indications that later prove to have greater market potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial drugs or profitable market opportunities. If we do not accurately evaluate the commercial potential or target market for a particular drug candidate, we may relinquish valuable rights to that drug candidate through collaboration, licensing or other royalty arrangements in circumstances under which it would have been more advantageous for us to retain sole development and commercialization rights to such drug candidate.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unsuccessful in identifying and developing additional drug candidates or are unable to do so, our key growth strategy and business will be harmed.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical trials are very expensive, time-consuming and difficult to design and implement.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our drug candidates will require clinical testing before we are prepared to submit a new drug application (&#8220;NDA&#8221;) for regulatory approval. We cannot predict with any certainty if or when we might submit an NDA for regulatory approval for any of our drug candidates or whether any such NDA will be approved by the FDA. Human clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. For instance, the FDA may not agree with our proposed endpoints for any future clinical trial of our drug candidates, which may delay the commencement of our clinical trials. In addition, we may not succeed in developing and validating disease-relevant clinical endpoints based on insights regarding biological pathways for the disorders we are studying. The clinical trial process is also time-consuming. We estimate that the successful completion of clinical trials of our drug candidates will take at least several years to complete, if not longer. Furthermore, failure can occur at any stage and we could encounter problems that cause us to abandon or repeat clinical trials.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identifying and qualifying patients to participate in our clinical trials is critical to our success. The number of patients suffering from Angelman syndrome, Fragile X syndrome and DEE, such as Dravet syndrome, Lennox-Gastaut syndrome, Dup15q syndrome and CDKL5 deficiency disorder is small and has not been established with precision. If the actual number of patients with these disorders is smaller than we anticipate, we may encounter difficulties in enrolling patients in our clinical trials, thereby delaying or preventing development and approval of our drug candidates. Even once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials. Patient enrollment and retention in clinical trials depends on many factors, including the size of the patient population, the nature of the trial protocol, the existing body of safety and efficacy data, the number and nature of competing treatments and ongoing clinical trials of competing therapies for the same indication, the proximity of patients to clinical sites and the eligibility criteria for the trial, any such enrollment issues could cause delays or prevent development and approval of our drug candidates. Because we are focused on addressing rare neurological disorders, there are limited patient pools from which to draw in order to complete our clinical trials in a timely and cost-effective manner. Furthermore, our efforts to build relationships with patient communities may not succeed, which could result in delays in patient enrollment in our clinical trials. In addition, any negative results we may report in clinical trials of our drug candidate may make it difficult or impossible to recruit and retain patients in other clinical trials of that same drug candidate. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our drug candidates, or could render further development impossible. <font style="color:#000000;">For example, the impact of public health pandemics, such as COVID-19, may delay or prevent patients from enrolling or from receiving treatment in accordance with the protocol and the required timelines, which could delay our clinical trials, or prevent us or our partners from completing our clinical trials at all, and harm our ability to obtain approval for such product candidate. </font>In addition, we may rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we will be limited in our ability to compel their actual performance.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;margin-left:0.41%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our drug candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial </font><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">potential</font><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> or result in significant negative consequences following any potential marketing approval.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts, to their doctor. Often, it is not possible to determine whether or not the drug candidate being studied caused these conditions. Regulatory authorities may draw different conclusions or require additional testing to confirm these determinations, if they occur. In addition, it is possible that as we test our drug candidates in larger, longer and more extensive clinical programs, or as use of these drug candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by subjects. Many times, side effects are only detectable after investigational drugs are tested in large-scale, Phase&#160;3 trials or, in some cases, after they are made available to patients on a commercial scale after approval. For example, in one of the trials conducted by Lundbeck, there were reports of hallucinations in drug abusers at 30mg and 45mg doses of OV101, which are higher than the 10mg and 15mg doses that were effective for insomnia. In addition, some patients treated with OV101 in the Lundbeck Phase&#160;3 trials experienced headaches, nausea and dizziness. In the STARS study, the most frequent adverse events for OV101 treated arms that were greater than placebo arm included pyrexia, rash, seizure, enuresis, myoclonic epilepsy, otitis media and viral infection. Patients in our ongoing or planned clinical trials may experience similar or other adverse events after treatment with OV101. In the Phase 1b/2a OV935 trial, adverse events that occurred more frequently in the OV935-treatment group versus the placebo group were dysarthria, insomnia, lethargy, seizure cluster, and upper respiratory infection. If additional clinical experience indicates that any of our current drug candidates, including OV101 and OV935, or any future drug candidates has adverse events or causes serious or life-threatening adverse events, the development of that drug candidate may fail or be delayed, or, if the drug candidate has received regulatory approval, such approval may be revoked, which would harm our business, prospects, operating results and financial condition.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of our drug candidates, the commercial prospects of our drug candidates may be harmed and our ability to generate revenue through their sale may be delayed or eliminated. Any of these occurrences may harm our business, financial condition and prospects significantly.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if any of our drug candidates receive marketing approval, the FDA could require us to include a black box warning in our label or adopt REMS to ensure that the benefits outweigh its risks, which may include, among other things, a medication guide outlining the risks of the drug for distribution to patients and a communication plan to health care practitioners. Furthermore, if we or others later identify undesirable side effects caused by our drug candidates, several potentially significant negative consequences could result, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>regulatory authorities may suspend or withdraw approvals of such drug candidate;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>regulatory authorities may require additional warnings on the label;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we may be required to change the way a drug candidate is administered or conduct additional clinical trials;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we could be sued and held liable for harm caused to patients;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we may need to conduct a recall; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our reputation may suffer.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could prevent us from achieving or maintaining market acceptance of our drug candidates and could significantly harm our business, prospects, financial condition and results of operations.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;margin-left:0.41%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If the market opportunities for our drug candidates are smaller than we believe they are, even assuming approval of a drug candidate, our business may suffer. Because the patient populations in the market for our drug candidates may be small, we must be able to successfully identify patients and acquire a significant market share to achieve profitability and growth.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We focus our research and drug development on treatments for rare neurological disorders. Given the small number of patients who have the disorders that we are targeting, our eligible patient population and pricing estimates may differ significantly from the actual market addressable by our drug candidates. Our projections of both the number of people who have these disorders, as well as the subset of people with these disorders who have the potential to benefit from treatment with our drug candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, patient foundations, or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these disorders. The number of patients may turn out to be lower than expected. Likewise, the potentially addressable patient population for each of our drug candidates may be limited or may not be amenable to treatment with our drug candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business.&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;margin-left:0.41%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face substantial competition, which may result in others developing or commercializing drugs before or more successfully than us.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development and commercialization of new drugs is highly competitive. We face competition with respect to our current drug candidates and will face competition with respect to any other drug candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell drugs or are pursuing the development of drug candidates for the treatment of the indications that we are pursuing. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">More established companies may have a competitive advantage over us due to their greater size, resources and institutional experience. In particular, these companies have greater experience and expertise in securing reimbursement, government contracts, relationships with key opinion leaders, conducting testing and clinical trials, obtaining and maintaining regulatory approvals and distribution relationships to market products, and marketing approved drugs. These companies also have significantly greater research and marketing capabilities than we do. If we are not able to compete effectively against existing and potential competitors, our business and financial condition may be harmed.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of these factors, our competitors may obtain regulatory approval of their drugs before we are able to, which may limit our ability to develop or commercialize our drug candidates. Our competitors may also develop therapies that are safer, more effective, more widely accepted and cheaper than ours, and may also be more successful than us in manufacturing and marketing their drugs. These appreciable advantages could render our drug candidates obsolete or non-competitive before we can recover the expenses of such drug candidates&#8217; development and commercialization.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;margin-left:0.41%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if our current or future drug candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if our current or future drug candidates receive marketing approval, they may fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If they do not achieve an adequate level of acceptance, we may not generate significant drug revenue and may not become profitable. The degree of market acceptance of our current or future drug candidates, if approved for commercial sale, will depend on a number of factors, including but not limited to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the efficacy and potential advantages compared to alternative treatments and therapies;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the safety profile of our drug candidate compared to alternative treatments and therapies;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>effectiveness of sales and marketing efforts;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the strength of our relationships with patient communities;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the cost of treatment in relation to alternative treatments and therapies, including any similar generic treatments;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our ability to offer such drug for sale at competitive prices;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the convenience and ease of administration compared to alternative treatments and therapies;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the strength of marketing and distribution support;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the availability of third-party coverage and adequate reimbursement;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the prevalence and severity of any side effects; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>any restrictions on the use of the drug together with other medications.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our efforts to educate physicians, patients, third-party payors and others in the medical community on the benefits of our drug candidates may require significant resources and may never be successful. Such efforts may require more resources than are typically required due to the complexity and uniqueness of our drug candidates. Because we expect sales of our drug candidates, if approved, to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">generate substantially </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all of</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> our drug revenues for the foreseeable future, the failure of our drugs to find market acceptance would harm our business and could require us to seek additional financing.</font></p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to establish sales and marketing capabilities, or enter into agreements with third parties to market and sell our current or any future drug candidates, we may be unable to generate any revenue from drug sales.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To successfully commercialize any drug candidate that may result from our development programs, we will need to build out our sales and marketing capabilities, either on our own or with others. The establishment and development of our own commercial team or the establishment of a contract sales force to market any drug candidate we may develop will be expensive and time-consuming and could delay any drug launch. Moreover, we cannot be certain that we will be able to successfully develop this capability. We may seek to enter into additional collaborations with other entities to utilize their established marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. If any current or future collaborators do not commit sufficient resources to commercialize our drug candidates, or we are unable to develop the necessary capabilities on our own, we will be unable to generate sufficient revenue to sustain our business. We compete with many companies that currently have extensive, experienced and well-funded marketing and sales operations to recruit, hire, train and retain marketing and sales personnel. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our current and future drug candidates. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we obtain and maintain approval for our current or future drug candidates from the FDA, we may never obtain approval for our current or future drug candidates outside of the United States, which would limit our market opportunities and could harm our business.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval of a drug candidate in the United States by the FDA does not ensure approval of such drug candidate by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. Sales of our current and future drug candidates outside of the United States will be subject to foreign regulatory requirements governing clinical trials and marketing approval. Even if the FDA grants marketing approval for a drug candidate, comparable regulatory authorities of foreign countries also must approve the manufacturing and marketing of the drug candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and more onerous than, those in the United States, including additional preclinical studies or clinical trials. In many countries outside the United States, a drug candidate must be approved for reimbursement before it can be approved for sale in that country. In some cases, the price that we intend to charge for any drug candidates, if approved, is also subject to approval. Obtaining approval for our current and future drug candidates in the European Union from the European Commission following the opinion of the EMA, if we choose to submit a marketing authorization application there, would be a lengthy and expensive process. Even if a drug candidate is approved, the FDA or the European Commission, as the case may be, may limit the indications for which the drug may be marketed, require extensive warnings on the drug labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our current and future drug candidates in certain countries.<font style="font-size:9pt;"> </font>In certain cases, including under our license with Angelini, which covers the European Economic Area as well as Switzerland, the United Kingdom, Russia and Turkey, we are dependent on third parties to obtain such foreign regulatory approvals, and any delay or failure of performance of such third parties could delay or prevent our ability to commercialize our products in the affected countries. Due to the ongoing COVID-19 pandemic, it is possible that we could experience delays in the timing of our interactions with regulatory authorities due to absenteeism by governmental employees, inability to conduct planned physical inspections related to regulatory approval, or the diversion of regulatory authority efforts and attention to approval of other therapeutics or other activities related to COVID-19, which could delay anticipated approval decisions and otherwise delay or limit our ability to make planned regulatory submissions or obtain new product approvals.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Also, regulatory approval for our drug candidates may be withdrawn. If we fail to comply with the regulatory requirements, our target market will be reduced and our ability to realize the full market potential of our current and future drug candidates will be harmed and our business, financial condition, results of operations and prospects could be harmed.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;margin-left:0.41%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we seek approval to commercialize our current or future drug candidates outside of the United States, in particular in the European Union and Israel, a variety of risks associated with international operations could harm our business.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we seek approval of our current or future drug candidates outside of the United States, we expect that we will be subject to additional risks in commercialization including:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">different regulatory requirements for approval of therapies in foreign </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">countries;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>reduced protection for intellectual property rights;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the potential requirement of additional clinical studies in international jurisdictions;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>unexpected changes in tariffs, trade barriers and regulatory requirements;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>economic weakness, including inflation, or political instability in particular foreign economies and markets;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>foreign reimbursement, pricing and insurance regimes;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>workforce uncertainty in countries where labor unrest is more common than in the United States;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>business interruptions resulting from geopolitical actions, including war and terrorism or natural disasters <font style="color:#000000;">and public health pandemics, such as COVID-19;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor and other legal requirements imposed by both the European Union, Israel and many of the individual countries in and outside of Europe with which we will need to comply. Many biopharmaceutical companies have found the process of marketing their own products in foreign countries to be very challenging.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;margin-left:0.41%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any drug candidate that we may develop.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face an inherent risk of product liability exposure related to the testing of our current and any future drug candidates in clinical trials and may face an even greater risk if we commercialize any drug candidate that we may develop. If we cannot successfully defend ourselves against claims that any such drug candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>decreased demand for any drug candidate that we may develop;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>loss of revenue;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>substantial monetary awards to trial participants or patients;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>significant time and costs to defend the related litigation;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>withdrawal of clinical trial participants;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the inability to commercialize any drug candidate that we may develop; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>injury to our reputation and significant negative media attention.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any drug candidate. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Licensing and Collaboration Arrangements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:19pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are heavily dependent on our relationship with Takeda for the development and commercialization of OV935. Any disruption in our relationship with Takeda could lead to delays in, or the termination of, the development of OV935, which would materially harm our business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.55%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are jointly developing OV935 with Takeda pursuant to the Takeda collaboration, which also granted us intellectual property rights to OV935. The development and commercialization of OV935 is highly dependent upon our relationship with Takeda, including Takeda&#8217;s submission of the IND to the FDA. If for any reason the Takeda collaboration is terminated, or we otherwise lose the intellectual property rights to OV935, our business would be adversely affected. The Takeda collaboration imposes on us rights and obligations, including but not limited to exclusivity, territorial rights, development, commercialization, funding, payment, diligence, sublicensing, insurance and intellectual property protection. After a negotiated time period, each party has the right to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terminate the license for convenience upon six to twelve months&#8217; notice to the other party, which would result in us being unable to co-develop and sell OV935. Further, if we breach any material obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages to Takeda, and Takeda may have the right to terminate the license. Takeda could also breach its obligations under the agreement or may not commit a sufficient </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amount</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of resources to satisfy its obligations, which would result in the development of OV935 being materially delayed or terminated.</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">entered into</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Takeda License and Termination Agreement</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;">under which Takeda will secure global rights at closing from us to develop and commercialize the investigational medicine OV935 for the treatment of developmental and epileptic encephalopathies, including DS and LGS</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Closing of the Takeda License and Termination Agreement is subject to satisfaction of customary closing conditions. See &#8220;Business&#8212;License and Collaboration Agreements&#8212;</font><font style="color:#000000;">Agreements with Takeda</font><font style="color:#000000;">&#8212;</font><font style="color:#000000;">2021 </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty, License and Termination Agreement with Takeda&#8221; for a discussion of the terms of the Takeda License and Termination Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:19pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are dependent on our relationship with Angelini for the development and commercialization of OV101 in European Economic Area as well as Switzerland, the United Kingdom, Russia and Turkey. Any disruption in our relationship with Angelini could lead to delays in the development and achievement of regulatory approval in these countries, which would materially harm our business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.55%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under our license agreement with Angelini, Angelini obtained exclusive rights to develop and commercialize OV101 in the European Economic Area as well as Switzerland, the United Kingdom, Russia and Turkey. The development and commercialization of OV101 is highly dependent upon our relationship with Angelini, and on Angelini&#8217;s performance of its obligations under the agreement, including with respect to the preparation and submission of applications for marketing approval in Europe and the other licensed countries. If for any reason Angelini fails to perform its obligations, we may not be able to achieve regulatory approval for OV101 in the licensed countries, or may be materially delayed in doing so, and our business would be adversely affected.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be required to make significant payments in connection with our licenses of OV101 from Lundbeck and OV935 from Takeda.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.55%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We acquired rights to OV101, pursuant to a license agreement with Lundbeck in March 2015 (the &#8220;Lundbeck Agreement&#8221;), as amended on May 10, 2019. Under the Lundbeck Agreement, as amended, we are subject to significant obligations, including payment obligations upon achievement of specified milestones and royalties on drug sales, as well as other material obligations. We are obligated to pay Lundbeck milestone payments up to an aggregate of $189.0 million upon the achievement of certain development, regulatory and sales milestone events. In addition, we are obligated to pay Lundbeck tiered royalties based on net sales of&#160;OV101. If these payments become due under the terms of the Lundbeck agreement, we may not have sufficient funds available to meet our obligations and our development efforts may be harmed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:13pt;text-indent:5.55%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also acquired rights to OV935 pursuant to a license and collaboration agreement with Takeda (the &#8220;Takeda collaboration&#8221;) in January 2017. Under the Takeda collaboration, we are obligated to pay Takeda future payments upon achievement of specified milestones. Upon the first patient enrollment in the first Phase 3 trial for the first of the initial indications we and Takeda are focusing on pursuant to the Takeda collaboration, we are obligated to issue to Takeda the number of unregistered shares of our common stock equal to the lesser of (i) 8% of our outstanding capital stock on the issuance date or (ii) $50.0&#160;million divided by the applicable share price, unless certain events occur. The remaining potential global commercial and regulatory milestone payments equal approximately $35.0&#160;million and can be satisfied in cash or unregistered shares of our common stock at our election, unless certain events occur in which Takeda can require us to pay such payments in cash. In the event a payment settled in shares of our common stock would cause Takeda to own over 19.99% of our outstanding capital stock or other events occur, such payment must be paid in cash. If these payments become due under the terms of the Takeda collaboration and we can only pay, or choose to pay, these payments in cash, we may not have sufficient funds available to meet our obligations and our development efforts may be harmed. In March 2021, we entered into the Takeda License and Termination Agreement <font style="color:#000000;">under which Takeda will secure global rights at closing from us to develop and commercialize the investigational medicine OV935 for the treatment of developmental and epileptic encephalopathies, including DS and LGS</font>. Closing of the Takeda License and Termination Agreement is subject to satisfaction of customary closing conditions. See &#8220;Business&#8212;License and Collaboration Agreements&#8212;<font style="color:#000000;">Agreements with Takeda&#8212;2021 </font>Royalty, License and Termination Agreement with Takeda&#8221; for a discussion of the terms of the Takeda License and Termination Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:19pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Risks associated with the in-licensing or acquisition of drug candidates could cause substantial delays in the preclinical and clinical development of our drug candidates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.55%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to March 2015, we had no involvement with or control over the preclinical and clinical research and development of OV101. We have relied on Lundbeck or its prior licensee to have conducted such research and development in accordance with the applicable protocol, legal, regulatory and scientific standards, having accurately reported the results of all clinical trials conducted prior to our acquisition of OV101 and having correctly collected and interpreted the data from these trials. If the research and development processes or the results of the development programs prior to our acquisition of OV101 prove to be unreliable, this could result in increased costs and delays in the development of OV101, which could adversely affect any future revenue from this drug candidate.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:13pt;text-indent:5.55%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similarly, we acquired rights to OV935 from Takeda in January 2017. Because we were not involved in the development of OV935 prior to January 2017, we may experience difficulties in the transition of certain development activities from Takeda and its affiliates to us, which may result in delays in clinical trials, as well as problems in our development efforts</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">entered into</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Takeda License and Termination Agreement</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;">under which Takeda will secure global rights at closing from us to develop and commercialize the investigational medicine OV935 for the treatment of developmental and epileptic encephalopathies, including DS and LGS</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Closing of the Takeda License and Termination Agreement is subject to satisfaction of customary closing conditions. See &#8220;Business&#8212;License and Collaboration Agreements&#8212;</font><font style="color:#000000;">Agreements with Takeda</font><font style="color:#000000;">&#8212;</font><font style="color:#000000;">2021 </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty, License and Termination Agreement with Takeda&#8221; for a discussion of the terms of the Takeda License and Termination Agreement.</font></p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:5.55%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also acquire or in-license additional drug candidates for preclinical or clinical development in the future as we continue to build our pipeline. The risks associated with acquiring or in-licensing current or future drug candidates could result in delays in the commencement or completion of our preclinical studies and clinical trials, if ever, and our ability to generate revenues from our drug candidates may be delayed.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be required to relinquish important rights to and control over the development and commercialization of our drug candidates to any future collaborators.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.55%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current and future collaborations could subject us to a number of risks, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we may be required to undertake the expenditure of substantial operational, financial and management resources;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we may be required to issue equity securities that would dilute our stockholders&#8217; percentage of ownership;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we may be required to assume substantial actual or contingent liabilities;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we may not be able to control the amount and timing of resources that our strategic collaborators devote to the development or commercialization of our drug candidates;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>strategic collaborators may delay clinical trials, provide insufficient funding, terminate a clinical trial or abandon a drug candidate, repeat or conduct new clinical trials or require a new version of a drug candidate for clinical testing;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>strategic collaborators may not pursue further development and commercialization of products resulting from the strategic collaboration arrangement or may elect to discontinue research and development programs;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>strategic collaborators may not commit adequate resources to the marketing and distribution of our drug candidates, limiting our potential revenues from these products;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we rely on our current collaborators to manufacture drug substance and drug product and may do so with respect to future collaborators, which could result in disputes or delays;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">disputes may arise between us and our strategic collaborators that result in the delay or termination of the research, development or commercialization of our drug candidates or that result in costly litigation or arbitration that diverts management&#8217;s attention and consumes resources;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>strategic collaborators may experience financial difficulties;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>strategic collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>business combinations or significant changes in a strategic collaborator&#8217;s business strategy may also adversely affect a strategic collaborator&#8217;s willingness or ability to complete its obligations under any arrangement;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>strategic collaborators could decide to move forward with a competing drug candidate developed either independently or in collaboration with others, including our competitors; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>strategic collaborators could terminate the arrangement or allow it to expire, which would delay the development and may increase the cost of developing our drug candidates.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may explore additional strategic collaborations that may never materialize or may fail.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.55%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business strategy is based on acquiring or in-licensing compounds directed at rare neurological disorders. As a result, we intend to periodically explore a variety of possible additional strategic collaborations in an effort to gain access to additional drug candidates or resources. At the current time, we cannot predict what form such a strategic collaboration might take. We are likely to face significant competition in seeking appropriate strategic collaborators, and strategic collaborations can be complicated and time consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any additional strategic collaborations because of the numerous risks and uncertainties associated with establishing them.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Regulatory Compliance</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0.41%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our relationships with customers, physicians, and third-party payors may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any drug candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors may subject us to various federal and state fraud and abuse laws and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims laws and the law commonly referred to as the Physician Payments Sunshine Act and regulations. These laws will impact, among other things, our clinical research, proposed sales, marketing and educational programs. In addition, we may be subject to patient privacy laws by both the federal government and the states in which we conduct or may conduct our business. The laws that will affect our operations include, but are not limited to:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the federal Anti-Kickback Statute, which prohibits, among other things, </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">persons</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for the purchase, recommendation, leasing or furnishing of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand, and prescribers, </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">purchasers</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and formulary managers on the other. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;PPACA&#8221;), amended the intent requirement of the federal Anti-Kickback Statute. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">violation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>federal civil and criminal false claims laws, including, without limitation, the False Claims Act, and civil monetary penalty laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other government payors that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. The PPACA provides, and recent government cases against pharmaceutical and medical device manufacturers support, the view that federal Anti-Kickback Statute violations and certain marketing practices, including off-label promotion, may implicate the False Claims Act;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which created additional federal criminal statutes that prohibit a person from knowingly and willfully executing a scheme or making false or fraudulent statements to defraud any healthcare benefit program, regardless of the payor (e.g., public or private);</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and their implementing regulations, and as amended again by the final HIPAA omnibus rule, Modifications to the HIPAA Privacy, Security, Enforcement, and Breach Notification Rules Under HITECH and the Genetic Information Nondiscrimination Act; Other Modifications to HIPAA, published in January 2013, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, healthcare clearinghouses and certain healthcare providers, known as covered entities, and their respective business associates, individuals or entities that perform certain services on behalf of a covered entity that involves the use or disclosure of individually identifiable health information and their subcontractors that use, disclose or otherwise process individually identifiable health information;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>Physician Payments Sunshine Act, which is part of the PPACA, that require certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;), information related to: (i)&#160;payments or other &#8220;transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals; and (ii)&#160;ownership and investment interests held by physicians and their immediate family members which will be expanded beginning in 2022, to require applicable manufacturers to report information regarding payments and other transfers of value provided to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>state and foreign law equivalents of each of the above federal laws, state laws that require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and/or information regarding drug pricing, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or to adopt compliance programs as prescribed by state laws and regulations, or that otherwise restrict payments that may be made to healthcare providers, state laws and regulations that require drug manufacturers to file reports relating to drug pricing and marketing information, and state and local laws that require the registration of pharmaceutical sales representatives; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</font></p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Coverage and adequate reimbursement may not be available for our current or any future drug candidates, which could make it difficult for us to sell profitably, if approved.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Market acceptance and sales of any drug candidates that we commercialize, if approved, will depend in part on the extent to which coverage and adequate reimbursement for these drugs and related treatments will be available from third-party payors, including government health administration authorities, managed care organizations and other private health insurers. Third-party payors decide which therapies they will pay for and establish reimbursement levels. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any drug candidates that we develop will be made on a payor-by-payor basis. One third-party payor&#8217;s determination to provide coverage for a drug does not assure that other payors will also provide coverage, and adequate reimbursement, for the drug. Additionally, a third-party payor&#8217;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Each third-party payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier of its formulary it will be placed. The position on a third-party payor&#8217;s list of covered drugs, or formulary, generally determines the co-payment that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our drugs unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our drugs.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be available for any drug that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage and reimbursement may impact the demand for, or the price of, any drug for which we obtain marketing approval. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize our current and any future drug candidates that we develop. Further, coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Healthcare legislative reform measures may have a negative impact on our business and results of operations.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of drug candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any drug candidates for which we obtain marketing approval.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In March 2010, the PPACA was passed, which substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been executive, judicial, Congressional and executive branch challenges to certain aspects of the PPACA. For example, President Trump signed Executive Orders and other directives designed to delay the implementation of certain provisions of the PPACA or otherwise circumvent some of the requirements for health insurance mandated by the PPACA.&#160;&#160;Concurrently, Congress considered legislation to repeal or repeal and replace all or part of the PPACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the PPACA such as removing penalties, starting January 1, 2019, for not complying with the PPACA&#8217;s individual mandate to carry health insurance, delaying the implementation of certain PPACA-mandated fees, and increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D.&#160;&#160;Additionally, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the PPACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. On December 14, 2018, a Texas U.S. District Court Judge ruled that the PPACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the PPACA are invalid as well. </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he United States Supreme Court </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is currently</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> review</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ing</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> this case, but it is unknown when a decision will be reached. Although the Supreme Court has not yet ruled on the constitutionality of the PPACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the PPACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that creat</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> barriers to obtaining access to health insurance coverage through Medicaid or the PPACA.</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is unclear how</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the Supreme Court ruling, other</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> such litigation and </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the healthcare reform measures of the Biden administration </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will impact the PPACA and our business.&#160;&#160;</font></p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other legislative changes have been proposed and adopted since the PPACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013, and due to subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2030 unless additional Congressional action is taken. However, COVID-19 relief legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2021. The American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional changes that may affect our business include the expansion of new programs such as Medicare payment for performance initiatives for physicians under the Medicare Access and CHIP Reauthorization Act of 2015 (&#8220;MACRA&#8221;), which ended the use of the statutory formula and established a quality payment program, also referred to as the Quality Payment Program. In November 2019, CMS issued a final rule finalizing the changes to the Quality Payment Program. At this time, the full impact to overall physician reimbursement as a result of the introduction of the Quality Payment Program remains unclear.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk64229735"></a><a name="_Hlk64470271"></a><a name="_Hlk64233949"></a><a name="_Hlk64754226"></a><a name="_Hlk64756190"></a><a name="_Hlk64540183"></a><a name="_Hlk64756210"></a><a name="_Hlk64230299"></a><a name="_Hlk64232142"></a>Also, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which have resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the federal level<a name="_Hlk64229735"></a><a name="_Hlk64470271"></a><a name="_Hlk64233949"></a>, the Trump administration <font style="color:#000000;">used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#8217;s proposals. The FDA also released a final rule, effective November 30, 2020, implementing a portion of the importation executive order providing guidance for states to build and submit importation plans for drugs from Canada.<a name="_Hlk64754226"></a> <a name="_Hlk64756190"></a><a name="_Hlk64540183"></a>Further, on November&#160;20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part&#160;D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new<a name="_Hlk64756210"></a> safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed pending review by the Biden administration until March 22, 2021. <a name="_Hlk64230299"></a><a name="_Hlk64232142"></a>On November 20, 2020, CMS issued an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. It is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives. At the state level, legislatures have increasingly passed and implemented regulations designed to control pharmaceutical and biological product pricing, including pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </font>We expect that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved drug. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">It is possible that additional governmental action is taken in response to the ongoing COVID-19 pandemic. </font></p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to obtain or maintain orphan drug designations or exclusivity for our drug candidates, which could limit the potential profitability of our drug candidates.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States. Generally, if a drug with an orphan drug designation subsequently receives the first marketing approval for an indication for which it receives the designation, then the drug is entitled to a period of marketing exclusivity that precludes the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applicable regulatory authority from approving another marketing application for the same drug for the same indication for the exclusivity period except in limited situations. For purposes of small molecule drugs, the FDA defines &#8220;same drug&#8221; as a drug that contains the same active moiety and is intended for the same use as the drug in question. A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation.</font></p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For OV101, the FDA granted orphan drug designation for OV101 for the treatment of Angelman syndrome and for the treatment of Fragile X syndrome in September 2016 and October 2017, respectively. The EMA granted orphan designation for OV101 for the treatment of Angelman syndrome in June 2019. The FDA granted orphan drug designation for OV935 for the treatment of Dravet syndrome and Lennox-Gastaut syndrome both in December 2017. We intend to pursue orphan drug designation for OV101 in additional indications, pending our further analysis of the NEPTUNE trial data and analysis of data from ELARA, for OV935 in additional indications, pending closing of the Takeda License and Termination Agreement, and for potential other future drug candidates. Obtaining orphan drug designations is important to our business strategy; however, obtaining an orphan drug designation can be difficult and we may not be successful in doing so. Even if we were to obtain orphan drug designation for a drug candidate, we may not obtain orphan exclusivity and that exclusivity may not effectively protect the drug from the competition of different drugs for the same condition, which could be approved during the exclusivity period. Additionally, after an orphan drug is approved, the FDA could subsequently approve another application for the same drug for the same indication if the FDA concludes that the later drug is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusive marketing rights in the United States also may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. The failure to obtain an orphan drug designation for any drug candidates we may develop, the inability to maintain that designation for the duration of the applicable period, or the inability to obtain or maintain orphan drug exclusivity could reduce our ability to make sufficient sales of the applicable drug candidate to balance our expenses incurred to develop it, which would have a negative impact on our operational results and financial condition.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have received Fast Track designations for&#160;OV101 for<font style="color:#000000;font-weight:normal;font-style:normal;"> </font><font style="color:#000000;">the treatment of Angelman syndrome and Fragile X syndrome</font>, but such designations may not actually lead to a faster development or regulatory review or approval process.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA granted Fast Track designations to&#160;OV101 <font style="color:#000000;">for the treatment of Angelman syndrome and Fragile X syndrome in December 2017 and March 2018, respectively</font>. If a drug is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical need for such condition, a sponsor may apply for FDA Fast Track designation. Even though we received Fast Track designations for&#160;OV101, such Fast Track designations do not ensure that we will receive marketing approval or that approval will be granted within any particular timeframe for any of these fast track-designated indications. We may not experience a faster development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Although the FDA has granted Rare Pediatric Disease&#160;Designation for OV101 for the treatment of Angelman Syndrome, an NDA for OV101,&#160;if approved, may not meet the eligibility criteria for a priority review voucher.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rare Pediatric Disease Designation has been granted for OV101 for the treatment of Angelman Syndrome. In 2012, Congress authorized the FDA to award priority review vouchers to sponsors of certain rare pediatric disease product applications. This provision is designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the U.S. within one year following the date of approval. For the purposes of this program, a &#8220;rare pediatric disease&#8221; is a (a)&#160;serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents; and (b)&#160;rare disease or conditions within the meaning of the Orphan Drug Act. Congress has only authorized the Rare Pediatric Disease Priority Review Voucher program until September 30, 2024. However, if a drug candidate receives Rare Pediatric Disease Designation before September 30, 2024, it is eligible to receive a voucher if it is approved before September 30, 2026.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, OV101 for the treatment of Angelman Syndrome may not be approved by that date, or at all, and, therefore, we may not be in a position to obtain a priority review voucher prior to expiration of the program, unless Congress further reauthorizes the program. Additionally, designation of a drug for a rare pediatric disease&#160;does not guarantee that an NDA will meet the eligibility criteria for a&#160;rare pediatric disease priority review voucher at the time the application is approved. Finally, a&#160;Rare Pediatric Disease Designation does not lead to faster development or regulatory review of the product, or increase the likelihood that it will receive marketing approval. We may or may not realize any benefit from receiving designation or a voucher.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we obtain regulatory approval for our current or future drug candidates, they will remain subject to ongoing regulatory oversight.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain any regulatory approval for our current or future drug candidates, such approvals will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information. Any regulatory approvals that we receive for our current or future drug candidates may also be subject to a REMS, limitations on the approved indicated uses for which the drug may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase&#160;4 trials, and surveillance to monitor the quality, safety and efficacy of the drug.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, drug manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the NDA or foreign marketing application. If we, or a regulatory authority, discover previously unknown problems with a drug, such as adverse events of unanticipated severity or frequency, or problems with the facility where the drug is manufactured or if a regulatory authority disagrees with the promotion, marketing or labeling of that drug, a regulatory authority may impose restrictions relative to that drug, the manufacturing facility or us, including requesting a recall or requiring withdrawal of the drug from the market or suspension of manufacturing.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with applicable regulatory requirements following approval of our current or future drug candidates, a regulatory authority may:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>issue an untitled letter or warning letter asserting that we are in violation of the law;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>seek an injunction or impose administrative, civil or criminal penalties or monetary fines;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>suspend or withdraw regulatory approval;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>suspend any ongoing clinical trials;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>refuse to approve a pending NDA or comparable foreign marketing application (or any supplements thereto) submitted by us or our strategic partners;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>restrict the marketing or manufacturing of the drug;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>seize or detain the drug or otherwise require the withdrawal of the drug from the market;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>refuse to permit the import or export of drug candidates; or</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>refuse to allow us to enter into supply contracts, including government contracts.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, the FDA strictly regulates the promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant civil, criminal and administrative penalties.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our current or future drug candidates and harm our business, financial condition, results of operations and prospects.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the FDA&#8217;s policies, and those of equivalent foreign regulatory agencies, may change and additional government regulations may be enacted that could cause changes to or delays in the drug review process, or suspend or restrict regulatory approval of our drug candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would harm our business, financial condition, results of operations and prospects.&#160;</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0.41%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to obtain and maintain patent protection for our current or any future drug candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our development programs and drug candidates. Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our current and any future drug candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our current and future development programs and drug candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Lundbeck Agreement, as amended, we obtained an exclusive, worldwide license to develop, manufacture and commercialize OV101 for the treatment of human disease. However, the Lundbeck Agreement, as amended, permits Lundbeck and certain other entities to manufacture and research OV101 and, in certain situations, to perform additional non-commercial activities involving OV101, all of which could result in new patentable inventions concerning the manufacture or use of OV101. While the Lundbeck Agreement, as amended, prohibits Lundbeck from filing certain patent applications regarding OV101 and obligates Lundbeck to include certain newly filed patents in the license granted to us, if new patents issue that cover valuable methods for making or using OV101, we would be prohibited from employing such methods to manufacture or use OV101 unless we obtain a license to such patents.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our current or any future drug candidates in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our current or any future drug candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any drug candidates or companion diagnostic that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a drug candidate and companion diagnostic under patent protection could be reduced.&#160;</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the patent applications we hold or have in-licensed with respect to our development programs and drug candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our current or any future drug candidates, it could dissuade companies from collaborating with us to develop drug candidates, and threaten our ability to commercialize, future drugs. Any such outcome could have a negative effect on our business.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or drugs, in whole or in part, or which effectively prevent others from commercializing competitive technologies and drugs. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On December&#160;16, 2011, the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The United States Patent Office recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective on March&#160;16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could harm our business and financial condition.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office (the &#8220;USPTO&#8221;) or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or drugs and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future drug candidates.</font></p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and drugs, or limit the duration of the patent protection of our technology and drugs. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years from the earliest filing date of a non-provisional patent application. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our current or future drug candidates, we may be open to competition from generic versions of such drugs. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;margin-left:0.41%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be unable to prevent third parties from selling, making, promoting, manufacturing, or distributing alternative polymorphic forms of OV101.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have issued patents directed to polymorphic forms of OV101. These patents would not prevent a third-party from creating, making and marketing alternative polymorphic forms that fall outside the scope of these patent claims. There can be no assurance that any such alternative polymorphic forms will not be therapeutically equivalent and/or commercially feasible. In the event an alternative polymorphic form of OV101 is developed and approved for use in indications that we may seek approval for, the marketability and commercial success of OV101, if approved, could be materially harmed.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned and licensed patents and/or applications and any patent rights we may own or license in the future. We rely on our outside counsel or our licensing partners to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could harm our business.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;margin-left:0.41%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent terms may be inadequate to protect our competitive position on our drug candidates for an adequate amount of time.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the amount of time required for the development, testing and regulatory review of new drug candidates such as OV101, patents protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved indication (or any additional indications approved during the period of extension). However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their drug earlier than might otherwise be the case.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;margin-left:0.41%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property rights do not necessarily address all potential threats to our business.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business. The following examples are illustrative:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">others may be able to make compounds or formulations that are similar to our drug candidates but that are not covered by the claims of any patents, should they issue, that we own or </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">control;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we or any strategic partners might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or control;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we might not have been the first to file patent applications covering certain of our inventions;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>it is possible that our pending patent applications will not lead to issued patents;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>issued patents that we own or control may not provide us with any competitive advantages, or may be held invalid or unenforceable because of legal challenges;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights and then use the information learned from such activities to develop competitive drugs for sale in our major commercial markets;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>we may not develop additional proprietary technologies that are patentable; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the patents of others may have an adverse effect on our business.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The proprietary map of disease-relevant biological pathways underlying orphan disorders of the brain that we developed would not be appropriate for patent protection and, as a result, we rely on trade secrets to protect this aspect of our business.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;margin-left:0.41%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends, in part, upon our ability and the ability of our current or future collaborators to develop, manufacture, market and sell our current and any future drug candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current and any future drug candidates and technology, including interference proceedings, post grant review and&#160;inter partes&#160;review before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit.&#160;There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could have a negative impact on our ability to commercialize our current and any future drug candidates.&#160;&#160;In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If we are found to infringe a third party&#8217;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our drug candidate(s) and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or drug candidate. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from manufacturing and commercializing our current or any future drug candidates or force us to cease some or all of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.&#160; See the section herein titled &#8220;Legal Proceedings&#8221; for additional information.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;margin-left:0.41%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</font></p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;margin-left:0.41%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring counter claims against us such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, inter partes review, or post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. For the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future drug candidates. Such a loss of patent protection could harm our business.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;margin-left:0.41%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current and any future drug candidates.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The United States has recently enacted and implemented wide-ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future.&#160;</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;margin-left:0.41%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prosecuting</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and defending patents covering our current and any future drug candidates throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own drugs and, further, may export otherwise infringing drugs to territories where we may obtain patent protection, but where patent enforcement is not as strong as that in the United States. These drugs may compete with our drugs in jurisdictions where we do not have any issued or licensed patents and any future patent </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claims</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</font></p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;margin-left:0.41%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we rely on third parties to manufacture or commercialize our current or any future drug candidates, or if we collaborate with additional third parties for the development of our current or any future drug candidates, we must, at times, share trade secrets with them. We may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure could have an adverse effect on our business and results of operations.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any third-party collaborators. A competitor&#8217;s discovery of our trade secrets would harm our business.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Dependence on Third Parties</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:0.41%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We do not have our own manufacturing capabilities and will rely on third parties to produce clinical and commercial supplies of our current and any future drug candidates.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not own or operate, and we do not expect to own or operate, facilities for drug manufacturing, storage and distribution, or testing. We will be dependent on third parties to manufacture the clinical supplies of our drug candidates. The drug substance for OV101 was manufactured by Lundbeck. We believe that the drug substance transferred from Lundbeck under the Lundbeck Agreement will be sufficient for us to complete our ongoing and future clinical trials. Until the closing of the <font style="color:#000000;">Takeda License and Termination Agreement</font>, we will also continue to rely on Takeda to provide the drug product supply for our planned clinical trials of OV935.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, we also will rely on third-party manufacturers to supply us with sufficient quantities of our drug candidates, including OV101 and OV935, to be used, if approved, for commercialization. Any significant delay in the supply of a drug candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our drug candidates.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, our reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured drug candidates ourselves including:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inability to meet our drug specifications and quality requirements </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consistently;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>delay or inability to procure or expand sufficient manufacturing capacity;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>issues related to scale-up of manufacturing;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>costs and validation of new equipment and facilities required for scale-up;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>failure to comply with cGMP and similar foreign standards;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>inability to negotiate manufacturing agreements with third parties under commercially reasonable terms, if at all;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>reliance on single sources for drug components;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>lack of qualified backup suppliers for those components that are currently purchased from a sole or single source supplier;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>carrier disruptions or increased costs that are beyond our control.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could lead to clinical trial delays, failure to obtain regulatory approval or impact our ability to successfully commercialize our current or any future drug candidates once approved. Some of these events could be the basis for FDA action, including injunction, request for recall, seizure, or total or partial suspension of production.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;margin-left:0.41%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We intend to rely on third parties to conduct, supervise and monitor our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently have the ability to independently conduct any clinical trials. We intend to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our preclinical studies and clinical trials, and we expect to have limited influence over their actual performance. We intend to rely upon CROs to monitor and manage data for our clinical programs, as well as the execution of future nonclinical studies. We expect to control only certain aspects of our CROs&#8217; activities. Nevertheless, we will be responsible for ensuring that each of our preclinical studies or clinical trials are conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and our CROs will be required to comply with good laboratory practices (&#8220;GLPs&#8221;) and good clinical practices (&#8220;GCPs&#8221;), which are regulations and guidelines enforced by the FDA and are also required by the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities in the form of International Conference on Harmonization guidelines for any of our drug candidates that are in preclinical and clinical development. The regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and clinical trial sites. Although we will rely on CROs to conduct GCP-compliant clinical trials, we remain responsible for ensuring that each of our GLP preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities. If we or our CROs fail to comply with GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. Accordingly, if our CROs fail to comply with these regulations or fail to recruit a sufficient number of subjects, we may be required to repeat clinical trials, which would delay the regulatory approval process.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we will have agreements governing their activities, our CROs will not be our employees, and we will not control whether or not they devote sufficient time and resources to our future clinical and nonclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities which could harm our business. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any drug candidate that we develop. As a result, our financial results and the commercial prospects for any drug candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our relationship with these CROs terminates, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management time and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can negatively impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a negative impact on our business, financial </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condition</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and prospects.</font></p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our current and future drug candidates.&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our contemplated royalty, license and repurchase agreement with Takeda is not successfully closed or if we fail to realize the benefits we anticipate from such strategic alliance, <font style="color:#000000;">it may harm our business</font>. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we entered into the Takeda License and Termination Agreement under which Takeda will secure global rights at closing from us to develop and commercialize the investigational medicine OV935 for the treatment of developmental and epileptic encephalopathies, including DS and LGS.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Takeda collaboration, Takeda received equity in us and was eligible to receive up to $85.0 million in payments for regulatory milestones, including the initiation of Phase 3 clinical trials. Since signing the agreement, we led global development of OV935.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should we close the Takeda License and Termination Agreement, all rights in OV935 will be owned by Takeda, or exclusively licensed to Takeda by us.&nbsp;&nbsp;Takeda will assume sole responsibility for further worldwide development and commercialization, and we will no longer have any financial obligation to Takeda under the original collaboration agreement, including for milestone payments or any future development and commercialization costs.&nbsp;&nbsp;Under the Takeda License and Termination Agreement we will be eligible to receive an upfront payment of $196.0 million at closing and eligible to receive up to an additional $660.0 million upon Takeda achieving development, regulatory and sales milestones. In addition, we would be entitled to receive tiered royalties beginning in the low double-digits, and up to 20% on sales of OV935, if approved and commercialized.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to close the Takeda License and Termination Agreement in the first half of 2021, subject to the satisfaction of customary closing conditions, including regulatory review by the appropriate regulatory agencies under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (&#8220;HSR Act&#8221;). We cannot assure you that such closing conditions will be satisfied or that the post-closing filing will be approved by the appropriate regulatory agencies under the HSR Act. If the regulatory agencies do not approve our filing, such agencies may request us to rescind the transactions related to the Takeda License and Termination Agreement. If we fail to close the Takeda License and Termination Agreement, then we will not be entitled to any of the payments described above, and the current terms of collaboration and related risks will remain in effect and our business and financial condition may be harmed.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Business Operations, Employee Matters and Managing Growth</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COVID-19 could adversely impact our business, including our clinical trials and access to capital.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ongoing COVID-19 pandemic has resulted in travel and other restrictions in order to reduce the spread of the disease, including state and local orders across the country, which, among other things, direct individuals to shelter at their places of residence, direct businesses and governmental agencies to cease non-essential operations at physical locations, prohibit certain non-essential gatherings, and order cessation of non-essential travel. In response to these public health directives and orders, we have implemented work-from-home policies for all employees.&#160;Our current plans to return to the office remain fluid as federal, state and local guidelines, rules and regulations continue to evolve.&#160;The effects of the executive orders, the shelter-in-place orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quarantines, shelter-in-place and similar government orders related to COVID-19 may adversely impact our business operations and the business operations of our contract research organizations conducting our clinical trials and our third-party manufacturing facilities in the United States and other countries.&#160;In particular, some of our third-party manufacturers which we use for the supply of materials for product candidates or other materials necessary to manufacture product to conduct preclinical studies and clinical trials are located in countries affected by COVID-19, and should they experience disruptions, such as temporary closures or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suspension of services, we would likely experience delays in advancing these tests and trials. Currently, we expect no material impact on the clinical supply of any of our product candidates.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:13pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our clinical trials may be affected by the COVID-19 pandemic.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:13pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Some patients may not be willing or able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 and adversely impact our clinical trial operations.&#160;As a result of the COVID-19 pandemic, we have faced and may continue to face delays in meeting our anticipated timelines for our ongoing and planned clinical trials.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:13pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:13pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The global pandemic of COVID-19 continues to rapidly evolve. The extent to which the COVID-19 pandemic impacts our business, our clinical development and regulatory efforts will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, travel restrictions, quarantines, social distancing requirements and business closures in the United States and other countries, and business disruptions, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.&#160;&#160;Accordingly, we do not yet know the full extent of potential delays or impacts on our business, our clinical and regulatory activities, healthcare systems or the global economy as a whole.&#160;&#160;However, these impacts could adversely affect our business, financial condition, results of operations and growth prospects.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:13pt;margin-left:0.91%;text-indent:4.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, to the extent the ongoing COVID-19 pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described in this &#8216;&#8216;Risk Factors&#8217;&#8217; section.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0.91%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are highly dependent on the services of our senior management team, including our Chairman and Chief Executive Officer, Dr.&#160;Jeremy Levin, and if we are not able to retain these members of our management team or recruit and retain additional management, clinical and scientific personnel, our business will be harmed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.55%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are highly dependent on our senior management team, including our Chairman and Chief Executive Officer, Dr.&#160;Levin. The employment agreements we have with these officers do not prevent such persons from terminating their employment with us at any time. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:13pt;text-indent:5.55%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we are dependent on our continued ability to attract, retain and motivate highly qualified additional management, clinical and scientific personnel. If we are not able to retain our management and to attract, on acceptable terms, additional qualified personnel necessary for the continued development of our business, we may not be able to sustain our operations or grow.&#160;&#160;This risk may be further amplified given the particularly competitive hiring market in New York City, the location of our corporate headquarters.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:13pt;text-indent:5.55%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to attract or retain qualified personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. Many of the other pharmaceutical companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates and consultants than what we have to offer. If we are unable to continue to attract, retain and motivate high-quality personnel and consultants to accomplish our business objectives, the rate and success at which we can discover and develop drug candidates and our business will be limited and we may experience constraints on our development objectives.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:13pt;text-indent:5.55%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future performance will also depend, in part, on our ability to successfully integrate newly hired executive officers into our management team and our ability to develop an effective working relationship among senior management. Our failure to integrate these individuals and create effective working relationships among them and other members of management could result in inefficiencies in the development and commercialization of our drug candidates, harming future regulatory approvals, sales of our drug candidates and our results of operations. Additionally, we do not currently maintain &#8220;key person&#8221; life insurance on the lives of our executives or any of our employees.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We </font><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</font><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had 67 full-time employees. As our development and commercialization plans and strategies develop, we expect to need additional managerial, operational, sales, marketing, financial, legal and other resources. Our management may need to divert a disproportionate amount of its attention away from our day-to-day operations and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational inefficiencies, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of our current and potential future drug candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance, our ability to commercialize drug candidates, develop a scalable infrastructure and compete effectively will depend, in part, on our ability to effectively manage any future growth.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;margin-left:0.41%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</p>
<p style="text-align:justify;margin-top:11pt;margin-bottom:0pt;text-indent:5.5%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk that our employees, consultants, distributors, and collaborators may engage in fraudulent or illegal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violates the regulations of the FDA and non-U.S. regulators, including those laws requiring the reporting of true, complete and accurate information to such regulators, manufacturing standards, healthcare fraud and abuse laws and regulations in the United States and abroad or laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry, including the sale of pharmaceuticals, are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. It is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Further, because of the work from home policies we implemented due to COVID-19, information that is normally protected, including company confidential information, may be less secure. If actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of significant fines or other sanctions, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and curtailment of operations, any of which could adversely affect our ability to operate our business and our results of operations. Whether or not we are successful in defending against such actions or investigations, we could incur substantial costs, including legal fees, and divert the attention of management in defending ourselves against any of these claims or investigations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Significant disruptions of our information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to us.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business. In the ordinary course of our business, we collect, store, process and transmit large amounts of sensitive information, including intellectual property, proprietary business information, personal information and other confidential information. It is critical that we do so in a secure manner to maintain the confidentiality, integrity and availability of such sensitive information. We have also outsourced elements of our operations (including elements of our information technology infrastructure) to third parties, and as a result, we manage a number of third-party vendors who may or could have access to our computer networks or our confidential information. In addition, many of those third parties in turn subcontract or outsource some of their responsibilities to third parties. While all information technology operations are inherently vulnerable to inadvertent or intentional security breaches, incidents, attacks and exposures, the accessibility and distributed nature of our information technology systems, and the sensitive information stored on those systems, make such systems potentially vulnerable to unintentional or malicious, internal and external attacks on our technology environment. In addition, due to the COVID-19 pandemic, we have enabled all of our employees to work remotely, which may make us more vulnerable to cyberattacks. Potential vulnerabilities can be exploited from inadvertent or intentional actions of our employees, third-party vendors, business partners, or by malicious third parties. Attacks of this nature are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives (including, but not limited to, industrial espionage) and expertise, including organized criminal groups, &#8220;hacktivists,&#8221; nation states and others. In addition to the extraction of sensitive information, such attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">confidentiality, integrity and availability of information. In addition, the prevalent use of mobile devices increases the risk of data security incidents.</font></p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant disruptions of our, our third-party vendors&#8217; and/or business partners&#8217; information technology systems or other similar data security incidents could adversely affect our business operations and/or result in the loss, misappropriation, and/or unauthorized access, use or disclosure of, or the prevention of access to, sensitive information, which could result in financial, legal, regulatory, business and reputational harm to us. In addition, information technology system disruptions, whether from attacks on our technology environment or from computer viruses, natural disasters, terrorism, war and telecommunication and electrical failures, could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no way of knowing with certainty whether we have experienced any data security incidents that have not been discovered. While we have no reason to believe this to be the case, attackers have become very sophisticated in the way they conceal access to systems, and many companies that have been attacked are not aware that they have been attacked. Any event that leads to unauthorized access, use or disclosure of personal information, including but not limited to personal information regarding our patients or employees, could disrupt our business, harm our reputation, compel us to comply with applicable federal and/or state breach notification laws and foreign law equivalents, subject us to time consuming, distracting and expensive litigation, regulatory investigation and oversight, mandatory corrective action, require us to verify the correctness of database contents, or otherwise subject us to liability under laws, regulations and contractual obligations, including those that protect the privacy and security of personal information. This could result in increased costs to us, and result in significant legal and financial exposure and/or reputational harm. In addition, any failure or perceived failure by us or our vendors or business partners to comply with our privacy, confidentiality or data security-related legal or other obligations to third parties, or any further security incidents&#160;or other inappropriate access events that result in the unauthorized access, release or transfer of sensitive information, which could include personally identifiable information, may result in governmental investigations, enforcement actions, regulatory fines, litigation, or public statements against us by advocacy groups or others, and could cause third parties, including clinical sites, regulators or current and potential partners, to lose trust in us or we could be subject to claims by third parties that we have breached our privacy- or confidentiality-related obligations, which could materially and adversely affect our business and prospects. Moreover, data security incidents and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. While we have implemented security measures intended to protect our information technology systems and infrastructure, there can be no assurance that such measures will successfully prevent service interruptions or security incidents.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to numerous and varying privacy and security laws, and our failure to comply could result in penalties and reputational damage.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to laws and regulations covering data privacy and the protection of personal information including health information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues which may affect our business. In the U.S., we may be subject to state security breach notification laws, state health information privacy laws and federal and state consumer protections laws which impose requirements for the collection, use, disclosure and transmission of personal information. Each of these laws is subject to varying interpretations by courts and government agencies, creating complex compliance issues for us. If we fail to comply with applicable laws and regulations we could be subject to penalties or sanctions, including criminal penalties if we knowingly obtain individually identifiable health information from a covered entity in a manner that is not authorized or permitted by HIPAA or for aiding and abetting the violation of HIPAA.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerous other countries have, or are developing, laws governing the collection, use and transmission of personal information as well. EU member states and other jurisdictions have adopted data protection laws and regulations, which impose significant compliance obligations. For example, in May 2016, the EU formally adopted the General Data Protection Regulation, or GDPR, which applies to all EU member states as of May 25, 2018 and replaces the former EU Data Protection Directive. The regulation introduces new data protection requirements in the EU and imposes substantial fines for breaches of the data protection rules. The GDPR must be implemented into national laws by the EU member states imposes strict obligations and restrictions on the ability to collect, analyze, and transfer personal data, including health data from clinical trials and adverse event reporting. Data protection authorities from different EU member states have interpreted the privacy laws differently, which adds to the complexity of processing personal data in the EU, and guidance on implementation and compliance practices are often updated or otherwise revised. Any failure to comply with the rules arising from the GDPR and related national laws of EU member states could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results. The GDPR will increase our responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with EU data protection rules.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, California enacted the California Consumer Privacy Act (the &#8220;CCPA&#8221;) legislation that has been dubbed the first &#8220;GDPR-like&#8221; law in the United States. <font style="Background-color:#FFFFFF;color:#000000;">The CCPA gives California residents expanded rights to access and delete their personal </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;color:#000000;">information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation.&#160;&#160;The CCPA may increase our compliance costs and potential liability. </font></p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34477615"></a>Risks Related to Being a Public Company</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; and the reduced disclosure requirements applicable to such companies may make our common stock less attractive to investors.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:2.77%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an emerging growth company (&#8220;EGC&#8221;), as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). We will remain an EGC until the earlier of: (i)&#160;the last day of the fiscal year in which we have total annual gross revenues of $1.07&#160; billion or more; (ii)&#160;December 31, 2022, the last day of the fiscal year following the fifth anniversary of the date of the completion of our IPO; (iii)&#160;the date on which we have issued more than $1.0 &#160;billion in nonconvertible debt during the previous three years; or (iv)&#160;the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission (&#8220;SEC&#8221;). For so long as we remain an EGC, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002 (&#8220;Section&#160;404&#8221;);</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>reduced disclosure obligations regarding executive compensation arrangements; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently intend to take advantage of some, but not all, of the reduced regulatory and reporting requirements that will be available to us so long as we qualify as an EGC. For example, our independent registered public accounting firm will not be required to provide an attestation report on the effectiveness of our internal control over financial reporting so long as we qualify as an EGC, which may increase the risk that material weaknesses or significant deficiencies in our internal control over financial reporting go undetected. Likewise, so long as we qualify as an EGC, we may elect not to provide you with certain information, including certain financial information and certain information regarding compensation of our executive officers, that we would otherwise have been required to provide in filings we make with the SEC, which may make it more difficult for investors and securities analysts to evaluate our company. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile and may decline.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:5.55%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the JOBS Act provides that an EGC may take advantage of an extended transition period for complying with new or revised accounting standards. This allows an EGC to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not an EGC.&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also a smaller reporting company as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as (i) our voting and&#160;non-voting&#160;common stock held by nonaffiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and&#160;non-voting&#160;common stock held by&#160;non-affiliates&#160;is less than $700.0&#160;million measured on the last business day of our second fiscal quarter.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will continue to incur increased costs as a result of operating as a public company, and our management will devote substantial time to new compliance initiatives.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.55%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, and particularly after we are no longer an EGC, we will incur significant legal, </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">accounting</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the SEC and The Nasdaq Stock Market LLC have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these and other compliance initiatives. Moreover, these rules and regulations will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to maintain an effective system of internal control over financial reporting in the future, we may not be able to accurately report our financial condition, results of operations or cash flows, which may adversely affect investor confidence in us and, as a result,&#160;the value of our common stock.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.55%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. We are required, under Section&#160;404, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting that results in more than a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. Section&#160;404 also generally requires an attestation from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. However, for as long as we remain an emerging growth company as defined in the JOBS Act, we intend to take advantage of the exemption permitting us not to comply with the independent registered public accounting firm attestation requirement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:13pt;text-indent:5.55%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our compliance with Section&#160;404 will require that we incur substantial expense and expend significant management efforts. We currently do not have an internal audit group, and we will need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge and compile the system and process documentation necessary to perform the evaluation needed to comply with Section&#160;404. We may not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begins its Section&#160;404 reviews, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by The Nasdaq Stock Market LLC, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:19pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Ownership of Our Common Stock and Other General Matters</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for our common stock<font style="font-weight:normal;font-style:normal;">.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.55%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The market price of our common stock is likely to be volatile. The stock market in general and the market for biopharmaceutical or pharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating performance of particular companies, including very recently in connection with the ongoing COVID-19 pandemic, which has resulted in decreased stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. Broad market and industry factors, including potentially worsening economic conditions and other adverse effects or developments relating to the ongoing COVID-19 pandemic, may negatively affect the market price of our common stock, regardless of our actual operating performance. As a result of this volatility, you may lose all or part of your investment in our common stock since you might be unable to sell your shares at or above the price you paid for the shares. The market price for our common stock may be influenced by many factors, including:</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results of clinical trials of our current and any future drug candidates or those of our </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competitors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the success of competitive drugs or therapies;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>regulatory or legal developments in the United States and other countries;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>developments or disputes concerning patent applications, issued patents or other proprietary rights;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the recruitment or departure of key personnel;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the level of expenses related to our current and any future drug candidates or clinical development programs;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the results of our efforts to discover, develop, acquire or in-license additional drug candidates;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our inability to obtain or delays in obtaining adequate drug supply for any approved drug or inability to do so at acceptable prices;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>significant lawsuits, including patent or stockholder litigation;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>variations in our financial results or those of companies that are perceived to be similar to us;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>changes in the structure of healthcare payment systems;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>market conditions in the pharmaceutical and biotechnology sectors;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>general economic, industry and market conditions; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the other factors described in this &#8220;Risk Factors&#8221; section.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in the past, stockholders have initiated class action lawsuits against companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#8217;s attention and resources.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">There is no public market for our Series A convertible preferred stock<font style="font-weight:normal;font-style:normal;">.</font></p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no established public trading market for our Series A convertible preferred stock, and we do not expect a market to develop. In addition, we do not intend to apply for listing of the Series A convertible preferred stock on any national securities exchange or other nationally recognized trading system. Without an active market, the liquidity of the Series A convertible preferred stock will be limited.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:19pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may sell additional equity or debt securities or enter into other arrangements to fund our operations, which may result in dilution to our stockholders and impose restrictions or limitations on our business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.55%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until we can generate a sufficient amount of revenue from our products, if ever, we expect to finance future cash needs through public or private equity or debt&#160;offerings. In November 2020, we filed a shelf registration statement on Form S-3 (Registration No.&#160;333-250054) that allows us to sell up to an aggregate of $250.0&#160;million of our common stock, preferred stock, debt securities and/or warrants (the &#8220;S-3 Registration Statement&#8221;), which includes a prospectus covering the issuance and sale of up to $75.0&#160;million of common stock pursuant to an at-the-market (&#8220;ATM&#8221;) offering program. As of December 31, 2020, we had $250.0 million available under our S-3 Registration Statement, including $75.0 million available pursuant to our ATM program. Financing activities may have an adverse impact on our stockholders&#8217; rights as well as on our operations, and such additional funding may not be available on reasonable terms, if at&#160;all. If we raise additional funds through the issuance of additional debt or equity securities, it may result in dilution to our existing stockholders and/or increased fixed payment obligations. Furthermore, these securities may have rights senior to those of our common stock and could contain covenants that would restrict our operations and potentially impair our competitiveness, such as redeeming our shares, making investments, issuing additional equity, limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, if we seek funds through arrangements with collaborative partners, these arrangements may require us to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us. Any of these events could significantly harm our business, financial condition and prospects.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.55%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">You will be diluted by any conversions of outstanding Series A convertible&#160;preferred&#160;stock and exercises of outstanding options.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.78%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had outstanding options to purchase an aggregate of 10,403,420 shares of our common stock at a weighted average exercise price of $5.26 per share and 3,250,000 shares of common stock issuable upon conversion of outstanding Series A convertible&#160;preferred&#160;stock for no additional consideration. Such Series A convertible preferred stock is convertible any time at the option of the holder thereof subject to the beneficial ownership limitations described in Note 6 to the financial statements contained in this Annual Report on Form 10-K. The exercise of such options and conversion of the Series A convertible&#160;preferred&#160;stock for shares of our common stock will result in further&#160;dilution&#160;of your investment and could negatively affect the market price of our common stock. In addition, you may experience further&#160;dilution&#160;if we issue common stock, or securities convertible into common stock, in the future. As a result of this&#160;dilution, you may receive significantly less than the full purchase price you paid for the shares in the event of liquidation.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:19pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of ownership of our common stock among our executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.55%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon our shares of our common stock outstanding as of March 8, 2021, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock, in the aggregate, beneficially own shares representing approximately&#160;35.54% of our outstanding common stock.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:13pt;text-indent:5.55%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Takeda, a greater than 5% holder, may receive additional securities upon the achievement of certain development, commercial and regulatory milestones pursuant to the Takeda collaboration. Specifically, we will be obligated to issue additional securities to Takeda equal to the lesser of 8% of our outstanding capital stock or $50.0&#160;million unless certain events occur, and may issue, at our discretion, additional securities to Takeda upon the achievement of other milestones. Further, pursuant to the Series B-1 preferred stock purchase agreement entered into with Takeda in January 2017, or the Takeda stock purchase agreement, Takeda has agreed to, among other things, (i)&#160;a standstill provision, (ii)&#160;restrictions on its ability to sell or otherwise transfer it shares of our stock, (iii)&#160;vote its shares on certain matters in accordance with the holders of a majority of shares of our common stock and (iv)&#160;restrictions on the percentage of our outstanding common stock it may own.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:13pt;text-indent:5.55%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock acted together, they may be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. The concentration of voting power, Takeda standstill provisions, voting obligations and transfer restrictions could delay or prevent an acquisition of our company on terms that other stockholders may desire or result in the management of our company in ways with which other stockholders disagree with.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock relies, in part, on the research and reports that industry or financial analysts publish about us or our business.&#160;&#160;We do currently have research coverage offered by several industry or financial analysts. If one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Provisions in our corporate charter documents and under Delaware law could </font><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">make an acquisition of</font><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>establish a classified board of directors such that not all members of the board are elected at one time;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>allow the authorized number of our directors to be changed only by resolution of our board of directors;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>limit the manner in which stockholders can remove directors from the board;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>limit who may call stockholder meetings;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a stockholder rights plan, or so-called &#8220;poison pill,&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>require the approval of the holders of at least 66&#160;2/3% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the Takeda standstill provisions and transfer restrictions in the Takeda Stock Purchase Agreement may delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to securities litigation, which is expensive and could divert management attention.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The market price of our common stock may be volatile.&#160;&#160;For example, on August 25, 2020, we announced the topline results of our ELEKTRA clinical trial, and our stock experienced a material decline.&#160;&#160;In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would benefit our stockholders and may prevent attempts by our stockholders to replace or remove our current management.</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders, or remove our current management. These provisions include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>authorizing the issuance of &#8220;blank check&#8221; preferred stock, the terms of which we may establish and shares of which we may issue without stockholder approval;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>prohibiting cumulative voting in the election of directors, which would otherwise allow for less than a majority of stockholders to elect director candidates;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>eliminating the ability of stockholders to call a special meeting of stockholders; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, who are responsible for appointing the members of our management. Because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), which may discourage, delay or prevent someone from acquiring us or merging with us whether or not it is desired by or beneficial to our stockholders. Under the DGCL, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other things, the board of directors has approved the transaction. Any provision of our amended and restated certificate of incorporation or amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change of control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors are willing to pay for our common stock.</p>
<p style="text-align:justify;margin-top:19pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business plan is to continue to evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary drugs, intellectual property rights, technologies, or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>increased operating expenses and cash requirements;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the assumption of additional indebtedness or contingent liabilities;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>assimilation of operations, intellectual property and drugs of an acquired company, including difficulties associated with integrating new personnel;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>the diversion of our management&#8217;s attention from our existing drug programs and initiatives in pursuing such a strategic partnership, merger or acquisition;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing drugs or drug candidates and regulatory approvals; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font>our inability to generate revenue from acquired technology and/or drugs sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if we engage in future acquisitions or strategic partnerships, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or drugs that may be important to the development of our business.</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market could cause the market price of our common stock to drop significantly.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a large number of</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares intend to sell shares, could reduce the market price of our common stock. Some of the holders of our securities have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. Registration of these shares would result in the shares becoming freely tradable without restriction under the Securities Act except for shares held by our affiliates. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a>Item&#160;1B. Unresolved Staff Comments</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_PROPERTIES"></a><a name="ITEM_2_PROPERTIES"></a>Item&#160;2. Properties</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We lease the space for our principal executive offices, which are located at 1460 Broadway, New York, New York, on a monthly basis. We believe that our facilities are adequate to meet our current needs.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_LEGAL_PROCEEDINGS"></a><a name="ITEM_3_LEGAL_PROCEEDINGS"></a>Item&#160;3. Legal Proceedings</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not currently subject to any material legal proceedings<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a>Item&#160;4. Mine Safety Disclosures</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a>PART</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> II</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a>Item&#160;5. Market for Registrant&#8217;s Common Equity,<a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a> Related Stockholder Matters and Issuer Purchases of Equity Securities</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Market Information</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock began trading on The Nasdaq Global Select Market on May 5, 2017, under the symbol &#8220;OVID.&#8221; </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Comparative Stock Performance Graph</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following performance graph and related information shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act or Exchange Act. The following graph shows a comparison from May 5, 2017 (the date our common stock commenced trading on the Nasdaq Global Select Market) through December&#160;31, 2020, of the cumulative total return for our common stock, the Nasdaq Composite Index, and the Nasdaq Biotechnology.</p>
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g30vudsvo52a000002.jpg" title="" alt="" style="width:686px;height:324px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The graph assumes an initial investment of $100 on May 5, 2017. The comparisons in the graph are not intended to forecast or be indicative of possible future performance of our common stock.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Holders of Record</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 8, 2021, we had approximately 11 holders of record of our common stock. Certain shares are held in &#8220;street&#8221; name and accordingly, the number of beneficial owners of such shares is not known or included in the foregoing number. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any cash dividends on our common stock. We currently intend to retain future earnings to fund the development and growth of our business. We do not expect to pay any cash dividends in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors and will depend on then-existing conditions, including our financial conditions, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Sales of Unregistered Securities</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a>Item&#160;6.&nbsp;&nbsp;Selected Financial Data</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This item is no longer required as we have elected to early adopt the changes to Item 301 of Regulation S-K contained in SEC Release No. 33-10890.</p><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a>Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion and analysis should be read in conjunction with our financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion and analysis and other parts of this Annual Report on Form 10-K contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K. You should carefully read the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section entitled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="text-align:justify;margin-top:11pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_change_7"></a>We are a biopharmaceutical company focused on developing impactful medicines for patients and families living with rare neurological disorders. We believe these disorders represent an attractive area for drug development as the understanding of the underlying biology has grown meaningfully over the last few years and today represent a substantial opportunity medically and commercially. Based on the rapid increase in scientific understanding of the role of genetics and key biological pathways relevant to diseases of the brain, we aim to identify, discover and develop novel compounds for the treatment of rare neurological disorders. We have built a deep knowledge of such diseases, how to treat them and how to develop the clinically meaningful endpoints required for development of a compound in these disorders. As a result of this knowledge, we have developed a pipeline of first-in-class compounds and programs and have demonstrated our model by progressing compounds through to late-stage development. We continue to execute on our strategy to build this pipeline by discovering in-licensing and collaborating with leading biopharmaceutical companies and academic institutions. </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our latest pipeline includes two late-stage programs and several earlier stage programs.</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:4.89%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g30vudsvo52a000003.jpg" title="" alt="" style="width:650px;height:318px;"></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception in April 2014, we have devoted substantially all of our efforts to organizing and planning our business, building our management and technical team, acquiring operating assets and raising capital.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, we generated $12.6 million of license and other revenue through our Collaboration and License Agreement, or the Angelini License Agreement, with Angelini Pharma Rare Diseases AG, or Angelini, and have otherwise funded our business primarily through the sale of our capital stock. Through December&#160;31, 2020, we have raised net proceeds of $275.4 million from the sale of our convertible preferred stock and our common stock. As of December&#160;31, 2020, we had $72.0 million in cash and cash equivalents. We recorded net losses of $81.0 million and $60.5 million for the years ended December&#160;31, 2020 and 2019, respectively. As of December&#160;31, 2020, we had an accumulated deficit of $294.2 million.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. Our net losses may fluctuate significantly from period to period, depending on the timing of our planned clinical trials and expenditures on our other research and development and commercial development activities. We expect our expenses will increase substantially over time as we:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">continue the ongoing and planned preclinical and clinical development of our drug candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">build a portfolio of drug candidates through the development, acquisition or in-license of drugs, drug candidates or technologies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">initiate preclinical studies and clinical trials for any additional drug candidates that we may pursue in the future;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">seek marketing approvals for our current and future drug candidates that successfully complete clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">establish a sales, marketing and distribution infrastructure to commercialize any drug candidate for which we may obtain marketing approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">develop, maintain, expand and protect our intellectual property portfolio;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">implement operational, financial and management systems; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">attract, hire and retain additional administrative, clinical, regulatory, manufacturing, commercial and scientific personnel.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Developments</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Royalty, License and Termination Agreement with Takeda</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 2, 2021, <font style="color:#000000;">we</font> entered into a royalty, license and termination agreement, or the <font style="color:#000000;">Takeda License and Termination Agreement</font>, with Takeda, relating to the Takeda collaboration agreement described above in Item 1. Business section. Under the terms of the <font style="color:#000000;">Takeda License and Termination Agreement</font>, upon closing of the transaction, the Takeda collaboration agreement will be terminated by mutual agreement, and Takeda will secure rights to our 50% global share in soticlestat, and an exclusive license under our relevant intellectual property rights, in exchange for an upfront payment, development and commercial milestone payments, and royalties.&#160;&#160;Takeda will assume all responsibility for, and costs of, both development and commercialization of soticlestat following closing. At closing, we will receive an upfront payment of $196.0 million and are eligible to receive up to an additional $660.0 million in development, regulatory and sales milestones.&#160;&#160;In addition, if soticlestat achieves regulatory approval, we will receive tiered royalties on net sales of soticlestat at percentages ranging from the low double-digits up to 20%, subject to standard reductions in certain circumstances.&#160;&#160;Royalties are payable on a country-by-country and product-by-product basis during the period beginning on the date of the first commercial sale of such product in such country and ending on the later to occur of the expiration of patent rights covering the product in such country and a specified anniversary of such first commercial sale. The <font style="color:#000000;">Takeda License and Termination Agreement</font> will remain in effect until Takeda&#8217;s cessation of commercialization of soticlestat.&#160;&#160;<font style="color:#000000;">We expect to close the Takeda License and Termination Agreement in the first half of 2021, subject to the satisfaction of customary closing conditions, including regulatory review by the appropriate regulatory agencies under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. </font>The <font style="color:#000000;">Takeda License and Termination Agreement </font>may be terminated upon the mutual agreement of the parties, or by either Takeda or the Company, if the closing has not occurred on or before May 14, 2021.&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 Update</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have implemented business continuity plans designed to address and mitigate the impact of the ongoing COVID-19 pandemic on our employees and our business. We continue to operate normally with the exception of enabling all of our employees to work productively at home and abiding by travel restrictions issued by federal, state and local governments. <font style="color:#000000;">Our current plans to return to the office remain fluid as federal, state and local guidelines, rules and regulations continue to evolve</font>. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Operations Overview</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk55389914"></a>We have generated limited revenue under the <font style="color:#000000;">Angelini License Agreement and expect to recognize additional revenue as we satisfy our performance obligations</font>. We have not generated any revenue from commercial drug sales and do not expect to generate any further revenue unless or until we obtain regulatory approval of and commercialize one or more of our current or future drug candidates. In the future, we may also seek to generate revenue from a combination of research and development payments, license fees and other upfront or milestone payments.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist primarily of costs incurred for our research activities, including our product discovery efforts and the development of our product candidates, which include, among other things:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">employee-related expenses, including salaries, benefits and stock-based compensation expense;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">fees paid to consultants for services directly related to our drug development and regulatory effort;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">expenses incurred under agreements with contract research organizations, as well as contract manufacturing organizations and consultants that conduct preclinical studies and clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">costs associated with preclinical activities and development activities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">costs associated with technology and intellectual property licenses;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">milestone payments and other costs under licensing agreements; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">depreciation expense for assets used in research and development activities.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs incurred in connection with research and development activities are expensed as incurred. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or other information provided to us by our vendors.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development activities are and will continue to be central to our business model.&#160;We expect our research and development expenses to increase for the foreseeable future as we advance our current and future drug candidates through preclinical studies and clinical trials. The process of conducting preclinical studies and clinical trials necessary to obtain regulatory approval is costly and time-consuming. It is difficult to determine with certainty the duration and costs of any preclinical study or clinical trial that we may conduct. The duration, costs and timing of clinical trial programs and development of our current and future drug candidates will depend on a variety of factors that include, but are not limited to, the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">number of clinical trials required for approval and any requirement for extension trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">per patient trial costs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">number of patients who participate in the clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">number of sites included in the clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">countries in which the clinical trial is conducted;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">length of time required to enroll eligible patients;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">number of doses that patients receive;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">drop-out or discontinuation rates of patients;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">potential additional safety monitoring or other studies requested by regulatory agencies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">duration of patient follow-up; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">efficacy and safety profile of the drug candidate.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the probability of success for any of our current or future drug candidates will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each drug candidate, as well as an assessment of each drug candidate&#8217;s commercial potential.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of employee-related expenses, including salaries, benefits and stock-based compensation expense, related to our executive, finance, business development and support functions. Other general and administrative expenses include costs associated with operating as a public company described below, travel expenses, conferences, professional fees for auditing, tax and legal services and facility-related costs.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Income, Net</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;margin-left:2.26%;text-indent:4.41%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income consists of interest income earned on our cash and cash equivalents maintained in money market funds and prior short-term investments that were maintained in U.S. treasury notes.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operations</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comparison of the Years Ended December&#160;31, 2020 and 2019</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the results of our operations for the periods indicated: </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change $</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;License and other revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,617</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,617</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;Research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,417</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,157</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,260</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,631</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,252</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,379</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,048</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,409</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,639</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81,431</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61,409</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,022</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">395</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">948</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(553</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81,036</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60,461</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,575</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.83%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue was $12.6 million for the year ended December&#160;31, 2020 as a result of revenue recorded in connection with the Angelini License Agreement. We did not generate any revenue during the year ended December&#160;31, 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:93.26%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65929426"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change $</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,612</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,034</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,578</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and payroll-related expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,439</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,496</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,943</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,366</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,627</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,417</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,157</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,261</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66228678"></a>Research and development expenses were $63.4 million for the year ended December&#160;31, 2020 compared to $42.2 million for the year ended December&#160;31, 2019. <font style="color:#000000;">The increase of $21.3 million was primarily due to an increase in development activities related to our ongoing development programs</font>. During the year ended December 31, 2020, total research and development expenses consisted of $43.6 million in preclinical and development expenses, including a credit of $0.7 million representing costs reimbursable to the Company from Takeda in respect of the Takeda collaboration, $15.4 million in payroll and payroll-related expenses, of which $2.8 million related to stock-based compensation, and $4.4 million in other expenses.&nbsp;&nbsp;<font style="color:#000000;">During the year ended December 31, 2019, total research and development expenses consisted of $27.0 million in preclinical and development expenses, including a credit of $4.7 million representing costs reimbursed to us from Takeda in respect of the Takeda collaboration, $11.5 million in payroll and payroll-related expenses, of which $2.4&#160;million related to stock-based compensation, and $3.6 million in other expenses</font><font style="Background-color:#FFFFFF;color:#000000;">.</font></p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:88.26%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65929428"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Change $</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and payroll-related expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,390</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,888</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,502</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal and professional fees</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,824</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,623</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,201</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General office expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,417</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,741</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(324</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total general and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,631</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,252</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.16%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,379</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.89%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:4.89%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $30.6 million for the year ended December&#160;31, 2020 compared to $19.3&#160;million for the year ended December&#160;31, 2019. <font style="color:#000000;">The increase of $11.4 million primarily consisted of increases in </font>legal fees, compliance and pre-commercialization expenses and professional fees<font style="font-size:9pt;"> </font><font style="color:#000000;">of $8.2 million and payroll-related expenses of $3.5 million. </font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Income, Net </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income includes interest income of $0.4 million for the year ended December&#160;31, 2020 and $0.9 million for the year ended December&#160;31, 2019.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There was no provision for income taxes for the years ended December&#160;31, 2020 and 2019 because we have historically incurred operating losses and we maintain a full valuation allowance against our net deferred tax assets.&nbsp;&nbsp;The valuation allowance was approximately $89.8 million and $76.5 million at December&#160;31, 2020 and 2019, respectively.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Overview </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had total cash, cash equivalents and short-term investments of $72.0 million as compared to $76.7 million as of December&#160;31, 2019.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;9, 2020, we entered into the Angelini License Agreement with Angelini, pursuant to which we granted to Angelini exclusive rights to develop and commercialize OV101 in the European Territory.&nbsp;&nbsp;Under the Angelini License Agreement, Angelini made an upfront payment and a milestone payment related to the transfer of a specified amount of compound and related information to the Company of $25.0 million during the year ended December 31, 2020. In addition, Angelini will be required to make additional milestone payments to us upon the completion of the specified components of the technology transfer, and achievement of specified regulatory milestones for OV101 in Angelman syndrome of up to $55.0&#160;million in the aggregate, as well as up to &#8364;162.5 million ($199.9 million) in sales milestone payments for achievement of specified levels of net sales in the European Territory.&#160;&#160;Angelini also will be required to pay tiered royalties on net sales by Angelini, its affiliates or sublicensees at double-digit percentages above the teens, subject to certain standard reductions and offsets.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, we filed a new shelf registration statement on Form&#160;S-3&#160;(Registration No.&#160;333-250054) that allows us to sell up to an aggregate of $250.0&#160;million of our common stock, preferred stock, debt securities and/or warrants (the &#8220;S-3 Registration Statement&#8221;), which includes a prospectus covering the issuance and sale of up to $75.0&#160;million of common stock pursuant to an at-the-market (&#8220;ATM&#8221;) offering program. As of December 31, 2020, we had $250.0 million available under our S-3 Registration Statement, including $75.0 million available pursuant to our ATM program.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In August 2020, we sold 6,250,000 shares of our common stock at a public offering price of $8.00 per share, for net proceeds of $46.7 million, after deducting underwriting discounts and commissions&#160;and other&#160;offering expenses payable by us, or the August 2020 Offering.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, we sold 13,993,778 shares of our common stock and 2,500 shares of Series A Convertible Preferred Stock at a public offering price of $2.00 and $2,000 per share, respectively, for net proceeds of $30.5 million, after deducting underwriting discounts and commissions and other offering expenses payable by us, or the February 2019 Offering. In October and November 2019, we sold 10,350,000 shares of our common stock, which included the full exercise of the underwriters&#8217; option to purchase additional shares, and 4,000 shares of Series A Convertible Preferred Stock at a public offering price of $2.50 and $2,500 per share, respectively, for net proceeds of $33.5 million after deducting underwriting discounts and commissions and other offering expenses payable by us, or the October 2019 Offering.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:11pt;text-indent:5.55%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2019, we sold 6,893,888 shares of our common stock under our previous ATM program for net proceeds of $22.3 million after deducting&#160;sales agent commissions and other offering expenses payable by us, or the ATM Offering.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar to other development-stage biotechnology companies, we have generated limited revenue, which has been through the Angelini License Agreement.&nbsp;&nbsp;We have incurred losses and experienced negative operating cash flows since our inception and anticipate that we will continue to incur losses for at least the next several years. We incurred net losses of approximately $81.0 million and $60.5 million for the year ended December&#160;31, 2020 and 2019, respectively. As of December&#160;31, 2020, we had an accumulated deficit of $294.2 million and working capital of $52.8 million.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:11pt;text-indent:5.83%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management has identified these conditions or events, which, considered in the aggregate, raise substantial doubt about our ability to continue as a going concern, including the risk that we will be unable to raise adequate additional capital to fund operations through at least the next 12 months from the date of filing of this Annual Report on Form 10-K.&nbsp;&nbsp;Management&#8217;s response to these conditions and events is that the successful closing of the Takeda License and Termination Agreement with Takeda (see note 12 of our Consolidated Financial Statements) will provide the liquidity needed to alleviate the substantial doubt referred to above.&nbsp;&nbsp;As described in note 12 of our Consolidated Financial Statements, there are certain conditions to close the Takeda License and Termination Agreement, however, management has determined that the likelihood of not closing in the first half of 2021 is remote. In the event that we are unable to close the Takeda License and Termination Agreement, we will need to raise additional capital in order to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:11pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">alleviate substantial doubt about our ability to continue as a going concern</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The failure to raise capital as and when needed could have a negative impact on our financial condition and ability to pursue our business strategy.&#160; If we are unable to raise capital, we may be required to delay, reduce the scope of or eliminate research and development programs, or obtain funds through arrangements with collaborators or others that may require us to relinquish rights to certain drug candidates that we might otherwise seek to develop or commercialize independently.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the proceeds we expect to receive upon closing of the Takeda License and Termination Agreement, we plan to finance our cash needs through either equity offerings, debt financings, collaborations, strategic alliances, or licensing agreements or a combination of any such transactions. To the extent that we raise additional capital through future equity offerings or debt financings, ownership<font style="color:#000000;"> interests may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt and equity financings, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. There can be no assurance that such financings will be obtained on terms acceptable to us, if at all. </font>The ongoing COVID-19 pandemic continues to rapidly evolve and has already resulted in a significant disruption of global financial markets.&nbsp;&nbsp;If the disruption persists and deepens, we could experience an inability to access additional capital, which could in the future negatively affect our operations. <font style="color:#000000;">If we raise additional funds through collaborations, strategic alliances or licensing agreements with third parties for one or more of our current or future drug candidates, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates or to grant licenses on terms that may not be favorable to us. Our failure to raise capital as and when needed would have a material adverse effect on our financial condition and our ability to pursue our business strategy.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Flows </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our cash flows for the periods indicated:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in):</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,584</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,091</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,648</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30,041</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,072</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,539</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,136</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,407</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Cash Used in Operating Activities</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash <font style="color:#000000;">used</font> in operating activities was $51.6 million for the year ended December&#160;31, 2020, which consisted of a net loss of $81.0 million offset by a net of $29.5 million of non-cash charges and indirect cash changes, primarily related to $7.5 million of stock-based compensation expense and $12.4 million of deferred revenue. Net cash used in operating activities was $51.1 million for the year ended December 31, 2019, which consisted of a net loss of $60.5 million offset by a net of $9.4 million of non-cash charges and indirect cash changes, primarily related to $5.2 million of stock-based compensation expense.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Cash Provided by (<font style="color:#000000;">Used</font> in) Investing Activities</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Net cash provided by investing activities was $34.6 million for the year ended December&#160;31, 2020, compared to $30.0 million used in investing activities for the year ended December&#160;31, 2019. </font>The change in net cash provided by investing activities was primarily due to the higher maturities of short-term investments during the year ended December 31, 2020 compared to net purchases during the year ended December 31, 2019.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Cash Provided by Financing Activities</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Net cash provided by financing activities of $47.0 million for the year ended December&#160;31, 2020 was primarily due to the net proceeds from the August 2020 Offering. Net cash provided by financing activities of $86.5 million for the year ended December 31, 2019 was primarily due to the net proceeds from the February 2019 Offering, October 2019 Offering and ATM Offering. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations and Commitments</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we agreed to continue certain studies that were ongoing at the time of signing the Angelini License Agreement.&nbsp;&nbsp;<font style="color:#000000;">In March 2021, we entered into the Takeda License and Termination Agreement </font>under which Takeda will secure global rights at closing from us to develop and commercialize the investigational medicine OV935 for the treatment of developmental and epileptic encephalopathies, including DS and LGS<font style="color:#000000;">. Closing of the Takeda License and Termination Agreement is subject to satisfaction of customary closing conditions,</font> including regulatory review by the appropriate regulatory agencies under the HSR Act<font style="color:#000000;">. </font>We had no other material contractual obligations or commitments. We had no long-term debt or leases and no material non-cancelable </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">purchase commitments with service providers, as we have generally contracted on a cancelable, purchase order basis. We excluded any potential contingent payments upon the achievement by us of clinical, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and commercial events, as applicable, or royalty payments that we may be required to make under license agreements we have entered into with various entities pursuant to which we have in-licensed certain intellectual property as contractual obligations or commitments, including agreements with H. Lundbeck A/S, Northwestern, and our Takeda license agreement. Pursuant to these license agreements, we have agreed to make milestone payments up to an aggregate of $</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279.3</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million upon the achievement of certain development, regulatory and sales milestones. We excluded these contingent payments given that the timing, probability, and amount, if any, of such payments cannot be reasonably estimated at this time.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Emerging Growth Company Status and Smaller Reporting Company Status</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may remain an emerging growth company until December 31, 2022. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">reduced disclosure about our executive compensation arrangements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">no non-binding stockholder advisory votes on executive compensation or golden parachute arrangements; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have taken advantage of reduced reporting requirements in this Annual Report on Form 10-K <font style="Background-color:#FFFFFF;">and may continue to do so until such time that we are no longer an emerging growth company. We will remain an &#8220;emerging growth company&#8221; until the earliest of (a) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more, (b) December 31, 2022, the last day of the fiscal year following the fifth anniversary of the completion of the our IPO, (c) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years or (d) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.</font> Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we are also a smaller reporting company as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as (i) our voting and&#160;non-voting&#160;common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and&#160;non-voting&#160;common stock held by&#160;non-affiliates&#160;is less than $700.0&#160;million measured on the last business day of our second fiscal quarter.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Estimates</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the revenue and expenses incurred during the reported periods. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses and stock-based compensation. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ from these estimates under different assumptions or conditions.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">During the&#160;year ended December&#160;31, 2020, we recognized revenue.&#160;&#160;In addition, see Note 2 of our Consolidated Financial Statements under the heading &#8220;Recent Accounting Pronouncements&#8221; for new accounting pronouncements or changes to the accounting pronouncements during the year ended December&#160;31, 2020.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;margin-left:3.94%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Clinical Expenses</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">When preparing our consolidated financial statements, we are required to estimate our accrued clinical expenses. This process involves reviewing open contracts and communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">otherwise notified of actual cost. Payments under some of the contracts we have with third parties depend on factors, such as successful enrollment of certain numbers of patients, site initiation and the completion of clinical trial milestones.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU79"></a><font style="Background-color:#FFFFFF;">When accruing clinical expenses, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If possible, we obtain information regarding unbilled services directly from our service providers. However, we may be required to estimate the cost of these services based only on information available to us. If we underestimate or overestimate the cost associated with a trial or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, our estimated accrued clinical expenses have approximated actual expense incurred.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;margin-left:3.94%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for stock-based compensation awards in accordance with the Financial Accounting Standards Board Accounting Standards Codification, or ASC, Topic 718,&#160;<font style="font-style:italic;">Compensation&#8212;Stock Compensation</font>, or ASC 718 (see Note 2 of <font style="Background-color:#FFFFFF;">our Consolidated Financial Statements</font>). ASC 718 requires all stock-based compensation awards to be recognized as expense based on their grant date fair values. We recognized expenses over the requisite service period, which is generally the vesting period of the award under the straight-line method.&#160;&#160;We account for forfeitures as they occur. We record the expense for stock-based compensation awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We measure the grant-date fair value based on the Black-Scholes option-pricing model, which uses subjective assumptions and other inputs.&#160;&#160;These assumptions and inputs include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Expected Volatility.&#160;&#160;</font><font style="color:#000000;">Due to the lack of sufficient volatility data, the expected volatility is estimated using weighted average measures of the historical volatility of a representative group of small, publicly traded drug development companies at a similar stage of development as ourselves.</font><font style="font-style:italic;color:#000000;">&#160;&#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Expected Term. </font><font style="color:#000000;">The expected term of the options outstanding is determined using the &#8220;simplified&#8221; method for &#8220;plain vanilla&#8221; options based on the mid-point between the vesting date and the end of the contractual term as prescribed by Staff Accounting Bulletin No. 107,</font><font style="font-style:italic;color:#000000;">&#160;Share-Based Payment.&#160;&#160;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Risk-Free Interest Rate</font><font style="color:#000000;">. The risk-free interest rate is based on U.S. Treasury notes with remaining terms similar to the expected term of the option.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Expected Dividends</font><font style="color:#000000;">.&#160;&#160;The dividend yield assumption is zero since we have never paid cash dividends and do not plan to pay cash dividends in the foreseeable future.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;margin-left:3.94%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We recognize revenue under sublicense agreements in accordance with the ASC 606. </font><font style="color:#000000;">We currently have one such agreement, the Angelini License Agreement</font><font style="Background-color:#FFFFFF;">. The terms of the agreement within this scope may contain multiple performance obligations, including but not limited to licenses and research and development activities. ASC 606 requires that we evaluate these agreements to determine the distinct performance obligations. Non-refundable, up-front fees that are not contingent on any future performance and require no consequential continuing involvement by us, are recognized as revenue when the license term commences and the licensed data, technology or product is delivered. We defer recognition of non-refundable upfront fees if the performance obligations are not satisfied.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;"><font style="Background-color:#FFFFFF;"></font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Prior to recognizing revenue, we make estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration may include</font><font style="color:#000000;"> all or portions of upfront</font><font style="Background-color:#FFFFFF;"> license fees, payments for research and development activities, reimbursement of certain third-party costs, payments based upon the achievement of specified milestones, royalty payments based on product sales derived from collaboration and other payments.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk56079679"></a><font style="Background-color:#FFFFFF;">If there are multiple distinct performance obligations, we allocate the transaction price to each distinct performance obligation based on its relative standalone selling price. For the Angelini License Agreement, t</font>he transaction price was allocated based on the standalone selling prices of the license and ongoing trials<font style="Background-color:#FFFFFF;"><a name="_Hlk56079679"></a>. The portion of the upfront payment allocated to the license was recognized in full as it was non-refundable and not contingent on any future performance and requires no consequential continuing involvement by the Company. Revenue related to ongoing trials is recognized by measuring the progress toward complete satisfaction of the performance obligations over time based on the portion of estimated total trial costs to be incurred. </font>Milestone payments are considered contingent variable consideration which are not accounted for until the contingencies are met.</p><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 7A</font><font style="font-style:italic;"><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a>. Quantitative and Qualitat</font><font style="font-style:italic;">ive Disclosures About Market Risk.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary objectives of our investment activities are to ensure liquidity and to preserve capital. As of December&#160;31, 2020, we had cash and cash equivalents of $72.0 million that were held in an interest-bearing money market account. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term maturities of our cash equivalents and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents. To minimize the risk in the future, we intend to maintain our portfolio of cash equivalents in institutional market funds that are comprised of U.S. Treasury and U.S. Treasury-backed repurchase agreements.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a>Item 8.<font style="font-weight:normal;"> </font><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a>Financial Statements and Supplementary Data</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financial statements, together with the report of our independent registered public accounting firm, appear in this Annual Report on Form 10-K beginning on page F-1.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a>Item 9<font style="font-weight:normal;">.</font><font style="font-size:12pt;font-weight:normal;"> </font><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a>Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9A_CONTROLS_PROCEDURES"></a><a name="ITEM_9A_CONTROLS_PROCEDURES"></a>Item 9A. Controls and Procedures.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) is (1)&#160;recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms and (2)&#160;accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of December&#160;31, 2020 our disclosure controls and procedures were effective at the reasonable assurance level.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Management&#8217;s Annual Report on Internal Control&#160;over&#160;Financial Reporting</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. Our management, under the supervision and with the participation of our Chief Executive Officer and Principal Financial and Accounting Officer, conducted an evaluation of the effectiveness of our internal control over financial reporting as of December&#160;31, 2020 based on the framework in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework). Based on the results of its evaluation, management concluded that our internal control over financial reporting was effective as of December&#160;31, 2020.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Attestation Report of the Registered Public Accounting Firm</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm due to an exemption established by the JOBS Act for &#8220;emerging growth companies.&#8221;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting</p>
<p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:4.89%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no changes in our internal control over financial reporting during our most recent quarter ended December&#160;31, 2020 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9B_OR_INFORMATION"></a><a name="ITEM_9B_OR_INFORMATION"></a>Item 9B.&nbsp;&nbsp;Other Information<font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_III"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_III"></a>PART</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> III</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a>Item&#160;10. Directors, Executive Officers, and Corporate Governance</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item is incorporated by reference to the information set forth in the sections titled &#8220;Proposal 1 &#8211; Election of Directors,&#8221; &#8220;Executive Officers,&#8221; and &#8220;Information Regarding the Board and Corporate Governance&#8221; and &#8220;Delinquent Section 16(a) Reports,&#8221; if any, in our 2021 Proxy Statement.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a>Item&#160;11. Executive Compensation</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item is incorporated by reference to the information set forth in the section titled &#8220;Executive Officer and Director Compensation&#8221; in our 2021 Proxy Statement.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a>Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item is incorporated by reference to the information set forth in the section titled &#8220;Security Ownership of Certain Beneficial Owners and Management and &#8220;Equity Compensation Plan Information&#8221; in our 2021 Proxy Statement.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a>Item&#160;13. Certain Relationships and Related Transactions and Director Independence</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item is incorporated by reference to the information set forth in the section titled &#8220;Transactions with Related Persons&#8221; and &#8220;Information Regarding the Board and Corporate Governance &#8211; Board Independence&#8221; in our 2021 Proxy Statement.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_14_PRINCIPAL_ACCOUNTANT_FEES_SERVIC"></a><a name="ITEM_14_PRINCIPAL_ACCOUNTANT_FEES_SERVIC"></a>Item&#160;14. Principal Accountant Fees and Services</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item is incorporated by reference to the information set forth in the section titled &#8220;Independent Registered Public Accounting Firm Fees&#8221; <font style="color:#000000;">and &#8220;Pre-Approval Policies and Procedures&#8221; </font>contained in our 2021 Proxy Statement.</p><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_IV"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_IV"></a>PAR</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">T IV</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENTS_SC"></a><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENTS_SC"></a>Item&#160;15. Exhibits, Financial Statements and Schedules</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)(1) Financial Statements.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The response to this portion of Item&#160;15 is set forth under Item&#160;8 hereof.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)(2) Financial Statement Schedules.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All schedules have been omitted because they are not required or because the required information is given in the Financial Statements or Notes thereto.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)(3) Exhibits.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The exhibits listed below are filed as part of this Annual Report on Form 10-K.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3<font style="Background-color:#FFFFFF;">.1</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000119312517166080/d382437dex31.htm"><font style="text-decoration:underline;">Amended and Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-38085), filed with the Commission on May 10, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000156459019035235/ovid-ex31_6.htm"><font style="text-decoration:underline;">Corrected Amended and Restated Certificate of Designation of Series A Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-38085), filed with the Commission on September 24, 2019).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000119312517166080/d382437dex32.htm"><font style="text-decoration:underline;">Amended and Restated Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K (File No. 001-38085), filed with the Commission on May 10, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000119312517135563/d286200dex41.htm"><font style="text-decoration:underline;">Form of Common Stock Certificate of the Company (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-1/A (File No. 333-217245), filed with the Commission on April 25, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000119312517118846/d286200dex42.htm"><font style="text-decoration:underline;">Second Amended and Restated Investors&#8217; Rights Agreement, by and among the Company and certain of its stockholders, dated January&#160;6, 2017 (incorporated herein by reference to Exhibit 4.2 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-217245), filed with the Commission on April 10, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001636651/000156459020010108/ovid-ex43_544.htm"><font style="text-decoration:underline;">Description of the Securities of Ovid Therapeutics Inc. (incorporated herein by reference to Exhibit 4.3 to the Company&#8217;s Annual Report on Form 10-K (File No. 001-38085), filed with the Commission on March 12, 2020).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000119312519047109/d714860dex41.htm"><font style="text-decoration:underline;">Form of Series A Preferred Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K (File No. 001-38085), filed with the Commission on February 21, 2019).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1+</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000119312517127476/d286200dex101.htm"><font style="text-decoration:underline;">Form of Indemnity Agreement by and between the Company and its directors and officers (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-217245), filed with the Commission on April 10, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2+</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000119312517178147/d399411dex412.htm"><font style="text-decoration:underline;">2017 Equity Incentive Plan (incorporated herein by reference to Exhibit 4.12 to the Company&#8217;s Registration Statement on Form S-8 (File No. 001-38085), filed with the Commission on May 22, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3+</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000119312517127476/d286200dex103.htm"><font style="text-decoration:underline;">Forms of Option Grant Notice and Option Agreement under 2017 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-217245), filed with the Commission on April 10, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4+</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000119312517118846/d286200dex105.htm"><font style="text-decoration:underline;">2014 Equity Incentive Plan, as amended (incorporated herein by reference to Exhibit 10.5 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-217245), filed with the Commission on April 10, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5+</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000119312517118846/d286200dex106.htm"><font style="text-decoration:underline;">Amendment to 2014 Equity Incentive Plan, effective as of March 9, 2015 (incorporated herein by reference to Exhibit 10.6 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-217245), filed with the Commission on April 10, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6+</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000119312517118846/d286200dex107.htm"><font style="text-decoration:underline;">Amendment to 2014 Equity Incentive Plan, effective as of June 4, 2015 (incorporated herein by reference to Exhibit 10.7 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-217245), filed with the Commission on April 10, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7+</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000119312517118846/d286200dex108.htm"><font style="text-decoration:underline;">Amendment to 2014 Equity Incentive Plan, effective as of July 28, 2015 (incorporated herein by reference to Exhibit 10.8 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-217245), filed with the Commission on April 10, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8+</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000119312517118846/d286200dex109.htm"><font style="text-decoration:underline;">Amendment to 2014 Equity Incentive Plan, effective as of February 11, 2016 (incorporated herein by reference to Exhibit 10.9 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-217245), filed with the Commission on April 10, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9+</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000119312517118846/d286200dex1010.htm"><font style="text-decoration:underline;">Form of Restricted Stock Purchase Agreement under the 2014 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.10 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-217245), filed with the Commission on April 10, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10+</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000119312517118846/d286200dex1011.htm"><font style="text-decoration:underline;">Form of Stock Option Agreement&#8212;Early Exercise under the 2014 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.11 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-217245), filed with the Commission on April 10, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11+</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000119312517118846/d286200dex1012.htm"><font style="text-decoration:underline;">Forms of Stock Option Agreement under the 2014 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.12 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-217245), filed with the Commission on April 10, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12+</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000119312517178147/d399411dex414.htm"><font style="text-decoration:underline;">2017 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 4.14 to the Company&#8217;s Registration Statement on Form S-8 (File No. 001-38085), filed with the Commission on May 22, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13+</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001636651/000156459020010108/ovid-ex1013_750.htm"><font style="text-decoration:underline;">Non-Employee Director Compensation Plan (incorporated herein by reference to Exhibit 10.13 to the Company&#8217;s Annual Report on Form 10-K (File No. 001-38085), filed with the Commission on March 12, 2020)</font></a><font style="text-decoration:underline;">.</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14+</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000119312517127476/d286200dex1013.htm"><font style="text-decoration:underline;">Executive Employment Agreement between the Registrant and Jeremy M. Levin, dated June 5, 2015 (incorporated herein by reference to Exhibit 10.13 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-217245), filed with the Commission on April 10, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15+</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001636651/000156459020010108/ovid-ex1015_795.htm"><font style="text-decoration:underline;">Second Amended and Restated Executive Employment Agreement between the Company and Amit Rakhit, effective November 1, 2019 (incorporated herein by reference to Exhibit 10.15 to the Company&#8217;s Annual Report on Form 10-K (File No. 001-38085), filed with the Commission on March 12, 2020</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16+</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001636651/000156459020010108/ovid-ex1016_797.htm"><font style="text-decoration:underline;">Third Amended and Restated Executive Employment Agreement between the Company and Tim Daly, effective December 18, 2019 (incorporated herein by reference to Exhibit 10.16 to the Company&#8217;s Annual Report on Form 10-K (File No. 001-38085), filed with the Commission on March 12, 2020</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17+</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ovid-ex1017_726.htm"><font style="text-decoration:underline;">Executive Employment Agreement between the Company and Jeff Rona, effective September 30, 2020</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18+</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ovid-ex1018_728.htm"><font style="text-decoration:underline;">Executive Employment Agreement between the Company and Jason Tardio, effective October 21, 2019</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19+</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ovid-ex1019_727.htm"><font style="text-decoration:underline;">Amended and Restated Executive Employment Agreement between the Company and Thomas Perone, effective January 1, 2020</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.20&#8224;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000119312517152270/d286200dex1016.htm"><font style="text-decoration:underline;">License Agreement by and between H. Lundbeck A/S and the Company, dated March 25, 2015 (incorporated herein by reference to Exhibit 10.16 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-217245), filed with the Commission on May 2, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.21&#8224;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000119312517118846/d286200dex1018.htm"><font style="text-decoration:underline;">Collaboration and License Agreement, by and between the Company and Takeda Pharmaceutical Company Limited, effective January 6, 2017 (incorporated herein by reference to Exhibit 10.18 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-217245), filed with the Commission on April 10, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22&#8224;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000119312517118846/d286200dex1019.htm"><font style="text-decoration:underline;">Series B-1 Preferred Stock Purchase Agreement, by and between the Company and Takeda Pharmaceutical Company Limited, dated January 6, 2017 (incorporated herein by reference to Exhibit 10.19 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-217245), filed with the Commission on April 10, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23&#8224;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000156459018007152/ovid-ex1019_672.htm"><font style="text-decoration:underline;">License Agreement by and between Northwestern University and the Company, dated December 15, 2016.&nbsp;&nbsp;(incorporated herein by reference to Exhibit 10.19 to the Company&#8217;s Annual Report on Form 10-K (File No. 001-38085), filed with the Commission on April 10, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.24&#94;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1636651/000156459019022662/ovid-ex101_6.htm"><font style="text-decoration:underline;">First Amendment to License Agreement, by and between H. Lundbeck A/S and the Company, dated May 10, 2019 (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K/A (File No. 001-38085), filed with the Commission on June 17, 2019).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ovid-ex1025_869.htm"><font style="text-decoration:underline;">Collaboration and License Agreement, by and between the Company and Angelini Pharma Rare Diseases AG, dated July 9, 2020</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">23.1</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ovid-ex231_7.htm"><font style="text-decoration:underline;">Consent of Independent Registered Public Accounting Firm.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">24.1</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#POWER_ATTORNEY"><font style="text-decoration:underline;">Power of Attorney (included on the signature page to this report).</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">31.1</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ovid-ex311_11.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">31.2</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ovid-ex312_9.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:6.45pt;">
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">32.1*</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ovid-ex321_13.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.INS</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.SCH</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.CAL</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.DEF</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Definition Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.LAB</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Document</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">101.PRE</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:89.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:93.33%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#FFFFFF;color:#000000;">Furnished herewith and not deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicates a management contract or compensatory plan.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Confidential treatment has been granted for certain portions of this exhibit. These portions have been omitted and filed separately with the SEC.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#94;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the Securities and Exchange Commission, certain portions of this exhibit have been redacted. The Registrant hereby agrees to furnish supplementally to the Securities and Exchange Commission, upon its request, an unredacted copy of this exhibit. </p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16_FORM_10K_SUMMARY"></a><a name="ITEM_16_FORM_10K_SUMMARY"></a>Item&#160;16. Form 10-K Summary</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="line-height:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a><a name="SIGNATURES"></a>SIGNATURES</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report on Form 10-K to be signed on its behalf by the undersigned thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="top"  BGCOLOR="#FFFFFF" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OVID THERAPEUTICS INC.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 15, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Jeremy M. Levin</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jeremy M. Levin</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:13.65pt;">
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 15, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Timothy Daly</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Timothy Daly</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Vice President, Finance, Corporate Controller &amp; Treasurer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
<tr>
<td colspan="5" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="POWER_ATTORNEY"></a><a name="POWER_ATTORNEY"></a>POWER OF ATTORNEY</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:16.4pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each person whose individual signature appears below hereby authorizes and appoints Jeremy M. Levin, DPhil, MB BChir and Timothy Daly, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue thereof. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:16.4pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Signature</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr style="height:8pt;">
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jeremy M. Levin, DPhil, MB BChir</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jeremy M. Levin, DPhil, MB BChir</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:-8pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer and Director</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:-8pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 15, 2021</p></td>
</tr>
<tr style="height:8pt;">
<td valign="middle"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Timothy Daly</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Timothy Daly</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:-8pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Vice President, Finance and Corporate Controller</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:-8pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 15, 2021</p></td>
</tr>
<tr style="height:8pt;">
<td valign="middle"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Karen Bernstein, PhD</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Karen Bernstein, PhD</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:-8pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 15, 2021</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:-8pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:auto;">
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Barbara Duncan</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 15, 2021</p></td>
</tr>
<tr style="height:8pt;">
<td colspan="2" valign="middle"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Barbara Duncan</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:8pt;">
<td colspan="2" valign="middle"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="3" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:auto;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Bart Friedman</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bart Friedman</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:-8pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 15, 2021</p></td>
</tr>
<tr style="height:8pt;">
<td colspan="2" valign="middle"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td colspan="3" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:auto;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Douglas Williams, PhD</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Douglas Williams, PhD</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:-8pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 15, 2021</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OVID THERAPEUTICS INC.</p>
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Index to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:91.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:-8pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><font style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:7.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:91.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:-8pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_BALANCE_SHEETS_UNAUDITED"><font style="text-decoration:underline;">Consolidated Balance Sheets</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:7.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:91.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:-8pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_STATEMENTS_OPERATIONS_COMPREHE"><font style="text-decoration:underline;">Consolidated Statements of Operations</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:7.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:91.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:-8pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CSofCL"><font style="text-decoration:underline;">Consolidated Statements of Comprehensive Loss</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:7.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:91.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:-8pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_STATEMENT_CHANGES_IN_STOCKHOLD"><font style="text-decoration:underline;">Consolidated Statements of Changes in Stockholders&#8217; Equity</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:7.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:5.4pt;">
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:-8pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_STATEMENTS_CASH_FLOWS_UNAUDITE"><font style="text-decoration:underline;">Consolidated Statements of Cash Flows</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:auto;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="width:91.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8pt;;text-indent:-8pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><font style="text-decoration:underline;">Notes to Consolidated Financial Statements</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:7.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8&#8211;F-23</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="width:0.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:center;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Report of Independent Registered Public Accounting Firm</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:6pt;margin-left:1.07%;margin-right:52.78%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Stockholders and Board of Directors <br />Ovid Therapeutics Inc.:</p>
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:1.07%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Opinion on the Consolidated Financial Statements</p>
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:1.07%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of Ovid Therapeutics Inc. and subsidiary (the Company) as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive loss, changes in stockholders&#8217; equity, and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</p>
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:1.07%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-top:5pt;margin-bottom:6pt;margin-left:1.07%;margin-right:1.48%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-top:5pt;margin-bottom:6pt;margin-left:1.07%;margin-right:1.48%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="margin-top:5pt;margin-bottom:6pt;margin-left:1.07%;margin-right:1.48%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;margin-left:1.06%;text-indent:0%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-family:Times New Roman;">/s/ KPMG LLP</font></p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;margin-left:1.06%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2015. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.06%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New York, New York</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:1.06%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 15, 2021</p><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_IFINANCIAL_INFORMATION"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_IFINANCIAL_INFORMATION"></a>PART I&#8212;FINANCIA</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">L INFORMATION</font></p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_FINANCIAL_STATEMENTS"></a><a name="ITEM_1_FINANCIAL_STATEMENTS"></a>Item 1. Financial Statements.</p>
<p style="text-align:center;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OVID THERAPEUTICS INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONDENSED_BALANCE_SHEETS_UNAUDITED"></a>Consolidated <a name="CONDENSED_BALANCE_SHEETS_UNAUDITED"></a>Balance Sheets</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65929430"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,033,930</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,897,144</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,841,969</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related party receivable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,763</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,131,146</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,667,508</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,942,933</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,843,201</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,813,192</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term prepaid expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">477,171</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">359,539</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Security deposit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150,626</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135,390</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135,620</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,363</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">318,900</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">467,247</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,925,518</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,843,731</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and Stockholders' Equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,446,206</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,256,098</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,032,685</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,266,706</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related party payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,370,992</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,804</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue - current</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,212,892</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,062,775</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,533,608</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related party payable - noncurrent</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,200</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">286,562</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, net of current portion</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,169,887</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,293,862</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,820,170</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders' equity:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 3,250 and 7,762 shares issued and outstanding at December&#160;31, 2020 and 2019, respectively</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.001 par value; 125,000,000 shares authorized; 65,743,170 and 54,710,322 shares issued and outstanding at December&#160;31, 2020 and 2019, respectively</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,743</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,711</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in-capital</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">337,758,007</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283,122,894</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,469</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(294,192,097</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(213,156,521</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,631,656</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,023,561</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:72.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders' equity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,925,518</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,843,731</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:6.67%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to these consolidated financial statements</p><a name="_AEIOULastRenderedPageBreakAEIOU12"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OVID THERAPEUTICS INC.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONDENSED_STATEMENTS_OPERATIONS_COMPREHE"></a>Consolidated <a name="CONDENSED_STATEMENTS_OPERATIONS_COMPREHE"></a>Statements of Operations</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:86.6%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65929432"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and other revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,617,221</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,417,394</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,157,641</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,630,804</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,251,826</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,048,198</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,409,467</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81,430,977</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61,409,467</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">395,401</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">948,224</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81,035,576</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60,461,243</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81,035,576</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60,461,243</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders, basic and diluted</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.39</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.54</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares outstanding basic and diluted</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,451,293</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,217,223</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to these consolidated financial statements</p><a name="_AEIOULastRenderedPageBreakAEIOU13"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OVID THERAPEUTICS INC.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CSofCL"></a><font style="Background-color:#FFFFFF;"><a name="CSofCL"></a>Consolidated Statements of Comprehensive Loss</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65929433"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81,035,576</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60,461,243</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive (loss) income:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized (loss) gain on available-for-sale securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,469</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,298</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81,038,045</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60,456,945</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to these consolidated financial statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU14"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OVID THERAPEUTICS INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONDENSED_STATEMENT_CHANGES_IN_STOCKHOLD"></a>Consolidated <a name="CONDENSED_STATEMENT_CHANGES_IN_STOCKHOLD"></a>Statement of Changes in Stockholders&#8217; Equity</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:98.84%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income/(Loss)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, December&#160;31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,762</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,710,322</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,711</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283,122,894</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,469</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(213,156,521</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,023,561</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATM costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(114,936</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(114,936</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from employee stock purchase plan</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,464</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203,361</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203,466</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from exercise of stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165,384</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300,656</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300,821</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of series A convertible preferred stock to common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,512</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,512,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,512</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,507</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from August 2020 Offering, net of underwriting costs and commissions</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,250,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,250</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,725,185</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,731,435</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,525,354</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,525,354</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,469</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,469</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81,035,576</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81,035,576</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, December&#160;31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,250</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,743,170</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,743</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">337,758,007</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(294,192,097</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,631,656</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income/(Loss)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,654,114</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,654</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191,477,598</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,829</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(152,695,278</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,805,145</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from February Offering, net of underwriting costs and commissions</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,993,778</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,994</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,506,838</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,520,835</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from employee stock purchase plan</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,542</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,814</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,895</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of common stock to series A convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,262</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,262,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,262</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,261</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from October Offering, net of underwriting costs and commissions</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,350,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,350</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,519,919</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,530,273</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from ATM Offerings, net of underwriting costs and commissions</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,893,888</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,894</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,279,672</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,286,566</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,205,792</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,205,792</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,298</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,298</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60,461,243</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60,461,243</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,762</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,710,322</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,711</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283,122,894</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,469</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(213,156,521</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,023,561</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to these consolidated financial statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OVID THERAPEUTICS INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONDENSED_STATEMENTS_CASH_FLOWS_UNAUDITE"></a>Consolidated <a name="CONDENSED_STATEMENTS_CASH_FLOWS_UNAUDITE"></a>Statements of Cash Flows</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81,035,576</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60,461,243</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to cash used in operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,525,354</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,205,792</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">306,848</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255,002</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in accrued interest and accretion of discount on short-term investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(199,408</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,633</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in operating assets and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(724,575</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224,458</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Security deposit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,236</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,235</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related party receivable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">989,383</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(531,042</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term prepaid expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(117,632</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,438,022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,333,716</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(653,953</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,835,607</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,177,844</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,382,779</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related party payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,134,826</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">297,366</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:54.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,583,914</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,090,622</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of short-term investments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,961,092</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34,797,004</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from maturities of short-term investments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,000,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(127,240</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,156</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software development and other assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(263,440</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(186,889</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:54.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,648,228</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30,041,049</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from August 2020 Offering, net of offering expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,731,435</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from February and October 2019 Offerings, net of offering expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,120,736</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from ATM Offerings, net of offering expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,286,566</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ATM costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(163,250</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from employee stock purchase plan</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203,466</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,895</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300,821</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:54.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,072,472</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,539,197</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,136,786</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,407,526</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents, at beginning of period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,897,144</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,489,618</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents, at end of period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,033,930</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,897,144</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash investing and financing activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software development and other costs in accrued expenses and accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">164,922</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Offering costs in accrued expenses and accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,314</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,628</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to these consolidated financial statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OVID THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a>NOTES TO <a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a>CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTE_1_NATURE_OPERATIONS"></a>NOTE 1<font style="color:#000000;"><a name="NOTE_1_NATURE_OPERATIONS"></a> &#8211; NATURE OF OPERATIONS</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ovid Therapeutics Inc. (the &#8220;Company&#8221;) was incorporated under the laws of the state of Delaware on April 1, 2014 and maintains its principal executive office in New York, New York. The Company commenced operations on April 1, 2014 (date of inception). The Company is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its inception, the Company has devoted substantially all of its efforts to business development, research and development, recruiting management and technical staff, and raising capital, and has financed its operations through issuance of convertible preferred stock (&#8220;Preferred Stock&#8221;), common stock and other equity instruments. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development and regulatory success, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and ability to secure additional capital to fund operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Historically, the Company&#8217;s major sources of cash have been comprised of proceeds from various public and private offerings of its capital stock and interest income. As of December 31, 2020, the Company had approximately $72.0 million in cash and cash equivalents. Since inception, the Company has generated $12.6 million in revenue as part of the Company&#8217;s license and collaboration agreement (the &#8220;Angelini License Agreement&#8221;) with Angelini Pharma Rare Diseases AG (&#8220;Angelini&#8221;). The Company has incurred recurring losses, has experienced recurring negative operating cash flows and requires significant cash resources to execute its business plans. <font style="color:#000000;">The Company has an accumulated deficit of $294.2 million as of December 31, 2020</font>, working capital of $52.8 million <font style="color:#000000;">and had cash outflows from operating activities of $51.6 million for the year ended December 31, 2020</font>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"><a name="_Hlk39668314"></a>&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred operating losses since inception and expects to continue to incur net losses for at least the next several years and ongoing operations are highly dependent on the Company&#8217;s ability to obtain additional sources of funding. Management has identified these conditions or events, which, considered in the aggregate, raise substantial doubt about our ability to continue as a going concern, including the risk that the Company will be unable to raise adequate additional capital to fund operations through at least the next 12 months from the date of filing of this Annual Report on Form 10-K.&nbsp;&nbsp;Management&#8217;s response to these conditions and events is that the successful closing of the Takeda License and Termination Agreement with Takeda (see note 12) will provide the liquidity needed to alleviate the substantial doubt referred to above.&nbsp;&nbsp;As described in note 12, there are certain conditions to close the Takeda License and Termination Agreement, however management has determined that the likelihood of not closing in the first half of 2021 is remote.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_7"></a><a name="_cp_text_1_9"></a><a name="_cp_text_1_11"></a><a name="_cp_text_1_7"></a>We have implemented business continuity plans designed to address and mitigate the impact of the COVID-19 pandemic on our business.&nbsp;&nbsp;The extent to which the ongoing COVID-19 pandemic impacts our business, our clinical development and regulatory efforts, our corporate development objectives and the value of and market for our common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic<a name="_cp_text_1_9"></a>, travel restrictions, quarantines, social distancing and business closure requirements in the U.S., Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease.&nbsp;&nbsp;The <a name="_cp_text_1_11"></a>global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_13"></a><a name="_cp_text_1_15"></a><a name="_cp_text_1_13"></a>In addition, we are subject to other challenges and risks specific to our business and our ability to execute on our strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of our late-stage product candidates; delays or problems in the supply of our products, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing our intellectual property rights; complying with applicable regulatory requirements.&nbsp;&nbsp;In addition, to the extent the ongoing <a name="_cp_text_1_15"></a>COVID-19 pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 2<font style="color:#000000;"> &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(A) Basis of Presentation and Consolidation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include the accounts of Ovid Therapeutics Inc. and its wholly-owned subsidiary, Ovid Therapeutics Hong Kong Limited.&nbsp;&nbsp;All intercompany transactions and balances have been eliminated in consolidation.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">B</font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">) </font><font style="color:#000000;">Use of Estimates</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(C) Risks and Uncertainties</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its drug candidates, ability to obtain regulatory approval of its drug candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition and untested manufacturing capabilities</font>.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(D) Deferred Transaction Costs</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred transaction costs, primarily consisted of direct incremental legal, accounting, and other fees related to the Company&#8217;s offering of its capital stock are capitalized as incurred. The deferred transaction costs are offset against proceeds upon the consummation of an offering.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(E) Comprehensive Loss</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. </p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(F) Collaboration Arrangement</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">License and Collaboration Agreement with Takeda Pharmaceutical Company Limited</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the current license and collaboration agreement with Takeda Ovid and Takeda are sharing 50/50 in the drug development, the Company records 50% of the development costs in research and development.&nbsp;&nbsp;When Ovid incurs the majority of the costs and Takeda transfers a payment to Ovid to equalize the costs, Ovid records the participation by Takeda as a reduction of its research and development expenses, as the parties under the collaboration are sharing in the costs and the payment represents reimbursement of costs by Takeda.&#160;When Takeda incurs the majority of the costs and Ovid transfers a payment to Takeda (to equalize the costs), Ovid records the participation in Takeda&#8217;s expenses as research and development costs in its statement of operations, as Ovid and Takeda are sharing in the research and development activities and this participation represents Ovid&#8217;s share of the research and development costs in the specific period. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(G) Cash and Cash Equivalents</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash and cash equivalents consist of cash held in checking accounts and money market funds. The Company considers all highly liquid investments with an original maturity date of three months or less to be cash and cash equivalents. Accounts held at U.S. financial institutions are insured by the FDIC up to $250,000. Cash balances could exceed insured amounts at any given time.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(H) Short-term Investments</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments<font style="Background-color:#FFFFFF;">&#160;consist of debt securities with maturities greater than&#160;</font>three months<font style="Background-color:#FFFFFF;">&#160;from the date of purchase.&#160;&#160;The Company&#160;</font>classifies<font style="Background-color:#FFFFFF;">&#160;all of its investments as available-for-sale securities. Debt securities are recorded at fair value with unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders&#8217; equity until realized. Realized gains and losses, amortization and accretion of premiums and discounts are included within net loss.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(I) Property and Equipment</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost and depreciated over their estimated useful lives of three years using the straight-line method. Repairs and maintenance costs are expensed. The Company reviews the recoverability of all long-lived assets, including the related useful life, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(J) Research and Development Expenses</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses the cost of research and development as incurred. Research and development expenses comprise costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when the cost is incurred, in accordance with ASC 730, Research and Development.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(K) Stock-Based Compensation</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for its stock-based compensation in accordance with ASC 718, Compensation&#8212;Stock Compensation, which establishes accounting for stock-based awards granted to employees for services and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company estimates the fair value of all awards granted using the Black-Scholes valuation model. Key inputs and assumptions include the expected term of the option, stock price volatility, risk-free interest rate, dividend yield, stock price and exercise price. Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense. The Company elected an accounting policy to record forfeitures as they occur. The Company recognizes employee stock-based compensation expense based on the fair value of the award on the date of the grant. The compensation expense is recognized over the vesting period under the straight-line method.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13.5pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for options awards granted to nonemployee consultants and directors in accordance with ASU 2018-07, Compensation &#8211; Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. The fair value of the option issued or committed to be issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company&#8217;s common stock award at the earlier of the date that the commitment for performance by the counterparty has been reached or the counterparty&#8217;s performance is complete.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(L) Fair Value of Financial Instruments</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial Accounting Standards Board (&#8220;FASB&#8221;) guidance specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The three levels of the fair value hierarchy are as follows:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Level 1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities. The Company&#8217;s Level 1 assets consisted of money market funds and short-term investments totaling $70.1 million and $76.2 million as of December&#160;31, 2020 and 2019, respectively.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Level 2&#8212;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models or other valuation methodologies. The Company had no Level 2 assets or liabilities as of December&#160;31, 2020 and 2019.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Level 3&#8212;Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable. The Company had no Level 3 assets or liabilities as of December&#160;31, 2020 and 2019.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts reported in the balance sheets for cash and cash equivalents, related-party receivables, other current assets, accounts payable, accrued expenses, and current related-party payables approximate their fair value based on the short-term maturity of these instruments.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(M) Income Taxes</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires deferred tax assets and liabilities to be recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts and respective tax bases of existing assets and liabilities, as well as for net operating loss carryforwards and research and development credit. Valuation allowances are provided if it is more likely than not that some portion or all of the deferred tax assets will not be realized.&nbsp;&nbsp;The impact of a change in the tax laws is recorded in the period in which the law is enacted.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(N) Net Loss Per Common Share</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period. For all periods presented, stock options have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss per common share are the same.<font style="color:#000000;"> Under the terms of the Series A Preferred Stock issued in 2019, Preferred stockholders do not share in losses of the Company and have no obligation to fund losses or transfer assets.&#160;&#160;Since there is a loss, diluted EPS should be computed in the same manner as basic EPS and because no potential common shares shall be included in the computation of any diluted per-share amounts when a loss exists, the Series A Preferred Stock should be excluded from the computation of basic and diluted EPS.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65929440"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options to purchase common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,403,420</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,405,295</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,250</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,762</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(O) Segment Data</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(P) Retirement Plan</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains a 401(k)-retirement plan for its employees that is intended to qualify under Sections 401(a) and 501(a) of the U.S. Internal Revenue Code of 1986, as amended (&#8220;Code&#8221;). The Company provides all active employees with a 100% matching contribution equal to 3% of an employee&#8217;s eligible compensation deferred and 50% matching contributions on employee contributions that are between 3% and 5% of an employee&#8217;s eligible compensation deferred. These safe harbor contributions vest immediately.&nbsp;&nbsp;For the years ended December&#160;31, 2020 and 2019 the Company contributed $321,000 and $285,000, respectively.<font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">(Q) Revenue Recognition</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;In applying ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) it satisfies the performance obligations.&#160;The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint.&#160;Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66632837"></a><a name="_Hlk66632837"></a>If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price.&#160;The standalone selling price is generally determined using expected cost and comparable transactions. Revenue for performance obligations recognized over time is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-refundable upfront fees allocated to licenses that are not contingent on any future performance and require no consequential continuing involvement by the Company, are recognized as revenue when the license term commences and the licensed data, technology or product is delivered.&#160;The Company defers recognition of upfront license fees if the performance obligations are not satisfied.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="font-weight:bold;">R) Recent Accounting Pronouncements</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Recent accounting standards which have been adopted</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.&#160;&#160;This new standard requires the measurement and recognition of expected credit losses for financial assets held at amortized cost, including loans and trade and other receivables. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The standard also amends the impairment model for available-for-sale debt securities and requires entities to determine whether all or a portion of the unrealized loss on an available-for-sale debt security is a credit loss. Under the new guidance, an entity recognizes an allowance for credit losses on available-for-sale debt securities as a contra-account to the amortized cost basis rather than as a direct reduction of the amortized cost basis of the investment, as was previously required. ASU 2016-13 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2019. As of December 31, 2020, the Company did not hold any debt securities with </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">credit losses, nor does it have any trade receivables. The adoption of this standard effective January 1, 2020 did not have a material impact on the Company&#8217;s </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial statements.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 29, 2018, the FASB issued ASU No. 2018-15, Intangibles &#8211; Goodwill and Other - Internal-Use Software (Subtopic 350-40) - which amends ASC 350-40 to address a customer&#8217;s accounting for implementation costs incurred in a cloud computing arrangement (&#8220;CCA&#8221;) that is a service contract. ASU No. 2018-15 aligns the accounting for costs incurred to implement a CCA that is a service arrangement with the guidance on capitalizing costs associated with developing or obtaining internal-use software. Specifically, the ASU amends ASC 350 to include in its scope implementation costs of a CCA that is a service contract and clarifies that a customer should apply ASC 350-40 to determine which implementation costs should be capitalized in a CCA that is considered a service contract. According to the standard the balance sheet line item for the presentation of capitalized implementation costs should be the same as that for the prepayment of fees related to the hosting arrangement and the manner in which an entity classifies the cash flows related to capitalized implementation costs should be the same as that in which it classifies the cash flows for the fees related to the hosting arrangement. ASU 2018-15 is effective for the Company for fiscal years beginning after December 15, 2019, including interim periods therein. Entities are permitted to apply either a retrospective or prospective transition approach to adopt the guidance. The adoption of this standard effective January 1, 2020 did not have a material impact on the Company&#8217;s consolidated financial statements and was adopted prospectively.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 5, 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808), - which amends ASC 808 to clarify when transactions between participants in a collaborative arrangement under ASC 808 are within the scope of the FASB&#8217;s new revenue standard, ASU 2014-09 (codified in ASC 606). The amendments require the application of ASC 606 existing guidance to determine the units of account that are distinct in a collaborative arrangement for purposes of identifying transactions with customers. If a unit of account within the collaborative arrangement is distinct and is with a customer, an entity shall apply the guidance in Topic 606 to that unit of account. In a transaction between collaborative participants, an entity is precluded by ASU 2018-18 from presenting a transaction together with &#8220;revenue from contracts with customers&#8221; unless the unit of account is within the scope of ASC 606 and the entity applies the guidance in ASC 606 to such unit of account. The amended guidance is effective for public business entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The retrospective adoption of this standard effective January 1, 2020 did not have a material impact on the Company&#8217;s consolidated financial statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, the FASB issued&#160;ASU&#160;2020-10, Codification Improvements, which updates various codification topics by clarifying or improving disclosure requirements. ASU 2020-10 is effective for annual and interim periods beginning after December 15, 2020. The Company early adopted&#160;ASU&#160;2020-10&#160;for the reporting period ending December 31, 2020. The adoption of this update did not have a material effect on the Company s consolidated financial statements.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk536566672"></a>N<font style="font-weight:bold;">OTE 3<a name="_Hlk536566672"></a> &#8211; CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All<font style="color:#000000;"> short-term investments are classified as available-for-sale. The following tables summarize the fair value of cash, cash equivalents, and short-term investments, as well as gross unrealized holding gains and losses as of December&#160;31, 2020 and December&#160;31, 2019:</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cost</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">holding gains</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">holding losses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Cash</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,977,320</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,977,320</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Money market funds</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,056,610</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,056,610</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash and cash equivalents</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,033,930</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,033,930</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;U.S. treasury notes</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term investments</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cost</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">holding gains</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">holding losses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Cash</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">501,537</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">501,537</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Money market funds</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,395,607</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,395,607</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash and cash equivalents</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,897,144</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,897,144</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;U.S. treasury notes</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,839,500</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,469</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,841,969</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term investments</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,839,500</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,469</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,841,969</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did&#160;not&#160;hold any securities that were in an unrealized loss position for more than 12 months as of&#160;December&#160;31, 2020 and 2019.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were&#160;no&#160;material realized gains or losses on available-for-sale securities during the years ended December&#160;31, 2020 and 2019.&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk536566728"></a><font style="Background-color:#FFFFFF;">NOTE</font><font style="color:#000000;"> 4<a name="_Hlk536566728"></a> &#8211; PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment is summarized as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65929444"></a>&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and equipment</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">320,957</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">193,717</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(185,337</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(125,354</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property, plant and equipment, net</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135,620</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,363</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense was $60,000 and $39,000 for the years ended December&#160;31, 2020 and 2019 respectively.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net of accumulated amortization, were $319,000 and $467,000 as of December&#160;31, 2020 and December&#160;31, 2019, respectively, and are included in other assets.&#160;Amortization expense was $247,000 and $216,000 for the years ended December&#160;31, 2020 and 2019, respectively.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 5 &#8211; ACCRUED EXPENSES</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65929445"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials accrual</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,175,497</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,235,527</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and bonus accrual</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,845,441</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,728,495</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees accrual</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,846,211</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,070,589</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165,536</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,095</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,032,685</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,266,706</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 6 &#8211; STOCKHOLDERS&#8217; EQUITY AND PREFERRED STOCK</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s capital structure consists of common stock and Preferred Stock. Pursuant to the Company&#8217;s amended and restated certificate of incorporation, as amended, the Company is authorized to issue up to 125,000,000 shares of common stock and 10,000,000 shares of Preferred Stock. The Company has designated 10,000 of the 10,000,000 authorized shares of Preferred Stock as non-voting Series A Convertible Preferred Stock (&#8220;Series A Preferred Stock&#8221;).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of common stock are entitled to one vote for each share held. The holders of common stock have no preemptive or other subscription rights, and there are no redemption or sinking fund provisions with respect to such shares. Subject to preferences that may apply to any outstanding series of Preferred Stock, holders of the common stock are entitled to <font style="Background-color:#FFFFFF;">receive ratably any dividends declared on a&#160;non-cumulative&#160;basis. Shares of Series A Preferred Stock will be entitled to receive dividends at a rate equal to (on an as-if-converted-to-common stock basis), and in the same form and manner as, dividends actually paid on shares of common stock. </font>The common stock is subordinate to all series of Preferred Stock with respect to rights upon liquidation, winding up and dissolution of the Company. The holders of common stock are entitled to liquidation proceeds after all liquidation preferences for the Preferred Stock are satisfied.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the Company entered into a sales agreement (the &#8220;2018 ATM agreement&#8221;) with Cowen and Company, LLC (&#8220;Cowen&#8221;) <font style="color:#000000;">under which the Company offered and sold in &#8220;at the market offerings,&#8221; from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $50.0 million through Cowen acting as sales agent. During the year ended December 31, 2019, the Company sold 6,893,888 shares of its common stock under the 2018 ATM agreement for net proceeds of $22.3 million after deducting </font>sales agent commissions and other offering expenses payable by the Company, (the &#8220;ATM Offerings&#8221;)<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, the Company entered into a new sales agreement (the &#8220;2020 ATM agreement&#8221;) with Cowen and <font style="color:#000000;">under which the Company may offer and sell in &#8220;at the market offerings,&#8221; from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $75.0 million through Cowen acting as sales agent. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were 3,250 and 7,762 shares of Series A Preferred Stock outstanding as of December 31, 2020 and December&#160;31, 2019, respectively. Each share of Series A Preferred Stock is convertible into 1,000 shares of common stock at any time at the holder&#8217;s option. However, the holder will be prohibited, subject to certain exceptions, from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than, at the written election of the holder, either 9.99% or 14.99% of the total number of shares of common stock then issued and outstanding, which percentage may be changed at the holder&#8217;s election to any other number less than or equal to 19.99% upon 61 days&#8217; notice to the Company; provided, however, that effective 61 days after delivery of such notice, such beneficial ownership limitations shall not be applicable to any holder that beneficially owns either 10.0% or 15.0%, as applicable based on the holder&#8217;s initial written election noted above, of the total number of shares of common stock issued and outstanding immediately prior to delivery of such notice. In the event of a liquidation, dissolution, or winding up of the Company, holders of Series A Preferred Stock will receive a payment equal to $0.001 per share of Series A Preferred Stock before any proceeds are distributed to the holders of common stock.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In December 2020, entities affiliated with Biotechnology Value Fund, L.P. elected to convert an aggregate of 2,256 shares of Series A Preferred Stock owned by such holders into an aggregate of 2,256,000 shares of the Company&#8217;s common stock.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company sold 6,250,000 shares of its common stock at a public offering price of $8.00 per share, for net proceeds of $46.7 million after deducting underwriting discounts and commissions and other offering expenses payable by the Company, (the &#8220;August 2020 Offering&#8221;).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In May 2020, entities affiliated with Biotechnology Value Fund, L.P. elected to convert an aggregate of 2,256 shares of Series A Preferred Stock owned by such holders into an aggregate of 2,256,000 shares of the Company&#8217;s common stock.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October and November 2019, the Company sold 10,350,000 shares of its common stock, which included the full exercise of the underwriters&#8217; option to purchase additional shares, and 4,000 shares of Series A Preferred Stock at a public offering price of $2.50 and $2,500 per share, respectively, for net proceeds of $33.5 million after deducting underwriting discounts and commissions and other offering expenses payable by the Company, (the &#8220;October 2019 Offering&#8221;).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, the Company entered into an exchange agreement with entities affiliated with Biotechnology Value Fund, L.P. (the &#8220;Exchanging Stockholders&#8221;), pursuant to which the Company exchanged an aggregate of 1,262,000 shares of the Company&#8217;s common&#160;stock owned by the Exchanging Stockholders for an aggregate of 1,262 shares of the Company&#8217;s Series A Preferred Stock (the &#8220;Exchange Shares&#8221;). The Exchange Shares were issued without registration under the Securities Act of 1933, as amended, in reliance on the exemption from registration contained in Section&#160;3(a)(9) of the Securities Act.&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, the Company sold 13,993,778 shares of its common stock and 2,500 shares of Series A Preferred Stock at a public offering price of $2.00 and $2,000 per share, respectively, for net proceeds of $30.5 million after deducting underwriting discounts and commission and other offering expenses payable by the Company (the &#8220;February 2019 Offering&#8221;).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dividends</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No dividends on the common stock shall be declared and paid unless dividends on the Preferred Stock have been declared and paid. Through December&#160;31, 2020, the Company has not declared any dividends.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 7 &#8211; STOCK-BASED COMPENSATION</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 29, 2014, the Company&#8217;s Board of Directors adopted and approved the 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;), which authorized the Company to grant shares of common stock in the form of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock and restricted stock units. The types of stock-based awards, including share purchase rights amount, terms, and exercisability provisions of grants are determined by the Company&#8217;s Board of Directors.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Company's Board of Directors adopted, and the Company's stockholders approved the 2017 equity incentive plan (&#8220;2017 Plan&#8221;),&#160;which became effective immediately prior to the execution of the underwriting agreement related to the IPO on May 4, 2017. The initial reserve of shares of common stock that may be issued under the 2017 Plan was 3,052,059 shares. The 2017 Plan provides </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance-based stock awards, and other forms of stock-based awards.&nbsp;&nbsp;Additionally, the 2017 Plan provides for the grant of performance cash awards. The Company's employees, officers, directors and consultants and advisors are eligible to receive awards under the 2017 Plan.&nbsp;&nbsp;Upon the adoption of the 2017 Plan, no further awards will be granted under the 2014 Plan. </font><font style="Background-color:#FFFFFF;">Pursuant to the terms of the 2017 Plan, on each January 1st, the plan limit shall be increased by the lesser of (x) </font><font style="Background-color:#FFFFFF;">5</font><font style="Background-color:#FFFFFF;">% of the number of shares of common stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine in its discretion.</font><font style="Background-color:#FFFFFF;"> </font><font style="Background-color:#FFFFFF;">On January 1, 2019, an additional </font><font style="Background-color:#FFFFFF;">1,232,705</font><font style="Background-color:#FFFFFF;"> shares were reserved for issuance under the 2017 Plan. As of December&#160;31, 2019, there were </font><font style="Background-color:#FFFFFF;">2,199,765</font><font style="Background-color:#FFFFFF;"> shares of the Company&#8217;s common stock reserved for issuance under the 2017 Plan. </font><font style="Background-color:#FFFFFF;">O</font><font style="Background-color:#FFFFFF;">n </font><font style="Background-color:#FFFFFF;">January 1, 20</font><font style="Background-color:#FFFFFF;">20</font><font style="Background-color:#FFFFFF;">, an </font><font style="Background-color:#FFFFFF;">additional </font><font style="Background-color:#FFFFFF;">2,735,516</font><font style="Background-color:#FFFFFF;"> shares were reserved for issuance under the 2017 Plan. As of </font><font style="Background-color:#FFFFFF;">December&#160;31, 2020</font><font style="Background-color:#FFFFFF;">, there were </font><font style="Background-color:#FFFFFF;">1,771,772</font><font style="Background-color:#FFFFFF;"> shares of the Company&#8217;s common stock reserved for issuance under the 2017 Plan.</font><font style="Background-color:#FFFFFF;"> </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's Board of Directors adopted, and the Company's stockholders approved the 2017 employee stock purchase plan (the &#8220;2017 ESPP&#8221;), which became effective immediately prior to the execution of the underwriting agreement related to the IPO on May 4, 2017. The initial reserve of shares of common stock that may be issued under the 2017 ESPP was 279,069 shares. On September 20, 2017, the Company&#8217;s Compensation Committee approved an offering period under the 2017 ESPP, which began on October 20, 2017. The ESPP allows employees to purchase common stock of the Company at a 15% discount to the market price on designated purchase dates. During the years ended December&#160;31, 2020 and 2019, 105,464 and 80,542 shares were purchased under the ESPP and the Company recorded expense of $152,973 and $109,319, respectively. The number of shares of common stock reserved for issuance under the 2017 ESPP will automatically increase on January 1 of each year, beginning on January 1, 2018 and continuing through and including January 1, 2027, by the lesser of (i) 1% of the total number of shares of the Company&#8217;s capital stock outstanding on December 31 of the preceding calendar year, (ii) 550,000 shares or (iii) such lesser number of shares determined by our Board. On January 1, 2019, an additional 246,541 shares were reserved for issuance under the 2017 ESPP. No shares were reserved for issuance under the 2017 ESPP during the year ended December 31, 2020. As of December&#160;31, 2020, there were 553,552 shares of the Company&#8217;s common stock reserved for issuance under the 2017 ESPP. </p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless specified otherwise in an individual option agreement, stock options granted under the 2014 Plan and 2017 Plan generally have a ten-year term and a four-year graded vesting period. The vesting requirement is generally conditioned upon the grantee&#8217;s continued service with the Company during the vesting period. Once vested, all awards are exercisable from the date of grant until they expire. The option grants are non-transferable. Vested options generally remain exercisable for 90 days subsequent to the termination of the option holder&#8217;s service with the Company. In the event of option holder&#8217;s death or disability while employed by or providing service to the Company, the exercisable period extends to 12 months. </p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance-based option awards generally have similar vesting terms, with vesting occurring on the date the performance condition is achieved and expire in accordance to the specific terms of the agreement. At December&#160;31, 2020, there were 125,000 performance-based options outstanding and unvested <font style="color:#000000;">that include options to vest upon the achievement of certain research and development milestones</font>.&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of options granted during the years ended December 31, 20</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 201</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> was estimated using the Black-Scholes option valuation model. The inputs for the Black-Scholes option valuation model require management&#8217;s significant assumptions and are detailed in the table below. The risk-free interest rates were based on the rate for U.S. Treasury securities at the date of grant with maturity dates approximately equal to the expected life at the grant date. The expected life was based on the simplified method in accordance with the SEC Staff Accounting Bulletin No. Topic 14D. The expected volatility was estimated based on historical volatility information of peer companies that </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">publicly available.</font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All assumptions used to calculate the grant date fair value of nonemployee options are generally consistent with the assumptions used for options granted to employees. In the event the Company terminates any of its consulting agreements, the unvested options underlying the agreements would also be cancelled.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company granted 10,000 and 175,000 stock options to nonemployee consultants for services rendered during the years ended December&#160;31, 2020 and 2019, respectively. There were 32,500 and 145,204 unvested nonemployee options outstanding as of December&#160;31, 2020 and 2019, respectively. Total expense recognized related to the nonemployee stock options for the years ended December&#160;31, 2020 and 2019 was $257,431 and $51,666, respectively. During the year ended December 31, 2019, the Company recognized a credit of $17,000 related to the nonemployee stock options including the modification of certain options in connection with the&#160;separation and consulting agreement with Dr. During (see Note 11). Total unrecognized compensation expenses related to the nonemployee stock options was $186,823 as of December 31, 2020. During the years ended December&#160;31, 2020, and 2019, the Company recognized $115,240 and zero, respectively, in expenses for nonemployee performance-based option awards.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company granted 3,573,160 and 3,372,513 stock options to employees during the years ended December&#160;31, 2020 and 2019, respectively. There were 4,975,262 and 3,963,544 unvested employee options outstanding as of December&#160;31, 2020 and 2019, respectively. Total expense recognized related to the employee stock options for the years ended December&#160;31, 2020 and 2019 was $7.1 million and $5.0 million, respectively. Total unrecognized compensation expense related to employee stock options was $12.2 million as of December&#160;31, 2020. During the years ended December&#160;31, 2020 and 2019, the Company recognized $2,340,808 and $9,391 in expenses for employee performance-based option awards. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s stock-based compensation expense was recognized in operating expenses as follows:</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,779,758</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,391,909</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,745,596</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,813,883</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,525,354</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,205,792</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,372,381</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,096,473</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152,973</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,319</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,525,354</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,205,792</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of employee options granted during the years ended December&#160;31, 2020 and 2019, respectively, was estimated by utilizing the following assumptions:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81.48</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81.87</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term in years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.88</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.07</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.58</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.04</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of option on grant date</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.62</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.26</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of nonemployee options granted and remeasured during the years ended December&#160;31, 2020 and 2019, respectively, was estimated by utilizing the following assumptions:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74.37</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74.56</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term in years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.64</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.30</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.32</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.37</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of option on grant date</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.18</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.07</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the number of options outstanding and the weighted average exercise price:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65929455"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life in Years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding at December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,714,383</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.10</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.89</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,485</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable at December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,337,931</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.88</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.20</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,485</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,547,513</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.93</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.56</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(856,601</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.43</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding December&#160;31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,405,295</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.82</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.01</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,488,930</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable at December&#160;31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,296,547</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.93</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.53</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">356,443</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,583,160</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.93</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.68</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(165,384</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.82</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(415,526</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding December&#160;31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,403,420</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.26</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.59</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">652,438</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable at December&#160;31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,395,658</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.45</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.13</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">445,599</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2020, there was $12.3 million of unamortized share&#8211;based compensation expense, which is expected to be recognized over a remaining average vesting period of 3.04 years.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 8 &#8211; INCOME TAXES</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2020, the Company has available approximately $<font style="color:#000000;">238.6</font> million and $186.7 million of unused NOL carryforwards for federal and state tax purposes, respectively, that may be applied against future taxable income. The Company also has approximately $<font style="color:#000000;">165.4</font> million of unused NOL carryforwards for New York City purposes. The NOL carryforwards will begin to expire in the year 2035 if not utilized prior to that date. There is no provision for income taxes because the Company has historically incurred operating losses and maintains a full valuation allowance against its net deferred tax assets. <font style="color:#000000;">The valuation allowance increased by approximately $13.3 million and $22.5 million during the years 2020 and 2019, respectively.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may be subject to the NOL utilization provisions of Section&#160;382 of the Code. The effect of an ownership change would be the imposition of an annual limitation on the use of NOL carryforwards attributable to periods before the change. The amount of the annual limitation depends upon the value of the Company immediately before the change, changes to the Company&#8217;s capital during a specified period prior to the change, and the federal published interest rate. The Company has not completed a Section&#160;382 analysis to determine if a change in ownership has occurred. Until an analysis is completed, there can be no assurance that the existing net operating loss carry-forwards or credits are not subject to significant limitation.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s reserves related to taxes are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies related to the tax benefit. For the years ended December&#160;31, 2020 and 2019, the Company had no unrecognized tax benefits or related interest and penalties accrued. The Company has not yet conducted a study of research and development credit carryforwards. This study may result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheet or statement of operations if an adjustment were required. The Company would recognize both accrued interest and penalties related to unrecognized benefits in income tax </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expense. The Company&#8217;s uncertain tax positions </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">yet to be determined would be</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> related to years that remain subject to examination by relevant tax authorities. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities were as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65929459"></a>&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets/liabilities:</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryovers</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,064,673</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,288,334</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,458,004</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,351,315</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,978,370</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,606,889</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">514,316</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">898,067</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,760</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,026</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Charitable contributions</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,120</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,072</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,742,031</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,208,519</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross deferred tax assets/liabilities</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,814,754</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,463,170</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,814,754</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(76,463,170</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets (liabilities)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the statutory U.S. Federal rate to the Company&#8217;s effective tax rate is as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal income tax benefit at statutory rate</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21.00</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21.00</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income tax, net of federal benefit (<font style="font-size:8pt;">1)</font></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.15</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13.80</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.75</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.50</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.72</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37.14</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.64</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.67</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.02</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.17</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax (benefit) expense rate</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="8" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) Inclusive of $5.8 million deferred tax benefit due to change in apportionment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 9 &#8211;<font style="color:#000000;"> </font>COMMITMENTS AND CONTINGENCIES</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">License Agreements</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">On March&#160;26, 2015, the Company entered into an exclusive agreement with H. Lundbeck A/S (&#8220;Lundbeck&#8221;) for a worldwide perpetual licensing right related the research, development and commercialization of OV101. On May 10, 2019, the parties amended the license agreement.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Lundbeck license agreement, as amended, the Company agreed to make milestone payments totaling up to $189.0 million upon the achievement of certain development, regulatory and sales milestones.&#160;The first payment of $1.0 million is due upon the successful completion of the first Phase 3 trial for a product in which OV101 is an active ingredient.&#160;In addition, the agreement calls for the Company to pay royalties for an initial term based on a low double-digit percentage of sales and provides for the reduction of royalties in certain limited circumstances.&nbsp;&nbsp;As of December&#160;31, 2020, none of these contingent payments were considered probable.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2016, the Company entered into a license agreement with Northwestern University, or Northwestern, pursuant to which Northwestern granted us an exclusive, worldwide license to patent rights in certain inventions, or the Northwestern Patent Rights, which relate to a specific compound and related methods of use for such compound, along with certain Know-How related to the practice of the inventions claimed in the Northwestern Patents.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Northwestern agreement, the Company was granted exclusive rights to research, develop, manufacture and commercialize products utilizing the Northwestern Patent Rights for all uses. The Company has agreed that it will not use the Northwestern Patent Rights to develop any products for the treatment of cancer, but Northwestern may not grant rights in the technology to others for use in cancer. The Company also has an option, exercisable during the term of the agreement to an exclusive license under certain intellectual property rights covering novel compounds with the same or similar mechanism of action as the primary compound that is </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the subject of the license agreement.&nbsp;&nbsp;Northwestern has retained the right, on behalf of itself and other non-profit institutions, to use the Northwestern Patent Rights and practice the inventions claimed therein for educational and research purposes and to publish information about the inventions covered by the Northwestern Patent Rights.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entry into the Northwestern agreement, the Company paid an upfront non-creditable one-time license issuance fee of $75,000, and is required to pay an annual license maintenance fee of $20,000, which will be creditable against any royalties payable to Northwestern following first commercial sale of licensed products under the agreement.&nbsp;&nbsp;The Company is responsible for all ongoing costs of filing, prosecuting and maintaining the Northwestern Patents, but also has the right to control such activities using its own patent counsel.&nbsp;&nbsp;In consideration for the rights granted to the Company under the Northwestern agreement, the Company is required to pay to Northwestern up to an aggregate of $5.3 million upon the achievement of certain development and regulatory milestones for the first product covered by the Northwestern Patents, and, upon commercialization of any such products, will be required to pay to Northwestern a tiered royalty on net sales of such products by the Company, its affiliates or sublicensees, at percentages in the low to mid single-digits, subject to standard reductions and offsets.&nbsp;&nbsp;The Company&#8217;s royalty obligations continue on a product-by-product and country-by-country basis until the later of the expiration of the last-to-expire valid claim in a licensed patent covering the applicable product in such country and 10 years following the first commercial sale of such product in such country.&nbsp;&nbsp;If the Company sublicenses a Northwestern Patent Right, it will be obligated to pay to Northwestern a specified percentage of sublicense revenue received by the Company, ranging from the high single digits to the low-teens.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Northwestern agreement requires that the Company use commercially reasonable efforts to develop and commercialize at least one product that is covered by the Northwestern Patent Rights.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated, the Northwestern agreement will remain in force until the expiration of the Company&#8217;s payment obligations thereunder.&nbsp;&nbsp;The Company has the right to terminate the agreement for any reason upon prior written notice or for an uncured material breach by Northwestern.&nbsp;&nbsp;Northwestern may terminate the agreement for the Company&#8217;s uncured material breach or insolvency.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, none of these contingent payments were considered probable.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contingencies</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. The Company is not currently involved in any legal matters arising in the normal course of business.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of their respective employment agreements, each of our named executive officers is eligible to receive severance payments and benefits upon a termination without &#8220;cause&#8221; or due to &#8220;permanent disability,&#8221; or upon &#8220;resignation for good reason,&#8221; contingent upon the named executive officer&#8217;s delivery to the Company of a satisfactory release of claims, and subject to the named executive officer&#8217;s compliance with non-competition and non-solicitation restrictive covenants for two years following the termination date.</p>
<p style="text-align:justify;margin-top:11pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Northwestern agreement, Northwestern granted the Company an exclusive license to certain patent rights and know-how, including a patent application covering a specified composition of matter (the &#8220;Patent Application&#8221;).&#160; Northwestern previously entered into a license agreement with Catalyst Pharmaceuticals, Inc. (&#8220;Catalyst&#8221;), dated August 27, 2009, pursuant to which Northwestern granted Catalyst rights under certain intellectual property rights covering a different composition of matter (the &#8220;Catalyst License&#8221;).&#160;&#160;In addition, the Company is a party to a confidential disclosure agreement with Catalyst, dated September 16, 2016 (the &#8220;CDA&#8221;). On June 25, 2018, Catalyst sent a letter to Northwestern and the Company alleging, among other things, that Northwestern breached the Catalyst License by licensing the Patent Application to the Company.&#160;Catalyst&#8217;s letter also asserted that the Company had breached its obligations under the CDA by allegedly failing to disclose that the Company had a license to the Patent Application, and that a further breach would occur if the Company makes any use of information obtained under the CDA in connection with its development program arising from the rights granted under the license agreement.&#160;&#160;Catalyst has asserted that the combined conduct of Northwestern and the Company gives rise to various claims, including breach of contract, fraud, and tortious interference.&#160;The Company believes that Catalyst&#8217;s claims are without merit and responded by letter dated June 28, 2018, which denies any and all liability to Catalyst, and further denies that Catalyst has been damaged in any way. On May 20, 2019, the Company entered into a Settlement Agreement with Catalyst (the &#8220;Settlement Agreement&#8221;), pursuant to which Catalyst released the Company from any and all claims, known or unknown, arising from or related to the dispute between Catalyst and Northwestern, the license agreement, and/or the claims that Catalyst asserted against the Company in the June 25, 2018 letter.&#160;&#160;Under the Settlement Agreement the Company retains all rights and privileges previously granted to the Company under the Northwestern license agreement.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 1</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">0</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> &#8211; COLLABORATION AGREEMENT</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Angelini Collaboration</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;9, 2020, the Company entered into the Angelini License Agreement with Angelini, pursuant to which the Company granted to Angelini exclusive rights to develop and commercialize OV101, a selective agonist of the GABA<sub style="font-size:85%; vertical-align:bottom">A</sub>&#160;receptor, for the treatment of Angelman syndrome in the European Economic Area as well as Switzerland, the United Kingdom, Russia and Turkey (the &#8220;European Territory&#8221;).&#160;&#160;The licenses granted to Angelini include sublicenses under the Lundbeck Agreement, as well as licenses under the Company&#8217;s patents and know-how covering OV101.&#160;&#160;Angelini will be responsible for conducting any clinical trials necessary to obtain regulatory approval for OV101 for Angelman syndrome in the European Territory, and the Company will be responsible for bearing a portion of the costs for such trials.&#160;&#160;The Company will also be responsible, at its expense, for the completion of certain ongoing clinical trials for OV101, to the extent applicable to obtaining regulatory approval for OV101 in the European Territory.&#160;&#160;Angelini has the exclusive right, at its election, to develop and commercialize OV101 for the treatment of Fragile X Syndrome in the European Territory.&#160;&#160;The parties may also mutually agree to pursue additional indications for OV101 in the European Territory, and in such case, Angelini would have the exclusive rights to commercialize in such additional indications. Angelini is required to use commercially reasonable efforts to conduct development activities for OV101, and following regulatory approval, to commercialize OV101 in each approved indication.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In conjunction with the entry into the Angelini License Agreement, the parties entered into a separate supply agreement, pursuant to which the Company will be responsible for supply of OV101 to Angelini for development and commercialization in the European Territory, through its existing supply relationship with Lundbeck.&#160;&#160;The Angelini License Agreement also provides for a transfer, at Angelini&#8217;s expense, of the relevant manufacturing technology from the Company and Lundbeck to Angelini, in order to enable Angelini to assume responsibility for its own manufacture and supply of OV101 in the future.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:13pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Angelini License Agreement, Angelini made an upfront payment and a milestone payment related to the transfer of a specified amount of compound and related information to the Company of $25.0 million during the year ended December 31, 2020.&#160; Angelini will be required to make additional milestone payments to the Company upon the completion of the specified components of the technology transfer and achievement of specified regulatory milestones for OV101 in Angelman syndrome of up to $55.0&#160;million in the aggregate, as well as up to &#8364;162.5 million ($199.9 million) in sales milestone payments for achievement of specified levels of net sales in the European Territory.&#160;&#160;In addition, Angelini will be required to pay tiered royalties on net sales by Angelini, its affiliates or sublicensees at double-digit percentages above the teens, subject to certain standard reductions and offsets.&#160;&#160;Royalties will be payable on a product-by-product and country-by-country basis until the latest of the expiration of the licensed patents covering such product in such country, the expiration of market exclusivity for such product in such country, and fifteen years from first commercial sale of such product in such country.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Either party may terminate the Angelini License Agreement for an uncured material breach of the other party or in the case of insolvency.&#160;&#160;The Company may terminate the Angelini License Agreement if Angelini challenges any of the licensed patents.&#160;&#160;Angelini may terminate the Angelini License Agreement for convenience on specified notice periods, which are determined based upon whether the product has been commercially launched in the European Territory.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company identified the following material promises under the Angelini License Agreement: (1) licensing of intellectual property with respect to OV101 (2) completion of certain ongoing trials (3) transfer of a specified amount of compound and related information (4) potential for funding 35% of the cost for Angelini future trials limited to $7.0 million and (5) completion of the manufacturing process technology transfer.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:6%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the $7.0 million represents a potential payment to a customer and should be deferred. The transfer of compound and related information is considered a contingent milestone payment that will be recognized upon acceptance by Angelini of the milestone which was achieved and recognized in December 2020. The Company further determined that the license and the completion of ongoing trials are distinct from each other, as each has value without the other.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined the transaction price is equal to the up-front fee of $20.0 million. The transaction price was allocated based on the standalone selling price of the license, the ongoing trials and $7.0 million for potential future trials.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the transfer of the specified amount of compound and related information and acceptance by Angelini, Angelini was required to and made a $5.0 million payment. <font style="color:#000000;">This performance obligation was determined to be variable consideration which was constrained and not considered part of the upfront transaction price allocation.</font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Angelini will be required to make a separate $5.0 million tech transfer payment towards the $55.0 million aggregate tech transfer and regulatory milestone payments upon the successful completion of the manufacturing process technology transfer. The Company earning this is fully dependent on performance and cooperation of Angelini and Lundbeck in implementing the Technology Transfer. At this time, the Company cannot estimate if or when this milestone-related performance obligation might be achieved.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, the Company recognized $6.1 million of license revenue and $1.5 million relating to the progress of the ongoing trials as well as $5.0 million for the transfer of the specified amount of compound and related information. The portion of the upfront payment allocated to License Revenue was recognized in full as it was non-refundable and not contingent on any future performance and requires no consequential continuing involvement by the Company. The Company did not have any such revenue during the year ended December 31, 2019. In addition, the Company recorded deferred revenue in the amount of approximately $12.4 million as of December 31, 2020 which will be recognized over the term of the ongoing trials based on the portion of total estimated expenses incurred. The Company has classified deferred revenue as current or noncurrent based on the expected timing of such expenses.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Takeda Collaboration</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66231254"></a><a name="_Hlk520969581"></a>On January&#160;6, 2017, the Company entered into a license and collaboration agreement with Takeda, pursuant to which Takeda granted the Company an exclusive license to commercialize the compound TAK-935, which the Company refers to as OV935, in certain territories, and a co-exclusive worldwide license, together with Takeda, to develop OV935. In consideration of certain license rights granted to the Company pursuant to the Takeda collaboration, the Company issued 1,781,996 shares of its Series B-1 Preferred Stock, pursuant to a Series B-1 preferred stock purchase agreement entered into on January&#160;6, 2017, at an ascribed price per share of $14.513 on January&#160;6, 2017 for an aggregate fair value of $25.9 million, which was recorded as research and development expense at the date of the transaction. The 1,781,996 shares of Series B-1 Preferred Stock held by Takeda automatically converted into 1,781,996 shares of the Company&#8217;s common stock upon the completion of its IPO in 2017. Under the Takeda collaboration, the Company is obligated to pay Takeda future payments if and when certain milestones are achieved. Upon the first patient enrollment in the first Phase 3 trial for the first of the initial indications the Company and Takeda are focusing on in the Takeda collaboration, the Company is obligated to issue to Takeda the number of unregistered shares of the Company&#8217;s common stock equal to the lesser of (a)&#160;8% of the Company outstanding capital stock on the issuance date or (b)&#160;$50.0 million divided by the applicable share price, unless certain events occur.<font style="Background-color:#FFFFFF;color:#000000;font-weight:bold;"> </font><font style="Background-color:#FFFFFF;color:#000000;">In the event such payment would cause Takeda to own over 19.99% of our outstanding capital stock or other events occur, such payment must be paid in cash</font>.&nbsp;&nbsp;The remaining potential global commercial and regulatory milestone payments equal approximately $35.0 million and can be satisfied in cash or unregistered shares of the Company&#8217;s common stock at its election, unless certain events occur. <font style="color:#000000;">As of December&#160;31, 2020, none of these contingent payments have been triggered.</font>&nbsp;&nbsp;During the year ended December&#160;31, 2020, the Company recognized $0.7 million in research and development expenses representing research and development expenses reimbursable to the Company from Takeda, of which $0.1 million was included in related party receivable as of December 31, 2020 and $2.1 million was included in related party payable as of December 31, 2020.&nbsp;&nbsp;During the year ended December 31, 2019, the Company recognized a credit in research and development expenses of $<a name="_Hlk520969581"></a>4.7 million <font style="color:#000000;">representing costs reimbursable to the Company from Takeda, </font>of <font style="color:#000000;">which $1.1 million was included in related party receivable as of December 31, 2019</font>. &nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Takeda collaboration will expire upon the cessation of commercialization of the products by both the Company and Takeda. Either party may terminate the Takeda collaboration because of the other party&#8217;s uncured material breach or insolvency, for safety reasons, or, after completion of the first proof of mechanism clinical trial, for convenience. Takeda may terminate the Takeda collaboration for the Company&#8217;s (or the Company&#8217;s sublicensee&#8217;s) challenge to the patents licensed under the Takeda collaboration. If the collaboration is terminated by Takeda for material breach by the Company, bankruptcy or patent challenge or by the Company for convenience or safety reasons, the Company&#8217;s rights to the products will cease, the Company will transition all activities related to the products to Takeda, and the Company will grant Takeda an exclusive, royalty-bearing license under certain patents and other intellectual property controlled by the Company to commercialize OV935 and products containing OV935 for the treatment of certain rare neurological disorders. If the collaboration is terminated by the Company for Takeda&#8217;s material breach or bankruptcy or by Takeda for convenience or safety reasons, Takeda&#8217;s rights to the products will cease, Takeda will transition all activities related to the products to us, and Takeda will grant us an exclusive, royalty-bearing license under certain patents and other intellectual property controlled by Takeda to commercialize OV935 and products containing OV935 for the treatment of certain rare neurological disorders.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, the Company entered into a royalty, license and termination agreement with Takeda (see note 12).</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 11 &#8211; RELATED PARTY TRANSACTIONS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the Company&#8217;s collaboration agreement with Takeda the Company recognized a long-term liability representing long-term prepaid expenses to be reimbursed to Takeda.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 24, 2019, the Company entered into a separation and consulting agreement with Dr. Matthew During in connection with Dr. During&#8217;s resignation as President and Chief Scientific Officer with the Company effective as of April 1, 2019. Pursuant to the separation and consulting agreement, Dr. During agreed to non-solicit and non-compete covenants through such time as he remains a consultant to the Company, as well as a general release of claims in connection therewith. Dr. During agreed to a three-year consulting arrangement, pursuant to which he will be paid, amongst other specific milestone and meeting related fees, $150,000 per year for his role as the Chairman of the Company&#8217;s Scientific Advisory Board and $150,000 per year for other advisory and consulting services. Further, Dr. During was granted options to acquire 100,000 shares of common stock at an exercise price of $1.76 per share, the fair market value on April 1, 2019, which options shall vest in full upon completion of a specific clinical milestone, subject to Dr. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During&#8217;s</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> continued service through such vesting date. In the event such option does not vest by December 31, 2020, the stock option will expire. Provided further, in recognition of Dr. </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During&#8217;s</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> service on the Scientific Advisory Board, Dr. During was granted options to acquire </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,000</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of common stock at an exercise price equal to $</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.76</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per share, the fair market value on April 1, 2019.</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ither Dr. During or the Company may terminate the consulting arrangements pursuant to the Consulting Agreement in accordance with its terms, at </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any time and for any reason, upon thirty (30) days written notice to the other party.</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Upon such termination, the Company will have no further obligations to Dr. During, including any obligation to pay further consulting fees.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, the Company issued and sold an aggregate of 6,325,000 shares of common stock and 2,500 shares of Series A Preferred Stock to entities affiliated with Takeda, a collaboration partner and an existing stockholder, entities affiliated with Biotechnology Value Fund, L.P., an existing stockholder, and Dr. Jeremy M. Levin, its Chief Executive Officer and Chairman, for aggregate gross proceeds of $17.7 million.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October and November 2019, the Company issued and sold an aggregate of 4,058,000 shares of common stock and 2,000 shares of Series A Preferred Stock to entities affiliated with Takeda, a collaboration partner and an existing stockholder, entities affiliated with Biotechnology Value Fund, L.P., an existing stockholder, and Dr. Jeremy M. Levin, its Chief Executive Officer and Chairman, for aggregate gross proceeds of $10.2 million.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, the Company entered into an exchange agreement with the Exchanging Stockholders pursuant to which the Company exchanged an aggregate of 1,262,000 shares of the Company&#8217;s common stock owned by the Exchanging Stockholders for an aggregate of 1,262 shares of the Company&#8217;s Series A Preferred Stock.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In May 2020, entities affiliated with Biotechnology Value Fund, L.P. elected to convert an aggregate of 2,256 shares of Series A Preferred Stock owned by such holders into an aggregate of 2,256,000 shares of the Company&#8217;s common stock.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company issued and sold an aggregate of 1,250,000 shares of common stock to entities affiliated with Biotechnology Value Fund, L.P., an existing stockholder for aggregate gross proceeds of $10.0 million.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, entities affiliated with Biotechnology Value Fund, L.P. elected to convert an aggregate of 2,256 shares of Series A Preferred Stock owned by such holders into an aggregate of 2,256,000 shares of the Company&#8217;s common stock.<font style="color:#000000;">&#160;</font> <font style="color:#000000;">&#160;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 12 &#8211; SUBSEQUENT EVENTS</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Equity Awards</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From January 1, 2021 t<font style="Background-color:#FFFFFF;color:#000000;">hrough the date of the filing of this Form 10-K, the Company has granted option awards for an aggregate of 643,600 shares of common stock to employees with a weighted average exercise price of $3.18.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Royalty, License and Termination Agreement with Takeda</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66458196"></a>In March 2021, the Company entered into a royalty, license and termination agreement (the &#8220;Takeda License and Termination Agreement&#8221;) with Takeda under which <font style="color:#000000;">Takeda will secure rights to the Company&#8217;s 50% global share in soticlestat, and an exclusive license under our relevant intellectual property rights and </font>global rights at closing from the Company to develop and commercialize the investigational medicine OV935 for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome and Lennox-Gastaut syndrome.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Takeda License and Termination Agreement, all rights in OV935 will be owned by Takeda, or exclusively licensed to Takeda by the Company.&nbsp;&nbsp;Takeda will assume sole responsibility for further worldwide development and commercialization, and the Company will no longer have any financial obligation to Takeda under the original collaboration agreement, including for milestone payments or any future development and commercialization costs. Should the Company close the Takeda License and Termination Agreement, the Company will receive an upfront payment of $196.0 million at closing and will be eligible to receive up to an additional $660.0 million upon achieving development, regulatory and sales milestones. In addition, the Company would be entitled receive tiered royalties beginning in the low double-digits, and up to 20% on sales of OV935, if approved and commercialized. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects to close the Takeda License and Termination Agreement in the first half of 2021, subject to the satisfaction of closing conditions, including regulatory review by the appropriate regulatory agencies under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. Either party may terminate the agreement if it does not close by May 14, 2021.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_2"></a><a name="_Hlk34477415"></a>&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>2
<FILENAME>ovid-ex1017_726.htm
<DESCRIPTION>EX-10.17
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ovid-ex1017_726.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.17</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">EXECUTIVE EMPLOYMENT AGREEMENT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:8pt;line-height:12pt;text-align:justify;margin-bottom:0pt;margin-right:0.64%;text-indent:7.69%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This <font style="font-weight:bold;">EXECUTIVE EMPLOYMENT AGREEMENT </font>(this &#8220;<font style="font-weight:bold;font-style:italic;">Agreement</font>&#8221;) is entered into as of the 30th day of September, 2020, between Jeff Rona (&#8220;<font style="font-weight:bold;font-style:italic;">Executive</font>&#8221;) and <font style="font-weight:bold;">OVID THERAPEUTICS INC. </font>(the &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221;). Certain capitalized terms used in this Agreement are defined in Section 6.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">WHEREAS<font style="font-weight:normal;">, the Company is a biopharmaceutical company;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">WHEREAS<font style="font-weight:normal;">, the Company desires to employ Executive in the position set forth below, and wishes to provide Executive with certain compensation and benefits in return for such services, as set forth in this Agreement; and</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="font-weight:bold;">WHEREAS</font>, Executive wishes to be employed by the Company and to provide personal services to the Company in return for certain compensation and benefits, as set forth in this Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">NOW, THEREFORE<font style="font-weight:normal;">, in consideration of the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company and Executive agree as follows:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">1.&nbsp;&nbsp;TERMS OF EMPLOYMENT</p>
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.1.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Position, Duties and Location.</font><font style="color:#000000;font-weight:normal;">&nbsp;&nbsp;Executive&#8217;s anticipated start date is September 30,  2020, (&#8220;Start Date&#8221;) or such other date as mutually agreed upon by the parties</font><font style="color:#000000;letter-spacing:-0.05pt;font-weight:normal;">. Executive shall initially serve as Chief Business Officer reporting to the Company&#8217;s CEO.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">Executive shall perform those duties and responsibilities as are customary for such position and as may be directed by the Company and the Board from time to time.  During Executive&#8217;s employment with the Company, Executive shall devote Executive&#8217;s best efforts and substantially all of Executive&#8217;s business time and attention to the business of the Company, except for approved vacation periods and reasonable periods of illness or other incapacities permitted by the Company&#8217;s general employment policies.&nbsp;&nbsp;Executive&#8217;s primary office location will be the Niwot, CO, the Executive will spend time at the Company&#8217;s New York office as required and expenses will be reimbursed under the Company&#8217;s reimbursement policy.&nbsp;&nbsp;Notwithstanding the foregoing, the Company reserves the right to reasonably require Executive to perform Executive&#8217;s duties at places other than Executive&#8217;s primary office location from time to time, and to require reasonable business travel.&nbsp;&nbsp;During Executive&#8217;s employment with the Company, Executive shall not engage in any activity that conflicts with or is detrimental to the Company&#8217;s best interests, as determined by the CEO.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive<font style="color:#000000;"> may participate as  Advisor and Board Member to Applied Immunotherapeutic and Brooklyn Defender Service (non-profit) and in wind down activities with Danforth Advisors and their clients for 90 days after the date of this agreement </font>(the &#8220;<font style="font-weight:bold;font-style:italic;">Activities</font>&#8221;),<font style="color:#000000;"> p</font>rovided that Executive obtains their manager&#8217;s prior written consent, and that none of the following activities involve activities in the area of neurology, detract from Ovid&#8217;s reputation, impact Executive&#8217;s full time duties to the Company, or could reasonably result in the disclosure or use of the Company&#8217;s proprietary or confidential information.&nbsp;&nbsp;The manager may rescind their consent to Executive&#8217;s participation in the Activities, or participation in other business or public activities, if the manager, in their sole discretion, determines that such activities compromise or threaten to compromise the Company&#8217;s business interests or conflict with Executive&#8217;s duties to the Company. </p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.2.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Employment Term</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Executive will be employed by the Company on an &#8220;at-will&#8221; basis.&nbsp;&nbsp;This means that either the Company or Executive may terminate Executive&#8217;s employment at any time, for </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:-10.58%;width:121.15%;">
<tr>
<td style="width:50.96%;"></td>
<td style="width:47.12%;"></td>
<td style="width:23.08%;"></td>
</tr>
<tr style="height:12pt;">
<td valign="top" >
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1460 Broadway, Suite 15021, New York, NY 10036</p></td>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office: (646) 661-7661 | Fax: (646) 661-4027</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">www.ovidrx.com</font></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">any reason, with or without C</font><font style="font-weight:normal;color:#000000;">ause, and with or without advance notice</font><font style="font-weight:normal;color:#000000;"> (provided that </font><font style="font-weight:normal;color:#000000;">(a) </font><font style="font-weight:normal;color:#000000;">Resignation for Good Reason </font><font style="font-weight:normal;color:#000000;">(as defined below) </font><font style="font-weight:normal;color:#000000;">requires certain advanced notice by Executive of Executive&#8217;s termination of employment</font><font style="font-weight:normal;color:#000000;"> as set forth below and (b) as a professional courtesy, Executive </font><font style="font-weight:normal;color:#000000;">agrees to provide the Company with at least sixty (60) days advance written notice of a </font><font style="font-weight:normal;color:#000000;">voluntary resignation by Executive that is not a Resignation for Good Reason</font><font style="font-weight:normal;color:#000000;">)</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">Subject to the terms herein, i</font><font style="font-weight:normal;color:#000000;">t also means that Executive&#8217;s job title, duties, responsibilities, reporting level, </font><font style="font-weight:normal;color:#000000;">compensation</font><font style="font-weight:normal;color:#000000;"> and benefits, as well as the Company&#8217;s personnel policies and procedures, may be changed </font><font style="font-weight:normal;color:#000000;">with or without notice at any time in the Company&#8217;s sole discretion.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;This at-will employment relationship shall not be modified by any conflicting actions or representations of any Company employee or other party before or during the term of Executive&#8217;s employment. </font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.3.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Compensation</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="color:#000000;">Annual Base Salary</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;&#160;Executive&#8217;s annual base salary shall be paid at the rate of $425,000 per year (&#8220;</font><font style="font-style:italic;color:#000000;">Annual Base Salary</font><font style="font-weight:normal;color:#000000;">&#8221;), payable in equal installments, less applicable payroll deductions and withholdings, on the Company&#8217;s ordinary payroll cycle.  Executive&#8217;s Annual Base Salary shall be subject to annual review by the Board and may be adjusted from time to time.&nbsp;&nbsp;As an exempt salaried employee, Executive will be required to work the Company&#8217;s normal business hours, and such additional time as appropriate for Executive&#8217;s work assignments and position, and Executive will not be entitled to overtime compensation.  </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="color:#000000;">Benefits</font><font style="font-weight:normal;color:#000000;">. Executive will be eligible to participate in all of the Company&#8217;s employee benefits and benefit plans that the Company generally makes available to its full-time employees and executives in accordance with the terms and conditions of the benefit plans and applicable policies as in effect from time to time.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">c)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="color:#000000;">Bonus</font><font style="font-weight:normal;color:#000000;">. Executive shall be eligible to earn an annual performance bonus of up to forty percent (40%) of Executive&#8217;s Annual Base Salary (the &#8220;</font><font style="font-style:italic;color:#000000;">Target Performance Bonus</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;The Target Performance Bonus shall be based upon the Company&#8217;s assessment of Executive&#8217;s attainment of written Company and individual objectives as set by the Company in its sole discretion.&nbsp;&nbsp;The Company may increase the Target Performance Bonus in its sole discretion.&nbsp;&nbsp;Bonus payments, if any, shall be subject to applicable payroll deductions and withholdings.&nbsp;&nbsp;Following the close of each calendar year, the Company shall determine whether Executive has earned a Target Performance Bonus, and the amount of any such bonus, based on the achievement of such objectives.&nbsp;&nbsp;Executive must be an employee of the Company in good standing on the Target Performance Bonus payment date to be eligible to receive a Target Performance Bonus, and no partial or prorated bonuses shall be provided.&nbsp;&nbsp;The Target Performance Bonus, if earned, shall be paid on or before March 15<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> of the calendar year after the applicable bonus year.&nbsp;&nbsp;Executive&#8217;s bonus eligibility is subject to change in the discretion of the Company.&nbsp;&nbsp; If Executive&#8217;s start date with the Company falls within the fourth quarter, the Executive will not be eligible for a target bonus for that calendar year.&nbsp;&nbsp;  </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">d)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="color:#000000;">Equity Compensation</font><font style="font-weight:normal;color:#000000;">. </font><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;">Subject to the approval of the Board, at the next meeting of the Board following the Start Date, Executive will be issued an option to purchase one three hundred twenty-five thousand (325,000) shares of the Company&#8217;s common stock (the &#8220;</font><font style="font-style:italic;color:#000000;letter-spacing:0.05pt;">Option</font><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;">&#8221;). The Option will be evidenced by a stock option agreement and be subject to the terms and conditions of the Company&#8217;s 2017 Equity Incentive Plan (the &#8220;</font><font style="font-style:italic;color:#000000;letter-spacing:0.05pt;">Equity Plan</font><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;">&#8221;). The exercise price per share of the Option will be equal to the per share fair market value of the Company&#8217;s common stock on the date the Option is granted, as defined under the Equity Plan. The vesting schedule of the Option will be as follows: twenty-five percent (25%) of the shares of the Company&#8217;s common stock subject to the Option will vest on the one year anniversary of the Start Date, and one thirty-sixth (1/36<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>) of the remaining shares of the Company&#8217;s common stock subject to the Option will vest each month thereafter on the same day of the month as </font></p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RONA - 2</a></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;">the Executive&#8217;s date of hire (and if there is no corresponding day, on the last day of the month), so long as Executive remains an employee, consultant, director or officer of the Company, and subject to the terms and conditions of the stock option agreement and the Equity Plan. Subject to the approval of the Board, the stock option agreement shall provide that upon a Change in Control Termination, the vesting and exercisability of the Option shall be accelerated in full. At the discretion of the Board, Executive will be eligible to receive additional options to purchase shares of the Company&#8217;s common stock.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.4.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Reimbursement of Expenses</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Subject to Section 4.8(c), the Company shall reimburse Executive for Executive&#8217;s necessary and reasonable business expenses incurred in connection with Executive&#8217;s duties in accordance with the Company&#8217;s generally applicable expense reimbursement policies as in effect from time to time.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.5.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Indemnification Agreement</font><font style="font-weight:normal;color:#000000;">. Executive and Company shall enter into an Indemnity Agreement (the &#8220;Indemnification Agreement&#8221;), which shall be effective as of the Start Date and is incorporated herein by reference.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.6.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Compliance with Confidentiality Agreement and Company Policies.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">Executive shall execute and abide by all terms and provisions of the </font><font style="color:#000000;font-weight:normal;">Confidentiality Agreement to be signed on or prior to the Start Date (or any successor agreement thereto), attached hereto as </font><font style="color:#000000;">Exhibit A</font><font style="color:#000000;font-weight:normal;">.</font><font style="font-weight:normal;color:#000000;"> Executive shall also abide by all terms and provisions of the Company&#8217;s Code of Business Conduct and Ethics, attached hereto as </font><font style="color:#000000;">Exhibit D</font><font style="font-weight:normal;color:#000000;">. In addition, Executive is required to abide by the Company&#8217;s policies and procedures, including but not limited to the Company&#8217;s Employee Handbook, as adopted or modified from time to time within the Company&#8217;s discretion; </font><font style="font-style:italic;font-weight:normal;color:#000000;">provided</font><font style="font-weight:normal;color:#000000;">, </font><font style="font-style:italic;font-weight:normal;color:#000000;">however</font><font style="font-weight:normal;color:#000000;">, that in the event the terms of this Agreement differ from or are in conflict with the Company&#8217;s general employment policies or practices, this Agreement shall control.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2.&nbsp;&nbsp;COVERED TERMINATION SEVERANCE BENEFITS</p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.1.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Severance Benefits</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Upon a Covered Termination, then subject to Section 4 below and Executive&#8217;s continued compliance with the terms of this Agreement, the Company shall provide Executive with the severance benefits set forth in this Section 2 (the &#8220;</font><font style="font-style:italic;color:#000000;">Severance Benefits</font><font style="font-weight:normal;color:#000000;">&#8221;).  </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.2.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Salary Payment</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The Company shall pay Executive, as cash severance, (i) Executive&#8217;s Monthly Base Salary, multiplied by (ii) the number of months in the Covered Termination Severance Period, less applicable payroll deductions and withholdings (the &#8220;</font><font style="font-style:italic;color:#000000;">Severance</font><font style="font-weight:normal;color:#000000;">&#8221;). The Severance shall be paid (except as set forth in Section 4) in equal installments on the Company&#8217;s ordinary payroll cycle commencing on the first regularly-scheduled payroll date occurring on or after the Release Deadline Date (as set forth in Section 4.1).</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.3.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Health Continuation Payments</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The Company will pay Executive on the first day of each month a fully taxable cash payment equal to the applicable premium for Executive, her spouse and any dependents for the group health plan maintained by the Company for the month in which the Covered Termination occurs, subject to applicable tax withholdings but grossed up for all taxes owed by the Executive on such payment, for the duration of the Covered Termination Benefits Period. Such coverage shall be counted as coverage pursuant to COBRA. The Company shall have no obligation in respect of any premium payments following the effective date of the Executive&#8217;s coverage by a health insurance plan of a subsequent employer. Executive shall be required to notify the Company immediately if Executive becomes covered by a health insurance plan of a subsequent employer. </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">For purposes of this Section&#160;2.3, (i)&#160;references to COBRA shall be deemed to include analogous provisions of state law, and (ii)&#160;any applicable insurance premiums that are paid by the </font></p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RONA - 3</a></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">Company shall not include any amounts payable by Executive under a Code Section&#160;125 health care reimbursement plan, which amounts, if any, are the sole responsibility of Executive. </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">3.&nbsp;&nbsp;CHANGE IN CONTROL SEVERANCE BENEFITS</p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.1.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Change in Control Severance Benefits</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Upon a Change in Control Termination, then subject to Section 4 below and Executive&#8217;s continued compliance with the terms of this Agreement, the Company shall provide Executive with the severance benefits set forth in this Section 3 (the &#8220;</font><font style="font-style:italic;color:#000000;">Change in Control Severance Benefits</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.2.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Salary Payment</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The Company shall pay Executive, as cash severance, (i) Executive&#8217;s Monthly Base Salary, multiplied by (ii) the number of months in the Change in Control Severance Period, less applicable payroll deductions and withholdings (the &#8220;</font><font style="font-style:italic;color:#000000;">Change in Control Severance</font><font style="font-weight:normal;color:#000000;">&#8221;). The Change in Control Severance shall be paid (except as set forth in Section 4) in equal installments on the Company&#8217;s ordinary payroll cycle commencing on the first regularly-scheduled payroll date occurring on or after the Release Deadline Date.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.3.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Health Continuation Payments</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:0pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The Company will pay Executive on the first day of each month a fully taxable cash payment equal to the applicable premium for Executive, her spouse and any dependents for the group health plan maintained by the Company for the month in which the Change in Control Termination occurs, subject to applicable tax withholdings but grossed up for all taxes owed by the Executive on such payment, for the duration of the Change in Control Benefits Period. Such coverage shall be counted as coverage pursuant to COBRA. The Company shall have no obligation in respect of any premium payments following the effective date of the Executive&#8217;s coverage by a health insurance plan of a subsequent employer. Executive shall be required to notify the Company immediately if Executive becomes covered by a health insurance plan of a subsequent employer. </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">For purposes of this Section&#160;3.3, (i)&#160;references to COBRA shall be deemed to include analogous provisions of state law, and (ii)&#160;any applicable insurance premiums that are paid by the Company shall not include any amounts payable by Executive under a Code Section&#160;125 health care reimbursement plan, which amounts, if any, are the sole responsibility of Executive. </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.4.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Change in Control Termination Vesting Acceleration Benefits</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Upon a Change in Control Termination, (i)&#160;the vesting and exercisability of all outstanding options to purchase the Company&#8217;s common stock (or stock appreciation rights or other rights with respect to the stock of the Company issued pursuant to any equity incentive plan of the Company) that are held by Executive on the Termination Date shall be accelerated in full, (ii) each such option shall be exercisable and to the extent not exercised, expire on the latest date permitted under the Equity Plan and (iii)&#160;any reacquisition or repurchase rights held by the Company with respect to common stock issued or issuable (or with respect to other rights with respect to the stock of the Company issued or issuable) pursuant to any other stock award granted to Executive pursuant to any equity incentive plan of the Company shall lapse.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">4.&nbsp;&nbsp;LIMITATIONS AND CONDITIONS ON BENEFITS</p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.1.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Release Prior to Payment of Severance Benefits and Change in Control Severance Benefits</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The receipt of any Severance Benefits or Change in Control Severance Benefits pursuant to this Agreement is subject to Executive signing and not revoking a separation agreement and general release of claims (the &#8220;</font><font style="font-style:italic;color:#000000;">Release</font><font style="font-weight:normal;color:#000000;">&#8221;), in substantially the form attached hereto and incorporated herein as </font><font style="color:#000000;">Exhibit B</font><font style="font-weight:normal;color:#000000;"> or </font><font style="color:#000000;">Exhibit C</font><font style="font-weight:normal;color:#000000;">, as appropriate, and subject to any further modifications as determined in the Company&#8217;s discretion, which Release must become effective and irrevocable no later than the sixtieth (60th)&#160;day following Executive&#8217;s Termination Date (the &#8220;</font><font style="font-style:italic;color:#000000;">Release Deadline Date</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;If the Release does not become </font></p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RONA - 4</a></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">effective and irrevocable by the Release Deadline Date, Executive&#160;will forfeit any right to any Severance Benefits </font><font style="font-weight:normal;color:#000000;">or Change in Control Severance Benefits </font><font style="font-weight:normal;color:#000000;">under this Agreement.&nbsp;&nbsp;In no event will Severance Benefits</font><font style="font-weight:normal;color:#000000;"> or Change in Control Severance Benefits</font><font style="font-weight:normal;color:#000000;"> be paid or provided until after the Release Deadline Date.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;O</font><font style="font-weight:normal;color:#000000;">n </font><font style="font-weight:normal;color:#000000;">the first </font><font style="font-weight:normal;color:#000000;">regularly-scheduled</font><font style="font-weight:normal;color:#000000;"> payroll date occurring on or after </font><font style="font-weight:normal;color:#000000;">the </font><font style="font-weight:normal;color:#000000;">Release Deadline</font><font style="font-weight:normal;color:#000000;"> Date, the Company will pay Executive the </font><font style="font-weight:normal;color:#000000;">Severance </font><font style="font-weight:normal;color:#000000;">or Change in Control Severance </font><font style="font-weight:normal;color:#000000;">amount</font><font style="font-weight:normal;color:#000000;"> that Executive would otherwise have received on or prior to such date but for the delay in payment related to the effectiveness of the Release, with the balance of the </font><font style="font-weight:normal;color:#000000;">S</font><font style="font-weight:normal;color:#000000;">everance </font><font style="font-weight:normal;color:#000000;">or Change in Control Severance </font><font style="font-weight:normal;color:#000000;">amount being paid as originally scheduled. The Company may modify the Release in its discretion to comply with changes in applicable law at any time prior to Executive</font><font style="font-weight:normal;color:#000000;">&#8217;</font><font style="font-weight:normal;color:#000000;">s execution of such Release.</font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.2.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Return of Company Property</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Not later than the Termination Date, or earlier if requested by the Company, Executive shall return to the Company all documents (and all copies thereof) and other property belonging to the Company that Executive has in his or her possession or control. The documents and property to be returned include, but are not limited to, all files, correspondence, email, memoranda, notes, notebooks, records, plans, forecasts, reports, studies, analyses, compilations of data, proposals, agreements, financial information, research and development information, marketing information, operational and personnel information, databases, computer-recorded information, tangible property and equipment (including, but not limited to, computers, facsimile machines, mobile telephones and servers), credit cards, entry cards, identification badges and keys, and any materials of any kind which contain or embody any proprietary or confidential information of the Company (and all reproductions thereof in whole or in part). Executive agrees to make a diligent search to locate any such documents, property and information. If Executive has used any personally owned computer, server or e-mail system to receive, store, review, prepare or transmit any Company confidential or proprietary data, materials or information, then within ten (10)&#160;business days after the Termination Date, or earlier if requested by the Company, Executive shall provide the Company with a computer-useable copy of all such information and then permanently delete and expunge such confidential or proprietary information from those systems. Executive agrees to provide the Company with a certification that the necessary copying and/or deletion is done.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.3.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Cooperation and Continued Compliance with Restrictive Covenants</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">After the Termination Date, Executive shall cooperate fully with the Company, at reasonable times as agreed between Executive and the Company, in connection with its actual or contemplated defense, prosecution or investigation of any existing or future litigation, arbitrations, mediations, claims, demands, audits, government or regulatory inquiries, or other matters arising from events, acts or failures to act that occurred during the time period in which Executive was employed by the Company (including any period of employment with an entity acquired by the Company). Such cooperation includes, without limitation, being available upon reasonable notice, without subpoena, to provide accurate and complete advice, assistance and information to the Company, including offering and explaining evidence, providing truthful and accurate sworn statements, and participating in discovery and trial preparation and testimony. Executive also agrees to promptly send the Company copies of all correspondence (for example, but not limited to, subpoenas) received by Executive in connection with any such legal proceedings, unless Executive is expressly prohibited by law from so doing.&nbsp;&nbsp;Nothing in this Agreement prohibits Executive from responding accurately and fully to any request for information if required by legal process or in connection with a government investigation.&nbsp;&nbsp;In addition, nothing in this Agreement is intended to prohibit or restrain Executive in any manner from making disclosures that are protected under the whistleblower provisions of federal law or regulation or under other applicable law or regulation.&nbsp;&nbsp;The Company will reimburse Executive for reasonable out-of-pocket expenses incurred in connection with any such cooperation (excluding foregone wages, salary or other compensation) within </font></p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RONA - 5</a></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">thirty (30)&#160;days of Executive</font><font style="font-weight:normal;color:#000000;">&#8217;</font><font style="font-weight:normal;color:#000000;">s timely presentation of appropriate documentation thereof, in accordance with the Company</font><font style="font-weight:normal;color:#000000;">&#8217;</font><font style="font-weight:normal;color:#000000;">s standard reimbursement policies and procedures</font><font style="font-weight:normal;color:#000000;">. The Company will reasonably </font><font style="font-weight:normal;color:#000000;">accommodat</font><font style="font-weight:normal;color:#000000;">e Executive</font><font style="font-weight:normal;color:#000000;">&#8217;</font><font style="font-weight:normal;color:#000000;">s scheduling needs</font><font style="font-weight:normal;color:#000000;"> with respect to any such cooperation after the Termination Date</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">After the Termination Date, Executive shall continue to abide by Executive&#8217;s continuing obligations under the Confidentiality Agreement. </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">c)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="color:#000000;font-weight:normal;">From the Start Date and through and including the Change in Control Severance Period or Covered Termination Severance Period as defined below, or, if Executive is Terminated with Cause, for one year after Executive&#8217;s Termination Date, whichever is applicable, Executive shall not, without the Company&#8217;s prior written consent, whether directly or indirectly be employed, under contract with, provide services to or on behalf of, or be involved with any business or organization (whether &#8220;for profit&#8221; or&nbsp;&nbsp;&#8220;not-for-profit&#8221;), or applicable Division thereof (as defined below), which researches, develops, creates, manufactures, designs and/or sells compounds and/or related pharmaceuticals, medicines and/or therapies to treat rare or orphan neurological conditions or diseases, and/or otherwise competes with products and/or services then under research or development by or offered or sold by the Company in the same therapeutic category.&nbsp;&nbsp;Nothing in Section 4.3(c) shall prohibit Executive from investing as a less than one percent (1%) shareholder in securities of any company listed on a national securities exchange or quoted on an automated quotation system.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">d)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="color:#000000;font-weight:normal;">From the Start Date until twelve (12) months after Termination Date, Executive shall not hire or retain, or attempt to hire or retain, any of the Company&#8217;s then-existing board members, employees, advisors, consultants, collaborators, investigators or agents and shall not induce any such to give up employment with or to cease providing services to the Company, and shall not otherwise interfere with, or attempt to interfere with, the relationship of any such person with the Company; or attempt in any manner to solicit, persuade or induce any Client of the Company to terminate, reduce or refrain from renewing or extending its contractual or other relationship with the Company in regard to the purchase of products or services marketed or sold by the Company, or to become a Client of or enter into any contractual or other relationship with Executive or any other individual, person or entity in regard to the purchase of products or services similar or identical to those marketed or sold by the Company.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">e)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="color:#000000;font-weight:normal;">Executive acknowledges and agrees that Executive&#8217;s obligations under this Section 4.3 are an essential part of the consideration Executive is providing hereunder in exchange for which and in reliance upon which the Company has agreed to provide the payments and benefits under this Agreement. Executive further acknowledges and agrees that Executive&#8217;s violation of this Section 4.3 inevitably would involve use or disclosure of the Company&#8217;s proprietary and confidential information. If it is determined by a court of competent jurisdiction in any state that any restriction in this Section 4.3 is excessive in duration or scope or is unreasonable or unenforceable under the laws of that state, it is the intention of the parties that such restriction may be modified or amended by the court to render it enforceable to the maximum extent permitted by the law of that state.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.4.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Parachute Payments</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-family:Arial;font-size:10.5pt;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Parachute Payment Limitation</font><font style="font-weight:normal;color:#000000;">.&#160; If any payment or benefit (including payments and benefits pursuant to this Agreement) Executive would receive in connection with a Change in Control from the Company or otherwise (&#8220;</font><font style="font-style:italic;color:#000000;">Payment</font><font style="font-weight:normal;color:#000000;">&#8221;) would (i)&#160;constitute a &#8220;parachute payment&#8221; within the meaning of Section&#160;280G of the Code, and (ii)&#160;but for this paragraph, be subject to the excise tax imposed by Section&#160;4999 of the Code (the &#8220;</font><font style="font-style:italic;color:#000000;">Excise Tax</font><font style="font-weight:normal;color:#000000;">&#8221;), then the Company shall cause to be determined, before any amounts of the Payment are paid to Executive, which of the following two alternative forms of payment shall be paid to Executive: (A)&#160;payment in full of the entire amount of the Payment (a &#8220;</font><font style="font-style:italic;color:#000000;">Full </font></p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RONA - 6</a></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-style:italic;color:#000000;">Payment</font><font style="font-weight:normal;color:#000000;">&#8221;), or (B)&#160;payment of only a part of the Payment so that Executive receives the largest payment possible without the imposition of the Excise Tax (a &#8220;</font><font style="font-style:italic;color:#000000;">Reduced Payment</font><font style="font-weight:normal;color:#000000;">&#8221;). A Full Payment shall be made </font><font style="font-weight:normal;color:#000000;">in the event that</font><font style="font-weight:normal;color:#000000;"> the amount received by the Executive on a net after-tax basis is </font><font style="font-weight:normal;color:#000000;">g</font><font style="font-weight:normal;color:#000000;">reater than what would be received by the Executive on a net after-tax basis if the Reduced Payment were made, otherwise a Reduced Payment shall be made. If a Reduced Payment is made, (</font><font style="font-weight:normal;color:#000000;">i</font><font style="font-weight:normal;color:#000000;">)&#160;the Payment shall be paid only to the extent permitted under the Reduced Payment alternative, and Executive shall have no rights to any additional payments and/or benefits constituting the Payment, and (ii)&#160;reduction in payments and/or benefits shall occur in the following order: (A)&#160;reduction of cash payments; (B)&#160;cancellation of accelerated vesting of equity awards other than stock options; (C)&#160;cancellation of accelerated vesting of stock options; and (D)&#160;reduction of other benefits paid to Executive. </font><font style="font-weight:normal;color:#000000;">In the event that</font><font style="font-weight:normal;color:#000000;"> acceleration of compensation from Executive&#8217;s equity awards is to be reduced, such acceleration of vesting shall be canceled in the reverse order of the date of grant.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The independent registered public accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the Change in Control shall make all determinations required to be made under this Section&#160;4.4. If the independent registered public accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">c)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The independent registered public accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive within fifteen (15)&#160;calendar days after the date on which Executive&#8217;s right to a Payment is triggered (if requested at that time by the Company or Executive) or such other time as requested by the Company or Executive. If the independent registered public accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish the Company and Executive with an opinion reasonably acceptable to Executive that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Company and Executive. </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.5.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Certain Reductions and Offsets</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;To the extent that any federal, state or local laws, including, without limitation, the Worker Adjustment and Retraining Notification Act or any other so-called &#8220;plant closing&#8221; laws, require the Company to give advance notice or make a payment of any kind to Executive because of Executive&#8217;s involuntary termination due to a layoff, reduction in force, plant or facility closing, sale of business, change in control or any other similar event or reason, the benefits payable under this Agreement shall be correspondingly reduced. The benefits provided under this Agreement are intended to satisfy any and all statutory obligations that may arise out of Executive&#8217;s involuntary termination of employment for the foregoing reasons, and the parties shall construe and enforce the terms of this Agreement accordingly.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.6.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Mitigation</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Except as otherwise specifically provided herein, Executive shall not be required to mitigate damages or the amount of any payment provided under this Agreement by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for under this Agreement be reduced by any compensation earned by Executive as a result of employment by another employer or by any retirement benefits received by Executive after the date of a Covered Termination or Change in Control Termination (except as expressly provided in Sections 2.3 and 3.3 above). </font></p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RONA - 7</a></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">4.7.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Indebtedness of Executive</font><font style="font-weight:normal;color:#000000;">. </font><font style="font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">If Executive is indebted to the Company on the effective date of a Covered Termination</font><font style="font-weight:normal;color:#000000;"> or Change in Control Termination Date</font><font style="font-weight:normal;color:#000000;">, the Company reserves the right to offset any </font><font style="font-weight:normal;color:#000000;">S</font><font style="font-weight:normal;color:#000000;">everance </font><font style="font-weight:normal;color:#000000;">Benefits </font><font style="font-weight:normal;color:#000000;">or </font><font style="font-weight:normal;color:#000000;">C</font><font style="font-weight:normal;color:#000000;">hange in </font><font style="font-weight:normal;color:#000000;">C</font><font style="font-weight:normal;color:#000000;">ontrol </font><font style="font-weight:normal;color:#000000;">Severance </font><font style="font-weight:normal;color:#000000;">Benefits </font><font style="font-weight:normal;color:#000000;">under this Agreement by the amount of such indebtedness</font><font style="font-weight:normal;color:#000000;">, subject to the requirements of Section 409A of the Code and applicable law</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.8.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Application of Section&#160;409A</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">Separation from Service</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Notwithstanding any provision to the contrary in this Agreement, no amount deemed deferred compensation subject to Section 409A of the Code shall be payable pursuant to Section 2 or Section 3 unless Executive&#8217;s termination of employment constitutes a &#8220;separation from service&#8221; with the Company within the meaning of Section 409A of the Code and the Department of Treasury Regulations and other guidance promulgated thereunder and, except as provided under Section 4.8(b) hereof, any such amount shall not be paid, or in the case of installments, commence payment, until the first regularly-scheduled payroll date occurring on or after the sixtieth (60th) day following Executive&#8217;s separation from service. Any installment payments that would have been made to Executive during the sixty (60) day period immediately following Executive&#8217;s separation from service but for the preceding sentence shall be paid to Executive on the first regularly-scheduled payroll date occurring on or after the sixtieth (60th) day after Executive&#8217;s separation from service and the remaining payments shall be made as provided in this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">Specified Executive</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed at the time of his or her separation from service to be a &#8220;specified employee&#8221; for purposes of Section 409A(a)(2)(B)(i) of the Code, to the extent delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, such portion of Executive&#8217;s benefits shall not be provided to Executive prior to the earlier of (i) the expiration of the six (6)-month period measured from the date of Executive&#8217;s &#8220;separation from service&#8221; with the Company (as such term is defined in the Treasury Regulations issued under Section 409A of the Code) or (ii) the date of Executive&#8217;s death. Upon the first business day following the expiration of the applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Section 4.8(b) shall be paid in a lump sum to Executive, and any remaining payments due under this Agreement shall be paid as otherwise provided herein.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">c)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">Expense Reimbursements</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;To the extent that any reimbursement payable pursuant to this Agreement is subject to the provisions of Section 409A of the Code, any such reimbursement payable to Executive pursuant to this Agreement shall be paid to Executive no later than December 31 of the year following the year in which the expense was incurred; the amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any subsequent year; and Executive&#8217;s right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">d)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">Installments</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;For purposes of Section 409A of the Code (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)), Executive&#8217;s right to receive any installment payments under this Agreement shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment shall at all times be considered a separate and distinct payment.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.9.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Tax Withholding</font><font style="font-weight:normal;color:#000000;">.  All payments under this Agreement shall be subject to applicable withholding for federal, state and local income and employment taxes. </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.10.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">No Duplication of Severance Benefits. </font><font style="font-weight:normal;color:#000000;">The Severance Benefits and Change in Control Severance Benefits provided in Section 2 and Section 3 are mutually exclusive of each other, and in no </font></p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RONA - 8</a></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">event shall Executive receive any </font><font style="font-weight:normal;color:#000000;">S</font><font style="font-weight:normal;color:#000000;">everance</font><font style="font-weight:normal;color:#000000;"> Benefits</font><font style="font-weight:normal;color:#000000;"> or </font><font style="font-weight:normal;color:#000000;">Change in Control </font><font style="font-weight:normal;color:#000000;">Severance </font><font style="font-weight:normal;color:#000000;">B</font><font style="font-weight:normal;color:#000000;">enefits pursuant to both </font><font style="font-weight:normal;color:#000000;">Section</font><font style="font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">2</font><font style="font-weight:normal;color:#000000;"> and </font><font style="font-weight:normal;color:#000000;">Section</font><font style="font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">3</font><font style="font-weight:normal;color:#000000;">.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">5.&nbsp;&nbsp;TERMINATION WITH CAUSE OR BY VOLUNTARY RESIGNATION; OTHER RIGHTS AND BENEFITS</p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.1.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Termination for Cause; Resignation Without Good Reason; Death or Disability</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;If, at any time, the Company terminates Executive&#8217;s employment with the Company for Cause, or upon a voluntary resignation by Executive that is not a Resignation for Good Reason, or Executive&#8217;s employment terminates for any reason not entitling Executive to the Severance Benefits or Change in Control Severance Benefits, or if Executive&#8217;s employment terminates as a result of Executive&#8217;s death or disability (other than a Permanent Disability in the case of a Covered Termination), then the Company shall have no further obligation to Executive hereunder except for the payment or provision, as applicable, of (i) the portion of the Annual Base Salary accrued through Executive&#8217;s last day of employment, (ii) all unreimbursed expenses (if any), subject to Sections 1.4 and 4.8(c), and (iii) any unused vacation (if applicable) accrued through Executive&#8217;s last day of employment.&nbsp;&nbsp;Under these circumstances, Executive will not be entitled to any other form of compensation, including any Severance Benefits or Change in Control Severance Benefits, other than Executive&#8217;s rights to the vested portion of Executive&#8217;s Option and any other rights to which Executive is entitled under the Company&#8217;s benefit programs.&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.2.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Other Rights and Benefits. </font><font style="font-weight:normal;color:#000000;">Nothing</font><font style="color:#000000;"> </font><font style="font-weight:normal;color:#000000;">in this Agreement shall prevent or limit Executive&#8217;s continuing or future participation in any benefit, bonus, incentive or other plans, programs, policies or practices provided by the Company and for which Executive may otherwise qualify, nor shall anything herein limit or otherwise affect such rights as Executive may have under other agreements with the Company except as provided in Section 4 and Section 5.1 above. Except as otherwise expressly provided herein, amounts that are vested benefits or that Executive is otherwise entitled to receive under any plan, policy, practice or program of the Company at or subsequent to the date of a Change in Control shall be payable in accordance with such plan, policy, practice or program. </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">6.&nbsp;&nbsp;DEFINITIONS</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of this Agreement, the following definitions shall apply: </p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.1.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:0pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Board</font><font style="font-weight:normal;color:#000000;">&#8221; means the Board of Directors of the Company, or the compensation committee thereof, as determinations or responsibilities may be delegated by the Board to the compensation committee.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.2.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Cause</font><font style="font-weight:normal;color:#000000;">&#8221; shall mean </font><font style="color:#000000;font-weight:normal;">a determination by the Company based upon reasonably available</font><font style="color:#000000;"> </font><font style="color:#000000;font-weight:normal;">information of Executive&#8217;s: (i) unauthorized use or disclosure of the Company&#8217;s confidential information or trade secrets; (ii) material breach of any agreement to which the Executive and the Company are a party; (iii) material failure to comply with the Company&#8217;s written policies or rules; (iv) conviction of, or plea of &#8220;guilty&#8221; or &#8220;no contest&#8221; to, a felony under the laws of the United States or any State; (v) negligence or willful misconduct relating to Executive&#8217;s performance of her duties on behalf of the Company; (vi) continuing failure to perform material and lawful assigned duties after receiving thirty (30) days&#8217; written notification of the failure from the Company if such breach is not cured (if curable) during that thirty (30) day period; (vii) failure to cooperate in good faith with a governmental or internal investigation of the Company or its directors, officers or employees, if the Company has requested Executive&#8217;s cooperation without prejudice or personal liability to Executive; (viii) violation of employee or ethical guidelines including, without limitation, violations of business practices and ethics commonly in place in similar companies in the United States; or (ix) violation of the Company code of conduct and/or any contractual code of conduct to which the Company is obligated</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RONA - 9</a></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">6.3.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Change in Control</font><font style="font-weight:normal;color:#000000;">&#8221;</font><font style="font-weight:normal;color:#000000;"> means the occurrence, in a single transaction or in a series of related transactions, of any one o</font><font style="font-weight:normal;color:#000000;">r more of the following events:</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">Any natural person, entity or group within the meaning of Section&#160;13(d) or 14(d) of the Securities Exchange Act of 1934, as amended (&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Exchange Act Person</font><font style="color:#000000;">&#8221;), becomes the owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%)&#160;of the combined voting power of the Company&#8217;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (i)&#160;on account of the acquisition of securities of the Company by any institutional investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#8217;s securities in a transaction or series of related transactions that are primarily a private financing transaction for the Company or (ii)&#160;solely because the level of ownership held by any Exchange Act Person (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Subject Person</font><font style="color:#000000;">&#8221;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur;</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">There is consummated a merger, consolidation or similar transaction involving, directly or indirectly, the Company if, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not own, directly or indirectly, either (i)&#160;outstanding voting securities representing more than fifty percent (50%)&#160;of the combined outstanding voting power of the surviving entity in such merger, consolidation or similar transaction or (ii)&#160;more than fifty percent (50%)&#160;of the combined outstanding voting power of the parent of the surviving entity in such merger, consolidation or similar transaction; or</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">c)</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">There is consummated a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries to an entity, more than fifty percent (50%)&#160;of the combined voting power of the voting securities of which are owned by stockholders of the Company in substantially the same proportion as their ownership of the Company immediately prior to such sale, lease, license or other disposition. </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:8.65%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company. Notwithstanding the foregoing or any other provision of this Agreement, the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any affiliate and the participant shall supersede the foregoing definition with respect to stock awards subject to such agreement (it being understood, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply). </p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.4.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Change in Control Benefits Period</font><font style="font-weight:normal;color:#000000;">&#8221; means the period of twelve (12) months commencing on the Termination Date. </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.5.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Change in Control Severance Period</font><font style="font-weight:normal;color:#000000;">&#8221; means the period of twelve (12) months commencing on the Termination Date. </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.6.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;"> &#8220;</font><font style="font-style:italic;color:#000000;">Change in Control Termination</font><font style="font-weight:normal;color:#000000;">&#8221; means an &#8220;</font><font style="font-style:italic;color:#000000;">Involuntary Termination Without Cause</font><font style="font-weight:normal;color:#000000;">&#8221; or &#8220;</font><font style="font-style:italic;color:#000000;">Resignation for Good Reason</font><font style="font-style:italic;font-weight:normal;color:#000000;">,</font><font style="font-weight:normal;color:#000000;">&#8221; either of which occurs within three (3)&#160;months prior to or upon or within twelve (12)&#160;months following the closing of a Change in Control or Dissolution Event, provided that </font></p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RONA - 10</a></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">any such termination is a &#8220;separation from service&#8221; within the meaning of Treasury Regulation Section&#160;1.409A-1(h).&nbsp;&nbsp;Death and disability shall not be deemed Change in Control Terminations. </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.7.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">COBRA</font><font style="font-weight:normal;color:#000000;">&#8221; means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.8.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Code</font><font style="font-weight:normal;color:#000000;">&#8221; means the Internal Revenue Code of 1986, as amended.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.9.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Company</font><font style="font-weight:normal;color:#000000;">&#8221; means Ovid Therapeutics Inc.</font><font style="text-transform:uppercase;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">or, following a Change in Control, the surviving entity resulting from such transaction, or any subsequent surviving entity resulting from any subsequent Change in Control.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.10.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Confidentiality Agreement</font><font style="font-weight:normal;color:#000000;">&#8221; means Senior Executive Confidential Information and Invention Assignment Agreement with the Company, (or any successor agreement thereto).</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.11.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;"> &#8220;</font><font style="font-style:italic;color:#000000;">Covered Termination</font><font style="font-weight:normal;color:#000000;">&#8221; means an &#8220;</font><font style="font-style:italic;color:#000000;">Involuntary Termination Without Cause</font><font style="font-weight:normal;color:#000000;">&#8221; or &#8220;</font><font style="font-style:italic;color:#000000;">Resignation for Good Reason</font><font style="font-style:italic;font-weight:normal;color:#000000;">,</font><font style="font-weight:normal;color:#000000;">&#8221; provided that any such termination is a &#8220;separation from service&#8221; within the meaning of Treasury Regulation Section&#160;1.409A-1(h). Death and disability, other than a Permanent Disability, shall not be deemed Covered Terminations.&nbsp;&nbsp;If an Involuntary Termination Without Cause or Resignation for Good Reason qualifies as a Change in Control Termination, it shall not constitute a Covered Termination.&nbsp;&nbsp;  </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.12.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Covered Termination Benefits Period</font><font style="font-weight:normal;color:#000000;">&#8221; means the period of twelve (12) months commencing on the Termination Date.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.13.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Covered Termination Severance Period</font><font style="font-weight:normal;color:#000000;">&#8221; means the period of twelve (12) months commencing on the Termination Date.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_2_88"></a><a name="_cp_text_5_89"></a><a name="_cp_text_2_91"></a><font style="Background-color:#auto;text-decoration:none;">6.14.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Dissolution Event</font><font style="font-weight:normal;color:#000000;"><a name="_cp_text_5_89"></a>&#8221; means the <a name="_cp_text_2_91"></a>stockholders of the Company approve or the Board approves a plan of complete dissolution or liquidation of the Company, or a complete dissolution or liquidation of the Company shall otherwise occur.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.15.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Involuntary Termination Without Cause</font><font style="font-weight:normal;color:#000000;">&#8221; means Executive&#8217;s dismissal or discharge by the Company for reasons other than Cause and other than as a result of death or disability; </font><font style="font-style:italic;font-weight:normal;color:#000000;">provided</font><font style="font-weight:normal;color:#000000;">, </font><font style="font-style:italic;font-weight:normal;color:#000000;">however</font><font style="font-weight:normal;color:#000000;">, that for purposes of a Covered Termination, Involuntary Termination Without Cause shall include Executive&#8217;s dismissal or discharge by the Company for reasons of Permanent Disability. </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.16.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;"> &#8220;</font><font style="font-style:italic;color:#000000;">Monthly Base Salary</font><font style="font-weight:normal;color:#000000;">&#8221; means 1/12<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> of Executive&#8217;s Annual Base Salary (excluding incentive pay, premium pay, commissions, overtime, bonuses and other forms of variable compensation) as in effect on the date of a Covered Termination or Change in Control Termination.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.17.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Permanent Disability</font><font style="font-weight:normal;color:#000000;">&#8221; means total and permanent disability as defined in Code Section 22(e)(3). </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.18.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Resignation for Good Reason</font><font style="font-weight:normal;color:#000000;">&#8221; means Executive&#8217;s resignation from all employee positions Executive then holds with the Company within ninety (90)&#160;days following any of the following events taken without Executive&#8217;s consent, provided Executive has given the Company written notice of such event within thirty (30)&#160;days after the first occurrence of such event and the Company has not cured such event within thirty (30)&#160;days thereafter:</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">A material decrease in Executive&#8217;s Annual Base Salary, other than in connection with a decrease in compensation for all comparable executives of the Company; </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">A relocation of Executive&#8217;s principal place of work outside of a fifty (50) mile radius of its current location; or</font></p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RONA - 11</a></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">c)</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">The Company&#8217;s material breach of this Agreement</font><font style="color:#000000;">.</font><font style="color:#000000;"> </font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.19.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Termination Date</font><font style="font-weight:normal;color:#000000;">&#8221; means the effective date of a Change in Control Termination, a Covered Termination, a termination for Cause or any other circumstance under which the employment relationship between Executive and the Company terminates, as applicable. </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.20.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;font-weight:normal;">&#8220;</font><font style="font-style:italic;color:#000000;">Division</font><font style="color:#000000;font-weight:normal;">&#8221; shall mean only that part, unit or therapeutic category of a larger entity that is competitive with the Company, but not an entire company itself, if other divisions, units or therapeutic categories of such larger company are not competitive with the Company.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.21.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;font-weight:normal;">"</font><font style="font-style:italic;color:#000000;">Client</font><font style="color:#000000;font-weight:normal;">" shall mean (A) anyone who is a client of the Company as of, or at any time during the one-year period immediately preceding, the termination of Executive&#8217;s employment, but only if Executive had a direct relationship with, supervisory responsibility for or otherwise were involved with such client during Executive&#8217;s employment with the Company; and (B) any prospective client to whom the Company made a new business presentation (or similar offering of services) at any time during the one-year period immediately preceding, or six-month period immediately following, Executive&#8217;s employment termination (but only if initial discussions between the Company and such prospective client relating to the rendering of services occurred prior to the termination date, and only if Executive participated in or supervised such presentation and/or its preparation or the discussions leading up to it).</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.22.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;font-weight:normal;">&#8220;</font><font style="font-style:italic;color:#000000;">Solicit</font><font style="color:#000000;font-weight:normal;">&#8221; shall mean: (A) active solicitation of any Client or Company employee, board member, advisor, consultant, collaborator, investigator or agents; (B) the provision of information regarding any Client or Company employee, board member, advisor, consultant, collaborator, investigator or agents to any third party where such information could be useful to such third party in attempting to obtain business from such Client or attempting to hire any such Company employee; (C) participation in any meetings, discussions, or other communications with any third party regarding any Client or Company employee, board member, advisor, consultant, collaborator, investigator or agents where the purpose or effect of such meeting, discussion or communication is to obtain business from such Client or employ such Company employee; and (D) any other passive use of information about any Client or Company employee, board member, advisor, consultant, collaborator, investigator or agents which has the purpose or effect of assisting a third party or causing harm to the business of the Company.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">7.&nbsp;&nbsp;GENERAL PROVISIONS</p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.1.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Employment Status.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">This Agreement does not constitute a contract of employment or impose upon Executive any obligation to remain as an employee, or impose on the Company any obligation (i) to retain Executive as an employee, (ii) to change the status of Executive as an at-will employee or (iii) to change the Company&#8217;s policies regarding termination of employment.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.2.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Notices</font><font style="font-weight:normal;color:#000000;">.  Any notices provided hereunder must be in writing, and such notices or any other written communication shall be deemed effective upon the earlier of personal delivery (including personal delivery by facsimile or email transmission (to a facsimile number or email address designated in advance by the receiving party)) or the third day after mailing by first class mail, to the Company at its primary office location and to Executive at Executive&#8217;s address as listed in the Company&#8217;s payroll records. Any payments made by the Company to Executive under the terms of this Agreement shall be delivered to Executive either in person or at the address as listed in the Company&#8217;s payroll records.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.3.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Severability</font><font style="font-weight:normal;color:#000000;">.  Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is determined to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other </font></p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RONA - 12</a></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">jurisdiction, </font><font style="font-weight:normal;color:#000000;">and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.4.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Waiver</font><font style="font-weight:normal;color:#000000;">.  If either party should waive any breach of any provisions of this Agreement, he, she or it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.5.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Complete Agreement</font><font style="font-weight:normal;color:#000000;">.  This Agreement, together with </font><font style="color:#000000;">Exhibits A </font><font style="font-weight:normal;color:#000000;">thru </font><font style="color:#000000;">D</font><font style="font-weight:normal;color:#000000;">, the Confidentiality Agreement and the Indemnification Agreement, forms the complete and exclusive statement of Executive&#8217;s employment agreement with the Company, and supersedes and replaces any other agreements or promises made to Executive by anyone, whether oral or written (including but not limited to the Prior Agreement).  </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.6.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Amendment or Termination of Agreement; Continuation of Agreement</font><font style="font-weight:normal;color:#000000;">.  Except for those changes expressly reserved to the Company&#8217;s or the Board&#8217;s discretion in this Agreement, this Agreement may be changed or terminated only upon the mutual written consent of the Company and Executive. The written consent of the Company to a change or termination of this Agreement must be signed by an executive officer of the Company (other than Executive) after such change or termination has been approved by the Board.  Unless so terminated, this Agreement shall continue in effect for as long as Executive continues to be employed by the Company or by any surviving entity following any Change in Control. For the avoidance of any doubt, if, following a Change in Control, Executive continues to be employed by the surviving entity without a Change in Control Termination and the surviving entity then undergoes a Change in Control, following which Executive is terminated by the subsequent surviving entity in a Change in Control Termination, Executive shall receive the benefits described in Section 3 hereof.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.7.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Counterparts</font><font style="font-weight:normal;color:#000000;">.  This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement.&nbsp;&nbsp;Facsimile and electronic image copies of signatures shall be equivalent to original signatures.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.8.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Headings</font><font style="font-weight:normal;color:#000000;">.  The headings of the Sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.9.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Successors and Assigns</font><font style="font-weight:normal;color:#000000;">.  This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive, and the Company, and any surviving entity resulting from a Change in Control and upon any other person who is a successor by merger, acquisition, consolidation or otherwise to the business formerly carried on by the Company, and their respective successors, assigns, heirs, executors and administrators, without regard to whether or not such person actively assumes any rights or duties hereunder; </font><font style="font-style:italic;font-weight:normal;color:#000000;">provided</font><font style="font-weight:normal;color:#000000;">, </font><font style="font-style:italic;font-weight:normal;color:#000000;">however</font><font style="font-weight:normal;color:#000000;">, that Executive may not assign any duties hereunder and may not assign any rights hereunder without the written consent of the Company, which consent shall not be withheld unreasonably.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.10.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Choice of Law</font><font style="font-weight:normal;color:#000000;">.  This Agreement shall be construed and enforced in accordance with the laws of the State of New York without regard to conflicts of law principles.&#160;</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.11.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Arbitration</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;To ensure the rapid and economical resolution of any disputes that may arise under or relate to this Agreement or Executive&#8217;s employment relationship, Executive and the Company agree that, unless otherwise prohibited by applicable law, any and all disputes, claims, or causes of action, in law or equity, arising from or relating to the performance, enforcement, execution, or interpretation of this Agreement, Executive&#8217;s employment with the Company, or the termination of Executive&#8217;s employment (collectively, &#8220;</font><font style="font-style:italic;color:#000000;">Claims</font><font style="font-weight:normal;color:#000000;">&#8221;), shall be resolved by final, binding, and (to the extent permitted by </font></p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RONA - 13</a></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">law) confidential arbitration before a single arbitrator in </font><font style="font-weight:normal;color:#000000;">New York, New York</font><font style="font-weight:normal;color:#000000;">.&#160;&#160;</font><font style="font-weight:normal;color:#000000;">Executive and the Company agree that they shall resolve all such </font><font style="font-weight:normal;color:#000000;">Claims</font><font style="font-weight:normal;color:#000000;"> in accordance with the provisions of Section </font><font style="font-weight:normal;color:#000000;">12 </font><font style="font-weight:normal;color:#000000;">of the Confidential Information and Invention Assignment</font><font style="font-weight:normal;color:#000000;"> Agreement attached hereto as </font><font style="font-weight:normal;color:#000000;">Exhibit</font><font style="font-weight:normal;color:#000000;"> A.</font><font style="font-weight:normal;color:#000000;">&#160;&#160;&#160;&#160; </font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.12.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Construction of Agreement</font><font style="font-weight:normal;color:#000000;">.  In the event of a conflict between the text of this Agreement and any summary, description or other information regarding this Agreement, the text of this Agreement shall control.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.13.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Circular 230 Disclaimer</font><font style="font-weight:normal;color:#000000;">.  </font><font style="color:#000000;">THE FOLLOWING DISCLAIMER IS PROVIDED IN ACCORDANCE WITH THE INTERNAL REVENUE SERVICE&#8217;S CIRCULAR 230 (21 C.F.R. PART 10). ANY TAX ADVICE CONTAINED IN THIS AGREEMENT IS INTENDED TO BE PRELIMINARY, FOR DISCUSSION PURPOSES ONLY AND NOT FINAL. ANY SUCH ADVICE IS NOT INTENDED TO BE USED FOR MARKETING, PROMOTING OR RECOMMENDING ANY TRANSACTION OR FOR THE USE OF ANY PERSON IN CONNECTION WITH THE PREPARATION OF ANY TAX RETURN. ACCORDINGLY, THIS ADVICE IS NOT INTENDED OR WRITTEN TO BE USED, AND IT CANNOT BE USED, BY ANY PERSON FOR THE PURPOSE OF AVOIDING TAX PENALTIES THAT MAY BE IMPOSED ON SUCH PERSON.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">REVIEWED, UNDERSTOOD AND ACCEPTED:<font style="font-weight:normal;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:8.64%;"></td>
<td style="width:41.28%;"></td>
<td style="width:9.17%;"></td>
<td style="width:40.8%;"></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Calibri;text-transform:uppercase;font-style:normal;font-variant: normal;">OVID THERAPEUTICS INC.</p></td>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">EXECUTIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&#160;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suzanne K. Wakamoto</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:&#160;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jeffrey Rona</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SVP, Human Resources</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:left;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RONA - 14</a></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rona - D-1</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>3
<FILENAME>ovid-ex1018_728.htm
<DESCRIPTION>EX-10.18
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ovid-ex1018_728.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.18</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">EXECUTIVE EMPLOYMENT AGREEMENT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:8pt;line-height:12pt;text-align:justify;margin-bottom:0pt;margin-right:0.64%;text-indent:7.69%;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This <font style="font-weight:bold;">EXECUTIVE EMPLOYMENT AGREEMENT </font>(this &#8220;<font style="font-weight:bold;font-style:italic;">Agreement</font>&#8221;) is entered into as of the 21<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup> day of October, 2019, between Jason Tardio (&#8220;<font style="font-weight:bold;font-style:italic;">Executive</font>&#8221;) and <font style="font-weight:bold;">OVID THERAPEUTICS INC. </font>(the &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221;). Certain capitalized terms used in this Agreement are defined in Section 6.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">WHEREAS<font style="font-weight:normal;">, the Company is a biopharmaceutical company;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">WHEREAS<font style="font-weight:normal;">, the Company desires to employ Executive in the position set forth below, and wishes to provide Executive with certain compensation and benefits in return for such services, as set forth in this Agreement; and</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="font-weight:bold;">WHEREAS</font>, Executive wishes to be employed by the Company and to provide personal services to the Company in return for certain compensation and benefits, as set forth in this Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">NOW, THEREFORE<font style="font-weight:normal;">, in consideration of the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company and Executive agree as follows:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">1.&nbsp;&nbsp;TERMS OF EMPLOYMENT</p>
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:5pt;margin-top:5pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.1.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Position, Duties and Location.</font><font style="color:#000000;font-weight:normal;">&nbsp;&nbsp;Executive&#8217;s anticipated start date is November 18, 2019, (&#8220;Start Date&#8221;) or such other date as mutually agreed upon by the parties</font><font style="color:#000000;letter-spacing:-0.05pt;font-weight:normal;">. Executive shall initially serve as Chief Commercial Officer reporting to the Company&#8217;s Chief Medical Officer and Head of Research &amp; Development, Amit Rakhit, MD, MBA (&#8220;Manager&#8221;).&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">Executive shall perform those duties and responsibilities as are customary for such position and as may be directed by the Company and the Board from time to time.  During Executive&#8217;s employment with the Company, Executive shall devote Executive&#8217;s best efforts and substantially all of Executive&#8217;s business time and attention to the business of the Company, except for approved vacation periods and reasonable periods of illness or other incapacities permitted by the Company&#8217;s general employment policies.&nbsp;&nbsp;Executive&#8217;s primary office location will be the Company&#8217;s offices in New York, New York.&nbsp;&nbsp;Notwithstanding the foregoing, the Company reserves the right to reasonably require Executive to perform Executive&#8217;s duties at places other than Executive&#8217;s primary office location from time to time, and to require reasonable business travel.&nbsp;&nbsp;During Executive&#8217;s employment with the Company, Executive shall not engage in any activity that conflicts with or is detrimental to the Company&#8217;s best interests, as determined by the CEO.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive<font style="color:#000000;"> may participate in side activities such as board or committee member, advisor or consultant </font>(the &#8220;<font style="font-weight:bold;font-style:italic;">Activities</font>&#8221;),<font style="color:#000000;"> p</font>rovided that Executive obtains Manager&#8217;s prior written consent, which consent shall not be unreasonably withheld, and that none of the following activities involve activities in the area of neurology, detract from Ovid&#8217;s reputation, impact Executive&#8217;s full time duties to the Company, or could reasonably result in the disclosure or use of the Company&#8217;s proprietary or confidential information.&nbsp;&nbsp;The Manager may rescind the consent to Executive&#8217;s participation in the Activities, or participation in other business or public activities, if the Manager in his sole discretion, determines that such activities compromise or threaten to compromise the Company&#8217;s business interests or conflict with Executive&#8217;s duties to the Company. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tardio - D-1</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.18</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">1.2.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Employment Term</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Executive will be employed by the Company on an &#8220;at-will&#8221; basis.&nbsp;&nbsp;This means that either the Company or Executive may terminate Executive&#8217;s employment at any time, f</font><font style="font-weight:normal;color:#000000;">or any reason, with or without C</font><font style="font-weight:normal;color:#000000;">ause, and with or without advance notice</font><font style="font-weight:normal;color:#000000;"> (provided that </font><font style="font-weight:normal;color:#000000;">(a) </font><font style="font-weight:normal;color:#000000;">Resignation for Good Reason </font><font style="font-weight:normal;color:#000000;">(as defined below) </font><font style="font-weight:normal;color:#000000;">requires certain advanced notice by Executive of Executive&#8217;s termination of employment</font><font style="font-weight:normal;color:#000000;"> as set forth below and (b) as a professional courtesy, Executive </font><font style="font-weight:normal;color:#000000;">agrees to provide the Company with at least sixty (60) days advance written notice of a </font><font style="font-weight:normal;color:#000000;">voluntary resignation by Executive that is not a Resignation for Good Reason</font><font style="font-weight:normal;color:#000000;">)</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">Subject to the terms herein, i</font><font style="font-weight:normal;color:#000000;">t also means that Executive&#8217;s job title, duties, responsibilities, reporting level, </font><font style="font-weight:normal;color:#000000;">compensation</font><font style="font-weight:normal;color:#000000;"> and benefits, as well as the Company&#8217;s personnel policies and procedures, may be changed </font><font style="font-weight:normal;color:#000000;">with or without notice at any time in the Company&#8217;s sole discretion.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;This at-will employment relationship shall not be modified by any conflicting actions or representations of any Company employee or other party before or during the term of Executive&#8217;s employment. </font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.3.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Compensation</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="color:#000000;">Annual Base Salary</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;&#160;Executive&#8217;s annual base salary shall be paid at the rate of $400,000 per year (&#8220;</font><font style="font-style:italic;color:#000000;">Annual Base Salary</font><font style="font-weight:normal;color:#000000;">&#8221;), payable in equal installments, less applicable payroll deductions and withholdings, on the Company&#8217;s ordinary payroll cycle.  Executive&#8217;s Annual Base Salary shall be subject to annual review by the Board and may be adjusted from time to time.&nbsp;&nbsp;As an exempt salaried employee, Executive will be required to work the Company&#8217;s normal business hours, and such additional time as appropriate for Executive&#8217;s work assignments and position, and Executive will not be entitled to overtime compensation.  </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="color:#000000;">Benefits</font><font style="font-weight:normal;color:#000000;">. Executive will be eligible to participate in all of the Company&#8217;s employee benefits and benefit plans that the Company generally makes available to its full-time employees and executives in accordance with the terms and conditions of the benefit plans and applicable policies as in effect from time to time.&nbsp;&nbsp;In accordance with the Company&#8217;s policies and procedures, as in effect from time to time, Executive will be eligible to accrue twenty (20) days of paid time off per year. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">c)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="color:#000000;">Bonus</font><font style="font-weight:normal;color:#000000;">. Executive shall be eligible to earn an annual performance bonus of up to thirty five percent (35%) of Executive&#8217;s Annual Base Salary (the &#8220;</font><font style="font-style:italic;color:#000000;">Target Performance Bonus</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;The Target Performance Bonus shall be based upon the Company&#8217;s assessment of Executive&#8217;s attainment of written Company and individual objectives as set by the Company in its sole discretion.&nbsp;&nbsp;The Company may increase the Target Performance Bonus in its sole discretion.&nbsp;&nbsp;Bonus payments, if any, shall be subject to applicable payroll deductions and withholdings.&nbsp;&nbsp;Following the close of each calendar year, the Company shall determine whether Executive has earned a Target Performance Bonus, and the amount of any such bonus, based on the achievement of such objectives.&nbsp;&nbsp;Executive must be an employee of the Company in good standing on the Target Performance Bonus payment date to be eligible to receive a Target Performance Bonus, and no partial or prorated bonuses shall be provided.&nbsp;&nbsp;The Target Performance Bonus, if earned, shall be paid on or before March 15<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> of the calendar year after the applicable bonus year.&nbsp;&nbsp;Executive&#8217;s bonus eligibility is subject to change in the discretion of the Company.&nbsp;&nbsp;&nbsp;&nbsp; If Executive&#8217;s&nbsp;&nbsp;start date with the Company falls within the fourth quarter, the Executive will not&nbsp;&nbsp;be eligible for a target bonus for that calendar year.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">d)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="color:#000000;">Equity Compensation</font><font style="font-weight:normal;color:#000000;">. </font><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;">Subject to the approval of the Board, at the next meeting of the Board following the Start Date, Executive will be issued an option to purchase one hundred twenty five thousand (125,000) shares of the Company&#8217;s common stock (the &#8220;</font><font style="font-style:italic;color:#000000;letter-spacing:0.05pt;">Option</font><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;">&#8221;). The Option will be evidenced by a stock option agreement and be subject to the terms and conditions of the Company&#8217;s 2017 Equity Incentive Plan (the &#8220;</font><font style="font-style:italic;color:#000000;letter-spacing:0.05pt;">Equity Plan</font><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;">&#8221;). The exercise price per share of the Option will be equal </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tardio - D-2</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.18</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;">to the per share fair market value of the Company&#8217;s common stock on the date the Option is granted, as </font><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;">defined under the Equity Plan</font><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;">. The vesting schedule of the Option will be as follows: twenty-five percent (25%) of the shares of the Company&#8217;s common stock subject to the Option will vest on the one year anniversary of the </font><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;">Start Date</font><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;">, and one thirty-sixth (1/36</font><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup></font><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;">) of the remaining shares of the Company&#8217;s common stock subject to the Option will vest each month thereafter on the same day of the month as the Executive&#8217;s date of hire (and if there is no corresponding day, on the last day of the month), so long as Executive remains an employee, consultant, director or officer of the Company, and subject to the terms and conditions of the stock option agreement and the Equity Plan. Subject to the approval of the Board, the stock option agreement shall provide that upon a Change in Control Termination, the vesting and exercisability of the Option shall be accelerated in full. At the discretion of the Board, Executive will be eligible to receive additional options to purchase shares of the Company&#8217;s common stock.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">e)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="color:#000000;">Sign-on Bonus</font><font style="font-weight:normal;color:#000000;">. Within thirty (30) days of the commencement of Executive&#8217;s employment, the Company will pay Executive a sign-on bonus in the amount of $110,000.&#160; Should Executive resign from the Company or be terminated by the Company with Cause within one (1) year of the commencement of Executive&#8217;s employment, Executive agrees to reimburse the Company </font><font style="font-style:italic;font-weight:normal;color:#000000;">pro rata</font><font style="font-weight:normal;color:#000000;"> for the amount of the sign-on bonus.&#160; This reimbursement will be due to the Company within thirty (30) days of Executive&#8217;s last day of employment. </font></p>
<p style="text-align:justify;margin-bottom:5pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.4.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Reimbursement of Expenses</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Subject to Section 4.8(c), the Company shall reimburse Executive for Executive&#8217;s necessary and reasonable business expenses incurred in connection with Executive&#8217;s duties in accordance with the Company&#8217;s generally applicable expense reimbursement policies as in effect from time to time.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.5.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Indemnification Agreement</font><font style="font-weight:normal;color:#000000;">. Executive and Company shall enter into an Indemnity Agreement (the &#8220;Indemnification Agreement&#8221;), which shall be effective as of the Start Date and is incorporated herein by reference.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.6.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Compliance with Confidentiality Agreement and Company Policies.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">Executive shall execute and abide by all terms and provisions of the </font><font style="color:#000000;font-weight:normal;">Confidentiality Agreement to be signed on or prior to the Start Date (or any successor agreement thereto), attached hereto as </font><font style="color:#000000;">Exhibit A</font><font style="color:#000000;font-weight:normal;">.</font><font style="font-weight:normal;color:#000000;"> Executive shall also abide by all terms and provisions of the Company&#8217;s Code of Business Conduct and Ethics, attached hereto as </font><font style="color:#000000;">Exhibit D</font><font style="font-weight:normal;color:#000000;">. In addition, Executive is required to abide by the Company&#8217;s policies and procedures, including but not limited to the Company&#8217;s Employee Handbook, as adopted or modified from time to time within the Company&#8217;s discretion; </font><font style="font-style:italic;font-weight:normal;color:#000000;">provided</font><font style="font-weight:normal;color:#000000;">, </font><font style="font-style:italic;font-weight:normal;color:#000000;">however</font><font style="font-weight:normal;color:#000000;">, that in the event the terms of this Agreement differ from or are in conflict with the Company&#8217;s general employment policies or practices, this Agreement shall control.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2.&nbsp;&nbsp;COVERED TERMINATION SEVERANCE BENEFITS</p>
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.1.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Severance Benefits</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Upon a Covered Termination, then subject to Section 4 below and Executive&#8217;s continued compliance with the terms of this Agreement, the Company shall provide Executive with the severance benefits set forth in this Section 2 (the &#8220;</font><font style="font-style:italic;color:#000000;">Severance Benefits</font><font style="font-weight:normal;color:#000000;">&#8221;).  </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.2.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Salary Payment</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The Company shall pay Executive, as cash severance, (i) Executive&#8217;s Monthly Base Salary, multiplied by (ii) the number of months in the Covered Termination Severance Period, less applicable payroll deductions and withholdings (the &#8220;</font><font style="font-style:italic;color:#000000;">Severance</font><font style="font-weight:normal;color:#000000;">&#8221;). The Severance shall be paid (except as set forth in Section 4) in equal installments on the Company&#8217;s ordinary payroll cycle commencing on the first regularly-scheduled payroll date occurring on or after the Release Deadline Date (as set forth in Section 4.1).</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tardio - D-3</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.18</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">2.3.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Health Continuation </font><font style="color:#000000;">Payments</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The Company will pay Executive on the first day of each month a fully taxable cash payment equal to the applicable premium for Executive, her spouse and any dependents for the group health plan maintained by the Company for the month in which the Covered Termination occurs, subject to applicable tax withholdings but grossed up for all taxes owed by the Executive on such payment, for the duration of the Covered Termination Benefits Period. Such coverage shall be counted as coverage pursuant to COBRA. The Company shall have no obligation in respect of any premium payments following the effective date of the Executive&#8217;s coverage by a health insurance plan of a subsequent employer. Executive shall be required to notify the Company immediately if Executive becomes covered by a health insurance plan of a subsequent employer. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">For purposes of this Section&#160;2.3, (i)&#160;references to COBRA shall be deemed to include analogous provisions of state law, and (ii)&#160;any applicable insurance premiums that are paid by the Company shall not include any amounts payable by Executive under a Code Section&#160;125 health care reimbursement plan, which amounts, if any, are the sole responsibility of Executive. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">3.&nbsp;&nbsp;CHANGE IN CONTROL SEVERANCE BENEFITS</p>
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.1.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Change in Control Severance Benefits</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Upon a Change in Control Termination, then subject to Section 4 below and Executive&#8217;s continued compliance with the terms of this Agreement, the Company shall provide Executive with the severance benefits set forth in this Section 3 (the &#8220;</font><font style="font-style:italic;color:#000000;">Change in Control Severance Benefits</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.2.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Salary Payment</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The Company shall pay Executive, as cash severance, (i) Executive&#8217;s Monthly Base Salary, multiplied by (ii) the number of months in the Change in Control Severance Period, less applicable payroll deductions and withholdings (the &#8220;</font><font style="font-style:italic;color:#000000;">Change in Control Severance</font><font style="font-weight:normal;color:#000000;">&#8221;). The Change in Control Severance shall be paid (except as set forth in Section 4) in equal installments on the Company&#8217;s ordinary payroll cycle commencing on the first regularly-scheduled payroll date occurring on or after the Release Deadline Date.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.3.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Health Continuation Payments</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:0pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The Company will pay Executive on the first day of each month a fully taxable cash payment equal to the applicable premium for Executive, her spouse and any dependents for the group health plan maintained by the Company for the month in which the Change in Control Termination occurs, subject to applicable tax withholdings but grossed up for all taxes owed by the Executive on such payment, for the duration of the Change in Control Benefits Period. Such coverage shall be counted as coverage pursuant to COBRA. The Company shall have no obligation in respect of any premium payments following the effective date of the Executive&#8217;s coverage by a health insurance plan of a subsequent employer. Executive shall be required to notify the Company immediately if Executive becomes covered by a health insurance plan of a subsequent employer. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">For purposes of this Section&#160;3.3, (i)&#160;references to COBRA shall be deemed to include analogous provisions of state law, and (ii)&#160;any applicable insurance premiums that are paid by the Company shall not include any amounts payable by Executive under a Code Section&#160;125 health care reimbursement plan, which amounts, if any, are the sole responsibility of Executive. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.4.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Change in Control Termination Vesting Acceleration Benefits</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Upon a Change in Control Termination, (i)&#160;the vesting and exercisability of all outstanding options to purchase the Company&#8217;s common stock (or stock appreciation rights or other rights with respect to the stock of the Company issued </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tardio - D-4</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.18</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">pursuant to any equity incentive plan of the Company) that are held by Executive on the </font><font style="font-weight:normal;color:#000000;">Termination Date</font><font style="font-weight:normal;color:#000000;"> shall be accelerated in full</font><font style="font-weight:normal;color:#000000;">,</font><font style="font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">(ii) each such option shall be exercisable and to the extent not exercised, expire on the latest date permitted under the Equity Plan and (iii)&#160;any reacquisition or repurchase rights held by the Company with respect to common stock issued or issuable (or with respect to other rights with respect to the stock of the Company issued or issuable) pursuant to any other stock award granted to Executive pursuant to any equity incentive plan of the Company shall lapse</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">4.&nbsp;&nbsp;LIMITATIONS AND CONDITIONS ON BENEFITS</p>
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.1.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Release Prior to Payment of Severance Benefits and Change in Control Severance Benefits</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The receipt of any Severance Benefits or Change in Control Severance Benefits pursuant to this Agreement is subject to Executive signing and not revoking a separation agreement and general release of claims (the &#8220;</font><font style="font-style:italic;color:#000000;">Release</font><font style="font-weight:normal;color:#000000;">&#8221;), in substantially the form attached hereto and incorporated herein as </font><font style="color:#000000;">Exhibit B</font><font style="font-weight:normal;color:#000000;"> or </font><font style="color:#000000;">Exhibit C</font><font style="font-weight:normal;color:#000000;">, as appropriate, and subject to any further modifications as determined in the Company&#8217;s discretion, which Release must become effective and irrevocable no later than the sixtieth (60th)&#160;day following Executive&#8217;s Termination Date (the &#8220;</font><font style="font-style:italic;color:#000000;">Release Deadline Date</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;If the Release does not become effective and irrevocable by the Release Deadline Date, Executive&#160;will forfeit any right to any Severance Benefits or Change in Control Severance Benefits under this Agreement.&nbsp;&nbsp;In no event will Severance Benefits or Change in Control Severance Benefits be paid or provided until after the Release Deadline Date.&nbsp;&nbsp;On the first regularly-scheduled payroll date occurring on or after the Release Deadline Date, the Company will pay Executive the Severance or Change in Control Severance amount that Executive would otherwise have received on or prior to such date but for the delay in payment related to the effectiveness of the Release, with the balance of the Severance or Change in Control Severance amount being paid as originally scheduled. The Company may modify the Release in its discretion to comply with changes in applicable law at any time prior to Executive&#8217;s execution of such Release.</font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.2.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Return of Company Property</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Not later than the Termination Date, or earlier if requested by the Company, Executive shall return to the Company all documents (and all copies thereof) and other property belonging to the Company that Executive has in his or her possession or control. The documents and property to be returned include, but are not limited to, all files, correspondence, email, memoranda, notes, notebooks, records, plans, forecasts, reports, studies, analyses, compilations of data, proposals, agreements, financial information, research and development information, marketing information, operational and personnel information, databases, computer-recorded information, tangible property and equipment (including, but not limited to, computers, facsimile machines, mobile telephones and servers), credit cards, entry cards, identification badges and keys, and any materials of any kind which contain or embody any proprietary or confidential information of the Company (and all reproductions thereof in whole or in part). Executive agrees to make a diligent search to locate any such documents, property and information. If Executive has used any personally owned computer, server or e-mail system to receive, store, review, prepare or transmit any Company confidential or proprietary data, materials or information, then within ten (10)&#160;business days after the Termination Date, or earlier if requested by the Company, Executive shall provide the Company with a computer-useable copy of all such information and then permanently delete and expunge such confidential or proprietary information from those systems. Executive agrees to provide the Company with a certification that the necessary copying and/or deletion is done.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.3.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Cooperation and Continued Compliance with Restrictive Covenants</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">After the Termination Date, Executive shall cooperate fully with the Company, at reasonable times as agreed between Executive and the Company, in connection with its actual or </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tardio - D-5</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.18</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">co</font><font style="font-weight:normal;color:#000000;">ntemplated defense, prosecution</font><font style="font-weight:normal;color:#000000;"> or investigation of any existing or future litigation, arbitrations, mediations, claims, demands, audits, government or regulatory inquiries, or other ma</font><font style="font-weight:normal;color:#000000;">tters arising from events, acts</font><font style="font-weight:normal;color:#000000;"> or failures to act that occurred during the time period in which Executive was employed by the Company (including any period of employment with an entity acquired by the Company). Such cooperation includes, without limitation, being available upon reasonable notice, without subpoena, to provide accurate and complete advice, </font><font style="font-weight:normal;color:#000000;">assistance</font><font style="font-weight:normal;color:#000000;"> and information to the Company, including offering and explaining evidence, providing truthful and accurate sworn statements, and participating in discovery and trial preparation and testimony. Executive also agrees to promptly send the Company copies of all correspondence (for example, but not limited to, subpoenas) received by Executive in connection with any such legal proceedings, unless Executive is expressly prohibited by law from so doing</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">N</font><font style="font-weight:normal;color:#000000;">othing in this Agreement prohibits Executive from </font><font style="font-weight:normal;color:#000000;">responding accurately and fully to any request for information if required by legal process or in connection with a government investigation.&nbsp;&nbsp;In addition, nothing in this Agreement is intended to prohibit or restrain Executive in any manner from making disclosures that are protected under the whistleblower provisions of federal law or regulation or under other applicable law or regulation.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">The Company will reimburse Executive for reasonable out-of-pocket expenses incurred in connection with any such cooperation (e</font><font style="font-weight:normal;color:#000000;">xcluding foregone wages, </font><font style="font-weight:normal;color:#000000;">salary</font><font style="font-weight:normal;color:#000000;"> or other compensation) within thirty (30)&#160;days of Executive</font><font style="font-weight:normal;color:#000000;">&#8217;</font><font style="font-weight:normal;color:#000000;">s timely presentation of appropriate documentation thereof, in accordance with the Company</font><font style="font-weight:normal;color:#000000;">&#8217;</font><font style="font-weight:normal;color:#000000;">s standard reimbursement policies and procedures</font><font style="font-weight:normal;color:#000000;">. The Company will reasonably </font><font style="font-weight:normal;color:#000000;">accommodat</font><font style="font-weight:normal;color:#000000;">e Executive</font><font style="font-weight:normal;color:#000000;">&#8217;</font><font style="font-weight:normal;color:#000000;">s scheduling needs</font><font style="font-weight:normal;color:#000000;"> with respect to any such cooperation after the Termination Date</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">After the Termination Date, Executive shall continue to abide by Executive&#8217;s continuing obligations under the Confidentiality Agreement. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">c)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="color:#000000;font-weight:normal;">From the Start Date and through and including the Change in Control Severance Period or Covered Termination Severance Period as defined below, or, if Executive is Terminated with Cause, for one year after Executive&#8217;s Termination Date, whichever is applicable, Executive shall not, without the Company&#8217;s prior written consent, whether directly or indirectly be employed, under contract with, provide services to or on behalf of, or be involved with any business or organization (whether &#8220;for profit&#8221; or&nbsp;&nbsp;&#8220;not-for-profit&#8221;), or applicable Division thereof (as defined below), which researches, develops, creates, manufactures, designs and/or sells compounds and/or related pharmaceuticals, medicines and/or therapies to treat rare or orphan neurological conditions or diseases, and/or otherwise competes with products and/or services then under research or development by or offered or sold by the Company in the same therapeutic category.&nbsp;&nbsp;Nothing in Section 4.3(c) shall prohibit Executive from investing as a less than one percent (1%) shareholder in securities of any company listed on a national securities exchange or quoted on an automated quotation system.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">d)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="color:#000000;font-weight:normal;">From the Start Date until twelve (12) months after Termination Date, Executive shall not hire or retain, or attempt to hire or retain, any of the Company&#8217;s then-existing board members, employees, advisors, consultants, collaborators, investigators or agents and shall not induce any such to give up employment with or to cease providing services to the Company, and shall not otherwise interfere with, or attempt to interfere with, the relationship of any such person with the Company; or attempt in any manner to solicit, persuade or induce any Client of the Company to terminate, reduce or refrain from renewing or extending its contractual or other relationship with the Company in regard to the purchase of products or services marketed or sold by the Company, or to become a Client of or enter into any contractual or other relationship with Executive or any other individual, person or entity in regard to the purchase of products or services similar or identical to those marketed or sold by the Company.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tardio - D-6</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.18</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">e)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="color:#000000;font-weight:normal;">Executive acknowledges and agrees that Executive&#8217;s obligations under this Section 4.3 are an essential part of the consideration Executive is providing hereunder in exchange for which and in reliance upon which the Company has agreed to provide the payments and benefits under this Agreement. Executive further acknowledges and agrees that Executive&#8217;s violation of this Section 4.3 inevitably would involve use or disclosure of the Company&#8217;s proprietary and confidential information. If it is determined by a court of competent jurisdiction in any state that any restriction in this Section 4.3 is excessive in duration or scope or is unreasonable or unenforceable under the laws of that state, it is the intention of the parties that such restriction may be modified or amended by the court to render it enforceable to the maximum extent permitted by the law of that state.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.4.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Parachute Payments</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-family:Arial;font-size:10.5pt;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Parachute Payment Limitation</font><font style="font-weight:normal;color:#000000;">.&#160; If any payment or benefit (including payments and benefits pursuant to this Agreement) Executive would receive in connection with a Change in Control from the Company or otherwise (&#8220;</font><font style="font-style:italic;color:#000000;">Payment</font><font style="font-weight:normal;color:#000000;">&#8221;) would (i)&#160;constitute a &#8220;parachute payment&#8221; within the meaning of Section&#160;280G of the Code, and (ii)&#160;but for this paragraph, be subject to the excise tax imposed by Section&#160;4999 of the Code (the &#8220;</font><font style="font-style:italic;color:#000000;">Excise Tax</font><font style="font-weight:normal;color:#000000;">&#8221;), then the Company shall cause to be determined, before any amounts of the Payment are paid to Executive, which of the following two alternative forms of payment shall be paid to Executive: (A)&#160;payment in full of the entire amount of the Payment (a &#8220;</font><font style="font-style:italic;color:#000000;">Full Payment</font><font style="font-weight:normal;color:#000000;">&#8221;), or (B)&#160;payment of only a part of the Payment so that Executive receives the largest payment possible without the imposition of the Excise Tax (a &#8220;</font><font style="font-style:italic;color:#000000;">Reduced Payment</font><font style="font-weight:normal;color:#000000;">&#8221;). A Full Payment shall be made in the event that the amount received by the Executive on a net after-tax basis is greater than what would be received by the Executive on a net after-tax basis if the Reduced Payment were made, otherwise a Reduced Payment shall be made. If a Reduced Payment is made, (i)&#160;the Payment shall be paid only to the extent permitted under the Reduced Payment alternative, and Executive shall have no rights to any additional payments and/or benefits constituting the Payment, and (ii)&#160;reduction in payments and/or benefits shall occur in the following order: (A)&#160;reduction of cash payments; (B)&#160;cancellation of accelerated vesting of equity awards other than stock options; (C)&#160;cancellation of accelerated vesting of stock options; and (D)&#160;reduction of other benefits paid to Executive. In the event that acceleration of compensation from Executive&#8217;s equity awards is to be reduced, such acceleration of vesting shall be canceled in the reverse order of the date of grant.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The independent registered public accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the Change in Control shall make all determinations required to be made under this Section&#160;4.4. If the independent registered public accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">c)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The independent registered public accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive within fifteen (15)&#160;calendar days after the date on which Executive&#8217;s right to a Payment is triggered (if requested at that time by the Company or Executive) or such other time as requested by the Company or Executive. If the independent registered public accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish the Company and Executive with an opinion reasonably acceptable to Executive that no Excise Tax will be imposed with respect to such Payment. Any </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tardio - D-7</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.18</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">good faith determinations of the accounting firm made hereunder shall be final, </font><font style="font-weight:normal;color:#000000;">binding</font><font style="font-weight:normal;color:#000000;"> and conclusive upon the Company and Executive. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.5.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Certain Reductions and Offsets</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;To the extent that any federal, state or local laws, including, without limitation, the Worker Adjustment and Retraining Notification Act or any other so-called &#8220;plant closing&#8221; laws, require the Company to give advance notice or make a payment of any kind to Executive because of Executive&#8217;s involuntary termination due to a layoff, reduction in force, plant or facility closing, sale of business, change in control or any other similar event or reason, the benefits payable under this Agreement shall be correspondingly reduced. The benefits provided under this Agreement are intended to satisfy any and all statutory obligations that may arise out of Executive&#8217;s involuntary termination of employment for the foregoing reasons, and the parties shall construe and enforce the terms of this Agreement accordingly.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.6.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Mitigation</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Except as otherwise specifically provided herein, Executive shall not be required to mitigate damages or the amount of any payment provided under this Agreement by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for under this Agreement be reduced by any compensation earned by Executive as a result of employment by another employer or by any retirement benefits received by Executive after the date of a Covered Termination or Change in Control Termination (except as expressly provided in Sections 2.3 and 3.3 above). </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.7.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Indebtedness of Executive</font><font style="font-weight:normal;color:#000000;">.  If Executive is indebted to the Company on the effective date of a Covered Termination or Change in Control Termination Date, the Company reserves the right to offset any Severance Benefits or Change in Control Severance Benefits under this Agreement by the amount of such indebtedness, subject to the requirements of Section 409A of the Code and applicable law. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.8.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Application of Section&#160;409A</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">Separation from Service</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Notwithstanding any provision to the contrary in this Agreement, no amount deemed deferred compensation subject to Section 409A of the Code shall be payable pursuant to Section 2 or Section 3 unless Executive&#8217;s termination of employment constitutes a &#8220;separation from service&#8221; with the Company within the meaning of Section 409A of the Code and the Department of Treasury Regulations and other guidance promulgated thereunder and, except as provided under Section 4.8(b) hereof, any such amount shall not be paid, or in the case of installments, commence payment, until the first regularly-scheduled payroll date occurring on or after the sixtieth (60th) day following Executive&#8217;s separation from service. Any installment payments that would have been made to Executive during the sixty (60) day period immediately following Executive&#8217;s separation from service but for the preceding sentence shall be paid to Executive on the first regularly-scheduled payroll date occurring on or after the sixtieth (60th) day after Executive&#8217;s separation from service and the remaining payments shall be made as provided in this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">Specified Executive</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed at the time of his or her separation from service to be a &#8220;specified employee&#8221; for purposes of Section 409A(a)(2)(B)(i) of the Code, to the extent delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, such portion of Executive&#8217;s benefits shall not be provided to Executive prior to the earlier of (i) the expiration of the six (6)-month period measured from the date of Executive&#8217;s &#8220;separation from service&#8221; with the Company (as such term is defined in the Treasury Regulations issued under Section 409A of the Code) or (ii) the date of Executive&#8217;s death. Upon the first business day following the expiration of the applicable Code Section 409A(a)(2)(B)(i) </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tardio - D-8</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.18</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">period, all payments deferred pursuant to this Section </font><font style="font-weight:normal;color:#000000;">4.8</font><font style="font-weight:normal;color:#000000;">(b) </font><font style="font-weight:normal;color:#000000;">shall be paid in a lump sum to Executive, and any remaining payments due under this Agreement shall be paid as otherwise provided herein.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">c)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">Expense Reimbursements</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;To the extent that any reimbursement payable pursuant to this Agreement is subject to the provisions of Section 409A of the Code, any such reimbursement payable to Executive pursuant to this Agreement shall be paid to Executive no later than December 31 of the year following the year in which the expense was incurred; the amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any subsequent year; and Executive&#8217;s right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">d)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">Installments</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;For purposes of Section 409A of the Code (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)), Executive&#8217;s right to receive any installment payments under this Agreement shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment shall at all times be considered a separate and distinct payment.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.9.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Tax Withholding</font><font style="font-weight:normal;color:#000000;">.  All payments under this Agreement shall be subject to applicable withholding for federal, state and local income and employment taxes. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.10.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">No Duplication of Severance Benefits. </font><font style="font-weight:normal;color:#000000;">The Severance Benefits and Change in Control Severance Benefits provided in Section 2 and Section 3 are mutually exclusive of each other, and in no event shall Executive receive any Severance Benefits or Change in Control Severance Benefits pursuant to both Section 2 and Section 3.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">5.&nbsp;&nbsp;TERMINATION WITH CAUSE OR BY VOLUNTARY RESIGNATION; OTHER RIGHTS AND BENEFITS</p>
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.1.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Termination for Cause; Resignation Without Good Reason; Death or Disability</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;If, at any time, the Company terminates Executive&#8217;s employment with the Company for Cause, or upon a voluntary resignation by Executive that is not a Resignation for Good Reason, or Executive&#8217;s employment terminates for any reason not entitling Executive to the Severance Benefits or Change in Control Severance Benefits, or if Executive&#8217;s employment terminates as a result of Executive&#8217;s death or disability (other than a Permanent Disability in the case of a Covered Termination), then the Company shall have no further obligation to Executive hereunder except for the payment or provision, as applicable, of (i) the portion of the Annual Base Salary accrued through Executive&#8217;s last day of employment, (ii) all unreimbursed expenses (if any), subject to Sections 1.4 and 4.8(c), and (iii) any unused vacation (if applicable) accrued through Executive&#8217;s last day of employment.&nbsp;&nbsp;Under these circumstances, Executive will not be entitled to any other form of compensation, including any Severance Benefits or Change in Control Severance Benefits, other than Executive&#8217;s rights to the vested portion of Executive&#8217;s Option and any other rights to which Executive is entitled under the Company&#8217;s benefit programs.&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.2.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Other Rights and Benefits. </font><font style="font-weight:normal;color:#000000;">Nothing</font><font style="color:#000000;"> </font><font style="font-weight:normal;color:#000000;">in this Agreement shall prevent or limit Executive&#8217;s continuing or future participation in any benefit, bonus, incentive or other plans, programs, policies or practices provided by the Company and for which Executive may otherwise qualify, nor shall anything herein limit or otherwise affect such rights as Executive may have under other agreements with the Company except as provided in Section 4 and Section 5.1 above. Except as otherwise expressly provided herein, amounts that are vested benefits or that Executive is otherwise entitled to receive under any plan, policy, practice or program of the Company at or subsequent to the date of a Change in Control shall be payable in accordance with such plan, policy, practice or program. </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tardio - D-9</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.18</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">6</font><font style="font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">DEFINITIONS</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of this Agreement, the following definitions shall apply: </p>
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.1.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:0pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Board</font><font style="font-weight:normal;color:#000000;">&#8221; means the Board of Directors of the Company, or the compensation committee thereof, as determinations or responsibilities may be delegated by the Board to the compensation committee.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.2.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Cause</font><font style="font-weight:normal;color:#000000;">&#8221; shall mean </font><font style="color:#000000;font-weight:normal;">a determination by the Company based upon reasonably available</font><font style="color:#000000;"> </font><font style="color:#000000;font-weight:normal;">information of Executive&#8217;s: (i) unauthorized use or disclosure of the Company&#8217;s confidential information or trade secrets; (ii) material breach of any agreement to which the Executive and the Company are a party; (iii) material failure to comply with the Company&#8217;s written policies or rules; (iv) conviction of, or plea of &#8220;guilty&#8221; or &#8220;no contest&#8221; to, a felony under the laws of the United States or any State; (v) negligence or willful misconduct relating to Executive&#8217;s performance of her duties on behalf of the Company; (vi) continuing failure to perform material and lawful assigned duties after receiving thirty (30) days&#8217; written notification of the failure from the Company if such breach is not cured (if curable) during that thirty (30) day period; (vii) failure to cooperate in good faith with a governmental or internal investigation of the Company or its directors, officers or employees, if the Company has requested Executive&#8217;s cooperation without prejudice or personal liability to Executive; (viii) violation of employee or ethical guidelines including, without limitation, violations of business practices and ethics commonly in place in similar companies in the United States; or (ix) violation of the Company code of conduct and/or any contractual code of conduct to which the Company is obligated</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.3.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Change in Control</font><font style="font-weight:normal;color:#000000;">&#8221; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">Any natural person, entity or group within the meaning of Section&#160;13(d) or 14(d) of the Securities Exchange Act of 1934, as amended (&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Exchange Act Person</font><font style="color:#000000;">&#8221;), becomes the owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%)&#160;of the combined voting power of the Company&#8217;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (i)&#160;on account of the acquisition of securities of the Company by any institutional investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#8217;s securities in a transaction or series of related transactions that are primarily a private financing transaction for the Company or (ii)&#160;solely because the level of ownership held by any Exchange Act Person (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Subject Person</font><font style="color:#000000;">&#8221;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">There is consummated a merger, consolidation or similar transaction involving, directly or indirectly, the Company if, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not own, directly or indirectly, either (i)&#160;outstanding voting securities representing more than fifty percent (50%)&#160;of the combined outstanding voting power of the surviving entity in such merger, consolidation or similar transaction or (ii)&#160;more than fifty percent (50%)&#160;of the combined outstanding voting power of the parent of the surviving entity in such merger, consolidation or similar transaction; or</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tardio - D-10</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.18</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">c)</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">There is consummated a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries to an entity, more than fifty percent (50%)&#160;of the combined voting power of the voting securities of which are owned by stockholders of the Company in substantially the same proportion as their ownership of the Company immediately prior to such sale, lease, license or other disposition. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:8.65%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company. Notwithstanding the foregoing or any other provision of this Agreement, the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any affiliate and the participant shall supersede the foregoing definition with respect to stock awards subject to such agreement (it being understood, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply). </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.4.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Change in Control Benefits Period</font><font style="font-weight:normal;color:#000000;">&#8221; means the period of twelve (12) months commencing on the Termination Date. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.5.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Change in Control Severance Period</font><font style="font-weight:normal;color:#000000;">&#8221; means the period of twelve (12) months commencing on the Termination Date. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.6.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;"> &#8220;</font><font style="font-style:italic;color:#000000;">Change in Control Termination</font><font style="font-weight:normal;color:#000000;">&#8221; means an &#8220;</font><font style="font-style:italic;color:#000000;">Involuntary Termination Without Cause</font><font style="font-weight:normal;color:#000000;">&#8221; or &#8220;</font><font style="font-style:italic;color:#000000;">Resignation for Good Reason</font><font style="font-style:italic;font-weight:normal;color:#000000;">,</font><font style="font-weight:normal;color:#000000;">&#8221; either of which occurs within three (3)&#160;months prior to or upon or within twelve (12)&#160;months following the closing of a Change in Control or Dissolution Event, provided that any such termination is a &#8220;separation from service&#8221; within the meaning of Treasury Regulation Section&#160;1.409A-1(h).&nbsp;&nbsp;Death and disability shall not be deemed Change in Control Terminations. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.7.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">COBRA</font><font style="font-weight:normal;color:#000000;">&#8221; means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.8.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Code</font><font style="font-weight:normal;color:#000000;">&#8221; means the Internal Revenue Code of 1986, as amended.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.9.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Company</font><font style="font-weight:normal;color:#000000;">&#8221; means Ovid Therapeutics Inc.</font><font style="text-transform:uppercase;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">or, following a Change in Control, the surviving entity resulting from such transaction, or any subsequent surviving entity resulting from any subsequent Change in Control.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.10.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Confidentiality Agreement</font><font style="font-weight:normal;color:#000000;">&#8221; means Senior Executive Confidential Information and Invention Assignment Agreement with the Company, (or any successor agreement thereto).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.11.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;"> &#8220;</font><font style="font-style:italic;color:#000000;">Covered Termination</font><font style="font-weight:normal;color:#000000;">&#8221; means an &#8220;</font><font style="font-style:italic;color:#000000;">Involuntary Termination Without Cause</font><font style="font-weight:normal;color:#000000;">&#8221; or &#8220;</font><font style="font-style:italic;color:#000000;">Resignation for Good Reason</font><font style="font-style:italic;font-weight:normal;color:#000000;">,</font><font style="font-weight:normal;color:#000000;">&#8221; provided that any such termination is a &#8220;separation from service&#8221; within the meaning of Treasury Regulation Section&#160;1.409A-1(h). Death and disability, other than a Permanent Disability, shall not be deemed Covered Terminations.&nbsp;&nbsp;If an Involuntary Termination Without Cause or Resignation for Good Reason qualifies as a Change in Control Termination, it shall not constitute a Covered Termination.&nbsp;&nbsp;  </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.12.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Covered Termination Benefits Period</font><font style="font-weight:normal;color:#000000;">&#8221; means the period of twelve (12) months commencing on the Termination Date.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.13.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Covered Termination Severance Period</font><font style="font-weight:normal;color:#000000;">&#8221; means the period of twelve (12) months commencing on the Termination Date.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tardio - D-11</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.18</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_2_88"></a><a name="_cp_text_5_89"></a><a name="_cp_text_2_91"></a><font style="text-decoration:none;Background-color:#auto;">6.14.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Dissolution Event</font><font style="font-weight:normal;color:#000000;"><a name="_cp_text_5_89"></a>&#8221; means the </font><font style="font-weight:normal;color:#000000;"><a name="_cp_text_2_91"></a>stockholders of the Company approve or the Board approves a plan of complete dissolution or liquidation of the Company, or a complete dissolution or liquidation of the Company </font><font style="font-weight:normal;color:#000000;">shall otherwise occur</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.15.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Involuntary Termination Without Cause</font><font style="font-weight:normal;color:#000000;">&#8221; means Executive&#8217;s dismissal or discharge by the Company for reasons other than Cause and other than as a result of death or disability; </font><font style="font-style:italic;font-weight:normal;color:#000000;">provided</font><font style="font-weight:normal;color:#000000;">, </font><font style="font-style:italic;font-weight:normal;color:#000000;">however</font><font style="font-weight:normal;color:#000000;">, that for purposes of a Covered Termination, Involuntary Termination Without Cause shall include Executive&#8217;s dismissal or discharge by the Company for reasons of Permanent Disability. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.16.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;"> &#8220;</font><font style="font-style:italic;color:#000000;">Monthly Base Salary</font><font style="font-weight:normal;color:#000000;">&#8221; means 1/12<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> of Executive&#8217;s Annual Base Salary (excluding incentive pay, premium pay, commissions, overtime, bonuses and other forms of variable compensation) as in effect on the date of a Covered Termination or Change in Control Termination.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.17.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Permanent Disability</font><font style="font-weight:normal;color:#000000;">&#8221; means total and permanent disability as defined in Code Section 22(e)(3). </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.18.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Resignation for Good Reason</font><font style="font-weight:normal;color:#000000;">&#8221; means Executive&#8217;s resignation from all employee positions Executive then holds with the Company within ninety (90)&#160;days following any of the following events taken without Executive&#8217;s consent, provided Executive has given the Company written notice of such event within thirty (30)&#160;days after the first occurrence of such event and the Company has not cured such event within thirty (30)&#160;days thereafter:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">A material decrease in Executive&#8217;s Annual Base Salary, other than in connection with a decrease in compensation for all comparable executives of the Company; </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">A relocation of Executive&#8217;s principal place of work outside of a fifty (50) mile radius of its current location; or</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">c)</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">The Company&#8217;s material breach of this Agreement.  </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.19.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Termination Date</font><font style="font-weight:normal;color:#000000;">&#8221; means the effective date of a Change in Control Termination, a Covered Termination, a termination for Cause or any other circumstance under which the employment relationship between Executive and the Company terminates, as applicable. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.20.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;font-weight:normal;">&#8220;</font><font style="font-style:italic;color:#000000;">Division</font><font style="color:#000000;font-weight:normal;">&#8221; shall mean only that part, unit or therapeutic category of a larger entity that is competitive with the Company, but not an entire company itself, if other divisions, units or therapeutic categories of such larger company are not competitive with the Company.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.21.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;font-weight:normal;">"</font><font style="font-style:italic;color:#000000;">Client</font><font style="color:#000000;font-weight:normal;">" shall mean (A) anyone who is a client of the Company as of, or at any time during the one-year period immediately preceding, the termination of Executive&#8217;s employment, but only if Executive had a direct relationship with, supervisory responsibility for or otherwise were involved with such client during Executive&#8217;s employment with the Company; and (B) any prospective client to whom the Company made a new business presentation (or similar offering of services) at any time during the one-year period immediately preceding, or six-month period immediately following, Executive&#8217;s employment termination (but only if initial discussions between the Company and such prospective client relating to the rendering of services occurred prior to the termination date, and only if Executive participated in or supervised such presentation and/or its preparation or the discussions leading up to it).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.22.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;font-weight:normal;">&#8220;</font><font style="font-style:italic;color:#000000;">Solicit</font><font style="color:#000000;font-weight:normal;">&#8221; shall mean: (A) active solicitation of any Client or Company employee, board member, advisor, consultant, collaborator, investigator or agents; (B) the provision of information regarding any Client or Company employee, board member, advisor, consultant, collaborator, investigator or agents to any third party where such information could be useful to such third party in attempting to obtain business from such Client or attempting to hire any such Company employee; (C) participation in any meetings, discussions, or other communications with any third party regarding any Client or Company employee, board member, advisor, consultant, collaborator, investigator </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tardio - D-12</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.18</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;font-weight:normal;">or agents where the purpose or effect of such meeting, discussion or communication is to obtain business from such Client or employ such Company employee; and (D) any other passive use of information about any Client or Company employee, board member, advisor, consultant, collaborator, investigator or agents which has the purpose or effect of assisting a third party or causing harm to the business of the Company.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">7.&nbsp;&nbsp;GENERAL PROVISIONS</p>
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:5pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.1.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Employment Status.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">This Agreement does not constitute a contract of employment or impose upon Executive any obligation to remain as an employee, or impose on the Company any obligation (i) to retain Executive as an employee, (ii) to change the status of Executive as an at-will employee or (iii) to change the Company&#8217;s policies regarding termination of employment.</font></p>
<p style="text-align:justify;margin-bottom:5pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.2.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Notices</font><font style="font-weight:normal;color:#000000;">.  Any notices provided hereunder must be in writing, and such notices or any other written communication shall be deemed effective upon the earlier of personal delivery (including personal delivery by facsimile or email transmission (to a facsimile number or email address designated in advance by the receiving party)) or the third day after mailing by first class mail, to the Company at its primary office location and to Executive at Executive&#8217;s address as listed in the Company&#8217;s payroll records. Any payments made by the Company to Executive under the terms of this Agreement shall be delivered to Executive either in person or at the address as listed in the Company&#8217;s payroll records.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.3.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Severability</font><font style="font-weight:normal;color:#000000;">.  Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is determined to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.4.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Waiver</font><font style="font-weight:normal;color:#000000;">.  If either party should waive any breach of any provisions of this Agreement, he, she or it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.5.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Complete Agreement</font><font style="font-weight:normal;color:#000000;">.  This Agreement, together with </font><font style="color:#000000;">Exhibits A </font><font style="font-weight:normal;color:#000000;">thru </font><font style="color:#000000;">D</font><font style="font-weight:normal;color:#000000;">, the Confidentiality Agreement and the Indemnification Agreement, forms the complete and exclusive statement of Executive&#8217;s employment agreement with the Company, and supersedes and replaces any other agreements or promises made to Executive by anyone, whether oral or written (including but not limited to the Prior Agreement).  </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.6.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Amendment or Termination of Agreement; Continuation of Agreement</font><font style="font-weight:normal;color:#000000;">.  Except for those changes expressly reserved to the Company&#8217;s or the Board&#8217;s discretion in this Agreement, this Agreement may be changed or terminated only upon the mutual written consent of the Company and Executive. The written consent of the Company to a change or termination of this Agreement must be signed by an executive officer of the Company (other than Executive) after such change or termination has been approved by the Board.  Unless so terminated, this Agreement shall continue in effect for as long as Executive continues to be employed by the Company or by any surviving entity following any Change in Control. For the avoidance of any doubt, if, following a Change in Control, Executive continues to be employed by the surviving entity without a Change in Control Termination and the surviving entity then </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tardio - D-13</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.18</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">undergoes a Change in Control, following which Executive is terminated by the subsequent surviving entity in a Change in Control Termination, Executive shall receive the benefits described in Section </font><font style="font-weight:normal;color:#000000;">3</font><font style="font-weight:normal;color:#000000;"> hereof.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.7.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Counterparts</font><font style="font-weight:normal;color:#000000;">.  This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement.&nbsp;&nbsp;Facsimile and electronic image copies of signatures shall be equivalent to original signatures.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.8.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Headings</font><font style="font-weight:normal;color:#000000;">.  The headings of the Sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.9.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Successors and Assigns</font><font style="font-weight:normal;color:#000000;">.  This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive, and the Company, and any surviving entity resulting from a Change in Control and upon any other person who is a successor by merger, acquisition, consolidation or otherwise to the business formerly carried on by the Company, and their respective successors, assigns, heirs, executors and administrators, without regard to whether or not such person actively assumes any rights or duties hereunder; </font><font style="font-style:italic;font-weight:normal;color:#000000;">provided</font><font style="font-weight:normal;color:#000000;">, </font><font style="font-style:italic;font-weight:normal;color:#000000;">however</font><font style="font-weight:normal;color:#000000;">, that Executive may not assign any duties hereunder and may not assign any rights hereunder without the written consent of the Company, which consent shall not be withheld unreasonably.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.10.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Choice of Law</font><font style="font-weight:normal;color:#000000;">.  This Agreement shall be construed and enforced in accordance with the laws of the State of New York without regard to conflicts of law principles.&#160;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.11.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Arbitration</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;To ensure the rapid and economical resolution of any disputes that may arise under or relate to this Agreement or Executive&#8217;s employment relationship, Executive and the Company agree that, unless otherwise prohibited by applicable law, any and all disputes, claims, or causes of action, in law or equity, arising from or relating to the performance, enforcement, execution, or interpretation of this Agreement, Executive&#8217;s employment with the Company, or the termination of Executive&#8217;s employment (collectively, &#8220;</font><font style="font-style:italic;color:#000000;">Claims</font><font style="font-weight:normal;color:#000000;">&#8221;), shall be resolved by final, binding, and (to the extent permitted by law) confidential arbitration before a single arbitrator in New York, New York.&#160;&#160;Executive and the Company agree that they shall resolve all such Claims in accordance with the provisions of Section 12 of the Confidential Information and Invention Assignment Agreement attached hereto as Exhibit A.&#160;&#160;&#160;&#160; </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.12.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Construction of Agreement</font><font style="font-weight:normal;color:#000000;">.  In the event of a conflict between the text of this Agreement and any summary, description or other information regarding this Agreement, the text of this Agreement shall control.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.13.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Circular 230 Disclaimer</font><font style="font-weight:normal;color:#000000;">.  </font><font style="color:#000000;">THE FOLLOWING DISCLAIMER IS PROVIDED IN ACCORDANCE WITH THE INTERNAL REVENUE SERVICE&#8217;S CIRCULAR 230 (21 C.F.R. PART 10). ANY TAX ADVICE CONTAINED IN THIS AGREEMENT IS INTENDED TO BE PRELIMINARY, FOR DISCUSSION PURPOSES ONLY AND NOT FINAL. ANY SUCH ADVICE IS NOT INTENDED TO BE USED FOR MARKETING, PROMOTING OR RECOMMENDING ANY TRANSACTION OR FOR THE USE OF ANY PERSON IN CONNECTION WITH THE PREPARATION OF ANY TAX RETURN. ACCORDINGLY, THIS ADVICE IS NOT INTENDED OR WRITTEN TO BE USED, AND IT CANNOT BE USED, BY ANY PERSON FOR THE PURPOSE OF AVOIDING TAX PENALTIES THAT MAY BE IMPOSED ON SUCH PERSON.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURE PAGE TO FOLLOW</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tardio - D-14</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.18</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">REVIEWED, UNDERSTOOD AND ACCEPTED:<font style="font-weight:normal;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:8.64%;"></td>
<td style="width:41.28%;"></td>
<td style="width:9.17%;"></td>
<td style="width:40.8%;"></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Calibri;text-transform:uppercase;font-style:normal;font-variant: normal;">OVID THERAPEUTICS INC.</p></td>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">EXECUTIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&#160;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suzanne K. Wakamoto</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:&#160;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jason Tardio</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SVP, Human Resources</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tardio - D-15</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>4
<FILENAME>ovid-ex1019_727.htm
<DESCRIPTION>EX-10.19
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ovid-ex1019_727.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.19</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thomas Perone (&#8220;<font style="font-weight:bold;font-style:italic;">Executive</font>&#8221;) is currently employed by <font style="font-weight:bold;">OVID THERAPEUTICS INC.</font> (the &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221;) as its General Counsel, Corporate Secretary and Chief Compliance Officer pursuant to the terms of an Executive Employment Agreement with the Company effective March 11, 2019 (the &#8220;<font style="font-weight:bold;font-style:italic;">Prior Agreement</font>&#8221;).&nbsp;&nbsp;  Executive and the Company hereby agree to this amended agreement.&nbsp;&nbsp; The terms and conditions set forth in this <font style="font-weight:bold;">AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT</font> (this &#8220;<font style="font-weight:bold;font-style:italic;">Agreement</font>&#8221;) shall become effective as of January 1, 2020 (the &#8220;<font style="font-weight:bold;font-style:italic;">Effective Date</font>&#8221;) and shall supersede and replace the terms and conditions set forth in the Prior Agreement.&nbsp;&nbsp;Certain bolded terms used in this Agreement are defined in Section 6.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">WHEREAS<font style="font-weight:normal;">, the Company is a biopharmaceutical company;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">WHEREAS<font style="font-weight:normal;">, the Company desires to employ Executive in the position set forth below, and wishes to provide Executive with certain compensation and benefits in return for such services, as set forth in this Agreement; and</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="font-weight:bold;">WHEREAS</font>, Executive wishes to be employed by the Company and to provide personal services to the Company in return for certain compensation and benefits, as set forth in this Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">NOW, THEREFORE<font style="font-weight:normal;">, in consideration of the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company and Executive agree as follows:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">1.&nbsp;&nbsp;TERMS OF EMPLOYMENT</p>
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:5pt;margin-top:5pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.1.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Position, Duties and Location.</font><font style="color:#000000;font-weight:normal;">&nbsp;&nbsp;</font><font style="color:#000000;letter-spacing:-0.05pt;font-weight:normal;">Executive shall initially serve as </font><font style="font-weight:normal;color:#000000;">General Counsel, Corporate Secretary and Chief Compliance Officer</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;color:#000000;"> </font><font style="color:#000000;letter-spacing:-0.05pt;font-weight:normal;">reporting to the Company&#8217;s Chief Executive Officer.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">Executive shall perform those duties and responsibilities as are customary for such position and as may be directed by the Company and the Board from time to time.  During Executive&#8217;s employment with the Company, Executive shall devote Executive&#8217;s best efforts and substantially all of Executive&#8217;s business time and attention to the business of the Company, except for approved vacation periods and reasonable periods of illness or other incapacities permitted by the Company&#8217;s general employment policies.&nbsp;&nbsp;Executive&#8217;s primary office location will be the Company&#8217;s offices in New York City, NY.&nbsp;&nbsp;Notwithstanding the foregoing, the Company reserves the right to reasonably require Executive to perform Executive&#8217;s duties at places other than Executive&#8217;s primary office location from time to time, and to require reasonable business travel.&nbsp;&nbsp;During Executive&#8217;s employment with the Company, Executive shall not engage in any activity that conflicts with or is detrimental to the Company&#8217;s best interests, as determined by the CEO.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive<font style="color:#000000;"> may participate as in side activities such as board or committee member, advisor or consultant </font>(the &#8220;<font style="font-weight:bold;font-style:italic;">Activities</font>&#8221;),<font style="color:#000000;"> p</font>rovided that Executive obtains their manager&#8217;s prior written consent, and that none of the following activities involve activities in the area of neurology, detract from Ovid&#8217;s reputation, impact Executive&#8217;s full time duties to the Company, or could reasonably result in the disclosure or use of the Company&#8217;s proprietary or confidential information.&nbsp;&nbsp;The manager may rescind their consent to Executive&#8217;s participation in the Activities, or participation in other business or public activities, if the manager, in their </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D-1</a></p>
<p style="text-align:left;line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Arial;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1946726.1 29165-0001-000</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1946726.1 29165-0001-000</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sole discretion, determines that such activities compromise or threaten to compromise the Company&#8217;s business interests or conflict with </font><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive&#8217;s</font><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> duties to the Company. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.2.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Employment Term</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Executive will be employed by the Company on an &#8220;at-will&#8221; basis.&nbsp;&nbsp;This means that either the Company or Executive may terminate Executive&#8217;s employment at any time, for any reason, with or without Cause, and with or without advance notice (provided that (a) Resignation for Good Reason (as defined below) requires certain advanced notice by Executive of Executive&#8217;s termination of employment as set forth below and (b) as a professional courtesy, Executive agrees to provide the Company with at least sixty (60) days advance written notice of a voluntary resignation by Executive that is not a Resignation for Good Reason).&nbsp;&nbsp;Subject to the terms herein, it also means that Executive&#8217;s job title, duties, responsibilities, reporting level, compensation and benefits, as well as the Company&#8217;s personnel policies and procedures, may be changed with or without notice at any time in the Company&#8217;s sole discretion.&nbsp;&nbsp;This at-will employment relationship shall not be modified by any conflicting actions or representations of any Company employee or other party before or during the term of Executive&#8217;s employment. &nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.3.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Compensation</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="color:#000000;">Annual Base Salary</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;&#160;Executive&#8217;s annual base salary shall be paid at the rate of $440,000 per year (&#8220;</font><font style="font-style:italic;color:#000000;">Annual Base Salary</font><font style="font-weight:normal;color:#000000;">&#8221;), payable in equal installments, less applicable payroll deductions and withholdings, on the Company&#8217;s ordinary payroll cycle.  Executive&#8217;s Annual Base Salary shall be subject to annual review by the Board and may be adjusted from time to time.&nbsp;&nbsp;As an exempt salaried employee, Executive will be required to work the Company&#8217;s normal business hours, and such additional time as appropriate for Executive&#8217;s work assignments and position, and Executive will not be entitled to overtime compensation.  </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="color:#000000;">Benefits</font><font style="font-weight:normal;color:#000000;">. Executive will be eligible to participate in all of the Company&#8217;s employee benefits and benefit plans that the Company generally makes available to its full-time employees and executives in accordance with the terms and conditions of the benefit plans and applicable policies as in effect from time to time.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">c)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="color:#000000;">Bonus</font><font style="font-weight:normal;color:#000000;">. Executive shall be eligible to earn an annual performance bonus of up to thirty percent 40% of Executive&#8217;s Annual Base Salary (the &#8220;</font><font style="font-style:italic;color:#000000;">Target Performance Bonus</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;The Target Performance Bonus shall be based upon the Company&#8217;s assessment of Executive&#8217;s attainment of written Company and individual objectives as set by the Company in its sole discretion.&nbsp;&nbsp;The Company may increase the Target Performance Bonus in its sole discretion.&nbsp;&nbsp;Bonus payments, if any, shall be subject to applicable payroll deductions and withholdings.&nbsp;&nbsp;Following the close of each calendar year, the Company shall determine whether Executive has earned a Target Performance Bonus, and the amount of any such bonus, based on the achievement of such objectives.&nbsp;&nbsp;Executive must be an employee of the Company in good standing on the Target Performance Bonus payment date to be eligible to receive a Target Performance Bonus, and no partial or prorated bonuses shall be provided.&nbsp;&nbsp;The Target Performance Bonus, if earned, shall be paid on or before March 15<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> of the calendar year after the applicable bonus year.&nbsp;&nbsp;Executive&#8217;s bonus eligibility is subject to change in the discretion of the Company.&nbsp;&nbsp; If Executive&#8217;s&nbsp;&nbsp;start date with the Company falls within the fourth quarter, the Executive will not&nbsp;&nbsp;be eligible for a target bonus for that calendar year.&nbsp;&nbsp;  </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">d)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="color:#000000;">Equity Compensation</font><font style="font-weight:normal;color:#000000;">.</font><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;">, Executive shall be granted options to purchase shares of the Company&#8217;s common stock (the &#8220;</font><font style="font-style:italic;color:#000000;letter-spacing:0.05pt;">Option</font><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;">&#8221;) as determined by Management and approved by the Compensation Committee. The Option will be evidenced by a stock option agreement and be subject to </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Perone - D-2</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;">the terms and conditions of the Company&#8217;s 2017 Equity Incentive Plan (the &#8220;</font><font style="font-style:italic;color:#000000;letter-spacing:0.05pt;">Equity Plan</font><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;">&#8221;). The exercise price per share of the Option will be equal to the per share fair market value of the Company&#8217;s common stock on the date the Option is granted, as </font><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;">defined under the Equity Plan</font><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;">. The vesting schedule of the Option will be as follows: twenty-five percent (25%) of the shares of the Company&#8217;s common stock subject to the Option will vest on the one year anniversary of the </font><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;">Start Date</font><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;">, and one thirty-sixth (1/36</font><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup></font><font style="color:#000000;letter-spacing:0.05pt;font-weight:normal;">) of the remaining shares of the Company&#8217;s common stock subject to the Option will vest each month thereafter on the same day of the month as the Executive&#8217;s date of hire (and if there is no corresponding day, on the last day of the month), so long as Executive remains an employee, consultant, director or officer of the Company, and subject to the terms and conditions of the stock option agreement and the Equity Plan. Subject to the approval of the Board, the stock option agreement shall provide that upon a Change in Control Termination, the vesting and exercisability of the Option shall be accelerated in full. At the discretion of the Board, Executive will be eligible to receive additional options to purchase shares of the Company&#8217;s common stock.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">e)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Any raise or bonus connected with performance in you first calendar year of service will be prorated from your start date. Ongoing Stock Option Grants are awarded at the Company&#8217;s discretion; eligible Ovidians typically are awarded these grants in the first quarter. New Ovidians who start in the fourth quarter are not eligible for a raise or bonus for that calendar year and are not eligible for the Ongoing Grant awarded in first quarter of the following year.</font></p>
<p style="text-align:justify;margin-bottom:5pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.4.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Reimbursement of Expenses</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Subject to Section 4.8(c), the Company shall reimburse Executive for Executive&#8217;s necessary and reasonable business expenses incurred in connection with Executive&#8217;s duties in accordance with the Company&#8217;s generally applicable expense reimbursement policies as in effect from time to time.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.5.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Indemnification Agreement</font><font style="font-weight:normal;color:#000000;">. Executive and Company shall enter into an Indemnity Agreement (the &#8220;Indemnification Agreement&#8221;), which shall be effective as of the Start Date and is incorporated herein by reference.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.6.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Compliance with Confidentiality Agreement and Company Policies.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">Executive shall execute and abide by all terms and provisions of the </font><font style="color:#000000;font-weight:normal;">Confidentiality Agreement to be signed on or prior to the Start Date (or any successor agreement thereto), attached hereto as </font><font style="color:#000000;">Exhibit A</font><font style="color:#000000;font-weight:normal;">.</font><font style="font-weight:normal;color:#000000;"> Executive shall also abide by all terms and provisions of the Company&#8217;s Code of Business Conduct and Ethics, attached hereto as </font><font style="color:#000000;">Exhibit D</font><font style="font-weight:normal;color:#000000;">. In addition, Executive is required to abide by the Company&#8217;s policies and procedures, including but not limited to the Company&#8217;s Employee Handbook, as adopted or modified from time to time within the Company&#8217;s discretion; </font><font style="font-style:italic;font-weight:normal;color:#000000;">provided</font><font style="font-weight:normal;color:#000000;">, </font><font style="font-style:italic;font-weight:normal;color:#000000;">however</font><font style="font-weight:normal;color:#000000;">, that in the event the terms of this Agreement differ from or are in conflict with the Company&#8217;s general employment policies or practices, this Agreement shall control.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">2.&nbsp;&nbsp;COVERED TERMINATION SEVERANCE BENEFITS</p>
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.1.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Severance Benefits</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Upon a Covered Termination, then subject to Section 4 below and Executive&#8217;s continued compliance with the terms of this Agreement, the Company shall provide Executive with the severance benefits set forth in this Section 2 (the &#8220;</font><font style="font-style:italic;color:#000000;">Severance Benefits</font><font style="font-weight:normal;color:#000000;">&#8221;).  </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.2.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Salary Payment</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The Company shall pay Executive, as cash severance, (i) Executive&#8217;s Monthly Base Salary, multiplied by (ii) the number of months in the Covered Termination Severance Period, less applicable payroll deductions and withholdings (the &#8220;</font><font style="font-style:italic;color:#000000;">Severance</font><font style="font-weight:normal;color:#000000;">&#8221;). The Severance shall be paid (except as set forth in Section 4) in equal installments on the Company&#8217;s ordinary payroll cycle </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Perone - D-3</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">commencing</font><font style="font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">on the</font><font style="font-weight:normal;color:#000000;"> first </font><font style="font-weight:normal;color:#000000;">regularly-scheduled</font><font style="font-weight:normal;color:#000000;"> payroll date </font><font style="font-weight:normal;color:#000000;">occurring on or after the </font><font style="font-weight:normal;color:#000000;">Release Deadline </font><font style="font-weight:normal;color:#000000;">Date</font><font style="font-weight:normal;color:#000000;"> (as set forth in Section 4.1)</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.3.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Health Continuation Payments</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The Company will pay Executive on the first day of each month a fully taxable cash payment equal to the applicable premium for Executive, her spouse and any dependents for the group health plan maintained by the Company for the month in which the Covered Termination occurs, subject to applicable tax withholdings but grossed up for all taxes owed by the Executive on such payment, for the duration of the Covered Termination Benefits Period. Such coverage shall be counted as coverage pursuant to COBRA. The Company shall have no obligation in respect of any premium payments following the effective date of the Executive&#8217;s coverage by a health insurance plan of a subsequent employer. Executive shall be required to notify the Company immediately if Executive becomes covered by a health insurance plan of a subsequent employer. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">For purposes of this Section&#160;2.3, (i)&#160;references to COBRA shall be deemed to include analogous provisions of state law, and (ii)&#160;any applicable insurance premiums that are paid by the Company shall not include any amounts payable by Executive under a Code Section&#160;125 health care reimbursement plan, which amounts, if any, are the sole responsibility of Executive. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">3.&nbsp;&nbsp;CHANGE IN CONTROL SEVERANCE BENEFITS</p>
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.1.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Change in Control Severance Benefits</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Upon a Change in Control Termination, then subject to Section 4 below and Executive&#8217;s continued compliance with the terms of this Agreement, the Company shall provide Executive with the severance benefits set forth in this Section 3 (the &#8220;</font><font style="font-style:italic;color:#000000;">Change in Control Severance Benefits</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.2.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Salary Payment</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The Company shall pay Executive, as cash severance, (i) Executive&#8217;s Monthly Base Salary, multiplied by (ii) the number of months in the Change in Control Severance Period, less applicable payroll deductions and withholdings (the &#8220;</font><font style="font-style:italic;color:#000000;">Change in Control Severance</font><font style="font-weight:normal;color:#000000;">&#8221;). The Change in Control Severance shall be paid (except as set forth in Section 4) in equal installments on the Company&#8217;s ordinary payroll cycle commencing on the first regularly-scheduled payroll date occurring on or after the Release Deadline Date.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.3.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Health Continuation Payments</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:0pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The Company will pay Executive on the first day of each month a fully taxable cash payment equal to the applicable premium for Executive, her spouse and any dependents for the group health plan maintained by the Company for the month in which the Change in Control Termination occurs, subject to applicable tax withholdings but grossed up for all taxes owed by the Executive on such payment, for the duration of the Change in Control Benefits Period. Such coverage shall be counted as coverage pursuant to COBRA. The Company shall have no obligation in respect of any premium payments following the effective date of the Executive&#8217;s coverage by a health insurance plan of a subsequent employer. Executive shall be required to notify the Company immediately if Executive becomes covered by a health insurance plan of a subsequent employer. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">For purposes of this Section&#160;3.3, (i)&#160;references to COBRA shall be deemed to include analogous provisions of state law, and (ii)&#160;any applicable insurance premiums that are paid by the Company shall not include any amounts payable by Executive under a Code Section&#160;125 health care reimbursement plan, which amounts, if any, are the sole responsibility of Executive. </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Perone - D-4</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">3.4.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Change in Control </font><font style="color:#000000;">Termination </font><font style="color:#000000;">Vesting Acceleration Benefits</font><font style="font-weight:normal;color:#000000;">.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;Upon a </font><font style="font-weight:normal;color:#000000;">Change in Control</font><font style="font-weight:normal;color:#000000;"> Termination</font><font style="font-weight:normal;color:#000000;">, (i)&#160;the vesting and exercisability of all outstanding options to purchase the Company&#8217;s common stock (or stock appreciation rights or other rights with respect to the stock of the Company issued pursuant to any equity incentive plan of the Company) that are held by Executive on the </font><font style="font-weight:normal;color:#000000;">Termination Date</font><font style="font-weight:normal;color:#000000;"> shall be accelerated in full</font><font style="font-weight:normal;color:#000000;">,</font><font style="font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">(ii) each such option shall be exercisable and to the extent not exercised, expire on the latest date permitted under the Equity Plan and (iii)&#160;any reacquisition or repurchase rights held by the Company with respect to common stock issued or issuable (or with respect to other rights with respect to the stock of the Company issued or issuable) pursuant to any other stock award granted to Executive pursuant to any equity incentive plan of the Company shall lapse</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">4.&nbsp;&nbsp;LIMITATIONS AND CONDITIONS ON BENEFITS</p>
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.1.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Release Prior to Payment of Severance Benefits and Change in Control Severance Benefits</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The receipt of any Severance Benefits or Change in Control Severance Benefits pursuant to this Agreement is subject to Executive signing and not revoking a separation agreement and general release of claims (the &#8220;</font><font style="font-style:italic;color:#000000;">Release</font><font style="font-weight:normal;color:#000000;">&#8221;), in substantially the form attached hereto and incorporated herein as </font><font style="color:#000000;">Exhibit B</font><font style="font-weight:normal;color:#000000;"> or </font><font style="color:#000000;">Exhibit C</font><font style="font-weight:normal;color:#000000;">, as appropriate, and subject to any further modifications as determined in the Company&#8217;s discretion, which Release must become effective and irrevocable no later than the sixtieth (60th)&#160;day following Executive&#8217;s Termination Date (the &#8220;</font><font style="font-style:italic;color:#000000;">Release Deadline Date</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;If the Release does not become effective and irrevocable by the Release Deadline Date, Executive&#160;will forfeit any right to any Severance Benefits or Change in Control Severance Benefits under this Agreement.&nbsp;&nbsp;In no event will Severance Benefits or Change in Control Severance Benefits be paid or provided until after the Release Deadline Date.&nbsp;&nbsp;On the first regularly-scheduled payroll date occurring on or after the Release Deadline Date, the Company will pay Executive the Severance or Change in Control Severance amount that Executive would otherwise have received on or prior to such date but for the delay in payment related to the effectiveness of the Release, with the balance of the Severance or Change in Control Severance amount being paid as originally scheduled. The Company may modify the Release in its discretion to comply with changes in applicable law at any time prior to Executive&#8217;s execution of such Release.</font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.2.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Return of Company Property</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Not later than the Termination Date, or earlier if requested by the Company, Executive shall return to the Company all documents (and all copies thereof) and other property belonging to the Company that Executive has in his or her possession or control. The documents and property to be returned include, but are not limited to, all files, correspondence, email, memoranda, notes, notebooks, records, plans, forecasts, reports, studies, analyses, compilations of data, proposals, agreements, financial information, research and development information, marketing information, operational and personnel information, databases, computer-recorded information, tangible property and equipment (including, but not limited to, computers, facsimile machines, mobile telephones and servers), credit cards, entry cards, identification badges and keys, and any materials of any kind which contain or embody any proprietary or confidential information of the Company (and all reproductions thereof in whole or in part). Executive agrees to make a diligent search to locate any such documents, property and information. If Executive has used any personally owned computer, server or e-mail system to receive, store, review, prepare or transmit any Company confidential or proprietary data, materials or information, then within ten (10)&#160;business days after the Termination Date, or earlier if requested by the Company, Executive shall provide the Company with a computer-useable copy of all such information and then permanently delete and expunge such confidential or proprietary information from those systems. Executive agrees to provide the Company with a certification that the necessary copying and/or deletion is done.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.3.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Cooperation and Continued Compliance with Restrictive Covenants</font><font style="font-weight:normal;color:#000000;">.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Perone - D-5</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">After the Termination Date, Executive shall cooperate fully with the Company, at reasonable times as agreed between Executive and the Company, in connection with its actual or contemplated defense, prosecution or investigation of any existing or future litigation, arbitrations, mediations, claims, demands, audits, government or regulatory inquiries, or other matters arising from events, acts or failures to act that occurred during the time period in which Executive was employed by the Company (including any period of employment with an entity acquired by the Company). Such cooperation includes, without limitation, being available upon reasonable notice, without subpoena, to provide accurate and complete advice, assistance and information to the Company, including offering and explaining evidence, providing truthful and accurate sworn statements, and participating in discovery and trial preparation and testimony. Executive also agrees to promptly send the Company copies of all correspondence (for example, but not limited to, subpoenas) received by Executive in connection with any such legal proceedings, unless Executive is expressly prohibited by law from so doing.&nbsp;&nbsp;Nothing in this Agreement prohibits Executive from responding accurately and fully to any request for information if required by legal process or in connection with a government investigation.&nbsp;&nbsp;In addition, nothing in this Agreement is intended to prohibit or restrain Executive in any manner from making disclosures that are protected under the whistleblower provisions of federal law or regulation or under other applicable law or regulation.&nbsp;&nbsp;The Company will reimburse Executive for reasonable out-of-pocket expenses incurred in connection with any such cooperation (excluding foregone wages, salary or other compensation) within thirty (30)&#160;days of Executive&#8217;s timely presentation of appropriate documentation thereof, in accordance with the Company&#8217;s standard reimbursement policies and procedures. The Company will reasonably accommodate Executive&#8217;s scheduling needs with respect to any such cooperation after the Termination Date.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">After the Termination Date, Executive shall continue to abide by Executive&#8217;s continuing obligations under the Confidentiality Agreement. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">c)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="color:#000000;font-weight:normal;">From the Start Date and through and including the Change in Control Severance Period or Covered Termination Severance Period as defined below, or, if Executive is Terminated with Cause, for one year after Executive&#8217;s Termination Date, whichever is applicable, Executive shall not, without the Company&#8217;s prior written consent, whether directly or indirectly be employed, under contract with, provide services to or on behalf of, or be involved with any business or organization (whether &#8220;for profit&#8221; or&nbsp;&nbsp;&#8220;not-for-profit&#8221;), or applicable Division thereof (as defined below), which researches, develops, creates, manufactures, designs and/or sells compounds and/or related pharmaceuticals, medicines and/or therapies to treat rare or orphan neurological conditions or diseases, and/or otherwise competes with products and/or services then under research or development by or offered or sold by the Company in the same therapeutic category.&nbsp;&nbsp;Nothing in Section 4.3(c) shall prohibit Executive from investing as a less than one percent (1%) shareholder in securities of any company listed on a national securities exchange or quoted on an automated quotation system.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">d)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="color:#000000;font-weight:normal;">From the Start Date until twelve (12) months after Termination Date, Executive shall not hire or retain, or attempt to hire or retain, any of the Company&#8217;s then-existing board members, employees, advisors, consultants, collaborators, investigators or agents and shall not induce any such to give up employment with or to cease providing services to the Company, and shall not otherwise interfere with, or attempt to interfere with, the relationship of any such person with the Company; or attempt in any manner to solicit, persuade or induce any Client of the Company to terminate, reduce or refrain from renewing or extending its contractual or other relationship with the Company in regard to the purchase of products or services marketed or sold by the Company, or to become a Client of or enter into any contractual or other relationship with Executive or any other individual, person or entity in regard to the purchase of products or services similar or identical to those marketed or sold by the Company.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Perone - D-6</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">e)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="color:#000000;font-weight:normal;">Executive acknowledges and agrees that Executive&#8217;s obligations under this Section 4.3 are an essential part of the consideration Executive is providing hereunder in exchange for which and in reliance upon which the Company has agreed to provide the payments and benefits under this Agreement. Executive further acknowledges and agrees that Executive&#8217;s violation of this Section 4.3 inevitably would involve use or disclosure of the Company&#8217;s proprietary and confidential information. If it is determined by a court of competent jurisdiction in any state that any restriction in this Section 4.3 is excessive in duration or scope or is unreasonable or unenforceable under the laws of that state, it is the intention of the parties that such restriction may be modified or amended by the court to render it enforceable to the maximum extent permitted by the law of that state.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.4.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Parachute Payments</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-family:Arial;font-size:10.5pt;font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Parachute Payment Limitation</font><font style="font-weight:normal;color:#000000;">.&#160; If any payment or benefit (including payments and benefits pursuant to this Agreement) Executive would receive in connection with a Change in Control from the Company or otherwise (&#8220;</font><font style="font-style:italic;color:#000000;">Payment</font><font style="font-weight:normal;color:#000000;">&#8221;) would (i)&#160;constitute a &#8220;parachute payment&#8221; within the meaning of Section&#160;280G of the Code, and (ii)&#160;but for this paragraph, be subject to the excise tax imposed by Section&#160;4999 of the Code (the &#8220;</font><font style="font-style:italic;color:#000000;">Excise Tax</font><font style="font-weight:normal;color:#000000;">&#8221;), then the Company shall cause to be determined, before any amounts of the Payment are paid to Executive, which of the following two alternative forms of payment shall be paid to Executive: (A)&#160;payment in full of the entire amount of the Payment (a &#8220;</font><font style="font-style:italic;color:#000000;">Full Payment</font><font style="font-weight:normal;color:#000000;">&#8221;), or (B)&#160;payment of only a part of the Payment so that Executive receives the largest payment possible without the imposition of the Excise Tax (a &#8220;</font><font style="font-style:italic;color:#000000;">Reduced Payment</font><font style="font-weight:normal;color:#000000;">&#8221;). A Full Payment shall be made in the event that the amount received by the Executive on a net after-tax basis is greater than what would be received by the Executive on a net after-tax basis if the Reduced Payment were made, otherwise a Reduced Payment shall be made. If a Reduced Payment is made, (i)&#160;the Payment shall be paid only to the extent permitted under the Reduced Payment alternative, and Executive shall have no rights to any additional payments and/or benefits constituting the Payment, and (ii)&#160;reduction in payments and/or benefits shall occur in the following order: (A)&#160;reduction of cash payments; (B)&#160;cancellation of accelerated vesting of equity awards other than stock options; (C)&#160;cancellation of accelerated vesting of stock options; and (D)&#160;reduction of other benefits paid to Executive. In the event that acceleration of compensation from Executive&#8217;s equity awards is to be reduced, such acceleration of vesting shall be canceled in the reverse order of the date of grant.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The independent registered public accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the Change in Control shall make all determinations required to be made under this Section&#160;4.4. If the independent registered public accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized independent registered public accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such independent registered public accounting firm required to be made hereunder.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">c)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:90pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The independent registered public accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive within fifteen (15)&#160;calendar days after the date on which Executive&#8217;s right to a Payment is triggered (if requested at that time by the Company or Executive) or such other time as requested by the Company or Executive. If the independent registered public accounting firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it shall furnish the Company and Executive with an opinion reasonably acceptable to Executive that no Excise Tax will be imposed with respect to such Payment. Any </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Perone - D-7</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">good faith determinations of the accounting firm made hereunder shall be final, </font><font style="font-weight:normal;color:#000000;">binding</font><font style="font-weight:normal;color:#000000;"> and conclusive upon the Company and Executive. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.5.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Certain Reductions and Offsets</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;To the extent that any federal, state or local laws, including, without limitation, the Worker Adjustment and Retraining Notification Act or any other so-called &#8220;plant closing&#8221; laws, require the Company to give advance notice or make a payment of any kind to Executive because of Executive&#8217;s involuntary termination due to a layoff, reduction in force, plant or facility closing, sale of business, change in control or any other similar event or reason, the benefits payable under this Agreement shall be correspondingly reduced. The benefits provided under this Agreement are intended to satisfy any and all statutory obligations that may arise out of Executive&#8217;s involuntary termination of employment for the foregoing reasons, and the parties shall construe and enforce the terms of this Agreement accordingly.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.6.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Mitigation</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Except as otherwise specifically provided herein, Executive shall not be required to mitigate damages or the amount of any payment provided under this Agreement by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for under this Agreement be reduced by any compensation earned by Executive as a result of employment by another employer or by any retirement benefits received by Executive after the date of a Covered Termination or Change in Control Termination (except as expressly provided in Sections 2.3 and 3.3 above). </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.7.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Indebtedness of Executive</font><font style="font-weight:normal;color:#000000;">.  If Executive is indebted to the Company on the effective date of a Covered Termination or Change in Control Termination Date, the Company reserves the right to offset any Severance Benefits or Change in Control Severance Benefits under this Agreement by the amount of such indebtedness, subject to the requirements of Section 409A of the Code and applicable law. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.8.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Application of Section&#160;409A</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">Separation from Service</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Notwithstanding any provision to the contrary in this Agreement, no amount deemed deferred compensation subject to Section 409A of the Code shall be payable pursuant to Section 2 or Section 3 unless Executive&#8217;s termination of employment constitutes a &#8220;separation from service&#8221; with the Company within the meaning of Section 409A of the Code and the Department of Treasury Regulations and other guidance promulgated thereunder and, except as provided under Section 4.8(b) hereof, any such amount shall not be paid, or in the case of installments, commence payment, until the first regularly-scheduled payroll date occurring on or after the sixtieth (60th) day following Executive&#8217;s separation from service. Any installment payments that would have been made to Executive during the sixty (60) day period immediately following Executive&#8217;s separation from service but for the preceding sentence shall be paid to Executive on the first regularly-scheduled payroll date occurring on or after the sixtieth (60th) day after Executive&#8217;s separation from service and the remaining payments shall be made as provided in this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">Specified Executive</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed at the time of his or her separation from service to be a &#8220;specified employee&#8221; for purposes of Section 409A(a)(2)(B)(i) of the Code, to the extent delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, such portion of Executive&#8217;s benefits shall not be provided to Executive prior to the earlier of (i) the expiration of the six (6)-month period measured from the date of Executive&#8217;s &#8220;separation from service&#8221; with the Company (as such term is defined in the Treasury Regulations issued under Section 409A of the Code) or (ii) the date of Executive&#8217;s death. Upon the first business day following the expiration of the applicable Code Section 409A(a)(2)(B)(i) </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Perone - D-8</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">period, all payments deferred pursuant to this Section </font><font style="font-weight:normal;color:#000000;">4.8</font><font style="font-weight:normal;color:#000000;">(b) </font><font style="font-weight:normal;color:#000000;">shall be paid in a lump sum to Executive, and any remaining payments due under this Agreement shall be paid as otherwise provided herein.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">c)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">Expense Reimbursements</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;To the extent that any reimbursement payable pursuant to this Agreement is subject to the provisions of Section 409A of the Code, any such reimbursement payable to Executive pursuant to this Agreement shall be paid to Executive no later than December 31 of the year following the year in which the expense was incurred; the amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any subsequent year; and Executive&#8217;s right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">d)</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">Installments</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;For purposes of Section 409A of the Code (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)), Executive&#8217;s right to receive any installment payments under this Agreement shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment shall at all times be considered a separate and distinct payment.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.9.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Tax Withholding</font><font style="font-weight:normal;color:#000000;">.  All payments under this Agreement shall be subject to applicable withholding for federal, state and local income and employment taxes. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.10.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">No Duplication of Severance Benefits. </font><font style="font-weight:normal;color:#000000;">The Severance Benefits and Change in Control Severance Benefits provided in Section 2 and Section 3 are mutually exclusive of each other, and in no event shall Executive receive any Severance Benefits or Change in Control Severance Benefits pursuant to both Section 2 and Section 3.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">5.&nbsp;&nbsp;TERMINATION WITH CAUSE OR BY VOLUNTARY RESIGNATION; OTHER RIGHTS AND BENEFITS</p>
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.1.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Termination for Cause; Resignation Without Good Reason; Death or Disability</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;If, at any time, the Company terminates Executive&#8217;s employment with the Company for Cause, or upon a voluntary resignation by Executive that is not a Resignation for Good Reason, or Executive&#8217;s employment terminates for any reason not entitling Executive to the Severance Benefits or Change in Control Severance Benefits, or if Executive&#8217;s employment terminates as a result of Executive&#8217;s death or disability (other than a Permanent Disability in the case of a Covered Termination), then the Company shall have no further obligation to Executive hereunder except for the payment or provision, as applicable, of (i) the portion of the Annual Base Salary accrued through Executive&#8217;s last day of employment, (ii) all unreimbursed expenses (if any), subject to Sections 1.4 and 4.8(c), and (iii) any unused vacation (if applicable) accrued through Executive&#8217;s last day of employment.&nbsp;&nbsp;Under these circumstances, Executive will not be entitled to any other form of compensation, including any Severance Benefits or Change in Control Severance Benefits, other than Executive&#8217;s rights to the vested portion of Executive&#8217;s Option and any other rights to which Executive is entitled under the Company&#8217;s benefit programs.&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.2.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Other Rights and Benefits. </font><font style="font-weight:normal;color:#000000;">Nothing</font><font style="color:#000000;"> </font><font style="font-weight:normal;color:#000000;">in this Agreement shall prevent or limit Executive&#8217;s continuing or future participation in any benefit, bonus, incentive or other plans, programs, policies or practices provided by the Company and for which Executive may otherwise qualify, nor shall anything herein limit or otherwise affect such rights as Executive may have under other agreements with the Company except as provided in Section 4 and Section 5.1 above. Except as otherwise expressly provided herein, amounts that are vested benefits or that Executive is otherwise entitled to receive under any plan, policy, practice or program of the Company at or subsequent to the date of a Change in Control shall be payable in accordance with such plan, policy, practice or program. </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Perone - D-9</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">6</font><font style="font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">DEFINITIONS</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of this Agreement, the following definitions shall apply: </p>
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.1.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:0pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Board</font><font style="font-weight:normal;color:#000000;">&#8221; means the Board of Directors of the Company, or the compensation committee thereof, as determinations or responsibilities may be delegated by the Board to the compensation committee.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.2.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Cause</font><font style="font-weight:normal;color:#000000;">&#8221; shall mean </font><font style="color:#000000;font-weight:normal;">a determination by the Company based upon reasonably available</font><font style="color:#000000;"> </font><font style="color:#000000;font-weight:normal;">information of Executive&#8217;s: (i) unauthorized use or disclosure of the Company&#8217;s confidential information or trade secrets; (ii) material breach of any agreement to which the Executive and the Company are a party; (iii) material failure to comply with the Company&#8217;s written policies or rules; (iv) conviction of, or plea of &#8220;guilty&#8221; or &#8220;no contest&#8221; to, a felony under the laws of the United States or any State; (v) negligence or willful misconduct relating to Executive&#8217;s performance of her duties on behalf of the Company; (vi) continuing failure to perform material and lawful assigned duties after receiving thirty (30) days&#8217; written notification of the failure from the Company if such breach is not cured (if curable) during that thirty (30) day period; (vii) failure to cooperate in good faith with a governmental or internal investigation of the Company or its directors, officers or employees, if the Company has requested Executive&#8217;s cooperation without prejudice or personal liability to Executive; (viii) violation of employee or ethical guidelines including, without limitation, violations of business practices and ethics commonly in place in similar companies in the United States; or (ix) violation of the Company code of conduct and/or any contractual code of conduct to which the Company is obligated</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.3.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Change in Control</font><font style="font-weight:normal;color:#000000;">&#8221; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">Any natural person, entity or group within the meaning of Section&#160;13(d) or 14(d) of the Securities Exchange Act of 1934, as amended (&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Exchange Act Person</font><font style="color:#000000;">&#8221;), becomes the owner, directly or indirectly, of securities of the Company representing more than fifty percent (50%)&#160;of the combined voting power of the Company&#8217;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (i)&#160;on account of the acquisition of securities of the Company by any institutional investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#8217;s securities in a transaction or series of related transactions that are primarily a private financing transaction for the Company or (ii)&#160;solely because the level of ownership held by any Exchange Act Person (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Subject Person</font><font style="color:#000000;">&#8221;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">There is consummated a merger, consolidation or similar transaction involving, directly or indirectly, the Company if, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not own, directly or indirectly, either (i)&#160;outstanding voting securities representing more than fifty percent (50%)&#160;of the combined outstanding voting power of the surviving entity in such merger, consolidation or similar transaction or (ii)&#160;more than fifty percent (50%)&#160;of the combined outstanding voting power of the parent of the surviving entity in such merger, consolidation or similar transaction; or</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Perone - D-10</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">c)</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">There is consummated a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries to an entity, more than fifty percent (50%)&#160;of the combined voting power of the voting securities of which are owned by stockholders of the Company in substantially the same proportion as their ownership of the Company immediately prior to such sale, lease, license or other disposition. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:8.65%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company. Notwithstanding the foregoing or any other provision of this Agreement, the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any affiliate and the participant shall supersede the foregoing definition with respect to stock awards subject to such agreement (it being understood, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply). </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.4.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Change in Control Benefits Period</font><font style="font-weight:normal;color:#000000;">&#8221; means the period of twelve (12) months commencing on the Termination Date. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.5.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Change in Control Severance Period</font><font style="font-weight:normal;color:#000000;">&#8221; means the period of twelve (12) months commencing on the Termination Date. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.6.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;"> &#8220;</font><font style="font-style:italic;color:#000000;">Change in Control Termination</font><font style="font-weight:normal;color:#000000;">&#8221; means an &#8220;</font><font style="font-style:italic;color:#000000;">Involuntary Termination Without Cause</font><font style="font-weight:normal;color:#000000;">&#8221; or &#8220;</font><font style="font-style:italic;color:#000000;">Resignation for Good Reason</font><font style="font-style:italic;font-weight:normal;color:#000000;">,</font><font style="font-weight:normal;color:#000000;">&#8221; either of which occurs within three (3)&#160;months prior to or upon or within twelve (12)&#160;months following the closing of a Change in Control or Dissolution Event, provided that any such termination is a &#8220;separation from service&#8221; within the meaning of Treasury Regulation Section&#160;1.409A-1(h).&nbsp;&nbsp;Death and disability shall not be deemed Change in Control Terminations. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.7.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">COBRA</font><font style="font-weight:normal;color:#000000;">&#8221; means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.8.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Code</font><font style="font-weight:normal;color:#000000;">&#8221; means the Internal Revenue Code of 1986, as amended.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.9.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Company</font><font style="font-weight:normal;color:#000000;">&#8221; means Ovid Therapeutics Inc.</font><font style="text-transform:uppercase;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">or, following a Change in Control, the surviving entity resulting from such transaction, or any subsequent surviving entity resulting from any subsequent Change in Control.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.10.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Confidentiality Agreement</font><font style="font-weight:normal;color:#000000;">&#8221; means Senior Executive Confidential Information and Invention Assignment Agreement with the Company, (or any successor agreement thereto).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.11.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;"> &#8220;</font><font style="font-style:italic;color:#000000;">Covered Termination</font><font style="font-weight:normal;color:#000000;">&#8221; means an &#8220;</font><font style="font-style:italic;color:#000000;">Involuntary Termination Without Cause</font><font style="font-weight:normal;color:#000000;">&#8221; or &#8220;</font><font style="font-style:italic;color:#000000;">Resignation for Good Reason</font><font style="font-style:italic;font-weight:normal;color:#000000;">,</font><font style="font-weight:normal;color:#000000;">&#8221; provided that any such termination is a &#8220;separation from service&#8221; within the meaning of Treasury Regulation Section&#160;1.409A-1(h). Death and disability, other than a Permanent Disability, shall not be deemed Covered Terminations.&nbsp;&nbsp;If an Involuntary Termination Without Cause or Resignation for Good Reason qualifies as a Change in Control Termination, it shall not constitute a Covered Termination.&nbsp;&nbsp;  </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.12.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Covered Termination Benefits Period</font><font style="font-weight:normal;color:#000000;">&#8221; means the period of twelve (12) months commencing on the Termination Date.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.13.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Covered Termination Severance Period</font><font style="font-weight:normal;color:#000000;">&#8221; means the period of twelve (12) months commencing on the Termination Date.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Perone - D-11</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_2_88"></a><a name="_cp_text_5_89"></a><a name="_cp_text_2_91"></a><font style="text-decoration:none;Background-color:#auto;">6.14.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Dissolution Event</font><font style="font-weight:normal;color:#000000;"><a name="_cp_text_5_89"></a>&#8221; means the </font><font style="font-weight:normal;color:#000000;"><a name="_cp_text_2_91"></a>stockholders of the Company approve or the Board approves a plan of complete dissolution or liquidation of the Company, or a complete dissolution or liquidation of the Company </font><font style="font-weight:normal;color:#000000;">shall otherwise occur</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.15.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Involuntary Termination Without Cause</font><font style="font-weight:normal;color:#000000;">&#8221; means Executive&#8217;s dismissal or discharge by the Company for reasons other than Cause and other than as a result of death or disability; </font><font style="font-style:italic;font-weight:normal;color:#000000;">provided</font><font style="font-weight:normal;color:#000000;">, </font><font style="font-style:italic;font-weight:normal;color:#000000;">however</font><font style="font-weight:normal;color:#000000;">, that for purposes of a Covered Termination, Involuntary Termination Without Cause shall include Executive&#8217;s dismissal or discharge by the Company for reasons of Permanent Disability. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.16.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;"> &#8220;</font><font style="font-style:italic;color:#000000;">Monthly Base Salary</font><font style="font-weight:normal;color:#000000;">&#8221; means 1/12<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> of Executive&#8217;s Annual Base Salary (excluding incentive pay, premium pay, commissions, overtime, bonuses and other forms of variable compensation) as in effect on the date of a Covered Termination or Change in Control Termination.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.17.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Permanent Disability</font><font style="font-weight:normal;color:#000000;">&#8221; means total and permanent disability as defined in Code Section 22(e)(3). </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.18.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Resignation for Good Reason</font><font style="font-weight:normal;color:#000000;">&#8221; means Executive&#8217;s resignation from all employee positions Executive then holds with the Company within ninety (90)&#160;days following any of the following events taken without Executive&#8217;s consent, provided Executive has given the Company written notice of such event within thirty (30)&#160;days after the first occurrence of such event and the Company has not cured such event within thirty (30)&#160;days thereafter:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">A material decrease in Executive&#8217;s Annual Base Salary, other than in connection with a decrease in compensation for all comparable executives of the Company; </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">A relocation of Executive&#8217;s principal place of work outside of a fifty (50) mile radius of its current location; or</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">c)</font><font style="font-size:12pt;font-family:Times New Roman;margin-left:22pt;color:#000000;"></font><font style="color:#000000;">The Company&#8217;s material breach of this Agreement.  </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.19.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Termination Date</font><font style="font-weight:normal;color:#000000;">&#8221; means the effective date of a Change in Control Termination, a Covered Termination, a termination for Cause or any other circumstance under which the employment relationship between Executive and the Company terminates, as applicable. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.20.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;font-weight:normal;">&#8220;</font><font style="font-style:italic;color:#000000;">Division</font><font style="color:#000000;font-weight:normal;">&#8221; shall mean only that part, unit or therapeutic category of a larger entity that is competitive with the Company, but not an entire company itself, if other divisions, units or therapeutic categories of such larger company are not competitive with the Company.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.21.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;font-weight:normal;">"</font><font style="font-style:italic;color:#000000;">Client</font><font style="color:#000000;font-weight:normal;">" shall mean (A) anyone who is a client of the Company as of, or at any time during the one-year period immediately preceding, the termination of Executive&#8217;s employment, but only if Executive had a direct relationship with, supervisory responsibility for or otherwise were involved with such client during Executive&#8217;s employment with the Company; and (B) any prospective client to whom the Company made a new business presentation (or similar offering of services) at any time during the one-year period immediately preceding, or six-month period immediately following, Executive&#8217;s employment termination (but only if initial discussions between the Company and such prospective client relating to the rendering of services occurred prior to the termination date, and only if Executive participated in or supervised such presentation and/or its preparation or the discussions leading up to it).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.22.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;font-weight:normal;">&#8220;</font><font style="font-style:italic;color:#000000;">Solicit</font><font style="color:#000000;font-weight:normal;">&#8221; shall mean: (A) active solicitation of any Client or Company employee, board member, advisor, consultant, collaborator, investigator or agents; (B) the provision of information regarding any Client or Company employee, board member, advisor, consultant, collaborator, investigator or agents to any third party where such information could be useful to such third party in attempting to obtain business from such Client or attempting to hire any such Company employee; (C) participation in any meetings, discussions, or other communications with any third party regarding any Client or Company employee, board member, advisor, consultant, collaborator, investigator </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Perone - D-12</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;font-weight:normal;">or agents where the purpose or effect of such meeting, discussion or communication is to obtain business from such Client or employ such Company employee; and (D) any other passive use of information about any Client or Company employee, board member, advisor, consultant, collaborator, investigator or agents which has the purpose or effect of assisting a third party or causing harm to the business of the Company.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">7.&nbsp;&nbsp;GENERAL PROVISIONS</p>
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:5pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.1.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Employment Status.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">This Agreement does not constitute a contract of employment or impose upon Executive any obligation to remain as an employee, or impose on the Company any obligation (i) to retain Executive as an employee, (ii) to change the status of Executive as an at-will employee or (iii) to change the Company&#8217;s policies regarding termination of employment.</font></p>
<p style="text-align:justify;margin-bottom:5pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.2.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Notices</font><font style="font-weight:normal;color:#000000;">.  Any notices provided hereunder must be in writing, and such notices or any other written communication shall be deemed effective upon the earlier of personal delivery (including personal delivery by facsimile or email transmission (to a facsimile number or email address designated in advance by the receiving party)) or the third day after mailing by first class mail, to the Company at its primary office location and to Executive at Executive&#8217;s address as listed in the Company&#8217;s payroll records. Any payments made by the Company to Executive under the terms of this Agreement shall be delivered to Executive either in person or at the address as listed in the Company&#8217;s payroll records.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.3.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Severability</font><font style="font-weight:normal;color:#000000;">.  Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is determined to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.4.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Waiver</font><font style="font-weight:normal;color:#000000;">.  If either party should waive any breach of any provisions of this Agreement, he, she or it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.5.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Complete Agreement</font><font style="font-weight:normal;color:#000000;">.  This Agreement, together with </font><font style="color:#000000;">Exhibits A </font><font style="font-weight:normal;color:#000000;">thru </font><font style="color:#000000;">D</font><font style="font-weight:normal;color:#000000;">, the Confidentiality Agreement and the Indemnification Agreement, forms the complete and exclusive statement of Executive&#8217;s employment agreement with the Company, and supersedes and replaces any other agreements or promises made to Executive by anyone, whether oral or written (including but not limited to the Prior Agreement).  </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.6.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Amendment or Termination of Agreement; Continuation of Agreement</font><font style="font-weight:normal;color:#000000;">.  Except for those changes expressly reserved to the Company&#8217;s or the Board&#8217;s discretion in this Agreement, this Agreement may be changed or terminated only upon the mutual written consent of the Company and Executive. The written consent of the Company to a change or termination of this Agreement must be signed by an executive officer of the Company (other than Executive) after such change or termination has been approved by the Board.  Unless so terminated, this Agreement shall continue in effect for as long as Executive continues to be employed by the Company or by any surviving entity following any Change in Control. For the avoidance of any doubt, if, following a Change in Control, Executive continues to be employed by the surviving entity without a Change in Control Termination and the surviving entity then </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Perone - D-13</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">undergoes a Change in Control, following which Executive is terminated by the subsequent surviving entity in a Change in Control Termination, Executive shall receive the benefits described in Section </font><font style="font-weight:normal;color:#000000;">3</font><font style="font-weight:normal;color:#000000;"> hereof.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.7.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Counterparts</font><font style="font-weight:normal;color:#000000;">.  This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement.&nbsp;&nbsp;Facsimile and electronic image copies of signatures shall be equivalent to original signatures.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.8.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Headings</font><font style="font-weight:normal;color:#000000;">.  The headings of the Sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.9.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Successors and Assigns</font><font style="font-weight:normal;color:#000000;">.  This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive, and the Company, and any surviving entity resulting from a Change in Control and upon any other person who is a successor by merger, acquisition, consolidation or otherwise to the business formerly carried on by the Company, and their respective successors, assigns, heirs, executors and administrators, without regard to whether or not such person actively assumes any rights or duties hereunder; </font><font style="font-style:italic;font-weight:normal;color:#000000;">provided</font><font style="font-weight:normal;color:#000000;">, </font><font style="font-style:italic;font-weight:normal;color:#000000;">however</font><font style="font-weight:normal;color:#000000;">, that Executive may not assign any duties hereunder and may not assign any rights hereunder without the written consent of the Company, which consent shall not be withheld unreasonably.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.10.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Choice of Law</font><font style="font-weight:normal;color:#000000;">.  This Agreement shall be construed and enforced in accordance with the laws of the State of New York without regard to conflicts of law principles.&#160;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.11.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Arbitration</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;To ensure the rapid and economical resolution of any disputes that may arise under or relate to this Agreement or Executive&#8217;s employment relationship, Executive and the Company agree that, unless otherwise prohibited by applicable law, any and all disputes, claims, or causes of action, in law or equity, arising from or relating to the performance, enforcement, execution, or interpretation of this Agreement, Executive&#8217;s employment with the Company, or the termination of Executive&#8217;s employment (collectively, &#8220;</font><font style="font-style:italic;color:#000000;">Claims</font><font style="font-weight:normal;color:#000000;">&#8221;), shall be resolved by final, binding, and (to the extent permitted by law) confidential arbitration before a single arbitrator in New York, New York.&#160;&#160;Executive and the Company agree that they shall resolve all such Claims in accordance with the provisions of Section 12 of the Confidential Information and Invention Assignment Agreement attached hereto as Exhibit A.&#160;&#160;&#160;&#160; </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.12.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Construction of Agreement</font><font style="font-weight:normal;color:#000000;">.  In the event of a conflict between the text of this Agreement and any summary, description or other information regarding this Agreement, the text of this Agreement shall control.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Calibri;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.13.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Circular 230 Disclaimer</font><font style="font-weight:normal;color:#000000;">.  </font><font style="color:#000000;">THE FOLLOWING DISCLAIMER IS PROVIDED IN ACCORDANCE WITH THE INTERNAL REVENUE SERVICE&#8217;S CIRCULAR 230 (21 C.F.R. PART 10). ANY TAX ADVICE CONTAINED IN THIS AGREEMENT IS INTENDED TO BE PRELIMINARY, FOR DISCUSSION PURPOSES ONLY AND NOT FINAL. ANY SUCH ADVICE IS NOT INTENDED TO BE USED FOR MARKETING, PROMOTING OR RECOMMENDING ANY TRANSACTION OR FOR THE USE OF ANY PERSON IN CONNECTION WITH THE PREPARATION OF ANY TAX RETURN. ACCORDINGLY, THIS ADVICE IS NOT INTENDED OR WRITTEN TO BE USED, AND IT CANNOT BE USED, BY ANY PERSON FOR THE PURPOSE OF AVOIDING TAX PENALTIES THAT MAY BE IMPOSED ON SUCH PERSON.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Perone - D-14</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">REVIEWED, UNDERSTOOD AND ACCEPTED:<font style="font-weight:normal;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:8.64%;"></td>
<td style="width:41.28%;"></td>
<td style="width:9.17%;"></td>
<td style="width:40.8%;"></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Calibri;text-transform:uppercase;font-style:normal;font-variant: normal;">OVID THERAPEUTICS INC.</p></td>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">EXECUTIVE</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&#160;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suzanne K. Wakamoto</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:&#160;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thomas Perone</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SVP, Human Resources</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: </p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;text-align:left;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General Counsel, Corporate Secretary and Chief Compliance Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:27pt;text-align:left;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.95%;"></td>
<td style="width:49.95%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;color:#auto;font-size:8pt;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">148402431 v2</strike></font><font style="font-size:8.5pt;color:#000000;"> </font></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Perone - D-15</a></p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>5
<FILENAME>ovid-ex1025_869.htm
<DESCRIPTION>EX-10.25
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ovid-ex1025_869.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font><font style="font-weight:bold;">Exhibit 10.25</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Hlk38187153"></a><a name="_Ref519522153"></a><a name="_Hlk37361551"></a><a name="_DV_C6"></a><a name="_Ref24399787"></a><a name="_Ref376936158"></a><a name="_Ref376935882"></a><a name="_Ref151397597"></a><a name="_Ref207963335"></a><a name="_Ref24400352"></a><a name="_Hlk31013405"></a><a name="_Hlk30774832"></a><a name="_Ref440878187"></a><a name="_Ref383111662"></a><a name="_Ref24275277"></a><a name="_Ref24280723"></a><a name="_Ref515965969"></a><a name="_Ref513467178"></a><a name="_Ref377132399"></a><a name="_Ref377142206"></a><a name="_Ref151411529"></a><a name="_Hlk30583775"></a><a name="_Ref151391859"></a><a name="_Ref151392638"></a><a name="_Ref151407602"></a><a name="_Ref384033248"></a><a name="_Ref440874540"></a><a name="_Ref378108140"></a><a name="_Ref24401004"></a><a name="_Hlk38198296"></a><a name="_Hlk38201282"></a><a name="_Ref24401015"></a><a name="_Ref32769201"></a><a name="_Hlk38201548"></a><a name="_Ref376930153"></a><a name="_Ref151404920"></a><a name="_Ref25053503"></a><a name="_Hlk38204716"></a>COLLABORATION AND LICENSE Agreement</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;"><a name="_cp_text_1_3"></a><a name="_Hlk38280228"></a><a name="_Hlk41656817"></a>This Collaboration and License Agreement<font style="font-weight:normal;font-variant: normal;"> (the &#8220;</font><font style="font-variant: normal;">Agreement</font><font style="font-weight:normal;font-variant: normal;">&#8221;) is entered into as of <a name="_cp_text_1_3"></a>July 8, 2020 (the &#8220;</font><font style="font-variant: normal;">Effective Date</font><font style="font-weight:normal;font-variant: normal;">&#8221;), by and between </font><font style="font-family:Times New Roman Bold;">Ovid Therapeutics Inc.</font><font style="font-weight:normal;font-variant: normal;">, a Delaware company having an address at 1460 Broadway, Suite 15021 New York, NY 10036, USA (&#8220;</font><font style="font-variant: normal;">Ovid</font><font style="font-weight:normal;font-variant: normal;"><a name="_Hlk38280228"></a><a name="_Hlk41656817"></a>&#8221;) and </font><font style="font-family:Times New Roman Bold;">Angelini Pharma Rare Diseases AG</font><font style="font-weight:normal;font-variant: normal;">, a Swiss company under direction and control of Angelini Pharma S.p.A. and having an address at Consulting GmbH Sumpfstrasse 26 6312 Steinhausen, Zurich, Switzerland (&#8220;</font><font style="font-variant: normal;">Licensee</font><font style="font-weight:normal;font-variant: normal;">&#8221;).&nbsp;&nbsp;Ovid and Licensee may be referred to herein individually as a &#8220;</font><font style="font-variant: normal;">Party</font><font style="font-weight:normal;font-variant: normal;">&#8221; or collectively as the &#8220;</font><font style="font-variant: normal;">Parties</font><font style="font-weight:normal;font-variant: normal;">&#8221;.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Recitals</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;">,</font><font style="font-variant: normal;"> </font><font style="font-weight:normal;font-variant: normal;">Ovid, a biopharmaceutical company, owns or controls certain patents, know-how, and other intellectual property relating to its proprietary compound known as OV101, a selective agonist of the GABA<sub style="font-size:85%; vertical-align:bottom">A</sub> receptor, including certain intellectual property rights in-licensed from H. Lundbeck A/S, which Ovid has been developing for the treatment of Angelman syndrome and Fragile X syndrome and potentially other Rare Diseases indications;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;">,</font> <font style="font-weight:normal;font-variant: normal;">Licensee is a subsidiary, 100% under direction and control of Angelini Pharma S.p.A., an Italian pharmaceutical company, which is experienced in the development and commercialization of pharmaceutical products; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;">,</font><font style="font-weight:normal;font-variant: normal;"> Licensee and Ovid desire to form a collaboration for the continued development and commercialization of OV101, with the status of Orphan Medicine and with Final Label 1a, 1b and/or 2, all on the terms and conditions set forth below. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Agreement</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;text-indent:7.69%;">Now, Therefore<font style="font-weight:normal;">,</font> <font style="font-weight:normal;font-variant: normal;">in consideration of the foregoing premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Ovid and Licensee hereby agree as follows:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Ref151411420"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;text-transform:none;color:#000000;"></font><font style="font-family:Times New Roman Bold;font-variant: small-caps;text-transform:none;color:#000000;">Definitions</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref207951667"></a><a name="_Ref381314621"></a><font style="Background-color:#auto;text-decoration:none;">1.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Additional Development Activities</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.3(a)</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Additional Indications</font><font style="font-weight:normal;color:#000000;">&#8221; means any Rare Diseases Indication other than the Initial Indication and the Second Indication that has been submitted to and approved by the CGB.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref24399584"></a><a name="_Hlk31383886"></a><a name="_cp_text_1_5"></a><font style="Background-color:#auto;text-decoration:none;">1.3</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Additional Pivotal Trial</font><font style="font-weight:normal;color:#000000;">&#8221; means the additional Phase 3 Clinical Trial of the Product for the Initial Indication,<a name="_Hlk31383886"></a> if required by the EMA or by Licensee at its own discretion, for the purpose of seeking or maintaining MAA Approval of the Product for the Initial Indication in the Licensee Territory, as described in </font><font style="text-decoration:underline;color:#000000;"><a name="_cp_text_1_5"></a>Exhibit H</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="OLE_LINK3"></a><a name="OLE_LINK4"></a><font style="Background-color:#auto;text-decoration:none;">1.4</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Affiliate</font><font style="font-weight:normal;color:#000000;">&#8221;</font><font style="color:#000000;"> </font><font style="font-weight:normal;color:#000000;"><a name="OLE_LINK3"></a><a name="OLE_LINK4"></a>means, with respect to any party, any entity that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with such party, but for only so long as such control exists.&nbsp;&nbsp;As used in this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 1.4</font><font style="font-weight:normal;color:#000000;">, &#8220;control&#8221; means (a) to possess, directly or indirectly, the power to direct the management or policies of an entity, whether through ownership of voting securities, by contract relating to voting rights or corporate </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">governance; or (b) direct or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="OLE_LINK39"></a><font style="Background-color:#auto;text-decoration:none;">1.5</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Allocated Quantity of Compound</font><font style="font-weight:normal;color:#000000;">&#8221; means [***] of the Compound in Ovid&#8217;s control as of the Effective Date, which Ovid has agreed, under the Supply Agreement, to allocate exclusively for the purpose of fulfilling Licensee&#8217;s or Licensee Affiliate&#8217;s Purchase Orders under the Supply Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.6</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Allowable Increases</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.5(b)</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk31647186"></a><font style="Background-color:#auto;text-decoration:none;">1.7</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Amended Development Budget</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.2</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.8</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Amended Development Plan</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.2</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.9</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Angelini Commercially Reasonable Efforts</font><font style="font-weight:normal;color:#000000;">&#8221; means, with respect to Licensee and its obligations under this Agreement, commercially reasonable efforts and resources as commonly used by a similar size pharmaceutical company to Develop and Commercialize a product controlled by Licensee or to which it has exclusive rights, which product is at similar stage in its development or product life and is of similar market potential taking into account efficacy, safety, approved and/or anticipated labelling, the competitiveness of alternative products sold by Third Parties in the marketplace, the patent and other proprietary position of the product, likelihood of regulatory approval given the regulatory structure involved, the profitability of the product, [***] and other relevant factors, including technical, legal, scientific and/or medical factors. Commercially Reasonable Efforts shall be determined on a country-by-country basis and indication-by-indication basis for a particular Product, and it is anticipated that the level of effort will change over the time, reflecting changes in the status of the Product and the country(s) involved.  [***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.10</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Applicable Laws</font><font style="font-weight:normal;color:#000000;">&#8221; means the applicable provisions (including Data Protection Legislation) of any and all national, supranational, regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, guidance, ordinances, judgments, decrees, directives, injunctions, orders, permits (including MAAs) of or from any court, Regulatory Authority, or governmental agency or authority having jurisdiction over or related to the subject item.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.11</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Auditor</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 9.4</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.12</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Calendar Quarter</font><font style="font-weight:normal;color:#000000;">&#8221; means each respective period of three (3) consecutive months ending on March 31, June 30, September 30, and December 31.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.13</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Calendar Year</font><font style="font-weight:normal;color:#000000;">&#8221; means each respective period of twelve (12) consecutive months ending on December 31. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.14</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">cGCP</font><font style="font-weight:normal;color:#000000;">&#8221; means the current good clinical practice standards as set out in (a) ICH Harmonized Guidance on current Good Clinical Practice (CPMP/ICH/135/95), (b) U.S. 21 C.F.R. Parts 50, 54, 56, 58, 210, 211 and 312, and (c) the equivalent law or regulation in any other applicable jurisdiction in the Territory, each as may be amended from time to time.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">1.15</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">cGLP</font><font style="font-weight:normal;color:#000000;">&#8221; means current good laboratory practice standards promulgated or endorsed by the FDA, as defined in U.S. 21 C.F.R. Part 58 (or such other comparable regulatory standards in jurisdictions outside the U.S.), as may be amended from time to time.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.16</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">cGMP</font><font style="font-weight:normal;color:#000000;">&#8221; means the current standards for systems to assure the proper design, monitoring, and control of processes and facilities to be used for the manufacture, processing, packing, or holding of a drug as specified by applicable laws of the relevant countries at the time of manufacturing conducted in accordance with this Agreement, defined under (a) U.S. 21 C.F.R. Parts 210 and 211 and (b) the equivalent law or regulation in any other applicable jurisdiction in the Territory, each as may be amended from time to time.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.17</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Claim</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 12.3</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.18</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Clawback</font><font style="font-weight:normal;color:#000000;">&#8221; means post sales clawback policies applied to manufacturers, requiring them to pass a part of their revenues in respect of a product to a national health service or other Governmental Authority. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.19</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Clinical Trial</font><font style="font-weight:normal;color:#000000;">&#8221; or &#8220;</font><font style="color:#000000;">Clinical Trials</font><font style="font-weight:normal;color:#000000;">&#8221; means Phase 1 Clinical Trial, Phase 2 Clinical Trial, Phase 3 Clinical Trial, or Phase 4 Clinical Trial, as the context dictates.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.20</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Collaboration Governance Board</font><font style="font-weight:normal;color:#000000;">&#8221; or &#8220;</font><font style="color:#000000;">CGB</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 3.1</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.21</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Combination Product</font><font style="font-weight:normal;color:#000000;">&#8221; means any pharmaceutical product containing the Compound as an active pharmaceutical ingredient in combination with one or more other therapeutically active ingredients, in any and all forms, presentations, dosages, and formulations.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.22</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Commercialization</font><font style="font-weight:normal;color:#000000;">&#8221; means the conduct of all activities undertaken before and after Regulatory Approval relating to the promotion, sales, marketing, medical and patient support and services, and distribution (including importing, exporting, transporting, customs clearance, warehousing, invoicing, handling, and delivering Products to customers) of Products in the Field, including sales force efforts, detailing, advertising, market research, market access (including price and reimbursement activities), medical education and information services, publication, scientific and medical affairs, advisory and collaborative activities with opinion leaders and professional societies including symposia, marketing, sales force training, and sales (including receiving, accepting and filling Product orders) and distribution.&nbsp;&nbsp;&#8220;</font><font style="color:#000000;">Commercialize</font><font style="font-weight:normal;color:#000000;">&#8221; and &#8220;</font><font style="color:#000000;">Commercializing</font><font style="font-weight:normal;color:#000000;">&#8221; have correlative meanings. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.23</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Commercialization Plan</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 6.2</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.24</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Committee</font><font style="font-weight:normal;color:#000000;">&#8221; means the CGB, JPT, or any other subcommittee established by the CGB, as applicable. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.25</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;Committee for Medicinal Products for Human Use (CHMP)&#8221; </font><font style="font-weight:normal;color:#000000;">means the EMA committee responsible for human medicines. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.26</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Competing Acquirer</font><font style="font-weight:normal;color:#000000;">&#8221; means a Third Party that, as of the closing date of the applicable transaction, is engaged in [***] of products, other than Products, for [***].</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">1.27</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Competing Product</font><font style="font-weight:normal;color:#000000;">&#8221; means any product or compound, other than the Compound and Products and the Current Licensee Pipeline Products, (a) </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;">, or (b) </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.28</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Compound</font><font style="font-weight:normal;color:#000000;">&#8221; means the &#948;-selective extrasynaptic GABA<sub style="font-size:85%; vertical-align:bottom">A</sub> receptor agonist known internally by Ovid as OV101, having the chemical structure set forth in </font><font style="text-decoration:underline;color:#000000;">Exhibit A</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.29</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Compound Invention</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 10.1(b)(i)</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.30</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Compounding</font><font style="font-weight:normal;color:#000000;">&#8221; or &#8220;</font><font style="color:#000000;">Compounding Activities</font><font style="font-weight:normal;color:#000000;">&#8221; means [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.31</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Confidentiality Agreement</font><font style="font-weight:normal;color:#000000;">&#8221; means that certain Confidential Disclosure Agreement between Ovid and Licensee dated as of July 8, 2019.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.32</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Confidential Information</font><font style="font-weight:normal;color:#000000;">&#8221; means all Know-How and other proprietary scientific, marketing, financial, or commercial information or data that is generated by or on behalf of a Party or its Affiliates or which one Party or any of its Affiliates has supplied or otherwise made available to the other Party or its Affiliates, whether made available orally, in writing, or in electronic form, including information comprising or relating to concepts, discoveries, inventions, data, designs, or formulae in relation to this Agreement; provided that all Ovid Technology will be deemed Ovid&#8217;s Confidential Information, all Licensee Technology will be deemed Licensee&#8217;s Confidential Information, and all Joint Inventions and Joint Patents will be deemed both Parties&#8217; Confidential Information.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.33</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Control</font><font style="font-weight:normal;color:#000000;">&#8221; or &#8220;</font><font style="color:#000000;">Controlled</font><font style="font-weight:normal;color:#000000;">&#8221; means, with respect to any Know-How, Patents, or other intellectual property rights, the legal authority or right (whether by ownership, license, or otherwise, but without taking into account any rights granted by one Party to the other Party pursuant to this Agreement) of a Party to grant access, a license, or a sublicense of or under such Know-How, Patents, or other intellectual property rights to another Party, or to otherwise disclose proprietary or trade secret information to such other Party, without breaching the terms of any agreement with a Third Party, or misappropriating the proprietary or trade secret information of a Third Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref24281615"></a><font style="Background-color:#auto;text-decoration:none;">1.34</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Cost of Goods</font><font style="font-weight:normal;color:#000000;">&#8221; means, with respect to the Drug Product, the fully burdened cost to manufacture and supply such Drug Product, which means: (a) in the case of products and services acquired from Third Parties, [***]; and (b) in the case of manufacturing services performed by a Party or its Affiliates, including manufacturing services to support products and services acquired from Third Parties as contemplated in subsection (a), [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_7"></a><font style="Background-color:#auto;text-decoration:none;">1.35</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Current Licensee Pipeline Products</font><font style="font-weight:normal;color:#000000;">&#8221; means, in each case as of the Effective Date, Licensee&#8217;s pipeline for products related to (a) [***], (b) [***], and (c) [***], in each case as better defined in </font><font style="text-decoration:underline;color:#000000;"><a name="_cp_text_1_7"></a>Exhibit I</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.36</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Data</font><font style="font-weight:normal;color:#000000;">&#8221; means any and all scientific, technical, test, marketing, or sales data pertaining to any Product that is generated by or on behalf of Ovid, Licensee, and their respective Affiliates and (sub)licensees, including research data, clinical pharmacology data, pre-clinical data, clinical data, clinical study reports, or submissions made in association with an IND or MAA with respect to any Product.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">1.37</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Data Protection Legislation</font><font style="font-weight:normal;color:#000000;">&#8221; means all applicable legislation relating to the protection and processing of personal data, data privacy and the privacy of electronic communications in any relevant jurisdiction, including the General Data Protection Regulation ((EU) 2016/679), and any national implementing laws, regulations and secondary legislation, as amended or updated from time to time.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_DV_M666"></a><font style="Background-color:#auto;text-decoration:none;">1.38</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Development</font><font style="font-weight:normal;color:#000000;"><a name="_DV_M666"></a>&#8221; means all non-clinical and clinical drug development activities, including toxicology, pharmacological, and other non-clinical efforts, statistical analysis, the performance of Clinical Trials, including the Manufacturing of the Products for use in the Clinical Trials, Manufacturing Development or other activities reasonably necessary in order to obtain or maintain Regulatory Approval of Products in the Field in the Territory, as detailed in a Development Plan for the Products. &#8220;Development&#8221; shall exclude all Commercialization activities. When used as a verb, &#8220;Develop&#8221; means to engage in Development activities. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.39</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Development Budget</font><font style="font-weight:normal;color:#000000;">&#8221; means the initial reasonably detailed budget estimated by the Parties for all Development activities set forth in the Development Plan.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.40</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Development Costs</font><font style="font-weight:normal;color:#000000;">&#8221; means the costs incurred by a Party or for its account or by the Parties jointly, during the Term and pursuant to this Agreement, that are specifically directed (or reasonably allocable) to the Development of a Product.&nbsp;&nbsp;The Development Costs shall include amounts that a Party pays to Third Parties involved in the Development of a Product (at cost), and all internal costs (calculated on an FTE basis at the then-current FTE Rate) and out-of-pocket costs incurred by or on account of a Party in performing Development in accordance with the Development Plan.&nbsp;&nbsp;For clarity, [***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.41</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Development Plan</font><font style="font-weight:normal;color:#000000;">&#8221; means the initial plan of Development activities for the Product set forth in </font><font style="text-decoration:underline;color:#000000;">Exhibit C</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.42</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Drug Product</font><font style="font-weight:normal;color:#000000;">&#8221; means the Compound, filled and finished into unit doses, but not packaged or labelled.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref33098379"></a><a name="_Ref529313247"></a><a name="_Hlk30757941"></a><a name="_cp_text_1_11"></a><font style="Background-color:#auto;text-decoration:none;">1.43</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Elara Trial</font><font style="font-weight:normal;color:#000000;"><a name="_Hlk30757941"></a>&#8221; means the open-label extension study for patients with Angelman Syndrome who have previously been enrolled in a Clinical Trial of the Product (including the Neptune Trial) as of the Effective Date, as further described in </font><font style="text-decoration:underline;color:#000000;"><a name="_cp_text_1_11"></a>Exhibit J</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;[***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.44</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">EMA</font><font style="font-weight:normal;color:#000000;">&#8221;</font><font style="color:#000000;"> </font><font style="font-weight:normal;color:#000000;">means the European Medicines Agency, and any successor agency or authority having substantially the same function.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.45</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Executive Officers</font><font style="font-weight:normal;color:#000000;">&#8221; means the [***] of Ovid and the [***] of Licensee. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.46</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Export Control Laws</font><font style="font-weight:normal;color:#000000;">&#8221; means all applicable U.S. laws and regulations relating to (a) sanctions and embargoes imposed by the Office of Foreign Assets Control of the U.S. Department of Treasury or (b) the export or re-export of commodities, technologies, or services, including the Export Administration Act of 1979, 24 U.S.C. &#167;&#167; 2401-2420, the International Emergency Economic Powers Act, 50 U.S.C. &#167;&#167; 1701-1706, the Trading with the Enemy Act, 50 U.S.C. &#167;&#167; 1 et. seq., the Arms Export Control Act, 22 U.S.C. &#167;&#167; 2778 and 2779, and the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">International Boycott Provisions of Section 999 of the U.S. Internal Revenue Code of 1986, in each case, as amended.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.47</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Extended Commercialization Term</font><font style="font-weight:normal;color:#000000;">&#8221; means the period commencing on the expiration of the Royalty Term and continuing for so long as Ovid continues to supply to Licensee or Licensee Affiliate the Product under the terms of the Lundbeck License Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.48</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">FCPA</font><font style="font-weight:normal;color:#000000;">&#8221; means the U.S. Foreign Corrupt Practices Act (15 U.S.C. Section 78dd-1, et. seq.), as amended. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.49</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">FDA</font><font style="font-weight:normal;color:#000000;">&#8221; means the U.S. Food and Drug Administration, and any successor agency or authority having substantially the same function. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk31014291"></a><font style="Background-color:#auto;text-decoration:none;">1.50</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Field</font><font style="font-weight:normal;color:#000000;">&#8221; means the treatment of (a) the Initial Indication, (b) the Second Indication (subject to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.2(e)</font><font style="font-weight:normal;color:#000000;"><a name="_Hlk31014291"></a>) and (c) any Additional Indication(s) for which the Parties agree to incorporate Additional Development Activities into the Development Plan and Development Budget in accordance with </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.3</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.51</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Final Label</font><font style="font-weight:normal;color:#000000;">&#8221; refers to the information regarding an approved Indication and population target that is included with a prescription drug as approved by an applicable Regulatory Authority.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.52</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Final Label 1a</font><font style="font-weight:normal;color:#000000;">&#8221; means the Final Label for a population from two (2) years of age up to twelve (12) years of age.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.53</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Final Label 1b</font><font style="font-weight:normal;color:#000000;">&#8221; means the Final Label for a population from four (4) years of age up to twelve (12) years of age. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.54</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Final Label 2</font><font style="font-weight:normal;color:#000000;">&#8221; means the Final Label for the population from twelve (12) years of age up to, at least seventeen (17) years of age or more. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_2_12"></a><a name="_cp_blt_1_15"></a><a name="_cp_blt_2_14"></a><font style="Background-color:#auto;text-decoration:none;">1.55</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">First Commercial Sale</font><font style="font-weight:normal;color:#000000;">&#8221; means, on a Product-by-Product and country-by-country basis, the first sale of such Product in such country by Licensee or its Affiliates or Sublicensees to a Third Party after Regulatory Approval for such Product has been obtained in such country.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_17"></a><a name="_cp_blt_2_16"></a><font style="Background-color:#auto;text-decoration:none;">1.56</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">FTE</font><font style="font-weight:normal;color:#000000;">&#8221; means the equivalent of a full-time individual&#8217;s work for a twelve (12) month period, consisting of a total of [***] hours per year of dedicated effort.&nbsp;&nbsp;Any person who devotes more or less than [***] hours per year on the applicable activities shall be treated as an FTE on a pro-rata basis, based upon the actual number of hours worked by such person on such activities, divided by [***].&nbsp;&nbsp;For clarity, the hours spent by temporary workers and contractors on applicable activities may be treated as FTE on a pro-rata basis.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_24"></a><a name="_cp_blt_2_23"></a><a name="_cp_text_1_19"></a><a name="_cp_text_1_21"></a><font style="Background-color:#auto;text-decoration:none;">1.57</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">FTE Rate</font><font style="font-weight:normal;color:#000000;">&#8221; means an initial rate of (a) with respect to Ovid&#8217;s personnel, [***] per FTE per year and (b) with respect to Licensee&#8217;s personnel, [***] per FTE per year, which rates shall apply through [***].&nbsp;&nbsp;Thereafter, the FTE Rate shall be changed annually on a Calendar Year basis to reflect any year-to-year percentage increase or decrease (as the case may be) (i) with respect to Ovid, in the Consumer Price Index for All Urban Consumers for the U.S., as published by the U.S. Department of Labor, Bureau of Labor Statistics, and (ii) with respect to Licensee, in </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;"><a name="_cp_text_1_19"></a>the </font><font style="font-weight:normal;color:#000000;">Italy Consumer Price Index </font><font style="font-weight:normal;color:#000000;"><a name="_cp_text_1_21"></a>as published by the </font><font style="font-weight:normal;color:#000000;">Italian National Statistical Institute </font><font style="font-weight:normal;color:#000000;">(both changes based on the change from the most recent applicable index available as of the Effective Date to the most recent applicable index available as of the date of the calculation of such revised FTE Rate).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_26"></a><a name="_cp_blt_2_25"></a><a name="_Hlk38029020"></a><a name="_Hlk38190673"></a><font style="Background-color:#auto;text-decoration:none;">1.58</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Generic Product</font><font style="font-weight:normal;color:#000000;">&#8221; means, (a<a name="_Hlk38029020"></a>) any pharmaceutical product <a name="_Hlk38190673"></a>which has received Regulatory Approval [***] of the Product; and/or (b) any other pharmaceutical product, approved under an Abbreviated New Drug Application, or ANDA, in the United States, under Section 505(b)(2) of the Food Drug and Cosmetic Act, or similar regulatory pathways outside of the U.S., in any case, with the Product as the reference product. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_30"></a><a name="_cp_blt_2_29"></a><a name="_cp_text_1_28"></a><font style="Background-color:#auto;text-decoration:none;">1.59</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Generic Product Competition</font><font style="font-weight:normal;color:#000000;">&#8221; with respect to a Product, on a country-by-country basis, Generic Product Competition shall exist if [***] there are one or more Generic Products sold [***] in such country and the sales of such Generic Product(s) account for [***] or more of the sales revenue of the Product and its Generic Product(s) in the given country during such [***] <a name="_cp_text_1_28"></a>as determined by reference to applicable sales data obtained from IMS Health, Verispan, or from such other reputable source for such sales data as may be used and relied upon by the Parties from time to time, provided however if sale of such Generic Product(s) [***], Generic Product Competition shall no longer exist.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_32"></a><a name="_cp_blt_2_31"></a><font style="Background-color:#auto;text-decoration:none;">1.60</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;"> &#8220;</font><font style="color:#000000;">Governmental Authority</font><font style="font-weight:normal;color:#000000;">&#8221; means any national, international, federal, state, provincial, or local government, or political subdivision thereof, or any multinational organization, or any authority, agency, or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power, or any court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_34"></a><a name="_cp_blt_2_33"></a><font style="Background-color:#auto;text-decoration:none;">1.61</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">ICH</font><font style="font-weight:normal;color:#000000;">&#8221; means the International Conference on Harmonization (of Technical Requirements for Registration of Pharmaceuticals for Human Use).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_36"></a><a name="_cp_blt_2_35"></a><font style="Background-color:#auto;text-decoration:none;">1.62</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">IND</font><font style="font-weight:normal;color:#000000;">&#8221; means an application filed with a Regulatory Authority for authorization to commence Clinical Trials, including (a) an Investigational New Drug Application or any successor application or procedure filed with the FDA, (b) a Clinical Trial Application or any successor application or procedure filed with the EMA, (c) any equivalent of the applications in (a) and (b) in countries or regulatory jurisdictions outside the U.S. and EU, and (d) all supplements, amendments, variations, extensions, and renewals thereof that may be filed with respect to the foregoing.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_38"></a><a name="_cp_blt_2_37"></a><font style="Background-color:#auto;text-decoration:none;">1.63</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Indemnitee</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 12.3</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_40"></a><a name="_cp_blt_2_39"></a><font style="Background-color:#auto;text-decoration:none;">1.64</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Indemnitor</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 12.3</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_42"></a><a name="_cp_blt_2_41"></a><font style="Background-color:#auto;text-decoration:none;">1.65</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Independent Development Activities</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.3(d)</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_44"></a><a name="_cp_blt_2_43"></a><a name="_cp_blt_1_46"></a><a name="_cp_blt_2_45"></a><font style="Background-color:#auto;text-decoration:none;">1.66</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Independent Development Costs</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.2(b)</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.67</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Indication</font><font style="font-weight:normal;color:#000000;">&#8221; means a separate and distinct disease, disorder, illness, or health condition and all of its associated signs, symptoms, stages, or progression (including precursor conditions), in each case for which a separate MAA may be filed.&nbsp;&nbsp;Subpopulations or patients with a primary disease or condition, however stratified (including stratification by stages or progression, particular combinations of symptoms associated with the primary disease or condition, prior treatment courses, response to prior treatment, family history, clinical history, phenotype, or other stratification) shall not be deemed to be separate &#8220;Indications&#8221; for the purposes of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_48"></a><a name="_cp_blt_2_47"></a><font style="Background-color:#auto;text-decoration:none;">1.68</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Initial Indication</font><font style="font-weight:normal;color:#000000;">&#8221; means Angelman syndrome (AS).</font><font style="border-bottom:double 2.5pt;font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_50"></a><a name="_cp_blt_2_49"></a><font style="Background-color:#auto;text-decoration:none;">1.69</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">International Transparency Reporting Requirements for Europe</font><font style="font-weight:normal;color:#000000;">&#8221;</font><font style="color:#000000;"> </font><font style="font-weight:normal;color:#000000;">means EFPIA consolidated Code for Pharmaceutical Companies to report transfers of value related to HCPs: donations and grants, contribution to costs related to events, fees for service and consultancy, research and development.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_52"></a><a name="_cp_blt_2_51"></a><font style="Background-color:#auto;text-decoration:none;">1.70</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Inventions</font><font style="font-weight:normal;color:#000000;">&#8221; means all inventions, whether or not patentable, discovered, made, conceived, or reduced to practice in the course of activities contemplated by this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_54"></a><a name="_cp_blt_2_53"></a><font style="Background-color:#auto;text-decoration:none;">1.71</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">JPT</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 3.2</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_56"></a><a name="_cp_blt_2_55"></a><font style="Background-color:#auto;text-decoration:none;">1.72</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Joint Development Activities</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.2(d). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_58"></a><a name="_cp_blt_2_57"></a><font style="Background-color:#auto;text-decoration:none;">1.73</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Joint Inventions</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 10.1(b)(ii)</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_60"></a><a name="_cp_blt_2_59"></a><font style="Background-color:#auto;text-decoration:none;">1.74</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Joint Patents</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 10.1(b)(ii)</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_62"></a><a name="_cp_blt_2_61"></a><font style="Background-color:#auto;text-decoration:none;">1.75</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Know-How</font><font style="font-weight:normal;color:#000000;">&#8221; means all technical and scientific information, know-how, and data, including inventions, discoveries, trade secrets, specifications, instructions, processes, formulae, compositions of matter, cells, cell lines, assays, animal models, and other physical, biological, or chemical materials, expertise, and other technology applicable to development, registration, use, or marketing or to methods of assaying or testing them, and including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical, and analytical safety, nonclinical, and clinical data, regulatory documents, data and filings, instructions, processes, formulae, expertise, and information relevant to the research, development, use, importation, offering for sale, or sale of, or which may be useful in studying, testing, developing, Products.&nbsp;&nbsp;Know-How excludes Patents.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_64"></a><a name="_cp_blt_2_63"></a><font style="Background-color:#auto;text-decoration:none;">1.76</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Licensee Data</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 10.1(a)</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_66"></a><a name="_cp_blt_2_65"></a><font style="Background-color:#auto;text-decoration:none;">1.77</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Licensee Indemnitee</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 12.1</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_68"></a><a name="_cp_blt_2_67"></a><font style="Background-color:#auto;text-decoration:none;">1.78</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Licensee Know-How</font><font style="font-weight:normal;color:#000000;">&#8221; means all Know-How that Licensee or its Affiliate(s) Controls as of the Effective Date or during the Term, including any Joint Inventions, that is necessary or reasonably useful for the research, Development, manufacture, use, importation, offer for sale, or sale of the Compound or any Product in the Field.&nbsp;&nbsp;For clarity, subject to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.2(b)</font><font style="font-weight:normal;color:#000000;"> in the case of any Licensee Data generated as a result of Licensee&#8217;s Independent Development Activities, the Licensee Know&#8209;How includes the Licensee Data.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_70"></a><a name="_cp_blt_2_69"></a><font style="Background-color:#auto;text-decoration:none;">1.79</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Licensee Patents</font><font style="font-weight:normal;color:#000000;">&#8221; means all Patents that Licensee or its Affiliate(s) Controls as of the Effective Date or during the Term (including any Joint Patents) that would be infringed, absent a license or other right to practice granted under such Patents, by the research, Development, manufacture, use, importation, offer for sale, or sale of any Compound or Product (considering patent applications to be issued with the then-pending claims and considering Joint Patents as if owned solely by Licensee or its Affiliate).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_72"></a><a name="_cp_blt_2_71"></a><font style="Background-color:#auto;text-decoration:none;">1.80</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Licensee Technology</font><font style="font-weight:normal;color:#000000;">&#8221; means the Licensee Know-How and the Licensee Patents, including Licensee&#8217;s interest in the Joint Inventions and Joint Patents.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_74"></a><a name="_cp_blt_2_73"></a><a name="_Hlk31611370"></a><font style="Background-color:#auto;text-decoration:none;">1.81</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Licensee Territory</font><font style="font-weight:normal;color:#000000;">&#8221; or &#8220;</font><font style="color:#000000;">Licensed Territory</font><font style="font-weight:normal;color:#000000;">&#8221; means Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein,&#160;Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, and the United Kingdom.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_76"></a><a name="_cp_blt_2_75"></a><font style="Background-color:#auto;text-decoration:none;">1.82</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Licensee Territory Development Activities</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.2(b)</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_78"></a><a name="_cp_blt_2_77"></a><font style="Background-color:#auto;text-decoration:none;">1.83</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Losses</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 12.1</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_84"></a><a name="_cp_blt_2_83"></a><a name="_Hlk38186938"></a><a name="_cp_text_1_81"></a><font style="Background-color:#auto;text-decoration:none;">1.84</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;"><a name="_Hlk38186938"></a>&#8220;</font><font style="color:#000000;">Lundbeck License Agreement</font><font style="font-weight:normal;color:#000000;">&#8221; means the License Agreement by and between Ovid and H. Lundbeck A/S (&#8220;</font><font style="color:#000000;">Lundbeck</font><font style="font-weight:normal;color:#000000;">&#8221;) dated 25 March, 2015, and amended on <a name="_cp_text_1_81"></a>July 7, 2020 to clarify certain sights of sublicensees upon termination of such agreement (such amendment, the &#8220;</font><font style="color:#000000;">Lundbeck Sublicense Amendment</font><font style="font-weight:normal;color:#000000;">&#8221;). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_86"></a><a name="_cp_blt_2_85"></a><font style="Background-color:#auto;text-decoration:none;">1.85</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">MAA</font><font style="font-weight:normal;color:#000000;">&#8221; means a marketing authorization application or equivalent application, and all amendments and supplements thereto, filed with the applicable Regulatory Authority in any country or jurisdiction.&nbsp;&nbsp;For clarity, MAA does not include any application for Pricing and Reimbursement Approval.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_88"></a><a name="_cp_blt_2_87"></a><font style="Background-color:#auto;text-decoration:none;">1.86</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">MAA Approval</font><font style="font-weight:normal;color:#000000;">&#8221; means approval of an MAA by the applicable Regulatory Authority for marketing and sale of a Product in the applicable country or jurisdiction, but excluding any Pricing and Reimbursement Approval. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_90"></a><a name="_cp_blt_2_89"></a><a name="_Ref151313606"></a><a name="_Ref151315896"></a><a name="_Ref208040690"></a><font style="Background-color:#auto;text-decoration:none;">1.87</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Major European Market</font><font style="font-weight:normal;color:#000000;">&#8221; means [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_92"></a><a name="_cp_blt_2_91"></a><font style="Background-color:#auto;text-decoration:none;">1.88</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Manufacturing Development</font><font style="font-weight:normal;color:#000000;">&#8221; means any of the following with respect to the Compound or a Product: manufacturing process development, process improvements and any analytical development or validation associated with such development or improvements.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_94"></a><a name="_cp_blt_2_93"></a><font style="Background-color:#auto;text-decoration:none;">1.89</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Market Exclusivity</font><font style="font-weight:normal;color:#000000;">&#8221; means any exclusive marketing rights or data exclusivity rights conferred by a Regulatory Authority with respect to a Product other than patents, including Directive 2001/83/EC and 2004/27/EC (as amended) in the EU and rights equivalent to those conferred in the U.S. under the Hatch-Waxman Act or the FDA Modernization Act of 1997 (including pediatric exclusivity).</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_96"></a><a name="_cp_blt_2_95"></a><font style="text-decoration:none;Background-color:#auto;">1.90</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Medical Affairs</font><font style="font-weight:normal;color:#000000;">&#8221; or</font><font style="color:#000000;"> </font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Medical Affairs Activities</font><font style="font-weight:normal;color:#000000;">&#8221; means activities designed to ensure or improve appropriate medical use of, conduct medical education of, or further research regarding, the Product, including by way of example:&nbsp;&nbsp;(a) activities of medical scientific liaisons/medical advisors who, among their other functions, may: (i) conduct service based medical activities including providing input and assistance with consultancy meetings, proposing investigators for clinical trials sponsored or co-sponsored by a Party or Affiliate, and providing input in the design of such trials and other research related activities; and/or (ii) deliver non-promotional communications and conduct non-promotional activities; (b) grants to support continuing medical education, symposia, or Third Party research related to the Product; (c) development, publication, and dissemination of original and literature review data relating to the Products; (d) medical information services provided in response to inquiries communicated via sales representatives or received by letter, phone call, or email; (e) conducting advisory board meetings, international advisory board activities, or other consultant programs, including the engagement of key opinion leaders and health care professional in individual or group advisory and consulting arrangements; and (f) the evaluation of applications submitted for support of investigator-initiated trials.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_100"></a><a name="_cp_blt_2_99"></a><a name="_cp_text_1_98"></a><font style="Background-color:#auto;text-decoration:none;">1.91</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Neptune Trial</font><font style="font-weight:normal;color:#000000;">&#8221; means the Phase 3 Clinical Trial of the Product for Angelman Syndrome ongoing as of the Effective Date and for which Ovid is the sponsor, as further described in </font><font style="text-decoration:underline;color:#000000;"><a name="_cp_text_1_98"></a>Exhibit J</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_102"></a><a name="_cp_blt_2_101"></a><a name="_Ref25053546"></a><font style="Background-color:#auto;text-decoration:none;">1.92</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Net Sales</font><font style="font-weight:normal;color:#000000;">&#8221; means, with respect to any Product, the aggregate gross amount invoiced by Licensee, its Affiliates, or Sublicensees for the sale of the Product to a Third Party, less the following deductions to the extent allowed and actually taken on such sales: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">transportation charges relating to the Product to the extent actually invoiced to Licensee&#8217;s, its Affiliate&#8217;s, or Sublicensee&#8217;s customers, including handling charges and insurance premiums relating thereto;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">sales taxes, excise taxes, use taxes, VAT, and duties paid by Licensee, its Affiliate, or Sublicensee in relation to the Product and any other equivalent governmental charges imposed on the importation, use, or sale of the Product;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">government-mandated rebates (including any Paybacks or Clawbacks charged with respect to the Product) and other rebates or fees;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">customary trade, quantity, and case discounts allowed on the Product;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">allowances or credits to customers on account of retrospective price reductions affecting the Product; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">customary rebates (including confidential discount agreements Success Fee and Performance based Payments). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:19.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_field_47_104"></a>The transfer of Product between Licensee and its Affiliates and Sublicensees shall not be considered a sale unless the Affiliate or Sublicensee is a bona fide purchaser at fair market value for resale.&nbsp;&nbsp;If the Affiliate or Sublicensee is not an end user, Net Sales shall be determined based </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:19.23%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the invoiced sale price by the Affiliate or Sublicensee to the first Third Party trade purchaser, less the deductions allowed under this </font><font style="text-decoration:underline;"><a name="_cp_field_47_104"></a>Section </font><font style="text-decoration:underline;">1.92</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Disposal of Product for or use of Product in Clinical Studies or as free samples in quantities common in the industry for this sort of Produ</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ct shall not give rise to any deemed sale under this definition. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Sales shall be calculated and accounted for in accordance with accounting standards during the Term (i.e., IFRS), consistently applied. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If Product is sold for other than cash payment, Net Sales of the Product shall be deemed to be the cash value of such other payment.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Product is sold as part of a Combination Product, Net Sales of such Product shall be deemed to be an amount equal to the following:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(X divided by Y) multiplied by Z,</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">where &#8220;<font style="font-weight:bold;">X</font>&#8221; is the average sales price during the applicable reporting period achieved for the relevant Product in the country in which such sale occurred when the Product contains only the Compound and no other active pharmaceutical ingredient;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Y</font>&#8221; is the sum of the average sales price as a single entity during the applicable reporting period achieved in that country (as applicable) of each product included in the Combination Product when such product is sold as a separate product and not as part of a Combination Product; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Z</font>&#8221; is the single price at which the relevant Combination Product was actually sold.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that no separate sale of either (a) the Product comprising the Compound as the sole active pharmaceutical ingredient, or (b) a product containing the other active pharmaceutical ingredient(s) included in the Combination Product, are made during the accounting period in which the sale was made or if the price for a particular therapeutically active ingredient cannot otherwise be determined for an accounting period, Net Sales allocable to the Product shall be determined by mutual agreement of the Parties prior to the end of the accounting period in question based on an equitable method of determining the same that takes into account, in the Territory, variations in potency, the relative contribution of each therapeutically active ingredient in the Combination Product, and relative value to the end user of each therapeutically active ingredient; provided, that if the Parties cannot reach mutual agreement prior to the end of the applicable accounting period, such matter shall be resolved in accordance with <font style="text-decoration:underline;">Article 15</font>. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_106"></a><a name="_cp_blt_2_105"></a><font style="Background-color:#auto;text-decoration:none;">1.93</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Orphan Drug Designation</font><font style="font-weight:normal;color:#000000;">&#8221; means a status assigned to a medicine intended for use against a rare condition. The medicine must fulfil certain criteria for designation as an orphan medicine so that it can benefit from incentives such as protection from competition once on the market.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_108"></a><a name="_cp_blt_2_107"></a><font style="Background-color:#auto;text-decoration:none;">1.94</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Orphan Drug Designation of the Product</font><font style="font-weight:normal;color:#000000;">&#8221; means the EMA orphan drug designation obtained for the Product. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_110"></a><a name="_cp_blt_2_109"></a><font style="text-decoration:none;Background-color:#auto;">1.95</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Orphan Medicine</font><font style="font-weight:normal;color:#000000;">&#8221;</font><font style="color:#000000;"> </font><font style="font-weight:normal;color:#000000;">means a medicine that continues to meet the criteria for maintaining its orphan status in parallel with the assessment of an application for </font><font style="color:#000000;font-weight:normal;">marketing authorisation</font><font style="font-weight:normal;color:#000000;"> by the European Medicines Agency (EMA).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_112"></a><a name="_cp_blt_2_111"></a><a name="_Hlk31647038"></a><font style="Background-color:#auto;text-decoration:none;">1.96</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;"><a name="_Hlk31647038"></a>&#8220;</font><font style="color:#000000;">Ovid Commercially Reasonable Efforts</font><font style="font-weight:normal;color:#000000;">&#8221; means, with respect to Ovid and its obligations under this Agreement, commercially reasonable efforts and resources as commonly used by a similar size pharmaceutical company to Develop and Commercialize a product controlled by Ovid or to which it has exclusive rights, which product is at similar stage in its development or product life and is of similar market potential taking into account efficacy, safety, approved and/or anticipated labelling, the competitiveness of alternative products sold by Third Parties in the marketplace, the patent and other proprietary position of the product, likelihood of regulatory approval given the regulatory structure involved, the profitability of the product, [***], and other relevant factors, including technical, legal, scientific and/or medical factors. Commercially Reasonable Efforts shall be determined on a country-by-country basis and indication-by-indication basis for a particular Product, and it is anticipated that the level of effort will change over the time, reflecting changes in the status of the Product and the country(s) involved. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_114"></a><a name="_cp_blt_2_113"></a><font style="Background-color:#auto;text-decoration:none;">1.97</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Ovid Data</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 10.1(a)</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_116"></a><a name="_cp_blt_2_115"></a><font style="Background-color:#auto;text-decoration:none;">1.98</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Ovid Indemnitee</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 12.2</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_118"></a><a name="_cp_blt_2_117"></a><a name="_Ref151378537"></a><font style="Background-color:#auto;text-decoration:none;">1.99</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Ovid Know-How</font><font style="font-weight:normal;color:#000000;"><a name="_Ref151378537"></a>&#8221; means all Know-How that Ovid Controls as of the Effective Date or, subject to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 2.7(b)</font><font style="font-weight:normal;color:#000000;">, during the Term, including any Joint Inventions, that is necessary or reasonably useful for the Development, use, importation, offer for sale, or sale of any Compound or Product in the Field in the Licensee Territory.&nbsp;&nbsp;For clarity, any Ovid Data generated during Ovid&#8217;s Independent Development Activities will be included within the Ovid Know&#8209;How following reimbursement by Licensee of its share of Development Costs in accordance with </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.2(b)</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_120"></a><a name="_cp_blt_2_119"></a><font style="Background-color:#auto;text-decoration:none;">1.100</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Ovid Ongoing Trials</font><font style="font-weight:normal;color:#000000;">&#8221; means the Rocket Trial, Elara Trial, and Neptune Trial.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_122"></a><a name="_cp_blt_2_121"></a><font style="Background-color:#auto;text-decoration:none;">1.101</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Ovid Patents</font><font style="font-weight:normal;color:#000000;">&#8221; means all Patents in the Licensee Territory that Ovid Controls as of the Effective Date or, subject to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 2.7(b)</font><font style="font-weight:normal;color:#000000;">, during the Term (including any Joint Patents) that would be infringed, absent a license or other right to practice granted under such Patents, by the Development, use, importation, offer for sale, or sale of any Compound or Product in the Field in the Licensee Territory (considering patent applications to be issued with the then-pending claims and considering Joint Patents as if owned solely by Ovid).&nbsp;&nbsp;The Ovid Patents existing as of the Effective Date are set forth in </font><font style="text-decoration:underline;color:#000000;">Exhibit B</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_124"></a><a name="_cp_blt_2_123"></a><font style="Background-color:#auto;text-decoration:none;">1.102</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Ovid Technology</font><font style="font-weight:normal;color:#000000;">&#8221; means the Ovid Know&#8209;How and the Ovid Patents, including Ovid&#8217;s interest in the Joint Inventions and Joint Patents.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_126"></a><a name="_cp_blt_2_125"></a><font style="Background-color:#auto;text-decoration:none;">1.103</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Ovid Territory</font><font style="font-weight:normal;color:#000000;">&#8221; means the world outside the Licensee Territory. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_128"></a><a name="_cp_blt_2_127"></a><font style="Background-color:#auto;text-decoration:none;">1.104</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Paediatric Investigational Plan (PIP)</font><font style="font-weight:normal;color:#000000;">&#8221; is the development plan aimed at ensuring that the necessary data are obtained through studies in children, to support the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">authorisation of a medicine for use in children</font><font style="font-size:8pt;font-weight:normal;color:#000000;">. </font><font style="font-weight:normal;color:#000000;">Any Applicants must obtain EMA approval of the PIP before MAA.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_130"></a><a name="_cp_blt_2_129"></a><font style="Background-color:#auto;text-decoration:none;">1.105</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Patents</font><font style="font-weight:normal;color:#000000;">&#8221; means (a) all patents, certificates of invention, applications for certificates of invention, priority patent filings, provisional patent applications and patent applications, and (b) any renewals, divisions, or continuations (in whole or in part) of any of such patents, certificates of invention and patent applications, and any all patents or certificates of invention issuing thereon, and any and all reissues, reexaminations, extensions, supplementary protection certificates, divisions, renewals, substitutions, confirmations, registrations, revalidations, revisions, and additions of or to any of the foregoing.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_132"></a><a name="_cp_blt_2_131"></a><font style="Background-color:#auto;text-decoration:none;">1.106</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Payback</font><font style="font-weight:normal;color:#000000;">&#8221; means payback policies which require manufacturers to pay back a share of their revenue in respect of a product, if a prespecified budget ceiling for public pharmaceutical expenditures is exceeded.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_134"></a><a name="_cp_blt_2_133"></a><font style="Background-color:#auto;text-decoration:none;">1.107</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Pharmacovigilance Agreement</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 5.4</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_136"></a><a name="_cp_blt_2_135"></a><font style="Background-color:#auto;text-decoration:none;">1.108</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Phase 1 Clinical Trial</font><font style="font-weight:normal;color:#000000;">&#8221; means a human clinical trial of a pharmaceutical product that satisfies the requirements for a Phase 1 study as defined in 21&#160;CFR &#167;&#160;312.21(a) (or any amended or successor regulations), regardless of where such clinical trial is conducted.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_138"></a><a name="_cp_blt_2_137"></a><font style="Background-color:#auto;text-decoration:none;">1.109</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Phase 2 Clinical Trial</font><font style="font-weight:normal;color:#000000;">&#8221; means a human clinical trial of a pharmaceutical product that satisfies the requirements for a Phase 2 study as defined in 21&#160;CFR &#167;&#160;312.21(b) (or any amended or successor regulations), regardless of where such clinical trial is conducted.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_140"></a><a name="_cp_blt_2_139"></a><font style="Background-color:#auto;text-decoration:none;">1.110</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Phase 3 Clinical Trial</font><font style="font-weight:normal;color:#000000;">&#8221; means a human clinical trial of a pharmaceutical product for an indication on a sufficient number of subject that is designed to establish that the pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions and adverse reactions that are associated with the pharmaceutical product in the dosage range to be described, and to support Regulatory Authority to market such Product in patients having the indication being studied and that satisfies the requirements for a Phase 3 study as defined in 21&#160;CFR &#167;&#160;312.21(c) (or any amended or successor regulations), regardless of where such clinical trial is conducted.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_142"></a><a name="_cp_blt_2_141"></a><font style="Background-color:#auto;text-decoration:none;">1.111</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Phase 4 Clinical Trial</font><font style="font-weight:normal;color:#000000;">&#8221; means a product support clinical trial of a Product that is commenced after receipt of MAA Approval in the country where such trial is conducted. Phase 4 Clinical Trial may include epidemiological studies, modeling and pharmacoeconomic studies, and post-marketing surveillance trials. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_144"></a><a name="_cp_blt_2_143"></a><font style="Background-color:#auto;text-decoration:none;">1.112</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">PIP Compliance Check</font><font style="font-weight:normal;color:#000000;">&#8221; means that PIP has been checked by EMA for compliance with all the measures mentioned in the PIP decision, including the timelines for the conduct of the studies or collection of the data.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_146"></a><a name="_cp_blt_2_145"></a><font style="Background-color:#auto;text-decoration:none;">1.113</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Pricing and Reimbursement Approval</font><font style="font-weight:normal;color:#000000;">&#8221; means, with respect to a Product, the approval, agreement, determination, or decision of any applicable Governmental Authority establishing the price or reimbursement level for such Product, as required in a given country or jurisdiction prior to sale of such Product in such country or jurisdiction.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_148"></a><a name="_cp_blt_2_147"></a><font style="text-decoration:none;Background-color:#auto;">1.114</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Product</font><font style="font-weight:normal;color:#000000;">&#8221; means any pharmaceutical product containing the Compound as an active ingredient,</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">alone or in combination with one or more other active pharmaceutical ingredients, in any form, presentation, dosage, or formulation, and for any mode of administration.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_150"></a><a name="_cp_blt_2_149"></a><font style="Background-color:#auto;text-decoration:none;">1.115</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Product Infringement</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 10.3(a)</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_152"></a><a name="_cp_blt_2_151"></a><font style="Background-color:#auto;text-decoration:none;">1.116</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Promotional Materials</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 6.4(c)</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_154"></a><a name="_cp_blt_2_153"></a><font style="Background-color:#auto;text-decoration:none;">1.117</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Proposal</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.3</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_156"></a><a name="_cp_blt_2_155"></a><font style="Background-color:#auto;text-decoration:none;">1.118</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Proposing Party</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.3</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_158"></a><a name="_cp_blt_2_157"></a><font style="Background-color:#auto;text-decoration:none;">1.119</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Public Official or Entity</font><font style="font-weight:normal;color:#000000;">&#8221; means (a)&#160;any officer, employee (including physicians, hospital administrators, or other healthcare professionals), agent, representative, department, agency, de facto official, representative, corporate entity, instrumentality, or subdivision of any government, military, or international organization, including any ministry or department of health or any state-owned or affiliated company or hospital, or (b)&#160;any candidate for political office, any political party, or any official of a political party. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_160"></a><a name="_cp_blt_2_159"></a><font style="Background-color:#auto;text-decoration:none;">1.120</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Rare Disease</font><font style="font-weight:normal;color:#000000;">&#8221; means a disease that affects one person per two thousand (2,000).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_162"></a><a name="_cp_blt_2_161"></a><font style="Background-color:#auto;text-decoration:none;">1.121</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Recall</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 5.7</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_164"></a><a name="_cp_blt_2_163"></a><font style="Background-color:#auto;text-decoration:none;">1.122</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Regulatory Approval</font><font style="font-weight:normal;color:#000000;">&#8221; means, with respect to a country or jurisdiction, any and all approvals (including MAA Approval and, if required by Applicable Law, Pricing and Reimbursement Approval), licenses, registrations, permits, notifications and authorizations (or waivers) of any Regulatory Authority that are necessary for the manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale, or other commercialization of a Product in such country or jurisdiction.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_166"></a><a name="_cp_blt_2_165"></a><font style="Background-color:#auto;text-decoration:none;">1.123</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Regulatory Authority</font><font style="font-weight:normal;color:#000000;">&#8221; means any Governmental Authority that has responsibility in its applicable jurisdiction over the testing, development, manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale, or other commercialization of pharmaceutical products in a given jurisdiction.&nbsp;&nbsp;For countries where Pricing and Reimbursement Approval is required, Regulatory Authority shall also include </font><font style="letter-spacing:-0.35pt;font-weight:normal;color:#000000;">any </font><font style="font-weight:normal;color:#000000;">Governmental Authority whose grant of Pricing and Reimbursement Approval of the Product is required.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_168"></a><a name="_cp_blt_2_167"></a><a name="_Ref151204100"></a><font style="Background-color:#auto;text-decoration:none;">1.124</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Regulatory Filing</font><font style="font-weight:normal;color:#000000;"><a name="_Ref151204100"></a>&#8221; means all applications, filings, submissions, approvals, licenses, registrations, permits, notifications, and authorizations (or waivers) with respect to the testing, Development, manufacture, or Commercialization of any Product made to or received from any Regulatory Authority in a given country, including INDs and MAAs.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_170"></a><a name="_cp_blt_2_169"></a><font style="Background-color:#auto;text-decoration:none;">1.125</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Regulatory Meeting</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 5.1(c)(ii)</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_172"></a><a name="_cp_blt_2_171"></a><a name="_Hlk31358311"></a><font style="Background-color:#auto;text-decoration:none;">1.126</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Regulatory Milestone Event</font><font style="font-weight:normal;color:#000000;">&#8221;</font><font style="color:#000000;"><a name="_Hlk31358311"></a> </font><font style="font-weight:normal;color:#000000;">has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.3(a)</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_176"></a><a name="_cp_blt_2_175"></a><a name="_cp_text_1_174"></a><font style="Background-color:#auto;text-decoration:none;">1.127</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Rocket Trial</font><font style="font-weight:normal;color:#000000;">&#8221; means the Phase 2 Clinical Trial of the Product for Fragile X Syndrome ongoing as of the Effective Date and for which Ovid is the sponsor, as further described in </font><font style="text-decoration:underline;color:#000000;"><a name="_cp_text_1_174"></a>Exhibit J</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_178"></a><a name="_cp_blt_2_177"></a><font style="Background-color:#auto;text-decoration:none;">1.128</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Safety Data</font><font style="font-weight:normal;color:#000000;">&#8221;</font><font style="color:#000000;"> </font><font style="font-weight:normal;color:#000000;">means Data related solely to any adverse drug experiences and serious adverse drug experience as such information is reportable to Regulatory Authorities.&nbsp;&nbsp;Safety Data also includes &#8220;adverse events&#8221;, &#8220;adverse drug reactions&#8221;, and &#8220;unexpected adverse drug reactions&#8221; as defined in the ICH Harmonised Tripartite Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_180"></a><a name="_cp_blt_2_179"></a><font style="Background-color:#auto;text-decoration:none;">1.129</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">SEC</font><font style="font-weight:normal;color:#000000;">&#8221; means the U.S. Securities and Exchange Commission, or any successor entity or its foreign equivalent, as applicable.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_182"></a><a name="_cp_blt_2_181"></a><font style="Background-color:#auto;text-decoration:none;">1.130</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Safety Reason</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.15</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_184"></a><a name="_cp_blt_2_183"></a><font style="Background-color:#auto;text-decoration:none;">1.131</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Sales Milestone Event</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.4(a)</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_186"></a><a name="_cp_blt_2_185"></a><font style="Background-color:#auto;text-decoration:none;">1.132</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Scientific Advice</font><font style="font-weight:normal;color:#000000;">&#8221; means any report of the advice provided by EMA to medicine developers on the most appropriate way to generate robust evidence on a medicine&#8217;s benefits and risks.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_188"></a><a name="_cp_blt_2_187"></a><font style="Background-color:#auto;text-decoration:none;">1.133</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Second Indication</font><font style="font-weight:normal;color:#000000;">&#8221; means Fragile X syndrome (FXS).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_190"></a><a name="_cp_blt_2_189"></a><a name="_Hlk34666359"></a><font style="Background-color:#auto;text-decoration:none;">1.134</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;"><a name="_Hlk34666359"></a>&#8220;</font><font style="color:#000000;">Second Indication Opt-In</font><font style="font-weight:normal;color:#000000;">&#8221; means the election by Licensee, following the Licensee&#8217;s exercise of the Second Indication Opt-Out, to resume the Licensee&#8217;s rights granted to Licensee according to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 2.1</font><font style="font-weight:normal;color:#000000;"> with respect to the Second Indication.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_192"></a><a name="_cp_blt_2_191"></a><font style="Background-color:#auto;text-decoration:none;">1.135</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Second Indication Opt-Out</font><font style="font-weight:normal;color:#000000;">&#8221; means the election by Licensee, in accordance with the terms hereof, not to participate in Development and/or Commercialization activities for the Product for the Second Indication.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_194"></a><a name="_cp_blt_2_193"></a><font style="Background-color:#auto;text-decoration:none;">1.136</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Segregate</font><font style="font-weight:normal;color:#000000;">&#8221; means, with respect to a Competing Product, to [***] segregate the Development, Manufacturing and Commercialization of such Competing Product in the Field from Development, Manufacture and Commercialization activities with respect to Compounds and Products under this Agreement, including [***]; provided that, [***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_196"></a><a name="_cp_blt_2_195"></a><font style="Background-color:#auto;text-decoration:none;">1.137</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Sponsor</font><font style="font-weight:normal;color:#000000;">&#8221; means the Party that takes the ultimate responsibility for the initiation, performance, and management of, including financing or arranging the financing for, the applicable Clinical Trial.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_198"></a><a name="_cp_blt_2_197"></a><font style="Background-color:#auto;text-decoration:none;">1.138</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Sublicensee</font><font style="font-weight:normal;color:#000000;">&#8221; means a Third Party to whom Licensee grants a sublicense to Develop, use, import, promote, offer for sale, or sell any Product in the Field in the Licensee Territory.&nbsp;&nbsp;In no event shall Ovid or any of its Affiliates be deemed a Sublicensee. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_200"></a><a name="_cp_blt_2_199"></a><font style="Background-color:#auto;text-decoration:none;">1.139</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Success Fee</font><font style="font-weight:normal;color:#000000;">&#8221; or &#8220;</font><font style="color:#000000;">Performance Based Payments</font><font style="font-weight:normal;color:#000000;">&#8221; means the returned part of the Product-generated revenues for those cases where outcomes are not meeting pre-defined clinical goals set by National Health Authority (e.g.QoL Gain, Survival, Progression, Course of Disease Modification).</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_202"></a><a name="_cp_blt_2_201"></a><font style="text-decoration:none;Background-color:#auto;">1.140</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Sunshine Reporting Laws</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">5.8</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_207"></a><a name="_cp_blt_2_206"></a><a name="_cp_text_1_205"></a><font style="Background-color:#auto;text-decoration:none;">1.141</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Supply Agreement</font><font style="font-weight:normal;color:#000000;">&#8221; means the supply agreement between Ovid and Licensee attached hereto as </font><font style="text-decoration:underline;color:#000000;"><a name="_cp_text_1_205"></a>Exhibit K</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_209"></a><a name="_cp_blt_2_208"></a><font style="Background-color:#auto;text-decoration:none;">1.142</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Take the Lead</font><font style="font-weight:normal;color:#000000;">&#8221; means, with the respect to a particular Party and a particular activity, that such Party is primarily responsible for, and has the authority to make, all day-to-day operational decisions, in accordance with the Development Plan and Commercialization Plan and the terms of this Agreement; provided that [***]; and provided further that [***].&nbsp;&nbsp;For clarity, [***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_216"></a><a name="_cp_blt_2_215"></a><a name="_cp_text_1_210"></a><a name="_cp_text_1_214"></a><font style="Background-color:#auto;text-decoration:none;">1.143</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Technology Transfer Completion Date</font><font style="font-weight:normal;color:#000000;"><a name="_cp_text_1_210"></a>&#8221; means the earlier of (a) the date on which the activities [***], as <a name="_cp_text_1_214"></a>set forth in the Technology Transfer Plan, has been completed, but for clarity, excluding [***] and (b) the [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_218"></a><a name="_cp_blt_2_217"></a><font style="Background-color:#auto;text-decoration:none;">1.144</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Technology Transfer Agreement</font><font style="font-weight:normal;color:#000000;">&#8221;</font><font style="color:#000000;"> </font><font style="font-weight:normal;color:#000000;">has the meaning set forth in Section 11.4(e).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_220"></a><a name="_cp_blt_2_219"></a><font style="Background-color:#auto;text-decoration:none;">1.145</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Technology Transfer Plan</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 11.4(e)</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_222"></a><a name="_cp_blt_2_221"></a><font style="Background-color:#auto;text-decoration:none;">1.146</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Term</font><font style="font-weight:normal;color:#000000;">&#8221; has the meaning set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 14.1</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_224"></a><a name="_cp_blt_2_223"></a><font style="Background-color:#auto;text-decoration:none;">1.147</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Third Party</font><font style="font-weight:normal;color:#000000;">&#8221; means any entity other than Ovid or Licensee or an Affiliate of Ovid or Licensee.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_226"></a><a name="_cp_blt_2_225"></a><a name="_Ref27301128"></a><font style="Background-color:#auto;text-decoration:none;">1.148</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Threshold Price Sale</font><font style="font-weight:normal;color:#000000;">&#8221; means, on a Product-by-Product and country-by-country basis, the first sale of such Product in such country (after Regulatory Approval for such Product has been obtained in such country) for which Licensee or its Affiliate or Sublicensee, as applicable, invoices a Third Party (a) [***], or (b) [***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_228"></a><a name="_cp_blt_2_227"></a><font style="Background-color:#auto;text-decoration:none;">1.149</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Total Supply Price</font><font style="font-weight:normal;color:#000000;">&#8221; means, for any Product, [***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_230"></a><a name="_cp_blt_2_229"></a><font style="Background-color:#auto;text-decoration:none;">1.150</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">U.S.</font><font style="font-weight:normal;color:#000000;">&#8221; means the United States of America, including its territories and possessions (including Puerto Rico).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_blt_1_232"></a><a name="_cp_blt_2_231"></a><a name="El2u91O"></a><a name="El2v91O"></a><a name="El2w91O"></a><a name="El2x91O"></a><a name="El2y91O"></a><a name="El2z91O"></a><a name="El2_91O"></a><a name="El20a1O"></a><a name="El2n91O"></a><a name="DocXTextRef74"></a><a name="Elo1a1O"></a><a name="El25a1O"></a><a name="El26a1O"></a><font style="Background-color:#auto;text-decoration:none;">1.151</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&#8220;</font><font style="color:#000000;">Valid Claim</font><font style="font-weight:normal;color:#000000;">&#8221; means (a) <a name="El2u91O"></a>a claim of an issued and unexpired patent that has not been revoked </font><font style="color:#000000;font-weight:normal;">or </font><font style="font-weight:normal;color:#000000;"><a name="El2v91O"></a>held unenforceable, unpatentable, </font><font style="color:#000000;font-weight:normal;">or </font><font style="font-weight:normal;color:#000000;"><a name="El2w91O"></a>invalid by a decision of a court </font><font style="color:#000000;font-weight:normal;">or </font><font style="font-weight:normal;color:#000000;"><a name="El2x91O"></a>other governmental agency of competent jurisdiction that is not appealable </font><font style="color:#000000;font-weight:normal;">or </font><font style="font-weight:normal;color:#000000;"><a name="El2y91O"></a>has not been appealed within the time allowed for appeal, and that has not been abandoned, disclaimed, denied, </font><font style="color:#000000;font-weight:normal;">or </font><font style="font-weight:normal;color:#000000;"><a name="El2z91O"></a>admitted to be invalid </font><font style="color:#000000;font-weight:normal;">or </font><font style="font-weight:normal;color:#000000;"><a name="El2_91O"></a>unenforceable through reissue, re-examination, </font><font style="color:#000000;font-weight:normal;">or </font><font style="font-weight:normal;color:#000000;"><a name="El20a1O"></a>disclaimer </font><font style="color:#000000;font-weight:normal;">or </font><font style="font-weight:normal;color:#000000;"><a name="El2n91O"></a>otherwise, </font><font style="color:#000000;font-weight:normal;"><a name="DocXTextRef74"></a><a name="Elo1a1O"></a>or (b) </font><font style="font-weight:normal;color:#000000;">a claim of a pending patent application </font><font style="color:#000000;font-weight:normal;">that </font><font style="font-weight:normal;color:#000000;"><a name="El25a1O"></a>has not been cancelled, withdrawn, </font><font style="color:#000000;font-weight:normal;">or </font><font style="font-weight:normal;color:#000000;"><a name="El26a1O"></a>abandoned </font><font style="color:#000000;font-weight:normal;">or </font><font style="font-weight:normal;color:#000000;">finally rejected by an administrative agency action from which no appeal can be taken. </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Ref381319537"></a><a name="_Ref151408973"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;text-transform:none;color:#000000;"></font><font style="font-variant: small-caps;text-transform:none;color:#000000;">Grant of Licenses</font></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref376898494"></a><a name="_Ref383109159"></a><a name="_Ref513461774"></a><font style="Background-color:#auto;text-decoration:none;">2.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licenses Granted to Licensee</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Subject to the terms and conditions of this Agreement, Ovid hereby grants to Licensee, during the Term:</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref37324586"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">an exclusive (even as to Ovid, except as expressly set forth herein), royalty-bearing license, with the right to grant sublicenses (through multiple tiers) solely as provided in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 2.2</font><font style="font-weight:normal;color:#000000;">, under the Ovid Technology to use and have used, sell, offer for sale, import, and otherwise Commercialize and have Commercialized (but not to make or have made, unless otherwise provided herein) the Products in the Field in the Licensee Territory; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref37324588"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">a non-exclusive license, with the right to grant sublicenses (through multiple tiers) solely as provided in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 2.2</font><font style="font-weight:normal;color:#000000;">, under the Ovid Technology to Develop (but not to make or have made unless otherwise provided herein) the Products on a worldwide basis in accordance with the Development Plan, and to use the Products for that purpose; and </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.15%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">a non-exclusive, royalty-bearing license, with the right to grant sublicenses (through multiple tiers) solely as provided in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 2.2</font><font style="font-weight:normal;color:#000000;">, under the Ovid Technology to make or have made the Products solely for use in the Field in the Licensee Territory in accordance with the licenses granted in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Sections 2.1(a)</font><font style="font-weight:normal;color:#000000;"> and </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">2.1(b)</font><font style="font-weight:normal;color:#000000;">, provided that, for clarity, Licensee&#8217;s rights under any Patents and Know-How Controlled by Lundbeck that are included within the Ovid Technology shall be subject to the completion of the Technology Transfer and the terms of the Lundbeck License Agreement; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.15%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">solely as and to the extent provided in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 14.5</font><font style="font-weight:normal;color:#000000;">, an exclusive (even as to Ovid, except as expressly set forth herein), royalty-bearing license, with the right to grant sublicenses (through multiple tiers) solely as provided in Section 2.2, under the Ovid Technology to Develop, have developed, use and have used, sell, offer for sale, import, and otherwise Commercialize and have Commercialized the Products in the Field in the Licensee Territory.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Sublicenses</font><font style="font-weight:normal;color:#000000;">.</font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">Licensee shall have the right to grant sublicenses under the licenses granted in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 2.1</font><font style="font-weight:normal;color:#000000;">: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref24400289"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">to an Affiliate of Licensee without Ovid&#8217;s express prior written consent but with written notice to Ovid, provided that such sublicense will terminate if such sublicensee no longer qualifies as an Affiliate of Licensee</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">to a Third Party other than as set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 2.2(a)</font><font style="font-weight:normal;color:#000000;"> with Ovid&#8217;s express prior written consent (not to be unreasonably withheld, conditioned or delayed).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:19.23%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All sublicenses granted under the licenses granted in <font style="text-decoration:underline;">Section 2.1</font> shall be in writing and shall be subject to, and consistent with, the terms and conditions of this Agreement and shall provide that any such Sublicensee (including any distributor) shall not further sublicense except with the written consent of Licensee and Ovid.&nbsp;&nbsp;Licensee shall ensure that each agreement with a Sublicensee grants Ovid all rights with respect to Data, Inventions, and Regulatory Filings made or generated by such Sublicensee as if such Data, Inventions, and Regulatory Filings were made or generated by Licensee. Licensee shall be responsible for the compliance of its Affiliates, Sublicensees (including any distributors), and subcontractors with the terms and conditions of this Agreement.&nbsp;&nbsp;Licensee shall provide written notice to Ovid of each sublicense granted to a Third Party hereunder, specifying the name of the Sublicensee, the territory, and the duration of the sublicense.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref381319272"></a><a name="_Ref381319310"></a><a name="_Ref383971778"></a><a name="_Ref376943875"></a><a name="_Ref381319293"></a><font style="text-decoration:none;Background-color:#auto;">2.3</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Reserved Rights</font><font style="font-weight:normal;color:#000000;">.</font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">Ovid hereby expressly reserves:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref33036073"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">the right under the Ovid Technology to exercise its rights and perform its obligations under this Agreement, whether directly or through one or more licensees or subcontractors; and </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">all rights to practice, and to grant licenses under, the Ovid Technology outside of the scope of the licenses granted in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 2.1</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref24195995"></a><font style="Background-color:#auto;text-decoration:none;">2.4</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licenses Granted to Ovid</font><font style="font-weight:normal;color:#000000;">.</font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">Subject to the terms and conditions of this Agreement, including </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 2.8</font><font style="font-weight:normal;color:#000000;">, Licensee hereby grants to Ovid:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">a non-exclusive, royalty-free, fully paid-up license, with the right to sublicense (through multiple tiers), under the Licensee Technology to use, sell, offer for sale, import, and otherwise Commercialize the Products in the Ovid Territory; and </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">a non-exclusive, worldwide, royalty-free, fully paid-up license, with the right to sublicense (through multiple tiers), under the Licensee Technology to (i) Develop the Compound and Products on a worldwide basis under the Development Plan, and (ii) to make and have made the Compound and Products anywhere in the world. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.5</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No Implied Licenses; Negative Covenant</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Except as set forth in this Agreement, neither Party shall acquire any license or other intellectual property interest, by implication or otherwise, under or to any Patents, Know-How, or other intellectual property owned or controlled by the other Party.&nbsp;&nbsp;Neither Party shall, nor shall it permit any of its Affiliates or (sub)licensees to, practice any Patents or Know-How licensed to it by the other Party outside the scope of the licenses granted to it under this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref209926524"></a><font style="Background-color:#auto;text-decoration:none;">2.6</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Disclosure of Know-How</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;For as long as the Parties are conducting Development activities under the Development Plan, upon Licensee&#8217;s written request no more frequently than [***], Ovid shall disclose and make available to Licensee, in electronic form where possible, all Ovid Know-How that comes into existence after the Effective Date and that was not previously provided to Licensee, promptly after the earlier of the development, making, conception, or reduction to practice of such Ovid Know-How.&nbsp;&nbsp;For as long as the Parties are conducting Development activities under the Development Plan, upon Ovid&#8217;s written request no more frequently than [***]<a name="_Ref209926524"></a>, Licensee shall, and shall cause its Affiliates to, disclose and make available to Ovid, in electronic form where possible, any Licensee Know-How not previously provided to Ovid, promptly after the earlier of the development, making, conception, or reduction to practice of such Licensee Know-How.&nbsp;&nbsp;The CGB shall establish a mechanism for the reciprocal disclosure of such Know-How. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.7</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Third Party Licenses</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notice</font><font style="font-weight:normal;color:#000000;">. Licensee shall promptly notify Ovid if it becomes aware of any Third Party Know-How or Patent that is necessary or reasonably useful to Develop, make, have made, use, sell, offer for sale, or import the Compound or Product in the Field in the Licensee Territory, and [***].</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref516216876"></a><a name="_Hlk38187084"></a><font style="text-decoration:none;Background-color:#auto;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Sublicense under Third Party License</font><font style="font-weight:normal;color:#000000;"><a name="_Hlk38187084"></a>.&nbsp;&nbsp;If Ovid enters into any agreement with a Third Party after the Effective Date that includes a license from such Third Party to Ovid under any Know-How or Patents that are necessary to Develop, use, sell, offer for sale, or import the Products in the Field in the Licensee Territory, and Ovid has the right to grant a sublicense under such Know-How or Patents to Licensee, then Ovid shall notify Licensee and identify the relevant Know-How or Patents and provide Licensee with the substantive terms of the applicable Third Party license agreement to Licensee, in each case to the extent applicable to the rights that would be sublicensed to Licensee.&nbsp;&nbsp;Such Know-How and Patents, to the extent falling within the definition of Ovid Technology, will be sublicensed to Licensee only if Licensee provides Ovid with written notice in which (i) Licensee consents to adding such Patents and Know-How to the definition of Ovid Technology and (ii) Licensee acknowledges in writing that its sublicense under such license agreement is </font><font style="font-weight:normal;color:#000000;">subject to the terms and conditions of such license agreement</font><font style="font-weight:normal;color:#000000;">.</font><font style="font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee Restriction</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Except with the prior written consent of Ovid, Licensee shall not obtain a license to any Third Party Patent or Know-How that is necessary to Develop, make, have made, use, sell, offer for sale, or import the Products in the Ovid Territory.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref24196023"></a><a name="_Hlk31355749"></a><font style="Background-color:#auto;text-decoration:none;">2.8</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Exclusivity</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref440874496"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Exclusivity</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Subject to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 2.8(c)</font><font style="font-weight:normal;color:#000000;">, for the period starting from the Effective Date and for [***] in the Licensee Territory, neither Party shall, directly or indirectly (including through an Affiliate or a Third Party), develop or commercialize any Competing Product that is directed to the treatment of the Initial Indication or Second Indication in the Licensee Territory. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Competing Program Exclusivity</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;If a Third Party becomes an assignee of this Agreement from a Party, or becomes an Affiliate of a Party after the Effective Date through merger, acquisition, consolidation, or other similar transaction, and such Third Party, as of the closing date of such transaction, is engaged in the development or commercialization of a Competing Product in the Licensee Territory (a &#8220;</font><font style="color:#000000;">Competing Program</font><font style="font-weight:normal;color:#000000;">&#8221;), then such Competing Program shall not be a breach of </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 2.8(a)</font><font style="font-weight:normal;color:#000000;">, so long as (i) such Third Party, or such Party or its Affiliates, [***], and (ii) [***] such Competing Product.&nbsp;&nbsp;[***] of such Competing Program.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref24295440"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Territory Exclusivity</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;During the Term, Licensee shall not, directly or indirectly (including through an Affiliate or a Third Party), Commercialize the Product in the Ovid Territory. Ovid shall not, directly or indirectly (including through an Affiliate or a Third Party), Commercialize the Product in the Licensee Territory, except as provided in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 2.3(a)</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.15%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref37326001"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Effect of Triggering Acquisition</font><font style="font-weight:normal;color:#000000;">. In the event of an acquisition of Ovid by a Competing Acquirer that closes prior to [***] (a &#8220;</font><font style="color:#000000;">Triggering Acquisition</font><font style="font-weight:normal;color:#000000;">&#8221;), then Ovid shall provide notice to Licensee of such Triggering Acquisition within [***] after the date upon which the Triggering Acquisition closes or otherwise becomes effective. On or before the date that is [***] after the date on which Licensee receives notice of a Triggering Acquisition, Licensee shall have the right to elect to Take the Lead on any or all then current Joint Development Activities and future Licensee activities in the Licensee Territory, [***] remaining in full force and effect. For sake of clarity, [***]. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">2.9</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee&#8217;s access to Ovid Data, Know-How and Patents</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.15%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk38030901"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;"><a name="_Hlk38030901"></a>Ovid hereby agrees to provide to Licensee, within [***] following the Effective Date, a list of (a) [***] the Ovid Know-How [***] and (b) [[***] the Compound and/or Product necessary for Licensee&#8217;s Development, use, manufacture, and Commercialization of the Product in the Field in the Licensee Territory, [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.15%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Promptly following the Effective Date, Ovid shall transfer to Licensee information in its possession and control that relate to [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.15%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">From time to time during the Term, and at no additional cost to Licensee (subject to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.5</font><font style="font-weight:normal;color:#000000;">), Ovid shall provide to Licensee [***] the Ovid Know-How solely relating to the Compound and/or the Product, reasonably requested by Licensee and necessary for Licensee&#8217;s Development, use, manufacture, and Commercialization of the Product.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.15%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref41483993"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Ovid hereby agrees that, [***] following the Effective Date, Ovid will provide to Licensee the Ovid Know-How [***] for Licensee to Develop, manufacture, use, and Commercialize the Compound and the Product in  the Field in the Licensee Territory in accordance with the terms of this Agreement. Licensee shall reimburse Ovid all out of pocket costs and reasonable, internal cost related to such technology transfer. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.10</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee&#8217;s Access to Ovid Personnel</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The Parties acknowledge the significant contribution and experience of Ovid and Ovid employees to the Development, manufacture, use, and Commercialization of the Compound and Product prior the Effective Date and that these contributions and experience may be valuable to Licensee. Accordingly, Licensee is entitled to meet with employees of Ovid who hold significant experience or expertise in the Development activities, and manufacture, use, and Commercialization of the Compound and Product. Licensee shall provide reasonable notice to Ovid requesting such a meeting and Ovid&#8217;s approval of date and agenda of meeting shall not be unreasonably withheld. Each Party shall bear its own cost in relation to such meetings.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Ref515879735"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;text-transform:none;color:#000000;"></font><font style="font-variant: small-caps;text-transform:none;color:#000000;">Governance</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref102383994"></a><a name="_Ref24025781"></a><a name="_Ref102384387"></a><font style="Background-color:#auto;text-decoration:none;">3.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Collaboration Governance Board</font><font style="font-weight:normal;color:#000000;"><a name="_Ref102384387"></a>.&nbsp;&nbsp;As of the Effective Date, the Parties have established a board to govern their collaboration under this Agreement (the &#8220;</font><font style="color:#000000;">Collaboration Governance Board</font><font style="font-weight:normal;color:#000000;">&#8221; or the &#8220;</font><font style="color:#000000;">CGB</font><font style="font-weight:normal;color:#000000;">&#8221;), composed of an equal number of up to [***] employees of each Party, to oversee and guide the strategic direction of the collaboration of the Parties under this Agreement.&nbsp;&nbsp;The CGB shall act as a joint consultative body and, to the extent expressly provided herein, a joint decision-making body.&nbsp;&nbsp;The CGB shall in particular: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">review and discuss the strategy for the Development of the Product worldwide, coordinate and oversee the overall implementation of the Development Plan; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">provide a forum for discussion of the Development and Commercialization of the Compound and Products in the Licensee Territory; </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">monitor performance of Development activities in and for the Licensee Territory, including performance against agreed budgets, and discuss and approve any budget overruns;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">oversee the activities of the JPT, and serve as a forum for resolution of disputes arising at the JPT; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">review and discuss any proposed amendments to the Development Plan, including corresponding budgets, and approve any proposed amendments to Joint Development Activities under the Development Plan;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">review, discuss, and approve Clinical Trial protocols for jointly-conducted Clinical Trials, and monitor the progress of all Clinical Trials in the Licensee Territory;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">review Clinical Trial Data from jointly-conducted Clinical Trials to determine whether progress to the next phase Clinical Trial is merited;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">review, discuss, and approve Proposals, including amendments to the Development Plan with respect to activities directed to Additional Indications; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">monitor and coordinate regulatory strategy and activities for the Licensee Territory, including activities directed to obtaining Regulatory Approval in Additional Indications;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(j)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">coordinating reporting of pharmacovigilance and safety matters for the Product worldwide (monitoring and coordinating of pharmacovigilance and safety matters will conducted in accordance with the pharmacovigilance agreement); </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(k)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">oversee and coordinate Medical Affairs Activities for the Product in all Indications in the Licensee Territory; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(l)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">review and discuss the Commercialization Plan for the Licensee Territory, including any amendments proposed thereto, and oversee the Commercialization of Products in the Licensee Territory in accordance with the global commercialization strategy for Products;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(m)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">provide a forum for discussion regarding launch sequencing, pricing and reimbursement strategy for Products in the Licensee Territory and discuss potential international pricing reference by relevant Regulatory Authorities;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(n)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">oversee the manufacturing and supply strategy and monitor supply of Products for the Licensee Territory;&nbsp;&nbsp;&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(o)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">oversee and facilitate the Parties&#8217; communications and activities with respect to publications under </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 13.4</font><font style="font-weight:normal;color:#000000;">;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(p)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">establish joint subcommittees as it deems necessary or advisable to further the purpose of this Agreement, including as set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 3.7</font><font style="font-weight:normal;color:#000000;">; and </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(q)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">perform such other functions as appropriate to further the purposes of this Agreement, as expressly set forth in this Agreement or allocated to it by the Parties&#8217; written agreement, including providing financial oversight of the activities conducted pursuant to this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref24290236"></a><font style="Background-color:#auto;text-decoration:none;">3.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Joint Project Team</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;No later than [***] following the Effective Date, the Parties will establish a cross-functional joint project team (the &#8220;</font><font style="color:#000000;">JPT</font><font style="font-weight:normal;color:#000000;">&#8221;), composed of an equal number of up to [***] employees of each Party, to (a) design and implement the Development Plan (subject to CGB review and approval), and (b) oversee the commercial strategy and Commercialization of the Products in the Licensee Territory.&nbsp;&nbsp;The JPT shall in particular:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">oversee the conduct of activities under the Development Plan in the Licensee Territory and report to the CGB on such activities;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">provide a forum for, and facilitate communications between the Parties with respect to the Development of Products in the Licensee Territory, including sharing of Data in accordance with </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.7</font><font style="font-weight:normal;color:#000000;">;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">prepare and submit to the CGB for approval protocols for jointly-conducted Clinical Trials;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">prepare amendments to the Development Plan as needed (including corresponding changes to the Development Budget) and submit such amendments to the CGB for approval; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">review and discuss Proposals and make recommendations to the CGB with respect thereto; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">review and discuss the CMC components of the Regulatory Filings in the Licensee Territory, and oversee and coordinate the manufacture and supply of Drug Product to Licensee for use in Clinical Trials for which Licensee is the Sponsor in the Licensee Territory;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">prepare and submit to the CGB for approval a plan for manufacture and supply of Drug Product for commercialization in the Licensee Territory; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">review the Commercialization Plan prepared by Licensee for alignment with the global commercialization strategy for Products, and provide comments thereto;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">monitor the conduct of Commercialization of Products in the Licensee Territory; and </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(j)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">perform such other functions as may be appropriate to further the purposes of this Agreement with respect to the Development of Products.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.3</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Committee Membership and Meetings</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Committee Members</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Each Committee representative shall have appropriate knowledge and expertise and sufficient seniority within the applicable Party to make </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">decisions arising within the scope of such Committee&#8217;s responsibilities.&nbsp;&nbsp;Each Party may replace its representatives on a Committee on written notice to the other Party.&nbsp;&nbsp;The CGB chairperson shall be one of the representatives appointed by Ovid.&nbsp;&nbsp;The chairperson of the JPT shall alternate between one of the representatives appointed by Ovid and one of the representatives appointed by Licensee.&nbsp;&nbsp;The chairperson shall prepare and circulate agendas to Committee members at least </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;"> before each Committee meeting and shall direct the preparation of reasonably detailed notes for each such Committee meeting, which shall be approved by the chairperson and circulated to Committee members within </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;"> after such meeting.&nbsp;&nbsp;If not determined as of the Effective Date, the Parties shall determine their respective initial members of each Committee promptly following the Effective Date. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Meetings</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Each Committee</font><font style="color:#000000;font-weight:normal;"> shall hold meetings at such times as it elects to do so, but in no event shall meetings of the JPT be held less frequently than [***], and meetings of the CGB once every [***].&nbsp;&nbsp;The first CGB meeting and first JPT meeting shall be held within [***] after the Effective Date.&nbsp;&nbsp;Committee meetings may be held in person or by audio or video teleconference.&nbsp;&nbsp;In-person Committee meetings shall be held at locations alternately selected by the Parties.&nbsp;&nbsp;Each Party shall be responsible for all of its own expenses of participating in any Committee meeting.&nbsp;&nbsp;No action taken at any Committee meeting shall be effective unless at least one (1) representative of each Party is participating.&nbsp;&nbsp;In addition, upon written notice to the other Party, either Party may request that a special </font><font style="font-style:italic;color:#000000;font-weight:normal;">ad hoc</font><font style="color:#000000;font-weight:normal;"> meeting of a Committee be convened for the purpose of resolving any disputes in connection with, or for the purpose of reviewing or making a decision pertaining to any material subject-matter within the scope of such Committee, the review or resolution of which cannot be reasonably postponed until the following scheduled Committee meeting.&nbsp;&nbsp;Such </font><font style="font-style:italic;color:#000000;font-weight:normal;">ad hoc</font><font style="color:#000000;font-weight:normal;"> meeting shall be convened at such time as may be mutually agreed by the Parties, but no later than [***] following the notification date of request that such meeting be held.&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Non-Member Attendance</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Each Party may from time to time invite a reasonable number of participants, in addition to its representatives, to attend Committee meetings in a non&#8209;voting capacity; provided that if either Party intends to have any Third Party (including any consultant) attend such a meeting, such Party shall provide reasonable prior written notice to the other Party and obtain the other Party&#8217;s approval for such Third Party to attend such meeting, which approval shall not be unreasonably withheld or delayed.&nbsp;&nbsp;Such Party shall ensure that such Third Party is bound by written confidentiality and non-use obligations consistent with the terms of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref24280706"></a><font style="Background-color:#auto;text-decoration:none;">3.4</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Decision-Making</font><font style="font-weight:normal;color:#000000;">.</font><font style="color:#000000;"> </font><font style="font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">All decisions of a Committee shall be made by unanimous vote, with each Party&#8217;s representatives collectively having one (1) vote.&nbsp;&nbsp;If after reasonable discussion and good faith consideration of each Party&#8217;s view on a particular matter, the representatives of the Parties cannot reach an agreement as to such matter within [***] after such matter was first considered, then if such disagreement arose within the JPT, it shall be referred to the CGB for resolution.&nbsp;&nbsp;If the CGB cannot resolve such matter within a further [***], or if the disagreement first arose within the CGB, then prior to any formal dispute resolution process such issue shall be referred to the Executive Officers for resolution.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">If the Executive Officers cannot resolve such matter within </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;"> after such matter has been referred to them, then: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Ovid shall have the final decision making authority, which shall be exercised in its reasonable discretion, with respect to (A) Ovid&#8217;s Independent Development Activities, (B) the Ovid Ongoing Trials, (C) all manufacturing matters outside the Licensee Territory, and (D) Joint Development Activities necessary for obtaining Regulatory Approvals for Products in any Indication in the Licensee Territory for which Ovid is the sponsor (including any necessary updates to the Development Plan and Development Budget pursuant to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.2</font><font style="font-weight:normal;color:#000000;">, but subject in all cases to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Sections 3.4(b)(i)(1)</font><font style="font-weight:normal;color:#000000;"> and </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">3.4(b)(i)(2)</font><font style="font-weight:normal;color:#000000;">), except for:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:16.67%;text-indent:14.1%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref515877736"></a><font style="Background-color:#auto;text-decoration:none;">(1)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;"><a name="_Ref515877736"></a> the addition of new Clinical Trials to the Development Plan as Joint Development Activities (the cost of which would be shared by the Parties); and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:17.31%;text-indent:13.46%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref37327401"></a><font style="Background-color:#auto;text-decoration:none;">(2)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">any material modification to a previously agreed upon Clinical Trial that is set forth in the Development Plan as Joint Development Activities (unless such modification is required by a Regulatory Authority or any local or regional IRB/ethics committee, or is reasonably necessary to protect patient safety); for the purpose of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 3.4(b)(i)(2)</font><font style="font-weight:normal;color:#000000;">, &#8220;material modification&#8221; means [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref515877431"></a><a name="_Ref37688348"></a><a name="_Ref41406712"></a><a name="OLE_LINK1"></a><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Licensee shall have the final decision making authority with respect to (A) Joint Development Activities necessary for obtaining Regulatory Approvals for Products in any Indication in the Licensee Territory for which Licensee is the sponsor (including any necessary updates to the Development Plan and Development Budget pursuant to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.2</font><font style="font-weight:normal;color:#000000;">, but subject in all cases to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Sections 3.4(b)(i)(1)</font><font style="font-weight:normal;color:#000000;"> and </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">3.4(b)(i)(2)</font><font style="font-weight:normal;color:#000000;">), (B) the determination of whether the Additional Pivotal Trial is necessary to obtain Regulatory Approval in the Licensee Territory (although [***] for the Additional Pivotal Trial) (C) Commercialization of the Product in the Licensee Territory, (D) Licensee Territory Development Activities and (E) Licensee&#8217;s Independent Development Activities in the Licensee Territory, and (F) Phase 4 Clinical Trials for the Licensee Territory (but subject in all cases to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Sections 3.4(b)(i)(1)</font><font style="font-weight:normal;color:#000000;"> and </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">3.4(b)(i)(2))</font><font style="font-weight:normal;color:#000000;">, in each case (A) through (F) provided that Licensee&#8217;s exercise of any such decision right does not adversely affect, the Development, manufacture, or Commercialization of the Product in the Ovid Territory, and complies with the terms and conditions of this Agreement.<a name="OLE_LINK1"></a>&nbsp;&nbsp;For clarity, [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Neither Party shall have the final decision making authority with respect to the matters in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Sections 3.4(b)(i)(1)</font><font style="font-weight:normal;color:#000000;"> and (</font><font style="text-decoration:underline;font-weight:normal;color:#000000;">2</font><font style="font-weight:normal;color:#000000;">), and the status quo shall persist with respect to such matter unless and until the Parties are able to agree. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref383108660"></a><font style="Background-color:#auto;text-decoration:none;">3.5</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Limitations on Authority</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Each Committee shall have only such powers as are expressly assigned to it in this Agreement, and such powers shall be subject to the terms and conditions of this Agreement.&nbsp;&nbsp;Without limiting the generality of the foregoing, no Committee will have the power to amend this Agreement, and no Committee decision may be in contravention of any terms and conditions of this Agreement.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref37688266"></a><a name="_Ref377058143"></a><a name="_Ref383108675"></a><font style="Background-color:#auto;text-decoration:none;">3.6</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Discontinuation of the Committees</font><font style="font-weight:normal;color:#000000;">. The activities to be performed by each Committee shall solely relate to governance under this Agreement and are not intended to be or involve the delivery of services.&nbsp;&nbsp;Each Committee shall continue to exist until the first to occur of (a) the Parties mutually agree to disband such Committee or (b) Ovid provides written notice to Licensee of its intention to disband and no longer participate in such Committee. Once the Parties mutually agree or Ovid has provided written notice to disband a Committee, such Committee shall have no further obligations under this Agreement and, thereafter, each Party shall designate a contact person for the exchange of information under this Agreement or such exchange of information shall be made through Alliance Managers, and decisions of such Committee shall be decisions as between the Parties, subject to the other terms and conditions of this Agreement.&nbsp;&nbsp;[***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref383110642"></a><a name="_Ref24375697"></a><font style="Background-color:#auto;text-decoration:none;">3.7</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Alliance Managers</font><font style="font-weight:normal;color:#000000;">. Promptly after the Effective Date, each Party shall appoint an individual who shall be an employee of such Party having appropriate qualification and experience to act as the alliance manager for such Party (the &#8220;</font><font style="color:#000000;">Alliance Manager</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;Each Alliance Manager shall be responsible for coordinating and managing processes and interfacing between the Parties on a day-to-day basis throughout the Term.&nbsp;&nbsp;The Alliance Manager will ensure communication to the CGB of all relevant matters raised at the JPT and any other subcommittee.&nbsp;&nbsp;Each Alliance Manager shall be permitted to attend meetings of the CGB and JPT, in each case as appropriate and as non-voting participants.&nbsp;&nbsp;The Alliance Managers shall be the primary contact for the Parties regarding the activities contemplated by this Agreement and shall facilitate all such activities hereunder.&nbsp;&nbsp;Each Party may replace its Alliance Manager with an alternative representative at any time with prior written notice to the other Party.&nbsp;&nbsp;Any Alliance Manager may designate a substitute to temporarily perform the functions of that Alliance Manager.&nbsp;&nbsp;Each Party shall bear its own costs of its Alliance Manager, which costs shall be excluded from the Parties&#8217; respective Development and manufacturing costs (including Cost of Goods) under this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.8</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Supply Contacts</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Each Party shall designate one (1) qualified and experienced supply chain professional to serve as that Party&#8217;s primary supply contact regarding the supply of Drug Product under this Agreement (&#8220;</font><font style="color:#000000;">Supply Contacts</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;Each Party may replace its Supply Contact with an alternative representative at any time with prior written notice to the other Party.&nbsp;&nbsp;The Supply Contacts shall be responsible for facilitating information exchange and discussion between the Parties regarding the supply of Drug Product under this Agreement.&nbsp;&nbsp;The Supply Contacts shall have decision-making authority with respect to the supply of Drug Product under this Agreement within the guidance of the JPT and subject to the review and approval of the CGB.&nbsp;&nbsp;Each Party shall bear its own costs of its Supply Contact, which costs shall be excluded from the Parties&#8217; respective Development and manufacturing costs (including Cost of Goods) under this Agreement.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Ref384018512"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;text-transform:none;color:#000000;"></font><font style="font-variant: small-caps;text-transform:none;color:#000000;">Development</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref376933859"></a><a name="_Ref377110919"></a><a name="_Ref151370373"></a><font style="Background-color:#auto;text-decoration:none;">4.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Overview</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Subject to the terms and conditions of this Agreement, the Parties will collaborate with respect to the Development of the Compound and Products and share the Data resulting from such collaboration as provided in this Article 4 to facilitate the Development of the Compound and Products throughout the Licensee Territory and the Ovid Territory. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref32320541"></a><a name="_Ref37330347"></a><a name="_Ref33117300"></a><a name="_Ref519512794"></a><font style="text-decoration:none;Background-color:#auto;">4.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Amendments to Development Plan</font><font style="font-weight:normal;color:#000000;">. Any amendment to the Development Plan for the Compound and Products </font><font style="font-weight:normal;color:#000000;">under this Agreement, including the Ovid Ongoing Trials, Licensee Territory Development Activities for registrational purposes, all Joint Development Activities, and all Independent Development Activities shall be conducted pursuant to a comprehensive written updated (from time to time) Development Plan (the &#8220;</font><font style="color:#000000;">Amended</font><font style="font-weight:normal;color:#000000;"> </font><font style="color:#000000;">Development Plan</font><font style="font-weight:normal;color:#000000;">&#8221;), which shall be incorporated by reference into this Agreement.&nbsp;&nbsp;The Amended Development Plan will include Clinical Trials for the Initial Indications that the Parties have agreed to conduct jointly (unless modification is required by a Regulatory Authority or any local or regional IRB/ethics committee, or is reasonably necessary to protect patient safety), the Clinical Trials for the Second Indication that Ovid may conduct under its sole responsibility and cost if Licensee exercises the Second Indication Opt-Out and not the Second Indication Opt-In, as well as Clinical Trials for the Additional Indications that the Parties (through the CGB) mutually agree to conduct and include in accordance with </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">4.3</font><font style="font-weight:normal;color:#000000;">. The Amended Development Plan will also include</font><font style="font-weight:normal;color:#000000;">:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.12%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:12.12%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:normal;">any other Development activities approved by the CGB in accordance with </font><font style="text-decoration:underline;font-weight:normal;">Article 3</font><font style="font-weight:normal;">; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.12%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:12.12%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(2</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:normal;">the PIP for the Initial Indication; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:12.12%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:12.12%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(3</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:normal;">the Additional Pivotal Trial, if applicable. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Amended Development Plan shall also set forth the amendments to the detailed budget of the anticipated costs for all Development activities (the &#8220;<font style="font-weight:bold;">Amended</font> <font style="font-weight:bold;">Development Budget</font>&#8221;) on a study-by-study or Clinical Trial-by-Clinical Trial basis.&nbsp;&nbsp;As of the Effective Date, the Parties have agreed upon an initial Development Plan and Development Budget, attached to this Agreement as <font style="font-weight:bold;text-decoration:underline;">Exhibit C</font>.&nbsp;&nbsp;If the terms of the Development Plan contradict, or create inconsistencies or ambiguities with, the terms of this Agreement, then the terms of this Agreement shall govern. In addition, the following shall apply to the Development of the Compound and Products under the Development Plan:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref24188366"></a><a name="_Ref519505852"></a><a name="_Ref519504008"></a><a name="_Ref519506013"></a><a name="_Ref515966822"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Neptune Trial, Rocket Trial and Elara Trial</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Ovid shall be responsible for, and shall use Commercially Reasonable Efforts to conduct, at its own expense, (i) the Neptune Trial, (ii) the Rocket Trial, and (iii) the Elara Trial ((i)-(iii) collectively, the &#8220;</font><font style="color:#000000;">Ovid Ongoing Trials</font><font style="font-weight:normal;color:#000000;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref25055192"></a><a name="_Ref25600507"></a><a name="_Ref24104097"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">PIP</font><font style="font-weight:normal;color:#000000;">. Ovid shall be responsible for the full applying process to obtain EMA agreement for the Paediatric Investigational Plan in order to allow the Licensee to submit the MAA for the Product for the Initial Indication in the Licensee Territory. Ovid shall discuss and agree with the Licensee the PIP before moving forward with the application process.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee Territory Development Activities for Initial Indication</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Licensee shall be solely responsible for and shall use Angelini Commercially Reasonable Efforts to conduct, at its sole expense, all Development activities that are exclusively for the benefit of one or more countries within the Licensee Territory for the Initial Indication, including (A) any and all Development activities required or recommended by a </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">Regulatory Authority for the exclusive benefit of the Licensee Territory, including any Phase 4 Clinical Trials for the Initial Indication in the Licensee Territory, and (B) any and all Development activities required for any Pricing and Reimbursement Approval in the Licensee Territory. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref32405283"></a><a name="_Ref33040195"></a><a name="_Ref37332448"></a><a name="_Hlk31014938"></a><a name="_Hlk31303170"></a><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;"><a name="_Ref37332448"></a><a name="_Hlk31014938"></a> Licensee shall be solely responsible for the Additional Pivotal Trial, and for the Phase 4 Clinical Trials of the Product in the Licensee Territory, but Licensee shall bear [***] and Ovid shall bear [***]<a name="_Hlk31303170"></a> of the Development Costs for the Development Activities for the Additional Pivotal Trial, up to a total amount of [***], and for any Additional Pivotal Trial Development Costs in excess of [***] Licensee shall bear [***] and Ovid shall bear [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk38204452"></a><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The activities specified in the foregoing subsections (i) and (ii) shall be referred to collectively as the &#8220;</font><font style="color:#000000;">Licensee Territory Development Activities</font><font style="font-weight:normal;color:#000000;">&#8221;.&nbsp;&nbsp;Prior to commencing any Licensee Territory Development Activities, Licensee shall provide the CGB with a draft workplan therefor, and following review and approval of such Licensee Territory Development activities by the CGB, such Licensee Territory Development Activities shall be included in and conducted in accordance with the Development Plan, subject to the oversight of the CGB and JPT as set forth in Article 3.<a name="_Hlk38204452"></a>&nbsp;&nbsp;Notwithstanding anything to the contrary herein, Licensee shall consider in good faith and incorporate Ovid&#8217;s reasonable comments on any proposed Licensee Territory Development Activities. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk31016290"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Joint Development Activities for Initial Indication and Second Indication</font><font style="font-weight:normal;color:#000000;">. The Development Plan shall set forth the timeline and details ([***]) of all preclinical (if any) and clinical Development activities ([***]<a name="_Hlk31016290"></a>) to be conducted jointly by the Parties in order to generate Data sufficient to meet the common requirements of the FDA, EMA, and other Regulatory Authorities agreed upon by the Parties for MAA Approval of the Compound and Products for each of the Initial Indication and eventually and separately for the Second Indication, ([***]) (such activities, the &#8220;</font><font style="color:#000000;">Joint Development Activities</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;All Joint Development Activities shall be included in and conducted in accordance with the Development Plan, subject to the oversight of the CGB and JPT as set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Article 3</font><font style="font-weight:normal;color:#000000;">. The Development Plan shall also set forth the allocation of responsibility for all Joint Development Activities as between the Parties.&nbsp;&nbsp;All Development Costs Associated with Joint Development Activities shall be borne in accordance with </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.2(a)</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref37333683"></a><a name="_Ref24188514"></a><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Second Indication Opt-Out and Second Indication Opt-In.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk38189652"></a><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Second Indication Opt-Out</font><font style="font-weight:normal;color:#000000;">. If Licensee determines, at its sole and absolute discretion, within [***]<a name="_Hlk38189652"></a>, not to pursue further additional Development activities with respect to the Second Indication, Licensee shall have the right to exercise the Second Indication Opt-Out, exercisable by written notice to Ovid. The Second Indication Opt-Out shall be effective as of the date of such notice. If Licensee exercises the Second Indication Opt-Out, then the definition of Field shall automatically be deemed to not include the Second Indication, provided that if Ovid undertakes to submit an MAA for the Product for the Second Indication in the Licensee Territory it shall do so with a trademark other than the Trademark for the Initial Indication. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Second Indication Opt-In</font><font style="font-weight:normal;color:#000000;">. In any case, after Licensee has made the Second Indication Opt-Out, Licensee will have the right, at any time as below and for any reason, to exercise the Second Indication Opt-In, exercisable by written notice to Ovid [***]. The Second </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">Indication Opt-In shall be effective as of the date of such notice.&nbsp;&nbsp;If Licensee makes the Second Indication Opt-In, then Licensee shall reimburse to Ovid an amount equal to </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;"> of all Development Costs incurred by Ovid in the conduct of Development activities for the Second Indication during the period of Licensee&#8217;s Second Indication Opt-Out, and </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;"> of all Development Costs incurred for such Development activities following the Second Indication Opt-In. Then the definition of Field shall automatically be deemed to include the Second Indication</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Regulatory Filings</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The Development Plan shall include a coordinated Development and regulatory strategy, including the Parties&#8217; respective roles in the development of the registration dossier and Regulatory Filings for the Products, and the countries in which Clinical Trials of the Products will occur.&nbsp;&nbsp;All costs associated with regulatory activities in connection with Regulatory Filings and obtaining MAA Approval for Products in the Licensee Territory shall be borne solely by Licensee. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref24383548"></a><a name="_Hlk31016050"></a><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Updates</font><font style="font-weight:normal;color:#000000;">. During the Term (at least on a [***] basis), the JPT shall review the Development Plan and prepare updates and amendments, as appropriate, to the then-current Development Plan, including budgets, and submit such updates and amendments to the CGB for review and approval.&nbsp;&nbsp;If the CGB determines that any pre-clinical studies or Clinical Trials not included in the Developm<a name="_Hlk31016050"></a>ent Plan are required in order to obtain or maintain MAA Approval for a Product for the Initial Indication in one or more countries in the Licensee Territory, then the CGB shall review and approve an amendment to the Development Plan reflecting such additional studies, including associated budget.&nbsp;&nbsp;Such additional Development activities for the Initial Indication shall be either Licensee Territory Development Activities or Joint Development Activities and the costs of such additional studies shall be borne by the Parties as provided in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.5(a)</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref513476635"></a><a name="_Ref24188073"></a><font style="Background-color:#auto;text-decoration:none;">4.3</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Additional Indications</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref24281775"></a><a name="_Hlk39744608"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Proposal</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;If either Party (the &#8220;</font><font style="color:#000000;">Proposing Party</font><font style="font-weight:normal;color:#000000;">&#8221;) desires to pursue additional Development of a Product in order to seek Regulatory Approval of the Product in one or more Additional Indications for the benefit of (a) the Ovid Territory and Licensee Territory in the case of Ovid, or (b) the Licensee Territory in the case of Licensee, in each case beyond what is set forth in the then-current Development Plan, then such Party shall provide the other Party (the &#8220;</font><font style="color:#000000;">Reviewing Party</font><font style="font-weight:normal;color:#000000;">&#8221;) with a written detailed plan and budget for such additional work (the &#8220;</font><font style="color:#000000;">Proposal</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;Within [***] after the Reviewing Party&#8217;s receipt of the Proposal (or at such other time as the Parties may mutually agree), the JPT shall meet to review and discuss in good faith the Proposal and permit the Reviewing Party an opportunity to ask questions and request additional information from the Proposing Party related to the Proposal, including whether such Proposal is reasonably likely to have any adverse effect on the Development or Commercialization of the Product in the Reviewing Party&#8217;s territory.&nbsp;&nbsp;No work under any Proposal shall proceed unless and until (i) the CGB determines in its reasonable discretion that such Proposal is not likely to adversely affect the Development or Commercialization of the Product in the Reviewing Party&#8217;s territory, and (ii) in the case of Licensee as the Proposing Party, Ovid consents in writing to such activities being included as Joint Development Activities, or to Licensee performing such additional Development as Licensee Territory Development Activities (where such Development Activities solely and specifically relate to the Licensee Territory), or as Independent Development Activities, such consent not to be unreasonably withheld.&nbsp;&nbsp;For clarity, (i) Licensee&#8217;s final decision </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">right under </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 3.4(b)(ii)</font><font style="font-weight:normal;color:#000000;"> shall not apply to Licensee Territory Development Activities proposed in connection of initiation of Development for any Additional Indication, but once Development Activities have been commenced in such Additional Indication in and for the Licensee Territory, any further Licensee Territory Development Activities proposed by Licensee in respect of such Additional Indication shall be subject to the process set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">4.2(b)</font><font style="text-decoration:underline;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;"><a name="_Hlk39744608"></a>and (ii) </font><font style="font-weight:normal;color:#000000;">Ovid will not develop in the Licensee Territory any Product in additional indications other than Rare Diseases</font><font style="font-weight:normal;color:#000000;"> without Licensee&#8217;s prior written consent</font><font style="font-weight:normal;color:#000000;">. Following each such determination and, if applicable, consent, the CGB shall incorporate such additional Development activities and the corresponding budget into the Development Plan (the &#8220;</font><font style="color:#000000;">Additional Development Activities</font><font style="font-weight:normal;color:#000000;">&#8221;).</font><font style="color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref24391572"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Costs</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;If the Parties jointly agree to conduct Additional Development Activities, such Additional Development Activities shall be included in the Development Plan and conducted as Joint Development Activities, subject to the allocation of responsibility for leading such activities set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.3(c)</font><font style="font-weight:normal;color:#000000;">, and the costs of such Joint Development Activities shall be shared as further set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.2(a)</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Notwithstanding the foregoing, for Additional Development Activities that would otherwise be Joint Development Activities (if the Parties agreed to conduct such activities together), the Reviewing Party may elect, at its discretion, and by written notice delivered to the Proposing Party within [***] following the receipt of the Proposal, to opt out of funding its share of the Development Costs for such Additional Development Activities.&nbsp;&nbsp;Upon such an election, such Additional Development Activities shall be deemed the &#8220;</font><font style="color:#000000;">Independent Development Activities</font><font style="font-weight:normal;color:#000000;">&#8221; of the Proposing Party and the Proposing Party may pursue such work subject to the remainder of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.3</font><font style="font-weight:normal;color:#000000;">, and the Development Costs with respect thereto shall be Independent Development Costs subject to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.2(b)</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref24384760"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Conduct of Additional Development Activities</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;In general, except as the Parties may agree in an amendment to the Development Plan, including to allocate specific activities to Licensee in the Licensee Territory, (i) Ovid shall be the lead Party responsible for conducting Additional Development Activities that relate to both the Ovid Territory and the Licensee Territory, provided that such activities shall be subject to the oversight of the CGB to the extent such activities impact the Licensee Territory, and (ii) Licensee shall be the lead Party responsible for conducting Additional Development Activities that relate to the Licensee Territory and not the Ovid Territory.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref24188396"></a><a name="_Ref33117330"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Independent Development Activities</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The CGB shall amend the Development Plan to include any Additional Development Activities in the Rare Diseases indications that are Independent Development Activities, and thereafter the Proposing Party may conduct such Independent Development Activities, provided that: (i) the Proposing Party shall have the right to make the final decision in the event of any dispute regarding the conduct of the Independent Development Activities, except to the extent that, where the Proposing Party is Licensee, Ovid reasonably believes that Licensee&#8217;s exercise of such right would adversely impact Ovid&#8217;s Development and Commercialization of Products outside the Licensee Territory, (ii) the Proposing Party shall have the right to make the final decision in the event of any dispute regarding the conduct of the Independent Development Activities, except to the extent that, where the Proposing Party is Ovid, Licensee reasonably believes that Ovid&#8217;s exercise of such right would adversely impact Licensee&#8217;s Development and Commercialization of Products in the Licensee Territory, (iii) to the extent applicable to the Licensee Territory, Independent Development Activities shall be conducted in accordance with the amended Development Plan, (iv) the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">Proposing Party shall provide updates to the CGB with respect to such Independent Development Activities impacting the Licensee Territory at each regularly scheduled CGB meeting, and (v) neither Party shall conduct any Independent Development Activities in a manner that would</font><font style="font-family:Calibri;font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">have any adverse effect on the Development or Commercialization of the Product in either Party&#8217;s territory.</font><font style="color:#000000;"> </font><font style="font-weight:normal;color:#000000;">The Investigator initiated trials (IIT) proposed to each Party for the Licensee Territory shall be discussed and agreed between the Parties before providing feedback to the proposing Investigator. The Party receiving the proposal will be responsible for the costs to support the IIT unless a different specific agreement is entered among the Parties.</font><font style="color:#000000;"> </font><font style="font-weight:normal;color:#000000;">For sake of clarity, Independent Development Activities shall not include indications other than Rare Disease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Ovid&#8217;s Right to Develop</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Notwithstanding anything to the contrary herein, Ovid shall have the right to conduct any Development activities with respect to the Compound or Product in or relating to the Ovid Territory outside the scope of the Development Plan.&nbsp;&nbsp;Such Development activities shall be at Ovid&#8217;s expense and Licensee shall have the right of reference to the Safety Data generated in such Development activities as necessary for regulatory purposes without any reimbursement obligation to Ovid.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.4</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Annual Update to Development Budge</font><font style="font-weight:normal;color:#000000;">t.&nbsp;&nbsp;The CGB shall review, discuss, and, with respect to Joint Development Activities, agree upon the subsequent year&#8217;s Development Budget on an annual basis no later than [***] of each year.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref513467133"></a><font style="Background-color:#auto;text-decoration:none;">4.5</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Development Costs</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref513476641"></a><a name="_Ref513479830"></a><a name="_Ref513479399"></a><a name="_Ref24189136"></a><a name="_Ref440817169"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee Territory Development Costs</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Licensee shall be solely responsible for all Development Costs incurred in connection with Licensee Territory Development Activities, except as provided in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.2(c)(ii)</font><font style="font-weight:normal;color:#000000;"> with respect to the Additional Pivotal Study.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref515887911"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Joint Development Costs</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The Development Costs associated with all Joint Development Activities that are shared by the Parties in accordance with </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.2(a)</font><font style="font-weight:normal;color:#000000;"><a name="_Ref515887911"></a> shall include Allowable Increases. &#8220;</font><font style="color:#000000;">Allowable Increases</font><font style="font-weight:normal;color:#000000;">&#8221; means increased Development Costs resulting from [***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref515885736"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Independent Development Costs</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The Party conducting Independent Development Activities pursuant to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.3</font><font style="font-weight:normal;color:#000000;"> shall be solely responsible for all Independent Development Costs as provided in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.2(b)</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.6</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Development Responsibilities</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Ovid shall be responsible for, and shall use Ovid Commercially Reasonable Efforts in connection with, the conduct of the Ovid Ongoing Trials.&nbsp;&nbsp;Licensee shall be responsible for the conduct of the Licensee Territory Development Activities, other than Additional Pivotal Study which shall be shared by the Parties as set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.2(c)(ii)</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The Parties shall each be responsible for the conduct of the Joint Development Activities, and the allocation of such agreed responsibility therefore (including which Party shall be the Sponsor for each applicable Clinical Trial), shall be set forth in the Development Plan.&nbsp;&nbsp;Each Party shall have the operational responsibility and be the Sponsor for its own Independent Development Activities.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref516000875"></a><a name="_Ref383109715"></a><a name="_Ref207970881"></a><a name="_Ref377130392"></a><a name="_Ref151310570"></a><a name="_Ref207954531"></a><font style="text-decoration:none;Background-color:#auto;">4.7</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Data Exchange and Use</font><font style="font-weight:normal;color:#000000;">.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref24105139"></a><a name="_Ref515882880"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">General</font><font style="font-weight:normal;color:#000000;">. With respect to all Joint Development Activities, Licensee Territory Development Activities, and Independent Development Activities (but subject to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.7(c)</font><font style="font-weight:normal;color:#000000;">), each Party shall promptly provide the other Party with [***].&nbsp;&nbsp;The Parties shall cooperate [***] to facilitate the sharing of reports, Data, and other information on a routine basis.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Joint Development Activities Data</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Each Party shall have the right to use and reference, without additional consideration, any and all Data generated by or on behalf of the other Party (including by any Sublicensee) in the performance of Joint Development Activities for obtaining and maintaining Regulatory Approval for the Products and Commercializing the Products in its territory in accordance with the terms of this Agreement.&nbsp;&nbsp;Notwithstanding the foregoing, should Licensee fail to obtain the foregoing use and reference rights from any Sublicensee, Licensee shall not have the right to grant use and access or other rights to such Sublicensee to any Data or other documentation provided to Licensee by Ovid pursuant to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.7(a)</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref515882872"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Independent and Licensee Territory Development Activities Data</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The Party receiving Data resulting from the other Party&#8217;s Independent Development Activities shall have the right to use such Data only to the extent reasonably necessary for the receiving Party to comply with its regulatory reporting and compliance obligations, including safety reporting obligations.&nbsp;&nbsp;Licensee shall have the right to use such Data only to support its own Development, Regulatory Approval, or Commercialization of the Product in the Field in such Party&#8217;s territory for the Initial Indication unless Licensee reimburses Ovid for Licensee&#8217;s share of Development Costs pursuant to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.2(b</font><font style="font-weight:normal;color:#000000;">). Ovid shall have the right to use Data resulting from the Licensee Territory Development Activities as necessary for Ovid or its Affiliates or licensees (other than Licensee) to comply with its regulatory reporting and compliance obligations, including safety reporting obligations, and to support its own Development, Regulatory Approval, or Commercialization of the Product in the Ovid Territory. </font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Any data transfer between the Parties under this Agreement shall comply with the applicable data privacy laws of the EU and USA. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.8</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Diligence</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Each Party shall use its Commercially Reasonable Efforts to perform the Development activities assigned to such Party under and in accordance with the Development Plan and the Amended Development Plan. In addition, Licensee shall use Commercially Reasonable Efforts to perform any Independent Development Activities of Licensee, and Licensee Territory Development Activities and file MAAs and seek and maintain Regulatory Approval (including Pricing and Reimbursement Approval, as applicable) for the Products throughout the Licensee Territory.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.9</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Compliance</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Each Party shall perform Development activities for the Compound and Products in and for the Licensee Territory in compliance with all Applicable Laws, including good scientific and clinical practices under the Applicable Laws of the country in which such activities are conducted.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref376954185"></a><a name="_Ref208050415"></a><font style="text-decoration:none;Background-color:#auto;">4.10</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Development Records</font><font style="color:#000000;font-weight:normal;">.&nbsp;&nbsp;Each Party </font><font style="font-weight:normal;color:#000000;">shall maintain complete, current, and accurate records of all Development activities conducted by it hereunder, and all data and other information resulting from such activities.&nbsp;&nbsp;Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory and patent purposes.&nbsp;&nbsp;Each Party shall document all non-clinical studies and Clinical Trials and/or Studies in formal written study reports according to Applicable Laws and national and international guidelines (e.g., ICH, GCP, GLP, and GMP).&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.11</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Development Reports</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;At each regularly scheduled JPT meeting, each Party shall provide the JPT with regular reports detailing its Development activities for the Products under this Agreement, and the results of such activities.&nbsp;&nbsp;In addition, after the completion of any Clinical Trial or other study of the Products, the Party responsible for the conduct of such Clinical Trial or study shall promptly provide the other Party with a data package consisting of, at a minimum, [***], as well as any other Data specified in the Development Plan or otherwise agreed by the Parties.&nbsp;&nbsp;The Parties shall discuss the status, progress, and results of each Party&#8217;s Development activities under this Agreement at such JPT meetings.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref513480436"></a><font style="Background-color:#auto;text-decoration:none;">4.12</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Use of Subcontractors</font><font style="font-weight:normal;color:#000000;">. Each Party may perform its Development activities under this Agreement through one or more subcontractors, provided that (a) such Party will remain responsible for the work allocated to, and payment to, such subcontractors to the same extent it would if it had done such work itself, (b) each subcontractor undertakes in writing obligations of confidentiality and non-use regarding Confidential Information that are substantially the same as those undertaken by the Parties pursuant to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Article 13</font><font style="font-weight:normal;color:#000000;">, (c) each subcontractor agrees in writing to assign all intellectual property developed in the course of performing any such work to such Party (or, in the event such assignment is not feasible, a license to such intellectual property with the right to sublicense to such other Party), and (d) in the case of Licensee engaging any subcontractor to conduct significant activities under this Agreement (e.g., a contract research organization to manage a Clinical Trial), Licensee will be responsible for the selection of the subcontractor and will inform Ovid on the selection process including the criteria applied and shall first obtain Ovid&#8217;s written consent to such subcontractor, such consent not to be unreasonably withheld.&nbsp;&nbsp;The Parties may also subcontract work on terms other than those set forth in this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.12</font><font style="font-weight:normal;color:#000000;"> with the prior approval of the CGB.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.13</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Restrictions</font><font style="font-weight:normal;color:#000000;">. During the Term, neither Party nor any of its Affiliates or Sublicensees shall, directly or through any Third Party, sponsor, conduct, cause to be conducted, otherwise assist in, supply any Product for use in connection with, or otherwise fund any research or Development of any Product in the Licensee Territory outside the scope of the Development Plan.&nbsp;&nbsp;For clarity and without limiting the foregoing, if Licensee wishes to perform or sponsor any study or test on the Compound or Products, including any pre-clinical or non-clinical study, toxicology study, CMC-related study, or comparator study, Licensee shall first prepare and provide to Ovid for Ovid&#8217;s approval a Proposal detailing such study in accordance with </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.3</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk31616287"></a><font style="Background-color:#auto;text-decoration:none;">4.14</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Materials Transfer</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;In order to facilitate the Development activities contemplated by this Agreement, either Party may provide to the other Party certain biological materials or chemical compounds Controlled by the supplying Party (collectively, &#8220;</font><font style="color:#000000;">Materials</font><font style="font-weight:normal;color:#000000;">&#8221;) for use by the other Party in furtherance of such Development activities.&nbsp;&nbsp;Except as otherwise provided for under this Agreement, all such Materials delivered to the other Party will remain the sole property of the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">supplying Party, and will be used only in furtherance of the Development activities conducted in accordance with this Agreement, will not be used or delivered to or for the benefit of any Third Party, except to subcontractors, without the prior written consent of the supplying Party, and will be used in compliance with all Applicable Laws.&nbsp;&nbsp;The Materials supplied under this Agreement must be used with prudence and appropriate caution in any experimental work because not all of their characteristics may be known.&nbsp;&nbsp;Except as expressly set forth in this Agreement, THE MATERIALS ARE PROVIDED &#8220;AS IS&#8221; AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY.</font><font style="font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref32853062"></a><a name="_Ref38904585"></a><a name="_Hlk34670178"></a><font style="Background-color:#auto;text-decoration:none;">4.15</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Suspension and Termination for Safety Reasons</font><font style="font-weight:normal;color:#000000;"><a name="_Hlk34670178"></a>. Each Party shall have the right, at any time, to request that the CGB meet promptly to discuss whether to suspend the continued Development and/or Commercialization of the Products in the Field in the Licensee Territory for a period of [***] (the &#8220;</font><font style="color:#000000;">Suspension</font><font style="font-weight:normal;color:#000000;">&#8221;), upon providing written notice to the other Party, if such Party reasonably determines in good faith that the Compound or any other Product caused or is likely to cause a safety issue (a &#8220;</font><font style="color:#000000;">Safety Reason</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;If the CGB does not come to a consensus with regard to such Safety Reason during the Suspension, either Party may terminate the Agreement (with the understanding that the other Party shall have the continuing right to Develop and Commercialize the Product; provided, however, that if the other Party is Licensee and Licensee wishes to continue the Development and Commercialization of the Product, this Agreement shall remain in force and effect, but the provisions of </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 14.5</font><font style="font-weight:normal;color:#000000;"> shall apply) with immediate effect, upon written notice to the other Party if: (i) the Executive Officers meet (in person or otherwise) within [***] to resolve the dispute in good faith; and (ii) such Executive Officers are unable to resolve the dispute.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Ref24397030"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;text-transform:none;color:#000000;"></font><font style="font-variant: small-caps;text-transform:none;color:#000000;">Regulatory Activities</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref24400759"></a><font style="Background-color:#auto;text-decoration:none;">5.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Regulatory Responsibilitie</font><font style="font-weight:normal;color:#000000;">s.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">General</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref24400736"></a><a name="_Hlk31018096"></a><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The Development Plan shall set forth the regulatory strategy for seeking Regulatory Approval for the Compound and Products by the appropriate Regulatory Authorities in the Licensee Territory and Ovid Territory.&nbsp;&nbsp;Subject to the oversight of the CGB and except as otherwise set forth in the Development Plan and the remainder of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 5.1(a)(i)</font><font style="font-weight:normal;color:#000000;">, each Party shall be responsible for implementing such regulatory strategy in its territory.&nbsp;&nbsp;The Development Plan shall also spec<a name="_Hlk31018096"></a>ify which Party shall apply for and hold Regulatory Filings in each country with respect to the conduct of Development activities, provided that (1) Ovid shall apply for and hold all Regulatory Filings and Regulatory Approvals for the Ovid Ongoing Trials and Ovid&#8217;s Independent Development Activities and (2) Licensee shall apply for and hold all Regulatory Filings for the Licensee Territory arising from the Licensee Territory Development Activities, Licensee&#8217;s Independent Development Activities, and Joint Development Activities.&nbsp;&nbsp;Except as otherwise provided herein or in the Development Plan or required by Applicable Law, each Party shall (A) be responsible for the preparation and submission of any and all Product </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">registrations and MAAs in its territory </font><font style="font-weight:normal;color:#000000;">and (B) own and hold all such Regulatory Filings (including Regulatory Approvals).&nbsp;&nbsp;For the avoidance of doubt, in no event shall Licensee submit any Regulatory Filing for the Product in the Ovid Territory.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Each Party shall be responsible for the costs of all regulatory activities in its territory, except that any costs incurred by Ovid in connection with regulatory activities in the Licensee Territory pursuant to Ovid&#8217;s Independent Development Activities shall be Independent Development Costs of Ovid and subject to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.2(b)</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Licensee acknowledges that Ovid may be required from time to time to communicate with Regulatory Authorities in the Licensee Territory as a result of Development and manufacturing activities in such territory. Ovid shall notify Licensee as soon as reasonably practicable of such communication with Regulatory Authorities in the Licensee Territory. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk43791393"></a><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Ovid</font><font style="color:#000000;"> </font><font style="font-weight:normal;color:#000000;"><a name="_Hlk43791393"></a>will provide to Licensee [***].  Licensee shall have the right to use such information to [***] for the Product for the Initial Indication [***] under this Agreement. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(v)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Prior to [***], Ovid will not, without Licensee&#8217;s input, (A) withdraw the IND for the Product in the Licensee Territory for any reason other than a Safety Reason, (B) file an MAA for the Product in the Licensee Territory, or (C) finalize the PIP for the Initial Indication.&nbsp;&nbsp;Prior to [***], Ovid shall notify Licensee of any scheduled meeting with a Regulatory Authority in the Licensee Territory that relates to the any of the Ovid Ongoing Trials and, to the extent permitted by Applicable Law and the relevant Regulatory Authority, shall permit a representative of Licensee to attend such meeting, at Licensee&#8217;s request and expense.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_cp_text_1_238"></a><a name="_cp_text_1_242"></a><font style="Background-color:#auto;text-decoration:none;">(vi)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;"><a name="_cp_text_1_238"></a>Ovid <a name="_cp_text_1_242"></a>will, upon Licensee&#8217;s reasonable request, cooperate with Licensee in [***] Product in the Initial Indication in the Licensee Territory.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:22.72%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_244"></a><a name="_cp_text_1_246"></a>(vii)<font style="font-weight:normal;margin-left:36pt;"><a name="_cp_text_1_244"></a>Ovid shall </font><font style="font-weight:normal;">[***] for the Compound [***].&nbsp;&nbsp;Licensee shall have the right to p<a name="_cp_text_1_246"></a>erform a Scientific Advice with the applicable Regulatory Authorities in the Licensee Territory.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref515914468"></a><a name="_cp_text_1_248"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Regulatory Filing Right of Reference</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Except as set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 5.1(c)</font><font style="font-weight:normal;color:#000000;">, Ovid shall grant and hereby grants to Licensee a right of reference and access to all Regulatory Approvals and Regulatory Filings Controlled by Ovid in the Licensee Territory for the Compound and Product, in each case to the extent <a name="_cp_text_1_248"></a>necessary for Licensee to submit Regulatory Filings and obtain MAA Approvals for Products in the Initial Indication in the Licensee Territory.&nbsp;&nbsp;For the purposes of this Agreement, &#8220;right of reference&#8221; means the &#8220;right of reference or use&#8221; as defined in 21 C.F.R. &#167;314.3(b) and any equivalent regulation outside the U.S., as each may be amended. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref516002304"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee Regulatory Information Sharing and Right of Referenc</font><font style="font-weight:normal;color:#000000;">e.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Licensee shall promptly provide Ovid with copies of any Regulatory Filings prepared (including any drafts), submitted, or received by Licensee in the Licensee Territory pertaining to the Compound and Products, and Ovid shall have the right to comment on </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">drafts of such Regulatory Filings.&nbsp;&nbsp;Licensee shall share with Ovid the following communications/correspondence with any Regulatory Authority: (1) </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;">, (2) </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;">, and (3) </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;"> relating to the Compound or Product.&nbsp;&nbsp;If any Regulatory Filing to be provided under this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">5.1(c)</font><font style="font-weight:normal;color:#000000;"> was originally created in a language other than the English language, then Licensee shall provide an English translation along with the original document to Ovid.&nbsp;&nbsp;Licensee shall use Commercially Reasonable Efforts to grant to Ovid access and rights to use any such c</font><font style="font-weight:normal;color:#000000;">ommunications with any Regulatory Authority generated by or on behalf of any Sublicensee.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">Should Licensee fail to obtain such access and rights from any Sublicensee despite the application of Commercially Reasonable Efforts, Licensee shall not have the right to grant access or rights to such Sublicensee to any Regulatory Filing or right of reference granted to Licensee by Ovid pursuant to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">5.1(b)</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref515912817"></a><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Licensee hereby grants to Ovid a right of reference to all Regulatory Filings for the Compound and Products submitted by or on behalf of Licensee.&nbsp;&nbsp;Ovid may use such right of reference to seek, obtain, and maintain Regulatory Approval of the Products in the Ovid Territory, except that Ovid may use such right of reference to any Regulatory Filings based on Data resulting from Licensee&#8217;s Independent Development Activities only to comply with its safety reporting obligations, unless Ovid reimburses Licensee for such work as set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.2(b)</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Meetings with Regulatory Authorities</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;On a current and ongoing basis, each Party (through the JPT) shall provide the other Party with a list and schedule of any in-person meeting or material teleconference with Regulatory Authorities (or related advisory committees) in the Licensee Territory planned for [***] that relates to the Development of the Compound and Products under the Development Plan in the Licensee Territory (each, a &#8220;</font><font style="color:#000000;">Regulatory Meeting</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;In addition, each Party shall notify the other Party as soon as reasonably possible if such Party becomes aware of any additional Regulatory Meetings that become scheduled for such Calendar Quarter and will keep the other Party informed of any significant interface or communication with any Regulatory Authority which might affect efforts to obtain Regulatory Approval for the Product in the Licensee Territory. Each Party shall be solely responsible for any communications with any Regulatory Authorities occurring or required in connection with performing its regulatory responsibilities set forth in this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Article 5</font><font style="font-weight:normal;color:#000000;"> with respect to the Product in the Licensee Territory. With respect to Regulatory Meetings for which Licensee is the responsible Party, Ovid shall have the right to comment in preparation for all such Regulatory Meetings and the right, but not the obligation, to have its representatives attend any such Regulatory Meetings.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.3</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Regulatory Inspections</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Licensee shall permit the Regulatory Authority(ies) in the Ovid Territory to conduct inspections of Licensee, its Affiliates, and its Sublicensees and subcontractors (including Clinical Trial sites) relating to the Development of the Product under the Development Plan, and shall ensure that such Affiliates and Sublicensees and subcontractors permit such inspections.&nbsp;&nbsp;In addition, Licensee shall promptly notify Ovid of any such inspection and shall supply Ovid with all information pertinent thereto.&nbsp;&nbsp;Ovid shall have the right to have a representative attend any such inspection. Ovid shall permit the Regulatory Authority(ies) in the Licensee Territory to conduct inspections of Licensee, its Affiliates, and its Sublicensees and subcontractors (including Clinical Trial sites) relating to the Development of the Product in the Licensee Territory under the Development Plan, and shall ensure that such Affiliates and Sublicensees and subcontractors permit such inspections.&nbsp;&nbsp;In addition, Ovid shall promptly notify the Licensee of any such inspection in the Licensee Territory and shall supply the Licensee with </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">all information pertinent thereto.&nbsp;&nbsp;The Licensee shall have the right to have a representative attend any such inspection.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref513467917"></a><a name="_Hlk32327796"></a><a name="_Hlk32328684"></a><font style="Background-color:#auto;text-decoration:none;">5.4</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Adverse Event Reporting; Pharmacovigilance Agreement</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;[***] after the Effective Date, the Parties shall enter into a pharmacovigilance agreement setting forth the worldwide pharmacovigilance procedures for the Parties with respect to the Products, such as Safety Data sharing, adverse event reporting, and safety signal and risk management (the &#8220;</font><font style="color:#000000;">Pharmacovigilance Agreement</font><font style="font-weight:normal;color:#000000;"><a name="_Hlk32327796"></a>&#8221;), which agreement shall be amended by the Parties from time to time as necessary to comply with any changes in Applicable Laws or any guidance received from Regulatory Authorities.&nbsp;&nbsp;Such procedures shall be in accordance with, and enable the Parties to fulfill, local and national regulatory reporting obligations under Applicable Laws (including, to the extent applicable, those obligations contained in ICH guidelines) to monitor patients&#8217; safety.&nbsp;&nbsp;Ovid has established, and shall continue to hold (either by itself or through a vendor engaged by Ovid) the global safety database for the Products, and shall maintain such global safety database for so long as such Product is under Development or Commercialization by the Parties.&nbsp;&nbsp;The Parties envision that Ovid will separately maintain the Product global safety database <a name="_Hlk32328684"></a>and Licensee will maintain its own Product safety database with respect to the Licensee Territory and the Parties will synchronize the Product databases in accordance with the Pharmacovigilance Agreement so that they each maintain all Product safety data; however, the Parties agree that the Ovid global safety database will be the source for all periodic reports. Ovid shall [***] from its database and Licensee will maintain [***] its own Product safety database. The CGB shall establish a safety subcommittee to draft the Pharmacovigilance Agreement to define the process for exchanging adverse event reports using the Ovid global safety database, as well as periodic reports, regulatory communication, and other key elements.&nbsp;&nbsp;The Parties will collaboratively agree on data cut points for periodic safety reports and Ovid will review and approve all such reports.&nbsp;&nbsp;The Parties will jointly review and approve such reports before submission to Regulatory Authorities in the Licensee Territory as required.&nbsp;&nbsp;Such safety subcommittee shall implement the Pharmacovigilance Agreement and coordinate with respect to any Safety Data reporting for the Products to the Regulatory Authorities in the Licensee Territory including,&nbsp;&nbsp;responding to safety issues, communicating with Regulatory Authorities related to the Products under any MAA or Regulatory Approval for the Product held by such Party and filed with such Regulatory Authorities, including maintaining the qualified person for Pharmacovigilance and individual case safety report processing, in each case at its own cost. Each Party agrees to comply with its respective obligations under the Pharmacovigilance Agreement and to cause its Affiliates, licensees, and Sublicensees to comply with such obligations. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.5</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No Harmful Actions</font><font style="font-weight:normal;color:#000000;">.</font><font style="color:#0000FF;font-weight:normal;">&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">If a Party reasonably believes that the other Party is taking or intends to take any action with respect to a Product that could reasonably be expected to have a material adverse impact upon the regulatory status of such Product in such Party&#8217;s territory, then such Party may bring the matter to the attention of the CGB and the Parties shall discuss in good faith to promptly resolve such concern.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.6</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notification of Threatened Action</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Each Party shall notify the other Party within twenty-four (24) hours of any information it receives regarding any threatened or pending action, inspection, or communication by any Regulatory Authority which may affect the safety or efficacy claims of any Product or the continued Development or Commercialization of any Product.&nbsp;&nbsp;Upon </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">receipt of such information, the Parties shall promptly consult with each other in an effort to arrive at a mutually acceptable procedure for taking appropriate action.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref515914845"></a><font style="Background-color:#auto;text-decoration:none;">5.7</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Recalls</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;In the event that a recall, withdrawal, or correction (including the dissemination of relevant information) of any Product in a Party&#8217;s territory is required by a Regulatory Authority of competent jurisdiction, or if any Regulatory Authority requires or advises either Party or such Party&#8217;s Affiliates or sublicensees to distribute a &#8220;Dear Doctor&#8221; letter or its equivalent regarding use of such Product in a Party&#8217;s territory, or if a recall, withdraw, or correction of a Product in its territory is deemed advisable by such Party in its sole discretion, such Party shall so notify the other Party no later than [***] in advance of the earlier of (a) [***], or (b) [***].&#160; Any such recall, withdrawal, correction, or dissemination of information (e.g., &#8220;Dear Doctor&#8221; letter) shall be referred to herein as a &#8220;</font><font style="color:#000000;">Recall</font><font style="font-weight:normal;color:#000000;">&#8221;.&#160; Promptly after being notified of a Recall, each Party shall provide the other Party with such assistance in connection with such Recall as may be reasonably requested by such other Party.&#160; All costs and expenses in connection with a Recall [***].&#160; Each Party shall handle exclusively the organization and implementation of all Recalls of Products in its territory.&nbsp;&nbsp;Notwithstanding the foregoing, any Recall related to the manufacture and supply of the Product by Ovid to Licensee shall be governed by the terms and conditions of the Supply Agreement. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref515914937"></a><font style="Background-color:#auto;text-decoration:none;">5.8</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Sunshine Reporting Laws and the International Transparency Reporting Requirements for Europe</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Each Party acknowledges that the other Party may be subject to federal, state, local, and international laws, regulations, and rules related to the tracking and reporting of payments and transfers of value provided to health care professionals, health care organizations, and other relevant individuals and entities, including, as applicable, International Transparency Reporting Requirements for Europe (collectively, &#8220;</font><font style="color:#000000;">Sunshine Reporting Laws</font><font style="font-weight:normal;color:#000000;">&#8221;),</font><font style="color:#000000;"> </font><font style="font-weight:normal;color:#000000;">and agrees to provide the other Party with all information regarding such payments or transfers of value by such Party as necessary for such other Party to comply in a timely manner with its reporting obligations under the Sunshine Reporting Laws.&nbsp;&nbsp;&nbsp;&nbsp; </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;">6.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Ref24395702"></a><a name="_Ref208041409"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;text-transform:none;color:#000000;"></font><font style="font-variant: small-caps;text-transform:none;color:#000000;">Commercialization</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref384030989"></a><a name="_Ref384022814"></a><font style="Background-color:#auto;text-decoration:none;">6.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">General</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Subject to the terms and conditions of this Agreement, including this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Article 6</font><font style="font-weight:normal;color:#000000;">, Licensee shall have the sole and exclusive responsibility, at its own expense, for all aspects of the Commercialization of the Products in the Licensee Territory, including (a) developing and executing a commercial launch and pre-launch plan, (b) negotiating with applicable Governmental Authorities and other payors regarding the price and reimbursement status of the Products, (c) marketing and promotion, (d) booking sales and distribution and performance of related services, (e) handling all</font><font style="color:#000000;"> </font><font style="font-weight:normal;color:#000000;">aspects of order</font><font style="color:#000000;"> </font><font style="font-weight:normal;color:#000000;">processing, invoicing and collection, inventory and receivables, (f) providing customer support, including handling medical queries, and performing other related functions, and (g) conforming its practices and procedures to Applicable Laws applying to the promotion, sales and marketing, access, and distribution of the Products in the Licensee Territory.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref384030902"></a><a name="_Ref515878986"></a><font style="Background-color:#auto;text-decoration:none;">6.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Commercialization Plan</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;As soon as reasonably practicable, but no later than [***], Licensee shall prepare and present to the CGB a reasonably detailed plan for the Commercialization of the Product in the Licensee Territory (the &#8220;</font><font style="color:#000000;">Commercialization Plan</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;The Commercialization Plan will include specific information on a country-by-country basis, as </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">applicable, and shall be consistent with the global commercialization plan for branding and messaging.&nbsp;&nbsp;Licensee shall update and amend the Commercialization Plan </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;"> following the First Commercial Sale of the Product in the Licensee Territory and present such updates and any amendments to the CGB for review and discussion.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">Subject to the terms of this Agreement and compliance with the Commercialization Plan, Licensee shall have full Control and authority with respect to the day-to-day Commercialization of the Products and implementation of the Commercialization Plan.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref515963578"></a><font style="Background-color:#auto;text-decoration:none;">6.3</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Ref515963578"></a> Diligence</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref515962731"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">General</font><font style="font-weight:normal;color:#000000;">.</font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">During the Term, Licensee shall use Commercially Reasonable Efforts to Commercialize the Products for each and every Indication that receives Regulatory Approval in the Licensee Territory.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Product Launch</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Licensee shall use Angelini Commercially Reasonable Efforts to launch the Product for each Indication that has received Regulatory Approval and, if required by Applicable Law, Pricing and Reimbursement Approval in the Licensee Territory (including any Indication that received Regulatory Approval as a result of Ovid&#8217;s Independent Development Activities). As applicable, Licensee shall obtain all necessary Pricing and Reimbursement Approvals necessary to list and to launch such Product for such Indication following receipt of MAA Approval of such Product in a country.&nbsp;&nbsp;Without limiting the generality of the foregoing, Licensee shall use Angelini Commercially Reasonable Efforts to launch the Product in each country in the Licensee Territory within [***] after receiving Regulatory Approval, or, where required by Applicable Law, after the publication of the Pricing and Reimbursement Approval, of the Product for an Indication from the applicable Regulatory Authority in such country.&nbsp;&nbsp;Thereafter, Licensee shall utilize Commercially Reasonable Efforts in the ongoing support for such Product in such country. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Commercial Updates</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Licensee shall update the CGB on [***] basis regarding its Commercialization activities with respect to the Products in the Licensee Territory.&nbsp;&nbsp;Each such update shall be in a form to be agreed by the CGB and shall summarize Licensee&#8217;s and its Affiliates&#8217; and Sublicensees&#8217; significant Commercialization activities with respect to the Products in the Licensee Territory, and shall contain at least such information at a level of detail reasonably required by Ovid to determine Licensee&#8217;s compliance with its diligence obligations set forth in this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 6.3</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Such updates shall include Licensee&#8217;s sales activities, sales forecasts for at least the next [***], marketing activities, and Medical Affairs Activities. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.4</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Coordination of Commercialization Activities</font><font style="font-weight:normal;color:#000000;">. </font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Generally</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The Parties, through the CGB (or JPT or other designated team), shall update each other on Commercialization strategies for the Product (e.g., for market and payor research, branding and messaging, international congresses, advisory boards) in their respective territories, and the Parties shall work together to identify and take advantage of any potential global strategies and messaging.&nbsp;&nbsp;The foregoing shall not be construed as requiring either Party to seek the other Party&#8217;s consent in connection with such first Party establishing or implementing any sales, marketing, or medical affairs practices in such first Party&#8217;s territory.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Pricing</font><font style="font-weight:normal;color:#000000;">. Following the CGB discussion and processes, Licensee shall keep Ovid timely informed on the status of any application for Pricing and Reimbursement Approval or material updates to an existing Pricing and Reimbursement Approval in the Licensee Territory, including any discussion with a Regulatory Authority with respect thereto. Licensee and its Affiliates and Sublicensees shall </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;"> include a Product, </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;"> of the Product </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;"> and the Product </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref24195695"></a><a name="_Ref440878271"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Sharing of Promotional Materials</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Licensee shall, at its own expense, prepare, develop, produce, or otherwise obtain and utilize sales, promotional, advertising, marketing, website, educational, and training materials (the &#8220;</font><font style="color:#000000;">Promotional Materials</font><font style="font-weight:normal;color:#000000;">&#8221;) to support its Commercialization activities in the Licensee Territory, and shall ensure that such Promotional Materials, as well as all information contained therein, comply with all Applicable Laws and are consistent with the Regulatory Approvals obtained for the Product in the applicable jurisdiction in the Licensee Territory.&nbsp;&nbsp;At Ovid&#8217;s request, Licensee shall share samples of and updates to Promotional Materials with respect to the Commercialization of the Products with Ovid. If Ovid has such promotional materials available for the Product for the Ovid Territory prior to the commercial launch of such Product in the Licensee Territory, Ovid will share such materials with the Licensee upon its request.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Commercialization in Ovid Territory</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;For clarity, Ovid shall have the exclusive right to Commercialize the Product in the Ovid Territory at its own expense, with or without Third Party(ies). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.5</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Medical Affairs Activities</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Coordination of Global Medical Affairs Activities</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Ovid shall be responsible for all Medical Affairs Activities for the Product in the Ovid Territory in accordance with the medical affairs portion of the Development Plan.&nbsp;&nbsp;Licensee shall be responsible for Medical Affairs Activities in the Licensee Territory in accordance with the medical affairs portion of the Development Plan, provided, however, that Ovid shall have the right, but not the obligation, to also conduct Medical Affairs Activities in the Licensee Territory in global support of the Product, consistent with the medical affairs portion of the Development Plan and in coordination and agreement with Licensee, such agreement not to be unreasonably withheld, conditioned, or delayed.&nbsp;&nbsp;Licensee will not undertake Medical Affairs Activities in the Ovid Territory without Ovid&#8217;s prior written consent, to be given on a case-by-case basis in Ovid&#8217;s sole discretion. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Advisory Panels</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;To the extent practicable, each Party shall give the other Party written notice at least [***] in advance of any major market or international level advisory panel meetings with key opinion leaders with respect to the Commercialization of the Products in the Licensee Territory and the Ovid Territory that are held, sponsored, or attended by either Party or its Affiliate or sublicensee, and each Party shall have the right to attend and participate in such meetings with the consent of the other Party.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Medical Information</font><font style="font-weight:normal;color:#000000;">. Ovid will provide Licensee with any relevant materials developed by Ovid for the Product in the Ovid Territory for medical information, including reports of collected and answered inquires, which Licensee may use in connection with </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">medical affairs activities in the Licensee Territory.&nbsp;&nbsp;For clarity, Ovid shall provide such materials in the form used by Ovid in the Ovid Territory.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Scientific Training</font><font style="font-weight:normal;color:#000000;">. At times reasonably agreed by the Parties, Ovid will deliver the onboarding scientific training to Licensee&#8217;s medical and commercial team and to share updates with respect to the Commercialization of the Product.&nbsp;&nbsp;Each Party shall bear its own cost in relation to such meetings.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.6</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Diversion</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;To enforce the Parties&#8217; respective rights and obligations set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Sections 2.1</font><font style="font-weight:normal;color:#000000;">, </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">2.4</font><font style="font-weight:normal;color:#000000;">, and </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">2.8</font><font style="font-weight:normal;color:#000000;"> of the Agreement, to the extent permitted by Applicable Law, each Party hereby covenants and agrees that it and its Affiliates shall not, and it shall contractually obligate (and use Commercially Reasonable Efforts to enforce such contractual obligation) its sublicensees not to, directly or indirectly, promote, market, distribute, import, sell, or have sold any Product, including via the Internet or mail order, to any Third Party or to any address or Internet Protocol address or the like in the other Party&#8217;s territory.&nbsp;&nbsp;Neither Party shall engage, nor permit its Affiliates and sublicensees to engage, in any advertising or promotional activities relating to any Product for use directed primarily to customers or other buyers or users of such Product located in any country or jurisdiction in the other Party&#8217;s territory, or solicit orders from any prospective purchaser located in any country or jurisdiction in the other Party&#8217;s territory.&nbsp;&nbsp;If a Party or its Affiliates or sublicensees receives any order for a Product for use from a prospective purchaser located in a country or jurisdiction in the other Party&#8217;s territory, such Party shall immediately refer that order to such other Party and shall not accept any such orders.&nbsp;&nbsp;Neither Party shall, nor permit its Affiliates and sublicensees to, deliver or tender (or cause to be delivered or tendered) any Product for use in the other Party&#8217;s territory.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.7</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Ovid&#8217;s Right to Commercialize</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Notwithstanding anything to the contrary herein, if Ovid conducts Development activities for the Product in the Licensee Territory as provided in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 2.3(a)</font><font style="font-weight:normal;color:#000000;"> for any Additional Indication(s) for which Licensee has elected to not share Development Costs as provided in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.2(a)</font><font style="font-weight:normal;color:#000000;"> and/or </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.2(b)</font><font style="font-weight:normal;color:#000000;">, as applicable, then prior to filing for Regulatory Approval for the Product in any Additional Indication, the Parties shall discuss in good faith whether Licensee wishes to include such Additional Indication within the Field&nbsp;&nbsp;and to Commercialize such Product in such Additional Indications.&nbsp;&nbsp;For clarity, neither Party may file for Regulatory Approval or Commercialize Products in (i) any Additional Indication for which Licensee has elected not to share Development Costs or (ii) any additional indication other than Rare Diseases unless the Parties mutually agree to do so. </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman Bold;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;">7.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;text-transform:none;color:#000000;"></font><font style="font-family:Times New Roman Bold;font-variant: small-caps;text-transform:none;color:#000000;">Manufacture and Supply</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk31359659"></a><a name="_Ref32769898"></a><a name="_Hlk31376219"></a><a name="_cp_text_1_259"></a><font style="Background-color:#auto;text-decoration:none;">7.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Upon Licensee&#8217;s request, Ovid will manufacture and supply, itself or through a Third Party contract manufacturer, all Drug Product for use in the Development and Commercialization of the Products under this Agreement and according to the Supply Agreement.&nbsp;&nbsp;All Drug Product supplied by Ovid to Licensee or Licensee Affiliate for use for Development and Commercial purposes shall be supplied at [***], provided that [***]<a name="_Hlk31376219"></a> (&#8220;</font><font style="color:#000000;">Total Supply Price Threshold</font><font style="font-weight:normal;color:#000000;">&#8221;). In case the Total Supply Price will be [***], the Cost of Good for such Drug Product will be [***] the Total Supply Price Threshold.&nbsp;&nbsp;For clarity, the Total Supply Price Threshold [***].&nbsp;&nbsp;Payment shall be due within [***] after Licensee&#8217;s receipt from Ovid of an invoice for such Drug Product.&nbsp;&nbsp;Drug Product shall be delivered EXW (Incoterms 2020) at supplier facility (or that </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">of its Third Party contract manufacturer), and </font><font style="font-weight:normal;color:#000000;">Licensee</font><font style="font-weight:normal;color:#000000;"> shall be responsible for all costs of freight, insurance, taxes and duties associated with shipment of Drug Product to </font><font style="font-weight:normal;color:#000000;">Licensee&#8217;s</font><font style="font-weight:normal;color:#000000;"><a name="_cp_text_1_259"></a> designated delivery point.&nbsp;&nbsp;Licensee shall be responsible, at its expense, for the final packaging and labeling of the Product for all countries in the Licensee Territory.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">Licensee shall also be responsible, at its sole expense, for any specific manufacturing requirements, such as stability studies or development of finished Product presentations, necessary to obtain MAA Approval of the Product in the Licensee Territory.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">If Licensee is manufacturing Drug Product following the Technology Transfer Completion Date, Ovid may request, and Licensee or Licensee Affiliate will supply Drug Product to Ovid, on the same terms as set forth above, pursuant to a mutually agreed supply agreement.&nbsp;&nbsp;</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;">8.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Ref38904388"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;text-transform:none;color:#000000;"></font><font style="font-variant: small-caps;text-transform:none;color:#000000;">Financial Provisions </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref378153445"></a><font style="Background-color:#auto;text-decoration:none;">8.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Upfront and Technology Transfer Financials</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Upfront Payment</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Licensee shall make a one-time, non-refundable, non&#8209;creditable upfront payment to Ovid of twenty million dollars ($20,000,000) within five (5) business days after the Effective Date.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref37267744"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Technology Transfer and Compound Delivery Payment</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref42952009"></a><a name="_Ref41484086"></a><a name="_Ref41403492"></a><a name="_Hlk42093672"></a><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Within [***]<a name="_Hlk42093672"></a> following (A) the transfer to Licensee of [***], (B) the delivery ([***]) to Licensee or to Licensee Affiliate of [***] and (C) [***], Licensee shall pay to Ovid a one-time, non-refundable, non-creditable payment of (1) </font><font style="font-size:11.5pt;font-weight:normal;color:#000000;">five million dollars ($5,000,000)</font><font style="font-weight:normal;color:#000000;"> if [***] </font><font style="font-size:11.5pt;font-weight:normal;color:#000000;">is transferred by Ovid to Licensee before December 10, 2020</font><font style="font-weight:normal;color:#000000;">, or (2) [***] if [***].&nbsp;&nbsp;Licensee shall use Angelini Commercially Reasonable Efforts to cooperate with Ovid and Lundbeck to implement the foregoing transfers within the timelines set forth in this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.1(b)(i)</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref41403522"></a><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Within [***] following the Technology Transfer Completion Date, Licensee shall make a one-time, non-refundable, non-creditable technology transfer payment of [***]. Licensee shall use Angelini Commercially Reasonable Efforts to cooperate with Ovid and Lundbeck to implement the Technology Transfer Agreement within [***] after the Effective Date. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref513472965"></a><a name="_Ref381318023"></a><a name="_Ref376904233"></a><a name="_Ref151312354"></a><a name="_Ref208027697"></a><a name="_Ref209930391"></a><font style="Background-color:#auto;text-decoration:none;">8.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Sharing/Reimbursements of Development Costs</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref513480086"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Shared Development Costs</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;With respect to Joint Development Activities conducted pursuant to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.2(b)</font><font style="font-weight:normal;color:#000000;"> or </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.3</font><font style="font-weight:normal;color:#000000;"> directed to obtaining Regulatory Approval for any Indication, excluding the Ovid Ongoing Trials,</font><font style="color:#000000;"> </font><font style="font-weight:normal;color:#000000;">Ovid shall bear [***] and Licensee shall bear [***] of all Development Costs for such Joint Development Activities.&nbsp;&nbsp;No later than [***] after the beginning of each Calendar Quarter during which a Party will perform any Joint Development Activities pursuant to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.2(b)</font><font style="font-weight:normal;color:#000000;"> or </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 4.3</font><font style="font-weight:normal;color:#000000;"> in such Calendar Quarter, such Party shall submit to the other Party a statement setting forth the Development Costs incurred, including the other Party&#8217;s share (calculated in accordance with the foregoing sentence) of (i) estimated Development Costs for the then current quarter; (ii) variances from prior invoiced estimates and actual Development Costs; and (iii) Development Costs incurred by or on account of such Party in the past quarter not previously invoiced.&nbsp;&nbsp;Such invoice shall include a reasonably detailed report for such Development Costs, including reasonable supporting documents.&nbsp;&nbsp;The other Party shall </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">pay the amount inv</font><font style="font-weight:normal;color:#000000;">oiced within </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;"> after the receipt of the invoice, subject to the other Party&#8217;s right to audit the invoicing Party&#8217;s records and books related to such costs as provided in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 9.4</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;If both Parties will perform Joint Development Activities pursuant to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">4.2(b)</font><font style="font-weight:normal;color:#000000;"> or </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">4.3</font><font style="font-weight:normal;color:#000000;"> under the Development Plan in such Calendar Quarter, the Parties shall consolidate the payments for such Calendar Quarter into a single payment from one Party to the other Party, as applicable.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref515910565"></a><a name="_Ref513467506"></a><a name="_Ref513467299"></a><a name="_Ref515964863"></a><a name="_Ref515897655"></a><a name="OLE_LINK6"></a><a name="OLE_LINK7"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Independent Development Costs</font><font style="font-weight:normal;color:#000000;">.<a name="_Ref515897655"></a>&nbsp;&nbsp;In general, each Party shall bear all Development Costs incurred by or on account of such Party in performing its own Independent Development Activities (the &#8220;</font><font style="color:#000000;">Independent Development Costs</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;After the completion of such Independent Development Activities, such Party shall provide the other Party (the &#8220;</font><font style="color:#000000;">Non-Funding Party</font><font style="font-weight:normal;color:#000000;"><a name="OLE_LINK6"></a><a name="OLE_LINK7"></a>&#8221;) with a report of such Independent Development Costs.&nbsp;&nbsp;If a Non-Funding Party desires to submit any portion of the Data, or reference any portion of a Regulatory Filing, resulting from Independent Development Activities conducted by the other Party to support any Regulatory Approval in the Non-Funding Party&#8217;s territory, then such Non-Funding Party may notify the other Party in writing of such request at any time following the completion of such Independent Development Activities.&nbsp;&nbsp;Within [***] after its receipt of such notice, the Party having conducted such Independent Development Activities shall submit to the other Party a reasonably detailed invoice for, [***] of the Independent Development Costs incurred [***] in connection with the performance of such Independent Development Activities, with such invoiced amount representing the Non-Funding Party&#8217;s base share of Development Costs ([***]), had such Party originally opted in, plus [***], provided that in no event will either Party be required to pay, as a result of the application of such premium, more than [***] the costs actually incurred in conducting such Independent Development Activities.&nbsp;&nbsp;If the Non-Funding Party subsequently uses or references such Data, in whole or in part to support Regulatory Approval of the Product in the applicable Indication in its territory, then such Party shall notify the conducting Party in writing of such decision and pay the amount set forth in the invoice within [***] after its submission of a Regulatory Filing including or referencing such Data.  </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Internal Development Cost</font><font style="font-weight:normal;color:#000000;">. Each Party shall record and calculate its Development Costs for the Development Activities implemented from the Effective Date on an FTE basis at the applicable FTE Rate.&nbsp;&nbsp;The Parties agree that [***] from the Effective Date.</font><font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref513468015"></a><font style="Background-color:#auto;text-decoration:none;">8.3</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Development Milestone Payments</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref33098756"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Development Milestones</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Subject to the remainder of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.3</font><font style="font-weight:normal;color:#000000;">, Licensee shall pay to Ovid the one-time, non-refundable, non-creditable payments set forth in the table below upon the achievement of the applicable milestone event (whether by or on behalf of Licensee or its Affiliates or Sublicensees or Ovid or its Affiliates or licensee(s) (other than Licensee)).&nbsp;&nbsp;</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:449.75pt;;">
<tr>
<td style="width:283.75pt;"></td>
<td style="width:166pt;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0.15pt;padding-Bottom:0.15pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Regulatory Milestone Event</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0.15pt;padding-Bottom:0.15pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0.25pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Regulatory Milestone Amount</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0.15pt;padding-Bottom:0.15pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.9pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0.15pt;padding-Bottom:0.15pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0.15pt;padding-Bottom:0.15pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:8.1pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0.15pt;padding-Bottom:0.15pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0.15pt;padding-Bottom:0.15pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:8.1pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0.15pt;padding-Bottom:0.15pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr style="height:21.85pt;">
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0.15pt;padding-Bottom:0.15pt; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.9pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0.15pt;padding-Bottom:0.15pt; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0.15pt;padding-Bottom:0.15pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:8.1pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0.15pt;padding-Bottom:0.15pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk31357552"></a><a name="_Ref383947118"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notice and Payment</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Each Party shall notify the other Party in writing within [***] after the achievement of any milestone event set forth in this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.3</font><font style="font-weight:normal;color:#000000;"> by such Party or its Affiliates or Sublicensees.&nbsp;&nbsp;Licensee shall pay to Ovid the applicable development milestone payment within [***] after the delivery or receipt of such notice.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.15%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;">One-time Payment</font><font style="font-weight:normal;">. Each of the above Regulatory Milestone amounts shall only be payable once no matter how many times the corresponding Regulatory Milestone Event is achieved.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.15%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk31358451"></a>(d)<font style="font-weight:normal;margin-left:36pt;">For clarity, Licensee shall pay to Ovid each Regulatory Milestone amount the first time that the corresponding Regulatory Milestone Event is achieved.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref513470964"></a><font style="Background-color:#auto;text-decoration:none;">8.4</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Sales Milestones Payments</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref513470811"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Licensee shall pay to Ovid the one-time, non-refundable, non-creditable payments set forth in the table below when the aggregated Net Sales of all Products in the Licensee Territory in any Calendar Year first reach the values indicated in the table below.&nbsp;&nbsp;For clarity, each payment in this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.4</font><font style="font-weight:normal;color:#000000;"> shall be payable once only upon first achievement of the applicable milestone event, regardles</font><font style="color:#3D4240;font-weight:normal;">s </font><font style="font-weight:normal;color:#000000;">of the number of times such mile</font><font style="color:#3D4240;font-weight:normal;">s</font><font style="font-weight:normal;color:#000000;">tone is sub</font><font style="color:#3D4240;font-weight:normal;">s</font><font style="font-weight:normal;color:#000000;">equently achieved.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:16.71%;width:373.5pt;;">
<tr>
<td style="width:256.85pt;"></td>
<td style="width:116.65pt;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:36pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate Net Sales of all Products in the Licensee Territory in a Calendar Year</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sales Milestone Payment Amount</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:12.6pt;;margin-right:4.49%;text-indent:-1pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:12.6pt;;margin-right:4.49%;text-indent:-1pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:12.6pt;;margin-right:4.49%;text-indent:-1pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:12.6pt;;margin-right:4.49%;text-indent:-1pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:-0.2pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:12.6pt;;margin-right:4.49%;text-indent:-1pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notice and Payment</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;As part of the report in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 9.1</font><font style="font-weight:normal;color:#000000;">, Licensee shall provide written notice to Ovid if the aggregated Net Sales of all Products in the Licensee Territory in any Calendar Year first reach the values set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.4(a)</font><font style="font-weight:normal;color:#000000;">, and Licensee shall pay to Ovid the corresponding Net Sales milestone payment along with its payment of royalties in accordance with </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 9.1</font><font style="font-weight:normal;color:#000000;">, following the end of the Calendar Quarter in which such Net Sales milestone is achieved. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">One-time Payment</font><font style="font-weight:normal;color:#000000;">. Each of the above Sales Milestone amounts shall only be payable once during the Term of this Agreement no matter how many times the corresponding Sales Milestone Event is achieved.&nbsp;&nbsp;For clarity, Licensee shall pay to Ovid each Sales Milestone amount the first time that the corresponding Sales Milestone Event is achieved.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref32495084"></a><a name="_Ref383109797"></a><font style="Background-color:#auto;text-decoration:none;">8.5</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Royalty During the Royalty Term</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref24274954"></a><a name="_Ref381319746"></a><a name="_Ref513471773"></a><a name="_Ref33038572"></a><a name="_Ref376954443"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Royalty Rate</font><font style="font-weight:normal;color:#000000;">. Subject to the remainder of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.5</font><font style="font-weight:normal;color:#000000;">, during the Royalty Term, Licensee shall make quarterly non-refundable, non-creditable royalty payments to&nbsp;&nbsp;Ovid on the annual Net Sales of all Products sold in the Licensee Territory at the applicable rate to the relevant portion of annual Net Sales as set forth below:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:14.79%;width:405.35pt;;">
<tr>
<td style="width:296.2pt;"></td>
<td style="width:109.15pt;"></td>
</tr>
<tr style="height:2.95pt;">
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:36pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual Net Sales of all Products in the Licensee Territory</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:-0.7pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Royalty Rate</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;margin-left:33.95pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portion of annual Net Sales up to [***]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]%</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;margin-left:33.95pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portion of annual Net Sales greater than [***] and less than or equal to [***]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]%</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;margin-left:33.95pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portion of annual Net Sales greater than [***] and less than or equal to [***] </p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]%</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;margin-left:33.95pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portion of annual Net Sales greater than [***]</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:12pt;margin-left:19.23%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref384576942"></a><a name="El2_73O"></a><a name="_Ref383956224"></a><a name="_Ref381316939"></a>For example purposes only, [***].</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Royalty Term</font><font style="font-weight:normal;color:#000000;">. Royalties shall be paid on a Product-by-Product and country-by-country basis in the Licensee Territory from the First Commercial Sale of such Product in such country by or on behalf of Licensee, its Affiliates, or Sublicensees, until the last to occur of (i) the expiration of the last&#8209;to&#8209;expire Valid Claim of the Ovid Patents (ii) the expiration of all Market Exclusivity covering such Product in such country, and (iii) fifteen (15) years after the First Commercial Sale of such Product in such country&nbsp;&nbsp;(the &#8220;</font><font style="color:#000000;">Royalty Term</font><font style="font-weight:normal;color:#000000;">&#8221;). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref37269383"></a><a name="_Ref32505185"></a><a name="_Ref33038524"></a><a name="_Ref25220206"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Royalty Stacking Reduction</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;If it is necessary for Licensee to obtain a license from a Third Party under any Patent in a particular country in the Licensee Territory in order to sell the Compound or the Compound incorporated into a Product for the Initial Indication or, if Licensee does not exercise the Second Indication Opt-Out, the Second Indication in such country and Licensee obtains such a license, then solely during the Royalty Term, Licensee may </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">deduct from the royalty payment that would otherwise have been due pursuant to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.5(a)</font><font style="font-weight:normal;color:#000000;"> with respect to Net Sales of such Product in such country in a particular Calendar Quarter an amount equal to </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;"> of the royalties paid by Licensee to such Third Party pursuant </font><font style="font-weight:normal;color:#000000;">to such license on account of the sale of such Product in such country during such Calendar Quarter.</font><font style="font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:72pt;color:#000000;"></font><font style="color:#000000;">Royalty Floor</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Notwithstanding the foregoing </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Sections 8.5(c)</font><font style="font-weight:normal;color:#000000;"> and </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.7</font><font style="font-weight:normal;color:#000000;"> with respect to any Product in any Calendar Quarter, the royalties that would otherwise have been due under </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.5(a)</font><font style="font-weight:normal;color:#000000;"> with respect to Net Sales of such Product in the applicable country(ies) during such Calendar Quarter shall not be reduced by more than [***] as a result of all such reductions.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref32521459"></a><a name="_Ref520662571"></a><a name="_Ref518053089"></a><a name="_Hlk34676014"></a><font style="Background-color:#auto;text-decoration:none;">8.6</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Royalties During the Extended Commercialization Term</font><font style="font-weight:normal;color:#000000;"><a name="_Ref520662571"></a><a name="_Ref518053089"></a>.&nbsp;&nbsp;During the Extended Commercialization Term, <a name="_Hlk34676014"></a>Licensee shall pay to Ovid a quarterly non-refundable, non-creditable royalty of [***] on the annual Net Sales of all Products sold in the Licensee Territory, as calculated by multiplying the foregoing royalty rate by the amount of Net Sales of the Product in the Territory in the applicable Calendar Quarter.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref37333519"></a><a name="_Hlk34676027"></a><font style="Background-color:#auto;text-decoration:none;">8.7</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Royalty Reduction for Generic Competition</font><font style="font-weight:normal;color:#000000;">. If at any time Generic Product Competition exists in a given country with respect to a Product, then the royalty rate set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.5(a)</font><font style="font-weight:normal;color:#000000;"> with respect to sales of such Product in such country shall be reduced by [***]<a name="_Hlk34676027"></a>.&nbsp;&nbsp;For clarity, if Generic Product Competition ceases to exist, then the royalty rate shall no longer be reduced. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.8</font><font style="font-weight:normal;margin-left:108pt;color:#000000;"></font><font style="color:#000000;">Upstream License Agreement Payments</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Any and all payments that become due under the Lundbeck License Agreement as a result of activities under this Agreement, whether by or on behalf of Ovid or by Licensee or its Affiliate or Sublicensee, shall be the responsibility of Ovid and Ovid shall make such payment in accordance with the terms of the Lundbeck License Agreement. </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;">9.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Ref208042754"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;text-transform:none;color:#000000;"></font><font style="font-variant: small-caps;text-transform:none;color:#000000;">Payment; Records; Audits</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref151314221"></a><a name="_Ref513470775"></a><a name="_Ref376954572"></a><font style="Background-color:#auto;text-decoration:none;">9.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Payment; Reports</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;All royalty payments due under this Agreement shall be accompanied by a report setting forth, on a country-by-country basis, Net Sales of the Products by Licensee and its Affiliates and Sublicensees in the Licensee Territory in sufficient detail to permit confirmation of the accuracy of the royalty payment made, including, for each country, the number of Products sold, the gross sales and Net Sales of Products, including the deductions from gross sales to arrive at Net Sales, the royalty payable, the exchange rates used, any adjustments to the royalty paid during the Royalty Term pursuant to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.5(c)</font><font style="font-weight:normal;color:#000000;">, and whether any Net Sales milestone under </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.4</font><font style="font-weight:normal;color:#000000;"> has been achieved.&nbsp;&nbsp;Within [***] following the end of each Calendar Quarter during the Royalty Term and Extended Commercialization Term, Licensee shall provide Ovid with the foregoing report and the payment due for such Calendar Quarter.&nbsp;&nbsp;For clarity, royalty payments during the Extended Commercialization Term shall not be subject to any offsets or reductions whatsoever, including those set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.5(c)</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Prior to the First Commercial Sale of the Product in the Licensee Territory, the Parties will agree on the form of royalty report.&nbsp;&nbsp;Licensee shall submit a single report for all Net Sales during a Calendar Year, including all of Licensee&#8217;s and its Affiliates&#8217; and Sublicensees&#8217; Net Sales, but shall separately identify the Net Sales and other information applicable to each entity.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Exchange Rate; Manner and Place of Payment</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;All references to dollars and &#8220;$&#8221; herein shall refer to U.S. dollars.&nbsp;&nbsp;Unless otherwise specified herein, all payments due under this Agreement shall be payable in U.S. dollars.&nbsp;&nbsp;When conversion of Net Sales from any currency other than U.S. dollars is required, such conversion shall be at the exchange rate equal to the conversion rate for the U.S. dollar for the currency of the country in which the applicable Net Sales were made as published by [***].&nbsp;&nbsp;All payments owed under this Agreement shall be made by wire transfer in immediately available funds to a bank and account designated in writing by Ovid, unless otherwise specified in writing by Ovid.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref378154429"></a><a name="_Ref383956837"></a><font style="Background-color:#auto;text-decoration:none;">9.3</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Taxes</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Taxes on Income</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Each Party shall be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the activities of the Parties under this Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tax Cooperation</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The Parties agree to cooperate with one another and use reasonable efforts to avoid or reduce tax withholding or similar obligations in respect of the milestone payments, royalty payments, and other payments made by Licensee to Ovid under this Agreement.&nbsp;&nbsp;To the extent that Licensee is required by Applicable Laws to deduct and withhold taxes on any payment to Ovid, Licensee shall withhold the amount of such taxes otherwise payable to Ovid and, if and when necessary pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Ovid an official tax certificate or other evidence of such payment sufficient to enable Ovid to claim such payment of taxes.&nbsp;&nbsp;Ovid shall provide Licensee any tax forms that may be reasonably necessary in order for Licensee to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty, to the extent legally able to do so.&nbsp;&nbsp;Ovid shall use reasonable efforts to provide any such tax forms to Licensee in advance of the due date.&nbsp;&nbsp;Licensee shall provide Ovid with reasonable assistance to enable the recovery, as permitted by Applicable Laws, of withholding taxes or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of Ovid.&nbsp;&nbsp;Licensee shall have the right to deduct any such tax, levy, or charge actually paid from payment due to Ovid.&nbsp;&nbsp;Each Party agrees to assist the other Party in claiming exemption from such deductions or withholdings under double taxation or similar agreement or treaty from time to time in force and in minimizing the amount required to be so withheld or deducted.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Taxes Resulting From Licensee&#8217;s Action</font><font style="font-weight:normal;color:#000000;">. If a Party takes any action of its own discretion (not required by a Regulatory Authority and without consent of the other Party), including any assignment, sublicense, change of place of incorporation, or failure to comply with Applicable Laws or filing or record retention requirements, which results in a withholding or deduction obligation (a &#8220;</font><font style="color:#000000;">Withholding Tax Action</font><font style="font-weight:normal;color:#000000;">&#8221;), then such Party shall pay the sum associated with such Withholding Tax Action.&nbsp;&nbsp;For clarity, if Licensee undertakes a Withholding Tax Action, then the sum payable by Licensee (in respect of which such deduction or withholding is required to be made) shall be increased to the extent necessary to ensure that Ovid receives a sum equal to the sum which it would have received had no such Withholding Tax Action occurred.&nbsp;&nbsp;If a change in Applicable Laws results in a withholding or deduction obligation absent either Party taking a Withholding Tax Action, then the amount of such withholding or deduction obligation shall be paid by Licensee to the applicable Governmental Authority on behalf of Ovid, provided that Licensee shall assist Ovid in minimizing or recovering such withholding or deduction obligation.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">The Parties shall use commercially reasonable efforts to invoke the application of any applicable bilateral income tax treaty that would reduce or eliminate otherwise applicable taxes with respect to payments payable pursuant to this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref37275295"></a><font style="Background-color:#auto;text-decoration:none;">9.4</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Records; Audit</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Each Party shall maintain complete and accurate records in sufficient detail in relation to this Agreement to permit the other Party to confirm the accuracy of the amount of Development Costs to be reimbursed or shared, achievement of Net Sales milestones, and the amount of royalty and other payments payable under this Agreement.&nbsp;&nbsp;Each Party will keep such books and records for at least [***] following the Calendar Year to which they pertain.&#160; Upon reasonable prior notice, such records shall be inspected during regular business hours at such place or places where such records are customarily kept by an independent certified public accountant (the &#8220;</font><font style="color:#000000;">Auditor</font><font style="font-weight:normal;color:#000000;">&#8221;) selected by the auditing Party and reasonably acceptable to the audited Party for the sole purpose of verifying for the auditing Party the accuracy of the financial reports furnished by the audited Party pursuant to this Agreement or of any payments made, or required to be made, by or to the audited Party pursuant to this Agreement.&nbsp;&nbsp;Before beginning its audit, the Auditor shall execute an undertaking acceptable to each Party by which the Auditor agrees to keep confidential all information reviewed during the audit.&nbsp;&nbsp;Such audits may occur no more often than [***].&nbsp;&nbsp;Each Party shall only be entitled to audit the books and records from the [***] in which the audit request is made.&nbsp;&nbsp;The Auditor shall not disclose the audited Party&#8217;s Confidential Information to the auditing Party, and shall only verify the accuracy or inaccuracy of the financial reports furnished by the audited Party or the amount of payments by such Party under this Agreement, and, in the case of any inaccuracy, the amount of such inaccuracy.&nbsp;&nbsp;In the event that the final result of the inspection reveals an undisputed underpayment or overpayment, the underpaid or overpaid amount shall be settled within [***] after the Auditor&#8217;s report.&nbsp;&nbsp;The auditing Party shall bear the full cost of such audit unless such audit reveals an overpayment to, or an underpayment by, the audited Party, which underpayment or overpayment was more than [***], in which case the audited Party shall reimburse the auditing Party for the costs for such audit.&nbsp;&nbsp;For clarity, the foregoing audit rights may also be exercised by Ovid on behalf of Lundbeck pursuant to the terms of the Lundbeck License Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref377142243"></a><font style="Background-color:#auto;text-decoration:none;">9.5</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Late Payments</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;In the event that any payment due under this Agreement is not paid when due in accordance with the applicable provisions of this Agreement, the payment shall accrue interest from the date due [***]; provided, however, that in no event shall such rate exceed the maximum legal annual interest rate.&nbsp;&nbsp;The payment of such interest shall not limit the Party entitled to receive payment from exercising any other rights it may have as a consequence of the lateness of any payment.&nbsp;&nbsp;</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;">10.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Ref208047274"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;text-transform:none;color:#000000;"></font><font style="font-variant: small-caps;text-transform:none;color:#000000;">Intellectual Property </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref151411538"></a><font style="Background-color:#auto;text-decoration:none;">10.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Ownership</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref384031623"></a><a name="_Ref515966335"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Data</font><font style="font-weight:normal;color:#000000;">. All Data generated in connection with any Development or Commercial activities with respect to any Product conducted solely by or on behalf of Ovid and its Affiliates and licensees (other than Licensee) (the &#8220;</font><font style="color:#000000;">Ovid Data</font><font style="font-weight:normal;color:#000000;">&#8221;) shall be the sole and exclusive property of Ovid or such Affiliates or licensees, as applicable.&nbsp;&nbsp;All Data generated in connection with any Development or Commercial activities with respect to any Product conducted solely by or on behalf of Licensee or its Affiliates or Sublicensees (the &#8220;</font><font style="color:#000000;">Licensee Data</font><font style="font-weight:normal;color:#000000;">&#8221;) shall be the sole </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">and exclusive property of Licensee or such Affiliates or Sublicensees, as applicable.&nbsp;&nbsp;All Data generated in connection with any Joint Development Activities or joint Commercial activities with respect to any Product and for which the Parties are sharing Development Costs pursuant to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">8.2(a)</font><font style="font-weight:normal;color:#000000;"> shall be jointly owned by the Parties.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">For clarity, each Party shall have access and right to use and reference the other Party&#8217;s Data as and to the extent set forth in this Agreement.</font><font style="font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Inventions</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Inventorship of any Inventions will be determined in accordance with the standards of inventorship and conception under U.S. patent laws.&nbsp;&nbsp;The Parties will work together to resolve any issues regarding inventorship or ownership of Inventions.&nbsp;&nbsp;Ownership of Inventions will be allocated as follows: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref24277713"></a><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Ovid shall solely own all data, Inventions, and Patents claiming such Inventions that relate to the composition, formulation, manufacture, dosing, new indications or method of use of the Compound, or any improvement of any such composition, manufacture, or use, including in combination with other agents or components (each, a &#8220;</font><font style="color:#000000;">Compound Invention</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;All Compound Inventions will be included in the Ovid Know-How, and Patents in the Licensee Territory claiming such Inventions will be included in the Ovid Patents.&nbsp;&nbsp;To the extent that any Compound Invention is made by Licensee, whether solely or jointly with Ovid, Licensee shall, and hereby does, transfer and assign to Ovid, without additional consideration, all of its right, title, and interest in such Compound Invention.&nbsp;&nbsp;To effectuate the foregoing assignment, Licensee shall ensure that all entities and individuals that perform any Development under this Agreement are under a written or other legally enforceable obligation to assign all of its right, title, and interest in such Invention to Licensee or to an entity that is obligated to assign all right, title, and interest to Licensee. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref515967800"></a><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Except for Compound Inventions, each Party shall solely own any Inventions made solely by it and its Affiliates&#8217; employees, agents, or independent contractors, and the Parties shall jointly own any Inventions that are made jointly by employees, agents, or independent contractors of one Party and its Affiliates together with employees, agents, or independent contractors of the other Party and its Affiliates (&#8220;</font><font style="color:#000000;">Joint Inventions</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;All Patents claiming patentable Joint Inventions shall be referred to herein as &#8220;</font><font style="color:#000000;">Joint Patents</font><font style="font-weight:normal;color:#000000;">&#8221;.&nbsp;&nbsp;Except to the extent either Party is restricted by the licenses granted to the other Party under this Agreement, each Party shall be entitled to practice, license, assign, and otherwise exploit its interest under the Joint Inventions and Joint Patents without the duty of accounting or seeking consent from the other Party.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref208043857"></a><font style="Background-color:#auto;text-decoration:none;">10.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Patent Prosecution and Maintenance</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref513473341"></a><a name="_Ref376938749"></a><a name="_Ref383960905"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Ovid Patents</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Subject to the remainder of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 10.2(a)</font><font style="font-weight:normal;color:#000000;">, and as between the Parties, Ovid shall have the sole right, but not the obligation, to control the preparation, filing, prosecution, and maintenance (including any interferences, reissue proceedings, reexaminations, inter partes review, patent term extensions, applications for supplementary protection certificates, oppositions, invalidation proceedings and defense of validity or enforceability challenges) of the Ovid Patents (other than Joint Patents) worldwide, using counsel of its own choice.&nbsp;&nbsp;Subject to the terms of the Lundbeck License Agreement, Ovid shall (A) keep Licensee informed of material </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">progress with regard to the preparation, filing, prosecution, and maintenance of the Ovid Patents in the Licensee Territory, sufficiently in advance for Licensee to be able to review any material documents, including content, timing, and jurisdiction of the filing of such Ovid Patents in the Licensee Territory, (B) consult with, and consider in good faith the requests and suggestions of, Licensee with respect to strategies for filing, prosecuting, and defending, if any, the Ovid Patents in the Licensee Territory, and (C), </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">In the event that Ovid desires to abandon or cease prosecution or maintenance of any Ovid Patent in any country in the Licensee Territory, Ovid shall provide reasonable prior written notice to Licensee of such intention to abandon (which notice shall, to the extent possible, be given no later than [***] prior to the next deadline for any action that must be taken with respect to any such Ovid Patent in the relevant patent office).&nbsp;&nbsp;In such case, upon Licensee&#8217;s written election provided no later than [***] after such notice from Ovid, Ovid shall continue prosecution and maintenance of such Ovid Patent at Licensee&#8217;s direction and expense.&nbsp;&nbsp;If Licensee does not provide such election within [***] after such notice from Ovid, Ovid may, in its sole discretion, continue prosecution and maintenance of such Ovid Patent or discontinue prosecution and maintenance of such Ovid Patent.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref513473533"></a><a name="_Ref377133634"></a><a name="_Ref383109901"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licensee Patents</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Subject to the remainder of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 10.2(b)</font><font style="font-weight:normal;color:#000000;">, Licensee shall have the first right, but not the obligation, to control the preparation, filing, prosecution and maintenance (including any interferences, reissue proceedings, reexaminations, patent term extensions, applications for supplementary protection certificates, oppositions, invalidation proceedings, and defense of validity or enforceability challenges) of all Licensee Patents (other than Joint Patents) worldwide, at its sole cost and expense and by counsel of its own choice in the Licensee Territory and by counsel mutually agreed to by the Parties in the Ovid Territory.&nbsp;&nbsp;Licensee shall keep Ovid informed of the status of filing, prosecution, maintenance, and defense, if any, of the Licensee Patents, and Licensee shall consult with, and consider in good faith the requests and suggestions of, Ovid with respect to strategies for filing, prosecuting, and defending the Licensee Patents.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">In the event that Licensee desires to abandon or cease prosecution or maintenance of any Licensee Patent, Licensee shall provide reasonable prior written notice to Ovid of such intention to abandon (which notice shall, to the extent possible, be given no later than [***] prior to the next deadline for any action that must be taken with respect to any such Licensee Patent in the relevant patent office).&nbsp;&nbsp;In such case, upon Ovid&#8217;s written election provided no later than [***] after such notice from Licensee, Ovid shall have the right to assume prosecution and maintenance of such Licensee Patent at Ovid&#8217;s expense and Licensee shall assign to Ovid all of its rights, title, and interest in and to such Licensee Patent.&nbsp;&nbsp;If Ovid does not provide such election within [***] after such notice from Licensee, Licensee may, in its sole discretion, continue prosecution and maintenance of such Licensee Patent or discontinue prosecution and maintenance of such Licensee Patent.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref377134235"></a><a name="_Ref208046341"></a><a name="_Ref208046284"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Joint Patents</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Subject to the remainder of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 10.2(c)</font><font style="font-weight:normal;color:#000000;">, Ovid shall have the first right, but not the obligation, to prepare, file, prosecute, and maintain (including any </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">interferences, reissue proceedings, reexaminations, patent term extensions, applications for supplementary protection certificates, oppositions, invalidation proceedings, and defense of validity or enforceability challenges) Joint Patents using a patent counsel selected by Ovid in the Ovid Territory a</font><font style="font-weight:normal;color:#000000;">nd counsel mutually agreed to by the Parties in the Licensee Territory.</font><font style="font-weight:normal;color:#000000;">.</font><font style="font-weight:normal;color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></font><font style="font-weight:normal;color:#000000;">Ovid shall keep Licensee informed of material progress with regard to the preparation, filing, prosecution, maintenance, and defense, if any, of the Joint Patents, including content, timing, and jurisdiction of the filing of such Joint Patents, and Ovid shall consult with, and consider in good faith the requests and suggestions of, Licensee with respect to filing, prosecuting, and defending of the Joint Patents in the Licensee Territory.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">In the event that Ovid desires to abandon or cease prosecution or maintenance of any Joint Patent in any country in the Licensee Territory, Ovid shall provide reasonable prior written notice to Licensee of such intention to abandon (which notice shall, to the extent possible, be given no later than sixty (60) days prior to the next deadline for any action that must be taken with respect to any such Joint Patent in the relevant patent office).&nbsp;&nbsp;In such case, at Licensee&#8217;s sole discretion, upon written notice from Licensee to Ovid, Licensee may elect to continue prosecution or maintenance of any such Joint Patent at its own expense, and Ovid shall execute such documents and perform such acts, at Licensee&#8217;s expense, as may be reasonably necessary to allow Licensee to continue the prosecution and maintenance of such Joint Patent in such country in the Licensee Territory.&nbsp;&nbsp;Any such assignment shall be completed in a timely manner to allow Licensee to continue prosecution and maintenance of any such Joint Patent and any such Patent so assigned shall cease to be either a Joint Patent or a Licensee Patent and shall no longer be subject to the licenses and other rights granted by Licensee to Ovid under this Agreement </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Cooperation</font><font style="font-weight:normal;color:#000000;">. Each Party agrees to cooperate fully in the preparation, filing, prosecution, maintenance, and defense, if any, of Patents under </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 10.2</font><font style="font-weight:normal;color:#000000;"> and in the obtaining and maintenance of any patent term extensions and supplementary protection certificates and their equivalents, at its own cost (except as expressly set forth otherwise in this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 10</font><font style="font-weight:normal;color:#000000;">).&nbsp;&nbsp;Such cooperation includes (i)&#160;executing all papers and instruments, or requiring its employees or contractors, to execute such papers and instruments, so as enable the other Party to apply for and to prosecute patent applications in any country as permitted by </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 10.2</font><font style="font-weight:normal;color:#000000;">; and (ii)&#160;promptly informing the other Party of any matters coming to such Party&#8217;s attention that may affect the preparation, filing, prosecution, or maintenance of any such patent application and the obtaining of any patent term extensions or supplementary protection certificates or their equivalents.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref104969846"></a><a name="_Ref513475056"></a><a name="_Ref376939860"></a><font style="Background-color:#auto;text-decoration:none;">10.3</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Patent Enforcement</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref515970228"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notice</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Each Party shall notify the other within [***] of becoming aware of any alleged or threatened infringement by a Third Party of any of the Ovid Patents (including Joint Patents) in the Licensee Territory, which infringement adversely affects or is reasonably expected to adversely affect any Product, including any declaratory judgment, opposition, or similar action alleging the invalidity, unenforceability, or non-infringement of any of the Ovid Patents (collectively, &#8220;</font><font style="color:#000000;">Product Infringement</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Enforcement Right</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Ovid shall have the first right to use Ovid Commercially Reasonable Efforts to bring and control any legal action in connection with such </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">Product Infringement at its own expense as it reasonably determines appropriate.&nbsp;&nbsp;If Ovid (i) decides not to bring such legal action against a Product Infringement (the decision of which Ovid shall inform Licensee promptly) or (ii) Ovid otherwise fails to bring such legal action against a Product Infringement within </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;"> after first becoming aware of such Product Infringement, subject to the terms of the Lundbeck License Agreement, Licensee shall have the right to bring and control any legal action in connection with such Product Infringement at </font><font style="font-weight:normal;color:#000000;">its own expense as it reasonably determines appropriate after </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;"> Ovid. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Collaboration</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Each Party shall provide to the enforcing Party reasonable assistance in such enforcement, at such enforcing Party&#8217;s request and expense, including to be named in such action if required by Applicable Laws to pursue such action.&nbsp;&nbsp;The enforcing Party shall keep the other Party regularly informed of the status and progress of such enforcement efforts, shall reasonably consider the other Party&#8217;s comments on any such efforts, including determination of litigation strategy and filing of material papers to the competent court.&nbsp;&nbsp;The non-enforcing Party shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party shall at all times cooperate fully with the enforcing Party.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Expense and Recovery</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Except as set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 10.3(d)(ii),</font><font style="font-weight:normal;color:#000000;"> the enforcing Party shall be solely responsible for any cost and expenses incurred by such Party as a result of such enforcement action.&nbsp;&nbsp;If such Party recovers monetary damages in such enforcement action, such recovery shall be allocated [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref24400897"></a><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Notwithstanding the foregoing, if [***] to bring such action.&nbsp;&nbsp;If [***], then [***]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Other Infringement</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Except for Product Infringement as set forth above, each Party shall have the exclusive right to enforce its own Patents against any infringement anywhere in the world.&nbsp;&nbsp;For clarity, as between the Parties, Ovid shall have the exclusive right to enforce (i) the Ovid Patents against any infringement in the Licensee Territory that is not a Product Infringement, and (ii) the Ovid Patents and Joint Patents against any infringement in the Ovid Territory, in each case at its own expense as it reasonably determines appropriate, and subject to the terms of the Lundbeck License Agreement. The Parties shall discuss global enforcement strategy for the Ovid Patents and Licensee Patents, including the defense of validity and enforceability challenges arising from any enforcement action.&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.4</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Infringement of Third Party Rights</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;If any Product used or sold by Licensee, its Affiliates, or Sublicensees becomes the subject of a Third Party&#8217;s claim or assertion of infringement of any intellectual property rights in a jurisdiction within the Licensee Territory, Licensee shall promptly notify Ovid and the Parties shall promptly meet to consider the claim or assertion and the appropriate course of action and may, if appropriate, agree on and enter into a &#8220;common interest agreement&#8221; wherein the Parties agree to their shared, mutual interest in the outcome of such potential dispute.&nbsp;&nbsp;Absent any agreement to the contrary, and subject to claims for indemnification under </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Article 12</font><font style="font-weight:normal;color:#000000;">, each Party may defend itself from any such Third Party claim at its own cost and expense, provided that [***].&nbsp;&nbsp;If [***]. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref378106170"></a><a name="_Ref381316772"></a><font style="text-decoration:none;Background-color:#auto;">10.5</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Trademarks</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Product Trademarks</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Ovid shall develop and adopt trademarks, including trade names, trade dresses, branding, and logos, to be used for the Products (the &#8220;</font><font style="color:#000000;">Product Marks</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;Ovid shall own all Product Marks throughout the world and all goodwill in the Product Marks shall accrue to Ovid.&nbsp;&nbsp;The Parties shall collaborate to have a global, worldwide trademark to be used on the Product.&nbsp;&nbsp;In the event Ovid is unable to obtain or maintain the Product Marks for the Product in the Licensee Territory or in some countries in the Licensee Territory, the Parties shall collaborate to select such other Product Marks as may be available for registration and marketing of the Product in those countries. Ovid shall be responsible for the registration, maintenance, defense and enforcement of the Product Marks using counsel of its own choice in the Ovid Territory and counsel mutually agreed to by the Parties in the Licensee Territory.&nbsp;&nbsp;Ovid shall keep Licensee informed of material progress with regard to the registration, prosecution, maintenance and defense, if any, of the Product Trademarks in the Licensee Territory, including content, timing, and jurisdiction of the filing of such Product Trademarks in the Licensee Territory, sufficiently in advance for Licensee to be able to review any material documents, and Ovid shall consult with, and consider in good faith the requests and suggestions of, Licensee with respect to strategies for filing, prosecuting and defending the Product Trademarks in the Licensee Territory. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Trademark License</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Licensee shall use the Product Marks to Commercialize the Product in the Licensee Territory.&nbsp;&nbsp;In addition, unless prohibited by Applicable Laws, Licensee shall use Commercially Reasonable Efforts to include Ovid&#8217;s corporate trademark on the packaging and product information of the Products sold in the Licensee Territory to indicate that the Product is licensed from Ovid.&nbsp;&nbsp;Ovid hereby grants to Licensee a limited, royalty-free license to use Ovid&#8217;s corporate trademark and Product Marks solely in connection with the Commercialization of the Product in the Licensee Territory under this Agreement.&nbsp;&nbsp;All use of the Product Marks and Ovid&#8217;s corporate trademark shall comply with Applicable Laws and shall be subject to Ovid&#8217;s review and approval.&nbsp;&nbsp;For clarity, Licensee shall also include its (or its Affiliate&#8217;s or Sublicensee&#8217;s, as applicable) corporate logo in the Product sold in the Licensee Territory.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Product Domain Names</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;In the Licensee Territory, Licensee shall have the exclusive right to register Product Marks as domain names, including all internet domain names under all existing top level domains. This includes as example top level domains such as .com, .net., .info and country code top level domains such as .dk, .uk and .it.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;">11.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;text-transform:none;color:#000000;"></font><font style="font-variant: small-caps;text-transform:none;color:#000000;">Representations and Warranties</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref37274050"></a><font style="Background-color:#auto;text-decoration:none;">11.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Mutual Representations and Warranties</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Each Party represents and warrants to the other that, as of the Effective Date: (a) it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof, (b) it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person or persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate or partnership action, (c)&#160;this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not conflict with any agreement, instrument, or understanding, oral or written, to which it is a Party or by which it may be bound, nor violate any material law or regulation of any court, governmental body, or administrative or other agency having jurisdiction </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">over it, (d)&#160;it has the right to grant the licenses granted by it under this Agreement; (e) the execution and delivery of this Agreement and the performance of such Party&#8217;s obligations under this Agreement do not and will not result in the breach of, constitute a default, cause the acceleration of performance, require any consent under, or result in the creation of any lien, charge or encumbrance upon any of its property or assets pursuant to any material instrument or agreement to which it is a party, or by which it or its properties may be bound or affected, as of the Effective Date; and (f) it is not a party to any agreement, arrangement or understanding with any Third Party which in any significant way prevents it from fulfilling any its material obligations under the terms of this Agreement.</font><font style="font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref377138516"></a><a name="_Ref151411616"></a><font style="Background-color:#auto;text-decoration:none;">11.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Covenants</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Employees, Consultants, and Contractors</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Each Party covenants that it has obtained or will obtain written agreements from each of its employees, consultants, and contractors who perform Development activities pursuant to this Agreement, which agreements will obligate such persons to obligations of confidentiality and non-use and to assign (or, in the case of contractor, grant a license under) Inventions, in each case in a manner consistent with the provisions of this Agreement. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Debarment</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Each Party represents, warrants, and covenants to the other Party that it is not debarred or disqualified under the U.S. Federal Food, Drug and Cosmetic Act, as may be amended, or comparable laws in any country or jurisdiction other than the U.S., and it does not, and will not during the Term, employ or use the services of any person who is debarred or disqualified, in connection with activities relating to the Compound or any Product.&nbsp;&nbsp;In the event that either Party becomes aware of the debarment or disqualification or threatened debarment or disqualification of any person providing services to such Party, including the Party itself or its Affiliates or Sublicensees, that directly or indirectly relate to activities contemplated by this Agreement, such Party shall immediately notify the other Party in writing and such Party shall cease employing, contracting with, or retaining any such person to perform any such services.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref377138518"></a><a name="_Ref513466296"></a><a name="_Ref208055308"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Compliance</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Licensee covenants as follows: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk31040546"></a><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">In the performance of its obligations under this Agreement, Licensee shall comply and shall cause its and its Affiliates&#8217; employees and contractors to comply with all Applicable Laws. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Licensee and its and its Affiliates&#8217; employees and contractors shall not, in connection with the performance of their respective obligations under this Agreement, directly or indirectly through Third Parties, pay, promise, or offer to pay, or authorize the payment of, any money or give any promise or offer to give, or authorize the giving of anything of value to a Public Official or Entity or other person for purpose of obtaining or retaining business for or with, or directing business to, any person, including, Licensee (and Licensee represents and warrants that as of the Effective Date, Licensee, and to its knowledge, its and its Affiliates&#8217; employees and contractors, have not directly or indirectly promised, offered, or provided any corrupt payment, gratuity, emolument, bribe, kickback, illicit gift, or hospitality or other illegal or unethical benefit to a Public Official or Entity or any other person in connection with the performance of Licensee&#8217;s obligations under this Agreement, and Licensee covenants that it and </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">its Affiliates&#8217; employees and contractors shall not, directly or indirectly, engage in any of the foregoing).&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Licensee and its Affiliates, and their respective employees and contractors, in connection with the performance of their respective obligations under this Agreement, (1) shall not violate or cause the violation of the FCPA, Export Control Laws, or any other Applicable Laws, or otherwise cause any reputational harm to Ovid, and (2) shall immediately notify Ovid if Licensee has any information or suspicion that there may be a violation of any of the foregoing in connection with activities under this Agreement. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref381319846"></a><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;"><a name="_Ref381319846"></a>In connection with the performance of its obligations under this Agreement, Licensee shall comply and shall cause its and its Affiliates&#8217; employees and contractors to comply with Licensee&#8217;s own anti-corruption and anti-bribery policy, a copy of which has been provided to Ovid prior to the Effective Date. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref381319856"></a><font style="Background-color:#auto;text-decoration:none;">(v)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Ovid will have the right, upon reasonable prior written notice and during Licensee&#8217;s regular business hours, to conduct at its own cost and expenses inspections of and to audit Licensee&#8217;s books and records in the event of a suspected violation or to ensure compliance with the representations, warranties, and covenants of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 11.2(c)</font><font style="font-weight:normal;color:#000000;"><a name="_Ref381319856"></a>; provided, however, that in the absence of good cause for such inspections and audits, Ovid may exercise this right no more than annually. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(vi)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">In the event that Licensee has violated or been suspected of violating any of the representations, warranties, or covenants in this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 11.2(c)</font><font style="font-weight:normal;color:#000000;">, Licensee will cause its or its Affiliates&#8217; personnel or others working under its direction or control to submit to periodic training that Licensee will provide on anti-corruption law compliance.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref340776472"></a><font style="Background-color:#auto;text-decoration:none;">(vii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Licensee will, at Ovid&#8217;s request, annually certify to Ovid in writing Licensee&#8217;s compliance, in connection with the performance of Licensee&#8217;s obligations under this Agreement, with the representations, warranties, or covenants in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 11.2(c)</font><font style="font-weight:normal;color:#000000;"><a name="_Ref340776472"></a>, which certification shall be issued by Licensee&#8217;s global commercial head for the Product.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(viii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Ovid shall have the right to suspend or terminate this Agreement in its entirety where there is a credible finding, after a reasonable investigation, that Licensee, its Affiliates, or its Sublicensees, in connection with performance of Licensee&#8217;s obligations under this Agreement, has engaged in chronic or material violations of the FCPA. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.3</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Additional Ovid Representations and Warranties</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Ovid represents, warrants, and covenants, on behalf of itself and its Affiliates, as applicable, to Licensee that, as of the Effective Date:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:3.03%;text-indent:12.12%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">to the extent applicable to the performance of its obligations under this Agreement, Ovid shall comply and shall cause its and its Affiliates&#8217; employees and contractors to comply with all Applicable Laws;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Exhibit B</font><font style="font-weight:normal;color:#000000;"> lists all of the Ovid Patents as of the Effective Date that are necessary or useful for the Development, registration, use or Commercialization of the Product in the Licensee Territory;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">to Ovid&#8217;s knowledge, Ovid has the right to grant all rights and licenses it purports to grant to Licensee with respect to the Ovid Technology under this Agreement;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">as set forth above, Ovid is not a party to any agreement, arrangement or understanding with any Third Party which in any manner prevents it from fulfilling or affects its ability to perform any of its obligations under the terms of this Agreement to a material extent;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Ovid and its Affiliates have not granted any liens or security interests on the Ovid Technology; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Ovid and its Affiliates have not received any written notice from a Third Party that the Development of any Product conducted by Ovid prior to the Effective Date has infringed any Patents of any Third Party; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref151408277"></a><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Ovid and&nbsp;&nbsp;its Affiliates have not as of the Effective Date, and will not during the Term, grant any right to any Third Party under the Ovid Technology that would conflict with or derogate the licenses or other rights granted to Licensee hereunder;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">no claim or action has been brought or, to Ovid&#8217;s knowledge, threatened in writing, by any Third Party alleging that the Ovid Patents are invalid or unenforceable, and no Ovid Patent is the subject of any interference, opposition, cancellation, or other protest proceeding; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">to Ovid&#8217;s knowledge, no Third Party is infringing or misappropriating or has materially infringed or misappropriated the Ovid Technology in the Licensee Territory;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk30584340"></a><a name="_Hlk30585257"></a><font style="Background-color:#auto;text-decoration:none;">(j)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;"><a name="_Hlk30585257"></a>to Ovid&#8217;s knowledge, all research and Development of the Product conducted by or on behalf of Ovid prior to the Effective Date has been conducted in compliance with all Applicable Laws;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(k)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">to Ovid&#8217;s knowledge, it has disclosed to Licensee the clinical and non-clinical data in Ovid&#8217;s Control that is material to the evaluation of the safety, efficacy, and manufacturing process of the Product; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(l)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">to Ovid&#8217;s knowledge, there are no issues or information, which to Ovid&#8217;s knowledge and reasonable opinion, are reasonably likely to have a material impact on the Development of the Product that have not been fully disclosed to Licensee in the course of Licensee&#8217;s due diligence;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(m)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">to Ovid&#8217;s knowledge, the Ovid Technology includes all intellectual property rights which are reasonably necessary for the Development, registration, manufacture, use and Commercialization of the Product in the Licensee Territory as contemplated by the terms of this Agreement;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(n)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">no litigation has been brought against Ovid or any of its Affiliate, or threatened in writing, which would adversely affect the rights granted to Licensee under the Ovid Technology;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(o)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">neither Ovid nor any of its Affiliates has granted to any Third Party any right (including any license or option or other right to obtain a license) to develop or commercialize Product in the Field in the Licensee Territory that would conflict with the rights granted to Licensee under this Agreement;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(p)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">as set forth above, Ovid has not granted any Third Party any license, option or other right under or with respect to the Ovid Technology that would conflict with or derogate from the licenses, options and other rights granted to Licensee hereunder;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(q)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Ovid has the right to grant the License under Ovid Know-How specified herein free and clear of any liens or encumbrances which would have prevent or impair the grant of such rights;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(r)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">as set forth above, to Ovid&#8217;s knowledge,&nbsp;&nbsp;it has the right to grant the License specified in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 2.1</font><font style="font-weight:normal;color:#000000;"> free and clear of any liens or encumbrances which would prevent or impair the grant of such rights;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(s)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">as set forth above, to its knowledge, Ovid has not and will not enter into any agreement that is or would be inconsistent with the obligations, rights and licenses granted to Licensee in this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(t)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">it will use Ovid Commercially Reasonable Efforts in the conduct of the Development and Commercialization of the Compound and/or Product under this Agreement and in compliance with Applicable Law; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(u)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">as set forth above, it has to not and will not enter into any agreement that is or would be inconsistent with the obligations, rights and licenses granted to Licensee under this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(v)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Ovid: (i) has provided or made available to Licensee all material relevant documents and written communications and materials in its and its Affiliates&#8217; possession or Control from and to any Regulatory Authority in the Licensee Territory related to the Product; (ii) as of the Effective Date, Ovid and its Affiliates have not received any oral or written communication (including any notice of inspection, deficiency letter, warning letter or similar notice) from any Regulatory Authority alleging that the Development of Product by or on behalf of Ovid and its Affiliates is not currently materially in compliance with any and all applicable laws or regulations implemented by any Regulatory Authority; and (iii) to Ovid&#8217;s knowledge, Ovid and its Affiliates have not made, with respect to the Product, any untrue statement of material fact to any Regulatory Authority, or failed to disclose a material fact required to be disclosed to such Regulatory Authority.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.4</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Ovid Covenants Regarding the Lundbeck License Agreement</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Ovid shall make any and all payments that become due under the Lundbeck License Agreement as a result of any </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">activity under this Agreement, whether by or on behalf of Ovid or by Licensee or its Affiliate or Sublicensee, in each case in accordance with the terms of the Upstream License Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Ovid is in compliance in all material respects with the Lundbeck License Agreement, and, to Licensor&#8217;s knowledge, the other party to the Lundbeck License Agreement is not in breach or default in any respect of the Lundbeck License Agreement pertaining to the Product.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_DV_M642"></a><a name="_DV_M643"></a><a name="_DV_M644"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;"><a name="_DV_M642"></a><a name="_DV_M643"></a><a name="_DV_M644"></a>In the event that Ovid receives a notice or other communication alleging it is in breach (including a notice or other communication threatening termination) of the Lundbeck License Agreement, Ovid shall promptly provide Licensee with a copy of such notice.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Ovid shall not agree to any amendment or other modification (including termination) to the Lundbeck License Agreement in a manner that materially adversely affects the rights sublicensed to Licensee under this Agreement without Licensee&#8217;s prior written consent, such consent not to be unreasonably withheld or delayed. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref37359237"></a><a name="_cp_text_1_271"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Ovid and Licensee have negotiated with Lundbeck a technology transfer agreement (the &#8220;</font><font style="color:#000000;">Technology Transfer Agreement</font><font style="font-weight:normal;color:#000000;">&#8221;) for the transfer from Lundbeck to Licensee of Know-How, information, and data owned or controlled by Lundbeck that is necessary or reasonably useful for the manufacture of the Compound and Drug Product in or for the Licensee Territory and according to the technology transfer&nbsp;&nbsp;plan (the &#8220;</font><font style="color:#000000;">Technology Transfer Plan</font><font style="font-weight:normal;color:#000000;">&#8221;) as attached to the Technology Transfer Agreement. Such Technology Transfer Agreement shall provide such transfer to be finalized over a period of [***] starting from the Effective Date, <a name="_cp_text_1_271"></a>provided that such time period shall be extended to the extent of any delay caused by Licensee or any other factor outside Ovid&#8217;s reasonable control, including delays caused by any force majeure event as described in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 16.8</font><font style="font-weight:normal;color:#000000;"> of the Agreement.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.5</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Additional Licensee Representations, Warranties, and Covenants</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Licensee represents, warrants, and covenants to Ovid that, as of the Effective Date, Licensee has not granted, and will not grant during the Term, any right to any Third Party under the Licensee Technology that would conflict with the rights granted to Ovid hereunder.&nbsp;&nbsp;Licensee further represents, warrants, and covenants to Ovid that, as of the Effective Date, Licensee does not own or control any Licensee Patents.&nbsp;&nbsp;Licensee further represents, warrants, and covenants to Ovid that Licensee has the personnel, expertise, capacity, resources, equipment, and facilities necessary to implement the Technology Transfer Plan in accordance with the timelines specified therein so that such plan can be completed over a period of [***] following the date such technology transfer is commenced. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref377142271"></a><font style="Background-color:#auto;text-decoration:none;">11.6</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Disclaimer</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Except as expressly set forth in this Agreement, THE TECHNOLOGY AND INTELLECTUAL PROPERTY RIGHTS PROVIDED BY EACH PARTY HEREUNDER ARE PROVIDED &#8220;AS IS&#8221; AND EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES, IN ALL CASES WITH RESPECT THERETO.&nbsp;&nbsp;Without limiting the foregoing, (a)&#160;neither Party represents or warrants that any data obtained from conducting Clinical </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">Trials in one country or jurisdiction will comply with the laws and regulations of any other country or jurisdiction, and (b)&#160;neither Party represents or warrants the success of any study or test conducted pursuant to this Agreement or the safety or usefulness for any purpose of the technology it provides hereunder.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;">12.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Ref151408747"></a><a name="_Ref151391123"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;text-transform:none;color:#000000;"></font><font style="font-variant: small-caps;text-transform:none;color:#000000;">Indemnification</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref151408899"></a><a name="_Ref513408732"></a><font style="Background-color:#auto;text-decoration:none;">12.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Indemnification by Ovid</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;font-weight:normal;">Ovid</font><font style="font-weight:normal;color:#000000;"> hereby agrees to defend, indemnify, and hold harmless </font><font style="color:#000000;font-weight:normal;">Licensee</font><font style="font-weight:normal;color:#000000;"> and its Affiliates and their respective directors, officers, employees, and agents (each, a &#8220;</font><font style="color:#000000;">Licensee Indemnitee</font><font style="font-weight:normal;color:#000000;">&#8221;) from and against any and all liabilities, expenses, and losses including any product liability, personal injury, property damage, including reasonable legal expenses and attorneys&#8217; fees (collectively, &#8220;</font><font style="color:#000000;">Losses</font><font style="font-weight:normal;color:#000000;">&#8221;) to which any Licensee Indemnitee may become subject as a result of any claim, demand, action, or other proceeding by any Third Party to the extent such Losses arise out of or result from: (a) the Development, use, handling, storage, Commercialization, or other disposition of any Compound or Product by Ovid or its Affiliates or licensees or the contractors of any of them (excluding any activities by or on behalf of Licensee or its Affiliates or Sublicensees), (b) the negligence or willful misconduct of any Ovid Indemnitee, or (c)&#160;the breach by Ovid of </font><font style="color:#000000;font-weight:normal;">any warranty, representation, covenant, or agreement made by Ovid in this Agreement;</font><font style="font-weight:normal;color:#000000;"> except, in each case (a)-(c), to the extent such Losses arise out of any activities for which Licensee is obligated to indemnify any Ovid Indemnitee(s) under </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 12.2</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref151408871"></a><a name="_Ref513408710"></a><font style="Background-color:#auto;text-decoration:none;">12.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Indemnification by Licensee</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Licensee hereby agrees to defend, indemnify, and hold harmless Ovid, its Affiliates, and licensees and their respective directors, officers, employees, and agents (each, a &#8220;</font><font style="color:#000000;">Ovid Indemnitee</font><font style="font-weight:normal;color:#000000;">&#8221;) from and against any and all Losses to which any Ovid Indemnitee may become subject as a result of any claim, demand, action, or other proceeding by any Third Party to the extent such Losses arise out of: (a)&#160;the Development, use, handling, storage, Commercialization, or other disposition of any Compound or Product by Licensee or its Affiliates or Sublicensees or the contractor of any of them, (b) the negligence or willful misconduct of any Licensee Indemnitee, or (c)&#160;the breach by Licensee of </font><font style="color:#000000;font-weight:normal;">any warranty, representation, covenant, or agreement made by Licensee in this Agreement;</font><font style="font-weight:normal;color:#000000;"> except, in each case (a)-(c), to the extent such Losses arise out of any activities for which Ovid is obligated to indemnify any Licensee Indemnitee(s) under </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 12.1</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref515971787"></a><a name="OLE_LINK8"></a><a name="OLE_LINK9"></a><font style="Background-color:#auto;text-decoration:none;">12.3</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Procedure</font><font style="font-weight:normal;color:#000000;"><a name="OLE_LINK8"></a><a name="OLE_LINK9"></a>. A party that intends to claim indemnification under this Article&#160;12 (the &#8220;</font><font style="color:#000000;">Indemnitee</font><font style="font-weight:normal;color:#000000;">&#8221;) shall promptly notify the indemnifying Party (the &#8220;</font><font style="color:#000000;">Indemnitor</font><font style="font-weight:normal;color:#000000;">&#8221;) in writing of any Third Party claim, demand, action, or other proceeding (each, a &#8220;</font><font style="color:#000000;">Claim</font><font style="font-weight:normal;color:#000000;">&#8221;) in respect of which the Indemnitee intends to claim such indemnification, and the Indemnitor shall have sole control of the defense or settlement thereof.&nbsp;&nbsp;The Indemnitee may participate at its expense in the Indemnitor&#8217;s defense of and settlement negotiations for any Claim with counsel of the Indemnitee&#8217;s own choice.&nbsp;&nbsp;The indemnity arrangement in this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Article&#160;12</font><font style="font-weight:normal;color:#000000;"> shall not apply to amounts paid in settlement of any action with respect to a Claim if such settlement is effected without the consent of the Indemnitor, which consent shall not be unreasonably withheld or delayed.&nbsp;&nbsp;The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any action with respect to a Third Party Claim shall only relieve the Indemnitor of its indemnification obligations under this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Article&#160;12</font><font style="font-weight:normal;color:#000000;"> if and to the extent the Indemnitor is actually prejudiced thereby.&nbsp;&nbsp;The Indemnitee shall cooperate fully with the Indemnitor and its legal </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">representatives in the investigation of any action with respect to a Claim covered by this indemnification.</font><font style="font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.4</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Insurance</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Each Party, at its own expense, hereby agrees and undertakes to maintain insurance policies with respect to the activities to be made by and obligations assumed by each of the Party in accordance to the provisions of this Agreement. In this respect the Parties agree to carry out at their sole expense and with a commercially reasonable insurance company, the following liability policies, in an amount consistent with sound business practice and reasonable in light of its obligations under this Agreement during the Term:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Clinical Trial liability policies reasonable for each specific phase and country in which a Party is conducting activities under this Agreement, with limits and warranties no less than those required by Applicable Law; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">product liability policies with limits at a minimum equivalent to [***] per each occurrence and per year.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Public and Product liability policies above shall start from the Effective Date and last for a period of [***] after the expiration or the earlier termination of the Agreement. Each Party shall provide a certificate of insurance (or evidence of self-insurance) evidencing such coverages to the other Party upon request.&nbsp;&nbsp;It is understood that such policies shall not be construed to create any limit of either Party&#8217;s obligations or liabilities with respect to its indemnification obligations hereunder.&nbsp;&nbsp;In the event of use by either Party of subcontractors, sublicensees, or any Third Party in the performance of such Party&#8217;s obligations under the Agreement, such Party shall ensure that its subcontractor, sublicensee, or Third Party has a proper and adequate general liability or professional liability insurance to cover its risks with respect to the other Party for damages mentioned above.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref151408743"></a><a name="_Ref151411619"></a><a name="_Ref381320203"></a><a name="_Ref513408056"></a><a name="_Ref513409232"></a><font style="Background-color:#auto;text-decoration:none;">12.5</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Limitation of Liability</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS, IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES; </font><font style="text-transform:uppercase;font-weight:normal;color:#000000;">provided, however, that this </font><font style="text-decoration:underline;text-transform:uppercase;font-weight:normal;color:#000000;">Section 12.5</font><font style="text-transform:uppercase;font-weight:normal;color:#000000;"> shall not be construed to limit either Party&#8217;s indemnification obligations under this </font><font style="text-decoration:underline;text-transform:uppercase;font-weight:normal;color:#000000;">Article 12</font><font style="text-transform:uppercase;font-weight:normal;color:#000000;"> or damages available as a result of a breach of a Party&#8217;s EXCLUSIVITY obligations under </font><font style="text-decoration:underline;text-transform:uppercase;font-weight:normal;color:#000000;">SECTION 2.8</font><font style="text-transform:uppercase;font-weight:normal;color:#000000;"> or CONFIDENTIALITY OBLIGATIONS UNDER Article 13</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;">13.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Ref513408205"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;text-transform:none;color:#000000;"></font><font style="font-variant: small-caps;text-transform:none;color:#000000;">Confidentiality</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref151411690"></a><a name="_Ref513459886"></a><a name="OLE_LINK29"></a><a name="OLE_LINK30"></a><font style="Background-color:#auto;text-decoration:none;">13.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Confidential Information</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, the Parties agree that, during the Term and for [***] thereafter, the receiving Party shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as expressly provided for in this Agreement any Confidential Information of the other Party, and both Parties shall keep confidential and, subject to the remainder of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Article 13</font><font style="font-weight:normal;color:#000000;">, shall not publish or otherwise disclose </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">the terms of this Agreement</font><font style="font-weight:normal;color:#000000;"><a name="OLE_LINK29"></a><a name="OLE_LINK30"></a>.&nbsp;&nbsp;Each Party may use the other Party&#8217;s Confidential Information only to the extent required to accomplish the purposes of this Agreement, including exercising its rights or performing its obligations under this Agreement.&nbsp;&nbsp;Each Party will use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but no less than reasonable care) to ensure that its employees, agents, consultants, contractors, and other representatives do not disclose or make any unauthorized use of the Confidential Information </font><font style="font-weight:normal;color:#000000;">of the other Party</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Each Party will promptly notify the other upon discovery of any unauthorized use or disclosure of the Confidential Information of the other Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref151411692"></a><font style="Background-color:#auto;text-decoration:none;">13.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Exceptions</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The obligations of confidentiality and restriction on use under </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 13.1</font><font style="font-weight:normal;color:#000000;"> will not apply to any information that the receiving Party can prove by competent written evidence: (a)&#160;is at the time of disclosure, or thereafter becomes, through no act or failure to act on the part of the receiving Party, generally known or available to the public; (b)&#160;is known by the receiving Party at the time of receiving such information, other than by previous disclosure of the disclosing Party, or its Affiliates, employees, agents, consultants, or contractors; (c)&#160;is disclosed to the receiving Party without restriction by a Third Party who has no obligation of confidentiality or limitations on use with respect thereto; or (d)&#160;is independently discovered or developed by the receiving Party without the use of or reference to the Confidential Information belonging to the disclosing Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref151411694"></a><a name="_Ref383971027"></a><font style="Background-color:#auto;text-decoration:none;">13.3</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Authorized Disclosure</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Each Party may disclose Confidential Information belonging to the other Party as expressly permitted by this Agreement or if and to the extent such disclosure is reasonably necessary in the following instances:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">filing, prosecuting, and maintaining Patents as permitted by this Agreement;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">submitting and maintaining Regulatory Filings for Products that such Party has a license or right to Develop or Commercialize under this Agreement in a given country or jurisdiction; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref151391348"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">prosecuting and defending litigation as permitted by this Agreement; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref151391358"></a><a name="_Ref381319945"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">complying with applicable court orders or governmental regulations, including regulations promulgated by securities exchanges; and </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref381319915"></a><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">disclosure to its and its Affiliates&#8217; employees, consultants, contractors, agents, licensees, and sublicensees, in each case on a need-to-know basis in connection with the Development, manufacture, or Commercialization of the Compound and Products in accordance with the terms of this Agreement, in each case under written obligations of confidentiality and non-use at least as stringent as those herein;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">disclosure to actual and bona fide potential investors, acquirors, licensees, and other financial or commercial partners solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition, collaboration, or other business relationship, in each case under written obligations of confidentiality and non-use at least as </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">stringent as those herein, provided that the disclosing Party redacts the financial terms and other provisions of this Agreement that are not reasonably required to be disclosed in connection with such potential investment, acquisition, collaboration, or business transaction which redaction shall be prepared in consultation with the other Party; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">disclosure to Third Party licensors of intellectual property that is related to the Compound or any Product (e.g., the Third Party that is party to the Lundbeck License Agreement) for the purpose of meeting reporting obligations under such Third Party agreement.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party&#8217;s Confidential Information pursuant to <font style="text-decoration:underline;">Section 13.3(c)</font> or <font style="text-decoration:underline;">13.3(d)</font>, it will, except where impracticable, give reasonable advance notice to the other Party of such disclosure, and to the extent possible, at least [***] notice, and use the same diligent efforts to secure confidential treatment of such Confidential Information as such Party would use to protect its own confidential information, but in no event less than reasonable efforts.&nbsp;&nbsp;In any event, the Parties agree to take all reasonable action to avoid disclosure of Confidential Information hereunder.&nbsp;&nbsp;Any information disclosed pursuant to <font style="text-decoration:underline;">Section 13.3</font> shall remain Confidential Information and subject to the restrictions set forth in this Agreement, including the foregoing provisions of this <font style="text-decoration:underline;">Section 13</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref440877349"></a><a name="_Ref151411700"></a><font style="Background-color:#auto;text-decoration:none;">13.4</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Publications</font><font style="font-weight:normal;color:#000000;">.</font><font style="color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref24400956"></a><a name="_Ref151411703"></a><a name="_Ref376902683"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Ovid shall have the right to review and comment on any material proposed for disclosure or publication by Licensee regarding results of and other information regarding Licensee&#8217;s Development activities during the Term with respect to the Compound and Product, whether by oral presentation, manuscript, or abstract.&nbsp;&nbsp;Before any such material is submitted for publication, or presentation of any such material is made, Licensee shall deliver a complete copy of the material proposed for disclosure to Ovid at least [***] prior to submitting the material to a publisher or initiating any other disclosure, or as close to these time frames as reasonably possible.&nbsp;&nbsp;Ovid shall review any such material and give its comments to Licensee within [***] of the receipt of such material.&nbsp;&nbsp;With respect to oral presentation materials and abstracts, Ovid shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to Licensee with comments, if any.&nbsp;&nbsp;Subject to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 13.4(b)</font><font style="font-weight:normal;color:#000000;">, following the expiration of the applicable time period for review, Licensee shall be free to submit such proposed manuscript for publication or presentation materials for public disclosure, and does not need to follow this process for subsequent publications or presentations of the same data.<a name="_Ref151411703"></a><a name="_Ref376902683"></a>&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref515974182"></a><a name="_Ref513461400"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">If Ovid notifies Licensee within the applicable time period set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 13.4(a)</font><font style="font-weight:normal;color:#000000;"> that such publication or presentation, in Ovid&#8217;s reasonable judgment: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">contains an invention for which Ovid desires to obtain patent protection, Licensee shall delay such publication or presentation for a period of up to [***] (or such other time period agreed by the Parties in writing) to permit the preparation and filing of a patent application for such invention, or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">contains any Confidential Information of Ovid, or could be expected to have an adverse effect on the commercial value of any Confidential Information disclosed by </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">Ovid to Licensee, the Parties shall attempt to agree on revisions to the applicable disclosure so as to preserve both the commercial value of such Confidential Information and the scientific merit of such disclosure, provided that if and to the extent the Parties are unable to agree, Licensee shall delete such Confidential Information from the proposed publication or presentation.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk38286763"></a><a name="_Ref513461639"></a><font style="Background-color:#auto;text-decoration:none;">13.5</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Publicity; Public Disclosures and Public Announcements.</font><font style="font-weight:normal;color:#000000;"> Save as permitted in this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 13.5</font><font style="font-weight:normal;color:#000000;">, neither Party shall make any public announcement or statement to the public containing Confidential Information of the other Party without the prior consent of such other Party. On or promptly after the Effective Date, the Parties shall issue a joint public announcement, or either Party may issue its own public announcement, regarding the execution of this Agreement with information substantially consistent with the information contained in the form of press release attached hereto as </font><font style="text-decoration:underline;color:#000000;">Exhibit D</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;It is understood that each Party may desire or be required to issue subsequent press releases relating to this Agreement or activities hereunder.&nbsp;&nbsp;The Parties agree to consult with each other reasonably and in good faith with respect to the text and timing of such press releases prior to the issuance thereof, to the extent practicable, and in the case of any press release Licensee wishes to issue, Licensee shall first obtain Ovid&#8217;s written approval of such release.&nbsp;&nbsp;Notwithstanding the foregoing, neither Party may unreasonably withhold, condition, or delay consent to such releases by more than [***], and either Party may issue such press releases or make such disclosures to the SEC or other applicable agency as it determines, based on advice of counsel, is reasonably necessary to comply with Applicable Laws or for appropriate market disclosure.&nbsp;&nbsp;Each Party shall provide the other Party with advance notice of legally required disclosures to the extent practicable, and to the extent possible, at least [***] prior to such disclosure.&nbsp;&nbsp;The Parties will consult with each other on the provisions of this Agreement to be redacted in any filings made by a Party with the SEC or as otherwise required by Applicable Laws; provided that each Party shall have the right to make any such filing as it reasonably determines necessary under Applicable Laws.&nbsp;&nbsp;In addition, following the initial joint press release announcing this Agreement, either Party shall be free to disclose, without the other Party&#8217;s prior written consent, the existence of this Agreement, the identity of the other Party, and those terms of the Agreement which have already been publicly disclosed in accordance with. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref381319515"></a><font style="Background-color:#auto;text-decoration:none;">13.6</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Prior Confidentiality Agreement</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;As of the Effective Date, the terms of this Article 13 shall supersede any prior non-disclosure, secrecy, or confidentiality agreement between the Parties (or their Affiliates) relating to the subject of this Agreement, including the Confidentiality Agreement.&nbsp;&nbsp;Any information disclosed pursuant to any such prior agreement shall be deemed Confidential Information under this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref381319973"></a><font style="Background-color:#auto;text-decoration:none;">13.7</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Equitable Relief</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Given the nature of the Confidential Information and the competitive damage that a Party would suffer upon unauthorized disclosure, use, or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages may not be a sufficient remedy for any breach of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Article 13</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;In addition to all other remedies, a Party shall be entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Article 13</font><font style="font-weight:normal;color:#000000;">.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;">14.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Ref377139497"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;text-transform:none;color:#000000;"></font><font style="font-variant: small-caps;text-transform:none;color:#000000;">Term and Termination</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref151405305"></a><a name="_Ref151407440"></a><a name="_Ref151407473"></a><a name="_Ref381319992"></a><a name="_Ref520889018"></a><font style="Background-color:#auto;text-decoration:none;">14.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Term</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;This Agreement shall commence on the Effective Date and shall continue until terminated as provided in this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Article 14</font><font style="font-weight:normal;color:#000000;"> (the &#8220;</font><font style="color:#000000;">Term</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;Notwithstanding anything herein, on </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">a Product-by-Product and country-by-country basis, upon the expiration of the Royalty Term the licenses granted to Licensee in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">2.1</font><font style="font-weight:normal;color:#000000;"> shall become perpetual&nbsp;&nbsp;and fully paid-up with respect to such Product in such country, subject to Licensee&#8217;s payment obligations under Article </font><font style="font-weight:normal;color:#000000;">8</font><font style="font-weight:normal;color:#000000;"> during the Extended Commercialization Term, but thereafter shall be on a non-exclusive basis.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref440874557"></a><a name="_Ref151391856"></a><a name="_Ref151407599"></a><a name="_Ref151410175"></a><a name="_Ref151412432"></a><a name="_Ref376902090"></a><a name="_Ref376943617"></a><a name="_Ref376943734"></a><a name="_Ref377141334"></a><a name="_Ref377141519"></a><font style="Background-color:#auto;text-decoration:none;">14.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Termination for Cause</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref520743872"></a><a name="_Ref513462850"></a><a name="_Ref513461860"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Material Breach</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Each Party shall have the right to terminate this Agreement immediately in its entirety upon written notice to the other Party if such other Party materially breaches this Agreement and has not cured such breach to the reasonable satisfaction of the other Party within [***] after notice of such breach from the non-breaching Party.&nbsp;&nbsp;In the event of any dispute, the Agreement shall remain in place during the pendency of any such dispute.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref37267050"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Insolvency Event</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref37502471"></a><a name="_Ref470883766"></a><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Either Party may terminate this Agreement in its entirety upon providing written notice to the other Party on or after the time that such other Party makes a general assignment for the benefit of creditors, files a petition for relief in bankruptcy, petitions for or acquiesces in the appointment of any receiver, trustee or similar officer to liquidate or conserve its business or any substantial part of its assets, commences under the laws of any jurisdiction any proceeding involving its insolvency, bankruptcy, reorganization, adjustment of debt, dissolution, liquidation or any other similar proceeding for the release of financially distressed debtors, or becomes the involuntary subject of any proceeding or action of the type described above and such proceeding or action remains un-dismissed or un-stayed for a period of more than [***].<a name="_Ref470883766"></a>&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">All rights and licenses granted under or pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes of Section&#160;365(n) of Title&#160;11 of the United States Code and other similar laws in any other jurisdiction outside of the Territory (collectively, the &#8220;</font><font style="text-decoration:underline;color:#000000;">Bankruptcy Laws</font><font style="font-weight:normal;color:#000000;">&#8221;), licenses of rights to &#8220;intellectual property&#8221; as defined under the Bankruptcy Laws.&nbsp;&nbsp;If a case is commenced during the Term by or against a Party under Bankruptcy Laws then, unless and until this Agreement is rejected as provided pursuant to such Bankruptcy Laws, such Party (in any capacity, including debtor-in-possession) and its successors and assigns (including a Title&#160;11 trustee) shall perform all of the obligations in this Agreement intended to be performed by such Party.&nbsp;&nbsp;If a case is commenced during the Term by or against a Party under the Bankruptcy Laws, this Agreement is rejected as provided for under the Bankruptcy Laws, and the non-bankrupt Party elects to retain its rights hereunder as provided for under the Bankruptcy Laws, then the Party subject to such case under the Bankruptcy Laws (in any capacity, including debtor-in-possession) and its successors and assigns (including a Title&#160;11 trustee), shall provide to the non-bankrupt Party copies of all Patents and Information necessary for the non-bankrupt Party to [***] enjoy its rights under the terms of this Agreement.&nbsp;&nbsp;All rights, powers and remedies of the non-bankrupt Party as provided herein are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity (including the Bankruptcy Laws) in the event of the commencement of a case by or against a Party under the Bankruptcy Laws.&nbsp;&nbsp;[***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref377141524"></a><a name="_Ref378106860"></a><a name="_Ref377141337"></a><a name="_Ref151391891"></a><a name="_Ref208055335"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Patent Challenge</font><font style="font-weight:normal;color:#000000;"><a name="_Ref377141524"></a>.<a name="_Ref378106860"></a><a name="_Ref377141337"></a><a name="_Ref151391891"></a><a name="_Ref208055335"></a>&nbsp;&nbsp;Ovid shall have the right to terminate this Agreement immediately in its entirety upon written notice to Licensee if Licensee or any of its </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">Affiliates or Sublicensees directly, or indirectly through any Third Party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any Ovid Patent.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.3</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Termination without Cause</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref513461910"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Prior to the First Commercial Sale</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Prior to the First Commercial Sale of the Product in the Licensee Territory, Licensee shall have the right to terminate this Agreement in its entirety without cause [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">After the First Commercial Sale</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Following the First Commercial Sale of the Product in the Licensee Territory, Licensee shall have the right to terminate this Agreement in its entirety without cause [***].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref520888288"></a><a name="_Hlk39747546"></a><a name="_Ref377141996"></a><a name="_Ref24401010"></a><font style="Background-color:#auto;text-decoration:none;">14.4</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Effects of Termination</font><font style="font-weight:normal;color:#000000;">.<a name="_Ref377141996"></a>&nbsp;&nbsp;Upon any termination of this Agreement by either Party, the following </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Sections 14.4(a)</font><font style="font-weight:normal;color:#000000;"> through </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">14.4(g)</font><font style="font-weight:normal;color:#000000;"> will apply.&nbsp;&nbsp;For clarity, during the pendency of any termination notice period, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder.<a name="_Ref24401010"></a>&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref37274975"></a><a name="_Ref377142019"></a><a name="_Hlk34677108"></a><a name="_Hlk38193476"></a><a name="_Ref513462997"></a><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Licenses</font><font style="font-weight:normal;color:#000000;"><a name="_Ref377142019"></a>.<a name="_Hlk34677108"></a>&nbsp;&nbsp;Except in the event of (i) termination by Licensee for&nbsp;&nbsp;an uncured material breach by Ovid, or (ii) termination by Licensee in the circumstances set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 14.2(b)(i)</font><font style="font-weight:normal;color:#000000;"><a name="_Hlk38193476"></a> with respect to Ovid, or (iii) Ovid&#8217;s termination for Safety Reason, the licenses granted by Licensee to Ovid shall survive such termination and shall automatically become worldwide<a name="_Ref513462997"></a>.&nbsp;&nbsp; All of the licenses granted by Ovid to Licensee shall be automatically terminated.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Regulatory Materials; Data</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Except in the event of (i) termination by Licensee for an uncured material breach by Ovid, or (ii) termination by Licensee in the circumstances set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 14.2(b)(i)</font><font style="font-weight:normal;color:#000000;"> with respect to Ovid, or (iii) Ovid&#8217;s termination for Safety Reason (where Licensee elects to continue the Development and Commercialization of the Product), within [***] after the effective date of such termination, Licensee shall transfer and assign to Ovid, at no cost to Ovid, all Regulatory Filings and Regulatory Approvals for the Products, Data from all pre-clinical, non-clinical, and clinical studies of the Product conducted by or on behalf of Licensee, its Affiliates, or Sublicensees, and all pharmacovigilance data (including all adverse event data) on the Products.&nbsp;&nbsp;In addition, at Ovid&#8217;s request, Licensee shall provide Ovid with reasonable assistance with any inquiries and correspondence with Regulatory Authorities regarding the Product in the Licensee Territory, such assistance shall be limited to a period of [***] after such termination. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk38198266"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Development Wind-Down</font><font style="font-weight:normal;color:#000000;">. Except in the event of (i) termination by Licensee for an uncured material breach by Ovid, or (ii) termination by Licensee in the circumstances set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 14.2(b)(i)</font><font style="font-weight:normal;color:#000000;"><a name="_Hlk38198266"></a> with respect to Ovid, or (iii) Ovid&#8217;s termination for Safety Reason (where Licensee elects to continue the Development and Commercialization of the Product), Licensee shall either, as directed by Ovid, (i) wind-down any ongoing Development activities (including any Clinical Trials) of Licensee or its Affiliates and Sublicensees with respect to any Product in the Licensee Territory in an orderly fashion or (ii) promptly transfer such </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">Development activities to Ovid or its designee, in each case in compliance with all Applicable Laws.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Cost of Ongoing Trials</font><font style="font-weight:normal;color:#000000;">. Except in the event of (i) termination by Licensee for&nbsp;&nbsp;an uncured material breach by Ovid, or (ii) termination by Licensee in the circumstances set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 14.2(b)(i)</font><font style="font-weight:normal;color:#000000;"> with respect to Ovid, or (iii) Ovid&#8217;s termination for Safety Reason, if there is any ongoing Clinical Trial of the Product under the Development Plan for which the Parties are sharing costs, then Licensee shall continue to share the cost of such Clinical Trial until the effective date of termination.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Commercial Wind-Down</font><font style="font-weight:normal;color:#000000;">. Except in the event of (i) termination by Licensee for&nbsp;&nbsp;an uncured material breach by Ovid, or (ii) termination by Licensee in the circumstances set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 14.2(b)(i)</font><font style="font-weight:normal;color:#000000;"> with respect to Ovid, or (iii) Ovid&#8217;s termination for Safety Reason (where Licensee elects to continue the Development and Commercialization of the Product), Licensee shall, as directed by Ovid, (A) continue certain ongoing Commercial activities of Licensee and its Affiliates and Sublicensees with respect to any Product in the Licensee Territory for a period of up to [***] after the effective date of termination, as determined by Ovid, and (B) handoff such Commercial activities to Ovid or its designee, on a timetable to be set by Ovid, not to exceed [***] after the effective date of termination, and in compliance with all Applicable Laws.&nbsp;&nbsp;During such commercial wind-down period, Licensee shall continue to book sales and pay royalties to Ovid in accordance with </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8.5</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Except as necessary to conduct the foregoing activities as directed by Ovid, Licensee shall immediately discontinue its (and shall ensure that its Affiliates and Sublicensees immediately discontinue their) promotion, marketing, offering for sale, and servicing of the Product and its use of all Product Marks.&nbsp;&nbsp;In addition, Licensee shall immediately deliver to Ovid (at Licensee&#8217;s expense) all samples, demonstration equipment, sales materials, catalogs, and literature of Ovid in Licensee&#8217;s possession or control.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Transition Assistance</font><font style="font-weight:normal;color:#000000;">. Except in the event of (i) termination by Licensee for&nbsp;&nbsp;an uncured material breach by Ovid, or (ii) termination by Licensee in the circumstances set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 14.2(b)(i)</font><font style="font-weight:normal;color:#000000;"> with respect to Ovid, or (iii) Ovid&#8217;s termination for Safety Reason (where Licensee elects to continue the Development and Commercialization of the Product), Licensee shall, at no cost to Ovid, provide reasonable consultation and assistance for a period of no more than [***] after the effective date of termination for the purpose of transferring or transitioning to Ovid all Licensee Know-How not already in Ovid&#8217;s possession and, at Ovid&#8217;s request, all then-existing commercial arrangements, customer lists, and similar information relating to the Products that Licensee is able, using Commercially Reasonable Efforts, to transfer or transition to Ovid or its designee, in each case, to the extent reasonably necessary for Ovid to continue the Development or Commercialization of the Compound and Products in the Licensee Territory.&nbsp;&nbsp;If any such contract between Licensee and a Third Party is not assignable to Ovid or its designee (whether by such contract&#8217;s terms or because such contract does not relate specifically to the Products) but is otherwise reasonably necessary for Ovid to continue the Development or Commercialization of the Compound and Products in the Licensee Territory, or if Licensee is performing such work for the Compound and Product itself (and thus there is no contract to assign), then Licensee shall reasonably cooperate with Ovid to negotiate for the continuation of such services for Ovid from such entity, or Licensee shall continue to perform such work for Ovid, as applicable, for a reasonable period (not to exceed [***]) after the effective date of termination at Ovid&#8217;s cost until Ovid establishes an alternate, validated source of such services.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref32854151"></a><font style="text-decoration:none;Background-color:#auto;">(g)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Remaining Inventories</font><font style="font-weight:normal;color:#000000;">. Except in the event of (i) termination by Licensee for an uncured material breach by Ovid, or (ii) termination by Licensee in the circumstances set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 14.2(b)(i)</font><font style="font-weight:normal;color:#000000;"> with respect to Ovid, or (iii) Ovid&#8217;s termination for Safety Reason (where Licensee elects to continue the Development and Commercialization of the Product), Ovid shall have the right, at its discretion, to obtain from Licensee any or all of the inventory of the Products held by Licensee as of the date of termination, free of charge.&nbsp;&nbsp;Ovid shall notify Licensee within </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;"> after the effective date of termination whether Ovid elects to exercise such right.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref41396690"></a><font style="Background-color:#auto;text-decoration:none;">14.5</font><font style="font-weight:normal;margin-left:144pt;color:#000000;"></font><font style="color:#000000;">Licensee Continuation</font><font style="font-weight:normal;color:#000000;">. If (a) Licensee has the right to terminate this Agreement in its entirety for an uncured material breach by Ovid, but elects to continue this Agreement in its entirety as modified by this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 14.5</font><font style="font-weight:normal;color:#000000;">, or (b) Licensee has the right to terminate in the circumstances set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 14.2(b)(i)</font><font style="font-weight:normal;color:#000000;">, but elects to continue this Agreement as modified by this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 14.5,</font><font style="font-weight:normal;color:#000000;"> or (c) Ovid elects to terminate this Agreement in its entirety for Safety Reason, but Licensee elects to continue this Agreement as modified by this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 14.5</font><font style="font-weight:normal;color:#000000;">, then, except as provided below, effective as of the date Licensee delivers notice of such election to Ovid, the following shall apply: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">i.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Licensee shall have the right to terminate the Supply Agreement, and if Licensee terminates the Supply Agreement, Ovid shall cooperate with Licensee for smooth technology transfer of the manufacturing process if termination occurs prior to the Technology Transfer Completion Date.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">ii.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Notwithstanding anything contained in this Agreement to the contrary, Ovid shall cease any and all Development/Regulatory activities with respect to the Product in the Field in the Licensee Territory (other than the Ovid Ongoing Trials if still ongoing);</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">iii.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">All Licensee payment obligations provided in this Agreement shall continue, including those that are accrued and unpaid as of the date of such election by Licensee, [***];</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">iv.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">After the effective date of such election by Licensee, the licenses granted by Ovid to Licensee in </font><font style="text-decoration:underline;color:#000000;">Section 2.1</font><font style="color:#000000;"> under the Product Marks, Ovid Know-How and Ovid Patents for the research, the Development, the use, and the Commercialization of the Product in the Field in the Licensee Territory shall continue and the Licensee shall have such rights to Develop, Manufacture and Commercialize any Product in the Field in the Licensee Territory at Licensee&#8217;s sole discretion;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">v.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The CGB shall coordinate the wind-down of Ovid&#8217;s efforts under this Agreement, and Ovid, as soon as reasonably practical after the effective date of such election, shall provide to Licensee, as applicable and to the extent permitted under any applicable Third Party contract, (1) any information, including copies of all Clinical Trial data and results, and the like developed by or for the benefit of Ovid for a Product in the Field in the Licensee Territory; and (2) other documents to the extent relating to the Products that are necessary for the continued Development, Commercialization and Manufacture of the Product (including material documents and agreements relating to the sourcing and Manufacture of a Product for sale, promotion, distribution, or use of a Product) in the Field throughout the Licensee Territory. Ovid will cooperate with Licensee to </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;">provide a transfer of such material information and documents.&nbsp;&nbsp;At Licensee&#8217;s request, Ovid shall use reasonable efforts to assign to Licensee any and all agreements to which Ovid, or its Affiliate, and a Third Party are parties, and that solely cover or govern the Development, Commercialization and Manufacturing activities conducted in connection with a Product in the Field in the Territory prior to such election by Licensee, or if such assignment is not permitted under the relevant agreement, (A) grant to Licensee other reasonable rights to provide to Licensee the benefit of such non-assignable agreement, at Licensee&#8217;s expense, to the extent permitted under the terms of such non-assignable agreement; or (B) to the extent not permitted under the terms of such non-assignable agreement, the Parties shall discuss in good faith an alternative solution to enable Licensee to receive, at Licensee&#8217;s expense, the benefit of the terms of such non-assignable agreement. Ovid shall take such other reasonable actions and execute such other instruments, assignments and documents as may be necessary to effect the transfer of rights to such Product(s) as described in this Section 14.5(v) hereunder to Licensee;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">vi.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Ovid shall transfer to Licensee any and all Regulatory Materials directly and solely related to the Product in the Field in the Licensee Territory, and, upon Licensee&#8217;s request, shall make available to Licensee any other relevant information reasonably requested by Licensee related to such Regulatory Materials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">vii.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">As long as Licensee is not in breach of this Agreement or the Lundbeck License Agreement at the effective date of such election, Licensee shall have the rights of a non-breaching sublicensee set forth in the Lundbeck License Agreement (as amended by the Lundbeck Sublicense Amendment) from and after such election;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">viii.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Licensee shall have no further obligation to use Angelini Commercially Reasonable Efforts with respect to its obligations hereunder;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">ix.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Ovid shall be obliged to bear the costs of the Ovid Ongoing Trials, if still ongoing; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">x.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Ref38903320"></a><a name="_Ref381320055"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">In lieu of </font><font style="text-decoration:underline;color:#000000;">Section 12.1</font><font style="color:#000000;"> and </font><font style="text-decoration:underline;color:#000000;">Section 12.2</font><font style="color:#000000;">, the following shall apply: Licensee hereby agrees to defend, indemnify, and hold harmless the Ovid Indemnitees from and against any and all Losses to which any Ovid Indemnitee may become subject as a result of any claim, demand, action, or other proceeding by any Third Party to the extent such Losses arise out of: (A) Licensee&#8217;s decision to continue the Development, Manufacture and Commercialization of Product following Ovid&#8217;s cessation of such activities for Safety Reason, (B) &#160;any Development, use, handling, storage, manufacture, Commercialization, or other disposition of any Compound or Product by Licensee or its Affiliates or Sublicensees or the contractor of any of them, (C) the negligence or willful misconduct of any Licensee Indemnitee or Licensee&#8217;s Affiliates or Sublicensees, or (D)&#160;the breach by Licensee of </font><font style="color:#000000;">any warranty, representation, covenant, or agreement made by Licensee in this Agreement.</font><font style="color:#000000;"> </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.6</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Confidential Information</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Upon expiration or termination of this Agreement in its entirety, except to the extent that a Party obtains or retains the right to use the other Party&#8217;s Confidential Information, each Party shall promptly return to the other Party, or delete or destroy, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">all relevant records and materials in such Party&#8217;s possession or control containing Confidential Information of the other Party; provided that such Party may keep one copy of such materials for archival purposes only subject to continuing confidentiality obligations.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;All Licensee Data and Regulatory Filings assigned to Ovid upon termination of this Agreement will be deemed Ovid&#8217;s Confidential Information and no longer Licensee&#8217;s Confidential Information.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.7</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Survival</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Expiration or termination of this Agreement shall not relieve the Parties of any obligation or right accruing prior to such expiration or termination.&nbsp;&nbsp;Except as set forth below or elsewhere in this Agreement, the obligations and rights of the Parties under the following provisions of this Agreement shall survive expiration or termination of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref151391923"></a><a name="_Ref151411717"></a><a name="_Ref151411933"></a><a name="_Ref376942643"></a><font style="Background-color:#auto;text-decoration:none;">14.8</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Exercise of Right to Terminate</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;All rights and obligations of a Party accrued prior to the effective date of a termination (including the rights to receive reimbursement for costs incurred prior to the effective date of such termination and payments accrued or due prior to the effective date of such termination) shall survive such termination.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;">15.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Ref208055372"></a><a name="_Ref376954671"></a><a name="_Ref38904674"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;text-transform:none;color:#000000;"></font><font style="font-variant: small-caps;text-transform:none;color:#000000;">Dispute Resolution </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref151411767"></a><font style="Background-color:#auto;text-decoration:none;">15.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">General</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Except as provided in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Sections 3.4</font><font style="font-weight:normal;color:#000000;"> and 9.4, any dispute between the Parties in connection with or relating to this Agreement or any document or instrument delivered in connection herewith (a &#8220;</font><font style="color:#000000;">Dispute</font><font style="font-weight:normal;color:#000000;">&#8221;) shall be resolved pursuant to this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 15</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref14328895"></a><font style="Background-color:#auto;text-decoration:none;">15.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Executive Officers</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Any Dispute shall first be referred to the Executive Officers of the Parties, who shall confer in good faith on the resolution of the issue.&nbsp;&nbsp;Any final decision mutually agreed to by the Executive Officers shall be conclusive and binding on the Parties.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref14328910"></a><a name="_Ref111882644"></a><a name="_Ref268549127"></a><a name="_Ref275274434"></a><font style="Background-color:#auto;text-decoration:none;">15.3</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Intellectual Property Disputes</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;If the Executive Officers are not able to agree on the resolution of a Dispute within thirty (30) days (or such other period of time as mutually agreed by the Executive Officers) after such Dispute was first referred to them and such Dispute is with respect to the validity, scope, enforceability, inventorship, or ownership of any Patent, trademark, or other intellectual property right (&#8220;</font><font style="color:#000000;">IP Dispute</font><font style="font-weight:normal;color:#000000;">&#8221;), then, if a Party wishes to pursue further resolution of such IP Dispute, an action, claim, or proceeding to resolve such IP Dispute shall be brought in any court of competent jurisdiction in any country or jurisdiction in which such intellectual property rights apply.<a name="_Ref111882644"></a><a name="_Ref268549127"></a><a name="_Ref275274434"></a>&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref14328955"></a><a name="_Ref14329211"></a><font style="Background-color:#auto;text-decoration:none;">15.4</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Arbitration</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;If the Executive Officers are not able to agree on the resolution of a Dispute within thirty (30) days (or such other period of time as mutually agreed by the Executive Officers) after such Dispute was first referred to them, then, except as otherwise set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 15.3</font><font style="font-weight:normal;color:#000000;">, if a Party wishes to pursue further resolution of such Dispute, such Dispute shall be finally resolved by binding arbitration in accordance with this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 15.4</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Such Dispute shall be referred to and finally resolved by arbitration under the International Chamber of Commerce (&#8220;</font><font style="color:#000000;">ICC</font><font style="font-weight:normal;color:#000000;">&#8221;) Rules, as then in effect, by a tribunal of three (3) arbitrators.&nbsp;&nbsp;The seat and legal place of the arbitration shall be [***].&nbsp;&nbsp;Each Party shall nominate one arbitrator and the third arbitrator shall be nominated by the two Party-nominated arbitrators within [***] after the second arbitrator&#8217;s appointment.&nbsp;&nbsp;If a Party does not nominate its arbitrator within [***] following the expiry of the allotted period, then such arbitrator shall be appointed by the ICC in accordance with its rules.&nbsp;&nbsp;Any arbitrator appointed by the ICC shall have at least [***] experience in the pharmaceutical </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">industry.&nbsp;&nbsp;The arbitration shall be conducted, and all documents submitted to the arbitrators shall be, in English.&nbsp;&nbsp;Each Party shall bear its own legal costs for its counsel and other expenses, and the Parties shall equally share the costs of the arbitration; provided that the arbitral tribunal shall have the discretion to provide that the losing party is responsible for all or a portion of such arbitration and legal costs, in such case the arbitral award will so provide.&nbsp;&nbsp;The arbitrators shall have no power to award damages</font><font style="font-weight:normal;color:#000000;"> excluded pursuant to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">12.5</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;In no event shall the arbitrators assign a value to any issue greater than the greatest value for such issue claimed by either Party or less than the smallest value for such issue for such item claimed by either Party.&nbsp;&nbsp;The award shall be final and binding upon the Parties and the Parties undertake to carry out any award without delay.&nbsp;&nbsp;Judgment on the award may be entered in any court of competent jurisdiction.&nbsp;&nbsp;Except to the extent necessary to confirm, enforce, or challenge an award of the arbitration, to protect or pursue a legal right, or as otherwise required by Applicable Law or regulation or securities exchang</font><font style="font-weight:normal;color:#000000;">e, neither Party nor any arbitrator may disclose the existence, content, or results of any arbitration hereunder without the prior written consent of both Parties.&nbsp;&nbsp;Notwithstanding anything to the contrary in the foregoing, in no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy, or claim would be barred by the applicable New York statute of limitations.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;Any disputes concerning the propriety of the commencement of the arbitration shall be finally settled by the arbitral tribunal</font><font style="font-weight:normal;color:#000000;">.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref24281005"></a><font style="Background-color:#auto;text-decoration:none;">15.5</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Interim Relief</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Notwithstanding anything herein to the contrary, nothing in this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Article 15 </font><font style="font-weight:normal;color:#000000;">shall preclude either Party from seeking interim or provisional relief, including a temporary restraining order, preliminary injunction, or other interim equitable relief concerning a Dispute in any court of competent jurisdiction before or after the initiation of an arbitration as set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 15.4</font><font style="font-weight:normal;color:#000000;">, if necessary to protect the interests of such Party.&nbsp;&nbsp;This </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 15.5</font><font style="font-weight:normal;color:#000000;"> shall be specifically enforceable.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;">16.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Ref381320539"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;text-transform:none;color:#000000;"></font><font style="font-variant: small-caps;text-transform:none;color:#000000;">General Provisions</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref513407983"></a><font style="Background-color:#auto;text-decoration:none;">16.1</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Governing Law</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;This Agreement, and all questions regarding the existence, validity, interpretation, breach, or performance of this Agreement, shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, United States, without reference to its conflicts of law principles.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">16.2</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Entire Agreement; Modification</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;This Agreement, including the exhibits, is both a final expression of the Parties&#8217; agreement and a complete and exclusive statement with respect to all of its terms.&nbsp;&nbsp;This Agreement supersedes all prior and contemporaneous agreements and communications, whether oral, written, or otherwise, concerning any and all matters contained herein</font><font style="color:#000000;font-weight:normal;">.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">This Agreement may only be modified or supplemented in a writing expressly stated for such purpose and signed by the Parties to this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">16.3</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Relationship Between the Parties</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The Parties&#8217; relationship, as established by this Agreement, is solely that of independent contractors.&nbsp;&nbsp;This Agreement does not create any partnership, joint venture, or similar business relationship between the Parties, including for all tax purposes.&nbsp;&nbsp;Neither Party is a legal representative of the other Party, and neither Party can assume or create any obligation, representation, warranty, or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever. The Parties (and any successor, assignee, transferee, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">or Affiliate of a Party) shall (a) use commercially reasonable efforts to structure the arrangement and activities contemplated by this Agreement to avoid the arrangement contemplated by this Agreement being treated as a partnership that is engaged in a &#8220;United States trade or business&#8221; for United States tax purposes and (b) not treat or report the relationship between the Parties arising under this Agreement as a partnership for United States tax purposes, without the prior written consent of the other Party unless required by a final &#8220;determination&#8221; as defined in Section 1313 of the United States Internal Revenue Code of 1986, as amended. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">16.4</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Non-Waiver</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that instance or in any other instance.&nbsp;&nbsp;Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref513407363"></a><font style="Background-color:#auto;text-decoration:none;">16.5</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Assignment</font><font style="font-weight:normal;color:#000000;">. Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of the other Party, such consent not to be unreasonably withheld. Any successor or assignee of rights and obligations permitted hereunder shall, in writing to the other Party, expressly assume performance of such rights and obligations. Notwithstanding the foregoing, either Party may assign this Agreement and its rights and obligations hereunder without the other Party&#8217;s consent: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;"> in connection with the transfer or sale, through whatever means, of all or substantially all of its assets or the business of such Party to which this Agreement relates (whatever by assignment, conveyance, reorganization, merger, assumption, purchase and sale of stock, by contract or by operation of law, provided that the intellectual property rights of the acquiring party to such transaction (if other than one of the Parties) shall not be included in the technology licensed under this Agreement; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">to an Affiliate, provided that if the entity to which this Agreement is assigned ceases to be an Affiliate of the assigning Party, the Agreement shall be automatically assigned back to the assigning Party or its successor.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any permitted assignment shall be binding on the successors and the permitted assigns of a Party. Any assignment or attempted assignment by either Party in violation of the terms of this <font style="text-decoration:underline;">Section 16.5</font> shall be null, void and of no legal effects. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">16.6</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Severability</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication shall not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Agreement.&nbsp;&nbsp;All remaining portions shall remain in full force and effect as if the original Agreement had been executed without the invalidated, unenforceable, or illegal part.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref151355122"></a><a name="_Ref208063669"></a><a name="_Ref513407426"></a><font style="Background-color:#auto;text-decoration:none;">16.7</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notices</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Any notice to be given under this Agreement must be in writing and delivered either in person, by (a) air mail (postage prepaid) requiring return receipt, (b) overnight courier, or (c) facsimile confirmed thereafter by any of the foregoing, to the Party to be notified at </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">its address(es) given below, or at any address such Party may designate by prior written notice to the other in accordance with this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">16.7</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;Notice shall be deemed sufficiently given for all purposes upon the earliest of:&nbsp;&nbsp;(i)&#160;the date of actual receipt, (ii)&#160;if air mailed, five (5) days after the date of postmark, (iii)&#160;if delivered by overnight courier, the next day the overnight courier regularly makes deliveries, or (iv) if sent by facsimile, the date of confirmation of receipt if during the recipient&#8217;s normal business hours, otherwise the next business day.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.15%;text-indent:-15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to Licensee, notices must be addressed to:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34757812"></a>Angelini Pharma Rare Diseases AG<font style="font-weight:bold;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consulting GmbH Sumpfstrasse 26 6312 </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Steinhausen, Zurich</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:24.31%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Switzerland<br />Attention: Chief Executive Officer</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With a copy to:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Angelini Pharma S.p.A<font style="font-weight:bold;">.</font><br />Viale Amelia 70, 00181</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roma, Italy</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:24.31%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Enza Maria Cristina Onnis, Global Pharma General Counsel<br />mail: [***]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to Ovid, notices must be addressed to:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk41656744"></a>Ovid Therapeutics</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:24.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1460 Broadway, Suite 15021</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:24.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New York, NY 10036<font style="color:#222222;"><br />USA<br /></font>Attention:&nbsp;&nbsp;Chief Executive Officer</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:16.67%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And a copy to:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:24.23%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention:&nbsp;&nbsp;General Counsel</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:16.67%;text-indent:0%;letter-spacing:-0.15pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With a copy to (which shall not constitute notice):</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:24.23%;text-indent:0%;letter-spacing:-0.15pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cooley LLP<br />3175 Hanover Street<br />Palo Alto, CA 94304<br />USA<br />Attention: Laura Berezin</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref151391873"></a><a name="_Ref208052560"></a><a name="_Ref383109499"></a><font style="Background-color:#auto;text-decoration:none;">16.8</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Force Majeure</font><font style="font-weight:normal;color:#000000;">.</font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">Each Party shall be excused from liability for the failure or delay in performance of any obligation under this Agreement </font><font style="color:#000000;font-weight:normal;">(other than failure to make payment when due) </font><font style="font-weight:normal;color:#000000;">by reason of any event beyond such Party&#8217;s reasonable control including Acts of God, fire, flood, explosion, earthquake, pandemic (including the COVID-19 pandemic), quarantine or similar restrictions, or other natural forces, war, civil unrest, acts of terrorism, accident, destruction </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">or other casualty, any lack or failure of transportation facilities, any injunction, order, proclamation, demand, or requirement of any Governmental Authority </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;">, any lack or failure of supply of raw materials, or any other event similar to those enumerated above. Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the Party has not caused such event(s) to occur and uses reasonable efforts to overcome such event.&nbsp;&nbsp;Notice of a Party&#8217;s failure or delay in performance due to force majeure must be given to the other Party within </font><font style="font-weight:normal;color:#000000;">[***]</font><font style="font-weight:normal;color:#000000;"> after its occurrence.&nbsp;&nbsp;All delivery dates under this Agreement that have been affected by force majeure shall be tolled for the duration of such force majeure.&nbsp;&nbsp;In no event shall any Party be required to prevent or settle any labor disturbance or dispute.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">16.9</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Interpretation</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;The headings of clauses contained in this Agreement preceding the text of the sections, subsections, and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction.&nbsp;&nbsp;All references in this Agreement to the singular shall include the plural where applicable.&nbsp;&nbsp;Unless otherwise specified, references in this Agreement to any Article shall include all Sections, subsections, and paragraphs in such Article, references to any Section shall include all subsections and paragraphs in such Section, and references in this Agreement to any subsection shall include all paragraphs in such subsection.&nbsp;&nbsp;The word &#8220;including&#8221; and similar words means including without limitation.&nbsp;&nbsp;The word &#8220;or&#8221; means &#8220;and/or&#8221; unless the context dictates otherwise because the subjects of the conjunction are, or are intended to be, mutually exclusive.&nbsp;&nbsp;The words &#8220;herein&#8221;, &#8220;hereof&#8221;, and &#8220;hereunder&#8221; and other words of similar import refer to this Agreement as a whole and not to any particular Section or other subdivision.&nbsp;&nbsp;All references to days in this Agreement mean calendar days, unless otherwise specified.&nbsp;&nbsp;Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist.&nbsp;&nbsp;This Agreement has been prepared in the English language and the English language shall control its interpretation.&nbsp;&nbsp;In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral, or other communications between the Parties regarding this Agreement shall be in the English language.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref381317787"></a><font style="Background-color:#auto;text-decoration:none;">16.10</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Counterparts; Electronic or Facsimile Signatures</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.&nbsp;&nbsp;This Agreement may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.</font><font style="color:#000000;"> </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk37361552"></a>{<font style="font-family:Times New Roman Bold;font-variant: small-caps;">Signature Page Follows</font><a name="_Hlk37361552"></a>}</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.99%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">In Witness Whereof<font style="font-weight:normal;">,</font><font style="font-weight:normal;font-variant: normal;"> the Parties hereto have caused this </font>Collaboration and License Agreement<font style="font-weight:normal;font-variant: normal;"> to be executed and entered into by their duly authorized representatives as of the Effective Date.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:49.89%;"></td>
<td style="width:50.11%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman Bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;">Ovid Therapeutics Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&nbsp;&nbsp;/s/ Jeremy Levin</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:&nbsp;&nbsp;Jeremy Levin</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&nbsp;&nbsp;Chief Executive Officer</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman Bold;font-variant: small-caps;font-size:12pt;font-style:normal;text-transform:none;">Angelini Pharma Rare Diseases<font style="font-family:Times New Roman;font-weight:normal;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-variant: normal;">AG</font><font style="font-family:Times New Roman;font-weight:normal;font-variant: normal;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&nbsp;&nbsp;/s/ Pierluigi Antonelli</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:&nbsp;&nbsp;Pierluigi Antonelli</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&nbsp;&nbsp;Chairman of the BoD</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_282"></a><font style="Background-color:#FFFFFF;">List of Exhibits and Schedules</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_284"></a><font style="Background-color:#FFFFFF;"><a name="_cp_text_1_284"></a>Exhibit A: Compound</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_287"></a><font style="Background-color:#FFFFFF;">Exhibit B: Ovid Patents</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_288"></a><a name="_cp_text_1_283"></a><font style="Background-color:#FFFFFF;">Exhibit C: Development Plan</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_289"></a><font style="Background-color:#FFFFFF;">Exhibit D: Press Release</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_290"></a><a name="_cp_text_1_285"></a><font style="Background-color:#FFFFFF;">Exhibit E: Technology Transfer Plan</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_291"></a><a name="_cp_text_1_286"></a><a name="_cp_field_47_292"></a><a name="_cp_field_47_287"></a><a name="_cp_text_1_293"></a><font style="Background-color:#FFFFFF;">Exhibit F: </font><font style="color:#000000;">Documents to be transferred according to </font><font style="text-decoration:underline;color:#000000;"><a name="_cp_field_47_292"></a><a name="_cp_field_47_287"></a>Section <a name="_cp_text_1_293"></a>8.1(b)(i)</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_294"></a><a name="_cp_text_1_292"></a><font style="Background-color:#FFFFFF;"><a name="_cp_text_1_292"></a>Exhibit G: Other Documents to be transferred</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_295"></a><font style="Background-color:#FFFFFF;">Exhibit H: Description of Additional Pivotal Trial</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_296"></a><font style="Background-color:#FFFFFF;">Exhibit I: </font><font style="color:#000000;">Current Licensee Pipeline Products</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_297"></a>Exhibit J: Descriptions of Elara Trial, Neptune Trial, and Rocket Trial</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_298"></a>Exhibit K: Supply Agreement</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit L: Finished Product Documentation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_299"></a><font style="Background-color:#FFFFFF;"><br /></font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_300"></a><font style="Background-color:#FFFFFF;">Exhibit A</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_301"></a><font style="Background-color:#FFFFFF;">Compound</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_302"></a><a name="_cp_text_1_303"></a><img src="gk2ifd22ejwl000001.jpg" title="" alt="" style="width:443px;height:367px;"><a name="_cp_text_1_303"></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:36.97%;"><a name="_cp_text_1_304"></a>&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;Background-color:#FFFFFF;color:#000000;">Exhibit B</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Ovid Patents</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;"><br /></font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Exhibit C</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Development Plan</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk38286902"></a>[***]<br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Exhibit D</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Press Release</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gk2ifd22ejwl000002.jpg" title="" alt="" style="width:115px;height:102px;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <font style="margin-left:36pt;"> <img src="gk2ifd22ejwl000003.jpg" title="" alt="" style="width:234px;height:120px;"></font>&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:14pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:14pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Hlk43904872"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Calibri;color:#000000;"><a name="_Hlk43904872"></a>Angelini Pharma obtains exclusive development, manufacturing and commercialization rights to OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the European Union and other countries in the European Economic Area, Switzerland, Turkey and the United Kingdom</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Calibri;">Ovid Therapeutics will receive an upfront payment of $20 million and additional payments of up to $212.5 million upon the achievement of development, manufacturing and sales milestones, in addition to double-digit royalties on net sales if </font><font style="color:#000000;">successfully commercialized</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Calibri;">Angelini Pharma will execute the agreement through its new affiliate Angelini Pharma Rare Diseases AG</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:14pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">NEW YORK and ROME,&#160;July XX, 2020&#160;--<font style="font-weight:normal;">&#160;Ovid Therapeutics Inc.&#160;(NASDAQ: OVID, hereinafter &#8220;Ovid&#8221;), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, and Angelini Pharma S.p.A. (hereinafter &#8220;Angelini Pharma&#8221;), an Italian family-owned pharmaceutical company committed to helping patients with a constant and prevalent focus on Mental Health, Rare Diseases and Consumer Health, announced an agreement in which Angelini Pharma will be responsible to develop, manufacture and commercialize OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the European Union, other countries in the European Economic Area, Switzerland, Turkey and United Kingdom.&nbsp;&nbsp;Angelini Pharma will execute the agreement through its new affiliate Angelini Pharma Rare Diseases AG. OV101 is believed to be the only delta (&#948;)-selective GABA<sub style="font-size:85%; vertical-align:bottom">A</sub> receptor agonist in development, and is currently being evaluated in the pivotal Phase 3 NEPTUNE trial in Angelman syndrome, with topline results expected in the fourth quarter of 2020.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the agreement, Ovid will receive an upfront payment of $20 million and is eligible to receive up to an additional $212.5 million in payments upon the achievement of development, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufacturing and sales milestones for the initial indication (Angelman syndrome), as well as double-digit royalties on net sales if OV101 is successfully commercialized. Ovid will retain all U.S. and rest-of-world commercial rights to OV101.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We are excited to enter into a strategic collaboration with Angelini Pharma with the goal of bringing OV101, if approved, to the Angelman community in Europe as quickly as possible. Angelini Pharma is an ideal partner for Europe as they have deep regional knowledge, an established infrastructure with a history of successful product launches, and a commitment to improving the quality of life of the patient communities they serve,&#8221; said Jeremy Levin, DPhil, MB, BChir, Chairman and Chief Executive Officer of Ovid Therapeutics. &#8220;Finding the right partners to bring OV101 to the Angelman community as rapidly as possible is a core part of our global strategy. We believe this partnership with Angelini will help to maximize the potential commercial value of OV101 and achieve our strategic objectives in this important geography."</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-style:normal;">Today is a day that we will remember. Through our collaboration with Ovid Therapeutics, we are laying the foundation to developing innovative health solutions for rare diseases, in line with Angelini Pharma&#8217;s new strategy,&#8221; said Pierluigi Antonelli, Angelini Pharma CEO. &#8220;The new business unit Angelini Pharma Rare Diseases AG will contribute to the development, registration, production and, if approved, commercialization in Europe of OV101, Ovid Therapeutics&#8217; very promising drug being evaluated in a Phase 3 clinical trial for the treatment of Angelman syndrome. As of now, there is no effective treatment for this rare genetic disease, characterized by severe psychomotor disability, which manifests itself from childhood. Delivering on our commitment makes us proud both from a scientific perspective and its social impact&#8221;.&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">"As shareholders and executives of Angelini Holding we continue to invest in the pharma area, which today represents half of our Group's turnover,&#8221; commented the executive vice president Thea Paola Angelini and the CEO Sergio Marullo di Condojanni. &#8220;Our global development and internationalization strategy focuses on business areas with high growth potential. Particularly, we look closely at all the opportunities that can open up, not only in healthcare, but also in the consumer and machinery sector."</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">About Angelman Syndrome </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Angelman syndrome is a rare genetic condition that is characterized by a variety of signs and symptoms. Characteristic features of this condition include delayed development, intellectual disability, severe speech impairment, problems with movement and balance, seizures, sleep disorders and anxiety. The most common cause of Angelman syndrome is the loss of function of the gene that codes for ubiquitin protein ligase E3A (UBE3A), which plays a critical role in nerve cell communication, resulting in impaired tonic inhibition. Individuals with Angelman syndrome typically have normal lifespans but are unable to live independently. Therefore, they require constant support from a network of specialists and caregivers. Angelman syndrome affects approximately 1 in 12,000 to 1 in 20,000 people globally.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are no approved therapies by the U.S. Food and Drug Administration (FDA), European Medicines Agency or rest&#8211;of-world for Angelman syndrome, and treatment primarily consists of behavioral interventions and pharmacologic management of symptoms.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Angelman syndrome is associated with a reduction in tonic inhibition, a function of the delta (&#948;)-selective GABA<sub style="font-size:85%; vertical-align:bottom">A</sub> receptor that allows a human brain to decipher excitatory and inhibitory neurological </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">signals correctly without being overloaded. If tonic inhibition is reduced, the brain becomes inundated with signals and loses the ability to separate background noise from critical information.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">About OV101 (gaboxadol)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OV101 is believed to be the only delta (&#948;)-selective GABA<sub style="font-size:85%; vertical-align:bottom">A</sub> receptor agonist in development and the first investigational drug to specifically target the disruption of tonic inhibition, a central physiological process of the brain that is thought to be the underlying cause of certain neurodevelopmental disorders. OV101 has demonstrated in laboratory studies and animal models to selectively activate the &#948;-subunit of GABA<sub style="font-size:85%; vertical-align:bottom">A</sub> receptors, which are found in the extrasynaptic space (outside of the synapse), and thereby impact neuronal activity through modulation of tonic inhibition.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ovid is developing OV101 for the treatment of Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and thereby address several core symptoms of these conditions. In both these syndromes, the underlying pathophysiology includes disruption of tonic inhibition modulated through the &#948;-subunit of GABA<sub style="font-size:85%; vertical-align:bottom">A</sub> receptors. In preclinical studies, it was observed that OV101 improved symptoms of Angelman syndrome and Fragile X syndrome. This compound has also previously been tested in more than 4,000 patients (more than 1,000 patient-years of exposure) and was observed to have favorable safety and bioavailability profiles. Ovid is conducting a pivotal Phase 3 clinical trial with OV101 in Angelman syndrome (NEPTUNE) and has completed a Phase 2 signal-finding clinical trial with OV101 in Fragile X syndrome (ROCKET).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OV101 has received Rare Pediatric Disease Designation from the FDA for the treatment of Angelman syndrome. The FDA has also granted Orphan Drug and Fast Track designations for OV101 for both the treatment of Angelman syndrome and Fragile X syndrome. In addition, the European Commission (EC) has granted orphan drug designation to OV101 for the treatment of Angelman syndrome. The U.S. Patent and Trademark Office has granted Ovid patents directed to methods of treating Angelman syndrome and Fragile X syndrome using OV101. The issued patents expire in 2035 without regulatory extensions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">About Ovid Therapeutics</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The Company&#8217;s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE). For more information on Ovid, please visit <font style="text-decoration:underline;">www.ovidrx.com</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">About Angelini Pharma</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Angelini Pharma, owned by Angelini Holding, is a pharmaceutical Company committed to helping patients with a constant and prevalent focus on Mental Health, including Pain, Rare Diseases and Consumer Health. Angelini Pharma has an extensive and recognized R&amp;D programs, "World Class" production plants and international commercialization activities of active ingredients and market-leading drugs. For further information, please visit <font style="text-decoration:underline;">www.angelinipharma.com</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">About Angelini Holding</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Angelini Holding is the parent company of an international group operating in the pharmaceutical and consumer goods sectors. Founded in Italy in 1919, today&#160;Angelini group&#160;operates in&#160;17 countries&#160;with a staff of&#160;5,600&#160;and a turnover of&#160;&#8364;1,7 billion. In addition to the&#160;Pharmaceutical&#160;sector, Angelini group operates in Personal and Home Care&#160;business area through Fater, a joint venture with Procter &amp; Gamble, in the&#160;Machinery&#160;field, again in joint venture with P&amp;G, with the group operating in automation and robotics for the consumer goods industry Fameccanica, in Perfumery and Skincare and Suncare with Angelini Beauty and in the&#160;Wine sector through Bertani Domains. Angelini Holding has recently entered the Baby food market as well through MadreNatura, a joint venture with Hero Group, which offers 100% organic baby food products.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Ovid Therapeutics Forward-Looking Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release includes certain disclosures that contain &#8220;forward-looking statements,&#8221; including, without limitation, statements regarding: advancing development of and commercializing OV101, the potential benefits and value of OV101; the anticipated reporting schedule of clinical data for OV101; and the potential benefits and outcome from this collaboration. You can identify forward-looking statements because they contain words such as &#8220;will,&#8221; &#8220;appears,&#8221; &#8220;believes&#8221; and &#8220;expects.&#8221; Forward-looking statements are based on Ovid&#8217;s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include uncertainties in the development and regulatory approval processes, and the fact that initial data from clinical trials may not be indicative, and are not guarantees, of the final results of the clinical trials and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth in Ovid&#8217;s filings with the Securities and Exchange Commission under the caption &#8220;Risk Factors&#8221;. Such risks may be amplified by the COVID-19 pandemic and its potential impact on Ovid&#8217;s business and the global economy. Ovid assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Ovid Therapeutics Contacts</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Investors and Media:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ovid Therapeutics Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investor Relations &amp; Public Relations</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">irpr@ovidrx.com</font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Or</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Investors: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Steve Klass</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Burns McClellan, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">sklass@burnsmc.com</font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(212) 213-0006</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Media:<br /><font style="font-weight:normal;">Katie Engleman<br />1AB<br /></font><font style="text-decoration:underline;font-weight:normal;">katie@1abmedia.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Angelini Pharma Contact:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Daniela Poggio</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Head of Global Communications Angelini Pharma </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+39 348 6558882</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">daniela.poggio@angelinipharma.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Angelini Holding Contact:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Institutional &amp; External Relations Director Angelini Holding </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+39 348 6707240</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">alessandra.favilli@angeliniholding.com</font> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Exhibit E</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Technology Transfer Plan</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk42093035"></a>[***]<font style="font-weight:bold;font-size:12pt;color:#000000;"><br /></font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit F</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_field_47_314"></a><a name="_cp_field_47_302"></a>Documents to be transferred according to <font style="text-decoration:underline;"><a name="_cp_field_47_314"></a><a name="_cp_field_47_302"></a>Section 8.1(b)(i)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Exhibit G</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:-3.85%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Other Documents to be transferred</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_305"></a><a name="_Hlk44864783"></a>[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_2_306"></a>&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_329"></a><a name="_cp_text_1_330"></a><a name="_cp_text_1_309"></a><font style="Background-color:#FFFFFF;">Exhibit H<br /><a name="_cp_text_1_330"></a><a name="_cp_text_1_309"></a>Description of Additional Pivotal Trial</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_331"></a><a name="_cp_text_1_332"></a><font style="Background-color:#FFFFFF;"><a name="_cp_text_1_332"></a>[To be completed if and when the Additional Pivotal Trial is required by the EMA or by Licensee at its own discretion.] <br /></font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_333"></a><a name="_cp_text_1_334"></a><font style="Background-color:#FFFFFF;">Exhibit I <br /><a name="_cp_text_1_334"></a></font><font style="color:#000000;">Current Licensee Pipeline Products</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:3.03%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_336"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_337"></a><a name="_cp_text_1_314"></a><a name="_cp_text_1_338"></a><a name="_cp_text_1_315"></a>Exhibit J<br /><a name="_cp_text_1_338"></a><a name="_cp_text_1_315"></a>Descriptions of Elara Trial, Neptune Trial, and Rocket Trial</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_339"></a><a name="_cp_text_1_316"></a><a name="_cp_text_1_340"></a><img src="gk2ifd22ejwl000004.jpg" title="" alt="" style="width:614px;height:345px;"><a name="_cp_text_1_340"></a></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_341"></a><a name="_cp_text_1_342"></a><img src="gk2ifd22ejwl000005.jpg" title="" alt="" style="width:614px;height:345px;"><a name="_cp_text_1_342"></a></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_343"></a><a name="_cp_text_1_344"></a><img src="gk2ifd22ejwl000006.jpg" title="" alt="" style="width:614px;height:345px;"><a name="_cp_text_1_344"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_345"></a><a name="_cp_text_1_317"></a><a name="_cp_text_1_346"></a><a name="_cp_text_1_318"></a>Exhibit K<br /><a name="_cp_text_1_346"></a><a name="_cp_text_1_318"></a>Supply Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.99%;font-family:Times New Roman;font-size:10pt;"><a name="_cp_blt_2_17"></a><a name="_cp_blt_1_20"></a><a name="_cp_blt_2_19"></a><a name="_cp_blt_1_22"></a><a name="_cp_blt_2_21"></a><a name="_cp_blt_1_31"></a><a name="_cp_blt_2_30"></a><a name="_cp_blt_1_33"></a><a name="_cp_blt_2_32"></a><a name="_cp_blt_1_35"></a><a name="_cp_blt_2_34"></a><a name="_cp_blt_1_37"></a><a name="_cp_blt_2_36"></a><a name="_cp_blt_1_39"></a><a name="_cp_blt_2_38"></a><a name="_cp_blt_1_41"></a><a name="_cp_blt_2_40"></a><a name="_cp_blt_1_43"></a><a name="_cp_blt_2_42"></a><a name="_cp_blt_1_45"></a><a name="_cp_blt_2_44"></a><a name="_cp_blt_2_46"></a><a name="_cp_blt_2_48"></a><a name="_cp_blt_1_51"></a><a name="_cp_blt_2_50"></a><a name="_cp_text_2_128"></a><a name="_cp_text_2_183"></a>&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:481.95pt;;">
<tr>
<td style="width:232.95pt;"></td>
<td style="width:0.55pt;"></td>
<td style="width:248.45pt;"></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">List of Exhibits</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A:<font style="margin-left:36pt;">The Compound</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit B:<font style="margin-left:36pt;">Mandatory Estimated Forecast</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit C:<font style="margin-left:36pt;">Initial Purchase Order for Allocated Quantity of Compound</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A:<font style="margin-left:36pt;">The Compound</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="gk2ifd22ejwl000007.jpg" title="" alt="" style="width:443px;height:367px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit B:<font style="margin-left:36pt;">Mandatory Estimated Forecast </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_289"></a><a name="_cp_blt_2_291"></a><a name="_cp_blt_2_293"></a><a name="_cp_blt_2_295"></a><a name="_cp_blt_2_300"></a><a name="_cp_blt_2_302"></a><a name="_cp_blt_2_304"></a><a name="_cp_blt_2_314"></a><a name="_cp_blt_2_316"></a><a name="_cp_blt_2_318"></a><a name="_cp_text_2_334"></a><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Exhibit C:</font><font style="Background-color:#FFFFFF;margin-left:36pt;">Initial Purchase Order for Allocated Quantity of Compound</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk45037814"></a>[***]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Exhibit L</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk44864802"></a><font style="Background-color:#FFFFFF;">Finished Product Documentation</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[***]</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</a></p>
<p style="text-align:left;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;text-transform:none;font-weight:bold;font-family:Times New Roman;font-variant: normal;">Certain identified information marked with [***] has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>ovid-ex231_7.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ovid-ex231_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="FIS_EXPERTS_CONSENT"></a><a name="FIS_EXPERTS_CONSENT"></a>EXHIBIT 23.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Calibri;letter-spacing:-0.05pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.25%;"><font style="text-decoration:underline;">Consent of Independent Registered Public Accounting Firm</font></p>
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:0.95%;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:1%;margin-right:49.48%;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To Board of Directors</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:1%;margin-right:49.48%;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ovid Therapeutics Inc.:</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0.95%;text-indent:0%;font-size:7.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:1%;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the registration statements (Nos. 333-218167, 333-224033, 333-233101, and 333-237098) on Form S-8 and (No. 333-250054) on Form S-3 of Ovid Therapeutics Inc. of our report dated March 15, 2021, with respect to the consolidated balance sheets of Ovid Therapeutics Inc. as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive loss, changes in stockholders&#8217; equity, and cash flows for the years then ended, and the related notes, which report appears in the December 31, 2020 annual report on Form 10-K of Ovid Therapeutics Inc.</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0.95%;text-indent:0%;font-size:7.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:1%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="color:#000000;">/s/ KPMG LLP</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:1%;margin-right:43.92%;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New York, New York</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:1%;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 15, 2021</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>ovid-ex311_11.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ovid-ex311_11.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Jeremy M. Levin, certify that:</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.25%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this Annual Report on Form 10-K of Ovid Therapeutics Inc.;</p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:4.25%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:4.25%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:4.25%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:8.51%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:8.51%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:8.51%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:8.51%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:4.25%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:8.51%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:8.51%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 15, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:45%;">
<tr>
<td valign="top"  style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jeremy M. Levin</p></td>
</tr>
<tr>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jeremy M. Levin</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>ovid-ex312_9.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ovid-ex312_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Timothy Daly, certify that:</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.25%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this Annual Report on Form 10-K of Ovid Therapeutics Inc.;</p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:4.25%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:4.25%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:4.25%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:8.51%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:8.51%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:8.51%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:8.51%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:4.25%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;margin-left:8.51%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;margin-left:8.51%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 15, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:45%;">
<tr>
<td valign="top"  style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Timothy Daly</p></td>
</tr>
<tr>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Timothy Daly</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Vice President, Finance and Corporate Controller</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer and Principal Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;line-height:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>ovid-ex321_13.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ovid-ex321_13.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="FIS_CERTIFICATION_3"></a><a name="FIS_CERTIFICATION_3"></a>Exhibit 32.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report on Form 10-K of Ovid Therapeutics Inc. (the &#8220;Company&#8221;) for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that to his or her knowledge:</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.25%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:4.25%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 15, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;">&#160;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:45%;">
<tr>
<td valign="top"  style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jeremy M. Levin</p></td>
</tr>
<tr>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jeremy M. Levin</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 15, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:45%;">
<tr>
<td valign="top"  style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By</p></td>
<td valign="top"  style="width:42%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Timothy Daly</p></td>
</tr>
<tr>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Timothy Daly<font style="font-weight:normal;"><br />Executive Vice President, Finance and Corporate Controller</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer and Principal Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gk2ifd22ejwl000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gk2ifd22ejwl000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1\!6H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0K!,89"Z;?F'IZUQYG"I]:K.-[)Z]O(J%N5&P !THIJMDX/#>E.KRBPHHHH
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M"2/L?TZ]ZL>%4O-;\33^.]0$=CIB0-' &/WH^>2?09Z]_P *Z*L<0O;RKO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !49!(P1P>N*DHII@0+$L;NZ
MQHK,>H'+?6C8F\2F(&51@$CD?0U/13YF!%M/&!SUP>U'EQ>8T@C4/T9MO)'U
MJ6BE<"$1HC-LB52QRS*N,_7UI<8[9 &/>I:*+@110QPKLB14!Y.U0*$A2(8C
MB1<G)V@#\:EHHYF T##8P>E.HHI %%%% !1110 4444 %%%% !1110 4444
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M@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;27,TBQQ1+N=G. JCJ:FKAJM&2A4BTWT8TT]BQDXZ#\Z6N%7XK^%7N$1KB=
M9 @=X2%!)QG/I[UW"R(\:R(P9& *L#P0>E%?"UJ%O:Q<;]T"DGL.HH!STHKG
M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>=CP,X[5E#"59\BBK\^WR=@YDCHRS<<@#OD50N=9LK.]M+2>XVW%VY2*/N2
M3T]..M<)-XZ\4Z,+2]\0>'X;?39F DDA8LR@]#C)Q^/\ZP->U;Q%>>.]#O?[
M*M?.!=M-428$\1R0S<\'&#CBO0H914E+WVK6>J:W2V_S[(EU%T/:0SX). ,<
M9ZT9/J>.M<?>^*M2L-=\-:9-90)+JB$W())\IAC.WGWK=\07TFC>&[_4(D$D
MEK"TBJ_1B/7%>=+"U(N"?VMOOM^97,C3Y .&SD<$FDW<@;B..IKBM2\:7EC\
M-K7Q+';0-<3A,Q/G8-QP?>H-/\2^-=5N;6X@\-P+I=PRDO+)B14R QQN^I'%
M;K+JSBYNR2;6K2U6Z%SH[T!MPRQZ?K06RY0$CC)K@;KQ[J>IZI<:?X2T;[<]
MJ^)IISLC.."!R.<U/H7C6]E\0MH/B+3ET^^<!K<QDLK\9(SDY/T]*'EN(47)
MI72O:ZO;O;<.=7.CC\0Z?+X@?0TED%_'#YS(8SMV\<[NAZBM/+<X8Y4<Y'%>
M?VQ!^.-X 1G^S1GU_AKT!P=H(^8XR,G'-9XJA&DX*/6*?S8XNY@^(/&FB^%Y
M(4U2[*-+DJL:&0X]P.E:>DZI;:SIT%_9R.]O<+OC9D*G&<<@].E>.W=YXHN/
MB5')-H5E)J7V3:EF[ HT8)^;DXS^->C^)_%EKX1T:(F%#?2J$@LXE_B/L.P)
MKMQ.7*$:5.DN:<]=&FON_6]MR5.]V]CIMS9.2?;OQ3LDGY2>F<$5YG+XZ\4Z
M,+2\\0Z!%;Z;,X#R6[%F4$<$\G'XUM>+O&9T'0-.U/24BO8;JX"<DG*D$\8[
M_6N=Y97YXP23YM$TTUZ7'SH['/\ M\CKZ4;LXPV,\C->:ZCXQ\;V6GS:J/#5
MI%IRIY@:63YPF?ER V<X/I2?\+$US4=,2^T30X[F*" />R.&"JY_A09RV,'.
M,]JM93B&N96:VOS*R?9A[1'INX^V,]33>1T;.>F37!#XAMK-G;Q^%].^VZHR
M[IH)LJL '4,>!D]N>U:G@[Q>GB.*XMKFW>UU.T_X^("IPOH1[?X5C4R_$4H.
M<XVMNNJ\VM[>8U--G4\_WCD>](<X)W=>A%<SH_B2?4?&^M:&\,:PV"(R2+G<
MV0.OYT>-?$MQX9@TV6V@BE-U=K;L),X4'/(Q4+!U75C1M[S2:^:O^0<RM<U+
M[7[#3M7L=+NIG2[O<^0JH2&QUY[5J\^OY5YWXN4+\4/" Y.?,QFM7Q)XS;3=
M830]-L7O=7E3=&@X1,]"Q]*VE@7.-+V2NY1;?96;7R6@N;>YUO+=R#CMQFES
MR26X^M></XY\1:)?6K^*=#CL[&<[&FMV+^6?4\GCFNQUNZU.+1FN=%M([JZ.
MTQQ2-M# ]3U':LJN"J4Y14K6EL[JWW[#4DS4+],D\\<<C-2+G;R0?I5>V9S
MC3($E9 9%7D*V.:L+TKDDK:%"T445(!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M (5!/.:0(!TZ8QCM3J*+@(%4+M   [4@0 Y]\_2G447 3:OH.#D4!0!@4M%
M"  # [4%0>O/M2T4 (% _P#KTHXHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"<#."?I3?,7G
MV.*+ /HIN]>>>G6E5MW0'%%@%HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BF,2">/E'OBN3U;QI;03-9:/$VHWY^58H3E5]V(Z5M1P
M]2L[05_ZZB;2W.OHKSJ'7?%GAY_M7B&PCN;"7EFM02UN.^[KQ^7>NPT;7M.U
MVU%QI]PLR_\ CR_45K7P52DN;>/=:H2DF:M%-7OGKW.*=7(4%%%% !1110 4
M444 %%%% !113&([XXH 5SA<BLB^\0VEC<_8UCGNKG&6AMDWNH]Q6HTB;E#,
M%ST!X-8'A!%DTZXOW7=<W%S*)'/5MKE1^@%=-*$>1SFKVM][_P"&$][%[3M8
ML[^62!%DCN(QF2"==L@'KCTK43[N<C:>F/2N<UW%KK^AW,((DGN?LKL!_P L
MRC,0?Q45OQL) 1N5U!QE?4=:*T(I1G'9K_@ F345&.@(+8)X J2N884444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM:@\F\A#'! D'#+[@CFN;$>O^$>$+:MI6>Y'FQC],UI[*C7_ (7NR[/;Y/\
M1_>%VMSMQG'/6EK*T;Q#INMP;K*<%E^]$V5=3[@\UIEU R37'.G.$N62LRD[
MCJ*3<,XI:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4A./I2TASU_2@#C] &/'?B#W$7\C78UQV@?\CYX@P>,1?R-=
MC79COXJ_PQ_])1,=@HHHKC*"BBB@ HHHH **** "BBB@ HHHH YKX@9_X0;5
M<?\ /!OY&M'3O^1;@QC'V<?RK-^('_(CZITY@8<_2M'3O^1;@[#[../PKO\
M^82/^)_DB?M&3\//^16CXQ^]D_\ 0VKJEZ5ROP\_Y%6/@9\V3./]]JZI>E9X
M_P#WFIZL(_"A:***Y"@HHHH **** "BBB@ HHHH **** "N/\;'_ $S01_T_
MI_)J["N/\;'_ $W01_T_K_)J[,!_'7S_ "9,MCL!THI!TI:XR@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOZ9'X-785Q_C7_C\T'(S_IZ9(/3AJ[,!_'7S_)DRV.P'2BD486EKC*"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M '[%%\'VE^ >\5O^$R\/?]!:U_[^"C_A,O#W_06M?^_@_P :L_\ ".:+_P!
MVU_[]BC_ (1S1?\ H&VO_?L47P?:7X![Q6_X3+P]_P!!:U_[^"C_ (3+P]_T
M%K7_ +^"K/\ PCFB_P#0-M?^_8H_X1S1?^@;:_\ ?L47P?:7X![Q6_X3+P]_
MT%K7_OX*/^$R\/?]!:U_[^"K/_".:+_T#;7_ +]BC_A'-%_Z!MK_ -^Q1?!]
MI?@'O%;_ (3+P]_T%K7_ +^"C_A,O#W_ $%K7_OX/\:L_P#".:+_ - VU_[]
MBC_A'-%_Z!MK_P!^Q1?!]I?@'O%;_A,O#W_06M?^_@_QKE?%OB#3;Z_T>/3[
MF*\E6\#>7&X). ?2NR_X1S1?^@;:_P#?L5Q>M6#^%==76(K&*XT>0@2JL:AH
M".C CGUKLP*PSJ^Y?FL[)M:^1,KVU.F\,^*H-<CE@F0V^H6[;9K=NH^GK71!
M@W2N&UK0X]>2'Q'X<N!%?QC>KQGB8>A'3-:OA7Q3%KL+0W"?9]2B.V>W;J,=
MQ[5SXC#1E%UJ*T6ZZQ?^7G]XT^C.EHHHKSBPHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW#3Z,Z6BFJVX4ZO.+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "D([@<TM% #/FZ9Y/?%9^JZ'I^M0>3?VR2X
M^XY'S+[@]JTZ*N$Y0ES1=F%C@GTWQ+X382:7+)JFG _-;RL2Z#_9ZYK<T'Q;
MI.LD6\,IANARUO+PX]>*WB3NQ@\]3Z5@:]X3TO71YLD1@O%_U=Q%PZFNY5Z5
M?3$*S_F7ZKK^#(LUL;ES=V]G"TUQ,D4:#+,QP *XRZ\8WNL3?8?"MJ;ENCWD
M@Q$G^-06O@6^N[I?^$CU>;488#^Y@'R@CU;KFNVM;2"S@$5M$D:*,*JKTHMA
ML/L_:2^Z/^;_  #5^1S&F^!HFN5O]>G;4;Y3E1)S''[*OUKK1$J@ #C&,9Z"
MG(,9S]X]3CK3JY:V(J5G>;_R7H4DD,^8$\=3UIXX&***P&%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 )@$D'-12QI-$T$R!HW&U@PR&'H
M:FI#]*:=@/.)[6[^'NHO>64;S^'IVS-;@<P'^\/;I6O?Z#::_/9>(=&O!!=C
M!,\?_+1?0^]=7-;Q7,4D,Z"2-QRK#C%4K2SL]!TYH[:,16T2/(5'8<DFO1>-
M<DIK^)M?I)>?G^9'+]Q?1ML8#G)4#+>M/R/7VKEK"UU'7HS>W.H7-I#(28([
M5MGR=BV<YSP>W6K.DW5U9ZI)H]_<?:),&6WF/WGC[Y]P2!FN>>'M>TKM;K^N
MPTSH:***Y2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI&:NV5A;Z? (;6)8XP<X'?WSUS77*M23E.%[N^G17W]?P)LRU1117$4%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 TL%Z_4TAD  ."0>]9>N^(M,T& /?W21,RDQQD9
M:0@9P!ZURL?Q7T-G0/::G&'8#S'@&%]SST'6NRC@<16CSTX-HER2W._W''*D
M4;^.5(JG8:E::K9K<VEREQ W >/H3FHM9U>VT32YM2NQ(885RRI]YN<<#/-8
M*E-SY+:[6'?J:0.2>.E*3@9-8_AOQ!9^)-+^W6:2H@<QE95"L"..1FM&]NX+
M&RFN[B58H84+O(W10.YI3I3A4]G):[6"ZM<E+^BDCUH+]>#GTK@[CXJZ!;W,
ML:0:C<*K?ZV*#<C?0YKHM \1:?XFL1=Z?(63)62-QB2,^XKHJX'$4H<]2#2$
MI)Z(V?, ;!!I=W/(('K2#IR3@<<CK7,^)O&NF^&+NWMKZ"[>2=2Z+ @;@''J
M*QHT)UI\E-78VTE=G49'ZXI"V#C';\ZX'_A;FBY_Y!^K>G_'L/\ XJM[P]XN
MTSQ/%(]DSK)$<203*%<#UQS6]7+\32CSU(-(2G%['0!\MC!!QFG4Q!M^7)(Z
M\T^N-E!2$XX[^E+36P#N/IBA &\!L'(]#ZTN[V/7%8VOZ[;>'[**ZNHKAD:4
M0J(1DY.<?RK51@%!*L.PW5HZ<E%3:T?Z"N2 @C(H)P.!FD3A0*H:UJ]GH>F2
MW]]+Y<$0Y/J>P^IZ"IA!SDHQ5VQE[S!GH<9QGTI]5K69+BTBG4861 P7T!Y%
M6:4E9V ****D IN\ \Y'%.KF[7QAI5WXFNM WO#>0' ,G D(&3M/? K6G1G4
M3<5>RN_03:1T6\9Q0'!.,'FF?-AN06/'6LG0/$EEX@>]6T29?L<QMY/,4#+#
MTYZ<4*E)Q<TM%N%S;HHHK(84444 %)NZ\=*7-8E_XBLK#Q'8Z-*DS75\C-&4
M4; !G.XY]JTITY5':*OU^X3=C:#9[8I:8G3H.!P13LCUJ&,6BBBD 4444 %%
M%%  3@9--W_-C!QW-17EY;6%G)=7<RPP1KN=V. !7$7'Q7T&"XDC2#4)XUSB
M6*$%''J#FNFAA*]>_LHMB<DMSO0<C-!.*J:7J5IJVG0WME,LL$JY5A3-7U2T
MT?39;V]F6.",98D\GV'O67LY\_L[:[6"^ER[O'H:"W^R<^E8^@:Y;>)-%CU*
MQ$T<,C,JK, K?*<'.">XJCKOC?0_#\[17$[W%VF-UM;KOD ;G./3\:UCA:LJ
MCI1BW)= YE:YTN\Y V'W]J-XS@ GC.:Y;P]X]T?Q!?/96WVF&<#<J7"!2X]N
M:N^(O%FE>%K2*:_D9C*V(XHAN=OH*<L'7C55%P?,^@N96N;N_P"8#!R?TI/,
MX)VG@UR.A_$'1M>U3[#&MS;7!7<BW,87S/9>>HK<U?7-.T&V2>_NE@1LA01R
MY S@>]%3"5J=14Y1?,^@U)-7-+S!Q@$GT]*=N]C7$:=\3="U"Z\J1KBQ)^Z]
MW%M5SG  Y/-=FI!(.[.>A'(Q4U\-5H.U6+0*2>Q+30V<\'@XIU<MXC\;:1X>
MNX[2<W$UTXRT5JF]E'J>1C_ZU11HU*TN2FKL&TMSJ P)(]*6N>\->+],\2B1
M;3S8IH_O0SKM;'J!Z5T&115I3I3<)JS!--70W?['_&G*=PR*Q+;Q)8WOB2ZT
M2!)3<VD8E=R!LP<=#GKS6VH ''?FE4IRIV4E:^OW@G<&8*,FFE\=0?;WIS'
MS52[NX-/M)+BYF$4$:[Y))#]VIC%R=D,M[O:@'/:L3PYXDLO$]A)>6*R"..0
MQ9D4 DC^G-;:]^M54IRI2<)JS0D[BT445F,**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.2:2.I^&5P+?X:P3E,[3,VWUPS'K7->%/$.A:/:WGBW5CF[U>Y?R8(T\R6)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEJ;K3[BV#!6FB:/=VY!%6:*YG4DY<[>I5CGO!_AZ?PSX<M]+FN(YFB=B712
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *,#&
M,444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gk2ifd22ejwl000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gk2ifd22ejwl000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0X!X$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HJ
M&XN[>T56N)DB5C@%CC)J:G9VN 4444@"BBB@ HHHH **** "BBL\ZYI:ZHNF
M&_@%\PR(-_SD?2JC"4OA5P;L:%%%%2 444UW6)&=V"JHR2>U #J*HZ=K.FZN
MLAT^]AN1&=KF)L[3Z5>JI1E!\LE9A>X4445(!1110 4444 %%07=Y;6%L]Q=
MS)#"@RSN< 4VPU"SU2T2ZL;B.XMW^[)&<@U7)+EYK:!<LT445(!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%&<#)H **HVNM:;>WTUE;7L,M
MU",R1(V64>XJ]52A*+M)6 ****D HK.U37M)T79_:>H6]IYAPOFOC-7HY$FB
M62-@R,,JPZ$53A)14FM&*ZO8?1114C"BBB@ HHHH ***BN+B&UB,L\BQQCJS
M' II-NR EHI$=70.A!4C(([TM(!&^Z:KU8;[IJO5Q ****8@HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #-%)2\FF 44X(3
MUIXC'UI70$8!/:G!":E HJ>88T1@=J<***5P"EI*6D 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %)Q124P%I:;3J0!1110
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MZ\>)J%%%%,04444 %%%% !1110 4444 %%%% !1110 4449I@%%%% !1110
M44X*3VIPC]:5P(\'M3@AJ4 #M2U/,,8(P*?@"EHI7 3\**6BD 4E+10 4444
M )2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 444V@!U%,SS0*=@'T4G%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J)Y%1&=F
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MXY-9_CC_ )$K5O\ K@?YBG^'/%^C>*;<RZ7=K(R@%XSPZ?45'XZ=4\$:LS$
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M!@)?@G/89%?4]M.EU;13Q,&CD4,I'<&OGOXV>%9[+7O[<@C8VUR/WC@?=?\
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M;HK:EF^*ITU233BMDTFOQ0.";N]SS?0OA8(M7&K^)-1;5KX'(W?<!]>@KT<
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MW63:)64@,>#ZUZOX!U47VBK;NV9(/E_#M7.:YI=I%X2MA'/"9H!N;##)S_\
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MRW)I7L>S1ZC:2G$=Q&Q] U-_M6Q!Q]JB_P"^J\X\#:.EY)+<B;$B#84QZ_\
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MX=UK1\RM"_EKSYL).!^-;>O>%M0/B&9[&W8QN?,$@. ">U,:[\6QVYLI(97
MXW$ G%:T*CC"*IS35M5)ZB:UU18\'>*;O^T8=/NF\R.7A6/45Z97GGA'PC=P
MWZZC?)Y3(<HG<GWKT3I7C9HZ+K_NOG;N:0O;4AN%<P2!#AL<&O+]$\4W$&LR
MQZC*9('8J=W\/->JD94UY3>>#]2NM?NEBB\N OE96Z'BM,L=%QJ0K66@IWTL
M=U<Z!H^KP!C!&0PR&CXS^5>?^+/"D>AA;BWF+1,<;6Z@_P!:%L?%6CLT5N9U
M0'@J00:!HOB77[B-;SS=G_/27&!^5>AAJ<L//F]LG#U);NMC4^'M\UM97[2G
M]Q'\WT/%95[XGU+5]4,>GA8ED;:@"C=CW/6N^L/#-OI^A/8)RTB_._\ >/K7
MG-SX6UK3+W]Q [;&^25,4L-5PU:O4J.U^EPDI))$^OZ!JMAI0NM0O'DW.%\O
M>6'.?6M3X:G_ $RZ_P"N?]13/^$<\3:]:EM0NBJI]R.3')_"LW3-+\2:/?\
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M HHHI %)M'I2T4 )@>E%+10 FT>E&!Z4M)FF G%&%]*,BE[4 )P.E'7M2T4
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M>7^,-<6^U:.*VE)BB^4E3P3]:] T:5#I5MF1<[!U-=E?!RHTHU)=>A*E=V-
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M3!3Q/,XNR1,I)'K]+4$'$2C?OP,%L]:GKC:L4%%%%( HHHH K4445H(****
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MUZ+7A8Q2ZM.YC+_*C8X./:MOX<_ZZZ_W1_.NW%1Y\$Y3:DUU1,?BT.D\8?\
M(NW ]JX/P/QX@3Z5WWC!3_PCEP0.U<%X&&?$48/I6&!_W&I\QR^)'K7<4NPY
MJ7 ':EKY^YL<9\1$ T&+_KK_ $-<W\//^0X_'\'^-=+\1SC0HO\ KK_0US7P
M\;_B>/G^Y7T.&_Y%D_F8OXSU;.>U>-^,K9+;Q)<", *Y!QCIQ7L4DJ11EG8
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MM7!.5E4\?6O:==N4M=%NI'( V$?GQ7C.C0M<:Q9Q(,DRJ3],\TLFTH5&]O\
M@!4W1[K"^^%&/=0:Q_%O/AN[_P!T?SK91-L2H.PQ6-XLX\,WG^Z/YUXF'_CQ
M]5^9J]CS;P.O_%3P'_9:O9 :\;\"C_BIH<G^%J]D%>EGG^\+T(I;"]Z,4=**
M\4T.&\;'6(I//M)"EHD9WX-<QX.N)I_%-JTLTCG)^\Q/8UZ%XO'_ !3%\?\
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M@_44@AC'(1?RI4,SC2I>R5-6Z^8.%W>Y6TFXEN]+M[BX0I+(F64C&#5SI0
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M4M,#!@".AZ4^LF,****0!1110!6HHHK004444 %%%%, HH!H)- !1TH!-&:
M GTH )[T<49H #P,T+@]:,BC(H .AH./2C(HR* #^&D7.:7-&10 C"E HR*,
MB@ V\T'Y>E&:,B@ !S011D49H 3K2G@49%&10 @I&4,K*X!!&"*=D48% &#)
MX2T:1RYLU+,<DFG6_A32K6X2>*V59$.5/I6Y@48%;_6JUK<S^\7*AH7BEQ2X
MHQ6 Q-M+M)/6C%)S0 O.<9I.0:7!]*<$8T7 3=QTH7GM4@0"G 5-QD87G)IP
M4#M3Z*5P&GCM2BEHI )]:7%%% #>].HHH ,4E+10 G(H%+10 TFEQFEHH ,
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M/^$*\5?\^,__ '^'^-'_  A7BK_GQG_[_#_&C^R,/_T$+\/\P]H^Q[GYT?\
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MA[1]CWCSH_[Z_G1YT?\ ?7\Z\'_X0KQ;_P ^$_\ W^'^-'_"%>+?^?"?_O\
M#_&C^Q\/_P!!$?P_S#VC['O'G1_WU_.CSH_[Z_G7@_\ PA7BW_GPG_[_  _Q
MH_X0KQ;_ ,^$_P#W^'^-']CX?_H(C^'^8>T?8]X\Z/\ OK^='G1_WU_.O!_^
M$*\6_P#/A/\ ]_A_C1_PA7BW_GPG_P"_P_QH_L?#_P#01'\/\P]H^Q[QYT?]
M]?SH\Z/^^OYUX/\ \(5XM_Y\)_\ O\/\:/\ A"O%O_/A/_W^'^-']CX?_H(C
M^'^8>T?8]X\Z/^^OYT>='_?7\Z\'_P"$*\6_\^$__?X?XT?\(5XM_P"?"?\
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M_F'M'V/>/.C_ +Z_G1YT?]]?SKP?_A"O%O\ SX3_ /?X?XT?\(5XM_Y\)_\
MO\/\:/['P_\ T$1_#_,/:/L>\>='_?7\Z/.C_OK^=>#_ /"%>+?^?"?_ +_#
M_&C_ (0KQ;_SX3_]_A_C1_8^'_Z"(_A_F'M'V/>/.C_OK^='G1_WU_.O!_\
MA"O%O_/A/_W^'^-'_"%>+?\ GPG_ ._P_P :/['P_P#T$1_#_,/:/L>\>='_
M 'U_.CSH_P"^OYUX/_PA7BW_ )\)_P#O\/\ &C_A"O%O_/A/_P!_A_C1_8^'
M_P"@B/X?YA[1]CWCSH_[Z_G1YT?]]?SKP?\ X0KQ;_SX3_\ ?X?XT?\ "%>+
M?^?"?_O\/\:/['P__01'\/\ ,/:/L>\>='_?7\Z/.C_OK^=>#_\ "%>+?^?"
M?_O\/\:/^$*\6_\ /A/_ -_A_C1_8^'_ .@B/X?YA[1]CWCSH_[Z_G1YT?\
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M $$1_#_,/:/L>\>='_?7\Z/.C_OK^=>#_P#"%>+?^?"?_O\ #_&C_A"O%O\
MSX3_ /?X?XT?V/A_^@B/X?YA[1]CWCSH_P"^OYT>='_?7\Z\'_X0KQ;_ ,^$
M_P#W^'^-'_"%>+?^?"?_ +_#_&C^Q\/_ -!$?P_S#VC['O'G1_WU_.CSH_[Z
M_G7@_P#PA7BW_GPG_P"_P_QH_P"$*\6_\^$__?X?XT?V/A_^@B/X?YA[1]CW
MCSH_[Z_G1YT?]]?SKP?_ (0KQ;_SX3_]_A_C1_PA7BW_ )\)_P#O\/\ &C^Q
M\/\ ]!$?P_S#VC['O'G1_P!]?SH\Z/\ OK^=>#_\(5XM_P"?"?\ [_#_ !H_
MX0KQ;_SX3_\ ?X?XT?V/A_\ H(C^'^8>T?8]X\Z/^^OYT>='_?7\Z\'_ .$*
M\6_\^$__ '^'^-'_  A7BW_GPG_[_#_&C^Q\/_T$1_#_ ##VC['O'G1_WU_.
MCSH_[Z_G7@__  A7BW_GPG_[_#_&C_A"O%O_ #X3_P#?X?XT?V/A_P#H(C^'
M^8>T?8]X\Z/^^OYT>='_ 'U_.O!_^$*\6_\ /A/_ -_A_C1_PA7BW_GPG_[_
M  _QH_L?#_\ 01'\/\P]H^Q[QYT?]]?SH\Z/^^OYUX/_ ,(5XM_Y\)_^_P /
M\:/^$*\6_P#/A/\ ]_A_C1_8^'_Z"(_A_F'M'V/>/.C_ +Z_G1YT?]]?SKP?
M_A"O%O\ SX3_ /?X?XT?\(5XM_Y\)_\ O\/\:/['P_\ T$1_#_,/:/L>\>='
M_?7\Z/.C_OK^=>#_ /"%>+?^?"?_ +_#_&C_ (0KQ;_SX3_]_A_C1_8^'_Z"
M(_A_F'M'V/>/.C_OK^='G1_WU_.O!_\ A"O%O_/A/_W^'^-'_"%>+?\ GPG_
M ._P_P :/['P_P#T$1_#_,/:/L>\>='_ 'U_.CSH_P"^OYUX/_PA7BW_ )\)
M_P#O\/\ &C_A"O%O_/A/_P!_A_C1_8^'_P"@B/X?YA[1]CWKS%_O#\Z*\P_X
M1W7?^?67_OX/\:*X_P"SZ/\ S]7]?,KG?8](HHHKSB@HHHH **** "BBB@ H
MHHI@%%%% !1110 4444 %%%% !1110 4<444 '%'%%+M)[4 )1BI!'ZT\*!4
M\P$(0GMBGB/UJ2BE=C$"CTI<4M%(!,"C I:*0"8%+110 8I,"EHH 3 HP*6B
M@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:
M* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"E
MHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*
M6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C
MI:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,
M"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 H
MP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"
MC I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P
M*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3
M HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!
M,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:*
M$P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH
M 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B
M@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:
M* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH **** *U%%%:""BBB@ HHHH
M**** "BBB@ HHHH ***,TP"BBB@ HHHP3VH **>$/>GA .U3<"( FGB/UJ3M
M2TN88T(!VI>*6BE<!*6BBD E%+10 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %
M:BBBM!!1110 4444 %%%% !1110 4448- !24NT]S3OE'O3 :!3PA/6D\P4>
M;2U >$%/ Q47F^]'F^]39C):6H?,]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/
M-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]
MZ.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.
M5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@
M345#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@34
M5#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@345#
MYOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YO
MO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1
MYOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YO
MO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1
MRL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL
M":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":
MBH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH
M?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-
M]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z
M/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-
M]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z
M.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5
M@345#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@3
M45#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@345
M#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@345#Y
MOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO
M1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1Y
MOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO
M1RL":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z/-]Z.5@345#YOO1YOO1R
ML":BH?-]Z/-]Z.5@345#YOO1YOO1RL":BH?-]Z424N5@2T4P-3Z0!1110 44
M44 %%%% !1110 4444 %%%% %:BBBM!!1113 **** "BG!2:<(_6E<"/K3@A
M/M4H4"EI<PQ@C'>E;"H33JCG.(6/M26K KO(>U5VF:IH,-NXSQ3\)_<%;72=
MK"*7V@T?:#5S;'_SS%&R/_GF*KFCV$4_M!H^T&KFR/\ YYBC9'_SS%'/'L!3
M^T&C[0:N;(_^>8HV1_\ /,4<\>P%/[0:/M!JYLC_ .>8HV1_\\Q1SQ[ 4_M!
MH^T&KFR/_GF*-D?_ #S%'/'L!3^T&C[0:N;(_P#GF*-D?_/,4<\>P%/[0:/M
M!JYLC_YYBC9'_P \Q1SQ[ 4_M!H^T&KFR/\ YYBC9'_SS%'/'L!3^T&C[0:N
M;(_^>8HV1_\ /,4<\>P%/[0:/M!JYLC_ .>8HV1_\\Q1SQ[ 4_M!H^T&KFR/
M_GF*-D?_ #S%'/'L!3^T&C[0:N;(_P#GF*-D?_/,4<\>P%/[0:/M!JYLC_YY
MBC9'_P \Q1SQ[ 4_M!H^T&KFR/\ YYBC9'_SS%'/'L!3^T&C[0:N;(_^>8HV
M1_\ /,4<\>P%/[0:/M!JYLC_ .>8HV1_\\Q1SQ[ 4_M!H^T&KFR/_GF*-D?_
M #S%'/'L!3^T&C[0:N;(_P#GF*-D?_/,4<\>P%/[0:/M!JYLC_YYBC9'_P \
MQ1SQ[ 4_M!H^T&KFR/\ YYBC9'_SS%'/'L!3^T&C[0:N;(_^>8HV1_\ /,4<
M\>P%/[0:/M!JYLC_ .>8HV1_\\Q1SQ[ 4_M!H^T&KFR/_GF*-D?_ #S%'/'L
M!3^T&C[0:N;(_P#GF*-D?_/,4<\>P%/[0:/M!JYLC_YYBC9'_P \Q1SQ[ 4_
MM!H^T&KFR/\ YYBC9'_SS%'/'L!3^T&C[0:N;(_^>8HV1_\ /,4<\>P%/[0:
M/M!JYLC_ .>8HV1_\\Q1SQ[ 4_M!H^T&KFR/_GF*-D?_ #S%'/'L!3^T&C[0
M:N;(_P#GF*-D?_/,4<\>P%/[0:/M!JYLC_YYBC9'_P \Q1SQ[ 4_M!H^T&KF
MR/\ YYBC9'_SS%'/'L!3^T&C[0:N;(_^>8HV1_\ /,4<\>P%/[0:/M!JYLC_
M .>8HV1_\\Q1SQ[ 4_M!H^T&KFR/_GF*-D?_ #S%'/'L!3^T&C[0:N;(_P#G
MF*-D?_/,4<\>P%/[0:/M!JYLC_YYBC9'_P \Q1SQ[ 4_M!H^T&KFR/\ YYBC
M9'_SS%'/'L!3^T&C[0:N;(_^>8HV1_\ /,4<\>P%/[0:/M!JYLC_ .>8HV1_
M\\Q1SQ[ 4_M!H^T&KFR/_GF*-D?_ #S%'/'L!3^T&C[0:N;(_P#GF*-D?_/,
M4<\>P%/[0:/M!JYLC_YYBC9'_P \Q1SQ[ 4_M!H^T&KFR/\ YYBC9'_SS%'/
M'L!3^T&C[0:N;(_^>8HV1_\ /,4<\>P%/[0:/M!JYLC_ .>8HV1_\\Q1SQ[
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M_P \Q1SQ[ 4_M!H^T&KFR/\ YYBC9'_SS%'/'L!3^T&C[0:N;(_^>8HV1_\
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M_P#GF*-D?_/,4<\>P%/[0:/M!JYLC_YYBC9'_P \Q1SQ[ 4_M!H^T&KFR/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !3D^]3:<GWJ&!3#?OS]:U1TK''^O/UK8'W115Z A:***Q&%%%%
M !1110 4444 %%%% !1110 F!12TE, I:2EI %%%% !1110 4444 %0W7_'M
M)]*FJ&Z_X]I/I51W0%"P_C^E6:K6'\?TJS6\_B8D%%%%0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG5E=0R,&!Z$4G%K= +1112 **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *<GWJ;3D^]0P* _UY^M; ^Z*QQ_KS]:V!
M]T4ZW0$+1116 PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *ANO^/:3Z5-4-U_Q[2?2JCN@*%A_']*LU6L/X_I5FMY_$Q(****@
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MY/,\L=%NK27N_D;PG?1G3T445XAH%%%% !1110 4444 %%%% !1110!'<_\
M'E<?]<V_E7SG<_\ '[/_ -=#_.OHRY_X\KC_ *YM_*OG.Y_X_9_^NA_G7TO#
MO_+SY&-;H1CK24HZTE?3&(4444 %%&** "BBB@ HHHH **** "BBB@ HHHH
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MW;U)6JU.,HI!TI:[20HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!&Z&O7] _Y 5K_N5Y W0UZ_H'_("M?]RO(SC^%'
MU-*>YI4445\\:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !3D^]3:<GWJ&!0'^O/UK8'W16./]>?K6P/NBG6Z A:*
M**P&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4-
MU_Q[2?2IJANO^/:3Z54=T!0L/X_I5FJUA_']*LUO/XF)!1114 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %'>BCO0!Y)\2O^1A7_ '?\
M:XT=Z[+XE?\ (PK_ +O^-<:.]?=Y=_NL/0YI_$Q!UHH'6BNPD**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 6I+:YFLKE;B!RDB\@BHZ*&D
MU9@>S>$_%L.MVPAF8)=H/F![UT^.>_XU\[VMS-:7"7%NY21#G(->P^$_%D.N
M6RPSL$NT&"#_ !5\GF>6.BW5I+W?R-X3OHSIZ*.]%>(:!1110 4444 %%%%
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MH:I>?VAJ$EP.%8_*/054HS0J,%4=1;L+Z6%C"F0!SA.YKIXM2TB/09-,#O\
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MM%%%8#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_A7]I_S\&NPHH_M#$_S!R(X__A7]I_S\&C_A7]I_S\&NPHH_M#$_S!R(X_\
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M_!H_X5_:?\_!KL**/[0Q/\P<B./_ .%?VG_/PU'_  K^T_Y^&KL**/[0Q/\
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M#5G!ZTE95<35K*TY7&HI;!1116 PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ IR?>IM.3[U# H#_7GZUL#[HK''^O
M/UK8'W13K= 0M%%%8#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ J&Z_X]I/I4U0W7_'M)]*J.Z H6'\?TJS5:P_C^E6:WG\3$@H
MHHJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "CO11WH
M\D^)7_(PK_N_XUQH[UV7Q*_Y&%?]W_&N-'>ON\N_W6'H<T_B8@ZT4#K2UV$B
M44=** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH[T %%%% !2TE%
M "U+;7,UI<)<6[E)$.>#4-'W:&DU9@>S>$_%L.N6RP3L$NT&"/[U=1SFOG>V
MN9K6X2X@<I(IR"*]@\)>+8=;MQ!,0ET@P03]ZOD\SRQT6ZM)>[^1O"=]&=11
M117B&@4444 %%%% $=S_ ,>5Q_US;^5?.=S_ ,?L_P#UT/\ .OHRY_X\KC_K
MFW\J^<[G_C]G_P"NA_G7TO#O_+SY&-;H1CK2'K2CK2'K7TQB!&170^&M?M/#
M\C3M:-+<$8!]JP.U,5N<5G5I1JP<)[ G8ZJ37M FFDFETI]SG+<__7J+4/%Q
MFTUM.TZU6TMCPV.K5SAP:-F/F%8K"4DTW=V[ML?,SI[3Q1:MH::9JMF9XHSE
M"O6I+/QC#I\DD$%@J6,B[64?>(KD\_+DTN?ES2>"HN]UH_/0?,SH=/\ $-MI
M%Y,UK:EK.9<-"_-36NNZ/I]TU]9Z?(EX02N3\H/YURX;D$TK-N.,<54L)3;=
M[Z[Z[^HN9FQIOB.[T[59KU6#_:#^^0]&%7I=:T)7:ZM]+=;H\@$_*#^=<O@C
MO3N?6G+"TY2YMO30.9F_H/B"WTO4I-0N+8R7#'Y=O04-K&EMKW]I?8WP6WE?
M?\ZP"=OXT@&1FAX:FY.?5JV_0.9G1:[K^GZWJ,=X]HZL/OCU'YU-KOB6QUC3
M8;86;(\"XC;_ ":Y8C)ZT['''2DL)2CRVO[NVH<S.GTGQ-8:7I<MG]B=C.N)
M6S_]>J.DZX^BW\DUHF;63AHF[BL4-D\=*7/.*?U6G[UU\6X<S.D?7="2=KBT
MTMA='G#'Y<_G7/S3M<3/*X +'.!46 #_ (4OUJZ=&%/:_P W<&[@#GC.,=#7
M46_BJVN-,2PUFS-RD?".OW@*Y8CCB@, .<45:,*J7-T!-HZFW\6V^DN%T:R$
M*D_O"_5AZ4^Z\567E7+Z?9M#<W0*RG/R\^G/O7*%/X@<"DR>M8_4J+?-;7UW
M]>X^9BXPQ;UY-)1R1BBNLD*1ON'Z4M(WW#]* />?!?\ R*EG_NUNUA>"_P#D
M5+/_ ':W:_/,5_'GZLZX[ :***YQA52\_P!?;?[U6ZJ7G^OMO]ZKA\0,MT44
M5 !2TE%  3A2?09KE)_&D4-Q)%Y#'8<&NJ<_NW_W37DM\W_$QN,C^,UZ.7X>
M%9RYUL1-M;'6_P#"<Q?\^S4?\)S%_P ^S5Q?'I1QZ5Z?]GX?L1SL[3_A.8O^
M?9J/^$YB_P"?9JXOCTHX]*/[/P_8.=G:?\)S%_S[-1_PG,7_ #[-7%\>E''I
M1_9^'[!SL[3_ (3F+_GV:C_A.8O^?9JXOCTHX]*/[/P_8.=G:?\ "<Q?\^S4
M?\)S%_S[-7%\>E''I1_9^'[!SL[3_A.8O^?9J/\ A.8O^?9JXOCTHX]*/[/P
M_8.=G:?\)S%_S[-1_P )S%_S[-7%\>E''I1_9^'[!SL[3_A.8O\ GV:C_A.8
MO^?9JXOCTHX]*/[/P_8.=G:?\)S%_P ^S4?\)S%_S[-7%\>E''I1_9^'[!SL
M[3_A.8O^?9J/^$YB_P"?9JXOCTHX]*/[/P_8.=G:?\)S%_S[-1_PG,7_ #[-
M7%\>E''I1_9^'[!SL[3_ (3F+_GV:C_A.8O^?9JXOCTHX]*/[/P_8.=G:?\
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MH;K_ (]I/I4U0W7_ ![2?2JCN@*%A_']*LU6L/X_I5FMY_$Q(****@ HHHH
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MZ1JL]DUHSIM^]Z'\Z!H,&GZ?%<N@EFG.Y$8\*M2L9'E4FFK[>8<IR"C)S06
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M?/\ 8%YSQ6:JU/8J=];A97*2:/YW$5RC,>@JC=6DUG(8YEVGL>QJ+S&7#*S
MCH0:Z25?[3\,_:).98?XJVE.=-IR=T]!;G-9SBE;DT@&%S2*>:Z!#J***0!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:]
M4T3_ ) UO_NUY6:]4T3_ ) UO_NUY>:_PX^I<-R_WHH[T5X1J%%%% !1110
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M)E<>FXUZS(?W;8_NFO)KW<-0N/\ ?->OE<I2G-R9G,@HI.:.:]@S%HI.:.:
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M-VEQ?)&AR(EVTOAN-SJ+':<;#SCCO6.V<Y)R3US5JVU2YMUVQ.%%$J35'V<
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M\@:W_P!VO*COKU31,_V/;Y_NUY>:_P ./J7#<T>])06YHKPC4**** "BBB@
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MBBB@ HHHH CN?^/*X_ZYM_*OG.Y_X_9_^NA_G7T9<_\ 'E<?]<V_E7SG<_\
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M44 %%%% !3D^]3:<GWJ&!0'^O/UK8'W16./]>?K6P/NBG6Z A:***P&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4-U_P >TGTJ
M:H;K_CVD^E5'= 4+#^/Z59JM8?Q_2K-;S^)B04445 !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1WHH[T >2?$K_ )&%?]W_ !KC1WKL
MOB5_R,*_[O\ C7&CO7W>7?[K#T.:?Q,0=:*!UHKL)"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ QBER />BNV\&>#7U&5;Z^0K;J
M<JI_BK#$8BGAZ;J5&-)MV0G@WP8^I2+?7Z%;=3E5/\5>KHB0Q+%&H1%&% I(
MXTAC6.)0J*,*!VIU?%XS&5,5/FEMT1T1BHH****XR@HHHH **** "BBB@".Y
M_P"/*X_ZYM_*OG.Y_P"/V?\ ZZ'^=?1ES_QY7'_7-OY5\YW/_'[/_P!=#_.O
MI>'?^7GR,:W0C'6DI1UI*^F,0HHHH **** "K>F1B35[1#T,H_G52K>F2"/6
M+-ST$@S45+\CMV!;G0_$0_\ %1J@^ZD2@"L7P\!_PD.GG'_+45M?$/\ Y&0.
M.5:)2*S_  OI\UQJUI<AE6**3+$GI7#0DHX%-_R_H6_B)O&V?^$KNC["JFB:
MO:Z;]H%Q9K<&5=JY'W36EXXM)#KDUXK(T#8 *FL_1-#75DN':Y2'R5W#=WJJ
M3IO"1Y]K(3OS:&0Y)E<XP&)( [5V/@'_ (]-9P/^6!KC7_UK+P<,1D=Z[[P7
M8265AJ+SR1I]HAQ'D]:,QDEAVGUM^80W//QD,WN36Y?:S:W&@PV"62)/&<M*
M!R:R[NTEL9&28#=UXK3N="6#0H=1^U([2'_5@\BNBHZ3<'+OIZB5S% &TUVF
MOG'P_P!'QQR/Z5R-M:R7<GDPXWGIFNZU[399/!6G6D<D;308+J#TZ5SXN<55
MI)OK^@X[,Y#06*>(;%P>1(*UO'<2Q^)I2HQO 8UE:'&S>(+)!][S0,5I^/)0
M_B>51SL !IR_WR-OY7^8?9.;'%'44'[N:2,\5W$A10>M% !1110 4C?</TI:
M1ON'Z4 >\^"_^14L_P#=K=K"\%_\BI9_[M;M?GF*_CS]6=<=@HH-%<XPJI>?
MZ^V_WJMU4O/]?;?[U7#X@9;HHHJ "@=:** $8G/%!=<8\Q?SI?X6_P!TUXKJ
M=Y=#5+H"ZE $AP WO7=@L$\4VD[6)E+E/:=R?\]$_.C<G_/1/SKPO[?>?\_4
MO_?1H^WWG_/U+_WT:]#^PY?S_@1[4]TW)_ST3\Z-R?\ /1/SKPO[?>?\_4O_
M 'T:/M]Y_P _4O\ WT:/[#E_/^ >U/=-R?\ /1/SHW)_ST3\Z\+^WWG_ #]2
M_P#?1H^WWG_/U+_WT:/[#E_/^ >U/=-R?\]$_.C<G_/1/SKPO[?>?\_4O_?1
MH^WWG_/U+_WT:/[#E_/^ >U/=-R?\]$_.C<G_/1/SKPO[?>?\_4O_?1H^WWG
M_/U+_P!]&C^PY?S_ (![4]TW)_ST3\Z-R?\ /1/SKPO[?>?\_4O_ 'T:/M]Y
M_P _4O\ WT:/[#E_/^ >U/=-R?\ /1/SHW)_ST3\Z\+^WWG_ #]2_P#?1H^W
MWG_/U+_WT:/[#E_/^ >U/=-R?\]$_.C<G_/1/SKPO[?>?\_4O_?1H^WWG_/U
M+_WT:/[#E_/^ >U/=-R?\]$_.C<G_/1/SKPO[?>?\_4O_?1H^WWG_/U+_P!]
M&C^PY?S_ (![4]TW)_ST3\Z-R?\ /1/SKPO[?>?\_4O_ 'T:/M]Y_P _4O\
MWT:/[#E_/^ >U/=-R?\ /1/SHW)_ST3\Z\+^WWG_ #]2_P#?1H^WWG_/U+_W
MT:/[#E_/^ >U/=-R?\]$_.C<G_/1/SKPO[?>?\_4O_?1H^WWG_/U+_WT:/[#
ME_/^ >U/=-R?\]$_.C<G_/1/SKPO[?>?\_4O_?1H^WWG_/U+_P!]&C^PY?S_
M (![4]TW)_ST3\Z-R?\ /1/SKPO[?>?\_4O_ 'T:/M]Y_P _4O\ WT:/[#E_
M/^ >U/=-R?\ /1/SHW)_ST3\Z\+^WWG_ #]2_P#?1H^WWG_/U+_WT:/[#E_/
M^ >U/=-R?\]$_.C<G_/1/SKPO[?>?\_4O_?1H^WWG_/U+_WT:/[#E_/^ >U/
M=-R?\]$_.C<G_/1/SKPO[?>?\_4O_?1H^WWG_/U+_P!]&C^PY?S_ (![4]TW
M)_ST3\Z-R?\ /1/SKPO[?>?\_4O_ 'T:/M]Y_P _4O\ WT:/[#E_/^ >U/=-
MR?\ /1/SHW)_ST3\Z\+^WWG_ #]2_P#?1H^WWG_/U+_WT:/[#E_/^ >U/=-R
M?\]$_.C<G_/1/SKPO[?>?\_4O_?1H^WWG_/U+_WT:/[#E_/^ >U/=-R?\]$_
M.C<G_/1/SKPO[?>?\_4O_?1H^WWG_/U+_P!]&C^PY?S_ (![4]TW)_ST3\Z-
MR?\ /1/SKPO[?>?\_4O_ 'T:/M]Y_P _4O\ WT:/[#E_/^ >U/=-R?\ /1/S
MHW)_ST3\Z\+^WWG_ #]2_P#?1H^WWG_/U+_WT:/[#E_/^ >U/=-R?\]$_.C<
MG_/1/SKPO[?>?\_4O_?1H^WWG_/U+_WT:/[#E_/^ >U/=-R?\]$_.C<G_/1/
MSKPO[?>?\_4O_?1H^WWG_/U+_P!]&C^PY?S_ (![4]TW)_ST3\Z-R?\ /1/S
MKPO[?>?\_4O_ 'T:/MUY_P _4O\ WT:/[#E_/^ >U/=-R?\ /1/SHW)_ST3\
MZ\+^W7G_ #]2_P#?1H^WWG_/S+_WU1_8<OY_P#VI[IN3_GHGYT;D_P">B?G7
MA?V^\_Y^I?\ OHT?;[S_ )^I?^^C1_8<OY_P#VI[IN3_ )Z)^=&Y/^>B?G7A
M?V^\_P"?J7_OHT?;[S_GZE_[Z-']AR_G_ /:GNFY/^>B?G1N3_GHGYUX7]OO
M/^?J7_OHT?;[S_GZE_[Z-']AR_G_  #VI[IN3_GHGYT;D_YZ)^=>%_;[S_GZ
ME_[Z-'V^\_Y^I?\ OHT?V'+^?\ ]J>Z;D_YZ)^=&Y/\ GHGYUX7]OO/^?J7_
M +Z-'V^\_P"?J7_OHT?V'+^?\ ]J>Z;D_P">B?G1N3_GHGYUX7]OO/\ GZE_
M[Z-'V^\_Y^I?^^C1_8<OY_P#VI[IN3_GHGYT;D_YZ)^=>%_;[S_GZE_[Z-'V
M^\_Y^I?^^C1_8<OY_P  ]J>Z;D_YZ)^=&Y/^>B?G7A?V^\_Y^I?^^C1]OO/^
M?J7_ +Z-']AR_G_ /:GNFY/^>B?G1N3_ )Z)^=>%_;[S_GZE_P"^C1]OO/\
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MU.54_P 58XC$4\/3<ZC&DV[(3P9X,?49%O[]"MNIRJG^*O5DC6&-8XU"HHP
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M* "BBB@ HHHH **** "BBB@ I&^X?I2T/]P_2@#WCP7_ ,BI9_[M;M87@O\
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M+.5C7N:H:YK4FM7GFD;84&(T]!71*]:M"45I&^OZ"V1FTG>A:#UKL)"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $?
M[AKVKP]_R+UG_N5XJWW#7M7A[_D7K/\ W*\7._X4?4TI[FG1117S9L%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %.
M3[U-IR?>H8% ?Z\_6M@?=%8X_P!>?K6P/NBG6Z A:***P&%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !4-U_Q[2?2IJANO\ CVD^
ME5'= 4+#^/Z59JM8?Q_2K-;S^)B04445 !1110 4444 %%%% !1110 4444
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M)+L<=S2<UV7_  K+7/[T7YFC_A6.N_WHOS-']HX3_GX@Y)=CC>:1\[#79_\
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M_P!Z/]:/^%?ZS_>B_6CZ]AOYT'*^QRNU1T _*C:O=1^5=5_PK_6?[T?ZT?\
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M:,FDHH 7)]:,FDHH 7)HR:2B@!<FC)I** %R:,FDHH 7)HR:2B@!<FC)I**
M%R:,FDHH 7)HR:2B@!<FC)I** %R:,FDHH 7)HR:2B@!<FC)I** %R:,FDHH
M 7)HR:2B@!<G/6D[TCNL<;.YPJC)-4-,UFUU8RBW;)1L$&J4).+DEH@N:&<4
M445(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !3D^]3:<GWJ&!0'^O/UK8'W16./]>?K6P/NBG6Z A:***P&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4-U_P >TGTJ
M:H;K_CVD^E5'= 4+#^/Z59JM8?Q_2K-;S^)B04445 !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %([
MK&C.QP *6J=X&F&P'BJBKNP'*:VCZM=%FSY2\ 5H^'IWLQ]EE)\L_=SVJ[]A
M'I1]A'4=NE>A*M&5/V?0BVMS9HJ&W8^6%;J*FKSFK.Q84444@"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHH)P,T 5KZZ%I;EOXCT%<+<6,EU=FXD),A.0?2NPN83<
MR;CT["H?L KOPU545INR6KDFBWC2VRP3']X@QD]ZU:R([4Q.'7J*U8WWJ#W[
MUS5DG+FB-#J***Q&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114<[D
M1D+U--*[ P_$%T\T9M("0#]\BL'3+>33+M9HB0,_,/45TS66X[F[]32?81Z5
MZ-.M&%/V:V(:N[FK!,MQ"LJ]^M250M$-NVW^$]JOUP3BD]"T%%%%0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3D^]3:<
MGWJ&!0'^O/UK8'W16./]>?K6P/NBG6Z A:***P&%%%% !1110 4444 %%%%
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MF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %,*9.33ZCN+F"TA::XE6*
M->2S&FKMV0!Y='EUSGAWQC#XDUN\L[6(^1;\"7^]3/$_C"31;R/3M/LVO=0D
M&0B]JZU@Z_M?8V][?_AR>96N=-Y=/7(%<1HGCN\GU=-,US36L9Y?]6QZ']:[
MFL\1AZE"7+46_P QII["4445SC"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *<GWJ;3D^]0P* _UY^M; ^Z*QQ_KS]:V!]T
M4ZW0$+1116 PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^%HZ?_SYR?G_ /6H_P"%HZ?_ ,^<GY__ %JO^R\7_(PYX]SO**X/_A:.G_\
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M  M'3_\ GSD_/_ZU']EXO^1ASQ[G>45P?_"T=/\ ^?.3\_\ ZU'_  M'3_\
MGSD_/_ZU']EXO^1ASQ[G>45P?_"T=/\ ^?.3\_\ ZU'_  M'3_\ GSD_/_ZU
M']EXO^1ASQ[G>45P?_"T=/\ ^?.3\_\ ZU'_  M'3_\ GSD_/_ZU']EXO^1A
MSQ[G>45P?_"T=/\ ^?.3\_\ ZU'_  M'3_\ GSD_/_ZU']EXO^1ASQ[G>45P
M?_"T=/\ ^?.3\_\ ZU'_  M'3_\ GSD_/_ZU']EXO^1ASQ[G>45P?_"T=/\
M^?.3\_\ ZU'_  M'3_\ GSD_/_ZU']EXO^1ASQ[G>45P?_"T=/\ ^?.3\_\
MZU'_  M'3_\ GSD_/_ZU']EXO^1ASQ[G>45P?_"T=/\ ^?.3\_\ ZU'_  M'
M3_\ GSD_/_ZU']EXO^1ASQ[G>45P?_"T=/\ ^?.3\_\ ZU'_  M'3_\ GSD_
M/_ZU']EXO^1ASQ[G>45P?_"T=/\ ^?.3\_\ ZU'_  M'3_\ GSD_/_ZU']EX
MO^1ASQ[G>45P?_"T=/\ ^?.3\_\ ZU'_  M'3_\ GSD_/_ZU']EXO^1ASQ[G
M>4$*Q!**<>HS7!_\+1T__GSD_/\ ^M1_PM'3_P#GSD_/_P"M1_9>+_D8<\>Y
MWF:*X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\
MX6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#S
MYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6
MH_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__
M #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]
M:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(
MPYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**
MX/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI
M_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G
M_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6
MCI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR
M?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R
M\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]
MSO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\
MX6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#S
MYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6
MH_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__
M #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]
M:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(
MPYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**
MX/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI
M_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G
M_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6
MCI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR
M?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R
M\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]
MSO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\
MX6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#S
MYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6
MH_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__
M #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]
M:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(
MPYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**
MX/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI
M_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G
M_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6
MCI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR
M?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R
M\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]
MSO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\
MX6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#S
MYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6
MH_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__
M #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]
M:C^R\7_(PYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(
MPYX]SO**X/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**
MX/\ X6CI_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO**X/\ X6CI
M_P#SYR?G_P#6H_X6CI__ #YR?G_]:C^R\7_(PYX]SO,#J ,^PI"B$_-&A/NH
MKA#\4]/ S]CD./?_ .M79Z?>KJ-A%=HI591N -8UL)7H)2J1M<:DGL3^7&.1
M&@/J%%.HHKF&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD>!?\(]K'_/A)^1H_P"$>UC_ )\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\
M"/:Q_P ^$GY&C_A'M8_Y\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\(]K'_/A
M)^1H_P"$>UC_ )\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\ "/:Q_P ^$GY&
MC_A'M8_Y\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\(]K'_/A)^1H_P"$>UC_
M )\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\ "/:Q_P ^$GY&C_A'M8_Y\)/R
M->^\>B_D*./1?R%']OU?Y$'LD>!?\(]K'_/A)^1H_P"$>UC_ )\)/R->^\>B
M_D*./1?R%']OU?Y$'LD>!?\ "/:Q_P ^$GY&C_A'M8_Y\)/R->^\>B_D*./1
M?R%']OU?Y$'LD>!?\(]K'_/A)^1H_P"$>UC_ )\)/R->^\>B_D*./1?R%']O
MU?Y$'LD>!?\ "/:Q_P ^$GY&C_A'M8_Y\)/R->^\>B_D*./1?R%']OU?Y$'L
MD>!?\(]K'_/A)^1H_P"$>UC_ )\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\
M"/:Q_P ^$GY&C_A'M8_Y\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\(]K'_/A
M)^1H_P"$>UC_ )\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\ "/:Q_P ^$GY&
MC_A'M8_Y\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\(]K'_/A)^1H_P"$>UC_
M )\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\ "/:Q_P ^$GY&C_A'M8_Y\)/R
M->^\>B_D*./1?R%']OU?Y$'LD>!?\(]K'_/A)^1H_P"$>UC_ )\)/R->^\>B
M_D*./1?R%']OU?Y$'LD>!?\ "/:Q_P ^$GY&C_A'M8_Y\)/R->^\>B_D*./1
M?R%']OU?Y$'LD>!?\(]K'_/A)^1H_P"$>UC_ )\)/R->^\>B_D*./1?R%']O
MU?Y$'LD>!?\ "/:Q_P ^$GY&C_A'M8_Y\)/R->^\>B_D*./1?R%']OU?Y$'L
MD>!?\(]K'_/A)^1H_P"$>UC_ )\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\
M"/:Q_P ^$GY&C_A'M8_Y\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\(]K'_/A
M)^1H_P"$>UC_ )\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\ "/:Q_P ^$GY&
MC_A'M8_Y\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\(]K'_/A)^1H_P"$>UC_
M )\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\ "/:Q_P ^$GY&C_A'M8_Y\)/R
M->^\>B_D*./1?R%']OU?Y$'LD>!?\(]K'_/A)^1H_P"$>UC_ )\)/R->^\>B
M_D*./1?R%']OU?Y$'LD>!?\ "/:Q_P ^$GY&C_A'M8_Y\)/R->^\>B_D*./1
M?R%']OU?Y$'LD>!?\(]K'_/A)^1H_P"$>UC_ )\)/R->^\>B_D*./1?R%']O
MU?Y$'LD>!?\ "/:Q_P ^$GY&C_A'M8_Y\)/R->^\>B_D*./1?R%']OU?Y$'L
MD>!?\(]K'_/A)^1H_P"$>UC_ )\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\
M"/:Q_P ^$GY&C_A'M8_Y\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\(]K'_/A
M)^1H_P"$>UC_ )\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\ "/:Q_P ^$GY&
MC_A'M8_Y\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\(]K'_/A)^1H_P"$>UC_
M )\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\ "/:Q_P ^$GY&C_A'M8_Y\)/R
M->^\>B_D*./1?R%']OU?Y$'LD>!?\(]K'_/A)^1H_P"$>UC_ )\)/R->^\>B
M_D*./1?R%']OU?Y$'LD>!?\ "/:Q_P ^$GY&C_A'M8_Y\)/R->^\>B_D*./1
M?R%']OU?Y$'LD>!?\(]K'_/A)^1H_P"$>UC_ )\)/R->^\>B_D*./1?R%']O
MU?Y$'LD>!?\ "/:Q_P ^$GY&C_A'M8_Y\)/R->^\>B_D*./1?R%']OU?Y$'L
MD>!?\(]K'_/A)^1H_P"$>UC_ )\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\
M"/:Q_P ^$GY&C_A'M8_Y\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\(]K'_/A
M)^1H_P"$>UC_ )\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\ "/:Q_P ^$GY&
MC_A'M8_Y\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\(]K'_/A)^1H_P"$>UC_
M )\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\ "/:Q_P ^$GY&C_A'M8_Y\)/R
M->^\>B_D*./1?R%']OU?Y$'LD>!?\(]K'_/A)^1H_P"$>UC_ )\)/R->^\>B
M_D*./1?R%']OU?Y$'LD>!?\ "/:Q_P ^$GY&C_A'M8_Y\)/R->^\>B_D*./1
M?R%']OU?Y$'LD>!?\(]K'_/A)^1H_P"$>UC_ )\)/R->^\>B_D*./1?R%']O
MU?Y$'LD>!?\ "/:Q_P ^$GY&C_A'M8_Y\)/R->^\>B_D*./1?R%']OU?Y$'L
MD>!?\(]K'_/A)^1H_P"$>UC_ )\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\
M"/:Q_P ^$GY&C_A'M8_Y\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\(]K'_/A
M)^1H_P"$>UC_ )\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\ "/:Q_P ^$GY&
MC_A'M8_Y\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\(]K'_/A)^1H_P"$>UC_
M )\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\ "/:Q_P ^$GY&C_A'M8_Y\)/R
M->^\>B_D*./1?R%']OU?Y$'LD>!?\(]K'_/A)^1H_P"$>UC_ )\)/R->^\>B
M_D*./1?R%']OU?Y$'LD>!?\ "/:Q_P ^$GY&C_A'M8_Y\)/R->^\>B_D*./1
M?R%']OU?Y$'LD>!?\(]K'_/A)^1H_P"$>UC_ )\)/R->^\>B_D*./1?R%']O
MU?Y$'LD>!?\ "/:Q_P ^$GY&C_A'M8_Y\)/R->^\>B_D*./1?R%']OU?Y$'L
MD>!?\(]K'_/A)^1H_P"$>UC_ )\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\
M"/:Q_P ^$GY&C_A'M8_Y\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\(]K'_/A
M)^1H_P"$>UC_ )\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\ "/:Q_P ^$GY&
MC_A'M8_Y\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\(]K'_/A)^1H_P"$>UC_
M )\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\ "/:Q_P ^$GY&C_A'M8_Y\)/R
M->^\>B_D*./1?R%']OU?Y$'LD>!?\(]K'_/A)^1H_P"$>UC_ )\)/R->^\>B
M_D*./1?R%']OU?Y$'LD>!?\ "/:Q_P ^$GY&C_A'M8_Y\)/R->^\>B_D*./1
M?R%']OU?Y$'LD>!?\(]K'_/A)^1H_P"$>UC_ )\)/R->^\>B_D*./1?R%']O
MU?Y$'LD>!?\ "/:Q_P ^$GY&C_A'M8_Y\)/R->^\>B_D*./1?R%']OU?Y$'L
MD>!?\(]K'_/A)^1H_P"$>UC_ )\)/R->^\>B_D*./1?R%']OU?Y$'LD>!?\
M"/:Q_P ^$GY&C_A'M8_Y\)/R->^\>B_D*./1?R%']OU?Y$'LD> -X>U?:?\
M09/R->V>'8I(/#]I'*I5U3!4UI\?W5_(45Q8[,IXN"C*-K%1ARA1117F%A11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !3D^]3:<GWJ&!0'^O/UK8'W16./]>?K6P/NBG6Z A:***P&%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4-U_Q[2?2IJANO^/:3
MZ54=T!0L/X_I5FJUA_']*LUO/XF)!1114 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1@GM2UP?Q#\37FD^3::<^+@_,Y'85T8;#SQ%54H;L4G97.[HKFO
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %.3[U-IR?>H8% ?Z\_6M@?=%8X_UY^M;
M^Z*=;H"%HHHK 84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %0W7_ ![2?2IJANO^/:3Z54=T!0L/X_I5FJ]B/O\ TJQ6T_B8@HHH
MJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1535*S7<N*M)Z&Z.>WX5Y!XP%RWQ$MQ9D"XXV$^O%>NON,;!3A\<'WKS:_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW%_+I"OJ)_> \$]2/>J9\3[_ !4-,BVM#MR7![UK]5FYRA'7E%S*QU)Z4ZF
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M5EP1[CFNO%**A*,87A;356)B8WB75KB?Q&UK<W,UO:HV%,9P<>O:K6BPWO\
M;-N]CJ?VNT5OFW.<@=\BF:Y? Z[/:ZI8^9!G",@.0/6LB*W6/7K8:-),ZE@>
M1C%$(*5!12M[OJO^'#J;OCB74K.Y\U;HK;3$*JJ<$<5NV%_):^"XKK+/(L/!
M)R2:YGQU??:#%9K'(TT)&\@<=*TM.UE5\%,@MV=X8PCH1Z\5RSI.6%I7CU_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M66XM;?F@YXGH:QHL8C50% P *J?V38>=YGV6+?G.[;S7#_\ "P=0_P"@:O\
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M *!J_P#?9_PH_LG$]E]Z#GB>D45YO_PL#4/^@:O_ 'V?\*/^%@:A_P! U?\
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MO_?9_P *;RS%M6_5!SQ/0I8HYE*2(&4]014,.G6=N^Z*W1&]0*X/_A8.H?\
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M U#_ *!J_P#?9_PH_P"%@:A_T#5_[[/^%']DXGLOO0<\3TBBO-_^%@:A_P!
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M%/\ OD4?9;?_ )XI_P!\BIJ*.9]P(?LMO_SQ3_OD4?9;?_GC'_WR*FHHYGW
MA^R6_P#SQC_[Y%'V6W_YXQ_]\BIJ*.9]P(?LMO\ \\4_[Y%'V6W_ .>*?]\B
MIJ*.9]P(?LMO_P \4_[Y%'V6W_YXI_WR*FHHYGW A^RV_P#SQ3_OD4?9;?\
MYXI_WR*FHHYGW A^RV__ #Q3_OD4?9;?_GBG_?(J:BCF?<"'[+;_ //%/^^1
M1]EM_P#GBG_?(J:BCF?<"'[+;_\ /%/^^11]EM_^>*?]\BIJ*.9]P(?LMO\
M\\4_[Y%'V6W_ .>*?]\BIJ*.9]P(?LMO_P \4_[Y%'V6W_YXI_WR*FHHYGW
MA^RV_P#SQ3_OD4?9;?\ YXI_WR*FHHYGW A^R0?\\8_^^11]D@_YXQ_]\BIJ
M*.:7<"'[)!_SQC_[Y%'V6W_YXI_WR*FHHYGW A^RV_\ SQ3_ +Y%'V6W_P">
M*?\ ?(J:BCF?<"'[+;_\\4_[Y%'V6W_YXI_WR*FHHYGW A^RV_\ SQ3_ +Y%
M'V6W_P">*?\ ?(J:BCF?<"'[+;_\\4_[Y%'V6W_YXI_WR*FHHYGW A^RV_\
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M<"'[+;_\\4_[Y%'V6W_YXI_WR*FHHYGW A^RV_\ SQ3_ +Y%'V6W_P">*?\
M?(J:BCF?<"'[+;_\\4_[Y%'V6W_YXI_WR*FHHYGW A^RV_\ SQ3_ +Y%'V6W
M_P">*?\ ?(J:BCF?<"'[+;_\\4_[Y%'V6W_YXI_WR*FHHYGW A^RV_\ SQ3_
M +Y%'V6W_P">*?\ ?(J:BCF?<"'[+;_\\4_[Y%'V6W_YXI_WR*FHHYGW A^R
MV_\ SQ3_ +Y%'V6W_P">*?\ ?(J:BCF?<"'[+;_\\4_[Y%'V6W_YXI_WR*FH
MHYGW A^RV_\ SQ3_ +Y%'V6W_P">*?\ ?(J:BCF?<"'[+;_\\8_^^14H0*,
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MIJ<'RRT8M"'[+;_\\4_[Y%'V6W_YXI_WR*FHJ>9]QD/V6W_YXI_WR*/LMO\
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MIJ*.9]P(?LMO_P \4_[Y%'V6W_YXI_WR*FHHYGW A^RV_P#SQ3_OD4?9;?\
MYXI_WR*FHHYGW A^RV__ #Q3_OD4?9;?_GBG_?(J:BCF?<"'[+;_ //%/^^1
M1]EM_P#GBG_?(J:BCF?<"'[+;_\ /%/^^11]EM_^>*?]\BIJ*.9]P(?LMO\
M\\4_[Y%'V6W_ .>*?]\BIJ*.9]P(?LMO_P \4_[Y%'V6W_YXI_WR*FHHYGW
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MM50TS2[32K86]G&$C':K]*NZ;J-TU:/0%>VIROQ!BC?PO(SHK%7&"1TZTO\
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M)'GF>&976<C.T@\9YJFFKV.MWEB-2U""(6[!UB!Y=NV?2M*&%@Z:G:ZUOO\
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M,'KQ4U%9<S[C&)#'$,1HJ@]@,4W[/"7WF--WKBI:*+L"(VT).?*3)[XI!:P
M$") #U 7K4JLK#*L"/8TM/FD!&D$4>=D:KGK@8I!;PA]_E)N]<5+12YF!$]O
M#(V7B1CZD5(JA1@< =!0S!1EB /4TH(/2B[L!C:[IEQ?-:RV[J?(?<8GZ/TJ
MG?Z;<ZO:26LMC!#O&#(1R/IBND-%;PQ,X))=-A6*=GIL%K:Q0E YC7&]ADFK
MFT;=N./2EHK&4I2=V,B6WA1MRQJ#Z@4]XTD&'4,/0BG44KL"(V\.S;Y2%<]"
M*YWQ/IE]J"VL-E%&(X91*=WMGC]:Z8TG?%:T:TJ4U-=!-7(+6%1"C/"B28YP
M*L8HQ1GWK-N[N,8T$3G+1J?J*58T1=JJ /0"G*RM]U@?H:6E=[ ,$,:L65%#
M'J0*1H(F;<T:EO4BI**+L"+[/%O#^6NX=#CFE:&)FW&-2WKBI*0T78%'4()Q
M:R-IZPI=8^4LO!_*J]M9W%S=Q7E^B+)$N$1>Q]:UJ,5HJK4;?CU%8!Z4M%%9
M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *.I=(?]^KU4
M=2Z0_P"_5ZM)?"A!3:=3<5 Q#7)>-/$=]H<<(LX-_F=7() KKCTJ*:VBN%VS
M1JZ]<,*WP]2%.HI3CS+L)IM:%30[Z74M'MKN>+RI)%RRGM6A2*H50H& .@%+
M64VI2;2LAG+Z_I^HQZS;ZQIJ+.\*%&@8]0<=/RJE-KECJLD5IJUE+87"L#'(
MXX!]B,UK:@NJP>((;BT3S;0Q'SHRV.>,8_6H=8237[1;*.S922"TD@QY>#VS
MUKTJ4U:'/;;=.S7J0R[>WE\^II:6ZK';[-S7+'CZ"JVGZO<#Q"^D7#I-^[\Q
M)5_#@_G56XLKJ+6@MVDMQIZQ!840Y 89SD?E44-K<6GBV/4?[/,5JT!C CY(
M/'7'TI1IT^1K3X=/7_,+NXFGQW"^.;]FN,A(<M[C(XJ>/7IM0>X:W8PPQ.4C
M(4G?CO\ 2F62S_\ "77L[VDHMYXO+60@]>*L:5'<^'S/926[RVYD,D+H,G![
M'\JNIRO5I-VC;]1(@OKZ_O\ PC?2N&M)H4;D?Q 9Y%/TF+4E\+0S0709Q$65
M2.O)K1O8;[4M O8)(U26:-EC3/KTS3?#[S1Z9!9RVSHT:[7+=.OZUDZB5%\J
M6DKV\K#MJ5-+U>XNO"[WLTZK<@D$8^ZW]W\ZV-*^U_88VO) \K@-P.!FN:73
M)T\6SV4>/[/E(N7'H^2?Z"NR'  ':L\5R1^#[6OHNPXW,[6+R[M88Q9P>9)*
M^W<3P@]363>ZO=Z/>6:R31W,=Q((V /*GCG]:L>)8+^1K1K?>;57_P!(2,X9
MEP?ZXK)UC3Y;A;*6PTTK';S*[,>&(R.W6M<-3IN,>:UG>_\ 7^0FV:VO:I?Z
M??V,=N(F2XE$>&SGFHM5U'4-&FLYI9$EBGE\MTP?EXSQ5?7WGNK[2Y8;.9EA
MF623"D8'Y4OBY;B[BT]+:UED*2B5L \#!%.E"/[N,DM;W!O<O:AJ]P^LQ:18
MA1,R^9)(W15_R#63J"747C71UN7$B[&VL.O5>M6[FTN+;Q%%KL$#212Q".6/
M'S+UP<?C4.I?;+CQ+IM\ME)]GA!!/4\D=OPJJ*C%KEM;E=_6S!G7UQNHQWK>
M.;.-+QE5HV*CLO!KL0=P!QU&:YS5+6XA\3V6II"9($1D;;R1D8_K7+@Y<LY>
M:?Y#D/O=5N5U:WT6T(:Y>/?)*W\(&/UYI6U6YTO6+6POBLJ77$<J]F]#^55[
MJSNX/$,.N1P%HVC,<L8.6 XP?TI;BSN-;UZSO&A:*TLCO&X89VY[?0UNHTK*
M]K6=^]Q:D-BXC\=ZL[?=6V4G\VHAUZYU))IH&,*(S+&-I.[!QDTRSBGD\6:A
M-):RK;W,(B5R#[Y_G5G1Q=Z!!+8SV[RQB1GA=!G()S@UI44-[7E:/Y:B5QTV
ML:DWAJ6^$"03Q#++)GGG'&*=83ZU>6EG?[X1'(FZ2+!SCV]Z76I+V;PY<1/;
M,T\PPD:#..>]6-%^T?\ "-10^6T-PD)0!AT;''ZUB^54N917Q?A8?4KI>:I=
M0SW#R1V95F$<3GD@'@FI-/U5M8\-SW#QA7VLK8Z'&16;IUK.+5TO;*2XORS
MM(<J>>Q]*?X=M;FUT:ZTZ>V9)1N(X^7GT/XU=2G347:UTU]P)L@\(PZA)X6A
M:"=(PN=BXZ_6KL6O7=UX>O;E(XX[JT++(KYQ\N1D?7%1: U]HN@16D]F[3 ?
M*$Y!^OI3$TRYT_PUJ'F1&2[O2[;$&<;LX'ZU=3DE5DY6^)6^_7Y"6Q9NKN2_
M\!2W,H =XLG'3[U0_;;K3_ UI=6OEDI$N0^?TJ!3=#P.UB;.87.S9LVGKG/6
MBY6Z?P-%9+9R_:0BH4P>U-0BO=TMS_@'^0_Q5+=3^#X;E+@Q;XT9U7^+(Z5;
MNQJUEX?%S;W(DDCC5MI'48%0W]I=ZGX*2UBA9;B.-04?C) Q6UI\KW-HD4D#
M1J(@K;NYQBLI34*:5D[2=UY:#MJ9G]J7$OAJVNX+A3/-MVGU).*W;-9EMHQ<
M,&EQ\Q'K7)Z'ILT6N7-BP!L+60R1?4\8_#%=G6&+4(/ECZ_?LAQ,&\U:XFUQ
M=)L0HD5-\LK?PCV]^E-75;FRUN/2KPAQ.A,4P]<'@U'<V-SIWB5M6@B\V&:/
M9*HZJ?4>O2FFSN=4\0PZC)$T=I:J=@;[S,0<\5LHTN5;<O+\[_\ #_@+4J>&
MHKC_ (2/5]\^Y0ZAE/\ %UKL. .!TKE?#ZW$>OZD\UK)''<,"C$''&?\:ZO\
M*QQKO5^2_(<=CCM ;^T?%VKW-Q\[6[>5$I_@'^36[X@MH[K0KQ' _P!4Q!]#
MCK6>^F7.E:]-JEFGF07 _?PYY!]13]5EO=8LY+"RMWB\T;7ED&-JGKP>M;3:
MG6A4@[15OE;<2T5C+M89=?\  "B7YIT4^6Y]5./Y"KUCKGG>#TNF_P!=M\IA
MWWGC^M;>FZ=%INFQ648^1%P??UKF+70KR'Q)-;[<:69#< =MQ[?H*I5*57G3
MT2?,O3J@LT=)H]F++3(HL?,1N?W8]:PK^-$\>:=L4+N@).!_M5UG:N0O7GD\
M6VMZEG,8(8RC-M/7-8X:3G4E)]4QO8G\9,S1Z=;@D)-<@/CO@@U?\2VT3^&K
MU-H CA++[$#BEU[3'U:QB:'B>%Q)'N]B./TJGJ4M]J^EMI\=J\4LPV2NW11W
MQZU=)IQIV=N5N_W[B?4O>'9FN_#]H\WS$I@Y]N*RO#ZA/%^MJJ@ $<#ZUT%M
M FF:;'"BL5B0# Y)KG-%-Q%XGU*YEM)DBN"-C%3ZTH-259QV>WWH'T.OK)U6
M[O8KFWM[2(;93^\G8\1BM6N;UVWO)-7M'82R:<!AXXSSN]QW%<^&BI3U*>PB
MZO=66OVVGS21W$=P#AU/*D FJ.KQWI\::?&MXP5XW*#LO2DNK*==<T^_@TXI
M:Q$ABOWCQW%7M6M[C_A(--U1(&>&-&5P!\PSC'%=\>2$TXVUB^V^I&MCHXD=
M(E5VW,!RWK7.:A?ZC:>);6U:94LKG.UB.00,XKH8)'EA#M&4)[$UD>*=-EU#
M3 UL/]*@</%]<BN+#.*J\L]GIZ>93VT*-OJ]X/&,FE2W"&,)YB8'7VI?[8N[
M--1OKB99+6 [8E Y8U2U#1=0_LVUU*WC!U57WO\ CR1^%;%UH37?AHV.0LS+
MOW>C'FNR7L%RMVL[)_+=_,6I0?6M2%LEU$ADE)!-N%/2K-YXAD^VP6,,9CD>
M(22L1DID=..]6+74;Y+.."2R<W:C:?[OUS5>ZL;RSUZ/6$C\U7B$<\:]0<<$
M?K4+V;E:44M[:[]O^ &I)IFIWKZB]I-$TD!7<D^,?@:R-(U&'3IM:>20*S7)
M5!W+8&*Z6*^N9Y&=;9DMU7DL/F8_2N4L=$2^N=4>]LI4DED,D,F.5],<>U72
MY&I\ZLM-O4'<Z71DU5D\W49%^;[L:]0/>MBN=\-WVH-']CU&WDWQ\+,5(#@=
M,^]=%7#B8N-1IV^6Q2V.3\41HNMZ*RJ QG;) _V:Z'4+4WMN(0X7+@M[@=JY
MWQ$9[C5M/:*UF=+:4L[!3TQ6_>7TD.F-<P6SRR8^6+&"36]12Y*5M_\ @B6[
M*GB"YM['0IDE 8E-B1@<N?05)X:M9K/P_:0W&?,5.0>U<S%?W;W7VR_T>XGN
M5_U8YVQ_08KKM(EN9].BFNE*2N,E",;?:BO3E2H\GG=_\ $[LO4445P%!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOM3M--B5[F54#'"C/+'VKD-7OH)_%>CFWFE5WD;>A<]-I[5+='=XXTO[4?\
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M&IZ%CBHX+^VN6*P3QR$=E;-+EE:]@+-%)FE[5(!1249H 6BDS1F@!:*3-&:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% #.:1W" LS!5'4DTX')Q6
M!XOTZ_U/0WM]/DV3%@2,XW#N,UK2@IU%&3LGU$]$;J2*XW(P8'N#FGUS?@[3
M-0TS2/)U"3=)G*KG.T>E=)3K0C"HXQ=TNH)W1@7TVJ7&O+:V3K%;QQDRNP/)
M.,8_6LBPU'7]5MM2,,\*R6DOEJ,'YN,UVN "3CDUR7@<?-K _P"GO^E==*I'
MV,I<J]VWYZDM:G0:9>F?2K>XG_=NR_,&.,&K:31N"4=6 ZX.:Y&^D?4?',6D
MRDBRBB\TQC@.>>OY4:IG1O%FE+9'9%=DI+"/ND9'.*EX52DE>S:YK>6]A\QM
MPZ_:SZU+IZ2(3$FYCGOD<?K6H\T<>-[JN>F37%:;I]F?B!JB&VBVB,$#;W^6
MK=R;,^(I_.EDO2$"K:HA98^3R:=3#4^9*%_A3$FSJ=XE0^6ZGT(.:YO0M0OY
M?$NJ6-U/YD<!&S'N ?ZU3\-S2IXJU*U"O%;A4986.0N0>E2Z%_R/.N<?W?Y+
M5*@J:J1>ONIKYM!>]CKLU&\\49P\B*?0MBBX<Q6\LH&2B%@/H*Y'PI;IKEE<
MZCJ*^?-+,Z#?SL4$@ >E<M.BI0E4D]%;\2F];'47]ZEGI\MT2"$7(YZUAZ%+
MJ6JPV>J"^7R9%+26YZ#Z5BV$KS:=K^G7!\^&T?$3/SM! ./UK>\$Q1Q^%+ H
MBJ6B!) ZUUSHJA1EU=TODU<E.[-F_O%L;-[AANVCA1W/I69=2ZQ'9M?1-"=J
M[_)(/(]*UYH([B/9*@9<YP1WK"US4I9(FTK2U\R[E7;N'W8AZDUS8=<S44O6
M^UALLVVO"]\/1ZG;P,[2 8C'4$\53U._U72-/_M.9H7C3!DB .0.^*MZ7'9>
M'M&MK22YC"KB/>6'S-5#Q58W3:?-=&<26L \Q[<C <#MFMZ:I^VY4O=;Z]5V
M$[V.CMIUN;6*=!A9%# >F:D:6./&]U7/3)Q5+1KR*_TBVN84V1NG"^F.*P/'
ML2_V;!*&=7^T1KE3C^(5STZ'/7]D]-;%-V5SJ_/BW[!(A;TW#- FC+[!(F[T
MW#-<=XHMDM+?3)H-T<S3QHTJG#%2>1FCQ%$EA?Z)-;?)*\X5V'5A@]:UAA(S
M4;2WO^ N8[)Y$C&7=5'J3BA)8Y,['5\?W3FN9U=[5M>A%Q<23[8^+.-2PSSR
M<?YXJAILSP^//L\,3V]O);ES#V) ZXI1PG-#FOTN'-J7[6_OU\:R:?-.'M_(
M,BJ.QR*Z5YHXSAY$4GL6 KDP2OQ$F(ZBR)_454T6"\UY+R\E>%]TS(%E3=Y8
MP.!Z5M5P\9I3;LDE][$F=TK!AD$$>HH)P,GBLG0=-NM,M7@N;O[1ERR<?='I
M4NNP3W.CW$-M<""9UPCDXP:XG3C[3D4M.Y5]"Z+F$G EC)/^T*/M$6_9YB;^
MFW<,UYS,YLX;6UU:QELI8G7%Y!\R,<]\#O\ 6M76HX5\5Z%/!@-+N+,G\?W:
M['@4I)7WOZ::]R>8[)IXD;:\B*W8%@,US/BS4;_39]/>WG"0S3!&7UYJMX^A
MC%G9W 7$OVE1N'!Q@TWQT@EMM(1LX-RH./PIX2A'GIR>JE?\ D]SL!/$S;%E
M0MZ!AFJ.I1W<MQ:_9;V. *^9$8\N/05B>++*'3=&%_9_N+F!U*NO!;V/KFJN
MNY?4O#MSEA)+*F\9X/RFHHX=2M.+WONNR&V=JTJ1@;W5?<G%"R+(,HRL/4'-
M<9F[UCQ;?V_F1F&T0!8I%W#KUQ4EU::AX=T[4]02Y4H8BR0HN%1@#R.:GZHM
M(N7O.VGJ',=:;F$-M,J;O3<*S]9UNWT>V625UWNZHJD]<D"LC3-"@U'PU&SR
M$W4Z[_M.?F#'WJAXPL%BT/35N2MQ-',B&5ARWS"JHX:BZZIMWULQ-NUSMHYT
M>+S Z[<<D'BA;B)B LB$GL&%8.OZ7++H7V;2WCMI"P8+G:']OQKGDNHHM5T]
M=0LY=,N8G $B<QR\="<8J:6$C5BY1??3K_7H-RL>AYICSQQG#R(OU.*<.F?4
M5R(-F^M7AE:349,A1&$)2+KQGD5A1I>TOY#;L=<CJXW*P8'N#FF-<1(VUI4#
M>A89KD/"$\YN=9MQO6.*3]W&YSLR,X%5-,-K<:/J$FJ-NU ,P;=]X''&VNEX
M+EE)-[6_$7,=X)4;.'4XZX/2D$\3-M61&;T#"O/7DO[/PWIMN28;B]G57E(P
MVW(P#[\UN/X=O6EMI8;F&V>)@2\<>-X]#S2G@X0^*?>WR#F;.G>:./&^15SV
M)Q2I(D@RCJP]CFN+UBVU*WUR2^6W74[78$,&\9C/J!S5OP?<6DCWBV\DR-NR
MUM,"&C//KVJ981*E[1.^W]>0<VMCJZY?7M>U'3-1LXDMD^S3R[/,8\_SKJ*Y
M#QQ]_1_^OK^E3@HQE649*Z=_R"6QU%S,;>VDF"%RBE@HZFL2YN=9CTY]1_<I
ML7?Y#9Z?XUMW-U#9P--<2+'&O5F/ K(URPNM3L)&MKP+$R;MF.&'UI8?ENN9
M*S>[_(;+^D:DNJZ5;WR*5$J[L'M5R201Q-(QPJC)-<SHVO1'PM'=6UBY$1\L
MPQ#.#[8%7M-U<ZPTD$NGSP)MP3*I /YBG5PTHRD[628DP2?4M1MS<VS1PID[
M%8')QZU'I/B+[99W;7,8CN+1RDJCH3CM^=3ZEJ4&D6HM[>,R7##$4*=2?Z"J
M?AW1?LMG<?;V22[NG\V=0<X/''Z5I:#I.4U975N_F&MR<R:M<VGVRW:),KN2
M)@>1VS4^@:P-:T[S]FR1&*2)Z$'']*@UC5/L<'V#3X_-O77;'&O1/<^@IWAO
M2QI.EB RK).S%Y2I_B)SC]:4XQ]BY25G?3TZ@MS:)QS7/>*M2GM-%EN;&ZC5
MX^H!R347C;4)['28TMW*-<2K&7'8$C-4?%.B65IX0E\J/$D8!W@\L??UJL+0
MBI4YS^T[6%)[I&\[W5UX?C:&Z2"YEA4B5SP"15^WW16L?GRJ[A?F?/!KE?$,
M2M\/Q*2P>.V5E*G'.!3[]H3HFEI<7KQ*V"8D!+2\=,4>PYXJSWDUL%SJEGB?
MA)$8^@8&G-*D:Y=E4>I.*X+5)A;ZSI$ME;268DF",<;=PR."*T=<D8^++&&]
M;&G-&2%S\I?(QN_6E]2UCKNF_/0?,=4+F$XVRH<^C"E\^+G]ZG'7YAQ7(6%G
M%+XPN/LD>ZP$0W9'R*^?X>W3%1:)8Q3>+=8AD+O#&$VHQXY)H>$@DWS;)/;N
M',=JDJ2<HZL/53FFO/%&</(BGT+ 5R.G,;#QCJ=K;Y6W6$2"(= <#H/QH\*6
MZ:WI]SJ&H?OIIY",/SL'H/2E+"*$7-O33UU#F.Q#J5W C&,YS3!<PDX$L9/H
M&%</I[7UW9ZWI$-V4^SRE()6;H"2-N?PJC-+]D2VM]4L9+&2)AMO(?F1CZM@
M=_K6D<OO)QYM?TM>_P#PPN<[B^CNY-0M3;WL<,:M^\B8\N,5?>5(\;W1<^IQ
M7':XJ+XHT&6*1B99#DYX(VFG:Y:ZBFO'4(84U"U6,*UJ6 *'U%3]64E!.5KI
MOMUV_P"'"YV"2)("496^AS3LUR7A"YLWN[Y(&FA=F#/:S @Q\=L]JTO%E_/I
MOAVYN+?_ %@ 53Z9(']:QGAFJZHK=V_$=]+FO]HAW;?-3=Z;A6/XFUEM)TY&
MB*B:601KD],]ZS_['MU\(&;+?:A;F;[1GYM^,YS]:Q-4F.J>#=*N[N-6G^T*
MA8CD@9'ZXKIP^%INHG>Z3LQ.3L=CI-M?0R2R7-]]I@D :,'JM0>*K^\TS26O
M+-T#(1D.#@YK7MHTCM8D10JA1@#@"L+QQG_A%[@#KN7K6%!JIB8\RT;0WI$D
MC36)K&*=+R%9)8PRJP.,D9JA<:GKK: ;RWBC%U <31$'YOI^%*EKK,G]B2-(
MC6J&,NJ+@XQ73W,L5O;R2S$"-1EB:UE.-.2T4M?Z0MS M_$*S^%4OQ.IG9<
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MSL15R<G ZT^BBE>X!1110 44A( R32]J "BD) &2<"C( R2* %HHHH ****
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M.C@U*TN8&FCF4HGWSG[OUJF?$NDB-I!=HRJ<-CM63:C_ (K^Z6#_ (]S /-
M^[NQQ_6F>#[>"675]T:-FYQCKQBAX:E&+F[Z)/[PNSK(9DN(5EB8,C#(([US
M]]J=S?>(!HUE)Y2(N^>4#) [ ?K71(BQH$0 *.@':N0@/]E>.[C[1\L-W&#'
M(>F1V_6LL+&+<VE=I-H<B_JNDW<5@\FG74HG49P3G?\ GTK/\52.-.TZ\,DD
M,AE0. Q QN&<UUDUQ#!$TLCJ$ SG-<KXMG2[TFPE"E4>X3Y6XR-PK;"5)3J0
M4EUW_04EH;W]MV"RI$TX&\@*QZ$U:N;RWM(Q)-(%!X7GK7/^,TCC\/1[ JXF
MCQBJ>HH9_$FDQSRO' ;<;&4\;_\ .:BGAH5(J2=EK^ VVCI[75+2[E:*.0>:
M.J'K3)]9L;>5HWF&Y.6 _A^M4)=(MH;L7?VF1[Q8V$62.>#Z54\&K#)I=QYX
M4W#3OYV[KUI>QI<CJ*[2M^/Z!=[%CQ/)%=>&9[JWG8[5W(\;D9Y]JLV^J6VF
MZ%:3WLNQ60 LQ[UG:U:V=CX0U".T8>6 21GN365!<3V\FG2:S&ITYT BQ]V-
MO]K]*WIT8U*-NB;]7IT$W9FEXKG2Z\/K?VTLJXD4*58C(J]JDE@^EV<-]>&#
M<$*E7(+'%0>-&C_X1DF,KL,J8P>*J^+0O_".6+''WH\$_2BC%3C36WO/] ?4
MZ6XOK6PB0S2A=W"@]6J.WU>RN96BBF5I4&YH^X%8^O6,5]<V1BOOLU]&-T)/
MW6XZ55T^YN+?Q+#!JEK']JDC(2XAZ,/<5C'#0E3YD];-_P!=T.[N7=/\3)>:
MU>6Q#B.)@J@KSG%=(*Y/0=H\4ZUNV@!UZ_[HKK!6>+C",TH*VB_((["T5DZE
M+K23@:?%;-'CK(#G]#5VR:Z:U0WBQK/_ !"/.*P=.T5*Z'<S_$>LG2+%#&N^
MXF<1Q*>F320:/,]LK75Y*;EAEF4X /L*S/&]O*8;"]C0NEK.'D ]#@5TMM=P
MW5LD\3J4<9SFNE^Y0A*&[O=_H+=ZF9H7VVWBNHM1<L8G^61NZ]:L#7M/9\"X
M7;G ;L36/XLOS/H-['9ECY>!(RCM5B]CLD\'MC9Y0A^4CU[?K5NDIVJ36LG:
MRZ;!?HC4N]6L;'R_M-RD?F$!<GJ3TI&UFQ6=87G56/W<_P 7TKC;T._A'13<
MCYS-%][KC(K3\5I'_P 2<87'VA,_D:I82G=1;>MU]PN9G0)J]DUT+;S@)&^Z
M#_%]*)]8L+>Z2UEN469^B$\U@^)@J:IH9&%_?'_T&CQ"L9\4Z-N"Y);G\JB&
M&IR<7KJF_NN.[-U=8L6F:$SJL@YVMU(]:=;ZI:7$[0)+^^49*'KCUK U98SX
MVTD$+_JVX_&G76U?']H!@9M^<?C1]7@TFKZQ;^X+LVK?6;*YOFLXY1]H49,9
MZXH?6K)-02Q>4+</PJG^+Z5B *GQ%)P!NMA^/%,U]X_^$OT/#+NW^M-8:#FE
MKK&_X!=V-^?6+"VNEMIKE$E/12:(M8LYKH6ZR@2D?*I_B^E8.N1Q-XQT8,H(
M+-G/^Z:7Q.%36]$VX4^:1QQW%$</3ERK6\DW]U_\@NS2O6T^77;(27A2ZC/R
M1*Y&[ZBJNH>)%M?$-KIX5PI),AV\'@]*KZZ$7QAHA  ))S[\TNJ;?^$ZTO(&
M#&<Y^C5=.G!J/-K[K?YB;-9O$&GQW*6S3;9G^ZIZFIKC5[2UN8[>5]LLGW1Z
MUD>++0_9[?5+8 RV<@<X[KGYOT%3:7,FM:A_:*@&&*,*G'4G!/Y&LO8TW355
M7MK?UZ#N[V.@'K2T@I:X2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:
M* .4\4W6HZ??6-S#=>78O*L<XQTSW_G5/4M7N[+Q=IUI]N_T2Z&3\O0^F<UT
MNO::-6T:XM,?,Z'9[-VKF&\,W]SX9D^T8.J AHS_ '2.!^E>MAJE%TX^TLMU
M]^S^1FT[Z&K$VH77B*[6"\"VL*8"E<_/SD9S]*A\.7U_JT&IP75P-\4S1JZ#
M;@ D?TK1T6WNK+1P]VFZ\<;Y57NU9?A&UU"RNM0%Y9O$MQ.TJ-VP23S^=0W%
MTZEK>[:VW3<?5%3P);3M'=RM=2,JW!!!/WJ-,BNIO'&M)!*(UP-Y(R>IZ5<\
M.V>HZ,UY;/:[A).9%D!XQ3=%MM0A\5:G>3V3I;W( 1N_!)K>I4O.K--:K3;N
MA):(LZ1J-VGB*\TBYE$PB571\8.",XKHWR%8J,D#(%<I96^H+XUNKZ2RD6VE
M14#X]!C-=-<J\EM(L3;7*D*?0UPXJ,>>-K:I7]>I4=CF_M&HRVT\]Y>Q6DR[
MC'"#T '&>:T/"VK3:SHRW,X7S [1DKT.#C-8^EZ=?6FG26\]CYUXP*M/*25;
M/?-7?"%G>Z78R6-Y;[&$KN'7[IR<UT8B-/V4K6NFK;;=;"5[FOK&HII6E7%Z
MXRL2YQZFL.(Z[=:,FI1SI]I<!Q!CC'I6YK&G)JVE7%D[;1*N,CL:R]+;5K'3
M8[&6TWS1#8LH^ZP]:QHN*I7C;FOU[?UN-[E>[UN_FU&PTB +#=SQ>;.Q&=@X
MR!^=.N=2O-"UBRMKB7S[6[.P.1RC?Y%+?Z1>IK5GK<"B6XC0QS)_>!QT_*DN
M=-O-<UJRN;B$P6MFV\*WWG;_ ":WC[&RVY;._>^OS[6%J0Q:AK$OB^YTO[3%
MY"PB3/E\C)/O[5/9ZA>VWBTZ//-YT3PF56(Y7'_ZZAM;6_7QM/J#6<@MGB$0
M;'H3_C226VH_\)TFH"Q<VJQ&(O\ 7'-5)0;<=+<GEO\ YBU*VF6TH^(6H?Z0
MQVQ;C[]*OZ7J.H2^*M2TZXG1XX8@T>$Q@DD5#8V^H1>,[N^>R<6TR;%;OV_P
MI-/@U"'QA?7\EC(+>>,(K8YX)-.HXS3O9^XK;;Z B.TN];O_ !!J.G?;(UCA
M52'"<@G/O2ZQ>ZYI1TJ)KN)WFG\N3$>,CGWJ71[?4(?%5_=SV3I!<;0K>F,_
MXT[Q7:7]Y>Z<;2T:5;>82,W;H1_6A2A[>,;1Y;>6]O\ ,-;"ZM?:CI>K6$<=
MPLB7;E&5E^[@9R*=<7][IGB:QLWG$L-VK94C[I&.GYU#K]OJ%YJNE306,C);
MN7<_48HUF#4+CQ-IMY#9.T%N#O/?G'\L4H1@U&]M8N^V^MOT#4=<:[<WFM7-
ME;"18+; =XT+$L0#VH@UR_T^SU"74(6,$"YAE9=I?/ !%3)IUYI.O7%_:Q&:
MVO &DC'WE; ']*L7EE>:YIUW;W48@CD7]TIZ@CD$U#='W59<NGKY_,>IG.FK
M7GAB>_FNE5YH#(L07Y0I&<=:T/!?_(JV>>OS9_[Z-5(UU@>''TQK(>>D)B5\
M_*P P#5OPE!=V>AQ6=W;F*2(G/H<DGBBN_W$EI\6EK;68+<W)O\ 4R?[IKS[
M0]8DTW0]6>&UEDD6XF965"1U-=]<LZVTA1"[;2 HKG/"5E=VEM>6]]:/&LLS
MR D<$,<UGAI1C1FY*^JT&]S3L(DN;.+49$'VEH""WL>:X2RQH][I^LH#LFF,
M$_\ 3]37I,_[FS<0Q%L*0J*.M<E:Z+>7GA:YTZYM6AG#;XR?7J/Y5KA*T4I.
M7PMI?)W_ "%)$'B_&IQZ@V<PV5N<>A9A_3%;?_,D9/\ SZC^0K)?1=0M_!,E
MAY#3WUPI\PCGDUJ[+S_A$?LOV207 B$>S'M5U''DA"+TC+_+7YL2W,/1O$<F
MC>&M+26Q8QRKL67?\N>V>.*V_#FAS6-Y>ZC=.IFO&W;4/"CG'UZU%HVD-<^$
MH])U*U,;)'M.1T/8BI/#4>K:>'TV_B:2&$D0W']Y>V?>IQ$XN-3V=D[Z^:OI
M8$MKE7QHH$VCD ?\?BY/X&NN7[B_2N3\4V]_?W-BMM92.MM.)6;'!&#T_.NF
MMI6D@1GC:-B.5;J*YJ_\"GY7_,I;LSO%$32^'+X+(4Q"Q.._%<]9+>VG@$75
MO=E9(XRZ9''7I72Z^D\NB7<%O"TLLL;(J@>HK+TS3;N?P:VF7,1MYRA3GIUS
M6M":C05VK<R^X36I;LY[J_\ "<-T9]EPT&\NH[\]JI^&]0NM1\+3S7D@>96D
M3<!C@4NF_P!J6V@QZ:;+]]'$8]Y/RGKSFJOAZUU+2_#MU97%DYFWN5V]&S5.
M$>2:5OB5MMM0$\,'_BAYS_M2]/\ >-:'@?/_  B5E_N?UK/T6VU&Q\+3V4MA
M)YY+[0!UR2?ZUI>$+>[LM"AL[NW:)X1CGO58IIPJ6:UE?\PCT)O%%U>6.A7%
MU9RK')$A;YESGBLF_P!0U2V\+Q:Q]I7SDC#E-ORM6KXI@N+K0;BUM8&EDE4J
M .U9&H6FI7/@I=/6QD^TE A&.F.]3AE#DAS6^+7;8)7N2ZOJ&I66C0:LEPH8
MLFZ+;\I!(']:?XEO[VRLK2_M9]GF21HT9&1R:@UJVU&]\*V]G%8R&;*;ACI@
M@_TJWK&F7>K>&H(XX_+N(7201OWV]JJ'LTX.5OB:>VW06I-XDGN[?P[)?VUQ
MY<L40?ID$UFZV]S?> DNFN'CD,89RAQNYJSJZZKJ?AV>RALO+D:(*?,XR?:E
M73KV[\$_V=)#Y-RL87:W0D'-*ERTXP;M=2\MAO4?I:WMGX5AG@<W,QMU,:,>
M <51U/4K[2](-_\ VE"]S& SPYX/MUJ::TU>Z\*QZ?#$;>:*-59B2"V!R!]:
M@O\ 2;N]\.O86NG+'*T8#O,>2?8\U<.3GO-K66NVW]=A.]M"7Q:\M[X/%VDS
MPY",54]<L*MPQWMGX4,\%V#(MN'4NN0,"HKK3[W4O!S6'V<PW"JH ?H<$&IB
MVH-X;>V^PMYGD>4%[DXQ^51=>S4$UI)]MM!];E!?$]U:^#K:^D"RWEPYB3C
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MO]GMB_ECH&;./I3-.^VI"ZW\D;2!CM9>Z]LU=!![BIG.>L7*Z!6*>HZ7;ZI
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MW/<5HYHW#/6FZU1IIL+(S=.T*STMY3:^8/-.7#-D$^M/@T:SMYGEB1EW-O*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%E]JJ:9I5UIL&I.D,ODS<0VV<E>OKTI-4G36R>G;7]?6X:W$M_$TT'A(:C=
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M4445QE!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX/@3[=JKDLQCGVIN.=HR>!7745Z2I5'!.X)W1D76F0-J!O(;K[/<LH5L,/F
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,"@,#Z_+74Q:58P2"2*W16'0^E-N-'T^ZG6>>U225>C'J*=+%4X)1ULK_BK
MXMG/ZTT?_":Z,&*\*?ZTZZD0?$*S&X9\@_R-;LFBZ=-.L\EI&TJ]&.<BE?1M
M.>Z%TUJAG'1^]"Q--)+72+7WA9ES-<CJ4B1^/]/,A !@.,^N377X&,5!-8VL
M\GF2PJSXV[CUQ7/0JJG)M]4U]XVKG.>(2MWKFE0VOS7$<C.Y7^%<=_R--TR\
MDN[J^>U6*SACE*R.>78@GG!KI+?3[2U9F@A5&;J1U-,;2K%YFE:V0R-]X^M;
MK$TU#DMLOUOL*SO<Y7PD\?VO7-TGF@S9) QN&T5!%IX6PFO="U#;;D%I+68
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M** "BBB@ I#TI:* &A0!@ #Z4ZBB@!#2!0O"@ 'TIU% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#6<L3><I6TEN.VAD-=W$ME<S6]D JK^[5AR_X5S5[8PW=DMS964]GJS $(G
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@"2BBBD,>>E)TI:",U(#&90I+G"^],4PL?E
M93]#6)XQ=DT";;G/'0^XKF]++V&L0LD3VZO&^(_,#B0XXZ5W4<)[2DZE^_X$
MN5G8[\F)3@LH/H32A8P!D@9Z<UP=C96NKVMU>ZC=LMT)&7F0 Q@$XQ0E[<36
M6C-<.1BY*[V/WAAJT>!ULI:K?3ROIW%S'>,(T&Y\ #N32((7^Z0WT-<[XOFC
MET5$CD!!F16*MV+"LM8UTC6M/CT^X9TN"!+%NR ..:SIX7GI\U[/7\!N6IW
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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<MZ&C:WH:**+@&UO0T;6]#111<"3!]****0S_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g30vudsvo52a000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g30vudsvo52a000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /U"& # 2(  A$! Q$!_\0
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M_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\
MC1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9U
MK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_
M (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C
M1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK
M_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\
M'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1
M_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G
M6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'
MC_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_
M9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9
MUK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C
M_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\
MC1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9U
MK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_
M (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C
M1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK
M_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\
M'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1
M_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G
M6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'
MC_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_
M9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9
MUK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C
M_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\
MC1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9U
MK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_
M (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C
M1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK
M_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\
M'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1
M_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G
M6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'
MC_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_
M9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9
MUK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C
M_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\
MC1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9U
MK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_
M (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C
M1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK
M_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\
M'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1
M_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G
M6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'
MC_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_
M9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9
MUK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C
M_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\
MC1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9U
MK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_
M (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C
M1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK
M_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\
M'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1
M_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G
M6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'
MC_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_
M9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9
MUK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C
M_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\
MC1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9U
MK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_
M (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C
M1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK
M_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\
M'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1
M_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G
M6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'
MC_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_
M9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9
MUK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C
M_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\
MC1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9U
MK_SR_P#'C_C5?R8X-6A6-=JE2<9SV-:54)?^0S!_N'^M $NG?\>,?X_S-6JJ
MZ=_QXQ_C_,U:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *H
M2_\ (9@_W#_6K]4)?^0S!_N'^M $NG?\>,?X_P S5JJNG?\ 'C'^/\S5J@ K
MG?%WB:#P_HUS+%<VW]H*JF&"1@6;+ 9VY!(P2:V[QY8[&X>W7=,L;&,>K8X_
M6O,_ &A:!XBT^>\U,"^U0S,9A+*VY0>AP",Y]>>] 'HNDZC#J>G07$5S!.S1
MJ9# X90V.1[<YJ>[O;2PA\Z\N8;>(<;Y7"C\S6;HWA;2= NIY]-@:$SJ%=/,
M9EX^N?6J^J>#=-UO6AJ&IF:Y5(PD=N7(C3'4\<\T :ECJ^FZGN%C?VUR5^\(
MI0Q'U J[7E'BG1;3PKXL\/W6AA[:2YFVO$K$@X91QGGD,017JQ(4$D@ <DF@
M"M?:E8Z9$LM]=PVT;':K2N%!/H,U-!/%<P)/!*DL4@W(Z-D,/4&O*/$>_P 7
M6FL:^Y8:7IR&"P7IYC[EW/\ 3_ZWH:[OPA(L/@?3)7^ZEJ&/T% &K?:II^F*
MK7U[;VP;[OG2!<_3/6G66H66HQ&6RNX+F,'!:&0, ?0XKSKPAH-OXRDOO$>O
M1M<-+.8X82Y"HHQZ=AG ^AI-3TR+P/XYT:[TK?%8ZA)Y$T.XE1R >3V^8$#U
M4T >GTA( ))P!U)I:X3XB7-S=7&D>'+61HQJ4V)G7KL! Q].23_NT =0GB/0
MY+G[.FKV+3$[0@N%R3Z=>M:=<9>?#3P_)I#VMM;&*Y"8CN3(Q;?C@GG!YZC\
ML51\&^)+B/X=WUS<YDGTL2(H<\L H*@_B<?A0!V=]K6EZ:ZI?:C:V[L,A995
M4D?0U8MKNWO8%GM9XIX6Z21.&4_B*\^\&^#=/UC1QK>NQM>WE\S2$R.0%&2.
MQZG&?RZ5'IEG_P (=\3H]*LW<:;J4)=8V8D(<-CD]2"N/HU 'I=%%% !1110
M 456N'NUD @B1UQR2>_YU#YNI?\ /O'^?_UZ +]%4/-U+_GWC_/_ .O1YNI?
M\^\?Y_\ UZ +]%4/-U+_ )]X_P __KT>;J7_ #[Q_G_]>@"_15#S=2_Y]X_S
M_P#KT>;J7_/O'^?_ ->@"_15#S=2_P"?>/\ /_Z]'FZE_P ^\?Y__7H OT50
M\W4O^?>/\_\ Z]'FZE_S[Q_G_P#7H OT50\W4O\ GWC_ #_^O1YNI?\ /O'^
M?_UZ +]%4/-U+_GWC_/_ .O1YNI?\^\?Y_\ UZ +]%4/-U+_ )]X_P __KT>
M;J7_ #[Q_G_]>@"_15#S=2_Y]X_S_P#KT>;J7_/O'^?_ ->@"_15#S=2_P"?
M>/\ /_Z]'FZE_P ^\?Y__7H OT50\W4O^?>/\_\ Z]'FZE_S[Q_G_P#7H OT
M50\W4O\ GWC_ #_^O1YNI?\ /O'^?_UZ +]%4/-U+_GWC_/_ .O1YNI?\^\?
MY_\ UZ +]%4/-U+_ )]X_P __KT>;J7_ #[Q_G_]>@"_15#S=2_Y]X_S_P#K
MT>;J7_/O'^?_ ->@"_15#S=2_P"?>/\ /_Z]'FZE_P ^\?Y__7H OT50\W4O
M^?>/\_\ Z]'FZE_S[Q_G_P#7H OT50\W4O\ GWC_ #_^O1YNI?\ /O'^?_UZ
M +]%4/-U+_GWC_/_ .O1YNI?\^\?Y_\ UZ +]%4/-U+_ )]X_P __KT>;J7_
M #[Q_G_]>@"_15#S=2_Y]X_S_P#KT>;J7_/O'^?_ ->@"_15#S=2_P"?>/\
M/_Z]'FZE_P ^\?Y__7H OT50\W4O^?>/\_\ Z]'FZE_S[Q_G_P#7H OT50\W
M4O\ GWC_ #_^O1YNI?\ /O'^?_UZ +]%4/-U+_GWC_/_ .O1YNI?\^\?Y_\
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M'FZE_P ^\?Y__7H OT50\W4O^?>/\_\ Z]'FZE_S[Q_G_P#7H OT50\W4O\
MGWC_ #_^O1YNI?\ /O'^?_UZ +]%4/-U+_GWC_/_ .O1YNI?\^\?Y_\ UZ +
M]%4/-U+_ )]X_P __KT>;J7_ #[Q_G_]>@"_15#S=2_Y]X_S_P#KT>;J7_/O
M'^?_ ->@"_15#S=2_P"?>/\ /_Z]'FZE_P ^\?Y__7H OT50\W4O^?>/\_\
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M]X_S_P#KT>;J7_/O'^?_ ->@"_15#S=2_P"?>/\ /_Z]'FZE_P ^\?Y__7H
MOT50\W4O^?>/\_\ Z]'FZE_S[Q_G_P#7H OT50\W4O\ GWC_ #_^O1YNI?\
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M #[Q_G_]>@"_15#S=2_Y]X_S_P#KT>;J7_/O'^?_ ->@"_15#S=2_P"?>/\
M/_Z]'FZE_P ^\?Y__7H OT50\W4O^?>/\_\ Z]'FZE_S[Q_G_P#7H OT50\W
M4O\ GWC_ #_^O1YNI?\ /O'^?_UZ +]%4/-U+_GWC_/_ .O1YNI?\^\?Y_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "J$O\ R&8/]P_UJ_5"7_D,P?[A_K0!+IW_ !XQ_C_,U:JK
MIW_'C'^/\S5J@ JJ^G6DFHQ:@\"F[B0QI*<Y53U%6J* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKP3IK(1^[C,;#T*DC_Z_XUA:R5O?B]HMO%\S6L!>4C^'AS@_I^8H ]!HHHH
M**** *UQ;2S2!DN7C &,#/\ C4/V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V
M&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O
M^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/
M])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS
M_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!
M0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ
M_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/
MU_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\
MY_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V
M&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O
M^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/
M])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS
M_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!
M0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ
M_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/
MU_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\
MY_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V
M&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O
M^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/
M])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS
M_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!
M0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ
M_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/
MU_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\
MY_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V
M&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O
M^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/
M])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS
M_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!
M0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ
M_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/
MU_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\
MY_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V
M&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O
M^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/
M])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS
M_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!
M0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ
M_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/
MU_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\
MY_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V
M&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O
M^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/
M])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS
M_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!
M0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ
M_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/
MU_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\
MY_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V
M&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O
M^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/
M])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS
M_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!
M0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ
M_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/
MU_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\
MY_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V
M&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O
M^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/
M])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS
M_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!
M0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ
M_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/
MU_QJ_10!0^PS_P#/])^O^-'V&?\ Y_I/U_QJ_3)IDMX))I6VQQJ78XS@ 9-#
M=@2OHBG]AG_Y_I/U_P :/L,__/\ 2?K_ (U4_P"$MT/_ )_O_(3_ .%'_"6Z
M'_S_ '_D)_\ "L?K-'^=?>C?ZK7_ )']S-A%*QJI8L0 "3WIU8O_  ENA_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEK'_($O_P#KVD_]!-7:I:Q_
MR!+_ /Z]I/\ T$U%3X'Z%TOC7J>1T445\>?:!6UX2_Y&>S_X'_Z U8M;7A+_
M )&>S_X'_P"@-6^&_C0]5^9ABOX$_1_D>GT445]8?'A5"7_D,P?[A_K5^J$O
M_(9@_P!P_P!: )=._P"/&/\ '^9JU573O^/&/\?YFK5 !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\*/[)@_OR?F/\* +]%4/[)@_OR?F/\*/[)@_OR?F/\* +]%4/[)@_OR?F/\
M"C^R8/[\GYC_  H OT50_LF#^_)^8_PH_LF#^_)^8_PH OT50_LF#^_)^8_P
MH_LF#^_)^8_PH OT50_LF#^_)^8_PH_LF#^_)^8_PH OT50_LF#^_)^8_P *
M/[)@_OR?F/\ "@"_15#^R8/[\GYC_"C^R8/[\GYC_"@"_15#^R8/[\GYC_"C
M^R8/[\GYC_"@"_15#^R8/[\GYC_"C^R8/[\GYC_"@"_15#^R8/[\GYC_  H_
MLF#^_)^8_P * +]%4/[)@_OR?F/\*/[)@_OR?F/\* +]%4/[)@_OR?F/\*/[
M)@_OR?F/\* +]%4/[)@_OR?F/\*/[)@_OR?F/\* +]%4/[)@_OR?F/\ "C^R
M8/[\GYC_  H OT50_LF#^_)^8_PH_LF#^_)^8_PH OT50_LF#^_)^8_PH_LF
M#^_)^8_PH OT50_LF#^_)^8_PH_LF#^_)^8_PH OT50_LF#^_)^8_P */[)@
M_OR?F/\ "@"_15#^R8/[\GYC_"C^R8/[\GYC_"@"_15#^R8/[\GYC_"C^R8/
M[\GYC_"@"_15#^R8/[\GYC_"C^R8/[\GYC_"@"_15#^R8/[\GYC_  H_LF#^
M_)^8_P * +]%4/[)@_OR?F/\*/[)@_OR?F/\* +]%4/[)@_OR?F/\*/[)@_O
MR?F/\* +]%4/[)@_OR?F/\*/[)@_OR?F/\* +]%4/[)@_OR?F/\ "C^R8/[\
MGYC_  H OT50_LF#^_)^8_PH_LF#^_)^8_PH OT50_LF#^_)^8_PH_LF#^_)
M^8_PH OT50_LF#^_)^8_PH_LF#^_)^8_PH OT50_LF#^_)^8_P */[)@_OR?
MF/\ "@"_15#^R8/[\GYC_"C^R8/[\GYC_"@"_15#^R8/[\GYC_"C^R8/[\GY
MC_"@"_15#^R8/[\GYC_"C^R8/[\GYC_"@"_15#^R8/[\GYC_  H_LF#^_)^8
M_P * +]%4/[)@_OR?F/\*/[)@_OR?F/\* +]%4/[)@_OR?F/\*/[)@_OR?F/
M\* +]%4/[)@_OR?F/\*/[)@_OR?F/\* +]%4/[)@_OR?F/\ "C^R8/[\GYC_
M  H OT50_LF#^_)^8_PH_LF#^_)^8_PH OT50_LF#^_)^8_PH_LF#^_)^8_P
MH OT50_LF#^_)^8_PH_LF#^_)^8_PH OT50_LF#^_)^8_P */[)@_OR?F/\
M"@"_15#^R8/[\GYC_"C^R8/[\GYC_"@"_15#^R8/[\GYC_"C^R8/[\GYC_"@
M"_15#^R8/[\GYC_"C^R8/[\GYC_"@"_15#^R8/[\GYC_  H_LF#^_)^8_P *
M +]%4/[)@_OR?F/\*/[)@_OR?F/\* +]%4/[)@_OR?F/\*/[)@_OR?F/\* +
M]%4/[)@_OR?F/\*/[)@_OR?F/\* +]%4/[)@_OR?F/\ "C^R8/[\GYC_  H
MOT50_LF#^_)^8_PH_LF#^_)^8_PH OT50_LF#^_)^8_PH_LF#^_)^8_PH OT
M50_LF#^_)^8_PH_LF#^_)^8_PH OT50_LF#^_)^8_P */[)@_OR?F/\ "@"_
M15#^R8/[\GYC_"C^R8/[\GYC_"@"_15#^R8/[\GYC_"C^R8/[\GYC_"@"_15
M#^R8/[\GYC_"C^R8/[\GYC_"@"_15#^R8/[\GYC_  H_LF#^_)^8_P * +]%
M4/[)@_OR?F/\*/[)@_OR?F/\* +]%4/[)@_OR?F/\*/[)@_OR?F/\* +]%4/
M[)@_OR?F/\*/[)@_OR?F/\* +]%4/[)@_OR?F/\ "C^R8/[\GYC_  H OT50
M_LF#^_)^8_PH_LF#^_)^8_PH OT50_LF#^_)^8_PH_LF#^_)^8_PH OT50_L
MF#^_)^8_PH_LF#^_)^8_PH OT50_LF#^_)^8_P */[)@_OR?F/\ "@"_15#^
MR8/[\GYC_"C^R8/[\GYC_"@"_15#^R8/[\GYC_"C^R8/[\GYC_"@"_15#^R8
M/[\GYC_"C^R8/[\GYC_"@"_15#^R8/[\GYC_  H_LF#^_)^8_P * +]%4/[)
M@_OR?F/\*/[)@_OR?F/\* +]%4/[)@_OR?F/\*/[)@_OR?F/\* +]%4/[)@_
MOR?F/\*/[)@_OR?F/\* +]%4/[)@_OR?F/\ "C^R8/[\GYC_  H OT50_LF#
M^_)^8_PH_LF#^_)^8_PH OT50_LF#^_)^8_PH_LF#^_)^8_PH OT50_LF#^_
M)^8_PH_LF#^_)^8_PH OT50_LF#^_)^8_P */[)@_OR?F/\ "@"_15#^R8/[
M\GYC_"C^R8/[\GYC_"@"_15#^R8/[\GYC_"C^R8/[\GYC_"@"_15#^R8/[\G
MYC_"C^R8/[\GYC_"@"_15#^R8/[\GYC_  H_LF#^_)^8_P * +]%4/[)@_OR
M?F/\*/[)@_OR?F/\* +]%4/[)@_OR?F/\*/[)@_OR?F/\* +]%4/[)@_OR?F
M/\*/[)@_OR?F/\* +]%4/[)@_OR?F/\ "C^R8/[\GYC_  H OT50_LF#^_)^
M8_PH_LF#^_)^8_PH OT50_LF#^_)^8_PH_LF#^_)^8_PH OT50_LF#^_)^8_
MPH_LF#^_)^8_PH OT50_LF#^_)^8_P */[)@_OR?F/\ "@"_15#^R8/[\GYC
M_"C^R8/[\GYC_"@"_15#^R8/[\GYC_"C^R8/[\GYC_"@"_15#^R8/[\GYC_"
MC^R8/[\GYC_"@"_15#^R8/[\GYC_  H_LF#^_)^8_P * +]%4/[)@_OR?F/\
M*/[)@_OR?F/\* +]%4/[)@_OR?F/\*/[)@_OR?F/\* +]%4/[)@_OR?F/\*/
M[)@_OR?F/\* +]%4/[)@_OR?F/\ "C^R8/[\GYC_  H OT50_LF#^_)^8_PH
M_LF#^_)^8_PH OT50_LF#^_)^8_PH_LF#^_)^8_PH OT50_LF#^_)^8_PH_L
MF#^_)^8_PH OT50_LF#^_)^8_P */[)@_OR?F/\ "@"_17+?VOX<_P"@A)_W
M[;_XFC^U_#G_ $$)/^_;?_$UC]9H_P Z^]&_U6O_ "/[F=317+?VOX<_Z"$G
M_?MO_B:?#J/A^XGCABOY&DD8(H\MADDX'\-"Q%%Z*:^]">&K+5P?W,Z:BJ']
MDP?WY/S'^%']DP?WY/S'^%;&)?HJA_9,']^3\Q_A1_9,']^3\Q_A0!?HJA_9
M,']^3\Q_A1_9,']^3\Q_A0!?HJA_9,']^3\Q_A1_9,']^3\Q_A0!?HJA_9,'
M]^3\Q_A1_9,']^3\Q_A0!?HJA_9,']^3\Q_A1_9,']^3\Q_A0!S/C_\ YAW_
M &T_]EKBZZWQO:1VOV'86.[S,[C_ +M<E7S.8?[S+Y?DCZG+?]UC\_S84445
MQ'<;WA[PV^M;II)?*M8VVD@99CP2!Z<'J?4<'FO0[*QMM.MQ!:0B*,$G R<D
M]R3R:Y;P;8Q7.CS.[."+@C@C^ZM=%_9,']^3\Q_A7TF H0A24TM6?,9C7J3K
M.#>BZ%^BJ']DP?WY/S'^%']DP?WY/S'^%=YYY?HIJ((XU09PH &:=0 4444
M%4)?^0S!_N'^M7ZH2_\ (9@_W#_6@"73O^/&/\?YFK55=._X\8_Q_F:M4 0W
M=U#8V<UW<OL@A0O(V"<*!DG YJ!9--UJPW!K:]M''/W70CWJS<0175O);SQK
M)#*I1T;HP/!%>9:A\-]//B^QM;6WO8],EB>2XD0EE0C.U0Q!QDXZYH ?X?BL
M].^*US9Z%+NL&MR9TC;<BD#.,^S8^F2*ZGQ3XJ&C>586$/VS6+GB"V7G'^TW
MM_/';DUH:)X<TOP] T>G6PC+_?D8[G?ZD_RZ5CZY\.](U_5I=2NKB]2:4*&$
M4BA>  ."I["@";PGX7?1Q+J.I2_:=9N_FGF)SM!_A'M_GH!63\4X94TC3]2B
M3=]CNU9O8'_ZX _&D_X5%H'_ #^:E_W]C_\ B*[5K"VDTW^SYHQ-;>6(F63G
M<H&.: (X-6L+C2UU)+J(6;)O\UG 51CN>U<-X'@.M7OBK50N+:_D:&$D$9!W
M$_H5J\WPI\.&Y\T->JF<^2)AM^G3=^M=A8V-KIEE'9V<*0V\8PJ*.!_]?WH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9!].>Q!R"0>>E '8T444 %%%% !14,MU# X61]K$9Q@FH_[1M?\ GK_XZ?\
M"@"U157^T;7_ )Z_^.G_  H_M&U_YZ_^.G_"@"U157^T;7_GK_XZ?\*/[1M?
M^>O_ (Z?\* +5%5?[1M?^>O_ (Z?\*/[1M?^>O\ XZ?\* +5%5?[1M?^>O\
MXZ?\*/[1M?\ GK_XZ?\ "@"U157^T;7_ )Z_^.G_  H_M&U_YZ_^.G_"@"U1
M57^T;7_GK_XZ?\*/[1M?^>O_ (Z?\* +5%5?[1M?^>O_ (Z?\*/[1M?^>O\
MXZ?\* +5%5?[1M?^>O\ XZ?\*/[1M?\ GK_XZ?\ "@"U157^T;7_ )Z_^.G_
M  H_M&U_YZ_^.G_"@"U157^T;7_GK_XZ?\*/[1M?^>O_ (Z?\* +5%5?[1M?
M^>O_ (Z?\*/[1M?^>O\ XZ?\* +5%5?[1M?^>O\ XZ?\*/[1M?\ GK_XZ?\
M"@"U157^T;7_ )Z_^.G_  H_M&U_YZ_^.G_"@"U157^T;7_GK_XZ?\*/[1M?
M^>O_ (Z?\* +5%5?[1M?^>O_ (Z?\*/[1M?^>O\ XZ?\* +5%5?[1M?^>O\
MXZ?\*/[1M?\ GK_XZ?\ "@"U157^T;7_ )Z_^.G_  H_M&U_YZ_^.G_"@"U1
M57^T;7_GK_XZ?\*/[1M?^>O_ (Z?\* +5%5?[1M?^>O_ (Z?\*/[1M?^>O\
MXZ?\* +5%5?[1M?^>O\ XZ?\*/[1M?\ GK_XZ?\ "@"U157^T;7_ )Z_^.G_
M  H_M&U_YZ_^.G_"@"U157^T;7_GK_XZ?\*/[1M?^>O_ (Z?\* +5%5?[1M?
M^>O_ (Z?\*/[1M?^>O\ XZ?\* +5%5?[1M?^>O\ XZ?\*/[1M?\ GK_XZ?\
M"@"U157^T;7_ )Z_^.G_  H_M&U_YZ_^.G_"@"U157^T;7_GK_XZ?\*/[1M?
M^>O_ (Z?\* +5%5?[1M?^>O_ (Z?\*/[1M?^>O\ XZ?\* +5%5?[1M?^>O\
MXZ?\*/[1M?\ GK_XZ?\ "@"U157^T;7_ )Z_^.G_  H_M&U_YZ_^.G_"@"U1
M57^T;7_GK_XZ?\*/[1M?^>O_ (Z?\* +5%5?[1M?^>O_ (Z?\*/[1M?^>O\
MXZ?\* +5%5?[1M?^>O\ XZ?\*/[1M?\ GK_XZ?\ "@"U157^T;7_ )Z_^.G_
M  H_M&U_YZ_^.G_"@"U157^T;7_GK_XZ?\*/[1M?^>O_ (Z?\* +5%5?[1M?
M^>O_ (Z?\*/[1M?^>O\ XZ?\* +5%5?[1M?^>O\ XZ?\*/[1M?\ GK_XZ?\
M"@"U157^T;7_ )Z_^.G_  H_M&U_YZ_^.G_"@"U157^T;7_GK_XZ?\*/[1M?
M^>O_ (Z?\* +5%5?[1M?^>O_ (Z?\*/[1M?^>O\ XZ?\* +5%5?[1M?^>O\
MXZ?\*/[1M?\ GK_XZ?\ "@"U157^T;7_ )Z_^.G_  H_M&U_YZ_^.G_"@"U1
M57^T;7_GK_XZ?\*/[1M?^>O_ (Z?\* +5%5?[1M?^>O_ (Z?\*/[1M?^>O\
MXZ?\* +5%5?[1M?^>O\ XZ?\*/[1M?\ GK_XZ?\ "@"U157^T;7_ )Z_^.G_
M  H_M&U_YZ_^.G_"@"U157^T;7_GK_XZ?\*/[1M?^>O_ (Z?\* +5%5?[1M?
M^>O_ (Z?\*/[1M?^>O\ XZ?\* +5%5?[1M?^>O\ XZ?\*/[1M?\ GK_XZ?\
M"@"U157^T;7_ )Z_^.G_  H_M&U_YZ_^.G_"@"U157^T;7_GK_XZ?\*/[1M?
M^>O_ (Z?\* +5%5?[1M?^>O_ (Z?\*/[1M?^>O\ XZ?\* +5%5?[1M?^>O\
MXZ?\*/[1M?\ GK_XZ?\ "@"U157^T;7_ )Z_^.G_  H_M&U_YZ_^.G_"@"U1
M57^T;7_GK_XZ?\*/[1M?^>O_ (Z?\* +5%5?[1M?^>O_ (Z?\*/[1M?^>O\
MXZ?\* +5%5?[1M?^>O\ XZ?\*/[1M?\ GK_XZ?\ "@"U157^T;7_ )Z_^.G_
M  H_M&U_YZ_^.G_"@"U157^T;7_GK_XZ?\*/[1M?^>O_ (Z?\* +5%5?[1M?
M^>O_ (Z?\*/[1M?^>O\ XZ?\* +5%5?[1M?^>O\ XZ?\*/[1M?\ GK_XZ?\
M"@"U157^T;7_ )Z_^.G_  H_M&U_YZ_^.G_"@"U157^T;7_GK_XZ?\*/[1M?
M^>O_ (Z?\* +5%5?[1M?^>O_ (Z?\*/[1M?^>O\ XZ?\* +5%5?[1M?^>O\
MXZ?\*/[1M?\ GK_XZ?\ "@"U157^T;7_ )Z_^.G_  H_M&U_YZ_^.G_"@"U1
M57^T;7_GK_XZ?\*/[1M?^>O_ (Z?\* +5%5?[1M?^>O_ (Z?\*/[1M?^>O\
MXZ?\* +5%5?[1M?^>O\ XZ?\*/[1M?\ GK_XZ?\ "@"U157^T;7_ )Z_^.G_
M  H_M&U_YZ_^.G_"@"U157^T;7_GK_XZ?\*/[1M?^>O_ (Z?\* +5%5?[1M?
M^>O_ (Z?\*/[1M?^>O\ XZ?\* +5%5?[1M?^>O\ XZ?\*/[1M?\ GK_XZ?\
M"@"U157^T;7_ )Z_^.G_  H_M&U_YZ_^.G_"@"U157^T;7_GK_XZ?\*/[1M?
M^>O_ (Z?\* +5%5?[1M?^>O_ (Z?\*/[1M?^>O\ XZ?\* +5%5?[1M?^>O\
MXZ?\*/[1M?\ GK_XZ?\ "@"U157^T;7_ )Z_^.G_  H_M&U_YZ_^.G_"@"U1
M57^T;7_GK_XZ?\*/[1M?^>O_ (Z?\* +5%5?[1M?^>O_ (Z?\*/[1M?^>O\
MXZ?\* +5%5?[1M?^>O\ XZ?\*/[1M?\ GK_XZ?\ "@"U157^T;7_ )Z_^.G_
M  H_M&U_YZ_^.G_"@"U157^T;7_GK_XZ?\*/[1M?^>O_ (Z?\* +5%5?[1M?
M^>O_ (Z?\*/[1M?^>O\ XZ?\* +5%5?[1M?^>O\ XZ?\*/[1M?\ GK_XZ?\
M"@"U157^T;7_ )Z_^.G_  H_M&U_YZ_^.G_"@"U157^T;7_GK_XZ?\*/[1M?
M^>O_ (Z?\* +5%5?[1M?^>O_ (Z?\*/[1M?^>O\ XZ?\* +5%5?[1M?^>O\
MXZ?\*/[1M?\ GK_XZ?\ "@"U157^T;7_ )Z_^.G_  H_M&U_YZ_^.G_"@"U1
M57^T;7_GK_XZ?\*/[1M?^>O_ (Z?\* +5%5?[1M?^>O_ (Z?\*/[1M?^>O\
MXZ?\* +5%5?[1M?^>O\ XZ?\*/[1M?\ GK_XZ?\ "@"U157^T;7_ )Z_^.G_
M  H_M&U_YZ_^.G_"@"U157^T;7_GK_XZ?\*/[1M?^>O_ (Z?\* +5%5?[1M?
M^>O_ (Z?\*/[1M?^>O\ XZ?\* +5%5?[1M?^>O\ XZ?\*/[1M?\ GK_XZ?\
M"@"U157^T;7_ )Z_^.G_  H_M&U_YZ_^.G_"@"U157^T;7_GK_XZ?\*/[1M?
M^>O_ (Z?\* +5%5?[1M?^>O_ (Z?\*/[1M?^>O\ XZ?\* +5%5?[1M?^>O\
MXZ?\*/[1M?\ GK_XZ?\ "@"U157^T;7_ )Z_^.G_  H_M&U_YZ_^.G_"@"U1
M57^T;7_GK_XZ?\*/[1M?^>O_ (Z?\* +5%5?[1M?^>O_ (Z?\*/[1M?^>O\
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M6T:%AIZ0$32A"BNY&.GJ3S^&:[O4=>TK294BU"_AMW==RK(V"1ZT <I\//\
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M3W5O?+/,4)B@53N+8X!&./J:R_"OAJ[;X;W]M.I2[U,22JK\$94!,_7&?QH
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M%'V:#_GA'_WP*EHH B^S0?\ /"/_ +X%'V:#_GA'_P!\"I:* (OLT'_/"/\
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MOLT'_/"/_O@4?9H/^>$?_? J6B@"+[-!_P \(_\ O@4?9H/^>$?_ 'P*EHH
MB^S0?\\(_P#O@4?9H/\ GA'_ -\"I:* (OLT'_/"/_O@4?9H/^>$?_? J6B@
M"+[-!_SPC_[X%'V:#_GA'_WP*EHH B^S0?\ /"/_ +X%'V:#_GA'_P!\"I:*
M (OLT'_/"/\ [X%'V:#_ )X1_P#? J6B@"+[-!_SPC_[X%'V:#_GA'_WP*EH
MH B^S0?\\(_^^!1]F@_YX1_]\"I:* (OLT'_ #PC_P"^!1]F@_YX1_\ ? J6
MB@"+[-!_SPC_ .^!1]F@_P">$?\ WP*EHH B^S0?\\(_^^!1]F@_YX1_]\"I
M:* (OLT'_/"/_O@4?9H/^>$?_? J6B@"+[-!_P \(_\ O@4?9H/^>$?_ 'P*
MEHH B^S0?\\(_P#O@4?9H/\ GA'_ -\"I:* (OLT'_/"/_O@4?9H/^>$?_?
MJ6B@"+[-!_SPC_[X%'V:#_GA'_WP*EHH B^S0?\ /"/_ +X%'V:#_GA'_P!\
M"I:* (OLT'_/"/\ [X%'V:#_ )X1_P#? J6B@"+[-!_SPC_[X%'V:#_GA'_W
MP*EHH B^S0?\\(_^^!1]F@_YX1_]\"I:* (OLT'_ #PC_P"^!1]F@_YX1_\
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M^^!1]F@_YX1_]\"I:* (OLT'_/"/_O@4?9H/^>$?_? J6B@"+[-!_P \(_\
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M%>5_9,_YD>O_ &Q#^5GD==)X5T6SUF*^2Z5]R>7L=&P5SNS[=NXKN/['TO\
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M\5O"O2.) JC\!4]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU[G9]?PM+W([+L>>T5Z%_P (+I?_ #WO/^^U_P#B:/\ A!=+_P">]Y_WVO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M96MIIBAM3OY?*@R =O0$X/&<D 9XY]JZNN \5$M\3/#"./W8R5S_ 'LG_ 4
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MH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH
MH?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?
MVM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM
M!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_
M<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D
M_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(
M?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?X
MT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?
MVM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM
M!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_
M<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D
M_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(
M?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?X
MU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?
MHH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH
M H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H
M?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?V
MM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!
M_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<
MD_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_
M(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?
MXT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT
M?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?V
MM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!
M_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<
MD_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_
M(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?
MXU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU
M?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?H
MH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH
MH?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?
MVM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM
M!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_
M<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D
M_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(
M?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?X
MT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?
MVM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM
M!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_
M<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D
M_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(
M?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?X
MU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?
MHH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH
M H?VM!_<D_(?XU6U#Q!%96,EPL#R,F,*2%SD@=>?6MBL7Q;_ ,BQ>?\  /\
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M?0]<\COZ@UKT %%%% !5"7_D,P?[A_K5^J$O_(9@_P!P_P!: )=._P"/&/\
M'^9JU573O^/&/\?YFK5 %74I;J#2[J6QB6:Z2)FAC;HS <#MWKB8_BK9P*(=
M3T?4;:\'#1*@//\ P(@_I7H%8]UH0NO%%CK37&/L<+QK#LSDMD;MV>.#Z4 <
MIX;@U'Q!XXE\47&GO8620F*%91AI.,9_F<].@YY-;_B3QKIOA>ZAM[V&[D>9
M-ZF!%( SCG+"NDHH \;\*^.]+T.]UJ:Y@O'6^NC-&(D4D#+'G+#GGMFN\\9:
M2_B?P<R6:%I\)<P(PP2<=/8X)%=110!YQ9?$Y+6PBLK_ $B__M6- AB5  [
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **Y;Q+XEO-'U&.WMXH&1H0Y,BDG.2.Q'I6-_PG6J?\\+/
M_OAO_BJXJF/HTY.$MT=U/+J]2"G'9GH5%>>_\)UJG_/"S_[X;_XJC_A.M4_Y
MX6?_ 'PW_P 54?VGA_/[B_[+Q'9?>>A45C>&M6GUC3I+BX2-768H!&"!C /<
MGUK9KMIU%4BIQV9PU*<J<W"6Z//?^$ZU3_GA9_\ ?#?_ !5'_"=:I_SPL_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BL7Q;_ ,BQ>?\  /\
MT-:\PKS\7COJ\U#EOI??_@'HX/+_ *S!SYK:VV_X)[317BU%<W]K_P!S\?\
M@'7_ &-_?_#_ ()[317FGA/4;73-5EFO)?+C: H#M)YW*>P]C6W=^/( F+.S
MD=R#S,0H4]N!G/YBNJGF%*5/GF[>6YQU<MK1J<D%?SV,WQW_ ,AN'_KV7_T)
MJYBK^K:M/K%TMQ<)&KJ@0",$#&2>Y/K5"O"Q-15*LIQV9]!AJ<J=&,);H***
M*P-S9TGQ+>:/:M;V\4#(SER9%).< =B/2HY_$NLW*!'OY  <_NP$/YJ :LZ%
MX9EUJ![C[2D,*L4^Z68L #TXXP?6N@A\!V B4375R\G=DVJ#^!!_G7HTJ.+J
M07*_=]3S:M?!TJCYDN;TN<#1117G'I!5W1_^0W8?]?,?_H0JE151?+),F4>:
M+7<]IHKSC1/%MSIH6"Y!N+50%49 :,9['OQV/MR*Z#_A.M+_ .>%Y_WPO_Q5
M?24\PH3C=NS/F*N75X2LE=>1T]%<Q_PG6E_\\+S_ +X7_P"*H_X3K2_^>%Y_
MWPO_ ,56GUW#_P R,_J.(_D9T]%<Y;>,].NKJ&W2&Z#RNJ*61<9)QS\U='6M
M.K"HKP=S*K1J4G::L%%%%:&04444 %%%% 'D>L?\AN__ .OF3_T(U2J[K'_(
M;O\ _KYD_P#0C5*OCZGQOU/M*7P+T"BBBH+);:VFN[A+>WC,DLAPJCO77Z;X
M&#0%]2F=9&P52!A\O'.20>?IZ=375:?IEII=N(;6(+P SX^9_=CWZFK=>_A\
MLA!7JZO\#Y[$YI.;M2T7XG,?\(+I?_/>\_[[7_XFC_A!=+_Y[WG_ 'VO_P 3
M73T5U_4L/_*CC^O8C^=G,?\ ""Z7_P ][S_OM?\ XFKVD^&K/1[IKBWEG9V0
MH1(P(QD'L!Z5LT4XX6C!\T8ZDSQ=><>64M HHHKH.<**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L[6]0_LW
M2Y)E.)6^2/\ WCWZ=N3SZ5HUP'B;4UU#40D+AH(!M5AR&)ZG^0_#/>@#'BE>
M"9)8SM=&#*<=".16IJ7B*^U'<F_R8#QY<9QD<]3U/!^GM616CHEC!J6I+;7$
MKQJRDC8.6('3/;N?PH HQ123R".*-Y'/147)/X5T5IX1N3"\MV=I"DK!&PW,
M><#=T'./7KVKK;.PM;"/R[6!8P>I'4_4]3UJQ0!YY_PC.L?\^?\ Y%3_ !H_
MX1G6/^?/_P BI_C7H=% 'GG_  C.L?\ /G_Y%3_&M70--U?2]1#26I%O(-LF
M)%./0XW=C^A-==10 4444 %4)?\ D,P?[A_K5^J$O_(9@_W#_6@"73O^/&/\
M?YFK55=._P"/&/\ '^9JU0 5E>(]970-!NM2,8D,(&(RV-Q+  9P?6KUY,UM
M8W$Z)O:.-G"^I SBO,?"_A>V\;V,FM:WJ-U<W+2LAC20 1XQQT./H,#% 'I]
MI,;FR@G90AEC5RH.<9&<9[U-7/>&_"<'AB6X%I>W<MO*!B&9@0A!/(P!Z^E.
MUZTUW4KF*RTZZ2QL&3-Q=+S+U^ZGIQW]Z -X,K$@,#C@X/2EKS[X90"UNO$5
MNKNZQ7FP,YRQP6&3[UZ#0 C,J#+,%'J3BE!!&0<@UY-XRGF\5C5+J"0KI&BK
ML1E/$TY(!^H /7_XJNZ\'.$\$Z6[G"K; DGL* -YF55W,0 .Y- (8 @@@]"*
M\NT?1Y/B/=7FL:O=7*:>DQCM;6-L 8 ^HZ$9(ZG/I3ULYOA]XSTRVM+N:72-
M3?RS#(V=K9 )]."RG/7&10!Z?117%^/]7OH%T[1-,E:*\U.;R_-4X*+D#KVR
M2.?0&@#LMZ[]FX;AU&>:=7G=S\*K*+3FDL;^\&J(N])F< -(.>@&0"??(]ZO
M^$?%DEUX#N-3ORTLVGAUD8]9-JAA^)! ^M ':,ZH,NP4>I.*6O,- \('QG9?
MV]XBO;J1[EF\F*-MH102.X.!D< =O7-3^'Q=^$/'@\,M=27&FW<1DMA(<E."
M1]/NL..O!H ](HHHH **** "BJ=W<7,4H6&'>I7).TGG\*@^VW__ #[?^0VH
M TZ*S/MM_P#\^W_D-J/MM_\ \^W_ )#:@#3HK,^VW_\ S[?^0VH^VW__ #[?
M^0VH TZ*S/MM_P#\^W_D-J/MM_\ \^W_ )#:@#3HK,^VW_\ S[?^0VH^VW__
M #[?^0VH TZ*S/MM_P#\^W_D-J/MM_\ \^W_ )#:@#3HK,^VW_\ S[?^0VH^
MVW__ #[?^0VH TZ*S/MM_P#\^W_D-J/MM_\ \^W_ )#:@#3HK,^VW_\ S[?^
M0VH^VW__ #[?^0VH TZ*S/MM_P#\^W_D-J/MM_\ \^W_ )#:@#3HK,^VW_\
MS[?^0VH^VW__ #[?^0VH TZ*S/MM_P#\^W_D-J/MM_\ \^W_ )#:@#3HK,^V
MW_\ S[?^0VH^VW__ #[?^0VH TZ*S/MM_P#\^W_D-J/MM_\ \^W_ )#:@#3H
MK,^VW_\ S[?^0VH^VW__ #[?^0VH TZ*S/MM_P#\^W_D-J/MM_\ \^W_ )#:
M@#3HK,^VW_\ S[?^0VH^VW__ #[?^0VH TZ*S/MM_P#\^W_D-J/MM_\ \^W_
M )#:@#3HK,^VW_\ S[?^0VH^VW__ #[?^0VH TZ*S/MM_P#\^W_D-J/MM_\
M\^W_ )#:@#3HK,^VW_\ S[?^0VH^VW__ #[?^0VH TZ*S/MM_P#\^W_D-J/M
MM_\ \^W_ )#:@#3HK,^VW_\ S[?^0VH^VW__ #[?^0VH TZ*S/MM_P#\^W_D
M-J/MM_\ \^W_ )#:@#3HK,^VW_\ S[?^0VH^VW__ #[?^0VH TZ*S/MM_P#\
M^W_D-J/MM_\ \^W_ )#:@#3HK,^VW_\ S[?^0VH^VW__ #[?^0VH TZ*S/MM
M_P#\^W_D-J/MM_\ \^W_ )#:@#3HK,^VW_\ S[?^0VH^VW__ #[?^0VH TZ*
MS/MM_P#\^W_D-J/MM_\ \^W_ )#:@#3HK,^VW_\ S[?^0VH^VW__ #[?^0VH
M TZ*S/MM_P#\^W_D-J/MM_\ \^W_ )#:@#3HK,^VW_\ S[?^0VH^VW__ #[?
M^0VH TZ*S/MM_P#\^W_D-J/MM_\ \^W_ )#:@#3HK,^VW_\ S[?^0VH^VW__
M #[?^0VH TZ*S/MM_P#\^W_D-J/MM_\ \^W_ )#:@#3HK,^VW_\ S[?^0VH^
MVW__ #[?^0VH TZ*S/MM_P#\^W_D-J/MM_\ \^W_ )#:@#3HK,^VW_\ S[?^
M0VH^VW__ #[?^0VH TZ*S/MM_P#\^W_D-J/MM_\ \^W_ )#:@#3HK,^VW_\
MS[?^0VH^VW__ #[?^0VH TZ*S/MM_P#\^W_D-J/MM_\ \^W_ )#:@#3HK,^V
MW_\ S[?^0VH^VW__ #[?^0VH TZ*S/MM_P#\^W_D-J/MM_\ \^W_ )#:@#3H
MK,^VW_\ S[?^0VH^VW__ #[?^0VH TZ*S/MM_P#\^W_D-J/MM_\ \^W_ )#:
M@#3HK,^VW_\ S[?^0VH^VW__ #[?^0VH TZ*S/MM_P#\^W_D-J/MM_\ \^W_
M )#:@#3HK,^VW_\ S[?^0VH^VW__ #[?^0VH TZ*S/MM_P#\^W_D-J/MM_\
M\^W_ )#:@#3HK,^VW_\ S[?^0VH^VW__ #[?^0VH TZ*S/MM_P#\^W_D-J/M
MM_\ \^W_ )#:@#3HK,^VW_\ S[?^0VH^VW__ #[?^0VH TZ*S/MM_P#\^W_D
M-J/MM_\ \^W_ )#:@#3HK,^VW_\ S[?^0VH^VW__ #[?^0VH TZ*S/MM_P#\
M^W_D-J/MM_\ \^W_ )#:@#3HK,^VW_\ S[?^0VH^VW__ #[?^0VH TZ*S/MM
M_P#\^W_D-J/MM_\ \^W_ )#:@#3HK,^VW_\ S[?^0VH^VW__ #[?^0VH TZ*
MS/MM_P#\^W_D-J/MM_\ \^W_ )#:@#3HK,^VW_\ S[?^0VH^VW__ #[?^0VH
M TZ*S/MM_P#\^W_D-J/MM_\ \^W_ )#:@#3HK,^VW_\ S[?^0VH^VW__ #[?
M^0VH TZ*S/MM_P#\^W_D-J/MM_\ \^W_ )#:@#3HK,^VW_\ S[?^0VH^VW__
M #[?^0VH TZ*S/MM_P#\^W_D-J/MM_\ \^W_ )#:@#3HK,^VW_\ S[?^0VH^
MVW__ #[?^0VH TZ*S/MM_P#\^W_D-J/MM_\ \^W_ )#:@#3HK,^VW_\ S[?^
M0VH^VW__ #[?^0VH TZ*S/MM_P#\^W_D-J/MM_\ \^W_ )#:@#3HK,^VW_\
MS[?^0VH^VW__ #[?^0VH TZ*S/MM_P#\^W_D-J/MM_\ \^W_ )#:@#3HK,^V
MW_\ S[?^0VK)_P"$RM?^>T?_ '[>HG4A#XVEZEPI3J?!%OT.IHKEO^$RM?\
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MO&""3[@<_C^==%]MO_\ GV_\AM0!IT5F?;;_ /Y]O_(;4?;;_P#Y]O\ R&U
M&G5=KZ!=02Q+XG>,R 'T!Q^?7\C5&34;R*)Y)+<*B*68F-N *XB35+A]7_M(
M$";>' [8' '';''O0!Z;16/;ZI=7,"310!D<9!"$_P!:E^VW_P#S[?\ D-J
M-.BLS[;?_P#/M_Y#:C[;?_\ /M_Y#:@#3HK,^VW_ /S[?^0VH^VW_P#S[?\
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M<FWEB;& >>V<#O@CKGDUJ^&="U>[\1S>)_$,20W)3R[:V4Y\L8QGOCC/?N:
M.WHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\B@"]K>H?V;I<DRG$K?)'_O'OT[<GGTKS:I[N\N+Z<S7,IDDQC)XP/8#I4%
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M)QU.1QC.<>U %:MNS\47]E:1VR)"ZQC :0,3C\^W2L2E3:74.2%SR0,D#Z4
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M2Z7I%SJLZK$I6+/SS$?*OK]3STKT.QL8-/M5M[=-J+R2>K'U/O0 VQT^VTZ
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MC\9/#*/*KWO^AYQ!X*U>9"SB" @XVR29)]_E!%<[7M->>_\ ""ZI_P ][/\
M[[;_ .)K?%Y?R*/L4WW,,'F/.Y>V:6UCF**Z?_A!=4_Y[V?_ 'VW_P 31_P@
MNJ?\][/_ +[;_P")KC^I8C^5G;]>P_\ .CFX8GN)XX8EW22,$49QDDX%7Y_#
M^KVSA'T^<DC/[M=X_-<BMZP\&:C:ZC:W#S6I2*9'8*[9(!!X^6NYKKP^6N<7
M[2Z9Q8G,U3DO96DCQ:BNG\=_\AN'_KV7_P!":N8KSZU/V51PO>QZ5"K[6FIV
MM<****R-2_'K6I0V4=G%>2101DE5C.TC.3U'/<]Z;_;&J?\ 02O/^_[?XUTF
MA^$[#4]'@O)I;E9)-V0C*!PQ'<>U:/\ P@NE_P#/>\_[[7_XFO2A@\5.*DGI
M;N>9/&X2$G%K6_8\]HHHKS3TPJ6V@:ZNH;=" \KJBEN@)..:BJ[H_P#R&[#_
M *^8_P#T(5<$G))DS;46T=/:> ON->WOKO2%?RPQ_#M_C5'Q9H]EI"6*VD94
MN'#LS$EL;<$]NYZ8KT.BOHIY?1=-P@K-]=SYJ&95E44YNZ738\6HKVFBN3^R
M/[_X?\$[/[9_N?C_ , \6KT+P)_R!)O^OEO_ $%:Z>BNC#9?["IS\U_E_P $
MYL5F/UBGR<MOG_P HHHKT3S HHHH **** "BBB@ HJ-9XGGD@5P9(P"ZC^'.
M<9_*I* "BBB@ HHHH **** "BBB@ HHHH :Z+(C(ZAD8896&01Z&O.O$OAIM
M*<W5J"UDQY'4Q'T/MZ'\#[^CTUT61&1U#(PPRL,@CT-<V)PT:\;/?HSJPN*G
MAYW6W5'D6GZA<:9>)<VS[77@@]&'<$=Q75?\)_\ ]0S_ ,C_ /V-9/BW3[?3
M]9"6R;$EC$I0=%))!QZ#CI6#7@*M7PLG3C(^A=&ABXJK*._]=#M/^$__ .H9
M_P"1_P#[&L37O$$VMO&-AA@C'$6_<"W/S=!VX_\ UUC44JF,KU(\LI:?(JG@
MJ%*7/".OS-?P_H;ZW>,I?9;Q8,KCKST ]S@_3]#Z;;6T-I;I;V\8CBC&%4=J
MR/"**OAJU*J 7+EB!U.XC)_ #\JW*]O 8>-*DI+=G@YAB9U:KB]D[!3)94@A
M>60[412S''0#DT^N8\8:AY=O'8(?FE^>3_=!X'3N1^GO7<<!N:;J$>IV,=S&
M-N[ADSDJ1U'^>Q%+?:A;:= 9;F0+P2JY^9_8#OU%<'I6N7&DQS)$BN),$!R<
M*1WQ[C^GI5&YNI[R8RW$KR.>['IWP/0>U &KJ_B2YU$M%"3!;9.%4X9QC'S'
M\^.G/>LB&WFN7*00R2L!DJBECC\*U](\-W.HE99@8+;(RS##.,9^4?ESTY[U
MVMCI]MIT BMHPO #-CYG]R>_4T >=?V5J/\ SX77_?EO\*/[*U'_ )\+K_OR
MW^%>GT4 >8?V5J/_ #X77_?EO\*ZKPHU[!'+9W5M<1H/GC:2,@#U&3^>/K72
MT4 1S6\-R@2>&.50<A74,,_C4']E:=_SX6O_ 'Y7_"K=% %3^RM._P"?"U_[
M\K_A1_96G?\ /A:_]^5_PJW10!!#96MLY>"VAB8C!9(PIQ^%3T44 9'B+4O[
M.TM]C8GF^2/!Y'J>N>!W]2*\\KUJB@#R6BO6J* .=\):E]IL6LY&S+!]W)Y*
M'IW[=/88KHJ** .5E\&O/,\LFI;G=BS'R.I/)_BIG_"$_P#40_\ (/\ ]E76
MT4 <E_PA/_40_P#(/_V536OA*2SNHKB+4L/&P8?N>OL?FZ&NGHH *R]=LKO4
M;$6MJ\2!F!D,A(R!R!T/?G\/>M2B@#A_^$-U'_GM:_\ ?3?_ !-'_"&ZC_SV
MM?\ OIO_ (FNXHH X?\ X0W4?^>UK_WTW_Q-=#H&GWNF6LEO=21.F[='L8G&
M>HY'3_$UKT4 9MSH&F72;6M(XR 0&B&PC/?CK^.:YS5_"R6%K+=PW?[I,?)*
MO/IU'4YQV'7K7:UQGC#4/,N([!#\L7SR?[Q' Z=@?U]J .8HHHH ]%\.7,5S
MHD'E($\H>6Z@?Q#J?QZ_C6K7 ^%M0^QZH(7/[JYPA]F_A/3WQ^/M7?4 %%%%
M !1110 4444 %%%% !1110 4444 %4)?^0S!_N'^M7ZH2_\ (9@_W#_6@"73
MO^/&/\?YFK55=._X\8_Q_F:M4 %%%<KXP\76FB:3=I;7\ U10!'""&8$D=1V
MXR>: .JHK,T/6+/6-/BDMKV"YE6-?.\MAE6(YR.HYS6DS*BEF8*H&22< 4 +
M15'3=9T[5_._L^[CN1"VV0QG(!^O?\*N.Z11M)(RHBC+,QP * '45A#QIX;-
MQY/]LVF_.,[_ )?^^NGZUN AE#*001D$=Z %HK-U/7])T<J-0OX+=F&0C-\Q
M'K@<U)INLZ;K$;/I][#<!?O!&Y7ZCJ* +U%%-DD2*-I)'5$499F. ![F@!U%
M82>-/#;W'D+K-KOSCEL+_P!]=/UK<!! (.0>A% "T5DZCXGT329O)OM2@AE[
MQELL/J!R*N6&I66J6_GV-U%<19P6C8'!]#Z&@"U1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y'K'_(;
MO_\ KYD_]"->N5Y'K'_(;O\ _KYD_P#0C7DYM\$?4]C)_CEZ%*BBE(*G!&"*
M\.SM<]ZZO82O::\6KTR'QAHLD2N]P\3'JCQ-D?D"/UKU<KJPAS\[MM^IY&;4
MJE3DY$W:^WR)IO$^CV\\D,MYMDC8HP\IS@@X/:F?\);H?_/]_P"0G_PKSK4I
MDN-5O)HFW1R3NZG&,@L2*JTI9I54FDE^/^94<IHN*;;_  _R/3_^$MT/_G^_
M\A/_ (4?\);H?_/]_P"0G_PKS"BI_M6MV7X_YC_LBAW?X?Y'M-%%5Y[^SM7"
M7%W!"Y&0LD@4D>O->^VDKL^>2;=D6**I?VQI?_02L_\ O^O^-']L:7_T$K/_
M +_K_C4^TAW17LI_RLNT52_MC2_^@E9_]_U_QJU#-%<1++#(DD;='1@0?Q%-
M3C+9B<)1U:'T454?5=.C=D>_M5=3AE:900?0\TW)1W8*,I;(MT52_MC2_P#H
M)6?_ '_7_&C^V-+_ .@E9_\ ?]?\:GVD.Z'[*?\ *R[15+^V-+_Z"5G_ -_U
M_P :NTU*,MF*491W5CF/'?\ R!(?^OE?_06KSVO0/';J-'MT+#>;@$+GD@*V
M3^H_.O/Z^>S/_>'Z(^DRO_=UZL****\\]$[3P!_S$?\ MG_[-74:Q_R!+_\
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M_"L3Q_\ \P[_ +:?^RUQ=>/BLPJT:SA%*R_R]3VL)EU*M1523=W_ )^AZ?\
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MCSW_ (075/\ GO9_]]M_\37H5%%=%##4Z%^3J<^(Q53$6Y^@4445T',%%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5@2^$K&>9Y9+BZ9W8LQW+R3R?X:WZ* .=_X0W3O^>UU_WTO_Q-'_"&
MZ=_SVNO^^E_^)KHJ* .=_P"$-T[_ )[77_?2_P#Q-="@*HJEBQ P6.,GWXI:
M* "BBB@ HHHH **** "BBB@ HHHH **** "J$O\ R&8/]P_UJ_5"7_D,P?[A
M_K0!+IW_ !XQ_C_,U:JKIW_'C'^/\S5J@""\,PL;@VW^O\MO+_WL<?K7FOP[
MT_PYJ=A,-1AM[G6#*QE2Z^9R/4 ]?<^O6O4:YG6_ FAZW,UR\+VUVQR9[9MK
M$^I'0GWQGWH T]-\.Z3H]U-<:?9I;R3*%?83@@>V<#\*J:YX</B"\A6[O9ET
MR-<R6<1V^<^>K,.<>W\JYSPU>ZOHGC.3PMJ-\U_;M$9()G^\O&1R>>F1C)Z#
M%>@T <!\-HHX+_Q+#$@2..^VHHZ  L *Z[6]&MM>TXV%VT@@9U=Q&V"VTYP?
M:N4^'G_(5\4_]A _^A/7>$@#). * .,\2>#_  [!X5OWCTZ"W:WMWDCE08<,
MH)'/4\\<T_X=W,H\ V\UPSLL7F;2>?D5CP/IR*S-9U";QYJ7]@:-(1I43!KZ
M]4<-@\*OKT_$\]!SV4NFPVWAR;3;./9$MJT,:CG'RD#ZF@#AO VA6GB5;[Q'
MK5NMU<7-PRHDHRBJ,=!^GL!3->TRW\(>.="U+2X_L]O>2^3/$APF,@'CW#9Q
MTRN:UOA7.DO@[RU/S0W#JP^N#_6JOQ%(GUKPO9IDRR7F<#L-R#_/T- 'H-<%
M\0Y)M0O]$\.1NR17\^Z<KUV@C'\R?P%=[7GWB]EM?B-X7NI#B-SY6>V=V/\
MV<4 ;-WX \/3Z0]E#I\,+[-L<ZCYU;L2W4\^M8/@S7[BU^'&HRRDM/I?F)&&
M.>-H*@^P)(^@KT5F5$9V(55&23V%>1>'X&N?AGXHG4,%EE9UR.RA6- &[X&\
M):;=Z!'JNJVJ7MY?%I7:X&[ +'& ?7KGWJM:V4?A+XJV]G8@QV&IP$F+<=JG
MYN!]&7\ QKJ/ DZ7'@G2V0Y"Q;#[%20?Y5@:\1<_%S0((\EHH"[X[#YS_3]1
M0!Z#1110 4444 5KA+MI 8)41<<@CO\ E4/E:E_S\1_E_P#6J_10!0\K4O\
MGXC_ "_^M1Y6I?\ /Q'^7_UJOT4 4/*U+_GXC_+_ .M1Y6I?\_$?Y?\ UJOT
M4 4/*U+_ )^(_P O_K4>5J7_ #\1_E_]:K]% %#RM2_Y^(_R_P#K4>5J7_/Q
M'^7_ -:K]% %#RM2_P"?B/\ +_ZU'E:E_P _$?Y?_6J_10!0\K4O^?B/\O\
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M1^ON/;^7Y9 /*Z***^,/MPHHHH **]G1%C1410J*,*JC  ]!7&>/_P#F'?\
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M)_O#OT[\'CUI>SAV0_:S[LA@TN6U<O;I9PN1@M'$JDCTX6K'E:E_S\1_E_\
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M7_UJOT5]2?)%#RM2_P"?B/\ +_ZU'E:E_P _$?Y?_6JY+*D$+RR':B*68XZ
M<FHK"\2_L8;I!@2+DCT/0C\#D4 0>5J7_/Q'^7_UJ/*U+_GXC_+_ .M5^B@"
MAY6I?\_$?Y?_ %J/*U+_ )^(_P O_K5?HH H>5J7_/Q'^7_UJ/*U+_GXC_+_
M .M5^B@"AY6I?\_$?Y?_ %J/*U+_ )^(_P O_K5?HH H>5J7_/Q'^7_UJ/*U
M+_GXC_+_ .M5^B@"AY6I?\_$?Y?_ %J/*U+_ )^(_P O_K5?HH H>5J7_/Q'
M^7_UJ/*U+_GXC_+_ .M5^B@"AY6I?\_$?Y?_ %J/*U+_ )^(_P O_K5?HH H
M>5J7_/Q'^7_UJ/*U+_GXC_+_ .M5^B@"AY6I?\_$?Y?_ %J/*U+_ )^(_P O
M_K5?HH H>5J7_/Q'^7_UJ/*U+_GXC_+_ .M5^B@"AY6I?\_$?Y?_ %J/*U+_
M )^(_P O_K5?K-U;6[;24429>9P2L:]?J?09H BOKBZT^U:XN+J-47@ #ECZ
M#CK7&ZGK-UJA596(B3E4'3/J?4U!?:A<ZC.9;F0MR2JY^5/8#MT%5: "BBB@
M#I8O!\D\*2QWL;(ZAE.P\@\BG_\ "%3_ //Y'_WP:M^#]0\RWDL'/S1?/'_N
MD\CIV)_7VKIZ .(NO";V=K+<2WL82-2Q^7K[#GJ:YRN]\2VVHWT$=K90%XR=
MTK;PN?0<G\>GI7,_\(SK'_/G_P"14_QH R**U_\ A&=8_P"?/_R*G^-'_",Z
MQ_SY_P#D5/\ &@"C9W]U82;[6=XR>H'0_4=#UK9M_%MX %N#N]611G\L5;M?
M"@N--5;F-[2\1B-X<.'&002,_4<$>M9-YX;U.SP?)\]3W@RV#],9[>F* .JM
M+R6^ -MJ%O(<9VCA@,XY!&15'Q%>7EC8>5).A:XR@ 7^'^+M[X_&N-1VC=71
MBK*<A@<$&I;BZGNF1KB5Y61=H9SDXR3U[]30!V^D7E]J>GK.MPFX'8X*_P 0
M_#Z'\:O>5J7_ #\1_E_]:N(T767T>:5A%YJ2* 4W;>1T.<'W_.MG_A-O^H?_
M .1O_L: -[RM2_Y^(_R_^M1Y6I?\_$?Y?_6K!_X3;_J'_P#D;_[&C_A-O^H?
M_P"1O_L: )O$5Y>6-AY4DZ%KC* !?X?XNWOC\:ET*]OM1L 5N4WQ?(X;&[V/
M0GGU]0:Y75M2?5;XW+)L&T*J9SM ]\#/.3^-3Z!J@TO40TC$6\@VR8R<>AQ[
M']": .V\K4O^?B/\O_K4>5J7_/Q'^7_UJMPW$-RA>":.50<%D8,,_A4E '-Z
MGX9?5KE9[F?YU0(-AP,9)_N^]4O^$%B_Y[O_ -]C_P")KL:*YY86C-\THZG1
M#%UX1Y8RT.._X06+_GN__?8_^)H_X06+_GN__?8_^)KL:CGGBM8'GG<)&@RS
M'M2^I8?^5%?7L1_.S(@M)]$TL1B[C2V@!.Y^<9.?3U-<QK&NW%_NMUF)M@>P
MQOQW^GM_D,UO6Y=6GP,I;(?W<?K[GW_E^>8-+TN?5;KRHAM1>9)".$'^/H*Z
M(Q44DMD<TI.3<GNQ-,TNXU6Y\J  *O+R-T4?X^U;?_"%3_\ /Y'_ -\&NJL;
M&#3[5;>W3:B\DGJQ]3[U8IB.-_X0J?\ Y_(_^^#2IX-N8W5TOD5E.0P4@@UV
M-% % 1:GM&ZXB)QR0N/Z4>5J7_/Q'^7_ -:K]% %#RM2_P"?B/\ +_ZU'E:E
M_P _$?Y?_6J_10!0\K4O^?B/\O\ ZU'E:E_S\1_E_P#6J_10!0\K4O\ GXC_
M "_^M1Y6I?\ /Q'^7_UJOT4 4/*U+_GXC_+_ .M1Y6I?\_$?Y?\ UJOT4 4/
M*U+_ )^(_P O_K4>5J7_ #\1_E_]:K]% %#RM2_Y^(_R_P#K4>5J7_/Q'^7_
M -:K]% %#RM2_P"?B/\ +_ZU'E:E_P _$?Y?_6J_10!0\K4O^?B/\O\ ZU'E
M:E_S\1_E_P#6J_10!0\K4O\ GXC_ "_^M1Y6I?\ /Q'^7_UJOT4 4/*U+_GX
MC_+_ .M1Y6I?\_$?Y?\ UJOT4 4/*U+_ )^(_P O_K4>5J7_ #\1_E_]:K]%
M %#RM2_Y^(_R_P#K4>5J7_/Q'^7_ -:K]% %#RM2_P"?B/\ +_ZU'E:E_P _
M$?Y?_6J_10!0\K4O^?B/\O\ ZU'E:E_S\1_E_P#6J_10!0\K4O\ GXC_ "_^
MM1Y6I?\ /Q'^7_UJOT4 4/*U+_GXC_+_ .M1Y6I?\_$?Y?\ UJOT4 4/*U+_
M )^(_P O_K4>5J7_ #\1_E_]:K]% %#RM2_Y^(_R_P#K4>5J7_/Q'^7_ -:K
M]% %#RM2_P"?B/\ +_ZU'E:E_P _$?Y?_6J_10!0\K4O^?B/\O\ ZU'E:E_S
M\1_E_P#6J_10 U PC4.06 &XCN:=110 4444 %4)?^0S!_N'^M7ZH2_\AF#_
M '#_ %H ET[_ (\8_P ?YFK55=._X\8_Q_F:M4 5=2L_[0TRZLQ*T)GB:/S%
MZKD8S7G#_P#"<Z1K5IX?@URVN'N8V:&65 2BJ#RQ*D]O]JO4:@:RM7O$O&MX
MS<QJ424J-RJ>H!]* .;\->$9],U.;6=7OS?ZK,NTN!A4'H/7IZ#CM5CQ%#XK
MDNH3X?N;.* )^\$XR2V>W!XQ71T4 >9:7X8\=Z//>2V=YIJO>2>;-N.<MR<_
M=XZFNI\5Z5K.L>%UL+&XACNI"HN6+%5=<'< 0,X)Q^&17244 >;Z9H'CW1[%
M+.PN=(AA3L%Y)]2=G)]ZZ[PY%XAB@G'B">UED+#RC;C&!CG/ K:HH X";P=K
MVC:M<WGA74H(+>Z;=);3CY0?;@C'/'0]N:N:#X/U!==&O>([]+W4$7;"D8^2
M,<^P]3QC')/-=G10!SOB33M?O;W37T;4$M88I";E68C>,C'0'/ /''6G^+/#
M$7B?3%@,I@N87\R"8#.T^A]C_05OT4 >=S>'?'NH6ITV^UVS6S8;)9$&7=?3
M[H)_,9[UV6E:'9:3H<>DPIOME0J^_DR;OO$_7)K2HH \\A\(^*_#TLT'AO5[
M?^SY&++%<CE"?^ D?B.OI6QX7\(SZ5?W&L:M>?;=7N!M:0?=0<<#IGH.<#@8
M KJZ* "BBB@ HHHH **** "BBB@ HHIJ2)*I:-U=0Q4E3D9!P1]001^% #J*
M** "BBB@ HJNU] NH)8E\3O&9 #Z X_/K^1JQ0 4444 %,EE2"%Y9#M1%+,<
M= .35=]5TZ-V1[^U5U.&5IE!!]#S7/>*=9@FLTL[2>.82'=*T;!@ .@_/GKV
M]ZE3BW9,IPDE=HZ'3=0CU.QCN8QMW<,F<E2.H_SV(JW7!>&M9CTV>2*Y<K;2
M#.<$[6'L/4>WI6I<^-(0F+2UD9B#S*0H![<#.?TJB3J:AGNK>VV_:+B*+=]W
MS'"Y_.N"NO$NJ7.X?:/*1L?+$-N/H>OZUDN[2.SNQ9F.2Q.230!VVH>+;-()
M$LS)+,R?(X7"J??/IUZ5Q%%% &OIWB*]TRU^SQ+$Z;BP\P$XSV'/3_$U;_X3
M+4?^>-K_ -\M_P#%5SM7=#T\ZS?R6ID\DI&7W;=V<$#&./6HE4C!I2ZEPIRF
MFX]-S5_X3+4?^>-K_P!\M_\ %4?\)EJ/_/&U_P"^6_\ BJEO/"/V2QN+G[=O
M\F-I-OE8S@9QG=7*QN77.W H=2*FH=6"IR<'/HBS=7,EY=2W$IR\C%C[>P]A
M6EX>U==*O6\[/V>8!7P/ND=&_#G\ZQZ*L@]2L[^UOX]]K.L@'4#J/J.HZ58K
MR9':-U=&*LIR&!P0:VK'Q1J%F DC"YCR.)<EL9YPW^.: -CQW_R!(?\ KY7_
M -!:O/:ZSQ)KT&KZ5#!%#,DJRB1MP&!\I! .<GD^E<GTKYW,T_;W/I<J:]A;
MS84586+,!_O'D57KEJT)TE%RZJYUT<1"JY*/1V.L\%W]I8IJ#W5Q'""$(WM@
MMC=G ZG\*Z";QAHL<3.EP\K#HB1-D_F /UKS.K4.FW]Q$LL-E<R1MT=(F(/X
M@5TT,=5ITU3IK8Y:^ HU*CJU'N5:.M%30)EMQZ"N2C2=6HH+J=E>JJ--S?0A
MI\,SV\\<T3;9(V#J<9P0<BG3IM?/9N:=9V_VN^M[;=L\Z18]V,XR<9Q3J4I4
MZCI]4%.K&I253HT:?_"6ZY_S_?\ D)/\*S+N[GOKI[FY??,^-S8 S@8'3V%=
M;_P@'_43_P#)?_[*N<URPBTW69[. NT<>W:7().5![?6M\12Q,87K-VOWN<^
M'K864[44KV[6,X DX'>GR1^6V.HQUJ2",AMS C'3-2R1B0 'L:WHY?*=!R^T
M]OZ\SGK9C&GB%'[*W_KR*==790Z!I5E#<7 ^WWLD8?RC@JA(/!'3V.<GO@5@
M+&B=!SZU-%%)/((XHWD<]%1<D_A79A,O5)\U2S9Q8S,G57+2ND;.H>*;Z\RD
M)^RQ>D9^8]/XOP[8Z]ZPZZ:Q\'7$H#WLP@&1^[3YF(SSST'Z]:K7GAG4/M<@
MM+(B ':A,RDL!QNZ]^OXUZ9Y1A45K_\ ",ZQ_P ^?_D5/\:/^$9UC_GS_P#(
MJ?XT 9%:ECX@U&P54CG\R)>D<HW#IC&>H'L#4B>&M75U8V(8 Y*F5<'VX:M6
M\\'^9B2QD\K=R89S]WVW#/3@=_K0!RLD']IZI/*9H;?SY&<>:3@%FZ9 /KU.
M!4UYH$VGV\5S)=6DT<C87R9"Q;'4].@Z'ZTMWIUY8DBYMI(QG&XC*DXSP1P:
MJUQ?V?0YN:QW?VCB.3DN6+'19M8N'CMY84D5=Q$A89'3(P#[5H?\(+JG_/>S
M_P"^V_\ B:SK.[EL;N.YA(\R,Y&1D'L1^5=-_P )M_U#_P#R-_\ 8T5,OH3D
MY-:L*>8UZ<%!/1'6UY[X[_Y#</\ U[+_ .A-6Y#XTM60F>UF1L\!"&&/J<5S
M7B6^CUC4([FV5U180A$@ .<D]B?6C,(2G0:BKL,NJ1IUTYNR,&I)(R@4^HY^
MM/CA8."PP!S4SKO0C\J\VAE\ITI2DK/I_7F>IB,QC"M&,'>/7^O(I5T^D^$/
M[4TR&]^W>5YF[Y/)W8PQ'7</2L1-)U*1%=-/NF5AD,(6((_*O1O#$,MOX=M8
MIHWCD7?E'4@CYV[&HP&&52HU5CI;S\B\PQ4J=).E+6_D^Y@_\(!_U$__ "7_
M /LJY*\M_LE]<6V[?Y,C1[L8S@XSBO8J\OU72M1DUB^=+"Z9&N)"K+"Q!&X\
MCBML?A*=.*=*/YF&78RI5E)59?DC&HJW)I=_"A>6RN8T'5WB8 ?4XH32[^5=
M\-E<RQGHZ1,0?Q KS?8U+7Y6>I[:G>W,BI7M->1_V/JG_0-O/^_#?X5ZY7K9
M3&4>>Z[?J>/F\HRY+.^_Z!15*[U:PL25N+J-&!P4!W,.,\@<USVL>*H;BTFM
M;..0^8"AE; &/8<YR,]<8KV#Q3*U'69)]>^WP-Q"P$/NH]>AP>>/?%=[:W,=
MY:Q7$1RDBAA[>Q]Q7E=68M0O8(Q'%=W$:#HJ2$ ?AF@#U&D=UC1G=@JJ,EB<
M "O+)[JXN=OVBXEEV_=\QRV/SJ&@#T_^U=._Y_[7_O\ +_C7GNJW[:EJ,MR<
M[2<1J?X5'3_$^Y-4J* -6T\0W]E8"S@:-5!RKE,LN3G [>O4=ZSIKB:Y<//-
M)*P& SL6./QJ.N^TSP[I<5O#.$^U%E#B24<$$?W>F._.30!Q]CH]]J#+Y%N^
MQO\ EHPPF,X//?\ #FM&\\-2V-B&(EN;IVP$@0E4'<DXY[>G7OBN[HH \P_L
MK4?^?"Z_[\M_A1_96H_\^%U_WY;_  KT^B@#S#^RM1_Y\+K_ +\M_A7<>'9K
MA]+2&Z@EBE@^0>8A7<O8]!]/P]ZUZ* "BBB@ HHHH **** "BBB@ HHHH YC
MQ%X=\_?>V2?ONLD2C[_N/?V[_7KR$$\MK.D\#E)$.58=J]6KC_$^A.))-1M5
MW(W,R ?=_P!H>WK^?T ,?1_#=OJ\;;=1\J9.6B,.3CU!W<C_ #Z5I_\ " ?]
M1/\ \E__ +*L"UN9+.ZBN(CAXV##W]C[&NY/B2V?1);Z,@2H-ODL>0YZ#MD=
M^.P/I7'_ &?AOY?Q?^9W?VCB?YOP7^1B_P#" ?\ 43_\E_\ [*C_ (0#_J)_
M^2__ -E72:)J']I:7',QS*OR2?[P[]._!X]:T:7]GX;^7\7_ )A_:6*_F_!?
MY!67K&A6NM>3]IDF3R=VWRR!G.,YR#Z5:N]1L[$$W-S'&<9VDY8C.. .36'<
M^,[:-]MM;23 $@LS;![$=?UQ77.$9QY9*Z.2$Y4Y<T79E'5?"FDZ;ITMR;BZ
MW 8C4NGS,>G;\3[ US2)"TB+/O\ )W#?LQNQWQGOBM#4]:N]6V"<JJ)R$C!"
MY]>O6LZLXX>E!-1CN:3Q-:;3E+;8[%/ ^DR(KI<W3*PR&$B$$?\ ?-96L>"Y
M[5?.TYGN8Q]Z-L;U&.O^UWX STZUL^%-72:U6PFD_?QY\O/\2^F?4<\>F/0U
MTM8SP%"4;<MO0VIYAB(2OS7]3QF&:6WE66&1XY%Z.C$$?B*Z-/'.JJBJ8K5R
M!@LR-D^YP<5TVN^&;?5]T\9\F\"X#C[K^F[^61^N *\SKQJL*^#E92T9[=&=
M#&QYI1U1T_\ PG6J?\\+/_OAO_BJ/^$ZU3_GA9_]\-_\57,45G]=Q'\S-?J.
M'_D1TS^.=59&416J$C 94;(]QDXKGKFYFN[A[BXD,DKG+,>]%M UU=0VZ$!Y
M75%+= 2<<UZ#HGA*VTTK/<D7%TI#*<$+&<=AWY[GVX%:TX8C&.S>B,JM3#X)
M72U?8Y73_"FIZC;B=5CAC8 H9F(WCU  )_/'44Z_\*7NFVIN;BXM=@(&U7.Y
ML^F1^/X5Z4[K&C.[!549+$X %<%XCUI-4FCBMR_V>+)Y&-S>N,],=._)KTXY
M9025[L\F>:UVW:R,+ QC''I4'V8Y/S8':K%36MN]W=16\94/(P4%VP*ZJV&I
MUK<ZV.6CBJM&_([7)=,U*YTB*=;1E5IMNYRN2,9Z=NYZYJ2;6]3G<,]],"!C
MY&V#\EQ6Q!X+N&W?:+N*/^[Y:E\_GC%3WF@:9H^G274YDN) FU5=L*SGI@#!
M_#/3-:0A&G'EBK(RJ5)5).4W=G(T4459 445Z'I<UOKFEPS7,$4TL>4?S$#8
M;C)Y'?@\>OM0!YY17I_]E:=_SX6O_?E?\*X'6Y[>?5)/LD44<$?R+Y:@!L=3
MQP><\^F* ,ZM'2=8GTB9VB5723&]&[X]#V/7\^E9U% '=6GB^PF %PLENV,G
M(W+UZ CG]*W(;B&Y0O!-'*H."R,&&?PKRT6\S0-.L,AA4X:0*=H/N?Q'YTD4
MLD$@DBD>-QT9&P1^- 'J]%<!;>*M3MTVL\<XP /-7)&/<8S^.:V8?&=L\3^;
M;21R $J VY3@< GJ,GCI0!L+JD#:P^F])5C#Y)ZGJ5^N,'C/?TJ]7ET5]/%J
M O@^9Q)YA/3))R<X[&O2[6YCO+6*XB.4D4,/;V/N* )J*** "BBB@ HHHH *
M**J:AJ5KID(DN9-N[.U0,LQ'H/\ (YH P_&&H>7;QV"'YI?GD_W0>!T[D?I[
MU3\'ZAY=Q)8.?EE^>/\ W@.1T[@?I[U@W]X]_?373C!D;('H.@'X# J&*5X)
MDEC.UT8,IQT(Y% 'J]%<#!XLU2+=O>*;/3S(\8_[YQ6A!XU8!!<60)S\[QOC
MC/8'V]Z .NHK#@\6:7+NWO+#CIYD><_]\YK2@U*RNBBP7<+LXRJ!QN/&>G6@
M">65((7ED.U$4LQQT Y-.1UD171@RL,A@<@BN9\8:AY=O'8(?FE^>3_=!X'3
MN1^GO4OA+4OM-BUG(V98/NY/)0]._;I[#% '14444 %%%% !14$%W#<RSQ1.
M&:!]C@$'G&?\1]0?2IZ "BBB@ HHHH **** "BBB@ KG+3Q"L_B66VWC[,X\
MJ)L\;ESSUQSDCCK\M7/$6I?V=I;[&Q/-\D>#R/4]<\#OZD5YZCM&ZNC%64Y#
M X(- '<ZYXDBLD>WLW#W>=I.,B/_ !/M^?H>)GGENIWGG<O(YRS'O1!!+=3I
M! A>1SA5'>NVT/PW%9(EQ>()+O.X#.1'_B??\O4@%'0_"[;TNM14;<;E@/7/
M^U_A^?I76HJQHJ(H55& H& !2T4 %%%% !1110 4444 %%%% !1110!S'B]+
M*.U1V@4WDK81QD' QDG'7L.?7BN,K1UO4/[2U2293F)?DC_W1WZ=^3SZUG4
M%:6F:'>:JC20"-8U)4N[8&>..,GOZ5FUN>%M0^QZH(7/[JYPA]F_A/3WQ^/M
M0!-_PANH_P#/:U_[Z;_XFL_5-$N-)2-KB6%C(2%5"Q/'4\@>H_.O2*\VUO4/
M[2U2293F)?DC_P!T=^G?D\^M &=1110!)#<36SEX)I(F(P61BIQ^%;]IXQO(
M@%N88[@ ?>'R,3GOCC]*Q;".WEOH8[MW2!VVLRD C/0Y/&,XS[5K7WA*^ME9
MX&6Y0=EX?&.>/\"30!T]CX@TZ_94CG\N5ND<HVGKC&>A/L#6F[K&C.[!549+
M$X %>4RQ202&.6-XW'577!'X5/'J-Y%:26B7,@@<8*9XQ[>F<\XZT =-I?B=
M)-2O/M<OEVSY>'=_#@=,<\D<]>HXZUB:WK<NK3X&4MD/[N/U]S[_ ,OSSE5J
MZ)HDNK3Y.4MD/[R3U]A[_P ORR ,TG1+G5G8QXCA0@-(W3Z#U.*] L;&#3[5
M;>W3:B\DGJQ]3[U)!!%:P)! @2-!A5':I* "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JA+_P AF#_<
M/]:OU0E_Y#,'^X?ZT 2Z=_QXQ_C_ #-6JJZ=_P >,?X_S-6J "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BN8\7ZM?:7]C^Q3^5YF_?\
MBMG&W'4'U-<O_P );KG_ #_?^0D_PKAK9A2HS<))W7]=ST*&75:U-5(M6?\
M78]/HKS;_A)]<\C=]M^;K_JDZ?E4/_"6ZY_S_?\ D)/\**N/IT[<T7JK]/\
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MM5R?C*YA40VZQ1FX<;FD*#<J G !QW.>A[>] '(U:T^_FTV[6Y@QN (*MG#
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M%'Y4*1[W?8H7<YRQQW)]:I_89_\ G^D_7_&C[#/_ ,_TGZ_XT 7Z*H?89_\
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M %^BJ'V&?_G^D_7_ !H^PS_\_P!)^O\ C0!?HJA]AG_Y_I/U_P :/L,__/\
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M]U<X0^S?PGI[X_'VK>_X1*R]?_0O\:/^$2LO7_T+_&@#H**H?89_^?Z3]?\
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MP _ &F_89_\ G^D_7_&C[#/_ ,_TGZ_XT 5_^$9T?_GS_P#(K_XT?\(SH_\
MSY_^17_QJQ]AG_Y_I/U_QH^PS_\ /])^O^- %?\ X1G1_P#GS_\ (K_XU=LM
M.M=.1DM8S&K')7>Q&?Q-1?89_P#G^D_7_&C[#/\ \_TGZ_XT 7Z*H?89_P#G
M^D_7_&C[#/\ \_TGZ_XT 7Z*H?89_P#G^D_7_&C[#/\ \_TGZ_XT 7Z*H?89
M_P#G^D_7_&C[#/\ \_TGZ_XT 7Z*H?89_P#G^D_7_&C[#/\ \_TGZ_XT 7Z*
MH?89_P#G^D_7_&C[#/\ \_TGZ_XT 7Z*H?89_P#G^D_7_&C[#/\ \_TGZ_XT
M 7Z*H?89_P#G^D_7_&C[#/\ \_TGZ_XT 7Z*H?89_P#G^D_7_&C[#/\ \_TG
MZ_XT 7Z*H?89_P#G^D_7_&C[#/\ \_TGZ_XT 7Z*H?89_P#G^D_7_&C[#/\
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M %^BJ'V&?_G^D_7_ !H^PS_\_P!)^O\ C0!?HJA]AG_Y_I/U_P :/L,__/\
M2?K_ (T 7Z*H?89_^?Z3]?\ &C[#/_S_ $GZ_P"- %^BJ'V&?_G^D_7_ !H^
MPS_\_P!)^O\ C0!?HJA]AG_Y_I/U_P :/L,__/\ 2?K_ (T 7Z*H?89_^?Z3
M]?\ &C[#/_S_ $GZ_P"- %^BJ'V&?_G^D_7_ !H^PS_\_P!)^O\ C0!?HJA]
MAG_Y_I/U_P :/L,__/\ 2?K_ (T 7Z*H?89_^?Z3]?\ &C[#/_S_ $GZ_P"-
M %^BJ'V&?_G^D_7_ !H^PS_\_P!)^O\ C0!?HJA]AG_Y_I/U_P :/L,__/\
M2?K_ (T 7Z*H?89_^?Z3]?\ &C[#/_S_ $GZ_P"- %^BJ'V&?_G^D_7_ !H^
MPS_\_P!)^O\ C0!?HJA]AG_Y_I/U_P :/L,__/\ 2?K_ (T 7Z*H?89_^?Z3
M]?\ &C[#/_S_ $GZ_P"- %^BJ'V&?_G^D_7_ !H^PS_\_P!)^O\ C0!?HJA]
MAG_Y_I/U_P :/L,__/\ 2?K_ (T 7Z*H?89_^?Z3]?\ &C[#/_S_ $GZ_P"-
M %^BJ'V&?_G^D_7_ !H^PS_\_P!)^O\ C0!?HIJ*5C52Q8@ $GO3J "BBB@
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M,;5Z @]06V@CT->U@4J5!U)?U8\_$/GJ*",^ZT6_LM*M=2N(&2WNF(C)!SP
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M444 %%%% !1110!Q&JZ1K6I:C+<FT.TG$:F5/E4=/XOQ/N35/_A&=8_Y\_\
MR*G^->AT4 >>?\(SK'_/G_Y%3_&K%AHFMV%]#=)9Y,;9(\U.1T(Z]QD5W=%
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M1H>JWD]_X;EDBU.[$DKQ-DQ9..V>!GOCZUWFMZQ;:#I$^HW6XQQ 85>K$G
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M_?8H EHJ+[3!_P ]X_\ OL4?:8/^>\?_ 'V* ):*B^TP?\]X_P#OL4?:8/\
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MM,'_ #WC_P"^Q1]I@_Y[Q_\ ?8H EHJ+[3!_SWC_ .^Q1]I@_P">\?\ WV*
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M6BHOM,'_ #WC_P"^Q1]I@_Y[Q_\ ?8H EHJ+[3!_SWC_ .^Q1]I@_P">\?\
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M_?8H EHJ+[3!_P ]X_\ OL4?:8/^>\?_ 'V* ):*B^TP?\]X_P#OL4?:8/\
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M%'VF#_GO'_WV* ):*B^TP?\ />/_ +[%'VF#_GO'_P!]B@"6BHOM,'_/>/\
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M_/>/_OL4?:8/^>\?_?8H EHJ+[3!_P ]X_\ OL4?:8/^>\?_ 'V* ):*0$$
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M[<[YE&59OFZ'ZL/^^3B@#T>BBB@ HHHH AEM89W#2)N8#&<D5'_9UK_SR_\
M'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1
M_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G
M6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"E_9%AY_G_9D\[;L\SG=MSG&?3/:
ML;Q+X-L]=LCY($%]&/W4Q)(/^RWM_+KZ@]-15PJ2A)2B]43**DK,^<)(WAE>
M*5&21&*LC#!4CJ".QKU;P9XBL==B6QOD5-21>#N($X'<>C>H_$<9 G\;^$(M
M8MI-2LTV:A"F6"J3YZ@=,#^+'0_@>V/)+>XEM+F*Y@;9-"XD1L X8'(//O7M
M?N\;2[-?@<'O8>?D?0?]G6O_ #R_\>/^-']G6O\ SR_\>/\ C6/X4\5V_B2T
MVMMBOXE_?0@\'_:7U7^70]B>BKQ9PE"7++<[XR4E=%7^SK7_ )Y?^/'_ !H_
MLZU_YY?^/'_&K5%045?[.M?^>7_CQ_QILEG8PQ/+*JI&BEF=G("@=23G@5<K
MB_'VM:.NE7&DW,\S7C*&6*W/*M@E2_;;D#(.3R"!T-:4J;J3443.2C&YQ?B[
MQ/'JUP;33E,>GH>I)S,?4YZ#T'XGL!RU%%?24Z<:<>6)Y,YN;NRUIVHW&EWJ
M75LP#KU4_=<=U/L:]G\/:AI/B+3Q<VT>R1<": N2T;?U!['O]00/#JV_#'B)
MO#6H/=+:1W'F)Y;;G*L%ZX!Z#D#J#TXQ7-B\,JT;KXD:T*S@[/8]L_LZU_YY
M?^/'_&C^SK7_ )Y?^/'_ !K.T7Q9I&O82UN-EP?^7>;Y9._0=&X&>"<#KBMN
MO"E"4':2LSTHR4E=%7^SK7_GE_X\?\:/[.M?^>7_ (\?\:S/$?BNP\-K"MQN
MEGE88AC(W!,\L?0=<>IX]2-:SO+?4+2*[M)5E@E7<CKT/^!]NU-TY**DUHQ*
M2;MU&?V=:_\ /+_QX_XT?V=:_P#/+_QX_P"-6J*@HJ_V=:_\\O\ QX_XT?V=
M:_\ /+_QX_XU:HH J_V=:_\ /+_QX_XT?V=:_P#/+_QX_P"-6J* ,77#9Z1H
M=Y?F-0T,1*;BQ!<\*#@YP6(%>$5ZE\4=3\K3[33(WPT[F60+)@[5X *]P2<_
M5/RXCPCIG]K>)[*W9-T*OYLN8]Z[5YPP]"0%Y_O5[6!BJ5%U'U_0\_$MSJ*"
M/7]'T&VTW1[2S:)?,BB D*NQ!?JQ&>Q.35W^SK7_ )Y?^/'_ !JU17C2;D[L
M[TK*R*O]G6O_ #R_\>/^-']G6O\ SR_\>/\ C5JBD,J_V=:_\\O_ !X_XUA^
M)?!MGKMD?) @OHQ^ZF))!_V6]OY=?4'IJ*N$Y0ES1W)E%25F?.MY9W&GW<MI
M=Q-%/$VUT;J/\1[]Z@KV_P 5^%+?Q):;EVQ7\2_N9B.#_LMZK_+J.X/*>$/
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MJU10!5_LZU_YY?\ CQ_QH_LZU_YY?^/'_&K5% %7^SK7_GE_X\?\:/[.M?\
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MZU_YY?\ CQ_QH_LZU_YY?^/'_&K5% %7^SK7_GE_X\?\:/[.M?\ GE_X\?\
M&K5% %7^SK7_ )Y?^/'_ !H_LZU_YY?^/'_&K5% %7^SK7_GE_X\?\:/[.M?
M^>7_ (\?\:M44 5?[.M?^>7_ (\?\:/[.M?^>7_CQ_QJU10!5_LZU_YY?^/'
M_&C^SK7_ )Y?^/'_ !JU10!5_LZU_P">7_CQ_P :/[.M?^>7_CQ_QJU10!5_
MLZU_YY?^/'_&C^SK7_GE_P"/'_&K5% %7^SK7_GE_P"/'_&C^SK7_GE_X\?\
M:M44 5?[.M?^>7_CQ_QH_LZU_P">7_CQ_P :M44 5?[.M?\ GE_X\?\ &C^S
MK7_GE_X\?\:M44 5?[.M?^>7_CQ_QH_LZU_YY?\ CQ_QJU10!5_LZU_YY?\
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M=/UZV$%_#OV9,<BG#1DC&0?Z'(X&0<5I44XR<7=;B:35F>)>)/!>H>'MT_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **B>X@CGB@DFC2:;/EQLP#/@9.!WP*EH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *H2_P#(9@_W#_6K]4)?^0S!
M_N'^M $NG?\ 'C'^/\S5JJNG?\>,?X_S-6J "BBB@ HHHH **I66K6>H7-Y;
MVTA>2SD\N8%2-K>G/7\*NT %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-^S@6_"GA2X\27>YMT5A$W[Z8#D_[*^K?RZGL#[;'&D,211(J1HH5448"@=
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M.3C+<].$E)704445!04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_O@4?9H/^>$?_? H B_M&U_YZ_\ CI_PH_M&U_YZ_P#CI_PJ7[-!_P \(_\
MO@4?9H/^>$?_ 'P* (O[1M?^>O\ XZ?\*/[1M?\ GK_XZ?\ "I?LT'_/"/\
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MU_\ '3_A4OV:#_GA'_WP*/LT'_/"/_O@4 1?VC:_\]?_ !T_X4?VC:_\]?\
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M_GA'_P!\"C[-!_SPC_[X% $7]HVO_/7_ ,=/^%']HVO_ #U_\=/^%2_9H/\
MGA'_ -\"C[-!_P \(_\ O@4 1?VC:_\ /7_QT_X4?VC:_P#/7_QT_P"%2_9H
M/^>$?_? H^S0?\\(_P#O@4 1?VC:_P#/7_QT_P"%']HVO_/7_P =/^%2_9H/
M^>$?_? H^S0?\\(_^^!0!%_:-K_SU_\ '3_A1_:-K_SU_P#'3_A4OV:#_GA'
M_P!\"C[-!_SPC_[X% $7]HVO_/7_ ,=/^%']HVO_ #U_\=/^%2_9H/\ GA'_
M -\"C[-!_P \(_\ O@4 1?VC:_\ /7_QT_X4?VC:_P#/7_QT_P"%2_9H/^>$
M?_? H^S0?\\(_P#O@4 1?VC:_P#/7_QT_P"%']HVO_/7_P =/^%2_9H/^>$?
M_? H^S0?\\(_^^!0!%_:-K_SU_\ '3_A1_:-K_SU_P#'3_A4OV:#_GA'_P!\
M"C[-!_SPC_[X% $7]HVO_/7_ ,=/^%']HVO_ #U_\=/^%2_9H/\ GA'_ -\"
MC[-!_P \(_\ O@4 1?VC:_\ /7_QT_X4?VC:_P#/7_QT_P"%2_9H/^>$?_?
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M% $7]HVO_/7_ ,=/^%']HVO_ #U_\=/^%2_9H/\ GA'_ -\"C[-!_P \(_\
MO@4 1?VC:_\ /7_QT_X4?VC:_P#/7_QT_P"%2_9H/^>$?_? H^S0?\\(_P#O
M@4 1?VC:_P#/7_QT_P"%']HVO_/7_P =/^%2_9H/^>$?_? H^S0?\\(_^^!0
M!%_:-K_SU_\ '3_A1_:-K_SU_P#'3_A4OV:#_GA'_P!\"C[-!_SPC_[X% $7
M]HVO_/7_ ,=/^%']HVO_ #U_\=/^%2_9H/\ GA'_ -\"C[-!_P \(_\ O@4
M1?VC:_\ /7_QT_X4?VC:_P#/7_QT_P"%2_9H/^>$?_? H^S0?\\(_P#O@4 1
M?VC:_P#/7_QT_P"%']HVO_/7_P =/^%2_9H/^>$?_? H^S0?\\(_^^!0!%_:
M-K_SU_\ '3_A1_:-K_SU_P#'3_A4OV:#_GA'_P!\"C[-!_SPC_[X% $7]HVO
M_/7_ ,=/^%']HVO_ #U_\=/^%2_9H/\ GA'_ -\"C[-!_P \(_\ O@4 1?VC
M:_\ /7_QT_X4?VC:_P#/7_QT_P"%2_9H/^>$?_? H^S0?\\(_P#O@4 1?VC:
M_P#/7_QT_P"%']HVO_/7_P =/^%2_9H/^>$?_? H^S0?\\(_^^!0!%_:-K_S
MU_\ '3_A1_:-K_SU_P#'3_A4OV:#_GA'_P!\"C[-!_SPC_[X% $7]HVO_/7_
M ,=/^%']HVO_ #U_\=/^%2_9H/\ GA'_ -\"C[-!_P \(_\ O@4 1?VC:_\
M/7_QT_X4?VC:_P#/7_QT_P"%2_9H/^>$?_? H^S0?\\(_P#O@4 1?VC:_P#/
M7_QT_P"%']HVO_/7_P =/^%2_9H/^>$?_? H^S0?\\(_^^!0!%_:-K_SU_\
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M1Z=/NT^3[\LQ&Z''7(&-V>V/H<=3Z!IFAZ?I%A'9VMNGEIU9@"SGNS'N3_\
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M]HVO_/7_ ,=/^%']HVO_ #U_\=/^%2_9H/\ GA'_ -\"C[-!_P \(_\ O@4
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M3(BQH$10J@8  P!0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ*H?;I_^?&3]?\*/MT__ #XR?K_A0!?HJA]NG_Y\9/U_PH^W3_\ /C)^O^%
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M,GZ_X4 7Z*H?;I_^?&3]?\*/MT__ #XR?K_A0!?HJA]NG_Y\9/U_PH^W3_\
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M@C(9&[,IQP1_];H:Z\+BG1=GL85J*J*ZW/$;.SN-0NXK2TB:6>5MJ(O4_P"
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M0B<](';#]^@QSP,\9]ZU_MT__/C)^O\ A7SDH2@[25F>K&2DKHOT50^W3_\
M/C)^O^%'VZ?_ )\9/U_PJ1E^BJ'VZ?\ Y\9/U_PH^W3_ //C)^O^% %^BJ'V
MZ?\ Y\9/U_PH^W3_ //C)^O^% %^BJ'VZ?\ Y\9/U_PH^W3_ //C)^O^% %^
MBJ'VZ?\ Y\9/U_PH^W3_ //C)^O^% %^BJ'VZ?\ Y\9/U_PH^W3_ //C)^O^
M% %^BJ'VZ?\ Y\9/U_PH^W3_ //C)^O^% %^BJ'VZ?\ Y\9/U_PH^W3_ //C
M)^O^% %^BJ'VZ?\ Y\9/U_PH^W3_ //C)^O^% %^BJ'VZ?\ Y\9/U_PH^W3_
M //C)^O^% %^BJ'VZ?\ Y\9/U_PH^W3_ //C)^O^% %^BJ'VZ?\ Y\9/U_PH
M^W3_ //C)^O^% %^BJ'VZ?\ Y\9/U_PH^W3_ //C)^O^% %^BJ'VZ?\ Y\9/
MU_PH^W3_ //C)^O^% %^BJ'VZ?\ Y\9/U_PH^W3_ //C)^O^% %^BJ'VZ?\
MY\9/U_PH^W3_ //C)^O^% %^BJ'VZ?\ Y\9/U_PH^W3_ //C)^O^% %^BJ'V
MZ?\ Y\9/U_PH^W3_ //C)^O^% %^BJ'VZ?\ Y\9/U_PH^W3_ //C)^O^% %^
MBJ'VZ?\ Y\9/U_PH^W3_ //C)^O^% %^BJ'VZ?\ Y\9/U_PH^W3_ //C)^O^
M% %^BJ'VZ?\ Y\9/U_PH^W3_ //C)^O^% %^BJ'VZ?\ Y\9/U_PH^W3_ //C
M)^O^% %^BJ'VZ?\ Y\9/U_PH^W3_ //C)^O^% %^BJ'VZ?\ Y\9/U_PH^W3_
M //C)^O^% %^BJ'VZ?\ Y\9/U_PH^W3_ //C)^O^% %^BJ'VZ?\ Y\9/U_PH
M^W3_ //C)^O^% %^BJ'VZ?\ Y\9/U_PH^W3_ //C)^O^% %^BJ'VZ?\ Y\9/
MU_PH^W3_ //C)^O^% %^BJ'VZ?\ Y\9/U_PH^W3_ //C)^O^% %^BJ'VZ?\
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MG-PM_J^GS&)#^[MI$*[R.[ CI[=^_'6[JG@-+S6DN;2%[6SD;=/"JG*^NSC
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M_P#6K=\2>(+[1;S38;32I+U+J0K(Z9^3D#L.O)Z^E9_C[0K^_BL-5TE/,O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7/XBTNWUR'1Y;E5O)5R%[ \84GLQ[#_$9SC%RV13:6YJ4445(PHHHH ****
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MBBG4J2J2YI!""@K(****S*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM $NG?\ 'C'^/\S5JJNG?\>,?X_S-6J "BBB@ KS3Q+%#K7Q+M='UF=X]-6
M/#'OVK(Y![^I.1^&*]+K&U_POI?B6!8[^$[T!\N:,[73Z'^AR* ,W_A7/AM)
MH9K:UEMY8G617CG<G(.1]XFMC7M(_MS29-/-U+;1RL/,>+[S+GE?QZ5PNJ0>
M(?A[''?6FJ/J.DAPCV]UU3/0 ]OJ,?2O2+:=+JUAN(\[)45USUP1F@#A-?\
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M=+8>//#U_P"6OVW[-(^?DN%*;<9ZM]T=/7]>*\.>%K0WB>C&M3ELS5\W4O\
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MD\L[=V8]R?\ ZW05YF93IM*/VCLPD97;Z">;J7_/O'^?_P!>CS=2_P"?>/\
M/_Z]7Z*\@[BAYNI?\^\?Y_\ UZ/-U+_GWC_/_P"O5^B@"AYNI?\ /O'^?_UZ
M/-U+_GWC_/\ ^O5^B@"AYNI?\^\?Y_\ UZ/-U+_GWC_/_P"O5^B@"AYNI?\
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M #[Q_G_]>K]% %#S=2_Y]X_S_P#KT>;J7_/O'^?_ ->K]% %#S=2_P"?>/\
M/_Z]'FZE_P ^\?Y__7J_10!0\W4O^?>/\_\ Z]'FZE_S[Q_G_P#7J_10!0\W
M4O\ GWC_ #_^O1YNI?\ /O'^?_UZOT4 4/-U+_GWC_/_ .O1YNI?\^\?Y_\
MUZOT4 4/-U+_ )]X_P __KT>;J7_ #[Q_G_]>K]% %#S=2_Y]X_S_P#KT>;J
M7_/O'^?_ ->K]% %#S=2_P"?>/\ /_Z]'FZE_P ^\?Y__7J_10!0\W4O^?>/
M\_\ Z]'FZE_S[Q_G_P#7J_10!0\W4O\ GWC_ #_^O1YNI?\ /O'^?_UZOT4
M4/-U+_GWC_/_ .O1YNI?\^\?Y_\ UZOT4 4/-U+_ )]X_P __KT>;J7_ #[Q
M_G_]>K]% %#S=2_Y]X_S_P#KT>;J7_/O'^?_ ->K]% %#S=2_P"?>/\ /_Z]
M'FZE_P ^\?Y__7J_10!0\W4O^?>/\_\ Z]'FZE_S[Q_G_P#7J_10!0\W4O\
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M \];2_%WCJUM!J[VNGZ2^V8I!]Z08R.,GG!Z$C'<9%=1XLM-8_X1@6/AR/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%?.RES-L]5*RL%%%%2,**** "BBB@"CJVDV>M:?)97L>^-N01PR-V93V(_\
MK=#7E/\ PKW5_P#A(/[.V_Z-]_[;M_=[/7_>_P!G.<^W->R45T4,54HIJ/4R
MJ48U'=E'2=)L]%T^.RLH]D:\DGEG;NS'N3_];H*O445@VY.[-$DE9!1112&%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP0SSRS)]KD7RVQG)YZ^_M4_V&?\ Y_I/U_QH OT50^PS_P#/])^O^-'V&?\
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MM8@_VN1LMC&2/ZT :U%4/L,__/\ 2?K_ (T?89_^?Z3]?\: +]%4/L,__/\
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M?Z3]?\: +]%9*PSM>/;_ &N0;%SNR>>GO[U/]AG_ .?Z3]?\: +]%4/L,_\
MS_2?K_C1]AG_ .?Z3]?\: +]%4/L,_\ S_2?K_C4%W#/:Q!_M<C9;&,D?UH
MUJ*H?89_^?Z3]?\ &C[#/_S_ $GZ_P"- %^BJ'V&?_G^D_7_ !H^PS_\_P!)
M^O\ C0!?HJA]AG_Y_I/U_P :@6&=KQ[?[7(-BYW9//3W]Z -:BJ'V&?_ )_I
M/U_QH^PS_P#/])^O^- %^BJ'V&?_ )_I/U_QH^PS_P#/])^O^- %^BLRXMIX
M(&E^V2-MQQDCO]:='9SR1(_VV0;E!QS_ (T :-%4/L,__/\ 2?K_ (T?89_^
M?Z3]?\: +]%4/L,__/\ 2?K_ (T?89_^?Z3]?\: +]%9,$,\\LR?:Y%\ML9R
M>>OO[5/]AG_Y_I/U_P : +]%4/L,_P#S_2?K_C1]AG_Y_I/U_P : +]%4/L,
M_P#S_2?K_C4%W#/:Q!_M<C9;&,D?UH UJ*SH[.>2)'^VR#<H..?\:=]AG_Y_
MI/U_QH OT50^PS_\_P!)^O\ C1]AG_Y_I/U_QH OT50^PS_\_P!)^O\ C5:S
M2>[W_P"E2)MQW)SG\: -BBJ'V&?_ )_I/U_QH^PS_P#/])^O^- %^BJ'V&?_
M )_I/U_QH^PS_P#/])^O^- %^BFHI6-5+%B  2>].H **** "J$O_(9@_P!P
M_P!:OU0E_P"0S!_N'^M $NG?\>,?X_S-6JJZ=_QXQ_C_ #-6J "BBB@ HHHH
M *0LHP&(&XX )ZTM8GB;PZGB33X[<W<MI+#*)HIHN2K $=/Q[$4 4-:^'VA:
ML'ECM_L5V>5GMOEPWJ5Z'G\?>LKP1?ZAJ_AS6=+OIS<R6I>W28G)8%2,9[\C
MK[UE:9I'B;6K[5-)?Q5<K;6$BPO* 2TF<Y[@]NY[UW_A_P /V7AS31962L5)
MW/(YRSMZF@#F_A5<I+X2: '$D%PZNO?G!!_7]*K_ !"*W?B+PQIT?S3-=>8R
MCJJ[E&?T/Y&K-]X"NH=7N-2\/:S+IKW)+2Q;24)/7'/3.3@@XSQBKGA[P5_9
M>J/J^J:A)J>I$$)+("!&#UQDGGJ/H>E '65Y]XS9;'Q_X7OY>(F8Q%CT'S8_
M]GK?\2>'[[6KS39K359+)+60M(B9^?D'L>O!Z^M6?$OART\3Z7]CNBR,K;XI
M4ZHW]1[4 :TTL=O!)-*X2.-2[L>@ &2:\G\.VDEU\,O$LX1@)Y'D0>H4!O\
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M !52[ADEN+9D7*HV6.>G(JW10 4444 %%%% !533X9(+=ED7:Q;.,Y["K=%
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M 7:*A-W;"S-V;B+[,$\PS;QLV]<YZ8K$L?'/AS4;X65OJ2&9FVH'1D#GT!(
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MWZCM^- %RBBB@ HI&944LQ"J!DDG  KFKKX@^%[24QOJB2,.ODQLX_,#'ZT
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MOEGQZ[5R<?A63'\2/"KN%_M%ESW:"3'\J .KHJM8ZC9ZG;^?8W45Q%TW1N&
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MI)P/2MSQ=H-QXCTB/3X9XX4:='F9@2=@SD#WSB@#>5@RAE.01D4M(H"J% P
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MC_'^9JU573O^/&/\?YFK5 !1110 4444 %%%% !1110 4444 %%%% !1110
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MY_,A=HWQ"2,@X-=;7$W?AW^SO'$6HV^F1W>GZE\EW&8E;R9.TG/0'O\ C[4
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MX-11^&QI7CF2:/2XKK2M34M(3$'^S2C)SST4Y/Y^PKJ?[%TK_H&67_?A?\*
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MKL_[%TK_ *!EE_WX7_"N<M-%EM/B9+>06(AL&L-@DC0*F_<..._% '8T444
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M*!(RW3&?YBMJN;\:>'?[?T?,"K_:%J?-MF(!RPZKSQ@X[\9 H H_\+0\,_\
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MT*R$X4?,. >G2NM_L72O^@99?]^%_P *Y[PQI%QIWB_Q'*;,V]I,T7D$* C
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M#IGAI=&\7W5M_945QH]\IFBD,*L+:0=5)/0'M^'O75?V+I7_ $#++_OPO^%
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MQ3 ?-&WJ/ZCO7G]C%KT/Q T*QUE&F:Q\Q8KL*2)8RIP2?7MZ^O/) /5J***
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MHDND^+O$.E3QN!<3&\MY-IVNK'D9]1D?D: *:>(O$_A2:-?%-NEWI[L%-];
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M?+N]_P"%>?H?SK0\?0302Z)K<4+S+IMV&E1!D[&(R<?\! _&NR1UDC5T.58
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M10!P^L>.KS^UYM(\.:4VHW4!*RRG)1&';C\LDCFJO]J?$P_/_85AMZ[=R_\
MQS-2_#JXM[2;6M*N9%34UOY'9'X9UP ",]>0?S]Z[V@#B-+\<WD6JP:7XETI
MM.N)SMBF&?+=O3G/&<<@GK7;UP?Q1NK5M"AT]75]0EN$,$2\N#Z^W7'XUW2;
MA&H<Y; R?>@!U9^M:Q:Z#I4VH7A;RH\851EF)Z >]:%<1\3HR=!L;AXS);6]
M]').H&?DP1T_''XT 48_%?C?6(UGTCPY#':N,HTYY8=B"64$?A3_ .W_ (A6
M(,M[X<MYX0,LL# O^&UV_D:[NSN[:^M8[BSFCF@<95XSD5,S*B%G8*H&22<
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M=N/RR2.:[BN"^'5Q;VDVM:5<R*FIK?R.R/PSK@ $9Z\@_G[T 1?VI\3#\_\
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M+&W;Y@/7Y6;^5>@12QSQ++#(LD;#*NAR"/8TD]Q#:P//<2I%$@RSNP4 >Y-
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M_'C'^/\ ,U:JKIW_ !XQ_C_,U:H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *;)&DT31R(KQN"K*PR"#U!%.KF/'VKW&C>$[B>T<QSR,
ML*..J9ZD>^ : ,NZ^&6D/=O)IU_=Z?*>2D4@('T'7]:A/PMCG^6]U_4+B/\
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M:P?&>JS:+X3OKVV.)U4)&W]TLP7/X9S0!B7WPST6:]:>PN[G3IFYV0.-H[\
M\C\\<57/PN6;Y;OQ#J$T?]T__7)JKIWPMM[S3H;V_P!4O?[2F42LZ,,*QY[@
MDD>N:MVFLZOX+OHM.\22F\TN5MEOJ6#E#Z/_ /7YZ\D= #H-"T?0?#$O]F6,
MD:WLZ>8PED!FE49Y^G!Z #K705PUXZR?&#2G1@RMIA(8'((S)7<T %<]XD\'
MZ-XCVRWRM%.HVK<1,%;'H<\$?45T->7QZ)+\0/$^K3:E>SQ:?83FWAAB89R"
M1D9! Z9/'?VH O\ _"LF Q%XEU!8NRYS_6K5AX"\/>')?[6O[IYVA(;S;R0!
M$.< XXYR1USSBJ4GAK7/!7^F^';R:_LD.9M/FY++W*X[_0 _7I4OB?Q!9>(_
MA?J%Y9O_ ,\A)$3\T;>:G!_Q[T =ZCI+&LD;!T8!E93D$'H13JHZ+_R =._Z
M]H__ $$5>H ;)&DT31R(KQN"K*PR"#U!%<-=?#+2'NWDTZ_N]/E/)2*0$#Z#
MK^M:GC[5[C1O"=Q/:.8YY&6%''5,]2/? -8%M\)[86J33:K>IJ9&]I8R-JN?
M;&3SWSS0!*?A;'/\M[K^H7$?]WI_,FNFT/3=#\/,VDZ<T27)7S9$:0&5QTW'
MOC]*YW3_ !#JOA748M(\5-YMK*=MMJ8^Z?0.?ZGD=\CFIHB#\89B#D'3!_Z$
M* .WHHHH YKQ'X+T7Q!*+F[#V]T !]HA8*Q],YX/\ZQ/^%8O]U?$NHB+IL]O
MS_I67IGAYOB'J6I:KJU]<):0W+6]O#$0"H&#W! &"O;DYJ_)HVO^!!]LT:YE
MU32DYFLIOO*/5<?S ^H- &EIO@KP[X4D_M6\N3)+&P(GO) %1CW'09SZYKL@
M00"#D'H17GOC76[+Q!\-WOK&3=&TT893]Z-L\JP[&N_M_P#CVB_W!_*@"2HY
MX(;JWD@GC62&12KHPR&![&I*Y+XAZG>:?X?BAT]S'<WMPMLLBG!4$$G!['C'
MXT 9\WPPTO[2[Z9J=[8L>2D<@8+_ %_,GK4?_"K()R!?:[J%P@_AR!_/-,B^
M$]I#;I+%K%[%J*C/GH1M#>H'!_\ 'JMZ1XEU+0]4CT'Q61OD.+74!PDP]"?7
MW^F?4@'0Z'9Z+HPDT?2VA66'#S1"3=)SCYF[^GZ5L5P^C_\ )6_$7_7M%_Z!
M'7<4 %8'B/PEH_B-5DOXS',@VK<1L%<#TR>"/K6_7F#:1+X_\7ZNM_>3PZ;I
MDOV>.&,C)8$@D9R!T))QW H O?\ "LF  M_$NH)%CA<Y_D15JQ^'WA_093JF
MH7,ER83O,EVX$:8Z$C_$FJ4OA;6_!H-]X:OI[VV3F73YQDNO?;C@GZ 'Z]*M
M:UXBL_$GPWU2YM24D6-5F@8_-$VX<'V]#WH [>*6.>%)H762*10R.IR&!Y!!
M]*?65X9_Y%31_P#KQA_] %:M &%XB\*Z1XCB4ZC&5DC&$GC;:ZCTST(]C7-C
MX9;0!;>)-0CB[*#G^1%4[K2IO'GC75+6\O)H=,TMEC6*,C)8Y&1GC)(;G!["
MK,GA#6?"7^F^%]0FN8DYEL+CGS!WQC )_ 'W[4 7++X=:!H\IU+4;F6Z\D;V
M:Z<"-<=R._XG%=K#-%<P)-!(LD4BAD=#D,#T(-<5?^);3Q+\/=7FA!BN(H"M
MQ;.?FB;^H]#_ %R*W_"7_(H:1_UZ1_\ H(H V:0@,I5@"",$'O2U@^,]5FT7
MPG?7ML<3JH2-O[I9@N?PSF@#$OOAGHLUZT]A=W.G3-SL@<;1WX!Y'YXXJN?A
M<LWRW?B'4)H_[I_^N3573OA;;WFG0WM_JE[_ &E,HE9T885CSW!)(]<U;M-9
MU?P7?1:=XDE-YI<K;+?4L'*'T?\ ^OSUY(Z '0:%H^@^&)?[,L9(UO9T\QA+
M(#-*HSS].#T '6N@KAKQUD^,&E.C!E;3"0P.01F2NYH *Y[Q)X/T;Q'MEOE:
M*=1M6XB8*V/0YX(^HKH:\OCT27X@>)]6FU*]GBT^PG-O##$PSD$C(R"!TR>.
M_M0!?_X5DP&(O$NH+%V7.?ZU:L/ 7A[PY+_:U_=/.T)#>;>2 (AS@'''.2.N
M><52D\-:YX*_TWP[>37]DAS-I\W)9>Y7'?Z 'Z]*E\3^(++Q'\+]0O+-_P#G
MD)(B?FC;S4X/^/>@#O4=)8UDC8.C ,K*<@@]"*=5'1?^0#IW_7M'_P"@BKU
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MCD9&>,DAN<'L* +@^&6T 6WB34(XNR@Y_D15FR^'6@:/*=2U&YENO)&]FNG
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MCKGG%=JCI+&LD;!T8!E93D$'H17!>)_$%EXC^%^H7EF__/(21$_-&WFIP?\
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MQ#U+4M5U:^N$M(;EK>WAB(!4#![@@#!7MR<T :G_  K%_NKXEU$1=-GM^?\
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M<,^R.>\D488]E' R>?4]:["O._'FJ6FL^$=(OK&420R:E%@]P=KY!'8BO1*
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MGZ'_ &<YJ;QE?VNJ1^%;VRF6:WEU*,JZ_4?D?:@#OZ*** *NH:=::K8R6=[
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M.M T>4ZEJ-S+=>2-[-=.!&N.Y'?\3BNUAFBN8$F@D62*10R.AR&!Z$&N*O\
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M6ZWHEEX@TR2QOH]T;<JP^]&W9E/8URW@WPMK&A^(]0NM2F6XB>!88I]^2X7
M7(ZC"J!_C71:3XIT36\"QU")Y#_RR8[7_P"^3S6Q0 4451UG3?[7TF>Q%S-;
M&4#$T)PRD$$8_*@#&L=%O],\=7]_ J/INHQ*TIW8:.1>G'<'G_OKVKIZX'[-
MX\\.?ZBX@UVS7'R2_+*!WZG.?Q;Z59L?B3IC3"VUBUNM)NN,I<1DKS[XR/Q
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M*V_YDESR,>AR?R%:VNZ4VLZ6]FEY-9N6#+-"<,I!R*Y/'CWPYT,&O6:^ORS
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M/#G^HN(-=LUQ\DORR@=^ISG\6^E6;'XDZ8TPMM8M;K2;KC*7$9*\^^,C\0*
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M+1@MY!*L]N2<#</?Z$_I70UQVK>&O$":I<:GH.OO$\S!FM+CF+MTZ@=/3\:
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M=%O]"U?6(&5&TRYF^TV[AN58]5(_+\O>M'Q%HLFN:<MM#J%Q82I()4F@.""
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MK=:3=<92XC)7GWQD?B!77VMY;7T GM+B*>)NCQ.&!_$4 5- LYM/\/:?9W
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MC7^G7'F(COM#J<;AG\!^M=/7#7/AOQ3I5W-=:#KIGBDD,AM+WD#)S@'D=_\
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MAUNT7_EE<<2X[\D_^S'Z4 =]7&>,?!;ZN7U'2)!;:H8S%)@[5N$(P5;WQW_
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M,>AR?R%:VNZ4VLZ6]FEY-9N6#+-"<,I!R*Y/'CWPYT,&O6:^ORS 8_//_?5
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M7\,UN4 %%%4]5L/[4TNXLO/EM_-7 EB.&4YSD4 8<&BW^G^/KG5+94?3M0A
MN,N 8Y%'! [CC_QXUU%<#]B\>>'<?9;R#7+5<?).-LN._4Y_\>/TJS9?$G3_
M #Q:ZU9W6DW7=9D)7\\9_,8H /&/@J353)J.C.+?4GC,<R@[5N$(P0WOCO\
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M]4)?^0S!_N'^M $NG?\ 'C'^/\S5JJNG?\>,?X_S-6J "BBB@ HHHH ****
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M?4D=?QS6E]N%MH?V^X.5CMO.D('7"Y->>:9I'B?QI;G6I_$$^FQ2L?L\$.[
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MU_"@"AJWP^\/ZH3(MJ;*XSD2VAV8/^[T_3-97]D>./#O.EZG'K%JO2"[X?\
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M/#WBKQ39)K-UXEN+ W&7AAAW8"]N P _7C%;_A+6-475K[PYKCK-?6:B2.X
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M;\5Z+JEQ+_8J:CI)8&,VY/FH..H&3Z]OQJ?2OB'X?U)A%)<FRN.ABNQLP?\
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M[QW/Y/@W4%".[S((D1!DDL0/\3^%:6@6DEAX=TVTF&)8;:-''HP49_6M&B@
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MQ/X;U/6$M?#<UU%<WLDJR$$#&3C&.V*U_!RZQ<^+M8U74])EL?M4,8 8'&5
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MSZ9Z'\ZZ8$, 000>010!QG@V.2X\2^)]4\MTMY[E8HBPQOV9R?IR/SKM***
M*FJQ//H][%&I:1[>154=R5( KS?P_K'BW0-$M],C\*3S)!NP[!@3N8MZ>]=K
MXEG\16JVT^@VMO=*I;[1#*<,PXQMY'^U^G!K&L_B39),+77;"ZTFZ[B5"R?G
MC/Z8]Z )_AW:7]II%_\ VA926LL]\\P208.&5?TR#4?C2.2_\0>&=/@C=G%X
M+AV X1%(SG]?RKK+._M-1@$]E<PW$1_BB<,/TJQ0 4444 <+XY@U5->T+4],
MTV6]-F9&94!(R=N,X_&L;6=0\5>(Q86UQX7G@C@O([@LH8YVY&.?K6U<^)?%
M.@W<W]J:%]LL/,.RXLN2J9XR.>V.H6M;2/'7A_6=J0WRP3-C]S<?NVR>P)X)
M^A- '1DX&3VKB_A]$\KZ]JAC=(K[4'>(.I!*Y)SS_O?I7:=1D44 %%%8_B.3
M78K".30(K>:Y63+Q3]'3!X'(YSCN* //O#5_XL\,:4=/C\+SSKYK/O8,.N/3
MZ5TG@*'5/MVNWFIZ;)9-=SI*H<8S][('TX_.H[?XCQ6DXMO$6E7>E3G^(H70
M^XXS^0/UKKK#5;#58?-L+R"Y0=3$X./J.WXT <K\2(GOM+T_2H8W>>\O45=J
MD[5&<D_3(KM:** "O-;N7Q#H7CG6;_3]!FOH;L1JKX.W 4="/>O0-2^V_P!F
MW']G&,7FP^3YGW=W;-<8OCO5-&81>*- GMQD W5L-T9_7'Y,3[4 0Z))KVK>
M/[?5=2T.:QC2S:W)(.T<D@Y/UQ74^+[A;;PAJK,K-OMGB4*"26<;1^IJ72?$
MNCZVH_L^_AE<C/ED[7'_  $\UJT 8OA&SDL/"6F6TRE9%@!96&"I/S8/TS6U
M110!A>,K2XOO".HVUK$TLTD8"(HR6^8'BN.M=?\ %UKH<.F#PG,R16RVX<AL
MD!=N>E=1XCOO%&G7T5QI&GP7^GB+][#G$H;)R1STQMZ ]^*IZ?\ $C2)YOLV
MIQ7&E78P&CN4.T'ZX_F!0!>\!V=U8>#;&UO+=X)XS)N1Q@\R,1^AK/U..2_^
M*6CK%&Y2QMGEFDQP-P( SZ]/SKK[>Y@NX5FMIHYHFY5XV#*?Q%2T %%%4=9_
MM+^R9SI'DF_ !B$WW3R,@_AF@#S])_$GAWQ3KT]EX>FO(;VX#*^#C"[L$8]=
MU7O#!UO4/'EQJ^IZ-+8H]B81N!VY#*1R>_!J2/Q_?:3(L/BC0KBR.0/M$ WQ
MD_Y]":ZK2]?TG6DW:??PSG&2@;#CZJ>1^5 &=X[G\GP;J"A'=YD$2(@R26('
M^)_"M+0+22P\.Z;:3#$L-M&CCT8*,_K6C10 5S/CZQNM1\'W=M9P//.S1E8T
M&2<.":Z:N6\0:EXITK4OM&G:7%J.F>6-T:'$H;OCO^0- '-76O\ BZZT.;3#
MX3F5);9K<N V0"NW/2NT\(V\]IX3TVWN86AFCA"O&PY!R>M96G?$?1+N7[/?
M>=IET#M:.Z3 !_WN@_'%=9#-%<1++!*DL;#*NC!@1[$4 <:8WOOBX)HXW\JP
MT_RY'*G;N)) S]'_ $-=K110 5Y;I]WXG\-ZGK"6OAN:ZBN;V259""!C)QC'
M;%>@:Z=672W;1%A>]5@56;[K#/(KEHOB'-ILJV_B;1;K3Y"=OG(I:-CZCV^A
M:@ \'+K%SXNUC5=3TF6Q^U0Q@!@<94!<#/7@9J]\2')\'3VL<<DDUW+'%$B*
M22=X;M[*:WM,UO3-9B\S3KZ&X&,E4;YE^JGD?B*OT 5["W-IIUK;,<F*)8R?
MH *L444 <C\1].O-3\+>18VTEQ,+A&V1C)QSS^M<_J^O^+M7TBZT]_"<T:W$
M90N Q(_2N@US5O%>D:K--:Z1%J6DX4HL1(E7@9SC)ZY['M2Z9\1=!OW\FXE?
M3[@'#1W:[0#_ +W3\\4 ;?AZ&6W\-:7!/$T4L5I$CHW52% .:YW3HY+SXJ:I
M>I&XM[6S6W+D8#.2#Q^1_*NRCD26-7C=71AD,IR#3J "BBJ>J_;_ .R[C^R_
M*^V[?W7F_=)SW_#- 'G\DWB/0/&.N7=AH$U[#>.FU\'& .Q'UJWX>?7-3\>_
MVMJ>BRV,?V(P98';PP(Y/>I$\>ZCI#+%XHT"XM.0/M%N-T9/YX_)C75:5XBT
MC6T!T^_AF;&3'G#CZJ>?TH J>-9Q;^#]3RK.TD)B55&22WRC^=6/#%I)8^%]
M,MIE*RQVR!U/53C)'X5K44 %<;\1+*_N],TY]/LY+J6WO5E,<8R< '],UV5<
M=JVM^*]%U2XE_L5-1TDL#&;<GS4''4#)]>WXT <[X@UCQ;K^B7&F2>%)X4GV
MY=0Q(VL&]/:O2M/5TTVU61"CB% R'^$X&17/:5\0_#^I,(I+DV5QT,5V-F#_
M +WW?US74JRNH96#*>00<@T <7X<C>[^(7B74UC=;<>7;*S*0&90 V/7E/U%
M=K110 5Y=:7/B;PYK^O-:>'9KN&\O7E5R#C&YL$8]0:]!ULZH-)F.C"%KX8,
M:S?=/(R/RS7)Q_$&ZTN18/%&B7-@Y.WSXEW1L>^/_K%J &^$_P"VKWQMJ&JZ
MGH\MBDUH$!8'&5*X'/J,G\*UOB#,8_!EY$L;R2W!2&-$4DDE@>WL#6OI>O:5
MK*;M.OH;CC)56^8#W4\C\16C0!2T>U:QT2PLW^]!;1Q-]54#^E7:** .&\?6
MVJ'5?#^H:9I\EZUE+([(@S_<QG'K@UA>(-2\6>(K&*SE\*SQ*LZ2Y4-SCMR/
M>M^\\1>*]"O[@W^AK?:;YA,<UF3N5,G&1ST&.H'UK2TCQ[X>U?:L=\MO,V/W
M5S^[.3V!Z'\#0!TM<5X%B>;5/$FJ^6Z07E[MBW*1N5=W/X[J[4$$9!R#10 4
M444 %%%% !1110 50E_Y#,'^X?ZU?JA+_P AF#_</]: )=._X\8_Q_F:M55T
M[_CQC_'^9JU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 445A>+/$)\,Z+_: MA<'S5CV%]O7/.<'TH N:IH.E:TFW4;"&<XP'9<.![,
M.1^!KE)/A]=Z5(T_A?7+BQ8G=Y$QW1L??_ZX-=O<W,5G:S7,[;(84,CL>P R
M:\\A\7^,]<WWN@Z% =/#$(9S\SX^KKG\/<9H M?\)5XI\/\ R^(="-S;KUN[
M(Y 'J1R/SVUUVC:S::]ID=_9%S"Y(PZX((Z@UF^%O% U]+BWN;5K/4K1MMQ;
MMGCT(SV_E^5= D:1+MC147).%&!D]: '4C*&4JP!4\$$=:6N>L-;N[[QKJFE
MA(A96,*9.T[VD8 ]<XQC(Z=J *^K?#[P_JA,BVILKCJ);0[,'_=Z?IFLK^R/
M''AWG2]3CUBU7I!=\/\ F3_[-^%7_&&OZK:7]AH>@HAU*]!;>X!\M!WP>.Q.
M3GH>*Q;FY\?^%X/[2O[BUU2SCP9HHP,JO<YV@CZC('I0!K:9X_2348-,UG2K
MO3+Z9Q&@=249B0!@\'DD=B/>NSJI9W-MJVGVM[$JR0RJLT>X9(SR/H15N@ K
M+U7PYI&MJ1J%A#,V,"3&''T8<UB?$'5-3TO3; Z5<^1<3WBP[MJG.0>.0>^*
MS(_'>K:#,MMXLT>2($[5N[<95OUP?P.?:@"5_ 6IZ.S2^%]?N+7J1;7!W1G]
M,?FI^M)_PF/B+0?E\2: [PKUN[+E<>XR1^9'TKK]+UK3=:@\[3KR*X7&2%/S
M+]0>1^-7Z *>E:I:ZSID.H6;,UO,#M++@\$@\?4&KE-CC2) D:*BCHJC IU
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M/PWT>XF^TZ<\^EW8.5DMG. ?]WM^!%0:O\0GM]9FTS1M'GU2: E9C&3A2.H
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M5_&7@^6&XU^2WU'2WD"2RPCF+/?A0?S!';(R*]#"Q2^7,%1R!E'QG (['Z4
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M\'*F)CLS^>5_ _A5[PJWBNWO)['Q"L4T,<>8;M"#O.>F1C]0#Q7544 %%%%
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M34=,LM6M3:W]M'<0D@[7'0CN/0T 5?#/_(J:/_UXP_\ H K5J.""*VMX[>%
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M9K5GC(&0?ERI'XX(JGX"@^S^"M-4HR.RL[!A@DEB<FNACC2*-8XT5$4855&
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M=KJ)\!>*=074(9#H^IS&XBN$7(C<\L"/\G 'O45MXET.U^(]QJ2:A"UGJ%F
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M+\-R7'GMHUKOSGA<+_WR./TH R/AN7N-*U+4#$T<5[J$LT0;J5./ZY'X&F:
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M)R?S-=M52RTRRTYKAK2W6(W$AEE*Y^9CU- %+6O"VCZ^G^GV:-)CB9/ED'_
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MP,5-0!@>,=1U/2?#DU]I:(\T+!GWKNPG<X]N/PS7+66I?$74;&"\MHM.>"9
MZ-E>0?QZUZ,Z+)&T;J&1@0RD9!![5E>'M!3P]9RV<%S)+;&5I(4<?ZH'^$'N
M,T <MYWQ,_Y]M._-?\:J>&FUEOB=,==2)+W^SSD18V[=RXZ5Z76.OA^)?%C:
M^)W\QK;[.8L#'4'.?PH V**** /,+?Q#X[U#6-0T^TBL1-9OAXW4*0"3@C)Y
M'O[CUJ_YWQ,_Y]M._-?\:Z>X\/12^)K;789W@N(XS%,JC(G3L&^GK[#TK9H
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M] K&T7P_%HM]JES'.\AU"X,[*P V$DG ]>IK9H **** "BBB@ HHHH ****
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M*W"[0#NQV- &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M><8RNX#(Z<^N*]6JAK>EIK6C76G22-$LZ;2ZC)'.?Z4 0^&?^14T?_KQA_\
M0!6K5;3K-=.TRTL5<NMM"D(8CDA5 S^E6: .0\?:YK.@6=G<Z6L/DO(8YWE7
M.TG&WZ#[W/TK-$_Q+90RP:<01D$%.?UKM]1T^WU73I[&Z3?#.A1A_4>XZBHM
M%TY])TBWL'NGN?(78LKJ 2N>!^ P/PH X[SOB9_S[:=^:_XTSX<&].O>*#J*
MJMYYT7G!,8#9DSC%>AUC:3X?BTG5M6OXYWD;49%D9&  3&[IZ_>- &S1110
M4444 %%%% !5"7_D,P?[A_K5^J$O_(9@_P!P_P!: )=._P"/&/\ '^9JU573
MO^/&/\?YFK5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5"7
M_D,P?[A_K5^J$O\ R&8/]P_UH ET[_CQC_'^9JU573O^/&/\?YFK5 !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !5"7_D,P?[A_K5^J$O_(9@
M_P!P_P!: )=._P"/&/\ '^9JU573O^/&/\?YFK5 !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !5"7_D,P?[A_K5^J$O\ R&8/]P_UH ET[_CQ
MC_'^9JU573O^/&/\?YFK5 !1110 4444 %%%% !1110 4444 %%%% !1110
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M)%]3^7<#GKF@#KZ*XO2_&E^FLV^D^(]).G3W/$$JME'/I_(<$\D59\6>,/\
MA%]0TZ.2!9+:X$C2L,EQMQ@+VR2>] '5T5R_AW7/$&IWY&I:";"RDB,D4A?+
M Y& P]>?0=*H7/BCQ9-=3KIGA5C!%(R"2X?:7 .,@''7VS0!V]%<MX5\7OKM
MY=Z;?6#6.I6HW/$6SN7H2,\C!(_,<U7U[QQ_8'B8:;+:&:)[821B($R/(6("
MCMSB@#L:*\]N?'7B'23'=ZQX9:#3W8#<DF77/K[^Q KK]0UZPTW06UB67=:>
M6)$*<F3=]T#W.: -.BO/QXR\63P?VA;^%&.GXW#<Y\QE]0.O_CIKJ=#\06OB
M#1!J5H"  0\;'E' Y!_3\"* ->BN?\&^()_$NA?;[B&.*3S6CVQYQ@8]?K3)
MO$4\?CRW\/B",P2VQF,F3N!^;CTQQ0!O/<P1S1PR31I+)]Q&<!F^@[U'J%]#
MIFGSWUQN\F!"[[1DX'M7EOB74/$1\=Z9(VDQ"X@DD%E'O&)UR>3SQQ]*[6#6
MM;B\*ZEJ.KZ9#:W5LCO'"&W*ZA<C.">^10!LZ3JEMK6EP:A:%_(F!*[UP>"0
M>/J#5VL+2-?CG\'PZY?!+>/R6DD" X4 D<?E7-Q>-_$NIQM>Z1X7:73P3M>1
M_F<#T]?PS0!Z#17.P>+8#X/?Q#<VLL"1@B2 \L'#;-O;^+CG%8*>,/%SVZWZ
M^$]]BZAU"R$N5/0^O_CM 'H%%(IW*#@C(S@]J6@ HHHH ***Y'6O&9L[R2UL
M8$=HFVO)+G&1G( &._?/KQWK&M7A1CS39M0H5*\N6".NHKSW_A.M4_YX6?\
MWPW_ ,51_P )UJG_ #PL_P#OAO\ XJN7^T\/Y_<=?]EXCLOO/0JQ?%O_ "+%
MY_P#_P!#6N7_ .$ZU3_GA9_]\-_\55;4?%E_J=A)9S16RQR8R45@>"#W/M6=
M;,*$Z<HK=IFM#+:\*L9.UDT8-%%%> ?0A73^!/\ D-S?]>S?^A+7,5?TG5I]
M'NFN+=(V=D*$2 D8R#V(]*WPTU3JQG+9&&)IRJ490CNSUJBO/?\ A.M4_P">
M%G_WPW_Q5'_"=:I_SPL_^^&_^*KW/[3P_G]QX']EXCLOO/0J*\]_X3K5/^>%
MG_WPW_Q520^/+\2J9K6V>/NJ;E)_$D_RIK,L/W_ 'E>([+[SOJANKF*RLY[J
M=ML4,;2.<=% R?T%-L;V'4;**[@),<@R-PP1V(/XU2\3?\BIK'_7C-_Z :[D
MU)71Y[3B[/<K^'_%VE>)6F2P>3S(0"R2IM.#W'J*O:SJ]KH6F2:A>;_(C(#;
M%R>3@<?C7D.E0S^']#T/Q=9J2L<CP7J+_$A<@'\N,GN%KNOB%<17GP\N+F!P
M\,ODNC#H074BF(ZZWG2ZM8;B//ERH'7(YP1D5+6/;W;V'@^WNX[>2Y>*R1EA
MC^\Y"#@5S,OBOQFD1N_^$3"VRC<RM(2^/IU_2@#OJ*Q_#/B"#Q+HT>H0QF([
MBDD1.=CCJ,]^H/XUS(\;Z]JTLTOAWP^+JQBD*>?*^"^/09']: .^HK&T_7&D
M\-'5M5M'T\QJ[30ODE I(] 3G'''>N6M_'7B/4D>^TSPNTVFJQ 8N=[@>GK^
M /I0!OZ;XBGO?&>JZ(\$:PV<:ND@)W-D+U_.NCKS;P5J4>L?$/7+^*.2-9;=
M3LD&&4C:"#^(-;6J^)/$B:K<6>D>&GGC@8+]HF?:K\ \=!^IH Z^BN.\/^,[
MN]UUM#UK2S87Y0O'ALJ^!DC\LG()Z&KWBSQ9'X:AMXX[9KN^NFVP6Z'KT&3P
M?48'>@#HZ*\_F\<Z]I-M)+KGAUK9&C8P31DL@?'RJ_)QD\=1]*ZSPYJDFM>'
M[/49HTCDG0LRIT')']* -2LO6O$6E>'XE?4;M8B_W(P"SM] .?QK3) !). .
M2:\R\%V$/B[7]3\2:H@N%2;R[:*095.XX]AC'U)ZT ;]I\3/#5U.(FN9;?)P
M&FB(7\QG'XUURL&4,I!4C((/!JC?Z)IFJ6IM[VQ@FB(X!0 K[@CD'W%5/$&O
MV/A31EN)U9@,10PH?F<XX'/;'4T ;5%>?OXO\81P&^?PGBS W%=Y\P+].O\
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MJ/\ SQM?^^6_^*H [BBN'_X3+4?^>-K_ -\M_P#%4?\ "9:C_P \;7_OEO\
MXJ@#N*X?_A(?^*H^V[O]%_U/3_EGGKTSU^;U[5#=>*M0NK66W9($612K%%.<
M'KU)K#H ]:HK@;7Q5J%K:Q6ZI ZQJ%4NIS@=.A%3?\)EJ/\ SQM?^^6_^*H
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MQ_\ XBO6Z*ZX8ZM"*BF82P].3N>2?\*NUO\ Y^M/_P"_C_\ Q%'_  J[6_\
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M 5W=8&E>'&TWQ-JNKFZ$BW^W$6S&S'OGF@";Q;_R*&K_ /7I)_Z":I^ $5/
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MK3"8P*5,@7;NY)Z?C5+3_#;6/B[4M<-T'6]C5!#LP4QM[YY^[Z4 <]X!9/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7##Z'WK0HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K)U?PSHVND-J-A'-(HVB0$JX'IN&#CVK6HH YNQ\!>&M/N%N(
M=,1I5.5,KLX'X$X_2M^ZMX[RTFMI@QBF0HX5BIP1@\CD5+10!2TO2K/1;!+&
MPA\JW0DA=Q)R3D\GFKM%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 50E_Y#,'^X?ZU?JA+_R&8/\
M</\ 6@"73O\ CQC_ !_F:M55T[_CQC_'^9JU0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_GK_ ..C_"C^T;K_ )Z_^.C_  HHH /[1NO^>O\ XZ/\*/[1NO\ GK_XZ/\
M"BB@ _M&Z_YZ_P#CH_PH_M&Z_P">O_CH_P *** #^T;K_GK_ ..C_"C^T;K_
M )Z_^.C_  HHH /[1NO^>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ_P#C
MH_PH_M&Z_P">O_CH_P *** #^T;K_GK_ ..C_"C^T;K_ )Z_^.C_  HHH /[
M1NO^>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z_P">O_CH
M_P *** #^T;K_GK_ ..C_"C^T;K_ )Z_^.C_  HHH /[1NO^>O\ XZ/\*/[1
MNO\ GK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z_P">O_CH_P *** #^T;K_GK_
M ..C_"C^T;K_ )Z_^.C_  HHH /[1NO^>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@
M _M&Z_YZ_P#CH_PH_M&Z_P">O_CH_P *** #^T;K_GK_ ..C_"C^T;K_ )Z_
M^.C_  HHH /[1NO^>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH
M_M&Z_P">O_CH_P *** #^T;K_GK_ ..C_"C^T;K_ )Z_^.C_  HHH /[1NO^
M>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z_P">O_CH_P *
M** #^T;K_GK_ ..C_"C^T;K_ )Z_^.C_  HHH /[1NO^>O\ XZ/\*/[1NO\
MGK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z_P">O_CH_P *** #^T;K_GK_ ..C
M_"C^T;K_ )Z_^.C_  HHH /[1NO^>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@ _M&
MZ_YZ_P#CH_PH_M&Z_P">O_CH_P *** #^T;K_GK_ ..C_"C^T;K_ )Z_^.C_
M  HHH /[1NO^>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z
M_P">O_CH_P *** #^T;K_GK_ ..C_"C^T;K_ )Z_^.C_  HHH /[1NO^>O\
MXZ/\*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z_P">O_CH_P *** #
M^T;K_GK_ ..C_"C^T;K_ )Z_^.C_  HHH /[1NO^>O\ XZ/\*/[1NO\ GK_X
MZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z_P">O_CH_P *** #^T;K_GK_ ..C_"C^
MT;K_ )Z_^.C_  HHH /[1NO^>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ
M_P#CH_PH_M&Z_P">O_CH_P *** #^T;K_GK_ ..C_"C^T;K_ )Z_^.C_  HH
MH /[1NO^>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z_P">
MO_CH_P *** #^T;K_GK_ ..C_"C^T;K_ )Z_^.C_  HHH /[1NO^>O\ XZ/\
M*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z_P">O_CH_P *** #^T;K
M_GK_ ..C_"C^T;K_ )Z_^.C_  HHH /[1NO^>O\ XZ/\*/[1NO\ GK_XZ/\
M"BB@ _M&Z_YZ_P#CH_PH_M&Z_P">O_CH_P *** #^T;K_GK_ ..C_"C^T;K_
M )Z_^.C_  HHH /[1NO^>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ_P#C
MH_PH_M&Z_P">O_CH_P *** #^T;K_GK_ ..C_"C^T;K_ )Z_^.C_  HHH /[
M1NO^>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z_P">O_CH
M_P *** #^T;K_GK_ ..C_"C^T;K_ )Z_^.C_  HHH /[1NO^>O\ XZ/\*/[1
MNO\ GK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z_P">O_CH_P *** #^T;K_GK_
M ..C_"C^T;K_ )Z_^.C_  HHH /[1NO^>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@
M _M&Z_YZ_P#CH_PH_M&Z_P">O_CH_P *** #^T;K_GK_ ..C_"C^T;K_ )Z_
M^.C_  HHH /[1NO^>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH
M_M&Z_P">O_CH_P *** #^T;K_GK_ ..C_"C^T;K_ )Z_^.C_  HHH /[1NO^
M>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z_P">O_CH_P *
M** #^T;K_GK_ ..C_"C^T;K_ )Z_^.C_  HHH /[1NO^>O\ XZ/\*/[1NO\
MGK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z_P">O_CH_P *** #^T;K_GK_ ..C
M_"C^T;K_ )Z_^.C_  HHH /[1NO^>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@ _M&
MZ_YZ_P#CH_PH_M&Z_P">O_CH_P *** #^T;K_GK_ ..C_"C^T;K_ )Z_^.C_
M  HHH /[1NO^>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z
M_P">O_CH_P *** #^T;K_GK_ ..C_"C^T;K_ )Z_^.C_  HHH /[1NO^>O\
MXZ/\*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z_P">O_CH_P *** #
M^T;K_GK_ ..C_"C^T;K_ )Z_^.C_  HHH /[1NO^>O\ XZ/\*/[1NO\ GK_X
MZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z_P">O_CH_P *** #^T;K_GK_ ..C_"C^
MT;K_ )Z_^.C_  HHH /[1NO^>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ
M_P#CH_PH_M&Z_P">O_CH_P *** #^T;K_GK_ ..C_"C^T;K_ )Z_^.C_  HH
MH /[1NO^>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z_P">
MO_CH_P *** #^T;K_GK_ ..C_"C^T;K_ )Z_^.C_  HHH /[1NO^>O\ XZ/\
M*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z_P">O_CH_P *** #^T;K
M_GK_ ..C_"C^T;K_ )Z_^.C_  HHH /[1NO^>O\ XZ/\*/[1NO\ GK_XZ/\
M"BB@ _M&Z_YZ_P#CH_PH_M&Z_P">O_CH_P *** #^T;K_GK_ ..C_"C^T;K_
M )Z_^.C_  HHH /[1NO^>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ_P#C
MH_PH_M&Z_P">O_CH_P *** #^T;K_GK_ ..C_"C^T;K_ )Z_^.C_  HHH /[
M1NO^>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z_P">O_CH
M_P *** #^T;K_GK_ ..C_"C^T;K_ )Z_^.C_  HHH /[1NO^>O\ XZ/\*/[1
MNO\ GK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z_P">O_CH_P *** #^T;K_GK_
M ..C_"C^T;K_ )Z_^.C_  HHH /[1NO^>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@
M _M&Z_YZ_P#CH_PH_M&Z_P">O_CH_P *** #^T;K_GK_ ..C_"C^T;K_ )Z_
M^.C_  HHH /[1NO^>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH
M_M&Z_P">O_CH_P *** #^T;K_GK_ ..C_"C^T;K_ )Z_^.C_  HHH /[1NO^
M>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z_P">O_CH_P *
M** #^T;K_GK_ ..C_"C^T;K_ )Z_^.C_  HHH /[1NO^>O\ XZ/\*/[1NO\
MGK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z_P">O_CH_P *** #^T;K_GK_ ..C
M_"C^T;K_ )Z_^.C_  HHH /[1NO^>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@ _M&
MZ_YZ_P#CH_PH_M&Z_P">O_CH_P *** #^T;K_GK_ ..C_"C^T;K_ )Z_^.C_
M  HHH /[1NO^>O\ XZ/\*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z
M_P">O_CH_P *** #^T;K_GK_ ..C_"C^T;K_ )Z_^.C_  HHH /[1NO^>O\
MXZ/\*/[1NO\ GK_XZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z_P">O_CH_P *** #
M^T;K_GK_ ..C_"C^T;K_ )Z_^.C_  HHH /[1NO^>O\ XZ/\*/[1NO\ GK_X
MZ/\ "BB@ _M&Z_YZ_P#CH_PH_M&Z_P">O_CH_P *** #^T;K_GK_ ..C_"GV
2DTD^HQ-(VY@",XQV-%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gk2ifd22ejwl000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gk2ifd22ejwl000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0X!X$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HJ
M&XN[>T56N)DB5C@%CC)J:G9VN 4444@"BBB@ HHHH **** "BBL\ZYI:ZHNF
M&_@%\PR(-_SD?2JC"4OA5P;L:%%%%2 444UW6)&=V"JHR2>U #J*HZ=K.FZN
MLAT^]AN1&=KF)L[3Z5>JI1E!\LE9A>X4445(!1110 4444 %%07=Y;6%L]Q=
MS)#"@RSN< 4VPU"SU2T2ZL;B.XMW^[)&<@U7)+EYK:!<LT445(!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%&<#)H **HVNM:;>WTUE;7L,M
MU",R1(V64>XJ]52A*+M)6 ****D HK.U37M)T79_:>H6]IYAPOFOC-7HY$FB
M62-@R,,JPZ$53A)14FM&*ZO8?1114C"BBB@ HHHH ***BN+B&UB,L\BQQCJS
M' II-NR EHI$=70.A!4C(([TM(!&^Z:KU8;[IJO5Q ****8@HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #-%)2\FF 44X(3
MUIXC'UI70$8!/:G!":E HJ>88T1@=J<***5P"EI*6D 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7->,?&%KX4T\,5\^^F^6WMAU<_X5O7MW%86,]W.P6.&-G8D]@,UXAX(EN?
M'_Q-GUV^/F6E@3Y"XX0Y^3]!7J9=@HU5/$5OX<%=^;Z+YD5)<D;]>AZ-X:\.
M74L@UKQ!,;G4)1NCC)^6 'L!_CGK78445PUZ\JT^:7W=%Y(<58*:[B-&=CA5
M&33JY'XCZ_\ V#X1N6C;%U<#R8!ZL?\ ZV:,/1E7JQI1W;L6O,\P'Q$8?&4W
M!E=K O\ 9%7=\IY(!_6O? 0P!!R#R#7R#XD\,WWA6;3Y9R0\\2S XQM?KC\*
M^E_A_KZ>(O!]E=JQ9T0129Z[EX/\J^GXAP-*%"EB,/K%+EOZ;?J<L)MU'?KK
M_7R.HHHHKY(Z0HHHH X#Q_I?BJ\L+RXT[68[.UAB9O*C!W. "3G(]/2O&_A-
M--/\1[5YY'=RK9+')ZBOI37?^1?U+_KUE_\ 0#7S5\)?^2D6WT;^8K[/):SJ
M9;B(M+W5T7D_O,,2O=3\SZDHHHKXPW&2^9Y3>3L\S'R[\XS[XKP/XN6/BK3+
M6"[O];,]K/(4$,7RA#@GT!Q7O]>4_'K_ )%"S_Z^O_937M\/UG#'0A9.[ZK^
MK US1:*WP$).A7I)R?-/]*]?KQ_X!_\ (!O?^NI_I7L%1G__ ",:OJ88;^']
MX4445XYN%%%% !534H[V6PDCT^2**Y885Y<X7WXJW13B^5I@?,'Q3M/$6DZS
M%!J^L/>K,A="IP ,XQT%>T?";_DGNG_[O]!7G/[07_(9TG_KW/\ Z$:]&^$W
M_)/=/_W?Z"OL,SJNKDE&;23;Z*W<YY*U=>AV]%%%?''0%%%% !1110 4444
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M.]B%4_Q=*=X\\:^)M#MKB32]"D^RQ#YKN4?=]\8P16O\+[J:[\!6$D[$LH*
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MB/UIX4#M2T9%3=@%%'%+0 4444@"BBB@ HHHH **** "BBB@ HHHS0 4444
M%%%% !1110 4444 %%%% !111F@ HHHH **** "BBC- !1110 4449H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BDR/6EH **** "BBC- !11FB@
MHHHH **** "BC(HH **** "BBB@ HHHH **,BB@ HHHH **,T4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 449HH **** "BBB@ HHHS0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111F@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]XR3V.(>2) , #^M76<Z,:DE223Z\VXE9VU,KXD?ZVTS_=KJO"$,<?AJS95
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M%V[R<<^N*6*PM6O2I>SZ+^F$9)-W,[0Q]F\<>7"2%\T@@>F:7Q0W_%9ID?\
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M(X)8XS&,DN#6]_PK34?^?VV_)JYO2==O=$EDDLS&&<8.]<UL?\+"UW^];_\
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MJ:.&.%=L4:HH[*,5)QFE[4W*35FP*\UE;7)!G@BE(Z;T!_G4B1)'&$C540#
M51@"G]J,TN9VM<"N^GVDLHEDMH7D'\3("?SJ?8NW;@8]*=10Y-[L"M%8VD#^
M9%;0QN?XE0 U++!#<)Y<T:2+_==013Z.U/F;=[@10VT%LI6"&.)3R0B@?RJ7
MMUH%&*3;;U @ELK6XYFMXI,?WT!IL6GVD#;H;:%#ZJ@%6<4M/GE:UP&X["H)
M=/M)GWRVL,C>K(":LT4E)K8"NUG:O'Y36\3(/X"@Q^5.CMXH8_+BB2-/[JJ
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MYD\BQH.['%87_"<Z+YWE>?)D'&=AQ^=<EXFN9];\2)IT3GRPP11GC)[UT2^
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MDW>0E*35SLI]:L+>S%U)<((CT.X<U0L_&6C7UP((IR')P-Z[1^9KA?!^A?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX77=0Z]"6)G-5'&^S6P6=K6.6U_2H=!O(Q97OF[N<AN1^5>K:!-//HMM)/\
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M-G'#$9Q6=X5\./X>@GC><3&1@V0N,<5Q0KTU@ITV_>;*:?-<X3Q2JQ^,E8\
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MO 5GI\ZW%PYFE0Y7C _*BMCJ;3G&L]=E8%%]AOCZ,)H$: YVG%+X"_Y%EO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %:BBBM!!24M%,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH YS^U+GU3_OFD_M*Y/=/^^:J8YIP/->K[.'8BY:&HW([I_P!\TO\
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M7WH.<[?^TKGU3_OFC^T;CU3_ +YKB/[<\0?\^.G_ /@0W^%']N>(/^?'3_\
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M_P"1PT[_ *X3?R%=J/O5PX[XH^GZLJ(8HHHKB*"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*[4?>KBM-_Y'#3O^N$W\A7:C[U<..^*/I^K*B%%%%<0PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** +U%%%<Y1E-TH["ANE'85UDG+:U_P C5'_UX?\
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MU<5IO_(X:=_UPF_D*[4?>KBQWQ1]/U940HHHKB&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHVCVTV=K=UZBLT:Q))KMK;1,GV:>#S.G.>._XU8_MZP%QY6^3;NV^;L^3/\
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MU-O"S,NXMENN2<U;I:*F4G)W>X!VIT?WU^M-[4Z/[Z_6I>PS7\'_ /(KVO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<W;\*[,).'LN5R2=^OR)EN)FC-/_ +&\1_\ /#3?^_S?X4?V-XC_ .>&F_\
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M?_/#3?\ O\W^%'-#^9?>&HS-&:?_ &-XC_YX:;_W^;_"C^QO$?\ SPTW_O\
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M1-%%%9C"BBB@04444 %%%% !1110,**/PH]N* "BC\** "BCM1^% !111[T
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MV2B=20?<8[UIZ98?V?9+"6W/G<S=B:N4M*=><X\K!)"4445D,****!!1110
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M7-6BJ^GW@U"PCNO*:/>#\C')!!Q5@UG).+:8Q:2C-%( HHHH$%%%% !1110
M4444 %'XT44#%I&..U'>L;3SXAU?[0UO<:;$(I-C))&Y9?3.#Z5<873DVDEW
M%<V03Z4I.*IC2/%0_P"7O2,?]<9/\:KZ7>WTMS>6]ZUO(86 $ENI )YR.?2G
MR)IN,D[!<TZ*,T5F,**2EH$%%%% !1110 4444 %'>BB@8$4G I:,#O0 NZD
MR3[5DR>)=+BF>%I)F>,E6V0.P!^H%-_X2C2O[UU_X"R?_$UK]7J_R/[A71L]
M>11BJ%AK-CJ4CQVKN70!F5XV0@?B*O;C6<H2B[25F/06D[4M)2 **2EH ***
M* "BBB@04444 %%%% !1110 4444 %%%% !1110,****!!1110,****!!111
M0 4444#"BBB@044=** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@"]1117.44:***Z"0HHHH **** "BBB@ HHHH **** "BBB@
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M,.9&YWH8U6L-1M-3MS/93I-&#@LO0'TJ8\M63BXNTM&,?VI*#P**D HHHIB
M'%(?FI<9I?E7[S!?J:!B+Q2TQGB_Y[)_WU2^8G]]/^^A18!U%-\Q?[Z?]]"C
MS%_OI_WT*+,!U%-\Q?[Z?]]"CS%_OI_WT*+,!U%-\Q?[Z?\ ?0H\Q?[Z?]]"
MBS =13?,7^^G_?0H\Q?[Z?\ ?0HLP'44WS%_OI_WT*/,7^^G_?0HLP'44WS%
M_OI_WT*/,7^^G_?0HLP'44WS%_OI_P!]"CS$_OI_WT*+,!<T9S0C))]U@Q'4
M ]*3H: '=*2@T4 %%%% @%9&DZ1I=QXBU"UOM/MIV8":-Y8PS'.<CGTK7!R:
MS+R06&NZ=J!'R[_(?'??@"M:3E:48NS:_'<&;Q\)^']O_(&L?^_*US6E6=I'
MKNIS65K%;PQOY"K$H4-C!SQ]:[+5;Y-.TFYO'Y6*,L:Y?1+=K;281)S(PW2'
MN236>'J5'2E*4F[Z;_-_UYC:5S1%!I!UH-( HHHH$%%%% !1110 4444 %%%
M% !1110 'KCUJGIY^Q>,E?HM_#L/L4!/]:MG[PK-US=##:WD?WX)T)/HA(W?
MI6E-<S</YE;_ "_&P/N=3K-\--T>ZO2,^3&6KG-$M_LND01'[V"Q/J22:L^*
MKE;JQL;.-LB\E3</^F9!R?Y4\#:H4=A@5E2CR4+=6_RT_P QO<7-%)2BF 44
M44""BBB@ HHHH **** "BBB@ HHHH ,<T'J*=3<<T#*FGS&Q\8&$<1WT.\G_
M &DP!_,UU5U*(+664G[B%OTKC-:<6T=MJ0X^QSK(Y_V!U%:OBJ^_XD4<,38E
MO2J1X_!C^@-*K1]K.FUUT?R_X )V3,K029M.-\XQ)>2&X/MNQQ6KGC-,CB2&
M-88QA$& !2_PUI4DI2;0D+1114 %%%% !1110 4444 %%%% !1110 4444 %
M,FC$L$B,.&4C%/I>V/SH3MJ,D\'3L^A+;.<R6C&!B>Y&/\:?XON#!X?FC0XE
MN2((SZ,W2LW0Y39^*;NU)Q%<1B2,>K\[OT H\12M=^(K"R!S%$IFD'HPQM_F
M:?LKXOFZ?%^OYA?W22TB%O:11 ?=4#'OWJ:CWHI-W=P"BBB@04444 %%%% !
M1110 4444 %%%% !571&^P^*;JWZ1WD?G?\  AA<?E5JLO5W-I-8ZD.%M9@T
MA]5P1C\R*NFN>\.Z_P"&_$/,[&^N!:6$]P2/W<;,/J!7'Z%"4T\3,/FN7:<_
M\".?ZUI^,9R^EP6<38DNI5"X[@$%OTIL:+'&J*,*HV@5G0CR4+_S/\AO<=11
M13 ****!!1110 4444 %%%% !1110 O>D;K12CUH&5?#\GV+Q)>V1.$G42Q+
M[C.[^8KK6("DGH!DUQ&HN;/5=-U%?X)1"Q_V7(S_ "KH]?OQ8:%=7:'+!/E'
MKFHQ--U)P:^UI\]O\@B[(YVP?[=J.H:@3D/*8XF]8QR/US6DO3%5-)M19:9!
M;?W$YJT>M;U6G-I;(2%HHHK, I 32TNX8H&(3SQ2\DX--]S3MV1[T )1110(
M*,+FBC S0,QM=O+R&ZTZSL)HX9+N1D,CQ[P %STJ!;+Q&!D:U;?^ >?_ &:G
M:X!_;^@<_P#+>3_T6:V<<5U\_LZ<+):KJD^K[DVNS$^R>)/^@U;?^ ?_ -E1
M]C\2?]!JV_\  /\ ^RK;I<U/UB79?^ K_(+&&;3Q)_T&K;_P#_\ LJSGU6ZC
M=D?Q?I2N#@AH5!S_ -]5UAZ&O#;.?PY#J>IC6]/N+J0W#>68L_*,GW%>C@*7
MUE2;6UMHQOKZDR?*>G6DFL:@&:S\2V$Z@\F.V#8_)JL_8_$G_0;MO_ /_P"R
MK(T*_P##VD>&KC5=.M)K6V!^99"=Q/'J?I5!?B#JL82\O-":+2G/%P"<X/2D
M\/6G.2I15EIJHIW[>OH%UU-^1M:@GCMY?$=BDLOW$:U +?0;J6-M9FG>VC\1
M63S1_?C6U!9?J-U<_P"(KF.\\9^%[F$Y23YE/XT[0I4@^(7B*:0X1(PQ/L,5
M7L'[+GTORWMRK^:UMA7UL=)]C\18_P"0U;?^ ?\ ]E2FS\1_]!JV_P# /_[*
MN9D\?ZI.\MQIFAM<:;$?FG).<#J:T+CQPHLM/OK:!9+2XD\N9F)!C//^%9O"
MXI6O&.OE'[GV8^:)K?8_$>?^0U;?^ ?_ -E0;/Q'G_D-6W_@'_\ 95ES^-5A
M\6P:,(HVAD7YI=QRIP3BM#1]?FU76-1M!;JMO:-M$H)RQR?\*RG2Q$(\\HJU
MK[1VV[#NA_V/Q)G_ )#=M_X!_P#V5'V/Q)_T&K;_ , __LJ@UGQ'+I?B'2]-
M2!'2\.&=B<KSVI=0\1S6?BRPT98$:.Y0LTA8Y7K_ (4E"NTFHK5-[1V6_0-"
M86?B3_H-6W_@'_\ 94?9/$G_ $&K;_P#_P#LJYV;QWJS:MJ&GV&BB[EMI-J[
M&/(!.2:V_"OB@>(8)EF@^SW<#;9(L]#6E6AB:4/:2C&VG2/42:;L3_9/$G_0
M:MO_  #_ /LJ/LGB3_H-6W_@'_\ 95MTM<?MY=E_X"O\BK&)]D\1_P#0:MO_
M  #_ /LJBGM_$4,,DQUFV/EJ6Q]CZX&?6M^H+[_D'W/_ %R;^1IQKR;2LO\
MP%?Y!8;H]Z^H:+97<P'F30J[8'&2*O5E>%]H\+:7S_R[)_*M6L:R2J22[L:V
M"BBBLP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +U%%%<
MY11HHHKH)"BBB@ HHHH *,$TA7FLKQ)<S6OAO49X7*2QP,RL#R#CK54X.<E%
M=0>AK8-&*\^2T9T1SJ.H[BH)Q=-SD4[["W_02U+_ ,"FKN^HQ_G_  )YCO\
M!I<'TKS[[$W_ $$M2_\  IJ!9/\ ]!+4O_ IJ/J,?Y_P#F/0=I]*,'TKS\V;
MG_F):E_X%-2?8G'_ #$M2_\  IJ7U&/\_P" <QZ#@^E)@UY^+-_^@EJ7_@4U
M+]B;_H):E_X%-3^HQ_G_  #F/0-IHP17GXLF!_Y"6I?^!34&R8G_ )"6I?\
M@4U+ZE'^?\/^"',>@<^E(<^E>?\ V-P/^0EJ7_@4U'V)_P#H):E_X%-3^HQ_
MG_ .8]!"G&:,&O/S9N1QJ6I?^!34GV)Q_P Q+4?_  *:E]1C_/\ @',>@X/I
M1@^E>??8GS_R$M2_\"FI?L3Y_P"0EJ7_ (%-1]1C_/\ @',>@8/I1@^E>?&Q
M<G_D):E_X%-6SX6EF34-2M7N)YHHA$4\Z0N1D'/)J*F#4(.2E>WE\AJ6IT]%
M  +&C!KC*"BC!HP: "BC!HP: "BC!I-Q7K0 M'>DW[NE."CO0!Q6J,?^$UN^
MA_T*/J/]IJ,@C[BX^E+J2_\ %97?_7G'_P"A-3<\U[2^&/HOR,PR!_ OY4<?
MW5_*E/--H 7C^ZOY4N/]A?RI.:X[Q=<7"ZS86\5^]I%*IW.'P!SU-;4*+K3Y
M$[";LCLL?["_E2<?W5_*N O?M&F+%/:^)#?2;P/)#9SS]:ZRZUJUTRQAFU!_
M*=U!**,G/TK6IA91MR/FOY/\F)2-/C^ZOY4<?W5_*LS3=?T[5@_V68Y3DAQM
M-5#XPT9+@P&=]V[;NV?+^=9K#U6W%1=T.Z-[C^ZOY4<?W5_*J=YJME8V@NII
M@(FY4CDGZ57TSQ#INKRF.UF.\?PN-I/TJ%1J.+FD[(+HU< \[%_*@XP/E7\J
MY;3[N9_$.NPRW,@BB0[1DD)UY J?3-6M;#P[]MGO9[F$2%?,=#NSGTS6LL+*
M.VNWXJXN8Z' _N+^5'']U?RK$3Q9I#7:6ZW!+/C#8X_.KFI:Q8Z3&'NY=N[H
M%&3^50Z%5-1<7=CNB_Q_=7\J./[J_E6?IFM6.K*S6DN['56&&_*I-6DN(=*N
M9;4$S*F4XS4^SDI\DM&%]+EW'^ROY4G']U?RKSJPO=026QGAU62ZGF?#VQR=
M@[YYKT4UKB,.Z#2;O<2=PX_NK^5'']U?RH/%%<Q0<?W5_*E&,_=7\J2E'6@#
M1\'?ZO5N!_Q^M_Z"M=&H^:N;\(=-5_Z_6_\ 05KI#UKSL9_&E\OR*CL#T4M)
MC#9KF*#!HHW\T'YFH  U<?XLB2ZUS2X)U\R)HYB4)X)&,5V#+S7*>)%_XJ+2
MO^N4W\EKKP+M6NNS_)DRV,8Z)IF[_CT3\S_C2_V/IO\ SYI^9_QJ]WHKT_:U
M/YG]Y%D4?['TW_GS3\S_ (T?V/IO_/FGYG_&KU%'M9_S/[PLBC_8^F_\^:?F
M?\:/[&TW_GS3\S_C6=XJU6]TJVM6LB@DFDV'>N16?-J'BRPA^U7<-K+;J,LL
M>-V*ZJ=&M."DIVOM=DMI'0_V/IO_ #YI^9_QH_L?3?\ GS3\S_C3["_BO=.C
MNT.U&7)S_#ZT^"_LKA]D-U#(XZJC@FN=RK)M-O3U*T(?['TW_GS3\S_C1_8^
MF_\ /FGYG_&IY[RUM"/M%Q%$3T#L!FI(IHKB,20RI(I_B4Y%+GJVO=V^8614
M_L?3?^?-/S/^-']C:;_SYI^9_P :E74+$S>0+R#S>FT.,YJR30YU5NW^(611
M_L?3?^?-/S/^-']CZ;_SYI^9_P :NYXI:7M:G\S^\+(H_P!CZ;_SYI^9_P :
M/['TW_GS3\S_ (U>HH]K/^9_>%D.\*P0VOBBZAMT$<1LU8J"<$[SS79/U_K7
M(^'2!XKNO^O%?_0S78<%2:\W'-^VN^R_(N.P+R*2C.%S17&4%%%%  HQ5'68
M#/I<X3_6(OF1_P"\.1^M7C2\$<C-.,G&2D!FZOJ(U+0M*M$;<UVRI,/]D##?
MK6AMVJ%'0"N:T;3;J'79O/0BVM0RPDC@[SN)_ UTU;5HQIVA!Z;_ '_\"PEK
MJ H-%%8#"B@X[4 $T %%!4BDR<T +11GUHXSS0 44I /2@#CF@!**% !YI0!
MM.: $HH7KQ1GYLT "CUJ"_@^U6,]O_STC91]2*G9B#Q0-QYIIM.X'-:1>G6-
M2MWP0NFPM;-G^]D8/Z5TW6JMG8VUDTYMX]IF;<_/4U9VFM*\XSE[NB_K]1)!
MBBC#4?6LAA12$G-+G% !102-M&: "BBC- !1032D'% "44*<GFEY% "449HQ
MF@ !XI?X:3:?PI#F@""YM5O;::VD^Y*A0CV-8=G>MJ]UI]O(<MI\9>3V?<5
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M:SQ6-KG_ "'O#_\ UWD_]%FMJNFI_#I^GZLE;L2BEI*P&!Z5PW@"U=+G6C/
MR[KHE2Z8R.>F:[JDSQ[5O3KN%*=-+XK?@)J[N8'B[29M3\.W%M:*OF\,J@8S
M@@UQ-UKNI:OH,?AN/1;A+H!4:1E^3CK7JWM2?T]ZZ,/C52@HRCS6=UY/]1.-
MSSC4-+FL?$/A6 1R.L*XD8*2%/UJ73[">X\9>)4,;HLT6U'*D _C7H5+5?VC
M+EM;6UOQO<.0\IL-;U'PYI,WAV;1KB6<[ECDC7*G/ )K13PQ=0_#JY@FC_TQ
MB9U0<X.3@?K7HE+53S)MWA"SNF_-K\A*!XU'I6H7'A:XUF2&0W\=QN *'=C
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M_BEM+_Z]D_E6M65X7_Y%;2_^O9/Y5JT\1_%EZO\ ,%L%%%%9 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 7J***YRBC111702%%%% !11
M10 =ZQO%W_(I:I_U[M_*MGH:Q_%O_(I:I_U[M_*ML-_&AZK\P>Q@1G]Q'_US
M7^5*![TD?^HB_P!Q?Y4[./I7JL@Y:\\47IOIH-+TW[4D!Q(Q.,&MG1]575K/
MS5C:-U.UT8=#6!?Z+>VM_)J&@W(8D[I8E8?CFC_A)KBZ\,WDHB$-S$WEDH.
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M^$F\2?\ /6X_[X/^%'_"3>)/^>MQ_P!\'_"C^QZW\R#VB/6<'WH<CIBO)O\
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MOU!YI+FP^RO;^?<HJ3KO#;3\M)4J#V7YCNR]_P )+,5_X](?^^C1_P ))/\
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M./\ ESA_[[-8V..:O0:;YNEG4)KN.&'?LY0GGGT^E*5&C%:K\PNRY_PDL_\
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MC@U->:9;V-P;>YU2%94'(\IC6?LJ%^6VOHQW9:_X22;/%G#_ -]FC_A))_\
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MBM'O]WY(0O:BCH**0!1110 4444 '-%%% !1110 A/-#'Y3BE/K2<^E &W<
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MW('2NBDFN9>8F(5^=/\ >'\ZZ+7M3B@U=8Q9P2* /,9T#,?8>E<Z1N9"3C#
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M3]U_<QI(S[GP[I]YH<>CRK(;.,*% ?YOEZ<TNH^'--U33H[&ZA+Q1*%0Y^8
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M3CSHFK$_\>G_ (^*4Z)JW:TX_P!\5U^YO4T;F]35?7:G9?U\PY4<A_8NK?\
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MM+_X$/\ XUOK0:VCB:T5RQDTO5A9&!_PAFA?\^TO_?\ ?_&C_A"]#_Y]I?\
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M$^E'6L*E2527-/<:5M@SS12X%)4#"BBB@04444 %%%% !1110 4444 %%%%
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M$<^)+G_OQ'_A3(_#E_"I6'7YHP3DA+:,9/Y5T2XP:48H^M5/+[E_D/E1S_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@"]1117.44:***Z"0HHHH **** "BBB@ HHHH ***,B@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH&%
M%%!XZT""BBB@84444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **,&@\=:!A1110(**** "BBB@ HHHH **** "BBB@ H
MHHH ***.M PHHHH$%%%% !1110 4444#"BBB@ HHHH **** "BBB@ HHHH$%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444#"BBB@ HHHH **
M** "BBB@ HHHH ****!!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% PQ1BC\:/QH ,4OK2?C1^- !BEHQ10 E'X
MTF:7K0 ?RHHZ44 %%%% @HHHH **** "BBC% PHHHH$%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444#"BC%% !1110(**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH O4445SE%&BBBN@D**** "BBB@ HHH
MH *AN;NULHQ)=7$<*$\-(VT&IJ9)"DJ[98U=?1E!IQM?78"E_P )!HA_YBEI
M_P!_12?V[HG_ $%+3_OZ*M?8[4?\NL'_ '[%+]DM/^?6#_OV*U_<]G]Z_P @
MU*G_  D&B_\ 04M/^_HH_P"$@T7_ *"EI_W]%6_L=I_SZP?]^Q1]CM/^?6#_
M +]BB]'L_O7^0:E3_A(-%_Z"EI_W]%'_  D&B_\ 04M/^_HJW]CM/^?6#_OV
M*/L=I_SZP?\ ?L47H]G]Z_R#4J?\)!HO_04M/^_HH_X2#1?^@I:?]_15O[':
M?\^L'_?L4?8[3_GU@_[]BB]'L_O7^0:E3_A(-%_Z"EI_W]%'_"0:+_T%+3_O
MZ*M_8[3_ )]8/^_8H^QVG_/K!_W[%*]'L_O7^0:E3_A(-%_Z"EI_W]%'_"0:
M+_T%+3_OZ*M_8[3_ )]8/^_8H^QV?_/K!_W[%.]'L_O7^0:E3_A(-%_Z"EI_
MW]%177B+25M)3#J=J9 IVXD!YK0^QVF/^/6#K_SS%17=A;R6DR1VL =EP/W8
MIQ=&ZT?WK_(-3CM(^("G;%JD8!_YZIW_  KM+2^MKZ 36TRRQGNIZ5R.D?#^
M"/$NIRB1O^>:]*[.WM8+2%88(UCC7H%%=&.>%YOW&_X$QYNH_&>E%!/I17 6
M%%%% @HHHH **** "BBB@ +4QY(XHVEE=411DECP*?MH(4C#*"#P010K#.-U
MCQ_:VV8=.3SI!P7/0?XU;T'Q-:W&F++J6H6\=P6Y5G"X_"G:OX)TW42TEN#;
M3]<IT-6]!T1-,TP6MU%!)(K'Y]@.?SKTYRP7L$H)\WXD+FOJ6O\ A(=% _Y"
MEK_W]%(?$6BG_F*6O_?T5;-G:8S]E@_[]BE%E:8_X]8/^_8KBO1[/[U_D5J4
MO^$@TH=+R,_B*/[?TO\ Y^X_S%7OLUN.EO%_WP*/LUO_ ,^\7_? I7H]G]__
M   U*/\ ;^E_\_<?YBC^W]+_ .?N/\Q5[[-;_P#/O%_WP*/LUO\ \^\7_? H
MO2[/[_\ @!J4?[?TO_G[C_,4?V_I?_/VGYBKWV:W_P">$7_? H^S6_\ SPB_
M[X%%Z79_?_P U,__ (2'3Q_%(??91_PD.G^LG_?%:7E0_P#/*/\ [Y%'EP_\
M\D_[Y%'-2_E?W_\  #4S?^$AT_UE_P"^:/\ A(=/_O2_]\UI>7#_ ,\D_P"^
M11Y4/_/)/^^11S4OY7]__ #4S?\ A(=/]9?^^:/^$@T_UE_[YK2\N'_GDG_?
M(H\N+_GDG_?(HYJ7\K^__@!J9G]OVO00W1]Q"31_;]M_S[WG_?DUJ[4'\"_E
M1A?[B_E1S4OY?Q"S,K^W[;_GWN_^_)I6\06P_P"7>\_[\&M3:O\ =7\J01CG
M*@\^E'-2_E_'_@!J>>^(?$=W;:Y'-9/-&NP9CE7 /X5N:!XM.KN();5UE_O(
MNY?Q]*LZKX7M]6U9+NX9O*50/+7HWUK6MK*ULHA';1+&H]!7;5KX:5",5'WK
M?=_F2E*Y8HHHKS2@HHHH ****!@7VGBLO6M:32+3SW@EESTVKP/J>U:PP>M-
MD6-UVNJNI[$9JJ;BI)R5T#/+)?%^HZCJ<&6:.W#_ .KBZD?UKO!K\6!_Q+M3
MZ?\ /J:J7/@_3YKV.\M@8)$;<0O1JZ0-@ >E=^+KX::C[..WR(BFMS&_X2"+
M_H&ZG_X"FC_A((O^@;J?_@*:V=_O1O\ >N/GI_R_B5J8_P#PD$7_ $#=4_\
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M]]52_P"$?TO_ )]V_P"_C?XT?\(_I?\ S[M_W\;_ !HM1[O[E_F&I=^TP_\
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MC1_8^G?\^P_[Z-%J/G^ :D_V^R_Y^HO^^A1]OLO^?J+_ +Z%0?V/IW_/L/\
MOHT?V/IW_/L/^^C1:CY_@&I/]OLO^?J+_OH4?;[+_GZB_P"^A4']CZ=_S[#_
M +Z-']CZ=_S[#_OHT6H^?X!J3_;[+_GZB_[Z%'V^S_Y^HO\ OH5!_8^G?\^P
M_P"^C1_8^G?\^P_[Z-%J/G^ :D_V^S_Y^HO^^A1]OL_^?J+_ +Z%0?V/IW_/
ML/\ OHT?V/IW_/L/^^C1:CY_@&I/]OL_^?J+_OH4QM4T]6VM?6X([;P#4?\
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M/]9?^^:TO*A_YY)_WR*/+A_YY)_WR*.:E_*_O_X :F;_ ,)#I_K+_P!\T?\
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M]W_WY-:N%_N+^5&%_N+^5'-2_E_'_@!9F5_;]M_S[W?_ 'Y-']OVW_/O=_\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% %ZBBBN<HHT445T$A1110
M4444 %%%% !1FBB@84O%)2'K0 N**/ZT4 &*,444 &*,444 &*,4?YQFB@ Q
M1BBB@!,4H'YT44 !!'0T ^O-%% #BH/2FT44@"BBBF(**** "BBB@ HHHH 7
M---+10, O;K2,,L/04M% "L!BD'2BB@ P?6C!]:** #!]:,'UHHH ,'UHP?6
MBB@ Q1BBB@ Q1BBB@ Q1BBB@ P?6C!]:** #!]:"V?:BB@! #]*7 HHH ***
M*!!1110 4444 !'O2 #N*6B@88]**** #%&*** #%&*** #%&*** #%&***
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MH9>A&12U%:_\>L/^X/Y5+7F-6=B@HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M7J***YRBC11170(**** "BBB@ HHHH **** "D;[I^E+10!S7A^:.T@U:25G
M^2[D9^,G&!VJKJ7]FW5[8:AI;1&_>>,,8V&\Q]PPZ@=*VX=-DM];GN$V&UN$
M&]2>0W.3[YXJU!I6GVT_G064$<QS\Z1@$YZUW.O",W45[M?ILR+.UCE[>[BT
MJ_UZ.\D$33GS(\G&\;0O'KS6QX4MY+;PU9)(I5_+!(/45I7&G65W(KW-K#*Z
M<*TD88C\ZL 8&!P.U9UL1&<.5+5VO\E8:5F<G!):VWB/5?[19 TBIY9?C>N#
MP,]>U8UE=PP>'=/C6&$R2W#B"6=?DB.6Y/X?SKO9["TN762XMH973[K2("5^
MF:1].LI+<0/:0-".1&4!7/TK:.,@EJGT_!-"Y6<3I$<M]XJU**ZN+6X:2T"&
M2WC*H?O>YS5BR>2^EL]$ESFUE+/Z;4.%!^HKK!90VD;-96<"RJN$"J%'L,BL
M_1--NH;B[O[Z*..\N",QQMN"@<#FKEBHR4I[62MZ[;!RF'J)6UU&_DT^^M8F
M;'VB"]C)W' ^YR.,8]:M7EPD_@:WE^S_ &</Y>V(C&PEA@5T=QIMC=RB2YLX
M)G485I(P2/SJIJNFR:BUK!M5;5'WOSR<<KQ]141Q,)."?2SOZ?F%F7K/(LH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!?SHI** %I*** "BBB@ -**2B@!3TZ]*3_
M #BBB@ _G0?Y444 %%%% !1110 4?YS110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW%9F=2YK0_LA_P#GJOY4G]D2?\]5_*CVL.X690HJ_P#V1)_SU7_OFC^R)/\
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M]\T>UAW"S,^BM#^R)/\ GJO_ 'S1_9$G_/5?^^:/:P[A9F?16A_9$G_/5?\
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MLS/HK0_LB3_GJO\ WS1_9$G_ #U7_OFCVL.X69GT5H?V1)_SU7_OFC^R)/\
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M^BM#^R)/^>J_]\T?V1)_SU7_ +YH]K#N%F9]%:']D2?\]5_[YH_LB3_GJO\
MWS1[6'<+,SZ*T/[(D_YZK_WS1_9$G_/5?^^:/:P[A9F?16A_9$G_ #U7_OFC
M^R)/^>J_]\T>UAW"S,^BM#^R)/\ GJO_ 'S1_9$G_/5?^^:/:P[A9F?16A_9
M$G_/5?\ OFC^R)/^>J_]\T>UAW"S,^BM#^R)/^>J_P#?-']D2?\ /5?^^:/:
MP[A9F?16A_9$G_/5?^^:/[(D_P">J_\ ?-'M8=PLS/HK0_LB3_GJO_?-']D2
M?\]5_P"^:/:P[A9F?16A_9$G_/5?^^:/[(D_YZK_ -\T>UAW"S,^BM#^R)/^
M>J_]\T?V1)_SU7_OFCVL.X69GT5H?V1)_P ]5_[YH_LB3_GJO_?-'M8=PLS/
MHK0_LB3_ )ZK_P!\T?V1)_SU7_OFCVL.X69GT5H?V1)_SU7_ +YH_LB3_GJO
M_?-'M8=PLS/HK0_LB3_GJO\ WS1_9$G_ #U7_OFCVL.X69GT5H?V1)_SU7_O
MFC^R)/\ GJO_ 'S1[6'<+,SZ*T/[(D_YZK_WS1_9$G_/5?\ OFCVL.X69GT5
MH?V1)_SU7_OFC^R)/^>J_P#?-'M8=PLS/HK0_LB3_GJO_?-']D2?\]5_[YH]
MK#N%F9]%:']D2?\ /5?^^:/[(D_YZK_WS1[6'<+,SZ*T/[(D_P">J_\ ?-']
MD2?\]5_[YH]K#N%F9]%:']D2?\]5_P"^:/[(D_YZK_WS1[6'<+,SZ*T/[(D_
MYZK_ -\T?V1)_P ]5_[YH]K#N%F9]%:']D2?\]5_[YH_LB3_ )ZK_P!\T>UA
MW"S,^BM#^R)/^>J_]\T?V1)_SU7_ +YH]K#N%F9]%:']D2?\]5_[YH_LB3_G
MJO\ WS1[6'<+,SZ*T/[(D_YZK_WS1_9$G_/5?^^:/:P[A9F?16A_9$G_ #U7
M_OFC^R)/^>J_]\T>UAW"S,^BM#^R)/\ GJO_ 'S1_9$G_/5?^^:/:P[A9F?1
M6A_9$G_/5?\ OFC^R)/^>J_]\T>UAW"S,^BM#^R)/^>J_P#?-']D2?\ /5?^
M^:/:P[A9F?16A_9$G_/5?^^:/[(D_P">J_\ ?-'M8=PLS/HK0_LB3_GJO_?-
M']D2?\]5_P"^:/:P[A9F?16A_9$G_/5?^^:/[(D_YZK_ -\T>UAW"S,^BM#^
MR)/^>J_]\T?V1)_SU7_OFCVL.X69GT5H?V1)_P ]5_[YH_LB3_GJO_?-'M8=
MPLS/HK0_LB3_ )ZK_P!\T?V1)_SU7_OFCVL.X69GT5H?V1)_SU7_ +YH_LB3
M_GJO_?-'M8=PLS/HK0_LB3_GJO\ WS1_9$G_ #U7_OFCVL.X69GT5H?V1)_S
MU7_OFC^R)/\ GJO_ 'S1[6'<+,SZ*T/[(D_YZK_WS1_9$G_/5?\ OFCVL.X6
M9GT5H?V1)_SU7_OFC^R)/^>J_P#?-'M8=PLS/HK0_LB3_GJO_?-']D2?\]5_
M[YH]K#N%F9]%:']D2?\ /5?^^:/[(D_YZK_WS1[6'<+,SZ*T/[(D_P">J_E1
M_9$G_/5?RH]K#N%F9]%:']D2?\]5_*C^R)/^>J_E1[6'<+,SZ*T/[(D_YZK^
M5']D2?\ /5?RH]K#N%F-HJU]@;^^/RHK'GCW*L7Z***Y1A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[AZBC</454HHY +>X>HHW#U%5**.0"WN'J*-P]152BCD M[AZBC</454HHY
M+>X>HHW#U%5**.0"WN'J*-P]152BCD M[AZBC</454HHY +>X>HHW#U%5**.
M0"WN'J*-P]152BCD M[AZBC</454HHY +>X>HHW#U%5**.0"WN'J*-P]152B
MCD M[AZBC</454HHY +>X>HHW#U%5**.0"WN'J*-P]152BCD M[AZBC</454
MHHY +>X>HHW#U%5**.0"WN'J*-P]152BCD M[AZBC</454HHY +>X>HHW#U%
M5**.0"WN'J*-P]152BCD M[AZBC</454HHY +>X>HHW#U%5**.0"WN'J*-P]
M152BCD M[AZBC</454HHY +>X>HHW#U%5**.0"WN'J*-P]152BCD M[AZBC<
M/454HHY +>X>HHW#U%5**.0"WN'J*-P]152BCD M[AZBC</454HHY +>X>HH
MW#U%5**.0"WN'J*-P]152BCD M[AZBC</454HHY +>X>HHW#U%5**.0"WN'J
M*-P]152BCD M[AZBC</454HHY +>X>HHW#U%5**.0"WN'J*-P]152BCD M[A
MZBC</454HHY +>X>HHW#U%5**.0"WN'J*-P]152BCD M[AZBC</454HHY +>
MX>HHW#U%5**.0"WN'J*-P]152BCD M[AZBC</454HHY +>X>HHW#U%5**.0"
MWN'J*-P]152BCD M[AZBC</454HHY +>X>HHW#U%5**.0"WN'J*-P]152BCD
M M[AZBC</454HHY +>X>HHW#U%5**.0"WN'J*-P]152BCD M[AZBC</454HH
MY +>1ZT5#12Y0)Z***D"H>IHX[&@]33)&6-&=C\JC)/M6PAU%8+>+]+ 9A]H
M**2"P@; Q[XIL?C+29E+1_:'4=2L#$#]*Z/JM?\ D?W"YD=!@^E&#VJM8W]O
MJ-LMS;DM$W0D8-6LGZUA).+LQB<^E%8FI^)K73-3ALI8W+R]P.E;=7*G."4I
M+1[!<7BD^G/THK$UOQ&FB,BRVSR!S@$'BE3I2J2Y8*[!NQN'%)45M*+FVCF
MVAUSBH=0O[?2X//N!)L[E$+8_*DH-RY5N!;HKGX_&>E2C,9N' ."5@8X^O%:
M=AJUEJ2YMIU<]U/##\*TGAZL%>46A)IEVBBBL1@*.]!XI'81QLYS@<\"@!3Q
MVHK&T;Q';:U<3P0HZ-#UR.HK9JZE.5.7+-68)W"BBBH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!+
M1114@3T445F,J'J:CE3S8GC/1E(_.I#U-)CN.*V3L(Q-6LX;'PK>0Q@8$3'/
MO6/\/D272+D$ YDP<_2MWQ,Z+H%Z"0"8C@$]:POAZZC39TW#<9.F?:O3IN3P
M4Y/NB'\2-6^NU\,Z9F&W:6(-] *S+GQK-%:Q746G/)&?OODA5_&KWC=POAN5
M20&++@9YZTOA%8I_#L*,J/R<@\T05-4/;U(W=[;@[WLBEJFO1QZG:1SZ;%(\
M@!C=N2 ?PK7UC5[BSGC@M+-KF5QG&< 5RWBYT'B73L%0%&" >G)JYXA\021Z
MM%813);1LH)N2,]?2M?JRFJ;C'=-]?Z^X5]S0MO$TZZQ'IVI6B6\D@&PH^X$
MG\!5/XA?\>-F1_SV&?R-85TT<?BS3Y&U![I%=29)% QT] *U_'4\4UA9-'(K
M9E!X/UK2%"-/$4I15KKS_4+W3.LTOC3+?_<%1ZT?^)+=C_IF:DTIU?3+?!!P
M@'!J/7&5-'N@S 9C.,FO*7\?Y_J7T.8^'R*]C>AP&'G>GM5'Q);_ -A>(;>\
MLV\I97&Y5&!UYJWX"NH(+2\$DJ)F7/)]JAUQSXC\0VUM8KYD,)#/(!Q[_P J
M]CWEC9M_#;7ML9_9.AO?$:0206EK'Y]Y,H94S@ 'U/;K4,?B6:#58[#4[58)
M)/N-&^Y3^.!7+ZO;QZ?XNC>^1VLW10'Y ' ]*Z2VM?"[2Q31;'E'*'<Y(-<\
MZ%&G33Y6[K==_O\ T&FVRS=^()&U)K#38%GN$'S[VVJ/QYIUCK-[<&Y@N;(1
MW$(R$#9#?CBL"^TNQU'5KJ>TOGL[Q'(96. 2.]3^&M0OS>W-O=RK<11C!GQ@
M CMFE+#T_97BM4E>][_Y#N[EWPWK,%]=W:I816QC!+,HP3S]*4>)[B_NYX=(
MM$G6 99I'V_EP<UB^#7C34]3+L-IW=^O-4]/U"WL+V]DM;J&W28[?+N V5]Q
M@5M/"P=6=HWLE;>W^8N9V.BT?Q+J&K7;Q+8PJ(FVR?O3N'X8IQ\7R?VI)8#3
MY&=.NWDTGA.WTR#SY+>^2YN)6W.1QBLJT=/^%@7#%UVD]<]>!6?LJ,JE1*&D
M5?J@N[(U+/Q=*VK#3]1LOLKM]T[NM=6#FO/O$3)_PFEF05P N>?>O0%8$9!!
M]ZY<92A&,)P5N9%1;&74RV]M),06"#) ZUR\WB?58K1KP:2HM5[M(0V/IBMO
M7-0?3=)GNDB\QE7(7UKAY+U]4T":XFU9E<_\NJ*-H]CQ6F"PZG'FE&ZO;K^@
MI,[BQUA-3T@7]LA<8R5'J.HK"MO&-Q?-<1VVFO))'P "<?B>U)X)NK=/#9A,
MJB0,Y(/89JAX&D1=0U$E@,N< GWK3ZO3A[6\;\KT"[=C;T'Q.=3NI;2ZMC;7
M*=4SFB]\3.=1-AI=J+J9?OEFPH_'FL#3G0^/+QD88);!S[&F>'[R'2/$MZM^
M?*\UR59OK6DL)34I2C'[*=O7\1<S"::67QU8M<1&.3=AEZ@<=C7HHQ7G-_>6
M\WCRTN(Y T0;E@#Z5Z*"& (/!KGS!/EIZ6]T<.IP_P 12!#:CU)J==5359+?
M1[6X5$,8\UP>3Q]T55^(C(R6R[AD$YYZ5!K>CA+"UU?3I LL*KOVGKQ771C"
M6'I*6CUMZDN]V=W#;V^FV8CC41PH,GVQZUA#Q'=W[RMI-FD\,1PSR2;<_3@Y
MI++6%U_P[*JL%N_+(9 >^.U<SX;72$22UU4>7<*V 69AG\JYJ.%24Y55>2>V
M_P ]T4Y;6.EA\537FGRS65HKS0'$L3/C'TXYJ7P]XBN-<MYIC;Q1!,@#S,DG
M\NE6=(M-&3SDTU$RP^?&?ZUR$YF\-^)+F"&-C%>#"8Z#.0*J%*C6YZ<(V>ZO
M^(-M:LZ_1M4OM2EF\VTCC@C8IO20MD@_2MG(_P *I:7:BRT^*':-V,N?5NYJ
M[G R>GJ:\ZLXN;Y%9%+8\^E)_P"%CJ?K_(UOZWXG;1[N* VC/YGW3GK6 TT7
M_"PP^]=O/.>.]3>-94;5M,VL#ALG!^E>O*E&I5I1FKKE,[V3+MWXOO+":)I]
M+9+60@"1R0?RQ6Y?:[96.FK>NQ99!E% Y.:YSQQ+&= L]C*3O'0^U9>NQ3/H
M.DW,8,D4)!<+SBLX86E6C3E;ENVG\AN35SH1XDU-)(9)=)(M92,2*Q.![C%9
M/BF3?XITH@<$9KHK#Q%I,]A#_I" A1E"I)4_E7.>*9HW\3Z:R,I&.QHPT;5[
M<G+H^_8'MN;FL^)9=(GAA^R;UD8*')P#4FN>(GT>SCN/LI=7 YS@9K%\=<#3
MINL:R9+#H!4/BO5+.^\.0QV\P=@R\ &BCA:<U2?+NW<&VKG43Z_!::+'?W V
M^8/E0'J?2LY_$.K0QQ7,FF1_9I"!N64EER<=,55NWTZ[\,V,%TS"-R%$B#_5
MG!YK(NX[[0?)^Q:F+FW=P!#]XG]**.&I/1K6[WOMY-?J#DS>\0ZW%97%J)M-
MCG\SE&?_ /56CJ7B&#3+2$E=TTJCRXE'^>*YCQI/YITEV 60C+)GH>*9XDCD
MCU+2[\@M;*@!8<@'TJJ>%ISC3YEO?\ <FKF]+XDOM-\J35;!(K>0_?BD+$?7
M@59UCQ$NFV$5Y' 9HI "#G'7I63XSO;>ZT2*&W999)6&T+R>U5=?A>U\$6L,
MQ'F@I\I/(J*>'I3]G*4;-NUO(&WJ7[GQ;>Q6:7<6E.T!&79R1CZ<=*Z'2-3A
MU:P2ZAX##D>AKGKN2(^ W&]=WD^M2^!"IT':&&0YR,UG7HTW0<XQLU*PTW<Z
MD8[UPGCF^DDO[33(W*QORV.__P!:N\QW[>M<-XXTV7[1;ZG A?R>& '3WK/+
M>7ZPN;Y>HY['5V>FVMM9I D$>P+@_*/UJDT$?ARRN9[>,R(6,A11@+WJ+3?%
MFF75JA>X6*4+\T; Y%%[JL%_HNH>3GRUB($C<!C@]*E4ZRGRU$[-ZA=6T,\>
M-9I=/-Q;Z<\K@\A<[0/<U'J?B5#I]C<W.FQRK/RH?G:?RI? 7EMILR-M)+]#
MWJ'Q^(TM;&--JXESM%=L:=%8KV*AUWN^Q-WRW%\8WEV?#\!AC6*W<*=RO@@^
MF/2M7P]<ZI]E@6>TA6W$>?-$I)Q],5D>*7\SP;:^6=^ F=O-;.D7UK>:%%;Q
M7"F4Q;< '.:SJ+_94N7[3[_>"^(8_B.XO;J6'2;5+@1??>1]H_#@YJ72O$8U
M!+B,P%+J#AH@<YQZ5QOA]-,M[NXM=80QR;N&9F /MQ79Z;!H5O+(^G[!(1EF
M!;I]31B:%&DG%1;VL_\ @W_0:;9GV_C-[DW"Q6$CR19"HO))]Z8_BB2ZT.:Z
MN-,4K')L>-CG'3V]ZS_!;)_PD&H;B.6;!)'/-;_B\0P^'+H*%4L0<# SR*JI
M3HT\0J2AO;6[$FVKCM.UB,>'1?QV@C4$@0QBJ5QXIU.SMEN[C2D2V+8)\P[@
M/7&*S['6CI7@I98D623=MP><9[UGZK<M=^'_ #Y-7>5VZP*HVC],U<,)%U'S
M1TYK=?T_4'+0]$L[N/4+.&ZA.4D7(S5CM6#X/N(G\/VL2N"Z1\@=JWC7DUH<
ME24.S+3N@HH[45D,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ H-%!H I:PC/H>H*@)8VT@ '<[37%_
M"NWN+>PU(7$+QDRI@,,9X-=W>W(L]/N;HKN$,3/M]<#-8'@WQ,GB:VNI$M1!
MY+J" .N1FN^C.HL'4BHWC=7?8EVYD=(?N-CKCBO//#[&3QW=F7[X9^O:O1,\
M<\5Q.KZ4]MK8UC3)XFDS\\6X?-ZXIX&4;3IO3F5@ET9U.K*ITJY#XVE"#FN#
M\++.VEZEY4S1!26#+ZUL:AJNH:O8M8QV8MC*-KR2.N!^1K0T[3;33M#>S2XB
M,KH=[[AR:UIOV%!PENVO,3U9F^$I[J_T.X,ES(9-QPY.2*B\(SW-[<:E%<7$
MLBAR@.X\?3TJGH1U;1FEL4MX7B8G$K.,?SJUX6AN].U"Z>X6)(YG))+CU^M=
M->"2JM6ULT2NAGZ7I<5QXOOK9I)PB=&64AOQ/>M[Q!J3Z%:6VG64K>=,VW?(
M=Q X]:RV6^TOQ3/?6T,=S%.>2KCY1^=7?$6GR:S907"SPQW<)W!0U*HU.M3=
M1WC9??;J"T3L6%\-WL;V]W;ZE<%Q@R([DJ<_C5.;4[G6_$ATD3-#;Q<.8VPS
M_B*LZ9K>LO$D$]I;QL@ \QWX('T-5+NQETW7QJ]DR7"R',L*L,YQVK.'-SM5
M;7L^5Z?UZ#] U&XN/"NLVJPW$LEI<,%*RN7Q]"?K3?%-W=Q:Q8B"[>..X&<#
MMTIUS;S>(]8@N+I5M+>!@P5W&YC^!-0^)5GNM:M'M;5GBMOX@ZX/3IS6M)1]
MI#FMS6=]OE\Q/89X@AU#19;6^CU&=VD8!E).W\LT[Q!'J%K91:R-1EWDK^['
M"\^V:D\5O<ZG:626]JY9"';YUX[8ZTNNR7%_X:M[.*T;S3C<"Z_+C'7FG2D[
M4G*U[M/;8'U-+5/$4MCX9M[L8^TRA0,^N.M8LBW,M@MQ;IJS:@?FW8;RV/TS
MC%7I[ :OX5CLI +:XBQM\QQR0/8]*9I.JZU8Q)92V44BH-HF+C]>:BG&,(/V
M:7,F[Z]/\AO?4ZG1)KN;2H&OHS'<;?G##!HUOC1;O_KF:6UO0T*F>: 2=PC<
M?K5/Q!>@Z5+%;IY[R#;A'7CWY->9&+==65M?D7T.*U2)M.32-4AP.=IQZY/]
M*W[F?^V;J>0<P6UJSJ?=@1_2H'A;4_";64T'DW$0_=[W7DY[8-.TN%M)\+/#
MY9GNIT(95=<KD=.3VKU9S3BF_B3:^3Z_<9H9X D"6-\S<!7!/ZU6M]5EUR]N
M&NUOFA0E8DM 1CZD$5+X/$VG>?:WELR+*<[RZ[1^M5H8-2\.:G-)8+%=V\K?
M=#CY??J*J:BZ]1JUW:VOWZAT1L>')-62YN;6:*X%J ?(DN%(8=>I_*J%[!!#
M'<M?:ZPO/F*(DQ4+Z< \UMIJ%[?V$RR"WMM\9"C?\P.*YC2+>_@AN+.:T@9I
M,XN)'!!_6LJ=W*4W9/316_/\[#?8W_!^JW-]HMR96,KP,55N[<9K M=6AO[^
MY76KRXMI02$5)"BK]<&KGA47FEP7=M)&D?F.65RX].W--DDEN;4P:CI*W,X&
M!.C* Q]3R*ODA&M4LM':S35UZ"Z(LRI<P>%KB>/4#)Y98QR(Y.1SP:L:*]Q=
M^#S*;F02@%MY.35:QT8P>&KRS>ZB$MP"57?PG7C]:IZ--K%GILNFM:Q+& 0L
MC..?UJ914X246KJ5^V@S2\%W-U?Z5<F:=V<L1N8YQ63I4VJZCK%[IZW\B@%E
MWXS@ XX%7O"(N]'LITN(DPV6"AQN)].M4] ^TV7B*:ZFLW6.=CSO7Y<GJ>:M
MI*=9QMY;"Z(EN;K5O"VER0S3&:::;$;LVXA<=>:BG6]^Q13V,>K-?@@L75MC
M?AG%;_BBPBUFP00W,231-N7+#FL_2M9UJWC2TFLHF"?*)BXP?<\U%.IS4_:1
M2YKZ]!M:V$U_6M3M])LC*CP^:,3N!@K_ (5'IXM+B^LY=,U64R%OWD,TQ.>#
MV)K0U2^OA/;RK'!<Q;2)H488)XP1GOUK'73!J6K0S06JZ<J'<Y9QES[8)HI<
MOLK/W=]K?BMQ/<]"HH'3\**\,U"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ):***D">BBBLQE0]34
M-P91;2^0 90A* ]-V./UJ8]325NG9B.#N[;Q7J "WFG6$P'9L'^M0VVF>)+*
M82VNDZ?$XZ,H&1^M>A45WK,))<J@K?/_ #)Y#@;VT\5:BR_:]-L)MOW2P!Q^
MM+9V?BK34<66FV$.[[VS S^M=[11_:$N7EY(V^?^8<AYU-HWB&XE::;1]-:1
MSEF*@D_K3I-*\1S6Z12Z3ISI&,(I POZUZ'13_M*?\JT]?\ ,7(CSR73/$DZ
MQB32=/81C" @?+^M)-I'B*Y8-/I&G2$# + <#\Z]$HH6936T5^/^8<B.&M8?
M%]A$(K6QL8HQT5< ?SIMY!XMU!!'=:?8RH#G#8_QKNZ*GZ^^;FY(W]/^"/E\
MSS8>']<#$_V)IG/^R/\ &M"UA\7V<6RWL;*-1T"X_P :[FBJEF,Y*THI_?\
MYBY#A;R'Q=>Q[+BPL94[JV/\:BM+'Q18,QMM,T^+/]P ?UKOZ*2S"2CR\D;>
MC_S'R'GEQI?B2[E,D^DZ=(Q[L!G^=3+9^*4M&M5TVP\AA@I@8/ZUWM%#S&35
MN1?C_F'(>=0Z+X@MY!+#I&GQR+R'4#(_6L:5=6MKB1;C2DN)BV6>2 O^1%>O
M45K#-))WE!/[Q<AY;IVC^(/M0U"SL8HLC&P_*/R)JXNBZ^LOF+HVFB3.=VT?
MXUZ-14RS2HW?E7X_YAR(\ZET?Q%-,9I-'TUI"<EB!S^M:$4GC2*-42TLPJC
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M(UHK#_D&6_\ WQ2?\(SHN/\ D&VW_?%:M%'MZO\ ,_O861E#PSHH'_(-M_\
MOBC_ (1K1/\ H&6__?%:M%'MZO\ ,_O861E?\(UH@Z:9;_\ ?-'_  C6B?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $M%
M%%2!/11168RH>II*4]325L(**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H[44=\4 4-
M</\ Q(-1_P"O:3_T$UQ'PC)_L_4^,9E3^1KT&ZMDN[*XMW8*DL3(S9Z C%8O
MA;P[:^'[>YCM;@3+*X)(.<8%=]&O".#J4GNVB6GS)F_1117 4%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!+1114@3T445F,J'J:2E/4TE;
M""BBB@ HHHH **** "BBB@ HHHH **** "BBC\,4 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^%P2_P#SR"@<CTJU#JNH6OB:[L+^\5H6B,ML?*"\<#\>:N6$3@G!]+]>]M-
MYNYU-%9NAM>2Z9'-?7'FR2_,#Y83:/3BM+\*XYQY)./8I!1114@%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@29,[7&1FN#T/P[X@TV"/3YM/T=[>(X6ZPIDQGKMV\G\:[V)#%"B$@E1C(&
M?PK+,?872I)==5VZ?UN.%^H^BBBO,+"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBLQE0]32$A02QP!U]J4]332 P((R#U'K6PCG--\=:)JFNR:/;32-=1[LDJ
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MQ@;67WQCCZU,L-3DN>3>R^6G];A=G6WVOVUG(T:075TT?^L%M'OV?7GBL?\
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M&'%MEJBBBN$H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *.]%':@"*Z:%+2=KG_4"-C)_NXYK&\,7&B7-O<'1 H0,/,QZ]JOZX?\
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M\]/:G6NCK/XMOM,FOKUK9;4$@7#@D[AR"#Q72Z3X=&DZC>7:WUQ,;IMS(X7
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M !K=2-(XUC10J*, #L*A5E1IJ--W=[_<%KO4XW1=0/B#3=.LI@WG0G_2U/\
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M 6D_/-17-S!:0M-<2K'&HY9C@"JMMK>F7<X@MKZ&64C(16Y-6J<VKI:!<O\
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M;6IN9IT2' .\G I\$\-S"DT$BR1L,JRG(-3RNU[:#)**/_UT=^WYU(!1110
M4=\44'IF@"*ZMTN[.XMY&"I+$R,?0$8K%\+>'K3P_;W,=I<"997!)!SC K1U
MEBN@:@0<'[-)@C_=-<5\)Y9);#4O,E=\2IC<Q..#7?1IS>$J34K)-77<EM<R
M/0Z***X"@HHHH **** "BBB@ I>WL>V:2B@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU"]OHI="ECO956=D65,##YQGM5F#P]?2:#)I>HWL,Z!0(VBA*%<=">3FJO\
MPC6LRPV:7.J6SM9RH\16W(^4=CSR:U]K1DVY26[Z;IK3H*S'0W-YKVHZFL=_
M+:06;>6JQ ?/E<Y.0:S=.-Q!X'NI+>\DAEBE)\Q0,MT]JUF\.:E:ZI/=:5J4
M,$5UAKB*6$ON.,97D8IL?AC4(M N-,34(<S.6$AA)P...M"JT4DE)6O'2W;>
M^G^8693N=?F+Z18/>/;>?;"6:X1<MD < 8/7/I2P:WJBZ?JR0++>?9L?9YV7
M#2 @9].1D]NU7'\+WBPV,]O?QQZG:1>4LQC)1EP!RN?;UK0_L_5GL9!+J:_;
M"/ED2,A ?]W/]:F53#I+EL_^'WVVMY_(=F97AW4$O]1\R'79[G$?[RTG3:4/
M/3Y16YKUPUIH%]<)G,<#,,>N*J6>B7 U1-1U&>WGN(TVHT46P^^>3GK6K>6R
MWEG-;/\ =E0H?H:YJTZ3K1E';3^ME^0TG8QM,'V'P<LD(S)Y1DXZDGG^M0>"
M((KCPM:W4R+)/<*9)7<9+$U=T19(++^RKN-RT0(W8RK*3QS]*@MM"O\ 2A)#
MI-[##:$[ECEB+E#['(XK6<XM5(-V;=[]UJ+LS(TZS23Q'KNBE2UA+&K;&^ZA
M8'-/T34I+;0[S2G7-Y:2F%5_O9Y'Z5T6DZ0NFF::24S7<YW32GO[#T'M5=_#
MD#>)5UC>P(3#1]F;L?RJY8FE-RC+:RMYM+]0Y6-U"WFTSPXZ6,@@\F(G<HYS
M5*ZUZYM/"6FW.XM<W8BC\P]BW>MG6[&ZU'39+6UN(X&D!!:1-^!^8K/7PW)-
MX;ATN]N4DD@"^5-&FW:5Z'K65*I2<4ZNKYM>]AM/H4=3GU+P_P#8KPZA+=PR
M2!)8I0, $9R, <U:OKV^A\4:5#]I(@N"VZ(#@@*2*D_L&^O);4:K>Q7$%LP=
M8XXBNYAP,\G(Q1J6AZE>:[97\-]!'%:DE8FA))R,=<UHIT6TI-7M+6VGET%9
MEN[\3:397OV.XNF6XR/E\ISU]P,50UF]OK;6]($5UMM[B<(T:CA@03SFNE&=
MOS$$]\"N?UK0]1U+5+*Z@OH(4M9!(%>$L2?KGWK##RH\^NFCO?7IZ:#=R/6E
MFO-56T37)M+5(P^8B@+DDC^(&K$,\/AS3O,U+6+B\C9L">5 QY[?(*K:G#X9
MO[_R-9CLWNXT^]<*%_[YS4?@V*2!;^-&D-@LY%N'[#)Z>W3%;-+V&NRMI9*_
MI+<7475?%,,MG:#2Y2QNYQ )2A79P3G!'M4.HW6H>';VQE>_EO+:X?RY$F R
MOH1@"MS6]'CUBU6/?Y<\3"2&0?P-ZU2&A7EY>6TVK7<-Q';'=&D<10;L8R>3
MFE2J4%%=M;IZM]K.W^0-,IV$]_XDDOI8M0GLHX9F@1(@O)4XR<@TFF:OJ&I:
M%>!Y52YM7,;RJ.3C."/?%6QH-]8W=U)I-[#!#<$N\<L1?#'J1R*EBT![+1);
M&QG1)I26DFD3=DGD\?C52J4+:6W5M-N]]/\ ,+,F\,74U[X<LKFY<R2R1Y9C
MWY-:U<LFD:AIGA/^S3?,TR +%+;H5(Y^IKH-/CN(=.MXKI_,G6,"1\]3CFN7
M$0AS2G!JS;MZ%*^QS?C*5VO-&LF+"WN;M5EYP&&#P:T_$&G6LOAZZ7RE79$6
M1E&"I'(_E5G6-'M]9M5BERLD;;XG'5&'>J,VCZQ>VXM;S4H6MSQ+Y415V'IG
M-;4ZL'&G:5N7?[Q-;G.3B>?PAH^ONI-W9A'=B/F9."WY@5T@FBUK4+,JH>".
M,3D]<,<8'Y&M46%NNG?8 @%OY?E;<?PXQBJ7A_0TT*R:!96E9G+%CZ9X'X"G
M/$PG!O9INWH_\OU$D[E#4;N^MO%.EP"XQ!.S*T2C@@*3237UWJGB:?28+J2T
MCMHU=I(P-S[LXZ_2I=3T/4;[7;+4(KZ".*U8E8FA))R".N?>I+O0K@ZJ-3T^
MZCM[IEV3%X]RN!TXR/>FIT;1U5^7ML[]=.WJ&I4TK4-036+[19YQ.\*^9%,X
MYQ@=<<=ZD\-ZE</#JC7UR\JVURRAR.BA0>PJWI^BS6DEU=RSI+J%QUEV848X
M&!Z?C4/A[1+_ $B>\>ZO89TN93+A(2I!P!Z^U%2=&49VM?3YOK;30%<LV/B'
M3M79X=.N?,E S\T3J/U K.T6^O9)];CN;AIOL[@1DX^7*YQ73.'*D(0'QP3R
M!7/Z-H6H:=J-]<7-]!-'=L&*+"5(P,=<UE"5'DG;3:U]7OWL-WN86@W.MP>%
MAJ$*6DL;;I9A,&+O@\XQQT'>MZ'Q=I2:59WES(UN+F,.J>6S8XZ?*#3(_#U]
M:Q2V5G?11V#Y'EM&2P!Z@-G^E;=A8PZ=8PV=N"(HE"KGK@>M:XFK0FW)J]WT
MTT\]&))HY^^UM]0UBQTS3[AX8KB,S&=5PV << CW]*@?5;W0=;DLKFX>\AD@
M,L;2 ;@PSQQ@8XK6U;1&O;VWU"SG6WOH!M61EW*5[@BH[?P^TE]+>ZK-'<SM
M'Y2[$VJJ_3GGD\TXU,.H*^UMNM[][!9W,J"75=1\.'7(M4FBD:,SI;X&S &=
MIXS^M+J6MW\_@U=5MIOL\@7YM@Y)'!Z]JM1^'-1M[&33(-2C73FRH0Q$NJ'L
M&SZ>U3:QX<GO- 72=/N8K:$*%)>/=G]16GM*'M%=JW-VVCV>G^86=C=MV+V\
M;,<L5!/Y5)7.:I9ZHUII]O!?2)=)(-SP@HC =0?;%=&*\ZI!12DG>]RDSF]1
MO[F[\30:-;W+6R^49I)$QN."!CGC'-95UJ6I6\FJ:6VH2^=;Q">*XP-Q&<8/
M&*WM2T%KC5H-5LIEM[Z-3&69=RLA[$?@*J3>&+F:"]D^V1"^NEV/,8CM"^@7
M/]:[Z-6@E&]METZWWVVL2TQ= M-5F6QU.XU>:6.6 >9;L!MR1P1QFI/'%W/9
M>$[Z:W)639@,O;WK3T>RGT[2;:SN)EFDA0(71=H.*FOK*#4;*2TN4#PRC#*:
MYW7C]94VDXI]%TN.VEBE8Z;9C0HH!"A1HN3C).1ZUR6F:>VJ^&-5T\@O]DNI
M!:L_."I^4#Z<5T46D:S;6GV.WU2 6X&U-\)+JO\ O9Y-:>EZ9#I-D+:$LW)9
MW<Y+,>I-:JNJ2DU*[;36_05KG/V>I+KFA65H5S)(WDSJ>H"_*Q_,58\43WFF
M:;%)9W'D(DB+A!U!(&#5K2_#EOI>JWE[&[$3G*)V3U_,\TGB71KW6[:.WMKR
M*W0.';?$6)(.?4>E"J4?K$;/W+WU\_ZL%G8BUS4[A-0T_2[>1H9+LL6F'50N
M"<?G59KO4=&\26EA+>/>6]XIPTP&Y&& .@''6K^HZ'-?Q6L_VE(]1MCE)U3Y
M?<8]#CUHM]$N'U6/4=3N8[B>%-D(C3:JYZG&3SD4H3HQII.VSNK:M]&OP"SN
M5["\O1XON[.XN3) MN) F.%.['%7(_$VD2Z@;%+HFY#;2GE/U'OC%5;?0]3B
M\2S:HU_;M')'Y?E"$@[<YZYKHJSKRHW5M=%MIK]PU<3O11VHKC**VHV[W>E7
MEM']^6!T7ZD$5S'@#PY?>'K2]CO=N99%*X] #73:I/);:1>SQ'$D<#LI]"%.
M*Y3X<ZYJ&MV5^^H2^8T4BA>/4&N^C[7ZG4Y;<MU?N2[<R.UHHHK@*"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAJ2;+]%%%<104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9HI+S$D S(HC8D?D*YJ&[ \=6$MUJ-I.'M&5)(@%7.X<=3DU;TJ2V;XB:O\
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MPNBG4I-H/,WDKDC.<8^M85VIC\43HVM'3G6!4\R6!7$V">5#<#\*] )"@EF
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:L0S17$2RPR+)&W(9#D&H<9)7:&/HHHJ0"BBB@ HHHH **** "BBB@ HHHH
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M=M;1"*&,811T K%N?MVKWZ6D^FO#:PS"0SNRD2 =@,YJL--1JRE]G6]]-/\
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MJ4E'KW_IZ_<-*S./T'RKW5_$(U"(-,DP"B49VKL'3/2N>9I?[-L48L8DU0B
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M14@3T445F,J'J:2E/4TE;""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXXQP.IIFDW\>BZOJ]G?)+'-=3!H0(V8,.>X&.]=W2U,L8I-WCHTO71WOM;\
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ML'*>>S/]M^'MHL$<C-;/&)5,9!&T'/!Z_A5O6GC\20Z78V".S+(&DD,97RP
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M=[G4+L7=ZX"F54VKM'3"Y..M:U1BZRJ226MEOW?<(JP4445RE!1110 4444
M%%%% $M%%%2!/11168RH>II*4]325L(**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H-
M%!H I:PC2:'?H@+.UM( !W.TUQGPMM+FUL=1%S \3&5,!AUX-=S>W/V/3KFZ
MV[O)A9]OK@9K \%^)SXFM;N3[,(?)=1@=\C-=]&518.HE'W;J[[$NW,CIJ**
M*X"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ):***D">BB
MBLQE0]324IZFDK804444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10
MF*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4
M )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M
M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )@48
M%+29YI@9GB#_ )%W4?\ KVD_]!-<#\(R?[.U/C_EJG\C7I%_ EU87$$K;8Y8
MV5CZ BN>\+:#8Z%;W,=E<"996!8@YQ@5Z6'KPC@ZE)[MHAKWDS?/(/OWKRRY
MO-3;XD3:-+XDO;6R,7F!A(B[3SQDCIQ7J?;/:O(+N71+GXOS'4WLY+,6^"9B
MI3<,\<]ZZLIBFZMU>T7TO]UR:G0[+1/M-O>RW?\ ;=UJ&F)&P=IB&PP/;:/K
M6A9>,=#U#[3]FO-YMEW3 QL"H_$52TK5?#VF7":7I=Q;/%(&E)BD!6/GVZ=:
MX3Q#-%;:O+XBTH*-+:017823'G<@Y_E^5:4\)'$U6IIKL]%?U5MWT!RY4>C/
MXST*.VAN'O"D4S!8V:)AD_E[T^V\7Z'=:DNGQWG^DO\ =1D9=WT)&#7%>/=0
MT[4_#VB7%BT;6IN4PJ_PC*\$=JA\3&QU?Q#X<ATAHY;N,KO:#GRP,9W$=*JG
MEU&<4Y*2OS?*W?03FRU:*(/B]-#'D1[,[0W%=IJ'BO1]-N&@N;L^:HRRQQL^
MWZ[0<5P<-S"?BW(%GC+>3L!W#[V.E+X7N[;1-?\ $D6M.L$\I)#3<>8O/0GK
M6N(PL:J4YW?+".BW?3S$I6.\E\4:/!IZ7SWB_9GZ.%)_/T_&HX?%^A7%[%:1
M7P>:5=R (<$?7'M7E*0R6OP]U^6X_=07-RS6J2'&1EN@KO\ 0K32$\(VNIP6
MD$T]O 6S& 23SP:PQ&7T*,&[MZV5K=KK_)E*;9H_\)QX?\X1&\8$ML#&%PN?
M][&*R_%GCR/0=1LK2W"R-*ZF4M&Q 0]P1U-<)K6N76M^"GE%Q;0P"X4?8(H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!+1114@3T445F,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ):**
M*D">BBBLQA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4TTZD/- %
M34KG[%I=U=;=WDQ,^/7 S7,^"_$Y\3VMW(;<0^0ZK@=\C-;^O_\ (NZC_P!>
MTG_H)K@?A+Q8:GC_ )ZI_(UZF'HPE@JM1KWDU8AM\R1Z+115-M5T];X6+7L
MNB,B$N-^/I7'&,I;(HN4445("_A25A^)==GT&VAGCLEN%DE6(@R;<;B .WO4
M/_"23VFIV=GJ5B+=;P[8723>"Q['CBNB.%JR@IQ6COU73?07,CHJ/<T5C>*+
MR]T_1)KNQE2.6/GYTW BLJ=-U)J"ZC;L;5)5;3IWNM,M;B3&^6)6;'J0":L,
MP1&8G@#)XJ7%IV 7 (QVK)_X1G1O-DE_L^(/(<L>>3^=6+/5(=3L9+FRRX4L
M@W#&6%&E7%[<V9DO[86\H<@(KYXSP:U7M::=G;OK9BT9<CC2*-8XU"HO  IU
M%%8C"E]\TE!Z'!P?6@ HKG]%U+4)]?U.QNYHY4M]IB*Q[< DC!]>E;EPTD=O
M(T$8>55)52< FM:E)TY\K\OQ$G<DJK?Z=9ZG;FWO8$GB/56Z4FFS7=Q81R7M
MNL$QZQJV['/K5RI]ZG/1ZKL/<KVEI;V-LEO:Q+%"G"HO05/114MMN[ ****0
M!3719$9'&Y6&T@]Q3J* *.GZ-IVE&0V-I'!YAR^W/)J]1152E*;O)W8!1114
M@+_2D_2EJD^J6J:I'IS.WVB12ZC'&!51BY;("Y11_C14@'X48K)\27-Y9:)<
MW5E,D4L2%LO'N!P.E6-&NI;W1;.ZF(,DL*.V!CD@$UJZ3]G[3I>PKZV+U%%%
M9#"BBB@ HHKF9=5U&#QW;:6TT;6<]N\FWR\,I7;W_&M:5*51M1Z)O[A-V.FH
MHHK(8445GZ;<ZA/-<K>VBP)&^(F#[MXQU]JI1;3?8#0HHJG>:K:V-S;03LPD
MN7V1@+U-$8RD[10%RBBBI **IZIJ$6E:=->S E(E)P.IIFEO>SVPN+MD E&Y
M8POW1VY[U?LWR<_0+E^BBBH **** "BBN=\4ZI?:5]@DM)8U26<1R*T><C!Z
M>E:4J3JS4([L3=D=%12 _*"?2EK,845S^IZCJ%GXFTVWCFC-I<G:\9CYSSW_
M  KH*TG3<%%OKJ),****S&%+25GV5SJ$M_=17-HL=NA'E2;\ENO:J46TWV T
M****D HHHH **** "B@YQ[US6G:KJ+^,[_2[F:.2WB@66/;'M(R2.3WZ5K3I
M.:DUT5Q-V.EHH[4R;=Y+^6P5L<,1G%9(8^BN?\*:I>ZG:WAOI$>2&X:(,B;1
M@ ?XUT%:5:3I3<);H2=T%%%%9C"C_(J.=97A=8)!'*1\K,N0/P[UFZ/JSWLM
MU9W*;+NU8*^.C9&015JFY1<ET"YK4445 !114-WYHM)3"X20(2K%<@''I32N
M[ 345B^%M0N]2T?SKUT>=961F1=H.#Z5M552FZ<W!] 3N@HHHJ "BBB@ HHH
MH **** "BBB@ HHHH **.GUILI=87:)-S@$JN<9- #J*I:7/>W-EOO[9;>;<
M1L5MW&?6KU5*+C)I@)15*UU6UO+VYM(68RVQ DRN!_GBKM$HN+M) %%%%2 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!+1114@3T445F,**** "BBB@ HHHH **** "BBB@!G?V%*,'I6=K5\EAIL
MLC'!(VK]32:!/+<:1%)*<OTSZUM[)^S]ITO85];&EWQ3J:!3JR8PHHHI %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8[>@KUL5ED</A:6(<_C5[6]#.,[R:['04445Y!H%%%% !1110 4444 %%%%
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M@(**G\@>IH\@>IHYD!!14_D#U-'D#U-',@(**G\@>IH\@>IHYD!!Z?XT5/Y
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *0TM)0!2U:V:\TB\MH_ORPNBY]2"*YCX?^&;
MSPW:7L=XRL9G5EV^P-=+K4TEOHE]-$<21P.RGT(!Q7(_#+6[_6;._:_F\QHY
M$"^V0:]*BJWU*HXM<MU?N0[<R.^HHHKS2PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M03#\HD!+9&2.:]+)1A@D8]*,IG@@&JGFU25WRI2::O\ .XO9H\N\9:+9Z,=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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KT447 -K>AHVMZ&BBBX!M;T-&UO0T447 -K>AHVMZ&BBBX$F#Z4444AG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gk2ifd22ejwl000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gk2ifd22ejwl000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0X!X$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HJ
M&XN[>T56N)DB5C@%CC)J:G9VN 4444@"BBB@ HHHH **** "BBL\ZYI:ZHNF
M&_@%\PR(-_SD?2JC"4OA5P;L:%%%%2 444UW6)&=V"JHR2>U #J*HZ=K.FZN
MLAT^]AN1&=KF)L[3Z5>JI1E!\LE9A>X4445(!1110 4444 %%07=Y;6%L]Q=
MS)#"@RSN< 4VPU"SU2T2ZL;B.XMW^[)&<@U7)+EYK:!<LT445(!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%&<#)H **HVNM:;>WTUE;7L,M
MU",R1(V64>XJ]52A*+M)6 ****D HK.U37M)T79_:>H6]IYAPOFOC-7HY$FB
M62-@R,,JPZ$53A)14FM&*ZO8?1114C"BBB@ HHHH ***BN+B&UB,L\BQQCJS
M' II-NR EHI$=70.A!4C(([TM(!&^Z:KU8;[IJO5Q ****8@HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #-%)2\FF 44X(3
MUIXC'UI70$8!/:G!":E HJ>88T1@=J<***5P"EI*6D 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7->,?&%KX4T\,5\^^F^6WMAU<_X5O7MW%86,]W.P6.&-G8D]@,UXAX(EN?
M'_Q-GUV^/F6E@3Y"XX0Y^3]!7J9=@HU5/$5OX<%=^;Z+YD5)<D;]>AZ-X:\.
M74L@UKQ!,;G4)1NCC)^6 'L!_CGK78445PUZ\JT^:7W=%Y(<58*:[B-&=CA5
M&33JY'XCZ_\ V#X1N6C;%U<#R8!ZL?\ ZV:,/1E7JQI1W;L6O,\P'Q$8?&4W
M!E=K O\ 9%7=\IY(!_6O? 0P!!R#R#7R#XD\,WWA6;3Y9R0\\2S XQM?KC\*
M^E_A_KZ>(O!]E=JQ9T0129Z[EX/\J^GXAP-*%"EB,/K%+EOZ;?J<L)MU'?KK
M_7R.HHHHKY(Z0HHHH X#Q_I?BJ\L+RXT[68[.UAB9O*C!W. "3G(]/2O&_A-
M--/\1[5YY'=RK9+')ZBOI37?^1?U+_KUE_\ 0#7S5\)?^2D6WT;^8K[/):SJ
M9;B(M+W5T7D_O,,2O=3\SZDHHHKXPW&2^9Y3>3L\S'R[\XS[XKP/XN6/BK3+
M6"[O];,]K/(4$,7RA#@GT!Q7O]>4_'K_ )%"S_Z^O_937M\/UG#'0A9.[ZK^
MK US1:*WP$).A7I)R?-/]*]?KQ_X!_\ (!O?^NI_I7L%1G__ ",:OJ88;^']
MX4445XYN%%%% !534H[V6PDCT^2**Y885Y<X7WXJW13B^5I@?,'Q3M/$6DZS
M%!J^L/>K,A="IP ,XQT%>T?";_DGNG_[O]!7G/[07_(9TG_KW/\ Z$:]&^$W
M_)/=/_W?Z"OL,SJNKDE&;23;Z*W<YY*U=>AV]%%%?''0%%%% !1110 4444
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M.]B%4_Q=*=X\\:^)M#MKB32]"D^RQ#YKN4?=]\8P16O\+[J:[\!6$D[$LH*
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M^(L$\+C7)+W9:K]?Q,L-+3E?0^2([@6OQ.-Q.0!'J3,W/;>:^M(&#V\3KT9
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MJ^/[%O\ =]W[/)G_ +Y-.TZ\AO\ 3K>YMY%DCD0$,IS7,?$GQ-;^'/"EP7D
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M4 .HHHI %%%% !111VH :!B@C-)DT9QUI@+FEI.U'04 %& :,YHS0 ZBBBD
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M+'9G/Y5W&B^&KG1[&6T_M[4+I639&TP3,7NN!_.NAHIU\TQ>(CRUI\R\TO\
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MAM58 J6.0:]RE3P=:,ZD8:1,FY+2YNCQY>R7T(:)8H]XW]>E>DV[B:%)%Z.
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M(Z%.26YZ!VKC?%'B^ZT6\-M;V@<!0=[ XYK4T'Q39:Z2D64F R4:H/&L:?\
M"/SL5!;CFM,-25/$*G7A?R!NZNC$\'>)=0UG7Y(KEAY7E%@@Z Y%>A5Y/\.?
M^1BD_P"N!_F*[SQ%XAA\/VBRR1F1Y#A%!ZFM\RP]\6J5&/1:$P?NW9N9HK \
M->)(O$$#LL9CDCQO4G-;O05YE6E.E-PFK-%IW#M7":YXUN]+U*2W6S#1H>'(
M/-=U7(?$2-?^$=9]HW>8H_6NO+U3==0J1NGH*=[:&(/B/>-]VR1OIG_&I8_B
M3*I_?V)'/.WC^9K,^'<$4^L2K*BNOE'AA[BN[U;POIM]:2@6R))@E75<$&O3
MQ/U*A6]E.G\R(\S5[BZ+XHL=:7$3;)>\;=16X/2O"(Y9]'U3,;;98'P2.,XZ
MBO:[*^CFTN*[D8*IC#,3QBN/,<"L.U*G\+*A*^Y?HS7#:E\1+2"4QVL#SX."
MV<?TJ&S^)-O)*J7-H\2'JX;/Z8K!99BG'FY!\\3OZ*J6U[#>6@N('#QD9!!K
MB)OB6D=PT7]G.=K8SY@_PK*C@ZU9M0C>VX.26YZ%17,VOBQ+GP[)JOV9E",R
M^7OSG'O6$GQ,0L!_9S_]_1_A6D,NQ$VU&.VG0'-(ZCQ'K$FBZ=]HB@,KDXP!
M7"Q>.-4OM6M8L+"C3*K*O<9KT;S5O=,\XI@/&6 /..*\7,BP>(?.?A8[@,2/
M0&O1RNC2J0G&4/>1$VTSW13E0?6C/%<#/\2H(Y L-F[H/XM^,_ABNFT'Q%::
M[ 6@.V1?OH>HKS*N!KTH<\XV1:DGH<OKOCF^L+^>UAM%"HQ4.P/-:7@?6KS6
M(KQ[N3>4D 7V!%4_B/&@L86"@'?S^E1?#,G[-?X_YZ+_ "->G.G1EE[JQA9Z
M?F1=\]CT*BLC6=?L]%@WW+_,?NH.2:Y,_$D%B5T]S&.^_P#^M7ET<#7K1YH1
MT+<DMST.FUB:%XFL];B(B.V91\T;=16WVK"I2G2ERS5F-.X9KD/$WBRYT2]6
M&.U\Q"N2Y!P*Z[ K!\8QJWAF]8J"1$<&M\'R>VBIQNGH*5[:')CXD79.%LT)
M/;G_ !I1\2+L-^\L5 _'_&N;\++$?$UD)MOEECG=TZ&O2-8L]!&G3L\=L#L.
M",9SBO<Q5/"4*JINE>YG%R:O<30?&%GK+>2089^R,>OTJ/Q3XHN-#FBB@MO,
MWIN+$' KSGP_!+-XDMEMLD++G([#/6O5_$<:GP]<,R@L(^M<N)PU##8J"M=/
MH-2;B<IX:\5ZEJ_B6*"=U6%D8E%Z9 KKO$>IR:3HTUU$F]U' [5YOX%7_BJ8
M,_W'Z?2N]\0^(M)T\-97X9S(O*;"011CL/%8N,*<+JRT7J$7[NI@^$/%E]J>
MHM:W2A@1D,.H_P#K5WX;FN$\(ZCIDVK2PZ?8>2",^83R?TK?U[Q-::#L6=7:
M1_N@#C\ZYL;1<\1R4H6;6Q479:LW:6N$LOB-;3W+B>!H850L&)R3CVJ%_B7'
MYV$L6,>>N_&?TK/^R\5>W*'/$]"HK*T76;;6K);BW)]&4]0:-7UNTT6W\VY?
MD_=7N:Y/85.?V=O>[%75KCM<U!M,TJ:Z2,R-&,A1WYKSF?Q[JD]Q''&BP9<
MXSGK[UJ'XD1/,5DL&\HGJ7_^M7&7US'>>()+F'/ERS[ER.Q-?09?@.1-5Z>N
M]S*<NS/;[20RVL3MRS("3Z\59JI8?\>$&?\ GFO\JM=J^=FO>9L+FBFX[T5(
M&1XAU2;2-.-Q#"96!^[@FN*_X61=@D&S0$=CG_&O2FP5(."*\.\1J%\1Z@%
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MGHM%>=?\+.3_ *!K_P#?T?X4?\+.3_H&O_W]'^%']DXO^3\4'M(GHM%>=?\
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M_GFXPWY57U3QII>D7?V:Y6<R8S\B C^=>8Z!&X\36PMBSJ)A\P[KGK73^/\
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MVVDV+W=P',:8R$&3S7*^ ],EL=-DFF7:9FRH/4"H_'&LV?\ 94^G>;FY8@[
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M**<BAFQG '6F W-%:$-C;R6ZR22&,NVU!5*6,PRM$W)4]:F,U)V06&44M%4
ME%+10(2BEHH 2BEHH&)12TE @HI:* $HI:* $HI:*!B44M% "44M% "44M%
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MM\C'L:Y<KPE*<95:FMN^PYR>R.FE\0>*=',<]ZI\ECT:,#-=SX?UV+7K 3J
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MTZB@!":*6B@!.]%+10 E%+10 AHI:* $S1FEHH *04M% !2=Z6B@!#0:6B@
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MQ<J0U<Y.:=116 Q!2X%%% !TI*6B@ I,4M% "&E[444 (.E+110 F*.]+10
M&@444 %)^-+10 4E+10 F:6BB@ [4WJ,&G44 <]>^#](OKHSR6X#L<MC^*M6
MRL+;3H!#:PK&@["KE%:RKU)Q492;2%9" TE.HK(8G%'2EHH 0&CO2T4 (312
MT4 %)BEHH 3&*#2T4 )@YI<XHHH 2BEHH !31]ZG44 %-SS3J* $-&,]Z6B@
M! ,4'FEHH *6DHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6B
MDHH 6BDHH 6DHHH ,T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !24M% !24M% !12T4 5J***L04444
M %%%% !D4C,%&20/K1MKEO'VFW^J>'/L^G1-)/YR-M5L<#.:VH4XU*D82=D^
MO83=D=/YR?WE_.CSH_[Z_G7AG_"&>*QQ]AG_ ._P_P :/^$*\5?\^,__ '^'
M^->S_9&'_P"@A?A_F9^T?8]S\Z/^^OYT>='_ 'U_.O#/^$*\5?\ /C/_ -_A
M_C1_PA7BK_GQG_[_  _QH_LC#_\ 00OP_P P]H^Q[GYT?]]?SH\Z/^^OYUX9
M_P (5XJ_Y\9_^_P_QH_X0KQ5_P ^,_\ W^'^-']D8?\ Z"%^'^8>T?8]S\Z/
M^^OYT>='_?7\Z\,_X0KQ5_SXS_\ ?X?XT?\ "%>*O^?&?_O\/\:/[(P__00O
MP_S#VC['N?G1_P!]?SH\Z/\ OK^=>&?\(5XJ_P"?&?\ [_#_ !H_X0KQ5_SX
MS_\ ?X?XT?V1A_\ H(7X?YA[1]CW/SH_[Z_G1YT?]]?SKPS_ (0KQ5_SXS_]
M_A_C1_PA7BK_ )\9_P#O\/\ &C^R,/\ ]!"_#_,/:/L>Y^='_?7\Z/.C_OK^
M=>&?\(5XJ_Y\9_\ O\/\:/\ A"O%7_/C/_W^'^-']D8?_H(7X?YA[1]CW/SH
M_P"^OYT>='_?7\Z\,_X0KQ5_SXS_ /?X?XT?\(5XJ_Y\9_\ O\/\:/[(P_\
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M_P#?X?XTO[(P_P#T$1_#_,?M'V/>/-B'\:_G2^;'_?7\Z\&_X0CQ;_SX3_\
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M_8^'_P"@B/X?YA[1]CWCSH_[Z_G1YT?]]?SKP?\ X0KQ;_SX3_\ ?X?XT?\
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M_P!_A_C1_8^'_P"@B/X?YA[1]CWCSH_[Z_G1YT?]]?SKP?\ X0KQ;_SX3_\
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M_P /\:/['P__ $$1_#_,/:/L>\>='_?7\Z/.C_OK^=>#_P#"%>+?^?"?_O\
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M_01'\/\ ,/:/L>\>='_?7\Z/.C_OK^=>#_\ "%>+?^?"?_O\/\:/^$*\6_\
M/A/_ -_A_C1_8^'_ .@B/X?YA[1]CWCSH_[Z_G1YT?\ ?7\Z\'_X0KQ;_P ^
M$_\ W^'^-'_"%>+?^?"?_O\ #_&C^Q\/_P!!$?P_S#VC['O'G1_WU_.CSH_[
MZ_G7@_\ PA7BW_GPG_[_  _QH_X0KQ;_ ,^$_P#W^'^-']CX?_H(C^'^8>T?
M8]X\Z/\ OK^='G1_WU_.O!_^$*\6_P#/A/\ ]_A_C1_PA7BW_GPG_P"_P_QH
M_L?#_P#01'\/\P]H^Q[QYT?]]?SH\Z/^^OYUX/\ \(5XM_Y\)_\ O\/\:/\
MA"O%O_/A/_W^'^-']CX?_H(C^'^8>T?8]Z\Q?[P_.BO,/^$=UW_GUE_[^#_&
MBN/^SZ/_ #]7]?,KG?8](HHHKSB@HHHH **** "BBB@ HHHI@%%%% !1110
M4444 %%%% !1110 4<444 '%'%%+M)[4 )1BI!'ZT\*!4\P$(0GMBGB/UJ2B
ME=C$"CTI<4M%(!,"C I:*0"8%+110 8I,"EHH 3 HP*6B@!,"C I:* $P*,"
MEHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP
M*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C
M I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*
M,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3
MHP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,
M"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $
MP*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH
M3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@
M!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:*
M $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EH
MH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6
MB@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I
M:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"
MEHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP*6B@!,"C I:* $P*,"EHH 3 HP
M*6B@!,"C I:* $P*,"EHH **** *U%%%:""BBB@ HHHH **** "BBB@ HHHH
M ***,TP"BBB@ HHHP3VH **>$/>GA .U3<"( FGB/UJ3M2TN88T(!VI>*6BE
M<!*6BBD E%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %:BBBM!!1110 444
M4 %%%% !1110 448/I1@^E !13@A/7BGA *+@1 $]*<$/>I<"ER*GF&,""G@
M8HR*,CUI7 *6DXHXI +129%+D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %
M%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11
MD4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %
M%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11
MD4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %
M%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11
MD4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %
M%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11
MD4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %
M%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11
MD4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %
M%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11
MD4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %
M%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11D4 %%&11
MD>M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5J***T$%%%%,
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M.@ HHX]1^=''J/SH **./4?G1QZC\Z "BCCU'YT<>H_.@ HHX]1^=''J/SH
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M^>[?G1]NNO\ GNWYU7HHY(]@+'VZZ_Y[M^='VZZ_Y[M^=5Z*.2/8"Q]NNO\
MGNWYT?;KK_GNWYU7HHY(]@+'VZZ_Y[M^='VZZ_Y[M^=5Z*.2/8"Q]NNO^>[?
MG1]NNO\ GNWYU7HHY(]@+'VZZ_Y[M^='VZZ_Y[M^=5Z*.2/8"Q]NNO\ GNWY
MT?;KK_GNWYU7HHY(]@+'VZZ_Y[M^='VZZ_Y[M^=5Z*.2/8"Q]NNO^>[?G1]N
MNO\ GNWYU7HHY(]@+'VZZ_Y[M^='VZZ_Y[M^=5Z*.2/8"Q]NNO\ GNWYT?;K
MK_GNWYU7HHY(]@+'VZZ_Y[M^='VZZ_Y[M^=5Z*.2/8"Q]NNO^>[?G1]NNO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(U+2-0@*D]48O\
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MKD/B%_R!8_\ ?_QKLR__ 'F'J3+X3S"BBBOLSF"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBCM0!ZSX%_Y%U/\
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M+1KMSY>:C<8D?_>KNY@3"_/\-<*_^M?_ 'JZJ.(G7E*<B6K#:***Z!!1110
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M,****U$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!6OX>_X_3_NUD5K^'O\ C]/^[6.(_A,:W.GHHHKQC0**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!5[_ $JBG^N;ZU>7O]*H
MI_KF^M7#J)FC%TJ<5!%TJ<5A+<H6BBBI **** "BBB@ HHHH **** "BBB@
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M,8?*!Z+58:OSJV]NHI*Q6HHHKJ)"@]**#0!ZSX%_Y%Y/]XUTM<UX%_Y%Y/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M62S0?[QIM.?[QIM9C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KD/B%_P @2/\ WJZ^N1^(7_($C_WJ[,!_
MO,/4F7PGEXZ4<8H%%?:',&<BBBBD 4444 %+FDHH .]%%%,!>U(/>BBD 444
M4 %'?BBB@ YS1110,._&:**/UIB"I(87GD$<8R3UHAA>>41QC)/Z5T]A8)91
M=,R'J:PK5E37F4E<+&P2SB P"_<U<%'M0HR< 5YDI.3NRP"D\"M&VM@HW,.:
M+6U"C>_X5;KEJ5+Z(:04"CO6C8V)D(=QA1TKGE)15V4%C8&0AY!\HK8"A!M
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MBC*?\]%_.C*?\]%_.@ HHRG_ #T7\Z,I_P ]%_.@ HHRG_/1?SHRG_/1?SH
M**,I_P ]%_.C*?\ /1?SH **,I_ST7\Z,I_ST7\Z "BC*?\ /1?SHRG_ #T7
M\Z "BC*?\]%_.C*?\]%_.@ HHRG_ #T7\Z,I_P ]%_.@ HHRG_/1?SHRG_/1
M?SH **,I_P ]%_.C*?\ /1?SH **,I_ST7\Z,I_ST7\Z "BC*?\ /1?SHRG_
M #T7\Z "BC*?\]%_.C*?\]%_.@ HHRG_ #T7\Z,I_P ]%_.@ HHRG_/1?SHR
MG_/1?SH **,I_P ]%_.C*?\ /1?SH **,I_ST7\Z,I_ST7\Z "BC*?\ /1?S
MHRG_ #T7\Z "BC*?\]%_.C*?\]%_.@ HHRG_ #T7\Z,I_P ]%_.@ HHRG_/1
M?SHRG_/1?SH **,I_P ]%_.C*?\ /1?SH **,I_ST7\Z,I_ST7\Z "BC*?\
M/1?SHRG_ #T7\Z "BC*?\]%_.C*?\]%_.@ HHRG_ #T7\Z,I_P ]%_.@ HHR
MG_/1?SHRG_/1?SH **,I_P ]%_.C*?\ /1?SH **,I_ST7\Z,I_ST7\Z "BC
M*?\ /1?SHRG_ #T7\Z "BC*?\]%_.C*?\]%_.@ HHRG_ #T7\Z,I_P ]%_.@
M HHRG_/1?SHRG_/1?SH **,I_P ]%_.C*?\ /1?SH **,I_ST7\Z,I_ST7\Z
M "BC*?\ /1?SHRG_ #T7\Z "BC*?\]%_.C*?\]%_.@ HHRG_ #T7\Z,I_P ]
M%_.@ HHRG_/1?SHRG_/1?SH **,I_P ]%_.DRI/RLI([ T +110 <T %%%%
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M]79@/]YAZDR^$\OHHHK[0Y@HHHI %%%% !1110 4444 %%%% !1110 4444
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M_GM)_P!]4;YO^>TG_?5+D4<4 )OF_P">TG_?5&^;_GM)_P!]4O%'% ";YO\
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M **** "BBB@ HHHH **** "BBB@ HHHH *1J6D:A 5)ZHQ?\?8^M7IZHQ?\
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M3=QBT444""BBB@ HHHH **** +$%Y-;1R)$<!QAC5>BBDDEJAA1113$%%%%
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MC"CI7/*2BKLH+&P,A#R#Y:V54(-H'':@*%  &*6O/J5'-W9:04445F 4444
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M*J>2H)]?2MJ&-G2FIV3^0G%-'$>'?#6J6,33SW+(A3_5@UF'[TF>NZO2I/\
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MXMK9CT)A/9WEE#:73O;2K]UAP#3-3AN56T25UFAWX$H-1/>6L]K'!=P;O+&
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MC\OA(SU5>]0,S.H#$D+]T>E,4'N:=WQ0HI:( &*3<>PI>!0<4P$!I<4<49H
M ,&@DCI03Q2')(YH 4=*.E!Z48]Z  ^M(.:6B@ QWHHS1F@ ()%&#CFCG/6E
M)XXH 0"C%'XT9H ,'-)FEZT8&* "@'# XR111QUH DFFDN)-\AZ# 'I4>* <
MT$\TDK:( Z"MGPK_ ,AAO]RL8]*V?"O_ "&&_P!RLL1_!EZ#CN=D*.] HKY\
MU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!R/Q'_ .1<7/\ >KR"O7?B1QX>3_?KR%O45]ADG^Z_-G/4^(WO
M">CKJVL*D@W1QC<P]:T-1@U"_O9((KF*$*=J0+QQ4?@*^CM-8D1V"&5"JDGO
M6<;6_/B4KLD,XFR&QQCZUM/F>)E=V22M<70S+B&:TG:&Y1EE7J&J(D;>*Z?Q
MV\$FMH(R"ZQ@.1Z\US/ '2NNA4=2E&;5KDM6=CTKX7'_ $6[^O/Z5Z$#7GOP
MM ^RWGU_PKT+H*^/S7_>YG1#X0/)HH4_-1WKSBPHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH YGQ\,^%I?K7B_(Q7M/CP_P#%+39]:\7STKZW(O\
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M10 J]_I5%/\ 7-]:O+W^E44_US?6KAU$S1BZ5.*@BZ5.*PEN4+1114@%%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX>BC^S<)_(@YY=SN/^%G:G_S[Q?E1_PL[4_^?>+\JX>BC^S<)_(@YY=SN/\
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M<?\ "SM3_P"?>+\J/^%G:G_S[Q?E7#T4?V;A/Y$'/+N=Q_PL[4_^?>+\J/\
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MX>BC^S<)_(@YY=SN/^%G:G_S[Q?E1_PL[4_^?>+\JX>BC^S<)_(@YY=SN/\
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MKJI_"R6:#_>--IS_ 'C3:S&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 444#DXH 7Z4E<#XM\?S:'K"6=K"DBK_K">U=KIUXFH:=!=IR)%R<=JZ:N$
MJTJ<:LUI+82DF[%FB@E1U8#V)HX/0@_0US#"BDW+_?7(ZC/-*.?\: "BC*DX
M#+GTS1]2!]: "BC*GHZG\:"0.I ^IH **!@]&!^AHX]1^= !10"#T8'Z&D!!
MZ$$CL#0 M%% *M]UE/T- !11P.I ^IHRHZLO/O0 45#=7,5G;23SN%1!DDFL
MKPWXBC\0V\TRJL81]JY/6M%2G*#J):(5U>QMTOTI/PKE?&>O:IH$"W5G;I)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ6$MRA:***D HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MI&I:1J$!5GJA%_Q]K]:OS#BJ48_TH?6NFG\+$R\_WC3:<_WC3:@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHNS0#J*0,&&0<BES4 %%%&: "BC(IK.JJ2S  =2: %HJC::K9WTCI;3J[)U
M-7<U<HRB[20#J*2EJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"&>X6
MW4,P."<<5-5'4_\ CW'/\0J]5M+E3 ****@ HHHH ***AFN[>W&99D3_ 'F
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHZ?+;2LP5AG*G!XKR*VLS+XC-@TLGE"8IG)SC->T/_JV]<5Y#8#_ (KEN/\
MEY/_ *%79E-22A45]E<FHM4>E"ZL= L8H)KA451\N]N34(\6:08&G^U*$5MO
M)ZFJ7C738+C19;J0$R0Q_+BN4\%Z!::LD\ET"X3HI/%94<-0J4'7J-Z/4;;3
MLCT#3?$&G:I(8[6=6D')7/-:$TT=M$TLKA$49))Z5Y/HT0L_'!@A)5%E90,]
MLUL?$/4YUFM[%6*1NNYL=Z=3+8O$1I4WI)7!3TNSI#XTT42%?M2D9QN!XK0=
MK76],D6*8/#(,;D-<MI?A#3[SPPI*@W$J;A)Z&KGA+0+S11.)YPZMC"KVK*M
M1PT8R=*34HOKU&G+J<;IELMIXVA@0E@DW!/6O1[SQ-IFGS>3<7"I(!R#7G]K
MC_A8"?\ 7:M?XB6-NMO!=+&!*[X+#OQ7H8JG"OB*4*E]8D1;2;1UK^(M-CL5
MO&G7R6. WO1I^OZ?JDYBM9@[ 9('I7.:/9V]YX&(FC#;58C/8XK&^'@"Z_<J
M!P(R/U%<;P5+V=62O>!7,[H[W4M=T_2F"W4ZJYY"YYJM!XLT>X=$6[3?(=JJ
M3SFN&\5VU]:^(WO7A^T0[LH#R,>G%06MUH^J:G TT;:?(K#)7[K']:VAEM)T
ME/5Z7NO\MQ.;O8[OQ3]@NM,:UNKQ8"PW*2:K^";>SMK"9+2X,XW_ #-VSQ53
MQKIEM)HRWNXL\281L]JC\ /Y>@W<@_A<D?D*Q4%]0;C)[[>8[^\=1J.MV&E@
M?:[A(V/0$\U5M/%FDWDPB2Y4.>@8XS7F]BA\1>,"EX[,C.6VD]@>E:OCC0;/
M28(+NS3RCNVD*>OO6O\ 9U",XT9R?/)?(7.[71Z/<74%K 9IY%2,=6)XK+B\
M5Z3+)(JW2$(,EL\5DZ$1KGA PWN6"C!)ZG'-<7HFDP7OBEK)RPA!;@'J!65#
M 4FJBJ-WAV&Y/2QZ1;>+-(NKH6\5RN]C@<]:W ?R->0>*].M](UR&*S3RP0#
MP>AXKUBR?=9Q$]=@K'&X6G2A"I3;M+N.,FW9E;6M332=,FNGQE1\H]3VKS32
M[?4/&&K227%PZP@Y;!X'MBNN^(2._AXE02 ZDX^M9/PWGB'VJ$D>8Q! ]1BN
MO!KV."G7@O>V]"9:RL/U7P*]II\DNG7,N]1DIN/-7O NI9T21+E\&!CN9NPK
ML2!M.>E9WE:=>P7%K$8^<B0)VKD>-E6HNG55]5KV*Y;.Z*X\5Z.TYB6[1B!D
MD'@41>(]*OX)PETH55PQ)Z#I7F*:7#<>*O[.5V2-I-NX=<5W-OX%L+&TN<R2
M2"1.=QZ8YKIKX3"4$KR=W9H2E)F;H-AI,/B;S(-1\^5MQ5%/_P!>KOC3Q-#:
M6LFG6[M]J<8)4_=%<WX0C6'Q>T:G*KN S6K\0]/MHXX[M8P)Y& +>HKIG3@\
M="-1MZ*Q-WRZ&AX5\36*:1:V]S=9N,8.XY.<UU-[J-M80>=<RK'&.[&N4\(^
M'],GT6UO);56G(SN).<YKFO&]_/<:[]FR3&F L?J:YGA*6)Q;A"ZM>__  "N
M9J)WD/C#1IYA&MVH). 3T-;$]W!;VYGEE5(@,EB>*\KN[&\N[***#1&B= ")
M%/)X^M=5H]E<WOA:2UU2)T:/(&X\D=<UGB,%1A%3C+K9JZ;!2;-5?%>D.SJM
MTA"#);/%))K>DZEILQ%XBQD;&;=C&:\ST71X]4\0R632.D8+<KUXKM7\%6-A
MHUPAEDD)/F9/J*UKX3"T)*/,[Z I297\'V.FVNK7!MK_ .TR;>B] ,_6NMU#
M5[+3$#7DZ1@],GK7GOP\7;K-T!SA,?K5[Q;96#:XES>7X"X7,'))Q^'>GB</
M&IC.2I)O3YB3M'0Z:W\6Z1<S")+E0S= 3UK<5@RY'0]*\7\175E<7%NUC;/
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MYW?2KHR>+PDW6U<=F#]V2L>@Q^,-&EE6-+I2S$ <]S4][XFTS3[DV]Q<*DH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-)+( &4?PY%;O'H*,BBOCO;5(U)06@*-E8\J\,V^KZ1JC2FQD*S?*>.G-/\
M$VBZE'X@-ZD#3QLP887/?H:]2X]!1Q6W]JR]K[7E6UF+DTL>4:SI>N:M#%=M
M9!(XAA47AL?2NU\)W5W/IWE75L\/E_*-PQFNAX]*7(K&OCG6I>S<4K;>0*-G
M<04HHR*,UP%CJ*;FC-%@'44W-&:+ .HIN:,T6 =13<CUHR*+ .HI,BEI %%%
M% %'5/\ 4+_O"KU4=4_U"_[PJ]6DO@7S$%%%)68Q:*;Q1QTIV IZC81ZC8RV
MTPRKC%>;C1M;\*ZD]Q9(98CP2HSN'TKU3(I./2NS#8R=!.%KQ>Z9,HW/,M1U
M'Q%XAB%FED\4;<,&0C/XUTWA/PP-$A::8AKF08)]!Z5T_P H[#\J7(JZN.E*
MG[*G%1CY HZW9YEXQT:_37EU*W@:6/*D;1D@@YZ57U@>(M;TY'FMB(4(^0*<
MD_2O5>#2?+[?E6U/-)1C%.";CLQ.!Q?@F:^CM?[/N;1XXXTX=E(R<U@ZGI&K
M:/XEEU&U@,BM(67:N>#7J?'M1Q6<<P<:LJBBK2W0<FECDK%M2\1V5S;ZE;^3
M"Z;5^7!KE([#7/"FHN]K TB-Q\JELC\*]8XI.#UQ13S!TW)*"Y7T!PN<-I[>
M)-9U"&>9C:6T9SMP06]L4SQCX7N[J^&I6/S/@!USSQTKO>!1D5,<?.%53A%*
MVEA\FEF>7WNH^(=2TY=,^QR*2 KL4(!'UKI?"GA^70=,FEE&ZZD4D@'L.@KJ
MOE]!^5+D4ZN/<Z?LH144]7YB4=;GDFK6NL7VNF_^PN"" !M/:M3Q5_:VJ:;9
M0)92 XW-@9P>1BO1^/04<>@K7^TW>#Y%[NP<AYYHKZM9>&[FS-B^X+M7WSQ6
M;X;M-6TG5Q*;*0J_!XZ9KU7BCCT%3_:3M-<B][<.0X+QAX7N;N5-1L1^] !=
M?>J,&K^)YK9;);5UF^Z9&0C]:]+R*3Y?05,,P:IJ$X*5MK@X:W1EZ!:7]IIJ
MQZA<>=,3DMZ>U:%P[Q6[LB[F R!ZU+D49%<,YN<^=HJVAY7*VLS>(5U7^SY
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4W&:=2=*: 0CO7(^*IM?2YB&DQNT>WYMN.N?>NOZTF*VH5?93YFD_4
M35SS'[1XU_YYS_\ CM'VCQK_ ,\Y_P#QVO3\#THP/2N[^TE_SZC]Q/)YGF'V
MCQK_ ,\Y_P#QVC[1XU_YYS_^.UZ?@>E&!Z4?VDO^?4?N#D\SS#[1XU_YYS_^
M.T?:/&O_ #SG_P#':]/P/2C ]*/[27_/J/W!R>9YA]H\:_\ /.?_ ,=H^T>-
M?^><_P#X[7I^!Z48'I1_:2_Y]1^X.3S/,/M'C7_GG/\ ^.TOVCQK_P \Y_\
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M !VC[3XV/6.?_P =KT\48]J/[27_ #ZC]P<GF>8_:/&O_/.?_P =H^T>-?\
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M_/.?_P =KT_ ]*,#TH_M)?\ /J/W!R>9YA]H\:_\\Y__ !VC[1XU_P"><_\
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M_P#X[7I^!Z48'I1_:2_Y]1^X.3S/,/M'C7_GG/\ ^.T?:/&O_/.?_P =KT_
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M?:/&O_/.?_QVO3\#THP/2C^TE_SZC]P<GF>8?:/&O_/.?_QVC[1XU_YYS_\
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M:_\ /.?_ ,=H^T>-?^><_P#X[7I^!Z48'I1_:2_Y]1^X.3S/,/M'C7_GG/\
M^.T?:/&O_/.?_P =KT_ ]*,#TH_M)?\ /J/W!R>9YA]H\:_\\Y__ !VC[1XU
M_P"><_\ X[7I^!Z48'I1_:2_Y]1^X.3S/,/M'C7_ )YS_P#CM'VCQK_SSG_\
M=KT_ ]*,#TH_M)?\^H_<')YGF'VCQK_SSG_\=H^T>-?^><__ ([7I^!Z48'I
M1_:2_P"?4?N#D\SS#[1XU_YYS_\ CM'VCQK_ ,\Y_P#QVO3\#THP/2C^TE_S
MZC]P<GF>8?:/&O\ SSG_ /':/M'C7_GG/_X[7I^!Z48'I1_:2_Y]1^X.3S/,
M/M'C7_GG/_X[1]H\:_\ /.?_ ,=KT_ ]*,#TH_M)?\^H_<')YGF'VCQK_P \
MY_\ QVC[1XU_YYS_ /CM>GX'I1@>E']I+_GU'[@Y/,\P^T>-?^><_P#X[1]H
M\:_\\Y__ !VO3\#THP/2C^TE_P ^H_<')YGF'VCQK_SSG_\ ':/M'C7_ )YS
M_P#CM>GX'I1@>E']I+_GU'[@Y/,\P^T>-?\ GG/_ ..T?:/&O_/.?_QVO3\#
MTHP/2C^TE_SZC]P<GF>8?:/&O_/.?_QVC[1XU_YYS_\ CM>GX'I1@>E']I+_
M )]1^X.3S/,/M'C7_GG/_P".T?:/&O\ SSG_ /':]/P/2C ]*/[27_/J/W!R
M>9YA]H\:_P#/.?\ \=H^T>-?^><__CM>GX'I1@>E']I+_GU'[@Y/,\P^T>-?
M^><__CM'VCQK_P \Y_\ QVO3\#THP/2C^TE_SZC]P<GF>8?:/&O_ #SG_P#'
M:/M'C7_GG/\ ^.UZ?@>E&!Z4?VDO^?4?N#D\SS#[1XU_YYS_ /CM'VCQK_SS
MG_\ ':]/P/2C ]*/[27_ #ZC]P<GF>8?:/&O_/.?_P =H^T>-?\ GG/_ ..U
MZ?@>E&!Z4?VDO^?4?N#D\SS#[1XU_P"><_\ X[1]H\:_\\Y__':]/P/2C ]*
M/[27_/J/W!R>9YA]H\:_\\Y__':/M'C7_GG/_P".UZ?@>E&!Z4?VDO\ GU'[
M@Y/,\P^T>-?^><__ ([1]H\:_P#/.?\ \=KT_ ]*,#TH_M)?\^H_<')YGF'V
MCQK_ ,\Y_P#QVC[1XU_YYS_^.UZ?@>E&!Z4?VDO^?4?N#D\SS#[1XU_YYS_^
M.T?:/&O_ #SG_P#':]/P/2C ]*/[27_/J/W!R>9YA]H\:_\ /.?_ ,=H^T>-
M?^><_P#X[7I^!Z48'I1_:2_Y]1^X.3S/,/M'C7_GG/\ ^.T?:/&O_/.?_P =
MKT_ ]*,#TH_M)?\ /J/W!R>9YA]H\:_\\Y__ !VC[1XU_P"><_\ X[7I^!Z4
M8'I1_:2_Y]1^X.3S/,/M'C7_ )YS_P#CM'VCQK_SSG_\=KT_ ]*,#TH_M)?\
M^H_<')YGE[3^-L9V3_\ CM=MX<?4GTU3J2L)\\[L9K9HK#$8Q5H<O(EZ#4;=
M0YIU)2CI7$4%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2DYHS1G-,!:6FYI<T
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M=4DFCM)A(T+;7X(P?QJE"33DEH@N:%%)FC-2 M%)FC- "T4F:,T +129HS0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+B0Y/"(O+'\*J:?XNL;V\6TD26VG?[JS(5W?G7$>/H95\3VMU*[K9L%VR 9
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M]:1=.LTN//2W19?[P'-6J*.>6UPL%%%%2 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M16,ZLIV3V0['.W&BW<7B!M5M&1RZ;&20=/H:AN=#U.76+;5/M$;RQ CRMN
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M$M;:."(85%"BIJ**YVVW=C"BBBD 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?0:C9QW5LV^*094XZBN)^(26=[X=@U&-%9FX1\<XK1T#5;;1_ ME=7;[8UC
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=:39WD@EDB_>#^)#M)^I%3VUK!:1;(4"COZGZU/BBL'4DURMZ%6 <"EI!2U
M!1110 444F: %HHHH **3-+0 4444 %%(31F@!:*3-&: %HI,TM !1110 44
M4E "T4F:,^U "T4@.:6@ HHHH **2EH **** "BBB@ HHHH **** "BBB@ H
MHI,T +129HS[4 +129HS0 M%)FEH **** "BDSS1F@!:*3-&: %HI <TM !1
M110 4444 %%%% !1110 4444 %%%)F@!:*2@&@!:*** "BBB@ HHHH ****
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M[:1I[8S:1''3BAM(T]@H:TB(48''2KIYE1AR>Z_=;>_<'!G >)(FUSP78SV
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZUIS6LUS# O4+$IP3VS738H_"JIXFI!12Z; XIE+3(KF"RCANC&6C4*"@/(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF1/^/D=QTXK2G2C4C1A):>\)NUS9N_$<>GW$2WD$D<,IVI(1P3VHN/$*6=Q
M+FWECAG<(DI'&:R?&\D>[2<.G_'VAZCIFF^.9(_L>E?.O_'RO?V-9TL/3G[.
MZ^*_X#;:N=#J6LV^FM#$P:2><XCC49)JJOB%(M0ALKV![>6?_5%APU4=6U+_
M (G]C8V\,(G:/>MU+]U1@\#WXK(UTLGB/1/.OA.PF&X#[J\CO11PL))*2W3?
MY_UJ#DSIM7\26VC7,$-Q#*?-;:'4<9IMWXC%@8I+JTFCMY&"B0CIGIFLCQI+
M&U_H>'3_ (^QSD>AJ;Q\Z?\ "-H-Z\S1D<]?F%%+#TY>R37Q;_>#;U.L#!E#
M _*1P:H:MK%OI,<9ERSRMLC1>K&K-BRM8P,"&&P<@^U8GBR/2[F*VMM3#*))
M,1S+_P LVP>:XZ%.,JRC).WD4WH3?\)&L5[!:75K+#)/G82/E/&>M,MO$OVC
M77TDV<J3(-S%AQCUKG;A=0\/7MENO%U6TDE"HC\O'[C%:7BR-M,U&Q\0P@@0
ML([@#NAQ_("N_P"K4N912OS)V?G_ %H1=FQ)K4B:O]@%E*WR[BX' %5[?Q3!
M=7]Q8PVLYN(1RA7_ .O4GA]3<B?59!\UR<IGLHX_I61X?DB;QWKN'0Y QS[U
MDJ5*TTXZQ7XW5QW9MV&O1W.I/ITT3P7:KOV..H]139_$$8U%M/M(7N;A!F0(
M,A![UC-+'_PM!/G3_CU(QGVIO@]EL]7UJWNV"7+3[QNXW+CM^E5+#4U%U+?9
M3MZNWW(+O8ATR99_B/<L(&A*VP#*5 YR:V[OQ5!::LNFM;3F9P=GR\,1Z<UD
MVT\,GQ+N"DBX%L%)SWR:=J,D7_"QM-&]>(7SR..E;3IQJ5%SK:%_N0D[+YFP
MGB2&*VNI;Z"6T%N0&\P8W9]*:WB3R(5NKJSFAM7( D8=,]":S?'T,CV%G,BE
MH8KA7E"CM@\FKGB6]M&\*S;763S$"HJG))/3BL(4:<E"2C\3MZ?UN.[U+.K^
M);72(8)I(Y9(IF4+)&,@YZ4E[XCBT\0S7-O+':RD 2D="?6N6UB-[3P3HT-R
MP6598=RL>1R*T?&\D7_"-V7SIS*AZ^U:0PM*\(VO=M7]!<S->\\1QV!ADGMY
M5M96"B7'&3TJ]J&KVNG1QM*V7F.(T'5C[5SOCB2,^';8"1>98\<_[0JMKT:?
MVYHES<IYECM*$Y^56.,9J*>&IU(PD]+\WSL-R:-Y?$4<5Y#;7L#V[3G$;-T)
M]/K6[6%+9:#%+ [0Q-(6_=8)8YK<'3BN*NH:.":*5Q:***P&%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 4=4_U"_[PJ]5'5/]0O\
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MADU2UFT6TFL]D@:5L%%9>XQWKI(/#^G6]W]J2V07!Y,@')K3%+3JXNI-6O\
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M4I.\F,****D HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"CJG^H7_>%7JHZI_J%_WA5ZM)? OF(*2EI*S&%5;^\CT^QFNY<[(E+-BK
M513PQW$+Q2J&1QA@>XJHVYES; <OX9\:P^(;Z:U%NT3QC<,G.1G%=761I7AK
M3=%FDELX-CR?>.2:U^*Z,5*C*I>@K1\Q1O;4@OKE;*QFN3R(D+5SOA"U%[:/
MJ]W^^N+AB59N=J],#TZ5T=Y;+>6<UN_"R*5-<QX8O#HR/H^HCR'B8^2QZ2+[
M?G6E'7#S4/BNON_X<3W-74]"2ZN[6]MPL=Q"X);'WE[BG76MXU0:;:0^?<[=
MS\X51[FI;G5E5UALT%Q.Q'RCH!W)K"T_&E>,+W[9\OVE%:.0].!R,_C3IPE.
M+]IKRIV0/R->WUO_ (F1TZ\A\BY*[D&[(<>QJ"U\1276KW.FK9,LD*ALEN#G
M/M[5GWG_ !-O&VGR6AW16:DRR#H.O'ZBFZ3=0_\ "?:H?,'S1J![D%LUK["G
MR.7+KRWMV=_\A79JVVORRW\VG/:$7D6#@-\I!]ZET[6FNM3NM/G@\JX@&[ ;
M(8<=_P :Q["Y@/C^^_>K\T2@>YP*-.N8#X^U$>:O,( ^N12GAX6E:/V4_GH%
MS0A\123:[-I7V-A(B!PV[@]?;VI\6O2?VI)I<MJ5NU7< K94CZ]JR;2XA'Q%
MNSYJ_- J@^I&[BG17<!^)$H\U>;? ^N!52P\+M*/V;]=PNS8LM:DFU:?3;B#
MRIT3>N&R&%1VNNS/XA;2+BU$;B/S X?((Y_PK,BN8?\ A8,A\U>;?:/KGI3I
MW%K\0DGG.R*2V"JQZ$C/%2Z$+M<N\;_,+LT=5UR?2K^UA>U#PW$@C5P_(S[4
M:YXA.C>07M6D25@H8'O6-XMO[>2_TL1R!E2X4NPZ*,U)XWN8/L>F?O!S<*?P
MQ54L/"3I<T=[WW!O<U+_ %RYTVW6[FLO]%+!6._YADXZ8IVNZPEAH_VPVOVB
M!DW$$]L54\:W$(\+N3(,.Z8]^153Q'<PM\/\+(I+6ZA0.YVU-&C"?LY..\K=
M?(&]S;N]<M]/TRWN'0[I@!%$O4D]J@GUVXL'MS?V9CBG8(K(V[:3Z_G6'JZ%
M[;0=2BS+;VK RA>PP1G]:ZF74K"2*,DI.'(V #.?>IE2A!1?+>][^7];A>Y#
M<ZPW]J?V;:6YEG";V).% ^M-L];,NJR:9=0&&Y5=X&<AA]:S&U">[\0W5J\J
M6,<2CG:-\F15"TEMX?'(<7#/&8-N]^A.>U7'#1<6FM>6_7_AOD',6;N]U0>.
M+>V$<;1K&S1INQG(/6M/6=8.GK;"ZL1())%4G=PK'\*H7S+#\0+.:4[8S;D!
MCTS@TWQG>6\EC9%9@<72''L"<FK4(SJ4H\NC73YBV3-G4=;BT][:!8S+<W'$
M<2_U]!4;ZY)8W<,&I6_DB<[8Y%?<,^E8^H?Z/XITO4I#NM&B\OS.R&I/%C+J
MCZ?8V7[V;SU<[?X%!!S^E9PP]-N$6M&G=]M_R'=E^]\2M9:S!I[63LTP)1@W
M7&/;WI]SKLVGWMK#?6NR.Y;8CJ^<'T(_"LC5YHD\:Z.&E'[N-E8^ARM/\:S1
M"ZTA3(.+D$CT&#S50P]-NG'E^).^_F%WJ=B*6LZ\UBRT_P"S_:9U3SVVQ^YJ
M^#D CD=C7FRA))-K<LK7]T]G:23I$9"@R5!Q638>()]2T7^T;>RP "S*S]AS
MZ5J:K*D>F7#.VT;#S7->%[J!? [AI5!2-PV>W%==&G%T7-QN[I?>2WJ:=OK\
MM_IAO;*T+JH.0[;>1U JQ9Z[;7.B?VHQ\N( EL]L'%8GA:ZM_P#A#9/WJC:T
MF?;FLZR@?4/ %Q;VS;Y59F*CJ?FK>6%I\THM62DE?R%S,Z1-<O)K#^T([ FT
MQN&6^8KZXQ5;7=9DN?"4U_IA5D:,[F8X*\<\>M2VNL68\+JQ< B J8^X..E8
ML&GW%M\.;Y)$8/*))53T!R113I04N9QM:27J@;9O:+>3PZ%'<7BI'"D6[?OS
MFDAUR[N[(W]M8[K0#<I9L,P]<8JA+MU'P/\ 8K:0-.T PJ^QZ5:TC5K./PM%
MYCA&BAV-&>H..E3.DK2GRW?-:WE_P0N69/$43:&VIVL1FC4$LN<%2.H-5[?Q
M%>7EI!=V^FN\$C;3EN1[]*Q["%K'P1JDER##]H\UT5O0Y(K>\(RQR>&[38X.
MU3G'U-.K2I4H2DHWM*WX FVS<'2LC4M<6SU&#3XT#W$P)4,VT8'O^-;':N7\
M1?V7=:E;V.HQM&SJ3%.I((/'<5R8:$9U+25UJ5+8T+36)I-5;3KFT,+A-ZOG
M*M]*R=(*Q^,]:;A56-3SP!R:KZ?]JTOQ%!9P71OK1URSN.8A]:HBUCUGQ7K,
M$=\804&-G\1R?TKT(T(KG2TBXK77NNFY%SI]/UF]O[R5([$?9HVQYV_AOIQS
M2:?K"77B"YL6LO*FC3<9.[#BJGAO6T0MI%[LBN[?Y1MZ./6JUA=V_P#PL&^_
M>K\T&!]>*QE07-47+:RNM_O'?8DM !\1+L 8'V9?YFEA 'Q(E   ^S#I]*AM
M+F#_ (6%=MYB[3 J[L]\GBEBNH#\2),2J<VX4?7'2MG&5WI_R[_R%_F:HU]K
MK4[BSL85D>WX?<^W)Z\5:T?5O[36</;M!+"Y1D:N=NK72=7U:Z1Y);"_A."Z
M,1N]\=ZM>&;N[2XU"WNG6:WMN5N0N"_UK&I0I^R;BK-);_U9W&F[G65#<3I;
M6\D\A^6,;CBH-/U.TU2 RVDHD4-M..QJ2]81V4SF/S JY*>M<'(U/EDBS$B\
M1W%QIIU*"R\VVQD!7^;'TQ5JY\16]MIMK=%6:2YP(H1U+'M7,"QTV>P;4](U
M"2SDP6,))*D^A!I+A[R>/0M7O("D<+XE"KP,D8;'X5ZKPM&4M%97?D]MO^"C
M/F9TD^N3:=Y4FHVOE0RL!O5]VT^]37VMQP7L-C;QF>ZE&X*#@*/4FLKQ;=PW
M^D)9VI$T]PX"*O./>J\43:-XOCGNP?)GMQ&LIZ!ADXK&%"G*"FU9ZZ=[?U^
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M,5N6DDDMNLDJA2PR #GBN(?4X=>L;>PNKZUBAXWE6.Y\>G%=U!L$*+&04"@
MCTK/%4E3BDXVEKWVZ#B[DE%%%<)04444 %%%% !1110 4444 %%%% !1110
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M'=EK4/$MI8:K;6#-F24\_*>!6B^I6D2([S* _P!WU_*N8U:*#_A*]#^4%"N
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MG//'/MT-5-%TO[=X85I+Z)5=<S%H\LK?7/6CZI22<G+31?-_Y!S,[:>\M[9
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MRW>WF4F-QA@"0:P_^$(T(+M6UD ]!,W^-=%150KU::M"30-)[D%I:165JEM
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M+0 4444 %%%% !1110 4444 %%%% !1110 4444 4=4_U"_[PJ]5'5/]0O\
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M\5]>W_#=1-O4['WKB/'XCADTJX*_,MTA)'4@$5VD((@0-U"C-<AX](5M().
M+M"?;D5EE^F)C\_R'/X35E\1QV4<<EW:SPV[X F8# ^O-6[_ %NTL! K$R2S
MG$4:=6K-\6W-M_PBES$661I8PJ*IR2?85EK<R6TVCZ;]FB.H+#N^T3=$SG]:
MTIX>%2"G:VKT]%>_^8FVM#?3Q#"FH165W#+;33?ZL2 8;Z5-J&M6]A=PVNUI
M;J8?)$O4CUKDO$!E3Q#HGVB\CF83#(7HO(K4\16>F:EJ]K$]R]KJ"H6@G0X[
M],U7U:E>#>S3;MY?C8.9FK9Z_!=:D^GM#+#<JF\K(.,4CZ_$T\L5I#)<^4<.
MT>, ^E<U;RZGI^OQZ?>O%?O/$PBN4'SIP>M/\(V-C+97,-Z@6\CN'\T.<$\]
M:J>%I0BY[JRVUWOKT?0%)['0?VA9:WHUS)%\P0$.C#E6K'\(W,=IX(CEEC:2
M,!LJHYQ6K'#I5II]^M@L<?'[PC@$X]:RO"#I_P (*V67B-^_L:E*/L9**=N:
M._HPZFII.J:<OA_[;8V[I:AC\@ SGO19>)X=2M3-8VL\NTD, !D8_&LOP=+'
M_P (3)\Z<-)GGI4W@)D_X1HG*Y\Z3//^T:*U"G#VDFKM2MOZ@F]#:TS6K75+
M62>(E?*)657X*$>M53XDB,;S6]M-/;H3ND0#''7O7,Z,KS:?XECMV'F-.^T
M]?E%:'A:PTFX\.6_FHBR(FR56;!# <Y%.IA:5/FD[M)K3U5P4FS8NM9ADT7^
MTK:=/LX&68_R^M8GA&\NWN)+,QB(*?,9)"=Q!Z$5T>F6NF"P\FRA06VX_*!Q
MG//ZU?$$2R>8$ <C!..U<[K4X0E34=^X[-ZCQ2T8HKB*"BBB@ HHHH ****
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M&<=?G'%.::-5#-(@!Z$G@T<K DI*:DJ2#*.K#U4YIU%@#O1Q69%#/_;4D_\
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M*%HARWZ5':^&W_L-M(O71[=>(W7[P]#35:BE[SO:5^^G]=!68^3PY!<:+'%
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M.JV\Q;-I'#YIW#K7AEFLGC_XMDR#S(//);_KDAQ_+%>U>,K@:?ID=K; ^=<
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MCT/PW96$:[=D0+C_ &B.?UJEXH=I##8P?ZR<_./5:^;Q&,>+Q\ZBV=TO)?\
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M&PLOBC'7\#&EK)R)****^6-PHHHH **0T9H 6BDSS1F@!:*0&C- "T4F:,T
M+12=Z* %HI,T<T +12 YHS0 M%)FC- "T4F:,T +12$T9YH 6BDHS0 M%)FC
M- "T4E&: %HI*,T +129HH 6BDS1GB@!:*3-&>* %HI,\T9H 6BD)HS0 M%)
MFC- "T4F:,T +129XHS0 M%(#1F@!:*3-&3B@!:*3-&: %HI,T9H 6BDS10
MM%)FC- "T4F:,T +129-&: %HI,T9H 6BDS1DT +129HS0 M%)2T %%)F@F@
M!:*3-&: %HI,T9H 6BDS1F@!:*3/I1F@!:*3-% "T4E&: %HI,T9H 6BDS1F
M@!:*3-&: %HI,TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3R+"XGLXM/@&T20DF611P 01@9'7%5[7PYJ^;:QN9K8:=:3&5'0GS'SGAAC
MZ]O2M.7#7=^7Y-[:Z^NW^0O>'S^+K^.XF=-)1K&"Y%L\QGPV20,A<=.15O4O
M$.H+?RVFCZ8EZ\"!YB\WE@9&1C@YJ.3PY=/IE];"2/=<7@N%.3@*"IQ]>*+K
M2M;L=1EN]&:S?[1&JRK<LP"E1@%<#G\:E+"MZ)7\V[/;?7U'[PMUXFOC)!;Z
M?I7G730F:6.:3R_+4'!YP<G-1R^+YWM=.>PT[SY[P-^[>39L(&>3BDGT778+
MJ&^L[FVN;IH##/\ :<JN"<Y&T=NE26?AF>S;2SYZO]EWF5CU8LN.*=L*HIZ/
M?J^SW^=K;![Q4M_&-],(GFTE8K9YC;O()^5DSC &.1G/-4M$UO4[CQ%"L5JQ
ML?(D)#W)9L!_O8QR<\8K4_X1F[_L^.W\R'<E^;G.3C;N)Q]:KV?A?5+*XA\N
M6V:,P20S'<P8;G+ KQ]*U4L(HR44E?U\]=Q>\+8>.6N=>CTZ>UMXA*6"[;D-
M*N!GYDQ\M21^+[YYUE.E(-/-U]E,WG?,&SC.W'2LZQ\(ZS%=:6]PNG(EB6R\
M98O*",98D9S6NOAR[71_LGF1>9]O-SG)QM+$X^M*K'!1DN6WWON]?R!<PWPU
M?ZI=:[K*7<*BWCE&QA-NV_*. ,?C5J3Q+Y=A>7/V;/V:Z%OMW_>R0,_K3](T
MN^L-9U&20P-:7)5T()W@A0.1T]:Q;_PQKD[7EI!-:"QN+M;DN[,)!@@XQC':
MLK8>I6]YI*T?TO\ ,>J1-J/C6:UU9K&UL[>9D1697N-DC9'\"X^8U-K_ (S3
M1Y+>!([;[3+'YK)=7 A"CZD=?:JGB#POJFI%HHX["XB8+MDF9HY(B/[I09/X
MFI+KPMJ$,EI<V/V.[N(H/)D6^&5QG.0<$YK6,,%:#=O/7?3J^GW(7O'0:'K$
M.MZ1'?Q[0&'S!6R ?KWK&_X2V[-QYPTP?V6+C[.;CS?GW9QG9CI[YK;TFRFM
M-*CM[IXWFV_.8E"KGV  KGE\-ZN&.G&:V_LLW1N?,R?-Y.=N,8Q7-26'<YWM
M:^EV]O+N^PW>Q%?R:K?>/K6V$3BPCB\P&.[*9&?O%0.>N,5?U;Q/?66J3V5G
MIBW(MX!-([2[<+DYQQR>*T5TJ5?$4>H!E\E;8P[>^<@_TJO<Z'<3ZIJ%TKQA
M+FU$*@DY!R?TYJE5HR<5-*RCY[W]0LS&F\6W$MH_VO3F@AGMFGA:.<AV &?3
MY>HI[>,+](IWMM)66TLU032/<889 / QSUJ2^\)WMU:V<:2PAH;)K=LD\L5
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBDH 6BBB@ HI*,B@!:*86 IAD]*:0$N132X%19;UI*KE <9">
ME-R3US113$%%%%, I:2BD M%)10 4444 %%%% !1110 4444 %%%% !1110
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MT_=SWKM=!N NF6EO/(!<F+>(V/S;,\''Y5R8C"*E!25_N\KZ%*5V:-Q>6UJ
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M#)&[D"N%MK%8]&U'[,@5;"]>:)%XP%;.![<5%.]YJ?A;4]:@#I<7*@1[1N*
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M_F2ILZB3Q#9C6;;3H2D[3@GS(Y 0F#C!]^:EM=<MKB6\#E8(K:7RS+(X"L<
M\?G7 +?>'K/6=,NM-:(R0VK-<+$1PWRYWX_BSZ^]7+J""VL]!DU?9]CDF9[H
MN/W?(;&[MCIUJY8"FK*S5U\[ZO;T7XAS,[_[;:^0)_M,/DGI)Y@VG\:?%<0S
MQ^9#+')'_>1@1^=>:3P6]QI$D=NN=,?4T\D+]PKO'W?]G%>A+9VUCIKP6L$<
M,04D)&H49KDQ&&A22U=V_P#+\=2E*Y*FH6<LOE1W<#R'^!9 3^5*+ZU,OE+<
MPF09^02#/'7BO,-..D&PTE+'R_[8\YMVS'FXRWWN^,5LVNF0G2-=O8H UY]H
MG E ^<#'(!ZBMZF A!ZM]MO.WW"4VSMH;ZUN79(+J&5EZA) Q'Y4G]H69N/L
M_P!K@\_./+\P;ORZUP>D?V:^LZ6VA>7YJVI%WY '#?+G?C^+KU]ZCTUO#?V6
M%;W!UT2G(3_CY+Y/X]/TI2P$4WO]VO7?RT#F/0&O[1)_(>Z@68](S( WY=:K
M:MK5II%G-/-)&7C0N(?, 9_H*\SGA676+DWVL06]Z+WY(6LE>X*[AC:Q.=M7
M=:.DI#K2ZXR_;VB7[.9.'(V_\L\]^F<=ZUCEL%.*;;[I)^6VVFHN=GHUEJ$5
MY:QS*0I=-^PL,@4][ZTCC5WNH%1NC-( #7!6^I6FEW<;W<RPI+I96(R' <[C
MP/>HM&M+?4T\,)>0!T:&1C$XR/N#J*R> BKR;:C_ ,!O]!\QZ!)J-G"4$MW;
MH7&4W2 ;A[<\U9# C(.1V->4>(+:(:WJ$5]J5K8QJB"VCFLUD8J%Y\HDC';I
M7HVE2QQV5M:&X\R<0A\.-KLN<9Q66)P<:5.,XN]_)^NXU*[-$'-+2"EK@*"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBC- !24A8"F&3TII,"3(I"X'>H2Q-)WJN4!YD]*:6)ZFDHIV
M$%%%%, HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ("#FL/1M4UFRM;B[C^SG3([^5)(V4F0C><D'./TJHX&KRM2=FK=>_H+F1Z
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MBCF>P *6BBI **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
MPD^AIA+_ -VBBJ0"$.>H-)M;T-%%.X@VM_=-&QO0T447 -K>AHVMZ&BBBX"[
M3Z4;6]#111<!-K>AHVMZ&BBBX!M;T-&UO0T447 -K>AHVMZ&BBBX!M;T-&UO
M0T447 -K>AHVMZ&BBBX!M;T-&UO0T447 -K>AHVMZ&BBBX!M;T-&UO0T447
M-K>AHVMZ&BBBX!M;T-&UO0T447 -K>AHVMZ&BBBX!M;T-&UO0T447 -K>AHV
MMZ&BBBX!M;T-&UO0T447 -K>AHVMZ&BBBX!M;T-&UO0T447 -K>AHVMZ&BBB
?X!M;T-&UO0T447 -K>AHVMZ&BBBX$F#Z4444AG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g30vudsvo52a000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g30vudsvo52a000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /B" \# 2(  A$! Q$!_\0
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M(W7_ '];_&C^V-3_ .@C=?\ ?UO\:K^SI]Q?VG'L?3V]?6C>OK7S#_;&I_\
M01NO^_K?XT?VQJ?_ $$;K_OZW^-']GS[A_:<>Q]/;U]:-Z^M?,/]L:G_ -!&
MZ_[^M_C1_;&I_P#01NO^_K?XT?V?/N']IQ['T]O7UHWKZU\P_P!L:G_T$;K_
M +^M_C2?VQJ?_01NO^_S?XT?V?/N']IQ['T_O7UHWKZU\P?VQJ?_ $$;K_O\
MW^-']L:G_P!!"Z_[_-_C2_L^?<7]IQ['T_O7UH\Q?6OF ZQJ?_00NO\ O\W^
M-']L:I_T$+K_ +_-_C3_ +.GW!YHNQ]/[U]:/,7UKY?_ +9U/_H(77_?YO\
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M3_Z"-U_W^;_&G_9T^X?VDCZ>\Q?6E\Q?6OF#^V=3_P"@C=?]_6_QI?[8U/\
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M"%U_W^;_ !H_L^?</[378^G_ #%]:-Z^M?,']LZG_P!!"Z_[_-_C1_;&I_\
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MP<H*[9I2QZF[6/6RP'M0'6O%_B5>7ECKRQV]Y<1H8U.%D(KB/[8U/_H(W?\
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M*I2<'9B4445OH9V"BBBC004444: +7I_PA_U]_\ \!_D:\PKT[X0_P"OO_\
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MI>JV<LYC0!U*9&?SJKKOCBQ?2/[*T.U-O;2+M;(Q@4^2;O&P_:1^*YK2 /\
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MJ9_"RZ?Q(^AX_P#D2#_U['^5?/EQ_P ?,W^^?YU]!1?\B2?^O?\ I7S[<?\
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M?3ZA_9]0\1'WN%Q]:0_0^]>W_P#"K-']_P J/^%5Z/[_ )4?7Z8?V?4/$,
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M]_RH_P"%5Z/[_E1]?IL%E]0\/SCK@Y]J.V.YZ5[?_P *KT?W_*E_X59H_O\
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M@T<>G([]C7N'_"J]']_RI/\ A5>C_P"U^5+Z]3!8"I<\0'KCZ>E P?>O;_\
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M#7?_ /"J](]_RK2T7P)IVB7RWD!.]?:L:V,A.#2-:&"G"=V<S\71_H%K_O\
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MFO;_ /A5>C^IX]J/^%5Z1ZG\J7UZF'U"H>(=N1@]J7(_.O;O^%5Z/[_E2_\
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M (59H_H?RI?^%6:1[_E0\?3#^SZAXA[=0.A%)GH>N>N*]O\ ^%5Z/[_E2_\
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MK-']#^5'_"K-']#^5']H0#^SZAXAQ1Q7M_\ PJS1_0_E2_\ "J]']_RH_M"
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M[0/]X5B?;;/_ )]9/^_E)]OL_P#GUD_[^4<@N8W/[0/]X4?V@?[PK"^WV?\
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MKB?^$KL_^@?)_P!_:/\ A+;+_H'2?]_:/92[![1';?;_ /:%'V__ &A7$?\
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M ****=P"BBBBX!1111< HHHHN 44447 ****+@%%%%%P"BBBD 4444 %%%%
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MCFD[#H5'2JT$Q/QIG/2G^N133G\>]/0D0TWO3CCFFG..2.. : 8A'I3>:7G
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7#-N[%BCDO;@R/GGMZ5UFE::L:J<5%I>F !25KHHT"* !7DMW=V>NE;85%
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ME1_;K/\ YZ/_ -\4GVZT_P">C_\ ?%%PL24E1?;;3_GK)_WP:/MEIC_6R?\
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MTUU'_"-6/_/_ "_]^J3_ (1JQ_Y_Y?\ OU1[>(O9LY8TTUU7_",6)_Y?Y?\
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MMG^S1]L_V: #[(WJ*/LC>HH^V?[-'VS_ &: #[(WJ*/LC>HH^V?[-'VS_9H
M/LC>HJR%^3;5<7>3]VK ;Y-U %8VA).349L,^E3&[Y/%-^V#^[0!%_9H]J/[
M-'M4OVS_ &:3[9[4 1_V:/:C^S1[5)]L]J7[9_LT 1?V:/\ 9I/[-'^S4WVS
MVH^V>U $/]FCU6C^S1ZK4WVP>E'VP>E $/\ 9H]5H_LT>U3?;!Z4?;/:@"'^
MS1ZBC^S1ZBIOMGM1]L]J (O[-'M1_9H]JE^V>U'VW_9H B_LWZ4?V;]*E^V?
M[/ZT?;/]G]: (O[-'M1_9H]JE^VC^[^M'VW_ &?UH B_LT>U']FCVJ7[;_LT
M?;/]F@"+^S1[4?V:/:I?MG^S1]L_V: (O[-'M1_9H]JE^V>U'VSVH B_LT>U
M']FCVJ7[9[?K1]L]OUH B_LT>U']FCVJ7[;_ +-'VW_9_6@"+^S1[4?V:/:I
M?M@_N_K1]L_V: (O[-'M1_9H]JE^V?[-'VS_ &: (O[-'M1_9H]JE^V>U)]L
M]J (_P"S1_LTG]FC_9J;[9[4?;/:@"'^SA_LTO\ 9P_V:E^V>U'VSVH B_LT
M>U']FCVJ3[9[4OVW_9H B_LT>U']FCVJ3[;_ +/ZTOVW_9_6@"+^S1[4?V;[
MBI?MO^S^M'VW_9_6@"+^S?I1_9H]JE^V?[/ZTGVSVH C_LT>U']FCVJ3[9[4
M?;/:@"/^S1[4?V:/:I?MG^S2?;/:@"/^S1[4?V:/:I/MGM2_;!Z?K0%B+^S1
M[4?V:/:I?M@_N_K2?;!_=_6@+$?]FCVH_LT>U2?;!_=_6C[8/[OZT!8C_LT>
MU']FCVJ7[8/[OZT?;!Z?K0%B+^S1[4?V</\ 9J7[9[?K1]L]J0$/]FC_ &:/
M[-'^S4WVSVH^V>U,"'^S1_LT?V:/:IOM@]*/M@]* (?[-'M2_P!F_2I?M@]*
M/M@]/UH B_LWZ4?V;]*E^V?[/ZT?;/;]: (?[-^E+_9H]JD^V>U+]L_V?UH
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ME&!Z4 8?V+4?[L7_ 'W1]BU'^[%_WW6Y@>E)0!B?8M1_NQ?]]T?8M1_NQ?\
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M\6@P#W;C'-'.A^R9BZU!%9^)=%:VC6+,I0[>-PVFG>'HX[[7-8DNPLTL<^Q
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M_,?<YI+'PXNG:C)=6]]<)&[[O(&-@J925BXP=S;[44=L45SG4%%%% !1110
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MMY&;DW-W#<>83A5$1(6G(F*=]"PD8N]:E68AA%&" 1P3FFVL*O>WEH0RQ-R
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MGFF4P$I#2TAI@,-)3C24 ,III]--.PAAI*<:;18&--)2FD-58D8:::>:::+
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M$#/([C:SL/FQ7044W5;$J$$SFM(\&VNDZQ-J4,\C/*Q8H0,"K>N^&+#7H_\
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M]>>QH].!D]_2K7V0_P!X4?9#_>HU"R*O]**M?9.?O"C[&?[U'095HJU]D/\
M>H^R?[5 %6BK7V3_ &J/LG^T* *M%6OLG^T*/LG^T* *M%6OLG^T*/LG^T*
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M6L&[06W_ 'Z%,_L^3_GC:_\ ?D4U6%[,\W/M3#7I?]GO_P \+7_OR*/[/?\
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M GFDSSFOH#^PX_\ GSLO^_ I/["B[V5E_P!^!1]>?87U(\"@A>XE6*-&=G.
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M=%5Z* +'VMO[HH^UM_=%5Z* +'VMO[HH^UM_=%5Z* +'VMO[HH^UM_=%5Z*
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M;QZ#\ZH_9K;^]-^=)]GMO[T_YT6"Y?\ MX]!^=']H#VJA]GMO[TWYTGDVO\
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MY\?'>C_\\+[\Q2?\)YHW_/"^_,4_8S[![>'<]"^WCT%'V\>@KSW_ (3W1O\
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MHHH#J%%%% !1110 4444 %%%% !1110 4444 %'I11Z4 :(_U'X5G]S6@/\
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M-%%%P#MCM1110 4444 %%%% !1110 5I1_ZM:S:TH_\ 5B@!]%%% !24M)0
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M /H%S?I_C2?\(AK_ /T"Y_T_QI^WI]Q>RGV,$TT_6MX^$/$'_0*G_3_&F_\
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MXFN.6D6W^A#4_P#LKQ%G']I9]]@KL>.W:D Y[4U$CV[?0XW[#XDAY%T)CZ$
M5 ^I^(;$[KS2T,0ZNDFX_D*[KC--VJP((XI<CN/ZQY'&VWC+3;@[':2&0'!\
MV,J/UK<@NX+A,P2*X;T.0*35?#.FZLA%S:QN<<,1S7 :EX:UOPP6N=&N99+9
M.3;D]?PJ7*43:$*57;1GH_U[<9I*\_T/XBPS2+:ZDOV>8'YCT4&N\AGCN(A)
M$X93R,=ZJ-2,M$9U\)4I/WB2BBCZUI9G)LPH'6B@4 :2C,8'M58VK$D@U84X
MC!]JA^U8)&* &?96]:/LC>M.^UCT-+]K'H: &?9&]:/LK>M/^UCT-'VL>AH
M9]D;UH^RMZT_[6/0T?:QZ&@!GV1O6C[(WK3_ +6/2C[6/2@!GV5O6C[*WK3_
M +6/0T?:QZ4 ,^R-ZT?97]:?]K'I1]K'H: &?96]:/LK>M/^UCT-'VL>AH 9
M]E;UH^RMZT_[6/2C[6/2@!GV5O6C[*WK3_M8]*/M8]* &?96]:/LK>M/^UCT
MH^UCTH 9]E;UH^RMZT_[6/2C[6/2@!GV5O6C[*WK3_M8]*/M8]* &?96]:/L
MK>M/^UCTH^UCTH 9]E;UH^RMZT_[6/2C[6/2@!GV5O6C[*WK3_M8]*/M8]*
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M%ZB@!G]D/_?;_OJC^R'_ +[?]]4_^V8O:C^V8O:@"/\ L=_[[?\ ?5']D/\
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M M!G]D-_?;_OJC^QV_OM_P!]5)_;,7K1_;,7K0/0C_L=O[[?]]4?V.W]]O\
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M5O6G_:QZ4?:QZ4 ,^RMZT?96]:?]K'I1]K'I0 S[*WK1]E;UI_VL>E'VL>E
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M4P$-%!HH 2DI:2@ I*6DH 2DI:2@!*2EI*8"4E+24 -/6B@]:*8A#3:<:;0
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M=-VH[U/M'<I44<ENN?$6KVLOV.>UMK0ER9EPS$C%6=%M+B'5-8:2)U229BK
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M_O"@"O15C[(_]X4?9'_O"@"O15C[(_\ >%'V1_[PH KT58^R/_>%'V1_[PH
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M% %K[9_L?K1]L_V/UJK10!:^V?['ZT?;/]C]:JT4 6OMG^Q^M'VS_8_6JM%
M%K[9_L?K1]L_V/UJK10!:^V?['ZT?:^1\G7WJK1Z4 :6[Y-V*K_;.?NU./\
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MW#V$3S\^ K;_ *"K?]^31_P@5M_T%6_[\FO0/(3T%'D)Z"G[:?</81//?^$
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MG_X\*/.N/^>?_CPKRSSY?^>K_P#?1I//E_YZO_WT:/K O[078]4\VX_YY_\
MCPH\ZX_YY_\ CPKRDSR_\]9/^^C2>?-_SV?_ +Z-'UD7]H+L>K>=<?\ //\
M\>%'G3_\\_\ QX5Y1Y\W_/5_^^C2>=-_SU?_ +Z-'UE"_M%'K'G7'_//_P >
M%'G3_P#/,?\ ?0KR?SI?^>K_ /?1IOG2_P#/1_\ OHT?6D']HH]9^T39_P!7
M_P"/"HYM1-N1YJE0?>O*O.FYQ*Y&/[QK3TK5MB&UN79H)#A6/5#36(N53QZD
M[,]"BU6-CUZ>]:$<P?!'>O.Y6FL[K:3\O\+@Y!%=%I.J!@%!X/KWKHBTT>E&
M:DM#I^V:M6G5JHQR!U'-7;/JU,H2[_UE5ZL77^M_"J] !1110 4444 %%%%
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M(P<5VV@ZDL@.X^U=B:9[:U5S;NO];^%05+<,&D!]145 !1110 4444 %%%%
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M ?1110 4E+24 %%%% !1110 E%%% "&B@T4 )1112$%)2TE !1110 E)2TE
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M** "BBB@ HHHH **** "BBB@ HHHH **** "K-G]]OI5:K-G]]OI0!<HHHH
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MC_,T6"QH_A25G_;[O_GTC_,T?;[K_GTC_,T6"Q?HJA]ON_\ GT3\S1]ONO\
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M9G&?A33GTKM/[/MO^@5#^9I\>EVKM@Z7"/Q-'L&+ZK(X8_2FFN]ETFTCZ:7
M?Q-0_P!FVO\ T"8?S-+V,A?5&</^%-./2NZ_LVU_Z!,/YFC^S;7_ *!,/YFC
MV#%]49PAIM=Y_9=K_P! F'\S1_95I_T"8/S-'L&'U.1P1IM=]_9=I_T"8?S-
M']E6G_0(A_,T>P8OJ<C@*::]!_LFS_Z!$'YFC^R;/_H$P?F:7U<7U*1YZ:;7
MHG]D6?\ T"8/S-']D6?_ $"(/S-'U=B^I29YU25Z+_9%E_T"(/S-']CV7_0(
M@_,TOJ[#ZA(\YI*]'_L>Q_Z!$'YFD_L:Q_Z!$'YFG]7)^H2/.*2O2/[%L?\
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MGU- :FCB+VI,1>U9^3ZFC/N: -#]U[4N8_:L[)]:,GU_6@#1S&.XH7!)VUG
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M_,W_ 'V:/;"^MH[_ ,VX_P">$GY4>=<_\\)/RKS_ .V77_/S-_W\-)]LNO\
MGYF_[[-'M@^MH]!\ZX_YX2?E2>;<?\\)/RKS[[;=?\_,W_?9IOVVZ_Y^9O\
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M@U:L_O-]*J*P89%6K/[S?2@9<HI*6@ HHHH **** "HYO]2_TJ2HY_\ 4/\
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M4478-(/<\_2@T44AW"BBB@ [?A6E'_JU^E9M:4?^K% #Z*** "BBB@!****
M"BBB@ HHHH *2EI* "BBB@ I*6DI"84&B@TQB4444D)"4444 %%%% !24M)0
M 4E+24 )1110(0T4&B@ HHHH 2BBB@!*2G4V@04E+24 )12TE(!**** $I*6
MDH$)1110 E%%%(!*2EI* $I*6DH *::=330(2BBBD E)2TE,0E)2TE(!*2EI
M*!"4E+24"8E)2TE "4E+24@$IM.IM "4E+24"$I*6DI"&T444 -I*6DI"$II
M^M.IM @YZ=>*9T';':G4G:D*XT@'J3D<\'%'N._7VHHH"[&]ER<X].]-.>I.
M?8<4ZDI"N)QSQCZTGZ4IIM.X7 X[=#T]:H:OIZ:MI<]E(<"4;2?2K]--(5RK
M8P26UE#!)(':-<%@.M3].0?I2T47%<R]=TQM7TXVJN(V+JV>W!S5RWA^SVT<
M1;)5=I/K4QI#2;%=B=.V0!P:;_>SGI\ISP:4TE KL/KR/;BF'H.O7M3J0]*D
M6HUL^V!V I#CGG@=,]Z6FFBX78'''!&/?J*;WZ\C^5./04TT7$Y,3D#:2#[B
MF^X!'< TZFTKBNV'4\]2.GI3?;J!U]Z=33Q1<6HA]N/:F_[W0'C%+24KBNPP
M=W//U[4WJ%[^HI3UI._%(5V)DY) SC]:8.PZXZT[O24M1.XASG&:3_\ 5SVI
M3ZTTT:BU#T('/>DXS[4M(:+L5V)VYSGVXJAJUE)?V#VT<HC+$9;'49J_3:+B
MNRO9VR65I%;Q\JB[:F/49^8=L4M)4]178TYXYX_E1@]L<4M)VHNQ.XG^Z1@]
M"1TIO&<C.WMS3NWXTVB[%<0]SU/7-)G@@=#2TG>E=BN(>O .?:D/!Q]X>M*:
M#3YF2V(>_(/H,=*;UZ\9ZYI:2B["X'.",CGTIN/0CBE-)4ZHE,0C).#SUR*:
MXW(<87(QDBGTTT[L.8H:58-I]N8C(&R<DXZ"KW.,8X[44E*[$Y"''O@=1GK1
MCJ">,\"BBAMBYI"'., C\11Z]<#I124KL3D["=%P.GO2'& 1QGJ#S2TG6CF9
M+F!/S,,9^E-/)Y."O(-+24KL5Q#VQD9///6COD],4II#R*+LGF=R,11[VDV*
M&88) YIV"!@?F>]+1VHN^XY2?<3H0?S [TG)^M+24:OJ2YR#_:)R<8I#T Y]
MO6BD_6C5=2>=AVP#P#Q0?O?_ %Z.1TH(W8 7/?ZTM6&KV$4$L H)8GI716EJ
MFCP>9(H:^D'R@\B,?3UI+"T73(%O+@ W3C]U&?X??ZU-;6\EW<;V)8GKFNRC
M2[GKX/!Z<TQ;.TDN)-S<ECDL>]=SH6GK%GY0.*IZ;IRQH,BNCL5"Y ':NM*R
M/8T2T+BC:N*=24M !1110 4444 %1S?ZE_I4E1S?ZIOI0!G44#TI>: $HI>:
M.: $HI>:.: $HI>:.: $HI>:.: $HI>:.: $HI>:.: $HI>:.: $HI>:.: $
MHI>:.: $HI>:.: $HI>:.: $HI>:.: $HI>:.: $HI>:.: $HI>:.: $HI>:
M.: $HI>:.: $HI>:.: $HI>:.: $HI>:* $HI:/RH'<2BE_*B@!**7FCF@0E
M%+S1S0 E%+S1S0 E%+S1SF@#0'^H_"LX_>-: _U'X50/4T )12\T<T )12_E
M1S0 E%+S1S0 E%+S1S0 E%+1^5 "44O-'- "44O-'- "44O-'- "49I>:.:
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MO_?(H"Q=HJEY]_\ \]%_[Y%'GW__ #T7_OD4!8N453\^_P#^>B_]\BCS[_\
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MR)ZFC[(GJ:@^TR?WA^5'VF3^\/RH G^R)ZFC[(GJ:@^TR?WA^5'VF3^\/RH
MG^R)ZFC[(GJ:@^TR?WA^5'VF3^\/RH G^R)ZFC[(GJ:@^TR?WA^5'VF3^\/R
MH G^R)ZFC[(GJ:@^TR?WA^5'VF3^\/RH G^R)ZFC[(GJ:@^TR?WA^5'VF3^\
M/RH G^R)ZFC[(GJ:@^TR?WA^5'VF3^\/RH G^R)ZFC[(GJ:@^TR?WA^5'VF3
M^\/RH G^R)ZFC[(GJ:@^TR?WA^5'VF3^\/RH G^R)ZFC[(GJ:@^TR?WA^5'V
MF3^\/RH G^R)ZFC[(GJ:@^TR?WA^5'VF3^\/RH G^R)ZFC[(GJ:@^TR?WA^5
M'VF3^\/RH G^R)ZFC[(GJ:@^TR?WA^5'VF3^\/RH G^R)ZFC[(GJ:@^TR?WA
M^5'VF3^\/RH G^R)ZFC[(GJ:@^TR?WA^5'VF3^\/RH G^R)ZFC[(GJ:@^TR?
MWA^5'VF3^\/RH G^R)ZFC[(GJ:@^TR?WA^5'VF3^\/RH G^R)ZFC[(GJ:@^T
MR?WA^5'VF3^\/RH G^R)ZFC[(GJ:@^TR?WA^5'VF3^\/RH G^R)ZFC[(GJ:@
M^TR?WA^5'VF3^\/RH G^R)ZFC[(GJ:@^TR?WA^5'VF3^\/RH G^R)ZFD^RH.
MYJ'[3)_>'Y4?:'[D?E0!<Q\NWVJ(VJ'O4FX^7NR.E5/M#Y/S#\J )_LB>IH^
MR)ZFH/M,G]X?E1]ID_O#\J )_LB>IH^R)ZFH/M,G]X?E1]ID_O#\J )_LB>I
MH^R)ZFH/M,G]X?E2?:9/4?E0!8^R)ZFC[(GJ:K_:9/4?E2_:9/[P_*@"?[(G
MJ:/LB>IJ#[3)_>'Y4GVF3^\/RH L?9$]31]D3U-5_M,GJ/RH^TR?WA^5 %C[
M(GJ:/LB>IJ#[3)_>'Y4?:9/[P_*@"?[(GJ:/LB>IJ#[3)_>'Y4?:9/4?E0!/
M]D3U-'V1/4U!]ID]1^5)]ID_O#\J +'V1/4T?9$]34'VF3^\/RI/M,GJ/RH
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MF^R)ZFC[(GJ:A^TR>H_*C[3)ZC\J N3?95]34P7"[:I_:9/[P_*C[3)ZC\J
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI-P]:-P]10 M%)O7UHWKZT +12;U]:-Z^M "T4F]?6C>OK0 M%)O7UHWKZT
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MU</2F&E8"K]BE'_+W'^1I/LDG_/Y%_WR:G-,-.P6(_LK_P#/Y%_WR:3[,_\
MS^1?]\FE-1G-"06'>2W_ #_0_P#?)IOE?]/\/_?)J)LU&U/E"Q9V#.?M\/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5-;?ZX?2H:FMO]</I0!+=_<7ZU4JW=_<7ZU4H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K
M5GU:JM6K/JU #;K_ %GX57JQ=?ZS\*KT %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %6;/[[?2JU6;/[[?2@"Y1110 4444 %%%%
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M]J2EI* $HHHH 0TVG&FTP$I#2TAH :>M--./6FF@8PTTTXTTTP&&F&GFF&F
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %6;/[[?2JU6;/[[?2@"Y1110 4444 %%%
M% !4<W^I?Z5)4<_^H?Z4 9U'L>A]:.]'8\9Q1=K8"K>6%K?0&.[A65?0BLR+
MP;X>BD62/2H%<<Y&?\:W<C*^A[T YSVST)Z&M%4=C)T8MW&QHD*X154#D*M.
MQQG)Z_G1Z< <<<48^8<'/<&H<GN:**2L8LGA+0Y+G[0^G1>=NW[^<YZULJ B
MK@84# 5: >H'/-+TZ=?2JE4;1$:23N4-0T33=47_ $VT24#NPYJ"Q\.:/ILG
MFV=A%&XYSSUK6&<\].^:,]P,^U-5&D#I1;N5;_3;34[86]Y"D\60V#V-9/\
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M36W^N'TH EN_N+]:J5;N_N+]:J4 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5T34M.@L+NP22W@'[M"3\OX]: .5U!X[[XIZ<^GE9/(MG6=T' ^8'D]^*?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'#;L#IT[U;\3 '4K>74TG;32N ("V5;GD[>>E#IC]L['9@KT!S2UC^'%TQ;
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"IK;_7#Z5#4UM_KA]* );O[B_6JE6[O[B_6JE !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5:L^K55JU9]6
MH ;=?ZS\*KU8NO\ 6?A5>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_(HY_P B@!**7G_(HY_R* $HI>?\BCG_ "* $HI>?\BCG_(H 2BEY_R*.?\
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M -FL[)HR: -']W_LT?N_]FL[)HR: -']W_LT?N_]FL[)HR: -']W_LT?N_\
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M -FL[)HR: -']W_LT?N_]FL[)HR: -']W_LT?N_]FL[)HR: -']W_LT?N_\
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M **** "BBB@ HHHH **** "BBB@ K07_ %/X5GUH*,P@>U &>W4TF14KVDK
M[,?C59K"]SP8_P Z ),_YS1D5#]@OO6+\Z3[#??WHO\ OJ@"?(HR*@^Q7O\
M>B_[ZI/L=[_>B_[ZH'8L9%&15;[+>9^]%_WU2?9KO^_%_P!]47'RLM9%&153
MR;K_ )ZQ?]]4ABN?^>L/_?5*Z"S+F11N'K5';..LL/\ WU29F'_+:#_OJCF0
M<DB_NI=P]:S2\@ZSP?\ ?5-,S#_EXM_^^Z7.AJG+L:>X4;JR_M)'6XM_^^Z:
M;P#_ )>K?_ONE[2(_93[&MFC=QUK(%Z/^?NWS_OU7EU<Q3;9.H/^334HR!TI
M1Z'09XHSQQ61:ZHDYQGFM175A\M49CZO6_\ J*H]ZOV_^HH IR?ZQJ93Y/\
M6-3* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ J:V_UHJ$U-;?ZT4 2WGW152K=Y]T54H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ J:V_UP^E0U-;?ZX?2@"6[^ZM5*MW?W%^M5* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JU9]6JK5JSZM
M0 VZ_P!9^%5ZL77^LJO0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 59L_OO]*K59L_OM]* +E%%% !1110 4444 %1S_ .I?Z5)4
M<_\ J'^E &=02!R> !FEZ54U)S'IETX&<1.?T-5"/,R*CM%L\]\0>+=3U/6/
M[&T1<?,5=L9)^A[4V;P7XFM;5KI-:DE91N$66R?UJG\-5%QXCO)VQN"@J#VY
M->LD C&.W)KKJ-0:C8X::E.+9P'@SQE=W]ZVF:DH\Y>$D Q^%8NH:C?:+X_1
M9+J8P,X^5G.W!QVJD5^Q_% )%PIN@,#Z"MOXG::1%:ZG&I#)\C'W/_ZJU<(W
M6FYBIRL>E1OOB608PZ[LUY;<ZA>:Q\0OL]M=3+ C;"JN0.,UUFD:U'/X*^V.
M_,<)3\0,5S'PXM&OM2O-5E&<GY<^N>:RC!1NV;2GS629+XK\1:C<:_'H6G2>
M4&;8SXYS]:RM8T_Q%X2CCU$ZNUP"P&TEB%/N":M^/M+DTW5X]8MIT5RVYEW#
M(^@K%OO$5WXJ>ST^Z"VD.X N6_7FMHPO&Z.><Y1G8]"'BIQX,&K[09"I4#'\
M5<CI=AXB\7V[:@-6-NH)PB[AT^AKMI_#]K+X0_LV-U$07*OGOZUYII?B+4?"
MC76GQ!+B,$@$-D+UYXJ813O8JI-I'0^#?$.I6VOOH>H2^:JL55V&3D5NZWIO
MB36+Z2"VN5M+,?<?:<M^(-8?P_L([[49=9NKA6N=Q*Q@@G/K7IC';\Q('&:S
MJNT]$;4?>AJ>+ZA<Z_X.U94FOWG7&0S$E6'T)KUW3+W^T-.@N<8+H":\E\<7
MH\0>*(K6QC$DD8\H8/#$G->L:1:?8=)MK<\%4&?K3KI<J?4=!R4K%ZBCK17#
M?0] **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH0#7=8T9V.
M%4$D^E4K'6=/U)F2TNDDD098+VIVLY_L/4,?\^TG_H)KP_X#.[:]JA9V;]PN
M 3G^*K2T%<][DD2)"[N H&2?2J5EK.GZA*T5K<)*Z]E/2F:_QH-\-WS"(UXI
M\'9)#KNJ;I&^XX'.<4XQN)NQ[3J7B+2=)4M?7T4(49.3FL:+XF>#YGVIK4+,
M3@#!_P *\)\/Z%+XU\=76G7-_-&#)*V1R,*3Q7HM_P# [38].D:"]D66-2P9
M5&21^-5RI;A<]5L[^TOU\RVG21,9R#4&H:WIVE1E[V[CB"]<GI7AWPMMM2T_
MQA<V\OVH0HI +J=IZUS>M07'B#XFR:7/=R*L]UY88'[HQZ4*F@;/=O\ A9_@
M[.TZY!N)X&UO\*Z&PU>PU1-]E=QRKUR#7F9^!>EM9[1>R+*5X8(.OYUYYX0%
MUH_Q&BTY+J1D2783G@X.*%!,3D?14WB'2[>Y^SS7D:39QL)YK2#*55@=P/\
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MJ5;N_N+]:J4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !5JSZM56K5GU:@!MU_K/PJO5BZ_UGX57H ****
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M_OOCC:2:<\<&GN\SH5"A^F11)7&M#TJVU30KB>6*RN;>2XP<K&?FKY\M\?\
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MK;_6B@":\^ZM4ZN7GW5JG0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !4UM_KA]*AJ:V_UP^E $MW]
MQ?K52K=W]Q?K52@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *M6?5JJU:L^K4 -NO\ 6?A5>K%U_K/PJO0
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M]5I*QD=D"L]0,:G>H'Q@D]JYY:'5$@?Z]Z;%"]Q*D<2[G)X]JD"/(X1%RS'
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MD##]*X+Q,F@6=];:<=+GU,1H-NFVRAEC'][!]?Z5G^!+E$\6:K:6FES:79F
MR?995VD-D#.![4 >DR:IIT&PRW]K&&Z;YE&1^)J1KNVC"%[B%%DXCRX^;Z5Y
MKX4\(Z3KFEWEQJT0NR9&6/SAGR1D\+Z>M95O;7&I^!3<EVEDTJ]9XG/)\M'/
M'Y 4 >Q2W$, 'GRQQYX&Y@ 34GIGBO-[Z\'BO6?#]I$0\*)Y\^.QV@C/XBO2
M,>G:F 4444@"BBB@ HHHH **** "BBBG< HHHI7 **** "CTHH[T :(_U'X5
MG'[QK1'^H_"LX_>- !1110.^@4444Q= YSBCC..]%'2BXN5!1110.X4444K#
MN%%%%%A7"BBB@&%%%% (/K1111<+=0HHHH ****+@%%%% [!111185PHHHH
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MZ4 2W?W%^M5*MW?W%^M5* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ JU9]6JK5JSZM0 VZ_P!9^%5ZL77^
ML_"J] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!+=_<7ZU4JW=_=6JE !1244 +1244 +1244 +1244 +1244 +1244 +1244
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M36W^N'TH EN_NBJGY5<N_NK5.@ H_&BB@ _&C\:** #\:/QHHH /QH_&BB@
M_&C\:** #\:/QHHH /QH_&BB@ _&C\:** #\:/QHHH /QH_&BB@ _&C\:**
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MZBE^SN8!"P,G;.!6KK4;3:1<1QKN9D.U1W.*&T-)E2RFN-0U?[3'=/\ 8HT
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%6K/JU5:M6?5J &W7^L_"J]6+K_6?A5>@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ JS9_?;Z56JS9_?;Z4 7**** "BBB@ HHHH
M *CG_P!0_P!*DJ.;_4O]* ,ZH;N'[1:30_WXV7\QBIJ#S[^U.+L[DR7,K'C/
MAVZ/A7Q?+!>@I$S;"Q';G%>J7FN:?:V,D[W<3*%SA7!./I5?6_"^FZZNZZB
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M*TUC<>6P..U>O1K*I$^3QN%="9Z/'*'4$&I*Y_2;[S$ -;RG(S70<0ZBBB@
MHHHH .]7K?\ U JCWJ];_P"H% %23_6-3*?)_K&IE !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 &IK;_6BH
M34UM_K10!->?=6J=7+S[JU3H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J:V_UP^E0U-;?ZX?2@"6
M[^XOUJI5N[^XOUJI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %6K/JU5:M6?5J &W7^L_"J]6+K_6?A5>@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JS9_?;Z
M56JS9_?;Z4 7**** "BBB@ HHHH *CG_ -0_TJ2HY_\ 4/\ 2@#.H[_UI:3M
MQUH .#C/8_G1VY/S>U'<Y'RXY^M'3MD^GM3N =P31[?E1QC HI %%%%'2P/4
M/X@??-'8CUHHH /3V]*.F<=Z**5@#'?G-'<=<&CK0?NMCMTI]+ ]0SUQT'4=
MZ,$L!CMTH8A>6QM[Y/2HH+F"YB\R"5)8\XW(V1^= $M':CV%0FZ@6<6[31B9
MQD1EADT!TL3444=/F% !D4?6C\S0??'X4 %%%%.X!VHP/_K&BC_.:0$(M;<#
M:((P"VXX48S4@C0-G8NYCACCG\Z<>1_2HOM,/VCR/.3SL9*%AG'TIW=K"Y5>
MXYX8Y'#O$C,GW6*@D4TVT!9F,*$N,/E0<U+Z<#\Z/PIJ5@LB V5J553;Q;5^
MZ-@XJ78FS9L!7&,$<4ZBAR8))$ L[55*BWB"D8(V#D4YK:!U1&AC*H<H"HPO
MTJ6BA2:!I,8\,3NK/&C,O1BO(^E.=$D0I(JLK=5(R*6BES,+(B%M J%5A15(
MP0% !IZ(D:[4554#  ' IU%/F8K$:PQ*I58T"M]X =::UK;M()&@C,B]'*C(
M_&IJ*.9A8;Y<98DQIDC!..M. "H$  4< 444F[C22(U@B3=MB0;OO84<_6DC
MMH8CF.)%^B@5+11=A9$(L[8*%^SQ8!R!L'6D%E:JH401[0<@;1P?6IZ*KF=A
M<JO</Z=****FY044447 ****+@%%%'I2 T /W(^E4#RQSZUH#_4_A6<<\_6@
M ^I&/I0>N/7I5>^OH--MFN;AF$2X#;1FLA/%^F/<I!B<>8<+*8CL_P"^NE7R
M71+FEN;_ %7'8=:,8ZG'-9^J:U::7"KS&1F;[J1)N9OPJ'3/$%AJTTB0^=%(
M@^9)8]K'Z T>S9/M(FMU'7!S1G'XUS\WC'3(&(Q<R,I*L(H2Q&/7TK8L;Z#4
M;1+FW),1Z9&#^-#@P51%G&>1V[56N[RWTZU>YN9=D2#+.><5)--';PM-,0L:
MC).:X?Q+XGL-3\.W<$*W4>Y#AI82JGZ$]:J--O<4ZB6QW"31R(K+(,.-RY/W
MA4G?ICWKEKI+4W.C23W$D;A5$2(N0QXZUI:EXCLM,N!#,+B20CE8(B^WZXZ4
M2@$:BM<UR,<8Z]Z.G YP/TJC:ZK;7&GB\VR0Q\Y$J;3Q]:HV?BO3[V[6&-;I
M6?A7DA*JWXU*INX_:+H:<=_;2WLEFDH,\8RR58_GZ5R^G?\ (ZW_ &!0\^G2
MKE[XMTZSGDA:.YE\O[S0PEU'XBJE!]!*HGN;O3^N:,=..*H'6;%=.%^)<P[<
M\<DGT^OM533_ !-9ZE<+##;7B,PR&E@*C\ZCV;L5[2-]3:]3V[4=U.:QM1\2
MZ?IL_DRK<32 9*P1%]OUQTJY9:M:WME]MBD*QX^;<,,OU':G[-B=6)/=74-E
M;R3W$FR.,98TZ*5)H5FB;<C@,ON#7&Z]XJTZ^T2\MXDN@"K!9'A(4GZUT^CC
M_B2V8/7R4.?P%5[.RNR54N[(O]SQCUHX. /P%<;?^+&M?%4=M_I9M@-K(L!.
M3S6]=Z_9V=I#/*L[>:,K&D9+_BO44N1E>T3-3TS1V)["LO2M>L]6\S[/YZ/&
M<,DL>T_@#5:/Q9ILTT<<2W,K,Q3*1$A#G'/I2]FQ>TB;O;-'OV]:Y^]\8:99
MW#Q,EU,8QEFBA+*/J1Z5=T_7;/4-/-]%O2 9RTB[:.1E>TB:>"0<<XH&#G!Z
M5S\7B_3+BY2(1W2AFVK+)"53_OKIBL_7O%3:?KUG;K]J\D$>:(X=P<>WK3Y&
M3[6)V'\O6CJ#Z^E8UQXCL+6TAN)(YSYGW(A&=_\ WSUJSI>LPZJKM!#<+LZB
M>(I^7K2<&BE43-#%%!XP1GGUHZ5!85I1_P"K'TK-K2C_ -6* '&F&GTTT,9&
MU0OTJ9JA>I9K$KO5:3I5EZK2=*RD=,"E+5*6KLO2J4M8S.^EL4)>IJA+WJ_+
MU-49>]<L_,]*D49>.W6J<G!S5N8>O)'2EL[(W<N?NQKR[GI7,X.;L=CK1IPO
M(BL-/^U,9IFV6\7S._K5J[N&U&Z7:FV-!M0=\>Y[TMW<+<-]FMAMMH^%'][W
M-:VDZ7D@N*]7"T>1'RF/Q?MYZ;%O1K-D .#BNE0845%;P")  *GKK/."BBB@
M HHHH .]7K?_ % JCWJ];_Z@4 5)/]8U,I\G^L:F4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  :FMO]:*A
M-36W^M% $UY]U:IU<O/NK5.@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "IK;_ %P^E0U-;?ZX?2@"
M6[^XOUJI5N[^XOUJI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %6K/JU5:M6?5J &W7^L_"J]6+K_6?A5>
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[U>M_P#4"@"I)_K&IE/D_P!8U,H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ****  U-;?ZT5":FMO\ 6B@":\^Z
MM4ZN7GW5JG0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !4UM_KA]*AJ:V_UP^E $MW]Q?K52K=W]Q?
MK52@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *M6?5JJU:L^K4 -NO]9^%5ZL77^L_"J] !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !5FS^^WTJM5FS^^WTH N4
M444 %%%% !1110 5'-_J7^E25'-_J7^E &=00&!! QW'K110!QU[X A?4Y[_
M $;5KW1Y)@//%F%_>'U.:N^'O"2:)<W%U/J-SJ-U<#8TUR!N*^G%=)W(P0#W
M%'TZ]![4 <9+X!>.YG?2?$.HZ3#,^YH+8+LSZ\BM.3PN;O0X-,O=4NKMHI1*
M;F4#S&(/&>V*Z#OQ^9[T>XZT 86O>%[?7]/MK2::2-()8Y R 9)0@@?CBHM=
M\(PZQ<P7=O>7&GWT0PMU;@;\8Z<UT7 ZY]L'BCUR?I[4 <_H/AZ_TBXDENO$
M6H:F'3 CN=N%.>O K1UO2H];T:[TR61T2ZB,;,HY7/I5_OD\\=!Q0: ,&Z\+
M6]UX=CT5IY5A3'S@#)Q3=9\*6VL:19Z?+<S*EJ\3JR@9;801G\JZ#MC/OGTH
MY[<?6@#F=>\%P:Q>V]_;7MQIVH1C;]JM@-Y7' .>W6IM \*0:*T\\MW-?WMQ
MQ)<W &]E].*Z#GZ_2CU _7M0!Q!^&\ N9DAU>]BTN:3=)IJ!?*8=QZX-:5EX
M*T^S\*2: KNUN2Q5F W(22>/IFNE],9'&":.XX(Q[T <(WPSBN884U'6[Z^^
MSNCVYF"YAVG.!CL< 5T$_AJWN/$-KK#SR":!-H3 VD8(_K6WQGG)SZ&C^= '
M'7W@,S:K<7VG:[?:6;@[I8[8+M<^IS5W0O!>GZ%9WUK$[SQ7C;I%8#&<8KI/
M?KVHZ\?=- ')Z-X(.C1W-NNMWLUE,K@6[A=B;O2K5OX.T]/#3Z%.6N+=W9P9
M ,JQY!_ ]*Z+VR/KBCU&>: .)L_AV(I+87^NW^I6EL?W5I<!=@].G-=!+H,,
MNO0ZJ9'66&/R]@'RGG-:O&<@'\^E+[<CUSS0!BGPY;MXJCU\SRB9(3"$(&W!
M(.?TK:YP0!B@_P"UR#Z4<Y&: .9U_P 'QZSJEOJ=OJ-WIUW ,&6V RXZ8.:M
MV_AR.'6(]4>[FEG2!86W ?-C/S'W.:V^^>GMZTGX\]Z ,9/#ENGB>37#+(99
M8/),1 VXSG-8\_@)UNYIM)\0:AI44S;FAM0NTGUY%=D>,XZ^] ZY_.@#F;GP
MC_:&@0:5J&K7=UY4ZSFXD W,5.0#6AJWA^UUG1/[,N&/E_+M<#YE(Z$5K=O<
M=*/7C!- '!M\-!<K''J/B+4KY82# LX7$>/3 _"JWB?1HM5\=6%LSR0/';#R
MYD'SQ'<?F'O7HIZ =<<G_P"M436\#7"W!B4S*,*Y'(_&@#G=!\'1Z-J3:C=:
ME<:G?D;4N+@#<B_W1CM7+>(] M=>^*VF849MT,LW^\,%:]/Q\O3!QP:C%K;K
M.URL4?G$8+[?F/XT 2 #''&*6CO^%'>@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *.]%'>@#1'^H_"LX_>-: _U'X5GG[QH *,T44 %%%% !1110 4
M444 %%%%  >E&:** "BBB@ [YHHHH **** "CMBBB@ HHHH **** # ]!111
M3NQ604?THHI#"BBB@ HHHH *T5.(0?:LZM!?]1^% %<W;#. #]:K2:A<*<+$
MAI2!DYI"!B@"+^T;S_GA'^9IIU"Z_P"?>+\S4^U?0T!![4!<KF]N3UMHOS-,
M-S,>MK$?SJWM%&T>E*Q7,RD97/6TB_6HSENME%^M:.T4;12Y4/VDC*,*L,-8
MPD?C39;=FA:.&W2$MP67KCTK7V+THV@TE!#=63ZG-QZ& WW16Q:V0A  %7,
M4M6M#-NX8[4444 %%%% !1110 4444 %7[?_ % JA5^W_P!0* *<G^L:F4^3
M_6-3* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ -36W^MJ&IK;_ %M $UY]U:IU;O.@JI0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !4UM_KA]*AJ:V_UP^E $MW]Q?K52K=W]Q?K52@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *M6G\55:M6
MG>@!MU_K/PJO5BZ_UOX57H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4?8Q_>/Y5:HH J_8Q_>/Y4?8Q_>/Y59H_.@"M]C']X_E1]C']X_E5G\Z/SH
MK?8Q_>/Y4?8Q_>/Y59_.C\Z *WV,?WC^5'V,?WC^56?SH_.@"M]C']X_E1]C
M']X_E5G\Z/SH K?8Q_>/Y4?8Q_>/Y59_.C\Z *WV,?WC^5'V,?WC^56?SH_.
M@"M]C']X_E1]C']X_E5G\Z/SH K?8Q_?/Y4?8Q_?/Y59_.B@"/9\FW)_*HC:
M \[C^56:* *WV,?WC^5'V,?WC^56:/SH K?8Q_>/Y4?8Q_>/Y59_.C\Z *WV
M,?WC^5'V,?WC^56?SH_.@"M]C']X_E1]C']X_E5G\Z/SH K?8Q_>/Y4?8Q_>
M/Y59_.C\Z *WV,?WC^5'V,?WC^56?SH_.@"M]C']X_E1]C']X_E5G\Z/SH K
M?8Q_>/Y4?8Q_>/Y59_.C\Z *WV,?WC^5'V,?WC^56?SH_.@"M]C']X_E1]C'
M]X_E5G\Z/SH K?8Q_>/Y4?8Q_>/Y59_.C\Z *WV,?WC^5'V,?WC^56?SH_.@
M"M]C']X_E1]C']X_E5G\Z/SH K?8Q_>/Y4?8Q_>/Y59_.C\Z *WV,?WC^5'V
M,?WC^56?SH_.@"M]C']X_E1]C']\_E5G\Z/SH K?8Q_?/Y5+L^3;N/Y5)10!
M6^R \[S^5'V0?WC^56>U% %?[(/[Q_*C[(/[Q_*K'YT4 5OL8_O'\J/L8_OG
M\JLT8H K?8Q_?/Y4?8Q_?/Y59HH K?9%_O'\J/L@_O'\JLT4 5OL@_OG\J/L
M8_O'\JLTM %7[&/[Q_*C[&/[Q_*K5)^= %;[&/[Q_*C[&/[Q_*K/YT?G0!6^
MQC^\?RH^QC^\?RJS^='YT 5OL8_O'\J/L8_O'\JL_G1^= %;[&O]X_E4J1[%
MV[C^524&@"N;4,V=Q_*F_8Q_?/Y5:HYH K?8Q_?/Y4?8Q_>/Y5:I/SH K?8Q
M_>/Y4?8Q_>/Y59_.C\Z *WV,?WC^5'V,?WC^56?SH_.@"M]C']X_E1]C']X_
ME5G\Z/SH K?8Q_>/Y4?8Q_>/Y59_.C\Z *WV,?WC^5'V,?WC^56?SH_.@"M]
MC']X_E1]C']X_E5G\Z/SH K?8Q_>/Y4?8Q_>/Y59_.C\Z *WV,?WC^5'V,?W
MC^56?SH_.@"M]C']X_E1]C']X_E5G\Z/SH K?8Q_>/Y4?8Q_>/Y59_.C\Z *
MWV,?WC^5'V,?WC^56?SH_.@"M]C']X_E1]C']X_E5G\Z* *WV,?WC^5.2W$;
M9#'\JG_.B@"*2+S."Q_*F?8Q_?/Y58H_.@"M]C']\_E1]C']X_E5G\Z/SH K
M?8Q_>/Y4?8Q_>/Y59_.C\Z *WV,?WC^5'V,?WC^56?SH_.@"M]C']X_E1]C'
M]X_E5G\Z/SH K?8Q_>/Y4?8Q_>/Y59_.C\Z *WV,?WC^5'V,?WC^56?SH_.@
M"M]C']X_E1]C']X_E5G\Z/SH K?8Q_>/Y4?8Q_>/Y59_.C\Z *WV,?WC^5'V
M,?WC^56?SH_.@"M]C']X_E1]C']X_E5G\Z/SH K?8Q_>/Y4?8Q_>/Y59_.C\
MZ *WV,?WC^5'V,?WC^56?SH_.@"M]C']X_E1]C']X_E5G\Z/SH K?8Q_>/Y4
M?8Q_>/Y59_.C\Z *WV,?WC^5.2W\MLAC^53_ )T4 120^9U8_E4?V,?WC^56
M?SH_.@"M]C']X_E1]C']X_E5G\Z/SH K?8Q_>/Y4?8Q_>/Y59_.C\Z *WV,?
MWC^5'V,?WC^56?SH_.@"M]C']X_E1]C']X_E5G\Z/SH K?8Q_>/Y4?8Q_>/Y
M59_.C\Z *WV,?WC^5'V,?WC^56?SH_.@"M]C']X_E1]C']X_E5G\Z/SH K?8
MQ_>/Y4?8Q_>/Y59_.C\Z *WV,?WC^5'V,?WC^56?SH_.@"M]C']X_E1]C']X
M_E5G\Z/SH K?8Q_>/Y4?8Q_>/Y59_.C\Z *WV,?WC^5'V,?WC^56?SH_.@"M
M]C']X_E1]C']X_E5G\Z* *WV,?WC^521P>5T8_E4U)0! ]OYAR6/Y4W[&/[Q
M_*K/YT?G0!6^QC^\?RH^QC^\?RJS^='YT 5OL8_O'\J/L8_O'\JL_G1^= %;
M[&/[Q_*C[&/[Q_*K/YT?G0!6^QC^\?RH^QC^\?RJS^='YT 5OL8_O'\J/L8_
MO'\JL_G1^= %;[&/[Q_*C[&/[Q_*K/YT?G0!6^QC^\?RH^QC^\?RJS^='YT
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gk2ifd22ejwl000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gk2ifd22ejwl000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %! 6H# 2(  A$! Q$!_\0
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M!_K7IJL&0,.A&16%&KSN2[,PHUO:.2[,6BBBMS<**** "BBB@ HHHH ****
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MH=&547"CSO[7Y!1117GGJ!1110 4444 %>3_ +0G_).8_P#K]C_DU>L5Y/\
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M_12$9!![U\>^/YO$/A;QOJFEC6=16%)B\'^DOS&W*]_0X_"@#[#HKX8'BGQ
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M_P#':]O\<>'U\3^#-4TD@&2:$F+/:1>5_4"@1\15] ?LX^(\KJ?AN9^G^EP
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M_#2!3U%Y$#^34 ?+=>P_LY_\CS?_ /7@W_H:UX]7L/[.?_(\W_\ UX-_Z&M
MSZ=HHHH$%%%% !4-W.MK9SW#_=BC9S] ,U-63XH+#PEK!7[PLIL?]\&@#X<N
M9WNKJ:XE.9)7+L?4DY-=U\&-,74_BEI2R*&CM]]PP/\ LJ<?^/8K@*]9_9Y"
MGXC3$]18R8_[Z6@9]2T444""BBB@ HHHH **** (YX4N+>2"0!DD0HP/<$8-
M?"6L6)TS6[ZQ/_+M</%_WRQ']*^\:^)?B %'Q$\1!/N_VA-_Z&: +OPJOVT[
MXFZ%*#@/<"$_1P5_K7V;7P]X*+#QUH!7K_:-OC_OXM?<- 'R!\9/#?\ PCOQ
M$OO+3;;7W^EQ8''S$[A_WT#7 5]._M">&_[1\(V^M0IF?3I<.0.?*?@_D=OZ
MU\Q4#/L7X1^(_P#A)/AWITSONN;1?LDYSSN0  GZKM/XUW-?-7[.WB/[%XDO
M=!F?$5]%YL0)_P"6B=OQ4G_OFOI6@05E^)-9B\/>&M1U>8C;:6[R '^)@.!^
M)P/QK4KQ7]HKQ']C\.V.@0OB6]E\Z4 _\LTZ#\6(_P"^: /G&[NI;Z]GNYV+
M33R-)(Q[LQR3^9K3\):%)XE\5Z9I$8/^DSJKD?PIG+'\!FL:O=/V<O#?GZGJ
M/B.9,I;I]E@)'\;8+$>X&!_P*@9]#6\$=K;16\*A8HD"(H[ # %245%<RB"U
MEF/2-"WY#- F['A/CS4CJ7B^\8-E(&\A/HO!_7->@_#7PV-,TK^T[A,75V/D
MR.5C[?GU_*O._"^DMXE\5I'("T1<S3G_ &<Y/Y]/QKWF1XK2V9W(2&)<GT %
M>MCZJI4U0C\SP\NI>UJ2Q,^^AB^*]:&DZ84C;_29P53U4=S7E9))R3DFM'7-
M5DUC5)+ELA,[8U]%'2H=+TZ75-1BM(ARY^8_W1W-?(UZCJST^15>JZU33Y'5
M^";%+2UNM:NOECC1@I/8#EC_ )]Z^5?%.N3>)/%&HZO,26N9V=03]U<X4?@,
M"OK'XD3IX?\ A1K(MOD"VGD)C_;(3/UY-?&]>I2I^S@HGK4::IP410"3@#)/
M05]@?"?P3%X.\(0>;$!J=ZHFNG(Y&1D)] /US7S-\.=)76_B'HEC(NZ)KE7D
M'JJ?,?T%?:U:&@4444 %%%% !7D_[0G_ "3F/_K]C_DU>L5Y/^T)_P DYC_Z
M_8_Y-0!\LU[#^SG_ ,CS?_\ 7@W_ *&M>/5[#^SG_P CS?\ _7@W_H:T#/IV
MBBB@04444 %5M0MOMFFW5J?^6T+Q_F"/ZU9HH ^ Y$:*1HW&&0E6![$5Z%\$
M-173_BGIH=L)<I);D^Y4D?J!65\4-#;P_P#$76+/9MB>;SXN."C_ ##'T)(_
M"N;TO4)M)U6TU"V.)K:594/NIS0,^\Z*H:)J]MKVB6>JV;;H+J(2)STSU'U!
MX_"K] @HHHH **** "BBB@!LCK'&TC'"J"Q/L*^%->OO[3\0ZE?@Y%Q=22@_
M[S$U]9_%WQ.GAGX?W[K)MNKQ3:P 'G+#!/X+D_E7QW0,ZSX9637_ ,2M A49
MVW:RGZ)\W]*^TJ^8_P!G?0FO?&-WK#IF*PMRJG'_ "T?@?\ CH:OIR@11UG2
MX-:T2]TRX4&&Z@>)O;(QG\.M?#6J:?/I.JW>G7*E9K69H7!]5.*^\Z^6_P!H
M#PW_ &5XVCU:%,6^IQ;V(''FKPWYC:?Q- 'G'AW6)O#_ (CT_5H"0]I.DN/4
M \C\1D?C7W)97<-_8V]Y;L&AGC66-AW5AD?SKX(KZN^!'B/^VO "6,KYN-+D
M^SD$\^7U0_3&1_P&@9ZA7QS\6_$?_"2?$349T?=;VK?9(#GC:A()'U;<?QKZ
MA^('B%?"_@;5=3W 3)"4@]Y&^5?U.?PKXG9F=BS$EF.23W- @ )( &2>@%?:
M'PT\.#POX!TNP9-MP\0GN/\ KHXR1^' _"OF#X6>'/\ A)_B#IMHZ;K>!_M-
MP,<;$(.#[$X'XU]F4 %9^NDKX>U(CJ+60C_ODUH56U"'[1IEU#_STA=?S!%5
M!VDF3-7BT<3\*]*%MHL^I.O[RYDVJ?\ 87_Z^?RJUX[UGRX4TN%OF?YY<=AV
M']:VM%6/1/!]F91M6"U5W'OC)_4UY??WDFH7TUU*<M(Q/T]JPS3$<TY6Z_D>
M;)^PPT:2W:_X<K5Z?X/T/^S+#[3.N+F<9.>JKV%<SX-T'^T;W[9.F;: \ CA
MV]*]+KEPE'_EX_D7@J'_ "\E\CSOXX;O^%5ZEC^_%G_OL5\BU]F?%>Q;4/AA
MKT2@EDM_. '^P0Q_0&OC.N\](]&^!H4_%33MW:.4CZ[#7UQ7QA\+=372/B7H
M=S(P6-KCR7)[!P5_K7V?0(**** "BBB@ KR;]H4@?#J(=S?1X_)J]9KPW]I+
M5%CT;1=*5AYDT[SL/15&!^K'\J /G.O9?V<(RWC/4W[+8_S=:\:KWG]FJS8W
M?B"^(^58X85/N2Q/\A0,^A:***!!1110 4444 >)?M"^$&O]'M?$UI'F6Q_=
M7.T<F)CPWX'_ -"KYNK[XN[6"^LYK2ZB66"9"DD;#(92,$5\<_$CP'=>!?$;
MVQ5WTZ<E[.<C[R_W2?[PZ'\#WH&=_P# ?XAQZ;<?\(IJLP2VG?=92.<!'/5#
M['M[_6OHVO@($JP9200<@CM7T)\+_C?"\$.B>+9_+E4!(=0<_*P])#V/^U^?
MK0![S13(Y8YHEEB=9(V&593D$>QI] @HHHH *9--%;P23SR+'%&I9W<X"@=2
M35?4=3L=(L9+W4;N&UMHQEI)7"@5\S_%3XPS>*]^C:&9(-'!Q)(?E>YQZ^B^
MW?OZ4 87Q8\>'QOXH)MF;^R[/,5JI_C]7(]_Y 5P0!9@J@DDX '>DKV#X(_#
ME]>U9/$>IP'^S+-\P*XXGE'3ZJO\^/6@9[+\)O")\(^!K6"=-M]=_P"DW((Y
M#,.%_ 8'US7<T44""O.?C9X;_M_X=W4T:;KG3F^UQD#G:!\X_P"^23^ KT:F
M30QW$$D$JAHY%*.IZ$$8(H ^!*]1^ _B/^QO'RV$KXM]3C,!!/'F#E#_ #'X
MUQ/C#09/#/BW4](<$"WG98R?XD/*G\01678W<VGW]O>V[%9K>598V'9E.1_*
M@9[O^T?XCRVE^&XGZ?Z9. ?JJ _^/'\J\!K=\8>)9_%OBB]UF=2AG8;$S]Q0
M, ?D*R+2UEOKV"T@4O-/(L<:CNS' 'YF@#Z+_9T\-_9="O\ Q#,F)+R3R(21
MSY:X)/T+?^@U[;65X9T6+P[X9T[2(0-MK L9(_B8#YC^)R?QK5H$%%%% ''>
M/=1\BQAL(SAI3N<#^Z.@_/\ E7#Z;83:G?Q6D(^9S@GT'<UH>++TWOB*Y(.5
MB/E+^'_U\UU_@K1?L.G_ &Z9?W]P/ER/NIV_/_"O,<77KM=#R7%XBNUT1T-A
M90Z=916L"X2-<?4]S5FBBO2225D>JDDK(@O+6.^L;BTF&8IXVC<>Q&#7PSKN
MDSZ%KU]I5PI$MK.T1]\'@_0CFONVOG[]H+P,_FQ^+K&(E2!#?!1TQPK_ -#^
M%,9X)'(\4BR1L5="&5AU!%?:'PY\7P>,_"%I?JZ_:XU$5W&#RL@')QZ'J/K7
MQ;74^!/'.I>!-<%]9GS+>3"W-LQ^65?Z$=C0,^U:*YOPEXYT+QG8+<:5>(9<
M9DM9"!+&?=?ZCBNDH$%%%07=Y:V%J]S>7$5O!&,O)*X55'N30!+)(D4;22.J
M(H)9F.  .YKXX^*7B\>,?&]U>P,38P#R+7W1?XOQ.3^5=O\ %CXRKKEO-H'A
MN1Q8-\MS=]#,/[J^B^I[_3KXG0,*^L_@;X>?1/AW!<3)MN-1D-RP(Y"]$_09
M_&OGGX<^#)_&WBVWL K"RC(ENY1T2,=L^IZ#ZU]G0Q1V\,<,**D<:A451@*!
MP *!#Z*** "BBB@ HHHH *Q?%/A;3/%^AS:5JD.Z)^4D7&^)NS*>QK:HH ^+
M?'/P_P!8\"ZF8+Z(RV;D^1>1J=D@]/9O:N3K[SU+3+'6+&2QU&UBNK648>*5
M0P->$^,?V>'WR7?A.[!4\_8KIN1[(^/T/YT#/+?"_P 1O%'A$A-,U)S; Y^R
MS_O(OP4]/PQ7J6E_M*2!%75O#ZLW=[2; /X-G^=>-:UX5U[P],T6K:3=VI'\
M4D1V'Z-T/X&L>@#Z4;]I+0-F5T/4BWH6C _/-<[K'[2.I31LFC:);VQ/22Y<
MR$?@,"O#:.IP* -OQ#XNU[Q5<^?K.I3W.#\L9;$:?[JC@5B5T_A[X>^*?$\B
MC3='N#$3_KY4,<0_X$>/RKW+P3\ M+T=X[WQ),FI7:\BW0?N%/OD9?\ ' ]J
M /-/AE\([_QC<1ZCJ:26FB(V2Y&U[CV3V]6_*OJBQL;73+&&RLH$@MH$"1QH
M,!0*FCC2*-8XT5$4855& !Z 4Z@04444 %%%% 'SO^T;X;\K4--\1PIA)U^R
MSD#^(9*D_49'_ :\)K[?\:>&(/&'A2]T:<A6E7=#(1_JY!RK?G^A-?&.MZ'J
M/AW59M-U2V>WN8F((8<,/4'N#ZT#,ZO3_@3X;_MOQ_'?2IFVTM/M!)''F9P@
M^N<G_@->;V=G<ZA=Q6EG!)/<2L%2.-2S,3Z 5]>?"GP,?!'A-8+D*=2NV$UT
M1SM..$SZ ?J30!W=%%% @IDTGE022'^!2WY"GU4U4D:1>D=1 _\ Z":3=E<4
MG97/+]"T]M;\0*CY,>\RRG_9S_6O6E 50J@  8 ':N2\!6 ATR6]9?GG?:I_
MV1_]?/Y5UU<V%I\L+]6<N#I\M/F>["BBBNHZPJ&[M+>_LYK2[A2:WF0I)&XR
M&4]0:FHH ^1_BA\+KWP1J#W=FDEQH<S9BF R82?X']/8]_K7G-??%U:V][:R
M6UU!'/!*I5XY%#*P]"#7A?C7]GM)I)+WPG<+$3\QL;AOE^B-V^A_.@9X#;75
MQ93K/:SRP3(<K)$Y5A]".:[?3?C+XZTV-8UUIKA5Z?:8UD/YD9_6N=UKP?XB
M\/2M'JNCWEN ?OM$2A^C#@_G6)0!Z5/\=O'<\>T7]M%[QVR@_KFN,UKQ5KWB
M.3?J^K7=Y@Y"22'8OT7H/P%9%7+#2M1U280Z?8W-W(QP%@B9S^@H IUK>'/#
M>J>*M7BTS2;9IIW/)Q\L8_O,>PKTCPE\ =?U:2.?7G72K/J8\[IV'L.B_C^5
M?0GACPCHOA#319:/9K"I_P!9(>9)3ZLW>@"CX!\#6'@3P^MA;8ENI,/=7)',
MK_X#L*ZJBB@04444 %%%% !1110 4444 %%%% #)(HYD*2QK(AZJRY!KGKWX
M?>$-1<O<^&],9CU9;=4)_%<5TE% '%K\)? BON'ARU^A9B/YUKZ?X+\,:4P:
MQT#38''1UMEW?F1FMVB@!  H    Z 4M%% !1110 4444 %%%% !6?JF@Z1K
M<8CU73+2]5?N_:(5?'TR.*T** ,G2O#&@Z&Q?2M'L;-SU>"!58_B!FM:BB@
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MW\< _B:NMX5\:ZF1%<PW;IG_ );SC:/S-=QX/^'T6A3+?W\BSWH'R*H^6/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
,* "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g30vudsvo52a000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g30vudsvo52a000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /B!_ # 2(  A$! Q$!_\0
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M *"-U_W^;_&C^V=3_P"@C=?]_F_QI_V?/N/^TX]CZ?WKZT>8OK7S!_;&I_\
M01NO^_S?XT?VQJ?_ $$;K_O\W^-']G3[B_M-=CZ?WKZT>8OK7S#_ &QJ?_01
MNO\ O\W^-)_;&J?]!"Z_[_-_C1_9TNX?VFNQ]/\ F+ZT;U]:^7_[9U/_ *"-
MU_W^;_&E_MG5/^@A=?\ ?YO\:7]GR[A_:<>Q]/[QZT;QZU\P?VQJG_01NO\
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MC4_^@C=?]_6_QH_MG4_^@A=?]_F_QH_L^?<?]IKL?3^Y?6C>OK7S#_;&J?\
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MD)[UC5PDJ2NV;4<<JCM8[W>/I2[U]:^=O$NIZA#X@NXX[^Y55D( $K>M9/\
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M;_&C^V-3_P"@C=?]_6_QI_V=/N+^TX]CZ?WKZT;U]:^8?[8U/_H(W7_?UO\
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MG&:T$(YI*6C->A8X1**7-&: $HI<T9I7"XE:WAC_ )&;3_\ KJ*RLUJ^&?\
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M*XU.:73H/*M2<HF,8K?"1E%NZ,,3.+2L=7\,Y9&UN=&=BJPX52V0.:Y;7_\
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M^5>Q''02/$> FV>(<4G%>X?\*LT?W_*C_A5FD>_Y4_K],7]GU#P_BEXKV_\
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MH\/I<D5[A_PJS1_?\J3_ (57H_O^5=7U^F<OU"I8\0X//..]'4X Z>M>W_\
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M-CQ'/7(Z4$D <#(_6O;_ /A5>C^I_*C_ (57H_J?RH^OPL'U"H>(<=R3FCZ
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M+/\ Z!TG_?VD_P"$MLO^@=)_W]H]E+L'M$=O]O\ ]H4?;_\ :%<.?%UE_P!
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M]:=C/RY_&FX!]2#T/THT$)VS3:<3P>#GU'2FGIQVIJQ+$IIQZT[MWX%-8DX
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MMBNLTO4A(H!KR6N5V/76JNCH:*8C!ER*?0.P4444 %%%%%P"BBBBX!1111<
MHHHHN 44447 ****+@%%%%%P"BBBBX!1111< HHHHN 4444@"BBB@ HHHH T
MH_\ 5K]*?3(O]4OTI] !1110 4444 %1S_ZA_I4E1S_ZA_I0!G4444 %%%%
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M112*"BBB@ HHHH *='_K5^M-IT?^M7ZT :7I2TGI2T %)2TE !1110 4444
M)1113 *2EI* "BBB@$)1110)B4444 !I*4TE "4444 )1113 2DI:2@ I*6D
MH 2BBB@!*2EI* $I*6DI@)1110 E-IU-IB$I*6DH$)24M)0 AI*4TE #:0TM
M(:8"&FTXTV@0AIM.--I@)24M)0 TTVG&FTP$I#2TTT ---IQIII@)333J::8
MAII*4TE,0TTTTXTTT -I*4TE"$-/6FGI3CUIIJ@&FFFG&FFF E,-/IAIB&4&
MBD- AIIIZ4XTT]*!#3333C3330#3333C3:8F--8?BBZN;72\VLOE2.X7>!G
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5>M?]55&KUK_ *F@"I-_K6J&9#)$
M\:G!92N<5/-_KC4>::T=Q-75CE+;P_KUA')#::Q;QP,Q;#6^2,^]:>EZ##IM
MK*I=I+B<'S923R3Z>@K8HYSUJ^<S]FC*T;2!I>F?8FE\P8/(&*R$\+:C#'-9
MP:E&FGRD[HS%EL'K\U=9VH[4*8.FC)TW118Z'_9KR"52&!)'J:K^'_#KZ/+<
MR37 G>4\8&-JCH*WL=B!0/H,4>T=Q^S5CG)= U"VO)I]'OX[9)CETDCWC/<B
MKPT^]NM(EM-1NDGE?(\R--@ [<5J\GIP*/3M1[07LD8^@Z9J&F6PM[N]CN(D
M7$:I'M*CZTW4=,U%[PW.FWZVS%=K+(F\'Z#M6SWQCCTI1Z#C^E3S:E<FEC'T
M?13IOG3W$OFWDYW2N. 3[#M7/^&](0^+M0O48M#"=B*>F2,FNXQ@DXPW\/O5
M>ULK>S#BWC6/><L5[FM%4,O9:E6+3#%K5Q?M(")% V8]!BH(="":G?W4DFY+
MR(1E,?= !']:V?:C\3R:E3U-?9JQR7_"*WYM'L&U-?[-YVQ*A##T^:K?_"-/
M]BTBV-PH^PG.=OWN,5T1]/>CUSVINH2J:,K7-%CUFV1=YCN(6WPR _=;U]ZI
M6VA7\M[#<:M?QW2P<QHD>P!O4^M=%G/J:.?;FDIA[-&39:.;/6KR^\X,MP0=
MF.G&*;IFBG3_ +:6FW_:&W# ^[UK8R><<4=.YYI^T&J:1S]KX7CCT.;3IY?-
M+S-*K@8VDG(_*FVVF>([=HT_MFW,"8&TV^25';-=%[<BCOR2/I1[07LE<.V#
MS[T445DW<V6@4444""BBB@ HHHH *='_ *U?K3:='_K5^M &EVI:3M2T %)2
MTE !1110 4444 )1113 *2EI* "BBB@!**** $HHHH #24II* $HHHH *2EI
M*8A*2EI* "DI:2@!**** $I*6DH 2DI:2F E%%% "4VG4VF(2DI:2@!*2EI*
M $-)2FDH ;24M)3$(:;2FDH 0TVG&FTQ"4E+24 ---IQIM,!*::=330 TTTT
M\TRF(2FFG4T]*86&FDI324P&FFFG&FF@0VDI324 ---/2G'K333$----.---
M,!*8:?3#3$----./6FFF(;333J::!#33:<:;30#3333C333 ::IW]A!J$'DW
M 8H#D;3@U<--/2F(C10D:HO11@9JHNGVZ7\EZ WG. "=W''M5RFFBP%$:5:K
M<7$^PE[A=LF3D$?Y-98\'Z4I)Q.5)!VM*2!@Y&!VKH:::=@N8M_X;L=0N/.F
MDN@V,8CG91^0JPVD6?\ 9JV'EGR N!SR/?/K6@:::.5$\S,.V\+V%G<I<127
M9=#D![AF'Y5=U'3K?4K?R;C?M!# HQ4@_6KIIK520M3)T[0;+3)6E@\UI&&-
MTLA<C\35N\M(KVW\B8$ID'@XZ59IIJD@;(TC6.)8U&%4 "JDNFV\U_'>.K&:
M/[I!X%7:;19$\QCW'ARPN+M[AA*'8Y8+(0I_"I1H]FMI;VP5O*MSE!N[^_YU
MH]Z::.5#<F5+FQ@NFA,H/[E@R8..12+8P)=R7*@^8^,G-6J;56);*T=C!#/-
M,J_/, 'SR#BLV3PW822,^ZX7)SM28@?E6UVIM'*A<S10N-+MKFT2VE#%$&%.
M[YA^-5X-"L;9XW59&>-MRL[DG-:AZTE-1%SLJWEE!?1;)P2 <\'%->R@>XBG
M(;?$NU#GH*M4E587,539PF[6Z(/FJI7.>QJ.WT^WM6E:)3F4Y;)S5RFFG9"N
M9T&D6MK)(\7F R9R"Y(YZ\4HTRU%FUKL/E,VXC/.:O&FFGRHES9FQ:%902QR
MH)2\9RI>0M3[G2K:YN5N'#B0#&5<C(]ZOTTT*$0]HRI;V%O;1R1QK\KG+!N:
MJIH5E'(''FG#9VF0E?RK3HJN2(N=E5+2&.Y:=00Y&.O%)%:10RR2H#OD^\2:
ML4G:GRHGF9GW>E6UY)OF,ASU <@4D>DVL<#PCS2C]0SDU?--[4^1"YW:Q"+>
M/[,+?!V 8QFDCMDBMQ N0@&!SS4U!I\J)<V97]@V2EBOG+N.3B0BII--MY(%
MA;>57H=WS?G5PT&CV<0]K,IQZ?!#;M"N[:WWB6Y/XU671;2/[AF4>@D.*U#T
MIE/V<275F49]+M[C:)#(0!C <T^VLHK3_5E^G\3$U;IAIJFD[F;J2:LP.<4S
MN13FQC) P/UKH_#^BK)_Q,+Y3]F0_)&1_K#_ (>]*I54$*G2E-DN@:,EO$NI
M7R\9S!$1RQ]?I[5O1127MP9'SSV]*0"6_N,L!@#@ \ >E=3I6F!0&*UXE>LY
ML]RA14$3:5IRQHIQ6XJ@ 4D:!%  I]<ZT.@**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#2B_P!4OTI]
M,B_U2_2GT %%%% !1110 5'/_J'^E25'/_J'^E &=1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!H_M&S_OO_WP:+@6#2<U!_:%G_??_O@TGV^S_OO_ -\&G<1/25%]OL_[[_\
M?!H^WV?]]_\ O@T7 DI*C^WV?_/1_P#O@TGVZT_YZ/\ ]\47"Q)147VVT_YZ
MR?\ ?!H^VVG_ #UD_P"^#1<+#Z2F?;+3_GK)_P!\&C[79_\ /63_ +X-/F"P
MXTAIOVJS_P">LG_?!I/M5G_SUD_[X-',A6%I*/M-G_SUD_[]TGVBS_YZR?\
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M?R7_ +]TG]B67_/Y)_WZH]LA>S9SY^E--=#_ &)9?\_DG_?JD_L*R_Y_)?\
MOU359"]FSG2*:171_P!@67_/[)_W[I1X:M'&1>RX_P"N5/VZ#V;.9XII-=,?
M#MD.#?2_]^J:?#ME_P _TO\ WZH]O$/9LYFFFNF_X1VR_P"?Z7_OU2?\(W9'
M_E^E_P"_5/V\1>S9S!IIKJ/^$:L?^?\ E_[]4?\ ",V/_/\ R_\ ?JG[>(O9
M,Y4TT_6NJ_X1>Q_Y_P"7_OU1_P (M9?]!"7_ +\T?6$'LI')FFDUUA\*V/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M-*+_ %2_2GTR+_5+]*?0 4444 %%%% !4<_^H?Z5)4<_^H?Z4 9U%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P!G#_9J7[9[4?;/:@"+^S1[4?V:/:I/MGM2_;/]F@"+^S1[4?V:/:I/MO\
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M/9BYS=Q/_P ]+?\ [^T8G_YZV_\ W]K IIS3]F'.=#^__P">MO\ ]_:/W_\
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MT$-D<4N*SK"]69!S6B#FLC0**** "BBB@ HHHH **** "BBB@ HHHH ****
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M4*@MUKQ:E-P>I[5.HIH[I:*J6MT)4'-6\\9K/J6%%%% !1110 4444 %%%%
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M5:>VJ^%98HP2P D'O@9KD_AOK4-D)M+NV$3AB4W''/>HWIN)J[1JIO8]!UE
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M**S-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH *?%_K5^M,I\7^M7ZT
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M,/Y@<C%.QQBD- KL0[LYX]L]:;P2VT'_  ^E*:;VII:@V)_%CGWSWIIY7!)
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MI7(ZI\-],U'47NA<2PF0Y94 Q79T4HU9(<J,6CG-5\'VFJ:7;V,D\B+ 05<
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M0H^R?[0H JT5:^R?[0H^R?[0H JT5:^R?[0H^R?[0H JT5:^R?[0H^R?[0H
MJT5:^R?[0H^R?[0H JT^+_6K]:G^R'^\*5;8JP;<.* +-+3#G'!'Y4QA/CY7
M7\J )J*SW-^#P\?_ 'S3-VI?WX_^^* -*BLW=J/_ #TC_P"^*-VH_P#/2/\
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ME1XU#^]%_P!\48O_ %B_[XIW ?13,7_K%_WQ28U#^]%_WQ1<0^FTF-0]8O\
MOBC%_P"L7_?%%P#O3:=B_P#6+_OBC%]ZQ?\ ?%%Q6&\>E)QZ"G[;_P#Z9?\
M?%)MOO\ IE_WQ1<+##]!2?@*EVWW_3+_ +XI-E]ZP_\ ?NBX6(?P%)GZ5/LO
MO6'_ +]T;+WU@_[]T7"Q6S29JULO?6#_ +]TGEWOK!_W[I\P6*I--JYLO?6#
M_OW1Y=[ZP?\ ?NCF"Q2-)VJ]Y=[ZP?\ ?NCR[W_IA_W[HY@L9U)6EY=Y_P!,
M/^_='E7GI!_W[I\X6,RD-:GE7GI!_P!^Z/*O/2#_ +]T<X6,D]*96SY-Y_TP
M_P"_=)Y-W_T[_P#?NCF"QC4TUM^1=^EO_P!^Z/(N_2W_ ._5',%C"-%;OD7?
MI;_]^J3R+O\ NV__ '[HYPL8!Z4A%=!]GNO[MO\ ]^J/L]U_=M_^_=/G%RG.
M&D_"ND^SW/\ =M_^_='V:Y_NV_\ W[HYP<3F33374?9;G^Y;_P#?JC[-<_W+
M?_OU3]H+E.5---=9]EN/[EO_ -^J3[)<_P#/.W_[]4>T#E.2--/2NO\ LEQ_
MSSM_^_5'V.X_YYV__?JCVH<IQU(:[+['<?\ /*W_ ._5)]CN/^>5O_WZ%'M1
M<AQ9ZTTUVWV.?/,5M_WZH^QS?\\[;_OU1[4.0X<TWBNY^Q3_ //*V_[]4?8I
MO^>5M_WZ%/VP<APAIIKOOL4W_/*V_P"_0I/L,W_/*U_[\BG[4.0X TT]*]!^
MQ3?\\K7_ +\BC[!+_P \K7_OR*/;![,\\IAZUZ+]@E_YXVO_ 'Y%.%@<<P6V
M?^N0H]N+V:/-S33BO2#8/GB&U_[\BD_L]_\ GC:_]^13]L'LSS8TTUZ7_9[_
M //"U_[\BC^SG_YX6O\ WY%/VXO9'F5-/2O3_P"SG_YX6O\ WY%']G/_ ,\+
M3_OR*/K >R/+J::]3_LU_P#GA:?]^11_9K?\^]I_WY%'U@7LCRHTS\*]7_LU
MO^?>T_[\BC^S6_Y][3_OR*?UD7LF>3FFGZUZU_9C?\^]I_WY%']EG_GVM/\
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M?^ XH_L2/_GSLO\ P'%'UY]B?J;/ C32>:]__L2/_GSLO^_ H_L./_GSLO\
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M4?9/]H4 5:*M?9/]H4?9/]H4 5:*M?9/]H4?9/\ :% %6BK7V3_:%'V3_:%
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M4=O:LFT\3Z'?ZB;"UU.WENU&6B5OF_"M;VHL =*.]%% !1110 4444 %%%%
M!1110 4444 %%%% ![@XXHHHH!VZ!1110 4444 %%%% !1110 4444 %%%%
M!5ZVYBJC5ZU_U5 $;W)5R,=*;]K;'W0*BF_UAIGX=>] %C[4WI0+MO[HJOQ]
M<=<T'IV [9I\K#F18^U-_=H^UM_=JN0?<Y/&.U Z>I S0TQ)HL?:F_NT?:V_
MNC\ZK@YY5L^H'7%!]\ CH/:BS&FBQ]K;^[1]K;T'YU7Z=>,G\*7C)Z$#O19@
MVB?[6V,[12_:F]*K=@3T R?2C/N,&BS8/1%@W;>E'VMO[HJMQ@'I@]^YI>@Y
M[TK-"5F6/M;?W11]K;'W:K\Y]J.N2#GOQ3U&VDRQ]K;^Z*/M;?W15?/ISGG-
M'?\ PI!H6/M;?W11]K;^Z*K^V1[#U%'Y?X4 6/M;?W11]K;^Z*KT4 6/M;?W
M11]K;^Z*K]Z.] %C[6W]T4?:V_NBJ]% %C[6W]T4?:V_NBJ]% %C[6W]T4?:
MV_NBJ]% %C[6W]T4?:V_NBJ]% %C[6W]T4Y+HL^W:.:JT^+_ %J_6@"[*Y2/
M.*K_ &MAS@5:= ZX-0-91L.2U $!OL'D#\Z/MX]!2-I,3'_62?G2?V-#_P ]
M9/SH =]O'M1_: ]J;_8T/_/:3\Z/[&A_YZR?G0 [[>/:C[>/:F_V-#_SUD_.
MD_L>+_GK)^= #_MX]J/MX]J9_8\7_/63\Z/['B_YZR?G0 _^T![4?V@/:F?V
M-#_SUD_.C^QX?^>LGYT /^WK[4?;U]J9_8\/_/63\Z3^R(/^>LGYTP)/MZ^U
M'V\>U1_V1!_SUE_.C^R8/^>LGYT@)/MX]J7[>/:HO[)@_P">DGYT?V3!_P ]
M9/SH D^WCVH^WCVJ+^R8/^>LGYTO]DP?\]9/SH E^WCVH^WCVJ#^RH/^>LOY
MT?V5!_SUE_.@"?[>/:D^WCT!_&H?[*@_YZ2_G1_9<'_/27\Z )OMX_NC\Z/M
MX_NC\Z@_LN#_ )Z2_G1_9D'_ #TE_.@"?[>/[H_.C[>/[H_.H/[,@_YZ2_G1
M_9MO_P ])?SH G^WCT'YT?;QZ#\ZK_V;;_\ /27\Z/[.M_\ GI+^=.P%C[>/
M04?;QZ#\ZK?V?;_\])?SI/[/M_\ GI-^=%@+7V\?W1^='V\>@JK_ &?;C^.;
M\Z/L%O\ WYOSHL!:^WCT%'V\?W1^=5?L-O\ WYOSI/L-M_STF_.BP%O[>/[H
M_.C[>OH*I_8K;_GI-^='V.V_YZ3?G18"Y]N'H*/MX]!^=4_LEK_STF_.D^R6
MW]^;\Z+"N7?MZ^@H^WCT'YU1^RVW]Z?\Z3[/;?WI_P Z+!<O_;QZ#\Z/MX]!
M5#[/;?WIOSI/)M?[TWYT6"YH?V@/:C[>/0?G6=Y-K_>F_.D\JU_O3?G18+FE
M]O'H*/MX]!6;Y=K_ 'I_S%)Y=K_>N/S%.P7-/[>/04?;QZ"LO;:?WKC\Q2;;
M3UN/S%*P7-7[>/0?G1]O'H*RL6GK<?F*3-H.]Q^8HY0N:WV\>U'V_P!A63NL
M_6X_,4F^S];C\Q1RL+FO]O\ 84?;Q[5D>99^MQ^8I#+9>MQ^8HY6%S8^WCT%
M'V\>@K%,]E_T\?F*3[19?]/'YBGRL+FW]O'H*/MX]!6']HLO^GG\Q1]JLO\
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M)QI'_/"^_,4G_"<Z/_SPOOS%'L9]A>VCW/0/[07T'YTOV\>@_.O/O^$YT?\
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MII*4TE A*;S3J2F G--.:=330(;29I324P$IIIQIIH ::::?3*8"4TTXTTT
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M6$'RHEVKD\US]SH>LIK=QJ&FW]I$)5P5EB+5T^.F>U)GI\M)3L4X*2T,'3]
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M.5QPARH****S+"BBB@ HHHH *='_ *U?K3:='_K5^M &EZ4M)Z4M !24M)0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%.X>8'D8/(H[8[444@"BBB@ HHHH **** "GQ_ZU?K3*?%_K5^M &C2TE+0
M4E+24 %%%% "4444P"D-+2&@ HHHH *2EI* $HHHH 2BBB@0E%%%,!*2EI*
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MQ6JF@Z7^]5F6NNEA6.-0*\AN[N>Q&-E9%:-=JXI]%%24%%%% !1110 4444
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M91IIJ\=*O?\ GW?]*;_9-]_S[/\ I3YT'*RB:8:O_P!E7_\ S[-^E-_LB_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^M.P!11SZ4=LT@"BBC\#Q0 444=J "BBB@ [44$@=<BC/:@ HH[44 %%%'-
M!110>!FBP!1110 44=J.U !1110 4444 %%%% !1110 4^/_ %BTRG1_ZU?K
M0!I$ C!INQ,8*K^5.HQ0!'Y$1ZQI_P!\BC[/#_SR3_OD5+24 1_9X?\ GBG_
M 'R*/L\/_/)/^^14E% $?D0_\\D_[Y%)Y$/_ #Q3_OD5+24 1^1#_P \4_[Y
M%'D1?\\H_P#OD5)24 ,\B+_GBG_?(H\B+_GBG_?(I]%,"/R8O^>4?_?(I/)B
M_P">4?\ WR*DHH C\F+_ )YQ_P#? H\F+_GG'_WP*?12 C\J+_GG'_WP*/*C
M_P"><?\ WP*?10 SRH_^><?_ 'P*/*C_ .>4?_? IU&:=@(_+C_YYQ_]\"CR
MX_\ GG'_ -\"GTE%@&E(_P#GG'_WP*-L?_/./_O@4XTE%@&[4_YYQ_\ ? I,
M)_SRC_[X%.I*+ )A/^>4?_? HPG_ #RC_P"^!2FFT[ &$_YY1_\ ? I/D_YY
M1_\ ? I<TTT6$+\O_/*/_O@4GR_\\H_^^!2?A2<>E%@%RO\ SRC_ .^12;E_
MYY1_]\"D./2D_"G8!=X_YXQ_]\"DWC_GE'_WR*;^%)QZ460AY<?\\HO^^!3?
M,'_/.+_O@4E--'*@N.,O_3.+_O@4GF_],XO^^!3*2BP7'^=_TSB_[X%)YW_3
M.+_O@5&:0T[(+DGV@_\ /*+_ +X%)]I/_/.+_O@5$132*?*A7)C<M_SSB_[X
M%-^TM_SSB_[X%14TT<J"Y/\ :F_YYQ?]\"F_;'_YYQ?]\"H#3<4<J"Y8-X__
M #RB_P"^!2?;9/\ GG%_WP*KFF\4^5"N6#?2?W(?^_8IOV^7^Y#_ -^Q5<TV
MCE07+7]H2_W(?^_8IIU&;^Y#_P!^Q58TPT^1!S%O^TIO[D/_ '[%-.I3?W(?
M^_8JK331R(7,6_[4G_N0_P#?L4G]JW']R#_OV*I&FFCD0<Q=.K3_ -R'_OV*
M:=6N/[D/_?L53(IAI\B%S,O'5[G^Y#_W[%,_MFY_NP?]^A5(TTT^1!S,O?VU
M<_W8/^_0I#K=U_=@_P"_0J@:8<^M/V:#F9H?VY=_W8/^_0I/[=N_[D'_ 'Z%
M9QII^M/V:%S,T?[>O,?=@_[]"F_V_>_W8/\ OT*S:0T>S0N9FD?$%[Z6_P#W
MY%-_X2*^]+?_ +\BLPTTT_91#G9J'Q'?>EO_ -^13?\ A)+[^[;_ /?D5EFF
M&FJ41<[-7_A);_TM_P#OR*0^)M0]+?\ [\BLCFFMFG[*(<[-@^)]0]+?_OR*
M8?%&H>EO_P!^161S3335&)/.S8_X2C4?2W_[\BF_\)5J(_AM_P#OR*QS]*8?
MI3]C$.=FT?%>I>EM_P!^13?^$LU+TMO^_(K%-,I^PB'.S</BW4_2V_[\BF_\
M)=J?I;?]^16&:::?L(D\[-T^+]3]+;_OR*3_ (3+5A]W[/\ ]^A6"33"!1["
M(<[-\^,=5]+;_OR*:?&>JCM;?]^16":8?I3]A$7M&;Y\::K_ -.O_?@4G_":
MZM_TZ_\ ?@5@&F&G]7B2ZK.A_P"$UU?_ *=?^_ IO_";:O\ ].O_ 'X%<\::
M:?U> O:LZ(^-]8_Z=?\ OP*:?'&LC_GU_P"_ KG3333^KP[ ZTCH_P#A.=8_
MZ=?^_ I#XZUG_IU_[\"N<XIIH^KP["]M(Z3_ (3O6?\ IU_[\"F_\)WK/_3K
M_P!^!7-&D-/ZO 7MI'2GQYK?_3K_ -^!2?\ ">ZWCK:_]^!7,GI3>U4L-3)=
M:1T__"?:WZVO_?@4G_"?ZW_TZ_\ ?@5S&.*8:?U:GV)=>1U'_"?ZY_TZ?]^%
MI#\0-<_Z=?\ OPM<Q3#1]6I]A>WD=2?B#KO_ $Z?]^%IO_"PM=];3_OPM<N?
MI3>/2CZM3["]O(ZG_A8>N>MI_P" ZTG_  L/7?6T_P# <5RU-JOJM/L2Z\SJ
M?^%B:]ZVG_@.M'_"Q==_O6@_[=Q7*G%--/ZI3[$_6)G70_$+5&E5;O[.]NW#
M>7"%)'U[5O2WYVQW$#EH'&4(/\Z\R/?N#U%;&@ZS]@?[/<$M:2<,#_![BL:V
M%2C>)M1Q3O9GI.EZMN(!/U![&NHAF$J\5YN0UK*LB/OC891QT-=)I.J;E +5
MY+BXO4]6,E)7.PMO]</I4MWT%5;&56D!!SQVJU=GA:114HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH THO]4OTI],B_U2_2GT
M %%%% !1110 5'/_ *A_I4E1S_ZA_I0!G4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% #7R48+]XCM7B7C/P]JEKJ,][.3/"[$AP/NCTKV_K44]M%<QE)8U<8Q@BL
MJM/G6IZ.7XUX6I>)XOX2TPVMYINK3C;$UR!D] N#S7O,4BM&K(01C@BN:O\
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M5466VR[$#Y3GK5.GH3[?4Z[KWX]#UHX^Z"!CFN5NKW5([FVT:&[#WCJ7>X*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBBB[ #CC('XU3OM*L=13;>6ZRKT^8=*N45,HIE0G*&S.:/@30"?\
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M3J7!44F&,<#I11VHK(W6@4444 %%%% !3H_]:OUIM/C_ -8OUH T?2EI*6@
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M$(>E-IQIM-$L2FTZFU1+$---.--ID,:>E-IQI,COQ32N0,/KFA4+NJH-S$X
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M^U%6/LC?WA1]D;^\* *]%6?L;_WA2?8W_O"@+E?C-'/7BK'V1_[PH^R-_>%
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M)JMY">@H\A/04 6/[4L_^>C?]\FC^T[3_GHW_?)JOY">@H\A/04"+']IV?\
MST;_ +Y-']IV?_/1O^^35?R%_NBCR%_NB@"?^TK/_GHW_?)H_M&S_P">C?\
M?)J#R$_NBCR$_NB@9/\ VC9_\]&_[Y-)_:%G_P ]&_[Y-0^0G]T4>0G]T4")
MO[0L_P#GHW_?)I/M]I_ST;_ODU%Y"?W11Y"?W10!+]OL_P#GHW_?)H^W6?\
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M<;VQBGRR^4.E5;?_ %P^E2W?W12 3[9_L?K1]L_V/UJK10!:^V?['ZT?;/\
M8_6JM% %K[9_L?K1]L_V/UJK10!:^V?['ZT?;/\ 8_6JM% %K[9_L?K1]L_V
M/UJK10!:^V?['ZT?;/\ 8_6JM% %K[9_L?K1]L_V/UJK10!:^V?['ZT?;/\
M8_6JM% %K[9_L?K1]L_V/UJK10!:^V?['ZT?;/\ 8_6JM% %K[9_L?K1]L_V
M/UJK10!:^V?['ZT?;/\ 8_6JM% %K[9_L?K1]L_V/UJK10!:^V?['ZT?;/\
M8_6JM% %K[9_L?K1]L_V/UJK10!:^V?['ZT?;/\ 8_6JM% %K[9_L?K1]L_V
M/UJK10!:^V?['ZT?;/\ 8_6JM% %K[9_L?K1]L_V/UJK10!:^V?['ZT?;/\
M8_6JM% %K[9_L?K1]L_V/UJK10!:^V?[-'VOG[M5:* --/F4'U%.ID7^J7Z4
M^@ HHHH **** "HY_P#4/]*DJ.?_ %#_ $H SCUHHHH **** "BBB@ HHHH
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MR'!,6/\ @0J>>XG=<"/_ ,>%<!YC_P!]O^^C2&23^^W_ 'U2]L'UD[;?<_\
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M_P"^C2&>7_GJ_P#WT:/K O[078]5\VX_YY_^/"CSKC_GG_X\*\H\^;_GJ_\
MWT://F_Y[/\ ]]&CZR+^T5V/5O.G_P">?_CPH\ZX_P">?_CPKR?SIO\ GJ__
M 'T://F_YZO_ -]&CZRA?VBCUCSI_P#GG_X\*0SSC_EG_P"/"O)S-+_ST?\
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M44 %%%% !1110 4444 %%%% &E%_JE^E/ID7^J7Z4^@ HHHH **** "HY_\
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M3([ZRF_X2.V U";Y\[3@97BMG4[&6YTF2V64R38X9^Y]ZJZI#=1ZG:7L5N9
MOWD'4<5>NI;L6(F@A*S=7B;D_04KHQG+5&98:A"[0VM[:F"X3E"RX7/J#5**
MRN#XED4:A,#L+;QC)''%7)DO-6NX!)9O;+"VYI),'\!BEEANK371<Q6S3QNF
MWY,#'YU5T6Y*Y7N[Z2?5&MOM_P!CCA7!<, 6/XTZRU&4PWMN;KSVA0LLV<D\
M$TMS:26^H27/]GB\CG +( ,QD<8YJPH!TZ\_XEALSY9SG'/'M2T!\G*48%U.
MYTTWIO)(RHSY:XVD"GW&I3365G()G@CEXEE3^'BH;*XU :6+9+1W#C:LHQM
M/'(K1,3V.GQ6RV#W@ PVW&/R-+04E"Z+&GQ[86/VUKH9X8X/\JN]\CM63HUO
M-#]HE>%H%DD.V(_PUJGOQC-936IP5U^\:&G']W/J:V=+U!&B^PW;_NV^Y)W0
M_P"%8W )P2<=:T-)TMM0N,L0ENG+N1P!5TF[FF&<E/W3:MS+8WBJV3W!'<>M
M=E97_FQH#7(2W OKN**!#LA4JA[D=S72:;9ND:,W'->C&]CZ6G=QNSH%.X4M
M,08%/JB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M2B_U2_2GTR+_ %2_2GT %%%% !1110 5'/\ ZA_I4E1W'^H?Z4 9U9OB",RZ
M#>HHRQA8 ?A6EW--=5="C<J>H]:NF[2(J*\6CRSX7SK'J%[;D[7)Z>N,UZE,
MX2)G8X54)/Y5YKJOA'5-&UEM5T/+8)/E#J<]:2?4_&NK0_8I-+:V5QAI0I'6
MNJIRS:9PT^:$7$R_#49O?B+)<1J&C$KG.>QS74?$W3C<:*ER@^>W;<3[=*T/
M!_A-/#\+33?/=R?>/8"MS6;(:CI5Q:D;Q(F #3E57.AQI?NV>67OB%I?A_:V
M:MF1F\EQGVS7H/@S3ET[PY;1D$.XW,,5Y;I_A'6CJL-O<6-P+?S=S/M^45[=
M"@B@2-<?* .:>(<;<J(PL97N^AF^)?\ D6M0.>?);^5<9\*>(M1XZ.O\C5CQ
M+J?BF:>\T^VT9I+-UV+(J'D$=:YWPZ/%?AQ9Q:Z),_G,"V].E*"2A8JK)RJ)
MFI\4D;[=ILA'R@GG\J[FPEW>&87X"BV['.?EK-\2:%-XD\/1>8BQW@0,0PZ'
M&2*Y""7QC;Z9_9":;+Y8RGG;3]WI0K2BEV)FI1G="?#^/SO%=[*H.P<@CZUW
M?C(Y\):CCO'_ %%4?!?AJ30+"22<YNIAEAZ"L+Q)J7BN]^V:;%HI:U8[$D5#
MDKZTFU*92O&F]"?X5<:5>#_IMV^@KT'U%>0>&W\6>'()+>VT61DE?>Q=#D=J
M]<A9W@0R+M8@$@^M9XA)R-L*VEJ/HHHKF.L**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@"6W_P!>M7ZH6_\ KUJ_0 4444 %)FBCI0"#-9VN:K#H
MND7%],P"QH2/KVK0)XKQ'XR>*#//%H-J_0@S 'KGH/S%:4H<\K&=27*CT3P-
MXM3Q7H@N^%G4X=,]*ZK)_*OFWX<Z_)X7\5?8[H&*&<^7(&X"^]?2*L&4,.XX
M-56I\DM":-3G0_-%("*6L3:P4444 %5KS[B_6K-5[S[B_6@"G1110 5>M?\
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M2(KJ<JPR#4E<AVIW"BBB@ JO>?<7ZU8JO>?<7ZT 4Z*** "KUK_JJHU>M?\
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M/I6=_:%W_P ^D?YFD_M"[_Y\X_S-%@L:/X45G?;[O_GSC_,TOV^Z_P"?2/\
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M1O[(LO\ H$0?F:/['L?^@1!^9H^KL/J$CSBD/UKT<Z/8_P#0(@_,T?V-9?\
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MB: -'$7H*,1>@K._$T?B: -'$7H*,1>@K._$T?B: -']U[4?NO:L[\31^)H
MT?W7M1B+T%9WXT9]Z -'$7H*,1>@K.S[T9/K0!HXB]!1B+T%9V3ZTO/K0!H?
MNO:C]U[5G?C1^- &C^Z]J/W7M6=^-'XT :/[KVHQ%Z"L[\:.?6@#1Q%[48B]
MJSLGUHY_O&@#1Q%[4?NO:L[\31^)H T?W7M1^Z]JSOQHY]: -'$7H*3]UZ"L
M_)]:.?6@#0_=>@H_=>@K/Y]31SZT :'[KT%+^Z]JSOQH_$T :&(O:C$?M6?D
M^II>?6@9?Q'[48B]JH<^M)GW- &A^Z]!1B+VK/S[FCGU- C0Q%[4?N_:L_\
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MYR\4J8<=.2*M^/M*O)(+/5M/@DFO;*0N(T&2^5(Q^M=KG&3CKZT?=&!Z8YH
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M4#-+_P ]7_[Z--\^7_GH_P#WT:.</:&CONO^?>3\JMV\\Z1D&!\_2L/SY?\
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MM_-N?^?=_P J/-N>]N_Y5PQN[G_GXE_[[-'VNY_Y^)?^^S2]J+ZTCN?-N?\
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MD*I9N !FHX+F&ZC+P.'4,5W#ID4-$\K'TAIW7I^=)D$MCG%2T2[H;24O!/#
MXZTA/N,#J:&@LQ*3M3OE/1@13?J<469/*Q**4?\ ZZ3!.,=^U*PK,2DI3_$0
M.!VJ&2XABF2*1PCR'Y >]%@462'I24O;D@<\4@]>WK18EIL0TE17=PMK;M,W
MS*HZ"EMYA<0)*JD!U#"@.1CZ*@%]:M<FV$RF;^YWITUQ%;Q-+,P1%ZY[46)]
MG*X^BJD.J6%S)Y<-RCN>@'>K3LL:EW<(J\G/:BP.G),**IQZM83S"*&Y1W/\
M(ZT^YU"TLV"W$Z1L1D TN1@J,MBP:2H?MEN;;[1YJ^4>C]JBM]3L[I]D,ZLP
M["GRL7LI%OI2=Z@GO+>VD5)YD5FZ*>M3\X'Z5+NB)0E'4N:;J#V<_3?$W#*W
M&X5K2H(MMQ;8>%^C9^X?0USA&>,]JOZ9J)M)&CF!:V<XD7^OUK>G5L[';A,4
MX.TCL-)U3!"%B0/7UKJK><2J.>:\ZD1K219(VWP2<QN.A]OJ*Z#2=4X"LV/K
M7>FF>_"2DKH[^/\ U:_2GU6M)1) A!ZBK%,H6BBB@ HHHH *CG_U#_2I*CG_
M -0_TH SAUK!\9_\B9K'&1]E?^5;U17%M#>6TEM<1K)#*I5T;HP/:@#B["W9
M_A2\-N@#/:/C:.<[:YGP_8:I>>%X[;_A,K6UA9#$]O+ @*\8(Y.?QKUFUM;>
MRMEMK:%8X5^ZBC@5A7?@'PK?73W-UH5G-,YR[LG+$T <AJNGCP])X5^TW?VJ
MRM78-.%^7E0![=:[2_U73[X7%G:S1SW1@)W1 -@8/<5>GT/3+C21I,ME"]@H
M"BW8?* .@J+2?#.B: 9#I.FV]H9!AO*&,T >7^#[/5WT#[.OBVWTT*2DEM-;
MIE?^^CDUHZ]IT/AOP;ID4]X+^"&Z#-*BY#CGH!UKM=1\$>&-6O'N[_1;2>9_
MO22+RQK,\3Z$D.EZ38:58[+:"Y&(XEX5<'_&@#*\7ZC8ZG::#::?*DT\EW$X
M$>"449SG'2G+/#9_%:+[1(L2M:$*TC;0QVKW-=/I7A'0-*N$OK/2;:"[*X:2
M-?FYZU8U7PSHFN3PS:IIL%U)#_JVE7)% '(Z3=V^G?$W5UOI%C-S#&8'D.%(
M .<,>*JDKJ'C3Q%?V0#VB:?Y;.O"E@KYP>]=OJGA?0]9@@AU+3+>XB@&(ED7
M(4>WY58L=%TW3-/-A964,%F<YB084YZT <]\,51/ ]EL &5YPO? KJKJ4P6L
MLFW=L4E5]:;96-MIMHEK90)!"G"H@X JP0.C?C0!X[-JVJZOX>U#4AX@@T^'
M:?\ B7"!2_\ NXZG\JBNC<'X:>'FME$MRMVK+O.U>K=2>!7H[^!O#$E^;YM$
MM3=E]_F[/FW>M87C;1G@T_3X;&SDETJ&4?:+&V7/F+DDC'I0!7T==1U[Q+97
M^IBRM#90F-(H;I)#)G!SQTZ4_2+JWTOXF:W%J$BPR3Q1-!)*<*0%.0&/%85K
MH]K>Z[II\.>%;C1)89!)-<2P[-R \KGWKTK5O#6C>(!#_:^G07?E@A/-7./7
M% '$P%-0\:^(-0L1NLUL=C.HPI8*P.#WYJYH\,?_  J^?;&HW0L2,=3CK78V
M.CZ=IFGM865I'!:'(,2#@YZT^/3+**Q^Q1V\:VN,>4!QB@#R>0D_"OPH3S@)
MDY[XKL_$>C07=W9W]KK4&F:I$@'G.5.4]-I/K6]_8&DFPM[#[!#]EM_]3%M^
M5/I5;5/!_AW6KA;G4])MKF55P&D7)QZ4 <M8:YJ&J>'=?TZ\87,MFIC6Z1?E
MGR <C''?'X5K_#R[@E\)VT22QM)'OW1AQN'S'MUKH-.T>PTFR^Q6%G%;VPZ1
MH,"JNF>%M"T>\DO-/TRWMKB3.Z2-<$YZT :_'7_(H]NU'KWH[4 %%%% !111
M0 4444 %%%% $D&?-7'K46H:6]Y.)$N&CP,8%36_^O6K^*!,YXZ#-N'^G/Z#
MB@>'IA@B]?/<UT./:C'&*=P2.>_X1^;#8OW]N.E4S8Q+=_9#J;"9>0#[UU??
MFN4;0GN_$-U<RJRP@QLAQR2*:9,B7^RQPQU(\MMS[T?V4#<- -2/F(-S+[5G
M?V+?_NY&>1D%T\AB/3!.13H](U&/6WU)LD3%T91V3!V_SJB-2W!913O*L.I,
M2/O#VH^P1^3%,=5S')PC9ZG\ZHZ9HUY8W+22Q966(H,?PGGDUF0>']2-A8V#
M0L(;5_.!(ZGD8_6F]P=SI3I(\]8#J3>:5W!>Y%3?V!.2/]/?V&*RQI6I'Q!'
MJNTX614"^D>.?UKLTZ9QC(J&6D80\/3#K>O[TG_"/S9XOGYZ<5T('>C I7*:
M,*VT.6"X63[8[;>H(ZUIW7W1]:M<56NQ\B_6ANXRI1112 *O6O\ JJHU>M?]
M30!5F_UA^M1DX4Y/'6I)_P#6M6?JLLL.FSM C/*5*J .Y&*J),]CE6^RZG=Z
MO<3W$2X'E1AG'53G-7;369I/!1NXI!]IA0 G'\612:3X/TM],A?4--ADNW0-
M*SKSN[U3&FW%C;ZQIMO:/]G<^9!L7Y>H^45T*UCD:E<2XOO$%II\>LSW:"+&
MY[8(/N_6M#5=3OIKZST^QE%NUQ'YC2D9Q[8-&NV=Q-X,:".)GF\O&P#YA6-X
MAC8ZI8.);E)H;?;LM0#*O3G%-)";DC4T:761KUS;WNHK-#;C! C SD9JNNJ:
MAJ\MQ):ZK!I\,;%$1]I+D'!Z]*G\-3VHN)K2078O91O+W:@/(!W_  S60-%L
M],O+F/4= ;4&=S(DT4>[@G.#0TK@I29J7.J'4_"5PTI5IHG\M]IX;!QFDO=2
MU"QTK0H[ @-,-K ]QM'\JD:SMY?"LRZ;I,EIN?\ U!3#'GKBDO+*ZDB\/JMO
M(3#GS!C[ORCK2]T=F5YKOQ#9:XNG&Z2X6Y0;)2H7RS]._2M#1[Z_@UFXTN_N
M/M$@3S$DVXXSC&*=J%G._BVPG$+M%&.7 X'!I#:7?_"87$ZQNL36FWS,<9W=
M*?NL?O(K:E-K&RXN%U>WLC'RMO\ *Q_.I;G7KQ_#%O?VNTS/($ /?J#^>*YX
MZ>CQ7$%]H4MUJ3,1]I>/*L>QS6M#IUVOA&RMS;.)DG!* =!D\T6BB;R;'RWN
MMZ3<V=S>7@E@N75&B" ;2Q]:['EEVYSZ'I7->)K2XN;+3DBA=RMQ"6P/N@$9
M-='R(SM + 8^;]*S=C>-SBFEO_"M_=32VGG:=-(9#(IR5W'G@=:O7FMRI<:7
M=6<@;3+AL. N,#'_ .JEO-;O!#/92Z5<R2L617B3* '@'-1?V#);>##:N )D
M7?D=B,'^E4K,RDI)EZ]U.Y/B&*SM9 J+'YD@QGCD5D6]UXCU.QGN8KM8!#D)
M\@/F_P"%2^"_M.H6ESJEW'^^N,JI']VM'0[:X@T.6.6)T?)P"*>B!<S*DOB.
MYD\,6]Q 0+JX?R5)'1N1G]*RM<@UBV?3?MUT+J.2YC8L%"[#GICO4R:5>KX4
MM&2!OM%K<&?RR.2 Q_7FEU.YU'6C8>7IL\4$5Q&TIE3#9![>U5&Q$N9EVZO=
M8N?$\VEV5RL,*Q(_F%0=O&>G?-.FO-5O=1_LBSO DEN@:>Y*#G/3C\*L6MI<
M+XSNYS$RPM"@#XXX6JEVMWHGB:74H[2:ZMKJ-481+EE*Y_QJ="[2L26&J:C:
M7MYIE_()9HHC+'. !N!SCC\*RK?4?$=[X>?58[Q8_+7(BV ^9SZ]JT;2VNM1
MU"]U:6!X%>$Q1PL,,<9[?C1IEC=1>!WMG@D$WE >6PYZT:"]\JRZIK<>F1:X
M;E4MR=[6VT=.GWJOZOK-Q]HL[&TG2UEN$\QIG(PH_&H-0L;I_ *6H@=IA#_J
MP.>M0Z[H@DFL+^XT_P"V00PA)( N6]<XH7*)N:+NF:I=VNMKIMW?17WGH725
M,#;C'&!]:ZCZ"N2T&WT?^T$-MX<ELY5!(F>+:!^-=9Q][&">M93L=%)MB]:*
M**R-@IT?^M7ZTVG1_P"M7ZT :7I2TGI2T %%%% !24M)0 4444 %%%% !111
M0 E%%% !24M)0)A1110,2BBBEU%U"DI:2F,****0@I*6DH *2EI#0 E%%% @
MI*6DH **** $HHHH *;3J;0(*0TM(:  TE*:2D E%%% "4E+24" TE*:2@!*
M***0"4E+24"$I*6DH *::=330 E%%%(!*2EI*8A#333C332 *2EI*!"4E+24
M )24M)0(2FFG4TT@ TVG4V@0E)2TE(!*2EI*!#:#THH/2D VDI:2@0E-[XZC
MN*=3??!^7M0(X/QE?6EAXGT>>]5G@\M\JL6_^(=JT(]6TG5M&U-M.MGB,4#Y
MWVYCZ@^HYJ#Q4US9^(=,OHK&YN8XT8,($W8R15O^W'UO3[ZV72K^W8P.!YT>
M,G!Z4R]"QX2.?#EMD]1Z5@^(XE\1>)1I:DE;&(S-Z$L" /P(HT7Q)<Z9I,5G
M+H.JF1."RP\'TJMI'AG4M6N;S5I]2O\ 2Y9Y6'E18!V Y&<_6@+&QX4O&G\*
MM;R'][:(8)<]=P%<9I.M:/%X?NK&:V9[N1B 6@.W/^_CBNCT32=0T'6]2LW:
M>\M;F(RB=QDLYZY]^*71=!ENO"-Y87D#QO(25#C% M#0AN9?#W@<37AQ<6\)
M8X.<\Y'Z5S6E6S>'=4TJ\;.V]5ED]RS9'Z5->P:OKGA_2M)G@GA:1]MQ)M^Z
MN2/\*DUOP=J,6F>?#K6H7LMIB2*&4@J2HX Q0&AWH/RY RN*XWPE(;K4M8U!
MS\QE,0/LI(KJ-.EDFTRW::-XI2@W@COCG-<OX-3[->ZO9,OS+.TF&]&8D5-B
M!OAFTCU34M1U.\02D3M"BOR %/I^--URWBT?Q3I%[:CRC/(8I548! 4GI383
M?>%-2NQ]AGO+2[D,J&!=S*Q.3GVJ9([[Q)KEG>RVTEK8V;%DCG&UW8C!X]*=
MBK$)O-?U76KZQM+I+:*WD.)=H8X],4ZQ\2W%KINKC4\2SZ<VUI!QOX!SC\:I
M0:I<Z5XHU:2.QEN8'F*8A7+AN#^52P>'[K5M*UNXFB\B?4VRD;C!48 PWY4@
MT*[ZKJ\&F_VP^M6TB*#(]F-N2O\ =SUJ]K.MZF]QI::8RI]LB)8,!\IXY_#-
M9$%CH<42PW'@V=YUX=T@RI([CFMZ_L6?7='>VM66W2(Y7;PAR,9H%*UANG7>
MK67B1-,U*\6Z6>(ND@0+MP,D8%+XEYU;2.X\QOZ5->6MPWC:RN5A8PK"X9P.
M <"H/%@G2ZTVYBM9KA8G8NL2Y;M2(T-S4'GCLI&M0N_&,.V /?FN5AU/4-.U
MRQM[C58;^&Z?R\(%!0X)[4_6=3O=:TF:&TTZ_@=2I?S8\;USR*Q[?3(7\0Z3
M<:;X?DLHXI3YCM'M/W304DBY#%JESXIU>'3K@6Z"7+2E0<\#C%7;+Q#<6=EJ
MBZGA[C3_ )6<?QC&>E0+<:CI'B+4+HZ=//9RR8'EKEN@Y^E)#H5SJMAK%Q-&
M;>;4?N(XP5XQS^5&@61 =2U5-/&K-K-NRI^\-K\N2OIFI/$%R+R30K@=))%;
M'H215*WLM'@C2&Z\(RO,GRLZ0Y5O?K6MKED\LND-:VCK"CJ64+]P9'6@F5BW
MXS8#P\[-R%E0GCWJOHVMZ1=?9K6"U<3[>&:V(&<>N*N>*X9IM#=(8VE<2HP5
M!DD U7L-?8K% =(OT(&TLT> *0E:Q0U#Q'=:-J-Y9W69'D4-:D+ZGI5;Q-;:
MJVA6\EQ? , /,38.6^M3:EI>HZY>75XRO#]F^6U0\'<#R?Q'%3ZM]NU+PDDQ
MLY!<( SQ;>_M2#0?J%_>Z+HT*372S74Y"1R%0H4D=ZK?VAJ&F75J]SJD%_!,
MZQM&FT%">_'6GZM;2:[HUO*UC(3;NKM;S+]\ =,56L;?1#=PK'X8FAE##$OD
MX"GUZ]*- TL6;J\UB[\1S:?93K# %5O,*@[>/2GZ=JU\D6I07;^?/:*61E7&
M[KC@?2K-M:RIXJNY3&PA**%;''2H;*.XM-;U6YDMY#&Z)M 'W\9Z4:$71'H<
MM_?>5=R:NC*PRUMY8ROM51]>FL]0U;>J.D0 C 4 Y+8ZU'%#'<:W;3Z?I5Q8
M-O8SRO'M#9[4RXT6ZO=0U@"';NPT;..&PV>*-!Z%F:37M,L(]3N;T2A #);B
M,=/3-2ZGJ6HR:G9VNG2!5N(MS$@?*<]:KW&I7^JZ8NGC3KB&>8!7D=,*.<]?
MPJ[+831^(+#RXR\44&TOC@<TG8EV0RPN;]=8DTO4)Q<;XRZ/MV\#&:=X5=A8
MSP,>8I6 _$FG203?\)<MR4;R/L[ L1P#D=:;X5&ZVN;CC$DK8_ D4G8EV,R>
MRU ^+XPM_M)1F5M@X&.F*GN;[5Y_$C:7:W"HBQ*Q<H.#W./>IM2^T6?B:WOA
M:RS1&-D;8N2,C%.@MYV\82WAAD$3VZ .1['BEH":L,:YN8O$EG9.Z2C9EY"H
M!)P:74IM1WSR1ZC#;"+A8VVDOCO[4E[:3OXMM9DC;RU3!?' .#61=V6;B^2^
MTIKR[>5O*EV90#ZT]!QM<EUB].H>%K.Y;EW;)'IUKH[V\%AH[W/5HX@VWUXK
MG)["[/@^PMQ;2><O!4#D=:W]4LGO=$FMEXE>''S=CBD[$RY;G/:HFL'09+F:
MZ62.09,6T# /?-:[R71TRS2WG2W5HEWROCC '&#67>76H7FB'3X]/F$JIAV=
M?E('''O3M2M)B^GFYM)+JU2#$D"+GYL#'%-6+2BR6TN[^Z-]8->I))$@99E4
M8(.>*3PQ#>)922&Y#QB5P8RH'S?6HM L6BU#4)$L#:0R1@(NW'K4FEFZBL[J
MQ:VF20N[1RE?E/XT.PFHC+R^U&T5;QK^)OF&^V&W*Y[9K<U&^%CILETR\JN0
M!ZUQ<M@9=.BC_L=_MX(,MPZ<L<]0:Z[4[%[_ $62V3[[)@9Z"DTD1-0,9]0U
M"VT\7\FHPRA1N>W&W./3-7=1U.>T^RWH/^B. )5 SC/>LN"VTQ(MDOAR1I1P
M66+BM34;>:\-O86T3QVSC?,V.,#^&FTAM0L-M=0O;O3[N_W!8 K>4NWGBJL5
MQK$]@;_[2L85<^7M!W 4^V6[MM+O[*<$I&C>6_8C!_E52QO[P:0+,64C.ZE5
MD1?EPW')J="4HEV\UJ4V%GY#+'/<_P 9(PO3--2_N;'48HKB\CNXYSM!3 *X
MY[5#>Z(T5C8AH%N5M\^9%C.[( XJ2R@TS[7'Y6ARP/VD:/&*-"DH6)%GU'4K
MVX6UG$$,#>7]T'<:S]0@U%M3L/.N@LSM@ *"$Z_G5V%[G1[V\C-K+-',^]61
M<_G1J7VLRZ=>- [&-LR1H,GO2T(?*GH.U&^NH)[>PCN5$T@W/*P X'%5VUB?
M3+AHKBY2Z5HV=&7'&.W%.U6S^UW-OJ$EB\\84JT++\PYZXJ(6&GWBS16VD/;
M2M&0KNF #3T*486"X&JR:,]T\ZLK@GR< 84^_P!*V;!?,TBW7/RM$ ?;BL:2
MXO9=(-@MFZS(NTLR_*0/2MRR#0:; '0DK$"0.O2I=C*=DC"CMHK3Q5%'"I"^
M7GYCG/6K4P-YX@6!R?+A0/M]3G%4WNKA_$"WOV"Z,00*04Y[U;O4N8KZ'4H(
M9'4H%= /F HT"UD.UZVCCL/M4*B-X>05&,FM!$6]T]%E&5<#=SBL+6=2N+R%
M84LKI(F.9"R=!6L;H+I9DLD\W8GRHOK0U=$U(NR,_5XX?MMG# @\]7!^48PH
M]:-.1+S5;UYQN* *H(SCBJVFW,D4K75W8W3W4AP7V<*/059S-IM_-,EM++#.
MH(V+D@XZ&FEH:6]VPW2(8[AKNV=<QI(2.?>EN%C;7[5+<#>@)DVC QBF1I=6
M&FSW$5N\EU,^0BC[H)_G1I4QM\M)9737$O,CLE%B;-:B:Y:10W%M,@(>67YB
M3GM6^O"*/05S^N2RW,L*Q6EPPBDRS;>&K;M)_M$(;RI8\<;7&*AHYZR?+=DW
MK33@=<XQ3L$]J!U '7IS6?70Y&W<U=,U 1_Z-=#=;R8[\H>QJ^RO87 &<QGE
M2.0161IFFF^E9W.R%?\ 62>GM]:V)Y1=-'!"H6WBX0>I]?K7=1O8]S RGRZG
M;Z%J)DAC4^E=0AW+7(Z!8LL:,PYKK8UPN*Z3U!]%%% !1110 5'/_J'^E25'
M/_J'^E &=1110 48'<DGKQ110 9[\4>GM110 =,#/?CZT8.,?Y%%% !GG(Z=
MQ1]3GWHHH .U%%% !]!VHX_'^=%% !_G-';/0444 '=3@YZTN<G-)10 '_)H
MY]J** #MWHZ\>M%% !P>_M1[444 'TH[T44 %%%% !1110 4444 %%%% #X2
M%F4DU<\^+^]5"B@"_P#:(O[U'VB/^]5"B@"_]HC_ +PIOFQGJ_-4J!TH"Q=\
MZ/DY!H,T9_B_"J7:B@+%SSH^[9I?M$?K]*I44Q6+GG)CAOQIPGB_O51HI7"U
MB^)X\?>I?M$7]X5GT4QFAY\7]X5!<R*ZKM;/-5J*0!VHHHH *O6O^JJC5ZU_
MU5 %2;_6D4S'KSBGS?ZTTRC8+A_#S^-)COT[4M%/F8K(,CDLIW'K6!J>AWTF
MIIJ.EWD$%QL*.TT>\$'VK?HJE)DN"9@:;H5W'JC:EJUW%<W2J4B:%"BJIZ@C
M\!6_V&..:**3FP4$@[_3O1Z9]:**6I2BA<MCJ*3UZG(Y%%%&H60#@<8]\BCC
MC/X^U%%-MA9(!Z[3^)H.2, CD_E114ZA9!GG'8<#WJIJ-M)>6$UO$_ENZ[0Q
MZ5;HIIL&D4]+L%TW3H+4'/E+M+#@5<XP>#UY&:**;;"*0<Y&<$=>* .IQU/2
MBBCF8.*#C!!R>>@ZT'KN/TP***5V%D')';(Z<4<' &0">0:**+L+(..N>G%)
MC (!Y'0TM%";!),.G((S]*._J:**&"L@HHHI#"G1_P"M7ZTVGQ?ZU?K0!H^E
M+24M !1110 4E+24 %%%% !1110 4444 )1110 4E+24"84444 A****74.H
M4E+24QA1112$%)2TE !2&EI#0 E%%% @I*6DH **** $HHHH *;3J2@0E(:6
MD-  :2EI*0"4444 )24M)0(#24II* $HHHI )24M)0 E)2TE !333J::!"44
M44@$I*6DIB$---.---( I*6DH$(:2E--H$%)2TE "4TTZFFD &FTZFT"$I*6
MDI )24M)0(;0>E%':@!M)2TE(0E-[]>E.IM(3$.2!3>?;CDTX]*;WH%=B8 ]
M<-R<FDYR.0,>W6EH-(+C>>>0"3R<4P^^3^-/I*8KC3[4GMW[>E*:2BX7$_KU
MK)BT@P>(9M3CD $R!'CQUP,"M:D-(5QO..3S2'I[#H:6DHN*YD:;H[6.IWUV
MTH9;F0L%[K6H>YZD]J6DI"NQI]@?<#K0>IP1CMZT4E+4F[$/WN,\CFD&0."!
MGUYI:::5PNQ.V._>D..1RP]0<44#H:+AS,;C@ GM@TG();(/'2EI*+D\S$(!
M/0@]SGBD/3#= >/>E-)2N)W$/!.,<_I2<9QR/ZTIIO>BX:H;SC!/&.:&YZ9V
M]AGK2TAZ4FQ-L:?X@#SGBD/4 ?6E-(:G45V-)//')-!SZ_G2]Z0\T:DZC3QQ
MZ>O>D]^K=O>@T47878AQGVSS2=SGG'3'%*:2B[)NRK?P27-A-!'*$D=" ^.E
M1Z98KIMC';J=Q7[V.^:N4E)A=B'MGYE].](<X'IGIZ4M)2N*[L)CL,>M)_N\
M ],\XI3TI#_6B[)NQ#C.1G;]:0]SU/7-%)1=B8F>"!T-(>O Y]J7O24KL&Q.
MAQ]X>M![\@^@QTI33:?,R;B=>O&>N:0YP1D<^E+24G=BDP[YR..U-(Y.#T//
MO2T4DV*Y!=PF>UEB4A/,4KR/6H=/M#9V:P%PVWJ<5;I*&V',!R>#^E)P3WQT
MQGD>]%)1=D\SZ!C(&XY--[KR,=\CFEI#2NPNP8;EYSZ<&D)_+T[TM)1S,GF8
M8&[@C&.]-!R.!SZTM)2NR;W$XY;/)XQ2< \9P!P,TM%%V)R8T]"",\]#SQ34
MBCC0*BA1GC:,4\\TE%V/F=A.3CT]*.F?T]J4TE%WW(YY=Q.>QP*,  #GUSFB
MDHL^Y/.Q">2Q//<#IFCDDGK]*./2CO@TKL.:^XW''.?SJWI]A)J$_E(=J#EG
M[**99V<M[<K%$N"Y^9CT4>];[M';0"PM#\@_UC@<N:WI4FW<[,)A9597>PDK
MH42RLUV6Z=?5SZYK6TK3"[!G7Z#%1:5IA<AF&177VEJL0'%=\8I'T%.G&G&R
M-2QMQ% F .E7*9%_JE^E24RPHHHH **** "HY_\ 4O\ 2I*BG_U+?2@#/HHY
MI>: $HI>:.: $HI>:.: $HI>:.: $HI>:.: $HI>:.: $HI>:.: $HI>:.:
M$HI>:.: $HI>:.: $HI>:.: $HI>:.: $HI>:.: $HI>:.: $HI>:.: $HI>
M:.: $HI>:.: $HI>:.: $HI>:.: $HI>:.: $HI>:* $HI?RH_*@=Q**7\J.
M:!"44O-'- "44O-'- "44O-'- "5>M?]55(YJ[:_ZJ@"I-_K33*DF_UIIG-
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M1]IU#_GJO_?- &S25C_:=0_YZK_WS1]IU#_GJO\ WS0!L45C_:-0_P">J_\
M?-'VC4/^>J_]\T :YI*R?M.H?\]5_P"^*3[3J'_/9?\ OB@5C7I*R?M.H?\
M/9?^^*/M.H?\]E_[XH"QK45D_:=0_P">R_\ ?%+]HU#_ )ZK_P!\B@+&I167
M]HU#_GJO_?(H^T:A_P ]5_[Y% 6-.DK,^T:A_P ]5_[Y%+]HU#_GJO\ WR*
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M?TA_[]"CV(OJAY_25Z#Y<_I#_P!^A1Y<_I#_ -^A1[%!]4//:2O0_+G](?\
MOT*/+G](?^_0I>Q0OJ9YV>E(?ZUZ+Y<_]V'_ +]"CRY_[L/_ 'Z%/V*%]3/.
M.:2O2/+G_NP_]^A1Y4_]V'_OT*7L4'U,\V/6BO2?*F_NP_\ ?H4GE3?W8?\
MOT*/8(7U*YYL:;7I?E3?W8?^_0H\F;^[#_WZ%+V"#ZB>9T5Z9Y,W]V'_ +]"
MD\F;^Y#_ -^A0J G@;GF5%>G>3-_<A_[]"CR9O[D/_?H4U0#Z@>84G->H>3+
M_<A_[]"CRI?[D/\ WZ%)X</J!Y=S28->I>3+_<A_[]"D\F7^Y#_WZ%'U87U
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MC@<4=#TJS8THO]6OTI],C_U:_2GT""BBB@ HHHH 0TUUW*0>]/J.5ML3'T%
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M_*@"?[''[T?8X_>H/M,GJ/RH^TR>H_*@";[''[T?9$J#[3)ZC\J/M,GJ/RH
MG^QI[T?8X_>H/M,GJ/RH^TR?WA^5 %C[)'[T?9(_>J_VF3^\/RH^TR?WA^5
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M]JYJWO;>_P#',$]K*LT36CX>,\?>%4H.UR745['844<8HK-FJ"BBB@ I\?\
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MKMM_JJ *LO\ K&^M,I\O^M;ZTR@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HP*** );;_7#Z5-=_=%0VW^N'TJ>
M[^Z* *=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%%P
M"BBBG< HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% &E%_JU^E/ID7^J7Z4^@ HHHH **** "HY_]0_TJ2HY_]0_TH SJ***
M"BBB@ HHHH **** "BBB@ HHHH ***.E !1110 4444 %%%% !1110 4444
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M3]B-1.S.H67_ $%8/^^32'4K$==6M_\ ODUP[9J)LU7L!\AW?]J:>.NKV_\
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M %%%% $UM_KA]*EN^@J*V_UP^E2W?04 5**** "BBB@ HHHH **** "BBB@
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M)7 4?Q,3P/SJ6/Q%J4#P2:EID=O9RD;95EW$9Z9%8;V<UWX#3R0XV76]MO4
M-DFA;?2;V*"*Y\5W#;F5O)DD')SD#\Z?*@YY(Z>?7Q::R+2ZC$<+)NCFSPQY
MR*L:3JC:IY\BP[85<K&^?]8/6N;\2Q?VU<P:+:@22P#S))#U3C_ZV*U_"5TL
MFFK9,@CN+,^7(@[$5$HHN$VWJ:FHWWV"W+)"TLC':B 'K63:Z[J*:E!:ZGI\
M=NLXQ$5EW9.>A]*=XKU"XLK*$1.T,<K[99UX,0_O5RN^)]>TEH-8N=34RC)9
M@RJ<]*(Q0JE1W.GOO$=S'JTFFV=D)YU (!;"XQZU/I/B'[9;737L7V>:UR94
M!S@<X_E4&GC'BV_PI VC^598B>?4?$<<>?,:)0 .I^4U7*F',]PU'Q%J-WHU
MS<-IBKI[!E64298^AVUT/A<[O#.GG)'[E>,>U<W_ &]9)X3:T0A[Q8?+:W3[
MXP,$XKI?#61X;L!D_P"I7^5*25@IWYC5I\7^M7ZTS\:?%_K5^M<QUFC1VHHH
M *2EI* $I*7\124 )24M)3 ::;3Z8: &FF'K3S333&,-,-/-,(- #&IAI[9I
MAIC(VJ,U*U1&F@(VJ-JD;'K4352 B;K43=:E:HFIC(FJ)ZE:HFYIH9"U0M4S
M5"U6AD+=:B:I6J)JI#2(6J%JF:H6JDAD#5$W6IFJ%JM%$![U$U2M4+52&B-J
MA-2M41JT4B)JB;I4K5"U6BD1M435(:C-6BD1FHSG/%2-CJ<^E1'.<G Q5;%[
M#2!N &2#VZ8-=3X>T6.VB75=03I_J83_ !GU/M4?A_1%DC_M'4%(M(_NH>LA
M]JWR9-0N0<851M11T4>@KBQ&(MHCGJ3%1);Z[+2?,S'MT KK-+TT1H"14>E:
M8(P&*X)ZUOQQA5QBO.;;9R7NQ40*,4ZBBD 4444 !J6W_P!:*B-2V_\ K10!
M/=_<'UJG5R[^X/K5.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "KMM_JJI5=MO]50!5E_UK?6F4^7
M_6M]:90 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 36W^N'TJ6[Z"HK;_7#Z5+=]!0!4HHHH **** "BBB@
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MY'IR: .>^&?EVO@-9UB5CM+, OWC[USLVL:_J_AS4=0M=6TW3M.PQ^QM:@R
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M/4T44 &!2X%)12 ,#WHP*** # ]:,444: &/K1BBB@ Q]:,444 '%'%%%(-
MP*,"BBJ'H'TI*6BD(**** "BBB@ HHHH #4MO_K14536_P#K10!-=_<'UJG5
MR[^X*IT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5=MO]55*KMM_JJ *LO^M;ZTRGR_ZUOK3* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@":V_UP^E2W?05%;?ZX?2I;OH* *E%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% &E%_JE^E/ID7^J7Z4^@ HHHH ****
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M_P"169H)12X/^11S_D4 )12\_P"11S_D4 )12\_Y%'/^10 E/B_UB_6FX/\
MD4Z(-YB\=Z +=S_J:HU>N/\ 551PW^10 44O/^11S_D4 )12\_Y%'/\ D4 )
M12\_Y%'/^10 E%+S_D4<_P"10 E%+S_D4<_Y% "44N#_ )%&#_D4 )12X/\
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M[4?)ZBL_/N:,GU- &C\GJM'R>J_G6=DT9- &A\GJOYT?)ZBL_)HS0!?^3U%
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M:/W?^S6=DT9- &C^[_V:/W?^S6=DT9- &C^[_P!FC]W_ +-9V31DT :/[O\
MV:/W?^S6=DT9- &C^[_V:/W?^S6=DT9- &C^[_V:/W?^S6=DT9- &C^[_P!F
MC]W_ +-9V31DT :/[O\ V:/W?^S6=DT9- &C^[_V:/W?^S6=DT9- &C^[_V:
M/W?^S6=DT9- &C^[_P!FC]W_ +-9V31DT :/[O\ V:/W?^S6=DT9- &C^[_V
M:/W?^S6=DT9- &C^[_V:/W?^S6=DT9- &C^[_P!FC]W_ +-9V31DT :/[O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+;_ZT4 3W?W!5.KEW]P53H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J[;?ZK\:I5=MO]50!5E_UC
M?6F4^7_6M]:90 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 36W^O'TJ:[Z+4-M_KA]*FN_NB@"G1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>%_-5>5 Z<U2=A,;KOA=[KP#I7B'3U NK098(.2!_%^&*9XL\3KXH^%UG,[
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M0 5+;_ZT5$:EM_\ 6B@">[^X/K5.KEW]P?6J= !1110 4444 %%%% !1110
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MG+I5C/;1VTUJCPH/E0C@5/;V\-I L4$2QQKPH':I?7FCZ?K0Y,=BI>:797[
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M1@8JQ-$(XEQ4%=3. **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "I;?\ UHJ(U+;_ .M% $]W]P?6J=7+O[@^
MM4Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *NVW^JJE5VV_U5 %67_6M]:93Y?\ 6M]:90 4444
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M*+<2<_I6K\/]4@CTKQ!J>\"$2B5FST&TF@!?$GB?6(?$G_$LF_XE]E-$ETA
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4(KQUP$>.'R\ <8JYJ=H;[3KFTW;&FB9 V.!D5:XSGG-&3SR>: .?_X1I_\
MA$I-#$XRT14R8]165?>!YY](T>*SU!(+[3$"Q7#1[E/ !^7\*[3@=!2\X&*
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M 59O]::CI\W^M-,H **,4E "T4E% "T4E% "T4E% "T48HH **2B@!:**,4
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M@".Y5F4  U6\F3^Z:O,ZIC<:;]HCYYH I^3)_<-'DR?W#5SSX_6C[1'ZG\J
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M].P7"C\31SWH -( S[FC\31T&1]#[T<XZ\T#N'/J:/QH[=,44"#\:/QH[44
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MIKW][IFHL+Z0S0R,D;X&<#%0V6LW5QX4W-<,-1/[LMCG?Z?E5_PQ'+'#>K+
MT9>=F"GN#BJ=EH5Q#XIN&*E;%G^T+GINZ?RI:"]X;J,U_:W]A;'4G19DS(Q
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MO2)EB=]BDIC)KB]$F;5+E='D8P6RS,[%O^6WL/RKI/%L44&EV<4*A(TEP!V
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M %%%% !1110 4444 %%%% $UM_KA]*EN^@J*V_UP^E2W?04 5**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -*+_5+]*?3(O\
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ME+R[8["O-/&\T4OC:UDBD1T!CR0P(ZUZ1KWA^WU[3%LI9'BC4CF/MCM7,?\
M"J=+S_Q^7)'8L!4TIP3;9=:$VDD=O#>6TB$I-')M7)",#C\JK6^MZ==QF1+N
M( \$,P4YK+\.^#+3PY-/);SRRB5 A$@%4M3^&VD7UPTJ&2W.>1$!BH]SFW-;
M3Y+6.+\4RPZOXUACT]?,96VG:."WUKV&V0I;QJ>H4 _E6)H?@_3-"8/ #-*/
M^6L@YKH/IT[4JM527*@PU)P;<@HHHKG6AUA1110 4=.>]%% #=BD'*KGUQ2[
M%SRJG_@-+15<S1/(A  HX %#,$ $C <_>)QUI>O49&>16%XJ<)I2EFV_Z1&
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M0 4444 36W^N'TJ6[Z"HK;_7#Z5+=]!0!4HHHH **** "BBB@ HHHH ****
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MK95=HKU+'S[%HHHH$%%%% !VJ6V_UJ_2HNU2VW^M7Z4 37?054-6[S[HJH:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ -2V_\ K141J6W_ -:* )[O[@^M4ZN7?W!]:IT %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5=MO]55*KMM_JJ *LO^M;ZTRGR_ZUOK3* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@":V_UP^E2W?05%
M;?ZX?2I;OH* *E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &E%_JE^E/ID7^J7Z4^@ HHHH **** "HY_]0_TJ2HY_P#4/]*
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MUP&=OKWK5FPOBSPT"VW-F!N_$<4 =H^JV*:DFFO<QB\D0ND.?F*CJ1^8KCO
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M?2ZG$0]G9PA$8'(\S//Z&@#O>#11Q1VH **** "BBB@ HHHH **** "BBB@
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M8JL*D'H<]:VK;3K6TN+B>%"'G(:0D]<<598!TVXW!N"#Z5'M%<M4V<>SV*^
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MH **** "BBB@ HHHH **** )K;_7#Z5+=]!45M_KA]*EN^@H J4444 %%%%
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M4 %&!Z"BBG>P6"BBBE< [YHHHH **** "GQ_ZU?K3*='_K5H O2OL3-56O'
M^50?K5BY_P!55' ]Z (WU&ZSQ"GZTW^T;O\ Y]XOS-2E1FC:OI0%R W]T?\
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M[Q_*K/YT?G0!6^QC^\?RH^QC^\?RJS^='YT 5OL8_O'\J/L8_O'\JL_G1^=
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gk2ifd22ejwl000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gk2ifd22ejwl000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %Z MP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ***X;Q?\ $6U\+^(M,TQE#B5@UVW>*,\ _7O]!50@YNT29245
M=G<T4U'61%=&#*PR"#P13JDH**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[5L2P/NQ_>'<'V(XKZMT;5K?7-'M=2M&S#<(&'L>X_ Y%>3_ /"AV_Z#H_\
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M^!C3!Y1/XF_I^-?.->EZUX ^(7B*^^V:JD=Q.%"!C*B@ =@%P*SO^%1>+_\
MGRA_[_K730=.G&W,KG/652I*]G8X6BNZ_P"%1>+_ /GRA_[_ *T?\*B\7_\
M/E#_ -_UK;VU/^9&7LI]CA:*[K_A47B__GRA_P"_ZT?\*B\7_P#/E#_W_6CV
MU/\ F0>RGV.%HKNO^%1>+_\ GRA_[_K1_P *B\7_ //E#_W_ %H]M3_F0>RG
MV.%HKNO^%1>+_P#GRA_[_K1_PJ+Q?_SY0_\ ?]:/;4_YD'LI]B[\(_%G]BZ_
M_95U)BROSM!)X27L?QZ?E7T+7S<OPD\8HX9;.(,IR")UXKL$M_C''&J+>1;5
M&!E8"?S*UQ8BG"I+FC)'71G.$>646=;\2_"@\3^&G," W]GF6 ]S_>7\0/S
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M(]+\2VLMSI-SY\,4GELVQE^; /<#L14<LN6]M"N:-[=35KYI^+7_ "4G4_\
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MLG.>QS6L9Q^KN-]3.4)>W3MH>JT445Q'6%%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
<B@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gk2ifd22ejwl000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gk2ifd22ejwl000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1\!6H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0K!,89"Z;?F'IZUQYG"I]:K.-[)Z]O(J%N5&P !THIJMDX/#>E.KRBPHHHH
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M"2/L?TZ]ZL>%4O-;\33^.]0$=CIB0-' &/WH^>2?09Z]_P *Z*L<0O;RKO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !49!(P1P>N*DHII@0+$L;NZ
MQHK,>H'+?6C8F\2F(&51@$CD?0U/13YF!%M/&!SUP>U'EQ>8T@C4/T9MO)'U
MJ6BE<"$1HC-LB52QRS*N,_7UI<8[9 &/>I:*+@110QPKLB14!Y.U0*$A2(8C
MB1<G)V@#\:EHHYF T##8P>E.HHI %%%% !1110 4444 %%%% !1110 4444
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M@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;27,TBQQ1+N=G. JCJ:FKAJM&2A4BTWT8TT]BQDXZ#\Z6N%7XK^%7N$1KB=
M9 @=X2%!)QG/I[UW"R(\:R(P9& *L#P0>E%?"UJ%O:Q<;]T"DGL.HH!STHKG
M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>=CP,X[5E#"59\BBK\^WR=@YDCHRS<<@#OD50N=9LK.]M+2>XVW%VY2*/N2
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MTQQ2-M# ]3U':LJN"J4Y14K6EL[JWW[#4DS4+],D\\<<C-2+G;R0?I5>V9S
MC3($E9 9%7D*V.:L+TKDDK:%"T445(!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M (5!/.:0(!TZ8QCM3J*+@(%4+M   [4@0 Y]\_2G447 3:OH.#D4!0!@4M%
M"  # [4%0>O/M2T4 (% _P#KTHXHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"<#."?I3?,7G
MV.*+ /HIN]>>>G6E5MW0'%%@%HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BF,2">/E'OBN3U;QI;03-9:/$VHWY^58H3E5]V(Z5M1P
M]2L[05_ZZB;2W.OHKSJ'7?%GAY_M7B&PCN;"7EFM02UN.^[KQ^7>NPT;7M.U
MVU%QI]PLR_\ CR_45K7P52DN;>/=:H2DF:M%-7OGKW.*=7(4%%%% !1110 4
M444 %%%% !113&([XXH 5SA<BLB^\0VEC<_8UCGNKG&6AMDWNH]Q6HTB;E#,
M%ST!X-8'A!%DTZXOW7=<W%S*)'/5MKE1^@%=-*$>1SFKVM][_P"&$][%[3M8
ML[^62!%DCN(QF2"==L@'KCTK43[N<C:>F/2N<UW%KK^AW,((DGN?LKL!_P L
MRC,0?Q45OQL) 1N5U!QE?4=:*T(I1G'9K_@ F345&.@(+8)X J2N884444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM:@\F\A#'! D'#+[@CFN;$>O^$>$+:MI6>Y'FQC],UI[*C7_ (7NR[/;Y/\
M1_>%VMSMQG'/6EK*T;Q#INMP;K*<%E^]$V5=3[@\UIEU R37'.G.$N62LRD[
MCJ*3<,XI:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4A./I2TASU_2@#C] &/'?B#W$7\C78UQV@?\CYX@P>,1?R-=
MC79COXJ_PQ_])1,=@HHHKC*"BBB@ HHHH **** "BBB@ HHHH YKX@9_X0;5
M<?\ /!OY&M'3O^1;@QC'V<?RK-^('_(CZITY@8<_2M'3O^1;@[#[../PKO\
M^82/^)_DB?M&3\//^16CXQ^]D_\ 0VKJEZ5ROP\_Y%6/@9\V3./]]JZI>E9X
M_P#WFIZL(_"A:***Y"@HHHH **** "BBB@ HHHH **** "N/\;'_ $S01_T_
MI_)J["N/\;'_ $W01_T_K_)J[,!_'7S_ "9,MCL!THI!TI:XR@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOZ9'X-785Q_C7_C\T'(S_IZ9(/3AJ[,!_'7S_)DRV.P'2BD486EKC*"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "FLP'L?>G4T@YSVQ0@.,T"YA'C_7D,J!V$>%+#)X/:NTW#.,\US.N>#['6
MI3=1O)9WYQBZ@.#D=,CI^E8ZZSK_ (4D$&NVIO\ 3Q]V]@&64?[0_P#K5ZE2
ME'%VE2?O62Y7OHK:=_S(3Y=SOMP^GUH!!Z'-9^FZO8ZQ:BXLIXYE[8/]*OKC
M/'ITQ7G3@X/EDK,L=1114 %%%% !1110 4444 %)D9QD9I:B( 8DD*O>F@'M
M@XS@@]O6JUY+'%93O(P10A^8\ <5S^L^,K2PG-G8JU_?GA8;<;@I]ST'YUG)
MX7UGQ),+KQ+>F*U."MA V%'^\>I_.NZGA.5*I6?+'\7Z+^D2Y=$1>!O$VC6?
MAM(;G4;>-Q+)\K. ?O$UT8\8^'U'.JVH[_ZP?XU);^%]$MK80Q:9;JBC R@;
MBI1X=T7'_(-MOQC%77JX2K5E4M+5^0DI)6*__"9>'O\ H+6O_?P4?\)EX>_Z
M"UK_ -_!5G_A'-%_Z!MK_P!^Q1_PCFB_] VU_P"_8K*^#[2_ ?O%;_A,O#W_
M $%K7_OX/\:/^$R\/?\ 06M?^_@_QJS_ ,(YHO\ T#;7_OV*/^$<T7_H&VO_
M '[%%\'VE^ >\5O^$R\/?]!:U_[^"C_A,O#W_06M?^_@_P :L_\ ".:+_P!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW#3Z,Z6BFJVX4ZO.+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI&:NV5A;Z? (;6)8XP<X'?WSUS77*M23E.%[N^G17W]?P)LRU1117$4%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 TL%Z_4TAD  ."0>]9>N^(M,T& /?W21,RDQQD9
M:0@9P!ZURL?Q7T-G0/::G&'8#S'@&%]SST'6NRC@<16CSTX-HER2W._W''*D
M4;^.5(JG8:E::K9K<VEREQ W >/H3FHM9U>VT32YM2NQ(885RRI]YN<<#/-8
M*E-SY+:[6'?J:0.2>.E*3@9-8_AOQ!9^)-+^W6:2H@<QE95"L"..1FM&]NX+
M&RFN[B58H84+O(W10.YI3I3A4]G):[6"ZM<E+^BDCUH+]>#GTK@[CXJZ!;W,
ML:0:C<*K?ZV*#<C?0YKHM \1:?XFL1=Z?(63)62-QB2,^XKHJX'$4H<]2#2$
MI)Z(V?, ;!!I=W/(('K2#IR3@<<CK7,^)O&NF^&+NWMKZ"[>2=2Z+ @;@''J
M*QHT)UI\E-78VTE=G49'ZXI"V#C';\ZX'_A;FBY_Y!^K>G_'L/\ XJM[P]XN
MTSQ/%(]DSK)$<203*%<#UQS6]7+\32CSU(-(2G%['0!\MC!!QFG4Q!M^7)(Z
M\T^N-E!2$XX[^E+36P#N/IBA &\!L'(]#ZTN[V/7%8VOZ[;>'[**ZNHKAD:4
M0J(1DY.<?RK51@%!*L.PW5HZ<E%3:T?Z"N2 @C(H)P.!FD3A0*H:UJ]GH>F2
MW]]+Y<$0Y/J>P^IZ"IA!SDHQ5VQE[S!GH<9QGTI]5K69+BTBG4861 P7T!Y%
M6:4E9V ****D IN\ \Y'%.KF[7QAI5WXFNM WO#>0' ,G D(&3M/? K6G1G4
M3<5>RN_03:1T6\9Q0'!.,'FF?-AN06/'6LG0/$EEX@>]6T29?L<QMY/,4#+#
MTYZ<4*E)Q<TM%N%S;HHHK(84444 %)NZ\=*7-8E_XBLK#Q'8Z-*DS75\C-&4
M4; !G.XY]JTITY5':*OU^X3=C:#9[8I:8G3H.!P13LCUJ&,6BBBD 4444 %%
M%%  3@9--W_-C!QW-17EY;6%G)=7<RPP1KN=V. !7$7'Q7T&"XDC2#4)XUSB
M6*$%''J#FNFAA*]>_LHMB<DMSO0<C-!.*J:7J5IJVG0WME,LL$JY5A3-7U2T
MT?39;V]F6.",98D\GV'O67LY\_L[:[6"^ER[O'H:"W^R<^E8^@:Y;>)-%CU*
MQ$T<,C,JK, K?*<'.">XJCKOC?0_#\[17$[W%VF-UM;KOD ;G./3\:UCA:LJ
MCI1BW)= YE:YTN\Y V'W]J-XS@ GC.:Y;P]X]T?Q!?/96WVF&<#<J7"!2X]N
M:N^(O%FE>%K2*:_D9C*V(XHAN=OH*<L'7C55%P?,^@N96N;N_P"8#!R?TI/,
MX)VG@UR.A_$'1M>U3[#&MS;7!7<BW,87S/9>>HK<U?7-.T&V2>_NE@1LA01R
MY S@>]%3"5J=14Y1?,^@U)-7-+S!Q@$GT]*=N]C7$:=\3="U"Z\J1KBQ)^Z]
MW%M5SG  Y/-=FI!(.[.>A'(Q4U\-5H.U6+0*2>Q+30V<\'@XIU<MXC\;:1X>
MNX[2<W$UTXRT5JF]E'J>1C_ZU11HU*TN2FKL&TMSJ P)(]*6N>\->+],\2B1
M;3S8IH_O0SKM;'J!Z5T&115I3I3<)JS!--70W?['_&G*=PR*Q+;Q)8WOB2ZT
M2!)3<VD8E=R!LP<=#GKS6VH ''?FE4IRIV4E:^OW@G<&8*,FFE\=0?;WIS'
MS52[NX-/M)+BYF$4$:[Y))#]VIC%R=D,M[O:@'/:L3PYXDLO$]A)>6*R"..0
MQ9D4 DC^G-;:]^M54IRI2<)JS0D[BT445F,**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.2:2.I^&5P+?X:P3E,[3,VWUPS'K7->%/$.A:/:WGBW5CF[U>Y?R8(T\R6)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEJ;K3[BV#!6FB:/=VY!%6:*YG4DY<[>I5CGO!_AZ?PSX<M]+FN(YFB=B712
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *,#&
M,444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>20
<FILENAME>ovid-20201231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Instance Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-15T02:26:45.6345776+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 8ac83ee457de40fa87b3ceabc3444e96 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xbrli:xbrl xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:ovid="http://www.ovidrx.com/20201231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="ovid-20201231.xsd" />
  <xbrli:unit id="U_xbrlishares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD_xbrlishares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlipure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_ovidInvestment">
    <xbrli:measure>ovid:Investment</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_ovidTrial">
    <xbrli:measure>ovid:Trial</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_ovidProduct">
    <xbrli:measure>ovid:Product</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217EUR">
    <xbrli:measure>iso4217:EUR</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="C_0001636651_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_20210308">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ovidAugustTwoThousandTwentyOfferingMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:AugustTwoThousandTwentyOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_ovidAugustTwoThousandTwentyOfferingMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:AugustTwoThousandTwentyOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapSubsidiarySaleOfStockAxis_ovidAugustTwoThousandTwentyOfferingMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:AugustTwoThousandTwentyOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ovidFebruaryOfferingMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:FebruaryOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ovidFebruaryOfferingMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:FebruaryOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_ovidFebruaryOfferingMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:FebruaryOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapSubsidiarySaleOfStockAxis_ovidFebruaryOfferingMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:FebruaryOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ovidOctoberOfferingMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:OctoberOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ovidOctoberOfferingMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:OctoberOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_ovidOctoberOfferingMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:OctoberOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapSubsidiarySaleOfStockAxis_ovidOctoberOfferingMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:OctoberOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTransactionTypeAxis_ovidATMOfferingsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ovid:ATMOfferingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapTransactionTypeAxis_ovidATMOfferingsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ovid:ATMOfferingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapTransactionTypeAxis_ovidATMOfferingsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ovid:ATMOfferingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapSubsidiarySaleOfStockAxis_ovidFebruaryAndOctoberTwoThousandNinteenOfferingsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:FebruaryAndOctoberTwoThousandNinteenOfferingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapSubsidiarySaleOfStockAxis_ovidATMMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:ATMMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapSubsidiarySaleOfStockAxis_ovidATMMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:ATMMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapTypeOfArrangementAxis_ovidLicenseAndCollaborationAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_srtRangeAxis_srtMaximumMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_srtRangeAxis_srtMinimumMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapFairValueByAssetClassAxis_ovidMoneyMarketFundsAndShortTermInvestmentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ovid:MoneyMarketFundsAndShortTermInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapFairValueByAssetClassAxis_ovidMoneyMarketFundsAndShortTermInvestmentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ovid:MoneyMarketFundsAndShortTermInvestmentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_ovidSeriesAConvertiblePreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_ovidSeriesAConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_srtStatementScenarioAxis_ovidScenarioOneMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ovid:ScenarioOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_srtRangeAxis_srtMinimumMember_srtStatementScenarioAxis_ovidScenarioTwoMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ovid:ScenarioTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_srtRangeAxis_srtMaximumMember_srtStatementScenarioAxis_ovidScenarioTwoMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ovid:ScenarioTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_srtStatementScenarioAxis_ovidScenarioTwoMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ovid:ScenarioTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapCashAndCashEquivalentsAxis_us-gaapCashMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapCashAndCashEquivalentsAxis_us-gaapCashMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_deiLegalEntityAxis_ovidCowenAndCompanyLLCMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_ovidATMAgreementMember_20180630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:ATMAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:CowenAndCompanyLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_deiLegalEntityAxis_ovidCowenAndCompanyLLCMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_ovidATMAgreementMember_20201130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:ATMAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:CowenAndCompanyLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_deiLegalEntityAxis_ovidCowenAndCompanyLLCMember_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ovidATMAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ovid:ATMAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:CowenAndCompanyLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_us-gaapStatementEquityComponentsAxis_ovidSeriesAConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200801_20200831">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-08-01</xbrli:startDate>
      <xbrli:endDate>2020-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200831">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_20200801_20200831">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-08-01</xbrli:startDate>
      <xbrli:endDate>2020-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_ovidSeriesAConvertiblePreferredStockMember_20200501_20200531">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-05-01</xbrli:startDate>
      <xbrli:endDate>2020-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200501_20200531">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-05-01</xbrli:startDate>
      <xbrli:endDate>2020-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20191031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-10-01</xbrli:startDate>
      <xbrli:endDate>2019-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191101_20191130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2019-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_ovidSeriesAConvertiblePreferredStockMember_20191001_20191031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-10-01</xbrli:startDate>
      <xbrli:endDate>2019-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_ovidSeriesAConvertiblePreferredStockMember_20191101_20191130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2019-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_ovidSeriesAConvertiblePreferredStockMember_20191031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_ovidSeriesAConvertiblePreferredStockMember_20191130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_20191001_20191031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-10-01</xbrli:startDate>
      <xbrli:endDate>2019-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_20191101_20191130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-11-01</xbrli:startDate>
      <xbrli:endDate>2019-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtAffiliatedEntityMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190901_20190930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-09-01</xbrli:startDate>
      <xbrli:endDate>2019-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtAffiliatedEntityMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190901_20190930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-09-01</xbrli:startDate>
      <xbrli:endDate>2019-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190201_20190228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_ovidSeriesAConvertiblePreferredStockMember_20190201_20190228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapStatementEquityComponentsAxis_ovidSeriesAConvertiblePreferredStockMember_20190228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ovid:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_20190201_20190228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEquityIncentivePlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEquityIncentivePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEquityIncentivePlanMember_20200101_20200101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-01-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEquityIncentivePlanMember_20190101_20190101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-01-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEquityIncentivePlanMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEmployeeStockPurchasePlanMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEmployeeStockPurchasePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEmployeeStockPurchasePlanMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEmployeeStockPurchasePlanMember_20190101_20190101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-01-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEmployeeStockPurchasePlanMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandSeventeenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandFourteenEquityIncentivePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ovid:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapAwardTypeAxis_ovidNonemployeePerformanceBasedOptionAwardsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonemployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapAwardTypeAxis_ovidNonemployeePerformanceBasedOptionAwardsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonemployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_srtTitleOfIndividualAxis_ovidChairmanOfScientificAdvisoryBoardMember_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_us-gaapTypeOfArrangementAxis_ovidSeparationAndConsultingAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:SeparationAndConsultingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ovid:ChairmanOfScientificAdvisoryBoardMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapAwardTypeAxis_ovidEmployeePerformanceBasedOptionAwardsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapAwardTypeAxis_ovidEmployeePerformanceBasedOptionAwardsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeePerformanceBasedOptionAwardsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapAwardTypeAxis_ovidStockOptionsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:StockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapAwardTypeAxis_ovidStockOptionsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:StockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapAwardTypeAxis_ovidEmployeeStockPurchasePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapAwardTypeAxis_ovidEmployeeStockPurchasePlanMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ovid:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapIncomeTaxAuthorityNameAxis_us-gaapNewYorkStateDivisionOfTaxationAndFinanceMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_srtCounterpartyNameAxis_ovidHLundbeckASMember_us-gaapTypeOfArrangementAxis_ovidLicenseAgreementMember_20150325_20150326">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:HLundbeckASMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-03-25</xbrli:startDate>
      <xbrli:endDate>2015-03-26</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_srtCounterpartyNameAxis_ovidHLundbeckASMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ovidLicenseAgreementMember_20150326">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:HLundbeckASMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-26</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_srtCounterpartyNameAxis_ovidNorthwesternUniversityMember_us-gaapTypeOfArrangementAxis_ovidLicenseAgreementMember_20161201_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:NorthwesternUniversityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-12-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_srtCounterpartyNameAxis_ovidNorthwesternUniversityMember_us-gaapTypeOfArrangementAxis_ovidLicenseAgreementMember_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:NorthwesternUniversityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_srtCounterpartyNameAxis_ovidNorthwesternUniversityMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ovidLicenseAgreementMember_20161231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:NorthwesternUniversityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_srtCounterpartyNameAxis_ovidNorthwesternUniversityMember_us-gaapTypeOfArrangementAxis_ovidLicenseAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:NorthwesternUniversityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_srtCounterpartyNameAxis_ovidAngeliniLicenseAgreementMember_us-gaapTypeOfArrangementAxis_ovidLicenseAgreementMember_20200709_20200709">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AngeliniLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-09</xbrli:startDate>
      <xbrli:endDate>2020-07-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_srtCounterpartyNameAxis_ovidAngeliniLicenseAgreementMember_us-gaapTypeOfArrangementAxis_ovidLicenseAgreementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:LicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AngeliniLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_srtCounterpartyNameAxis_ovidAngeliniLicenseAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AngeliniLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_srtCounterpartyNameAxis_ovidAngeliniLicenseAgreementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AngeliniLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_srtCounterpartyNameAxis_ovidAngeliniLicenseAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ovid:AngeliniLicenseAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_deiLegalEntityAxis_ovidTakedaPharmaceuticalCompanyLimitedMember_us-gaapStatementClassOfStockAxis_ovidSeriesB1PreferredStockMember_20170106">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesB1PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-01-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_deiLegalEntityAxis_ovidTakedaPharmaceuticalCompanyLimitedMember_us-gaapStatementClassOfStockAxis_ovidSeriesB1PreferredStockMember_20170105_20170106">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ovid:SeriesB1PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-05</xbrli:startDate>
      <xbrli:endDate>2017-01-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_deiLegalEntityAxis_ovidTakedaPharmaceuticalCompanyLimitedMember_20170106">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-01-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_deiLegalEntityAxis_ovidTakedaPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_deiLegalEntityAxis_ovidTakedaPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_deiLegalEntityAxis_ovidTakedaPharmaceuticalCompanyLimitedMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_deiLegalEntityAxis_ovidTakedaPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_deiLegalEntityAxis_ovidTakedaPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ovid:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_srtTitleOfIndividualAxis_ovidChairmanOfScientificAdvisoryBoardMember_us-gaapTypeOfArrangementAxis_ovidSeparationAndConsultingAgreementMember_20190401_20190401">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:SeparationAndConsultingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ovid:ChairmanOfScientificAdvisoryBoardMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-04-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_srtTitleOfIndividualAxis_ovidChairmanOfScientificAdvisoryBoardMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTypeOfArrangementAxis_ovidSeparationAndConsultingAgreementMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20190401_20190401">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:SeparationAndConsultingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ovid:ChairmanOfScientificAdvisoryBoardMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-04-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_srtTitleOfIndividualAxis_ovidChairmanOfScientificAdvisoryBoardMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTypeOfArrangementAxis_ovidSeparationAndConsultingAgreementMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20190401_20190401">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:SeparationAndConsultingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ovid:ChairmanOfScientificAdvisoryBoardMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-04-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ovidAffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember_20190228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ovid:AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ovidAffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20190228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ovid:AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ovidAffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember_us-gaapTypeOfArrangementAxis_ovidChiefExecutiveOfficerAndChairmanMember_20190201_20190228">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:ChiefExecutiveOfficerAndChairmanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ovid:AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-01</xbrli:startDate>
      <xbrli:endDate>2019-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ovidAffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember_20191031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ovid:AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ovidAffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember_20191130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ovid:AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ovidAffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ovid:AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ovidAffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ovid:AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ovidAffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember_us-gaapTypeOfArrangementAxis_ovidChiefExecutiveOfficerAndChairmanMember_20191001_20191031">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:ChiefExecutiveOfficerAndChairmanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ovid:AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-10-01</xbrli:startDate>
      <xbrli:endDate>2019-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtAffiliatedEntityMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200501_20200531">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-05-01</xbrli:startDate>
      <xbrli:endDate>2020-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtAffiliatedEntityMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20200501_20200531">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-05-01</xbrli:startDate>
      <xbrli:endDate>2020-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtAffiliatedEntityMember_20200831">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtAffiliatedEntityMember_20200801_20200831">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-08-01</xbrli:startDate>
      <xbrli:endDate>2020-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtAffiliatedEntityMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtAffiliatedEntityMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210315">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-01-01</xbrli:startDate>
      <xbrli:endDate>2021-03-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_ovidRoyaltyAndTerminationAgreementMember_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:RoyaltyAndTerminationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_ovidRoyaltyAndTerminationAgreementMember_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:RoyaltyAndTerminationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_ovidRoyaltyAndTerminationAgreementMember_20210301_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:RoyaltyAndTerminationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-03-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001636651_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_ovidRoyaltyAndTerminationAgreementMember_20210301_20210331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ovid:RoyaltyAndTerminationAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2021-03-01</xbrli:startDate>
      <xbrli:endDate>2021-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <dei:DocumentType id="F_000000" contextRef="C_0001636651_20200101_20201231">10-K</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0001636651_20200101_20201231">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000002" contextRef="C_0001636651_20200101_20201231">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalYearFocus id="F_000003" contextRef="C_0001636651_20200101_20201231">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="F_000004" contextRef="C_0001636651_20200101_20201231">FY</dei:DocumentFiscalPeriodFocus>
  <dei:EntityRegistrantName id="F_000005" contextRef="C_0001636651_20200101_20201231">Ovid Therapeutics Inc.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000006" contextRef="C_0001636651_20200101_20201231">0001636651</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate id="F_000007" contextRef="C_0001636651_20200101_20201231">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityWellKnownSeasonedIssuer id="F_000008" contextRef="C_0001636651_20200101_20201231">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityCurrentReportingStatus id="F_000009" contextRef="C_0001636651_20200101_20201231">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityVoluntaryFilers id="F_000010" contextRef="C_0001636651_20200101_20201231">No</dei:EntityVoluntaryFilers>
  <dei:EntityFilerCategory id="F_000011" contextRef="C_0001636651_20200101_20201231">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityInteractiveDataCurrent id="F_000012" contextRef="C_0001636651_20200101_20201231">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityExTransitionPeriod id="F_000013" contextRef="C_0001636651_20200101_20201231">true</dei:EntityExTransitionPeriod>
  <dei:IcfrAuditorAttestationFlag id="F_000014" contextRef="C_0001636651_20200101_20201231">false</dei:IcfrAuditorAttestationFlag>
  <dei:EntityCommonStockSharesOutstanding id="F_000015" contextRef="C_0001636651_20210308" decimals="INF" unitRef="U_xbrlishares">65753570</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityPublicFloat id="F_000016" contextRef="C_0001636651_20200630" decimals="-5" unitRef="U_iso4217USD">293700000</dei:EntityPublicFloat>
  <dei:EntityShellCompany id="F_000017" contextRef="C_0001636651_20200101_20201231">false</dei:EntityShellCompany>
  <dei:EntitySmallBusiness id="F_000018" contextRef="C_0001636651_20200101_20201231">true</dei:EntitySmallBusiness>
  <dei:EntityEmergingGrowthCompany id="F_000019" contextRef="C_0001636651_20200101_20201231">true</dei:EntityEmergingGrowthCompany>
  <dei:Security12bTitle id="F_000020" contextRef="C_0001636651_20200101_20201231">Common Stock, par value $0.001 per share</dei:Security12bTitle>
  <dei:TradingSymbol id="F_000021" contextRef="C_0001636651_20200101_20201231">OVID</dei:TradingSymbol>
  <dei:SecurityExchangeName id="F_000022" contextRef="C_0001636651_20200101_20201231">NASDAQ</dei:SecurityExchangeName>
  <dei:EntityFileNumber id="F_000023" contextRef="C_0001636651_20200101_20201231">001-38085</dei:EntityFileNumber>
  <dei:EntityIncorporationStateCountryCode id="F_000024" contextRef="C_0001636651_20200101_20201231">DE</dei:EntityIncorporationStateCountryCode>
  <dei:EntityTaxIdentificationNumber id="F_000025" contextRef="C_0001636651_20200101_20201231">46-5270895</dei:EntityTaxIdentificationNumber>
  <dei:EntityAddressAddressLine1 id="F_000026" contextRef="C_0001636651_20200101_20201231">1460 Broadway</dei:EntityAddressAddressLine1>
  <dei:EntityAddressAddressLine2 id="F_000027" contextRef="C_0001636651_20200101_20201231">Suite 15021</dei:EntityAddressAddressLine2>
  <dei:EntityAddressCityOrTown id="F_000028" contextRef="C_0001636651_20200101_20201231">New York</dei:EntityAddressCityOrTown>
  <dei:EntityAddressStateOrProvince id="F_000029" contextRef="C_0001636651_20200101_20201231">NY</dei:EntityAddressStateOrProvince>
  <dei:EntityAddressPostalZipCode id="F_000030" contextRef="C_0001636651_20200101_20201231">10036</dei:EntityAddressPostalZipCode>
  <dei:CityAreaCode id="F_000031" contextRef="C_0001636651_20200101_20201231">646</dei:CityAreaCode>
  <dei:LocalPhoneNumber id="F_000032" contextRef="C_0001636651_20200101_20201231">661-7661</dei:LocalPhoneNumber>
  <dei:DocumentsIncorporatedByReferenceTextBlock id="F_000033" contextRef="C_0001636651_20200101_20201231">&lt;p&gt;Portions of the registrant&amp;#8217;s definitive proxy statement for its 2021 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&amp;#8217;s fiscal year ended December 31, 2020, are incorporated by reference into Part III of this Annual Report on Form 10-K.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
  <dei:DocumentAnnualReport id="F_000034" contextRef="C_0001636651_20200101_20201231">true</dei:DocumentAnnualReport>
  <dei:DocumentTransitionReport id="F_000035" contextRef="C_0001636651_20200101_20201231">false</dei:DocumentTransitionReport>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000036" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">72033930</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000037" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">41897144</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent id="F_000038" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">34841969</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AccountsReceivableRelatedParties id="F_000039" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">141763</us-gaap:AccountsReceivableRelatedParties>
  <us-gaap:AccountsReceivableRelatedParties id="F_000040" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">1131146</us-gaap:AccountsReceivableRelatedParties>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000041" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">2667508</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000042" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">1942933</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000043" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">74843201</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000044" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">79813192</us-gaap:AssetsCurrent>
  <us-gaap:PrepaidExpenseNoncurrent id="F_000045" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">477171</us-gaap:PrepaidExpenseNoncurrent>
  <us-gaap:PrepaidExpenseNoncurrent id="F_000046" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">359539</us-gaap:PrepaidExpenseNoncurrent>
  <us-gaap:SecurityDeposit id="F_000047" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">150626</us-gaap:SecurityDeposit>
  <us-gaap:SecurityDeposit id="F_000048" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">135390</us-gaap:SecurityDeposit>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000049" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">135620</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000050" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">68363</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OtherAssetsNoncurrent id="F_000051" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">318900</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000052" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">467247</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets id="F_000053" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">75925518</us-gaap:Assets>
  <us-gaap:Assets id="F_000054" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">80843731</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="F_000055" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">5446206</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000056" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">3256098</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000057" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">12032685</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="F_000058" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">7266706</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:DueToRelatedPartiesCurrent id="F_000059" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">2370992</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:DueToRelatedPartiesCurrent id="F_000060" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">10804</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:DeferredRevenueCurrent id="F_000061" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">2212892</us-gaap:DeferredRevenueCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000062" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">22062775</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000063" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">10533608</us-gaap:LiabilitiesCurrent>
  <us-gaap:DueToRelatedPartiesNoncurrent id="F_000064" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">61200</us-gaap:DueToRelatedPartiesNoncurrent>
  <us-gaap:DueToRelatedPartiesNoncurrent id="F_000065" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">286562</us-gaap:DueToRelatedPartiesNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="F_000066" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">10169887</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:Liabilities id="F_000067" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">32293862</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000068" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">10820170</us-gaap:Liabilities>
  <us-gaap:PreferredStockValue id="F_000069" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">3</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue id="F_000070" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">8</us-gaap:PreferredStockValue>
  <us-gaap:CommonStockValue id="F_000071" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">65743</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="F_000072" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">54711</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000073" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">337758007</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000074" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">283122894</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000075" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">2469</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000076" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">-294192097</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000077" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">-213156521</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="F_000078" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">43631656</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000079" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">70023561</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000080" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">75925518</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000081" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">80843731</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000082" contextRef="C_0001636651_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000083" contextRef="C_0001636651_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="F_000084" contextRef="C_0001636651_20201231" decimals="INF" unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000085" contextRef="C_0001636651_20191231" decimals="INF" unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
  <ovid:PreferredStockShareDesignated id="F_000086" contextRef="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">10000</ovid:PreferredStockShareDesignated>
  <ovid:PreferredStockShareDesignated id="F_000087" contextRef="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">10000</ovid:PreferredStockShareDesignated>
  <us-gaap:PreferredStockSharesIssued id="F_000088" contextRef="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">3250</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="F_000089" contextRef="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">7762</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="F_000090" contextRef="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">3250</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000091" contextRef="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">7762</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000092" contextRef="C_0001636651_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000093" contextRef="C_0001636651_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000094" contextRef="C_0001636651_20201231" decimals="INF" unitRef="U_xbrlishares">125000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000095" contextRef="C_0001636651_20191231" decimals="INF" unitRef="U_xbrlishares">125000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000096" contextRef="C_0001636651_20201231" decimals="INF" unitRef="U_xbrlishares">65743170</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000097" contextRef="C_0001636651_20191231" decimals="INF" unitRef="U_xbrlishares">54710322</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000098" contextRef="C_0001636651_20201231" decimals="INF" unitRef="U_xbrlishares">65743170</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000099" contextRef="C_0001636651_20191231" decimals="INF" unitRef="U_xbrlishares">54710322</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="F_000100" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">12617221</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
  <us-gaap:TypeOfRevenueExtensibleList id="F_000101" contextRef="C_0001636651_20200101_20201231">us-gaap:LicenseMember</us-gaap:TypeOfRevenueExtensibleList>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000102" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">63417394</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000103" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">42157641</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000104" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">30630804</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000105" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">19251826</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="F_000106" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">94048198</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000107" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">61409467</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000108" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">-81430977</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000109" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">-61409467</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherOperatingIncomeExpenseNet id="F_000110" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">395401</us-gaap:OtherOperatingIncomeExpenseNet>
  <us-gaap:OtherOperatingIncomeExpenseNet id="F_000111" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">948224</us-gaap:OtherOperatingIncomeExpenseNet>
  <us-gaap:NetIncomeLoss id="F_000112" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">-81035576</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000113" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">-60461243</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000114" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">-81035576</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000115" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">-60461243</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000116" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-1.39</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000117" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-1.54</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000118" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">58451293</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000119" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">39217223</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000120" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">-2469</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000121" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">4298</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000122" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">-81038045</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000123" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">-60456945</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:SharesIssued id="F_000124" contextRef="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">7762</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity id="F_000125" contextRef="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" decimals="0" unitRef="U_iso4217USD">8</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued id="F_000126" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">54710322</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity id="F_000127" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="0" unitRef="U_iso4217USD">54711</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000128" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="0" unitRef="U_iso4217USD">283122894</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000129" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="0" unitRef="U_iso4217USD">2469</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000130" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="0" unitRef="U_iso4217USD">-213156521</us-gaap:StockholdersEquity>
  <ovid:ATMOfferingCosts id="F_000131" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">-114936</ovid:ATMOfferingCosts>
  <ovid:ATMOfferingCosts id="F_000132" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">-114936</ovid:ATMOfferingCosts>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="F_000133" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">105464</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000134" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">105</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000135" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">203361</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000136" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">203466</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000137" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">165384</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000138" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">165</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000139" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">300656</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000140" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">300821</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000141" contextRef="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">-4512</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000142" contextRef="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">-5</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000143" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">4512000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000144" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">4512</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000145" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">-4507</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000146" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ovidAugustTwoThousandTwentyOfferingMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">6250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000147" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ovidAugustTwoThousandTwentyOfferingMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">6250</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000148" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_ovidAugustTwoThousandTwentyOfferingMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">46725185</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000149" contextRef="C_0001636651_us-gaapSubsidiarySaleOfStockAxis_ovidAugustTwoThousandTwentyOfferingMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">46731435</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000150" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">7525354</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000151" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">7525354</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax id="F_000152" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">-2469</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax id="F_000153" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">-2469</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:NetIncomeLoss id="F_000154" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">-81035576</us-gaap:NetIncomeLoss>
  <us-gaap:SharesIssued id="F_000155" contextRef="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">3250</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity id="F_000156" contextRef="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231" decimals="0" unitRef="U_iso4217USD">3</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued id="F_000157" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">65743170</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity id="F_000158" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="0" unitRef="U_iso4217USD">65743</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000159" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="0" unitRef="U_iso4217USD">337758007</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000160" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="0" unitRef="U_iso4217USD">-294192097</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued id="F_000161" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">24654114</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity id="F_000162" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="0" unitRef="U_iso4217USD">24654</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000163" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="0" unitRef="U_iso4217USD">191477598</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000164" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231" decimals="0" unitRef="U_iso4217USD">-1829</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000165" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="0" unitRef="U_iso4217USD">-152695278</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000166" contextRef="C_0001636651_20181231" decimals="0" unitRef="U_iso4217USD">38805145</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000167" contextRef="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ovidFebruaryOfferingMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">2500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000168" contextRef="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ovidFebruaryOfferingMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">3</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000169" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ovidFebruaryOfferingMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">13993778</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000170" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ovidFebruaryOfferingMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">13994</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000171" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_ovidFebruaryOfferingMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">30506838</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000172" contextRef="C_0001636651_us-gaapSubsidiarySaleOfStockAxis_ovidFebruaryOfferingMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">30520835</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="F_000173" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">80542</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000174" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">81</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000175" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">131814</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000176" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">131895</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000177" contextRef="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">1262</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000178" contextRef="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">1</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000179" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">-1262000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000180" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">-1262</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000181" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">1261</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000182" contextRef="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ovidOctoberOfferingMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">4000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000183" contextRef="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_ovidOctoberOfferingMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">4</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000184" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ovidOctoberOfferingMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">10350000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000185" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ovidOctoberOfferingMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">10350</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000186" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_ovidOctoberOfferingMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">33519919</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000187" contextRef="C_0001636651_us-gaapSubsidiarySaleOfStockAxis_ovidOctoberOfferingMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">33530273</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000188" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTransactionTypeAxis_ovidATMOfferingsMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">6893888</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000189" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTransactionTypeAxis_ovidATMOfferingsMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">6894</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000190" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapTransactionTypeAxis_ovidATMOfferingsMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">22279672</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000191" contextRef="C_0001636651_us-gaapTransactionTypeAxis_ovidATMOfferingsMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">22286566</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000192" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">5205792</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000193" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">5205792</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax id="F_000194" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">4298</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax id="F_000195" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">4298</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:NetIncomeLoss id="F_000196" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">-60461243</us-gaap:NetIncomeLoss>
  <us-gaap:ShareBasedCompensation id="F_000197" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">7525354</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000198" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">5205792</us-gaap:ShareBasedCompensation>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000199" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">306848</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000200" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">255002</us-gaap:DepreciationDepletionAndAmortization>
  <ovid:AccruedInterestAndAccretionOfDiscountsShortTermInvestments id="F_000201" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">-199408</ovid:AccruedInterestAndAccretionOfDiscountsShortTermInvestments>
  <ovid:AccruedInterestAndAccretionOfDiscountsShortTermInvestments id="F_000202" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">-29633</ovid:AccruedInterestAndAccretionOfDiscountsShortTermInvestments>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000203" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">724575</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000204" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">-224458</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInSecurityDeposits id="F_000205" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">-15236</us-gaap:IncreaseDecreaseInSecurityDeposits>
  <us-gaap:IncreaseDecreaseInSecurityDeposits id="F_000206" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">-13235</us-gaap:IncreaseDecreaseInSecurityDeposits>
  <us-gaap:IncreaseDecreaseDueFromAffiliates id="F_000207" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">-989383</us-gaap:IncreaseDecreaseDueFromAffiliates>
  <us-gaap:IncreaseDecreaseDueFromAffiliates id="F_000208" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">531042</us-gaap:IncreaseDecreaseDueFromAffiliates>
  <ovid:IncreaseDecreaseInPrepaidExpenseNoncurrent id="F_000209" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">117632</ovid:IncreaseDecreaseInPrepaidExpenseNoncurrent>
  <ovid:IncreaseDecreaseInPrepaidExpenseNoncurrent id="F_000210" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">-2438022</ovid:IncreaseDecreaseInPrepaidExpenseNoncurrent>
  <us-gaap:IncreaseDecreaseInAccountsPayableTrade id="F_000211" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">2333716</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
  <us-gaap:IncreaseDecreaseInAccountsPayableTrade id="F_000212" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">-653953</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="F_000213" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">4835607</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="F_000214" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">2177844</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="F_000215" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">12382779</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDueToRelatedParties id="F_000216" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">2134826</us-gaap:IncreaseDecreaseInDueToRelatedParties>
  <us-gaap:IncreaseDecreaseInDueToRelatedParties id="F_000217" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">297366</us-gaap:IncreaseDecreaseInDueToRelatedParties>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000218" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">-51583914</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000219" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">-51090622</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt id="F_000220" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">9961092</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt id="F_000221" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">34797004</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
  <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities id="F_000222" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">45000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities id="F_000223" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">5000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000224" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">127240</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000225" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">57156</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToDevelopSoftware id="F_000226" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">263440</us-gaap:PaymentsToDevelopSoftware>
  <us-gaap:PaymentsToDevelopSoftware id="F_000227" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">186889</us-gaap:PaymentsToDevelopSoftware>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000228" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">34648228</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000229" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">-30041049</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000230" contextRef="C_0001636651_us-gaapSubsidiarySaleOfStockAxis_ovidAugustTwoThousandTwentyOfferingMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">46731435</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000231" contextRef="C_0001636651_us-gaapSubsidiarySaleOfStockAxis_ovidFebruaryAndOctoberTwoThousandNinteenOfferingsMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">64120736</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000232" contextRef="C_0001636651_us-gaapSubsidiarySaleOfStockAxis_ovidATMMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">22286566</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000233" contextRef="C_0001636651_us-gaapSubsidiarySaleOfStockAxis_ovidATMMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">163250</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromStockPlans id="F_000234" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">203466</us-gaap:ProceedsFromStockPlans>
  <us-gaap:ProceedsFromStockPlans id="F_000235" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">131895</us-gaap:ProceedsFromStockPlans>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000236" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">300821</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000237" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">47072472</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000238" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">86539197</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000239" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">30136786</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect id="F_000240" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">5407526</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000241" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">41897144</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000242" contextRef="C_0001636651_20181231" decimals="0" unitRef="U_iso4217USD">36489618</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000243" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">72033930</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <ovid:SoftwareDevelopmentAndOtherCostsInAccountsPayableAndAccruedExpenses id="F_000244" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">164922</ovid:SoftwareDevelopmentAndOtherCostsInAccountsPayableAndAccruedExpenses>
  <us-gaap:NoninterestExpenseOfferingCost id="F_000245" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">21314</us-gaap:NoninterestExpenseOfferingCost>
  <us-gaap:NoninterestExpenseOfferingCost id="F_000246" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">69628</us-gaap:NoninterestExpenseOfferingCost>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock id="F_000247" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;a name="NOTE_1_NATURE_OPERATIONS"&gt;&lt;/a&gt;NOTE 1&lt;font style="color:#000000;"&gt;&lt;a name="NOTE_1_NATURE_OPERATIONS"&gt;&lt;/a&gt; &amp;#8211; NATURE OF OPERATIONS&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ovid Therapeutics Inc. (the &amp;#8220;Company&amp;#8221;) was incorporated under the laws of the state of Delaware on April 1, 2014 and maintains its principal executive office in New York, New York. The Company commenced operations on April 1, 2014 (date of inception). The Company is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since its inception, the Company has devoted substantially all of its efforts to business development, research and development, recruiting management and technical staff, and raising capital, and has financed its operations through issuance of convertible preferred stock (&amp;#8220;Preferred Stock&amp;#8221;), common stock and other equity instruments. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development and regulatory success, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and ability to secure additional capital to fund operations.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Historically, the Company&amp;#8217;s major sources of cash have been comprised of proceeds from various public and private offerings of its capital stock and interest income. As of December 31, 2020, the Company had approximately $72.0 million in cash and cash equivalents. Since inception, the Company has generated $12.6 million in revenue as part of the Company&amp;#8217;s license and collaboration agreement (the &amp;#8220;Angelini License Agreement&amp;#8221;) with Angelini Pharma Rare Diseases AG (&amp;#8220;Angelini&amp;#8221;). The Company has incurred recurring losses, has experienced recurring negative operating cash flows and requires significant cash resources to execute its business plans. &lt;font style="color:#000000;"&gt;The Company has an accumulated deficit of $294.2 million as of December 31, 2020&lt;/font&gt;, working capital of $52.8 million &lt;font style="color:#000000;"&gt;and had cash outflows from operating activities of $51.6 million for the year ended December 31, 2020&lt;/font&gt;. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has incurred operating losses since inception and expects to continue to incur net losses for at least the next several years and ongoing operations are highly dependent on the Company&amp;#8217;s ability to obtain additional sources of funding. Management has identified these conditions or events, which, considered in the aggregate, raise substantial doubt about our ability to continue as a going concern, including the risk that the Company will be unable to raise adequate additional capital to fund operations through at least the next 12 months from the date of filing of this Annual Report on Form 10-K.&amp;nbsp;&amp;nbsp;Management&amp;#8217;s response to these conditions and events is that the successful closing of the Takeda License and Termination Agreement with Takeda (see note 12) will provide the liquidity needed to alleviate the substantial doubt referred to above.&amp;nbsp;&amp;nbsp;As described in note 12, there are certain conditions to close the Takeda License and Termination Agreement, however management has determined that the likelihood of not closing in the first half of 2021 is remote.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We have implemented business continuity plans designed to address and mitigate the impact of the COVID-19 pandemic on our business.&amp;nbsp;&amp;nbsp;The extent to which the ongoing COVID-19 pandemic impacts our business, our clinical development and regulatory efforts, our corporate development objectives and the value of and market for our common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S., Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease.&amp;nbsp;&amp;nbsp;The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on our business, financial condition, results of operations and growth prospects.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition, we are subject to other challenges and risks specific to our business and our ability to execute on our strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of our late-stage product candidates; delays or problems in the supply of our products, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing our intellectual property rights; complying with applicable regulatory requirements.&amp;nbsp;&amp;nbsp;In addition, to the extent the ongoing COVID-19 pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="F_000248" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 2&lt;font style="color:#000000;"&gt; &amp;#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(A) Basis of Presentation and Consolidation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;) and include the accounts of Ovid Therapeutics Inc. and its wholly-owned subsidiary, Ovid Therapeutics Hong Kong Limited.&amp;nbsp;&amp;nbsp;All intercompany transactions and balances have been eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(B) &lt;font style="color:#000000;"&gt;Use of Estimates&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(C) Risks and Uncertainties&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its drug candidates, ability to obtain regulatory approval of its drug candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition and untested manufacturing capabilities&lt;/font&gt;.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(D) Deferred Transaction Costs&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred transaction costs, primarily consisted of direct incremental legal, accounting, and other fees related to the Company&amp;#8217;s offering of its capital stock are capitalized as incurred. The deferred transaction costs are offset against proceeds upon the consummation of an offering.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(E) Comprehensive Loss&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&amp;#8217; equity that result from transactions and economic events other than those with stockholders. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(F) Collaboration Arrangement&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;License and Collaboration Agreement with Takeda Pharmaceutical Company Limited&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the current license and collaboration agreement with Takeda Ovid and Takeda are sharing 50/50 in the drug development, the Company records 50% of the development costs in research and development.&amp;nbsp;&amp;nbsp;When Ovid incurs the majority of the costs and Takeda transfers a payment to Ovid to equalize the costs, Ovid records the participation by Takeda as a reduction of its research and development expenses, as the parties under the collaboration are sharing in the costs and the payment represents reimbursement of costs by Takeda.&amp;#160;When Takeda incurs the majority of the costs and Ovid transfers a payment to Takeda (to equalize the costs), Ovid records the participation in Takeda&amp;#8217;s expenses as research and development costs in its statement of operations, as Ovid and Takeda are sharing in the research and development activities and this participation represents Ovid&amp;#8217;s share of the research and development costs in the specific period. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(G) Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s cash and cash equivalents consist of cash held in checking accounts and money market funds. The Company considers all highly liquid investments with an original maturity date of three months or less to be cash and cash equivalents. Accounts held at U.S. financial institutions are insured by the FDIC up to $250,000. Cash balances could exceed insured amounts at any given time.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(H) Short-term Investments&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;font style="Background-color:#FFFFFF;"&gt;&amp;#160;consist of debt securities with maturities greater than&amp;#160;&lt;/font&gt;three months&lt;font style="Background-color:#FFFFFF;"&gt;&amp;#160;from the date of purchase.&amp;#160;&amp;#160;The Company&amp;#160;&lt;/font&gt;classifies&lt;font style="Background-color:#FFFFFF;"&gt;&amp;#160;all of its investments as available-for-sale securities. Debt securities are recorded at fair value with unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders&amp;#8217; equity until realized. Realized gains and losses, amortization and accretion of premiums and discounts are included within net loss.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(I) Property and Equipment&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost and depreciated over their estimated useful lives of three years using the straight-line method. Repairs and maintenance costs are expensed. The Company reviews the recoverability of all long-lived assets, including the related useful life, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(J) Research and Development Expenses&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expenses the cost of research and development as incurred. Research and development expenses comprise costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when the cost is incurred, in accordance with ASC 730, Research and Development.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(K) Stock-Based Compensation&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for its stock-based compensation in accordance with ASC 718, Compensation&amp;#8212;Stock Compensation, which establishes accounting for stock-based awards granted to employees for services and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company estimates the fair value of all awards granted using the Black-Scholes valuation model. Key inputs and assumptions include the expected term of the option, stock price volatility, risk-free interest rate, dividend yield, stock price and exercise price. Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense. The Company elected an accounting policy to record forfeitures as they occur. The Company recognizes employee stock-based compensation expense based on the fair value of the award on the date of the grant. The compensation expense is recognized over the vesting period under the straight-line method.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13.5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for options awards granted to nonemployee consultants and directors in accordance with ASU 2018-07, Compensation &amp;#8211; Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. The fair value of the option issued or committed to be issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company&amp;#8217;s common stock award at the earlier of the date that the commitment for performance by the counterparty has been reached or the counterparty&amp;#8217;s performance is complete.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(L) Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) guidance specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The three levels of the fair value hierarchy are as follows:&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160; &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&lt;font style="color:#000000;"&gt;&lt;/font&gt;&lt;font style="font-size:10pt;color:#000000;"&gt;Level 1&amp;#8212;Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities. The Company&amp;#8217;s Level 1 assets consisted of money market funds and short-term investments totaling $70.1 million and $76.2 million as of December&amp;#160;31, 2020 and 2019, respectively.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&lt;font style="color:#000000;"&gt;&lt;/font&gt;&lt;font style="font-size:10pt;color:#000000;"&gt;Level 2&amp;#8212;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models or other valuation methodologies. The Company had no Level 2 assets or liabilities as of December&amp;#160;31, 2020 and 2019.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&lt;font style="color:#000000;"&gt;&lt;/font&gt;&lt;font style="font-size:10pt;color:#000000;"&gt;Level 3&amp;#8212;Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable. The Company had no Level 3 assets or liabilities as of December&amp;#160;31, 2020 and 2019.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts reported in the balance sheets for cash and cash equivalents, related-party receivables, other current assets, accounts payable, accrued expenses, and current related-party payables approximate their fair value based on the short-term maturity of these instruments.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(M) Income Taxes&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes under the asset and liability method, which requires deferred tax assets and liabilities to be recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts and respective tax bases of existing assets and liabilities, as well as for net operating loss carryforwards and research and development credit. Valuation allowances are provided if it is more likely than not that some portion or all of the deferred tax assets will not be realized.&amp;nbsp;&amp;nbsp;The impact of a change in the tax laws is recorded in the period in which the law is enacted.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(N) Net Loss Per Common Share&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period. For all periods presented, stock options have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss per common share are the same.&lt;font style="color:#000000;"&gt; Under the terms of the Series A Preferred Stock issued in 2019, Preferred stockholders do not share in losses of the Company and have no obligation to fund losses or transfer assets.&amp;#160;&amp;#160;Since there is a loss, diluted EPS should be computed in the same manner as basic EPS and because no potential common shares shall be included in the computation of any diluted per-share amounts when a loss exists, the Series A Preferred Stock should be excluded from the computation of basic and diluted EPS.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,403,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,405,295&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,762&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(O) Segment Data&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(P) Retirement Plan&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company maintains a 401(k)-retirement plan for its employees that is intended to qualify under Sections 401(a) and 501(a) of the U.S. Internal Revenue Code of 1986, as amended (&amp;#8220;Code&amp;#8221;). The Company provides all active employees with a 100% matching contribution equal to 3% of an employee&amp;#8217;s eligible compensation deferred and 50% matching contributions on employee contributions that are between 3% and 5% of an employee&amp;#8217;s eligible compensation deferred. These safe harbor contributions vest immediately.&amp;nbsp;&amp;nbsp;For the years ended December&amp;#160;31, 2020 and 2019 the Company contributed $321,000 and $285,000, respectively.&lt;font style="color:#000000;"&gt; &lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;(Q) Revenue Recognition&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&amp;#160;In applying ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) it satisfies the performance obligations.&amp;#160;The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint.&amp;#160;Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price.&amp;#160;The standalone selling price is generally determined using expected cost and comparable transactions. Revenue for performance obligations recognized over time is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-refundable upfront fees allocated to licenses that are not contingent on any future performance and require no consequential continuing involvement by the Company, are recognized as revenue when the license term commences and the licensed data, technology or product is delivered.&amp;#160;The Company defers recognition of upfront license fees if the performance obligations are not satisfied.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(&lt;font style="font-weight:bold;"&gt;R) Recent Accounting Pronouncements&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;Recent accounting standards which have been adopted&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &amp;#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.&amp;#160;&amp;#160;This new standard requires the measurement and recognition of expected credit losses for financial assets held at amortized cost, including loans and trade and other receivables. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The standard also amends the impairment model for available-for-sale debt securities and requires entities to determine whether all or a portion of the unrealized loss on an available-for-sale debt security is a credit loss. Under the new guidance, an entity recognizes an allowance for credit losses on available-for-sale debt securities as a contra-account to the amortized cost basis rather than as a direct reduction of the amortized cost basis of the investment, as was previously required. ASU 2016-13 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2019. As of December 31, 2020, the Company did not hold any debt securities with credit losses, nor does it have any trade receivables. The adoption of this standard effective January 1, 2020 did not have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August 29, 2018, the FASB issued ASU No. 2018-15, Intangibles &amp;#8211; Goodwill and Other - Internal-Use Software (Subtopic 350-40) - which amends ASC 350-40 to address a customer&amp;#8217;s accounting for implementation costs incurred in a cloud computing arrangement (&amp;#8220;CCA&amp;#8221;) that is a service contract. ASU No. 2018-15 aligns the accounting for costs incurred to implement a CCA that is a service arrangement with the guidance on capitalizing costs associated with developing or obtaining internal-use software. Specifically, the ASU amends ASC 350 to include in its scope implementation costs of a CCA that is a service contract and clarifies that a customer should apply ASC 350-40 to determine which implementation costs should be capitalized in a CCA that is considered a service contract. According to the standard the balance sheet line item for the presentation of capitalized implementation costs should be the same as that for the prepayment of fees related to the hosting arrangement and the manner in which an entity classifies the cash flows related to capitalized implementation costs should be the same as that in which it classifies the cash flows for the fees related to the hosting arrangement. ASU 2018-15 is effective for the Company for fiscal years beginning after December 15, 2019, including interim periods therein. Entities are permitted to apply either a retrospective or prospective transition approach to adopt the guidance. The adoption of this standard effective January 1, 2020 did not have a material impact on the Company&amp;#8217;s consolidated financial statements and was adopted prospectively.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On November 5, 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808), - which amends ASC 808 to clarify when transactions between participants in a collaborative arrangement under ASC 808 are within the scope of the FASB&amp;#8217;s new revenue standard, ASU 2014-09 (codified in ASC 606). The amendments require the application of ASC 606 existing guidance to determine the units of account that are distinct in a collaborative arrangement for purposes of identifying transactions with customers. If a unit of account within the collaborative arrangement is distinct and is with a customer, an entity shall apply the guidance in Topic 606 to that unit of account. In a transaction between collaborative participants, an entity is precluded by ASU 2018-18 from presenting a transaction together with &amp;#8220;revenue from contracts with customers&amp;#8221; unless the unit of account is within the scope of ASC 606 and the entity applies the guidance in ASC 606 to such unit of account. The amended guidance is effective for public business entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The retrospective adoption of this standard effective January 1, 2020 did not have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2020, the FASB issued&amp;#160;ASU&amp;#160;2020-10, Codification Improvements, which updates various codification topics by clarifying or improving disclosure requirements. ASU 2020-10 is effective for annual and interim periods beginning after December 15, 2020. The Company early adopted&amp;#160;ASU&amp;#160;2020-10&amp;#160;for the reporting period ending December 31, 2020. The adoption of this update did not have a material effect on the Company s consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock id="F_000249" contextRef="C_0001636651_20200101_20201231">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;N&lt;font style="font-weight:bold;"&gt;OTE 3 &amp;#8211; CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All&lt;font style="color:#000000;"&gt; short-term investments are classified as available-for-sale. The following tables summarize the fair value of cash, cash equivalents, and short-term investments, as well as gross unrealized holding gains and losses as of December&amp;#160;31, 2020 and December&amp;#160;31, 2019:&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;holding gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;holding losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;Cash&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,977,320&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,977,320&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,056,610&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,056,610&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,033,930&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,033,930&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;U.S. treasury notes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;holding gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;holding losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;Cash&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;501,537&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;501,537&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,395,607&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,395,607&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,897,144&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,897,144&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;U.S. treasury notes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,839,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,841,969&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,839,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,841,969&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company did&amp;#160;not&amp;#160;hold any securities that were in an unrealized loss position for more than 12 months as of&amp;#160;December&amp;#160;31, 2020 and 2019.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were&amp;#160;no&amp;#160;material realized gains or losses on available-for-sale securities during the years ended December&amp;#160;31, 2020 and 2019.&amp;#160;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock>
  <us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock id="F_000250" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;NOTE&lt;/font&gt;&lt;font style="color:#000000;"&gt; 4 &amp;#8211; PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment is summarized as follows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;320,957&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;193,717&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(185,337&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(125,354&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property, plant and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;135,620&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,363&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense was $60,000 and $39,000 for the years ended December&amp;#160;31, 2020 and 2019 respectively.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets, net of accumulated amortization, were $319,000 and $467,000 as of December&amp;#160;31, 2020 and December&amp;#160;31, 2019, respectively, and are included in other assets.&amp;#160;Amortization expense was $247,000 and $216,000 for the years ended December&amp;#160;31, 2020 and 2019, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock id="F_000251" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 5 &amp;#8211; ACCRUED EXPENSES&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consist of the following:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical trials accrual&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,175,497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,235,527&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payroll and bonus accrual&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,845,441&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,728,495&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional fees accrual&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,846,211&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,070,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;165,536&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232,095&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,032,685&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,266,706&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="F_000252" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 6 &amp;#8211; STOCKHOLDERS&amp;#8217; EQUITY AND PREFERRED STOCK&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s capital structure consists of common stock and Preferred Stock. Pursuant to the Company&amp;#8217;s amended and restated certificate of incorporation, as amended, the Company is authorized to issue up to 125,000,000 shares of common stock and 10,000,000 shares of Preferred Stock. The Company has designated 10,000 of the 10,000,000 authorized shares of Preferred Stock as non-voting Series A Convertible Preferred Stock (&amp;#8220;Series A Preferred Stock&amp;#8221;).&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The holders of common stock are entitled to one vote for each share held. The holders of common stock have no preemptive or other subscription rights, and there are no redemption or sinking fund provisions with respect to such shares. Subject to preferences that may apply to any outstanding series of Preferred Stock, holders of the common stock are entitled to &lt;font style="Background-color:#FFFFFF;"&gt;receive ratably any dividends declared on a&amp;#160;non-cumulative&amp;#160;basis. Shares of Series A Preferred Stock will be entitled to receive dividends at a rate equal to (on an as-if-converted-to-common stock basis), and in the same form and manner as, dividends actually paid on shares of common stock. &lt;/font&gt;The common stock is subordinate to all series of Preferred Stock with respect to rights upon liquidation, winding up and dissolution of the Company. The holders of common stock are entitled to liquidation proceeds after all liquidation preferences for the Preferred Stock are satisfied.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2018, the Company entered into a sales agreement (the &amp;#8220;2018 ATM agreement&amp;#8221;) with Cowen and Company, LLC (&amp;#8220;Cowen&amp;#8221;) &lt;font style="color:#000000;"&gt;under which the Company offered and sold in &amp;#8220;at the market offerings,&amp;#8221; from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $50.0 million through Cowen acting as sales agent. During the year ended December 31, 2019, the Company sold 6,893,888 shares of its common stock under the 2018 ATM agreement for net proceeds of $22.3 million after deducting &lt;/font&gt;sales agent commissions and other offering expenses payable by the Company, (the &amp;#8220;ATM Offerings&amp;#8221;)&lt;font style="color:#000000;"&gt;.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2020, the Company entered into a new sales agreement (the &amp;#8220;2020 ATM agreement&amp;#8221;) with Cowen and &lt;font style="color:#000000;"&gt;under which the Company may offer and sell in &amp;#8220;at the market offerings,&amp;#8221; from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $75.0 million through Cowen acting as sales agent. &lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were 3,250 and 7,762 shares of Series A Preferred Stock outstanding as of December 31, 2020 and December&amp;#160;31, 2019, respectively. Each share of Series A Preferred Stock is convertible into 1,000 shares of common stock at any time at the holder&amp;#8217;s option. However, the holder will be prohibited, subject to certain exceptions, from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than, at the written election of the holder, either 9.99% or 14.99% of the total number of shares of common stock then issued and outstanding, which percentage may be changed at the holder&amp;#8217;s election to any other number less than or equal to 19.99% upon 61 days&amp;#8217; notice to the Company; provided, however, that effective 61 days after delivery of such notice, such beneficial ownership limitations shall not be applicable to any holder that beneficially owns either 10.0% or 15.0%, as applicable based on the holder&amp;#8217;s initial written election noted above, of the total number of shares of common stock issued and outstanding immediately prior to delivery of such notice. In the event of a liquidation, dissolution, or winding up of the Company, holders of Series A Preferred Stock will receive a payment equal to $0.001 per share of Series A Preferred Stock before any proceeds are distributed to the holders of common stock.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;In December 2020, entities affiliated with Biotechnology Value Fund, L.P. elected to convert an aggregate of 2,256 shares of Series A Preferred Stock owned by such holders into an aggregate of 2,256,000 shares of the Company&amp;#8217;s common stock.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020, the Company sold 6,250,000 shares of its common stock at a public offering price of $8.00 per share, for net proceeds of $46.7 million after deducting underwriting discounts and commissions and other offering expenses payable by the Company, (the &amp;#8220;August 2020 Offering&amp;#8221;).&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;In May 2020, entities affiliated with Biotechnology Value Fund, L.P. elected to convert an aggregate of 2,256 shares of Series A Preferred Stock owned by such holders into an aggregate of 2,256,000 shares of the Company&amp;#8217;s common stock.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October and November 2019, the Company sold 10,350,000 shares of its common stock, which included the full exercise of the underwriters&amp;#8217; option to purchase additional shares, and 4,000 shares of Series A Preferred Stock at a public offering price of $2.50 and $2,500 per share, respectively, for net proceeds of $33.5 million after deducting underwriting discounts and commissions and other offering expenses payable by the Company, (the &amp;#8220;October 2019 Offering&amp;#8221;).&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2019, the Company entered into an exchange agreement with entities affiliated with Biotechnology Value Fund, L.P. (the &amp;#8220;Exchanging Stockholders&amp;#8221;), pursuant to which the Company exchanged an aggregate of 1,262,000 shares of the Company&amp;#8217;s common&amp;#160;stock owned by the Exchanging Stockholders for an aggregate of 1,262 shares of the Company&amp;#8217;s Series A Preferred Stock (the &amp;#8220;Exchange Shares&amp;#8221;). The Exchange Shares were issued without registration under the Securities Act of 1933, as amended, in reliance on the exemption from registration contained in Section&amp;#160;3(a)(9) of the Securities Act.&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2019, the Company sold 13,993,778 shares of its common stock and 2,500 shares of Series A Preferred Stock at a public offering price of $2.00 and $2,000 per share, respectively, for net proceeds of $30.5 million after deducting underwriting discounts and commission and other offering expenses payable by the Company (the &amp;#8220;February 2019 Offering&amp;#8221;).&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividends&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;No dividends on the common stock shall be declared and paid unless dividends on the Preferred Stock have been declared and paid. Through December&amp;#160;31, 2020, the Company has not declared any dividends.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000253" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 7 &amp;#8211; STOCK-BASED COMPENSATION&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August 29, 2014, the Company&amp;#8217;s Board of Directors adopted and approved the 2014 Equity Incentive Plan (the &amp;#8220;2014 Plan&amp;#8221;), which authorized the Company to grant shares of common stock in the form of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock and restricted stock units. The types of stock-based awards, including share purchase rights amount, terms, and exercisability provisions of grants are determined by the Company&amp;#8217;s Board of Directors.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;The Company&apos;s Board of Directors adopted, and the Company&apos;s stockholders approved the 2017 equity incentive plan (&amp;#8220;2017 Plan&amp;#8221;),&amp;#160;which became effective immediately prior to the execution of the underwriting agreement related to the IPO on May 4, 2017. The initial reserve of shares of common stock that may be issued under the 2017 Plan was 3,052,059 shares. The 2017 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance-based stock awards, and other forms of stock-based awards.&amp;nbsp;&amp;nbsp;Additionally, the 2017 Plan provides for the grant of performance cash awards. The Company&apos;s employees, officers, directors and consultants and advisors are eligible to receive awards under the 2017 Plan.&amp;nbsp;&amp;nbsp;Upon the adoption of the 2017 Plan, no further awards will be granted under the 2014 Plan. Pursuant to the terms of the 2017 Plan, on each January 1st, the plan limit shall be increased by the lesser of (x) 5% of the number of shares of common stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine in its discretion. &lt;/font&gt;&lt;font style="Background-color:#FFFFFF;"&gt;On January 1, 2019, an additional 1,232,705 shares were reserved for issuance under the 2017 Plan. As of December&amp;#160;31, 2019, there were 2,199,765 shares of the Company&amp;#8217;s common stock reserved for issuance under the 2017 Plan. &lt;/font&gt;&lt;font style="Background-color:#FFFFFF;"&gt;On January 1, 2020, an additional 2,735,516 shares were reserved for issuance under the 2017 Plan. As of December&amp;#160;31, 2020, there were 1,771,772 shares of the Company&amp;#8217;s common stock reserved for issuance under the 2017 Plan.&lt;/font&gt; &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&apos;s Board of Directors adopted, and the Company&apos;s stockholders approved the 2017 employee stock purchase plan (the &amp;#8220;2017 ESPP&amp;#8221;), which became effective immediately prior to the execution of the underwriting agreement related to the IPO on May 4, 2017. The initial reserve of shares of common stock that may be issued under the 2017 ESPP was 279,069 shares. On September 20, 2017, the Company&amp;#8217;s Compensation Committee approved an offering period under the 2017 ESPP, which began on October 20, 2017. The ESPP allows employees to purchase common stock of the Company at a 15% discount to the market price on designated purchase dates. During the years ended December&amp;#160;31, 2020 and 2019, 105,464 and 80,542 shares were purchased under the ESPP and the Company recorded expense of $152,973 and $109,319, respectively. The number of shares of common stock reserved for issuance under the 2017 ESPP will automatically increase on January 1 of each year, beginning on January 1, 2018 and continuing through and including January 1, 2027, by the lesser of (i) 1% of the total number of shares of the Company&amp;#8217;s capital stock outstanding on December 31 of the preceding calendar year, (ii) 550,000 shares or (iii) such lesser number of shares determined by our Board. On January 1, 2019, an additional 246,541 shares were reserved for issuance under the 2017 ESPP. No shares were reserved for issuance under the 2017 ESPP during the year ended December 31, 2020. As of December&amp;#160;31, 2020, there were 553,552 shares of the Company&amp;#8217;s common stock reserved for issuance under the 2017 ESPP. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unless specified otherwise in an individual option agreement, stock options granted under the 2014 Plan and 2017 Plan generally have a ten-year term and a four-year graded vesting period. The vesting requirement is generally conditioned upon the grantee&amp;#8217;s continued service with the Company during the vesting period. Once vested, all awards are exercisable from the date of grant until they expire. The option grants are non-transferable. Vested options generally remain exercisable for 90 days subsequent to the termination of the option holder&amp;#8217;s service with the Company. In the event of option holder&amp;#8217;s death or disability while employed by or providing service to the Company, the exercisable period extends to 12 months. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Performance-based option awards generally have similar vesting terms, with vesting occurring on the date the performance condition is achieved and expire in accordance to the specific terms of the agreement. At December&amp;#160;31, 2020, there were 125,000 performance-based options outstanding and unvested &lt;font style="color:#000000;"&gt;that include options to vest upon the achievement of certain research and development milestones&lt;/font&gt;.&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of options granted during the years ended December 31, 2020 and 2019 was estimated using the Black-Scholes option valuation model. The inputs for the Black-Scholes option valuation model require management&amp;#8217;s significant assumptions and are detailed in the table below. The risk-free interest rates were based on the rate for U.S. Treasury securities at the date of grant with maturity dates approximately equal to the expected life at the grant date. The expected life was based on the simplified method in accordance with the SEC Staff Accounting Bulletin No. Topic 14D. The expected volatility was estimated based on historical volatility information of peer companies that is publicly available.&lt;font style="color:#000000;"&gt; &lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All assumptions used to calculate the grant date fair value of nonemployee options are generally consistent with the assumptions used for options granted to employees. In the event the Company terminates any of its consulting agreements, the unvested options underlying the agreements would also be cancelled.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company granted 10,000 and 175,000 stock options to nonemployee consultants for services rendered during the years ended December&amp;#160;31, 2020 and 2019, respectively. There were 32,500 and 145,204 unvested nonemployee options outstanding as of December&amp;#160;31, 2020 and 2019, respectively. Total expense recognized related to the nonemployee stock options for the years ended December&amp;#160;31, 2020 and 2019 was $257,431 and $51,666, respectively. During the year ended December 31, 2019, the Company recognized a credit of $17,000 related to the nonemployee stock options including the modification of certain options in connection with the&amp;#160;separation and consulting agreement with Dr. During (see Note 11). Total unrecognized compensation expenses related to the nonemployee stock options was $186,823 as of December 31, 2020. During the years ended December&amp;#160;31, 2020, and 2019, the Company recognized $115,240 and zero, respectively, in expenses for nonemployee performance-based option awards.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company granted 3,573,160 and 3,372,513 stock options to employees during the years ended December&amp;#160;31, 2020 and 2019, respectively. There were 4,975,262 and 3,963,544 unvested employee options outstanding as of December&amp;#160;31, 2020 and 2019, respectively. Total expense recognized related to the employee stock options for the years ended December&amp;#160;31, 2020 and 2019 was $7.1 million and $5.0 million, respectively. Total unrecognized compensation expense related to employee stock options was $12.2 million as of December&amp;#160;31, 2020. During the years ended December&amp;#160;31, 2020 and 2019, the Company recognized $2,340,808 and $9,391 in expenses for employee performance-based option awards. &lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s stock-based compensation expense was recognized in operating expenses as follows:&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,779,758&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,391,909&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,745,596&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,813,883&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,525,354&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,205,792&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,372,381&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,096,473&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee Stock Purchase Plan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;152,973&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;109,319&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,525,354&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,205,792&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of employee options granted during the years ended December&amp;#160;31, 2020 and 2019, respectively, was estimated by utilizing the following assumptions:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81.48&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81.87&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term in years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.88&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.58&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.04&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value of option on grant date&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of nonemployee options granted and remeasured during the years ended December&amp;#160;31, 2020 and 2019, respectively, was estimated by utilizing the following assumptions:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74.37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74.56&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term in years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.64&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.32&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value of option on grant date&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.18&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the number of options outstanding and the weighted average exercise price:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life in Years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Outstanding at December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,714,383&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.10&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;153,485&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and exercisable at December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,337,931&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.88&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.20&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;153,485&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,547,513&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.56&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(856,601&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.43&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Outstanding December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,405,295&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.82&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.01&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,488,930&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and exercisable at December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,296,547&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.53&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;356,443&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,583,160&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.68&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(165,384&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.82&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(415,526&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Outstanding December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,403,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.59&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;652,438&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and exercisable at December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,395,658&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.45&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;445,599&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&amp;#160;31, 2020, there was $12.3 million of unamortized share&amp;#8211;based compensation expense, which is expected to be recognized over a remaining average vesting period of 3.04 years.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000254" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 8 &amp;#8211; INCOME TAXES&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&amp;#160;31, 2020, the Company has available approximately $&lt;font style="color:#000000;"&gt;238.6&lt;/font&gt; million and $186.7 million of unused NOL carryforwards for federal and state tax purposes, respectively, that may be applied against future taxable income. The Company also has approximately $&lt;font style="color:#000000;"&gt;165.4&lt;/font&gt; million of unused NOL carryforwards for New York City purposes. The NOL carryforwards will begin to expire in the year 2035 if not utilized prior to that date. There is no provision for income taxes because the Company has historically incurred operating losses and maintains a full valuation allowance against its net deferred tax assets. &lt;font style="color:#000000;"&gt;The valuation allowance increased by approximately $13.3 million and $22.5 million during the years 2020 and 2019, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company may be subject to the NOL utilization provisions of Section&amp;#160;382 of the Code. The effect of an ownership change would be the imposition of an annual limitation on the use of NOL carryforwards attributable to periods before the change. The amount of the annual limitation depends upon the value of the Company immediately before the change, changes to the Company&amp;#8217;s capital during a specified period prior to the change, and the federal published interest rate. The Company has not completed a Section&amp;#160;382 analysis to determine if a change in ownership has occurred. Until an analysis is completed, there can be no assurance that the existing net operating loss carry-forwards or credits are not subject to significant limitation.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s reserves related to taxes are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies related to the tax benefit. For the years ended December&amp;#160;31, 2020 and 2019, the Company had no unrecognized tax benefits or related interest and penalties accrued. The Company has not yet conducted a study of research and development credit carryforwards. This study may result in an adjustment to the Company&amp;#8217;s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&amp;#8217;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheet or statement of operations if an adjustment were required. The Company would recognize both accrued interest and penalties related to unrecognized benefits in income tax expense. The Company&amp;#8217;s uncertain tax positions yet to be determined would be related to years that remain subject to examination by relevant tax authorities. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities were as follows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets/liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryovers&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74,064,673&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,288,334&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,458,004&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,351,315&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,978,370&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,606,889&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;514,316&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;898,067&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(29,760&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,026&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Charitable contributions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;87,120&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;132,072&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,742,031&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,208,519&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total gross deferred tax assets/liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89,814,754&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,463,170&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(89,814,754&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(76,463,170&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets (liabilities)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the statutory U.S. Federal rate to the Company&amp;#8217;s effective tax rate is as follows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.28%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal income tax benefit at statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income tax, net of federal benefit (&lt;font style="font-size:8pt;"&gt;1)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.15&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13.80&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent items&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.50&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.72&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37.14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.64&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.67&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.02&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax (benefit) expense rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1) Inclusive of $5.8 million deferred tax benefit due to change in apportionment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="F_000255" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 9 &amp;#8211;&lt;font style="color:#000000;"&gt; &lt;/font&gt;COMMITMENTS AND CONTINGENCIES&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;License Agreements&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;On March&amp;#160;26, 2015, the Company entered into an exclusive agreement with H. Lundbeck A/S (&amp;#8220;Lundbeck&amp;#8221;) for a worldwide perpetual licensing right related the research, development and commercialization of OV101. On May 10, 2019, the parties amended the license agreement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the Lundbeck license agreement, as amended, the Company agreed to make milestone payments totaling up to $189.0 million upon the achievement of certain development, regulatory and sales milestones.&amp;#160;The first payment of $1.0 million is due upon the successful completion of the first Phase 3 trial for a product in which OV101 is an active ingredient.&amp;#160;In addition, the agreement calls for the Company to pay royalties for an initial term based on a low double-digit percentage of sales and provides for the reduction of royalties in certain limited circumstances.&amp;nbsp;&amp;nbsp;As of December&amp;#160;31, 2020, none of these contingent payments were considered probable.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2016, the Company entered into a license agreement with Northwestern University, or Northwestern, pursuant to which Northwestern granted us an exclusive, worldwide license to patent rights in certain inventions, or the Northwestern Patent Rights, which relate to a specific compound and related methods of use for such compound, along with certain Know-How related to the practice of the inventions claimed in the Northwestern Patents.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Northwestern agreement, the Company was granted exclusive rights to research, develop, manufacture and commercialize products utilizing the Northwestern Patent Rights for all uses. The Company has agreed that it will not use the Northwestern Patent Rights to develop any products for the treatment of cancer, but Northwestern may not grant rights in the technology to others for use in cancer. The Company also has an option, exercisable during the term of the agreement to an exclusive license under certain intellectual property rights covering novel compounds with the same or similar mechanism of action as the primary compound that is the subject of the license agreement.&amp;nbsp;&amp;nbsp;Northwestern has retained the right, on behalf of itself and other non-profit institutions, to use the Northwestern Patent Rights and practice the inventions claimed therein for educational and research purposes and to publish information about the inventions covered by the Northwestern Patent Rights.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon entry into the Northwestern agreement, the Company paid an upfront non-creditable one-time license issuance fee of $75,000, and is required to pay an annual license maintenance fee of $20,000, which will be creditable against any royalties payable to Northwestern following first commercial sale of licensed products under the agreement.&amp;nbsp;&amp;nbsp;The Company is responsible for all ongoing costs of filing, prosecuting and maintaining the Northwestern Patents, but also has the right to control such activities using its own patent counsel.&amp;nbsp;&amp;nbsp;In consideration for the rights granted to the Company under the Northwestern agreement, the Company is required to pay to Northwestern up to an aggregate of $5.3 million upon the achievement of certain development and regulatory milestones for the first product covered by the Northwestern Patents, and, upon commercialization of any such products, will be required to pay to Northwestern a tiered royalty on net sales of such products by the Company, its affiliates or sublicensees, at percentages in the low to mid single-digits, subject to standard reductions and offsets.&amp;nbsp;&amp;nbsp;The Company&amp;#8217;s royalty obligations continue on a product-by-product and country-by-country basis until the later of the expiration of the last-to-expire valid claim in a licensed patent covering the applicable product in such country and 10 years following the first commercial sale of such product in such country.&amp;nbsp;&amp;nbsp;If the Company sublicenses a Northwestern Patent Right, it will be obligated to pay to Northwestern a specified percentage of sublicense revenue received by the Company, ranging from the high single digits to the low-teens.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Northwestern agreement requires that the Company use commercially reasonable efforts to develop and commercialize at least one product that is covered by the Northwestern Patent Rights.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unless earlier terminated, the Northwestern agreement will remain in force until the expiration of the Company&amp;#8217;s payment obligations thereunder.&amp;nbsp;&amp;nbsp;The Company has the right to terminate the agreement for any reason upon prior written notice or for an uncured material breach by Northwestern.&amp;nbsp;&amp;nbsp;Northwestern may terminate the agreement for the Company&amp;#8217;s uncured material breach or insolvency.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020, none of these contingent payments were considered probable.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingencies&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. The Company is not currently involved in any legal matters arising in the normal course of business.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of their respective employment agreements, each of our named executive officers is eligible to receive severance payments and benefits upon a termination without &amp;#8220;cause&amp;#8221; or due to &amp;#8220;permanent disability,&amp;#8221; or upon &amp;#8220;resignation for good reason,&amp;#8221; contingent upon the named executive officer&amp;#8217;s delivery to the Company of a satisfactory release of claims, and subject to the named executive officer&amp;#8217;s compliance with non-competition and non-solicitation restrictive covenants for two years following the termination date.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:11pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the Northwestern agreement, Northwestern granted the Company an exclusive license to certain patent rights and know-how, including a patent application covering a specified composition of matter (the &amp;#8220;Patent Application&amp;#8221;).&amp;#160; Northwestern previously entered into a license agreement with Catalyst Pharmaceuticals, Inc. (&amp;#8220;Catalyst&amp;#8221;), dated August 27, 2009, pursuant to which Northwestern granted Catalyst rights under certain intellectual property rights covering a different composition of matter (the &amp;#8220;Catalyst License&amp;#8221;).&amp;#160;&amp;#160;In addition, the Company is a party to a confidential disclosure agreement with Catalyst, dated September 16, 2016 (the &amp;#8220;CDA&amp;#8221;). On June 25, 2018, Catalyst sent a letter to Northwestern and the Company alleging, among other things, that Northwestern breached the Catalyst License by licensing the Patent Application to the Company.&amp;#160;Catalyst&amp;#8217;s letter also asserted that the Company had breached its obligations under the CDA by allegedly failing to disclose that the Company had a license to the Patent Application, and that a further breach would occur if the Company makes any use of information obtained under the CDA in connection with its development program arising from the rights granted under the license agreement.&amp;#160;&amp;#160;Catalyst has asserted that the combined conduct of Northwestern and the Company gives rise to various claims, including breach of contract, fraud, and tortious interference.&amp;#160;The Company believes that Catalyst&amp;#8217;s claims are without merit and responded by letter dated June 28, 2018, which denies any and all liability to Catalyst, and further denies that Catalyst has been damaged in any way. On May 20, 2019, the Company entered into a Settlement Agreement with Catalyst (the &amp;#8220;Settlement Agreement&amp;#8221;), pursuant to which Catalyst released the Company from any and all claims, known or unknown, arising from or related to the dispute between Catalyst and Northwestern, the license agreement, and/or the claims that Catalyst asserted against the Company in the June 25, 2018 letter.&amp;#160;&amp;#160;Under the Settlement Agreement the Company retains all rights and privileges previously granted to the Company under the Northwestern license agreement.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock id="F_000256" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 10 &amp;#8211; COLLABORATION AGREEMENT&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Angelini Collaboration&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July&amp;#160;9, 2020, the Company entered into the Angelini License Agreement with Angelini, pursuant to which the Company granted to Angelini exclusive rights to develop and commercialize OV101, a selective agonist of the GABA&lt;sub style="font-size:85%; vertical-align:bottom"&gt;A&lt;/sub&gt;&amp;#160;receptor, for the treatment of Angelman syndrome in the European Economic Area as well as Switzerland, the United Kingdom, Russia and Turkey (the &amp;#8220;European Territory&amp;#8221;).&amp;#160;&amp;#160;The licenses granted to Angelini include sublicenses under the Lundbeck Agreement, as well as licenses under the Company&amp;#8217;s patents and know-how covering OV101.&amp;#160;&amp;#160;Angelini will be responsible for conducting any clinical trials necessary to obtain regulatory approval for OV101 for Angelman syndrome in the European Territory, and the Company will be responsible for bearing a portion of the costs for such trials.&amp;#160;&amp;#160;The Company will also be responsible, at its expense, for the completion of certain ongoing clinical trials for OV101, to the extent applicable to obtaining regulatory approval for OV101 in the European Territory.&amp;#160;&amp;#160;Angelini has the exclusive right, at its election, to develop and commercialize OV101 for the treatment of Fragile X Syndrome in the European Territory.&amp;#160;&amp;#160;The parties may also mutually agree to pursue additional indications for OV101 in the European Territory, and in such case, Angelini would have the exclusive rights to commercialize in such additional indications. Angelini is required to use commercially reasonable efforts to conduct development activities for OV101, and following regulatory approval, to commercialize OV101 in each approved indication.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In conjunction with the entry into the Angelini License Agreement, the parties entered into a separate supply agreement, pursuant to which the Company will be responsible for supply of OV101 to Angelini for development and commercialization in the European Territory, through its existing supply relationship with Lundbeck.&amp;#160;&amp;#160;The Angelini License Agreement also provides for a transfer, at Angelini&amp;#8217;s expense, of the relevant manufacturing technology from the Company and Lundbeck to Angelini, in order to enable Angelini to assume responsibility for its own manufacture and supply of OV101 in the future.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:13pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Angelini License Agreement, Angelini made an upfront payment and a milestone payment related to the transfer of a specified amount of compound and related information to the Company of $25.0 million during the year ended December 31, 2020.&amp;#160; Angelini will be required to make additional milestone payments to the Company upon the completion of the specified components of the technology transfer and achievement of specified regulatory milestones for OV101 in Angelman syndrome of up to $55.0&amp;#160;million in the aggregate, as well as up to &amp;#8364;162.5 million ($199.9 million) in sales milestone payments for achievement of specified levels of net sales in the European Territory.&amp;#160;&amp;#160;In addition, Angelini will be required to pay tiered royalties on net sales by Angelini, its affiliates or sublicensees at double-digit percentages above the teens, subject to certain standard reductions and offsets.&amp;#160;&amp;#160;Royalties will be payable on a product-by-product and country-by-country basis until the latest of the expiration of the licensed patents covering such product in such country, the expiration of market exclusivity for such product in such country, and fifteen years from first commercial sale of such product in such country.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Either party may terminate the Angelini License Agreement for an uncured material breach of the other party or in the case of insolvency.&amp;#160;&amp;#160;The Company may terminate the Angelini License Agreement if Angelini challenges any of the licensed patents.&amp;#160;&amp;#160;Angelini may terminate the Angelini License Agreement for convenience on specified notice periods, which are determined based upon whether the product has been commercially launched in the European Territory.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company identified the following material promises under the Angelini License Agreement: (1) licensing of intellectual property with respect to OV101 (2) completion of certain ongoing trials (3) transfer of a specified amount of compound and related information (4) potential for funding 35% of the cost for Angelini future trials limited to $7.0 million and (5) completion of the manufacturing process technology transfer.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:6%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that the $7.0 million represents a potential payment to a customer and should be deferred. The transfer of compound and related information is considered a contingent milestone payment that will be recognized upon acceptance by Angelini of the milestone which was achieved and recognized in December 2020. The Company further determined that the license and the completion of ongoing trials are distinct from each other, as each has value without the other.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined the transaction price is equal to the up-front fee of $20.0 million. The transaction price was allocated based on the standalone selling price of the license, the ongoing trials and $7.0 million for potential future trials.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon the transfer of the specified amount of compound and related information and acceptance by Angelini, Angelini was required to and made a $5.0 million payment. &lt;font style="color:#000000;"&gt;This performance obligation was determined to be variable consideration which was constrained and not considered part of the upfront transaction price allocation.&lt;/font&gt;&lt;font style="font-size:12pt;color:#000000;"&gt; &lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Angelini will be required to make a separate $5.0 million tech transfer payment towards the $55.0 million aggregate tech transfer and regulatory milestone payments upon the successful completion of the manufacturing process technology transfer. The Company earning this is fully dependent on performance and cooperation of Angelini and Lundbeck in implementing the Technology Transfer. At this time, the Company cannot estimate if or when this milestone-related performance obligation might be achieved.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended December 31, 2020, the Company recognized $6.1 million of license revenue and $1.5 million relating to the progress of the ongoing trials as well as $5.0 million for the transfer of the specified amount of compound and related information. The portion of the upfront payment allocated to License Revenue was recognized in full as it was non-refundable and not contingent on any future performance and requires no consequential continuing involvement by the Company. The Company did not have any such revenue during the year ended December 31, 2019. In addition, the Company recorded deferred revenue in the amount of approximately $12.4 million as of December 31, 2020 which will be recognized over the term of the ongoing trials based on the portion of total estimated expenses incurred. The Company has classified deferred revenue as current or noncurrent based on the expected timing of such expenses.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Takeda Collaboration&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January&amp;#160;6, 2017, the Company entered into a license and collaboration agreement with Takeda, pursuant to which Takeda granted the Company an exclusive license to commercialize the compound TAK-935, which the Company refers to as OV935, in certain territories, and a co-exclusive worldwide license, together with Takeda, to develop OV935. In consideration of certain license rights granted to the Company pursuant to the Takeda collaboration, the Company issued 1,781,996 shares of its Series B-1 Preferred Stock, pursuant to a Series B-1 preferred stock purchase agreement entered into on January&amp;#160;6, 2017, at an ascribed price per share of $14.513 on January&amp;#160;6, 2017 for an aggregate fair value of $25.9 million, which was recorded as research and development expense at the date of the transaction. The 1,781,996 shares of Series B-1 Preferred Stock held by Takeda automatically converted into 1,781,996 shares of the Company&amp;#8217;s common stock upon the completion of its IPO in 2017. Under the Takeda collaboration, the Company is obligated to pay Takeda future payments if and when certain milestones are achieved. Upon the first patient enrollment in the first Phase 3 trial for the first of the initial indications the Company and Takeda are focusing on in the Takeda collaboration, the Company is obligated to issue to Takeda the number of unregistered shares of the Company&amp;#8217;s common stock equal to the lesser of (a)&amp;#160;8% of the Company outstanding capital stock on the issuance date or (b)&amp;#160;$50.0 million divided by the applicable share price, unless certain events occur.&lt;font style="Background-color:#FFFFFF;color:#000000;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="Background-color:#FFFFFF;color:#000000;"&gt;In the event such payment would cause Takeda to own over 19.99% of our outstanding capital stock or other events occur, such payment must be paid in cash&lt;/font&gt;.&amp;nbsp;&amp;nbsp;The remaining potential global commercial and regulatory milestone payments equal approximately $35.0 million and can be satisfied in cash or unregistered shares of the Company&amp;#8217;s common stock at its election, unless certain events occur. &lt;font style="color:#000000;"&gt;As of December&amp;#160;31, 2020, none of these contingent payments have been triggered.&lt;/font&gt;&amp;nbsp;&amp;nbsp;During the year ended December&amp;#160;31, 2020, the Company recognized $0.7 million in research and development expenses representing research and development expenses reimbursable to the Company from Takeda, of which $0.1 million was included in related party receivable as of December 31, 2020 and $2.1 million was included in related party payable as of December 31, 2020.&amp;nbsp;&amp;nbsp;During the year ended December 31, 2019, the Company recognized a credit in research and development expenses of $4.7 million &lt;font style="color:#000000;"&gt;representing costs reimbursable to the Company from Takeda, &lt;/font&gt;of &lt;font style="color:#000000;"&gt;which $1.1 million was included in related party receivable as of December 31, 2019&lt;/font&gt;. &amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Takeda collaboration will expire upon the cessation of commercialization of the products by both the Company and Takeda. Either party may terminate the Takeda collaboration because of the other party&amp;#8217;s uncured material breach or insolvency, for safety reasons, or, after completion of the first proof of mechanism clinical trial, for convenience. Takeda may terminate the Takeda collaboration for the Company&amp;#8217;s (or the Company&amp;#8217;s sublicensee&amp;#8217;s) challenge to the patents licensed under the Takeda collaboration. If the collaboration is terminated by Takeda for material breach by the Company, bankruptcy or patent challenge or by the Company for convenience or safety reasons, the Company&amp;#8217;s rights to the products will cease, the Company will transition all activities related to the products to Takeda, and the Company will grant Takeda an exclusive, royalty-bearing license under certain patents and other intellectual property controlled by the Company to commercialize OV935 and products containing OV935 for the treatment of certain rare neurological disorders. If the collaboration is terminated by the Company for Takeda&amp;#8217;s material breach or bankruptcy or by Takeda for convenience or safety reasons, Takeda&amp;#8217;s rights to the products will cease, Takeda will transition all activities related to the products to us, and Takeda will grant us an exclusive, royalty-bearing license under certain patents and other intellectual property controlled by Takeda to commercialize OV935 and products containing OV935 for the treatment of certain rare neurological disorders.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2021, the Company entered into a royalty, license and termination agreement with Takeda (see note 12).&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="F_000257" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 11 &amp;#8211; RELATED PARTY TRANSACTIONS&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the Company&amp;#8217;s collaboration agreement with Takeda the Company recognized a long-term liability representing long-term prepaid expenses to be reimbursed to Takeda.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 24, 2019, the Company entered into a separation and consulting agreement with Dr. Matthew During in connection with Dr. During&amp;#8217;s resignation as President and Chief Scientific Officer with the Company effective as of April 1, 2019. Pursuant to the separation and consulting agreement, Dr. During agreed to non-solicit and non-compete covenants through such time as he remains a consultant to the Company, as well as a general release of claims in connection therewith. Dr. During agreed to a three-year consulting arrangement, pursuant to which he will be paid, amongst other specific milestone and meeting related fees, $150,000 per year for his role as the Chairman of the Company&amp;#8217;s Scientific Advisory Board and $150,000 per year for other advisory and consulting services. Further, Dr. During was granted options to acquire 100,000 shares of common stock at an exercise price of $1.76 per share, the fair market value on April 1, 2019, which options shall vest in full upon completion of a specific clinical milestone, subject to Dr. During&amp;#8217;s continued service through such vesting date. In the event such option does not vest by December 31, 2020, the stock option will expire. Provided further, in recognition of Dr. During&amp;#8217;s service on the Scientific Advisory Board, Dr. During was granted options to acquire 75,000 shares of common stock at an exercise price equal to $1.76 per share, the fair market value on April 1, 2019. Either Dr. During or the Company may terminate the consulting arrangements pursuant to the Consulting Agreement in accordance with its terms, at any time and for any reason, upon thirty (30) days written notice to the other party. Upon such termination, the Company will have no further obligations to Dr. During, including any obligation to pay further consulting fees.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2019, the Company issued and sold an aggregate of 6,325,000 shares of common stock and 2,500 shares of Series A Preferred Stock to entities affiliated with Takeda, a collaboration partner and an existing stockholder, entities affiliated with Biotechnology Value Fund, L.P., an existing stockholder, and Dr. Jeremy M. Levin, its Chief Executive Officer and Chairman, for aggregate gross proceeds of $17.7 million.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October and November 2019, the Company issued and sold an aggregate of 4,058,000 shares of common stock and 2,000 shares of Series A Preferred Stock to entities affiliated with Takeda, a collaboration partner and an existing stockholder, entities affiliated with Biotechnology Value Fund, L.P., an existing stockholder, and Dr. Jeremy M. Levin, its Chief Executive Officer and Chairman, for aggregate gross proceeds of $10.2 million.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2019, the Company entered into an exchange agreement with the Exchanging Stockholders pursuant to which the Company exchanged an aggregate of 1,262,000 shares of the Company&amp;#8217;s common stock owned by the Exchanging Stockholders for an aggregate of 1,262 shares of the Company&amp;#8217;s Series A Preferred Stock.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;In May 2020, entities affiliated with Biotechnology Value Fund, L.P. elected to convert an aggregate of 2,256 shares of Series A Preferred Stock owned by such holders into an aggregate of 2,256,000 shares of the Company&amp;#8217;s common stock.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020, the Company issued and sold an aggregate of 1,250,000 shares of common stock to entities affiliated with Biotechnology Value Fund, L.P., an existing stockholder for aggregate gross proceeds of $10.0 million.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2020, entities affiliated with Biotechnology Value Fund, L.P. elected to convert an aggregate of 2,256 shares of Series A Preferred Stock owned by such holders into an aggregate of 2,256,000 shares of the Company&amp;#8217;s common stock.&lt;font style="color:#000000;"&gt;&amp;#160;&lt;/font&gt; &lt;font style="color:#000000;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:SubsequentEventsTextBlock id="F_000258" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 12 &amp;#8211; SUBSEQUENT EVENTS&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;Equity Awards&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From January 1, 2021 t&lt;font style="Background-color:#FFFFFF;color:#000000;"&gt;hrough the date of the filing of this Form 10-K, the Company has granted option awards for an aggregate of 643,600 shares of common stock to employees with a weighted average exercise price of $3.18.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Royalty, License and Termination Agreement with Takeda&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2021, the Company entered into a royalty, license and termination agreement (the &amp;#8220;Takeda License and Termination Agreement&amp;#8221;) with Takeda under which &lt;font style="color:#000000;"&gt;Takeda will secure rights to the Company&amp;#8217;s 50% global share in soticlestat, and an exclusive license under our relevant intellectual property rights and &lt;/font&gt;global rights at closing from the Company to develop and commercialize the investigational medicine OV935 for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome and Lennox-Gastaut syndrome.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Takeda License and Termination Agreement, all rights in OV935 will be owned by Takeda, or exclusively licensed to Takeda by the Company.&amp;nbsp;&amp;nbsp;Takeda will assume sole responsibility for further worldwide development and commercialization, and the Company will no longer have any financial obligation to Takeda under the original collaboration agreement, including for milestone payments or any future development and commercialization costs. Should the Company close the Takeda License and Termination Agreement, the Company will receive an upfront payment of $196.0 million at closing and will be eligible to receive up to an additional $660.0 million upon achieving development, regulatory and sales milestones. In addition, the Company would be entitled receive tiered royalties beginning in the low double-digits, and up to 20% on sales of OV935, if approved and commercialized. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expects to close the Takeda License and Termination Agreement in the first half of 2021, subject to the satisfaction of closing conditions, including regulatory review by the appropriate regulatory agencies under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. Either party may terminate the agreement if it does not close by May 14, 2021.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:ConsolidationPolicyTextBlock id="F_000259" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(A) Basis of Presentation and Consolidation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;) and include the accounts of Ovid Therapeutics Inc. and its wholly-owned subsidiary, Ovid Therapeutics Hong Kong Limited.&amp;nbsp;&amp;nbsp;All intercompany transactions and balances have been eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:UseOfEstimates id="F_000260" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(B) &lt;font style="color:#000000;"&gt;Use of Estimates&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates.&lt;/font&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ConcentrationRiskCreditRisk id="F_000261" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(C) Risks and Uncertainties&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its drug candidates, ability to obtain regulatory approval of its drug candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition and untested manufacturing capabilities&lt;/font&gt;.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:DeferredChargesPolicyTextBlock id="F_000262" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(D) Deferred Transaction Costs&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred transaction costs, primarily consisted of direct incremental legal, accounting, and other fees related to the Company&amp;#8217;s offering of its capital stock are capitalized as incurred. The deferred transaction costs are offset against proceeds upon the consummation of an offering.&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock id="F_000263" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(E) Comprehensive Loss&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&amp;#8217; equity that result from transactions and economic events other than those with stockholders. &lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:CollaborativeArrangementAccountingPolicy id="F_000264" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(F) Collaboration Arrangement&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;License and Collaboration Agreement with Takeda Pharmaceutical Company Limited&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the current license and collaboration agreement with Takeda Ovid and Takeda are sharing 50/50 in the drug development, the Company records 50% of the development costs in research and development.&amp;nbsp;&amp;nbsp;When Ovid incurs the majority of the costs and Takeda transfers a payment to Ovid to equalize the costs, Ovid records the participation by Takeda as a reduction of its research and development expenses, as the parties under the collaboration are sharing in the costs and the payment represents reimbursement of costs by Takeda.&amp;#160;When Takeda incurs the majority of the costs and Ovid transfers a payment to Takeda (to equalize the costs), Ovid records the participation in Takeda&amp;#8217;s expenses as research and development costs in its statement of operations, as Ovid and Takeda are sharing in the research and development activities and this participation represents Ovid&amp;#8217;s share of the research and development costs in the specific period. &lt;/p&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="F_000265" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(G) Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s cash and cash equivalents consist of cash held in checking accounts and money market funds. The Company considers all highly liquid investments with an original maturity date of three months or less to be cash and cash equivalents. Accounts held at U.S. financial institutions are insured by the FDIC up to $250,000. Cash balances could exceed insured amounts at any given time.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:MarketableSecuritiesPolicy id="F_000266" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(H) Short-term Investments&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;font style="Background-color:#FFFFFF;"&gt;&amp;#160;consist of debt securities with maturities greater than&amp;#160;&lt;/font&gt;three months&lt;font style="Background-color:#FFFFFF;"&gt;&amp;#160;from the date of purchase.&amp;#160;&amp;#160;The Company&amp;#160;&lt;/font&gt;classifies&lt;font style="Background-color:#FFFFFF;"&gt;&amp;#160;all of its investments as available-for-sale securities. Debt securities are recorded at fair value with unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders&amp;#8217; equity until realized. Realized gains and losses, amortization and accretion of premiums and discounts are included within net loss.&lt;/font&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="F_000267" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(I) Property and Equipment&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost and depreciated over their estimated useful lives of three years using the straight-line method. Repairs and maintenance costs are expensed. The Company reviews the recoverability of all long-lived assets, including the related useful life, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="F_000268" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(J) Research and Development Expenses&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expenses the cost of research and development as incurred. Research and development expenses comprise costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when the cost is incurred, in accordance with ASC 730, Research and Development.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock id="F_000269" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(K) Stock-Based Compensation&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for its stock-based compensation in accordance with ASC 718, Compensation&amp;#8212;Stock Compensation, which establishes accounting for stock-based awards granted to employees for services and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company estimates the fair value of all awards granted using the Black-Scholes valuation model. Key inputs and assumptions include the expected term of the option, stock price volatility, risk-free interest rate, dividend yield, stock price and exercise price. Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense. The Company elected an accounting policy to record forfeitures as they occur. The Company recognizes employee stock-based compensation expense based on the fair value of the award on the date of the grant. The compensation expense is recognized over the vesting period under the straight-line method.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13.5pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for options awards granted to nonemployee consultants and directors in accordance with ASU 2018-07, Compensation &amp;#8211; Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. The fair value of the option issued or committed to be issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company&amp;#8217;s common stock award at the earlier of the date that the commitment for performance by the counterparty has been reached or the counterparty&amp;#8217;s performance is complete.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock id="F_000270" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(L) Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) guidance specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The three levels of the fair value hierarchy are as follows:&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160; &lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&lt;font style="color:#000000;"&gt;&lt;/font&gt;&lt;font style="font-size:10pt;color:#000000;"&gt;Level 1&amp;#8212;Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities. The Company&amp;#8217;s Level 1 assets consisted of money market funds and short-term investments totaling $70.1 million and $76.2 million as of December&amp;#160;31, 2020 and 2019, respectively.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&lt;font style="color:#000000;"&gt;&lt;/font&gt;&lt;font style="font-size:10pt;color:#000000;"&gt;Level 2&amp;#8212;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models or other valuation methodologies. The Company had no Level 2 assets or liabilities as of December&amp;#160;31, 2020 and 2019.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="color:#000000;font-family:&apos;Times New Roman&apos;;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#x2022;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"&gt;&lt;font style="color:#000000;"&gt;&lt;/font&gt;&lt;font style="font-size:10pt;color:#000000;"&gt;Level 3&amp;#8212;Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable. The Company had no Level 3 assets or liabilities as of December&amp;#160;31, 2020 and 2019.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts reported in the balance sheets for cash and cash equivalents, related-party receivables, other current assets, accounts payable, accrued expenses, and current related-party payables approximate their fair value based on the short-term maturity of these instruments.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock id="F_000271" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(M) Income Taxes&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes under the asset and liability method, which requires deferred tax assets and liabilities to be recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts and respective tax bases of existing assets and liabilities, as well as for net operating loss carryforwards and research and development credit. Valuation allowances are provided if it is more likely than not that some portion or all of the deferred tax assets will not be realized.&amp;nbsp;&amp;nbsp;The impact of a change in the tax laws is recorded in the period in which the law is enacted.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock id="F_000272" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(N) Net Loss Per Common Share&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period. For all periods presented, stock options have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss per common share are the same.&lt;font style="color:#000000;"&gt; Under the terms of the Series A Preferred Stock issued in 2019, Preferred stockholders do not share in losses of the Company and have no obligation to fund losses or transfer assets.&amp;#160;&amp;#160;Since there is a loss, diluted EPS should be computed in the same manner as basic EPS and because no potential common shares shall be included in the computation of any diluted per-share amounts when a loss exists, the Series A Preferred Stock should be excluded from the computation of basic and diluted EPS.&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,403,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,405,295&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,762&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock id="F_000273" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(O) Segment Data&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:PensionAndOtherPostretirementPlansPensionsPolicy id="F_000274" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;(P) Retirement Plan&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company maintains a 401(k)-retirement plan for its employees that is intended to qualify under Sections 401(a) and 501(a) of the U.S. Internal Revenue Code of 1986, as amended (&amp;#8220;Code&amp;#8221;). The Company provides all active employees with a 100% matching contribution equal to 3% of an employee&amp;#8217;s eligible compensation deferred and 50% matching contributions on employee contributions that are between 3% and 5% of an employee&amp;#8217;s eligible compensation deferred. These safe harbor contributions vest immediately.&amp;nbsp;&amp;nbsp;For the years ended December&amp;#160;31, 2020 and 2019 the Company contributed $321,000 and $285,000, respectively.&lt;font style="color:#000000;"&gt; &lt;/font&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementPlansPensionsPolicy>
  <us-gaap:RevenueRecognitionPolicyTextBlock id="F_000275" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;(Q) Revenue Recognition&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&amp;#160;In applying ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) it satisfies the performance obligations.&amp;#160;The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint.&amp;#160;Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price.&amp;#160;The standalone selling price is generally determined using expected cost and comparable transactions. Revenue for performance obligations recognized over time is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-refundable upfront fees allocated to licenses that are not contingent on any future performance and require no consequential continuing involvement by the Company, are recognized as revenue when the license term commences and the licensed data, technology or product is delivered.&amp;#160;The Company defers recognition of upfront license fees if the performance obligations are not satisfied.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000276" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(&lt;font style="font-weight:bold;"&gt;R) Recent Accounting Pronouncements&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;Recent accounting standards which have been adopted&lt;/font&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &amp;#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.&amp;#160;&amp;#160;This new standard requires the measurement and recognition of expected credit losses for financial assets held at amortized cost, including loans and trade and other receivables. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The standard also amends the impairment model for available-for-sale debt securities and requires entities to determine whether all or a portion of the unrealized loss on an available-for-sale debt security is a credit loss. Under the new guidance, an entity recognizes an allowance for credit losses on available-for-sale debt securities as a contra-account to the amortized cost basis rather than as a direct reduction of the amortized cost basis of the investment, as was previously required. ASU 2016-13 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2019. As of December 31, 2020, the Company did not hold any debt securities with credit losses, nor does it have any trade receivables. The adoption of this standard effective January 1, 2020 did not have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August 29, 2018, the FASB issued ASU No. 2018-15, Intangibles &amp;#8211; Goodwill and Other - Internal-Use Software (Subtopic 350-40) - which amends ASC 350-40 to address a customer&amp;#8217;s accounting for implementation costs incurred in a cloud computing arrangement (&amp;#8220;CCA&amp;#8221;) that is a service contract. ASU No. 2018-15 aligns the accounting for costs incurred to implement a CCA that is a service arrangement with the guidance on capitalizing costs associated with developing or obtaining internal-use software. Specifically, the ASU amends ASC 350 to include in its scope implementation costs of a CCA that is a service contract and clarifies that a customer should apply ASC 350-40 to determine which implementation costs should be capitalized in a CCA that is considered a service contract. According to the standard the balance sheet line item for the presentation of capitalized implementation costs should be the same as that for the prepayment of fees related to the hosting arrangement and the manner in which an entity classifies the cash flows related to capitalized implementation costs should be the same as that in which it classifies the cash flows for the fees related to the hosting arrangement. ASU 2018-15 is effective for the Company for fiscal years beginning after December 15, 2019, including interim periods therein. Entities are permitted to apply either a retrospective or prospective transition approach to adopt the guidance. The adoption of this standard effective January 1, 2020 did not have a material impact on the Company&amp;#8217;s consolidated financial statements and was adopted prospectively.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On November 5, 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808), - which amends ASC 808 to clarify when transactions between participants in a collaborative arrangement under ASC 808 are within the scope of the FASB&amp;#8217;s new revenue standard, ASU 2014-09 (codified in ASC 606). The amendments require the application of ASC 606 existing guidance to determine the units of account that are distinct in a collaborative arrangement for purposes of identifying transactions with customers. If a unit of account within the collaborative arrangement is distinct and is with a customer, an entity shall apply the guidance in Topic 606 to that unit of account. In a transaction between collaborative participants, an entity is precluded by ASU 2018-18 from presenting a transaction together with &amp;#8220;revenue from contracts with customers&amp;#8221; unless the unit of account is within the scope of ASC 606 and the entity applies the guidance in ASC 606 to such unit of account. The amended guidance is effective for public business entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The retrospective adoption of this standard effective January 1, 2020 did not have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2020, the FASB issued&amp;#160;ASU&amp;#160;2020-10, Codification Improvements, which updates various codification topics by clarifying or improving disclosure requirements. ASU 2020-10 is effective for annual and interim periods beginning after December 15, 2020. The Company early adopted&amp;#160;ASU&amp;#160;2020-10&amp;#160;for the reporting period ending December 31, 2020. The adoption of this update did not have a material effect on the Company s consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="F_000277" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.64%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,403,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,405,295&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.64%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,762&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <ovid:ScheduleOfCashEquivalentsAndShortTermInvestmentsTableTextBlock id="F_000278" contextRef="C_0001636651_20200101_20201231">The following tables summarize the fair value of cash, cash equivalents, and short-term investments, as well as gross unrealized holding gains and losses as of December&amp;#160;31, 2020 and December&amp;#160;31, 2019:
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;holding gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;holding losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;Cash&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,977,320&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,977,320&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,056,610&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,056,610&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,033,930&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,033,930&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;U.S. treasury notes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;holding gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;holding losses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;Cash&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;501,537&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;501,537&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,395,607&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,395,607&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,897,144&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,897,144&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp;U.S. treasury notes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,839,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,841,969&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,839,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,469&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,841,969&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ovid:ScheduleOfCashEquivalentsAndShortTermInvestmentsTableTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="F_000279" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment is summarized as follows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;320,957&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;193,717&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(185,337&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(125,354&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property, plant and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;135,620&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,363&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="F_000280" contextRef="C_0001636651_20200101_20201231">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consist of the following:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical trials accrual&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,175,497&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,235,527&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payroll and bonus accrual&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,845,441&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,728,495&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional fees accrual&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,846,211&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,070,589&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;165,536&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232,095&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,032,685&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,266,706&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="F_000281" contextRef="C_0001636651_20200101_20201231">
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s stock-based compensation expense was recognized in operating expenses as follows:&lt;/p&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,779,758&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,391,909&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,745,596&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,813,883&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,525,354&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,205,792&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock id="F_000282" contextRef="C_0001636651_20200101_20201231">
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.48%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,372,381&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,096,473&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee Stock Purchase Plan&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;152,973&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;109,319&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,525,354&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,205,792&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="F_000283" contextRef="C_0001636651_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of employee options granted during the years ended December&amp;#160;31, 2020 and 2019, respectively, was estimated by utilizing the following assumptions:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81.48&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81.87&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term in years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.88&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.58&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.04&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value of option on grant date&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="F_000284" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_20200101_20201231">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of nonemployee options granted and remeasured during the years ended December&amp;#160;31, 2020 and 2019, respectively, was estimated by utilizing the following assumptions:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74.37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74.56&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term in years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.64&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.30&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.32&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value of option on grant date&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.18&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="F_000285" contextRef="C_0001636651_20200101_20201231">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the number of options outstanding and the weighted average exercise price:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life in Years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Outstanding at December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,714,383&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.10&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.89&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;153,485&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and exercisable at December 31, 2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,337,931&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.88&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.20&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;153,485&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,547,513&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.56&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(856,601&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.43&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Outstanding December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,405,295&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.82&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.01&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,488,930&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and exercisable at December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,296,547&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.53&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;356,443&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,583,160&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.68&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(165,384&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.82&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(415,526&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Outstanding December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,403,420&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.59&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;652,438&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and exercisable at December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,395,658&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.45&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;445,599&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="F_000286" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities were as follows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets/liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryovers&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74,064,673&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,288,334&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,458,004&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,351,315&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,978,370&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,606,889&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;514,316&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;898,067&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(29,760&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,026&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Charitable contributions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;87,120&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;132,072&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,742,031&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,208,519&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total gross deferred tax assets/liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89,814,754&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,463,170&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(89,814,754&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(76,463,170&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets (liabilities)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock id="F_000287" contextRef="C_0001636651_20200101_20201231">
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the statutory U.S. Federal rate to the Company&amp;#8217;s effective tax rate is as follows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.28%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal income tax benefit at statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income tax, net of federal benefit (&lt;font style="font-size:8pt;"&gt;1)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.15&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13.80&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent items&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.50&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.72&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37.14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.64&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.67&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.02&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax (benefit) expense rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1) Inclusive of $5.8 million deferred tax benefit due to change in apportionment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="F_000288" contextRef="C_0001636651_us-gaapTypeOfArrangementAxis_ovidLicenseAndCollaborationAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">12600000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
  <ovid:WorkingCapital id="F_000289" contextRef="C_0001636651_20201231" decimals="-5" unitRef="U_iso4217USD">52800000</ovid:WorkingCapital>
  <ovid:DescriptionOfOwnershipPatternAsPerLicenseAndCollaborationAgreement id="F_000290" contextRef="C_0001636651_20200101_20201231">Ovid and Takeda are sharing 50/50 in the drug development</ovid:DescriptionOfOwnershipPatternAsPerLicenseAndCollaborationAgreement>
  <ovid:PercentageOfNetExpensesOfDevelopmentCostsRecordedInResearchAndDevelopment id="F_000291" contextRef="C_0001636651_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.50</ovid:PercentageOfNetExpensesOfDevelopmentCostsRecordedInResearchAndDevelopment>
  <us-gaap:CashFDICInsuredAmount id="F_000292" contextRef="C_0001636651_srtRangeAxis_srtMaximumMember_20201231" decimals="INF" unitRef="U_iso4217USD">250000</us-gaap:CashFDICInsuredAmount>
  <ovid:AvailableForSaleSecuritiesInvestmentsMaturityPeriod id="F_000293" contextRef="C_0001636651_srtRangeAxis_srtMinimumMember_20200101_20201231">P3M</ovid:AvailableForSaleSecuritiesInvestmentsMaturityPeriod>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives id="F_000294" contextRef="C_0001636651_20200101_20201231">Property and equipment are stated at cost and depreciated over their estimated useful lives of three years using the straight-line method.</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000295" contextRef="C_0001636651_20200101_20201231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:AssetsFairValueDisclosure id="F_000296" contextRef="C_0001636651_us-gaapFairValueByAssetClassAxis_ovidMoneyMarketFundsAndShortTermInvestmentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-5" unitRef="U_iso4217USD">70100000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000297" contextRef="C_0001636651_us-gaapFairValueByAssetClassAxis_ovidMoneyMarketFundsAndShortTermInvestmentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231" decimals="-5" unitRef="U_iso4217USD">76200000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000298" contextRef="C_0001636651_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000299" contextRef="C_0001636651_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure id="F_000300" contextRef="C_0001636651_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure id="F_000301" contextRef="C_0001636651_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000302" contextRef="C_0001636651_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000303" contextRef="C_0001636651_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure id="F_000304" contextRef="C_0001636651_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:LiabilitiesFairValueDisclosure id="F_000305" contextRef="C_0001636651_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000306" contextRef="C_0001636651_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">10403420</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000307" contextRef="C_0001636651_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">7405295</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000308" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_ovidSeriesAConvertiblePreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">3250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000309" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_ovidSeriesAConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">7762</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <ovid:DefinedContributionPlanName id="F_000310" contextRef="C_0001636651_20200101_20201231">401(k)-retirement plan</ovid:DefinedContributionPlanName>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch id="F_000311" contextRef="C_0001636651_srtStatementScenarioAxis_ovidScenarioOneMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">1.00</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent id="F_000312" contextRef="C_0001636651_srtStatementScenarioAxis_ovidScenarioOneMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent id="F_000313" contextRef="C_0001636651_srtRangeAxis_srtMinimumMember_srtStatementScenarioAxis_ovidScenarioTwoMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent id="F_000314" contextRef="C_0001636651_srtRangeAxis_srtMaximumMember_srtStatementScenarioAxis_ovidScenarioTwoMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch id="F_000315" contextRef="C_0001636651_srtStatementScenarioAxis_ovidScenarioTwoMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount id="F_000316" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">321000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount id="F_000317" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">285000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:CashEquivalentsAtCarryingValue id="F_000318" contextRef="C_0001636651_us-gaapCashAndCashEquivalentsAxis_us-gaapCashMember_20201231" decimals="0" unitRef="U_iso4217USD">1977320</us-gaap:CashEquivalentsAtCarryingValue>
  <us-gaap:CashEquivalentsAtCarryingValue id="F_000319" contextRef="C_0001636651_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="0" unitRef="U_iso4217USD">70056610</us-gaap:CashEquivalentsAtCarryingValue>
  <us-gaap:CashEquivalentsAtCarryingValue id="F_000320" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">72033930</us-gaap:CashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000321" contextRef="C_0001636651_us-gaapCashAndCashEquivalentsAxis_us-gaapCashMember_20201231" decimals="0" unitRef="U_iso4217USD">1977320</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000322" contextRef="C_0001636651_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="0" unitRef="U_iso4217USD">70056610</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000323" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">72033930</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashEquivalentsAtCarryingValue id="F_000324" contextRef="C_0001636651_us-gaapCashAndCashEquivalentsAxis_us-gaapCashMember_20191231" decimals="0" unitRef="U_iso4217USD">501537</us-gaap:CashEquivalentsAtCarryingValue>
  <us-gaap:CashEquivalentsAtCarryingValue id="F_000325" contextRef="C_0001636651_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="0" unitRef="U_iso4217USD">41395607</us-gaap:CashEquivalentsAtCarryingValue>
  <us-gaap:CashEquivalentsAtCarryingValue id="F_000326" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">41897144</us-gaap:CashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000327" contextRef="C_0001636651_us-gaapCashAndCashEquivalentsAxis_us-gaapCashMember_20191231" decimals="0" unitRef="U_iso4217USD">501537</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000328" contextRef="C_0001636651_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20191231" decimals="0" unitRef="U_iso4217USD">41395607</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000329" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">41897144</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000330" contextRef="C_0001636651_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="0" unitRef="U_iso4217USD">34839500</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis id="F_000331" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">34839500</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000332" contextRef="C_0001636651_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="0" unitRef="U_iso4217USD">2469</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax id="F_000333" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">2469</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent id="F_000334" contextRef="C_0001636651_us-gaapFinancialInstrumentAxis_us-gaapUSTreasurySecuritiesMember_20191231" decimals="0" unitRef="U_iso4217USD">34841969</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions id="F_000335" contextRef="C_0001636651_20201231" decimals="INF" unitRef="U_ovidInvestment">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
  <ovid:DebtSecuritiesAvailableForSaleContinuousUnrealizedGainPosition12MonthsOrLongerNumberOfPositions id="F_000336" contextRef="C_0001636651_20201231" decimals="INF" unitRef="U_ovidInvestment">0</ovid:DebtSecuritiesAvailableForSaleContinuousUnrealizedGainPosition12MonthsOrLongerNumberOfPositions>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet id="F_000337" contextRef="C_0001636651_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet id="F_000338" contextRef="C_0001636651_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000339" contextRef="C_0001636651_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="0" unitRef="U_iso4217USD">320957</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000340" contextRef="C_0001636651_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231" decimals="0" unitRef="U_iso4217USD">193717</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000341" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">185337</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000342" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">125354</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:Depreciation id="F_000343" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">60000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="F_000344" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">39000</us-gaap:Depreciation>
  <us-gaap:FiniteLivedIntangibleAssetsNet id="F_000345" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">319000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsNet id="F_000346" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">467000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:AmortizationOfIntangibleAssets id="F_000347" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">247000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets id="F_000348" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">216000</us-gaap:AmortizationOfIntangibleAssets>
  <ovid:ClinicalTrialsAccrualCurrent id="F_000349" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">4175497</ovid:ClinicalTrialsAccrualCurrent>
  <ovid:ClinicalTrialsAccrualCurrent id="F_000350" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">3235527</ovid:ClinicalTrialsAccrualCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000351" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">3845441</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000352" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">2728495</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000353" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">3846211</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000354" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">1070589</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000355" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">165536</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000356" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">232095</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:CommonStockVotingRights id="F_000357" contextRef="C_0001636651_20200101_20201231">one vote for each share held</us-gaap:CommonStockVotingRights>
  <ovid:AggregateOfferingPriceOfCommonStock id="F_000358" contextRef="C_0001636651_deiLegalEntityAxis_ovidCowenAndCompanyLLCMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_ovidATMAgreementMember_20180630" decimals="INF" unitRef="U_iso4217USD">50000000</ovid:AggregateOfferingPriceOfCommonStock>
  <ovid:AggregateOfferingPriceOfCommonStock id="F_000359" contextRef="C_0001636651_deiLegalEntityAxis_ovidCowenAndCompanyLLCMember_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_ovidATMAgreementMember_20201130" decimals="INF" unitRef="U_iso4217USD">75000000</ovid:AggregateOfferingPriceOfCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000360" contextRef="C_0001636651_deiLegalEntityAxis_ovidCowenAndCompanyLLCMember_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ovidATMAgreementMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">6893888</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity id="F_000361" contextRef="C_0001636651_deiLegalEntityAxis_ovidCowenAndCompanyLLCMember_us-gaapStatementClassOfStockAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ovidATMAgreementMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">22300000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000362" contextRef="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_us-gaapStatementEquityComponentsAxis_ovidSeriesAConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">1000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <ovid:MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates id="F_000363" contextRef="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.0999</ovid:MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates>
  <ovid:MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders id="F_000364" contextRef="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.1499</ovid:MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders>
  <us-gaap:ConvertiblePreferredStockTermsOfConversion id="F_000365" contextRef="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20200101_20201231">percentage may be changed at the holder&#8217;s election to any other number less than or equal to 19.99% upon 61 days&#8217; notice to the Company; provided, however, that effective 61 days after delivery of such notice, such beneficial ownership limitations shall not be applicable to any holder that beneficially owns either 10.0% or 15.0%</us-gaap:ConvertiblePreferredStockTermsOfConversion>
  <us-gaap:PreferredStockLiquidationPreference id="F_000366" contextRef="C_0001636651_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20201231" decimals="3" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockLiquidationPreference>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000367" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_ovidSeriesAConvertiblePreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">2256</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000368" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">2256000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000369" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200801_20200831" decimals="INF" unitRef="U_xbrlishares">6250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare id="F_000370" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200831" decimals="INF" unitRef="U_iso4217USD_xbrlishares">8.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity id="F_000371" contextRef="C_0001636651_20200801_20200831" decimals="-5" unitRef="U_iso4217USD">46700000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000372" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_ovidSeriesAConvertiblePreferredStockMember_20200501_20200531" decimals="INF" unitRef="U_xbrlishares">2256</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000373" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200501_20200531" decimals="INF" unitRef="U_xbrlishares">2256000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000374" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20191031" decimals="INF" unitRef="U_xbrlishares">10350000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000375" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191101_20191130" decimals="INF" unitRef="U_xbrlishares">10350000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000376" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_ovidSeriesAConvertiblePreferredStockMember_20191001_20191031" decimals="INF" unitRef="U_xbrlishares">4000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000377" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_ovidSeriesAConvertiblePreferredStockMember_20191101_20191130" decimals="INF" unitRef="U_xbrlishares">4000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare id="F_000378" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191031" decimals="INF" unitRef="U_iso4217USD_xbrlishares">2.50</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare id="F_000379" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191130" decimals="INF" unitRef="U_iso4217USD_xbrlishares">2.50</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare id="F_000380" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_ovidSeriesAConvertiblePreferredStockMember_20191031" decimals="INF" unitRef="U_iso4217USD_xbrlishares">2500</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare id="F_000381" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_ovidSeriesAConvertiblePreferredStockMember_20191130" decimals="INF" unitRef="U_iso4217USD_xbrlishares">2500</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity id="F_000382" contextRef="C_0001636651_20191001_20191031" decimals="-5" unitRef="U_iso4217USD">33500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity id="F_000383" contextRef="C_0001636651_20191101_20191130" decimals="-5" unitRef="U_iso4217USD">33500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000384" contextRef="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtAffiliatedEntityMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190901_20190930" decimals="INF" unitRef="U_xbrlishares">1262000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000385" contextRef="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtAffiliatedEntityMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190901_20190930" decimals="INF" unitRef="U_xbrlishares">1262</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000386" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190201_20190228" decimals="INF" unitRef="U_xbrlishares">13993778</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000387" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_ovidSeriesAConvertiblePreferredStockMember_20190201_20190228" decimals="INF" unitRef="U_xbrlishares">2500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare id="F_000388" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190228" decimals="INF" unitRef="U_iso4217USD_xbrlishares">2.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare id="F_000389" contextRef="C_0001636651_us-gaapStatementEquityComponentsAxis_ovidSeriesAConvertiblePreferredStockMember_20190228" decimals="INF" unitRef="U_iso4217USD_xbrlishares">2000</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity id="F_000390" contextRef="C_0001636651_20190201_20190228" decimals="-5" unitRef="U_iso4217USD">30500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:DividendPaymentRestrictionsScheduleDescription id="F_000391" contextRef="C_0001636651_20200101_20201231">No dividends on the common stock shall be declared and paid unless dividends on the Preferred Stock have been declared and paid.</us-gaap:DividendPaymentRestrictionsScheduleDescription>
  <us-gaap:Dividends id="F_000392" contextRef="C_0001636651_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:Dividends>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000393" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEquityIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">3052059</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms id="F_000394" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEquityIncentivePlanMember_20200101_20201231">Pursuant to the terms of the 2017 Plan, on each January 1st, the plan limit shall be increased by the lesser of (x) 5% of the number of shares of common stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine in its discretion.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum id="F_000395" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEquityIncentivePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized id="F_000396" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEquityIncentivePlanMember_20200101_20200101" decimals="INF" unitRef="U_xbrlishares">2735516</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized id="F_000397" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEquityIncentivePlanMember_20190101_20190101" decimals="INF" unitRef="U_xbrlishares">1232705</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000398" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEquityIncentivePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">1771772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000399" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEquityIncentivePlanMember_20191231" decimals="INF" unitRef="U_xbrlishares">2199765</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000400" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEmployeeStockPurchasePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">279069</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:InitialOfferingPeriod id="F_000401" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEmployeeStockPurchasePlanMember_20200101_20201231">On September 20, 2017, the Company&#8217;s Compensation Committee approved an offering period under the 2017 ESPP, which began on October 20, 2017.</us-gaap:InitialOfferingPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate id="F_000402" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward id="F_000403" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">105464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward id="F_000404" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEmployeeStockPurchasePlanMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">80542</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000405" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">152973</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000406" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEmployeeStockPurchasePlanMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">109319</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms id="F_000407" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEmployeeStockPurchasePlanMember_20200101_20201231">The number of shares of common stock reserved for issuance under the 2017 ESPP will automatically increase on January 1 of each year, beginning on January 1, 2018 and continuing through and including January 1, 2027, by the lesser of (i) 1% of the total number of shares of the Company&#8217;s capital stock outstanding on December 31 of the preceding calendar year, (ii) 550,000 shares or (iii) such lesser number of shares determined by our Board.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum id="F_000408" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee id="F_000409" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">550000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized id="F_000410" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEmployeeStockPurchasePlanMember_20190101_20190101" decimals="INF" unitRef="U_xbrlishares">246541</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000411" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEmployeeStockPurchasePlanMember_20201231" decimals="INF" unitRef="U_xbrlishares">553552</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000412" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEmployeeStockPurchasePlanMember_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="F_000413" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandFourteenEquityIncentivePlanMember_20200101_20201231">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000414" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandFourteenEquityIncentivePlanMember_20200101_20201231">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000415" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandFourteenEquityIncentivePlanMember_20200101_20201231">P90D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="F_000416" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEquityIncentivePlanMember_20200101_20201231">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000417" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEquityIncentivePlanMember_20200101_20201231">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000418" contextRef="C_0001636651_us-gaapPlanNameAxis_ovidTwoThousandSeventeenEquityIncentivePlanMember_20200101_20201231">P90D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares id="F_000419" contextRef="C_0001636651_us-gaapAwardTypeAxis_us-gaapPerformanceSharesMember_20201231" decimals="INF" unitRef="U_xbrlishares">125000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000420" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000421" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares id="F_000422" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_20201231" decimals="INF" unitRef="U_xbrlishares">32500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares id="F_000423" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_20191231" decimals="INF" unitRef="U_xbrlishares">145204</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000424" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">257431</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000425" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">51666</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="F_000426" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_20191231" decimals="0" unitRef="U_iso4217USD">186823</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000427" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidNonemployeePerformanceBasedOptionAwardsMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">115240</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000428" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidNonemployeePerformanceBasedOptionAwardsMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000429" contextRef="C_0001636651_srtTitleOfIndividualAxis_ovidChairmanOfScientificAdvisoryBoardMember_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_us-gaapTypeOfArrangementAxis_ovidSeparationAndConsultingAgreementMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">17000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000430" contextRef="C_0001636651_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">3573160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000431" contextRef="C_0001636651_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">3372513</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares id="F_000432" contextRef="C_0001636651_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="INF" unitRef="U_xbrlishares">4975262</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares id="F_000433" contextRef="C_0001636651_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231" decimals="INF" unitRef="U_xbrlishares">3963544</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000434" contextRef="C_0001636651_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">7100000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000435" contextRef="C_0001636651_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">5000000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="F_000436" contextRef="C_0001636651_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="-5" unitRef="U_iso4217USD">12200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000437" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidEmployeePerformanceBasedOptionAwardsMember_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">2340808</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000438" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidEmployeePerformanceBasedOptionAwardsMember_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">9391</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000439" contextRef="C_0001636651_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">2779758</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000440" contextRef="C_0001636651_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">2391909</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000441" contextRef="C_0001636651_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">4745596</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000442" contextRef="C_0001636651_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">2813883</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000443" contextRef="C_0001636651_20200101_20201231" decimals="0" unitRef="U_iso4217USD">7525354</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000444" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD">5205792</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000445" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidStockOptionsMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">7372381</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000446" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidStockOptionsMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">5096473</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000447" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidEmployeeStockPurchasePlanMember_20200101_20201231" decimals="0" unitRef="U_iso4217USD">152973</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000448" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidEmployeeStockPurchasePlanMember_20190101_20191231" decimals="0" unitRef="U_iso4217USD">109319</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000449" contextRef="C_0001636651_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="4" unitRef="U_xbrlipure">0.8148</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000450" contextRef="C_0001636651_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.8187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000451" contextRef="C_0001636651_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">P5Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000452" contextRef="C_0001636651_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000453" contextRef="C_0001636651_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="4" unitRef="U_xbrlipure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000454" contextRef="C_0001636651_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000455" contextRef="C_0001636651_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="4" unitRef="U_xbrlipure">0.0058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000456" contextRef="C_0001636651_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.0204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000457" contextRef="C_0001636651_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">2.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000458" contextRef="C_0001636651_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">2.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000459" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_20200101_20201231" decimals="4" unitRef="U_xbrlipure">0.7437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000460" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.7456</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000461" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_20200101_20201231">P5Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000462" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_20190101_20191231">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000463" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_20200101_20201231" decimals="4" unitRef="U_xbrlipure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000464" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000465" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_20200101_20201231" decimals="4" unitRef="U_xbrlipure">0.0232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000466" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.0237</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000467" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000468" contextRef="C_0001636651_us-gaapAwardTypeAxis_ovidNonEmployeeStockOptionsMember_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000469" contextRef="C_0001636651_20181231" decimals="INF" unitRef="U_xbrlishares">4714383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="F_000470" contextRef="C_0001636651_20181231" decimals="INF" unitRef="U_xbrlishares">2337931</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000471" contextRef="C_0001636651_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">3547513</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000472" contextRef="C_0001636651_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000473" contextRef="C_0001636651_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">856601</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000474" contextRef="C_0001636651_20191231" decimals="INF" unitRef="U_xbrlishares">7405295</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="F_000475" contextRef="C_0001636651_20191231" decimals="INF" unitRef="U_xbrlishares">3296547</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000476" contextRef="C_0001636651_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">3583160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000477" contextRef="C_0001636651_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">165384</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000478" contextRef="C_0001636651_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">415526</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000479" contextRef="C_0001636651_20201231" decimals="INF" unitRef="U_xbrlishares">10403420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber id="F_000480" contextRef="C_0001636651_20201231" decimals="INF" unitRef="U_xbrlishares">5395658</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000481" contextRef="C_0001636651_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">8.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice id="F_000482" contextRef="C_0001636651_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">7.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000483" contextRef="C_0001636651_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">2.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000484" contextRef="C_0001636651_20190101_20191231" decimals="0" unitRef="U_iso4217USD_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000485" contextRef="C_0001636651_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">6.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000486" contextRef="C_0001636651_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">5.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice id="F_000487" contextRef="C_0001636651_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">7.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000488" contextRef="C_0001636651_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">3.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000489" contextRef="C_0001636651_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000490" contextRef="C_0001636651_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">5.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000491" contextRef="C_0001636651_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">5.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice id="F_000492" contextRef="C_0001636651_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">6.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000493" contextRef="C_0001636651_20180101_20181231">P7Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 id="F_000494" contextRef="C_0001636651_20180101_20181231">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
  <ovid:ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife id="F_000495" contextRef="C_0001636651_20190101_20191231">P9Y6M21D</ovid:ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000496" contextRef="C_0001636651_20190101_20191231">P8Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 id="F_000497" contextRef="C_0001636651_20190101_20191231">P6Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
  <ovid:ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife id="F_000498" contextRef="C_0001636651_20200101_20201231">P9Y8M4D</ovid:ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000499" contextRef="C_0001636651_20200101_20201231">P7Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 id="F_000500" contextRef="C_0001636651_20200101_20201231">P6Y1M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000501" contextRef="C_0001636651_20181231" decimals="0" unitRef="U_iso4217USD">153485</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue id="F_000502" contextRef="C_0001636651_20181231" decimals="0" unitRef="U_iso4217USD">153485</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000503" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">4488930</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue id="F_000504" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">356443</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000505" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">652438</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue id="F_000506" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">445599</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="F_000507" contextRef="C_0001636651_20201231" decimals="-5" unitRef="U_iso4217USD">12300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000508" contextRef="C_0001636651_20200101_20201231">P3Y14D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:OperatingLossCarryforwards id="F_000509" contextRef="C_0001636651_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" unitRef="U_iso4217USD">238600000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="F_000510" contextRef="C_0001636651_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-5" unitRef="U_iso4217USD">186700000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="F_000511" contextRef="C_0001636651_us-gaapIncomeTaxAuthorityNameAxis_us-gaapNewYorkStateDivisionOfTaxationAndFinanceMember_20201231" decimals="-5" unitRef="U_iso4217USD">165400000</us-gaap:OperatingLossCarryforwards>
  <ovid:OperatingLossCarryforwardsExpirationPeriodStart id="F_000512" contextRef="C_0001636651_20200101_20201231">2035</ovid:OperatingLossCarryforwardsExpirationPeriodStart>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000513" contextRef="C_0001636651_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000514" contextRef="C_0001636651_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">13300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000515" contextRef="C_0001636651_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">22500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued id="F_000516" contextRef="C_0001636651_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued id="F_000517" contextRef="C_0001636651_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:LiabilityForUncertainTaxPositionsCurrent id="F_000518" contextRef="C_0001636651_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
  <us-gaap:LiabilityForUncertainTaxPositionsCurrent id="F_000519" contextRef="C_0001636651_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000520" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">74064673</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000521" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">57288334</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000522" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">5458004</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000523" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">3351315</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_000524" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">4978370</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_000525" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">6606889</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation id="F_000526" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">514316</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation id="F_000527" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">898067</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment id="F_000528" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">29760</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment id="F_000529" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">22026</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards id="F_000530" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">87120</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
  <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards id="F_000531" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">132072</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets id="F_000532" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">4742031</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets id="F_000533" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">8208519</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <us-gaap:DeferredTaxAssetsGross id="F_000534" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">89814754</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross id="F_000535" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">76463170</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000536" contextRef="C_0001636651_20201231" decimals="0" unitRef="U_iso4217USD">89814754</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000537" contextRef="C_0001636651_20191231" decimals="0" unitRef="U_iso4217USD">76463170</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000538" contextRef="C_0001636651_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000539" contextRef="C_0001636651_20190101_20191231" decimals="INF" unitRef="U_xbrlipure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_000540" contextRef="C_0001636651_20200101_20201231" decimals="4" unitRef="U_xbrlipure">0.0615</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes id="F_000541" contextRef="C_0001636651_20190101_20191231" decimals="4" unitRef="U_xbrlipure">-0.1380</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense id="F_000542" contextRef="C_0001636651_20200101_20201231" decimals="4" unitRef="U_xbrlipure">0.0075</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense id="F_000543" contextRef="C_0001636651_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.0050</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000544" contextRef="C_0001636651_20200101_20201231" decimals="4" unitRef="U_xbrlipure">0.1672</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000545" contextRef="C_0001636651_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.3714</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="F_000546" contextRef="C_0001636651_20200101_20201231" decimals="4" unitRef="U_xbrlipure">0.0264</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch id="F_000547" contextRef="C_0001636651_20190101_20191231" decimals="4" unitRef="U_xbrlipure">0.0267</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments id="F_000548" contextRef="C_0001636651_20200101_20201231" decimals="4" unitRef="U_xbrlipure">0.0002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments id="F_000549" contextRef="C_0001636651_20190101_20191231" decimals="4" unitRef="U_xbrlipure">-0.0017</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_000550" contextRef="C_0001636651_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_000551" contextRef="C_0001636651_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:DeferredIncomeTaxExpenseBenefit id="F_000552" contextRef="C_0001636651_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">5800000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <ovid:LicenseAgreementEnteredDate id="F_000553" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidHLundbeckASMember_us-gaapTypeOfArrangementAxis_ovidLicenseAgreementMember_20150325_20150326">2015-03-26</ovid:LicenseAgreementEnteredDate>
  <ovid:LicenseAgreementMilestonePayments id="F_000554" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidHLundbeckASMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ovidLicenseAgreementMember_20150326" decimals="INF" unitRef="U_iso4217USD">189000000</ovid:LicenseAgreementMilestonePayments>
  <ovid:FirstPaymentDueUponCompletionOfFirstPhase id="F_000555" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidHLundbeckASMember_us-gaapTypeOfArrangementAxis_ovidLicenseAgreementMember_20150325_20150326" decimals="-5" unitRef="U_iso4217USD">1000000</ovid:FirstPaymentDueUponCompletionOfFirstPhase>
  <ovid:NumberOfTrial id="F_000556" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidHLundbeckASMember_us-gaapTypeOfArrangementAxis_ovidLicenseAgreementMember_20150325_20150326" decimals="INF" unitRef="U_ovidTrial">3</ovid:NumberOfTrial>
  <ovid:LicenseAgreementEnteredMonthAndYear id="F_000557" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidNorthwesternUniversityMember_us-gaapTypeOfArrangementAxis_ovidLicenseAgreementMember_20161201_20161231">2016-12</ovid:LicenseAgreementEnteredMonthAndYear>
  <ovid:UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment id="F_000558" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidNorthwesternUniversityMember_us-gaapTypeOfArrangementAxis_ovidLicenseAgreementMember_20161201_20161231" decimals="0" unitRef="U_iso4217USD">75000</ovid:UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment>
  <ovid:AnnualLicenseMaintenanceFeePayable id="F_000559" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidNorthwesternUniversityMember_us-gaapTypeOfArrangementAxis_ovidLicenseAgreementMember_20161231" decimals="0" unitRef="U_iso4217USD">20000</ovid:AnnualLicenseMaintenanceFeePayable>
  <ovid:ConsiderationPayableForRightsGrant id="F_000560" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidNorthwesternUniversityMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ovidLicenseAgreementMember_20161231" decimals="INF" unitRef="U_iso4217USD">5300000</ovid:ConsiderationPayableForRightsGrant>
  <us-gaap:CollaborativeArrangementRightsAndObligations id="F_000561" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidNorthwesternUniversityMember_us-gaapTypeOfArrangementAxis_ovidLicenseAgreementMember_20200101_20201231">In consideration for the rights granted to the Company under the Northwestern agreement, the Company is required to pay to Northwestern up to an aggregate of $5.3 million upon the achievement of certain development and regulatory milestones for the first product covered by the Northwestern Patents, and, upon commercialization of any such products, will be required to pay to Northwestern a tiered royalty on net sales of such products by the Company, its affiliates or sublicensees, at percentages in the low to mid single-digits, subject to standard reductions and offsets.  The Company&#8217;s royalty obligations continue on a product-by-product and country-by-country basis until the later of the expiration of the last-to-expire valid claim in a licensed patent covering the applicable product in such country and 10 years following the first commercial sale of such product in such country.  If the Company sublicenses a Northwestern Patent Right, it will be obligated to pay to Northwestern a specified percentage of sublicense revenue received by the Company, ranging from the high single digits to the low-teens.</us-gaap:CollaborativeArrangementRightsAndObligations>
  <ovid:MinimumNumberOfProductCoveredUnderLicenseAgreement id="F_000562" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidNorthwesternUniversityMember_us-gaapTypeOfArrangementAxis_ovidLicenseAgreementMember_20161201_20161231" decimals="INF" unitRef="U_ovidProduct">1</ovid:MinimumNumberOfProductCoveredUnderLicenseAgreement>
  <ovid:LicenseAgreementEnteredDate id="F_000563" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidAngeliniLicenseAgreementMember_us-gaapTypeOfArrangementAxis_ovidLicenseAgreementMember_20200709_20200709">2020-07-09</ovid:LicenseAgreementEnteredDate>
  <ovid:LicenseAgreementUpfrontPayment id="F_000564" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidAngeliniLicenseAgreementMember_us-gaapTypeOfArrangementAxis_ovidLicenseAgreementMember_20201231" decimals="-5" unitRef="U_iso4217USD">25000000</ovid:LicenseAgreementUpfrontPayment>
  <ovid:AggregateLicenseAgreementMilestonePayments id="F_000565" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidAngeliniLicenseAgreementMember_us-gaapTypeOfArrangementAxis_ovidLicenseAgreementMember_20201231" decimals="-5" unitRef="U_iso4217USD">55000000</ovid:AggregateLicenseAgreementMilestonePayments>
  <ovid:SalesMilestonePaymentsThroughLicenseAgreement id="F_000566" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidAngeliniLicenseAgreementMember_us-gaapTypeOfArrangementAxis_ovidLicenseAgreementMember_20201231" decimals="-5" unitRef="U_iso4217EUR">162500000</ovid:SalesMilestonePaymentsThroughLicenseAgreement>
  <ovid:SalesMilestonePaymentsThroughLicenseAgreement id="F_000567" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidAngeliniLicenseAgreementMember_us-gaapTypeOfArrangementAxis_ovidLicenseAgreementMember_20201231" decimals="-5" unitRef="U_iso4217USD">199900000</ovid:SalesMilestonePaymentsThroughLicenseAgreement>
  <ovid:PotentialFundingCostPercent id="F_000568" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidAngeliniLicenseAgreementMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.35</ovid:PotentialFundingCostPercent>
  <ovid:CostOfAgreementNet id="F_000569" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidAngeliniLicenseAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">7000000</ovid:CostOfAgreementNet>
  <ovid:DeferredUpfrontPaymentCosts id="F_000570" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidAngeliniLicenseAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">7000000</ovid:DeferredUpfrontPaymentCosts>
  <ovid:UpFrontFeeAmount id="F_000571" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidAngeliniLicenseAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">20000000</ovid:UpFrontFeeAmount>
  <ovid:AmountForPotentialFutureTrials id="F_000572" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidAngeliniLicenseAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">7000000</ovid:AmountForPotentialFutureTrials>
  <ovid:AggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement id="F_000573" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidAngeliniLicenseAgreementMember_20201231" decimals="-5" unitRef="U_iso4217USD">5000000</ovid:AggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement>
  <ovid:AdditionalTechTransferThroughLicenseAgreement id="F_000574" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidAngeliniLicenseAgreementMember_20201231" decimals="-5" unitRef="U_iso4217USD">5000000</ovid:AdditionalTechTransferThroughLicenseAgreement>
  <ovid:AdditionalAggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement id="F_000575" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidAngeliniLicenseAgreementMember_20201231" decimals="-5" unitRef="U_iso4217USD">55000000</ovid:AdditionalAggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement>
  <ovid:LicenseRevenue id="F_000576" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidAngeliniLicenseAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">6100000</ovid:LicenseRevenue>
  <ovid:LicenseRevenue id="F_000577" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidAngeliniLicenseAgreementMember_20190101_20191231" decimals="-6" unitRef="U_iso4217USD">0</ovid:LicenseRevenue>
  <ovid:IncomeFromOngoingTrials id="F_000578" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidAngeliniLicenseAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">1500000</ovid:IncomeFromOngoingTrials>
  <ovid:IncomeFromTransferOfSpecifiedAmountOfCompoundAndRelatedInformation id="F_000579" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidAngeliniLicenseAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">5000000</ovid:IncomeFromTransferOfSpecifiedAmountOfCompoundAndRelatedInformation>
  <us-gaap:DeferredRevenue id="F_000580" contextRef="C_0001636651_srtCounterpartyNameAxis_ovidAngeliniLicenseAgreementMember_20201231" decimals="-5" unitRef="U_iso4217USD">12400000</us-gaap:DeferredRevenue>
  <us-gaap:PreferredStockSharesIssued id="F_000581" contextRef="C_0001636651_deiLegalEntityAxis_ovidTakedaPharmaceuticalCompanyLimitedMember_us-gaapStatementClassOfStockAxis_ovidSeriesB1PreferredStockMember_20170106" decimals="INF" unitRef="U_xbrlishares">1781996</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000582" contextRef="C_0001636651_deiLegalEntityAxis_ovidTakedaPharmaceuticalCompanyLimitedMember_us-gaapStatementClassOfStockAxis_ovidSeriesB1PreferredStockMember_20170106" decimals="INF" unitRef="U_iso4217USD_xbrlishares">14.513</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000583" contextRef="C_0001636651_deiLegalEntityAxis_ovidTakedaPharmaceuticalCompanyLimitedMember_us-gaapStatementClassOfStockAxis_ovidSeriesB1PreferredStockMember_20170105_20170106" decimals="-5" unitRef="U_iso4217USD">25900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <ovid:PercentageOfOutstandingSharesOfCapitalStock id="F_000584" contextRef="C_0001636651_deiLegalEntityAxis_ovidTakedaPharmaceuticalCompanyLimitedMember_20170106" decimals="INF" unitRef="U_xbrlipure">0.08</ovid:PercentageOfOutstandingSharesOfCapitalStock>
  <ovid:ValueForObligationUnderLicenseAgreement id="F_000585" contextRef="C_0001636651_deiLegalEntityAxis_ovidTakedaPharmaceuticalCompanyLimitedMember_20170106" decimals="-5" unitRef="U_iso4217USD">50000000</ovid:ValueForObligationUnderLicenseAgreement>
  <ovid:ThresholdPercentageOfOutstandingCapitalStockToMakeCashPayment id="F_000586" contextRef="C_0001636651_deiLegalEntityAxis_ovidTakedaPharmaceuticalCompanyLimitedMember_20170106" decimals="INF" unitRef="U_xbrlipure">0.1999</ovid:ThresholdPercentageOfOutstandingCapitalStockToMakeCashPayment>
  <ovid:LicenseAgreementMilestonePayments id="F_000587" contextRef="C_0001636651_deiLegalEntityAxis_ovidTakedaPharmaceuticalCompanyLimitedMember_20170106" decimals="-5" unitRef="U_iso4217USD">35000000</ovid:LicenseAgreementMilestonePayments>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000588" contextRef="C_0001636651_deiLegalEntityAxis_ovidTakedaPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">700000</us-gaap:ResearchAndDevelopmentExpense>
  <ovid:ResearchAndDevelopmentExpenseReimbursementReceived id="F_000589" contextRef="C_0001636651_deiLegalEntityAxis_ovidTakedaPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">4700000</ovid:ResearchAndDevelopmentExpenseReimbursementReceived>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000590" contextRef="C_0001636651_deiLegalEntityAxis_ovidTakedaPharmaceuticalCompanyLimitedMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">1781996</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent id="F_000591" contextRef="C_0001636651_deiLegalEntityAxis_ovidTakedaPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231" decimals="-5" unitRef="U_iso4217USD">2100000</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:AccountsReceivableRelatedParties id="F_000592" contextRef="C_0001636651_deiLegalEntityAxis_ovidTakedaPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:AccountsReceivableRelatedParties>
  <us-gaap:AccountsReceivableRelatedParties id="F_000593" contextRef="C_0001636651_deiLegalEntityAxis_ovidTakedaPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231" decimals="-5" unitRef="U_iso4217USD">1100000</us-gaap:AccountsReceivableRelatedParties>
  <ovid:ConsultingArrangementPeriod id="F_000594" contextRef="C_0001636651_srtTitleOfIndividualAxis_ovidChairmanOfScientificAdvisoryBoardMember_us-gaapTypeOfArrangementAxis_ovidSeparationAndConsultingAgreementMember_20190401_20190401">P3Y</ovid:ConsultingArrangementPeriod>
  <us-gaap:ProfessionalFees id="F_000595" contextRef="C_0001636651_srtTitleOfIndividualAxis_ovidChairmanOfScientificAdvisoryBoardMember_us-gaapTypeOfArrangementAxis_ovidSeparationAndConsultingAgreementMember_20190401_20190401" decimals="0" unitRef="U_iso4217USD">150000</us-gaap:ProfessionalFees>
  <ovid:OtherAdvisoryAndConsultingServicesFee id="F_000596" contextRef="C_0001636651_srtTitleOfIndividualAxis_ovidChairmanOfScientificAdvisoryBoardMember_us-gaapTypeOfArrangementAxis_ovidSeparationAndConsultingAgreementMember_20190401_20190401" decimals="0" unitRef="U_iso4217USD">150000</ovid:OtherAdvisoryAndConsultingServicesFee>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000597" contextRef="C_0001636651_srtTitleOfIndividualAxis_ovidChairmanOfScientificAdvisoryBoardMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTypeOfArrangementAxis_ovidSeparationAndConsultingAgreementMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20190401_20190401" decimals="INF" unitRef="U_xbrlishares">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000598" contextRef="C_0001636651_srtTitleOfIndividualAxis_ovidChairmanOfScientificAdvisoryBoardMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTypeOfArrangementAxis_ovidSeparationAndConsultingAgreementMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20190401_20190401" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000599" contextRef="C_0001636651_srtTitleOfIndividualAxis_ovidChairmanOfScientificAdvisoryBoardMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTypeOfArrangementAxis_ovidSeparationAndConsultingAgreementMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20190401_20190401" decimals="INF" unitRef="U_xbrlishares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000600" contextRef="C_0001636651_srtTitleOfIndividualAxis_ovidChairmanOfScientificAdvisoryBoardMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTypeOfArrangementAxis_ovidSeparationAndConsultingAgreementMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20190401_20190401" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement id="F_000601" contextRef="C_0001636651_20200101_20201231">any time and for any reason, upon thirty (30) days written notice to the other party.</us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement>
  <us-gaap:CommonStockSharesIssued id="F_000602" contextRef="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ovidAffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember_20190228" decimals="INF" unitRef="U_xbrlishares">6325000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000603" contextRef="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ovidAffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20190228" decimals="INF" unitRef="U_xbrlishares">2500</us-gaap:CommonStockSharesIssued>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000604" contextRef="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ovidAffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember_us-gaapTypeOfArrangementAxis_ovidChiefExecutiveOfficerAndChairmanMember_20190201_20190228" decimals="-5" unitRef="U_iso4217USD">17700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:CommonStockSharesIssued id="F_000605" contextRef="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ovidAffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember_20191031" decimals="INF" unitRef="U_xbrlishares">4058000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000606" contextRef="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ovidAffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember_20191130" decimals="INF" unitRef="U_xbrlishares">4058000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000607" contextRef="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ovidAffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191031" decimals="INF" unitRef="U_xbrlishares">2000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000608" contextRef="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ovidAffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20191130" decimals="INF" unitRef="U_xbrlishares">2000</us-gaap:CommonStockSharesIssued>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000609" contextRef="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ovidAffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember_us-gaapTypeOfArrangementAxis_ovidChiefExecutiveOfficerAndChairmanMember_20191001_20191031" decimals="-5" unitRef="U_iso4217USD">10200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000610" contextRef="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtAffiliatedEntityMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200501_20200531" decimals="INF" unitRef="U_xbrlishares">2256000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000611" contextRef="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtAffiliatedEntityMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20200501_20200531" decimals="INF" unitRef="U_xbrlishares">2256</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:CommonStockSharesIssued id="F_000612" contextRef="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtAffiliatedEntityMember_20200831" decimals="INF" unitRef="U_xbrlishares">1250000</us-gaap:CommonStockSharesIssued>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000613" contextRef="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtAffiliatedEntityMember_20200801_20200831" decimals="-5" unitRef="U_iso4217USD">10000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000614" contextRef="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtAffiliatedEntityMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">2256000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000615" contextRef="C_0001636651_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_srtAffiliatedEntityMember_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">2256</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000616" contextRef="C_0001636651_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210315" decimals="INF" unitRef="U_xbrlishares">643600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000617" contextRef="C_0001636651_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101_20210315" decimals="2" unitRef="U_iso4217USD_xbrlishares">3.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <ovid:UpfrontPaymentReceivable id="F_000618" contextRef="C_0001636651_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_ovidRoyaltyAndTerminationAgreementMember_20210331" decimals="-5" unitRef="U_iso4217USD">196000000</ovid:UpfrontPaymentReceivable>
  <ovid:AgreementMilestonePayments id="F_000619" contextRef="C_0001636651_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_ovidRoyaltyAndTerminationAgreementMember_20210331" decimals="-5" unitRef="U_iso4217USD">660000000</ovid:AgreementMilestonePayments>
  <ovid:AdditionalPaymentReceivableOnSalesPercentage id="F_000620" contextRef="C_0001636651_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_ovidRoyaltyAndTerminationAgreementMember_20210301_20210331" decimals="2" unitRef="U_xbrlipure">0.20</ovid:AdditionalPaymentReceivableOnSalesPercentage>
  <ovid:AgreementClosingDate id="F_000621" contextRef="C_0001636651_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_ovidRoyaltyAndTerminationAgreementMember_20210301_20210331">March 2021</ovid:AgreementClosingDate>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage id="F_000622" contextRef="C_0001636651_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_ovidRoyaltyAndTerminationAgreementMember_20210331" decimals="2" unitRef="U_xbrlipure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="#F_000540" xlink:label="F_000540_lbl" />
    <link:footnote xlink:type="resource" xlink:label="FNT_000000" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Inclusive of $5.8 million deferred tax benefit due to change in apportionment</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000540_lbl" xlink:to="FNT_000000" />
    <link:loc xlink:type="locator" xlink:href="#F_000541" xlink:label="F_000541_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="F_000541_lbl" xlink:to="FNT_000000" />
  </link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>21
<FILENAME>ovid-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-15T02:26:45.6345776+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 8ac83ee457de40fa87b3ceabc3444e96 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:ovid="http://www.ovidrx.com/20201231" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ovidrx.com/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.ovidrx.com/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ovid-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ovid-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ovid-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ovid-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementOfChangesInStockholdersEquity" id="Role_StatementConsolidatedStatementOfChangesInStockholdersEquity">
        <link:definition>100050 - Statement - Consolidated Statement of Changes in Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureNatureOfOperations" id="Role_DisclosureNatureOfOperations">
        <link:definition>100070 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestments" id="Role_DisclosureCashEquivalentsAndShortTermInvestments">
        <link:definition>100090 - Disclosure - Cash Equivalents and Short-Term Investments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAndIntangibleAssets" id="Role_DisclosurePropertyAndEquipmentAndIntangibleAssets">
        <link:definition>100100 - Disclosure - Property and Equipment and Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>100110 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockholdersEquityAndPreferredStock" id="Role_DisclosureStockholdersEquityAndPreferredStock">
        <link:definition>100120 - Disclosure - Stockholders&apos; Equity and Preferred Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100130 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100140 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100150 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCollaborationAgreement" id="Role_DisclosureCollaborationAgreement">
        <link:definition>100160 - Disclosure - Collaboration Agreement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100170 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100180 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100190 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100200 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsTables" id="Role_DisclosureCashEquivalentsAndShortTermInvestmentsTables">
        <link:definition>100210 - Disclosure - Cash Equivalents and Short-Term Investments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAndIntangibleAssetsTables" id="Role_DisclosurePropertyAndEquipmentAndIntangibleAssetsTables">
        <link:definition>100220 - Disclosure - Property and Equipment and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>100230 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100240 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100250 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetail" id="Role_DisclosureNatureOfOperationsAdditionalInformationDetail">
        <link:definition>100260 - Disclosure - Nature of Operations - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100270 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSchedulePotentiallyDilutiveSecuritiesExcludedFromComputationsOfDilutedWeightedAverageSharesOutstandingDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesSchedulePotentiallyDilutiveSecuritiesExcludedFromComputationsOfDilutedWeightedAverageSharesOutstandingDetail">
        <link:definition>100280 - Disclosure - Summary of Significant Accounting Policies - Schedule Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsSummaryOfFairValueOfCashEquivalentsShortTermInvestmentsAndGrossUnrealizedHoldingGainsAndLossesDetail" id="Role_DisclosureCashEquivalentsAndShortTermInvestmentsSummaryOfFairValueOfCashEquivalentsShortTermInvestmentsAndGrossUnrealizedHoldingGainsAndLossesDetail">
        <link:definition>100290 - Disclosure - Cash Equivalents and Short-Term Investments - Summary of Fair Value of Cash Equivalents, Short-Term Investments and Gross Unrealized Holding Gains and Losses (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsAdditionalInformationDetail" id="Role_DisclosureCashEquivalentsAndShortTermInvestmentsAdditionalInformationDetail">
        <link:definition>100300 - Disclosure - Cash Equivalents and Short-Term Investments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAndIntangibleAssetsSummaryOfPropertyAndEquipmentDetail" id="Role_DisclosurePropertyAndEquipmentAndIntangibleAssetsSummaryOfPropertyAndEquipmentDetail">
        <link:definition>100310 - Disclosure - Property and Equipment and Intangible Assets - Summary of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAndIntangibleAssetsAdditionalInformationDetail" id="Role_DisclosurePropertyAndEquipmentAndIntangibleAssetsAdditionalInformationDetail">
        <link:definition>100320 - Disclosure - Property and Equipment and Intangible Assets - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" id="Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail">
        <link:definition>100330 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockholdersEquityAndPreferredStockAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityAndPreferredStockAdditionalInformationDetail">
        <link:definition>100340 - Disclosure - Stockholders&apos; Equity and Preferred Stock - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
        <link:definition>100350 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseDetail" id="Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseDetail">
        <link:definition>100360 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAllocationOfStockBasedCompensationExpenseByPlanDetail" id="Role_DisclosureStockBasedCompensationScheduleOfAllocationOfStockBasedCompensationExpenseByPlanDetail">
        <link:definition>100370 - Disclosure - Stock-Based Compensation - Schedule of Allocation of Stock-Based Compensation Expense by Plan (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToComputeFairValueOfEmployeeOptionGrantedDetail" id="Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToComputeFairValueOfEmployeeOptionGrantedDetail">
        <link:definition>100380 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used to Compute Fair Value of Employee Option Granted (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionsOutstandingAndWeightedAverageExercisePriceDetail" id="Role_DisclosureStockBasedCompensationSummaryOfOptionsOutstandingAndWeightedAverageExercisePriceDetail">
        <link:definition>100390 - Disclosure - Stock-Based Compensation - Summary of Options Outstanding and Weighted Average Exercise Price (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100400 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail">
        <link:definition>100410 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryUSFederalRateToEffectiveTaxRateDetail" id="Role_DisclosureIncomeTaxesReconciliationOfStatutoryUSFederalRateToEffectiveTaxRateDetail">
        <link:definition>100420 - Disclosure - Income Taxes - Reconciliation of Statutory U.S. Federal Rate to Effective Tax Rate (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryUSFederalRateToEffectiveTaxRateParentheticalDetail" id="Role_DisclosureIncomeTaxesReconciliationOfStatutoryUSFederalRateToEffectiveTaxRateParentheticalDetail">
        <link:definition>100430 - Disclosure - Income Taxes - Reconciliation of Statutory U.S. Federal Rate to Effective Tax Rate (Parenthetical) (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetail">
        <link:definition>100440 - Disclosure - Commitment and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetail" id="Role_DisclosureCollaborationAgreementAdditionalInformationDetail">
        <link:definition>100450 - Disclosure - Collaboration Agreement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail">
        <link:definition>100460 - Disclosure - Related Party Transactions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" id="Role_DisclosureSubsequentEventsAdditionalInformationDetail">
        <link:definition>100470 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="ovid_PreferredStockShareDesignated" name="PreferredStockShareDesignated" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ovid_ATMOfferingCosts" name="ATMOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ovid_ATMOfferingsMember" name="ATMOfferingsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_FebruaryOfferingMember" name="FebruaryOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_AugustTwoThousandTwentyOfferingMember" name="AugustTwoThousandTwentyOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_OctoberOfferingMember" name="OctoberOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_AccruedInterestAndAccretionOfDiscountsShortTermInvestments" name="AccruedInterestAndAccretionOfDiscountsShortTermInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent" name="IncreaseDecreaseInPrepaidExpenseNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ovid_SoftwareDevelopmentAndOtherCostsInAccountsPayableAndAccruedExpenses" name="SoftwareDevelopmentAndOtherCostsInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ovid_FebruaryAndOctoberTwoThousandNinteenOfferingsMember" name="FebruaryAndOctoberTwoThousandNinteenOfferingsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_ATMMember" name="ATMMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_ScheduleOfCashEquivalentsAndShortTermInvestmentsTableTextBlock" name="ScheduleOfCashEquivalentsAndShortTermInvestmentsTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ovid_NonEmployeeStockOptionsMember" name="NonEmployeeStockOptionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_WorkingCapital" name="WorkingCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_LicenseAndCollaborationAgreementMember" name="LicenseAndCollaborationAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_DescriptionOfOwnershipPatternAsPerLicenseAndCollaborationAgreement" name="DescriptionOfOwnershipPatternAsPerLicenseAndCollaborationAgreement" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ovid_PercentageOfNetExpensesOfDevelopmentCostsRecordedInResearchAndDevelopment" name="PercentageOfNetExpensesOfDevelopmentCostsRecordedInResearchAndDevelopment" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ovid_SummaryOfSignificantAccountingPolicyLineItems" name="SummaryOfSignificantAccountingPolicyLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_SummaryOfSignificantAccountingPolicyTable" name="SummaryOfSignificantAccountingPolicyTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_MoneyMarketFundsAndShortTermInvestmentsMember" name="MoneyMarketFundsAndShortTermInvestmentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_ScenarioOneMember" name="ScenarioOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_ScenarioTwoMember" name="ScenarioTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_AvailableForSaleSecuritiesInvestmentsMaturityPeriod" name="AvailableForSaleSecuritiesInvestmentsMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ovid_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_DefinedContributionPlanName" name="DefinedContributionPlanName" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ovid_DebtSecuritiesAvailableForSaleContinuousUnrealizedGainPosition12MonthsOrLongerNumberOfPositions" name="DebtSecuritiesAvailableForSaleContinuousUnrealizedGainPosition12MonthsOrLongerNumberOfPositions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ovid_ClinicalTrialsAccrualCurrent" name="ClinicalTrialsAccrualCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ovid_ATMAgreementMember" name="ATMAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_CowenAndCompanyLLCMember" name="CowenAndCompanyLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_AggregateOfferingPriceOfCommonStock" name="AggregateOfferingPriceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" name="MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" name="MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ovid_TwoThousandSeventeenEquityIncentivePlanMember" name="TwoThousandSeventeenEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" name="TwoThousandSeventeenEmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_TwoThousandFourteenEquityIncentivePlanMember" name="TwoThousandFourteenEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_NonemployeePerformanceBasedOptionAwardsMember" name="NonemployeePerformanceBasedOptionAwardsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_SeparationAndConsultingAgreementMember" name="SeparationAndConsultingAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_ChairmanOfScientificAdvisoryBoardMember" name="ChairmanOfScientificAdvisoryBoardMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_EmployeePerformanceBasedOptionAwardsMember" name="EmployeePerformanceBasedOptionAwardsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_StockOptionsMember" name="StockOptionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" name="ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ovid_OperatingLossCarryforwardsExpirationPeriodStart" name="OperatingLossCarryforwardsExpirationPeriodStart" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ovid_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_LicenseAgreementEnteredDate" name="LicenseAgreementEnteredDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ovid_HLundbeckASMember" name="HLundbeckASMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_LicenseAgreementMember" name="LicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_NorthwesternUniversityMember" name="NorthwesternUniversityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_LicenseAgreementMilestonePayments" name="LicenseAgreementMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ovid_FirstPaymentDueUponCompletionOfFirstPhase" name="FirstPaymentDueUponCompletionOfFirstPhase" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ovid_NumberOfTrial" name="NumberOfTrial" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ovid_LicenseAgreementEnteredMonthAndYear" name="LicenseAgreementEnteredMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" name="UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ovid_AnnualLicenseMaintenanceFeePayable" name="AnnualLicenseMaintenanceFeePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ovid_ConsiderationPayableForRightsGrant" name="ConsiderationPayableForRightsGrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" name="MinimumNumberOfProductCoveredUnderLicenseAgreement" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ovid_AngeliniLicenseAgreementMember" name="AngeliniLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_TakedaPharmaceuticalCompanyLimitedMember" name="TakedaPharmaceuticalCompanyLimitedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_SeriesB1PreferredStockMember" name="SeriesB1PreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_LicenseAgreementUpfrontPayment" name="LicenseAgreementUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ovid_AggregateLicenseAgreementMilestonePayments" name="AggregateLicenseAgreementMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ovid_SalesMilestonePaymentsThroughLicenseAgreement" name="SalesMilestonePaymentsThroughLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ovid_PotentialFundingCostPercent" name="PotentialFundingCostPercent" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ovid_CostOfAgreementNet" name="CostOfAgreementNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ovid_DeferredUpfrontPaymentCosts" name="DeferredUpfrontPaymentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ovid_UpFrontFeeAmount" name="UpFrontFeeAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ovid_AggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement" name="AggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ovid_AdditionalAggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement" name="AdditionalAggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ovid_LicenseRevenue" name="LicenseRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ovid_IncomeFromOngoingTrials" name="IncomeFromOngoingTrials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ovid_IncomeFromTransferOfSpecifiedAmountOfCompoundAndRelatedInformation" name="IncomeFromTransferOfSpecifiedAmountOfCompoundAndRelatedInformation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ovid_AmountForPotentialFutureTrials" name="AmountForPotentialFutureTrials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ovid_AdditionalTechTransferThroughLicenseAgreement" name="AdditionalTechTransferThroughLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ovid_ResearchAndDevelopmentExpenseReimbursementReceived" name="ResearchAndDevelopmentExpenseReimbursementReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ovid_PercentageOfOutstandingSharesOfCapitalStock" name="PercentageOfOutstandingSharesOfCapitalStock" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ovid_ValueForObligationUnderLicenseAgreement" name="ValueForObligationUnderLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ovid_ThresholdPercentageOfOutstandingCapitalStockToMakeCashPayment" name="ThresholdPercentageOfOutstandingCapitalStockToMakeCashPayment" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ovid_ConsultingArrangementPeriod" name="ConsultingArrangementPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ovid_OtherAdvisoryAndConsultingServicesFee" name="OtherAdvisoryAndConsultingServicesFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ovid_ChiefExecutiveOfficerAndChairmanMember" name="ChiefExecutiveOfficerAndChairmanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember" name="AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_RoyaltyAndTerminationAgreementMember" name="RoyaltyAndTerminationAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ovid_UpfrontPaymentReceivable" name="UpfrontPaymentReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ovid_AgreementMilestonePayments" name="AgreementMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ovid_AgreementClosingDate" name="AgreementClosingDate" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ovid_AdditionalPaymentReceivableOnSalesPercentage" name="AdditionalPaymentReceivableOnSalesPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>22
<FILENAME>ovid-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-15T02:26:45.6345776+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 8ac83ee457de40fa87b3ceabc3444e96 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="ovid-20201231.xsd#TemplateLink" roleURI="http://www.ovidrx.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="ovid-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedParties" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_SecurityDeposit" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableRelatedParties" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10230.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="ovid-20201231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="ovid-20201231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="ovid-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent" xlink:type="locator" xlink:label="ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseDueFromAffiliates" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseDueFromAffiliates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AccruedInterestAndAccretionOfDiscountsShortTermInvestments" xlink:type="locator" xlink:label="ovid_AccruedInterestAndAccretionOfDiscountsShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToDevelopSoftware" xlink:type="locator" xlink:label="us-gaap_PaymentsToDevelopSoftware" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToDevelopSoftware" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ovid_AccruedInterestAndAccretionOfDiscountsShortTermInvestments" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10180.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseDueFromAffiliates" order="10200.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent" order="10210.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="10250.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsSummaryOfFairValueOfCashEquivalentsShortTermInvestmentsAndGrossUnrealizedHoldingGainsAndLossesDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureCashEquivalentsAndShortTermInvestmentsSummaryOfFairValueOfCashEquivalentsShortTermInvestmentsAndGrossUnrealizedHoldingGainsAndLossesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsSummaryOfFairValueOfCashEquivalentsShortTermInvestmentsAndGrossUnrealizedHoldingGainsAndLossesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10650.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10660.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10670.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAndIntangibleAssetsSummaryOfPropertyAndEquipmentDetail" xlink:href="ovid-20201231.xsd#Role_DisclosurePropertyAndEquipmentAndIntangibleAssetsSummaryOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAndIntangibleAssetsSummaryOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ClinicalTrialsAccrualCurrent" xlink:type="locator" xlink:label="ovid_ClinicalTrialsAccrualCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="ovid_ClinicalTrialsAccrualCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="10090.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryUSFederalRateToEffectiveTaxRateDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureIncomeTaxesReconciliationOfStatutoryUSFederalRateToEffectiveTaxRateDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryUSFederalRateToEffectiveTaxRateDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>23
<FILENAME>ovid-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-15T02:26:45.6345776+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 8ac83ee457de40fa87b3ceabc3444e96 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="ovid-20201231.xsd#TemplateLink" roleURI="http://www.ovidrx.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="ovid-20201231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_PreferredStockShareDesignated" xlink:type="locator" xlink:label="ovid_PreferredStockShareDesignated" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ovid_PreferredStockShareDesignated" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10480.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="ovid-20201231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10070.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10760.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="ovid-20201231.xsd#Role_StatementConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementOfChangesInStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ATMOfferingCosts" xlink:type="locator" xlink:label="ovid_ATMOfferingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_OctoberOfferingMember" xlink:type="locator" xlink:label="ovid_OctoberOfferingMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AugustTwoThousandTwentyOfferingMember" xlink:type="locator" xlink:label="ovid_AugustTwoThousandTwentyOfferingMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_FebruaryOfferingMember" xlink:type="locator" xlink:label="ovid_FebruaryOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ATMOfferingsMember" xlink:type="locator" xlink:label="ovid_ATMOfferingsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain_2" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="ovid_ATMOfferingsMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ovid_FebruaryOfferingMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ovid_AugustTwoThousandTwentyOfferingMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ovid_OctoberOfferingMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ovid_ATMOfferingCosts" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12060.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="ovid-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseOfferingCost" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SoftwareDevelopmentAndOtherCostsInAccountsPayableAndAccruedExpenses" xlink:type="locator" xlink:label="ovid_SoftwareDevelopmentAndOtherCostsInAccountsPayableAndAccruedExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToDevelopSoftware" xlink:type="locator" xlink:label="us-gaap_PaymentsToDevelopSoftware" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent" xlink:type="locator" xlink:label="ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseDueFromAffiliates" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseDueFromAffiliates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AccruedInterestAndAccretionOfDiscountsShortTermInvestments" xlink:type="locator" xlink:label="ovid_AccruedInterestAndAccretionOfDiscountsShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ATMMember" xlink:type="locator" xlink:label="ovid_ATMMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_FebruaryAndOctoberTwoThousandNinteenOfferingsMember" xlink:type="locator" xlink:label="ovid_FebruaryAndOctoberTwoThousandNinteenOfferingsMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AugustTwoThousandTwentyOfferingMember" xlink:type="locator" xlink:label="ovid_AugustTwoThousandTwentyOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="10260.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ovid_AugustTwoThousandTwentyOfferingMember" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ovid_FebruaryAndOctoberTwoThousandNinteenOfferingsMember" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ovid_ATMMember" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ovid_AccruedInterestAndAccretionOfDiscountsShortTermInvestments" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseDueFromAffiliates" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToDevelopSoftware" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="11710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="11950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ovid_SoftwareDevelopmentAndOtherCostsInAccountsPayableAndAccruedExpenses" order="12030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_NoninterestExpenseOfferingCost" order="12070.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="ovid-20201231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_NonEmployeeStockOptionsMember" xlink:type="locator" xlink:label="ovid_NonEmployeeStockOptionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ovid_NonEmployeeStockOptionsMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10470.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureNatureOfOperationsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetail">
    <link:loc xlink:href="ovid-20201231.xsd#ovid_WorkingCapital" xlink:type="locator" xlink:label="ovid_WorkingCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAndCollaborationAgreementMember" xlink:type="locator" xlink:label="ovid_LicenseAndCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="locator" xlink:label="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="locator" xlink:label="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ovid_LicenseAndCollaborationAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="ovid_WorkingCapital" order="10200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_DefinedContributionPlanName" xlink:type="locator" xlink:label="ovid_DefinedContributionPlanName" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AvailableForSaleSecuritiesInvestmentsMaturityPeriod" xlink:type="locator" xlink:label="ovid_AvailableForSaleSecuritiesInvestmentsMaturityPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_PercentageOfNetExpensesOfDevelopmentCostsRecordedInResearchAndDevelopment" xlink:type="locator" xlink:label="ovid_PercentageOfNetExpensesOfDevelopmentCostsRecordedInResearchAndDevelopment" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_DescriptionOfOwnershipPatternAsPerLicenseAndCollaborationAgreement" xlink:type="locator" xlink:label="ovid_DescriptionOfOwnershipPatternAsPerLicenseAndCollaborationAgreement" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ScenarioTwoMember" xlink:type="locator" xlink:label="ovid_ScenarioTwoMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ScenarioOneMember" xlink:type="locator" xlink:label="ovid_ScenarioOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_MoneyMarketFundsAndShortTermInvestmentsMember" xlink:type="locator" xlink:label="ovid_MoneyMarketFundsAndShortTermInvestmentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SummaryOfSignificantAccountingPolicyTable" xlink:type="locator" xlink:label="ovid_SummaryOfSignificantAccountingPolicyTable" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:type="locator" xlink:label="ovid_SummaryOfSignificantAccountingPolicyLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="ovid_SummaryOfSignificantAccountingPolicyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ovid_SummaryOfSignificantAccountingPolicyTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ovid_SummaryOfSignificantAccountingPolicyTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ovid_SummaryOfSignificantAccountingPolicyTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="ovid_MoneyMarketFundsAndShortTermInvestmentsMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ovid_SummaryOfSignificantAccountingPolicyTable" xlink:to="srt_StatementScenarioAxis" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_2" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ovid_ScenarioOneMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ovid_ScenarioTwoMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="ovid_DescriptionOfOwnershipPatternAsPerLicenseAndCollaborationAgreement" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="ovid_PercentageOfNetExpensesOfDevelopmentCostsRecordedInResearchAndDevelopment" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="ovid_AvailableForSaleSecuritiesInvestmentsMaturityPeriod" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="ovid_DefinedContributionPlanName" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="11630.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSchedulePotentiallyDilutiveSecuritiesExcludedFromComputationsOfDilutedWeightedAverageSharesOutstandingDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSchedulePotentiallyDilutiveSecuritiesExcludedFromComputationsOfDilutedWeightedAverageSharesOutstandingDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSchedulePotentiallyDilutiveSecuritiesExcludedFromComputationsOfDilutedWeightedAverageSharesOutstandingDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="ovid_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="ovid_SeriesAConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsSummaryOfFairValueOfCashEquivalentsShortTermInvestmentsAndGrossUnrealizedHoldingGainsAndLossesDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureCashEquivalentsAndShortTermInvestmentsSummaryOfFairValueOfCashEquivalentsShortTermInvestmentsAndGrossUnrealizedHoldingGainsAndLossesDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsSummaryOfFairValueOfCashEquivalentsShortTermInvestmentsAndGrossUnrealizedHoldingGainsAndLossesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember" xlink:type="locator" xlink:label="us-gaap_CashMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="11200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAndIntangibleAssetsSummaryOfPropertyAndEquipmentDetail" xlink:href="ovid-20201231.xsd#Role_DisclosurePropertyAndEquipmentAndIntangibleAssetsSummaryOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAndIntangibleAssetsSummaryOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockholdersEquityAndPreferredStockAdditionalInformationDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureStockholdersEquityAndPreferredStockAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockholdersEquityAndPreferredStockAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends" xlink:type="locator" xlink:label="us-gaap_Dividends" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendPaymentRestrictionsScheduleDescription" xlink:type="locator" xlink:label="us-gaap_DividendPaymentRestrictionsScheduleDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" xlink:type="locator" xlink:label="ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:type="locator" xlink:label="ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AggregateOfferingPriceOfCommonStock" xlink:type="locator" xlink:label="ovid_AggregateOfferingPriceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_PreferredStockShareDesignated" xlink:type="locator" xlink:label="ovid_PreferredStockShareDesignated" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember" xlink:type="locator" xlink:label="srt_AffiliatedEntityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="ovid_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_CowenAndCompanyLLCMember" xlink:type="locator" xlink:label="ovid_CowenAndCompanyLLCMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain_2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ATMAgreementMember" xlink:type="locator" xlink:label="ovid_ATMAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ovid_ATMAgreementMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="ovid_CowenAndCompanyLLCMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="ovid_SeriesAConvertiblePreferredStockMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_AffiliatedEntityMember" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ovid_PreferredStockShareDesignated" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ovid_AggregateOfferingPriceOfCommonStock" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" order="11710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" order="11750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" order="11790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreference" order="11830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendPaymentRestrictionsScheduleDescription" order="12560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_Dividends" order="12580.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InitialOfferingPeriod" xlink:type="locator" xlink:label="us-gaap_InitialOfferingPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_EmployeePerformanceBasedOptionAwardsMember" xlink:type="locator" xlink:label="ovid_EmployeePerformanceBasedOptionAwardsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ChairmanOfScientificAdvisoryBoardMember" xlink:type="locator" xlink:label="ovid_ChairmanOfScientificAdvisoryBoardMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SeparationAndConsultingAgreementMember" xlink:type="locator" xlink:label="ovid_SeparationAndConsultingAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_NonemployeePerformanceBasedOptionAwardsMember" xlink:type="locator" xlink:label="ovid_NonemployeePerformanceBasedOptionAwardsMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_NonEmployeeStockOptionsMember" xlink:type="locator" xlink:label="ovid_NonEmployeeStockOptionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:type="locator" xlink:label="us-gaap_PerformanceSharesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_TwoThousandFourteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="ovid_TwoThousandFourteenEquityIncentivePlanMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="locator" xlink:label="ovid_TwoThousandSeventeenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ovid_TwoThousandSeventeenEquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ovid_TwoThousandFourteenEquityIncentivePlanMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ovid_NonEmployeeStockOptionsMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ovid_NonemployeePerformanceBasedOptionAwardsMember" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ovid_SeparationAndConsultingAgreementMember" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ovid_ChairmanOfScientificAdvisoryBoardMember" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ovid_EmployeePerformanceBasedOptionAwardsMember" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_InitialOfferingPeriod" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="11890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="12060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="12460.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAllocationOfStockBasedCompensationExpenseByPlanDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureStockBasedCompensationScheduleOfAllocationOfStockBasedCompensationExpenseByPlanDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAllocationOfStockBasedCompensationExpenseByPlanDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="ovid_EmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_StockOptionsMember" xlink:type="locator" xlink:label="ovid_StockOptionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ovid_StockOptionsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ovid_EmployeeStockPurchasePlanMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToComputeFairValueOfEmployeeOptionGrantedDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToComputeFairValueOfEmployeeOptionGrantedDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToComputeFairValueOfEmployeeOptionGrantedDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_NonEmployeeStockOptionsMember" xlink:type="locator" xlink:label="ovid_NonEmployeeStockOptionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ovid_NonEmployeeStockOptionsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10360.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_OperatingLossCarryforwardsExpirationPeriodStart" xlink:type="locator" xlink:label="ovid_OperatingLossCarryforwardsExpirationPeriodStart" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:type="locator" xlink:label="us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="ovid_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="ovid_IncomeTaxDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ovid_IncomeTaxDisclosureLineItems" xlink:to="ovid_IncomeTaxDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ovid_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ovid_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ovid_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ovid_IncomeTaxDisclosureLineItems" xlink:to="ovid_OperatingLossCarryforwardsExpirationPeriodStart" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ovid_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ovid_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ovid_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ovid_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="10510.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="ovid-20201231.xsd#ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" xlink:type="locator" xlink:label="ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementRightsAndObligations" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementRightsAndObligations" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ConsiderationPayableForRightsGrant" xlink:type="locator" xlink:label="ovid_ConsiderationPayableForRightsGrant" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AnnualLicenseMaintenanceFeePayable" xlink:type="locator" xlink:label="ovid_AnnualLicenseMaintenanceFeePayable" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" xlink:type="locator" xlink:label="ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAgreementEnteredMonthAndYear" xlink:type="locator" xlink:label="ovid_LicenseAgreementEnteredMonthAndYear" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_NumberOfTrial" xlink:type="locator" xlink:label="ovid_NumberOfTrial" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_FirstPaymentDueUponCompletionOfFirstPhase" xlink:type="locator" xlink:label="ovid_FirstPaymentDueUponCompletionOfFirstPhase" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAgreementMilestonePayments" xlink:type="locator" xlink:label="ovid_LicenseAgreementMilestonePayments" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAgreementEnteredDate" xlink:type="locator" xlink:label="ovid_LicenseAgreementEnteredDate" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_NorthwesternUniversityMember" xlink:type="locator" xlink:label="ovid_NorthwesternUniversityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAgreementMember" xlink:type="locator" xlink:label="ovid_LicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_HLundbeckASMember" xlink:type="locator" xlink:label="ovid_HLundbeckASMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ovid_HLundbeckASMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ovid_LicenseAgreementMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ovid_NorthwesternUniversityMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ovid_LicenseAgreementEnteredDate" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ovid_LicenseAgreementMilestonePayments" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ovid_FirstPaymentDueUponCompletionOfFirstPhase" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ovid_NumberOfTrial" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ovid_LicenseAgreementEnteredMonthAndYear" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ovid_AnnualLicenseMaintenanceFeePayable" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ovid_ConsiderationPayableForRightsGrant" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_CollaborativeArrangementRightsAndObligations" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" order="11320.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureCollaborationAgreementAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedParties" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ResearchAndDevelopmentExpenseReimbursementReceived" xlink:type="locator" xlink:label="ovid_ResearchAndDevelopmentExpenseReimbursementReceived" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAgreementMilestonePayments" xlink:type="locator" xlink:label="ovid_LicenseAgreementMilestonePayments" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ThresholdPercentageOfOutstandingCapitalStockToMakeCashPayment" xlink:type="locator" xlink:label="ovid_ThresholdPercentageOfOutstandingCapitalStockToMakeCashPayment" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ValueForObligationUnderLicenseAgreement" xlink:type="locator" xlink:label="ovid_ValueForObligationUnderLicenseAgreement" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_PercentageOfOutstandingSharesOfCapitalStock" xlink:type="locator" xlink:label="ovid_PercentageOfOutstandingSharesOfCapitalStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_IncomeFromTransferOfSpecifiedAmountOfCompoundAndRelatedInformation" xlink:type="locator" xlink:label="ovid_IncomeFromTransferOfSpecifiedAmountOfCompoundAndRelatedInformation" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_IncomeFromOngoingTrials" xlink:type="locator" xlink:label="ovid_IncomeFromOngoingTrials" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseRevenue" xlink:type="locator" xlink:label="ovid_LicenseRevenue" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AdditionalAggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement" xlink:type="locator" xlink:label="ovid_AdditionalAggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AdditionalTechTransferThroughLicenseAgreement" xlink:type="locator" xlink:label="ovid_AdditionalTechTransferThroughLicenseAgreement" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement" xlink:type="locator" xlink:label="ovid_AggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AmountForPotentialFutureTrials" xlink:type="locator" xlink:label="ovid_AmountForPotentialFutureTrials" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_UpFrontFeeAmount" xlink:type="locator" xlink:label="ovid_UpFrontFeeAmount" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_DeferredUpfrontPaymentCosts" xlink:type="locator" xlink:label="ovid_DeferredUpfrontPaymentCosts" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_CostOfAgreementNet" xlink:type="locator" xlink:label="ovid_CostOfAgreementNet" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_PotentialFundingCostPercent" xlink:type="locator" xlink:label="ovid_PotentialFundingCostPercent" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SalesMilestonePaymentsThroughLicenseAgreement" xlink:type="locator" xlink:label="ovid_SalesMilestonePaymentsThroughLicenseAgreement" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AggregateLicenseAgreementMilestonePayments" xlink:type="locator" xlink:label="ovid_AggregateLicenseAgreementMilestonePayments" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAgreementUpfrontPayment" xlink:type="locator" xlink:label="ovid_LicenseAgreementUpfrontPayment" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAgreementEnteredDate" xlink:type="locator" xlink:label="ovid_LicenseAgreementEnteredDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SeriesB1PreferredStockMember" xlink:type="locator" xlink:label="ovid_SeriesB1PreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="locator" xlink:label="ovid_TakedaPharmaceuticalCompanyLimitedMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAgreementMember" xlink:type="locator" xlink:label="ovid_LicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AngeliniLicenseAgreementMember" xlink:type="locator" xlink:label="ovid_AngeliniLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ovid_AngeliniLicenseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ovid_LicenseAgreementMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="ovid_TakedaPharmaceuticalCompanyLimitedMember" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ovid_SeriesB1PreferredStockMember" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_LicenseAgreementEnteredDate" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_LicenseAgreementUpfrontPayment" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_AggregateLicenseAgreementMilestonePayments" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_SalesMilestonePaymentsThroughLicenseAgreement" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_PotentialFundingCostPercent" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_CostOfAgreementNet" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_DeferredUpfrontPaymentCosts" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_UpFrontFeeAmount" order="11640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_AmountForPotentialFutureTrials" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_AggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_AdditionalTechTransferThroughLicenseAgreement" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_AdditionalAggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_LicenseRevenue" order="11840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_IncomeFromOngoingTrials" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_IncomeFromTransferOfSpecifiedAmountOfCompoundAndRelatedInformation" order="11920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="11960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="12030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="12070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="12110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_PercentageOfOutstandingSharesOfCapitalStock" order="12150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_ValueForObligationUnderLicenseAgreement" order="12190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_ThresholdPercentageOfOutstandingCapitalStockToMakeCashPayment" order="12230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_LicenseAgreementMilestonePayments" order="12270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_ResearchAndDevelopmentExpenseReimbursementReceived" order="12350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" order="12430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableRelatedParties" order="12470.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_OtherAdvisoryAndConsultingServicesFee" xlink:type="locator" xlink:label="ovid_OtherAdvisoryAndConsultingServicesFee" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees" xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ConsultingArrangementPeriod" xlink:type="locator" xlink:label="ovid_ConsultingArrangementPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember" xlink:type="locator" xlink:label="srt_AffiliatedEntityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember" xlink:type="locator" xlink:label="ovid_AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ChiefExecutiveOfficerAndChairmanMember" xlink:type="locator" xlink:label="ovid_ChiefExecutiveOfficerAndChairmanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ChairmanOfScientificAdvisoryBoardMember" xlink:type="locator" xlink:label="ovid_ChairmanOfScientificAdvisoryBoardMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SeparationAndConsultingAgreementMember" xlink:type="locator" xlink:label="ovid_SeparationAndConsultingAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ovid_SeparationAndConsultingAgreementMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ovid_ChairmanOfScientificAdvisoryBoardMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_VestingAxis" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_2" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ovid_ChiefExecutiveOfficerAndChairmanMember" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ovid_AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_AffiliatedEntityMember" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ovid_ConsultingArrangementPeriod" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProfessionalFees" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ovid_OtherAdvisoryAndConsultingServicesFee" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" order="11920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12210.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AgreementClosingDate" xlink:type="locator" xlink:label="ovid_AgreementClosingDate" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AdditionalPaymentReceivableOnSalesPercentage" xlink:type="locator" xlink:label="ovid_AdditionalPaymentReceivableOnSalesPercentage" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AgreementMilestonePayments" xlink:type="locator" xlink:label="ovid_AgreementMilestonePayments" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_UpfrontPaymentReceivable" xlink:type="locator" xlink:label="ovid_UpfrontPaymentReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_RoyaltyAndTerminationAgreementMember" xlink:type="locator" xlink:label="ovid_RoyaltyAndTerminationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ovid_RoyaltyAndTerminationAgreementMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ovid_UpfrontPaymentReceivable" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ovid_AgreementMilestonePayments" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ovid_AdditionalPaymentReceivableOnSalesPercentage" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ovid_AgreementClosingDate" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="10670.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>24
<FILENAME>ovid-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-15T02:26:45.6355768+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 8ac83ee457de40fa87b3ceabc3444e96 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedParties" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedParties" xlink:to="us-gaap_AccountsReceivableRelatedParties_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term prepaid expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&apos; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Parties Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue - current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party payable - noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Parties Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 3,250 and 7,762 shares issued and outstanding at December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 125,000,000 shares authorized; 65,743,170 and 54,710,322 shares issued and outstanding at December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in-capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_PreferredStockShareDesignated" xlink:type="locator" xlink:label="ovid_PreferredStockShareDesignated" />
    <link:label xml:lang="en-US" xlink:label="ovid_PreferredStockShareDesignated_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock shares designated.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_PreferredStockShareDesignated" xlink:to="ovid_PreferredStockShareDesignated_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_PreferredStockShareDesignated_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, share designated</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_PreferredStockShareDesignated_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Share Designated</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and other revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Including Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, Product and Service [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRevenueExtensibleList" xlink:to="us-gaap_TypeOfRevenueExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Revenue Extensible List</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Operating Income Expense Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive (loss) income:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized (loss) gain on available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive (loss) gain</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ATMOfferingCosts" xlink:type="locator" xlink:label="ovid_ATMOfferingCosts" />
    <link:label xml:lang="en-US" xlink:label="ovid_ATMOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">ATM offering costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_ATMOfferingCosts" xlink:to="ovid_ATMOfferingCosts_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income/(Loss) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_TransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction [Domain]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ATMOfferingsMember" xlink:type="locator" xlink:label="ovid_ATMOfferingsMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_ATMOfferingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">ATM offerings member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_ATMOfferingsMember" xlink:to="ovid_ATMOfferingsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_ATMOfferingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM Offerings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_ATMOfferingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A T M Offerings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_FebruaryOfferingMember" xlink:type="locator" xlink:label="ovid_FebruaryOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_FebruaryOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">February Offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_FebruaryOfferingMember" xlink:to="ovid_FebruaryOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_FebruaryOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">February Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_FebruaryOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">February Offering [Member]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AugustTwoThousandTwentyOfferingMember" xlink:type="locator" xlink:label="ovid_AugustTwoThousandTwentyOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_AugustTwoThousandTwentyOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">August two thousand twenty offering member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_AugustTwoThousandTwentyOfferingMember" xlink:to="ovid_AugustTwoThousandTwentyOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_AugustTwoThousandTwentyOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">August 2020 Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AugustTwoThousandTwentyOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">August Two Thousand Twenty Offering [Member]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_OctoberOfferingMember" xlink:type="locator" xlink:label="ovid_OctoberOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_OctoberOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">October Offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_OctoberOfferingMember" xlink:to="ovid_OctoberOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_OctoberOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">October Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_OctoberOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">October Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_ATMOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM costs</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_ATMOfferingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A T M Offering Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from exercise of stock options, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from employee stock purchase plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from employee stock purchase plan, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of series A convertible preferred stock to common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of series A convertible preferred stock to common stock, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Offering, net of underwriting costs and commissions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Offering, net of underwriting costs and commissions, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, Shares</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AccruedInterestAndAccretionOfDiscountsShortTermInvestments" xlink:type="locator" xlink:label="ovid_AccruedInterestAndAccretionOfDiscountsShortTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="ovid_AccruedInterestAndAccretionOfDiscountsShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued interest and accretion of discounts, short term investments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_AccruedInterestAndAccretionOfDiscountsShortTermInvestments" xlink:to="ovid_AccruedInterestAndAccretionOfDiscountsShortTermInvestments_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent" xlink:type="locator" xlink:label="ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in prepaid expense, noncurrent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent" xlink:to="ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SoftwareDevelopmentAndOtherCostsInAccountsPayableAndAccruedExpenses" xlink:type="locator" xlink:label="ovid_SoftwareDevelopmentAndOtherCostsInAccountsPayableAndAccruedExpenses" />
    <link:label xml:lang="en-US" xlink:label="ovid_SoftwareDevelopmentAndOtherCostsInAccountsPayableAndAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Software development and other costs in accounts payable and accrued expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_SoftwareDevelopmentAndOtherCostsInAccountsPayableAndAccruedExpenses" xlink:to="ovid_SoftwareDevelopmentAndOtherCostsInAccountsPayableAndAccruedExpenses_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_FebruaryAndOctoberTwoThousandNinteenOfferingsMember" xlink:type="locator" xlink:label="ovid_FebruaryAndOctoberTwoThousandNinteenOfferingsMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_FebruaryAndOctoberTwoThousandNinteenOfferingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">February and october two thousand ninteen offerings member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_FebruaryAndOctoberTwoThousandNinteenOfferingsMember" xlink:to="ovid_FebruaryAndOctoberTwoThousandNinteenOfferingsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_FebruaryAndOctoberTwoThousandNinteenOfferingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">February and October 2019 Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_FebruaryAndOctoberTwoThousandNinteenOfferingsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">February And October Two Thousand Ninteen Offerings [Member]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ATMMember" xlink:type="locator" xlink:label="ovid_ATMMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_ATMMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">ATM.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_ATMMember" xlink:to="ovid_ATMMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_ATMMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_ATMMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A T M [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Sale Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AccruedInterestAndAccretionOfDiscountsShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accrued interest and accretion of discount on short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AccruedInterestAndAccretionOfDiscountsShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Interest And Accretion Of Discounts Short Term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Security Deposits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseDueFromAffiliates" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseDueFromAffiliates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseDueFromAffiliates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Related party receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseDueFromAffiliates" xlink:to="us-gaap_IncreaseDecreaseDueFromAffiliates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseDueFromAffiliates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease Due From Affiliates</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Long-term prepaid expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Expense Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable Trade</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Due To Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Available For Sale Securities Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToDevelopSoftware" xlink:type="locator" xlink:label="us-gaap_PaymentsToDevelopSoftware" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToDevelopSoftware_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Software development and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToDevelopSoftware" xlink:to="us-gaap_PaymentsToDevelopSoftware_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToDevelopSoftware_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Develop Software</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from August, February and October Offering, net of offering expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">ATM costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from employee stock purchase plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents, at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents, at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_SoftwareDevelopmentAndOtherCostsInAccountsPayableAndAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software development and other costs in accrued expenses and accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_SoftwareDevelopmentAndOtherCostsInAccountsPayableAndAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Software Development And Other Costs In Accounts Payable And Accrued Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseOfferingCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoninterestExpenseOfferingCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs in accrued expenses and accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseOfferingCost" xlink:to="us-gaap_NoninterestExpenseOfferingCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoninterestExpenseOfferingCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noninterest Expense Offering Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Debt And Equity Securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents and Short-Term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments In Debt And Equity Instruments Cash And Cash Equivalents Unrealized And Realized Gains Losses [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment and Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment And Intangible Assets [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Equity and Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RELATED PARTY TRANSACTIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks and Uncertainties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Transaction Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Accounting Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Data</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:to="us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pension And Other Postretirement Plans Pensions Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ScheduleOfCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="locator" xlink:label="ovid_ScheduleOfCashEquivalentsAndShortTermInvestmentsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="ovid_ScheduleOfCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of cash equivalents and short term investments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_ScheduleOfCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="ovid_ScheduleOfCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_ScheduleOfCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value of Cash Equivalents, Short-Term Investments and Gross Unrealized Holding Gains and Losses</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_ScheduleOfCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Cash Equivalents And Short Term Investments Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_NonEmployeeStockOptionsMember" xlink:type="locator" xlink:label="ovid_NonEmployeeStockOptionsMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_NonEmployeeStockOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nonemployee stock options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_NonEmployeeStockOptionsMember" xlink:to="ovid_NonEmployeeStockOptionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_NonEmployeeStockOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonemployee Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_NonEmployeeStockOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Employee Stock Options [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Recognized Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Allocation of Stock-based Compensation Expense by Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions Used to Compute Fair Value of Employee Option Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Options Outstanding and Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Statutory U.S. Federal Rate to Effective Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_WorkingCapital" xlink:type="locator" xlink:label="ovid_WorkingCapital" />
    <link:label xml:lang="en-US" xlink:label="ovid_WorkingCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Working capital.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_WorkingCapital" xlink:to="ovid_WorkingCapital_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="locator" xlink:label="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <link:label xml:lang="en-US" xlink:label="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="locator" xlink:label="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <link:label xml:lang="en-US" xlink:label="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAndCollaborationAgreementMember" xlink:type="locator" xlink:label="ovid_LicenseAndCollaborationAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_LicenseAndCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License and Collaboration Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_LicenseAndCollaborationAgreementMember" xlink:to="ovid_LicenseAndCollaborationAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_LicenseAndCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_LicenseAndCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License And Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash outflows from operating activities</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_WorkingCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Working capital</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_WorkingCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Working Capital</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_DescriptionOfOwnershipPatternAsPerLicenseAndCollaborationAgreement" xlink:type="locator" xlink:label="ovid_DescriptionOfOwnershipPatternAsPerLicenseAndCollaborationAgreement" />
    <link:label xml:lang="en-US" xlink:label="ovid_DescriptionOfOwnershipPatternAsPerLicenseAndCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of ownership pattern as per license and collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_DescriptionOfOwnershipPatternAsPerLicenseAndCollaborationAgreement" xlink:to="ovid_DescriptionOfOwnershipPatternAsPerLicenseAndCollaborationAgreement_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_PercentageOfNetExpensesOfDevelopmentCostsRecordedInResearchAndDevelopment" xlink:type="locator" xlink:label="ovid_PercentageOfNetExpensesOfDevelopmentCostsRecordedInResearchAndDevelopment" />
    <link:label xml:lang="en-US" xlink:label="ovid_PercentageOfNetExpensesOfDevelopmentCostsRecordedInResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of net expenses of development costs recorded in research and development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_PercentageOfNetExpensesOfDevelopmentCostsRecordedInResearchAndDevelopment" xlink:to="ovid_PercentageOfNetExpensesOfDevelopmentCostsRecordedInResearchAndDevelopment_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:type="locator" xlink:label="ovid_SummaryOfSignificantAccountingPolicyLineItems" />
    <link:label xml:lang="en-US" xlink:label="ovid_SummaryOfSignificantAccountingPolicyLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="ovid_SummaryOfSignificantAccountingPolicyLineItems_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SummaryOfSignificantAccountingPolicyTable" xlink:type="locator" xlink:label="ovid_SummaryOfSignificantAccountingPolicyTable" />
    <link:label xml:lang="en-US" xlink:label="ovid_SummaryOfSignificantAccountingPolicyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_SummaryOfSignificantAccountingPolicyTable" xlink:to="ovid_SummaryOfSignificantAccountingPolicyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_SummaryOfSignificantAccountingPolicyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policy [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_SummaryOfSignificantAccountingPolicyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policy [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_MoneyMarketFundsAndShortTermInvestmentsMember" xlink:type="locator" xlink:label="ovid_MoneyMarketFundsAndShortTermInvestmentsMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_MoneyMarketFundsAndShortTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Money market funds and short-term investments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_MoneyMarketFundsAndShortTermInvestmentsMember" xlink:to="ovid_MoneyMarketFundsAndShortTermInvestmentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_MoneyMarketFundsAndShortTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds and Short-term Investments [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_MoneyMarketFundsAndShortTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds And Short Term Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Unspecified [Domain]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ScenarioOneMember" xlink:type="locator" xlink:label="ovid_ScenarioOneMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_ScenarioOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Scenario one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_ScenarioOneMember" xlink:to="ovid_ScenarioOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_ScenarioOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_ScenarioOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario One [Member]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ScenarioTwoMember" xlink:type="locator" xlink:label="ovid_ScenarioTwoMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_ScenarioTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Scenario two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_ScenarioTwoMember" xlink:to="ovid_ScenarioTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_ScenarioTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_ScenarioTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_SummaryOfSignificantAccountingPolicyLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policy [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_SummaryOfSignificantAccountingPolicyLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policy [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_DescriptionOfOwnershipPatternAsPerLicenseAndCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership pattern</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_DescriptionOfOwnershipPatternAsPerLicenseAndCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Ownership Pattern As Per License And Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_PercentageOfNetExpensesOfDevelopmentCostsRecordedInResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of net expenses of development costs recorded in research and development</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_PercentageOfNetExpensesOfDevelopmentCostsRecordedInResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Net Expenses Of Development Costs Recorded In Research And Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FDIC insured amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash F D I C Insured Amount</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AvailableForSaleSecuritiesInvestmentsMaturityPeriod" xlink:type="locator" xlink:label="ovid_AvailableForSaleSecuritiesInvestmentsMaturityPeriod" />
    <link:label xml:lang="en-US" xlink:label="ovid_AvailableForSaleSecuritiesInvestmentsMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available-for-sale securities investments maturity period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_AvailableForSaleSecuritiesInvestmentsMaturityPeriod" xlink:to="ovid_AvailableForSaleSecuritiesInvestmentsMaturityPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_AvailableForSaleSecuritiesInvestmentsMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short term investments, maturity period</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AvailableForSaleSecuritiesInvestmentsMaturityPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Investments Maturity Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful lives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, useful lives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="ovid_SeriesAConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_SeriesAConvertiblePreferredStockMember" xlink:to="ovid_SeriesAConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options to purchase common stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dilutive Securities Included and Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dilutive Securities Excluded from computations of Diluted Weighted Average shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_DefinedContributionPlanName" xlink:type="locator" xlink:label="ovid_DefinedContributionPlanName" />
    <link:label xml:lang="en-US" xlink:label="ovid_DefinedContributionPlanName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution plan name.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_DefinedContributionPlanName" xlink:to="ovid_DefinedContributionPlanName_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_DefinedContributionPlanName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan name</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_DefinedContributionPlanName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Name</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of company matching contribution to 401(k) retirement plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent Of Match</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company matching contributions to employee&apos;s eligible compensation deferred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company contributions to 401(k) retirement plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember" xlink:type="locator" xlink:label="us-gaap_CashMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Notes [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cash and cash equivalents, Amortized cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cash and cash equivalents, Fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total short-term investments, Amortized cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total short-term investments, Gross unrealized holding gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total short-term investments, Gross unrealized holding losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total short-term investments, Fair value</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_DebtSecuritiesAvailableForSaleContinuousUnrealizedGainPosition12MonthsOrLongerNumberOfPositions" xlink:type="locator" xlink:label="ovid_DebtSecuritiesAvailableForSaleContinuousUnrealizedGainPosition12MonthsOrLongerNumberOfPositions" />
    <link:label xml:lang="en-US" xlink:label="ovid_DebtSecuritiesAvailableForSaleContinuousUnrealizedGainPosition12MonthsOrLongerNumberOfPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized gain position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_DebtSecuritiesAvailableForSaleContinuousUnrealizedGainPosition12MonthsOrLongerNumberOfPositions" xlink:to="ovid_DebtSecuritiesAvailableForSaleContinuousUnrealizedGainPosition12MonthsOrLongerNumberOfPositions_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of securities in an unrealized loss position for more than 12 months</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_DebtSecuritiesAvailableForSaleContinuousUnrealizedGainPosition12MonthsOrLongerNumberOfPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of securities in an unrealized gain position for more than 12 months</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_DebtSecuritiesAvailableForSaleContinuousUnrealizedGainPosition12MonthsOrLongerNumberOfPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Gain Position12 Months Or Longer Number Of Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gains or losses on available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Gross Realized Gain Loss Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property, plant and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net of accumulated amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Intangible Assets</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ClinicalTrialsAccrualCurrent" xlink:type="locator" xlink:label="ovid_ClinicalTrialsAccrualCurrent" />
    <link:label xml:lang="en-US" xlink:label="ovid_ClinicalTrialsAccrualCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical trials accrual current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_ClinicalTrialsAccrualCurrent" xlink:to="ovid_ClinicalTrialsAccrualCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_ClinicalTrialsAccrualCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical trials accrual</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_ClinicalTrialsAccrualCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trials Accrual Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll and bonus accrual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees accrual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series A Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ATMAgreementMember" xlink:type="locator" xlink:label="ovid_ATMAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_ATMAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">ATM Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_ATMAgreementMember" xlink:to="ovid_ATMAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_ATMAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_ATMAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A T M Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_CowenAndCompanyLLCMember" xlink:type="locator" xlink:label="ovid_CowenAndCompanyLLCMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_CowenAndCompanyLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cowen and Company, LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_CowenAndCompanyLLCMember" xlink:to="ovid_CowenAndCompanyLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_CowenAndCompanyLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cowen And Company, LLC [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_CowenAndCompanyLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cowen And Company L L C [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember" xlink:type="locator" xlink:label="srt_AffiliatedEntityMember" />
    <link:label xml:lang="en-US" xlink:label="srt_AffiliatedEntityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biotechnology Value Fund, L.P [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AffiliatedEntityMember" xlink:to="srt_AffiliatedEntityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_AffiliatedEntityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Affiliated Entity [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock voting rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AggregateOfferingPriceOfCommonStock" xlink:type="locator" xlink:label="ovid_AggregateOfferingPriceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="ovid_AggregateOfferingPriceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate offering price of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_AggregateOfferingPriceOfCommonStock" xlink:to="ovid_AggregateOfferingPriceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_AggregateOfferingPriceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from offering, value</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AggregateOfferingPriceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Offering Price Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance of stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Or Sale Of Equity</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:type="locator" xlink:label="ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" />
    <link:label xml:lang="en-US" xlink:label="ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum allowable owning percentage of outstanding common stock by associates or affiliates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:to="ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" xlink:type="locator" xlink:label="ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" />
    <link:label xml:lang="en-US" xlink:label="ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum allowable voting right percentage of outstanding common stock holders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" xlink:to="ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued for each share of convertible preferred stock that is converted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Shares Issued Upon Conversion</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum allowable owning percentage of outstanding common stock by associates or affiliates</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Allowable Owning Percentage Of Outstanding Common Stock By Associates Or Affiliates</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum allowable voting right percentage of outstanding common stock holders</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Allowable Voting Right Percentage Of Outstanding Common Stock Holders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, terms of conversion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Terms Of Conversion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, liquidation preference per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Liquidation Preference</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issued, price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of common stock to series A convertible preferred stock, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendPaymentRestrictionsScheduleDescription" xlink:type="locator" xlink:label="us-gaap_DividendPaymentRestrictionsScheduleDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendPaymentRestrictionsScheduleDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends declaration and payment terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendPaymentRestrictionsScheduleDescription" xlink:to="us-gaap_DividendPaymentRestrictionsScheduleDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendPaymentRestrictionsScheduleDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividend Payment Restrictions Schedule Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends" xlink:type="locator" xlink:label="us-gaap_Dividends" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Dividends_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends declared</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Dividends_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividends</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="locator" xlink:label="ovid_TwoThousandSeventeenEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2017 equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_TwoThousandSeventeenEquityIncentivePlanMember" xlink:to="ovid_TwoThousandSeventeenEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Seventeen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2017 employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:to="ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 ESPP [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Seventeen Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_TwoThousandFourteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="ovid_TwoThousandFourteenEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2014 Equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_TwoThousandFourteenEquityIncentivePlanMember" xlink:to="ovid_TwoThousandFourteenEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:type="locator" xlink:label="us-gaap_PerformanceSharesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-based Option Awards [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_NonemployeePerformanceBasedOptionAwardsMember" xlink:type="locator" xlink:label="ovid_NonemployeePerformanceBasedOptionAwardsMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_NonemployeePerformanceBasedOptionAwardsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-employee performance based option awards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_NonemployeePerformanceBasedOptionAwardsMember" xlink:to="ovid_NonemployeePerformanceBasedOptionAwardsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_NonemployeePerformanceBasedOptionAwardsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-employee Performance Based Option Awards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_NonemployeePerformanceBasedOptionAwardsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonemployee Performance Based Option Awards [Member]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SeparationAndConsultingAgreementMember" xlink:type="locator" xlink:label="ovid_SeparationAndConsultingAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_SeparationAndConsultingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Separation and consulting agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_SeparationAndConsultingAgreementMember" xlink:to="ovid_SeparationAndConsultingAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_SeparationAndConsultingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Separation and Consulting Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_SeparationAndConsultingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Separation And Consulting Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ChairmanOfScientificAdvisoryBoardMember" xlink:type="locator" xlink:label="ovid_ChairmanOfScientificAdvisoryBoardMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_ChairmanOfScientificAdvisoryBoardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Chairman of scientific advisory board.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_ChairmanOfScientificAdvisoryBoardMember" xlink:to="ovid_ChairmanOfScientificAdvisoryBoardMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_ChairmanOfScientificAdvisoryBoardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dr. During [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_ChairmanOfScientificAdvisoryBoardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Chairman Of Scientific Advisory Board [Member]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_EmployeePerformanceBasedOptionAwardsMember" xlink:type="locator" xlink:label="ovid_EmployeePerformanceBasedOptionAwardsMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_EmployeePerformanceBasedOptionAwardsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee performance based option awards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_EmployeePerformanceBasedOptionAwardsMember" xlink:to="ovid_EmployeePerformanceBasedOptionAwardsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_EmployeePerformanceBasedOptionAwardsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Performance Based Option Awards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_EmployeePerformanceBasedOptionAwardsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Performance Based Option Awards [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, reserved for future issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase of equity incentive plan/ employee stock purchase plan limit description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of number of shares of common stock outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional shares reserved for issuance under the plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of company&apos;s common stock reserved for issuance under the plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InitialOfferingPeriod" xlink:type="locator" xlink:label="us-gaap_InitialOfferingPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InitialOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering period description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InitialOfferingPeriod" xlink:to="us-gaap_InitialOfferingPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InitialOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Offering Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation, percentage of discount from market price on purchase date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Purchase Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation, number of shares purchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in number of shares each year under the plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation, term of plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation, graded vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation, exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested stock options, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options, granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expenses [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expenses [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense, Total</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_StockOptionsMember" xlink:type="locator" xlink:label="ovid_StockOptionsMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_StockOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_StockOptionsMember" xlink:to="ovid_StockOptionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_StockOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_StockOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options [Member]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="ovid_EmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_EmployeeStockPurchasePlanMember" xlink:to="ovid_EmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average, Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average, Expected term in years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average, Dividend rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average, Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average, Fair value of option on grant/measurement date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Options Outstanding, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Vested and exercisable, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Shares, Granted</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Options Outstanding, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Vested and exercisable, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Options Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Vested and exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Options Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Vested and exercisable</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" xlink:type="locator" xlink:label="ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" />
    <link:label xml:lang="en-US" xlink:label="ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation by share based payment award options granted contractual life.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" xlink:to="ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life, Options Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life, Vested and exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life, Granted</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation By Share Based Payment Award Options Granted Contractual Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Options Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation not yet recognized, period for recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_OperatingLossCarryforwardsExpirationPeriodStart" xlink:type="locator" xlink:label="ovid_OperatingLossCarryforwardsExpirationPeriodStart" />
    <link:label xml:lang="en-US" xlink:label="ovid_OperatingLossCarryforwardsExpirationPeriodStart_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration period start.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_OperatingLossCarryforwardsExpirationPeriodStart" xlink:to="ovid_OperatingLossCarryforwardsExpirationPeriodStart_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="ovid_IncomeTaxDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="ovid_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_IncomeTaxDisclosureLineItems" xlink:to="ovid_IncomeTaxDisclosureLineItems_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="ovid_IncomeTaxDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="ovid_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_IncomeTaxDisclosureTable" xlink:to="ovid_IncomeTaxDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:type="locator" xlink:label="us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New York State Division of Taxation and Finance Member [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:to="us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New York State Division Of Taxation And Finance [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_OperatingLossCarryforwardsExpirationPeriodStart_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_OperatingLossCarryforwardsExpirationPeriodStart_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Period Start</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits or related interest and penalties accrued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax position</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liability For Uncertain Tax Positions Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets/liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryovers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Charitable contributions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Charitable Contribution Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Goodwill And Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross deferred tax assets/liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets (liabilities)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Federal income tax benefit at statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income tax, net of federal benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent items</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax (benefit) expense rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAgreementEnteredDate" xlink:type="locator" xlink:label="ovid_LicenseAgreementEnteredDate" />
    <link:label xml:lang="en-US" xlink:label="ovid_LicenseAgreementEnteredDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement entered date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_LicenseAgreementEnteredDate" xlink:to="ovid_LicenseAgreementEnteredDate_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_HLundbeckASMember" xlink:type="locator" xlink:label="ovid_HLundbeckASMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_HLundbeckASMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">H. Lundbeck A/S.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_HLundbeckASMember" xlink:to="ovid_HLundbeckASMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_HLundbeckASMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lundbeck [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_HLundbeckASMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">H Lundbeck A S [Member]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAgreementMember" xlink:type="locator" xlink:label="ovid_LicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_LicenseAgreementMember" xlink:to="ovid_LicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_NorthwesternUniversityMember" xlink:type="locator" xlink:label="ovid_NorthwesternUniversityMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_NorthwesternUniversityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Northwestern University.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_NorthwesternUniversityMember" xlink:to="ovid_NorthwesternUniversityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_NorthwesternUniversityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Northwestern University [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_NorthwesternUniversityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Northwestern University [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_LicenseAgreementEnteredDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement entered date</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_LicenseAgreementEnteredDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Entered Date</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAgreementMilestonePayments" xlink:type="locator" xlink:label="ovid_LicenseAgreementMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="ovid_LicenseAgreementMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Global commercial and regulatory milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_LicenseAgreementMilestonePayments" xlink:to="ovid_LicenseAgreementMilestonePayments_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_FirstPaymentDueUponCompletionOfFirstPhase" xlink:type="locator" xlink:label="ovid_FirstPaymentDueUponCompletionOfFirstPhase" />
    <link:label xml:lang="en-US" xlink:label="ovid_FirstPaymentDueUponCompletionOfFirstPhase_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">First payment due upon completion of first phase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_FirstPaymentDueUponCompletionOfFirstPhase" xlink:to="ovid_FirstPaymentDueUponCompletionOfFirstPhase_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_NumberOfTrial" xlink:type="locator" xlink:label="ovid_NumberOfTrial" />
    <link:label xml:lang="en-US" xlink:label="ovid_NumberOfTrial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of trial.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_NumberOfTrial" xlink:to="ovid_NumberOfTrial_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_LicenseAgreementMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_LicenseAgreementMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_FirstPaymentDueUponCompletionOfFirstPhase_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First payment due upon completion of first phase</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_FirstPaymentDueUponCompletionOfFirstPhase_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">First Payment Due Upon Completion Of First Phase</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_NumberOfTrial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of trial</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_NumberOfTrial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Trial</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAgreementEnteredMonthAndYear" xlink:type="locator" xlink:label="ovid_LicenseAgreementEnteredMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="ovid_LicenseAgreementEnteredMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement entered month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_LicenseAgreementEnteredMonthAndYear" xlink:to="ovid_LicenseAgreementEnteredMonthAndYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_LicenseAgreementEnteredMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement entered Period</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_LicenseAgreementEnteredMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Entered Month And Year</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" xlink:type="locator" xlink:label="ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" />
    <link:label xml:lang="en-US" xlink:label="ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront non-creditable one-time license issuance fee payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" xlink:to="ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AnnualLicenseMaintenanceFeePayable" xlink:type="locator" xlink:label="ovid_AnnualLicenseMaintenanceFeePayable" />
    <link:label xml:lang="en-US" xlink:label="ovid_AnnualLicenseMaintenanceFeePayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual license maintenance fee payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_AnnualLicenseMaintenanceFeePayable" xlink:to="ovid_AnnualLicenseMaintenanceFeePayable_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ConsiderationPayableForRightsGrant" xlink:type="locator" xlink:label="ovid_ConsiderationPayableForRightsGrant" />
    <link:label xml:lang="en-US" xlink:label="ovid_ConsiderationPayableForRightsGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Consideration payable for rights grant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_ConsiderationPayableForRightsGrant" xlink:to="ovid_ConsiderationPayableForRightsGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront non-creditable one-time license issuance fee payment</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Non Creditable One Time License Issuance Fee Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AnnualLicenseMaintenanceFeePayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual license maintenance fee payable</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AnnualLicenseMaintenanceFeePayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual License Maintenance Fee Payable</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_ConsiderationPayableForRightsGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consideration payable for rights grant</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_ConsiderationPayableForRightsGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consideration Payable For Rights Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementRightsAndObligations" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementRightsAndObligations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementRightsAndObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement, description of rights and obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementRightsAndObligations" xlink:to="us-gaap_CollaborativeArrangementRightsAndObligations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementRightsAndObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Rights And Obligations</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" xlink:type="locator" xlink:label="ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" />
    <link:label xml:lang="en-US" xlink:label="ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum number of product covered under license agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" xlink:to="ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum number of product covered under license agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Number Of Product Covered Under License Agreement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AngeliniLicenseAgreementMember" xlink:type="locator" xlink:label="ovid_AngeliniLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_AngeliniLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Angelini License Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_AngeliniLicenseAgreementMember" xlink:to="ovid_AngeliniLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_AngeliniLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Angelini License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AngeliniLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Angelini License Agreement [Member]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="locator" xlink:label="ovid_TakedaPharmaceuticalCompanyLimitedMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_TakedaPharmaceuticalCompanyLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Takeda Pharmaceutical Company Limited.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="ovid_TakedaPharmaceuticalCompanyLimitedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_TakedaPharmaceuticalCompanyLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Takeda Pharmaceutical Company Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_TakedaPharmaceuticalCompanyLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Takeda Pharmaceutical Company Limited [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SeriesB1PreferredStockMember" xlink:type="locator" xlink:label="ovid_SeriesB1PreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_SeriesB1PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B-1 preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_SeriesB1PreferredStockMember" xlink:to="ovid_SeriesB1PreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_SeriesB1PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B-1 Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_SeriesB1PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B1 Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaborative Arrangement, Co-promotion [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement, Co-promotion [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAgreementUpfrontPayment" xlink:type="locator" xlink:label="ovid_LicenseAgreementUpfrontPayment" />
    <link:label xml:lang="en-US" xlink:label="ovid_LicenseAgreementUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement upfront payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_LicenseAgreementUpfrontPayment" xlink:to="ovid_LicenseAgreementUpfrontPayment_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AggregateLicenseAgreementMilestonePayments" xlink:type="locator" xlink:label="ovid_AggregateLicenseAgreementMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="ovid_AggregateLicenseAgreementMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate license agreement milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_AggregateLicenseAgreementMilestonePayments" xlink:to="ovid_AggregateLicenseAgreementMilestonePayments_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SalesMilestonePaymentsThroughLicenseAgreement" xlink:type="locator" xlink:label="ovid_SalesMilestonePaymentsThroughLicenseAgreement" />
    <link:label xml:lang="en-US" xlink:label="ovid_SalesMilestonePaymentsThroughLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales milestone payments through license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_SalesMilestonePaymentsThroughLicenseAgreement" xlink:to="ovid_SalesMilestonePaymentsThroughLicenseAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_LicenseAgreementUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment under license agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_LicenseAgreementUpfrontPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AggregateLicenseAgreementMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AggregateLicenseAgreementMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate License Agreement Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_SalesMilestonePaymentsThroughLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales milestone payments for achievement of specified levels of net sales</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_SalesMilestonePaymentsThroughLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestone Payments Through License Agreement</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_PotentialFundingCostPercent" xlink:type="locator" xlink:label="ovid_PotentialFundingCostPercent" />
    <link:label xml:lang="en-US" xlink:label="ovid_PotentialFundingCostPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential funding cost percent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_PotentialFundingCostPercent" xlink:to="ovid_PotentialFundingCostPercent_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_CostOfAgreementNet" xlink:type="locator" xlink:label="ovid_CostOfAgreementNet" />
    <link:label xml:lang="en-US" xlink:label="ovid_CostOfAgreementNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of agreement net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_CostOfAgreementNet" xlink:to="ovid_CostOfAgreementNet_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_DeferredUpfrontPaymentCosts" xlink:type="locator" xlink:label="ovid_DeferredUpfrontPaymentCosts" />
    <link:label xml:lang="en-US" xlink:label="ovid_DeferredUpfrontPaymentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred upfront payment costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_DeferredUpfrontPaymentCosts" xlink:to="ovid_DeferredUpfrontPaymentCosts_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_UpFrontFeeAmount" xlink:type="locator" xlink:label="ovid_UpFrontFeeAmount" />
    <link:label xml:lang="en-US" xlink:label="ovid_UpFrontFeeAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Up-front fee amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_UpFrontFeeAmount" xlink:to="ovid_UpFrontFeeAmount_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement" xlink:type="locator" xlink:label="ovid_AggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement" />
    <link:label xml:lang="en-US" xlink:label="ovid_AggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate tech transfer and regulatory payments through license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_AggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement" xlink:to="ovid_AggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AdditionalAggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement" xlink:type="locator" xlink:label="ovid_AdditionalAggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement" />
    <link:label xml:lang="en-US" xlink:label="ovid_AdditionalAggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional aggregate tech transfer and regulatory payments through license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_AdditionalAggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement" xlink:to="ovid_AdditionalAggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseRevenue" xlink:type="locator" xlink:label="ovid_LicenseRevenue" />
    <link:label xml:lang="en-US" xlink:label="ovid_LicenseRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_LicenseRevenue" xlink:to="ovid_LicenseRevenue_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_IncomeFromOngoingTrials" xlink:type="locator" xlink:label="ovid_IncomeFromOngoingTrials" />
    <link:label xml:lang="en-US" xlink:label="ovid_IncomeFromOngoingTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income from ongoing trials</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_IncomeFromOngoingTrials" xlink:to="ovid_IncomeFromOngoingTrials_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_IncomeFromTransferOfSpecifiedAmountOfCompoundAndRelatedInformation" xlink:type="locator" xlink:label="ovid_IncomeFromTransferOfSpecifiedAmountOfCompoundAndRelatedInformation" />
    <link:label xml:lang="en-US" xlink:label="ovid_IncomeFromTransferOfSpecifiedAmountOfCompoundAndRelatedInformation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income from transfer of specified amount of compound and related information.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_IncomeFromTransferOfSpecifiedAmountOfCompoundAndRelatedInformation" xlink:to="ovid_IncomeFromTransferOfSpecifiedAmountOfCompoundAndRelatedInformation_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AmountForPotentialFutureTrials" xlink:type="locator" xlink:label="ovid_AmountForPotentialFutureTrials" />
    <link:label xml:lang="en-US" xlink:label="ovid_AmountForPotentialFutureTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount for potential future trials.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_AmountForPotentialFutureTrials" xlink:to="ovid_AmountForPotentialFutureTrials_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AdditionalTechTransferThroughLicenseAgreement" xlink:type="locator" xlink:label="ovid_AdditionalTechTransferThroughLicenseAgreement" />
    <link:label xml:lang="en-US" xlink:label="ovid_AdditionalTechTransferThroughLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional tech transfer through license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_AdditionalTechTransferThroughLicenseAgreement" xlink:to="ovid_AdditionalTechTransferThroughLicenseAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_PotentialFundingCostPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential funding cost percent</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_PotentialFundingCostPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Potential Funding Cost Percent</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_CostOfAgreementNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future cost of agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_CostOfAgreementNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Agreement Net</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_DeferredUpfrontPaymentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred upfront payment costs</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_DeferredUpfrontPaymentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Upfront Payment Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_UpFrontFeeAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Up-front fee</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_UpFrontFeeAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Up Front Fee Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AmountForPotentialFutureTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount for potential future trials</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AmountForPotentialFutureTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amount For Potential Future Trials</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate tech transfer and regulatory payments through license agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Tech Transfer And Regulatory Payments Through License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AdditionalTechTransferThroughLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional tech transfer through license agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AdditionalTechTransferThroughLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Tech Transfer Through License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AdditionalAggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional aggregate tech transfer and regulatory payments through license agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AdditionalAggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Aggregate Tech Transfer And Regulatory Payments Through License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_LicenseRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_LicenseRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_IncomeFromOngoingTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ongoing trials</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_IncomeFromOngoingTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income From Ongoing Trials</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_IncomeFromTransferOfSpecifiedAmountOfCompoundAndRelatedInformation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer of specified amount of compound and related information</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_IncomeFromTransferOfSpecifiedAmountOfCompoundAndRelatedInformation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income From Transfer Of Specified Amount Of Compound And Related Information</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ResearchAndDevelopmentExpenseReimbursementReceived" xlink:type="locator" xlink:label="ovid_ResearchAndDevelopmentExpenseReimbursementReceived" />
    <link:label xml:lang="en-US" xlink:label="ovid_ResearchAndDevelopmentExpenseReimbursementReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense reimbursement received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_ResearchAndDevelopmentExpenseReimbursementReceived" xlink:to="ovid_ResearchAndDevelopmentExpenseReimbursementReceived_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_PercentageOfOutstandingSharesOfCapitalStock" xlink:type="locator" xlink:label="ovid_PercentageOfOutstandingSharesOfCapitalStock" />
    <link:label xml:lang="en-US" xlink:label="ovid_PercentageOfOutstandingSharesOfCapitalStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of outstanding shares of capital stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_PercentageOfOutstandingSharesOfCapitalStock" xlink:to="ovid_PercentageOfOutstandingSharesOfCapitalStock_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ValueForObligationUnderLicenseAgreement" xlink:type="locator" xlink:label="ovid_ValueForObligationUnderLicenseAgreement" />
    <link:label xml:lang="en-US" xlink:label="ovid_ValueForObligationUnderLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Value for obligation under license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_ValueForObligationUnderLicenseAgreement" xlink:to="ovid_ValueForObligationUnderLicenseAgreement_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ThresholdPercentageOfOutstandingCapitalStockToMakeCashPayment" xlink:type="locator" xlink:label="ovid_ThresholdPercentageOfOutstandingCapitalStockToMakeCashPayment" />
    <link:label xml:lang="en-US" xlink:label="ovid_ThresholdPercentageOfOutstandingCapitalStockToMakeCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Threshold percentage of outstanding capital stock to make cash payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_ThresholdPercentageOfOutstandingCapitalStockToMakeCashPayment" xlink:to="ovid_ThresholdPercentageOfOutstandingCapitalStockToMakeCashPayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, price per share</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value of Series B-1 Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_PercentageOfOutstandingSharesOfCapitalStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding capital stock on the issuance date</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_PercentageOfOutstandingSharesOfCapitalStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Outstanding Shares Of Capital Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_ValueForObligationUnderLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Value fixed on collaboration for share obligation terms</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_ValueForObligationUnderLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Value For Obligation Under License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_ThresholdPercentageOfOutstandingCapitalStockToMakeCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Threshold percentage of outstanding capital stock to make cash payment</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_ThresholdPercentageOfOutstandingCapitalStockToMakeCashPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Threshold Percentage Of Outstanding Capital Stock To Make Cash Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_LicenseAgreementMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Global commercial and regulatory milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_ResearchAndDevelopmentExpenseReimbursementReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense reimbursement received</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_ResearchAndDevelopmentExpenseReimbursementReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Reimbursement Received</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Related Parties Current And Noncurrent</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ConsultingArrangementPeriod" xlink:type="locator" xlink:label="ovid_ConsultingArrangementPeriod" />
    <link:label xml:lang="en-US" xlink:label="ovid_ConsultingArrangementPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Consulting arrangement period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_ConsultingArrangementPeriod" xlink:to="ovid_ConsultingArrangementPeriod_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_OtherAdvisoryAndConsultingServicesFee" xlink:type="locator" xlink:label="ovid_OtherAdvisoryAndConsultingServicesFee" />
    <link:label xml:lang="en-US" xlink:label="ovid_OtherAdvisoryAndConsultingServicesFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other advisory and consulting services fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_OtherAdvisoryAndConsultingServicesFee" xlink:to="ovid_OtherAdvisoryAndConsultingServicesFee_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">75000 Shares Vest After December, 2020 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche Two [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">100,000 Shares Vest Before December 31, 2020 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche One [Member]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ChiefExecutiveOfficerAndChairmanMember" xlink:type="locator" xlink:label="ovid_ChiefExecutiveOfficerAndChairmanMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_ChiefExecutiveOfficerAndChairmanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Chief Executive Officer and Chairman.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_ChiefExecutiveOfficerAndChairmanMember" xlink:to="ovid_ChiefExecutiveOfficerAndChairmanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_ChiefExecutiveOfficerAndChairmanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chief Executive Officer And Chairman [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_ChiefExecutiveOfficerAndChairmanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Chief Executive Officer And Chairman [Member]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember" xlink:type="locator" xlink:label="ovid_AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Affiliated with Takeda, Biotechnology Value Fund, L.P., and Shira Capital, LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember" xlink:to="ovid_AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Affiliated with Takeda, Biotechnology Value Fund, L.P., and Shira Capital, LLC [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Affiliated With Takeda Biotechnology Value Fund L P And Shira Capital L L C [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_ConsultingArrangementPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting arrangement period</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_ConsultingArrangementPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consulting Arrangement Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees" xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfessionalFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fees to be paid per year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfessionalFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Professional Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_OtherAdvisoryAndConsultingServicesFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other advisory and consulting services to be paid per year</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_OtherAdvisoryAndConsultingServicesFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Advisory And Consulting Services Fee</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel">Options granted to acquire shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise price per share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting arrangement termination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:to="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Terms And Manner Of Settlement</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from Offerings, net of offering expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_RoyaltyAndTerminationAgreementMember" xlink:type="locator" xlink:label="ovid_RoyaltyAndTerminationAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ovid_RoyaltyAndTerminationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty and termination agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_RoyaltyAndTerminationAgreementMember" xlink:to="ovid_RoyaltyAndTerminationAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_RoyaltyAndTerminationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty and Termination Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_RoyaltyAndTerminationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty And Termination Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Granted option awards</link:label>
    <link:loc xlink:href="ovid-20201231.xsd#ovid_UpfrontPaymentReceivable" xlink:type="locator" xlink:label="ovid_UpfrontPaymentReceivable" />
    <link:label xml:lang="en-US" xlink:label="ovid_UpfrontPaymentReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_UpfrontPaymentReceivable" xlink:to="ovid_UpfrontPaymentReceivable_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AgreementMilestonePayments" xlink:type="locator" xlink:label="ovid_AgreementMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="ovid_AgreementMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_AgreementMilestonePayments" xlink:to="ovid_AgreementMilestonePayments_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AgreementClosingDate" xlink:type="locator" xlink:label="ovid_AgreementClosingDate" />
    <link:label xml:lang="en-US" xlink:label="ovid_AgreementClosingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement closing date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_AgreementClosingDate" xlink:to="ovid_AgreementClosingDate_lbl" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AdditionalPaymentReceivableOnSalesPercentage" xlink:type="locator" xlink:label="ovid_AdditionalPaymentReceivableOnSalesPercentage" />
    <link:label xml:lang="en-US" xlink:label="ovid_AdditionalPaymentReceivableOnSalesPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional payment receivable on sales percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ovid_AdditionalPaymentReceivableOnSalesPercentage" xlink:to="ovid_AdditionalPaymentReceivableOnSalesPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="ovid_UpfrontPaymentReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment under royalty and termination agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_UpfrontPaymentReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AgreementMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AgreementMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AdditionalPaymentReceivableOnSalesPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional payment on sales percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AdditionalPaymentReceivableOnSalesPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Payment Receivable On Sales Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AgreementClosingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement closing date</link:label>
    <link:label xml:lang="en-US" xlink:label="ovid_AgreementClosingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Closing Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement ownership share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Ownership Percentage</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>25
<FILENAME>ovid-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-15T02:26:45.6355768+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 8ac83ee457de40fa87b3ceabc3444e96 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/role/TemplateLink" xlink:href="ovid-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ovid-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="12070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="12130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="ovid-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedParties" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableRelatedParties" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_SecurityDeposit" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="ovid-20201231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_PreferredStockShareDesignated" xlink:type="locator" xlink:label="ovid_PreferredStockShareDesignated" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ovid_PreferredStockShareDesignated" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="ovid-20201231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementTable" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="ovid-20201231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="ovid-20201231.xsd#Role_StatementConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementOfChangesInStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ATMOfferingCosts" xlink:type="locator" xlink:label="ovid_ATMOfferingCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_OctoberOfferingMember" xlink:type="locator" xlink:label="ovid_OctoberOfferingMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AugustTwoThousandTwentyOfferingMember" xlink:type="locator" xlink:label="ovid_AugustTwoThousandTwentyOfferingMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_FebruaryOfferingMember" xlink:type="locator" xlink:label="ovid_FebruaryOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ATMOfferingsMember" xlink:type="locator" xlink:label="ovid_ATMOfferingsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="ovid_ATMOfferingsMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ovid_FebruaryOfferingMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ovid_AugustTwoThousandTwentyOfferingMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ovid_OctoberOfferingMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ovid_ATMOfferingCosts" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="12230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued_li0l2" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="ovid-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoninterestExpenseOfferingCost" xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseOfferingCost" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SoftwareDevelopmentAndOtherCostsInAccountsPayableAndAccruedExpenses" xlink:type="locator" xlink:label="ovid_SoftwareDevelopmentAndOtherCostsInAccountsPayableAndAccruedExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToDevelopSoftware" xlink:type="locator" xlink:label="us-gaap_PaymentsToDevelopSoftware" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent" xlink:type="locator" xlink:label="ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseDueFromAffiliates" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseDueFromAffiliates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AccruedInterestAndAccretionOfDiscountsShortTermInvestments" xlink:type="locator" xlink:label="ovid_AccruedInterestAndAccretionOfDiscountsShortTermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ATMMember" xlink:type="locator" xlink:label="ovid_ATMMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_FebruaryAndOctoberTwoThousandNinteenOfferingsMember" xlink:type="locator" xlink:label="ovid_FebruaryAndOctoberTwoThousandNinteenOfferingsMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AugustTwoThousandTwentyOfferingMember" xlink:type="locator" xlink:label="ovid_AugustTwoThousandTwentyOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="locator" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ovid_AugustTwoThousandTwentyOfferingMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ovid_FebruaryAndOctoberTwoThousandNinteenOfferingsMember" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ovid_ATMMember" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ovid_AccruedInterestAndAccretionOfDiscountsShortTermInvestments" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseDueFromAffiliates" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToDevelopSoftware" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ovid_SoftwareDevelopmentAndOtherCostsInAccountsPayableAndAccruedExpenses" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_NoninterestExpenseOfferingCost" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureNatureOfOperations" xlink:href="ovid-20201231.xsd#Role_DisclosureNatureOfOperations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureNatureOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="ovid-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestments" xlink:href="ovid-20201231.xsd#Role_DisclosureCashEquivalentsAndShortTermInvestments" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestments">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAndIntangibleAssets" xlink:href="ovid-20201231.xsd#Role_DisclosurePropertyAndEquipmentAndIntangibleAssets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAndIntangibleAssets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureAccruedExpenses" xlink:href="ovid-20201231.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureAccruedExpenses">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockholdersEquityAndPreferredStock" xlink:href="ovid-20201231.xsd#Role_DisclosureStockholdersEquityAndPreferredStock" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockholdersEquityAndPreferredStock">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="ovid-20201231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="ovid-20201231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="ovid-20201231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCollaborationAgreement" xlink:href="ovid-20201231.xsd#Role_DisclosureCollaborationAgreement" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCollaborationAgreement">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="ovid-20201231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="ovid-20201231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ovid-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementAccountingPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CollaborativeArrangementAccountingPolicy" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="ovid-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsTables" xlink:href="ovid-20201231.xsd#Role_DisclosureCashEquivalentsAndShortTermInvestmentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsTables">
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ScheduleOfCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="locator" xlink:label="ovid_ScheduleOfCashEquivalentsAndShortTermInvestmentsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="ovid_ScheduleOfCashEquivalentsAndShortTermInvestmentsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAndIntangibleAssetsTables" xlink:href="ovid-20201231.xsd#Role_DisclosurePropertyAndEquipmentAndIntangibleAssetsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAndIntangibleAssetsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables" xlink:href="ovid-20201231.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="ovid-20201231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_NonEmployeeStockOptionsMember" xlink:type="locator" xlink:label="ovid_NonEmployeeStockOptionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ovid_NonEmployeeStockOptionsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="ovid-20201231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureNatureOfOperationsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetail">
    <link:loc xlink:href="ovid-20201231.xsd#ovid_WorkingCapital" xlink:type="locator" xlink:label="ovid_WorkingCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="locator" xlink:label="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAndCollaborationAgreementMember" xlink:type="locator" xlink:label="ovid_LicenseAndCollaborationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="locator" xlink:label="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ovid_LicenseAndCollaborationAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="ovid_WorkingCapital" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_DefinedContributionPlanName" xlink:type="locator" xlink:label="ovid_DefinedContributionPlanName" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AvailableForSaleSecuritiesInvestmentsMaturityPeriod" xlink:type="locator" xlink:label="ovid_AvailableForSaleSecuritiesInvestmentsMaturityPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_PercentageOfNetExpensesOfDevelopmentCostsRecordedInResearchAndDevelopment" xlink:type="locator" xlink:label="ovid_PercentageOfNetExpensesOfDevelopmentCostsRecordedInResearchAndDevelopment" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_DescriptionOfOwnershipPatternAsPerLicenseAndCollaborationAgreement" xlink:type="locator" xlink:label="ovid_DescriptionOfOwnershipPatternAsPerLicenseAndCollaborationAgreement" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:type="locator" xlink:label="ovid_SummaryOfSignificantAccountingPolicyLineItems" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ScenarioTwoMember" xlink:type="locator" xlink:label="ovid_ScenarioTwoMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ScenarioOneMember" xlink:type="locator" xlink:label="ovid_ScenarioOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_MoneyMarketFundsAndShortTermInvestmentsMember" xlink:type="locator" xlink:label="ovid_MoneyMarketFundsAndShortTermInvestmentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SummaryOfSignificantAccountingPolicyTable" xlink:type="locator" xlink:label="ovid_SummaryOfSignificantAccountingPolicyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ovid_SummaryOfSignificantAccountingPolicyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_SummaryOfSignificantAccountingPolicyTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_SummaryOfSignificantAccountingPolicyTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_SummaryOfSignificantAccountingPolicyTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="ovid_MoneyMarketFundsAndShortTermInvestmentsMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_SummaryOfSignificantAccountingPolicyTable" xlink:to="srt_StatementScenarioAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ovid_ScenarioOneMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ovid_ScenarioTwoMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_SummaryOfSignificantAccountingPolicyTable" xlink:to="ovid_SummaryOfSignificantAccountingPolicyLineItems" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="ovid_DescriptionOfOwnershipPatternAsPerLicenseAndCollaborationAgreement" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="ovid_PercentageOfNetExpensesOfDevelopmentCostsRecordedInResearchAndDevelopment" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="ovid_AvailableForSaleSecuritiesInvestmentsMaturityPeriod" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="ovid_DefinedContributionPlanName" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSchedulePotentiallyDilutiveSecuritiesExcludedFromComputationsOfDilutedWeightedAverageSharesOutstandingDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSchedulePotentiallyDilutiveSecuritiesExcludedFromComputationsOfDilutedWeightedAverageSharesOutstandingDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSchedulePotentiallyDilutiveSecuritiesExcludedFromComputationsOfDilutedWeightedAverageSharesOutstandingDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="ovid_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="ovid_SeriesAConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsSummaryOfFairValueOfCashEquivalentsShortTermInvestmentsAndGrossUnrealizedHoldingGainsAndLossesDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureCashEquivalentsAndShortTermInvestmentsSummaryOfFairValueOfCashEquivalentsShortTermInvestmentsAndGrossUnrealizedHoldingGainsAndLossesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsSummaryOfFairValueOfCashEquivalentsShortTermInvestmentsAndGrossUnrealizedHoldingGainsAndLossesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USTreasurySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember" xlink:type="locator" xlink:label="us-gaap_CashMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsAdditionalInformationDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureCashEquivalentsAndShortTermInvestmentsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_DebtSecuritiesAvailableForSaleContinuousUnrealizedGainPosition12MonthsOrLongerNumberOfPositions" xlink:type="locator" xlink:label="ovid_DebtSecuritiesAvailableForSaleContinuousUnrealizedGainPosition12MonthsOrLongerNumberOfPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="ovid_DebtSecuritiesAvailableForSaleContinuousUnrealizedGainPosition12MonthsOrLongerNumberOfPositions" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAndIntangibleAssetsSummaryOfPropertyAndEquipmentDetail" xlink:href="ovid-20201231.xsd#Role_DisclosurePropertyAndEquipmentAndIntangibleAssetsSummaryOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAndIntangibleAssetsSummaryOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAndIntangibleAssetsAdditionalInformationDetail" xlink:href="ovid-20201231.xsd#Role_DisclosurePropertyAndEquipmentAndIntangibleAssetsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAndIntangibleAssetsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ClinicalTrialsAccrualCurrent" xlink:type="locator" xlink:label="ovid_ClinicalTrialsAccrualCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="ovid_ClinicalTrialsAccrualCurrent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockholdersEquityAndPreferredStockAdditionalInformationDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureStockholdersEquityAndPreferredStockAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockholdersEquityAndPreferredStockAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends" xlink:type="locator" xlink:label="us-gaap_Dividends" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendPaymentRestrictionsScheduleDescription" xlink:type="locator" xlink:label="us-gaap_DividendPaymentRestrictionsScheduleDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" xlink:type="locator" xlink:label="ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" xlink:type="locator" xlink:label="ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AggregateOfferingPriceOfCommonStock" xlink:type="locator" xlink:label="ovid_AggregateOfferingPriceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_PreferredStockShareDesignated" xlink:type="locator" xlink:label="ovid_PreferredStockShareDesignated" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember" xlink:type="locator" xlink:label="srt_AffiliatedEntityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="ovid_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember_li0l2" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_CowenAndCompanyLLCMember" xlink:type="locator" xlink:label="ovid_CowenAndCompanyLLCMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ATMAgreementMember" xlink:type="locator" xlink:label="ovid_ATMAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ovid_ATMAgreementMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="ovid_CowenAndCompanyLLCMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember_li0l2" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="ovid_SeriesAConvertiblePreferredStockMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_AffiliatedEntityMember" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ovid_PreferredStockShareDesignated" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ovid_AggregateOfferingPriceOfCommonStock" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreference" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendPaymentRestrictionsScheduleDescription" order="12550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_Dividends" order="12570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InitialOfferingPeriod" xlink:type="locator" xlink:label="us-gaap_InitialOfferingPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_EmployeePerformanceBasedOptionAwardsMember" xlink:type="locator" xlink:label="ovid_EmployeePerformanceBasedOptionAwardsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ChairmanOfScientificAdvisoryBoardMember" xlink:type="locator" xlink:label="ovid_ChairmanOfScientificAdvisoryBoardMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SeparationAndConsultingAgreementMember" xlink:type="locator" xlink:label="ovid_SeparationAndConsultingAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_NonemployeePerformanceBasedOptionAwardsMember" xlink:type="locator" xlink:label="ovid_NonemployeePerformanceBasedOptionAwardsMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_NonEmployeeStockOptionsMember" xlink:type="locator" xlink:label="ovid_NonEmployeeStockOptionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:type="locator" xlink:label="us-gaap_PerformanceSharesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_TwoThousandFourteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="ovid_TwoThousandFourteenEquityIncentivePlanMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="locator" xlink:label="ovid_TwoThousandSeventeenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ovid_TwoThousandSeventeenEquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ovid_TwoThousandFourteenEquityIncentivePlanMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ovid_NonEmployeeStockOptionsMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ovid_NonemployeePerformanceBasedOptionAwardsMember" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ovid_SeparationAndConsultingAgreementMember" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ovid_ChairmanOfScientificAdvisoryBoardMember" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ovid_EmployeePerformanceBasedOptionAwardsMember" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_InitialOfferingPeriod" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="12450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAllocationOfStockBasedCompensationExpenseByPlanDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureStockBasedCompensationScheduleOfAllocationOfStockBasedCompensationExpenseByPlanDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAllocationOfStockBasedCompensationExpenseByPlanDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="ovid_EmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_StockOptionsMember" xlink:type="locator" xlink:label="ovid_StockOptionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ovid_StockOptionsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ovid_EmployeeStockPurchasePlanMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToComputeFairValueOfEmployeeOptionGrantedDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToComputeFairValueOfEmployeeOptionGrantedDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToComputeFairValueOfEmployeeOptionGrantedDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_NonEmployeeStockOptionsMember" xlink:type="locator" xlink:label="ovid_NonEmployeeStockOptionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ovid_NonEmployeeStockOptionsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionsOutstandingAndWeightedAverageExercisePriceDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfOptionsOutstandingAndWeightedAverageExercisePriceDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionsOutstandingAndWeightedAverageExercisePriceDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" xlink:type="locator" xlink:label="ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_li0l2" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_li0l2" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="12510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife" order="12610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="13210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="13310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_OperatingLossCarryforwardsExpirationPeriodStart" xlink:type="locator" xlink:label="ovid_OperatingLossCarryforwardsExpirationPeriodStart" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="ovid_IncomeTaxDisclosureLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:type="locator" xlink:label="us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="ovid_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ovid_IncomeTaxDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_IncomeTaxDisclosureTable" xlink:to="ovid_IncomeTaxDisclosureLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_IncomeTaxDisclosureLineItems" xlink:to="ovid_OperatingLossCarryforwardsExpirationPeriodStart" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ovid_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryUSFederalRateToEffectiveTaxRateDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureIncomeTaxesReconciliationOfStatutoryUSFederalRateToEffectiveTaxRateDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryUSFederalRateToEffectiveTaxRateDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryUSFederalRateToEffectiveTaxRateParentheticalDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureIncomeTaxesReconciliationOfStatutoryUSFederalRateToEffectiveTaxRateParentheticalDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryUSFederalRateToEffectiveTaxRateParentheticalDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="ovid-20201231.xsd#ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" xlink:type="locator" xlink:label="ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementRightsAndObligations" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementRightsAndObligations" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ConsiderationPayableForRightsGrant" xlink:type="locator" xlink:label="ovid_ConsiderationPayableForRightsGrant" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AnnualLicenseMaintenanceFeePayable" xlink:type="locator" xlink:label="ovid_AnnualLicenseMaintenanceFeePayable" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" xlink:type="locator" xlink:label="ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAgreementEnteredMonthAndYear" xlink:type="locator" xlink:label="ovid_LicenseAgreementEnteredMonthAndYear" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_NumberOfTrial" xlink:type="locator" xlink:label="ovid_NumberOfTrial" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_FirstPaymentDueUponCompletionOfFirstPhase" xlink:type="locator" xlink:label="ovid_FirstPaymentDueUponCompletionOfFirstPhase" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAgreementMilestonePayments" xlink:type="locator" xlink:label="ovid_LicenseAgreementMilestonePayments" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAgreementEnteredDate" xlink:type="locator" xlink:label="ovid_LicenseAgreementEnteredDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_NorthwesternUniversityMember" xlink:type="locator" xlink:label="ovid_NorthwesternUniversityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAgreementMember" xlink:type="locator" xlink:label="ovid_LicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_HLundbeckASMember" xlink:type="locator" xlink:label="ovid_HLundbeckASMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ovid_HLundbeckASMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ovid_LicenseAgreementMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ovid_NorthwesternUniversityMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ovid_LicenseAgreementEnteredDate" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ovid_LicenseAgreementMilestonePayments" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ovid_FirstPaymentDueUponCompletionOfFirstPhase" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ovid_NumberOfTrial" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ovid_LicenseAgreementEnteredMonthAndYear" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ovid_AnnualLicenseMaintenanceFeePayable" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ovid_ConsiderationPayableForRightsGrant" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_CollaborativeArrangementRightsAndObligations" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureCollaborationAgreementAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedParties" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ResearchAndDevelopmentExpenseReimbursementReceived" xlink:type="locator" xlink:label="ovid_ResearchAndDevelopmentExpenseReimbursementReceived" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAgreementMilestonePayments" xlink:type="locator" xlink:label="ovid_LicenseAgreementMilestonePayments" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ThresholdPercentageOfOutstandingCapitalStockToMakeCashPayment" xlink:type="locator" xlink:label="ovid_ThresholdPercentageOfOutstandingCapitalStockToMakeCashPayment" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ValueForObligationUnderLicenseAgreement" xlink:type="locator" xlink:label="ovid_ValueForObligationUnderLicenseAgreement" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_PercentageOfOutstandingSharesOfCapitalStock" xlink:type="locator" xlink:label="ovid_PercentageOfOutstandingSharesOfCapitalStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_IncomeFromTransferOfSpecifiedAmountOfCompoundAndRelatedInformation" xlink:type="locator" xlink:label="ovid_IncomeFromTransferOfSpecifiedAmountOfCompoundAndRelatedInformation" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_IncomeFromOngoingTrials" xlink:type="locator" xlink:label="ovid_IncomeFromOngoingTrials" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseRevenue" xlink:type="locator" xlink:label="ovid_LicenseRevenue" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AdditionalAggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement" xlink:type="locator" xlink:label="ovid_AdditionalAggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AdditionalTechTransferThroughLicenseAgreement" xlink:type="locator" xlink:label="ovid_AdditionalTechTransferThroughLicenseAgreement" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement" xlink:type="locator" xlink:label="ovid_AggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AmountForPotentialFutureTrials" xlink:type="locator" xlink:label="ovid_AmountForPotentialFutureTrials" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_UpFrontFeeAmount" xlink:type="locator" xlink:label="ovid_UpFrontFeeAmount" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_DeferredUpfrontPaymentCosts" xlink:type="locator" xlink:label="ovid_DeferredUpfrontPaymentCosts" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_CostOfAgreementNet" xlink:type="locator" xlink:label="ovid_CostOfAgreementNet" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_PotentialFundingCostPercent" xlink:type="locator" xlink:label="ovid_PotentialFundingCostPercent" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SalesMilestonePaymentsThroughLicenseAgreement" xlink:type="locator" xlink:label="ovid_SalesMilestonePaymentsThroughLicenseAgreement" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AggregateLicenseAgreementMilestonePayments" xlink:type="locator" xlink:label="ovid_AggregateLicenseAgreementMilestonePayments" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAgreementUpfrontPayment" xlink:type="locator" xlink:label="ovid_LicenseAgreementUpfrontPayment" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAgreementEnteredDate" xlink:type="locator" xlink:label="ovid_LicenseAgreementEnteredDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SeriesB1PreferredStockMember" xlink:type="locator" xlink:label="ovid_SeriesB1PreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="locator" xlink:label="ovid_TakedaPharmaceuticalCompanyLimitedMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_LicenseAgreementMember" xlink:type="locator" xlink:label="ovid_LicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AngeliniLicenseAgreementMember" xlink:type="locator" xlink:label="ovid_AngeliniLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ovid_AngeliniLicenseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ovid_LicenseAgreementMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="ovid_TakedaPharmaceuticalCompanyLimitedMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ovid_SeriesB1PreferredStockMember" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember_li0l2" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_LicenseAgreementEnteredDate" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_LicenseAgreementUpfrontPayment" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_AggregateLicenseAgreementMilestonePayments" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_SalesMilestonePaymentsThroughLicenseAgreement" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_PotentialFundingCostPercent" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_CostOfAgreementNet" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_DeferredUpfrontPaymentCosts" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_UpFrontFeeAmount" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_AmountForPotentialFutureTrials" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_AggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_AdditionalTechTransferThroughLicenseAgreement" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_AdditionalAggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_LicenseRevenue" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_IncomeFromOngoingTrials" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_IncomeFromTransferOfSpecifiedAmountOfCompoundAndRelatedInformation" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="12100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_PercentageOfOutstandingSharesOfCapitalStock" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_ValueForObligationUnderLicenseAgreement" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_ThresholdPercentageOfOutstandingCapitalStockToMakeCashPayment" order="12220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_LicenseAgreementMilestonePayments" order="12260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ovid_ResearchAndDevelopmentExpenseReimbursementReceived" order="12340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableRelatedParties" order="12460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_OtherAdvisoryAndConsultingServicesFee" xlink:type="locator" xlink:label="ovid_OtherAdvisoryAndConsultingServicesFee" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees" xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ConsultingArrangementPeriod" xlink:type="locator" xlink:label="ovid_ConsultingArrangementPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember" xlink:type="locator" xlink:label="srt_AffiliatedEntityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember" xlink:type="locator" xlink:label="ovid_AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ChiefExecutiveOfficerAndChairmanMember" xlink:type="locator" xlink:label="ovid_ChiefExecutiveOfficerAndChairmanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_ChairmanOfScientificAdvisoryBoardMember" xlink:type="locator" xlink:label="ovid_ChairmanOfScientificAdvisoryBoardMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_SeparationAndConsultingAgreementMember" xlink:type="locator" xlink:label="ovid_SeparationAndConsultingAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ovid_SeparationAndConsultingAgreementMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ovid_ChairmanOfScientificAdvisoryBoardMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_VestingAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ovid_ChiefExecutiveOfficerAndChairmanMember" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ovid_AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_AffiliatedEntityMember" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember_li0l2" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ovid_ConsultingArrangementPeriod" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProfessionalFees" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ovid_OtherAdvisoryAndConsultingServicesFee" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="ovid-20201231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AgreementClosingDate" xlink:type="locator" xlink:label="ovid_AgreementClosingDate" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AdditionalPaymentReceivableOnSalesPercentage" xlink:type="locator" xlink:label="ovid_AdditionalPaymentReceivableOnSalesPercentage" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_AgreementMilestonePayments" xlink:type="locator" xlink:label="ovid_AgreementMilestonePayments" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_UpfrontPaymentReceivable" xlink:type="locator" xlink:label="ovid_UpfrontPaymentReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ovid-20201231.xsd#ovid_RoyaltyAndTerminationAgreementMember" xlink:type="locator" xlink:label="ovid_RoyaltyAndTerminationAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ovid_RoyaltyAndTerminationAgreementMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ovid_UpfrontPaymentReceivable" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ovid_AgreementMilestonePayments" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ovid_AdditionalPaymentReceivableOnSalesPercentage" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ovid_AgreementClosingDate" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552581251848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 08, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Ovid Therapeutics Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001636651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,753,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 293.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OVID<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-5270895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1460 Broadway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 15021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">661-7661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p>Portions of the registrant&#8217;s definitive proxy statement for its 2021 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year ended December 31, 2020, are incorporated by reference into Part III of this Annual Report on Form 10-K.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552581348008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 72,033,930<span></span>
</td>
<td class="nump">$ 41,897,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,841,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Related party receivable</a></td>
<td class="nump">141,763<span></span>
</td>
<td class="nump">1,131,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,667,508<span></span>
</td>
<td class="nump">1,942,933<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">74,843,201<span></span>
</td>
<td class="nump">79,813,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Long-term prepaid expenses</a></td>
<td class="nump">477,171<span></span>
</td>
<td class="nump">359,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">150,626<span></span>
</td>
<td class="nump">135,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">135,620<span></span>
</td>
<td class="nump">68,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">318,900<span></span>
</td>
<td class="nump">467,247<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">75,925,518<span></span>
</td>
<td class="nump">80,843,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,446,206<span></span>
</td>
<td class="nump">3,256,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">12,032,685<span></span>
</td>
<td class="nump">7,266,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related party payable</a></td>
<td class="nump">2,370,992<span></span>
</td>
<td class="nump">10,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue - current</a></td>
<td class="nump">2,212,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">22,062,775<span></span>
</td>
<td class="nump">10,533,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Related party payable - noncurrent</a></td>
<td class="nump">61,200<span></span>
</td>
<td class="nump">286,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">10,169,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">32,293,862<span></span>
</td>
<td class="nump">10,820,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 3,250 and 7,762 shares issued and outstanding at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 125,000,000 shares authorized; 65,743,170 and 54,710,322 shares issued and outstanding at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">65,743<span></span>
</td>
<td class="nump">54,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">337,758,007<span></span>
</td>
<td class="nump">283,122,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(294,192,097)<span></span>
</td>
<td class="num">(213,156,521)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">43,631,656<span></span>
</td>
<td class="nump">70,023,561<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 75,925,518<span></span>
</td>
<td class="nump">$ 80,843,731<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552581325288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">65,743,170<span></span>
</td>
<td class="nump">54,710,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">65,743,170<span></span>
</td>
<td class="nump">54,710,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_PreferredStockShareDesignated', window );">Preferred stock, share designated</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">3,250<span></span>
</td>
<td class="nump">7,762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">3,250<span></span>
</td>
<td class="nump">7,762<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_PreferredStockShareDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock shares designated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_PreferredStockShareDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552581361864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and other revenue</a></td>
<td class="nump">$ 12,617,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Revenue, Product and Service [Extensible List]</a></td>
<td class="text">us-gaap:LicenseMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 63,417,394<span></span>
</td>
<td class="nump">$ 42,157,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">30,630,804<span></span>
</td>
<td class="nump">19,251,826<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">94,048,198<span></span>
</td>
<td class="nump">61,409,467<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(81,430,977)<span></span>
</td>
<td class="num">(61,409,467)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income, net</a></td>
<td class="nump">395,401<span></span>
</td>
<td class="nump">948,224<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(81,035,576)<span></span>
</td>
<td class="num">(60,461,243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (81,035,576)<span></span>
</td>
<td class="num">$ (60,461,243)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (1.39)<span></span>
</td>
<td class="num">$ (1.54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding basic and diluted</a></td>
<td class="nump">58,451,293<span></span>
</td>
<td class="nump">39,217,223<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552581160056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (81,035,576)<span></span>
</td>
<td class="num">$ (60,461,243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on available-for-sale securities</a></td>
<td class="num">(2,469)<span></span>
</td>
<td class="nump">4,298<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) gain</a></td>
<td class="num">$ (81,038,045)<span></span>
</td>
<td class="num">$ (60,456,945)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552575569448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>February Offering [Member]</div></th>
<th class="th"><div>August 2020 Offering [Member]</div></th>
<th class="th"><div>October Offering [Member]</div></th>
<th class="th"><div>ATM Offerings [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>February Offering [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>August 2020 Offering [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>October Offering [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>ATM Offerings [Member]</div>
</th>
<th class="th"><div>Additional Paid-In Capital [Member]</div></th>
<th class="th">
<div>Additional Paid-In Capital [Member] </div>
<div>February Offering [Member]</div>
</th>
<th class="th">
<div>Additional Paid-In Capital [Member] </div>
<div>August 2020 Offering [Member]</div>
</th>
<th class="th">
<div>Additional Paid-In Capital [Member] </div>
<div>October Offering [Member]</div>
</th>
<th class="th">
<div>Additional Paid-In Capital [Member] </div>
<div>ATM Offerings [Member]</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income/(Loss) [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Convertible Preferred Stock [Member]</div></th>
<th class="th">
<div>Convertible Preferred Stock [Member] </div>
<div>February Offering [Member]</div>
</th>
<th class="th">
<div>Convertible Preferred Stock [Member] </div>
<div>October Offering [Member]</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 38,805,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191,477,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,829)<span></span>
</td>
<td class="num">$ (152,695,278)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,654,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options, Shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock from employee stock purchase plan</a></td>
<td class="nump">$ 131,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock from employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of series A convertible preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,262)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of series A convertible preferred stock to common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,262,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from Offering, net of underwriting costs and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,520,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,530,273<span></span>
</td>
<td class="nump">$ 22,286,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,350<span></span>
</td>
<td class="nump">$ 6,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,506,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,519,919<span></span>
</td>
<td class="nump">$ 22,279,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from Offering, net of underwriting costs and commissions, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,993,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,350,000<span></span>
</td>
<td class="nump">6,893,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,205,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,205,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">4,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(60,461,243)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,461,243)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">70,023,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,122,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,469<span></span>
</td>
<td class="num">(213,156,521)<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,710,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_ATMOfferingCosts', window );">ATM costs</a></td>
<td class="num">(114,936)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114,936)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from exercise of stock options</a></td>
<td class="nump">$ 300,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from exercise of stock options, Shares</a></td>
<td class="nump">165,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock from employee stock purchase plan</a></td>
<td class="nump">$ 203,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock from employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of series A convertible preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,507)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of series A convertible preferred stock to common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,512,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,512)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from Offering, net of underwriting costs and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,731,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,725,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from Offering, net of underwriting costs and commissions, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,256,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">7,525,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,525,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(2,469)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,469)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(81,035,576)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81,035,576)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 43,631,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 337,758,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (294,192,097)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,743,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_ATMOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ATM offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_ATMOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552580966056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (81,035,576)<span></span>
</td>
<td class="num">$ (60,461,243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">7,525,354<span></span>
</td>
<td class="nump">5,205,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">306,848<span></span>
</td>
<td class="nump">255,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_AccruedInterestAndAccretionOfDiscountsShortTermInvestments', window );">Change in accrued interest and accretion of discount on short-term investments</a></td>
<td class="num">(199,408)<span></span>
</td>
<td class="num">(29,633)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(724,575)<span></span>
</td>
<td class="nump">224,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Security deposit</a></td>
<td class="num">(15,236)<span></span>
</td>
<td class="num">(13,235)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseDueFromAffiliates', window );">Related party receivable</a></td>
<td class="nump">989,383<span></span>
</td>
<td class="num">(531,042)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent', window );">Long-term prepaid expenses</a></td>
<td class="num">(117,632)<span></span>
</td>
<td class="nump">2,438,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">2,333,716<span></span>
</td>
<td class="num">(653,953)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">4,835,607<span></span>
</td>
<td class="nump">2,177,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">12,382,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Related party payable</a></td>
<td class="nump">2,134,826<span></span>
</td>
<td class="nump">297,366<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(51,583,914)<span></span>
</td>
<td class="num">(51,090,622)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of short-term investments</a></td>
<td class="num">(9,961,092)<span></span>
</td>
<td class="num">(34,797,004)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of short-term investments</a></td>
<td class="nump">45,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(127,240)<span></span>
</td>
<td class="num">(57,156)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToDevelopSoftware', window );">Software development and other assets</a></td>
<td class="num">(263,440)<span></span>
</td>
<td class="num">(186,889)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">34,648,228<span></span>
</td>
<td class="num">(30,041,049)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">203,466<span></span>
</td>
<td class="nump">131,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">300,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">47,072,472<span></span>
</td>
<td class="nump">86,539,197<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">30,136,786<span></span>
</td>
<td class="nump">5,407,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, at beginning of period</a></td>
<td class="nump">41,897,144<span></span>
</td>
<td class="nump">36,489,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, at end of period</a></td>
<td class="nump">72,033,930<span></span>
</td>
<td class="nump">41,897,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_SoftwareDevelopmentAndOtherCostsInAccountsPayableAndAccruedExpenses', window );">Software development and other costs in accrued expenses and accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoninterestExpenseOfferingCost', window );">Offering costs in accrued expenses and accounts payable</a></td>
<td class="nump">21,314<span></span>
</td>
<td class="nump">69,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ovid_AugustTwoThousandTwentyOfferingMember', window );">August 2020 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from August, February and October Offering, net of offering expenses</a></td>
<td class="nump">46,731,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ovid_FebruaryAndOctoberTwoThousandNinteenOfferingsMember', window );">February and October 2019 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from August, February and October Offering, net of offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,120,736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ovid_ATMMember', window );">ATM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from August, February and October Offering, net of offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,286,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">ATM costs</a></td>
<td class="num">$ (163,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AccruedInterestAndAccretionOfDiscountsShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued interest and accretion of discounts, short term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AccruedInterestAndAccretionOfDiscountsShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in prepaid expense, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_IncreaseDecreaseInPrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_SoftwareDevelopmentAndOtherCostsInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Software development and other costs in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_SoftwareDevelopmentAndOtherCostsInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseDueFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from an entity that is controlling, under the control of, or within the same control group as the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseDueFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in security deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Includes offering costs of open-end investment companies, and closed-end funds with a continuous offering period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToDevelopSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToDevelopSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ovid_AugustTwoThousandTwentyOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ovid_AugustTwoThousandTwentyOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ovid_FebruaryAndOctoberTwoThousandNinteenOfferingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ovid_FebruaryAndOctoberTwoThousandNinteenOfferingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ovid_ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ovid_ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552669755688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Operations</a></td>
<td class="text">
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTE_1_NATURE_OPERATIONS"></a>NOTE 1<font style="color:#000000;"><a name="NOTE_1_NATURE_OPERATIONS"></a> &#8211; NATURE OF OPERATIONS</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ovid Therapeutics Inc. (the &#8220;Company&#8221;) was incorporated under the laws of the state of Delaware on April 1, 2014 and maintains its principal executive office in New York, New York. The Company commenced operations on April 1, 2014 (date of inception). The Company is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its inception, the Company has devoted substantially all of its efforts to business development, research and development, recruiting management and technical staff, and raising capital, and has financed its operations through issuance of convertible preferred stock (&#8220;Preferred Stock&#8221;), common stock and other equity instruments. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development and regulatory success, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and ability to secure additional capital to fund operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Historically, the Company&#8217;s major sources of cash have been comprised of proceeds from various public and private offerings of its capital stock and interest income. As of December 31, 2020, the Company had approximately $72.0 million in cash and cash equivalents. Since inception, the Company has generated $12.6 million in revenue as part of the Company&#8217;s license and collaboration agreement (the &#8220;Angelini License Agreement&#8221;) with Angelini Pharma Rare Diseases AG (&#8220;Angelini&#8221;). The Company has incurred recurring losses, has experienced recurring negative operating cash flows and requires significant cash resources to execute its business plans. <font style="color:#000000;">The Company has an accumulated deficit of $294.2 million as of December 31, 2020</font>, working capital of $52.8 million <font style="color:#000000;">and had cash outflows from operating activities of $51.6 million for the year ended December 31, 2020</font>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred operating losses since inception and expects to continue to incur net losses for at least the next several years and ongoing operations are highly dependent on the Company&#8217;s ability to obtain additional sources of funding. Management has identified these conditions or events, which, considered in the aggregate, raise substantial doubt about our ability to continue as a going concern, including the risk that the Company will be unable to raise adequate additional capital to fund operations through at least the next 12 months from the date of filing of this Annual Report on Form 10-K.&nbsp;&nbsp;Management&#8217;s response to these conditions and events is that the successful closing of the Takeda License and Termination Agreement with Takeda (see note 12) will provide the liquidity needed to alleviate the substantial doubt referred to above.&nbsp;&nbsp;As described in note 12, there are certain conditions to close the Takeda License and Termination Agreement, however management has determined that the likelihood of not closing in the first half of 2021 is remote.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have implemented business continuity plans designed to address and mitigate the impact of the COVID-19 pandemic on our business.&nbsp;&nbsp;The extent to which the ongoing COVID-19 pandemic impacts our business, our clinical development and regulatory efforts, our corporate development objectives and the value of and market for our common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S., Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease.&nbsp;&nbsp;The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we are subject to other challenges and risks specific to our business and our ability to execute on our strategy, as well as risks and uncertainties common to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and uncertainties associated with: obtaining regulatory approval of our late-stage product candidates; delays or problems in the supply of our products, loss of single source suppliers or failure to comply with manufacturing regulations; identifying, acquiring or in-licensing additional products or product candidates; pharmaceutical product development and the inherent uncertainty of clinical success; and the challenges of protecting and enhancing our intellectual property rights; complying with applicable regulatory requirements.&nbsp;&nbsp;In addition, to the extent the ongoing COVID-19 pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552658932792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 2<font style="color:#000000;"> &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(A) Basis of Presentation and Consolidation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include the accounts of Ovid Therapeutics Inc. and its wholly-owned subsidiary, Ovid Therapeutics Hong Kong Limited.&nbsp;&nbsp;All intercompany transactions and balances have been eliminated in consolidation.</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(B) <font style="color:#000000;">Use of Estimates</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(C) Risks and Uncertainties</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its drug candidates, ability to obtain regulatory approval of its drug candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition and untested manufacturing capabilities</font>.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(D) Deferred Transaction Costs</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred transaction costs, primarily consisted of direct incremental legal, accounting, and other fees related to the Company&#8217;s offering of its capital stock are capitalized as incurred. The deferred transaction costs are offset against proceeds upon the consummation of an offering.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(E) Comprehensive Loss</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. </p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(F) Collaboration Arrangement</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">License and Collaboration Agreement with Takeda Pharmaceutical Company Limited</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the current license and collaboration agreement with Takeda Ovid and Takeda are sharing 50/50 in the drug development, the Company records 50% of the development costs in research and development.&nbsp;&nbsp;When Ovid incurs the majority of the costs and Takeda transfers a payment to Ovid to equalize the costs, Ovid records the participation by Takeda as a reduction of its research and development expenses, as the parties under the collaboration are sharing in the costs and the payment represents reimbursement of costs by Takeda.&#160;When Takeda incurs the majority of the costs and Ovid transfers a payment to Takeda (to equalize the costs), Ovid records the participation in Takeda&#8217;s expenses as research and development costs in its statement of operations, as Ovid and Takeda are sharing in the research and development activities and this participation represents Ovid&#8217;s share of the research and development costs in the specific period. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(G) Cash and Cash Equivalents</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash and cash equivalents consist of cash held in checking accounts and money market funds. The Company considers all highly liquid investments with an original maturity date of three months or less to be cash and cash equivalents. Accounts held at U.S. financial institutions are insured by the FDIC up to $250,000. Cash balances could exceed insured amounts at any given time.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(H) Short-term Investments</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments<font style="Background-color:#FFFFFF;">&#160;consist of debt securities with maturities greater than&#160;</font>three months<font style="Background-color:#FFFFFF;">&#160;from the date of purchase.&#160;&#160;The Company&#160;</font>classifies<font style="Background-color:#FFFFFF;">&#160;all of its investments as available-for-sale securities. Debt securities are recorded at fair value with unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders&#8217; equity until realized. Realized gains and losses, amortization and accretion of premiums and discounts are included within net loss.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(I) Property and Equipment</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost and depreciated over their estimated useful lives of three years using the straight-line method. Repairs and maintenance costs are expensed. The Company reviews the recoverability of all long-lived assets, including the related useful life, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(J) Research and Development Expenses</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses the cost of research and development as incurred. Research and development expenses comprise costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when the cost is incurred, in accordance with ASC 730, Research and Development.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(K) Stock-Based Compensation</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for its stock-based compensation in accordance with ASC 718, Compensation&#8212;Stock Compensation, which establishes accounting for stock-based awards granted to employees for services and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company estimates the fair value of all awards granted using the Black-Scholes valuation model. Key inputs and assumptions include the expected term of the option, stock price volatility, risk-free interest rate, dividend yield, stock price and exercise price. Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense. The Company elected an accounting policy to record forfeitures as they occur. The Company recognizes employee stock-based compensation expense based on the fair value of the award on the date of the grant. The compensation expense is recognized over the vesting period under the straight-line method.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13.5pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for options awards granted to nonemployee consultants and directors in accordance with ASU 2018-07, Compensation &#8211; Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. The fair value of the option issued or committed to be issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company&#8217;s common stock award at the earlier of the date that the commitment for performance by the counterparty has been reached or the counterparty&#8217;s performance is complete.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(L) Fair Value of Financial Instruments</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial Accounting Standards Board (&#8220;FASB&#8221;) guidance specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The three levels of the fair value hierarchy are as follows:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Level 1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities. The Company&#8217;s Level 1 assets consisted of money market funds and short-term investments totaling $70.1 million and $76.2 million as of December&#160;31, 2020 and 2019, respectively.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Level 2&#8212;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models or other valuation methodologies. The Company had no Level 2 assets or liabilities as of December&#160;31, 2020 and 2019.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Level 3&#8212;Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable. The Company had no Level 3 assets or liabilities as of December&#160;31, 2020 and 2019.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts reported in the balance sheets for cash and cash equivalents, related-party receivables, other current assets, accounts payable, accrued expenses, and current related-party payables approximate their fair value based on the short-term maturity of these instruments.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(M) Income Taxes</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires deferred tax assets and liabilities to be recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts and respective tax bases of existing assets and liabilities, as well as for net operating loss carryforwards and research and development credit. Valuation allowances are provided if it is more likely than not that some portion or all of the deferred tax assets will not be realized.&nbsp;&nbsp;The impact of a change in the tax laws is recorded in the period in which the law is enacted.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(N) Net Loss Per Common Share</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period. For all periods presented, stock options have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss per common share are the same.<font style="color:#000000;"> Under the terms of the Series A Preferred Stock issued in 2019, Preferred stockholders do not share in losses of the Company and have no obligation to fund losses or transfer assets.&#160;&#160;Since there is a loss, diluted EPS should be computed in the same manner as basic EPS and because no potential common shares shall be included in the computation of any diluted per-share amounts when a loss exists, the Series A Preferred Stock should be excluded from the computation of basic and diluted EPS.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,403,420</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,405,295</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,250</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,762</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(O) Segment Data</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(P) Retirement Plan</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains a 401(k)-retirement plan for its employees that is intended to qualify under Sections 401(a) and 501(a) of the U.S. Internal Revenue Code of 1986, as amended (&#8220;Code&#8221;). The Company provides all active employees with a 100% matching contribution equal to 3% of an employee&#8217;s eligible compensation deferred and 50% matching contributions on employee contributions that are between 3% and 5% of an employee&#8217;s eligible compensation deferred. These safe harbor contributions vest immediately.&nbsp;&nbsp;For the years ended December&#160;31, 2020 and 2019 the Company contributed $321,000 and $285,000, respectively.<font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">(Q) Revenue Recognition</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;In applying ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) it satisfies the performance obligations.&#160;The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint.&#160;Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price.&#160;The standalone selling price is generally determined using expected cost and comparable transactions. Revenue for performance obligations recognized over time is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-refundable upfront fees allocated to licenses that are not contingent on any future performance and require no consequential continuing involvement by the Company, are recognized as revenue when the license term commences and the licensed data, technology or product is delivered.&#160;The Company defers recognition of upfront license fees if the performance obligations are not satisfied.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="font-weight:bold;">R) Recent Accounting Pronouncements</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Recent accounting standards which have been adopted</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.&#160;&#160;This new standard requires the measurement and recognition of expected credit losses for financial assets held at amortized cost, including loans and trade and other receivables. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The standard also amends the impairment model for available-for-sale debt securities and requires entities to determine whether all or a portion of the unrealized loss on an available-for-sale debt security is a credit loss. Under the new guidance, an entity recognizes an allowance for credit losses on available-for-sale debt securities as a contra-account to the amortized cost basis rather than as a direct reduction of the amortized cost basis of the investment, as was previously required. ASU 2016-13 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2019. As of December 31, 2020, the Company did not hold any debt securities with credit losses, nor does it have any trade receivables. The adoption of this standard effective January 1, 2020 did not have a material impact on the Company&#8217;s consolidated financial statements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 29, 2018, the FASB issued ASU No. 2018-15, Intangibles &#8211; Goodwill and Other - Internal-Use Software (Subtopic 350-40) - which amends ASC 350-40 to address a customer&#8217;s accounting for implementation costs incurred in a cloud computing arrangement (&#8220;CCA&#8221;) that is a service contract. ASU No. 2018-15 aligns the accounting for costs incurred to implement a CCA that is a service arrangement with the guidance on capitalizing costs associated with developing or obtaining internal-use software. Specifically, the ASU amends ASC 350 to include in its scope implementation costs of a CCA that is a service contract and clarifies that a customer should apply ASC 350-40 to determine which implementation costs should be capitalized in a CCA that is considered a service contract. According to the standard the balance sheet line item for the presentation of capitalized implementation costs should be the same as that for the prepayment of fees related to the hosting arrangement and the manner in which an entity classifies the cash flows related to capitalized implementation costs should be the same as that in which it classifies the cash flows for the fees related to the hosting arrangement. ASU 2018-15 is effective for the Company for fiscal years beginning after December 15, 2019, including interim periods therein. Entities are permitted to apply either a retrospective or prospective transition approach to adopt the guidance. The adoption of this standard effective January 1, 2020 did not have a material impact on the Company&#8217;s consolidated financial statements and was adopted prospectively.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 5, 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808), - which amends ASC 808 to clarify when transactions between participants in a collaborative arrangement under ASC 808 are within the scope of the FASB&#8217;s new revenue standard, ASU 2014-09 (codified in ASC 606). The amendments require the application of ASC 606 existing guidance to determine the units of account that are distinct in a collaborative arrangement for purposes of identifying transactions with customers. If a unit of account within the collaborative arrangement is distinct and is with a customer, an entity shall apply the guidance in Topic 606 to that unit of account. In a transaction between collaborative participants, an entity is precluded by ASU 2018-18 from presenting a transaction together with &#8220;revenue from contracts with customers&#8221; unless the unit of account is within the scope of ASC 606 and the entity applies the guidance in ASC 606 to such unit of account. The amended guidance is effective for public business entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The retrospective adoption of this standard effective January 1, 2020 did not have a material impact on the Company&#8217;s consolidated financial statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, the FASB issued&#160;ASU&#160;2020-10, Codification Improvements, which updates various codification topics by clarifying or improving disclosure requirements. ASU 2020-10 is effective for annual and interim periods beginning after December 15, 2020. The Company early adopted&#160;ASU&#160;2020-10&#160;for the reporting period ending December 31, 2020. The adoption of this update did not have a material effect on the Company s consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552659000744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Short-Term Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock', window );">Cash Equivalents and Short-Term Investments</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N<font style="font-weight:bold;">OTE 3 &#8211; CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All<font style="color:#000000;"> short-term investments are classified as available-for-sale. The following tables summarize the fair value of cash, cash equivalents, and short-term investments, as well as gross unrealized holding gains and losses as of December&#160;31, 2020 and December&#160;31, 2019:</font></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cost</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">holding gains</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">holding losses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Cash</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,977,320</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,977,320</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Money market funds</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,056,610</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,056,610</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash and cash equivalents</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,033,930</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,033,930</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;U.S. treasury notes</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term investments</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cost</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">holding gains</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">holding losses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Cash</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">501,537</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">501,537</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Money market funds</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,395,607</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,395,607</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash and cash equivalents</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,897,144</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,897,144</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;U.S. treasury notes</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,839,500</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,469</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,841,969</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term investments</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,839,500</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,469</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,841,969</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div></div>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company did&#160;not&#160;hold any securities that were in an unrealized loss position for more than 12 months as of&#160;December&#160;31, 2020 and 2019.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were&#160;no&#160;material realized gains or losses on available-for-sale securities during the years ended December&#160;31, 2020 and 2019.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552661743832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock', window );">Property and Equipment and Intangible Assets</a></td>
<td class="text">
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">NOTE</font><font style="color:#000000;"> 4 &#8211; PROPERTY AND EQUIPMENT AND INTANGIBLE ASSETS</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment is summarized as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and equipment</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">320,957</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">193,717</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(185,337</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(125,354</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property, plant and equipment, net</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135,620</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,363</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense was $60,000 and $39,000 for the years ended December&#160;31, 2020 and 2019 respectively.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net of accumulated amortization, were $319,000 and $467,000 as of December&#160;31, 2020 and December&#160;31, 2019, respectively, and are included in other assets.&#160;Amortization expense was $247,000 and $216,000 for the years ended December&#160;31, 2020 and 2019, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets and long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552583470312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 5 &#8211; ACCRUED EXPENSES</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials accrual</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,175,497</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,235,527</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and bonus accrual</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,845,441</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,728,495</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees accrual</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,846,211</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,070,589</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165,536</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,095</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,032,685</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,266,706</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552658940248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity and Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity and Preferred Stock</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 6 &#8211; STOCKHOLDERS&#8217; EQUITY AND PREFERRED STOCK</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s capital structure consists of common stock and Preferred Stock. Pursuant to the Company&#8217;s amended and restated certificate of incorporation, as amended, the Company is authorized to issue up to 125,000,000 shares of common stock and 10,000,000 shares of Preferred Stock. The Company has designated 10,000 of the 10,000,000 authorized shares of Preferred Stock as non-voting Series A Convertible Preferred Stock (&#8220;Series A Preferred Stock&#8221;).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of common stock are entitled to one vote for each share held. The holders of common stock have no preemptive or other subscription rights, and there are no redemption or sinking fund provisions with respect to such shares. Subject to preferences that may apply to any outstanding series of Preferred Stock, holders of the common stock are entitled to <font style="Background-color:#FFFFFF;">receive ratably any dividends declared on a&#160;non-cumulative&#160;basis. Shares of Series A Preferred Stock will be entitled to receive dividends at a rate equal to (on an as-if-converted-to-common stock basis), and in the same form and manner as, dividends actually paid on shares of common stock. </font>The common stock is subordinate to all series of Preferred Stock with respect to rights upon liquidation, winding up and dissolution of the Company. The holders of common stock are entitled to liquidation proceeds after all liquidation preferences for the Preferred Stock are satisfied.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the Company entered into a sales agreement (the &#8220;2018 ATM agreement&#8221;) with Cowen and Company, LLC (&#8220;Cowen&#8221;) <font style="color:#000000;">under which the Company offered and sold in &#8220;at the market offerings,&#8221; from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $50.0 million through Cowen acting as sales agent. During the year ended December 31, 2019, the Company sold 6,893,888 shares of its common stock under the 2018 ATM agreement for net proceeds of $22.3 million after deducting </font>sales agent commissions and other offering expenses payable by the Company, (the &#8220;ATM Offerings&#8221;)<font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, the Company entered into a new sales agreement (the &#8220;2020 ATM agreement&#8221;) with Cowen and <font style="color:#000000;">under which the Company may offer and sell in &#8220;at the market offerings,&#8221; from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $75.0 million through Cowen acting as sales agent. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were 3,250 and 7,762 shares of Series A Preferred Stock outstanding as of December 31, 2020 and December&#160;31, 2019, respectively. Each share of Series A Preferred Stock is convertible into 1,000 shares of common stock at any time at the holder&#8217;s option. However, the holder will be prohibited, subject to certain exceptions, from converting shares of Series A Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than, at the written election of the holder, either 9.99% or 14.99% of the total number of shares of common stock then issued and outstanding, which percentage may be changed at the holder&#8217;s election to any other number less than or equal to 19.99% upon 61 days&#8217; notice to the Company; provided, however, that effective 61 days after delivery of such notice, such beneficial ownership limitations shall not be applicable to any holder that beneficially owns either 10.0% or 15.0%, as applicable based on the holder&#8217;s initial written election noted above, of the total number of shares of common stock issued and outstanding immediately prior to delivery of such notice. In the event of a liquidation, dissolution, or winding up of the Company, holders of Series A Preferred Stock will receive a payment equal to $0.001 per share of Series A Preferred Stock before any proceeds are distributed to the holders of common stock.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In December 2020, entities affiliated with Biotechnology Value Fund, L.P. elected to convert an aggregate of 2,256 shares of Series A Preferred Stock owned by such holders into an aggregate of 2,256,000 shares of the Company&#8217;s common stock.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company sold 6,250,000 shares of its common stock at a public offering price of $8.00 per share, for net proceeds of $46.7 million after deducting underwriting discounts and commissions and other offering expenses payable by the Company, (the &#8220;August 2020 Offering&#8221;).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In May 2020, entities affiliated with Biotechnology Value Fund, L.P. elected to convert an aggregate of 2,256 shares of Series A Preferred Stock owned by such holders into an aggregate of 2,256,000 shares of the Company&#8217;s common stock.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October and November 2019, the Company sold 10,350,000 shares of its common stock, which included the full exercise of the underwriters&#8217; option to purchase additional shares, and 4,000 shares of Series A Preferred Stock at a public offering price of $2.50 and $2,500 per share, respectively, for net proceeds of $33.5 million after deducting underwriting discounts and commissions and other offering expenses payable by the Company, (the &#8220;October 2019 Offering&#8221;).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, the Company entered into an exchange agreement with entities affiliated with Biotechnology Value Fund, L.P. (the &#8220;Exchanging Stockholders&#8221;), pursuant to which the Company exchanged an aggregate of 1,262,000 shares of the Company&#8217;s common&#160;stock owned by the Exchanging Stockholders for an aggregate of 1,262 shares of the Company&#8217;s Series A Preferred Stock (the &#8220;Exchange Shares&#8221;). The Exchange Shares were issued without registration under the Securities Act of 1933, as amended, in reliance on the exemption from registration contained in Section&#160;3(a)(9) of the Securities Act.&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, the Company sold 13,993,778 shares of its common stock and 2,500 shares of Series A Preferred Stock at a public offering price of $2.00 and $2,000 per share, respectively, for net proceeds of $30.5 million after deducting underwriting discounts and commission and other offering expenses payable by the Company (the &#8220;February 2019 Offering&#8221;).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dividends</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No dividends on the common stock shall be declared and paid unless dividends on the Preferred Stock have been declared and paid. Through December&#160;31, 2020, the Company has not declared any dividends.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552583543576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 7 &#8211; STOCK-BASED COMPENSATION</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 29, 2014, the Company&#8217;s Board of Directors adopted and approved the 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;), which authorized the Company to grant shares of common stock in the form of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock and restricted stock units. The types of stock-based awards, including share purchase rights amount, terms, and exercisability provisions of grants are determined by the Company&#8217;s Board of Directors.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Company's Board of Directors adopted, and the Company's stockholders approved the 2017 equity incentive plan (&#8220;2017 Plan&#8221;),&#160;which became effective immediately prior to the execution of the underwriting agreement related to the IPO on May 4, 2017. The initial reserve of shares of common stock that may be issued under the 2017 Plan was 3,052,059 shares. The 2017 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance-based stock awards, and other forms of stock-based awards.&nbsp;&nbsp;Additionally, the 2017 Plan provides for the grant of performance cash awards. The Company's employees, officers, directors and consultants and advisors are eligible to receive awards under the 2017 Plan.&nbsp;&nbsp;Upon the adoption of the 2017 Plan, no further awards will be granted under the 2014 Plan. Pursuant to the terms of the 2017 Plan, on each January 1st, the plan limit shall be increased by the lesser of (x) 5% of the number of shares of common stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine in its discretion. </font><font style="Background-color:#FFFFFF;">On January 1, 2019, an additional 1,232,705 shares were reserved for issuance under the 2017 Plan. As of December&#160;31, 2019, there were 2,199,765 shares of the Company&#8217;s common stock reserved for issuance under the 2017 Plan. </font><font style="Background-color:#FFFFFF;">On January 1, 2020, an additional 2,735,516 shares were reserved for issuance under the 2017 Plan. As of December&#160;31, 2020, there were 1,771,772 shares of the Company&#8217;s common stock reserved for issuance under the 2017 Plan.</font> </p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's Board of Directors adopted, and the Company's stockholders approved the 2017 employee stock purchase plan (the &#8220;2017 ESPP&#8221;), which became effective immediately prior to the execution of the underwriting agreement related to the IPO on May 4, 2017. The initial reserve of shares of common stock that may be issued under the 2017 ESPP was 279,069 shares. On September 20, 2017, the Company&#8217;s Compensation Committee approved an offering period under the 2017 ESPP, which began on October 20, 2017. The ESPP allows employees to purchase common stock of the Company at a 15% discount to the market price on designated purchase dates. During the years ended December&#160;31, 2020 and 2019, 105,464 and 80,542 shares were purchased under the ESPP and the Company recorded expense of $152,973 and $109,319, respectively. The number of shares of common stock reserved for issuance under the 2017 ESPP will automatically increase on January 1 of each year, beginning on January 1, 2018 and continuing through and including January 1, 2027, by the lesser of (i) 1% of the total number of shares of the Company&#8217;s capital stock outstanding on December 31 of the preceding calendar year, (ii) 550,000 shares or (iii) such lesser number of shares determined by our Board. On January 1, 2019, an additional 246,541 shares were reserved for issuance under the 2017 ESPP. No shares were reserved for issuance under the 2017 ESPP during the year ended December 31, 2020. As of December&#160;31, 2020, there were 553,552 shares of the Company&#8217;s common stock reserved for issuance under the 2017 ESPP. </p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless specified otherwise in an individual option agreement, stock options granted under the 2014 Plan and 2017 Plan generally have a ten-year term and a four-year graded vesting period. The vesting requirement is generally conditioned upon the grantee&#8217;s continued service with the Company during the vesting period. Once vested, all awards are exercisable from the date of grant until they expire. The option grants are non-transferable. Vested options generally remain exercisable for 90 days subsequent to the termination of the option holder&#8217;s service with the Company. In the event of option holder&#8217;s death or disability while employed by or providing service to the Company, the exercisable period extends to 12 months. </p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Performance-based option awards generally have similar vesting terms, with vesting occurring on the date the performance condition is achieved and expire in accordance to the specific terms of the agreement. At December&#160;31, 2020, there were 125,000 performance-based options outstanding and unvested <font style="color:#000000;">that include options to vest upon the achievement of certain research and development milestones</font>.&#160;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of options granted during the years ended December 31, 2020 and 2019 was estimated using the Black-Scholes option valuation model. The inputs for the Black-Scholes option valuation model require management&#8217;s significant assumptions and are detailed in the table below. The risk-free interest rates were based on the rate for U.S. Treasury securities at the date of grant with maturity dates approximately equal to the expected life at the grant date. The expected life was based on the simplified method in accordance with the SEC Staff Accounting Bulletin No. Topic 14D. The expected volatility was estimated based on historical volatility information of peer companies that is publicly available.<font style="color:#000000;"> </font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All assumptions used to calculate the grant date fair value of nonemployee options are generally consistent with the assumptions used for options granted to employees. In the event the Company terminates any of its consulting agreements, the unvested options underlying the agreements would also be cancelled.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company granted 10,000 and 175,000 stock options to nonemployee consultants for services rendered during the years ended December&#160;31, 2020 and 2019, respectively. There were 32,500 and 145,204 unvested nonemployee options outstanding as of December&#160;31, 2020 and 2019, respectively. Total expense recognized related to the nonemployee stock options for the years ended December&#160;31, 2020 and 2019 was $257,431 and $51,666, respectively. During the year ended December 31, 2019, the Company recognized a credit of $17,000 related to the nonemployee stock options including the modification of certain options in connection with the&#160;separation and consulting agreement with Dr. During (see Note 11). Total unrecognized compensation expenses related to the nonemployee stock options was $186,823 as of December 31, 2020. During the years ended December&#160;31, 2020, and 2019, the Company recognized $115,240 and zero, respectively, in expenses for nonemployee performance-based option awards.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company granted 3,573,160 and 3,372,513 stock options to employees during the years ended December&#160;31, 2020 and 2019, respectively. There were 4,975,262 and 3,963,544 unvested employee options outstanding as of December&#160;31, 2020 and 2019, respectively. Total expense recognized related to the employee stock options for the years ended December&#160;31, 2020 and 2019 was $7.1 million and $5.0 million, respectively. Total unrecognized compensation expense related to employee stock options was $12.2 million as of December&#160;31, 2020. During the years ended December&#160;31, 2020 and 2019, the Company recognized $2,340,808 and $9,391 in expenses for employee performance-based option awards. </p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s stock-based compensation expense was recognized in operating expenses as follows:</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,779,758</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,391,909</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,745,596</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,813,883</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,525,354</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,205,792</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></div>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,372,381</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,096,473</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152,973</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,319</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,525,354</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,205,792</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of employee options granted during the years ended December&#160;31, 2020 and 2019, respectively, was estimated by utilizing the following assumptions:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81.48</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81.87</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term in years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.88</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.07</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.58</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.04</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of option on grant date</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.62</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.26</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of nonemployee options granted and remeasured during the years ended December&#160;31, 2020 and 2019, respectively, was estimated by utilizing the following assumptions:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74.37</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74.56</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term in years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.64</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.30</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.32</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.37</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of option on grant date</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.18</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.07</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the number of options outstanding and the weighted average exercise price:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life in Years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding at December 31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,714,383</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.10</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.89</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,485</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable at December 31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,337,931</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.88</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.20</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,485</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,547,513</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.93</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.56</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(856,601</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.43</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,405,295</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.82</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.01</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,488,930</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable at December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,296,547</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.93</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.53</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">356,443</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,583,160</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.93</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.68</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(165,384</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.82</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(415,526</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding December&#160;31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,403,420</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.26</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.59</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">652,438</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable at December&#160;31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,395,658</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.45</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.13</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">445,599</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2020, there was $12.3 million of unamortized share&#8211;based compensation expense, which is expected to be recognized over a remaining average vesting period of 3.04 years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552583711208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 8 &#8211; INCOME TAXES</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2020, the Company has available approximately $<font style="color:#000000;">238.6</font> million and $186.7 million of unused NOL carryforwards for federal and state tax purposes, respectively, that may be applied against future taxable income. The Company also has approximately $<font style="color:#000000;">165.4</font> million of unused NOL carryforwards for New York City purposes. The NOL carryforwards will begin to expire in the year 2035 if not utilized prior to that date. There is no provision for income taxes because the Company has historically incurred operating losses and maintains a full valuation allowance against its net deferred tax assets. <font style="color:#000000;">The valuation allowance increased by approximately $13.3 million and $22.5 million during the years 2020 and 2019, respectively.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may be subject to the NOL utilization provisions of Section&#160;382 of the Code. The effect of an ownership change would be the imposition of an annual limitation on the use of NOL carryforwards attributable to periods before the change. The amount of the annual limitation depends upon the value of the Company immediately before the change, changes to the Company&#8217;s capital during a specified period prior to the change, and the federal published interest rate. The Company has not completed a Section&#160;382 analysis to determine if a change in ownership has occurred. Until an analysis is completed, there can be no assurance that the existing net operating loss carry-forwards or credits are not subject to significant limitation.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s reserves related to taxes are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies related to the tax benefit. For the years ended December&#160;31, 2020 and 2019, the Company had no unrecognized tax benefits or related interest and penalties accrued. The Company has not yet conducted a study of research and development credit carryforwards. This study may result in an adjustment to the Company&#8217;s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheet or statement of operations if an adjustment were required. The Company would recognize both accrued interest and penalties related to unrecognized benefits in income tax expense. The Company&#8217;s uncertain tax positions yet to be determined would be related to years that remain subject to examination by relevant tax authorities. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities were as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets/liabilities:</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryovers</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,064,673</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,288,334</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,458,004</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,351,315</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,978,370</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,606,889</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">514,316</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">898,067</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,760</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,026</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Charitable contributions</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,120</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,072</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,742,031</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,208,519</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross deferred tax assets/liabilities</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,814,754</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,463,170</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,814,754</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(76,463,170</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets (liabilities)</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the statutory U.S. Federal rate to the Company&#8217;s effective tax rate is as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal income tax benefit at statutory rate</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21.00</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21.00</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income tax, net of federal benefit (<font style="font-size:8pt;">1)</font></p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.15</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13.80</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.75</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.50</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.72</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37.14</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.64</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.67</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.02</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.17</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax (benefit) expense rate</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) Inclusive of $5.8 million deferred tax benefit due to change in apportionment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552583722360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 9 &#8211;<font style="color:#000000;"> </font>COMMITMENTS AND CONTINGENCIES</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">License Agreements</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">On March&#160;26, 2015, the Company entered into an exclusive agreement with H. Lundbeck A/S (&#8220;Lundbeck&#8221;) for a worldwide perpetual licensing right related the research, development and commercialization of OV101. On May 10, 2019, the parties amended the license agreement.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Lundbeck license agreement, as amended, the Company agreed to make milestone payments totaling up to $189.0 million upon the achievement of certain development, regulatory and sales milestones.&#160;The first payment of $1.0 million is due upon the successful completion of the first Phase 3 trial for a product in which OV101 is an active ingredient.&#160;In addition, the agreement calls for the Company to pay royalties for an initial term based on a low double-digit percentage of sales and provides for the reduction of royalties in certain limited circumstances.&nbsp;&nbsp;As of December&#160;31, 2020, none of these contingent payments were considered probable.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2016, the Company entered into a license agreement with Northwestern University, or Northwestern, pursuant to which Northwestern granted us an exclusive, worldwide license to patent rights in certain inventions, or the Northwestern Patent Rights, which relate to a specific compound and related methods of use for such compound, along with certain Know-How related to the practice of the inventions claimed in the Northwestern Patents.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Northwestern agreement, the Company was granted exclusive rights to research, develop, manufacture and commercialize products utilizing the Northwestern Patent Rights for all uses. The Company has agreed that it will not use the Northwestern Patent Rights to develop any products for the treatment of cancer, but Northwestern may not grant rights in the technology to others for use in cancer. The Company also has an option, exercisable during the term of the agreement to an exclusive license under certain intellectual property rights covering novel compounds with the same or similar mechanism of action as the primary compound that is the subject of the license agreement.&nbsp;&nbsp;Northwestern has retained the right, on behalf of itself and other non-profit institutions, to use the Northwestern Patent Rights and practice the inventions claimed therein for educational and research purposes and to publish information about the inventions covered by the Northwestern Patent Rights.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon entry into the Northwestern agreement, the Company paid an upfront non-creditable one-time license issuance fee of $75,000, and is required to pay an annual license maintenance fee of $20,000, which will be creditable against any royalties payable to Northwestern following first commercial sale of licensed products under the agreement.&nbsp;&nbsp;The Company is responsible for all ongoing costs of filing, prosecuting and maintaining the Northwestern Patents, but also has the right to control such activities using its own patent counsel.&nbsp;&nbsp;In consideration for the rights granted to the Company under the Northwestern agreement, the Company is required to pay to Northwestern up to an aggregate of $5.3 million upon the achievement of certain development and regulatory milestones for the first product covered by the Northwestern Patents, and, upon commercialization of any such products, will be required to pay to Northwestern a tiered royalty on net sales of such products by the Company, its affiliates or sublicensees, at percentages in the low to mid single-digits, subject to standard reductions and offsets.&nbsp;&nbsp;The Company&#8217;s royalty obligations continue on a product-by-product and country-by-country basis until the later of the expiration of the last-to-expire valid claim in a licensed patent covering the applicable product in such country and 10 years following the first commercial sale of such product in such country.&nbsp;&nbsp;If the Company sublicenses a Northwestern Patent Right, it will be obligated to pay to Northwestern a specified percentage of sublicense revenue received by the Company, ranging from the high single digits to the low-teens.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Northwestern agreement requires that the Company use commercially reasonable efforts to develop and commercialize at least one product that is covered by the Northwestern Patent Rights.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated, the Northwestern agreement will remain in force until the expiration of the Company&#8217;s payment obligations thereunder.&nbsp;&nbsp;The Company has the right to terminate the agreement for any reason upon prior written notice or for an uncured material breach by Northwestern.&nbsp;&nbsp;Northwestern may terminate the agreement for the Company&#8217;s uncured material breach or insolvency.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, none of these contingent payments were considered probable.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contingencies</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. The Company is not currently involved in any legal matters arising in the normal course of business.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of their respective employment agreements, each of our named executive officers is eligible to receive severance payments and benefits upon a termination without &#8220;cause&#8221; or due to &#8220;permanent disability,&#8221; or upon &#8220;resignation for good reason,&#8221; contingent upon the named executive officer&#8217;s delivery to the Company of a satisfactory release of claims, and subject to the named executive officer&#8217;s compliance with non-competition and non-solicitation restrictive covenants for two years following the termination date.</p>
<p style="text-align:justify;margin-top:11pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Northwestern agreement, Northwestern granted the Company an exclusive license to certain patent rights and know-how, including a patent application covering a specified composition of matter (the &#8220;Patent Application&#8221;).&#160; Northwestern previously entered into a license agreement with Catalyst Pharmaceuticals, Inc. (&#8220;Catalyst&#8221;), dated August 27, 2009, pursuant to which Northwestern granted Catalyst rights under certain intellectual property rights covering a different composition of matter (the &#8220;Catalyst License&#8221;).&#160;&#160;In addition, the Company is a party to a confidential disclosure agreement with Catalyst, dated September 16, 2016 (the &#8220;CDA&#8221;). On June 25, 2018, Catalyst sent a letter to Northwestern and the Company alleging, among other things, that Northwestern breached the Catalyst License by licensing the Patent Application to the Company.&#160;Catalyst&#8217;s letter also asserted that the Company had breached its obligations under the CDA by allegedly failing to disclose that the Company had a license to the Patent Application, and that a further breach would occur if the Company makes any use of information obtained under the CDA in connection with its development program arising from the rights granted under the license agreement.&#160;&#160;Catalyst has asserted that the combined conduct of Northwestern and the Company gives rise to various claims, including breach of contract, fraud, and tortious interference.&#160;The Company believes that Catalyst&#8217;s claims are without merit and responded by letter dated June 28, 2018, which denies any and all liability to Catalyst, and further denies that Catalyst has been damaged in any way. On May 20, 2019, the Company entered into a Settlement Agreement with Catalyst (the &#8220;Settlement Agreement&#8221;), pursuant to which Catalyst released the Company from any and all claims, known or unknown, arising from or related to the dispute between Catalyst and Northwestern, the license agreement, and/or the claims that Catalyst asserted against the Company in the June 25, 2018 letter.&#160;&#160;Under the Settlement Agreement the Company retains all rights and privileges previously granted to the Company under the Northwestern license agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552661728216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreement</a></td>
<td class="text">
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 10 &#8211; COLLABORATION AGREEMENT</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Angelini Collaboration</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;9, 2020, the Company entered into the Angelini License Agreement with Angelini, pursuant to which the Company granted to Angelini exclusive rights to develop and commercialize OV101, a selective agonist of the GABA<sub style="font-size:85%; vertical-align:bottom">A</sub>&#160;receptor, for the treatment of Angelman syndrome in the European Economic Area as well as Switzerland, the United Kingdom, Russia and Turkey (the &#8220;European Territory&#8221;).&#160;&#160;The licenses granted to Angelini include sublicenses under the Lundbeck Agreement, as well as licenses under the Company&#8217;s patents and know-how covering OV101.&#160;&#160;Angelini will be responsible for conducting any clinical trials necessary to obtain regulatory approval for OV101 for Angelman syndrome in the European Territory, and the Company will be responsible for bearing a portion of the costs for such trials.&#160;&#160;The Company will also be responsible, at its expense, for the completion of certain ongoing clinical trials for OV101, to the extent applicable to obtaining regulatory approval for OV101 in the European Territory.&#160;&#160;Angelini has the exclusive right, at its election, to develop and commercialize OV101 for the treatment of Fragile X Syndrome in the European Territory.&#160;&#160;The parties may also mutually agree to pursue additional indications for OV101 in the European Territory, and in such case, Angelini would have the exclusive rights to commercialize in such additional indications. Angelini is required to use commercially reasonable efforts to conduct development activities for OV101, and following regulatory approval, to commercialize OV101 in each approved indication.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In conjunction with the entry into the Angelini License Agreement, the parties entered into a separate supply agreement, pursuant to which the Company will be responsible for supply of OV101 to Angelini for development and commercialization in the European Territory, through its existing supply relationship with Lundbeck.&#160;&#160;The Angelini License Agreement also provides for a transfer, at Angelini&#8217;s expense, of the relevant manufacturing technology from the Company and Lundbeck to Angelini, in order to enable Angelini to assume responsibility for its own manufacture and supply of OV101 in the future.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:13pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Angelini License Agreement, Angelini made an upfront payment and a milestone payment related to the transfer of a specified amount of compound and related information to the Company of $25.0 million during the year ended December 31, 2020.&#160; Angelini will be required to make additional milestone payments to the Company upon the completion of the specified components of the technology transfer and achievement of specified regulatory milestones for OV101 in Angelman syndrome of up to $55.0&#160;million in the aggregate, as well as up to &#8364;162.5 million ($199.9 million) in sales milestone payments for achievement of specified levels of net sales in the European Territory.&#160;&#160;In addition, Angelini will be required to pay tiered royalties on net sales by Angelini, its affiliates or sublicensees at double-digit percentages above the teens, subject to certain standard reductions and offsets.&#160;&#160;Royalties will be payable on a product-by-product and country-by-country basis until the latest of the expiration of the licensed patents covering such product in such country, the expiration of market exclusivity for such product in such country, and fifteen years from first commercial sale of such product in such country.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Either party may terminate the Angelini License Agreement for an uncured material breach of the other party or in the case of insolvency.&#160;&#160;The Company may terminate the Angelini License Agreement if Angelini challenges any of the licensed patents.&#160;&#160;Angelini may terminate the Angelini License Agreement for convenience on specified notice periods, which are determined based upon whether the product has been commercially launched in the European Territory.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company identified the following material promises under the Angelini License Agreement: (1) licensing of intellectual property with respect to OV101 (2) completion of certain ongoing trials (3) transfer of a specified amount of compound and related information (4) potential for funding 35% of the cost for Angelini future trials limited to $7.0 million and (5) completion of the manufacturing process technology transfer.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:6%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the $7.0 million represents a potential payment to a customer and should be deferred. The transfer of compound and related information is considered a contingent milestone payment that will be recognized upon acceptance by Angelini of the milestone which was achieved and recognized in December 2020. The Company further determined that the license and the completion of ongoing trials are distinct from each other, as each has value without the other.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined the transaction price is equal to the up-front fee of $20.0 million. The transaction price was allocated based on the standalone selling price of the license, the ongoing trials and $7.0 million for potential future trials.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the transfer of the specified amount of compound and related information and acceptance by Angelini, Angelini was required to and made a $5.0 million payment. <font style="color:#000000;">This performance obligation was determined to be variable consideration which was constrained and not considered part of the upfront transaction price allocation.</font><font style="font-size:12pt;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Angelini will be required to make a separate $5.0 million tech transfer payment towards the $55.0 million aggregate tech transfer and regulatory milestone payments upon the successful completion of the manufacturing process technology transfer. The Company earning this is fully dependent on performance and cooperation of Angelini and Lundbeck in implementing the Technology Transfer. At this time, the Company cannot estimate if or when this milestone-related performance obligation might be achieved.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, the Company recognized $6.1 million of license revenue and $1.5 million relating to the progress of the ongoing trials as well as $5.0 million for the transfer of the specified amount of compound and related information. The portion of the upfront payment allocated to License Revenue was recognized in full as it was non-refundable and not contingent on any future performance and requires no consequential continuing involvement by the Company. The Company did not have any such revenue during the year ended December 31, 2019. In addition, the Company recorded deferred revenue in the amount of approximately $12.4 million as of December 31, 2020 which will be recognized over the term of the ongoing trials based on the portion of total estimated expenses incurred. The Company has classified deferred revenue as current or noncurrent based on the expected timing of such expenses.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Takeda Collaboration</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;6, 2017, the Company entered into a license and collaboration agreement with Takeda, pursuant to which Takeda granted the Company an exclusive license to commercialize the compound TAK-935, which the Company refers to as OV935, in certain territories, and a co-exclusive worldwide license, together with Takeda, to develop OV935. In consideration of certain license rights granted to the Company pursuant to the Takeda collaboration, the Company issued 1,781,996 shares of its Series B-1 Preferred Stock, pursuant to a Series B-1 preferred stock purchase agreement entered into on January&#160;6, 2017, at an ascribed price per share of $14.513 on January&#160;6, 2017 for an aggregate fair value of $25.9 million, which was recorded as research and development expense at the date of the transaction. The 1,781,996 shares of Series B-1 Preferred Stock held by Takeda automatically converted into 1,781,996 shares of the Company&#8217;s common stock upon the completion of its IPO in 2017. Under the Takeda collaboration, the Company is obligated to pay Takeda future payments if and when certain milestones are achieved. Upon the first patient enrollment in the first Phase 3 trial for the first of the initial indications the Company and Takeda are focusing on in the Takeda collaboration, the Company is obligated to issue to Takeda the number of unregistered shares of the Company&#8217;s common stock equal to the lesser of (a)&#160;8% of the Company outstanding capital stock on the issuance date or (b)&#160;$50.0 million divided by the applicable share price, unless certain events occur.<font style="Background-color:#FFFFFF;color:#000000;font-weight:bold;"> </font><font style="Background-color:#FFFFFF;color:#000000;">In the event such payment would cause Takeda to own over 19.99% of our outstanding capital stock or other events occur, such payment must be paid in cash</font>.&nbsp;&nbsp;The remaining potential global commercial and regulatory milestone payments equal approximately $35.0 million and can be satisfied in cash or unregistered shares of the Company&#8217;s common stock at its election, unless certain events occur. <font style="color:#000000;">As of December&#160;31, 2020, none of these contingent payments have been triggered.</font>&nbsp;&nbsp;During the year ended December&#160;31, 2020, the Company recognized $0.7 million in research and development expenses representing research and development expenses reimbursable to the Company from Takeda, of which $0.1 million was included in related party receivable as of December 31, 2020 and $2.1 million was included in related party payable as of December 31, 2020.&nbsp;&nbsp;During the year ended December 31, 2019, the Company recognized a credit in research and development expenses of $4.7 million <font style="color:#000000;">representing costs reimbursable to the Company from Takeda, </font>of <font style="color:#000000;">which $1.1 million was included in related party receivable as of December 31, 2019</font>. &nbsp;&nbsp;</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Takeda collaboration will expire upon the cessation of commercialization of the products by both the Company and Takeda. Either party may terminate the Takeda collaboration because of the other party&#8217;s uncured material breach or insolvency, for safety reasons, or, after completion of the first proof of mechanism clinical trial, for convenience. Takeda may terminate the Takeda collaboration for the Company&#8217;s (or the Company&#8217;s sublicensee&#8217;s) challenge to the patents licensed under the Takeda collaboration. If the collaboration is terminated by Takeda for material breach by the Company, bankruptcy or patent challenge or by the Company for convenience or safety reasons, the Company&#8217;s rights to the products will cease, the Company will transition all activities related to the products to Takeda, and the Company will grant Takeda an exclusive, royalty-bearing license under certain patents and other intellectual property controlled by the Company to commercialize OV935 and products containing OV935 for the treatment of certain rare neurological disorders. If the collaboration is terminated by the Company for Takeda&#8217;s material breach or bankruptcy or by Takeda for convenience or safety reasons, Takeda&#8217;s rights to the products will cease, Takeda will transition all activities related to the products to us, and Takeda will grant us an exclusive, royalty-bearing license under certain patents and other intellectual property controlled by Takeda to commercialize OV935 and products containing OV935 for the treatment of certain rare neurological disorders.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, the Company entered into a royalty, license and termination agreement with Takeda (see note 12).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552583700040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 11 &#8211; RELATED PARTY TRANSACTIONS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the Company&#8217;s collaboration agreement with Takeda the Company recognized a long-term liability representing long-term prepaid expenses to be reimbursed to Takeda.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 24, 2019, the Company entered into a separation and consulting agreement with Dr. Matthew During in connection with Dr. During&#8217;s resignation as President and Chief Scientific Officer with the Company effective as of April 1, 2019. Pursuant to the separation and consulting agreement, Dr. During agreed to non-solicit and non-compete covenants through such time as he remains a consultant to the Company, as well as a general release of claims in connection therewith. Dr. During agreed to a three-year consulting arrangement, pursuant to which he will be paid, amongst other specific milestone and meeting related fees, $150,000 per year for his role as the Chairman of the Company&#8217;s Scientific Advisory Board and $150,000 per year for other advisory and consulting services. Further, Dr. During was granted options to acquire 100,000 shares of common stock at an exercise price of $1.76 per share, the fair market value on April 1, 2019, which options shall vest in full upon completion of a specific clinical milestone, subject to Dr. During&#8217;s continued service through such vesting date. In the event such option does not vest by December 31, 2020, the stock option will expire. Provided further, in recognition of Dr. During&#8217;s service on the Scientific Advisory Board, Dr. During was granted options to acquire 75,000 shares of common stock at an exercise price equal to $1.76 per share, the fair market value on April 1, 2019. Either Dr. During or the Company may terminate the consulting arrangements pursuant to the Consulting Agreement in accordance with its terms, at any time and for any reason, upon thirty (30) days written notice to the other party. Upon such termination, the Company will have no further obligations to Dr. During, including any obligation to pay further consulting fees.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, the Company issued and sold an aggregate of 6,325,000 shares of common stock and 2,500 shares of Series A Preferred Stock to entities affiliated with Takeda, a collaboration partner and an existing stockholder, entities affiliated with Biotechnology Value Fund, L.P., an existing stockholder, and Dr. Jeremy M. Levin, its Chief Executive Officer and Chairman, for aggregate gross proceeds of $17.7 million.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October and November 2019, the Company issued and sold an aggregate of 4,058,000 shares of common stock and 2,000 shares of Series A Preferred Stock to entities affiliated with Takeda, a collaboration partner and an existing stockholder, entities affiliated with Biotechnology Value Fund, L.P., an existing stockholder, and Dr. Jeremy M. Levin, its Chief Executive Officer and Chairman, for aggregate gross proceeds of $10.2 million.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, the Company entered into an exchange agreement with the Exchanging Stockholders pursuant to which the Company exchanged an aggregate of 1,262,000 shares of the Company&#8217;s common stock owned by the Exchanging Stockholders for an aggregate of 1,262 shares of the Company&#8217;s Series A Preferred Stock.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">In May 2020, entities affiliated with Biotechnology Value Fund, L.P. elected to convert an aggregate of 2,256 shares of Series A Preferred Stock owned by such holders into an aggregate of 2,256,000 shares of the Company&#8217;s common stock.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company issued and sold an aggregate of 1,250,000 shares of common stock to entities affiliated with Biotechnology Value Fund, L.P., an existing stockholder for aggregate gross proceeds of $10.0 million.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, entities affiliated with Biotechnology Value Fund, L.P. elected to convert an aggregate of 2,256 shares of Series A Preferred Stock owned by such holders into an aggregate of 2,256,000 shares of the Company&#8217;s common stock.<font style="color:#000000;">&#160;</font> <font style="color:#000000;">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552658954120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 12 &#8211; SUBSEQUENT EVENTS</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Equity Awards</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From January 1, 2021 t<font style="Background-color:#FFFFFF;color:#000000;">hrough the date of the filing of this Form 10-K, the Company has granted option awards for an aggregate of 643,600 shares of common stock to employees with a weighted average exercise price of $3.18.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Royalty, License and Termination Agreement with Takeda</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, the Company entered into a royalty, license and termination agreement (the &#8220;Takeda License and Termination Agreement&#8221;) with Takeda under which <font style="color:#000000;">Takeda will secure rights to the Company&#8217;s 50% global share in soticlestat, and an exclusive license under our relevant intellectual property rights and </font>global rights at closing from the Company to develop and commercialize the investigational medicine OV935 for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome and Lennox-Gastaut syndrome.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Takeda License and Termination Agreement, all rights in OV935 will be owned by Takeda, or exclusively licensed to Takeda by the Company.&nbsp;&nbsp;Takeda will assume sole responsibility for further worldwide development and commercialization, and the Company will no longer have any financial obligation to Takeda under the original collaboration agreement, including for milestone payments or any future development and commercialization costs. Should the Company close the Takeda License and Termination Agreement, the Company will receive an upfront payment of $196.0 million at closing and will be eligible to receive up to an additional $660.0 million upon achieving development, regulatory and sales milestones. In addition, the Company would be entitled receive tiered royalties beginning in the low double-digits, and up to 20% on sales of OV935, if approved and commercialized. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects to close the Takeda License and Termination Agreement in the first half of 2021, subject to the satisfaction of closing conditions, including regulatory review by the appropriate regulatory agencies under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. Either party may terminate the agreement if it does not close by May 14, 2021.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552575528232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text">
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(A) Basis of Presentation and Consolidation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include the accounts of Ovid Therapeutics Inc. and its wholly-owned subsidiary, Ovid Therapeutics Hong Kong Limited.&nbsp;&nbsp;All intercompany transactions and balances have been eliminated in consolidation.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(B) <font style="color:#000000;">Use of Estimates</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Risks and Uncertainties</a></td>
<td class="text">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(C) Risks and Uncertainties</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its drug candidates, ability to obtain regulatory approval of its drug candidates, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition and untested manufacturing capabilities</font>.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Transaction Costs</a></td>
<td class="text">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(D) Deferred Transaction Costs</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred transaction costs, primarily consisted of direct incremental legal, accounting, and other fees related to the Company&#8217;s offering of its capital stock are capitalized as incurred. The deferred transaction costs are offset against proceeds upon the consummation of an offering.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(E) Comprehensive Loss</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Arrangement</a></td>
<td class="text">
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(F) Collaboration Arrangement</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">License and Collaboration Agreement with Takeda Pharmaceutical Company Limited</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the current license and collaboration agreement with Takeda Ovid and Takeda are sharing 50/50 in the drug development, the Company records 50% of the development costs in research and development.&nbsp;&nbsp;When Ovid incurs the majority of the costs and Takeda transfers a payment to Ovid to equalize the costs, Ovid records the participation by Takeda as a reduction of its research and development expenses, as the parties under the collaboration are sharing in the costs and the payment represents reimbursement of costs by Takeda.&#160;When Takeda incurs the majority of the costs and Ovid transfers a payment to Takeda (to equalize the costs), Ovid records the participation in Takeda&#8217;s expenses as research and development costs in its statement of operations, as Ovid and Takeda are sharing in the research and development activities and this participation represents Ovid&#8217;s share of the research and development costs in the specific period. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(G) Cash and Cash Equivalents</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash and cash equivalents consist of cash held in checking accounts and money market funds. The Company considers all highly liquid investments with an original maturity date of three months or less to be cash and cash equivalents. Accounts held at U.S. financial institutions are insured by the FDIC up to $250,000. Cash balances could exceed insured amounts at any given time.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Short-term Investments</a></td>
<td class="text">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(H) Short-term Investments</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments<font style="Background-color:#FFFFFF;">&#160;consist of debt securities with maturities greater than&#160;</font>three months<font style="Background-color:#FFFFFF;">&#160;from the date of purchase.&#160;&#160;The Company&#160;</font>classifies<font style="Background-color:#FFFFFF;">&#160;all of its investments as available-for-sale securities. Debt securities are recorded at fair value with unrealized gains and losses included in other comprehensive income (loss) as a component of stockholders&#8217; equity until realized. Realized gains and losses, amortization and accretion of premiums and discounts are included within net loss.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(I) Property and Equipment</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost and depreciated over their estimated useful lives of three years using the straight-line method. Repairs and maintenance costs are expensed. The Company reviews the recoverability of all long-lived assets, including the related useful life, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(J) Research and Development Expenses</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expenses the cost of research and development as incurred. Research and development expenses comprise costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when the cost is incurred, in accordance with ASC 730, Research and Development.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(K) Stock-Based Compensation</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for its stock-based compensation in accordance with ASC 718, Compensation&#8212;Stock Compensation, which establishes accounting for stock-based awards granted to employees for services and requires companies to expense the estimated fair value of these awards over the requisite service period. The Company estimates the fair value of all awards granted using the Black-Scholes valuation model. Key inputs and assumptions include the expected term of the option, stock price volatility, risk-free interest rate, dividend yield, stock price and exercise price. Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense. The Company elected an accounting policy to record forfeitures as they occur. The Company recognizes employee stock-based compensation expense based on the fair value of the award on the date of the grant. The compensation expense is recognized over the vesting period under the straight-line method.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13.5pt;">&nbsp;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for options awards granted to nonemployee consultants and directors in accordance with ASU 2018-07, Compensation &#8211; Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. The fair value of the option issued or committed to be issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company&#8217;s common stock award at the earlier of the date that the commitment for performance by the counterparty has been reached or the counterparty&#8217;s performance is complete.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(L) Fair Value of Financial Instruments</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial Accounting Standards Board (&#8220;FASB&#8221;) guidance specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The three levels of the fair value hierarchy are as follows:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Level 1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities. The Company&#8217;s Level 1 assets consisted of money market funds and short-term investments totaling $70.1 million and $76.2 million as of December&#160;31, 2020 and 2019, respectively.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Level 2&#8212;Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models or other valuation methodologies. The Company had no Level 2 assets or liabilities as of December&#160;31, 2020 and 2019.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Level 3&#8212;Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable. The Company had no Level 3 assets or liabilities as of December&#160;31, 2020 and 2019.</font></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts reported in the balance sheets for cash and cash equivalents, related-party receivables, other current assets, accounts payable, accrued expenses, and current related-party payables approximate their fair value based on the short-term maturity of these instruments.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(M) Income Taxes</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires deferred tax assets and liabilities to be recognized for the estimated future tax consequences attributable to differences between financial statement carrying amounts and respective tax bases of existing assets and liabilities, as well as for net operating loss carryforwards and research and development credit. Valuation allowances are provided if it is more likely than not that some portion or all of the deferred tax assets will not be realized.&nbsp;&nbsp;The impact of a change in the tax laws is recorded in the period in which the law is enacted.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(N) Net Loss Per Common Share</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average common shares outstanding during the period. For all periods presented, stock options have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to calculate both basic and diluted loss per common share are the same.<font style="color:#000000;"> Under the terms of the Series A Preferred Stock issued in 2019, Preferred stockholders do not share in losses of the Company and have no obligation to fund losses or transfer assets.&#160;&#160;Since there is a loss, diluted EPS should be computed in the same manner as basic EPS and because no potential common shares shall be included in the computation of any diluted per-share amounts when a loss exists, the Series A Preferred Stock should be excluded from the computation of basic and diluted EPS.</font></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,403,420</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,405,295</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,250</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,762</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Data</a></td>
<td class="text">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(O) Segment Data</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy', window );">Retirement Plan</a></td>
<td class="text">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(P) Retirement Plan</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains a 401(k)-retirement plan for its employees that is intended to qualify under Sections 401(a) and 501(a) of the U.S. Internal Revenue Code of 1986, as amended (&#8220;Code&#8221;). The Company provides all active employees with a 100% matching contribution equal to 3% of an employee&#8217;s eligible compensation deferred and 50% matching contributions on employee contributions that are between 3% and 5% of an employee&#8217;s eligible compensation deferred. These safe harbor contributions vest immediately.&nbsp;&nbsp;For the years ended December&#160;31, 2020 and 2019 the Company contributed $321,000 and $285,000, respectively.<font style="color:#000000;"> </font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">(Q) Revenue Recognition</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;In applying ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the promises and performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) it satisfies the performance obligations.&#160;The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint.&#160;Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price.&#160;The standalone selling price is generally determined using expected cost and comparable transactions. Revenue for performance obligations recognized over time is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-refundable upfront fees allocated to licenses that are not contingent on any future performance and require no consequential continuing involvement by the Company, are recognized as revenue when the license term commences and the licensed data, technology or product is delivered.&#160;The Company defers recognition of upfront license fees if the performance obligations are not satisfied.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="font-weight:bold;">R) Recent Accounting Pronouncements</font></p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Recent accounting standards which have been adopted</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.&#160;&#160;This new standard requires the measurement and recognition of expected credit losses for financial assets held at amortized cost, including loans and trade and other receivables. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The standard also amends the impairment model for available-for-sale debt securities and requires entities to determine whether all or a portion of the unrealized loss on an available-for-sale debt security is a credit loss. Under the new guidance, an entity recognizes an allowance for credit losses on available-for-sale debt securities as a contra-account to the amortized cost basis rather than as a direct reduction of the amortized cost basis of the investment, as was previously required. ASU 2016-13 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2019. As of December 31, 2020, the Company did not hold any debt securities with credit losses, nor does it have any trade receivables. The adoption of this standard effective January 1, 2020 did not have a material impact on the Company&#8217;s consolidated financial statements.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 29, 2018, the FASB issued ASU No. 2018-15, Intangibles &#8211; Goodwill and Other - Internal-Use Software (Subtopic 350-40) - which amends ASC 350-40 to address a customer&#8217;s accounting for implementation costs incurred in a cloud computing arrangement (&#8220;CCA&#8221;) that is a service contract. ASU No. 2018-15 aligns the accounting for costs incurred to implement a CCA that is a service arrangement with the guidance on capitalizing costs associated with developing or obtaining internal-use software. Specifically, the ASU amends ASC 350 to include in its scope implementation costs of a CCA that is a service contract and clarifies that a customer should apply ASC 350-40 to determine which implementation costs should be capitalized in a CCA that is considered a service contract. According to the standard the balance sheet line item for the presentation of capitalized implementation costs should be the same as that for the prepayment of fees related to the hosting arrangement and the manner in which an entity classifies the cash flows related to capitalized implementation costs should be the same as that in which it classifies the cash flows for the fees related to the hosting arrangement. ASU 2018-15 is effective for the Company for fiscal years beginning after December 15, 2019, including interim periods therein. Entities are permitted to apply either a retrospective or prospective transition approach to adopt the guidance. The adoption of this standard effective January 1, 2020 did not have a material impact on the Company&#8217;s consolidated financial statements and was adopted prospectively.</p>
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 5, 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808), - which amends ASC 808 to clarify when transactions between participants in a collaborative arrangement under ASC 808 are within the scope of the FASB&#8217;s new revenue standard, ASU 2014-09 (codified in ASC 606). The amendments require the application of ASC 606 existing guidance to determine the units of account that are distinct in a collaborative arrangement for purposes of identifying transactions with customers. If a unit of account within the collaborative arrangement is distinct and is with a customer, an entity shall apply the guidance in Topic 606 to that unit of account. In a transaction between collaborative participants, an entity is precluded by ASU 2018-18 from presenting a transaction together with &#8220;revenue from contracts with customers&#8221; unless the unit of account is within the scope of ASC 606 and the entity applies the guidance in ASC 606 to such unit of account. The amended guidance is effective for public business entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The retrospective adoption of this standard effective January 1, 2020 did not have a material impact on the Company&#8217;s consolidated financial statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, the FASB issued&#160;ASU&#160;2020-10, Codification Improvements, which updates various codification topics by clarifying or improving disclosure requirements. ASU 2020-10 is effective for annual and interim periods beginning after December 15, 2020. The Company early adopted&#160;ASU&#160;2020-10&#160;for the reporting period ending December 31, 2020. The adoption of this update did not have a material effect on the Company s consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for pension plans. This accounting policy may address (1) the types of plans sponsored by the entity (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6412939&amp;loc=d3e15145-114933<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65877416&amp;loc=d3e29149-114947<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552658839448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding</a></td>
<td class="text">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding as they would be anti-dilutive:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options to purchase common stock</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,403,420</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,405,295</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A convertible preferred stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,250</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,762</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552661783320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Short-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_ScheduleOfCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Summary of Fair Value of Cash Equivalents, Short-Term Investments and Gross Unrealized Holding Gains and Losses</a></td>
<td class="text">The following tables summarize the fair value of cash, cash equivalents, and short-term investments, as well as gross unrealized holding gains and losses as of December&#160;31, 2020 and December&#160;31, 2019:
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cost</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">holding gains</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">holding losses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Cash</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,977,320</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,977,320</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Money market funds</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,056,610</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,056,610</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash and cash equivalents</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,033,930</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,033,930</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;U.S. treasury notes</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term investments</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cost</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">holding gains</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">holding losses</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">value</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Cash</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">501,537</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">501,537</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Money market funds</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,395,607</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,395,607</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash and cash equivalents</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,897,144</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,897,144</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;U.S. treasury notes</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,839,500</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,469</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,841,969</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term investments</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,839,500</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,469</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,841,969</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_ScheduleOfCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of cash equivalents and short term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_ScheduleOfCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552583540696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text">
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment is summarized as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and equipment</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">320,957</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">193,717</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(185,337</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(125,354</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property, plant and equipment, net</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135,620</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,363</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552583761384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consist of the following:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials accrual</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,175,497</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,235,527</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and bonus accrual</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,845,441</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,728,495</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional fees accrual</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,846,211</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,070,589</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165,536</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,095</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,032,685</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,266,706</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552582448200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Recognized Stock-Based Compensation Expense</a></td>
<td class="text">
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s stock-based compensation expense was recognized in operating expenses as follows:</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,779,758</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,391,909</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,745,596</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,813,883</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,525,354</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,205,792</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Allocation of Stock-based Compensation Expense by Plan</a></td>
<td class="text">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,372,381</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,096,473</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152,973</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,319</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,525,354</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,205,792</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Options Outstanding and Weighted Average Exercise Price</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the number of options outstanding and the weighted average exercise price:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life in Years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding at December 31, 2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,714,383</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.10</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.89</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,485</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable at December 31, 2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,337,931</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.88</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.20</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,485</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,547,513</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.93</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.56</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(856,601</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.43</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,405,295</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.82</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.01</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,488,930</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable at December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,296,547</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.93</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.53</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">356,443</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,583,160</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.93</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.68</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(165,384</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.82</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(415,526</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding December&#160;31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,403,420</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.26</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.59</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">652,438</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable at December&#160;31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,395,658</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.45</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.13</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">445,599</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used to Compute Fair Value of Employee Option Granted</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of employee options granted during the years ended December&#160;31, 2020 and 2019, respectively, was estimated by utilizing the following assumptions:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81.48</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81.87</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term in years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.88</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.07</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.58</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.04</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of option on grant date</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.62</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.26</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ovid_NonEmployeeStockOptionsMember', window );">Nonemployee Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used to Compute Fair Value of Employee Option Granted</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of nonemployee options granted and remeasured during the years ended December&#160;31, 2020 and 2019, respectively, was estimated by utilizing the following assumptions:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74.37</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74.56</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term in years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.64</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.30</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.32</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.37</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of option on grant date</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.18</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.07</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ovid_NonEmployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ovid_NonEmployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552658853048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities were as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.34%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets/liabilities:</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryovers</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,064,673</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,288,334</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,458,004</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,351,315</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,978,370</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,606,889</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">514,316</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">898,067</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,760</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,026</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Charitable contributions</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,120</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,072</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,742,031</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,208,519</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross deferred tax assets/liabilities</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,814,754</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,463,170</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(89,814,754</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(76,463,170</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets (liabilities)</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Statutory U.S. Federal Rate to Effective Tax Rate</a></td>
<td class="text">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the statutory U.S. Federal rate to the Company&#8217;s effective tax rate is as follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.28%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal income tax benefit at statutory rate</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21.00</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21.00</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income tax, net of federal benefit (<font style="font-size:8pt;">1)</font></p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.15</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13.80</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent items</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.75</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.50</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.72</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37.14</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.64</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.67</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.02</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.17</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax (benefit) expense rate</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:99%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) Inclusive of $5.8 million deferred tax benefit due to change in apportionment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552581237928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 294,192,097<span></span>
</td>
<td class="nump">$ 213,156,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash outflows from operating activities</a></td>
<td class="num">(51,583,914)<span></span>
</td>
<td class="num">(51,090,622)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">72,033,930<span></span>
</td>
<td class="nump">$ 41,897,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and other revenue</a></td>
<td class="nump">12,617,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_WorkingCapital', window );">Working capital</a></td>
<td class="nump">52,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ovid_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and other revenue</a></td>
<td class="nump">$ 12,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ovid_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ovid_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552579907560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_DescriptionOfOwnershipPatternAsPerLicenseAndCollaborationAgreement', window );">Ownership pattern</a></td>
<td class="text">Ovid and Takeda are sharing 50/50 in the drug development<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_PercentageOfNetExpensesOfDevelopmentCostsRecordedInResearchAndDevelopment', window );">Percentage of net expenses of development costs recorded in research and development</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">Property and equipment are stated at cost and depreciated over their estimated useful lives of three years using the straight-line method.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_DefinedContributionPlanName', window );">Defined contribution plan name</a></td>
<td class="text">401(k)-retirement plan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Company contributions to 401(k) retirement plan</a></td>
<td class="nump">$ 321,000<span></span>
</td>
<td class="nump">$ 285,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=ovid_ScenarioOneMember', window );">Scenario One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Percentage of company matching contribution to 401(k) retirement plan</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Company matching contributions to employee's eligible compensation deferred</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=ovid_ScenarioTwoMember', window );">Scenario Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Percentage of company matching contribution to 401(k) retirement plan</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value Level 1 [Member] | Money Market Funds and Short-term Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value assets</a></td>
<td class="nump">$ 70,100,000<span></span>
</td>
<td class="nump">76,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">FDIC insured amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Scenario Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Company matching contributions to employee's eligible compensation deferred</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_AvailableForSaleSecuritiesInvestmentsMaturityPeriod', window );">Short term investments, maturity period</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Scenario Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Company matching contributions to employee's eligible compensation deferred</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AvailableForSaleSecuritiesInvestmentsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available-for-sale securities investments maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AvailableForSaleSecuritiesInvestmentsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_DefinedContributionPlanName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan name.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_DefinedContributionPlanName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_DescriptionOfOwnershipPatternAsPerLicenseAndCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of ownership pattern as per license and collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_DescriptionOfOwnershipPatternAsPerLicenseAndCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_PercentageOfNetExpensesOfDevelopmentCostsRecordedInResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of net expenses of development costs recorded in research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_PercentageOfNetExpensesOfDevelopmentCostsRecordedInResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_SummaryOfSignificantAccountingPolicyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_SummaryOfSignificantAccountingPolicyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ovid_ScenarioOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ovid_ScenarioOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ovid_ScenarioTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ovid_ScenarioTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=ovid_MoneyMarketFundsAndShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=ovid_MoneyMarketFundsAndShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552666387608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options to purchase common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Dilutive Securities Included and Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive Securities Excluded from computations of Diluted Weighted Average shares outstanding</a></td>
<td class="nump">10,403,420<span></span>
</td>
<td class="nump">7,405,295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ovid_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Dilutive Securities Included and Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive Securities Excluded from computations of Diluted Weighted Average shares outstanding</a></td>
<td class="nump">3,250<span></span>
</td>
<td class="nump">7,762<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ovid_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ovid_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552581090920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Short-Term Investments - Summary of Fair Value of Cash Equivalents, Short-Term Investments and Gross Unrealized Holding Gains and Losses (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents, Amortized cost</a></td>
<td class="nump">$ 72,033,930<span></span>
</td>
<td class="nump">$ 41,897,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents, Fair value</a></td>
<td class="nump">72,033,930<span></span>
</td>
<td class="nump">41,897,144<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total short-term investments, Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,839,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Total short-term investments, Gross unrealized holding gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total short-term investments, Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,841,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total short-term investments, Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,839,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Total short-term investments, Gross unrealized holding gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total short-term investments, Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,841,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents, Amortized cost</a></td>
<td class="nump">1,977,320<span></span>
</td>
<td class="nump">501,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents, Fair value</a></td>
<td class="nump">1,977,320<span></span>
</td>
<td class="nump">501,537<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents, Amortized cost</a></td>
<td class="nump">70,056,610<span></span>
</td>
<td class="nump">41,395,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash and cash equivalents, Fair value</a></td>
<td class="nump">$ 70,056,610<span></span>
</td>
<td class="nump">$ 41,395,607<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552581220392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Short-Term Investments - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Investment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of securities in an unrealized loss position for more than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_DebtSecuritiesAvailableForSaleContinuousUnrealizedGainPosition12MonthsOrLongerNumberOfPositions', window );">Number of securities in an unrealized gain position for more than 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet', window );">Gains or losses on available-for-sale securities | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_DebtSecuritiesAvailableForSaleContinuousUnrealizedGainPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized gain position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_DebtSecuritiesAvailableForSaleContinuousUnrealizedGainPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552581170504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment and Intangible Assets - Summary of Property and Equipment (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">$ (185,337)<span></span>
</td>
<td class="num">$ (125,354)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net</a></td>
<td class="nump">135,620<span></span>
</td>
<td class="nump">68,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture and equipment</a></td>
<td class="nump">$ 320,957<span></span>
</td>
<td class="nump">$ 193,717<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552580890920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment and Intangible Assets - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 39,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net of accumulated amortization</a></td>
<td class="nump">319,000<span></span>
</td>
<td class="nump">467,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 247,000<span></span>
</td>
<td class="nump">$ 216,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552669442712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_ClinicalTrialsAccrualCurrent', window );">Clinical trials accrual</a></td>
<td class="nump">$ 4,175,497<span></span>
</td>
<td class="nump">$ 3,235,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and bonus accrual</a></td>
<td class="nump">3,845,441<span></span>
</td>
<td class="nump">2,728,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees accrual</a></td>
<td class="nump">3,846,211<span></span>
</td>
<td class="nump">1,070,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">165,536<span></span>
</td>
<td class="nump">232,095<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 12,032,685<span></span>
</td>
<td class="nump">$ 7,266,706<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_ClinicalTrialsAccrualCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical trials accrual current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_ClinicalTrialsAccrualCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552575157144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity and Preferred Stock - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one vote for each share held<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from issuance of stock</a></td>
<td class="nump">$ 46,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,500,000<span></span>
</td>
<td class="nump">$ 33,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendPaymentRestrictionsScheduleDescription', window );">Dividends declaration and payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">No dividends on the common stock shall be declared and paid unless dividends on the Preferred Stock have been declared and paid.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=ovid_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,256<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">2,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Stock issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">6,250,000<span></span>
</td>
<td class="nump">2,256,000<span></span>
</td>
<td class="nump">10,350,000<span></span>
</td>
<td class="nump">10,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,993,778<span></span>
</td>
<td class="nump">2,256,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Stock issued, price per share</a></td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of common stock to series A convertible preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,512,000<span></span>
</td>
<td class="num">(1,262,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Biotechnology Value Fund, L.P [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of common stock to series A convertible preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,256,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,256,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ovid_ATMAgreementMember', window );">ATM Agreement [Member] | Maximum [Member] | Cowen And Company, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_AggregateOfferingPriceOfCommonStock', window );">Net proceeds from offering, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | ATM Agreement [Member] | Cowen And Company, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,893,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_PreferredStockShareDesignated', window );">Preferred stock, share designated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250<span></span>
</td>
<td class="nump">7,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates', window );">Maximum allowable owning percentage of outstanding common stock by associates or affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders', window );">Maximum allowable voting right percentage of outstanding common stock holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Convertible preferred stock, terms of conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">percentage may be changed at the holder&#8217;s election to any other number less than or equal to 19.99% upon 61 days&#8217; notice to the Company; provided, however, that effective 61 days after delivery of such notice, such beneficial ownership limitations shall not be applicable to any holder that beneficially owns either 10.0% or 15.0%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock, liquidation preference per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock | Biotechnology Value Fund, L.P [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of common stock to series A convertible preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock | Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of shares issued for each share of convertible preferred stock that is converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of common stock to series A convertible preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,512)<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member] | Biotechnology Value Fund, L.P [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of common stock to series A convertible preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AggregateOfferingPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate offering price of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AggregateOfferingPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum allowable owning percentage of outstanding common stock by associates or affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_MaximumAllowableOwningPercentageOfOutstandingCommonStockByAssociatesOrAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum allowable voting right percentage of outstanding common stock holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_MaximumAllowableVotingRightPercentageOfOutstandingCommonStockHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_PreferredStockShareDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock shares designated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_PreferredStockShareDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockTermsOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific terms relevant to convertibility. Includes class of preferred stock and number of shares convertible into, exercise (or conversion) price or rates, dates relevant to conversion timing and events relevant to conversion. Describe also any beneficial conversion features. where convertible preferred stock with a nondetachable conversion feature is in-the-money at commitment date. For contingently convertible preferred stock, discuss the circumstances of the contingency, including the events or changes in circumstance that would cause the contingency to be met and any of the significant features necessary to understand the conversion rights and the timing of those rights. Include also an events or changes in circumstance, if any, that could adjust or change the contingency, conversion price, or number of shares, including significant terms of those changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockTermsOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendPaymentRestrictionsScheduleDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of dividends paid, restrictions on dividend payments, statutory capital and surplus amounts, requirements and future requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6486098&amp;loc=d3e24708-158529<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendPaymentRestrictionsScheduleDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=ovid_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=ovid_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ovid_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ovid_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ovid_CowenAndCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ovid_CowenAndCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552574539352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,525,354<span></span>
</td>
<td class="nump">$ 5,205,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,583,160<span></span>
</td>
<td class="nump">3,547,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based Option Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested stock options, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ovid_NonEmployeeStockOptionsMember', window );">Nonemployee Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 257,431<span></span>
</td>
<td class="nump">$ 51,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested stock options, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,500<span></span>
</td>
<td class="nump">145,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 186,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ovid_NonEmployeeStockOptionsMember', window );">Nonemployee Stock Options [Member] | Separation and Consulting Agreement [Member] | Dr. During [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ovid_NonemployeePerformanceBasedOptionAwardsMember', window );">Non-employee Performance Based Option Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,240<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested stock options, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,975,262<span></span>
</td>
<td class="nump">3,963,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,573,160<span></span>
</td>
<td class="nump">3,372,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ovid_EmployeePerformanceBasedOptionAwardsMember', window );">Employee Performance Based Option Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,340,808<span></span>
</td>
<td class="nump">$ 9,391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ovid_TwoThousandSeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,052,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms', window );">Increase of equity incentive plan/ employee stock purchase plan limit description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pursuant to the terms of the 2017 Plan, on each January 1st, the plan limit shall be increased by the lesser of (x) 5% of the number of shares of common stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine in its discretion.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of number of shares of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares reserved for issuance under the plan</a></td>
<td class="nump">2,735,516<span></span>
</td>
<td class="nump">1,232,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of company's common stock reserved for issuance under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,771,772<span></span>
</td>
<td class="nump">2,199,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share based compensation, term of plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based compensation, graded vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share based compensation, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember', window );">2017 ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms', window );">Increase of equity incentive plan/ employee stock purchase plan limit description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The number of shares of common stock reserved for issuance under the 2017 ESPP will automatically increase on January 1 of each year, beginning on January 1, 2018 and continuing through and including January 1, 2027, by the lesser of (i) 1% of the total number of shares of the Company&#8217;s capital stock outstanding on December 31 of the preceding calendar year, (ii) 550,000 shares or (iii) such lesser number of shares determined by our Board.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of number of shares of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares reserved for issuance under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of company's common stock reserved for issuance under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">553,552<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialOfferingPeriod', window );">Offering period description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On September 20, 2017, the Company&#8217;s Compensation Committee approved an offering period under the 2017 ESPP, which began on October 20, 2017.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Share based compensation, percentage of discount from market price on purchase date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Share based compensation, number of shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,464<span></span>
</td>
<td class="nump">80,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,973<span></span>
</td>
<td class="nump">$ 109,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Increase in number of shares each year under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ovid_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share based compensation, term of plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based compensation, graded vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share based compensation, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the time period when the company made its initial offering of a class of securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ovid_NonEmployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ovid_NonEmployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ovid_SeparationAndConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ovid_SeparationAndConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ovid_ChairmanOfScientificAdvisoryBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ovid_ChairmanOfScientificAdvisoryBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ovid_NonemployeePerformanceBasedOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ovid_NonemployeePerformanceBasedOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ovid_EmployeePerformanceBasedOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ovid_EmployeePerformanceBasedOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ovid_TwoThousandSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ovid_TwoThousandSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ovid_TwoThousandSeventeenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ovid_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ovid_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552734302968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense, Total</a></td>
<td class="nump">$ 7,525,354<span></span>
</td>
<td class="nump">$ 5,205,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense, Total</a></td>
<td class="nump">2,779,758<span></span>
</td>
<td class="nump">2,391,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense, Total</a></td>
<td class="nump">$ 4,745,596<span></span>
</td>
<td class="nump">$ 2,813,883<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552587689784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Allocation of Stock-Based Compensation Expense by Plan (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">$ 7,525,354<span></span>
</td>
<td class="nump">$ 5,205,792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ovid_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">7,372,381<span></span>
</td>
<td class="nump">5,096,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ovid_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">$ 152,973<span></span>
</td>
<td class="nump">$ 109,319<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ovid_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ovid_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ovid_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ovid_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552577031384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Assumptions Used to Compute Fair Value of Employee Option Granted (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Weighted Average, Volatility</a></td>
<td class="nump">81.48%<span></span>
</td>
<td class="nump">81.87%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Weighted Average, Expected term in years</a></td>
<td class="text">5 years 10 months 17 days<span></span>
</td>
<td class="text">6 years 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Weighted Average, Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted Average, Risk-free interest rate</a></td>
<td class="nump">0.58%<span></span>
</td>
<td class="nump">2.04%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average, Fair value of option on grant/measurement date</a></td>
<td class="nump">$ 2.62<span></span>
</td>
<td class="nump">$ 2.26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ovid_NonEmployeeStockOptionsMember', window );">Nonemployee Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Weighted Average, Volatility</a></td>
<td class="nump">74.37%<span></span>
</td>
<td class="nump">74.56%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Weighted Average, Expected term in years</a></td>
<td class="text">5 years 7 months 20 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Weighted Average, Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted Average, Risk-free interest rate</a></td>
<td class="nump">2.32%<span></span>
</td>
<td class="nump">2.37%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average, Fair value of option on grant/measurement date</a></td>
<td class="nump">$ 1.18<span></span>
</td>
<td class="nump">$ 1.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ovid_NonEmployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ovid_NonEmployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552574997992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Options Outstanding and Weighted Average Exercise Price (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Options Outstanding, Beginning balance</a></td>
<td class="nump">7,405,295<span></span>
</td>
<td class="nump">4,714,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of Shares, Vested and exercisable, Beginning balance</a></td>
<td class="nump">3,296,547<span></span>
</td>
<td class="nump">2,337,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
<td class="nump">3,583,160<span></span>
</td>
<td class="nump">3,547,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares, Exercised</a></td>
<td class="num">(165,384)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Forfeited</a></td>
<td class="num">(415,526)<span></span>
</td>
<td class="num">(856,601)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Options Outstanding, Ending balance</a></td>
<td class="nump">10,403,420<span></span>
</td>
<td class="nump">7,405,295<span></span>
</td>
<td class="nump">4,714,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of Shares, Vested and exercisable, Ending balance</a></td>
<td class="nump">5,395,658<span></span>
</td>
<td class="nump">3,296,547<span></span>
</td>
<td class="nump">2,337,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Outstanding</a></td>
<td class="nump">$ 5.82<span></span>
</td>
<td class="nump">$ 8.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and exercisable</a></td>
<td class="nump">7.93<span></span>
</td>
<td class="nump">7.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">3.93<span></span>
</td>
<td class="nump">2.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">1.82<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">5.00<span></span>
</td>
<td class="nump">6.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Outstanding</a></td>
<td class="nump">5.26<span></span>
</td>
<td class="nump">5.82<span></span>
</td>
<td class="nump">$ 8.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and exercisable</a></td>
<td class="nump">$ 6.45<span></span>
</td>
<td class="nump">$ 7.93<span></span>
</td>
<td class="nump">$ 7.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Options Outstanding</a></td>
<td class="text">7 years 7 months 2 days<span></span>
</td>
<td class="text">8 years 3 days<span></span>
</td>
<td class="text">7 years 10 months 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Vested and exercisable</a></td>
<td class="text">6 years 1 month 17 days<span></span>
</td>
<td class="text">6 years 6 months 10 days<span></span>
</td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife', window );">Weighted Average Remaining Contractual Life, Granted</a></td>
<td class="text">9 years 8 months 4 days<span></span>
</td>
<td class="text">9 years 6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Options Outstanding</a></td>
<td class="nump">$ 652,438<span></span>
</td>
<td class="nump">$ 4,488,930<span></span>
</td>
<td class="nump">$ 153,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and exercisable</a></td>
<td class="nump">$ 445,599<span></span>
</td>
<td class="nump">$ 356,443<span></span>
</td>
<td class="nump">$ 153,485<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation by share based payment award options granted contractual life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552579884680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_OperatingLossCarryforwardsExpirationPeriodStart', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">13,300,000<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits or related interest and penalties accrued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Uncertain tax position</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember', window );">New York State Division of Taxation and Finance Member [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">165,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">238,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 186,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_OperatingLossCarryforwardsExpirationPeriodStart">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration period start.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_OperatingLossCarryforwardsExpirationPeriodStart</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552575471112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract', window );"><strong>Deferred tax assets/liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryovers</a></td>
<td class="nump">$ 74,064,673<span></span>
</td>
<td class="nump">$ 57,288,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">5,458,004<span></span>
</td>
<td class="nump">3,351,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">4,978,370<span></span>
</td>
<td class="nump">6,606,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Accrued compensation</a></td>
<td class="nump">514,316<span></span>
</td>
<td class="nump">898,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="num">(29,760)<span></span>
</td>
<td class="num">(22,026)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards', window );">Charitable contributions</a></td>
<td class="nump">87,120<span></span>
</td>
<td class="nump">132,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">4,742,031<span></span>
</td>
<td class="nump">8,208,519<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets/liabilities</a></td>
<td class="nump">89,814,754<span></span>
</td>
<td class="nump">76,463,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (89,814,754)<span></span>
</td>
<td class="num">$ (76,463,170)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552581178472">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Statutory U.S. Federal Rate to Effective Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax benefit at statutory rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6.15%<span></span>
</td>
<td class="num">(13.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent items</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.75%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16.72%<span></span>
</td>
<td class="nump">37.14%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2.64%)<span></span>
</td>
<td class="num">(2.67%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.02%<span></span>
</td>
<td class="num">(0.17%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax (benefit) expense rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Inclusive of $5.8 million deferred tax benefit due to change in apportionment</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552583711208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Statutory U.S. Federal Rate to Effective Tax Rate (Parenthetical) (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax benefit</a></td>
<td class="nump">$ 5.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552575094664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Additional Information (Detail) - License Agreement [Member]<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 26, 2015 </div>
<div>USD ($) </div>
<div>Trial</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>Product</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ovid_HLundbeckASMember', window );">Lundbeck [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_LicenseAgreementEnteredDate', window );">License agreement entered date</a></td>
<td class="text">Mar. 26,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_FirstPaymentDueUponCompletionOfFirstPhase', window );">First payment due upon completion of first phase</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_NumberOfTrial', window );">Number of trial | Trial</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ovid_HLundbeckASMember', window );">Lundbeck [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_LicenseAgreementMilestonePayments', window );">License agreement milestone payments</a></td>
<td class="nump">$ 189,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ovid_NorthwesternUniversityMember', window );">Northwestern University [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_LicenseAgreementEnteredMonthAndYear', window );">License agreement entered Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2016-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment', window );">Upfront non-creditable one-time license issuance fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_AnnualLicenseMaintenanceFeePayable', window );">Annual license maintenance fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementRightsAndObligations', window );">License agreement, description of rights and obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In consideration for the rights granted to the Company under the Northwestern agreement, the Company is required to pay to Northwestern up to an aggregate of $5.3 million upon the achievement of certain development and regulatory milestones for the first product covered by the Northwestern Patents, and, upon commercialization of any such products, will be required to pay to Northwestern a tiered royalty on net sales of such products by the Company, its affiliates or sublicensees, at percentages in the low to mid single-digits, subject to standard reductions and offsets.  The Company&#8217;s royalty obligations continue on a product-by-product and country-by-country basis until the later of the expiration of the last-to-expire valid claim in a licensed patent covering the applicable product in such country and 10 years following the first commercial sale of such product in such country.  If the Company sublicenses a Northwestern Patent Right, it will be obligated to pay to Northwestern a specified percentage of sublicense revenue received by the Company, ranging from the high single digits to the low-teens.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement', window );">Minimum number of product covered under license agreement | Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ovid_NorthwesternUniversityMember', window );">Northwestern University [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_ConsiderationPayableForRightsGrant', window );">Consideration payable for rights grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AnnualLicenseMaintenanceFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual license maintenance fee payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AnnualLicenseMaintenanceFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_ConsiderationPayableForRightsGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration payable for rights grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_ConsiderationPayableForRightsGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_FirstPaymentDueUponCompletionOfFirstPhase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>First payment due upon completion of first phase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_FirstPaymentDueUponCompletionOfFirstPhase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LicenseAgreementEnteredDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement entered date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LicenseAgreementEnteredDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LicenseAgreementEnteredMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement entered month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LicenseAgreementEnteredMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LicenseAgreementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global commercial and regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LicenseAgreementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum number of product covered under license agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_MinimumNumberOfProductCoveredUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_NumberOfTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of trial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_NumberOfTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront non-creditable one-time license issuance fee payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_UpfrontNonCreditableOneTimeLicenseIssuanceFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementRightsAndObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of rights and obligations under the collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementRightsAndObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ovid_HLundbeckASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ovid_HLundbeckASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ovid_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ovid_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ovid_NorthwesternUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ovid_NorthwesternUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552574870120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement - Additional Information (Detail)<br> $ / shares in Units, &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 09, 2020</div></th>
<th class="th">
<div>Jan. 06, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,417,394<span></span>
</td>
<td class="nump">$ 42,157,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Related party receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141,763<span></span>
</td>
<td class="nump">$ 1,131,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of common stock to series A convertible preferred stock, Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,512,000<span></span>
</td>
<td class="num">(1,262,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ovid_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda Pharmaceutical Company Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_PercentageOfOutstandingSharesOfCapitalStock', window );">Percentage of outstanding capital stock on the issuance date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_ValueForObligationUnderLicenseAgreement', window );">Value fixed on collaboration for share obligation terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_ThresholdPercentageOfOutstandingCapitalStockToMakeCashPayment', window );">Threshold percentage of outstanding capital stock to make cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_LicenseAgreementMilestonePayments', window );">Global commercial and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ovid_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda Pharmaceutical Company Limited [Member] | Series B-1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,781,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Fair value of Series B-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ovid_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda Pharmaceutical Company Limited [Member] | IPO [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of common stock to series A convertible preferred stock, Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,781,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement, Co-promotion [Member] | Takeda Pharmaceutical Company Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_ResearchAndDevelopmentExpenseReimbursementReceived', window );">Research and development expense reimbursement received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent', window );">Related party payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Related party receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ovid_AngeliniLicenseAgreementMember', window );">Angelini License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_PotentialFundingCostPercent', window );">Potential funding cost percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_CostOfAgreementNet', window );">Future cost of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_DeferredUpfrontPaymentCosts', window );">Deferred upfront payment costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_UpFrontFeeAmount', window );">Up-front fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_AmountForPotentialFutureTrials', window );">Amount for potential future trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_AggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement', window );">Aggregate tech transfer and regulatory payments through license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_AdditionalTechTransferThroughLicenseAgreement', window );">Additional tech transfer through license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_AdditionalAggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement', window );">Additional aggregate tech transfer and regulatory payments through license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_LicenseRevenue', window );">License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_IncomeFromOngoingTrials', window );">Ongoing trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_IncomeFromTransferOfSpecifiedAmountOfCompoundAndRelatedInformation', window );">Transfer of specified amount of compound and related information</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ovid_AngeliniLicenseAgreementMember', window );">Angelini License Agreement [Member] | License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_LicenseAgreementEnteredDate', window );">License agreement entered date</a></td>
<td class="text">Jul.  09,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_LicenseAgreementUpfrontPayment', window );">Upfront payment under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_AggregateLicenseAgreementMilestonePayments', window );">Aggregate milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_SalesMilestonePaymentsThroughLicenseAgreement', window );">Sales milestone payments for achievement of specified levels of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 162.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AdditionalAggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional aggregate tech transfer and regulatory payments through license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AdditionalAggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AdditionalTechTransferThroughLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional tech transfer through license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AdditionalTechTransferThroughLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AggregateLicenseAgreementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate license agreement milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AggregateLicenseAgreementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate tech transfer and regulatory payments through license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AggregateTechTransferAndRegulatoryPaymentsThroughLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AmountForPotentialFutureTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for potential future trials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AmountForPotentialFutureTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_CostOfAgreementNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of agreement net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_CostOfAgreementNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_DeferredUpfrontPaymentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred upfront payment costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_DeferredUpfrontPaymentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_IncomeFromOngoingTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income from ongoing trials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_IncomeFromOngoingTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_IncomeFromTransferOfSpecifiedAmountOfCompoundAndRelatedInformation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income from transfer of specified amount of compound and related information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_IncomeFromTransferOfSpecifiedAmountOfCompoundAndRelatedInformation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LicenseAgreementEnteredDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement entered date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LicenseAgreementEnteredDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LicenseAgreementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Global commercial and regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LicenseAgreementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LicenseAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LicenseAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_LicenseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_LicenseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_PercentageOfOutstandingSharesOfCapitalStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding shares of capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_PercentageOfOutstandingSharesOfCapitalStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_PotentialFundingCostPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential funding cost percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_PotentialFundingCostPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_ResearchAndDevelopmentExpenseReimbursementReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense reimbursement received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_ResearchAndDevelopmentExpenseReimbursementReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_SalesMilestonePaymentsThroughLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales milestone payments through license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_SalesMilestonePaymentsThroughLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_ThresholdPercentageOfOutstandingCapitalStockToMakeCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold percentage of outstanding capital stock to make cash payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_ThresholdPercentageOfOutstandingCapitalStockToMakeCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_UpFrontFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Up-front fee amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_UpFrontFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_ValueForObligationUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value for obligation under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_ValueForObligationUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ovid_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ovid_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ovid_SeriesB1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ovid_SeriesB1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ovid_AngeliniLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ovid_AngeliniLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ovid_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ovid_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552576308040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2019</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,583,160<span></span>
</td>
<td class="nump">3,547,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.93<span></span>
</td>
<td class="nump">$ 2.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement', window );">Consulting arrangement termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">any time and for any reason, upon thirty (30) days written notice to the other party.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,743,170<span></span>
</td>
<td class="nump">54,710,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ovid_AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember', window );">Affiliated with Takeda, Biotechnology Value Fund, L.P., and Shira Capital, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,058,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,058,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Biotechnology Value Fund, L.P [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Offerings, net of offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of common stock to series A convertible preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,512)<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member] | Biotechnology Value Fund, L.P [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of common stock to series A convertible preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock | Affiliated with Takeda, Biotechnology Value Fund, L.P., and Shira Capital, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock | Biotechnology Value Fund, L.P [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of common stock to series A convertible preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ovid_SeparationAndConsultingAgreementMember', window );">Separation and Consulting Agreement [Member] | Dr. During [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_ConsultingArrangementPeriod', window );">Consulting arrangement period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Fees to be paid per year</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_OtherAdvisoryAndConsultingServicesFee', window );">Other advisory and consulting services to be paid per year</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ovid_ChiefExecutiveOfficerAndChairmanMember', window );">Chief Executive Officer And Chairman [Member] | Affiliated with Takeda, Biotechnology Value Fund, L.P., and Shira Capital, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Offerings, net of offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of common stock to series A convertible preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,512,000<span></span>
</td>
<td class="num">(1,262,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Biotechnology Value Fund, L.P [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of common stock to series A convertible preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,256,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,256,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Separation and Consulting Agreement [Member] | Dr. During [Member] | 75000 Shares Vest After December, 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted to acquire shares</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price per share</a></td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Separation and Consulting Agreement [Member] | Dr. During [Member] | 100,000 Shares Vest Before December 31, 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted to acquire shares</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price per share</a></td>
<td class="nump">$ 1.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_ConsultingArrangementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consulting arrangement period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_ConsultingArrangementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_OtherAdvisoryAndConsultingServicesFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other advisory and consulting services fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_OtherAdvisoryAndConsultingServicesFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118262090&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the terms and manner of settlement of the related party transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ovid_AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ovid_AffiliatedWithTakedaBiotechnologyValueFundLPAndShiraCapitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ovid_SeparationAndConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ovid_SeparationAndConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ovid_ChairmanOfScientificAdvisoryBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ovid_ChairmanOfScientificAdvisoryBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ovid_ChiefExecutiveOfficerAndChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ovid_ChiefExecutiveOfficerAndChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140552579816248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 15, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,583,160<span></span>
</td>
<td class="nump">3,547,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.93<span></span>
</td>
<td class="nump">$ 2.93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">643,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Royalty and Termination Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_UpfrontPaymentReceivable', window );">Upfront payment under royalty and termination agreement</a></td>
<td class="nump">$ 196.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_AgreementClosingDate', window );">Agreement closing date</a></td>
<td class="text">March 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Agreement ownership share</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Royalty and Termination Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_AgreementMilestonePayments', window );">Aggregate milestone payments</a></td>
<td class="nump">$ 660.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ovid_AdditionalPaymentReceivableOnSalesPercentage', window );">Additional payment on sales percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AdditionalPaymentReceivableOnSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional payment receivable on sales percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AdditionalPaymentReceivableOnSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AgreementClosingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement closing date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AgreementClosingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_AgreementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_AgreementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ovid_UpfrontPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ovid_UpfrontPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ovid_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ovid_RoyaltyAndTerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ovid_RoyaltyAndTerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M[#RJOPHDMD'JX'/EHB2%*)T!.+(%@S>440 @N&41YQ#';%KG'LF,8J6EG,V
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M&2YWHD#H5@!_WRIE7F[LR\#3R]^;_P!02P,$%     @ @$)O4E\W'OO3 @
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M>H)DA'SW#GF.Y_3(%X/E[NQ0;NN<V\2]-G&O\AN?\5OJSP6$T%GK&B<O=ZC
M NTP+:$OM=IK6GF9F;&+G9'CN)&]ZV9P+>H U&]!_=M ZQ> <*DR+L@_2/N
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MZO-&W5&\J+;L-5?Z % U,WU& V$"]/,-Y^JU8TX![:DO_@]02P,$%     @
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M/*[%;7D_JN8EBR>-49Z-$ !TE,=I,3@Z:)Y=ED<'?%%G:<$N2Z]:Y'E<_O[
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M\FNHY4W-Y\UG#'>\KGG>7,Y8+/J7!(C?IYS7JQOY9<3ZF[2C_P!02P,$%
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MZ;37+_5G=J_?2:@VC8 (-_J5!5\5Y=FPQ<%0B@.O/>^4V/$B?_)WMXK46Z&
M"90"(QV7=U;AP+9!3%@8AR-;.00)82Q,W,;")TR"_7DG &6A'X%%=[(IM!,E
M=G@T)'1<IIQRE-!P B090!(OR$^B;*ENQQ4@A:03Q8&O2F=R':<Z!9$F*4WH
M&*PM-P\I#MA$?N&!6C#UHOU%UILN47:CV'#BI0ZCX3BB9 S8%H3ZGP1D"O#
M4=A/4M=9F^4-V/=QTJS,7IU2&F,K"&S!>132-)S(:SQP%0[/P6SKE=>:H;4Z
M2V@8!?$8IBU(<!PGC$W '(@,^YGL5JP%Y'T.<7H0]=YM39N2,*$)B>-T8OF!
ME+"?E9[GBL^C#G[!E"7$\JA#,(UI%$U '9@(^ZG(;([.;BZ<T!W4$>(PH2D>
M<[];-$B#:#)O!J;!9ZAFM(GL>/'E>R,RD PY0S)[E6VY81=@Y9<S,7'02YI&
MH/ZXN+@D*8O3. @F$H(,%$/\%'.G9"9$?C02-'&&<(I7ZV*3"X/=D/DWUL66
M' L^UV3@(>+GH2<W&.0[9:(54LSPO?AW7^P,="=R!]-@ C1O 7=14HS#B40C
M R,1/R/=R[5^X$H R1]$*5ND)_N4Z?T)<9 3B2BSH;M8+(F29**>D8&<R/D.
MJBT28/!# <TH6CVB[X\5XP=GSCDUL6F)L@BJ'1EO2QV2<PII %N#*64&"B/^
M?FM<,=9%S:'A>GG%&%B(^%GH>=*):E?*1R%08]HLM'N*XUW):Z>U;'XB =AK
M3 T..4QQDD[L^,C 8L3/8B/X7X3*BB[OY,YT)VX?NQJK("%X LU 5.2%1'4:
M@R[?.5'9#,3B -(_MHJP+9F8K1-.XPD-!JHBZ5D-BAI:.^-U8-I6&U,!V@=3
MO@Z\G"R]J<.NF$9Q8L6#+1FR +KRB1)&!P:D?@9<3@%^@[A&*[$IZMKXPE1F
MH0J9NQ2A-LLQB-88L_&VP2%)H5H =TYT7'2@0^JG0[\FPE1EKPXVN\60FS2E
MXYKLD+2T?:[#0(24>.O81UG/6_@GY1> O[:<T9/CNJ]BL$PVT+Z<G&D\Z\;Y
M^?YF26T"PQ%+IS:)=. OZN>O7]?0#AB3?#7&&^KHP:#<6K%KBT5I1*8"=R O
M>J;_VF_VC6X/<%&OU5\?1+42ZF^?EP?2HM$WI4<Z\ M]#;]TFKU![\5*[;GJ
M]G2_9EJ"9KVJ;]I#4<- 3[K[&E%J<Q&+8G#6U&D('=B(^MG(B=*<B[_.*P-W
MT->U.:_U"AN*/#MWEO9MO;)D=EF/&"9!3"<(B@UEG?G+^O5O'UYB=C;46.:O
ML5]M]J&X,G]Q_?9FI]8%!H&-=Q1.G2&PD_N5,V=78/:VLCIO6!P7)SBB)!QW
M@HN3N[A*J$U[1=F@MB1W=US]U_X:]+J]_!M]O\'OEMUEYC!-=[?Z@2O8HS2H
M%&N8,G@;0Q"J[KJR>]%RU][XK:36LFH?MX+G0AD!^'TMI7YZ,0OTE\97_P-0
M2P,$%     @ @$)O4@<$L4P_"@  JA@  !@   !X;"]W;W)K<VAE971S+W-H
M965T."YX;6RE66UOW+@1_BN$&Q0)L%E[-\[E/8"3W$O0YA(DN3L413]PI=&*
M9XK4D937VU_?9X:45K9C]XI^B%>BR.',,S//#)F7.Q_.8TN4U&5G77QUU*;4
M/S\^CE5+G8Y+WY/#E\:'3B>\ANUQ[ /I6A9U]GA]<O+=<:>-.WK]4L8^A=<O
M_9"L<?0IJ#ATG0[[-V3][M71ZF@<^&RV;>*!X]<O>[VE+Y1^Z3\%O!U/4FK3
MD8O&.Q6H>75TMGK^YI3GRX1?#>WB[%FQ)1OOS_GE??WJZ(05(DM58@D:/Q?T
MEJQE05#CCR+S:-J2%\Z?1^D_B.VP9:,CO?7V-U.G]M71TR-54Z,'FS[[W4]4
M['G,\BIOH_Q5NSSWR;,C50TQ^:XLA@:=<?E77Q8<9@N>GMRR8%T6K$7OO)%H
M^4XG_?IE\#L5>#:D\8.8*JNAG''LE"\IX*O!NO3Z9YV&0,HWZF-/03-2\>5Q
M@F3^?EP5*6^RE/4M4E9K]<&[U$;UO:NIOBK@&"I->JU'O=ZL[Y3XCJJE>K1:
MJ/7)^N0.>8\F.Q^)O$>WR/L8MMJ9?XN!ZBV,]-;4^>W,U>I3H$@NY8&/C?K!
M..TJHZWZ@D%"%*:H_GFVB2D@COYUAT*GDT*GHM#I_PG\W5(^7IA:?6TAH*<A
MF2JJ]P[ W4\MJ;_^Y>EZ??+BK>]Z[?;RMGKQ0.UT5,95/O0>VU*M!K@L*%YA
M]2ZR1OP<V6Y^>4<8UJPJH.J#L4J\LCI5&L!QWB?\@TP@A,] K0=L=$G5P D'
M$8VI"%NJGY&C_T".+J:G)>NNBH:J\AV KJ"2GR"YN>O]NBB&K:CG20^NBC%1
M:;4QOF\UTK827*!153XW'FF%/>BRLD.$AG;/F]2$)]\;MU4&$ZO4#%9U5)L*
MD$>L"JJ'2A((;'BC.V,-OEASP8MV)K4J,$Z.AN"MW\JNM8D^ -^X5%]888%I
MTGPA4(^*M_ ,U/#LE#@@UK1+"$'HAS]B,=92 U7PF[S:0'WH%D?=.4H7BB-9
MAZH5+:]]J<)@$FO;:0?*Y6&9EJAJG>B+39MF(8-!F\AS*]V;I&T>9!T;20XH
MR?K,7)7:X(=M"P?$@2>PRI5W%Q22V5A"=%!#(;!UR5?GZGZ)T$_3^!<>'R-U
M(0$!U^39O+L'7$'1'[ "?G;(QD%2\T8  +[?P?N,4C#Q/+ML@$Z!@S6QWXIP
MS !<=O\0EF^I1 E_1\"R<Q!(@@Y[E/>LP<EAOV ?VJ$&/@OX(2GG$R*A,^R[
MY!=SX#.8M!VL3C[LH5M5P6M7YVPD_'M*!G,D"1UR9-I9?&.<\Q<9:UZ,NER3
MP.S4.>T5'!&]<P1/]8&5%C*#)+PA@RBAZ!XD[@7>WAKQE$3OUL-53M0IZN:M
M6'^]0;0#=, 5D=D(<UW7AB=P:N4(X8_-X.;INU0_&;@OL/YV?R7<V<VK)R\B
M8O%W)%?T0P L$C,ZM@@T<,>&R(F:<"+3@MA2$=4(PN [=:&#\0-X9]A84XFB
MF'J1"0(Q!??$,7%&)0_1A$ @9$L2.NQHJ<YB)KR*N@WB;"P_U[,4:/30X]*@
M*6#VN/=DO3Q!<;:6 4?<B &\@SQPN%YHF^.TD,#M!+ E1YF7[ZW6R^_F8@/B
MQ0U '@;KD$:FOHXGD$#31%D!;ZW>^.P-I;>!<M+/"\29VQ+JBE%_+PO/QFF'
MFL'A,<W[),2J/C/9O8-CT!1%=?;CE,_CQ''YU>QL<_T9).$#QQ*[25D?(68A
MG^D2 61R*3C,<+35N:+D\!)J KX-&LM8D@Q0PZ,JFJTS*#L@T#P'@R6^.-^E
M-F4JGCBTM]K%FYIJ;ARKH>-L(.932#4"_;WUL]/E>O*/_G;L%-(LH8"N.&LK
MT7NP0WI3([3$DA^O9H[GRL/>VH.F%*=\_8U=;@7XL$<&&-!<"4#1C_&N<DT!
M7V,V@@S/(@2PIW$MJZ+Q!H\GT<G190(?@#:06*Q@]H-W6\];SFH#QTJ+#AGI
M,C)78N+Z5@#/N,9OF*_G7#/C">8:;+-4'P[53(QGX7 _4W&+:LA&Y?58!@PO
M.!47:M>:JF46Q D#%9KK6=9';Y$ B#5:2 VD>3%6M1\VH/0-7 EWAKFR$W8<
M-RI#@#$4'3>K%[(%%R4\Z'0E_W=P.3@/A4ISO>3B)?OK&H'-I/:G.'>JPS==
MA3Z]RWVZ!""/C]U4 S/89<PI**!GS@V0_IG0)8JC^ RD5B</_S:'>W(9\JOW
MS!U0YP;F$F(".I?FR>I2![G/JA!@T^ZDONISJO7$1[S^*P6<?DK#/M&8\%*9
M?3\2<1DF6/D@0PF21G],N;<UX(::/>50/Z1*<UM%%X8!R/I<]_+4E_#<#:JC
ME(B:8A7,)L=+V5!XG(LB_I4F8XX !P=,I/_).G"AWW%NS;NUW",FF2_Q7<"T
MYAR<VWHO59*[D1'3$M2-"9&7VX8G@#16[(Q '0Q8JM\H%URTOE8V@NR)&DM<
M,W;"DHP "+;@4M>!)\EA .9N1SAS%ST5J8^_OG_W</4,E0NYWZ%8<V^"_!EW
MR=2+(&4K(5>R4Y:.;')31-XB7I&SD+>*ZX_TW[?W8:63+@O&\]"5%5ZZ2-2<
M;!]K@TH^2,+DTT\X!STR+V8AAWYUD4,PDQT;VPQRX)N)+[DPH\:I0RW=@V-'
M;J1SQD&$G2(1#X<T)O=^XG[.*M.!KI!2+;,/*SK8) V*JH=2_HLK1O@0LP$^
MMYR\"1U:Z?; -(&SP'$UCEX.P3C%)#X/<ZER\\A C+%1I?!FHTK _;+\LERH
M[W$6ZFG6O%=^<-B-2E_),^&(C++(9&BKDC;(%*>VUF_D%%0H=H0G!2K!7^<F
M)(=0GJX(4ST'243!K?VNM%I>:I58%(9^A*6L:4G;U%;LD+B/./8?W)Z5O^TL
MH:, -3EH#C-;;.N<7EJQ1P)#JFMH$D?CKV?#HARRC!Q<"X_(V0YN%8SFM17Z
M;(/?86,P7I1:OE3O#V43L9BI:78L*MYHF0/1KY4&2NQC"=P]R;294MF+5VO>
MV$L5_?E^)!$?+A"%.P+0^/WO)[ ;IZYK9_?QV)71O9[3<F\0!*L#*E=.:+R,
M"[:<T'3!\L_Y\GGI03CV9^0A)X ++<=R-IS;PW*$Q(=ZJ+CQA-^XO,874-GJ
MO70?^(K:WDV6QJ'O^08BBREKH3VW7#S*'(Y>(+<]>;:A(*(:;2QG7P'0%GA0
M+88&*32$F<X,R8NQ,]H+*+KBI)6R&Z#-PWQND!P_M!FC0D7U&X9=<]0XY;J+
MI" X+I$8.. M=D]<71J"%].*673FHY\<:@L)D6L+)3%P?):S?-4[9"T0!Y >
M^$X6 C,\TS6-9A KZ;%F+IV3V+7TR5W-5)WN+$HEL?G61E([WLRA;Z8Q C;!
M=WS9$WVFBP,Y\M16;IC)E?N;_<CG=U,3B*X:(I^><P?SK:O+X]G],3)I*[?D
M,5-UODJ>1J>+^+-\_WR8GF_Q/^BPY=M 2PV6GBR?/#[*7AA?DN_E-GKC4_*=
M/()VT7_S!'QO/+Q<7GB#Z;\G7O\'4$L#!!0    ( (!";U(-6R=.MQH  !!0
M   8    >&PO=V]R:W-H965T<R]S:&5E=#DN>&ULS5Q;<]O(E7[WK^AR)EM2
M%453E&5[[)FIDF5[HF1L:RT[J=36/H! D^PQ"#!H0#+SZ_<[EVXT>)%<V=VJ
MO-@2B>X^MSZ7[QSHI[NZ^>J7UK;FVZJL_,^/EVV[?OGDB<^7=I7Y<;VV%;Z9
MU\TJ:_%KLWCBUXW-"EZT*I],)Y-G3U:9JQ[_\A-_=MW\\E/=M:6K['5C?+=:
M9<WFM2WKNY\?GSX.'WQRBV5+'SSYY:=UMK WMOVROF[PVY.X2^%6MO*NKDQC
MYS\_OCA]^?HI/<\/_-79.Y_\;(B365U_I5^NBI\?3X@@6]J\I1TR_'=K+VU9
MTD8@XQ^ZY^-X)"U,?PZ[OV/>P<LL\_:R+O_FBG;Y\^,7CTUAYUE7MI_JNS]9
MY>><]LOKTO._YDZ>?7KVV.2=;^N5+@8%*U?)_]DWE4.RX,7DP(*I+I@RW7(0
M4_DF:[-??FKJ.]/0T]B-?F!6>36(<Q4IY:9M\*W#NO:7&U&&J>?FQBTJ-W=Y
M5K7F(L_KKFI=M3#7=>ER9_U/3UJ<1ZN>Y+KW:]E[>F#OTZEY7U?MTINW56&+
MX09/0&BD=AJH?3V]=\<W-A^;L].1F4ZFDWOV.XO<G_%^9P?VV\.F^:^+F6\;
M6,M_WW/ TWC 4S[@Z?^+>._?^\/'SV_-U/S''UY,3T]?F9LO[]]??/J[^?C.
MW%S]^N'JW=7EQ8?/YN+R\N.7#Y^O/OQJKC_^=G5Y]?;&'%T<F]>9=Y[HNFZL
MMU6;R26I"G-95QY$%?+)YZ7%U<GKU3JK-D1P'K^VA9F[*JMREY7&8P>+V]IZ
ML\QNK9E96QGXB776X#E7T3KR(:[=P,3;)6^J,E@W#INL2TA_82O;9&6YH>_M
MNI6U+8CX4CGZ[8;.8<(O5K:!.,T126 Z>?7KQ<4U_WCZZI@9P:9E5UA>K:?Q
MPH^WKB"^FFQMN];EWEQ5L"M>@B?NEC7./ZGO*ASGNYEWA8,.1WO6_:D&]7^A
M?WYS*R)O;"[*$@>WME&1&=A2Y3/V09[/F&4E9&93.=D2RZNLC9+J%3 V1Z^/
MS1=OB?*WOG4KYI_4(M(5->'+O;K8(WB2$_SI/SH'S<.75'"^]+!I:_SVU1H;
M3R%R,P^'O1;RVV76FFP^ATMEJ8* NB&JLU64+IZWK2PM739SI6N=;E4XGY>U
M[QIF!G21]NGD0VOD%#(U6D _[V62UATBQWY#_/+8K.@:LK7^.;8\F%!-6LO;
M#GM"(/#F'J1U)9$+3AM#HF@<V^2\J5?8H?:)D*"@RV/SR?FO0L@7Z+9I$0Z9
M!=+3I5H"[AO,Z7<67FT:7@$K64%]^%WLA=:HP1?V%C%SS:H!LPNK!@VZ1V;6
MM::J6U.*W6&#$1: U<)6.?R-;)'#9^"*E$P8'06S9-EUN%R>Y4,67S0=[C6>
MX5OM1T94L"&RZAGQ LDLNC)K:_BR;+UNZEOL<F@UG5Q9\@YUPQ>HA<^C8[.B
M<&1(^%'U2 JI<3F7#LSR;HLZ*[%'%Z7(SG/6U!G46M3K8.WTK%""@_!?T>4M
MUCD88(6[.MN8]7+CX5HSO79TJSH(@-C#KSYQQR1ZV[KH 6$[4"_VQ>7HYKB[
M8CIYMNYM\^C-L7EC81_DWC[W=QS:]B M?I5<?YSCB4:X.P0%!WLBFAR?!(X*
MW$>8!I3<L%U#2J5=9.4H<95">PT)-V9N049CRTSTSV)74^.8\/P5*1AD$.TJ
M,;#@6KX\=?[5P#6'3]P_Z=J0[>4=T3UFRRT.<L%KL3ONK<D6T)-O20LYU.Y-
MMP[VQS)?11>559$B7)NWQTQO8Y>4Y$'_O]6PR>%')7VDCMS#JEKY!)3>(9.C
M_T48^3*#*^&[P[S!AQ?0M0K"D+<C>R;_)9=<[_*V<[8@N5ZYW, >V8/P[EA7
MZ;UG%YH> 4;>$2-EF<UJ]<8734/D\-7]S>7D@#2T#IY:-%:>X4T_P_<6F;E>
M9L@V<XXPT%1P'AI@X%X*)@AAS38K'_PB:ZTB?]"?E@].R_:>QC&-'M;?2:T>
M%)#-G$^>G$^B-Z);GKBD46IOD&E>-]#\^>2/@:+4?8G)L!OQ-FORI82#_HFQ
M^1LT+M2P"7K>8Y7]7C=.7(#8DU=WK^2R_F!0^-"LLTT(8[P/_H?:V;3[Q1K%
M [WT.6(H1.W6(B8XCB *VA3&W^6ISSG$00PT(UH8]X5)=E%C6PI)1.VJ+?YD
M V$(X4IR-#K=K6:0CBB2@RBMB$2K')6#[Y*DR&J_''6?H[VB/'Y0EBY0$OU1
MC,;9/9*,UD+RCF&>*$<M*L(3*=]GO"K1@X=P.=BG)NT2T7E(?2)V.BCR0"?$
M?.1A)N@IO[8Y!9N8;QS]"I>1>5G&/[R%AT)0Y>,^[_'D>7B:?[#)TQI$V!KH
MNZ4M)8U<VOPKB2+FOK0<V8;=P!R:K_"E<]BF'P^2%-ZM8$N ?UVBJ$6<*AW.
MHTUO$1<EYY(<'M>B<0M'$1U>OF,+Z],U.!PZCRI 9 (E91RPI)D]S,PXE$9>
MV("[_C*^&2=I'T4:UW;JL1M*BBBA+.@.D*C?O;FZ1 "B@WZ8GD]&D\ED+!*.
M>;=D=_8;!:NX/*2,E.!"# L$'^C.K2R4]:=C<[-$QGA"+A?%0B^%Y.-4.(E*
M"CM#^F9SD@T9&\M-946_PRM3?BDA1O/+/N5==["MS-NACD@SZH[24\EAW68.
M+J:T)\B]3CR$FIP]1E8R)(;D)]?7LJSGF6L,5-%IG.LJ4">Y <=XR= 1@&T,
MRFQJ&H,'D1O?URMKCNCQ8W&F] #,3^[R/6&:<AU*QN7HL?ETB(@1J0UW]I]]
M]0IC;VQPV"!GY;I57WVHCAO;DT^,@H606D#=5\<HBLG5@!1:2%=3+O7@8QL_
M9K_3<AZ6R<U7=X#S8;2<W]U*#(!\0^6 /-/;>8<L#^+R_8W9P*$@:OA0K1 :
M0=C2"0$ 9F61A[!,UE"6WFG*DRW=$)MD9^IKBZ'M-/:6D"UU7CG1%;)]2M!@
M627JV1.BJ="Z;-07'KJL')(_MR-4S:C<B<F0. URLMPU.?30R@5TJ!5RLG#.
MQSB@9$W#Z()<0R9EAQ"S(C%PV3-+B"_IBOX9)5CJBM\DKOAM"#JI'&(D"O&,
MSCP<+=+,^--#*8#<!.=MC *RE"0!^^%J'+Q^1VQ*11^+N9:JT9#.;)4H?![5
M73/<R6']!V,\B1^$HG9?*@V/3?@7H1^VN45"B6-"7DE%1UJ$V&_8IPKDC,V'
M&BZ#P@KI!07;+1NEIA1"V:*N"[';L+W8P9T#%5 LS(HE->_:KOG.")Z8.UNB
M8C[\ !?>*G:ZB4W_A)#2XS"P*4OV-C)(,V+B'Q]G,W&]/DD['%V;@MEDGWEQ
M<VF>GTU&!^T1UOH7!!1R?R>O,Z*8;!*T]X!;=/0A&)+<)!NB53->E:>K#A%R
M^F(TV)X][?05GS[X@FZP ['P3E"=\TL2:P_1<2F?')[=993S+9 W:OEI5^NR
MWE!-RL\&U1+S$6SJ,0Y:( ICR?8^,0E!DF)1,2.'!1\J^WF40^&8F%<-;GB$
ML1@X&NQ+?FZ+A=[AOBXS\'F3(SAA,:T1&:_JPI9C\Q?D3ZY:=^TN/I8BCL0>
M7R+.#C1=%/QBI/4W? 1HOZWA3MD#CQ@4.IE3%& ,$2R0)<*]%K#DPN*XC4->
M--R @]$W@G:\E8_&YCU)0 ]-*515#."/W[MB(3>*V*$<4!VW)$I\/;+H,8R#
M>!FGT#*/^"/P4F/N01-5?6\IJ10A9=4 $"90G.$GR4[(I.;6D3_P6EZ!NQRW
M<#NXY37X^B>>"N;X(#U&OE+$8L?\Q$S"URD4R88CY^_=U_F>GCX!,)2O]=!C
M4AWNC_,'W4&M&MV]B15RK, ](S E 7 A"2*0J6[\?H_QQ4PGIR].)L^'7J-O
M,NSX#7/TN5ZCLH&G.7YIKE:,R(FS!RD?$E)NJ&Y2CW>M-6;?"!%.=\6OB)^#
M#8OS)AC3M<KJS(9OG)? 02"VS1AC9I"D!WBT,"?_[7&7.;00VES:@._L.S\Z
MLA ;=@BEW>3$(B#6@QUV*CF!?!6"8^O290@7I8,U! 1EF"(QWRPU4K\&-%:>
MECXL2MM0%;O!K?4AIF6H!%ETVP]%DM+-G+CI$O<:D>JW8_..6/UKX.A=K,2N
M4(DUG:BZ_S1I;=W [ HVSM<U<1D:->\N;E['1LT"A26?JS4R77"4G4CL$#K9
MA?4.N+7YLD(IBF?BI45PUDAM@U=F+)2PNKTKN7B?D5I9]1!+5_6_C\W'_CO=
M#PD->:E0-$,MF<+B%*^H9$-"J]@[RJL:-1LE28BGV"/=_,"&B7\6X^K97W!I
MT/)GBZ5ED-4)D ,NNRHK?N\8/_Y'5[<,A#M)L+7=K4=H D'T23HH_18JRI-V
MR]%OE*28TV#.I-KCB$:5]=WN^;N\Z29G@TV$+2EO2OH^XI;)/>JY)A5E1'.)
M0_W+1VPLSUX]4OHTA_GR?\M]O&A]=X@6Z%7B2-!W13+IG^B*A%6^M&,3)+D#
M]?MAI\XE=^@NVBQ?PFCARIP:B_+H.THL"5"38'T"1R?%>+^AM--80%Q8,P2P
M#UL*U*I@!EV)7;Q(4O?]P$=;4R\!HOOA^60,0T)*'PKS'YX_&T_[3U@0;^!3
M5S/<WM#3YR<1@GX<4=Y/"1346&[&6R8P51.X$IM+0/IM2Q@6^8%1Z6,.'<%<
M':24FHEQ("U#ZD$G2/"$,LF<JOC;D1TOQJ.MHRD3<N V:P[8VXZ5CNB)X29#
MNZ6T^J$M@\5'#JE:EG..@UE.^X;*?DN,B]D80VK,Z2^?*?).$F/.5>JR7FR;
M&.Y. 1+BP?OI?L@8MM5_%CW KO\YK,9Q$J4&UZ2Q$?4$L\%_A:H/_JEW4O)T
MR'FC:$A=O8A&$6JRBG#.R8^E^DOC4<7QOX0/ ;W5,#7G#9, (98'1CG?&<2M
M@U(_^U>E+JGM$)GQ?9-="P"%50W/((G\#\*[HX =G4B2(CD5T4_6+^B#-K("
M]!1SWG6VH0?YDX:L,FFXT%&Z;GB +M)6\3>N!W>4.JP $L\6(>U8B29V@^3H
M_3%-CA#*^3G[MH4O#4MW>:KEI_J,7VPTG7K8Z%T*U7BLG/M.;/;MT+B$Y,-)
MS1'N0E)="Z9"FY#)8W?+B%S6MHV;=:UDP[6./LAW,]O>42*Y9_1BUSJDW ^>
MFP\BZ>HHAI/29S_]HQ2*(M()DM6.#Q9QWY?/PW=2\^AA!QHPD)9#??;7Z*8R
M2B<$@:1;3)6*XYA)4'HL"DKW%1%'H@DY3W:&GM3':8'<047@VT&/O-<,0UD1
MIPPP-IF'%L^,;TKD#O>(EI?9G0]U8U/T=TQK15>I67 ^EMW1H[9BJ [6^.'8
M?(#$N(E^#0N[E#J#RRX>]\JU BP[,H782U\+=,\U"3_K?.KA4%PP^$ ZZ/OO
M6_:2UC2*Z8>JY(X'(W$C,T)K%W9P%NP"3IOJ!-H^&=$)@,X[%;;\[HVVY&R$
M0$(9G Q3?=.@'[LI")XY3:]P?]?F6>>#$[ RRW3'0,>,H)36G;"$8+VL,>3J
ML(K1?E;V\!"*T'"F%21VMB/__;+/M&[U&76>#C3[;R ,''M!LWMJ?%*8AUJX
MTARJ_WZ@F:)FXU1M5Z&C,ZQ7F5B6:D530*5;:"E5<QH8%S6Q>:S6/S8WC@("
MN7,VIHR?'47.WU[?D)=5D5.QV27QA#@G5+OB#55PM(1GYU1[(&F-1$G&BH8&
MA?\$1TX;5%I XZ!D%F43*8(:3E3^ZL<X^@OAXK=TKNF@Z'N&]MC?\.1=6P![
M"BMPR2,0F+)7*IGD3I/6W;WVWI_G9;)(COD>^PWHVOXK\?+1.XTI?X?7E;G>
M00KQB%*(1V1]CVX&]Q-F$YJ9 V_QZ'0R>CHY&SW%LN?XZ7PT_?'\410SHA1H
M;1WYF?70FA^=C:;GM.CYL^FCHX_'T(W F#0(/8C%,N/H&4'O1PBD)TGY&W=)
M%Q%:8?_3->M:+P69M?>*V46<1!IOW&#O@U1A<^>ED#^ZII94Z[0NO$:6M$64
MJUKI9YJGD].CK\<G3?_XFAX/J'\/K7,PX@Y$:UGV$"L/9LPWFE?<6)UFHCTS
M*=_/Y4>]W]Q0OZJT;_.)^G4=D54POG/ZXXMG'(EQ#?F$@-K0 P&U&6:;&DAE
M8D!KFIYD&10PIY/)'RFARI<Z1"P!A %3XH X.?NC#HF%U?W<"-P/V\  :8VA
M5Y@\L+^GS"X%1)-O8J43DAR0P)O]BY2P8#PYL;G%%6UF=;-U(M7*R )62$X0
M',J-A#C2B_1][<Z5&F;E Q<=M\:2'\ZFIS3M(,7V],4Y_;)51INC_SR.&O\D
MB2+3+X&&.D;/)J3^*F ?":+>Z#IVC3Q,R*\G$%XY$T-F<NI2.N_URE$HE!9;
MTA&2IED5.KTZDL> 6&C&2BVFX2; ,DJ0M%6\]@:L3!I$&$3O+P$I.P>3T5,=
M4'+"&GE-Y:GW6SM&T1?/V?>V=NU?FB-WK"7Y/*"NTBX]\L?!UH-@7N'I[<=5
M,)*\IOZD#[&^CUBR->^#C6)6M@UM"UY C]T><YJKW?4]#X5)T>\^FN@\PK;1
M$H:&<$0)&EA'!DUWP<^= I8'#ABZCKHJ>:"X#*M(U"<D:BU].;<44GRP/.[G
M-O4L0/<M?<8I-PW8A=GT+3.J-766Y6Q,I>0&6[:SQW(0./LD1^47=#PV%VTD
MD7(.JRV^6G.@Y,M!7BW5F@)3G/CDB"/\8L,^TY0@I%+:I3#>-]V00/]X\J@_
MU^OMB([OD!UH:U/.#" [[SJXV@D1S!]7>'D[U'*[E-YZ\"19[TRX#(XS'P<L
M5H->,.PX[9P4FOO9&)KH8:ODT7RU7OCP:\*X0_>1:)9I#:9XJ!5Z7\(GG>9#
M/*1S'+=9(UVG/8YN^(I QH]06Y :C1?]2PT'MAC,-86R\I #H,F-X'_WW:EL
M $01]XUGY&Q+9WFWXMKJMG<,"001*V'NUK)5Q7&*=,8?IE;KJ!0[4>FB[>52
M9"38!<&OL(*ZY,;<U5R+#A($J&KIG:)HDX=,?>N>J9'YP]+C6_# KCVF)$/#
M*B%.L[.283Y;E@$[5/CNT+?$<O]BU [Z&"<-XN09SUDTHLMDPGT<8_]V!S&]
M^3M-:[?:;F;/-MKSB.5Z4R\:F>_DAF;H(.JMRN((]7VA1[C)*D4XM:O",T4G
MR5!1MT:A0ZFZM5L^08>4MM#OY#TC;D5L @JVG<V'V8BJ[L$Q+3!IAT[&BF_)
MV#A'5X!#+6<4IRE52-E6RL2@C8Y1,;S(+^1484@F^;K@'N-(4&*"U;GCH"^Y
M2!BAL;AF>[:/L]"HJ"#R(*]TA(LPK_M4$627.,4C\XERQWS8MJ>1R*JFFRQ@
MNCZ0S'+XV 66 -P7KOPZ#YA%6O;G#C:/]%:#'G6( YA!0PD?ZC%_>W)Z-CK0
M@0X3"I<,^S$*1BU-&4XXFSX[?FG>)VTZR&7X)&2U=V.2L*,W3^XB)STJN]W\
M$RL:2+^_G'*<PB9T 7M 56'#,/*L0ZUZH]/84=;A=2;N]R6#> F4/@Z#'"0O
MPNO++%=B(P0;1Q+E!9L5#9,R"Y)VA>GN2#T_UO=Y-@&@9O^N;]10^XD05'(8
MY69;$ /^4W]'\P^EKZ7@%#)WZ"%Q[9EMWAZN'@R;<8ZGN'B?.8=4AA'<AEYW
M"*CN7(-2''EFGFLI5NX_>R,P5\)BBMV1[80QAP.U59:@T])"&5A+_2 %VM#)
M-.<[T0L8@OW0HAB!\H,91UZK;Z -WGDYN%J_Z[N_@M]GC-'>NKKS; .LC&)H
MDI2 ,_!*(9%56U7R^N7PO4QM[? HG%M%##CFS)3(<M4\@D-9N*KB^#&G<?I8
M0)^>C[2;=;&_WS4,_X4KV/$15"H0X;[Y_8%V1EC0F*)F@$FGY>2]W\(.KR79
M?/H.(P\CQ4O0B^3/&<31;$RH_2-1^R?QM'&U.V?TP(O:8_.Q,A?= I6,F?[(
M8GIQK_]]<4+2O*I ,6,@O=?]%:4 NP)^HXC-ZB1B3"?T]O)-/6_O**P<W72S
M5KSR^>3DZ>083XHO40= Y8]\Q3EP47!BT5?5D<&M\51'*<<JOLJ^.WJ-+<JZ
M*Q0>95M)WM.+.-?E11Q.BI5'K'%"237>E@ON+])E'109$K9%"9B*I&)GG+?G
MG)2RF!#'62EB+[RWV8]];^?0V@UCA#* -.+[52^$I'O5R]C<Z$M*E&2*&1"+
M0Z4P\3KD&E[0XK)UK_"YR[6?OU@4<[I:(M.?QR&<7M4!56?49LLP4I?.A?T^
M"I(V0_*>*]M"2E?2_M^K:IZ3U)>5VS1P[33 #0]O.MRP'DI._\ "OZ254'(_
MT;$?DJEHDCW#:WHT3[3G36 XQQT3#VFF=E=B.[$/2="$]RYB.,GP0K+]_X:!
M>"9<Y>'# IO?R=BXGUS%1=R)+JE_E[S+TSB-X*T/!HXT_=J.1%QMNFILWH9<
M0R&5?D)53%<'B.A]TK:I(VHA67W?+:=:35]#IWD%JC/9!2)D#!S OUTHD<*>
MD@C-Z1.V"'=&H/E <\$DV//[(HTHD5]:B._*@M+DA>J8U+^8O#@>[0L>^(+-
ME+W*1HNO]$7O /;']SWU+V5DZ1NZMT,GW$6$G+8G->^#[@)+47*4^X4J,*AG
M%#A]>C+YT1SE=4&7@-V20G_:8&&>5OKBK]2F'%X(+\VC/]$U?6X?P\3 2TIR
MZ]0MA_0P%,H1SGA # P<)+VQ@&VS<TQE+'F2^G'/V$S&YZ?')R(\?&0"*THZ
MZ+=Q]C2IEO:OW+I!S*27D=EN2%;L2[)VFR!I$0Q0GV K0_I2RTE/9Q3-*@(W
MVZ0F+>U9#0;L;P;GM/5""A/F37.18#F\-,'!![+5; 6\R!NVJN=4SL[?!S3'
MN*!,I'A\*K[P.(3'XZ<[PHLV2^!P7+CMCM?=#.9K9@3W$,&Q3OM7?/.#]4&Z
MH5 X=,'_1DZ4K>]CWM;$8E^:[+K(Z>3D=$(NLN!\C<E/W[P(Q7FWYK_(PD J
MZC&3IPLX!^<I'764FB<ZWHB;V?V?ZU'WHV0F5!RLY?8IY@%]3B=;[P9E#76'
M-**DAX:HOETP4O>4?MLI\@X$3!'007WJ=-!0G^9[-+GO3X<]2?Y*&^[M@O\6
MG9<7,N0/ML5/XY^[NY"_\M8_+G\K[WW6+*CA6MHYED[&S\\?FT;^_IS\ N7R
MWWR;U2V<!/^XM*A'&WH W\_KN@V_T 'QCP#^\C]02P,$%     @ @$)O4HA)
M&3/Z P  MPD  !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&ULM59+<^,V
M#+[K5V#43$^R];+C.+4]XR3>36::;!H[Z:'3 RW!%B>2Z"6I>-U?7Y!R%.7E
M/>U!$@D"^(!/!,C15LA'E2%J^%'DI1J[F=:;4]]7288%4UVQP9)65D(63--4
MKGVUD<A2:U3D?A0$QW[!>.E.1E9V*R<C4>F<EW@K055%P>3N#'.Q';NA^RRX
MX^M,&X$_&6W8&N>H[S>WDF9^XR7E!9:*BQ(DKL;N-#P]ZQE]J_# <:M:8S"9
M+(5X-).K=.P&)B#,,='& Z//$YYCGAM'%,;WO4^W@32&[?&S]R\V=\IER12>
MB_QOGNIL[)ZXD.**5;F^$]M+W.?3-_X2D2O[AFVMVP]<2"JE1;$WI@@*7M9?
M]F//0\O@Y#.#:&\0V;AK(!OE!=-L,I)B"])HDS<SL*E::PJ.E^:GS+6D54YV
M>G+.5 :S[Q5_8CF66@$K4YAG0NK. F4!5^43*EV8I9&O"="8^<G>^5GM//K$
M>1C!M2AUIF!6IIB^=N!3I$VXT7.X9]%!CQ>8="$./8B"*#C@+V[2CZV_^!-_
MK?3@ I<:II2^H4/O8(Y));GFJ."?Z5)I23OHWP.8O0:S9S%[OX;R@\Y-#9^J
M#4MP[%*1*I1/Z$YNX-MB!C'\_MM)%(9_P/ET?@FSO^ZO'J9_SFX6<YC>7,#\
M\MO=HK.8W5W#U<W#;+ZXKI?R')0-3IO@>(LP)A&2G"G%5QQ38"1Y8CQGRQP[
MU"XZBO+KPB)#6(F<JI^7:]!F5>U[ /\/09MEQB40&Q6"6$%"_'CV#?C"DF=I
M^C@2SV!OJ;+-=RV%4E"5U*)R D@A$WEJH-?4HFJR<]*@($B9X&A+8;%$V6PK
MJ_)&&@Y/G7>*SK2@: R&\_4-Z'O!%\K12832SJMXFED=DV-9<,P6<8Z<T!L.
M!EY,2$=.9_^\R*BT<$>]0#Y2[UY59:J<0> %_6/O. Q(M].>+H1F>4VJ2>\M
MN^1X$'E!''O#N(W6$MYWYUW0E(^JY Y*H5&U% U<C?'Q+WJE:IYW!/]R-OM!
MZ/7C02N*9\D'3/9"+Q[VO>-@8%-K37_.)"F?# =>V.NUL%K"CYF,>]Y)//3Z
M@>$_\GK'0VMIQ&0[I.E/^/W$P=$K%U1MYZ+8L'('*4\-N*T/, +UTO!TQC15
M%!4XIY.S;)>3H18V0G%[JE*= _TW4\>D1@V_J!O^H=HR?]OV!3*S&*4@\BDC
M3NDU.'6YDOM]M9HC_%U[:<><TL!T&$IQATPJ0'/H'(SAHV[NMP[3 N7:7AD4
M)*(J=7VN-M+F5C*M#^,7]?I*<\WDVB21XXI,@^Z@[X*LKPGU1(N-/9J70M-!
M;X<9W:Q0&@5:7PG:'/N) 6CN:I/_ 5!+ P04    " " 0F]2OZZG"C0#   R
M!P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6RU5=N.VS80??=7#%2C
M: '!NOFZM0W862<QD'7<M9.@*/I 2V.;B$0J)!7OYNL[I+Q>JTBV0(&^2#,4
MY\PY,^)P?)+JLSXB&G@H<J$GWM&8\B8(='K$@NF.+%'0E[U4!3/DJD.@2X4L
M<T%%'L1AV \*QH4W';NUM9J.965R+G"M0%=%P=3C''-YFGB1][1PSP]'8Q>"
MZ;AD!]R@^5"N%7G!!27C!0K-I0"%^XDWBV[F7;O?;?C(\:2O;+!*=E)^MLXR
MFWBA)80YIL8B,'I]Q5>8YQ:(:'PY8WJ7E#;PVGY"?^VTDY8=T_A*YI]X9HX3
M;^A!AGM6Y>9>GM[B64_/XJ4RU^X)IWIOM^=!6FDCBW,P,2BXJ-_LX5R'JX!A
M^(. ^!P0.]YU(L?READV'2MY F5W$YHUG%073>2XL$W9&$5?.<69Z5I1?Y5Y
M!"8R6'RI>$D5-\Y;"L/$@>]RA)G6:/0X,)31Q@7I&7U>H\<_0(]BN)/"'#4L
M1(99$R @JA>^\1/?>?PBXBVF'4@B'^(P#E_ 2R[Z$X>7_)O^=<Y(]ZQ1A3]G
M.VT4_3A_O9"I>\G4=9FZ_U.E7T9?O=\NH L__S2,H^@W6-^_7R_NMW_ ;'4+
MB]\_+-=WB]76><O5=K9ZLYR_6\!LLUEL-]!@AA=F7)^/*O^&&3 ->YG3&=8W
M+6H"%CM4MA%-QW:%'M&H];I2@IM*81.UU6XE<>B/>@.RHE'B#Z)!ZQUJ3><S
MK8HJ9X:294@3)N7,'MS6+]&PYR?)H/4KF3&9O2Z96VE8#N69N@^EZU\CEP\"
M;<(HZ?E]XM5N]8=^TD^(\C,\X ,-.(UP(H7M?NB'8>A@VLG(V33XP!P1'I$I
M#6C_8[C6[/Y$%V%UTZ#2);I1DS]VKCO+7&<=)Y#[AEQ62&7X-\?'AQ-2T=I)
M-'JFTNT/:D?;T.]G_\<JA3>X^&X3(V@NTKRR*K@ 2<K4F5H'9E<\FG6)NX-G
M-G'4_P^5:=+I?.]$!5=SK$!U<--:0RHK8>J1=EF]7 BS>@X^;Z]ODSNF#EQH
MR'%/H6%G0/-7U1.Z=HPLW53<24,SUIE'NM10V0WT?2^E>7)L@LLU.?T;4$L#
M!!0    ( (!";U*:,W]QH (  '$%   9    >&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;*54W6^;,!!_YZ^PV+0G5,!\I5T2*4DS;0]MHZ;=)DU[<. (: 9G
MMEG:_WYGD]!46O.R%_#9]_NX@_-X+^0O50%H\M3P5DW<2NO=E>^KO(*&J0NQ
M@Q9/2B$;IC&46U_M)+#"@AKNTR!(_8;5K3L=V[V5G(Y%IWG=PDH2U34-D\]S
MX&(_<4/WN'%?;RMM-OSI>,>VL ;]N%M)C/R!I:@;:%4M6B*AG+BS\&H>FWR;
M\+6&O3I9$U/)1HA?)OA23-S & (.N38,#%]_8 &<&R*T\?O Z0Z2!GBZ/K)_
MLK5C+1NF8"'XM[K0U<0=N:2 DG5<WXO]9SC4DQB^7'!EGV3?YT:12_).:=$<
MP.B@J=O^S9X.?3@!C((W /0 H-9W+V1=7C/-IF,I]D2:;&0S"UNJ1:.YNC4?
M9:TEGM:(T]-9GLL."K)\PL^L0(U]C:SFS,\/#/.>@;[!$%)R(UI=*;)L"RA>
M$_AH9_!$CY[F]"SC->07) H]0@,:G.&+AAHCRQ>]P;=BSVS#09%96Q!;,..*
M_)AME);X5_P\(Q$/$K&5B/^CC><9;N\>EB0A']Z-:!A^)+/%XOYQ>4V6WU?+
MV_5R38X*<% @N<#)4)J(DN@*2"DX#EC=;J\<[!\T&Y"FAZ\#TU!\A)?. O7K
MG'&B96VZP?JV..^=V NSQ(LO,UQ''HT2+Z&9@SV4J$ 8MG CVNX%$7FC&//C
MT*%>1D>(3)R5%"4H,[BH4 *\SDX]+-$)O2 +O&1TZ=RA?^F$*2I%J4,CZ@7(
M\2"T]1-BB%OI*,$@\VB:>EF0_NN;^2=CT(#<VF$WC>I:W4_$L#O<)[-^C%[2
M^\OHALEMW2K"H41H<)$E+I']@/>!%CL[5!NA<43MLL([$:1)P/-2"'T,C,!P
MRT[_ E!+ P04    " " 0F]2TY0JZBL)   ='   &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6SE6?MSV[@1_E<P;JY-9A19HOR\.)YQ;&>2:QZN[;M.
MI],?(!(2T9  0X"6U;^^WRY(BK(HY7)MIYWI3&+Q 2SV\>WN!_!L8<LO+E7*
MB\<\,^[U7NI]\>/^OHM3E4LWM(4R>#.S92X];LOYOBM*)1.>E&?[T6ATM)]+
M;?;.S_C937E^9BN?::-N2N&J/)?E\HW*[.+UWGBO>7"KYZFG!_OG9X6<JSOE
M?RYN2MSMMU(2G2OCM#6B5+/7>Q?C']\<T'@>\(M6"]>Y%F3)U-HO=/,^>;TW
M(H54IF)/$B1^'M2ERC(2!#6^UC+WVB5I8O>ZD?Z6;8<M4^G4I<W^K!.?OMX[
MV1.)FLDJ\[=V\4[5]AR2O-AFCO^*11A[@!7CRGF;UY-QGVL3?N5C[8?.A)/1
ME@E1/2%BO<-"K.65]/+\K+0+4=)H2*,+-I5G0SEM*"AWOL1;C7G^_,[;^$MJ
MLT25[@_B^FNE_5)(DX@;>$>5I4H$#SG;]UB-YNS'M>0W07*T1?(X$A^M\:D3
MUR91R;J ?:C9ZAHUNKZ)=DJ\4O%03,8#$8VBT0YYD];V"<N;;)%76_O7BZGS
M)>#QMQTR#UJ9!RSSX#_@S]V2/WV^OQ9'XO>_.XG&XU?B[O[SY1_???YP=7U[
MQ\^.7XGK/_W\_OXOXN+3E;BYO7Y[?7M[?14&BOM4B4N;%](LZ]%.Q++07F8"
MUE>QKTHE8HML<]X).\-UGB-M'&G;9\%0W%2EJZ3QPEOA>^1+)"\BSY-+Y;ST
MN(E5Z?5,Q[BA5;2);5G84E*.#H1L9PVZ(H7&\\JGMM3_@ RLIYVKE*@*NAY'
MAX/1:$3_A4LEENK5?SSJ&;5A5,=1(H4ZB7)Z;ECU((!FD6H=<1W5MDHFTXPU
M+Q^LUV8N[E2I,>X":YD'<LDT4QM3GI,KH]&K=O"3 ?QZ_.I%T+I&W:;M"*PR
M7OLLN,X:):"%$BCI0LDX#4J+5&7);DFI?% P0J#\J[R@<BH@PL(;5.:G+BYU
MP;6VI%KH!NQV>JM8"<R$ZCP38S#3:?.%G#&K,*XH[8.F6N]0 GU*B"E0NDEC
M5S5*NJ&XJZ9_KY\7[ YE8CC'I]*C,"+9BB);TEN*(-H0<&<26L4%+VZ&9M U
MF$*[TWVEBA59#LC*:;;D91+]H!/ EN 29Y(D4\?A@,=57F62G87VH<F"%B/;
M @L/9)F8]B^\6@P62](#X[Y62&0,>D[KXI][J6<OXX ME;ST]N6:4:S)BQ @
M;=AHA\0C2.3\,)?&(*H20>RLARHA,]A<2,T6]F?;4+PWXJ<*,(M&XY/U1(9!
MBLS4AB*$13/,EW,"%%Z)YS2V1CU-%A?W'U>O&[P'@%S:A3*L;"U\(#Y\N&R3
MAE^W,X PF+-(-9#4U<?.9JP/B7%  7FC%@#OTDAPE2\@1SP0,'*#6J:8E387
M'@R%ZQ_]8H9&\80<BA+2086JMG(3O7Z:4H1-"MD<9LY#60Q+ =\ZYBH9ZMRS
MP]%P!!*0990_/BUM-6_=$'-909%I7 I_#<55Q8+(CJ622'<NR&BD*I_"'Z&9
MCD_78\1^.!J<G$X&)R<GN[0/7J6YF\'B\F+@.21VK%3"$IY%T7#2FB!G  -2
M)JF"]@R<3_8A*$==?B=X##C?;@!%HU\'H&WHH'K"T0CX '?\G\;'\>'WXN.>
MB_."_DP&T>&([3P>'!]%':6V5JEN=94\] FRHB"P!V]U=4<]RY9#<;WJ0KO6
MT^2<5;MD&(QWMGW/Y;EQOF][6\M1+#>CH7@'+T'PH#.F+<( <*JGVA,I<:ON
M0TP&NQZA'F/%4E K.>:-CM1SONU$MF*+_GH6*!&Y"]L,>L^],*S@&#PKA7%M
MYXJ[,>.;P"1G,YUIH ;*+6R%Q+8+(W(+3Z-C$N,*;EF4VGO@I-TNU:VPD:PT
MRST=GI[^0*U[?!"NPBAOB4>:BH-,2O:;@Z$F,+=0<#OX&=395Z@R!C(!3TX^
M>#^&FG.:T!N_5M^FX;.:M28 .A,#)AMMBQP'(ZH"LX[&(I%+UQ!H W(6JR=\
M]E6@)LQ)TQ5,H(]"(C*&&SEM1<OPL%RV\0IR!^%FJHP" =;0!K% &%-=B$SG
MX.*,(O(>@(<Y9#[1&;!EPGMM8HU.UF E"UT9TEP3J#%:10@4:L(/ 44K2;2/
MY0;>XU%MM"?=-A !A2@,4]3GP7<&OC_F0N>Y2@B<1"E*#6UAXA;G<6^@)>%_
MPYD@X33LKY)ZZX""BL):A1M+*1 606VLE6UI0H?N[69@#>628#Q+[B\MBI[!
MP:,QX?57%*ZIFE'&4?3:;DASH+,O];3R@>'Y[=R;S6_K:&B-3 YIP3;)DY#X
M;S1"%:?&9G:^%+_(#%NEM^AQ($C#FV&(:%BQ+E5/^XN(T R.?E4+ ((3,5V&
M4#7*AP;=)_-)M>[;-FZ8?5'-*^=[^$!-5-"WGHC=:*/,E(MJB@3H:9_/3A#+
M52@'_=3EX&AXO)6Z,(.@E*$;ZNVV,E1^@7A2!-CDU.8,X 1MM5"/A3(.>@-B
M(3F7ZVCM4IJ.*\3G6L)J%PA??431_/]"Q^?8VVG-T#K<L9?48L\^^298FE:D
M39Q51)=)S*Q".5"/Z$[:J4:W-NBPJFDA@5#P[K0JT;LP6B:)IH=TU,*KAGW7
MP1,]MGKQ&^"-AC5O>Q8-#M=QW&596U ]F0P/_]NH;D)(4>N']1T8UK;(KN\*
MF(\Q9>CL"ACWOS4ANII>!]E\@M,YZ6MT'5#0VS.QS?U$HUJR ?_Q(#J*OA/^
MJ_2BD5M4XZCWKO:-E;;"L<<?JC[36#^0>O(R;#-J*D".!Q4 0N?4 [F'=[:3
M=RJNRA"MBYB[_?AT,ED_']3T50!Q-)0'-3=X;$Z7F(BO"4<Q([K.0"'Y_'#R
M7+YX?OJB\<'ZLHR\MVI:5K)<;BTID\$I-LK'QSLWRI0A(3O_'?D^:O-]]/WY
M/OI7\_TWI/L:9M8\VI/N5^UYTR?;.7RJ0[SFUL"4P9+;8S?2C4^G*L/L?V/^
M4V?SF>94@>ANR" 4ASWTQK9V'0@IG^WZKH3.F>"P[[/"?N>33:[*.7^8(M#
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MJ3T!X';PL"=_M5X;))>.N6,I.(*>LMB8CE-Z18@5#A'^>'"M>.&<]6,T"M"
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MK1 ;\%WL-;.UM@9MEQ(Y$H41BKC?TI9)FVH"3 - 3K)P6J%LG>^H.=*F&9^
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MFX<RK& XK#P<$S[B-VAH07L:XHE3.44 RY$9*H .]T;N\"7[\>&=9J=RLO&
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MN7A\?1%MRE^"[?@W&AL;@FWXXTY)*$\+<+^V-N0OM,'PHYV7_P502P,$%
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M==CPU& =(L=!EK  Z=]_SQ%V%HIL[LWA7C0-@!'W*XVQ.(!.O[-J3Z9WM#_
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M$ISDV,&Y#":98%:#3H,;B1'N=J.KDDUZU99D<E30C6H=K0<XY$OM^4VS?VS
M;#LX6"@[;T_.#N-F&'-?"(\MXH^(C$C[?P^*-F+_/J$0"ZW_$^.@ZY5_:@@8
M\1,C8_3(R8-C7]1]-%Q$QTBY=_H3ARARM!T ?IX>C??]".FD]V,PZ+W@G[SY
M\'8O_"XL7\V_JKL*/R;K'@\_R8,J"S0,H*@YCIZ.GUT<A!!*7QI;\T_+T.0
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M/=JSI-Y1$GS;&(8(NPH0"O5 D%:%GJGX7A^H6B%]FF1$N3;=N4J6$8->6#H
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M 2Z!<QL(:?QH8_H=I'7LO^^COW>Y8RXKJN%2\O]88<J9?^:3 M:TYN:+W'V
M-I^AC9=+KMV=[%K;R"=YK8VL6F=D4#'1/.G/M@Y_XI"T#HGCW0 YEE?4T/E4
MR1U1UAJCV1>7JO-&<DS8IBR-PE6&?F9^275)WOVHV0/E((PF5!1D64IE3F]!
M5>2C> !M*K?TSRU=<=#_3D.#R-8_S%N4BP8E.8(2)^2S%*;4Y)THH'@>($3*
M'>]DS_LB>3/B%>0#DL8!2:(D>B->VM4A=?'2(_'Z>5[!RI %UL'6Q3R2)>2U
M8H:!)M\6*VT4;J7O;V!F'6;F,+,CF,MF$(A<D_>4*?*5\AJL]+(IP;&.V&9=
M*ZDUN1,XDIS]@H)\D+Q@8D.N<20;DT]H ?I0V]XF>%L"64N.@VOC&=?]=GP1
MB1B[;(D_[(GG2#QP=P)]^I:$=BD8FP)[2@'7--GA4-KGQJ52/Z52MJELNE2X
M2\4:(QQN JA6H+J-X$Q>:./)N??*T%M4R,9B>-<O0%\K;'.\7&KC/>/320TG
MSU7!L[WS3KPXF(S'08I()]YI>SWI<!C@$<=8W>-G=UV+0GOC*(B&HV 41VA[
MVA=OI:&\*:I-[V5U,? X":(T#29I'ZVGO!LL!\1@/KK&[2:D =TSM' -QN$6
M/3.UUZL"__5J#J,X&*;C'HN]YD ELSA()\-@%(U=:CWQ]Y5$X[/).(BSK(?5
M4QZN9)H%9^DD&$:V_DF0C2;.TZK1=X+B;^I[),!)+\2A[TW8^^Y7H#;N=-,D
ME[4PS1'0:;L#=-&<&T_FS>G[F:J-G3$.:W2-!N.A3U1SHC6"D5MWBJRDP3/)
MO9;X$P#*&N#Z6F(Q6L$"=+\5\_\!4$L#!!0    ( (!";U(+E$ $A (  &\%
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;(54RV[;,!"\ZRL((8<$
M$**77PEL W8>:( &,)*T/10]T-+*(D*1"DG52;^^2TI6;<!Q+](NN3LS'&DY
MW4KUJDL 0]XK+O3,+XVIK\-09R545%_*&@3N%%)5U&"J-J&N%=#<-54\3*)H
M%%:4"7\^=6LK-9_*QG F8*6(;JJ*JH\E<+F=^;&_6WABF]+8A7 ^K>D&GL%\
MJU<*L[!'R5D%0C,IB()BYB_BZ^7 UKN"[PRV>B\F]B1K*5]M\I#/_,@* @Z9
ML0@47[_A!CBW0"CCK</T>TK;N!_OT._=V?$L:ZKA1O(?+#?ES)_X)(>"-MP\
MR>T7Z,XSM'B9Y-H]R;:M'0Y\DC7:R*IK1@45$^V;OG<^[#5,HD\:DJXA<;I;
M(J?REAHZGRJY)<I6(YH-W%%=-XICPGZ49Z-PEV&?F:\4?E]E/@@5.;E[:UB-
MCAN7/0A#Q8:M.9"%UF T.7^AF.F+:6B0V@*$64>S;&F23VCBA#Q*84I-[D0.
M^2% B)I[X<E.^#(YB7@+V25)XX D41*=P$M[(U*'E_[/B!6G:,#BP(Z?B[4V
M"O^@7R>8!CW3P#$-/F%Z;O]_(@MRW/UC]IZ&/,"!7C;3W;"Q/Y 3JDDA.4ZA
MOO;0/:C6H*R#AXFU$Q_QE7??*,%,H^ 0U3OSTB0*KH9CC.*K-!C'8^\K:(T3
MEC55PZE!LASPCL@8M:/GG<>389"F8^\"PP3#X0##%VDH)W4G/2"U,_Z *R "
M+&&<#H,1ZCKS1I,@':7'OD*X-P05J(T;=4TRV0C3SD._VM\FBW:(_I6W5]$C
M51LF-.%08&MT.1[Z1+7CW29&UFZDUM+@@+JPQ!L1E"W _4)*LTLL07_'SO\"
M4$L#!!0    ( (!";U)>'/RKE (  &8%   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;'U436_;, R]^U<(Q@X;8-2V_)4628"D[; =B@5MMQV&'12;
MCHW*4B;)2_OO1\F)FPY-+I9(\3T^4J:F.ZF>= -@R'/'A9[YC3';JS#490,=
MTQ=R"P)/:JDZ9M!4FU!O%;#*@3H>TBC*PXZUPI]/G6^EYE/9&]X*6"FB^ZYC
MZF4)7.YF?NP?'/?MIC'6$<ZG6[:!!S#?MRN%5CBR5&T'0K=2$ 7US%_$5\O4
MQKN 'RWL]-&>V$K64CY9XVLU\R,K"#B4QC(P7/["-7!NB5#&GSVG/Z:TP./]
M@?VSJQUK63,-UY+_;"O3S/R)3RJH6<_-O=Q]@7T]F>4K)=?N2W9#;)+XI.RU
MD=T>C JZ5@PK>][WX0@PB4X Z!Y G>XAD5-YPPR;3Y7<$66CD<UN7*D.C>):
M82_EP2@\;1%GYHNR5#U4Y/89KUF#)A\?V9J#_C0-#=+;H+#<4RT'*GJ"*J;D
M3@K3:'(K*JC>$H2H:Q1'#^*6]"SC#907)(D#0B,:G>%+QF(3QY><X%NQ%U<<
M68B*N,H9U^378JV-PM_C]YD4Z9@B=2G2$RD><&JJG@.1-?F_M^^U]#S;@0$.
MMU-*' =M++MI@-22XU2U8G/E8:^@6X.R_7IKV.;A)[[TKI&_+1DG1K6V<C:T
MP/O@I4%<9$%Z6> ^"6B2!1DM/.R7P@R$8;O64O2OB"28I!B?QAX-"CI!9.:M
ME*Q!VVG%##7 V^@\H''LQ4%41$$VN?2^H7[EQ3EF2G*/)C2(D.-1&J<G1A-=
M^21#HPAHG@=%E+]W/^'1O]^!VK@)MXWJA1G&8/2.C\ABF)W7\.$%NF-JTPI-
M.-0(C2Z*S"=JF.K!,'+K)FDM#<ZEVS;X$(*R 7A>2VD.ADTP/JWS?U!+ P04
M    " " 0F]2>5EF_JX%  #X#P  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6S=5UEOVS@0?N>O(+P'6D"5=1_9)$"2'EM@VP9)FV*QV =:&MM"='A)
M*J[[ZW>&LA0G=02W+PLL;(B4-)SY9N:;H7B\;N2M6@)H_J4J:W4R66J].II.
M5;:$2BB[64&-;^:-K(3&6[F8JI4$D9M%53GU'">:5J*H)Z?'YMFE/#UN6ET6
M-5Q*KMJJ$G)S#F6S/IFXD_[!5;%8:GHP/3U>B05<@_ZTNI1X-QVTY$4%M2J:
MFDN8GTS.W*/SE.2-P$T!:[4SY^3)K&ENZ>9M?C)Q"!"4D&G2('"X@PLH2U*$
M,/[9ZIP,)FGA[KS7_MKXCK[,A(*+IOQ<Y'IY,DDF/(>Y:$M]U:Q_AZT_(>G+
MFE*9*U]WLG$\X5FK=%-M%R."JJB[47S9QF%G0>(\L<#;+O ,[LZ00?E2:'%Z
M+)LUER2-VFAB7#6K$5Q14U*NM<2W!:[3I]>ZR6Y?G*-?.;]H*LRU$B9<SSZ*
M60GJ^?%4HQD2GF9;E>>=2N\)E:['WS6U7BK^JLXA?ZA@BO@&D%X/\MP;U?@2
M,IO[KL4]QW-&]/F#T[[1%SSE=,= WLSY%63-HBZ^HOM/AN+5%YK#ODB,V_FX
M!*-)U)M??TH\-_Y-<66LS(R5;-<*=%;X6BAD^X"JJ#E6H$29>M'+*(XR\Z;$
MBE)'#-G)-5KZ$X3L0LXQ8%#-0%+0& 4-+V[*KD"A3+;DHLZ1NG=8DBLL,,U^
M9IX5QZD5AXF9^ZEKI4[*WD"-IDLC+W*D7Z$T0;D#%EAQ$%IA&J%XXOI6DOCL
M8Z-%B0IB*_1"RP\#G(>6YX16G'HC>0N&O 7C><.6E+<E4.+.T/NLBQS>7>]$
M=5_N^&S#+TM1[\OAN,W#HVLP8++(KC)1\&,,9>*:*#AI9 6QSUY5J[+9 '20
M^66+^4#8!AUS0\]*4<AU4LM'E3\:T' (:'AH(7SH</,/K58:\TUTH[1_-GT-
MO3Z[0RHL ",*,BL(L2RRO44Q;I.*HN,NF=#49;9; O)=F5C7K0DOHMI&DS>/
M4)'4ND<FMLB@1[8B9$>LAWX_V?HPC%= ^Q8J96>+A82%T,#>]\99[RF[P'8F
M<?]H,1EO<5K@GI2QZZ60H)@) _NCF /5*M%$L1M1ML#VAE0_H ]V-#>A6G(#
M9(J/Z4ULUV&QG:0X=T/?"I*0W8 R?J+C6Q]-U/;J0L;YL97ZQ#I4D^ %"7JO
MZXT4-87"M\( :>7ZS+-3GZ5V& T.Y^P%_I#Y<RA(]ED21E;DN.PYB^S W^O8
M8R0IDC9 HGII2*2U$P]=<PA5@#@21.A\AU\IXO6P@A"S\0L11W9(\?(16H"8
M=OQ*?,N-'.9W?D7)CE_/W CK* G0$Y<@/? R<+&A>1&^"VW'.<1+C*SKH)L8
M6A/DT,;EL1U2\B*LY<!/#G<2-2"V-+0BTX4QTB%>7'(R,*TV':GX:*CX:+3Z
M'K6?SD?^USL#Y.\1 _%@(#ZTI9PIK.MM$#]19]:-:<ZM!OY:%)*;,B') =46
MSS:9^YK+N'737$CU7:\:>M5]*UETNGG>2M. <,6&BI;#-\W=),5DCBAHX;:L
M5F ^(\N-939JS&V!GX:X#C>85A=E\;57>M_CQ'T<OF>W?MQYOWUPTY2";.H-
M2UP[2-@O-"8QCK3O922K05;4F(R/5(<)DLJ)V<OBKLC192ZIZ3E$^%_ZX:I0
MMR_F$JBCX7ITLI<*R89G.P$.KQ_$N0LOQ[\),,]I 7Y+V)%G!B\:(5<RD"L9
M3>_[IH9]!%:',#@=C*3_*8/'K7_+X'K'Z<<D)FY*J$"H5O[O.!T'MD]<QA$W
MIQ%.1P%><#_Y$4Y[MN\93AM3!W':M=W$#$Z\CV[3G=-8!7)ASIP*/_;;6G<'
ML^'I<*P]ZTYS]^+=F?B=D O\V. ES'&I8\?X:26[<V9WHYN5.=O-&HTG13-=
MXM$<) G@^WG3Z/Z&# R'_=-_ 5!+ P04    " " 0F]2^J0'G'@$  ##"0
M&0   'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6R-5FUOVS80_LY?07C=8 .J
MK'<IF6/ 25HLP+H%<=I]&/:!EDXV48ET22I._OV.E.RXG>OU@RV^W#WWW/'N
MR-E.JL]Z V#H<]L(?37:&+.]G$YUN8&6:5]N0>!.+57+#$[5>JJW"ECEE-IF
M&@5!-FT9%Z/YS*W=J_E,=J;A NX5U5W;,O5R#8W<78W"T7[A@:\WQBY,Y[,M
M6\,2S,?MO<+9](!2\1:$YE)0!?75:!%>7J=6W@E\XK#31V-J/5E)^=E.[JJK
M46 )00.EL0@,/T]P TUC@9#&EP%S=#!I%8_'>_3WSG?T9<4TW,CF+UZ9S=6H
M&-$*:M8UYD'N?H/!'T>PE(UV_W37RV8H7';:R'901@8M%_V7/0]Q.%(H@N\H
M1(-"Y'CWAAS+6V;8?*;DCBHKC6AVX%QUVDB."WLH2Z-PEZ.>F=^)4K9 ']DS
M:#I^9*L&]&0V-0AM!:;E '/=PT3?@0DC^D$*L]'TG:B@^AI@BIP.Q*(]L>OH
M+.(ME#Z-0X]&012<P8L/CL8.+_Y?1^DMUV4C=:> _KU8::,P-?XY8R(YF$B<
MB>0[)I98,577 )4UO84:E(+*&5QH#493)BKZ.V<KWG##09^*\GD#CQN@!O&@
MKC&IM;5CH-U*A>5$*XZK"D2)!VDVS- U>P*JN$8=235?"U[SD@E#4<%61*^/
MD-6>J\5FKUR;5ZYTA]"X1VO98!WK2X+G ^T*E#TC8L\(_\(+<OM?K.D1SB7Y
M QL-MA3%#!=KBL>@:<F4>I%/H#1Y0_+$"[+$R_(8)VGN147AQ7%"'D #4^7&
M,:O@"=O)%IN#<89*M,B-)JF7I(47! F)O3@-O3A,R7+#%+RUE5M13 'L9II9
M]TGB7>2(G0<D\[(@\XKB@BS*4G7?"J9A@D@9*2X0.\O11^Q_)>\WQ]&%EV<!
MF> H\H(HP]$-FN3&UA("":/XJG,!)T7NA1BI,$;)/")WPC"QYE:N#Q5RRA/<
MBT-2>%%0>"F&]%$:UM"ULJ$Z<53'X46*7H%L\S0A>>8E6>R%Z-\GUG2L;X+V
M]!CF"!D?B2+W(^F).Z-323$^,C7!XWEK?V<*)ST43GHVKQ\ PU0B<$\2TW)I
MF.F,Q+3^Z"]]^AXJS)B&/C#CLOF=*P!LYZZ\[.JI8CIO=(%WRK=F;37HTZ;5
M8-J*W&!V,/'RRT]%%.:_ZJ$>+1T;+"?)]8]4RQZ<]\W):J] 0,T-Q0)^96(A
M,;]"/^@3;1C8*,&1LD>%K:Z:U@/N'FQ,PPG)?*R&<1C[A=6]![S3A"T@CCU$
MD\#/4_Q+ YN]8FUAZ=.)O DS'S,WSOWP!VMR'/F92S'\YOC]$R.HT%(0D7'@
MAW;I]3B/ C$>R$\H/-M:A#X* ?G9_<;AA&)/;SIM]=#G-ZE?X W9-);O5]F[
MCT+5N1,L#_ZQ[= *+>E3>3P]NEA;4&OW?,"&)3MA^COVL'IXH2SZB_E5O'_>
M?&!JS;'G-E"CJHWV")NS>S+T$R.W[II>28.7OAMN\)4%R@K@?BVEV4^L@<.[
M;?XO4$L#!!0    ( (!";U+.BL=91 ,  $@)   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;,V636_;.!"&_PHA[*$%VDBDOJS"-N X+39 LPD:='LH
M>J"ED464(EV2LMO]]4M2BNHDLK>'/32'F*0X[SPS_!C.#U)]U0V 0=];+O0B
M:(S9O0E#73;04GTA=R#LEUJJEAK;5=M0[Q30RANU/"11E(4M92)8SOW8G5K.
M96<X$W"GD.[:EJH?E\#E81'@X&'@ ]LVQ@V$R_F.;N$>S,?=G;*]<%2I6 M"
M,RF0@GH1K/";-?8&?L;?# [ZJ(U<*!LIO[K.=;4((D<$'$KC)*C]V<,:.'=*
MEN/;(!J,/IWA<?M!_9T/W@:SH1K6DG]BE6D6P2Q %=2TX^:#//P)0T"ITRLE
MU_X_.@QSHP"5G3:R'8PM0<M$_TN_#XDX,L#9"0,R&)"G!LD)@W@PB'V@/9D/
MZXH:NIPK>4#*S;9JKN%SXZUM-$RX9;PWRGYEULXL_Z*F4X!DC6YWH*A+K4:O
MT:JJF&M3CJY%OUE<TE]<@:&,O[0S/MY?H1=_O)R'QE(XK; </%[V'LD)CYB@
M&RE,H]%;44'U6""T^&,,Y"&&2W)6\0K*"Q3C5XA$))H 6O^R.2[.X,1C2F.O
M%Y_0NU5;*M@_?<;6-I^2LZKOK42%[A1H$*8?N*W1.R:H*)G-]+T=!'M$C$:?
MWUM1=&V[^LL9I&1$2CQ2<@)I599=VW$K7[D]SDIFIA:N%\F]B#O_^R4I$ER0
MJ,CGX?XXHQ,S<8S3+"5XG/F(-!U)T[.D:ZH;9*^;VMXO&M5*MDCV&U-L^S-O
M]R7H*?I>.#UB>IWB=!87.'E"/SDS*J*,D&GZ;*3/_IN>VD4N70.^=6Q/N5O0
M*=[L&45.HC@NXN@);O8LV0F>%3E.DFG:?*3-S]*^9Z6]C\$#2]. LO?R'D0'
M4[3Y,UI,,IR34PL^&R%F9R$^V5O>K6U)=\Q0/N5Z]LQU2F:1^YMV78RNBU^.
MWY8!3C=2#>=TJ\"?1/3Y!MH-J'.'$$<_[]KH=[D9\%$!P/_?+ABT\L?;8&HM
MPJ.:U(+:^E*M42D[8?JK?1P=GP,K7P2?C%^Z9X*O=3]E^C?&#55;9LL5A]I*
M1A>YW2*J+]M]Q\B=KWP;:6P=]<W&/G5 N0GV>RVE>>@X!^/C:?DO4$L#!!0
M   ( (!";U+(\EZD? 4  &H9   9    >&PO=V]R:W-H965T<R]S:&5E=#(X
M+GAM;,59;6_;-A#^*X2Q82W0Q!(9QTF1&$B<%0O0H$'==A^*?:"ELT5$$CV2
MLF-@/WY'2A'MQ*:=#O6^)!)%WCWWPN>.],5"J@>= 1CR6.2EONQDQLS>=[LZ
MR:#@^EC.H,0O$ZD*;O!53;MZIH"G;E&1=VD4G78++LK.X,*-W:O!A:Q,+DJX
M5T171<'5\AIRN;CLQ)VG@<]BFAD[T!U<S/@41F"^SNX5OG5;*:DHH-1"ED3!
MY+)S%;\?LG.[P,WX)F"A5YZ)-64LY8-]N4TO.Y%%!#DDQHK@^&\.0\AS*PEQ
M_-T([;0Z[<+5YR?I'YSQ:,R8:QC*_$^1FNRR<]8A*4QXE9O/<O$'- ;UK+Q$
MYMK])8MF;M0A2:6-+)K%B* 09?V?/S:.V&<!;1;09POBDRT+6+. .4-K9,ZL
M&V[XX$+)!5%V-DJS#\XW;C5:(TH;QI%1^%7@.C,8U>$C<D)&8EJ*B4AX:<A5
MDLBJ-**<DGN9BT2 )D?D*DV%=3[/R6U9IY -Q9L;,%SD;W'&U]$->?/+VXNN
M06Q60S=I<%S7..@6'#$E=[(TF2:_ERFDZP*Z:%1K&7VR[)H&)=Y <DQ8_([0
MB$8;  WW7AZ?!^"PUM',R6/_S=%+\OTCKB2W!@K]5T#O2:OWQ.D]V:+WTZ($
MI3,Q(S-N#*AR4VQVB)B+E/ R)5_X Z2<< 5$9UQ9T+VHVXN(*(G)@*2JFN(>
MFB,YS'"KFP#\7@N_%]1]#RI!2<@HUG,E\AH\(H5IS$=\7]%%$JF-1F9)I,($
MLI 4:. JR1SVK;!J#X11]*+C*/HU8,YI:\YIV!R%!*S,TD&"OROA +TCH(W
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M?EA?^WLQ]:\0>#:8(@F3'"8H,CKNXX91]<5^_6+DS-V-CZ4QLG"/&? 4E)V
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M@>67!?ZE .T,\#Y7.#":C4O0_DF9_@902P,$%     @ @$)O4LD^N'>M P
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MV16Q @  Q@8  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULK55-;]I
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M..G7=TC)JA(OK0X2EYDW[PTYHV0KU9,N 0QYK;C0$Z\T9G/M^SHOH:+Z4FY
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M0@:78\R<:MIA,S%RXSK*4AKL3VY8XA\$E#7 _9649C>Q ;I_4OH'4$L#!!0
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M1E?OKF-;*@[M9J==SKLV)[Z0<PWI#?+<]P@[V!F1K]XL=^>OY;:JOF\![EN
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M5&F\O7+;B60'<VOMF%1WH!D6ZBL%7 >H_9PQ^3+1%V'_W4O^ 5!+ P04
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M? 9T?L 6>)Z,)Z2C5&"#SM@-E/U)AWY%3V+-9>4D; '(FC0'[@M; ;U?2B&
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MLMY)/-T:9 7T3@N9)= ]R,]" 99$\Q(\&_ /H5&Q1M?M!>XC[\RP%G8J:SG
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MVD9JI,ANVD/4PQK&!@5VZ>[:3OKKN[M@0EP;I0=?S'[,>_-F!L\PW%+VS#,
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M<JP#@B8?AMM1CQRW3;NK^=S_3?O3-VF)[@24_%>/'Z_UXVD_7J^?A?:3=/U
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M)*(?"0M96)/0Y-WN]+HAG:BJ1^3P.F?PJOUSA=GMXO=[R%Y _=,0H%,%Z+@
M4=N"?_\3+<D7 YENBM.MXG0;B7QS+Q &N5F#0D'X2)YEBI%28;9U=6]&ZU._
MT_]05YZ+?OW>AP8Z<44G;DGG[FV)4F3?!5 9$3G9 E>U1[H9N5LX$AJ2K#C:
MM$<2OJV#FC1#Q244Z]8 '-'N5;1[+6G?BK5(($^(X@;JV#8#AGX8UM:QM=L1
MGW[%I]^2SZ/0KU<SA6^<0*%"43)GF35#AWZW_H0VNS$_[#0QNZZ87;=DYH1Y
MO1-F62@)_LVM) <9<+U2@!W9X&&I)UQ$O'81[?? &K.-V2!8']*K,V)Q971$
MAH;[MA0VTOE+YE GA?H]6D@/NA_]7]60LGTD]E/U\ )<K^-'I\)6U..R8S=N
M.G!TWZIH<Z_Z$4V\ +T3Q=Y.$UEX5A/?"155\MJ_I(YTWTQIYV?KXP7$LP+9
MWN^8T[YQT[:=NX5&7L!F?L3JV5WT:VSC=-_':=M&_N,Z688\U$#JT_Z)4-9:
MA;T3I0P.ON4S4',WXF@RE:O<%%^UU6HU1MVXX>%D?6S'*S<C[&&*V>R>J[E
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MF@]X<>!8/$BVR8_@YDQ*EN:W:TH6E&L!]?^2,;E_T ZJ8]_)_U!+ P04
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M5WWQ42R6CKX83"<97\ G< _9O<&[08T2BQ24%5HQ \EE[RIX=QU<D(%?\9>
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M%K96#WF;5"91 08/HB#._[+[8B)* &PW $@!(&T!M #00P!M -@%P&[;@U,
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M*@X4Q<#(+-\QKZ7!_7?^N,-#&"AK@.\W4IKCP"Y0'>MF_P%02P,$%     @
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ @$)O4G,.EBL>!   <"    \
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M-X5'SZOAK2/@HACZ4PT7_+SJP?D@S^'<&5W!TROQ01II2R7ZX 8$F!& V<$
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MZNW/U#OETRZF6\]UC>]_)M7Y_&R\O?ZRO&ZBA,,+S@'^:[[_ E!+ P04
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MR*I09%4HLBH46=5_ROINS/*O_\"U][3697/(9]UOSNDG4$L! A0#%     @
M@$)O4@=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " " 0F]2Z2 3;.\    K @  $0
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M+Q4  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( (!";U)
ME1,]" 0  . ,   8              " @3@8  !X;"]W;W)K<VAE971S+W-H
M965T-"YX;6Q02P$"% ,4    " " 0F]2]!GYQ;H"  #\!@  &
M    @(%V'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
M@$)O4F=V_B20!P  GR8  !@              ("!9A\  'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    ( (!";U(!27&U,@<  $ >   8
M          " @2PG  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    " " 0F]2!P2Q3#\*  "J&   &               @(&4+@  >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ @$)O4@U;)TZW&@  $%
M !@              ("!"3D  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    ( (!";U*(21DS^@,  +<)   9              " @?93  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ @$)O4K^NIPHT
M P  ,@<  !D              ("!)U@  'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    " " 0F]2FC-_<: "  !Q!0  &0
M@(&26P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( (!"
M;U+3E"KJ*PD  !T<   9              " @6E>  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ @$)O4HLH.%_Z#0  ?2L  !D
M         ("!RV<  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    " " 0F]24RC,AO '  #?$@  &0              @('\=0  >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( (!";U)YTL</J@P  , C
M   9              " @2-^  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ @$)O4N_W@G9O#0  =R@  !D              ("!!(L
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " " 0F]2BW1%
M_;\&  #I$P  &0              @(&JF   >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    ( (!";U*?I$Z51@4  -$+   9
M  " @:"?  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
M@$)O4IL@JJG8&P  >5D  !D              ("!':4  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    " " 0F]2_MBPV]0"   $!@  &0
M            @($LP0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    ( (!";U(I'V9$5P,  &((   9              " @3?$  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ @$)O4@N40 2$ @
M;P4  !D              ("!Q<<  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    " " 0F]27AS\JY0"  !F!0  &0              @(&
MR@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( (!";U)Y
M66;^K@4  /@/   9              " @4O-  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ @$)O4OJD!YQX!   PPD  !D
M     ("!,-,  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (!";U+4*]D5L0(  ,8&   9              "
M@27H  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ @$)O
M4OV)ID., @  W08  !D              ("!#>L  'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    " " 0F]2+-.%(9@"  "?!@  &0
M        @('0[0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   ( (!";U)@OT5LEP(   ,'   9              " @9_P  !X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ @$)O4E<C 0ST!P  GB8
M !D              ("!;?,  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"% ,4    " " 0F]28-!W76<(  !#*0  &0              @(&8^P
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( (!";U)!A"MF
MT0(  '0(   9              " @38$ 0!X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L! A0#%     @ @$)O4IM:-1[) @  5P@  !D
M ("!/@<! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "
M0F]2GYEJ![<#  " #@  &0              @($^"@$ >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( (!";U*W;[O&" 4   (6   9
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M970T-"YX;6Q02P$"% ,4    " " 0F]2X#$U1ZD%  "K$0  &0
M    @('H( $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (
M (!";U(:([FL10<  / A   9              " @<@F 0!X;"]W;W)K<VAE
M971S+W-H965T-#8N>&UL4$L! A0#%     @ @$)O4I-I;:*+!@  [B$  !D
M             ("!1"X! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"
M% ,4    " " 0F]2G#L&8,H#  #B#0  &0              @($&-0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( (!";U(CUPA$7@(
M ( ,   -              "  0<Y 0!X;"]S='EL97,N>&UL4$L! A0#%
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K 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     X #@ /P\  )]$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>178</ContextCount>
  <ElementCount>362</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statement of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statement of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureNatureOfOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Cash Equivalents and Short-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestments</Role>
      <ShortName>Cash Equivalents and Short-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Property and Equipment and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAndIntangibleAssets</Role>
      <ShortName>Property and Equipment and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Stockholders' Equity and Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockholdersEquityAndPreferredStock</Role>
      <ShortName>Stockholders' Equity and Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Collaboration Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCollaborationAgreement</Role>
      <ShortName>Collaboration Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Cash Equivalents and Short-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsTables</Role>
      <ShortName>Cash Equivalents and Short-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Property and Equipment and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAndIntangibleAssetsTables</Role>
      <ShortName>Property and Equipment and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ovidrx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAndIntangibleAssets</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureAccruedExpenses</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Nature of Operations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetail</Role>
      <ShortName>Nature of Operations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Summary of Significant Accounting Policies - Schedule Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSchedulePotentiallyDilutiveSecuritiesExcludedFromComputationsOfDilutedWeightedAverageSharesOutstandingDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Cash Equivalents and Short-Term Investments - Summary of Fair Value of Cash Equivalents, Short-Term Investments and Gross Unrealized Holding Gains and Losses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsSummaryOfFairValueOfCashEquivalentsShortTermInvestmentsAndGrossUnrealizedHoldingGainsAndLossesDetail</Role>
      <ShortName>Cash Equivalents and Short-Term Investments - Summary of Fair Value of Cash Equivalents, Short-Term Investments and Gross Unrealized Holding Gains and Losses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Cash Equivalents and Short-Term Investments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCashEquivalentsAndShortTermInvestmentsAdditionalInformationDetail</Role>
      <ShortName>Cash Equivalents and Short-Term Investments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Property and Equipment and Intangible Assets - Summary of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAndIntangibleAssetsSummaryOfPropertyAndEquipmentDetail</Role>
      <ShortName>Property and Equipment and Intangible Assets - Summary of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Property and Equipment and Intangible Assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAndIntangibleAssetsAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment and Intangible Assets - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Stockholders' Equity and Preferred Stock - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockholdersEquityAndPreferredStockAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity and Preferred Stock - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Stock-Based Compensation - Schedule of Allocation of Stock-Based Compensation Expense by Plan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfAllocationOfStockBasedCompensationExpenseByPlanDetail</Role>
      <ShortName>Stock-Based Compensation - Schedule of Allocation of Stock-Based Compensation Expense by Plan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used to Compute Fair Value of Employee Option Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToComputeFairValueOfEmployeeOptionGrantedDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Assumptions Used to Compute Fair Value of Employee Option Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Stock-Based Compensation - Summary of Options Outstanding and Weighted Average Exercise Price (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionsOutstandingAndWeightedAverageExercisePriceDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Options Outstanding and Weighted Average Exercise Price (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Income Taxes - Reconciliation of Statutory U.S. Federal Rate to Effective Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryUSFederalRateToEffectiveTaxRateDetail</Role>
      <ShortName>Income Taxes - Reconciliation of Statutory U.S. Federal Rate to Effective Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Income Taxes - Reconciliation of Statutory U.S. Federal Rate to Effective Tax Rate (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfStatutoryUSFederalRateToEffectiveTaxRateParentheticalDetail</Role>
      <ShortName>Income Taxes - Reconciliation of Statutory U.S. Federal Rate to Effective Tax Rate (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Commitment and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitment and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Collaboration Agreement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetail</Role>
      <ShortName>Collaboration Agreement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Related Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ovid-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ovid-20201231.xml</File>
    <File>ovid-20201231.xsd</File>
    <File>ovid-20201231_cal.xml</File>
    <File>ovid-20201231_def.xml</File>
    <File>ovid-20201231_lab.xml</File>
    <File>ovid-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>79
<FILENAME>0001564590-21-013016-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-013016-xbrl.zip
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MW-1&$!.X2<C4GG"CCFJ(&W5T -QP!_K!!TV&=O32TCSO;O+@._J/\4_3BQZ
M:8@WO@?_D4!H9] 'OI+9$W&/R7NQ;B?/"/ZRMV0 &#_GEJF;/@-6,4QXCN51
M^-(^9"[^S6_1(]G+_]/[U(E67+ DA)47FMTPQM$$[RP9XR : Z?AOE^-U*KH
M^P&:ROI^RYC=B^^W+'+7_PY@=9?.;.[8\*<GBAU\.W/L92U\;)]\MU*7MOY8
M\E8P<"AYJT,8L2TK'5_$SXZ5ZJ*5LAR!2\=^(:YO/EGD7)V!-2@X48=@>UUS
M$FQ141538688&X:).ZV:=:]AQO=2FYN^9IT78^0B03+)?*SKP2RPX$GCSI\2
M%Y]RR12Q_4)N;-V9D3-CF*((D<PS_T9\S;2)<:VYMFD_>^?%*>FKEVRQUO"<
M5R!="0M4QZ!Z\TCHU!BL\B%1'=FK7!P5OAT\>:9A:N[B0;.(R)Q89S .G@//
M?WQU'J=.X&FV\?@*(R_N)D 8L! GRY\[CLU*P9!%D#>L\J,02:28[,/02Y$Y
MCL\@Q:<"XB.97C)9-71TB03/J?!;33,]I\9ZF>FA\^*SX^:)ZLA4VT3^)\%0
ME0_XCUPM5[YTYR38HO)[H)5CAO6IZ#-@C$IDH"O,)#E^RAEP1U6VL2K'%JG%
M-,,SX(@*&!)U6#%F6%M,<PZ,43%#4CTF*5-,<Q8,4[442X69)[N8YAPXI2I>
MR$'8XH@TK3QN=I4+*K01\YD\N0'\MK+S<FH'-/:64"H%S9I]H'1J'"-16I?#
M(GNH83D;D:APT8H4A(I5J4BAJ%99BA20G=2AG#Q;2S:JC)X]'::J4:ZLCBRV
MS0'HTV*PRE<!G!-[%3*H=[KOP,,G:T]KE4Y()884C8-F$\Y%("J<3)!B4*U<
M@A2)2J42I'CL(I-PZDPMF:@"KL:CJ]F>IJ/:>%S,27R<ZO%KB'GOY#BO AY&
M"M[#DULKF)=,OT?'0@K \?T)*0Q;"<,YLK!DF0/HSU)]S$Z"K>I:@WEJK)?3
M!>V<^*PZQURKSE2%]N3'=AA4"XT1;DT8FM@G:RF+;MB70(YDP++-21Z_GAM;
M14N6S+(%LYQ*5X<J,TO%.SB,7S77B.(Z_N7U;&XY"T(H(N_F& :=&L\DUAV[
M1)DKEZRSAG50TFX=.P6!)]=%9HEWJ([)7;IDGM6L$J#O;C)V7<U^IJ%*Q$1?
M3!T03L!AO'0L2WMR7'J=^OC9)?3!4^.F5$QPKBJ&"\E>,7MYKO\-$4G9"?[X
MJOTT9\%,8)HZ\@HLY$.TK#>_X9^)A1V* P[<^V&%F*:]1,Q::X TJHHKE'*]
M8C8^:Z;[=\T*R*?%V/,(*VN,3,=7QR:+KYK[@_B? ]OP0&\^3!W7?R3N++X9
M._1'5H>,/OX9**RY^G3QA;P02W2-HT=N['G@>_1WM>;:);1$F<CEUJ@4>G>Y
M@U>,1+$7GT.D$]64]1"/>N>DI'CL0SP.>1?*]KS</CU5OS'+M,],HV[-,B>C
M_NK',O72,AVI999Q(;5,49:16N9H+'-(+3,&^ S3"GSSA3P0/7!-WR3>]4_=
M"@QB?':=&99]!#Y-&-Y-PAJ/>^(^3#47?=C4 <YM&VA_6)2;2C5DZQ,IGS@_
MMJYZ349N62*F#QY@'L#P^5V5F%ZC2#,JQ7 BM>@^V>U$-&*]V:VJVLUS_0BQ
M#SJQ-1@M9C'^Q9U],O=5X19=ZH)##EI>LM1-17=S"['2XZMS2JRTS>;O+MDU
M0JMDUZ*5)))=RU6@2':M@BD^,8:4S+)=F'"I>5.L+81_T"U^T2RRW-D!?CJ1
MS8CLQ0I-&:+EGO9^PWK"+Q<SG!$3I"_]W!DBH0GJG0NHNB8XY#;2%IK@])F@
M*IK@H-4+IJW9NJE9-S")&T1',_C/WQ\>7:)Y@;N(MP5.A",R5AZS0_;:3YLE
M[ET'!O(7]Q;, #*#\C+'=7Q:+)\<_!RXMND'+AY9^6S^Q$^GXCH4P()0EI")
MA]/V(W;%*O76)+5EE8-H%8.87\BS9EU3 *,<Q:7S2FQZTFTVU^S%ER^7<:HM
M)Q%7]-#[ZOE!==CJ=UIUY;$"A]Y+'A.L2AH0^./#$H/P-66QR!$$97C1ZE]T
M6F<A*+!<50J*%)1-G0^U:H)2_(:)C5KHIUN;$ZFC.(HTK51QY%UGL8>^NM65
MM#I4B105-UY_DWN9RR[KZ&HMAP>K9]JQ?.80^;1#XZW8O_;;M?7BD!KMX6[8
MH)\RU) S5&MX @RUXW;[^V*E86E6@E=JP$J2@PYBKA+,L!=S507-<,9B5O8L
M2"^D5.]D);#BQ?G(.[WR[-:K!+OE:_4S8*ZCJ_=S8"5UI+;"Y%=+LM*!DD%J
MJWPRJ%4#5HKRJ'7>E:@9*VV05Q33_C7QI\Y#3U7<GZJUYBK+;F>@RVK ;K75
M;FM\KI-584>WC\F:J=:A]Q V\9I.5L%4C!GV7NZP'[_G9'5%!>U/%;5':<_E
M9/5)Y1EF[QJF"I'0:08157#Z3]I?_D;HQ:GW -1"N,;7^[00?PE+9,>3B6F9
M^/4U14:9:J-<=ZLUXC1NC4Y63^ZUY"X<O#@]695M.D6/%%BV1J4%!5ZIL:!D
M5](6Z#-V4B*35Z%ZL'H\*3S5R\I@ 1__T![6GLTK&I$OLU*[/"NU+]K#X[-2
MV5Z-9\!<%0S/3H;=UFBND^6IHRNL1("?8(;:9(1.F#TJJ'(.S#!5,"XGK9>Q
M5\"M-HLO4WY\=1ZG3N!I-@CA"ZR9$)MQYXVM(PI>"+YS(N>9Q.5S>2N%@,.+
MW4';:FS/'"=Q>J@N7%*C\T.[9"W\(%FKZJR5>*72K"6<F9>L58>SY'5B+6D'
M3ZZS5"GF$&\ON@]<?:IYY^A0YZ-!NM6%&.6LG.MJ<,S)N=AKV>Q$.@C5E\TJ
MWE]G]VQV#D[WJ;!9Q5SO FPFE=CYNN&?G<"5.<LBB)#^U.H=P:^::RRWD[XG
M[L1Q9QI@D-YA>RIMQQ.+C3>J,Y9[VO%:DO H2K>.G7(-L7=J/O,2$U EDKOT
M^O@M1](:19CGI!1'=7BF/KI#DO]DG-%4\A..#,&8?@('W6!XH:]XI^:.9O!%
M<51(AW0/S'7:?DJUF:NJ?HOG^H^FCTW6;VS#!%0&FA7WMI]J)F+R;O*@FXR4
M^MAX,3W'77QR *') SIEK1]_#=^XFXQ=%V\R0(0+=:%SS=4H^;#YN>T%EF_:
MSR?;]W[GYK3,Y*EDB*I2BQ!B%]#@ :%4A@Q;X1=C22GBQ1(:*:QUXD(5?IVY
M<LDZV[/.27FOE>&8*L2TA?2&)/[I1K37,IRECDAQ/,A8=M=L=9J>20W8JN)^
MRHVM.S,2';/[XN@L9A$,US?B$<W5\5;N*_)"+(=>F7K]<P[$(:>FMW+P$5NV
M AB1&FQ_K'8BNJS.K%9_K?9 +,NTGW\G-G$U"] [-F:F;7H^)FU>",?PR?EE
MA9BN%&ZDICL$^YV3SJL\^U5<^ZV&"AEE%">AT=)"@FH4WE1<2Q5DDQ/1/-5E
MD]IID[,Y>967;:C0P83:Z9FS.5-5$P:JJ@:":88A'PR/Q =;8G98'K/#0P<J
MC]K/<>!/'=?D?67YKU?PF^>;^J43V+Z[$+1[G64R?<UQ])&ZZM/>K\QG QJM
M012&P9KUE\ U/</43VCO>AU#K%G_N;%&='2,/W%+7O_AN#\HEJ[,%Q.1>S>!
M-\+BI\^FC7LR)\LM\2&R\)ER*#E1!O)<GZI0XLZQF77BQ.&?OP2V\43T'^.'
MHH6-7TP=LSXIA8R]5J?="S_TZ\976+V7AB?N+:Y@:AVWE.'EO/K%='P?Q3OM
M7;0Z%^U>&1^*O=+?JP]5CL'AZ6^(YK!Q_U?MISD+9KMA?\GU1^7ZHBN.&(!U
M]4^PP!&*HI:$Y.!6X-9Q_>DK.-O$M;_;Y@MQO94;+#:1B+[*&^+VZ^AHK!&-
M/*156TKV8AOZZ,F4BZ_[ASDC<@RVE]Q^<MPNZ.O^D;WV7,;=FW\CV;I*;%U3
M5Z?2HK.Y<-1\G^UDI>2<=OGRV'X,"+5,V\Q@X*T8?] :11].C/'ST7:>K#^X
M:(W*L7[BE5-B_3JJ^N-[)'N3MQ/,SZ]AWE-W/*K!#R=N_"7O2%UR"K5>M>"'
M.E1[&<3\0IXUZYJN*NY.J_T@AG8_U=R9II/ -W7-PGL -7OQQ9R9/EEJJ9-]
MYW5\;^(G->NVQ 'P8NUVTP!S'Y90%W:T+8B\7<84.5=M"_<UII/@"*FA 96&
M_>Z"58:U>Y+'SX;'$SJ?<7FI&HHEP:BDSI?<+#5EFJ9,SZM$MVA;EO;DL-.$
MPC.G$MU62U5F9'SBF[WSB"%C[8J)1LV#-2D:,G0LX%^GW38?B\ALYMBB;QV^
M'3QYIF%J[N)!PV:<L7<>UM+?WTDYVHLWGH7Y6)8BW.\E"DCC%U&.ESA&BF[E
MK)H4PK,P9@=N"5D)YI9!S-DQ]Z$V?7;6!W\W#>V[X?V8W?K>CRE[RN_ T>F6
MOZ93?*7RUT9L%ZAL+6Q\G+_C.7GX53PKCG?>T>ZK"!-PDQ;U8'V$Z4#&'E\=
M*;(U%MDRB!$81#A.7YQ%SCE6DRJLLBKLSB92A4D55HA%I JKE@J+&DU;,+1Q
MCP5;2#)/HQU=O$\+\9>XAFTR,2T3O_]?TY^R /23Z?A$G]J.Y3PO_JY9 ?D<
MV,:7>Q"2AZGI:I?:W/0UZ\N72U%9M-O#NNJ(XC@+2]]V@+6C)(9:[8OV<*^Q
M\Q'9<&TM4=2A&$M8QEG51+5FY9SRG;@)<>;R=ZG3I5"=DE!ENZ674Y-,KG\2
M/< 4X1W,J1,7_2GNTB0$*W0H:RQA>0YE,5Q(*=O0[2K;#V-)-$_1[5);]=L
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MJ_9D6RTRMU'JCE3C=FVS-I2SW/:J6U??#$O)&=BU7E=5NUO+66Y;UMTO*K<
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MT:.O7KO5&XCW(9]LB?;:JS+JA[V2A<BYMVWLK;!F?[WH=E:AO?9:CR,L(:M
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MYEK(WW%IF**K &$NCSDI,R&Y,."DCPD<P*0HZ3&&X2=G%A!DX";,@H$6>"7
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M]V(O[D5;<"]N6%0O'/U?]C*25=^A 8VN%Q R!.%E3*S>47 \%@V%F'0&MLV
M3;%=6DC)_WI+FL_-QM+4M$,V($]S,WR9%0^H@4\D!TGZ1+@GO&[(T)N*5H@E
MFVR>=Z'+TXY;-:1[.='+U-$)]W7IWBV=D^%;V-6E&VWTWL(E]X7>CV4[T<3I
M<!=V,J1;(=V*XYM*Z59(MT*Z%2?F5G0268O5G8-L]Z I;$,F0GN7B#?@A3L/
M80FKZ0I9=?:T<*<8,[GH!L2FMQ&=:2.&>"FGX!>(.TFV$5]3!^1(U"O1 86M
M'>;1P$)IM4%BQRG3FG?.P)I7>*M&;EJ)FU9+IYB\N#MU>*\W.Y^O>%,29ALS
M^P0TPG-6%ZS:A!7((.NAD\XJ\WE7H_"85E3$--<6^"#]QD7G66BU@U/Q]Y(3
M\)<\\1KD%1V1K+(3$GM1;X2HVE.\*EU6N-2HPN7K.[QR 0]3/VH_Y7DIJ>/6
ME[4S=O&1781*6.:FB"W^%SQ,#ZO4HXKRN(FJ]C/K;@!6D"C4XH;ND%!USLX(
MX2#H]<#HA)XXU7S?-9\"/[QWE_7Y9[\]$?\5J_A2[AE8U>C\-BJ^QT G>J*7
MH]-[!TQ6$IP.?^+6-P0=C_\G[W!F\\%OK/"43Y;1'0MOG?2;M Z-MR+ $@AV
MPA8=.7X-KH'=N$T_JLJD]\,N6*(*\S(TS^(A^>AN%G/#>,<'/]'>-J8,/9H5
MG</E+1/2>M0])FX?U7A%>F@.<41+>_7"$FO7B$TE+ZLV;>&N47@6'R4V/8TF
MC4J=C,KM.QC*I_U[E7O0#Y>L1)=6+9^[7CU(N^\J+1AO&M-YT;P5H.*.VO7.
M27Q3+^T2:":NN7Y:L",TJ#'C%K]+VETL_^8=7\(";K8.\'DU[!WP3!)SX<V#
M/C8IH,,+M\>$QY(^<]7(_O84WN&01 =YPI,#PDU1/WGV/VKKHVN6SB^=A$=T
M+?!"-YM?7?A*C^L\X8$@W[R@& );0X-@EP!Z22-]*2EK"&OVPSD).P?\M(+_
M=-QKO,S?TWB3L#5)$"6C_>H#P3N%E3'>+,>M"3OJ$)XNL/GV??Q[@GB&0ZT-
M9P@[; F4/ % UT,1;^.%&1;>?VVR6SVP%"%ZR8U:=G)SEMI7Z<'$0,VG=[F;
M'NU&X='D!\/7]?T#1C^<4%C)'PAQ'N(+3V+;= Z.;GR%7B?&:0Y0SAV\'Y.=
MWA;9T,.K/>GI"Z'I$3^A !,)K>(7$41 O M.->ZKT"0/ YSY)OQ6D$QJQ M*
MX=KDS*L<!,L[_KU(55)R,FX0XP96H,L.!7*FMSCSHB,M- G+U9TQ%WKL2@C&
M?$5T87C>,%V]+E<.BVF]TIM-/!FNHVUP"^\]#0IL/3'ZOU&>GBF!?WW#^2.:
MA(/!]OZ0GN$7WRA%6\U!3_CR$9F'?<5@Z/>;_>X?/O+%ANQ&;S=4V(-,>^(%
MDK;_,2777VIS$O].<BY^40&Y+;[!M6^*J,W!T0F2V?Y1/=)>\7KR ,B $Z!/
M_\T!2!5^]2E&,J->I]7L#?/)E_"@,@T$TR7EMOYSI&M-*U-*W6$1XFYS,HJG
M;_Y!-%>YME'1IV[85$,,T[:L]ZG_JD"A(K+V7C14YVNS:J@BI06K-'DB"]8^
MJ@53.\U1.R8?HCS5?$D3ET)J+#6HA@Q*\W5\&B3TX$:"M$91GK8P2;UY-J3&
M;' U9%;JS=VY_9>?/[<^7^Y1YG@D<# 7\F@YJH?$;I/O1'=$)/:^-I2@O9.)
M&<+3I]+6_L?^*5' 0!U,_TG2E2)=NYA_48Q\@COA(D2[\":J1$^UU>BV.HWN
MQN'8(4112EHU*2/-554H(<U5;4DGS54)>@[ 6O4:[5&OLN24UDKNB-6';%')
MF^[8+\3U32SHF2>+#:N1;ZKF7EFEY>T@Y"GBD^2E<*6VK";UDF[)]A0\=<^D
MTVCW*K.E651/2N&K +FD9:LF>:1E.TWJ2<M6-N8>]-O54)7UL&R,&O-*UL^)
M,7C<L*5>YX3IIX.WEUFI0A#(=> SPW?OE ?"KC2[TGPMQLQY'J.2!\K2&E'
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M]QN#UJ:9Z[,TBO6[C"F3J>MYUU'<:GX)$56^;RJ^#&?#FVR2U^$\^/#5U+%
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M[7CF)7#$QT=;UH@F4PXQ6H<DK]:AJ8_PZ)"\G, 53NV@.99>^\> ^1[SO6-
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MZT]D7W)3T=URT!4[E;=U*KN]\X$['.Q[7@FK/DTB3Q:--J/#HM$BTYXE8L.
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MIUEZB8M_@RO^XLVG@$KZ#8[P31B/?OSU/__#<?ZB'_8Q@AV);][/\JG%)YW
M_^W9AW\"'7<'_6>P]0AQ^"K&OSU[B[_M#'O#X:#S3SS6=J<M?^AT>YUG?]WV
M1N']Z1CWR;AA=5=*W9.K./3O?,?N<:$^??[VWCESC,O@?/ST]O/?WSO?+O[?
M^\L[$-(;;_3C.HGSR#]1C%)*A-THK-SA2G[W="M:R?C;3\_Y-W, !RG'B^;.
M!/B =^,%H<SIF,V2^&<P!4(*YPXI:?@6?7[5/=*KNKVSEBQMP0_B;PJ&@@DC
MSSMGP]9IE<?DR$@^??[#&7E),H?]W'J)GSKP@S,6(,R]D+Z:9K *)_-^.K,\
MF<6I2%U@'RDRF. &EH?[\#)GZLV1U<#*PP"S5*Z!OZ29,\XSH&7\.FTL(#IO
M.=^,K7MA&LO]WWG7G>&@U:_?]:8M(O#_&R<_G+=!-B^V)E>V_(U;>"IL#^X=
MLE1@KT&"FR$(D44"HKV!$XP!_LS)LR D9CL#5IK@%^B$?-@7/1^_FL(GX>_Q
M39#B:G%%\FSPJ.!>7HF1!ZM?NB.3(,WB)!AY(1P1?"-/$N3JP+4]8M_ .V$;
M!!QR^ Q1 'X_SF']H _F4F+ M^-;+QJ) J<@@Q4)6*08"WHD N[!LS(XDRV0
MP&.K>SXL,1$DLJ[FBP!W>H;8HUO:!8VQ^(V?)[@C?<0I40U]#MC[>?42MBJ7
M@#FA;9S0I'?%*=+\ZD^ 3Y*'I#E)./(*%;21(BE?(M!Q9'#1LR[^7I*'KSB*
M&(_QB?![#QC ;222=!+,G-'$BT##N8WST,<WXY>"*=![D"E.X>']BW+@>&$P
M#3*Y@EB2-U(A?&29)WA9E@17.6GKN NI.2'IPD?D6^2;Y>) I<NC3"]Z^76^
M !4*OI[/U(N1G$2Y27EXP70J_$ 2T-*+7/7?5!^J^E:A,9R^3F$3,WAEJ,G+
M<Y"*@C$R;:7[&6RK?#+2'?Y;BX896'A!.H%O 9<!E@8\)-$,KL*QD".BNAH*
MREZLA]*+O'">!K1P'SZ83(-((#_U-'J!B2@^-QY)YM=ROD=P;R2&ZBGP?\4K
MM:8]@@\ ^,!V@:WE"7$GXLNX*_$SD.HO\L J-Y6HGQ2PP]$ 2_.188)R2]LS
MKG(*I R'"2_+#'!;S)$LYD@5\H";+!(PAN 'LF.(#D@D(]K2^D)Q55Q33S.1
MVXG FT:4,HEOG6D.QA@R%Y*E5R(2XP#NB/=#1"@,*U0=D0#&SXV!!4;7=,TT
MAZ+[/$52#X,?2/AP;2.Z>-J\\Z2^,8Y1[N+%A5W$85ZR-]!PX@Q0"(!RT8""
MSXAH%"QL<R+,I;:<#\@&"O$+W D^MUJA-41S56OQD>CRR+!"C;?03O4B"E:"
MCP)VZ(49KM$;C9(<*;V.M\P%\I?(ST>2OZ19[L]QUXBDEP &^#!?@)H0S] &
M5>1;Y>;X;#AE^6644/#M/,P0&60L/M("?7D-9[W3"U_C'8'/)"X<#?$O]?(J
M[\)'D9)<K@ ^\","7N@2+R.IHBZG( ,>EQ'16: >"$\?B03U0*G#JSO5<BY6
M*X5XM%="*"'L&^K\CELGA=0E?AXM;"41_\I!F28V#?\T_EC(ZW@\!CV4%,@Z
M*&IV@&CF:>%CT0^"\P*Y[Y5*QY47TH9!CB'?3Z2Q0P^'"Z3D !'@XLIO\<%Z
M[=6+*5]7W'8'V.-$7^%5-]R@P@JA%$2"'**P#[3'I_+>"A[UH*=$+))I%%+6
M+\_'6(4D>9*/TE=D"CGQTRL8WQ622BAN4."1S9!G$S!0<%<MYS*04M;@=+05
MSY"LBB"*1;J+GP=.A1H'\+W52\"O?&]=MK1ZXBJS%4\YC,%:,D_/6"(97O!L
M^KW<,RQ/^M'J%AD85CH+=2N%.M$'&0)D.0 YS^+$2^:.'\!O$Q![0EWL:^\&
M[GR0BD7%;8;.5V5YX,VJ,8KES0J\*Q#7=)&((7BIDL'IJP4H3"^^M!ADQ.2W
M9^UGSDB$(<9$@'T7_U;1%OJWBN.,D*TG1=1&A5S@_$-OEHI7^H?7C@S+G+;-
MH:[U-5S3P/=#\7BAH>%IJ]W?=\MG"R(=VP?$'QN13FM@8P]NV^&!)<.9 #[#
M9T\ U<I,Y5Z[U=M 3Q6WW$HQ('G)0P3%ER(BJP3"V3;RX!Y(:LO$ 8/$#E)[
MPD&TUJ#P,+7%1R&7&L@&64I9#4\AI;I[E5*=7NML>/>^A2S&*)*[;=D^BZ\]
MB:^]\<&="&D#HSQL8F*^>3108^3!#IIEOOEP:O^CMUA6EL#AJY#OEIV8OQH.
MS%<[TL[C-S8G$7CX^-Q;\["BQ?P^$_P9NM70=;?3+.Y<6_-PB@0#>D=:9%*S
M$QF65[8@P?*JL= ]J+QB^%@Z68/,/H-?CVT%=WJM4^M!^K0BQ1M+(],]>Y!8
MJ[#%_\Z\;:=6$?L 1.H*5K6%V!M*IWVW/>R[P]/M6ADQ_3!G8QEC'Q)'2B,L
M8YJ TN#4[9Z=N;U>WUJXCI1^CCT*VPC[\^NJ6CD,S*IZ.6L=.ZPBV(($LSA;
MD6%=P= 5W/[@S&VW=U45F(Z.EXY8UMB"!-.(K<BPK"GAZKF]0<?M=;:;/<)T
M9!4=<5ATSR!1K]:3Y?:RUOIX6#VP!0EF:[8BP^I!"5??/3\]<WNG^ZZN9#IJ
M'AVQK+$%":816Y%A65/"-72'[:%[=K;OBE2F(XZ0-L\4O5#-,A_ #&4OM2T"
MB+UKQXL,JP9&1+33=WN=H;58,179B@Q+&EN08!JQ%1F6-"5<9^=G;GMX:BU6
M3$4<#;45I'=BEHA1P!%0"[!H@.^369FMR+!"4,+UHGONG@XY_FD9+"^M!80%
MC"U('"EI-  9%C"F@.FZ[>ZNODVFHJ<7,!SKW#,V;R?P6SD1# =STD1AG#UF
MK=>&=0);D#A2;M8 9%@G,+S0IVYGYXDF3$3'2T0L:&Q!@FG$5F18T)1P=7I@
M?)YVK<6*J<C*<.=>!D(VPC3]&&5>=!V@:2KGQ>S9K\.C(1OJ(MUN8#%S1SO1
MJ[;BOS^"AZZ']-W3/F@BO8X=[')[7LD$: %<+-WLA(>EVV&BQ]+MCNY<M]L^
M<P?VS%IEZ;8'X[LI(6#[$?H69U[H7"<XAL9?/Z+56L\6>^IM08)'IC46NL>:
MT'J86LBY>]8!0WO ?84M0Z8!E+9*7!TZT30 &I9?C86.Y===QK0-W?ZPYW9V
M;D;(\JMA%G.CP]7VP_8/+\RI6-?QPC"^]:*1L,-!Q?[\IGF$V9_?9/38GW_'
MDJU[F]+LT;>DEJM)8NW0R:H!G)+E7)/18SEW1SEW;Y.;Y9PE<FZ? >MUYK<?
MYY@KW6T=GUGW261UT6OGA1&^WE5S>5CH:C67(T:N 9[E+;S*Z_ \:DWFN;6H
M;ADO>#AD#UW#.;&#OV[/7(^2(*WAMRP.K8:'Q2&+0Q:'+ Z?AB E$AJ(=9CM
M-]K^*W7**C[E!S=K+_:?>9H%X_GFJUTYHU_N<G-7;F/CHMYXHQ_729Q'_HE"
M1'J8[K;:?FO0_V4UI.VGQ_3"2<0HCD9@]LN(?#QVLHF D_"R/(N3N?.]==ER
M/@@@"B]T$B\33A;31][&TYD7S>DX_^NLVSE]G3IB/!:C++@1Y%>@3P>IXZ7.
M.,9(?_IJX<C-.R'[JDGZ^^U9^YDS$F&(% :T6OQ;T2[]6W&%$9RL2 H>H @8
M#CGT9JEXI7]X[4@B/VV;^83U+BF)YJ-FA'3VGA'2*-WML1'I$&7:FOKQ%D[A
M*@GL@066"F<!N R?[3.PTFNWNAM"F_HXURM5DH<\A%9E8G(5A_Y*;G^V#;._
M!Y+OQ$A,KT3B]#JN+4&4)].:K$&A,1F*^Y='-MDCUL24FR"=K(6GD%+=O4JI
M3F\G=P&+,=QKM[US/U(67X>MI>]$2*S&,X,\, 9I3WL/9I"VI4"MI#FE\A^^
MKJA=ET$TBJ?2+WDE(C$.,L?+##\G.BNM#3B1W+LO5L/6V<!ZN XCIGN4\=H&
M0,=USW<:$-5IM;GFV3)4MLO,7;;$&B*D&F]3L62RCV8: !U+)I9,#4?E@:N
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MFE=O%V-,\9S"'BNML&)_ROY2!M)F[I+237?E*FH]$KA3PD/?++>XT)MV[SF
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MM51@^NM9.7(;^&VEI\F_UH]X4&M*4*6.1)Y@D(-(P ]2*@I)M[TTBR#+$ZH
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M<63+4QP^Z7C76#Z;E;EW1AM/9'C30@&G E*YHEJ&M9X/+>J%4U#O)SB.[$:
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MO(JC_+YF[]XR)0X,EP84MC-/LQ49TAU8-9"JP5D?K-=^QUJPF(QL188EC25
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MX.%<4(3@H6=H@1'L/]3_HG- ;HGMEA.D_O()1<XC$D,G0?34/09@%\ N@%T
MNP!V07Q-(VQA4?L<:EG^&?H..<:3+(4]*PM5145! DJT]18ZM9P3!>?)";4V
MUCFVL%">::FVGX0%!(J*"@L-6*S>0@<6JYK%LBUAH02+)=)6)P2]'WZ0:RW(
ME1(4S20O2&_&=)PF@@!8E$T$4&3]0R;U%L 9(-0:0[MN] HB=+XB!&&LL-"
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M&EJ]]4#0H-7;2<$)>K/_4$.KMSZ@!,'#N: (P4//T (CV'^HH:4/M/017].
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MJIXB!X:J@J&JO\L(-NI<!0QLE"A @(2("0RT/EN!-1J:MJ@P@?R("@Q8&$&
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MG?*);?*C(<[G%XLO79=>+,[5S>4BF881N;C*,KZ$B]\DX\D?Y9U92S,,Q6R
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ME<K+J,A&+"DY*?C//=1D3[R9X'C@-4-5^@8<3VYR.GM36.3<F_K *MN!57C
M'HED93_)&P 12<&?__:&RN$OY+]O_S]02P,$%     @ @$)O4J(P\5+:$P
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MBWXOUO2Z;622/$P[3)!I7RZA71C.3$_S^TW5 S74-JP3X5G9S[@9J K=1GL
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MSP#,19MMZ/IT\XW@J-GIKNWG^_77?SP0. ?(N5G,H4=ASW/N_2DD/4I9^_V
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M!%XS$W*XX\ML1AI+DH1_=IM[#R2"I;#81[P.WHWQQ']EW,GHG2)$+X:>_6>
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MI#P9H^-]Q^<RSEE6BO+]C6:[P\W5\5Z3O/Z!_^\)4/C3_P%02P,$%     @
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M>Y-##8!O7X,U\^"5A#']YV^O2MS[]1@%;W#T]/;\]/3=V_6O7^4_)]]Z2?%
M^<<?WF9?%C_= ?WRCO[V[,N7+V_IM\5/8[_JAP#T[.U_WXX?W#E:.*_AK29
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M5.B]/YP@17<HHCA)TE,/3@===P +11'RNF^65E"FZ!'?,DU0FJG85>GDDRJ
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MK]^Y" 6MH'300\KVP *:$^V(GE& E^3HDZ"F!9 1>1H]$IZZ8ANZ'H@.&J:
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MC9#,..#N:^GB"/E_$O!Y=@*RC^X!S\AW86^1+P#=S0]*OQ1E1X>%K.=%9A?
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MT<-),.3-"TY+!*]L=X4>F/0.^Z0TX4,@K"\-^K#HU16C);[<9%9"3C166P-
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M&V%+\Q18A%K(H>NXDA9N4&0R)._@W:!UVZ\0H?5 ]+BJY0T_]D$1>/E)2+Y
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M6<GE*IKA[ LE>COEMW&0:Y2OAJ(E:T $'<2:-,H%_S>-_-CS7;E,8"LH'?2
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M9(3;[Y9*GD%MG:5LL)3]EJ64;E$UM8$_,:6KD9Y<Y83^F9*<_#/UWI4UT$M
M-M\X+X*TM@*X6Y3,L7<#HA4G1-E.7D#[DL00FY$D7A3'!52NW:RX=Q1X2H+
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M2J B5K"B#)+PIX3]\@:O&$8*<H'63]!_G68?.Z6_.GW_X?3;]V^^).L_$6T
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ML5Z3$23BOV[""+[7<XI& D,TWT#0F3,()B?9#[0(+03+R)OIHPL>K*0U+Z%
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M*:RA.H]104V "%<S\)26GH&+QX_+S092-SS'2:ITX]7R1</.@%5"3IH!$B8
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MNWHA35FRC0&1A1:C(7&C>)"[SQ_D\I!1J?[L=;#0-!S%=80B3K,V$M5UA61
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M6;?04_5NH1,YFGNS;'91Q_!^#2;8$.Q9W?%RO)>D+O(4:A9;B"[R&,0_F/2
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M!?(L%2[4H(V'*LU!=ZM*/)Q<E!><6;$,/_Q*&TELJLVYH(:: !.96,+S?'#
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M;")-Y^\Y\%(Q-F85%1L:$$%:L@9^Q?'O9,E['NS#-$ J3M[X-<,+Z#(9)XD
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M#E9-7M:F/(]QJ7L0Y\2140'&]=J2U70X1T&2#%A.5HE868>4B3KH)4+I \;
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MG)( =D(86D:*2./#9FF(,>"A0,P-^-(^@-W55[-.3JH8#Y_4)QNMB$0Y?][
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MUP\I7OVNFZNC2,XTM42)O)NL'L8:+&C?VXPY[7C+N8.$LO?A %L34&R@V1F
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MC U-@2T835]UM1L%W*L@[S2.9&4O965;N8,V,^U?P_29%3VFV9'/X?X1Z_:
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M\&>ZAKR &QC'<$VWJ$D"T_-GFDQ_'2UV]%1?QTWT:9N#ILO+R1(VA@$!,HS
M2R8-"#)Q_/ N8[CQ4%7/#5KAJ#ESD','&7M^MD(% %P"6E61RS"R%\N/ 8A0
M(I0D>22[@U& TA F9*]X'1&KA4FZ6*WB ]3J)CJ(C;D!#&#K^-T%31]\$N(
M]K8"T3:B) 1P*=A9S#X3#P1<*#]"@0V;P19!FK%]H ;3H+$ADP1(TWTN##NW
MR<0!BS[3<!(W;L+@*41A>KS"\2=B,7$:A!'5&$[8FXGD_$ "G=ZLKT[3''%5
M'B[<7W!COK\7_/SP:&TTL:E&YX*<<,R<*7L35$#(_#%C# 3GL7.T*FN9)!.6
MA(A;F"Z>$E9$12MK2Y7D@&0B-1;V_2]?>U'W"QAK@E?.^R<_/%$75&RHV9D
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M4O$(DXJ:;_2A_(&XU+'T81VOL\)N0'G_X>Q=S(=92;WBQ6#V\@$$*2W4SN4
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M@H_A#@H1KI/D0-]B7L%LD: <'\R(&QJ>"3,G$40( B(<G:YR40!9])RF1!B
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MS'GX8%4M.L<=2C'"EO=U)BN2W3+:8K)+9<4VU3<5K=\W1+N%GA/814]KJG6
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M.ME/,KZ?"B(ZYC"C+$[G:8[+)5-Q DQE^PW='9!95)+1LZ_BH:^H]DV5JQC
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M(#4I3J_0HQ]9OBQK99]KV766B])JA+?6BOYSYM-[V[*9A(-GFHE0TS*KZ#'
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MQ'TG'EHG#:6N(L\IJPH*/(U JEI7(-&%TW8RSI1><%0W\:D0/;,"'/SPR&.
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M<>$JN9Q)L7(Q%(>N:@S+5$K3RQ\J$92ESXFA^*WKGF2DK?=FBX[67@'<BG6
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MN#D;]RA _G-\8U]%8>2C3; *!!X)XKW>/?M6]#;WR(UHM>>2RG<;Y9N>VMB
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MA%G_L[)'5'MP*^?M(!#?\-P_O(&<'03:E?:![J"&L-4+G,<;](!6XW#OSL/
MMWX/)8T ^K6O$YYZI9V(;QK]@.X-?DC(%:A..K$K'%X+;LP^RSKY(N<BXCT!
M8V:#?!3'1NK 8)&@?@B[I;!1AK[=4CC\(>!VR/? 82#<KQM@#-5&QH=JJ]\S
M/"A3>8# 4W+_A)8?]B5,H']+(BX1>9C:N%)=K%1EPZ[C4^6+4E1*U:P%D5!8
MVXAG^I;@[<6>=\=@O-MX-V4+\G%<D,ZO\XT1(%N43RU=%9?>N"S*C%W9:GT>
M5ZO30U1M^\UZ<ZJ_ZD?]2X-O)%L_]:'0X_JI=BMFBZ50K>ACW'H/EPGH:,]6
M2KVN,:Z4XA"4;*W4:QI#7RNUT5G90GT95<)#TS3VUO#KN(:2:Z@[')CW#1_E
MH][E4AE,GZWBJ)$(KJ+ZM)-L#49-HSM-8S<#:K,H']1;,,9%:2OU+ULT'1G<
M^E*"DY:>,^L5!1/'P<D$KKTY\5?QL%(IOC"B?4C9%>180V#'#;8>XZ(H]%7Y
MP[.13P?V*&-W)(C9"LXCGQT\2 B'.$T=H2L_/!_99.'AO^CYLU[/D(?FF!FD
MTB6X0Q3[$-.5\)Q-%86);?L1+ ZOT3 Z<&"")9%?KDM>+(\E>B=2@W(W"0(4
MGB^97+OV)BL2P58<3EO'C#/L-YTGDS6!3*R4A%1:\92^X"A,WN*&!,&YY?MK
M>N+9?<'JK& _1O".&Y6%4X?!='6@7\X49 &JJ$BM0;:B7!K?0(HY"Q#1@>XM
M>OD'\7_&S;%9<9X L\:KE*/D&'K.%?;8.8271X92UGJ2)U&XC-4@N=K'U72Z
MFPFTH'$5%3TA[71ST*W 6K*[_S?R<>!@FVT/^':K):4EO)6B&838/F>7D[^&
MSZ*$0#<[2L6YZ/9,-#\/(F=!_(80KL1=0T KFGQTF3CL2C*=O_5%)DEJE\/T
MPM5BVYG4GZ.A5*.ND4252 VMM'3MO4-JK\>AE(:&0%6K#YG>95.!T.+*\+;@
M.C4.+,"SHA:Q/0%V\M'(#09Z5!+YA['IQ=B%#ZJ R<3T>NGBIB<B9OLRO7HY
M"# Y(ZCI19*E]ERIP5MKC>)#00ON]^ PCN=6C>^,IZ(-ZYJM1%3<!<N3QC0\
M)SH)-.#-8G8/)]M/&Z3H[FH:?" Y4,\"$J"ST&&>WV4DQ\4M@I67J".EQ=VP
MR\3^/=)H3D7D.ID7N&Q/&85NN"?$><&NF]PZ]!['+&(K_E6S.571[62F5$NA
M(I^]V^*03OP8L=TC[;27HZ]YYKF#?^<3^G@(UZSY6LC"]?X9X:<5,.H)3+J3
ME68J1/JS5,/?"FWTG(WRM6DSE_]UHSW0<.1^HU4<*<I"3O5@5C5^5\B=T_^-
MPZU#?D_U&:KQ+IN"4DFZD_FJB78"D>UDGMOJDE2!+U&2H[-<K[,<O$"F>Z)D
M#T$5EF(V73.-X&W@67<9\$I=9H9XM(1I<ZV# V^F6:Y3X(M59&Y;'N5Q/>1B
MCS2.J3IG>$\+G2G<R$+O?0[M>-V) EMI.N*>D/&N$P9TIZ!G"TXD$EJNB= 5
M69G;\":9+RYW?1 <1?416'N[L1.?W#VRB6?3.<?C3><LJ"JB[^OUCX<K1"=O
MN:R1]8Q<SN?(#O$S^XK]I*F+3LVX/?/8-9R4!C-+-G+&-1N?Z0;8B^AC.'T5
M$P]D+8-0U6%,*N9G9W7")?(GSG]'01B7'V@^WSKZ?9EY]E*7L@++CM"7V6_B
M@!2[?I4/W1>\;@F3E!'],ZK@IH]AU< 4C]$7!+82 7+27C4*Y>/T!8E)F%YC
MV<6V]<>J :D=;G1,=..84+)X/"/DB^$OE!;0+9<5+;8IZ97MH050BZ\A#JB9
M\=8M @I2>$Q/I&@1YR)]F[M]U&4*#T:\[C_>.)SJ;BMC=V?QR[_--)_#-J;=
MQ<NR1"&FMWE7EK4*)@PQLQ7-4&/HEH(J:+6DQA=1MZ%:]5E[ZOL\=IG=<TY6
M*QS?D?0QDHC]!:)G4V55T49C]$%TR4U IF+2=^SA5;1*^EM-YW<^8<^9<_*,
MZ&;Z02?DWV";[<O)PD=(-+!>FK0.:71.7,HF85K&,\I5!+YGY<I9HM3TT<4+
MN$\#1E>JOA7="@%V4@7ISEJS,(TKXB<CQ)6]A5='A)04CQ//BXN*QTO[W<(>
M/1?LO7:%4#J,,(\BI*1X_/%$9;<7TN=[\@IBI*8>FN$52D=C72[Y4*!]+T=<
M:AZ[!^@RSK!UOM/AEW3#_8.^[(39%J(EQ>5& LQ\;+G"_.Q\)37R%?:#,(7X
M(D(_GEB((Q/LB1J8_'IIB?DGH!25K.AW[*(@)-YFHX@7.A6@I'+/70B:\^MI
MZ+@#XA#N_+UZ RDD*T)%[J00/UR^L-+SOO?#H]>('U"%3[RFI0 1"70#/\PA
M2__7+JKT1YO;7IS7@H]:X\UZE>!M^Z.V>+MG:@*,LZU/6N5+M)CGS@=J)!]L
MUY=]KD.:Y#O T:N2WOP6_\F,_BNPXCIP ;PZ+9BTCOG.*./3>8XU:-'7$@)2
M^^;O-Y'G/"+[Y^0!N&4*OFSM-*&GR+>97I!MT+B@(O*?+!]:$AM(L*TY[8X'
M$1;%WW9R\PL7"*ZCH.?MNC$,!+N6@6:V-2#ASJUM<D"0^E4TO;"PX#D@5>?4
M])K"M=*-@(6PZ:6%Y2XY4GX3#Z7 </TYK%&:AE(GMUKI) U49AY'8K;(EWVF
MD)HGUE"J#HM=F;EW\/;1_&@<,,5V E)@I3 ]8;3,DD,*;4D\9=',;.\Z-+:M
M?J;GOC93C:JMN1P[,\\57$NJLLEG#=Z/S3QW .]&V9V^Y8GA>)D=&=X KP*O
M&D?-S*>>!&H KRE';V 2K1R]'4]XAI#AM;N:2['MV 6.F]EI&0#<Y$)5,B!/
MQPT(B%3BL)FIYTK )A*$QF$;F'6A$#:Y8$..X:B2-(A.S6#4T79&9TAVMI?H
M2FVFJS(<6Y)^/T*QH<SK"#BQ;68]8'DM"#\SJ7F/7)9A=V?YK!01*,*DEI:6
M$)J4B_02V&8A[7B2V*SM3?L3^!0!Q/6TXB;V3Z9@T?=VY%.9E?:X8J4YF1B+
M;3WL?93\.TXR?D"410Q=XZ8C207F;#)+*;(7Z!FY)*[+F*:YW".\>HRHS(LO
MK7CK\0-;&[DC0UK'BE;R!5FP&D*&AA;/Z&^#)7$=NCUM)MX7:#J?1F$06IY#
M=^VY]43?*&Z\FV?DN_43G5O!$AJ?WW 4J9FQ]'6FV7*MK%ENC3 ]*6Y+@$G$
M!142.8"$.0;1[%#ZQLC>HI?X-RJ$["Y!'7.[V^B>,4_THIOZ<?V/A!G*5PP[
M9'*B%/7/+ME!">[R,]JFHK,_PSV5[UXDU34J^U3JE">9IU?T 17[_N?L&?3P
MA&P\Q\A)FAXRA6#U1/_ET(LH59MR"J_PX5<Q5,,Y3KT%H6<RMJ&*WW2EWS>Y
M@0$K7OB97%I>]F*9+.CUP.IQS)"]W*Q'#/HB<AD/Z\TU3F]*$BV6TK>4TC$;
MSCH_L+IY"5&5XUS?*G6U-O&YITK,':'O]9">JZLH9$VH84>TCHQD@N@5,XQ?
M(;3I_BK(S?Z'4N-O)'QJH$\7@+5G$ >FDH9D^G% Y72V[H+]&TL_E=--^2HG
MVCHEG.J6XKIH%0TIKAXL^@+:>P8U/9E JLWDC+KG(82DDI?L]@Z7?L;NDAEN
M>FR9=R$-&[5+?IV/(=VWO#<HH2 W;I=(P3/]JBG]Z>)C]]2L.<G*6OJL1L'9
MR?8##IC[5TU$"\JN%02L%!4=5SSWK^IK/583*H1B/2+' #3]LX*(KB0Z5A 5
MM&LJ/M92;/F?$0[7\1/98T%4X U30D#KGMGA(9#>-\6$M)0RNYO"]TSN(RUX
M6ZP%?+Q%66 Q"QS+[D?XQA&AIF56T6. '6SYZQQ'X!U43D3.8V']1(YUM[3\
ME66C**X3R+:EY:UO\ J'R '>2^($ZS$/-J 'R'ZW(,_O'803O.D_=F&F/_J3
MZIGT6(EOD?UO6F#JACXEW&04T=4N_&PL2C$6I=!6E&)"2="_P@WW3QV9L5R%
MZ>4J'NPE<B)V52EX&X-+7;0QN@[4IO["\O!?:4];+R N=C:-6.]RH6,L]8#%
MZ>*DZ40Z(XGR&8H&[#R 4BUPI-V=-)12'2W*@+',QUCF0U\N:YTZ,Y2:'^T>
MZ+%>R%@O9*P7T@/\VCWFA48.TRN.5!F$2)%!*@/DBYFYBJ5F.P(V*'*HS!9K
M>F[?"DOS]B'];"[0M19[ G,S#*5^!\"!0PJ]3!RH\2@K.,K5;L?MX_S57+"%
MW+BDUN4\E/HHU2Y[4AE2,)0J*)H/\'Z\R=;A/3$8Z-JXG?R&+ @NXM53S+Y2
M*L*RB%#L& ?*[-=M ^N :'A@BZ4_GI'_2 8$YB9^E$,Z7BS-+Q:U\<J\O(C9
MDJ.5Z')80<,/9I< TXKP;MI$!K*AU6VU@ S)H>& &ZZ:M0DX,->*8S[*:FG,
M*_/P,H0_F5U\ME6$B](N.;#C)2@-;&5R+4?XVXBP+,+[F=09K)_-C$?2HUC4
MI,MSD+^,(#?6WN1+*F3K\&6\_N37 5:H@V,^WHP*,%=Z"L:;M.F#/:L?E('Z
M=;Q'I4$MK0S%T1TO4 7HRA<,RQ;BVWB#RBQ$:;4Y#NQX338!MJH"X0;C4\,C
M>/1B7%ZWDN.M/"BE9Z[&MA$7+(.: :Z^B\U  (>7U>68CT9K:<2%2R]SM,UV
MM;>*=L-BW=D:&-YS1ZO#M\(%>:J^P<Q I/F&?DWE_PSH#Z-S77I#R[2/X,"/
M=V<+ZJ%P*Q*^#LIOU8%)&HFN.!GX8Z2)$NC+>RYQI#4D2>AK-9:;YCJ/EKIF
M8PU&Z$.[,1GVQU95PJVJ5#4@(39"3L#LTYL&J;$Y>I/& YFP #'-15%E.ZJ4
MDM#3>JOPX,R0OV)2^[OE>;$3 86AFS[0Q6<F05Q+<3"&\ID5((>Y0JCRFMZ1
M_+XZ6_._25]KDQ?+=Z;QW9&T6 VNO>2,_8%8\U#D3.BYHN_LRU?ZY,8!NO/I
M^P]TA'6RU0N<0?/YS2<!3"2V,;Q46<-IN$3^Q'G& ?'7=..S$F&1R]JM/B#_
MF:Y'<(7$R]P+4M,DT><H".(+E@X*6I[];R6;:VQFGUO99,F$$:VDT:$4WE>&
MY87NC=X"_TFRWT2VV+P F0:E_84*7T[F<^QB!N5E7"A$G/FJK_7H))F*UQ3_
M6E)R95XS</[ X3(IM7*&28CLI4=<LE@GSH+(<V[NJ(![6&+?2BW6-S?GT&*P
M2@;3+07@!<>+ONY0=E%E)?\;:%5A"%6Y>V.)T9PJ17;$K!%3NDGL.,KN?&EA
M^D[T@+M,E)P9LG=L]6%VJX\2U9DIQ^PPVDLT]9#$CH*0[<<\9R^DC7GFR.J8
MY^\H8-HM_!#M?*B15^B)V?I,\D9(1#4];39F.1Y4AF^>66>$KAWX2A"DUY8&
M.\,AR^2_]AQ,^8DLERE \?7);M(E?IJ12V#K"BFRVN8'J4U?\K%D:ZTGRT_.
M>/XY+MN^0)3<V Y#_7R[:8>AW!8]-N@:&W3!YI(5?A%[>37HB0$:H,L7K$Q'
MBWI:G7OIA:=;V(<"M'K#:S4A<WID:V8:C*?BFIFF]I40NT7%:F8.IWM$PS,Z
M-HAHO4&$V3NQ:8,(T?=AAN>IV4'/C4]VA3W ],X0]7:4,GSJK#X9<A_,O'N;
M6-@(U$3(P31;-"J[I+?,P4/I'%%D.M_'9.^ ?C([-:/8^4$DW34<-3/%FD+4
M<LZ\#+7/HRH",P34U-X?0N.,IK7WCS^;?52K:^\+A7-PJ$Q/#VOZ^!(-].%M
MP<R^795)/$C$UU#:CTC$UI4@NM_8S^R'1$4L)5$:&)H!^M5LS4;LDJF-%^9M
M7H:\_ZHBQ%OLWM(KA!IK+7N]64;;2*.;]J:@I<H7LS5GX;P;7AB^(E.(HV9V
M"4L(:N797D.I40O>8X+Y?;Q@JMEU.F5V6RNIGRW6_WTB 6;/R=_[]59N!7J5
M6<Q\29275.V9V4)F*232[X=2_%<&SM(Z#1RT45LJN/?KRG3P&K*FES25DJ>J
M"G^I#P(I0E=?3:2'Z#% _XQ8D.!S;,Q55@M)@G(?:B!!V-86V?\=A4OB7-.M
M&83LBIF^T#N'14;PPJ3P:'\AHG*9Z9L8JG.**7-_QOTOZ_FK^%B.CVSM4@V)
MESR;>G'//1A^$D2;X5=0[!2*8@$)*9ZV>XWQ.0MS5$Z@%U5TQFI%8[4BJ6I%
MBG#;OG;VE1F1R9?2:"MW]#OV\"I:P8JZ['S4&F_6JP1OVQ^UQ=L]VXXPSK8^
M:94O2/YO[@.I6^6>K"TW9/8Y]I[&7G)<)3-^Q8B-^;[JYWO(^;X[4E.B3D4Q
M@0YX9RC"<W\KB'0T!W#F;QF)+O@'I_06?M\!YU*9NN4T.K<3U4Z/U"W"8!)O
MJ[9P!4K9.1M,1FV-K*K&:FCYM/6W4SE>@\NK%3R"8]ILZVFS9@>,-8W<%GMD
M<32')>**<F)S;^0AY,'NVQ!(@04C0\+09BYE5AY2:&?B:)@I?.K0V+8(<C3&
M.[_:KLO3*,T.FZ^UCNN*6CO^I#RB9Q.U9B36;82I'7]2_LCL682+R!+4^%0Y
M6(.2H>50B300-3ZO6A@L4(P#A\],74Y^KVV%L'"8S%3R9"X00"22UCST\@"\
M]#?L/Q[II?;O_Q]02P$"% ,4    " " 0F]2Z"<#J>$C 0!'I14 $0
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64$L%!@     &  8 B@$  ,8S @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
